<SEC-DOCUMENT>0000200406-23-000056.txt : 20230428
<SEC-HEADER>0000200406-23-000056.hdr.sgml : 20230428
<ACCEPTANCE-DATETIME>20230428160702
ACCESSION NUMBER:		0000200406-23-000056
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20230402
FILED AS OF DATE:		20230428
DATE AS OF CHANGE:		20230428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		23866001

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>jnj-20230402.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:58e186d7-ec31-41bf-b939-580d103359b5,g:2048fc28-099b-4a2a-a431-d29d26f24517,d:7c615dc7aec24dc98e6c850313251c4e--><html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:jnj="http://www.jnj.com/20230402" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jnj-20230402</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80L2ZyYWc6YTMyZmRjNzg3NDNkNDcxOWE0YzAyOTYxMmQ2MmI1MDEvdGFibGU6M2FhNTAwNzQ0NGM0NGZkMWEzZTFhZThiMjcxNTIxOGMvdGFibGVyYW5nZTozYWE1MDA3NDQ0YzQ0ZmQxYTNlMWFlOGIyNzE1MjE4Y180LTEtMS0xLTExNTYyNw_a2fd08dc-f508-4493-994b-2549d06b28c1">0000200406</ix:nonNumeric><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80L2ZyYWc6YTMyZmRjNzg3NDNkNDcxOWE0YzAyOTYxMmQ2MmI1MDEvdGFibGU6M2FhNTAwNzQ0NGM0NGZkMWEzZTFhZThiMjcxNTIxOGMvdGFibGVyYW5nZTozYWE1MDA3NDQ0YzQ0ZmQxYTNlMWFlOGIyNzE1MjE4Y181LTEtMS0xLTExNTYyNw_c06ce72c-cbbc-4d00-98ea-c088f2b37cbb">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80L2ZyYWc6YTMyZmRjNzg3NDNkNDcxOWE0YzAyOTYxMmQ2MmI1MDEvdGFibGU6M2FhNTAwNzQ0NGM0NGZkMWEzZTFhZThiMjcxNTIxOGMvdGFibGVyYW5nZTozYWE1MDA3NDQ0YzQ0ZmQxYTNlMWFlOGIyNzE1MjE4Y185LTEtMS0xLTExNTYyNw_49b91b1d-77b7-4453-881a-74984e3a5cd5">2023</ix:nonNumeric><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80L2ZyYWc6YTMyZmRjNzg3NDNkNDcxOWE0YzAyOTYxMmQ2MmI1MDEvdGFibGU6M2FhNTAwNzQ0NGM0NGZkMWEzZTFhZThiMjcxNTIxOGMvdGFibGVyYW5nZTozYWE1MDA3NDQ0YzQ0ZmQxYTNlMWFlOGIyNzE1MjE4Y18xMC0xLTEtMS0xMTU2Mjc_79717867-df6d-4ab0-b61c-46b2cab481ed">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80L2ZyYWc6YTMyZmRjNzg3NDNkNDcxOWE0YzAyOTYxMmQ2MmI1MDEvdGFibGU6M2FhNTAwNzQ0NGM0NGZkMWEzZTFhZThiMjcxNTIxOGMvdGFibGVyYW5nZTozYWE1MDA3NDQ0YzQ0ZmQxYTNlMWFlOGIyNzE1MjE4Y18xMS0xLTEtMS0xMTU2Mjc_83ebaa88-cda5-408f-bf70-8644f1898bf1">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzI5ODUzNDg5MzQ2NA_6b98e8e9-0203-4faa-b7c5-6f9e7ebf5ed3">http://www.jnj.com/20230402#AccountingStandardsUpdate202204Member</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jnj-20230402.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4185cc0226f40acb9724055d3655952_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd2bfae49cc471b8e8f8f061eeb877b_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5985eba1fdd445c088f418dadd94f1c6_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie611e2d28014400cb2d7774070bd6ea5_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56880e9c6bfe4b0985d48f5d5f70bb4f_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8cdf2a1534245f6aaf14d9138fb6495_I20230421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ie7987f4710274da781b044c04aa38be0_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if241137260614532b6020bfeda156ac3_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2188b6c0f7514c949842cbb0fdfabbab_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77ff9cf53ba540b9a5e6aeca7ca5804f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e69e8dd1c3d465ea6435891bf59621c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb53f128b06d4aba845d354b0be0e42a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b3fd2b8861e424999c7010d105bfd21_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a21dc14a504f8ea99bb332930384c0_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4da4c2095b244be8c3cc67e88df5d15_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5578ef4542b444f5ac1a50c33d446bb1_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i455ec88d396c41248d806ba599269e74_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09e8821bbba242a6923019b0a460d64e_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifab9bbc2a1a94a03a0a926fea40d151c_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae6ce94080c14bf3947a9c53d1a7596d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d9051e5238a4ac9baecaaf4941dc3a4_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e2d68ed978242baaa348359c8c9ca9a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78fcc13d384f4330aec9188cab3a6947_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96bae56901ee43a5b70044963ee0eb2f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5ba501b50bc44c68b5053ecd96d9a08_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f1e92fdb7cb435b85c3f0ef4f00add4_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaae68b8ec38442eab92d9dc3b0260cd9_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i047e4a043e444bcba72ba4e9efc5393a_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8919e9f61f8f44749d28698f8da6d82c_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5c9ee590fe74fbea7151627b39b194d_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06bfeb1f5de646c1882f0ac3995b15aa_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1a577429d7543cb917887d15b2934a5_I20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibba084db76814e3ea3789881d3aff00a_D20230402-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfde879145bf49229de003973cc34868_D20230101-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38228c4f861c4d53b47d4201d723003c_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3e842812a5248e0bef37aa2b2e9b2fa_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7b4546281ac435aa92aec6c7e41c91b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3230083ab32476fb09c3bc58c85a4ba_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26813cf41e0b40518f5acdbd9c90332b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i197e0943ce2a43d7936e32486da181f8_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cfc80b6878c4f6f932fc48b92669884_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0507cd24d2e4b288dd7a9b0753017af_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0799f3dd7e1443109b9ff412c554094d_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54a01f5eb53d4ab89d3cbe7a3ba985c1_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie416bf3f26e54604b272b38173898aa1_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26cdc03025f14afa93aeea4d2797344e_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f3967ed8804b3484a788194a6b55e2_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia44d907a039b4ea4b07c28589766bd8a_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i580a3adc3cf744379ba4cf5f599f7937_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i621fb40d2bb940e1b24bdcca1e4136e8_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ee98f9e7d6a4590b9ac7b2d9cdb9144_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcd0d6c747a149e19fbcded0d930ca35_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i882e2c7e02fc4e118e5a1079393bf3a8_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if54031088777474188c6dca64d2fb710_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf8c231701af4202b803070c0de9def8_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ad211fc0f6c4a23b3511340169453c0_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0c30aae843c488795f8e7c12bdf070d_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82b6d9a04c804ccfa99f995cf671dd34_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68677eb45407447cb144946c0f01f334_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41f4633d6ab6401e9804fb1a385a3531_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5588691f505049b895ad7d374a5c3a41_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b45f400dac942d296156e124dc1e9b9_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaff6b065b8f45f384f79c9289dacd25_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i831a75e27b404331b68d0e1d0c6dd089_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95ad3c15d3724acf827b842d7dbf0f89_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifebd08ff3dce4721a4b99e42c41bef26_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia39a02e3ee104b9ba558b07af3c8b6f4_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7b9d91b169a40358401cf82127d3e79_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice47da4dbb604bc89bb47d0c82573768_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9068df14ebfc48e38d180f60734ca507_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic52c17526572465e9e1b5a35d8831216_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb38841a93344de99840a565926c66a5_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4779df903b7b429d8d7c7bd175fed19d_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee79a709871d48e79e9780dda18549cf_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7667c30e53b74e189bee49ab6ab578aa_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic67e218f34d2463381b9461693780c78_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39a3c4d59b0242d5872c4a78d9b2f266_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b8e5036b85e4f42ab00ba31e3cc72e0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ab5b9880cd4f64ada5ab99bbe01129_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968b152e9828408dbcfff2d958bb2ffa_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f8f4aec6be94d6fbddc3da727226560_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i518fab6babc2450f8b8bfc59a05e3df0_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d1e2c54d6bb479292b9652c120a6541_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0c6b0431ad94e9aaac1f8408e9e643f_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cc8515d00ca476a938ce6b49ef1d594_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie051977e19b94b39a0ddaa23a4b507b3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53b711721e994f5fac5c2f261e490da8_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf1da9ad33c847a19893c85c250bba48_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba41bab8774e437ea305e80eaf3595db_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife40f1a43412473da55b7933c850ee6c_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13f98824188a4648a8a09d1453d2780b_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f10659432f044afbd1fba6198533009_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iece4bb18d3dc46fc9364b46a20d5f69d_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id81ca34bf19c4617889e951ac6dfbc59_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28d280475a264030901bece015a4dc31_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff16d560d4c47149af82242e78d7c81_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18eb2772b356408db2d5bed81f211a2c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf982a48aaff440bb1776f320d637a69_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4443adb601eb4729914e2ba1f143557c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a044beb1efb4064b0c24daf2024f934_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if77451a376c4461ebd92a6a553653653_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06741010c1a64e268867848027daba0c_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6330ab077ff46f38183eaaac192c351_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i530924810ee74f0498a5b576273161b3_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1c1b995a63246e89358347d16f7c60e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i075611e2f1c34545856ee1fb67001c5b_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ca12285d2874df69fab0b80f4e166fc_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c4f8bd9f0f44566948524fae883de74_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i652d6068f154428ba681e62b55ce5132_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f485b1f7c7942f49f325dd462771cde_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd652ec5aec24fbfa5838b3c7c1bc608_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i307781a0dd6f4fee83ba5f3b83bacf6a_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8fce605d8bf42a4809c31f01fea678e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4c4f1b4529e4b4e94c51763f2b03fee_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i205b08e0d52a41018c1f1aac759297b4_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief14a8d3f839490ea2f5004d02e9ea85_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eecc4b339cc4793b846af6357408a8a_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb9204df17c4b71bb33876248a6fc03_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d229fdf0aac48939a630ab1e339fe6a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93b2a01d5e1942d0934133917a0b41c4_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id75635b8099d4b48b2cd2669062d8331_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia81349c4bdf242e682e3fd1ce2fbe13d_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7a1713ee90b4874b872f2aa9e7ff7cb_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c27bfe420f54e1ca9c1eeb355beb0b2_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f03697427554f22b26c5738cd4a66e3_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dd646702260408ea267396967e28f41_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bdc0608d83a46fca52c9bb31b17d8bf_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd3150f03c284a7c8af03baa7bea76ca_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf72c1b6f094918ab2d8aac314f3e7b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f05b2c736c746f9bbb497d86e2362a0_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47f2667d72af493883f17ca87070a398_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c83227b39104d4d82056ac6bfea554b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c31014b15774921a5f30a4880f42786_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92e0aa803ceb4db2aff7a0bbab1124fc_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cbc0e3c61c34bc3bdcd6deaea9d806b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99ffa091217a4323bc5c0aed611527aa_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">jnj:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3200f710ae4ab696b549ce19c468e9_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie33a79c5f8cb4a83813ae704160ed98f_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf23f95e6fb14d838dd8f888af18a5dc_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54377ee71ddc46f195fb7d79c03086c4_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7e10a1fefa741b8b65c1bc8d547367e_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5115b43c247a46cb8480efe59a9a01e2_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4af82efbb61a401e9e04b30f3cd374c2_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b85c7849ee2491c98f1a6384d52b0b3_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia22c34150afa480cbfb032861aa89f53_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica912cc5502e4edfac4509644a475663_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28b97484a76e4109b1cc8fb5d4f35ca3_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib55fd172e7b345698937c728fa47ea35_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76cf9f7d43b546acb7b030654e84376e_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38b034ded43b4398ab07f2c8eb4df69c_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8fb8551fca949dea98f62de1af8e1fb_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i74fbc3262ac245c6b06dbfaa60a35912_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2c5ffc25a414b4eb02918f1226b594b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7901b5b213e45cfad73dbf6c939e3a1_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i201ea42815f84447b0563ee2d6978dbf_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc07e47d11a24f3d84ea26db566510ba_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7899493f2a04f03b8d3a44ba0c57ce8_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id55a3b7fc5a045b8b30ed7f0edeef623_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00240ca013be4736a3577b6e2e4e6e8f_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d061251a667491cb3ccfb55f7e0fdf1_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27aece83874544b59d6a3aeaf4140c57_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib72ea9d48ff044b48b8f3531137328b3_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2d24b4e1a0d4ff0b2f3b876efb8f98d_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id922d848f11649e8bb4d6a787425f3d9_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d10576f649d4fcaa6628e37339ed7d7_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6efd100445841fd9e4073832291ac05_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if128e6a98f974c349bec0f4b8249d2e9_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8830cb3725a43db940330000abf4afe_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i368a811b66144aceb4879d90f93ca849_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1212e32453564047b7f1d38ae4b843e4_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79e9145f348e4338a78e8f59378476ae_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48f4f2f5d47242ce9696a233b88c95d8_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i909ade28c6444d4abeff119bf7fda238_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2867cf9e16e54b48951692ded48ddfec_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib925ed2921f044c7b6a52dcd57f43461_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1f4ccd1b3ab4f02bad67727e76ccb50_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a544d1c051b4c1a82b7d2c87b858546_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i227ac8f50abd4fa982cb5d05a9110d6e_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b249c5b4e484ae4a30c7aece7e87a09_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a6f9a852e704a75b988ca1c5efcda90_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia133568690864c2c80040ff64a3bd09d_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57ad96c98de046ca96f7fb7c74dca343_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib27758560e174afab9810f4bf86f5335_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e6d8ba2689941f9b382cef18e8e510d_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6539619b042047df93391dc561673fce_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee5802a254024b95b747bbfcf78a55d8_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3725ff0a163f4284b203c37c1a364bb1_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief4a308916ec45049d576f86d454ed54_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94f8018599af4e97a1cf4a42f83a48c3_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e731198db6248e18229839dfbbb9b60_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7ecfe4e547b48e2bf37c8b07270def0_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d3943f6e0ae4e0587c9c4d74a075a18_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b67cb6ca9a44edaab52a8871fcc3df_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4f9ebffba3147cf8d00c064683c36e2_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c63abc9f5cf4a73a4a82c7b3a2282c6_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fa813e2d18f4d07a5ba47a2be3612d2_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c8bd52c349746b1881e96b11ce47bf6_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief71832a9018470cb79070bc07ffdec0_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb5347aa05834f46ac9daf1613e272ca_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i816cf20f9e104bf6b19a363b6ba3c457_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a7bfa3080844dec82b6603a0abd071c_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1aeff3a19174fbaa6c309a6a87828c3_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a929f2577cd41d8b9bb8a882be4e1b4_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3946c9afdf54418086ade08e21fa3a2b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82f6eaa7f0c74d57aafe2c652a9c905b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib652901c5fce4f24af8075006cd9aa10_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bec9abf70944616ba30c3702874dcfa_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i339a1d20f63346cb832562ac3c78a237_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaacba4e8463a4d2e83aee15b14146669_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cfb0968d3344cd78090b4f6ead3bd76_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0a4b17867e147fcbe4c359e1afbd038_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i724b3a0e6f5147afb4e0ba7665d6ef80_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib37fac857ce1416bbf734b81d98d767b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3e1a1289b7d4dc7817b8a11b9bdba25_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89ee2bcaaa4345b49e22759f9172507a_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93d5e74486b449e89b3a9220a64520f0_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9923a50e9724fc481bdd65773cf31a0_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a612e6189440309a78a24f6aaabefb_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e60148e6e194dce942bd04838e31cbc_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4c126d2c7894910adb1770911c549ed_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie24382cee4f042c7954a6d0aa1419fb4_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3f1f5aa22a94cdbb91e0e86cd25fcaa_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24b45cbd53644d79afe96aa1ef132108_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i022de5a785f24bcd9f3083e4891f2ccc_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6862fde9a77c43f0bd130d62e09598e6_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia86125a3d772402db1a30fdce3dcd466_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b0b8630278f405ba64f234c38a4a3ae_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie533216722654c1e9ba1846224e6ec14_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74486a5277344ce59312540a7f416cbe_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a9fa797383949bba12905735e92ed19_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f065931abb84eccba21550140a470ca_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bb4ca4a34d6461dbc0d107842b6a046_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6552612946f41819e903a05f07bf91c_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i918f92a298af41bda8fe834dd3b26150_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A550DebentureDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f501e2baabd405c810574367101a19d_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A550DebentureDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a69ae7c0f5d41bf986a42afdbbfb628_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A550DebentureDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0a6b938d37244aa8e09a786396d444a_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A535DebentureDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3a99eecd02148a2a368b8096810c2b5_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A535DebentureDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03eb671135b6424d97690216188682fa_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A535DebentureDue2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if08f43d66b2b4b1789c28c89f773bcd9_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A505DebentureDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92360a98889d40b2bee328fb5755cfb0_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A505DebentureDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i741825ad780746bea2f2c6a35aed64c1_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A505DebentureDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3fb8e7a45764351bb0b176fcbcb6e26_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A500DebentureDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieedfdd205ab143638b2c4e0babcb3bcc_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A500DebentureDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e9541bc07fa4ed8a81ca1e22b84a82a_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A500DebentureDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id69efa8053fb47178e9e37e201313747_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A490DebentureDue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0cf278aad3544b68d1287619e1ff5db_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A490DebentureDue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66beed51389f4daebb6d2d780254c5d2_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A490DebentureDue2033Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51d9ee539efe4210a650dbc237af95c4_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A510DebentureDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i638e9c268a244ef0bdd12369ee16af36_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A510DebentureDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e2c136ed07a4293bbc96e175b9bbdfe_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A510DebentureDue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21e0e43d753d451b9ac7010d74e12a35_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A505DebentureDue2053Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b160e5cf382471abfa01a07b6979dcd_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A505DebentureDue2053Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6091369129b642cfa7e758e78afae422_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A505DebentureDue2053Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i024e2dfb671f4922b572b41f106efb1e_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A520DebentureDue2063Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89b252fa9afc4f6895a65928a3dc4679_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A520DebentureDue2063Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6b6aef384bf4a9b80ea47648fea1fee_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A520DebentureDue2063Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id967b50670d04639aa79dfa133928a7b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if123e4fc41a748d3a7f0c30e5548e9dd_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30b84b721a8a47b89119d6e1923faac2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61afdda999f44da2a95e6ba9519c4fa0_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e12ceb17aec40709533c417fa7976aa_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a87b5a064e4c7a899475e0dbadc527_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50e2318413734df39c6c543008cbcb21_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">jnj:AccruedTaxesOnIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ec8770b399d406faad6d9a6b24fac59_D20230403-20230701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-03</xbrli:startDate><xbrli:endDate>2023-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a79593849c348e791c81a2228ea6405_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b50bef376d94029914fd830a153b7aa_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b6f17374cb84625bb4b63c7a5d62e2c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia51b75ec8ed24459b26207e74f51ad4d_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39da497bc9a345169e8c633fc9ccb4c8_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f8ef72c3cba4a74a4cbe42bd9004f33_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b26df561bd946948e1a78379354d9b5_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03d933225100466a8dad732be7b062f9_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99a10cb23bf04c2a9aefd04cd01d1d5b_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i248120dc95c44c078c9b33b2c6c60b4d_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaf739bb046840338e03bd31a098d3ec_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib70396f99f564ac9938bee2564160961_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if52ae96f4fc946d0926968e3c2defc87_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41317b52070e4c52a074c754ab815d1c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c740c593a5e49d1a9b8f5e7e616b946_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i984d66aa451f4fddafb447e2b3a07b38_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa2e564e1714834a088812e21dfe9e7_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85292bb163e24d1a8b532b0152757469_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff776c204ddd4fe4af24bb0222ea1874_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07b3f305984a48ad85f9a74e74005373_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25ae31c7c436415cacd6f0634ac5e358_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a06685196204a4799f887412650fe40_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15733073985a4ce5959e11ca5f252bf1_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e96376a42a04152b58e3882a9b14ef3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579190aae8a9475783a0704c6aa14097_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c3a3dafb62444ad8218b38dd1ed838e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a8851c22232454e975ee3658a578864_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3fc8b5552e4871a6f2db9f1a367083_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c9625e879e043e09db9ba52fa49c414_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77d45dffb4d24df982e0a69a2edb48b5_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a140c2966c4d39be0eb69abb0cd291_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if081b963d9144c09a6d20b20d26d3d66_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01f0cdd79a5d41e2b78a6bf7fcb0b94f_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id17d813e9a0a41f89c0e446fdf68e56a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f0aee6f09e5488091b12bba39e31ee2_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c384167ae1453abbb9d0b6c0c04854_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i736ac00e11af42359794eaeaddc3a97a_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icacbe869dfec46a8be4b9c12f04f7cc6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f04259b9e384d4386a146f306a64433_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4456f20d70b4883b575d2169dd71544_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2627fcecbe54a53bd26bd35bb03ae37_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7f08dd82e14407f93f9374ec1c64bba_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63462697f7cb451f9132abc3d2242368_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e48079566be4bc3891e3fe4dd109037_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29728a150c174ada8da66efe8fb411d7_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i262a53f9ec2547dc9bc3e7376b7a007a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4510efc748d54bb7930912ba6509e096_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i767c65868b3d4650833e3270ece3465a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b25c8c23a664e359b78c1353fbb6375_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e4c728c6f644bf29493a4b4e9dad170_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0598fae3f054742badc9b82185f5c04_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18dc481a2ecf4435be42bac0b2119b30_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4623992e0dd14d1a9e9f595afd28bd4a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e5f74d7507448aa8240b9c69285bd57_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0ee1a5c112245ef922eeb1907bc70a7_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29c3c1f4c5bf4928852da60e04089160_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89d74a9d646040ac8bda4a109e5316d2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1e47778732e44aea0320f24635c55e6_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i000088d3af5046b2921cb4af5f6fc205_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide60c30a5fc749e0b67837f69ae698e5_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53b79714bdfb42359807a488bf5a74ec_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i359821ae58ad4ff8a87eaa12e4efdb78_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10d2670c3b13416fb7a206927fd88687_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd662d1267e49139b46c4a297215a54_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ef2ee88e44043efbb8a96f8b9d8c89d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie188724cc3dd4a949ef2fbaa68fca7b1_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31b8c4e7570d486f9a67881129d6fa3a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i339e5f7a0cc1453d976a0dc292d89c27_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2ce733a0ef4e72980327ed5e0107f8_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b9072482295465bb3ae5b67b3338abb_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec663daee5fb47d4a96c14b56bbddb1c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dba4cd103d24bc9b66b596eab786d18_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68917d7a1b8842be98f382c714c21a1e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cedda0d436f4730a24d2cce6e535f50_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b46548a1c9e4da6ade074b1560663d9_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf3bbabc22fe40489b09d4860798d9fc_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dc26d7592994955bfeeae65142c46b8_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic43daf65754947459d5aba53e5b92e81_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8a2811670fd4e388c4cff13e473d4c0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if25545d4d3224f2683d6c36402df6c2c_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i583fb109cf304e3293199bb1d895aece_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d6adf3e8198442a90339cfc887ae4e4_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63aa3f3d8b9249c185e61668767dfbf3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i602b3a8f8c684e07855a432b44f877e7_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057cb94031764e83922e91e90e55ad2a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f466a267f5244d987f9d84b05b1dd94_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69aa70e212f144c0a94a01e8c886be13_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1581f8ac08c84383b20e0e6e3b0b3231_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64ff97d1a3024cd4aa22d2ca000bb716_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea40143a881c4e9fa30c030d13484367_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26bdbd0a33904170961ee857f7f75ec2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a944b7eb27347a88ca02d5d4d2a3ae3_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a5cd0e89145489b9adb25e4375d33c2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d1731aeb98946a7b4ae917d048b33e9_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if862ee47ff57402ab4003df617f3cbb7_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic411e2d070f641dda19f24eba87d762f_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i617fe07827554cea8265f01074aeb1a0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1d744c7c8d14f1fb8fea48cff62dbdd_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52ae5dd1fae940ffb2cc4d896705c30c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a022c685c4343d79523d6f83bf6d043_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadbb5deb5a1b4cc08f416461ce834cf6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4967a757b464053a991e793b0594a48_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0098733b5de24bea987487c0dc5edf73_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a690fd862144f769bca79051212a40a_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i131a7455bdfa4e3e8cee654b964e7506_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id11db793f4614fa5837a25d9b63156c9_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5573f6f5a5d9481c98d29c616f628da0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib59a8dcb5bf443089bf51815435371fa_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03761710c3c6468698fff19815667abe_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6d4e5e284b940f0abc9192313e3810c_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7db52f7f1f8f4820addc27c47eeb5cee_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i629cb97dd9014b8a9866cd4d248ef278_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica7fe9702d8b45e98e6fe37ca13068af_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if79e147a672e45f0884726eebc14855e_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb5a5fc555d24f308104655c998bf305_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2615b59268ff4c7d937c9cf5cf4ce170_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c978427d57f48948b5dca33ba9a8790_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i785d0ef07e4f4fc6899d3084d7bde419_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3c0840358a442fea238d7d4ecefdddf_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcfcee01500e40b6a181c5d82cba6ce5_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i044647ef59d14e6ca30f9418a2cb334e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab3e83e7566542ea969c626ac4818791_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54ff8960370c41909dbf45d3630c3d78_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ff8415c7ec740b5af1069a9d5615847_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if178d1ce94e54a8b9f23398ad0e2c083_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2f647ec067747e6b33e6c21b46b9acf_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id01edf890de640d3ad17b53da34d46f7_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17723664c2b44d548c8c8e8627ed427d_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaea78f2bf0b45eb910fc188d04fbfbd_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11798e595eff476180e4de36a00ef239_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83d752ce08cf496391503b82c9f8093e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f629283443f49d8aaad385960bb0673_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i093f63f72e8e49ecb668d13b75d40bb2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i686c8541b42b4c05a464ef7ee07f890d_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae059ef9a71a4eb791f9e711bc7a3a8b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i540168e260374772b2846cd65772d665_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eda79b80e2049239e63855bc02299d9_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7c7de0d76674b90ae3e372bc29d4f72_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86f3e2bce1e74415a5032c634535117d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a1a49f5edb04dcbbfd9179b3bc6605d_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64eef9047d8b4024881a1e71e04644ab_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd5f7ebb194146fe824e76df773868ab_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib75875ac7da34c28b177112493ce9e3b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5219d9e2234c1581c5cbbbc318e9ca_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f3287ef468347f78f62d4695c0a6c33_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dc3cc05679b42978b02eabd70ac7223_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if98063295c35488990378b212f03f0c0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied3b20670e8f435991a56e4ff15b778d_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac15c39db3b94e89978df479bba14ca0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i333de10c5e194bb8a7cde19cd0859df9_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib525ff83930a455288c90417291f93fb_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68673ce635ab4895a3a71deec80d927b_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e28bea10b16493bb218d5f6672559a2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f2133a562294f9fad3ef124cc3f62af_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0119131cf0458084a6a1dbfcc10ee5_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60f30737549148d78386d683bd7971cf_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22ec3b93d6a4485d9565624fd37520b1_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e2961eace9b41418fe529105d0a94b4_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dec4567146a4b51add1694785443d3f_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c0955b8e0a143aca601efbe6babf21c_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib16a26859ccb46d6947b21484d429b1e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee98c5cb0708407396e22087c411d285_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifab9674d8a57440385daec43e3b872b5_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd48985d52ea4f1693cc1042d3c8fdc3_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c6fb890aee4700b7cabd1224a7a9f7_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3a9c49693c4528b8b24e19524f85c9_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i160565feac454261b5cf8029f03df1d1_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4815237e89d4db1b540f9d011fad6bd_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic942fa98d0f54d4abd3aa101ed8cfd4e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51623904c8e7456683c43cae3c239cbd_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d32e645ff894945ad0436a18173134f_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5f9f5c36c324901a0f9ef4ee74902fb_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ebd3fdfaab847999b1abbed0df2881e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c5ac73df6614e86b2c68e2bb0b7b04c_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i076a0601ecf14a4288789888d685888e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c8f0d46d42a41e097f8a42fea7efc04_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6beee782dab74a55ae5b50d1a126075a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i652dff8c442f438c8266669ccab6b186_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a7d9521630e4ed4a0f926999bb837f2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bd82b4bf5fb40b3a12d708741b67d0f_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35bd295b8c6c45a49ecf26261ae4958d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c53ac8f0c6c4ea2aaaf494a42d823c8_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88768a59c84946cc86069b6c72c10e17_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie04f0afe64d04e5f81ea459941636bb7_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4da66669adf2490a954dfa605b57620e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i995cfb4d674e4f669792e3fcce3e446a_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c00ddbe0f14783b81b783b0481b7d0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic70082fa2bd84d2abfaa197163d58036_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic93c8ff581fb4066a25be356733d40b9_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ab9aaf299b94d139444f75057ae76ce_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345f37b977dd4873a272254f2cd7b0b7_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i150f063107274f55809b1b424526240f_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7326763483de473c80ee9447ae7d5874_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id31a5ffdbdb34a8da796905e5c398b22_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505ae89dce3d4c318427fd4433c5ac85_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i136fdab820ca4a628cd28ba7b37ed9d6_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1212b07b91c147ce8e0d1b45004d468c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05688666a73b489f9d6fb95983420710_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37d4e70638d24648963bbcebc8758c59_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16171e8c53424225a58ffa109cbddc6f_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad42b84534d649ba85fbccdcd13e9e92_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc6a67ff3e2c46c8b750cddad69dc4d3_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3581abfcda4f839a0c590c86c694a7_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67d976ab3276405b924504695f2c3e16_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fedce0cd42349b4ac489cf459d784b6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdb91f2c98f843f3bf1a457a9e524b19_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6130edb225934eb28e1c70739f5d063d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic918fc23c9474840bab3b6e74a8b4c59_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5df37fa4b554bda930ce40e6cfe2580_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c88a8d200f40b4bacde02a32dd9329_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa1ad776d62d468da5fc409a793fe0d2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43b4a5127e1b4328bc2a43a45710bde8_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id490f83accb14c9fa6698c9ccc80525a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb0bb69e2c4c4516a56e8f1e3dc2d643_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6afd1882f62f4386a785d02f1a23bdb9_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c3060e9d95943b589436fb77dc77a35_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37be37c17b20438193f60193db94a428_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21df6a06501347ef989f179b4cf7dd2a_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i291cca6f20e64e3c8cebcfda2c8ccccb_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0152d0f99144507acb484aac822034c_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04c171c0b08d4ba39f9cc175df531847_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i236ad63ca35a41cd8f969b4e2938f2fc_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafc33bbf42804adb85ccdf725d2e83cc_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01a03416efc042fba5eb7b5f63640595_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id46b580cb2ea4c188253514d7ee59c8e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e7f61f9e4f74352b9c8f412986189e3_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5efb947632c47e19d68b8280af2e44d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85bb32425f664497b088763671d4d454_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i098d2b32fc074e018e965ef42cd425b3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic47106d021b544a9b064a88a11f29db6_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a6f8cd2d6443ff9d286090d2f06423_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b0c223e01d14534a29b703d9ffca9a1_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i569502cf2f0f4e4a8dfc490844775e54_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if748627f3368423685d8be9fda1d9fe3_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac40786f71940aebc5e207db586eb04_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac741c82fc14439fbb4cda5efa014094_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6e46509ea6b444880c2eada1a0364ee_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12677390b1eb4de7a97ffc8bc444bbde_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4b42c17ade64ae7ac0f6eb0f8faeda6_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie49526704b3f443cb8d37f9e340cec4a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e9f540147284f2b909c9bdcc3fa5530_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2e93949a9b44381a7f3701eee7f9ac8_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91c597ec59014a40ae4281f9275dd4c1_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6f4fa75b8a74a9dac7059e98c19f5b6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i588fd7f2edcb4507904e6ad2502e9f06_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ElectrophysiologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd3f73f1f8144c4eba42b6ed8a810de7_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ElectrophysiologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ca28df51b6440c696c0314691bbe427_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ElectrophysiologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2fa133450684e3dabae5a9de5d13ce8_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ElectrophysiologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i238eddc286cc4e6ea38e56b95db65cf5_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ElectrophysiologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7044bf88210248c884a8bef89b77d4eb_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ElectrophysiologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90c97bfc6a2b44d78898de9f3bff5d87_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94dff6bcd4564c4eaddba70ccb2a8de2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bfeff988ad0455782b5383e4bde3dac_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccfe7ce7ecc24b40a8d287f61d0e19a3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e5e294252c54f9da688d735b42fe26f_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if98abe23095c49038b3e34d99b190cbb_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9d23239da0148da8bb85076fc21c555_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OtherInterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifca62b1259c54fcba069f4a9034206b1_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OtherInterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ea8359aa454362b30d54da0aab13a6_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OtherInterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e7e328557ce4073882ac9143166a882_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OtherInterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42e4f8a3fab14e74a2530932f1029f2d_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OtherInterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42eb9f30337047a0b6994260a328fbdb_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OtherInterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i020c283a9b454f4c91205f8a5aecc950_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id12435a3d01c4f3c9b3518fa0cc67836_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29f9872cc99b44b5b1cccfb6c75db81a_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e718713cf094373a8d40c5920af2f60_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib807084fc7c8485b9668410e22e4f2bf_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8e6ddf9e58e4f528caa4e6cce761163_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6901dd295b24125b4138f0b272f8777_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18df14d793b446acaebb489d09b54690_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ccac7306a934e89a59dcc66dc558644_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f491788cb63462fb654dbad9c0775b6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06411c6af6a74c35ac5cfad22270bc75_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a5c0148e3e41e483ac0ea77b562ac2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba51dfb57e344d5a0fea2a350310cc4_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6fa3f9ddb7146f995f2f94806cfc5ec_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabc10b6383d0489e8b8bb5a496eaf21a_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57664aba083e478a9546149bfc85f5c2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if29cd966f54442938b637f209a34b811_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b174ade6ec43a9a47fa3978d28bd77_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c27feb9bba3448a96cf3d833cc77e87_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec996af35e9d4904a9164c9042ba5927_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e256570168449b0bbdd5ac1802e0273_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8496c9c84c6f40d2b659a19f28f6f5b6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i060b7639c5944fe3aa7774d6f5d6087d_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60b40c723a94457c91bbb0eb8f7292e6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a4bd2851d954128945886c150131c9a_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf832e226abb4c3b93f4a76b0876c785_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i341a9238ebd54b549ec9e2262b87e9dd_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cf8369cc3964063aedd59972566936c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i697f77c1d355434a9a8b15ca4ddad302_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e33ba2cabb410cb020c140d48b86f5_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e5596ec20ad4b459dfd9d49c8be8280_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie645a8f76fd04bdd9b7b72c99f5627e3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8552e76d9d3b4733be32dc860982d8e4_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic807b109c8d14499aa4a84252589e37c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0dee0d184434eecb3b25dcaf1f98eba_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a5e69efde44189a532234286ccde39_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e384d939a2447cea4dadc0e5a0c2ba0_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaed173f3390944eeb61ad6efe66a23f6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49de9bf99ea94180be433fa61b42ba88_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14f40102c79e405caf79b8aa335221bc_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d75beb452e47f4893b94abbefb8bba_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2400dc461764134b3d942c32d0168b5_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8aa22293d2d40f6b58a4dec4c64b355_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ba49a1061e421f816cbb74a729895b_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic05893454bf84c37b75cefbd3d5459a8_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ce2e1faf70848a0bfcd29eeafb93a9c_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1677e46a9474356b3c9dfb976393db7_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i517534deb5ca4eb3aaae15c62790e025_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd11491a92ce4672bdb3774057431a46_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i339f955c262f45dfb4f389ca7e08c4a0_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie597f3c11e0747f68e8d3493b85a2080_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72679ec91b0f470ea17b2acaf9ad9344_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1bb18c06f4c40b296683224f79a53f4_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade9c6803cc4447ca6535fa706f5fca2_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98b473235c7a47cf859add062d06101a_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68cff8e717ca4f708d166109353460b5_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie56c32de3e2e41eba3b2b9cc344394db_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d829554c2047b198f4d4504c6c4bad_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa18e49624849a3bf980a89602d76c9_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i744e82d777a14f4dbc24cf9ac953202f_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i848d69207c1f4c90b5cc68c1f1eb7bf0_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74605a46308f4807bcd58248b6e0db65_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i115ea6c058084298bd8bfd6a9c9d7b23_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a59d2f00ca14a8fa8f0a3d5f5602967_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb91eb7b4af04d58ad7789571043edbf_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2a973165fa46a79af877784002fe9a_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i787acd4164eb45deb0403c444006faf9_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf4ce4d283a4b7280171759a01baa0e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c64cc3fc6694b9495fdc5efad8fb4d4_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib78785c8a47a4c63b2c807c981cf27ba_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0b0bf9e3b4b4097ab7bdcaefa80578e_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib18fd463fe944955b813ba83e60464c6_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a29daeaf368468580d88ec00d701e07_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf1fef094458495f8b29e9d3d2c96404_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9092a20f7ec442c6abb4a5f03939e991_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76b70d99f03547bebaa68b9a5dfb0b6b_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e23b581651e49f0a5450b48eca550f3_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i266ded4d880644b384a30db64ac42be7_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32d86be298e0484a81aaed029e8f90b8_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e11113be4ef43419386891473e5f667_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c0748aae7984d91b72595fdb3674877_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i255efac904da4926972f85e5d3721be3_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6478dcb7f72f406bb51f1ce2d06bbe1d_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6422d8dc1a9349d8ad4352f323889e7e_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia33598a52aed4f398e20f2837c3224a6_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e99be17669548568e7cf2506dae3d92_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92e0a38cfc3b4adbbf4d6b479e3c1cb5_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b6b9854fc844374a84fb9c3498a9aa8_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a82343349b46cfa5a11eced6ece9f7_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0468e2eece0f48cb874e2856e754bfea_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id60f2cfdf1f24ce795240fc4f13586e0_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65cb348676ea488598ee39d3f57d3991_D20220103-20220403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie51821e4cdcc40f9935183e51ba866a3_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36d5c84c5814468ba35bfdbf20ca360c_D20221222-20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81a2ab2c858b4a97bf160fe849e1cb84_D20221222-20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc8de83c4d3041d09bb523dcfd66b52e_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8836b8f3d5ba484189de37af4b30f820_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06197fa8dff142f592975553bd6a4d84_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ImpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0794a9f898cd4ed580c9795984a4df7d_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ClassIRecommendationForImpellaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814ccd0c40684dd8ae2ed1e023cd3b2a_D20221222-20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccd1694ce0dc40e78004ae73676d4941_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3a0b329d181434f981a08002ca2cd3b_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74c08a50ff5f419b83ba7dba4d025c2a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4c5e1157e174c7b9992d3b947faa46d_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:InghamVsJohnsonJohnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9af996ed5624621b676a456a070b7db_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:InghamVsJohnsonJohnsonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a2da6f47c794efc85b034ec75f9880b_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6ec52a5f6d5422d88184d297ffc6e51_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i503d1efd449c494a99b00f5571fe65d2_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i304dd0295691432abf102897083e51f0_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i043b133272cb49e4ad4a3a90ff5a68b9_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168a38aa9d2c44faab5619fe9ffe4231_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>jnj:claimant</xbrli:measure></xbrli:unit><xbrli:context id="i0ab721ca3d7d460192200182b3872c5a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6d0bc5404442dc9fbb22defa52977d_I20210704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia97ebcbe40d746e3998c9afa253624ee_D20230102-20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-02</xbrli:startDate><xbrli:endDate>2023-04-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>jnj:claim</xbrli:measure></xbrli:unit><xbrli:context id="i67bea373bcf745f8b39c99720a13df20_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cf78e7db6fe424ca92d366884d15cc1_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b4ceb386c184c2b93d06b92b82b2bbb_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaeb7772b11c47759bd2f3879d60dc10_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5a55c1aa53f481d8979dcf3332bb680_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51cf8df9cdd74871b6625778ba7d91de_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4790b713aa2844809fa453cd9fcb88bd_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ElmironMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc7d93f749d74c228eda4c9d482b9c1a_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TylenolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77bc5b03664c43aea0c4d8e95bd4da26_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5638d3163f64eb384c2d26990c2bf2d_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cases"><xbrli:measure>jnj:cases</xbrli:measure></xbrli:unit><xbrli:context id="i8056c4aa7c884f9cb93c3477b3ab1519_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82887472019e4389baf706d14d575072_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62a7dab5fc114de782c92d25060c9210_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EthiconMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28f2b9ddeb654daeb2f97d59eea0473d_I20230402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b5262aa703a4c79ad88ac4d66f46761_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8420d4da9f3346f483112422335f21db_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cec5795e9f24927925718a962fd322c_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f8d53e5a09b495182048bc044c3b582_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7c615dc7aec24dc98e6c850313251c4e_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="15" style="border-bottom:3pt double #6d6d6d;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDY5_1a82dd62-06e8-4e8a-9e6c-23691f11f02a">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6ZTQzZDU0MmZhOTE3NDU5NWFjYzI5Zjk0MTFiYmY3YzAvdGFibGVyYW5nZTplNDNkNTQyZmE5MTc0NTk1YWNjMjlmOTQxMWJiZjdjMF8xLTAtMS0xLTExNTYyNw_5f418fb6-0154-4a63-9168-5ab70288ee2d">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarterly Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">for the quarterly period ended <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8xMjQ_8b9bbf80-c516-453b-a8a9-80086dd7775b">April 2, 2023</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6NjdmMDQ1NzU4ZjM3NGQzMzgyZGExNjUwYTdlMDc4ZmQvdGFibGVyYW5nZTo2N2YwNDU3NThmMzc0ZDMzODJkYTE2NTBhN2UwNzhmZF8xLTAtMS0xLTExNTYyNw_1a7f536f-16a9-4246-9c63-51bf120986fc">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934<br/>for the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDYz_c0e68cc8-7279-47e7-9d84-d031ce425127">1-3215</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDY0_af451115-b668-448d-ba7b-5533a11701b4">Johnson &amp; Johnson</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6MWZkNDZlOWI3Nzc5NDY5ODk3ZTAwMmRlYzRiNzg4MzcvdGFibGVyYW5nZToxZmQ0NmU5Yjc3Nzk0Njk4OTdlMDAyZGVjNGI3ODgzN18wLTAtMS0xLTExNTYyNw_4b70211d-0815-48b2-80ac-79356314e472">New Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6MWZkNDZlOWI3Nzc5NDY5ODk3ZTAwMmRlYzRiNzg4MzcvdGFibGVyYW5nZToxZmQ0NmU5Yjc3Nzk0Njk4OTdlMDAyZGVjNGI3ODgzN18wLTItMS0xLTExNTYyNw_cff8468c-4a46-4185-9807-820ca7f33932">22-1024240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDY1_c721b047-b3b6-46e6-8d3c-89ca879999b7">One Johnson &amp; Johnson Plaza</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDcw_8ef5415c-8cc2-4c6f-be94-1e23c109aa93">New Brunswick</ix:nonNumeric>, <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDY2_1e804ab2-57dd-49d2-a202-00d7b277fbe4">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDY3_ea9c3a89-41d0-41b0-9311-83b909849ffa">08933</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code (<ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDcx_7557421d-5846-45d4-a4c2-1e978310f603">732</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDcy_d8196b03-0cf5-4a1f-893b-be7acdf31506">524-0400</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDcz_95eff410-101a-4805-8ab4-5a1869b160ac">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDY4_cd4b25d1-7405-456b-8607-cf07bc9c328f">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:12.797%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.440%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6OTQ2MjU1Njk4NDUyNDk3Yzk0YzU2MGE2MTlkNjIyOWEvdGFibGVyYW5nZTo5NDYyNTU2OTg0NTI0OTdjOTRjNTYwYTYxOWQ2MjI5YV8wLTEtMS0xLTExNTYyNw_56706e8d-2c7d-45ee-82ac-7107b2753d9c">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6OTQ2MjU1Njk4NDUyNDk3Yzk0YzU2MGE2MTlkNjIyOWEvdGFibGVyYW5nZTo5NDYyNTU2OTg0NTI0OTdjOTRjNTYwYTYxOWQ2MjI5YV8xLTQtMS0xLTExNTYyNw_2b84da8a-8294-49a7-b453-5feab6efd563">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6OTQ2MjU1Njk4NDUyNDk3Yzk0YzU2MGE2MTlkNjIyOWEvdGFibGVyYW5nZTo5NDYyNTU2OTg0NTI0OTdjOTRjNTYwYTYxOWQ2MjI5YV8yLTItMS0xLTExNTYyNw_7ef6c9c1-bda6-4372-a0db-f79229325fbf">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If&#160;an&#160;emerging&#160;growth&#160;company,&#160;indicated&#160;by&#160;check&#160;mark&#160;if&#160;the&#160;registrant&#160;has&#160;elected&#160;not&#160;to&#160;use&#160;the&#160;extended&#160;transition period&#160;for&#160;complying with&#160;any&#160;new&#160;or&#160;revised&#160;financial&#160;accounting&#160;standards&#160;provided pursuant&#160;to&#160;Section&#160;13(a)&#160;of&#160;the&#160;Exchange&#160;Act. &#9744;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDYy_d13d4d78-e9ea-4cc7-b4f1-44513a3ec03a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(b) OF THE ACT</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:41.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4185cc0226f40acb9724055d3655952_D20230102-20230402" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18xLTAtMS0xLTExNTYyNw_d14728b9-e62d-4849-aef5-acb68fec3f4f">Common Stock, Par Value $1.00</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4185cc0226f40acb9724055d3655952_D20230102-20230402" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18xLTEtMS0xLTExNTYyNw_778c9a27-2be5-4373-bb87-910ddf9a88f3">JNJ</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4185cc0226f40acb9724055d3655952_D20230102-20230402" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18xLTItMS0xLTExNTYyNw_df46d161-4983-413f-84d0-85bea80b014f">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5cd2bfae49cc471b8e8f8f061eeb877b_D20230102-20230402" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18yLTAtMS0xLTExNTYyNw_68184dd3-55f9-40fc-8055-0f12b0b04d7a">0.650% Notes Due May 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5cd2bfae49cc471b8e8f8f061eeb877b_D20230102-20230402" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18yLTEtMS0xLTExNTYyNw_bec1f400-4204-4663-879e-dabb2a70f379">JNJ24C</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5cd2bfae49cc471b8e8f8f061eeb877b_D20230102-20230402" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18yLTItMS0xLTExNTYyNw_a1240378-aef9-4b4c-974e-e53d7aa714d0">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5985eba1fdd445c088f418dadd94f1c6_D20230102-20230402" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18zLTAtMS0xLTExNTYyNw_a4a6fbd3-9a70-44d5-925e-d6a2732cf2b3">5.50% Notes Due November 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5985eba1fdd445c088f418dadd94f1c6_D20230102-20230402" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18zLTEtMS0xLTExNTYyNw_a4bea152-ef6b-4282-a5e0-4fd9f828d0da">JNJ24BP</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5985eba1fdd445c088f418dadd94f1c6_D20230102-20230402" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18zLTItMS0xLTExNTYyNw_6d27c089-5ce0-4b9e-871b-004dcac21205">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie611e2d28014400cb2d7774070bd6ea5_D20230102-20230402" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y180LTAtMS0xLTExNTYyNw_1e7f60b9-57fc-45f6-82f8-65087c8c9538">1.150% Notes Due November 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie611e2d28014400cb2d7774070bd6ea5_D20230102-20230402" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y180LTEtMS0xLTExNTYyNw_25eda0a7-bedf-4004-8002-ed09a69c3425">JNJ28</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie611e2d28014400cb2d7774070bd6ea5_D20230102-20230402" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y180LTItMS0xLTExNTYyNw_f5c0b587-b4ca-45af-9a45-37be3553b72a">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i56880e9c6bfe4b0985d48f5d5f70bb4f_D20230102-20230402" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y181LTAtMS0xLTExNTYyNw_58021816-de76-4b2b-9fcb-133b69a25d74">1.650% Notes Due May 2035</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i56880e9c6bfe4b0985d48f5d5f70bb4f_D20230102-20230402" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y181LTEtMS0xLTExNTYyNw_c7d58c82-68ea-49a0-ba5c-aa14e994885c">JNJ35</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i56880e9c6bfe4b0985d48f5d5f70bb4f_D20230102-20230402" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y181LTItMS0xLTExNTYyNw_68166a06-cada-4c56-8d53-de7181d532d1">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date.</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, <ix:nonFraction unitRef="shares" contextRef="ib8cdf2a1534245f6aaf14d9138fb6495_I20230421" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDAx_32ec39ff-1ee3-4fc7-8db9-45c27de232a6">2,598,734,075</ix:nonFraction> shares of Common Stock, $1.00 par value, were outstanding.</span></div><div style="margin-top:6pt;text-indent:15.75pt"><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_7"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_13">Part I &#8212; Financial Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_16">Item&#160;1. Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_19">Consolidated Balance Sheets &#8212; April 2, 2023 and January 1, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_25">Consolidated Statements of Earnings for the Fiscal First Quarters Ended April 2, 2023 and April 3, 2022</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_25">2</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_31">Consolidated Statements of Comprehensive Income for the Fiscal First Quarters Ended April 2, 2023 and April 3, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_31">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_37">Consolidated Statements of Equity for the Fiscal First Quarters Ended April 2, 2023 and April 3, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_37">4</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_43">Consolidated Statements of Cash Flows for the Fiscal Three Months Ended April 2, 2023 and April 3, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_43">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_46">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_46">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_103">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_103">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_106">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_106">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_109">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_109">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_112">Part II &#8212; Other Information</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_112">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_115">Item&#160;1 - Legal Proceedings</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_115">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_118">Item&#160;2 - Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_118">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_121">Item&#160;6 - Exhibits</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_121">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_124">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7c615dc7aec24dc98e6c850313251c4e_124">52</a></span></div></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="12" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7c615dc7aec24dc98e6c850313251c4e_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Johnson &amp; Johnson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s other publicly available documents contain </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forward-looking statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.&#160;Management and representatives of Johnson &amp; Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements do not relate strictly to historical or current facts and reflect management&#8217;s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;estimates,&#8221; and other words of similar meaning in conjunction with, among other things: discussions of future operations, expected operating results, financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives including associated cost savings and other benefits; the Company&#8217;s strategy for growth; product development activities; regulatory approvals; market position and expenditures.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company&#8217;s control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company&#8217;s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:</span></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Development, Market Success and Competition</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company&#8217;s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges to the Company&#8217;s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Increasingly aggressive and frequent challenges to the Company&#8217;s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Allegations that the Company&#8217;s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company&#8217;s ability to sell the products in question and require the payment of money damages and future royalties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Liability, Litigation and Regulatory Activity</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Compliance with local regulations and laws that may restrict the Company&#8217;s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union&#8217;s Medical Devices Regulation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Company&#8217;s Strategic Initiatives, Healthcare Market Trends and the Planned Separation of the Company&#8217;s Consumer Health Business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges to the Company&#8217;s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s ability to consummate the planned separation of the Company&#8217;s Consumer Health business on a timely basis or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company&#8217;s ability to successfully separate the Company&#8217;s Consumer Health business and realize the anticipated benefits from the planned separation; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The New Consumer Health Company&#8217;s ability to succeed as a standalone publicly traded company.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Economic Conditions, Financial Markets and Operating Internationally</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of global public health crises and pandemics;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes to global climate, extreme weather and natural disasters that could affect demand for the Company&#8217;s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company&#8217;s products and operations; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Supply Chain and Operations </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Interruptions and breaches of the Company&#8217;s information technology systems or those of the Company&#8217;s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company&#8217;s products; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. </span></div><div style="margin-bottom:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors also should carefully read the Risk Factors described in Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended January&#160;1, 2023, for a description of certain risks that could, among other things, cause the Company&#8217;s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7c615dc7aec24dc98e6c850313251c4e_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part&#160;I &#8212; FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1 &#8212; FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions Except Share and Per Share Data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:69.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Note 4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMy0yLTEtMS0xMTU2Mjc_5aad73a8-b90a-42ba-a44c-20c5fae1e24d">19,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMy00LTEtMS0xMTU2Mjc_145874ab-ae6d-497a-a419-e9dc015a48b7">14,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNC0yLTEtMS0xMjQyMDA_ecf5e242-e382-4e52-8310-e9e9e6569f0a">7,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNC00LTEtMS0xMjcwMzc_a46ecc80-223b-4221-bc00-c3ecc7724ac2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNC0yLTEtMS0xMTU2Mjc_0a00285c-bd7a-489e-b4bd-483333177105">5,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNC00LTEtMS0xMTU2Mjc_de8e4270-2fa5-4a87-a3ba-38eafb0b7d3a">9,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, trade, less allowances $<ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNS0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjpiMDQ5MTA2NTE5YjM0MzNiYWU4Mjc3MDI1NTFkMTE5M180OA_55b216c1-27b8-49ed-8413-eb46124e338e">207</ix:nonFraction> (2022, $<ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNS0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjpiMDQ5MTA2NTE5YjM0MzNiYWU4Mjc3MDI1NTFkMTE5M181OA_56943255-a018-413f-8f0a-67fb3bbfaf26">203</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNS0yLTEtMS0xMTU2Mjc_814dc276-451a-4806-9e4e-4fe8bc22885b">16,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNS00LTEtMS0xMTU2Mjc_1050177d-90e5-4285-ae5e-6540a9d859c6">16,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (Note 2)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNi0yLTEtMS0xMTU2Mjc_b345ff66-3893-4771-8305-006e8a33e369">12,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNi00LTEtMS0xMTU2Mjc_e28701ca-b580-4661-8024-b63acf8f662a">12,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNy0yLTEtMS0xMTU2Mjc_d942afd9-14b0-4680-acc2-b312a95c916c">2,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNy00LTEtMS0xMTU2Mjc_906a2075-af82-4900-a79c-9f197d5617de">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfOS0yLTEtMS0xMTU2Mjc_564e9bbf-d492-4d39-a483-55d142527423">64,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfOS00LTEtMS0xMTU2Mjc_c3b67f49-d536-473b-8145-b1760d437c89">55,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment at cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTAtMi0xLTEtMTE1NjI3_de657ac4-b8ec-4f3f-9997-685054e8952c">50,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTAtNC0xLTEtMTE1NjI3_31224f38-8aa9-4c57-b123-14e9dd6dcd22">49,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTEtMi0xLTEtMTE1NjI3_5c90e248-e631-4d3c-ae84-22a0af203c9d">30,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTEtNC0xLTEtMTE1NjI3_07900aba-a393-416c-83f5-0bbd4478d4c8">29,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTItMi0xLTEtMTE1NjI3_a1bdf784-47de-46c7-a2b3-d7556a93aebf">20,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTItNC0xLTEtMTE1NjI3_a629aebc-b851-40a5-b31f-6032ece8a158">19,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net (Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTMtMi0xLTEtMTE1NjI3_8a8474dd-73ba-47d1-8832-e95f86b66e2c">47,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTMtNC0xLTEtMTE1NjI3_9947635d-c313-478c-acdd-88ebcf262c97">48,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTQtMi0xLTEtMTE1NjI3_608eaf9f-698b-4ceb-8db5-3c9d12d0a60f">45,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTQtNC0xLTEtMTE1NjI3_dd3c8591-09e0-4598-9738-0c9d69a215ab">45,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTUtMi0xLTEtMTE1NjI3_27276647-346d-49ff-951b-e97d83927823">8,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTUtNC0xLTEtMTE1NjI3_15e8ad4a-1a9f-4d25-ad28-6de0f1a9062a">9,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTYtMi0xLTEtMTE1NjI3_77e13e3a-286a-48b3-a55d-fefa1e47591d">9,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTYtNC0xLTEtMTE1NjI3_dd79c3b9-0825-4971-b56a-7400711cc183">9,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTctMi0xLTEtMTE1NjI3_91bda055-a32b-46a9-a5a2-5f826d9d94d1">195,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTctNC0xLTEtMTE1NjI3_f8d6f0bd-0871-4edf-a8e2-1a6de1207a7a">187,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans and notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjAtMi0xLTEtMTE1NjI3_e7ec3fb0-10f4-4ccd-a8f8-471939f9d8e8">17,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjAtNC0xLTEtMTE1NjI3_454990ca-5198-4c8a-acea-6ae064e1287f">12,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjEtMi0xLTEtMTE1NjI3_b4fbef45-1ef8-4db9-ad8e-c12421946fc7">9,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjEtNC0xLTEtMTE1NjI3_f6530810-9ce9-4205-a7ad-81e23cb9b339">11,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjItMi0xLTEtMTE1NjI3_7e18d627-8009-4d68-a181-391e934ee8e5">11,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjItNC0xLTEtMTE1NjI3_54f4c8f9-9d3a-4da2-a1bd-fcee027cba0e">11,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, returns and promotions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjMtMi0xLTEtMTE1NjI3_8dada9af-7c51-4aba-9e0a-09605e550260">14,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjMtNC0xLTEtMTE1NjI3_6ff8d247-8804-459b-b081-f9c79f8b8da7">14,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjQtMi0xLTEtMTE1NjI3_92ae07e9-9838-4d39-bbc2-6ffd922380e5">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjQtNC0xLTEtMTE1NjI3_a7339738-74cf-45e3-abec-a911c903d9e7">3,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjUtMi0xLTEtMTE1NjI3_2f9f30dc-0852-485c-a82a-86d2727a9787">4,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjUtNC0xLTEtMTE1NjI3_6c8427c5-bc58-4218-96c8-9a03e55a40d3">2,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjYtMi0xLTEtMTE1NjI3_9ac6dddc-a517-420f-a2e6-ef81e291cb42">60,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjYtNC0xLTEtMTE1NjI3_a98a4bbe-e0ff-4e7f-9ec7-43b21ac36c45">55,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note 4)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjctMi0xLTEtMTE1NjI3_0af59aa7-1ac8-42ce-a658-4e7eecd8d641">34,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjctNC0xLTEtMTE1NjI3_078eb6ac-558d-4fbd-b209-5a8aa332c0d7">26,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjgtMi0xLTEtMTE1NjI3_af54a401-5216-451b-98aa-e76935d28876">4,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjgtNC0xLTEtMTE1NjI3_9458ccfb-7fe9-4d1c-a521-a08c719ef8aa">6,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations (Note 6)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjktMi0xLTEtMTE1NjI3_8a8a9148-0ef4-4db3-8c9d-d8bd3a26ca6c">6,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjktNC0xLTEtMTE1NjI3_df5e0aa4-fff2-453d-8cca-34a984661819">6,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term taxes payable (Note 5)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzAtMi0xLTEtMTE1NjI3_281d3b4a-313a-4123-8a6d-8bb70a32a539">4,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzAtNC0xLTEtMTE1NjI3_c023e2e6-ad98-442c-82b1-fdd108af85e7">4,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzEtMi0xLTEtMTE1NjI3_578d5885-05e7-41e4-8a22-e91ca16bb927">14,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzEtNC0xLTEtMTE1NjI3_c34dbe7a-4a4b-436e-9643-860831481c96">10,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzItMi0xLTEtMTE1NjI3_3dad61ae-4a6f-46c1-a8bc-7fdfd7a07666">125,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzItNC0xLTEtMTE1NjI3_e0f51d97-278d-4276-bf3c-9adf55bd6ae5">110,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 11)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzMtMi0xLTEtMTE1NjI3_3ba747e3-df38-450d-98b6-47509d9ce5da"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzMtNC0xLTEtMTE1NjI3_76c636b6-b045-402b-8dcc-ea2621a13c8a"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock &#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzVlOThhMDQzNGNhNDU0Mzg0MDNhZTkxODY1N2QwMTJfMjk_44b92829-ec6b-4f84-93e4-3a224711e25d"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzVlOThhMDQzNGNhNDU0Mzg0MDNhZTkxODY1N2QwMTJfMjk_5f1c6257-4638-43f0-bff9-a0efeb5bc492">1.00</ix:nonFraction></ix:nonFraction> per share (authorized <ix:nonFraction unitRef="shares" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzVlOThhMDQzNGNhNDU0Mzg0MDNhZTkxODY1N2QwMTJfNTQ_532d13be-e601-4ec0-bfce-b751e130bf64"><ix:nonFraction unitRef="shares" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzVlOThhMDQzNGNhNDU0Mzg0MDNhZTkxODY1N2QwMTJfNTQ_89d134f1-e716-45b3-878c-33e6a984ea03">4,320,000,000</ix:nonFraction></ix:nonFraction> shares; issued <ix:nonFraction unitRef="shares" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzVlOThhMDQzNGNhNDU0Mzg0MDNhZTkxODY1N2QwMTJfNzI_27b2816f-24ff-4ed0-ae6b-51c651476e16"><ix:nonFraction unitRef="shares" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzVlOThhMDQzNGNhNDU0Mzg0MDNhZTkxODY1N2QwMTJfNzI_a496a3ba-5462-45a4-b8db-dce11eceea4c">3,119,843,000</ix:nonFraction></ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMi0xLTEtMTE1NjI3_a6c6acb3-a4e0-45f4-8926-a9651443982a">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtNC0xLTEtMTE1NjI3_a257f877-5db9-4a6c-ab97-9e3111cc4fe7">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss) (Note 7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzYtMi0xLTEtMTE1NjI3_d36221d9-d1d6-4d6a-a2fc-df1feb0aa019">12,626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzYtNC0xLTEtMTE1NjI3_bbad7828-7ec0-4276-9f51-cfecc17f0e0c">12,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings and Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzctMi0xLTEtMTE1NjI3_0f62f0af-4572-4b05-9e86-203d51a1e510">124,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzctNC0xLTEtMTE1NjI3_c36424bf-456a-40e4-b5fd-b259d3e16263">128,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: common stock held in treasury, at cost (<ix:nonFraction unitRef="shares" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzgtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZmYyM2Y3MzM4NGI5NDAyZWI5Mzk2ZDlkNTI5YzU5NGJfNTA_6081d911-df64-4b47-8c0b-b1bdffb70639">521,519,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzgtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZmYyM2Y3MzM4NGI5NDAyZWI5Mzk2ZDlkNTI5YzU5NGJfNTc_cb7c8671-04f5-4300-bf0a-f85870ce9d7a">506,246,000</ix:nonFraction> shares)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzgtMi0xLTEtMTE1NjI3_20b7e6ea-8f6e-4eaa-bbe5-6804262319d4">44,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzgtNC0xLTEtMTE1NjI3_84e970d5-0575-4f05-b499-f0f7c1d9e820">41,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzktMi0xLTEtMTE1NjI3_95431654-4209-4cbb-aa09-c62c15c148be">70,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzktNC0xLTEtMTE1NjI3_1b93f708-4d5f-4673-982a-0cff89eebfa6">76,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNDAtMi0xLTEtMTE1NjI3_3722aa7a-776e-4e6b-a610-424833edf066">195,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNDAtNC0xLTEtMTE1NjI3_b42e0c7d-884a-4600-92cc-7a080932ce90">187,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i7c615dc7aec24dc98e6c850313251c4e_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EARNINGS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars &amp; Shares in Millions Except Per Share Amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:54.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.752%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.756%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>to Sales</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMi0yLTEtMS0xMTU2Mjc_a1fd8204-3d8d-47e2-a1a0-a0871772ba71">24,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMi00LTEtMS0xMTU2Mjc_8dc0f6ab-2334-41a5-93ad-1776e71495b0">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMi02LTEtMS0xMTU2Mjc_0a892fea-f6c8-4379-897e-462f7d89dcd1">23,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" name="jnj:SalesRevenueGoodsNetPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMi04LTEtMS0xMTU2Mjc_99a9c4e7-ff53-467c-9e70-c796f48e973c">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMy0yLTEtMS0xMTU2Mjc_c0c5f715-2673-4e1e-8281-c609d890aeaf">8,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMy00LTEtMS0xMTU2Mjc_568b0478-efd4-4fe2-9ee0-e2143e5396d2">33.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMy02LTEtMS0xMTU2Mjc_ae41a72a-d421-446d-9e61-9c1558fef673">7,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" name="jnj:CostOfGoodsSoldPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMy04LTEtMS0xMTU2Mjc_546a037e-b455-4706-89ba-bc9ef6b7ec22">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNC0yLTEtMS0xMTU2Mjc_1cac9543-e8f4-4307-ad48-c8ebe64c47d5">16,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNC00LTEtMS0xMTU2Mjc_f7476e01-c7b9-47b3-b251-abc9f9015733">66.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNC02LTEtMS0xMTU2Mjc_2fbc5f2a-24e3-49ec-8302-cbd072ee126a">15,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" name="jnj:GrossProfitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNC04LTEtMS0xMTU2Mjc_d7a10c85-4c4b-4e4a-81f1-4b6eb9365aeb">67.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNS0yLTEtMS0xMTU2Mjc_91d2e874-f85b-4503-9a97-7ab28c041cab">6,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNS00LTEtMS0xMTU2Mjc_4c304f41-0f40-45bf-b546-e5180d030673">24.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNS02LTEtMS0xMTU2Mjc_516d39ec-2be8-42d3-8548-cedafd03ffac">5,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" name="jnj:SellingGeneralAndAdministrativeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNS04LTEtMS0xMTU2Mjc_842044d4-cbdd-4748-a543-1f50bbc11759">25.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNi0yLTEtMS0xMTU2Mjc_7cfc36da-1a63-4f4a-a7a2-3ec9686a861a">3,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNi00LTEtMS0xMTU2Mjc_f4f01882-f233-4e43-8b4b-913011f4390b">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNi02LTEtMS0xMTU2Mjc_84879e78-9332-4a24-9a7b-b6997f280afb">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" name="jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNi04LTEtMS0xMTU2Mjc_c61735e9-2584-439d-86e2-f2a658ff16cc">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNy0yLTEtMS0xMTU2Mjc_192c5ca0-5ed0-444d-975d-44325f7a918e">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNy00LTEtMS0xMTU2Mjc_94e7cc2d-736d-4652-812a-7ce6c8635dd5">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNy02LTEtMS0xMTU2Mjc_5cdae3a7-ad61-4b66-88e8-343598a3ee24">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" name="jnj:ResearchAndDevelopmentInProcessPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNy04LTEtMS0xMTU2Mjc_daa3b9d0-f22d-4f69-8f27-9153a553b66d">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOC0yLTEtMS0xMTU2Mjc_db573efd-6a09-4de0-b95d-b4b820fa6305">235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOC00LTEtMS0xMTU2Mjc_1332e234-5814-4694-a7d2-b65befdf9043">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOC02LTEtMS0xMTU2Mjc_34d9ef9d-3c19-45cc-a998-912aff7f8e1c">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" sign="-" name="jnj:InvestmentIncomeInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOC04LTEtMS0xMTU2Mjc_a4afe8a4-db2f-48b5-b473-34a2141ee286">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of portion capitalized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOS0yLTEtMS0xMTU2Mjc_933dd26c-fd62-47b2-b6fc-0e73e761e171">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOS00LTEtMS0xMTU2Mjc_cbb441ec-04d6-4ced-b466-c63577d74271">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOS02LTEtMS0xMTU2Mjc_3ec1f080-f776-4fa0-b805-03c911b7270a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" name="jnj:InterestExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOS04LTEtMS0xMTU2Mjc_adff735d-3745-432c-80a4-b4ea03c2fb77">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTAtMi0xLTEtMTE1NjI3_831b4190-cbc5-4aef-879f-51e78900b517">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTAtNC0xLTEtMTE1NjI3_a37b069c-363a-4aa4-b8bf-38852ca4aa2c">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTAtNi0xLTEtMTE1NjI3_b10e0fb1-ed6e-43d6-8bb8-0a99ae6b5619">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" sign="-" name="jnj:OtherNonOperatingIncomeExpensePercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTAtOC0xLTEtMTE1NjI3_bff76057-59ba-45c7-9b85-9f955f7b9c30">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTEtMi0xLTEtMTE1NjI3_65ae8550-7005-4070-a809-b587628fbb77">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTEtNC0xLTEtMTE1NjI3_c67c786d-347a-49fc-a1da-d7385af3486a">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTEtNi0xLTEtMTE1NjI3_ab4bdb4f-4058-4fbf-9cfd-d05b0c7fce0d">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" name="jnj:Restructuringchargepercenttosales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTEtOC0xLTEtMTE1NjI3_87d5a81f-cdf7-41a2-a618-6ff02d7db57c">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings/(Loss) before provision for taxes on income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTItMi0xLTEtMTE1NjI3_f3fd8102-dce4-4af5-820a-653c43045475">737</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" sign="-" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTItNC0xLTEtMTE1NjI3_4b57a49c-b829-41f3-aa4e-f4ebc19a2b5a">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTItNi0xLTEtMTE1NjI3_9fefaae0-a771-43b8-b83d-cccacf960d54">5,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" name="jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTItOC0xLTEtMTE1NjI3_09e83d52-58ff-45cb-8dfe-873e2c6d8356">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for/(Benefit from) taxes on income (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTMtMi0xLTEtMTE1NjI3_94e51dbb-682f-47a7-a4f0-55a5ac14c44e">669</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" sign="-" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTMtNC0xLTEtMTE1NjI3_a29bff19-bcb1-474c-b5e7-552ef7f4c2ab">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTMtNi0xLTEtMTE1NjI3_7562326d-e330-44fb-a4a6-068c8d8a1eeb">713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" name="jnj:IncomeTaxExpenseBenefitPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTMtOC0xLTEtMTE1NjI3_80e6372d-22be-470b-841a-4c4c8f06d7f3">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS/(LOSS) </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTQtMi0xLTEtMTE1NjI3_da6c6efd-d385-41f9-b96e-ebd0677c6aab">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" sign="-" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTQtNC0xLTEtMTE1NjI3_44657d72-ac0a-4ef7-a927-0718e0b9a506">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTQtNi0xLTEtMTE1NjI3_8ba2a07a-d61d-4d36-8fa1-af09ea87f4b5">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" name="jnj:NetIncomeAttributableToParentPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTQtOC0xLTEtMTE1NjI3_01f102af-72d6-41b9-8d4f-cf8d2fcbc2b5">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET EARNINGS/(LOSS) PER SHARE (Note 8)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTctMi0xLTEtMTE1NjI3_e53e200b-326e-44d6-bafd-0989b8dfccc2">0.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTctNi0xLTEtMTE1NjI3_60788230-2698-43d8-9b77-656a05e5be1f">1.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTgtMi0xLTEtMTE1NjI3_588cbd4f-dd03-44a2-a253-ca05e0f716ce">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTgtNi0xLTEtMTE1NjI3_7065b02f-c48b-4714-87dd-4cbc57559917">1.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AVG. SHARES OUTSTANDING</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMjEtMi0xLTEtMTE1NjI3_dc565ae9-f6cf-4068-92b6-b532ae9d482f">2,605.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMjEtNi0xLTEtMTE1NjI3_9c75adca-2a1c-474e-82d3-876cbbec29b1">2,629.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMjItMi0xLTEtMTE1NjI3_2122c920-d92c-4823-b6da-68fa325de703">2,605.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMjItNi0xLTEtMTE1NjI3_ff5f9fc3-3d05-4975-9611-2ce7c649b974">2,666.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i7c615dc7aec24dc98e6c850313251c4e_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.900%"><tr><td style="width:1.0%"></td><td style="width:59.166%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.323%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMy0xLTEtMS0xMTU2Mjc_13a2f8e0-70c8-47f9-a8be-02db92ca6d46">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMy0zLTEtMS0xMTU2Mjc_aa6e6b29-5428-47ab-a7d0-633ba97d6a45">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfNi0xLTEtMS0xMTU2Mjc_94ac46ef-8bd9-41bb-8953-ad9005602a79">181</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfNi0zLTEtMS0xMTU2Mjc_b2017a4e-0d1b-4ad0-873f-480b4657850e">554</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized holding gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfOS0xLTEtMS0xMTU2Mjc_8792324b-b659-475f-8009-df48008dd4ab">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfOS0zLTEtMS0xMTU2Mjc_d6e28a5b-cba4-433b-ac37-051f919bd4ed">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTAtMS0xLTEtMTE1NjI3_ec85537c-9021-4f44-bf14-eaa6a20017ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTAtMy0xLTEtMTE1NjI3_276a932c-3f5e-4fc9-bf69-21e509cdd705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTItMS0xLTEtMTE1NjI3_a9ad79fd-5b0a-4da0-9754-6a7507a0527a">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTItMy0xLTEtMTE1NjI3_6bc8c2e9-b389-494a-93aa-a6dfc977bbb8">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Prior service cost amortization during period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTUtMS0xLTEtMTE1NjI3_802df04b-368a-44d1-8c3d-ae1b416c48a1">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTUtMy0xLTEtMTE1NjI3_c58067b1-d76f-4300-aafa-8cdc8cbdff90">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Gain (loss) amortization during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTYtMS0xLTEtMTE1NjI3_6c217c72-ed6e-4a0c-bb24-512d09091cde">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTYtMy0xLTEtMTE1NjI3_3475b006-03a2-4f8f-adff-54b0ae36b62b">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTgtMS0xLTEtMTE1NjI3_c037d64f-9385-48c5-9cb3-58be85dbc72c">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTgtMy0xLTEtMTE1NjI3_407b3a20-af8c-49af-9321-8060d8459dd5">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivatives &amp; hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjEtMS0xLTEtMTE1NjI3_001ceda9-b261-46c8-b383-b78a17f16882">570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjEtMy0xLTEtMTE1NjI3_65e41ba1-39de-43c2-b13b-c981052d5455">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjItMS0xLTEtMTE1NjI3_9a402cef-4f5c-4eff-9736-93c1a1653761">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjItMy0xLTEtMTE1NjI3_ab53f1e3-3c4e-4eb0-bf58-154a0589af12">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjMtMS0xLTEtMTE1NjI3_e19e26f0-e907-489b-a258-69cf6f2ab6dd">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjMtMy0xLTEtMTE1NjI3_9ae03bc5-085d-4c7b-a37a-21a5755ff220">296</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjUtMS0xLTEtMTE1NjI3_bb505917-eb7c-4683-a909-df2e4f3a7854">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjUtMy0xLTEtMTE1NjI3_fa507cdb-bc36-451d-8c18-a4ed0c86a4e9">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjctMS0xLTEtMTE1NjI3_341669c3-0b7d-4210-9b5c-43bf172d842e">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjctMy0xLTEtMTE1NjI3_3c89cd55-d5fb-4d95-a261-5b739505011d">4,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The tax effects in other comprehensive income/(loss) for the fiscal first quarter were as follows for 2023 and 2022, respectively: Foreign Currency Translation: $<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8xNTk_19ca06ad-ffe7-4a28-968c-cb15913ce49e">234</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8xNzQ_3af7c6e0-2018-4849-bf5f-65b69453813a">145</ix:nonFraction> million; Securities: $<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8yMTk5MDIzMjU1ODc0_2d97c914-0286-4fe8-aed2-dcdee223bbf6">5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8yMTk5MDIzMjU1ODgy_9b9c6fc9-c557-4cd6-8f24-712224403c6c">3</ix:nonFraction> million; Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8yMTE_17f95772-5a5b-4636-ab24-3104e629f396">22</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8yMjc_167cf3d8-1fa6-4a71-b912-df122a625d44">19</ix:nonFraction> million; Derivatives &amp; Hedges: $<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8yNjI_6090b566-a4ba-4f7f-b02f-06db84d01c5d">154</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8yNzg_4fa27d37-c233-49cc-957c-cd54ecd8d421">78</ix:nonFraction> million.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i7c615dc7aec24dc98e6c850313251c4e_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal First Quarter Ended April&#160;2, 2023 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings and Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, January 1, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMS0xLTEtMS0xMTU2Mjc_2b758979-3206-47c6-8ab1-a974cc05ee7c">76,804</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2188b6c0f7514c949842cbb0fdfabbab_I20230101" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMS0zLTEtMS0xMTU2Mjc_0b9aa358-76f7-4608-a597-ea5f324002f7">128,345</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77ff9cf53ba540b9a5e6aeca7ca5804f_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMS01LTEtMS0xMTU2Mjc_0bf36ed3-c1b4-4b0a-8899-4e38524fb6d7">12,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e69e8dd1c3d465ea6435891bf59621c_I20230101" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMS03LTEtMS0xMTU2Mjc_59b55e12-514d-4384-9ede-c67f82d26b6b">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb53f128b06d4aba845d354b0be0e42a_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMS05LTEtMS0xMTU2Mjc_0a6b8149-5e0c-44fe-b290-e2167ac7f8a4">41,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMi0xLTEtMS0xMTU2Mjc_aee416cf-ea64-4597-9572-c84ace4bfb27">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b3fd2b8861e424999c7010d105bfd21_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMi0zLTEtMS0xMTU2Mjc_5e56f31c-3dc1-448c-8bee-a90488c3a563">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMy0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo3NDg2YWVmMTM4NWU0ZTgyOWE5ODc2ZDJhNTcwYTU2NV8yNg_d35dcb9a-18b4-44b9-bad9-bc916cd53252">1.13</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMy0xLTEtMS0xMTU2Mjc_f9d8c029-694e-46b3-84fb-1e3018c3ef69">2,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b3fd2b8861e424999c7010d105bfd21_D20230102-20230402" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMy0zLTEtMS0xMTU2Mjc_273576c3-fd8f-411c-9434-73558488bc2f">2,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNC0xLTEtMS0xMTU2Mjc_78ff70eb-c666-4cb8-82ce-88778a905bb7">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b3fd2b8861e424999c7010d105bfd21_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNC0zLTEtMS0xMTU2Mjc_44f147be-813e-4209-ade3-f7fe775c7f35">777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a21dc14a504f8ea99bb332930384c0_D20230102-20230402" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNC05LTEtMS0xMTU2Mjc_58750e59-f13e-4470-accf-3a6a4bb4c7f1">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNS0xLTEtMS0xMTU2Mjc_eeaa95d5-3949-4f67-8594-8232d8622f8c">3,537</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6a21dc14a504f8ea99bb332930384c0_D20230102-20230402" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNS05LTEtMS0xMTU2Mjc_fa305c1d-f5ee-4e40-8797-0ccce7e0c260">3,537</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNi0xLTEtMS0xMTU2Mjc_98051648-49df-4932-b47b-ed00e6e9b4c9">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6a21dc14a504f8ea99bb332930384c0_D20230102-20230402" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNi05LTEtMS0xMTU2Mjc_602e5468-efd7-4082-951e-45fd0432c5ed">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNy0xLTEtMS0xMTU2Mjc_0cbf2311-d9bb-49ea-8fc7-9952170d527e">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4da4c2095b244be8c3cc67e88df5d15_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNy01LTEtMS0xMTU2Mjc_3588fc4f-a5a5-4278-ae65-fffc7747f53c">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, April 2, 2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfOC0xLTEtMS0xMTU2Mjc_e6ff43b4-c2f1-43b7-a3ef-ad660dcc525e">70,869</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5578ef4542b444f5ac1a50c33d446bb1_I20230402" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfOC0zLTEtMS0xMTU2Mjc_7025d2b4-7981-485f-a40b-f1d16ca80028">124,558</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i455ec88d396c41248d806ba599269e74_I20230402" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfOC01LTEtMS0xMTU2Mjc_01c1e336-9f5b-4318-a7b4-6a7058946eb9">12,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09e8821bbba242a6923019b0a460d64e_I20230402" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfOC03LTEtMS0xMTU2Mjc_caf137e9-9369-48fe-a396-4d110101816b">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifab9bbc2a1a94a03a0a926fea40d151c_I20230402" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfOC05LTEtMS0xMTU2Mjc_c8d8cae7-ae91-40dc-859a-372068d9e825">44,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:38.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.037%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal First Quarter Ended April&#160;3, 2022 </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:37.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.860%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.478%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings and Additional paid-in capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, January 2, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6ce94080c14bf3947a9c53d1a7596d_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMS0xLTEtMS0xMTU2Mjc_fd34f429-a521-4e86-9188-0800ada848fe">74,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d9051e5238a4ac9baecaaf4941dc3a4_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMS0zLTEtMS0xMTU2Mjc_3ff579d7-d036-401d-8759-e89905f110a3">123,060</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e2d68ed978242baaa348359c8c9ca9a_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMS01LTEtMS0xMTU2Mjc_9d32dc00-65a1-4feb-8025-a546f208b59b">13,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fcc13d384f4330aec9188cab3a6947_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMS03LTEtMS0xMTU2Mjc_d7706a05-6d6a-4a6a-93a3-19be71d4ed2c">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96bae56901ee43a5b70044963ee0eb2f_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMS05LTEtMS0xMTU2Mjc_01249eb9-950b-4211-818e-27930eea0234">39,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMy0xLTEtMS0xMTU2Mjc_3edbe23e-65dc-489a-8e4d-ed9bbebcd9af">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5ba501b50bc44c68b5053ecd96d9a08_D20220103-20220403" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMy0zLTEtMS0xMTU2Mjc_5a59831a-8f45-4b15-a8c0-37fc2d222277">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjoxNTUwYWRiYTM1MmI0OTRlYjJhNjcwMWUyMDFhOWZjZF8yNg_85a3d7dc-7b1d-41ab-8484-7bb7f76fac51">1.06</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNC0xLTEtMS0xMTU2Mjc_ca25697b-88d2-4619-bcaa-429a3e0868ea">2,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5ba501b50bc44c68b5053ecd96d9a08_D20220103-20220403" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNC0zLTEtMS0xMTU2Mjc_9de2080d-7177-4211-9203-37daacc03eb6">2,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNS0xLTEtMS0xMTU2Mjc_2bcab640-b0ee-4078-82d9-0616a085bc28">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5ba501b50bc44c68b5053ecd96d9a08_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNS0zLTEtMS0xMTU2Mjc_f4c99356-c0a7-4557-8361-168b0764ae58">1,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f1e92fdb7cb435b85c3f0ef4f00add4_D20220103-20220403" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNS05LTEtMS0xMTU2Mjc_8438ab4b-4015-4647-a786-042e7ec1245f">1,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNi0xLTEtMS0xMTU2Mjc_87179f73-a8f4-4f03-877b-8c8b4969eb30">1,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f1e92fdb7cb435b85c3f0ef4f00add4_D20220103-20220403" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNi05LTEtMS0xMTU2Mjc_5528a6c9-b457-4819-b14d-4d72b185839c">1,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOC0xLTEtMS0xMTU2Mjc_9df71788-a69c-4736-9bcd-cd961f41c824">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaae68b8ec38442eab92d9dc3b0260cd9_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOC01LTEtMS0xMTU2Mjc_b698e049-84f1-4575-848c-dcf130c4e935">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, April 3, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047e4a043e444bcba72ba4e9efc5393a_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOS0xLTEtMS0xMTU2Mjc_e0a279d3-5040-4826-829c-b2f82f52c231">74,709</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8919e9f61f8f44749d28698f8da6d82c_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOS0zLTEtMS0xMTU2Mjc_bff2e78f-7a7a-48df-bf7b-83a50bb04540">124,380</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5c9ee590fe74fbea7151627b39b194d_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOS01LTEtMS0xMTU2Mjc_ede161d6-533d-4428-b061-39ced556515e">13,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06bfeb1f5de646c1882f0ac3995b15aa_I20220403" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOS03LTEtMS0xMTU2Mjc_d2fb9334-ea99-48c6-8693-2b82a28ad1ac">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1a577429d7543cb917887d15b2934a5_I20220403" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOS05LTEtMS0xMTU2Mjc_f26a0dc9-7c8f-4c62-9b4f-2019b3cf4eab">39,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.993%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:13pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i7c615dc7aec24dc98e6c850313251c4e_43"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited; Dollars in Millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:76.319%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal Three Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss)/earnings </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMy0yLTEtMS0xMTU2Mjc_8d239e29-58d3-42b1-a1b8-6ddb0c8a5457">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMy00LTEtMS0xMTU2Mjc_a49e197e-fd32-4d20-ac33-cc5b33f348bf">5,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization of property and intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNS0yLTEtMS0xMTU2Mjc_089e4661-6de0-4d2f-85a4-307616850cdb">1,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNS00LTEtMS0xMTU2Mjc_754aad8e-917d-4fa7-9824-d6ded2606ad1">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNi0yLTEtMS0xMTU2Mjc_693bf459-b92d-443c-aa38-a72f19b346da">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNi00LTEtMS0xMTU2Mjc_e3c14f5c-a12d-4362-8585-59de61939179">278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset write-downs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfOS0yLTEtMS0xMTU2Mjc_1cefa27a-d032-44fb-b940-7f427c17f8b7">426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfOS00LTEtMS0xMTU2Mjc_f486c9fc-df8a-49e6-8f53-3c25bab93afd">610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sale of assets/businesses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTEtMi0xLTEtMTE1NjI3_c4bd34c6-84d8-440d-86c5-a1da64bc84b4">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTEtNC0xLTEtMTE1NjI3_e4380841-2d4e-4bd8-85db-e4db5cd99444">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTMtMi0xLTEtMTE1NjI3_9e1f190b-09e4-4bd3-8787-9ff8971b63d4">1,543</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTMtNC0xLTEtMTE1NjI3_08fcaf0a-208c-4905-9d02-874ebbeaf6bb">926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit losses and accounts receivable allowances </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTQtMi0xLTEtMTE1NjI3_6e59e9d5-2fed-4b02-b273-885da34e9ac7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTQtNC0xLTEtMTE1NjI3_8e0e8325-585a-4f69-886d-979cb4127761">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTYtMi0xLTEtMTE1NjI3_84e5c9f1-25d2-4042-a2ad-af95f6b35b60">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTYtNC0xLTEtMTE1NjI3_c56a6ce9-afe1-4b0a-bf53-19660e963c60">427</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTctMi0xLTEtMTE1NjI3_f3374c9b-67b7-4d40-912d-b28e2293a7b4">524</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTctNC0xLTEtMTE1NjI3_49686c4a-be33-4f26-a8d3-41b7bd25c8b6">600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in accounts payable and accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTgtMi0xLTEtMTE1NjI3_1e30deac-27c2-4ddc-9ab7-afbf0e9d28f1">2,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTgtNC0xLTEtMTE1NjI3_760a1f60-15ae-415a-a7c3-5a8624ac821e">2,817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase)/Decrease in other current and non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTktMi0xLTEtMTE1NjI3_bfe91b1b-d8e2-4e13-8d6f-a024f2777791">915</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTktNC0xLTEtMTE1NjI3_a71b24ce-1d4e-41e0-b21f-503cb556710f">995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase in other current and non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjAtMi0xLTEtMTE1NjI3_e6f3c7de-3c6e-4a32-9a9f-005636ad7f56">6,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjAtNC0xLTEtMTE1NjI3_ef397aa4-7523-4d35-8189-db68ff0ea1e7">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH FLOWS FROM OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjItMi0xLTEtMTE1NjI3_88aa319b-9e56-4a2b-86bc-41c18287f26f">3,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjItNC0xLTEtMTE1NjI3_46a2de79-78c7-4919-99eb-6de642ec40d2">3,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions to property, plant and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjUtMi0xLTEtMTE1NjI3_d97c8c36-7e75-4853-8f47-91bcc55d1a26">863</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjUtNC0xLTEtMTE1NjI3_cf9adfee-a46b-4c61-82bd-1ab3614342c8">607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the disposal of assets/businesses, net (Note 10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjYtMi0xLTEtMTE1NjI3_1b4cbc2c-1f99-40fb-8984-13f5895677e4">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjYtNC0xLTEtMTE1NjI3_2ae2b647-b668-4fca-abe1-6dce4d10686a">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjctMi0xLTEtMTE1NjI3_b95ce2e8-b6af-45b6-bec9-5f15fe5472f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjctNC0xLTEtMTE1NjI3_0679aa95-6c1a-4b5c-8c77-f2c1d3ef0414">252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjgtMi0xLTEtMTE1NjI3_1d18be87-ab65-4dda-818b-45ff15c0f211">3,774</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjgtNC0xLTEtMTE1NjI3_59479393-4b2a-4103-b846-99a9fb08f589">9,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjktMi0xLTEtMTE1NjI3_82d501e7-904b-4ea2-b370-f8c5afb357d1">7,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjktNC0xLTEtMTE1NjI3_9ea04da5-1995-4f63-b9ee-77dd7000e413">6,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzAtMi0xLTEtMTE1NjI3_7c6adeb4-28f7-4aaf-8408-1efba8385e16">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzAtNC0xLTEtMTE1NjI3_1c4aa5b6-ebbd-4044-8fcb-804c4e8cea79">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (primarily licenses and milestones)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzEtMi0xLTEtMTE1NjI3_c4349d4a-50af-4d9b-a874-8b7e3da40bc0">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzEtNC0xLTEtMTE1NjI3_dce94209-f5c5-4423-aeb2-effc1049d4be">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH FROM/(USED BY) INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzMtMi0xLTEtMTE1NjI3_9faf80ff-a278-4e66-8041-948dc1ef8581">3,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzMtNC0xLTEtMTE1NjI3_b450d352-bb9b-4984-a23d-b6113fb88a27">3,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzYtMi0xLTEtMTE1NjI3_a2f2a6da-527d-4df4-9291-83179c1fe497">2,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzYtNC0xLTEtMTE1NjI3_496250ec-d533-458d-92e1-b4dc169f05db">2,787</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzctMi0xLTEtMTE1NjI3_bb054f93-178f-492e-bd25-98ed5b3abffe">3,537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzctNC0xLTEtMTE1NjI3_2263a5b3-f0e6-4233-a18e-db45cd9e5a84">1,577</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzgtMi0xLTEtMTE1NjI3_a97edcbe-95b9-46a8-a434-42cb6a3b55c4">11,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzgtNC0xLTEtMTE1NjI3_cb59832e-cdc4-4e9b-8bc9-30268ec7d25b">3,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzktMi0xLTEtMTE1NjI3_441779ee-1d17-4ea5-8675-306a3b41d64b">5,388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzktNC0xLTEtMTE1NjI3_09014788-572d-475f-b6e9-f619bcc760e2">856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net of issuance costs (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDAtMi0xLTEtMTE1NjI3_9f594440-9d19-48e6-b14f-bd01125aac82">7,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDAtNC0xLTEtMTE1NjI3_4a947199-2d61-40e8-a050-c4643df468bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDEtMi0xLTEtMTE1NjI3_435461a8-f7f0-414e-aef2-ecd618d6d1d3">500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDEtNC0xLTEtMTE1NjI3_490d539d-bea7-4acb-a073-07936da410c7">2,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDItMi0xLTEtMTE1NjI3_c25d2c12-8c10-45c8-b1cb-7cafa1b91d0e">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDItNC0xLTEtMTE1NjI3_fa86ffb4-416d-489e-9ba8-8bd06789ce79">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDMtMi0xLTEtMTE1NjI3_fab8289e-ad5f-492d-9a95-b51b51d4db10">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDMtNC0xLTEtMTE1NjI3_45c74bea-e047-498a-9a2e-0b6245655b97">235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDQtMi0xLTEtMTE1NjI3_9662d9fd-1c4b-415c-b9d9-66c5d298d5f7">239</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDQtNC0xLTEtMTE1NjI3_ec720cb5-7efa-482f-885b-0afadcf51e18">138</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NET CASH FROM/(USED BY) FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDYtMi0xLTEtMTE1NjI3_a47e8732-0149-408c-a6ce-99b0e96b6761">6,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDYtNC0xLTEtMTE1NjI3_2542d0fd-2fe5-4aa5-89b4-3add55cc4917">4,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDgtMi0xLTEtMTE1NjI3_6fb725b2-af0c-4205-9f39-6d4b74870419">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDgtNC0xLTEtMTE1NjI3_bb8bbcb5-8d6c-402f-87fe-3576d1ca3dc7">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase/(Decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDktMi0xLTEtMTE1NjI3_864eedcf-993a-4664-abef-1cf8afc73a7e">12,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDktNC0xLTEtMTE1NjI3_802b3bc7-c14f-4f54-9bb7-4f295dc1c9e0">4,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and Cash equivalents beginning of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTAtMi0xLTEtMTE1NjI3_17756112-1954-4f59-9fb6-846ed5428943">14,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6ce94080c14bf3947a9c53d1a7596d_I20220102" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTAtNC0xLTEtMTE1NjI3_23b3a87e-fe63-4226-b551-3bccf6e87c5c">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTEtMi0xLTEtMTE1NjI3_df6529a7-9ed5-4fc0-aef8-c064648c3dc5">26,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047e4a043e444bcba72ba4e9efc5393a_I20220403" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTEtNC0xLTEtMTE1NjI3_daf0b347-dacc-464e-b009-aeda2d223448">10,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTgtMi0xLTEtMTE1NjI3_3212d9dc-e163-4d57-9d43-7777f126a891">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTgtNC0xLTEtMTE1NjI3_4c8ff6f5-43fb-436b-a2ea-fe7f853aa2e2">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTktMi0xLTEtMTE1NjI3_fd92359f-3db4-4858-a8c2-56dbe6744c89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTktNC0xLTEtMTE1NjI3_7fe1b999-4923-48a1-ba6f-396b38f23259">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNjAtMi0xLTEtMTE1NjI3_7223e21e-c245-43f4-bec7-00c3c3548f2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNjAtNC0xLTEtMTE1NjI3_587cd7e7-9ab5-469f-b088-4ab901314dcb">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i7c615dc7aec24dc98e6c850313251c4e_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 1 &#8212; <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzM5OQ_d752334b-6151-4986-a59e-8691c8126d16" continuedAt="i96c56005bdba4954ab33d31ba9c28ece" escape="true">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;1, 2023. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i96c56005bdba4954ab33d31ba9c28ece"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzI5ODUzNDg5MzQ2Mg_b1eea87b-2fc6-4327-8c03-bcb0c09cef6d" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;1, 2023. </span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzI5ODUzNDg5MzQ2NA_6b98e8e9-0203-4faa-b7c5-6f9e7ebf5ed3">ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50)</span> &#8211; Disclosure of Supplier Finance Program Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company adopted the standard as of the beginning of fiscal year 2023, which requires that a buyer in a supplier finance program disclose additional information about the program for financial statement users. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company&#8217;s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier&#8217;s decision to participate in the program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of April 2, 2023, and January 1, 2023, $<ix:nonFraction unitRef="usd" contextRef="ibba084db76814e3ea3789881d3aff00a_D20230402-20230402" decimals="-8" name="jnj:SupplierFinanceProgramObligationCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfNTQ5NzU1ODIzOTk0_e708fea9-2780-42ee-8219-c28b29addb22">0.9</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="icfde879145bf49229de003973cc34868_D20230101-20230101" decimals="-8" name="jnj:SupplierFinanceProgramObligationCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfNTQ5NzU1ODI0MDA4_65db5a3d-3871-48af-ba9a-b0bdcaec7f09">1.0</ix:nonFraction>&#160;billion, respectively, were valid obligations under the program. The obligations are presented as Accounts payable on the Consolidated Balance Sheets. </span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Not Adopted as of April 2, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no new material accounting standards issued in fiscal first quarter of 2023.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzM5NQ_d2b0da32-8ca8-411a-ad0a-ebf5284c5c4e" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_52"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 2 &#8212; <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RleHRyZWdpb246Yjg4YzcwNzczOTFiNDA3NjhkZWI1YTU0ZDM3MWM3ODRfNDM_f2c6a8d7-eea2-4441-bcb9-a2ea36426798" continuedAt="if6d5d1d9d52143ed8510acf9fcd0c858" escape="true">INVENTORIES </ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="if6d5d1d9d52143ed8510acf9fcd0c858"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RleHRyZWdpb246Yjg4YzcwNzczOTFiNDA3NjhkZWI1YTU0ZDM3MWM3ODRfMzE_2cf5360e-dc4b-4c1a-9126-1117852339df" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"></td><td style="width:51.896%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.622%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfMS0yLTEtMS0xMTU2Mjc_16475834-f3c2-498c-936d-85418a0908f8">2,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfMS00LTEtMS0xMTU2Mjc_cd151aa5-732e-4ca2-89bf-3333c51b91ff">2,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfMi0yLTEtMS0xMTU2Mjc_ece27d95-d813-403f-873a-78815d7e12d3">1,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfMi00LTEtMS0xMTU2Mjc_94d7e961-0c18-4dc3-abdf-7893d2c3983a">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfMy0yLTEtMS0xMTU2Mjc_05d49fa6-f1cd-4399-8e0b-71ea2f67c9fe">8,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfMy00LTEtMS0xMTU2Mjc_00fd7a1f-61f9-4957-9964-4a9a13f4ad5f">8,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfNC0yLTEtMS0xMTU2Mjc_fd89acea-5189-41c7-b6cd-58694ce0ab62">12,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfNC00LTEtMS0xMTU2Mjc_1375e671-3861-4baa-b5fe-9f38d4c5b385">12,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i7c615dc7aec24dc98e6c850313251c4e_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 3 &#8212; <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMjUyNQ_7421352d-cc9a-46f7-bbd1-356a19006982" continuedAt="if8beeab207ae456e952c4882498b46e7" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="if8beeab207ae456e952c4882498b46e7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2022. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.</span></div><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMjUyMw_7da67e74-7da9-41fc-98ae-f057365a26ca" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:61.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38228c4f861c4d53b47d4201d723003c_I20230402" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMi0yLTEtMS0xMTU2Mjc_e47f5bed-558e-4f29-994f-da0c516a559f">44,636</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e842812a5248e0bef37aa2b2e9b2fa_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMi00LTEtMS0xMTU2Mjc_661a1ca1-cc29-4cab-b571-080f945c2c33">44,012</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i38228c4f861c4d53b47d4201d723003c_I20230402" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMy0yLTEtMS0xMTU2Mjc_77ce5853-5993-4c6d-b27f-7d242c4324ba">23,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3e842812a5248e0bef37aa2b2e9b2fa_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMy00LTEtMS0xMTU2Mjc_c3038b37-5197-498e-ad32-37d103084137">22,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38228c4f861c4d53b47d4201d723003c_I20230402" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNC0yLTEtMS0xMTU2Mjc_e7cbab84-fdba-4109-b3e9-70034b4c9ada">21,124</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e842812a5248e0bef37aa2b2e9b2fa_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNC00LTEtMS0xMTU2Mjc_216fc4e0-6a1c-49d5-8472-2d04fda56ed9">21,746</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b4546281ac435aa92aec6c7e41c91b_I20230402" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNS0yLTEtMS0xMTU2Mjc_ee69e3a1-43ae-4632-94a3-990ab0be26b2">23,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3230083ab32476fb09c3bc58c85a4ba_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNS00LTEtMS0xMTU2Mjc_9656bb13-6c1a-44ed-892b-60a32ac5bfd0">22,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7b4546281ac435aa92aec6c7e41c91b_I20230402" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNi0yLTEtMS0xMTU2Mjc_eacfe685-4399-458f-8924-719e922252ec">13,211</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3230083ab32476fb09c3bc58c85a4ba_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNi00LTEtMS0xMTU2Mjc_632f24ff-b7a8-4317-bf02-d52151233911">12,901</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b4546281ac435aa92aec6c7e41c91b_I20230402" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNy0yLTEtMS0xMTU2Mjc_c8a1441c-d02f-4ca2-91cd-4d5f800ece8e">9,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3230083ab32476fb09c3bc58c85a4ba_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNy00LTEtMS0xMTU2Mjc_7c758051-2954-4268-91ae-115bb70806d6">10,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26813cf41e0b40518f5acdbd9c90332b_I20230402" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfOS0yLTEtMS0xMTU2Mjc_ee4c3c45-bff3-4cac-aacb-4d53b05ab733">6,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197e0943ce2a43d7936e32486da181f8_I20230101" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfOS00LTEtMS0xMTU2Mjc_b64828be-ac6a-4061-933a-72b5af44ea0c">6,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cfc80b6878c4f6f932fc48b92669884_I20230402" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMTAtMi0xLTEtMTE1NjI3_8d01234e-051c-441f-8362-a40fe5ffc2ee">9,684</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0507cd24d2e4b288dd7a9b0753017af_I20230101" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMTAtNC0xLTEtMTE1NjI3_84a57246-508c-4c5e-9a13-2da48add8854">9,686</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMTEtMi0xLTEtMTE1NjI3_06cbb657-2c3c-4836-9121-6f0444a4fa01">16,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMTEtNC0xLTEtMTE1NjI3_00aa9fc1-ec12-44be-aae9-2c2982e0c8d8">16,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMTItMi0xLTEtMTE1NjI3_6bb2de62-a54b-43a2-91b1-43e624e793ca">47,448</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMTItNC0xLTEtMTE1NjI3_47c34571-aca9-4713-a83a-bc24f3c7936b">48,325</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The majority is comprised of customer relationships</span></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMjUxMg_58aeffe9-681c-4e21-a42a-dab384cc76e1" continuedAt="i6780be6e78c9415a9dff207b626d0302" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of April&#160;2, 2023 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:37.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.399%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January&#160;1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0799f3dd7e1443109b9ff412c554094d_I20230101" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMS0yLTEtMS0xMTU2Mjc_865137e8-d261-4a7b-aa03-c7195bf53d0b">9,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54a01f5eb53d4ab89d3cbe7a3ba985c1_I20230101" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMS00LTEtMS0xMTU2Mjc_ae2527a5-c54d-4a00-9a65-090685ad7219">10,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie416bf3f26e54604b272b38173898aa1_I20230101" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMS02LTEtMS0xMTU2Mjc_a2e044ce-49d5-4b0c-9767-fffc2f1e61a4">25,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMS04LTEtMS0xMTU2Mjc_86105be6-4202-4ed1-8ca2-66382cbd7dd5">45,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26cdc03025f14afa93aeea4d2797344e_D20230102-20230402" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMi0yLTEtMS0xMTU2Mjc_0e25f99d-b5b9-4aa6-b3d8-90bf2c141a33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3967ed8804b3484a788194a6b55e2_D20230102-20230402" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMi00LTEtMS0xMTU2Mjc_da0d5059-c450-450f-8ef4-d867ab6e6bae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44d907a039b4ea4b07c28589766bd8a_D20230102-20230402" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMi02LTEtMS0xMTU2Mjc_cff2abbe-2315-4698-a7e6-964a5a515b48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMi04LTEtMS0xMTU2Mjc_a1ced11f-dcdf-44b8-a7e5-2d9de477a3ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26cdc03025f14afa93aeea4d2797344e_D20230102-20230402" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNC0yLTEtMS0xMTU2Mjc_433e71cd-f9de-4f55-96fc-26b13b4ac11c">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3967ed8804b3484a788194a6b55e2_D20230102-20230402" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNC00LTEtMS0xMTU2Mjc_870aab87-bd2b-4650-ae77-e11590c85bfb">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44d907a039b4ea4b07c28589766bd8a_D20230102-20230402" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNC02LTEtMS0xMTU2Mjc_775715d8-25b9-4000-afb2-a66c93d2e1b8">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNC04LTEtMS0xMTU2Mjc_f68ecaa8-2397-4566-ad5d-b91ae50c0e33">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at April&#160;2, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i580a3adc3cf744379ba4cf5f599f7937_I20230402" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNS0yLTEtMS0xMTU2Mjc_db16236c-902b-4e95-8d37-5b0b6f652e06">9,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i621fb40d2bb940e1b24bdcca1e4136e8_I20230402" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNS00LTEtMS0xMTU2Mjc_6b14a4d9-5b51-4858-90d6-5b23b3b12a72">10,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ee98f9e7d6a4590b9ac7b2d9cdb9144_I20230402" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNS02LTEtMS0xMTU2Mjc_5339e6fa-b5a6-487e-964e-e81aa70848fc">26,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNS04LTEtMS0xMTU2Mjc_519882b7-56f2-4679-814b-2ade429d0fb9">45,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="i6780be6e78c9415a9dff207b626d0302">*Includes purchase price allocation adjustment for Abiomed</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is <ix:nonNumeric contextRef="ibcd0d6c747a149e19fbcded0d930ca35_D20230102-20230402" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMTc4OA_7b7695f2-1333-4135-a91b-6c2385f053da">12</ix:nonNumeric> years. The weighted average amortization period for customer relationships and other intangible assets is <ix:nonNumeric contextRef="i882e2c7e02fc4e118e5a1079393bf3a8_D20230102-20230402" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMTg5Nw_51295037-54ca-4141-9d75-7b6c35535430">21</ix:nonNumeric> years. The amortization expense of amortizable intangible assets included in cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMjAwMw_365b75bb-d5a2-4dfe-846f-5e80a809061f">1.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMjAxMA_b62eebe7-ef5f-446c-b86d-f8cc18e725d4">1.1</ix:nonFraction>&#160;billion for the fiscal first quarters ended April&#160;2, 2023 and April&#160;3, 2022, respectively.  Intangible asset write-downs are included in Other (income) expense, net. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMjUyMA_ff3e4514-51d2-4319-8376-04b0568ecb19" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"></td><td style="width:18.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmQxZTI5N2M0MjA0OTRhN2Y4ODA0OTYwZGRmZmQxZjM3L3RhYmxlcmFuZ2U6ZDFlMjk3YzQyMDQ5NGE3Zjg4MDQ5NjBkZGZmZDFmMzdfMi0wLTEtMS0xMTU2Mjc_6322f116-fba7-4864-b346-8e4eaeba6757">4,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmQxZTI5N2M0MjA0OTRhN2Y4ODA0OTYwZGRmZmQxZjM3L3RhYmxlcmFuZ2U6ZDFlMjk3YzQyMDQ5NGE3Zjg4MDQ5NjBkZGZmZDFmMzdfMi0yLTEtMS0xMTU2Mjc_19065162-5753-43a2-97f9-99333b10dba3">4,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmQxZTI5N2M0MjA0OTRhN2Y4ODA0OTYwZGRmZmQxZjM3L3RhYmxlcmFuZ2U6ZDFlMjk3YzQyMDQ5NGE3Zjg4MDQ5NjBkZGZmZDFmMzdfMi00LTEtMS0xMTU2Mjc_09e658ea-031a-4141-94d5-74c754ba35f7">3,800</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmQxZTI5N2M0MjA0OTRhN2Y4ODA0OTYwZGRmZmQxZjM3L3RhYmxlcmFuZ2U6ZDFlMjk3YzQyMDQ5NGE3Zjg4MDQ5NjBkZGZmZDFmMzdfMi02LTEtMS0xMTU2Mjc_1ed20e9b-1682-4e58-a099-736f61d9690c">3,200</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmQxZTI5N2M0MjA0OTRhN2Y4ODA0OTYwZGRmZmQxZjM3L3RhYmxlcmFuZ2U6ZDFlMjk3YzQyMDQ5NGE3Zjg4MDQ5NjBkZGZmZDFmMzdfMi04LTEtMS0xMTU2Mjc_15148941-695d-446d-87ac-c1a98f3d93f3">2,600</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 4 &#8212; <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE2OTM_30ac4094-154d-46d2-8774-5c062a24eab5" continuedAt="i94fb225925874b82bfc80b6d218756c6" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i94fb225925874b82bfc80b6d218756c6" continuedAt="i039c4f5bf3d14fe39f4148d30374d824"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of April&#160;2, 2023, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $<ix:nonFraction unitRef="usd" contextRef="if54031088777474188c6dca64d2fb710_I20230402" decimals="-8" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTY1MQ_857ee5d2-cfd1-4dab-8513-c62e67fdc7f7">0.7</ix:nonFraction> billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April&#160;2, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="if54031088777474188c6dca64d2fb710_I20230402" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMjMxNg_b622c3e9-192b-431c-8f14-e3b07df4712a">44.3</ix:nonFraction>&#160;billion, $<ix:nonFraction unitRef="usd" contextRef="idf8c231701af4202b803070c0de9def8_I20230402" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMjMyMA_a784e0de-722c-40a2-8862-d5b82dc4fcf8">36.5</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i2ad211fc0f6c4a23b3511340169453c0_I20230402" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMjMyNw_3d7346cb-cbe3-46fa-bf61-cb8fca6deb79">10.0</ix:nonFraction>&#160;billion, respectively. As of January&#160;1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="ia0c30aae843c488795f8e7c12bdf070d_I20230101" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMjUwMg_2039b403-250c-465a-b8f6-c3c6a1178488">43.3</ix:nonFraction> billion,  $<ix:nonFraction unitRef="usd" contextRef="i82b6d9a04c804ccfa99f995cf671dd34_I20230101" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMjUwNw_ccb200d1-4933-42e7-86dc-385ec7fbf725">36.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i68677eb45407447cb144946c0f01f334_I20230101" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMjUxNA_c89269dd-ac2e-41da-9076-68b6e3aa3d56">12.4</ix:nonFraction> billion respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;2, 2023, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $<ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" sign="-" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfNDY0NA_dcdc4291-bdcb-4f5c-9ef9-cb898e344775">343</ix:nonFraction>&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investment hedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3NDE_86b7c1ba-79d9-4bec-917e-c8fc5177c4dd" continuedAt="ib93b698845d944849590cb0ad2938f2c" escape="true">The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2023 and 2022, net of tax:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><ix:continuation id="i039c4f5bf3d14fe39f4148d30374d824" continuedAt="i8b7af36cf4784031a5e6f96b80a9e3ee"><ix:continuation id="ib93b698845d944849590cb0ad2938f2c" continuedAt="i0c3249e7b58045499cc5d72655ae27f9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.102%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.413%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.563%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f4633d6ab6401e9804fb1a385a3531_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy0xLTEtMS0xMTU2Mjc_92b1b253-c483-41e6-b3f6-db952aa49a13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5588691f505049b895ad7d374a5c3a41_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy0yLTEtMS0xMTU2Mjc_97004675-58d5-497b-9daf-0baaa694306e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b45f400dac942d296156e124dc1e9b9_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy0zLTEtMS0xMTU2Mjc_d3fba935-c7d1-4054-8a0c-e1616dd64487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieaff6b065b8f45f384f79c9289dacd25_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy00LTEtMS0xMTU2Mjc_a9b343b3-3469-4991-9be5-b8a75b41b02e">929</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i831a75e27b404331b68d0e1d0c6dd089_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy01LTEtMS0xMTU2Mjc_c27853d4-817f-4d5f-bc14-b0158161b1a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ad3c15d3724acf827b842d7dbf0f89_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy02LTEtMS0xMTU2Mjc_1e98a9b3-3cc6-4f9c-9ccf-8cfd94874423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifebd08ff3dce4721a4b99e42c41bef26_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy03LTEtMS0xMTU2Mjc_9c6f6ba0-f052-4e73-bb02-52fd74e67b24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39a02e3ee104b9ba558b07af3c8b6f4_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy04LTEtMS0xMTU2Mjc_dc56c68d-75a3-48f7-abe7-ab34d183d977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7b9d91b169a40358401cf82127d3e79_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy05LTEtMS0xMTU2Mjc_5287e70e-b833-44c8-8ed6-eaee8457f449">531</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice47da4dbb604bc89bb47d0c82573768_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy0xMC0xLTEtMTE1NjI3_b77f778b-6188-4f7f-a196-23d99679dc1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41f4633d6ab6401e9804fb1a385a3531_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC0xLTEtMS0xMTU2Mjc_94eee325-ecaa-4dde-b059-2cac07fa4b5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5588691f505049b895ad7d374a5c3a41_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC0yLTEtMS0xMTU2Mjc_3086c6ab-f973-4571-ae7b-bb2ed2cf9ee8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b45f400dac942d296156e124dc1e9b9_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC0zLTEtMS0xMTU2Mjc_3f11b213-c88b-4d53-9a21-30c8e5d24d79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaff6b065b8f45f384f79c9289dacd25_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC00LTEtMS0xMTU2Mjc_eec08004-0830-4844-b858-2d1c05f87735">929</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i831a75e27b404331b68d0e1d0c6dd089_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC01LTEtMS0xMTU2Mjc_410f07e2-8e18-4fd4-97fb-823bcca0e3b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ad3c15d3724acf827b842d7dbf0f89_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC02LTEtMS0xMTU2Mjc_69adf4cd-e800-49e2-80fb-cc05f22f99cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifebd08ff3dce4721a4b99e42c41bef26_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC03LTEtMS0xMTU2Mjc_ee7c1421-ff8f-4fb4-8e10-4bf995331a7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39a02e3ee104b9ba558b07af3c8b6f4_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC04LTEtMS0xMTU2Mjc_a0be054b-6fa2-4b0d-a2f5-048b0df7ea33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7b9d91b169a40358401cf82127d3e79_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC05LTEtMS0xMTU2Mjc_bd7af7b3-579e-4373-b26f-8a5fabfda72e">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice47da4dbb604bc89bb47d0c82573768_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC0xMC0xLTEtMTE1NjI3_35e0a974-9492-4054-96e1-cd38c7e885c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9068df14ebfc48e38d180f60734ca507_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItMS0xLTEtMTE1NjI3_3a08bd47-8856-4323-b7b8-d8481baf4ecc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic52c17526572465e9e1b5a35d8831216_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItMi0xLTEtMTE1NjI3_051b1bbf-18f0-4e0e-9324-fcd474efef3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38841a93344de99840a565926c66a5_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItMy0xLTEtMTE1NjI3_e2216f95-eca2-4cb9-b01b-5b1313ed7e69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4779df903b7b429d8d7c7bd175fed19d_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItNC0xLTEtMTE1NjI3_f2db5037-ee7f-41d5-9656-7642ff029a31">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee79a709871d48e79e9780dda18549cf_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItNS0xLTEtMTE1NjI3_a3aa22b8-cb23-4cd1-8679-cd4f137d11f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7667c30e53b74e189bee49ab6ab578aa_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItNi0xLTEtMTE1NjI3_d5f7cc7f-2831-41f7-97e6-78229646c09a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic67e218f34d2463381b9461693780c78_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItNy0xLTEtMTE1NjI3_9f1073e3-8a9a-47a6-810f-1c9723870a3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a3c4d59b0242d5872c4a78d9b2f266_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItOC0xLTEtMTE1NjI3_300eba11-0800-48db-b510-fdc913e95d63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b8e5036b85e4f42ab00ba31e3cc72e0_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItOS0xLTEtMTE1NjI3_603c34b7-75e8-46c6-b40d-175db47273da">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ab5b9880cd4f64ada5ab99bbe01129_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItMTAtMS0xLTExNTYyNw_563aa724-cb30-48b9-921d-e194aca27c29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9068df14ebfc48e38d180f60734ca507_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtMS0xLTEtMTE1NjI3_6ec52655-8a30-4e96-bcd1-622ba104e4a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic52c17526572465e9e1b5a35d8831216_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtMi0xLTEtMTE1NjI3_04c7fae3-450f-4b1d-ba23-301a45fba11c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb38841a93344de99840a565926c66a5_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtMy0xLTEtMTE1NjI3_aab2e00e-594f-4b8c-a848-d46966550d21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4779df903b7b429d8d7c7bd175fed19d_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtNC0xLTEtMTE1NjI3_11b04895-e124-430f-b26f-45448c9c26e7">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee79a709871d48e79e9780dda18549cf_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtNS0xLTEtMTE1NjI3_e5db70c0-5087-4a0c-ba92-5b89f0439b37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7667c30e53b74e189bee49ab6ab578aa_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtNi0xLTEtMTE1NjI3_24108b67-198e-4306-a99a-a83d3c950af9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic67e218f34d2463381b9461693780c78_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtNy0xLTEtMTE1NjI3_3f733cf3-5259-4c78-b819-2bea71d33d01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a3c4d59b0242d5872c4a78d9b2f266_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtOC0xLTEtMTE1NjI3_561f70c7-79d4-40bb-8c63-f28b7910e500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b8e5036b85e4f42ab00ba31e3cc72e0_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtOS0xLTEtMTE1NjI3_ae03b1ca-14f3-4f8e-824c-ffdc582a496f">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ab5b9880cd4f64ada5ab99bbe01129_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtMTAtMS0xLTExNTYyNw_3be7fa0f-5ef7-44c7-baac-663e1360bb2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968b152e9828408dbcfff2d958bb2ffa_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctMS0xLTEtMTE1NjI3_b3073e8b-a21a-48ac-ba18-22c263a96a74">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f8f4aec6be94d6fbddc3da727226560_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctMi0xLTEtMTE1NjI3_7fc2f528-46e0-4d22-9f1e-911c8afe950e">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i518fab6babc2450f8b8bfc59a05e3df0_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctMy0xLTEtMTE1NjI3_df7a4554-8a1a-4a1d-9147-eebd387d5c9e">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1e2c54d6bb479292b9652c120a6541_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctNC0xLTEtMTE1NjI3_725e7ea3-8b46-4cf3-8d23-3e36b85ea788">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0c6b0431ad94e9aaac1f8408e9e643f_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctNS0xLTEtMTE1NjI3_7eafd66d-acc6-4421-bf98-30443af7fd8f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cc8515d00ca476a938ce6b49ef1d594_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctNi0xLTEtMTE1NjI3_419f4f07-5221-4a18-9de7-8e53671c18f0">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie051977e19b94b39a0ddaa23a4b507b3_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctNy0xLTEtMTE1NjI3_ce4cdaea-3ecd-4f92-8b4c-a4633f12cb78">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b711721e994f5fac5c2f261e490da8_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctOC0xLTEtMTE1NjI3_0b6a3ef0-b4a3-4613-bece-db50659c5f13">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1da9ad33c847a19893c85c250bba48_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctOS0xLTEtMTE1NjI3_0a49b7e5-1487-4ca4-b9b9-a2d738be017a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba41bab8774e437ea305e80eaf3595db_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctMTAtMS0xLTExNTYyNw_2e976bc8-d4cf-471f-a9c9-bc01a0709ba8">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968b152e9828408dbcfff2d958bb2ffa_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtMS0xLTEtMTE1NjI3_4bfc0842-3613-4a6e-a028-a835f64ddba9">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f8f4aec6be94d6fbddc3da727226560_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtMi0xLTEtMTE1NjI3_e8cec205-a3e4-47d1-89e3-334fbefdd8d0">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i518fab6babc2450f8b8bfc59a05e3df0_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtMy0xLTEtMTE1NjI3_163d6f95-33eb-4524-bc00-cb74990b028a">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1e2c54d6bb479292b9652c120a6541_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtNC0xLTEtMTE1NjI3_fd5b332f-f2e6-4dbb-9f5f-20e46766da96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0c6b0431ad94e9aaac1f8408e9e643f_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtNS0xLTEtMTE1NjI3_ee04a7d8-fbff-40af-9671-a34e58cda0d0">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cc8515d00ca476a938ce6b49ef1d594_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtNi0xLTEtMTE1NjI3_87371cbe-4711-4b6b-bcab-34d72df615bb">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie051977e19b94b39a0ddaa23a4b507b3_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtNy0xLTEtMTE1NjI3_48f1ed26-a718-40c6-8454-f09e06af53ad">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b711721e994f5fac5c2f261e490da8_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtOC0xLTEtMTE1NjI3_a493f98d-ff70-4d2c-bacd-3b63ec4ea3de">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1da9ad33c847a19893c85c250bba48_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtOS0xLTEtMTE1NjI3_8242f42c-6004-4624-bda0-a551da4b95ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba41bab8774e437ea305e80eaf3595db_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtMTAtMS0xLTExNTYyNw_1c4552bd-d4ec-4ed1-af9b-b66218680d08">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife40f1a43412473da55b7933c850ee6c_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtMS0xLTEtMTE1NjI3_2c0a0839-c4e9-424f-a68d-fcf8e61dd37c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f98824188a4648a8a09d1453d2780b_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtMi0xLTEtMTE1NjI3_5593c757-0ddd-482c-980d-8cb4f4ee3484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f10659432f044afbd1fba6198533009_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtMy0xLTEtMTE1NjI3_ccff3eb7-d2e2-48f5-8dcd-2c538c5d01b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iece4bb18d3dc46fc9364b46a20d5f69d_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtNC0xLTEtMTE1NjI3_e00aa282-fbad-4277-ab96-bd125ea57da2">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81ca34bf19c4617889e951ac6dfbc59_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtNS0xLTEtMTE1NjI3_a57b3760-7504-4df9-97fa-e2539599f241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d280475a264030901bece015a4dc31_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtNi0xLTEtMTE1NjI3_6b1e2e23-6f6d-4d29-bdca-9732ce762c06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff16d560d4c47149af82242e78d7c81_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtNy0xLTEtMTE1NjI3_cecc60fd-9880-4a20-9174-37e9db55a9f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18eb2772b356408db2d5bed81f211a2c_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtOC0xLTEtMTE1NjI3_2e8aed29-3190-4839-8349-6fef882d0dca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf982a48aaff440bb1776f320d637a69_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtOS0xLTEtMTE1NjI3_202355ca-9f1b-411a-8ecb-bf759750443f">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4443adb601eb4729914e2ba1f143557c_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtMTAtMS0xLTExNTYyNw_7e9cd0a7-6369-4226-a782-c6ae71150dfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife40f1a43412473da55b7933c850ee6c_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtMS0xLTEtMTE1NjI3_04f38af8-555e-4c9c-b04d-44540bfa2a78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f98824188a4648a8a09d1453d2780b_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtMi0xLTEtMTE1NjI3_dfce6a30-5312-43c7-9558-e39351717f3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f10659432f044afbd1fba6198533009_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtMy0xLTEtMTE1NjI3_f3e7fdd2-c1bd-4d3a-a7d5-a59802506b04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iece4bb18d3dc46fc9364b46a20d5f69d_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtNC0xLTEtMTE1NjI3_80c02646-3a58-44f6-af24-bd604161b63d">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id81ca34bf19c4617889e951ac6dfbc59_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtNS0xLTEtMTE1NjI3_f4018615-9e7c-49a3-a6f6-726cdc1ac68f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d280475a264030901bece015a4dc31_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtNi0xLTEtMTE1NjI3_77cf27ca-3733-45a1-8a94-e1e96a3b8ea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icff16d560d4c47149af82242e78d7c81_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtNy0xLTEtMTE1NjI3_b2022e65-440f-4488-81c0-5f878ecb16de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18eb2772b356408db2d5bed81f211a2c_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtOC0xLTEtMTE1NjI3_baeaade5-064e-46e5-b4ac-15c946b8910a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf982a48aaff440bb1776f320d637a69_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtOS0xLTEtMTE1NjI3_0a0636d3-04a1-4472-80ad-886dd522dc07">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4443adb601eb4729914e2ba1f143557c_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtMTAtMS0xLTExNTYyNw_62112581-959a-4a66-b315-ed0b7abff6cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.302%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.760%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="margin-bottom:7pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i8b7af36cf4784031a5e6f96b80a9e3ee" continuedAt="i8d80e5a75c5b45cba8c0b18998a168ce"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3NTU_8b98f557-dede-4d79-be8b-b3cdc32f148b" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;2, 2023, and January&#160;1, 2023, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a044beb1efb4064b0c24daf2024f934_I20230402" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjNlODUzZDNhNzE3ZjQ3MmZhMWI4ODVhNDM2YmU4NjVlL3RhYmxlcmFuZ2U6M2U4NTNkM2E3MTdmNDcyZmExYjg4NWE0MzZiZTg2NWVfNC0yLTEtMS0xMTU2Mjc_e8e479c6-3c2a-4b2e-865d-59c5312f2d08">8,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if77451a376c4461ebd92a6a553653653_I20230101" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjNlODUzZDNhNzE3ZjQ3MmZhMWI4ODVhNDM2YmU4NjVlL3RhYmxlcmFuZ2U6M2U4NTNkM2E3MTdmNDcyZmExYjg4NWE0MzZiZTg2NWVfNC00LTEtMS0xMTU2Mjc_7d7e1d4b-4d68-4892-851b-968e6114b3bb">8,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a044beb1efb4064b0c24daf2024f934_I20230402" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjNlODUzZDNhNzE3ZjQ3MmZhMWI4ODVhNDM2YmU4NjVlL3RhYmxlcmFuZ2U6M2U4NTNkM2E3MTdmNDcyZmExYjg4NWE0MzZiZTg2NWVfNC02LTEtMS0xMTU2Mjc_e0b9541f-40cd-43f6-9fab-93bef5f944df">1,214</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if77451a376c4461ebd92a6a553653653_I20230101" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjNlODUzZDNhNzE3ZjQ3MmZhMWI4ODVhNDM2YmU4NjVlL3RhYmxlcmFuZ2U6M2U4NTNkM2E3MTdmNDcyZmExYjg4NWE0MzZiZTg2NWVfNC04LTEtMS0xMTU2Mjc_9acf362e-c381-4a16-baf3-ba2643be0e13">1,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE2OTE_bb4fa461-76c3-4309-b53b-4cac762fbcef" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2023 and 2022: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"></td><td style="width:34.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.628%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.634%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06741010c1a64e268867848027daba0c_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOmE2ODg1ZDM1MWNiMjRjZTViZGY1N2I5ZTdlYTI5ZDYyL3RhYmxlcmFuZ2U6YTY4ODVkMzUxY2IyNGNlNWJkZjU3YjllN2VhMjlkNjJfNC00LTEtMS0xMTU2Mjc_394d5689-cec9-4895-8be0-44752645c7b7">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6330ab077ff46f38183eaaac192c351_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOmE2ODg1ZDM1MWNiMjRjZTViZGY1N2I5ZTdlYTI5ZDYyL3RhYmxlcmFuZ2U6YTY4ODVkMzUxY2IyNGNlNWJkZjU3YjllN2VhMjlkNjJfNC02LTEtMS0xMTU2Mjc_3f2a41f7-9656-49b5-90dc-7298f39f724b">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="i0c3249e7b58045499cc5d72655ae27f9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal first quarters ended in 2023 and 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.363%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.610%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.959%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfMy0yLTEtMS0xMTU2Mjc_42e521fc-d3ae-4b5b-943f-ecfeff0666a3">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfMy00LTEtMS0xMTU2Mjc_1de65132-c355-4eac-aeb5-53641c148251">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530924810ee74f0498a5b576273161b3_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfMy04LTEtMS0xMTU2Mjc_8432521d-ed26-405d-a4ff-33a01842febb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1c1b995a63246e89358347d16f7c60e_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfMy0xMC0xLTEtMTE1NjI3_06d63eae-f34e-4088-bb00-89c0b7e015be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i075611e2f1c34545856ee1fb67001c5b_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfNC0yLTEtMS0xMTU2Mjc_bcc2459b-cca1-4fc6-959f-598f32eb2969">690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ca12285d2874df69fab0b80f4e166fc_D20220103-20220403" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfNC00LTEtMS0xMTU2Mjc_af2f8649-8de6-4500-b3c6-d42858121ef9">560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c4f8bd9f0f44566948524fae883de74_D20230102-20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfNC04LTEtMS0xMTU2Mjc_690a69a3-9227-466d-8cfe-db1c47ddbf81">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i652d6068f154428ba681e62b55ce5132_D20220103-20220403" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfNC0xMC0xLTEtMTE1NjI3_df22596c-a8cb-4467-9d1b-07c5cca06469">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:continuation><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:24.725%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.758%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.001%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.265%"></td><td style="width:0.1%"></td></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3MDU_899abed1-879d-43bb-8728-00452f7eb9b9" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:26.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.871%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f485b1f7c7942f49f325dd462771cde_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfMi0yLTEtMS0xMTU2Mjc_7b368ea3-4565-4b97-9252-c56a4c6e0969">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd652ec5aec24fbfa5838b3c7c1bc608_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfMi00LTEtMS0xMTU2Mjc_d13c402b-aad6-4497-95e0-b1b7d863d41a">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd652ec5aec24fbfa5838b3c7c1bc608_D20230102-20230402" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfMi02LTEtMS0xMTU2Mjc_1388fb99-94b6-478a-a891-331c44cd69bf">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307781a0dd6f4fee83ba5f3b83bacf6a_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfMi04LTEtMS0xMTU2Mjc_531a0771-c887-422f-9e37-57b2b813f702">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307781a0dd6f4fee83ba5f3b83bacf6a_I20230402" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfMi0xMC0xLTEtMTE1NjI3_21018c38-7d26-45d5-87a6-e6c0444ce448">505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8fce605d8bf42a4809c31f01fea678e_I20230101" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfNC0yLTEtMS0xMTU2Mjc_dec7dd38-1484-40ad-9cda-05f8e60b5c08">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4c4f1b4529e4b4e94c51763f2b03fee_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfNC00LTEtMS0xMTU2Mjc_752ab98f-e03b-4bb4-a586-7097f81d8cf7">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4c4f1b4529e4b4e94c51763f2b03fee_D20230102-20230402" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfNC02LTEtMS0xMTU2Mjc_4e32b4e3-fb93-47e4-bbae-a7480dc3f22d">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205b08e0d52a41018c1f1aac759297b4_I20230402" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfNC04LTEtMS0xMTU2Mjc_65705391-d6e9-469a-b4c5-89546db24b5f">724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205b08e0d52a41018c1f1aac759297b4_I20230402" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfNC0xMC0xLTEtMTE1NjI3_7b6c5b17-9039-4448-ad5c-9257bd1718c1">724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i8d80e5a75c5b45cba8c0b18998a168ce" continuedAt="id0bead6816c7417499966fbcc68f1ccc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Significant unobservable inputs.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3MzY_d654ddc5-4d6a-4ce7-9f93-bf3e2f4bb6fc" continuedAt="i4500a8929f344691bf9027df5f188a42" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of April&#160;2, 2023 and January&#160;1, 2023 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:48.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.202%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief14a8d3f839490ea2f5004d02e9ea85_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNC0yLTEtMS0xMTU2Mjc_0f6cbd78-f727-4fe4-bda8-34ce40d874fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eecc4b339cc4793b846af6357408a8a_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNC00LTEtMS0xMTU2Mjc_e984a8dc-5485-4f72-82e7-a981cb221a9b">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb9204df17c4b71bb33876248a6fc03_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNC02LTEtMS0xMTU2Mjc_b8e830d6-094c-4da1-9b87-8f6dc77ff55b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54031088777474188c6dca64d2fb710_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNC04LTEtMS0xMTU2Mjc_592de3f1-eb19-4289-b220-a4851810e5d7">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d229fdf0aac48939a630ab1e339fe6a_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNC0xMC0xLTEtMTE1NjI3_ef31248f-99d5-479c-9540-a8a4114bf246">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b2a01d5e1942d0934133917a0b41c4_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNS0yLTEtMS0xMTU2Mjc_31ae1da8-ec41-46e3-9b4a-73f5a430b18a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75635b8099d4b48b2cd2669062d8331_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNS00LTEtMS0xMTU2Mjc_d7453ccc-9cd3-4862-a2b6-9b6e13a906b1">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia81349c4bdf242e682e3fd1ce2fbe13d_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNS02LTEtMS0xMTU2Mjc_57b0e62a-b554-4de7-8bed-37780a6b0a74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a1713ee90b4874b872f2aa9e7ff7cb_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNS04LTEtMS0xMTU2Mjc_e27e2492-0598-4933-a797-e56e2bf7215a">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c27bfe420f54e1ca9c1eeb355beb0b2_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNS0xMC0xLTEtMTE1NjI3_6fa97844-9365-4037-8a37-7850906393f8">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f03697427554f22b26c5738cd4a66e3_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNy0yLTEtMS0xMTU2Mjc_5ff5c871-16d7-49f5-9d3b-2df3bc2873a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd646702260408ea267396967e28f41_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNy00LTEtMS0xMTU2Mjc_3d671100-5e83-43c7-ae05-2302d2edb53d">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdc0608d83a46fca52c9bb31b17d8bf_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNy02LTEtMS0xMTU2Mjc_beb07daa-a17c-498c-9c7a-89d8cbb0299b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNy04LTEtMS0xMTU2Mjc_fa973007-9a86-49cf-9116-4a45543b77c8">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3150f03c284a7c8af03baa7bea76ca_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNy0xMC0xLTEtMTE1NjI3_d3cc40da-c5bf-4e41-8170-36db72bdd115">2,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief14a8d3f839490ea2f5004d02e9ea85_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfOS0yLTEtMS0xMTU2Mjc_47fc3804-f248-411c-b8d9-422c5dd59828">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eecc4b339cc4793b846af6357408a8a_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfOS00LTEtMS0xMTU2Mjc_1ac95945-f7e7-4d15-ab3b-0c0154114197">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb9204df17c4b71bb33876248a6fc03_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfOS02LTEtMS0xMTU2Mjc_b3c65afa-56e9-4a95-b2d7-8d5bb9c213b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54031088777474188c6dca64d2fb710_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfOS04LTEtMS0xMTU2Mjc_fe3f111e-c2bc-4d32-8e70-00dac149056c">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d229fdf0aac48939a630ab1e339fe6a_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfOS0xMC0xLTEtMTE1NjI3_313681f1-91df-4af9-8003-606e1408b1d8">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b2a01d5e1942d0934133917a0b41c4_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTAtMi0xLTEtMTE1NjI3_f097dd1f-a3b2-4a0e-9220-614efa4b0aa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75635b8099d4b48b2cd2669062d8331_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTAtNC0xLTEtMTE1NjI3_d9b7db45-83d7-4dcd-8cff-bfa83274ffda">2,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia81349c4bdf242e682e3fd1ce2fbe13d_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTAtNi0xLTEtMTE1NjI3_5a24ceb4-125a-4051-b79c-1a17348624e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7a1713ee90b4874b872f2aa9e7ff7cb_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTAtOC0xLTEtMTE1NjI3_26b2e750-2e9e-469c-990e-ac7309d6562f">2,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c27bfe420f54e1ca9c1eeb355beb0b2_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTAtMTAtMS0xLTExNTYyNw_4d6f579c-c673-454a-974e-13331eaabc42">2,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f03697427554f22b26c5738cd4a66e3_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTItMi0xLTEtMTE1NjI3_c504f524-82e3-42c8-8c69-835583eb6ddf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd646702260408ea267396967e28f41_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTItNC0xLTEtMTE1NjI3_28c46505-46f2-4a1c-8592-3bd4f022b99a">2,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdc0608d83a46fca52c9bb31b17d8bf_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTItNi0xLTEtMTE1NjI3_251da0a6-74a4-461f-ac6a-15d2099effad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTItOC0xLTEtMTE1NjI3_7d19e758-9492-432e-a81f-26ba297cd449">2,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd3150f03c284a7c8af03baa7bea76ca_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTItMTAtMS0xLTExNTYyNw_59bdb42b-8308-44c4-8883-58211384e894">3,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief14a8d3f839490ea2f5004d02e9ea85_I20230402" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTUtMi0xLTEtMTE1NjI3_6c31f7d5-4a74-487e-bd51-0e8a0638f4ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eecc4b339cc4793b846af6357408a8a_I20230402" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTUtNC0xLTEtMTE1NjI3_615b52bc-5d40-4081-9e89-bc2458bdbd8e">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb9204df17c4b71bb33876248a6fc03_I20230402" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTUtNi0xLTEtMTE1NjI3_37c3de38-c0fe-419c-9712-78f7936ab03c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54031088777474188c6dca64d2fb710_I20230402" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTUtOC0xLTEtMTE1NjI3_ec99fd7d-f915-4051-aa58-4a8998bfa243">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d229fdf0aac48939a630ab1e339fe6a_I20230101" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTUtMTAtMS0xLTExNTYyNw_da65f4fb-7236-4087-9b2a-e79453712887">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief14a8d3f839490ea2f5004d02e9ea85_I20230402" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTctMi0xLTEtMTE1NjI3_d00906b3-8d17-4d89-8605-a08d8775f195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eecc4b339cc4793b846af6357408a8a_I20230402" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTctNC0xLTEtMTE1NjI3_66c74fdd-3ea1-45bf-90ed-393ae721e9a2">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb9204df17c4b71bb33876248a6fc03_I20230402" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTctNi0xLTEtMTE1NjI3_6f59c1a3-83b3-4004-bbda-60c33a181537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if54031088777474188c6dca64d2fb710_I20230402" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTctOC0xLTEtMTE1NjI3_2510eb7d-4027-4cb8-b1ff-d854134982ce">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d229fdf0aac48939a630ab1e339fe6a_I20230101" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTctMTAtMS0xLTExNTYyNw_83b9f70c-2691-4c53-b34f-3829ef30988d">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f03697427554f22b26c5738cd4a66e3_I20230402" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTktMi0xLTEtMTE1NjI3_584ff95d-497d-49fc-9421-154615bcf8b9">505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd646702260408ea267396967e28f41_I20230402" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTktNC0xLTEtMTE1NjI3_0b68bbe7-77b7-4ce6-a930-1f86a7c4db2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdc0608d83a46fca52c9bb31b17d8bf_I20230402" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTktNi0xLTEtMTE1NjI3_fac61fb5-d6e8-4f86-a25b-1b7af92e17a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTktOC0xLTEtMTE1NjI3_ac948f61-88c2-41e8-847a-e8911f51f6cd">505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTktMTAtMS0xLTExNTYyNw_3a959351-ebb2-406d-9838-0be9508d280e">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f03697427554f22b26c5738cd4a66e3_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjAtMi0xLTEtMTE1NjI3_ea95ecd2-daf0-4f8b-a6ea-5aff533ccb81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd646702260408ea267396967e28f41_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjAtNC0xLTEtMTE1NjI3_a936b173-12eb-4685-975c-a491d5a0791a">8,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdc0608d83a46fca52c9bb31b17d8bf_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjAtNi0xLTEtMTE1NjI3_09728e2d-0bc5-43c8-8897-33e8a1bf8dbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjAtOC0xLTEtMTE1NjI3_777b8699-b124-4408-9458-d9fbef0d992a">8,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjAtMTAtMS0xLTExNTYyNw_d9ffb273-94b2-4ddf-b3ad-b31197819a5f">10,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f03697427554f22b26c5738cd4a66e3_I20230402" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjItMi0xLTEtMTE1NjI3_49b64911-837d-4279-8b10-48a3f1de5449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd646702260408ea267396967e28f41_I20230402" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjItNC0xLTEtMTE1NjI3_df52a0d7-6331-42d6-8800-5850ccdacac7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bdc0608d83a46fca52c9bb31b17d8bf_I20230402" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjItNi0xLTEtMTE1NjI3_cba45723-2d7e-4f38-9cd8-6d9d039b003a">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjItOC0xLTEtMTE1NjI3_f2a988ee-e5be-42de-9d1e-3d2f5a06a8c0">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjItMTAtMS0xLTExNTYyNw_fbd9ab25-de85-4ce5-b758-7d1dfe4465eb">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="id0bead6816c7417499966fbcc68f1ccc" continuedAt="i931281493e424aeba7de5c577c483a7f"><ix:continuation id="i4500a8929f344691bf9027df5f188a42" continuedAt="i5d61c9f89bd64ce29c5e9ac39c586120"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.905%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfMi0yLTEtMS0xMTU2Mjc_bbc7fc75-0d3c-4ac4-9d0f-505caf1a9e40">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfMi00LTEtMS0xMTU2Mjc_d27ad9ac-1de5-479e-9175-3b81eb796125">2,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfMy0yLTEtMS0xMTU2Mjc_e7287ca8-bab0-48cb-8b73-42822a1fc2e8">2,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfMy00LTEtMS0xMTU2Mjc_8af42a83-a117-4d94-9275-9225409dde94">2,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfNC0yLTEtMS0xMTU2Mjc_8f6ae478-4a04-4603-834e-a304e3ecc7fa">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfNC00LTEtMS0xMTU2Mjc_4a3cc1ff-843b-4a10-9583-d1f978228730">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfNi0yLTEtMS0xMTU2Mjc_ad642cef-ade1-4624-852e-737a359c1790">2,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfNi00LTEtMS0xMTU2Mjc_bbd39295-a612-4edd-85b9-1a085b54ef44">3,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfNy0yLTEtMS0xMTU2Mjc_37547fb5-05ec-4e80-8170-11e6d9e2f394">2,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfNy00LTEtMS0xMTU2Mjc_0a0e520a-c963-4d63-aae4-755ad885ebfa">3,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfOC0yLTEtMS0xMTU2Mjc_1262a5f0-23aa-4006-ab32-89d5db7a6fa0">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfOC00LTEtMS0xMTU2Mjc_45cb4b74-921f-4dfe-9177-72ab57be936c">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration for the fiscal first quarters ended 2023 and 2022 is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"></td><td style="width:41.269%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.606%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.609%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241137260614532b6020bfeda156ac3_I20230101" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfMy0yLTEtMS0xMTU2Mjc_75cd5072-e3b5-43fc-8c51-1b932718e760">1,120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae6ce94080c14bf3947a9c53d1a7596d_I20220102" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfMy00LTEtMS0xMTU2Mjc_0f8130a1-0554-4570-ae11-8fe5f9a88b04">533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNC0yLTEtMS0xMTU2Mjc_1fb4c6e2-add2-4de7-a9e4-04aeb623ddc0">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" sign="-" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNC00LTEtMS0xMTU2Mjc_ee4d4bd9-ee07-4aba-8f56-dabdaaec2055">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNS0yLTEtMS0xMTU2Mjc_40d888c7-dccd-451a-b410-45c851a4cb44">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNS00LTEtMS0xMTU2Mjc_fd9729e4-a286-4fc5-8b0a-72438864185f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNi0yLTEtMS0xMTU2Mjc_fc2f445d-0389-4f76-9225-957f25e71ed2">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNi00LTEtMS0xMTU2Mjc_937a8e19-44e7-4ca8-8d02-636a5eb7d445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNy0yLTEtMS0xMTU2Mjc_d4062a23-6d4c-474a-b4b5-b2a8a7313b3c">1,142</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i047e4a043e444bcba72ba4e9efc5393a_I20220403" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNy00LTEtMS0xMTU2Mjc_1633283d-c8cd-4a67-87c2-aa0078e1d4f2">486</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2022 assets and liabilities are all classified as Level 2 with the exception of equity investments of $<ix:nonFraction unitRef="usd" contextRef="iecf72c1b6f094918ab2d8aac314f3e7b_I20230101" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfOTEzMQ_94cca867-e738-41e7-ac26-edfcf98d8e52">576</ix:nonFraction> million, which are classified as Level 1 and contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i7f05b2c736c746f9bbb497d86e2362a0_I20230101" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfOTE5OQ_3923d3a4-2170-4dd6-95d5-a769bc459f38">1,120</ix:nonFraction> million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $<ix:nonFraction unitRef="usd" contextRef="i47f2667d72af493883f17ca87070a398_I20230402" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfOTQ1NQ_ba4bddf6-a28e-4c54-b5d1-a9a1d31f24a3">1,138</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3c83227b39104d4d82056ac6bfea554b_I20230101" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfOTQ3MA_0fecc2c6-82a5-4af1-bf57-8cebbf83bba3">1,116</ix:nonFraction> million, classified as non-current other liabilities as of April&#160;2, 2023 and January&#160;1, 2023, respectively.  Includes $<ix:nonFraction unitRef="usd" contextRef="i4c31014b15774921a5f30a4880f42786_I20230402" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfOTU2Nw_86f57747-bd3e-4f2f-ac92-4c74c81629a7">4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i92e0aa803ceb4db2aff7a0bbab1124fc_I20230101" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfOTU4Mg_e0ba53af-88cc-486a-a150-b605ff49ad00">4</ix:nonFraction> million classified as current liabilities as of April&#160;2, 2023 and January&#160;1, 2023, respectively.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i5d61c9f89bd64ce29c5e9ac39c586120" continuedAt="i9db7524adf3e490bbcd8b9279dd64473">           (6)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9db7524adf3e490bbcd8b9279dd64473">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.</ix:continuation> </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:18pt"><span><br/></span></div><ix:continuation id="i931281493e424aeba7de5c577c483a7f" continuedAt="if268635894d84395adfeafd13cafb723"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3Mzc_35455523-340e-4e3f-9501-521655f6cdfc" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents, restricted cash and current marketable securities as of April&#160;2, 2023 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"></td><td style="width:33.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.201%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.513%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.589%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cbc0e3c61c34bc3bdcd6deaea9d806b_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMS0xLTEtMS0xMTU2Mjc_acd12e39-fdcf-4346-9223-3340dbc22a0d">4,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cbc0e3c61c34bc3bdcd6deaea9d806b_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMS01LTEtMS0xMTU2Mjc_7a3aa3de-39b6-49c3-b1fa-44613b7629be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cbc0e3c61c34bc3bdcd6deaea9d806b_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMS03LTEtMS0xMTU2Mjc_3096a03e-d802-49e7-a1e5-fa2d962884fb">4,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cbc0e3c61c34bc3bdcd6deaea9d806b_I20230402" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMS05LTEtMS0xMTU2Mjc_45b7ec9a-f6f0-4a4f-b289-98b8691af183">4,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cbc0e3c61c34bc3bdcd6deaea9d806b_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMS0xMS0xLTEtMTE1NjI3_b621cbe4-ad3a-4f6f-88b2-d8625167e63c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ffa091217a4323bc5c0aed611527aa_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMi0xLTEtMS0xMTU2Mjc_1a855f08-dce0-4a0c-8b6a-a1b52a0cc8c2">7,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ffa091217a4323bc5c0aed611527aa_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMi01LTEtMS0xMTU2Mjc_56dd15ff-c85a-4b58-a44b-2fc24c92a72a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ffa091217a4323bc5c0aed611527aa_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMi03LTEtMS0xMTU2Mjc_caba33a0-2a86-47ed-80f0-72ff8e9d851c">7,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ffa091217a4323bc5c0aed611527aa_I20230402" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMi05LTEtMS0xMTU2Mjc_d5505a4b-5ff1-439c-af4e-90b0de7a437d">7,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ffa091217a4323bc5c0aed611527aa_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMi0xMS0xLTEtMTE1NjI3_f6838282-b648-4db3-8556-aa510b403690">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3200f710ae4ab696b549ce19c468e9_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNC0xLTEtMS0xMTU2Mjc_4c2fd1aa-03e8-45df-9f75-918c0c5cb5c4">6,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3200f710ae4ab696b549ce19c468e9_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNC01LTEtMS0xMTU2Mjc_5743caef-a0d7-452a-8035-086681cefb15">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3200f710ae4ab696b549ce19c468e9_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNC03LTEtMS0xMTU2Mjc_a7345620-7b09-4814-ae78-ff3b64b633a4">6,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3200f710ae4ab696b549ce19c468e9_I20230402" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNC05LTEtMS0xMTU2Mjc_876a29b8-b78c-42db-b425-eff93db6ca08">6,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3200f710ae4ab696b549ce19c468e9_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNC0xMS0xLTEtMTE1NjI3_935f8c9d-3cfc-4eef-a654-07f6be882a47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33a79c5f8cb4a83813ae704160ed98f_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNi0xLTEtMS0xMTU2Mjc_cb096b81-3d54-4260-a3cb-ea7fcb109c1d">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33a79c5f8cb4a83813ae704160ed98f_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNi01LTEtMS0xMTU2Mjc_223496bf-b141-4c8a-870e-9e539dfcc48b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33a79c5f8cb4a83813ae704160ed98f_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNi03LTEtMS0xMTU2Mjc_18d90571-ac93-44de-9569-6a756a0f42c8">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33a79c5f8cb4a83813ae704160ed98f_I20230402" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNi05LTEtMS0xMTU2Mjc_b7fb828b-5953-4198-8e03-476ba4efd589">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie33a79c5f8cb4a83813ae704160ed98f_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNi0xMS0xLTEtMTE1NjI3_0485a9ee-eafa-4ff4-a6bc-4e8bba5c595b">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf23f95e6fb14d838dd8f888af18a5dc_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNy0xLTEtMS0xMTU2Mjc_cd7916de-098e-45ee-8ac9-c8141612fc0c">3,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf23f95e6fb14d838dd8f888af18a5dc_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNy01LTEtMS0xMTU2Mjc_6a30a225-9d27-44a1-9e65-ba1d852552bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf23f95e6fb14d838dd8f888af18a5dc_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNy03LTEtMS0xMTU2Mjc_b52a2d3f-7952-479b-8e78-0cacdc510645">3,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf23f95e6fb14d838dd8f888af18a5dc_I20230402" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNy05LTEtMS0xMTU2Mjc_fec8f58a-bdf2-4da6-b159-7460a1d05b8a">3,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf23f95e6fb14d838dd8f888af18a5dc_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNy0xMS0xLTEtMTE1NjI3_7c450266-3503-4102-b3e2-419a28318b24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54377ee71ddc46f195fb7d79c03086c4_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOC0xLTEtMS0xMTU2Mjc_3c9c2ce0-225f-4fbe-ba4b-8754baf7b5c0">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54377ee71ddc46f195fb7d79c03086c4_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOC01LTEtMS0xMTU2Mjc_c4dd94ad-f604-4b9d-8ce3-6a7e18d9a77f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54377ee71ddc46f195fb7d79c03086c4_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOC03LTEtMS0xMTU2Mjc_b6895172-bedc-4029-b6ce-2f2332a4cc52">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54377ee71ddc46f195fb7d79c03086c4_I20230402" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOC05LTEtMS0xMTU2Mjc_f6d9eeae-6b2b-45f3-972d-0fee676f037a">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54377ee71ddc46f195fb7d79c03086c4_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOC0xMS0xLTEtMTE1NjI3_48784723-4624-494b-89d2-4a1de3373697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e10a1fefa741b8b65c1bc8d547367e_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOS0xLTEtMS0xMTU2Mjc_f81a07e0-7136-4a48-9c1a-bca5e4cd8437">23,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e10a1fefa741b8b65c1bc8d547367e_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOS01LTEtMS0xMTU2Mjc_001f6cde-33ec-49bd-b6b1-fe8bf48f93a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e10a1fefa741b8b65c1bc8d547367e_I20230402" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOS03LTEtMS0xMTU2Mjc_12e033cd-4877-410e-8026-0ce7e8b2b063">23,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e10a1fefa741b8b65c1bc8d547367e_I20230402" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOS05LTEtMS0xMTU2Mjc_919f9327-b98b-4833-91a5-a10e67d280ca">22,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7e10a1fefa741b8b65c1bc8d547367e_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOS0xMS0xLTEtMTE1NjI3_999a3bc6-8bb9-4bd9-a856-a1a18de5397e">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov&#8217;t securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5115b43c247a46cb8480efe59a9a01e2_I20230402" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTItMS0xLTEtMTE1NjI3_97564c61-2827-41fa-8f2d-b54f8453fe28">8,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5115b43c247a46cb8480efe59a9a01e2_I20230402" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTItNS0xLTEtMTE1NjI3_0a9bb659-70fc-413e-ad96-7f293f06a81f">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5115b43c247a46cb8480efe59a9a01e2_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTItNy0xLTEtMTE1NjI3_2c9f5feb-6d5c-4b49-bdfc-fc951050da48">8,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af82efbb61a401e9e04b30f3cd374c2_I20230402" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTItOS0xLTEtMTE1NjI3_406a8bb8-9c78-4394-91a2-ac392fecf758">3,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4af82efbb61a401e9e04b30f3cd374c2_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTItMTEtMS0xLTExNTYyNw_29a332cc-61f9-415e-8c3a-69561983a45d">4,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov&#8217;t Agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b85c7849ee2491c98f1a6384d52b0b3_I20230402" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTMtMS0xLTEtMTE1NjI3_5fc50286-6d8f-4922-9ff3-34ce96338848">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b85c7849ee2491c98f1a6384d52b0b3_I20230402" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTMtNS0xLTEtMTE1NjI3_5ac7f793-b70f-4b4b-ab53-0848a4fc6823">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b85c7849ee2491c98f1a6384d52b0b3_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTMtNy0xLTEtMTE1NjI3_5128cb93-78dc-49a5-860c-2dc4cc21d56d">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22c34150afa480cbfb032861aa89f53_I20230402" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTMtOS0xLTEtMTE1NjI3_0689c96c-ea8d-4fd1-806c-80e311db8ef9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22c34150afa480cbfb032861aa89f53_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTMtMTEtMS0xLTExNTYyNw_8d4cf730-75aa-40dc-999f-c012569b32f7"><ix:nonFraction unitRef="usd" contextRef="ia22c34150afa480cbfb032861aa89f53_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTMtMTEtMS0xLTExNTYyNw_c63ac2c9-5b40-49c5-8af1-6356931e6a14">182</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica912cc5502e4edfac4509644a475663_I20230402" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTQtMS0xLTEtMTE1NjI3_d836d16b-840f-4468-9215-9d33e334251b">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica912cc5502e4edfac4509644a475663_I20230402" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTQtNS0xLTEtMTE1NjI3_45b8d3bb-79c3-4d56-9acd-d02ea4bdeae6">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica912cc5502e4edfac4509644a475663_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTQtNy0xLTEtMTE1NjI3_1ba86279-84d9-4ae0-96d0-39594d839714">307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b97484a76e4109b1cc8fb5d4f35ca3_I20230402" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTQtOS0xLTEtMTE1NjI3_2aa641e4-05f3-40d1-b548-14e6369bf534">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28b97484a76e4109b1cc8fb5d4f35ca3_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTQtMTEtMS0xLTExNTYyNw_7fc15e8a-c248-40d6-959d-b9df7f3d74e5">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55fd172e7b345698937c728fa47ea35_I20230402" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTUtMS0xLTEtMTE1NjI3_c190078c-d30e-4b99-a411-fce745325019">8,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib55fd172e7b345698937c728fa47ea35_I20230402" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTUtNS0xLTEtMTE1NjI3_bc7ad87f-cfd8-4795-87f7-e46c0ccb797c">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55fd172e7b345698937c728fa47ea35_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTUtNy0xLTEtMTE1NjI3_2ac8aef7-2bcb-4366-877e-87d6c34d318f">8,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55fd172e7b345698937c728fa47ea35_I20230402" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTUtOS0xLTEtMTE1NjI3_da8380ae-8445-43ee-8ff2-2d3e80b50a46">3,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55fd172e7b345698937c728fa47ea35_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTUtMTEtMS0xLTExNTYyNw_f44fde4d-e4e3-41be-be79-4649cffc5d23">5,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and current marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTYtMS0xLTEtMTE1NjI3_78c3b5e3-9703-412d-8436-8df2d28a1f9e">32,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTYtNS0xLTEtMTE1NjI3_08f215ec-7436-4633-ba47-7219e2a0eac7">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTYtNy0xLTEtMTE1NjI3_8117f494-2e00-460e-8793-b27f630d2e8c">32,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTYtOS0xLTEtMTE1NjI3_5f5421eb-a722-4e90-83f0-1c2f8ccf75b0">26,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTYtMTEtMS0xLTExNTYyNw_f623ddd2-7f3a-4cff-8410-3d409d02c62f">5,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relates to the Kenvue Inc. (Kenvue) debt offering. See debt schedule below for additional details.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the fiscal year ended January&#160;1, 2023, the carrying amount was approximately the same as the estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3MjA_fc598bfd-7fd6-44c0-81d5-ef75ecc228e6" escape="true">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</ix:nonNumeric></span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE2NzE_67a4a660-0751-4c79-b39a-76afbe7eb41f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of April&#160;2, 2023 are as follows:  </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"></td><td style="width:43.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.031%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfMS0yLTEtMS0xMTU2Mjc_a4aa386e-abd8-4f1f-8b64-e5b55893dc67">8,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfMS00LTEtMS0xMTU2Mjc_0d6e8141-bc9d-4a44-87bd-631795299d3c">8,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfMi0yLTEtMS0xMTU2Mjc_d39e4d90-6d60-4a08-a4f6-3f4daff5a447">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfMi00LTEtMS0xMTU2Mjc_56df7ef6-d246-4cc0-bb1f-413381fe07b8">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfMy0yLTEtMS0xMTU2Mjc_34450bb8-e41e-4b9f-ae28-5979358488cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfMy00LTEtMS0xMTU2Mjc_5329fea1-a452-4971-a2bb-437c572693c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfNC0yLTEtMS0xMTU2Mjc_990709f4-60bb-44c7-a890-a028059df2f1">8,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfNC00LTEtMS0xMTU2Mjc_1e2b7be7-af84-4205-9bd7-1e9c03400239">8,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="if268635894d84395adfeafd13cafb723" continuedAt="i671d11ef8bb6466280685d908d233426"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3MDg_755898fb-8496-49d9-999d-e8cbea628112" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;2, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:78.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76cf9f7d43b546acb7b030654e84376e_I20230402" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNC0yLTEtMS0xMTU2Mjc_38cbda2d-856a-4059-a1c6-c24c2b664688">17,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38b034ded43b4398ab07f2c8eb4df69c_I20230402" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNC00LTEtMS0xMTU2Mjc_45379b81-dbc5-4f96-a859-64c8f89f0009">17,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8fb8551fca949dea98f62de1af8e1fb_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZTUxNTMzYTc5MDRiNDhjMWFlODdkMGZjYWU2NzJiZmRfNA_b54256b2-d4df-461a-a0e8-59d59fa4ccb6">0.650</ix:nonFraction>% Notes due 2024 (<ix:nonFraction unitRef="eur" contextRef="ia8fb8551fca949dea98f62de1af8e1fb_I20230402" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZTUxNTMzYTc5MDRiNDhjMWFlODdkMGZjYWU2NzJiZmRfMjM_8d3b2363-7f7b-406b-863d-53b87b53e34e">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="ia8fb8551fca949dea98f62de1af8e1fb_I20230402" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZTUxNTMzYTc5MDRiNDhjMWFlODdkMGZjYWU2NzJiZmRfNTQ5NzU1ODEzOTM4_aaf5dbf1-6c9a-47f8-85dc-a75a97e403ea">1.0909</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74fbc3262ac245c6b06dbfaa60a35912_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTAtMi0xLTEtMTE1NjI3_f9adbd31-907c-42dc-a03e-c6835e90cfaf">812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2c5ffc25a414b4eb02918f1226b594b_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTAtNC0xLTEtMTE1NjI3_6fe66ade-d9b7-4459-91a4-6d6dbd26d6f2">796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id7901b5b213e45cfad73dbf6c939e3a1_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTEtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NDJiOTlmY2FlODU2NGE3NjlmZDYxNGFkN2JmOTAyYzVfNA_97bbdd8e-e03f-44c5-b128-4d4b018f1db1">5.50</ix:nonFraction>% Notes due 2024 (<ix:nonFraction unitRef="gbp" contextRef="id7901b5b213e45cfad73dbf6c939e3a1_I20230402" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTEtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NDJiOTlmY2FlODU2NGE3NjlmZDYxNGFkN2JmOTAyYzVfMjM_7f5b15c6-273e-4e1a-839b-85d315b15048">500</ix:nonFraction>MM GBP <ix:nonFraction unitRef="number" contextRef="id7901b5b213e45cfad73dbf6c939e3a1_I20230402" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTEtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NDJiOTlmY2FlODU2NGE3NjlmZDYxNGFkN2JmOTAyYzVfMzI_1d737324-4a5c-4a7e-9f10-3d06e8e538da">1.2359</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201ea42815f84447b0563ee2d6978dbf_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTEtMi0xLTEtMTE1NjI3_f1c44195-8d5c-4d81-a470-ef4b3c33386d">617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc07e47d11a24f3d84ea26db566510ba_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTEtNC0xLTEtMTE1NjI3_dc103db4-3367-412b-8531-d7cac20fbaac">626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic7899493f2a04f03b8d3a44ba0c57ce8_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTItMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NmYxMjA0Yjk3MWM0NDhhMTk3ODg0ZGUzMmM4ODU1MTFfNA_26e7de16-48d1-4e27-a473-92a7dee1a92c">2.625</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55a3b7fc5a045b8b30ed7f0edeef623_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTItMi0xLTEtMTE1NjI3_1845f623-aaec-420f-bb0c-61f7699f4820">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00240ca013be4736a3577b6e2e4e6e8f_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTItNC0xLTEtMTE1NjI3_2b6ae2cc-613d-4841-8c5e-f29ed8a7b169">732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4d061251a667491cb3ccfb55f7e0fdf1_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTMtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YmVmYzA2NjA4YzRjNDUyOTkwYzljZjdkMTI1ZjNiYTRfNTQ5NzU1ODEzODkwNQ_47e5874a-d471-4c00-b442-1ddae62f9921">0.55</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27aece83874544b59d6a3aeaf4140c57_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTMtMi0xLTEtMTE1NjI3_8c40ef3b-24dc-4845-816b-62d6529ffc50">936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib72ea9d48ff044b48b8f3531137328b3_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTMtNC0xLTEtMTE1NjI3_30a5acf4-484f-42d9-a11a-9bab6de088aa">920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id2d24b4e1a0d4ff0b2f3b876efb8f98d_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzdiZjc5MjQ5MTQ1NGRlY2I0NTM1YjAxODMwNDc2ZWRfNA_bf829c3f-2775-4224-84d5-b3ba15e57d63">2.45</ix:nonFraction>% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id922d848f11649e8bb4d6a787425f3d9_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTUtMi0xLTEtMTE1NjI3_25f362b0-196c-4ece-99fb-d577f6d29969">1,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d10576f649d4fcaa6628e37339ed7d7_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTUtNC0xLTEtMTE1NjI3_61b4a4f4-844b-42c8-94c7-509545cf89f1">1,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6efd100445841fd9e4073832291ac05_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTYtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ODBiMTA2OGEwODU4NDQ1NWFmYzkxNzA2MTBjYzNkZDJfNA_9d8411d2-2225-449b-b281-ad16bee861b9">2.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if128e6a98f974c349bec0f4b8249d2e9_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTYtMi0xLTEtMTE1NjI3_da79a071-6979-4768-b35c-33264a908532">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8830cb3725a43db940330000abf4afe_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTYtNC0xLTEtMTE1NjI3_63f62180-56d3-4a35-a3b8-7be1135359a8">968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i368a811b66144aceb4879d90f93ca849_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTgtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246M2IxMTk1MDAwNGU2NDE1Mjg0YTY1YmIyMTQ3MjM1MTNfNA_f76d4aa9-a461-431d-8cc2-51f061227a5b">0.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1212e32453564047b7f1d38ae4b843e4_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTgtMi0xLTEtMTE1NjI3_00957f1a-2f9f-4329-922d-f1adf965f35e">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e9145f348e4338a78e8f59378476ae_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTgtNC0xLTEtMTE1NjI3_9f54a076-5741-4a17-a293-7b14dd7daebf">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i48f4f2f5d47242ce9696a233b88c95d8_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTktMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NzM5NGYwMGMwODRmNGJiOTkyMGFmMThlYWU4NDRiM2JfNA_e143266b-e68b-4b53-822d-30d6abddf9b2">2.90</ix:nonFraction>%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i909ade28c6444d4abeff119bf7fda238_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTktMi0xLTEtMTE1NjI3_e038e75e-0e9e-4de0-8f0e-345658209372">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2867cf9e16e54b48951692ded48ddfec_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTktNC0xLTEtMTE1NjI3_021c436d-56ec-4c70-bf1f-76ef60a31467">1,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib925ed2921f044c7b6a52dcd57f43461_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YjY5ZTUzOTU4MDRkNGIzZDhlNTAzNzllZDI1OGFlOGNfNA_fd74bf39-823c-4314-8452-a5f7f3a7b2e5">1.150</ix:nonFraction>% Notes due 2028 (<ix:nonFraction unitRef="eur" contextRef="ib925ed2921f044c7b6a52dcd57f43461_I20230402" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YjY5ZTUzOTU4MDRkNGIzZDhlNTAzNzllZDI1OGFlOGNfMjM_890306d5-04b1-4135-aa29-f281ca7896a0">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="ib925ed2921f044c7b6a52dcd57f43461_I20230402" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YjY5ZTUzOTU4MDRkNGIzZDhlNTAzNzllZDI1OGFlOGNfMzM_f4a94813-3787-45de-a90d-0a6f47dc6f5c">1.0909</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f4ccd1b3ab4f02bad67727e76ccb50_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjAtMi0xLTEtMTE1NjI3_d730ff87-154d-4e40-ae69-9e0144fd2ea2">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a544d1c051b4c1a82b7d2c87b858546_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjAtNC0xLTEtMTE1NjI3_fc350081-bbed-402d-a712-03ef88b6f4f4">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i227ac8f50abd4fa982cb5d05a9110d6e_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjEtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YTBkODZkZWIzN2IzNDMzODhjMTRkYzk3MGYxZjUzYTlfNA_430c5bdd-6231-4a67-844f-f2db34ab5837">6.95</ix:nonFraction>% Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b249c5b4e484ae4a30c7aece7e87a09_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjEtMi0xLTEtMTE1NjI3_76d8159f-f115-4a4e-b8bb-5f7acd2d3b43">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6f9a852e704a75b988ca1c5efcda90_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjEtNC0xLTEtMTE1NjI3_567464ac-e413-4f98-90ea-bbf730102699">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia133568690864c2c80040ff64a3bd09d_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjItMC0xLTEtMTE1NjI3L3RleHRyZWdpb246OGRhNjdiOTdjMjVjNDc4NjgxMDY0YmIyYzU2YjM1MmFfNA_13c02670-fe66-4b26-b3ca-56ba1196a0b4">1.30</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57ad96c98de046ca96f7fb7c74dca343_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjItMi0xLTEtMTE1NjI3_c57defdf-b2bf-4367-83eb-0caa21af67b8">1,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib27758560e174afab9810f4bf86f5335_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjItNC0xLTEtMTE1NjI3_87231ce3-5874-4e7c-afb0-b74513fa1cf7">1,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e6d8ba2689941f9b382cef18e8e510d_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjMtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ODYyYTkzMWU1OTczNDAxMjhjYWNkNTY2YzAxMzE3YzFfNA_1f49ff4b-4c3c-46d1-9d91-b2c2a6f7b4e7">4.95</ix:nonFraction>% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6539619b042047df93391dc561673fce_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjMtMi0xLTEtMTE1NjI3_fce72d7c-9c17-49f3-bbd6-7521578e75cf">498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee5802a254024b95b747bbfcf78a55d8_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjMtNC0xLTEtMTE1NjI3_1a1fe730-a561-4dfd-ae55-b423c94a03f4">543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3725ff0a163f4284b203c37c1a364bb1_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjQtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZjBlMzEwZTJlNTYxNDhkNjg5OTNiMDA3M2Y5MTM2ZTZfNA_700ae797-5125-48b5-8eec-be8f4584a006">4.375</ix:nonFraction>% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4a308916ec45049d576f86d454ed54_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjQtMi0xLTEtMTE1NjI3_7375f65f-fede-43ce-8c63-244b796bfab5">854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f8018599af4e97a1cf4a42f83a48c3_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjQtNC0xLTEtMTE1NjI3_eca0a400-9968-4e08-8794-4173a3750771">879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e731198db6248e18229839dfbbb9b60_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YmNhMDc3ZWQxNTVhNDU2NzllNmNlYTJmYjU5NjE3MDNfNA_0e82565b-12b9-445b-8c5a-8b719d9599fb">1.650</ix:nonFraction>% Notes due 2035 (<ix:nonFraction unitRef="usd" contextRef="i4e731198db6248e18229839dfbbb9b60_I20230402" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YmNhMDc3ZWQxNTVhNDU2NzllNmNlYTJmYjU5NjE3MDNfMjM_5e646982-944a-43fd-a9d0-724d1499eabb">1.5</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="i4e731198db6248e18229839dfbbb9b60_I20230402" decimals="4" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YmNhMDc3ZWQxNTVhNDU2NzllNmNlYTJmYjU5NjE3MDNfMzI_7c962cc3-61d9-4029-b27e-eb73e8aa111b">1.0909</ix:nonFraction>)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e731198db6248e18229839dfbbb9b60_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjUtMi0xLTEtMTE1NjI3_fe28838f-d328-4597-ac28-84954d77f821">1,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7ecfe4e547b48e2bf37c8b07270def0_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjUtNC0xLTEtMTE1NjI3_d0a2276a-79cf-4f0d-acae-a898b91f5f41">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d3943f6e0ae4e0587c9c4d74a075a18_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjYtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246M2U4N2Y2NTNjZTFmNGViOWE5YzkwYjg0YmQ5ZDAzMDlfNA_ad97ce0f-efb1-4816-82f6-66f9ae1f1b21">3.55</ix:nonFraction>% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b67cb6ca9a44edaab52a8871fcc3df_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjYtMi0xLTEtMTE1NjI3_dda81be4-8c2b-4cf4-9c57-f1756d97d2f7">864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4f9ebffba3147cf8d00c064683c36e2_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjYtNC0xLTEtMTE1NjI3_3994a79c-061d-45b6-8f10-5047fa217a38">933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6c63abc9f5cf4a73a4a82c7b3a2282c6_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjctMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NTgzOGQ4M2UxNzQzNDIwYzhmM2VkNjdlYjYxNTlmNWVfNA_f2ffe2a0-6432-45c4-b39d-2ca1a8bb201e">5.95</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa813e2d18f4d07a5ba47a2be3612d2_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjctMi0xLTEtMTE1NjI3_8748be9a-e046-4fc1-989e-f3a4cf331f79">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c8bd52c349746b1881e96b11ce47bf6_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjctNC0xLTEtMTE1NjI3_0f8f61da-94ff-4f30-be32-a75975adfa8d">1,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ief71832a9018470cb79070bc07ffdec0_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjgtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NzA5ZGY2MGI4ODdiNGFmOTlhYTI1ZWIyNTllOGU3Y2VfNA_2077abe8-8bfb-4394-9b5e-10f983e938a3">3.625</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb5347aa05834f46ac9daf1613e272ca_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjgtMi0xLTEtMTE1NjI3_437916cc-39a6-4290-ab76-850c8e094d1a">1,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816cf20f9e104bf6b19a363b6ba3c457_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjgtNC0xLTEtMTE1NjI3_5db69d77-998e-4f10-ab0c-4805c72f02f7">1,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2a7bfa3080844dec82b6603a0abd071c_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjktMC0xLTEtMTE1NjI3L3RleHRyZWdpb246N2M0ZmQ5MzYyNzkyNDhhNzlkNmE0NGQ2ZDY2NmU4M2VfNA_00313c4f-a55e-41df-b580-251c28bdb49b">3.40</ix:nonFraction>%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1aeff3a19174fbaa6c309a6a87828c3_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjktMi0xLTEtMTE1NjI3_30f69494-2c89-4cc8-858f-1cd69f88de3f">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a929f2577cd41d8b9bb8a882be4e1b4_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjktNC0xLTEtMTE1NjI3_6ce74297-c926-4a83-8666-8944aa782795">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3946c9afdf54418086ade08e21fa3a2b_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NzUyNWQzYjUwYzdkNDM1YmI5NGYzNzRkMzYyMDQ2NmRfNA_916b240a-7271-4a32-a55e-58e4a7fc87ad">5.85</ix:nonFraction>% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82f6eaa7f0c74d57aafe2c652a9c905b_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzAtMi0xLTEtMTE1NjI3_12af8237-f39a-41a2-b3f1-f6180b8c9f34">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib652901c5fce4f24af8075006cd9aa10_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzAtNC0xLTEtMTE1NjI3_0b6a48c1-02e8-4f09-834c-674f7cc86a1b">806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7bec9abf70944616ba30c3702874dcfa_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzEtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246MWJhMjBiNGEzYjc5NDA4ZTlmNTNmZjFjYzFhOTQ1NDZfNA_8f065251-0158-46e9-8355-de5d8697d11a">4.50</ix:nonFraction>% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339a1d20f63346cb832562ac3c78a237_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzEtMi0xLTEtMTE1NjI3_59d211c6-e474-4f82-8eb6-a061058ebfb6">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacba4e8463a4d2e83aee15b14146669_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzEtNC0xLTEtMTE1NjI3_2bee42bd-2eb7-492c-85aa-60a63fcc40a7">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8cfb0968d3344cd78090b4f6ead3bd76_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzItMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZmUxNjUzZDA1N2VkNGMwM2I2NWRlZDU3Y2QzY2M2NGVfNA_c67da85b-73f3-4509-bf23-334d84824e46">2.10</ix:nonFraction>% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0a4b17867e147fcbe4c359e1afbd038_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzItMi0xLTEtMTE1NjI3_b93673c0-2b29-487d-bcd9-c6089ad4ee28">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724b3a0e6f5147afb4e0ba7665d6ef80_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzItNC0xLTEtMTE1NjI3_07b5b8c5-66c0-41f3-8aa5-cf5606c508a9">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib37fac857ce1416bbf734b81d98d767b_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzMtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246MzQxZjc2YzM5MjZjNGZmYjg4MDg4OTgyYTg4OTgxZGNfNA_61dc91f4-2c61-4128-b642-cb29dc5e50d4">4.85</ix:nonFraction>% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3e1a1289b7d4dc7817b8a11b9bdba25_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzMtMi0xLTEtMTE1NjI3_abce8e94-5258-4fd0-b15a-22f56ac422f3">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89ee2bcaaa4345b49e22759f9172507a_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzMtNC0xLTEtMTE1NjI3_abf3b59e-ccf2-4c57-9c40-098527cb58f7">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93d5e74486b449e89b3a9220a64520f0_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzQtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246MjQwODRmZjA3MWI4NGZjNmI1MmRiYWI1OTdlYTRkODFfNA_876b4da4-7e11-4e2d-90a4-1c906c76003b">4.50</ix:nonFraction>% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9923a50e9724fc481bdd65773cf31a0_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzQtMi0xLTEtMTE1NjI3_2b559c8d-b712-43bb-a1b5-ab72baf633b3">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a612e6189440309a78a24f6aaabefb_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzQtNC0xLTEtMTE1NjI3_defc0fd0-7ac7-449a-8a58-a4a578d40853">501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e60148e6e194dce942bd04838e31cbc_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246MmM1NGFlNTY3ZTlhNDEzMmIxZTI1ZjMzODY3ZDg1MzhfNA_b25b0978-73b5-4a03-8603-5b5d18cd981c">3.70</ix:nonFraction>% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c126d2c7894910adb1770911c549ed_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzUtMi0xLTEtMTE1NjI3_4860611a-cfa3-440e-8097-59c255e4cff5">1,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie24382cee4f042c7954a6d0aa1419fb4_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzUtNC0xLTEtMTE1NjI3_5507dfca-30df-4de9-8e54-c0473e4d7bb6">1,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3f1f5aa22a94cdbb91e0e86cd25fcaa_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzYtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246OTlhNGJhZDNiNmU2NDJhOWFjNjBmNjhmNjQ5ZWE4MzhfNA_9aba9499-78a7-461c-b888-8331d523883d">3.75</ix:nonFraction>% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b45cbd53644d79afe96aa1ef132108_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzYtMi0xLTEtMTE1NjI3_3bffbbbe-55a6-467c-8a95-a7c88ea860fa">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022de5a785f24bcd9f3083e4891f2ccc_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzYtNC0xLTEtMTE1NjI3_127ba633-ddc3-48dd-bf7f-b6f835c633b5">899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6862fde9a77c43f0bd130d62e09598e6_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzctMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NGE1YWI1MTg3YjRmNDJhMTk3OTc2MzYyMTdhODNmMzdfNA_20d50236-acbf-4fa2-bbf6-406434bebffd">3.50</ix:nonFraction>% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86125a3d772402db1a30fdce3dcd466_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzctMi0xLTEtMTE1NjI3_96d0152e-25ea-4ed9-8120-cd58898be151">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b0b8630278f405ba64f234c38a4a3ae_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzctNC0xLTEtMTE1NjI3_b3dffdc8-ff33-4aaf-aeeb-4c108ea5de59">651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie533216722654c1e9ba1846224e6ec14_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzgtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NjUwNzI1NGRhNTIwNGVlNzg1ZGZjOGRlYjEwMDY3N2JfNA_75fd749c-3948-4338-a191-47eb087b3b20">2.25</ix:nonFraction>% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74486a5277344ce59312540a7f416cbe_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzgtMi0xLTEtMTE1NjI3_adaabf10-6ba7-4880-9c12-17dadb64c809">834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a9fa797383949bba12905735e92ed19_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzgtNC0xLTEtMTE1NjI3_ae68323a-c69f-424f-92ed-ca938b81a784">667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f065931abb84eccba21550140a470ca_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzktMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NmNkOGEyMzVmMDNiNDMxYTgxZDEwMjk2NmNhNjNiYTZfNA_ed3fca3a-cb0b-41a1-8127-043a9cc92f7e">2.45</ix:nonFraction>% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb4ca4a34d6461dbc0d107842b6a046_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzktMi0xLTEtMTE1NjI3_4d21e9ba-e876-4dba-a6ef-0432cae938f0">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6552612946f41819e903a05f07bf91c_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzktNC0xLTEtMTE1NjI3_321c8c08-d6cd-4b48-8883-dbbac3c966f8">819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i918f92a298af41bda8fe834dd3b26150_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzgtMC0xLTEtMTI1OTIzL3RleHRyZWdpb246ODBmYTE4ZDlkMzE4NGUzM2FhMmEyY2Y3NmI5YWRjNzdfNTQ5NzU1ODEzODkwOQ_630f3299-3b0f-4a3c-bd23-271c53becd66">5.50</ix:nonFraction>% Debentures due 2025*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f501e2baabd405c810574367101a19d_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzgtMi0xLTEtMTI1Njk0_15402734-d281-420d-9702-4015feb2d9ba">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a69ae7c0f5d41bf986a42afdbbfb628_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzgtNC0xLTEtMTI1NzAz_8087da38-4363-4478-9558-0605df791b25">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0a6b938d37244aa8e09a786396d444a_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzktMC0xLTEtMTI1OTMxL3RleHRyZWdpb246MWY5OGU2Y2YxZGJjNGNhNWI4YTBkZThiZTdiNGIxMjVfNTQ5NzU1ODEzODkwOQ_4dc35ef1-386d-456d-8b90-a6b5ed50655f">5.35</ix:nonFraction>% Debentures due 2026*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a99eecd02148a2a368b8096810c2b5_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzktMi0xLTEtMTI1Njk0_f715a8d8-c839-438a-9001-1264eb8b711e">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03eb671135b6424d97690216188682fa_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzktNC0xLTEtMTI1NzAz_7d2bc623-53e4-40ed-bdcc-ba24dac0ad39">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if08f43d66b2b4b1789c28c89f773bcd9_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDAtMC0xLTEtMTI1OTMzL3RleHRyZWdpb246OTAzMTY1MTViMzQxNGY1NjlmMWVjOWZmNWFhNjQ5NDRfNTQ5NzU1ODEzODkwOQ_3d49aeb6-be56-41a3-8e88-e15a924cd3c8">5.05</ix:nonFraction>% Debentures due 2028*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92360a98889d40b2bee328fb5755cfb0_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDAtMi0xLTEtMTI1Njk0_5ba9e760-6526-4627-9b3a-5cd35404c2fd">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i741825ad780746bea2f2c6a35aed64c1_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDAtNC0xLTEtMTI1NzAz_bd93e914-e9b1-44ff-b2be-787153735b62">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3fb8e7a45764351bb0b176fcbcb6e26_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDEtMC0xLTEtMTI1OTQwL3RleHRyZWdpb246ZTU3ZWFjNzA4YTQ3NDRhN2EyNGVmNDY0MzEwOTA0NTBfNTQ5NzU1ODEzODkwOQ_e2572d76-0bd9-48a2-a65a-5472699a9786">5.00</ix:nonFraction>% Debentures due 2030*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieedfdd205ab143638b2c4e0babcb3bcc_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDEtMi0xLTEtMTI1Njk0_cb6557ca-2181-450e-812a-b999562ebf3c">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e9541bc07fa4ed8a81ca1e22b84a82a_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDEtNC0xLTEtMTI1NzAz_59b5a31d-e5ba-41ec-bbca-ab8e8a33d000">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id69efa8053fb47178e9e37e201313747_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDItMC0xLTEtMTI1OTM4L3RleHRyZWdpb246Y2EyZDQyNzI5ZmU2NGMxYTlmZjU1Y2ZiMjRhNDg0MjhfNTQ5NzU1ODEzODkwOQ_6e37a396-992a-4f54-a040-b1a09606b363">4.90</ix:nonFraction>% Debentures due 2033*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0cf278aad3544b68d1287619e1ff5db_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDItMi0xLTEtMTI1Njk0_0b2970a7-b3c0-4d04-8c8f-44e89f3aa51f">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66beed51389f4daebb6d2d780254c5d2_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDItNC0xLTEtMTI1NzAz_ee570e46-a750-434c-960c-4864e33c5e92">1,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51d9ee539efe4210a650dbc237af95c4_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDMtMC0xLTEtMTI1OTQyL3RleHRyZWdpb246ZjRlNWIzZTcxNDQyNDg5Y2FjMjYxMTcyZDU2ZWRlMmJfNTQ5NzU1ODEzODkwOQ_52216086-75b9-4b9c-8756-c182358abfcc">5.10</ix:nonFraction>% Debentures due 2043*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i638e9c268a244ef0bdd12369ee16af36_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDMtMi0xLTEtMTI1Njk0_4837e41d-1e7f-4803-9579-44ff4f7fab95">741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2c136ed07a4293bbc96e175b9bbdfe_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDMtNC0xLTEtMTI1NzAz_6a5388bc-7a2d-4138-9f68-e10acb94bf33">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21e0e43d753d451b9ac7010d74e12a35_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDQtMC0xLTEtMTI1OTQ0L3RleHRyZWdpb246OWZiYjM3OWQzMTI0NDlkMjgwMWYwNjkzMDczMTM2ODZfNTQ5NzU1ODEzODkwOQ_0606598a-4184-4c7d-9a71-495e4a087732">5.05</ix:nonFraction>% Debentures due 2053*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b160e5cf382471abfa01a07b6979dcd_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDQtMi0xLTEtMTI1Njk0_6f64708f-dea4-4470-8fba-ec530a7be028">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6091369129b642cfa7e758e78afae422_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDQtNC0xLTEtMTI1NzAz_685fb7f8-3945-4e18-a468-bafdcecae4c3">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i024e2dfb671f4922b572b41f106efb1e_I20230402" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDUtMC0xLTEtMTI1OTQ2L3RleHRyZWdpb246YjE5Y2JkODBkMTJjNDU0Y2I3ZDc1YWZlZWZkNjUwODNfNTQ5NzU1ODEzODkxNA_2a3351ff-bea8-4cf2-a78f-4ae04eddbaea">5.20</ix:nonFraction>% Debentures due 2063*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89b252fa9afc4f6895a65928a3dc4679_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDUtMi0xLTEtMTI1Njk0_73798644-671b-4f7d-a538-b8396f35abf1">738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6b6aef384bf4a9b80ea47648fea1fee_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDUtNC0xLTEtMTI1NzAz_bffd218e-0f79-47d6-8d55-9146db4dc126">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id967b50670d04639aa79dfa133928a7b_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDAtMi0xLTEtMTE1NjI3_9039a571-4287-47a4-8fa7-e2f4b9cb4690">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if123e4fc41a748d3a7f0c30e5548e9dd_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDAtNC0xLTEtMTE1NjI3_7ba9aaf4-43e4-4480-a195-76bd88aafe8a">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76cf9f7d43b546acb7b030654e84376e_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDEtMi0xLTEtMTE1NjI3_f8f8d217-c317-4d12-a55c-6e81ae8ea2d4">34,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38b034ded43b4398ab07f2c8eb4df69c_I20230402" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDEtNC0xLTEtMTE1NjI3_4ba2935f-97e9-4a68-b22c-1527f25f5241">34,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i671d11ef8bb6466280685d908d233426"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average effective interest rate on non-current debt is <ix:nonFraction unitRef="number" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="4" name="us-gaap:LongtermDebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTEyMzg_1bbd998b-af18-49f8-9f2e-d40fae0dbf62">3.47</ix:nonFraction>%.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The excess of the carrying value over the estimated fair value of debt was $<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-8" name="jnj:ExcessOfCarryingValueOverFairValueOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTEzMTg_25eb046b-7ffd-40ef-b847-788f15bc2d11">1.6</ix:nonFraction> billion at January 1, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2023, Kenvue, a wholly owned subsidiary of the Company, priced an offering of senior unsecured notes in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i30b84b721a8a47b89119d6e1923faac2_I20230331" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfNTQ5NzU1ODM2NjY1_d969074d-d220-4127-886e-adf40259c15a">7.75</ix:nonFraction>&#160;billion (tranches with an * in the above table). The senior unsecured notes (the Notes) will be senior unsecured obligations of Kenvue and will initially be fully and unconditionally guaranteed (the Guarantees) on a senior unsecured basis by the Company. The Guarantees will terminate upon (1) the completion in all material respects of the transfer of the assets and liabilities of Johnson &amp; Johnson&#8217;s Consumer Health Business to Kenvue and (2) Kenvue having registered equity securities. The Notes were issued in connection with Johnson &amp; Johnson&#8217;s separation of its Consumer Health Business. The proceeds of the Notes offering were placed in a segregated escrow account pending the transfer of the assets and liabilities of the Consumer Health Business to Kenvue and as such, classified as restricted cash as of the balance sheet date. On April 5, 2023, the net proceeds of the Notes were released from escrow upon completion of the Consumer Health Business transfer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current debt balance as of April&#160;2, 2023 includes $<ix:nonFraction unitRef="usd" contextRef="i61afdda999f44da2a95e6ba9519c4fa0_I20230402" decimals="-8" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTEzODU_6811fb0b-a788-41d7-8650-7152ca84f6cc">16.9</ix:nonFraction>&#160;billion of commercial paper which has a weighted average interest rate of <ix:nonFraction unitRef="number" contextRef="i61afdda999f44da2a95e6ba9519c4fa0_I20230402" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE0NTQ_200c8738-8388-4adf-be46-9ce8ba7b2451">4.85</ix:nonFraction>% and a weighted average maturity of approximately <ix:nonNumeric contextRef="i3e12ceb17aec40709533c417fa7976aa_D20230102-20230402" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE1MDY_21c83a68-67e6-4d7c-9c94-230a585dcc58">three months</ix:nonNumeric>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div></ix:continuation><div id="i7c615dc7aec24dc98e6c850313251c4e_67"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 5 &#8212; <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfMzUxMw_7fb6b2bc-6574-4980-922b-7b11d5cc1103" continuedAt="i39b01644ce79447a8f5f4844ec4b993c" escape="true">INCOME TAXES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i39b01644ce79447a8f5f4844ec4b993c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rates for the fiscal first quarters of 2023 and 2022 were <ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfMTE1_5f287730-668d-41d0-94e6-90f90789c531">90.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfMTIy_d3ee8309-8ae5-425a-928d-976ae786159b">12.2</ix:nonFraction>%, respectively. This increase in the consolidated tax rate as compared to the prior year fiscal first quarter is primarily due to a $<ix:nonFraction unitRef="usd" contextRef="ia2a87b5a064e4c7a899475e0dbadc527_D20230102-20230402" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfNTQ5NzU1ODI1MzUy_3573de1e-c6f1-4035-9d87-cfa18a81171b">6.9</ix:nonFraction>&#160;billion charge related to the talc settlement proposal at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="ia2a87b5a064e4c7a899475e0dbadc527_D20230102-20230402" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfNTQ5NzU1ODE4MDAw_3aa79f01-d353-476f-832e-4aaffc5e75f4">23.5</ix:nonFraction>% (for further information see Note 11 to the Consolidated Financial Statements).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the first fiscal quarter of 2022, there were favorable tax benefits due to income mix for mark to market adjustments to the Company&#8217;s investment portfolio and the impairment of the bermekimab AD IPR&amp;D, both at the U.S. statutory rate. Additionally, the prior year&#8217;s effective tax rate benefited from the impact of certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in 2022. These benefits were partially offset by incremental tax costs directly related to the planned separation of the Company&#8217;s Consumer Health business in the first fiscal quarter of 2022 as compared to the first fiscal quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company also received tax benefits from stock-based compensation that were either exercised or vested during each of the fiscal first quarters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of April&#160;2, 2023, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i50e2318413734df39c6c543008cbcb21_I20230402" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfMjY5Mw_ce1f02e4-9aba-4edc-812f-1031364563d0">3.8</ix:nonFraction> billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities in the next 12 months. As a result, the Company has classified approximately $<ix:nonFraction unitRef="usd" contextRef="ie7987f4710274da781b044c04aa38be0_I20230402" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfMzI5ODUzNDg5NDg3MQ_24b7b4e4-61ae-424a-9982-aa6912915ac9">1.7</ix:nonFraction>&#160;billion of unrecognized tax benefits and associated interest as a current liability on the &#8220;Accrued taxes on Income&#8221; line of the Consolidated Balance Sheet as of the end of the first fiscal quarter of 2023 in anticipation of final settlement. Subsequent to April 2, 2023, the Company made a payment for approximately $<ix:nonFraction unitRef="usd" contextRef="i3ec8770b399d406faad6d9a6b24fac59_D20230403-20230701" decimals="-8" name="jnj:UnrecognizedTaxBenefitLiabilityPayment" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfNTQ5NzU1ODI1NDQ2_e9f65f99-23ae-4b99-bad2-16a47ec88973">1.4</ix:nonFraction>&#160;billion to the U.S. Treasury for the estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Company&#8217;s unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 6 &#8212; <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RleHRyZWdpb246NmEyYjU2YjZjNzhkNDE5Njk2YjE2MmZhNzhiYWFmMTJfMTAwMg_f7d63153-a70a-4a7c-ac5f-9025c98f5880" continuedAt="i9d8878c6aaec4a4aa817f75cabfee382" escape="true">PENSIONS AND OTHER BENEFIT PLANS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9d8878c6aaec4a4aa817f75cabfee382"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RleHRyZWdpb246NmEyYjU2YjZjNzhkNDE5Njk2YjE2MmZhNzhiYWFmMTJfMTAwNg_c2f0bfee-4e38-4b9f-8cc2-58ee42218402" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.877%"><tr><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.763%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMy0yLTEtMS0xMTU2Mjc_b1b8f5fa-7e4f-429d-ad80-a79f750828ec">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMy00LTEtMS0xMTU2Mjc_2c534e4a-81f3-42ee-8c7b-b4a833599e14">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMy02LTEtMS0xMTU2Mjc_25b5e637-1b85-4cbe-8ec4-b2b9afafe4fa">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMy04LTEtMS0xMTU2Mjc_f2d9d74e-2358-4ef2-99b9-159a7d90f502">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNC0yLTEtMS0xMTU2Mjc_a5135c6b-4ebe-4f62-9400-46c04e7d5a5f">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNC00LTEtMS0xMTU2Mjc_93e227f3-9f7d-4c3e-be86-c62d47f00992">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNC02LTEtMS0xMTU2Mjc_550c8788-6a21-4c68-a6be-560bfbd74ac8">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNC04LTEtMS0xMTU2Mjc_500c6408-9832-422b-b08a-be0816b8dae8">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNS0yLTEtMS0xMTU2Mjc_4df40baa-ea5b-4d65-bd9a-e872e4ad7dc2">668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNS00LTEtMS0xMTU2Mjc_eabc71b0-7d72-4816-ac26-0509806adbde">699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNS02LTEtMS0xMTU2Mjc_88f8debe-b1a7-4d9e-8bf8-648ce922aa55">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNS04LTEtMS0xMTU2Mjc_20f54a12-fcca-4490-8bb7-c4b045cbdbdb">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNi0yLTEtMS0xMTU2Mjc_95b8e18e-bea7-45b0-ac65-9e48ba4cdd29">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNi00LTEtMS0xMTU2Mjc_d6cc2d09-f067-43ab-ae43-edd514001760">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNi02LTEtMS0xMTU2Mjc_de5ba8b5-d10b-455c-b8f0-d863b8d20126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNi04LTEtMS0xMTU2Mjc_51955ed1-5fbb-493d-b03c-b092bdbdb3a6">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial (gains) losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOC0yLTEtMS0xMTU2Mjc_dad724dc-6128-4332-a4ef-8fb1964cba2b">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOC00LTEtMS0xMTU2Mjc_0d1e960c-220d-489f-bf22-dcf568dff429">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOC02LTEtMS0xMTU2Mjc_17b9c0e1-2941-4556-9abb-ee545aebaacd">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOC04LTEtMS0xMTU2Mjc_9a1fde3a-234c-4a66-9aa8-eca20372f0b0">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOS0yLTEtMS0xMTU2Mjc_48e3feda-9ee2-49fa-9a92-41010275f8c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOS00LTEtMS0xMTU2Mjc_349e5c86-43cd-43cb-ba68-bb2fd84d9397">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOS02LTEtMS0xMTU2Mjc_0607a308-955f-43b3-882c-dcc632379af8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOS04LTEtMS0xMTU2Mjc_aef6bc9f-ac04-4329-82a4-16dc1d95e062">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMTAtMi0xLTEtMTE1NjI3_a1fb9b2d-eec4-4049-8574-576b6d37df7a">198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMTAtNC0xLTEtMTE1NjI3_6f6060fa-f1a5-4b4e-8a77-acd3fff1e500">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMTAtNi0xLTEtMTE1NjI3_00c741b6-e436-4bc1-8fc6-738d724916ef">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMTAtOC0xLTEtMTE1NjI3_9d0dc196-fa6e-4d75-a4c1-594468500455">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company Contributions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal three months ended April&#160;2, 2023, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i6a79593849c348e791c81a2228ea6405_D20230102-20230402" decimals="-6" name="us-gaap:PensionContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RleHRyZWdpb246NmEyYjU2YjZjNzhkNDE5Njk2YjE2MmZhNzhiYWFmMTJfNzQy_807469ac-7d9b-4260-a31b-b2efcdc4c526">27</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7b50bef376d94029914fd830a153b7aa_D20230102-20230402" decimals="-6" name="us-gaap:PensionContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RleHRyZWdpb246NmEyYjU2YjZjNzhkNDE5Njk2YjE2MmZhNzhiYWFmMTJfNzQ5_21cc35be-a64f-4807-b269-beda9f5fd5a9">6</ix:nonFraction> million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.</span></div></ix:continuation><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_73"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 7 &#8212; <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RleHRyZWdpb246ZGExZjNiYjIxNDIwNDJlY2I3NmIwNDVjNzdjNGQ3ZmVfOTI5_99e2387e-fafe-4c76-9b2f-8d778525c669" continuedAt="i892321d6ce9947f08e2f26bd79218e3e" escape="true">ACCUMULATED OTHER COMPREHENSIVE INCOME</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i892321d6ce9947f08e2f26bd79218e3e"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RleHRyZWdpb246ZGExZjNiYjIxNDIwNDJlY2I3NmIwNDVjNzdjNGQ3ZmVfOTM2_ccef692f-5ad7-45d9-b178-7b4e0084d003" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:34.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.719%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.991%"></td><td style="width:0.1%"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b6f17374cb84625bb4b63c7a5d62e2c_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNC0yLTEtMS0xMTU2Mjc_175169a6-166d-4a11-9d2e-1163c3e9a8c0">11,813</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia51b75ec8ed24459b26207e74f51ad4d_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNC00LTEtMS0xMTU2Mjc_67ece337-51e5-4fb7-ae5f-e5ebffc6216e">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i39da497bc9a345169e8c633fc9ccb4c8_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNC02LTEtMS0xMTU2Mjc_80d3f77e-2ad9-44ef-9a77-d82c3f3488aa">897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f8ef72c3cba4a74a4cbe42bd9004f33_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNC04LTEtMS0xMTU2Mjc_4aadc106-7089-44b7-ae7f-300b75c1bed1">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77ff9cf53ba540b9a5e6aeca7ca5804f_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNC0xMC0xLTEtMTE1NjI3_54c1c48c-f526-49c9-bbf0-99259af9f19a">12,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNS0yLTEtMS0xMTU2Mjc_9cd28387-fc27-4a64-8187-c29f08fd5d1f">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNS00LTEtMS0xMTU2Mjc_df17b72d-66be-4ae8-806e-592e9b2be9d1">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNS02LTEtMS0xMTU2Mjc_6b19ecd1-6da5-4006-883c-c15b9c90ac48">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNS04LTEtMS0xMTU2Mjc_e9a1f846-30b2-4338-869c-97a02953536e">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNS0xMC0xLTEtMTE1NjI3_973eb5f5-a216-4161-b947-722a78d3ef74">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b26df561bd946948e1a78379354d9b5_I20230402" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNy0yLTEtMS0xMTU2Mjc_1e35fb8f-8bf1-4ab3-b0f2-eefcef916a1a">11,994</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03d933225100466a8dad732be7b062f9_I20230402" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNy00LTEtMS0xMTU2Mjc_2f07e1e5-5269-4d8b-855c-1262d55d7cb6">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99a10cb23bf04c2a9aefd04cd01d1d5b_I20230402" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNy02LTEtMS0xMTU2Mjc_f6f09361-602f-487d-90a0-26eebd72061c">965</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248120dc95c44c078c9b33b2c6c60b4d_I20230402" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNy04LTEtMS0xMTU2Mjc_b8656267-9d90-4482-b603-5eadac34e046">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i455ec88d396c41248d806ba599269e74_I20230402" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNy0xMC0xLTEtMTE1NjI3_e29cee0d-c11a-41d1-aaf2-c0e67f628de3">12,626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i7c615dc7aec24dc98e6c850313251c4e_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 8 &#8212; <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RleHRyZWdpb246ZmQ3YTY4MzNhZTE2NDU3Njg0NDU3YWUwMGNjODJlNGNfNjEz_8f730cb3-d686-46b2-bf8c-e62c6afaad40" continuedAt="i14ef3e07e31b41fd838ae7d59366b635" escape="true">EARNINGS/(LOSS) PER SHARE</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i14ef3e07e31b41fd838ae7d59366b635" continuedAt="i22d86d70503e4b418d01de286aabe860"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RleHRyZWdpb246ZmQ3YTY4MzNhZTE2NDU3Njg0NDU3YWUwMGNjODJlNGNfNjAy_95702610-5be1-4caa-9e50-46667f677d6f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings/(loss) per share to diluted net earnings/(loss) per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.454%"><tr><td style="width:1.0%"></td><td style="width:69.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.789%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.919%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.068%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings/(loss) per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfMi0yLTEtMS0xMTU2Mjc_e53e200b-326e-44d6-bafd-0989b8dfccc2">0.03</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfMi00LTEtMS0xMTU2Mjc_bfda86c1-fbe1-4d7a-874d-d058059fc8c8">1.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfMy0yLTEtMS0xMTU2Mjc_dc565ae9-f6cf-4068-92b6-b532ae9d482f">2,605.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfMy00LTEtMS0xMTU2Mjc_ca263a88-a897-4b52-8f6b-5b54f84ff1d1">2,629.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfNC0yLTEtMS0xMTU2Mjc_936639ed-c76d-4679-aad8-b9e9022c582e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfNC00LTEtMS0xMTU2Mjc_266698a9-2ce8-434a-b375-9a266f6b227b">140.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfNS0yLTEtMS0xMTU2Mjc_f69a5f77-0763-45ea-9702-8230d6ea5b34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfNS00LTEtMS0xMTU2Mjc_8be35c6d-93dd-4694-85cb-0a1119722e91">102.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic/diluted*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfNy0yLTEtMS0xMTU2Mjc_2122c920-d92c-4823-b6da-68fa325de703">2,605.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfNy00LTEtMS0xMTU2Mjc_2faa52ce-c359-461a-8d04-1b14715d6af4">2,666.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings/(loss) per share (basic/diluted)*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfOC0yLTEtMS0xMTU2Mjc_588cbd4f-dd03-44a2-a253-ca05e0f716ce">0.03</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfOC00LTEtMS0xMTU2Mjc_c10140f6-4fe3-4b13-a379-bce6e8400bba">1.93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i22d86d70503e4b418d01de286aabe860">The diluted net earnings per share calculation for the fiscal first quarter ended April&#160;3, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">* Basic shares are used to calculate loss per share when in a loss position.</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.327%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i7c615dc7aec24dc98e6c850313251c4e_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 9 &#8212; <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfNDIxNQ_751c933b-bdf4-40d8-9377-2048cbbf6dad" continuedAt="iff9b5df9fa5e48e799dd88da29608257" escape="true">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iff9b5df9fa5e48e799dd88da29608257" continuedAt="i8ff1410928dd486a9cbc6d824f31e4a6"><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="jnj:SalesBySegmentOfBusinessTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfNDIwNA_52ef2f98-9612-4488-bf5f-0a5d07459eba" continuedAt="if72a8dae95224a9fa1ee0efa44759ee6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaf739bb046840338e03bd31a098d3ec_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNS0yLTEtMS0xMTU2Mjc_d4d5fef9-b41f-41fb-a476-28c100ad1bda">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib70396f99f564ac9938bee2564160961_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNS00LTEtMS0xMTU2Mjc_9806183b-760e-4f02-91f2-93582d3911c5">670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaaf739bb046840338e03bd31a098d3ec_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNS02LTEtMS0xMTU2Mjc_7a16b98a-8776-471a-b020-0d112d814acd">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if52ae96f4fc946d0926968e3c2defc87_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNi0yLTEtMS0xMTU2Mjc_a4966656-cff8-4fc8-ae7d-759e4e7ae61e">897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41317b52070e4c52a074c754ab815d1c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNi00LTEtMS0xMTU2Mjc_d34460b4-fc8f-4099-a7a4-c5d222787a85">791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if52ae96f4fc946d0926968e3c2defc87_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNi02LTEtMS0xMTU2Mjc_6edb572f-76f6-46ec-ab3e-d02d42d59594">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c740c593a5e49d1a9b8f5e7e616b946_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNy0yLTEtMS0xMTU2Mjc_efb74bc6-ed94-4ba0-9d64-348f70dfbb8a">1,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i984d66aa451f4fddafb447e2b3a07b38_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNy00LTEtMS0xMTU2Mjc_28e9910e-fcd5-4d46-bc5a-c0bb990d2640">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c740c593a5e49d1a9b8f5e7e616b946_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNy02LTEtMS0xMTU2Mjc_61c26106-72ff-467c-bb05-e6186365892a">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaa2e564e1714834a088812e21dfe9e7_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOS0yLTEtMS0xMTU2Mjc_052493f5-d80f-47a4-aba3-df16f6a2a3fc">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85292bb163e24d1a8b532b0152757469_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOS00LTEtMS0xMTU2Mjc_5aed0654-62ed-481b-b557-efc664999626">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieaa2e564e1714834a088812e21dfe9e7_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOS02LTEtMS0xMTU2Mjc_7eddff93-c512-4bc6-927c-659887ee0220">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff776c204ddd4fe4af24bb0222ea1874_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAtMi0xLTEtMTE1NjI3_2c8b01b7-da78-4ee3-84c7-710e20e29715">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07b3f305984a48ad85f9a74e74005373_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAtNC0xLTEtMTE1NjI3_9f6c3e1b-3fb5-4b06-a119-80791afbe2d3">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff776c204ddd4fe4af24bb0222ea1874_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAtNi0xLTEtMTE1NjI3_fcf2c36b-faf4-4297-b29c-6cadea5813d2">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ae31c7c436415cacd6f0634ac5e358_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEtMi0xLTEtMTE1NjI3_92794257-273e-41b6-9738-9b2b69a5c7fb">1,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a06685196204a4799f887412650fe40_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEtNC0xLTEtMTE1NjI3_79ed43cf-00bf-42c4-894b-0e3fa72dfc98">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i25ae31c7c436415cacd6f0634ac5e358_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEtNi0xLTEtMTE1NjI3_7912db33-fbc2-455b-9289-d34c7d892487">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15733073985a4ce5959e11ca5f252bf1_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMtMi0xLTEtMTE1NjI3_cdf62cbe-d2f5-4304-b1e0-b99b7c55ccb3">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e96376a42a04152b58e3882a9b14ef3_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMtNC0xLTEtMTE1NjI3_ebc16545-a2a5-4cac-b031-daa818f111cc">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15733073985a4ce5959e11ca5f252bf1_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMtNi0xLTEtMTE1NjI3_f6fe2664-d715-4588-8905-6b004b0fec13">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579190aae8a9475783a0704c6aa14097_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQtMi0xLTEtMTE1NjI3_2428aef2-37d5-4470-a242-41c32a608cca">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c3a3dafb62444ad8218b38dd1ed838e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQtNC0xLTEtMTE1NjI3_edecf5f8-a849-4f8d-afab-04b9153223b2">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i579190aae8a9475783a0704c6aa14097_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQtNi0xLTEtMTE1NjI3_d634a0b5-09c8-4b10-b5dd-4f3d61d01dc3">9.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8851c22232454e975ee3658a578864_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUtMi0xLTEtMTE1NjI3_44c60ca4-4082-4734-8e2a-7e9d74aa5f6c">361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c3fc8b5552e4871a6f2db9f1a367083_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUtNC0xLTEtMTE1NjI3_fffd25c3-2b41-41e5-9fb8-75ab0d1a728f">366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9a8851c22232454e975ee3658a578864_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUtNi0xLTEtMTE1NjI3_bd6767e6-c857-4d8e-a37d-cfc873b998d2">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c9625e879e043e09db9ba52fa49c414_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTctMi0xLTEtMTE1NjI3_e10a5d46-3ed1-4a2c-9995-fa1055e51f0f">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77d45dffb4d24df982e0a69a2edb48b5_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTctNC0xLTEtMTE1NjI3_85767dbf-0a81-4651-9d25-42655f74e132">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c9625e879e043e09db9ba52fa49c414_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTctNi0xLTEtMTE1NjI3_787fba13-d986-42c9-9be3-496ece12d07d">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37a140c2966c4d39be0eb69abb0cd291_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTgtMi0xLTEtMTE1NjI3_b90c6485-88b8-4dc4-b45b-c0c27ca7384d">263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if081b963d9144c09a6d20b20d26d3d66_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTgtNC0xLTEtMTE1NjI3_1e1ffca3-842e-4381-b51b-f7fb2d0fd903">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i37a140c2966c4d39be0eb69abb0cd291_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTgtNi0xLTEtMTE1NjI3_2de1810a-5b47-45c9-b02b-58e6c2b5ef1e">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01f0cdd79a5d41e2b78a6bf7fcb0b94f_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTktMi0xLTEtMTE1NjI3_a6ede553-a9f8-4cab-b259-2ba092407e3b">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id17d813e9a0a41f89c0e446fdf68e56a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTktNC0xLTEtMTE1NjI3_2b6bf766-1ad0-4ced-b996-8449e7c5b414">355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01f0cdd79a5d41e2b78a6bf7fcb0b94f_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTktNi0xLTEtMTE1NjI3_959e02ad-ae5e-4ea0-8572-ef617df3bb83">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0aee6f09e5488091b12bba39e31ee2_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEtMi0xLTEtMTE1NjI3_481cb609-6cac-4d75-8899-631f45b6082d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c384167ae1453abbb9d0b6c0c04854_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEtNC0xLTEtMTE1NjI3_c1251064-9488-4ca8-8b34-1b96b894f246">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8f0aee6f09e5488091b12bba39e31ee2_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEtNi0xLTEtMTE1NjI3_5a02a9ea-1654-4561-a3e3-6b3eedb73fdb">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i736ac00e11af42359794eaeaddc3a97a_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjItMi0xLTEtMTE1NjI3_cb9c5454-65d7-41c1-b89d-27f8ac6964b6">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacbe869dfec46a8be4b9c12f04f7cc6_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjItNC0xLTEtMTE1NjI3_2944edbf-b6e9-4716-9f21-8a1a2af0005f">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i736ac00e11af42359794eaeaddc3a97a_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjItNi0xLTEtMTE1NjI3_42d71047-ace2-4006-a9f3-8b917222e915">4.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f04259b9e384d4386a146f306a64433_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMtMi0xLTEtMTE1NjI3_a1640853-4c2b-4443-95b0-8ddddbd522a9">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4456f20d70b4883b575d2169dd71544_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMtNC0xLTEtMTE1NjI3_a5d421cc-8957-4918-b1ba-efc25364d7ff">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9f04259b9e384d4386a146f306a64433_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMtNi0xLTEtMTE1NjI3_a81c1eab-172e-4dd3-9f19-9a81ddd9d40d">4.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2627fcecbe54a53bd26bd35bb03ae37_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjUtMi0xLTEtMTE1NjI3_0d46fc0d-34e4-41b5-8811-57deee2ace5b">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7f08dd82e14407f93f9374ec1c64bba_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjUtNC0xLTEtMTE1NjI3_20fa074d-e4a1-4fac-9d9b-b359ff60cc8a">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie2627fcecbe54a53bd26bd35bb03ae37_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjUtNi0xLTEtMTE1NjI3_f6ad2d1d-19dc-4f3e-9465-30d69ffa66f8">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63462697f7cb451f9132abc3d2242368_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjYtMi0xLTEtMTE1NjI3_9f9155a6-dada-486e-ac04-645fbdf0111c">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e48079566be4bc3891e3fe4dd109037_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjYtNC0xLTEtMTE1NjI3_4a74ea9c-8c08-4cc8-8b4e-79000fee4ac7">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i63462697f7cb451f9132abc3d2242368_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjYtNi0xLTEtMTE1NjI3_3a0ddad3-6fe2-4193-8b8a-64687e9946e4">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29728a150c174ada8da66efe8fb411d7_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjctMi0xLTEtMTE1NjI3_41430659-843e-44ea-a083-26682ebfb206">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262a53f9ec2547dc9bc3e7376b7a007a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjctNC0xLTEtMTE1NjI3_deb3906d-a27b-4578-a195-d208cfaf900c">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i29728a150c174ada8da66efe8fb411d7_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjctNi0xLTEtMTE1NjI3_5330d7bd-da46-4385-8b4c-ae3c785f7ecd">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4510efc748d54bb7930912ba6509e096_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjktMi0xLTEtMTE1NjI3_f2d9fb92-b8a7-42cc-835e-46d0cc69cb05">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i767c65868b3d4650833e3270ece3465a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjktNC0xLTEtMTE1NjI3_f3cc47d3-3b4a-4337-863e-268ee65695b5">1,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4510efc748d54bb7930912ba6509e096_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjktNi0xLTEtMTE1NjI3_5e036ded-6f0e-4b75-895a-ad3b4d33d6ce">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b25c8c23a664e359b78c1353fbb6375_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzAtMi0xLTEtMTE1NjI3_34541deb-92bb-48ce-9c1a-7d4a377bed61">2,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e4c728c6f644bf29493a4b4e9dad170_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzAtNC0xLTEtMTE1NjI3_08c16e9f-cdc5-49e4-8fcc-b71aeb67dd62">2,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b25c8c23a664e359b78c1353fbb6375_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzAtNi0xLTEtMTE1NjI3_a7b2b5b0-4e04-425e-8670-d1312d4ef780">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26cdc03025f14afa93aeea4d2797344e_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzEtMi0xLTEtMTE1NjI3_e1d8257b-7185-418f-82fb-78d599dcf91f">3,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0598fae3f054742badc9b82185f5c04_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzEtNC0xLTEtMTE1NjI3_bd7cd5ce-75eb-41a4-be4f-6f7ddf1c5ee4">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26cdc03025f14afa93aeea4d2797344e_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzEtNi0xLTEtMTE1NjI3_b028e2f7-a4c7-4335-8ce0-05e97ebc7bd4">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i8ff1410928dd486a9cbc6d824f31e4a6" continuedAt="id32ddee10dfa4f43af81e5429217dcee"><ix:continuation id="if72a8dae95224a9fa1ee0efa44759ee6" continuedAt="i16e25211b3ef40c09d6390050540db6f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18dc481a2ecf4435be42bac0b2119b30_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzYtMi0xLTEtMTE1NjI3_70c96096-91c1-48bf-8e76-3dda0384f86b">2,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4623992e0dd14d1a9e9f595afd28bd4a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzYtNC0xLTEtMTE1NjI3_2d2ef260-64e9-4fd7-abc2-01c87c32a75b">2,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i18dc481a2ecf4435be42bac0b2119b30_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzYtNi0xLTEtMTE1NjI3_c9c1d94f-f30f-4706-b0d3-463da4012d1d">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e5f74d7507448aa8240b9c69285bd57_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzctMi0xLTEtMTE1NjI3_1c4ba8e1-3d7f-4c25-a664-5772fd2b0d45">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0ee1a5c112245ef922eeb1907bc70a7_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzctNC0xLTEtMTE1NjI3_87fae189-9322-4824-83a6-9c5360821ab3">1,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e5f74d7507448aa8240b9c69285bd57_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzctNi0xLTEtMTE1NjI3_09c5a6c0-0e94-41c4-a6e1-b9d5cc9db82e">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29c3c1f4c5bf4928852da60e04089160_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzgtMi0xLTEtMTE1NjI3_bac3e36d-3f3c-418f-91f6-a8d09a8a5e72">4,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d74a9d646040ac8bda4a109e5316d2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzgtNC0xLTEtMTE1NjI3_1231c53f-2635-40d8-a466-2655d4b13174">4,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i29c3c1f4c5bf4928852da60e04089160_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzgtNi0xLTEtMTE1NjI3_79cff87d-0b0b-47ab-aa3e-a186fb055865">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1e47778732e44aea0320f24635c55e6_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDAtMi0xLTEtMTE1NjI3_09bff553-57d4-4272-a8f5-39571f831c20">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i000088d3af5046b2921cb4af5f6fc205_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDAtNC0xLTEtMTE1NjI3_c89697d7-e94d-4038-852b-3480f1cc70d3">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib1e47778732e44aea0320f24635c55e6_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDAtNi0xLTEtMTE1NjI3_596e92b7-71df-4593-ace3-41388e741496">22.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide60c30a5fc749e0b67837f69ae698e5_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDEtMi0xLTEtMTE1NjI3_803fdb68-1818-402f-ae22-930bada23b0e">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b79714bdfb42359807a488bf5a74ec_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDEtNC0xLTEtMTE1NjI3_87112034-54cd-4821-805f-66835eb014d1">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ide60c30a5fc749e0b67837f69ae698e5_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDEtNi0xLTEtMTE1NjI3_a4d51fc3-9141-4efc-a031-fdc9efa1c860">48.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i359821ae58ad4ff8a87eaa12e4efdb78_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDItMi0xLTEtMTE1NjI3_d3a7d674-1522-4bdd-9baf-76883ab40441">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10d2670c3b13416fb7a206927fd88687_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDItNC0xLTEtMTE1NjI3_38efce56-ceb5-4b58-9ea5-42cad29266ac">225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i359821ae58ad4ff8a87eaa12e4efdb78_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDItNi0xLTEtMTE1NjI3_7a876792-845c-4ee3-86c6-637837a5df3d">24.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd662d1267e49139b46c4a297215a54_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDMtMi0xLTEtMTE1NjI3_96f767a4-944f-47fb-b8e5-7dc90b698af4">487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef2ee88e44043efbb8a96f8b9d8c89d_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDMtNC0xLTEtMTE1NjI3_ffc1dddb-8084-4f03-a46c-6c1306aab0e2">663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1cd662d1267e49139b46c4a297215a54_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDMtNi0xLTEtMTE1NjI3_4a758182-fbd9-4a84-b419-c072dff74d9f">26.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie188724cc3dd4a949ef2fbaa68fca7b1_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDUtMi0xLTEtMTE1NjI3_db67127a-f0f2-44ce-b6a4-747b4f1bbe43">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31b8c4e7570d486f9a67881129d6fa3a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDUtNC0xLTEtMTE1NjI3_92b86d89-3ef1-42cd-8b8b-8687b8edb075">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie188724cc3dd4a949ef2fbaa68fca7b1_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDUtNi0xLTEtMTE1NjI3_16700b05-d8e0-463d-8672-f169fbe9b794">5.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339e5f7a0cc1453d976a0dc292d89c27_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDYtMi0xLTEtMTE1NjI3_bff3c634-3177-4eaa-87cf-ac62b34b1c0c">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2ce733a0ef4e72980327ed5e0107f8_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDYtNC0xLTEtMTE1NjI3_b19259fd-8bea-43b5-85c8-fba7a9938f6f">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i339e5f7a0cc1453d976a0dc292d89c27_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDYtNi0xLTEtMTE1NjI3_29343a1d-4088-444b-aca7-5bf468928880">6.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b9072482295465bb3ae5b67b3338abb_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDctMi0xLTEtMTE1NjI3_b4672c3d-8fef-4542-a63e-21c1107b966e">537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec663daee5fb47d4a96c14b56bbddb1c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDctNC0xLTEtMTE1NjI3_2d6093c1-5971-4b4f-8c39-14350738318d">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0b9072482295465bb3ae5b67b3338abb_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDctNi0xLTEtMTE1NjI3_470cb763-f7e8-4340-9959-08f16c0f546f">5.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dba4cd103d24bc9b66b596eab786d18_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDktMi0xLTEtMTE1NjI3_11f4df22-2bac-4ef1-a2fb-40e6563cbffa">1,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68917d7a1b8842be98f382c714c21a1e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDktNC0xLTEtMTE1NjI3_ed33ff26-742e-4225-936d-aba0e031a1c2">1,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1dba4cd103d24bc9b66b596eab786d18_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDktNi0xLTEtMTE1NjI3_1ca4af57-5807-422b-9dd1-e0f12c7e6676">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cedda0d436f4730a24d2cce6e535f50_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTAtMi0xLTEtMTE1NjI3_befffdd0-ca88-4ef4-851e-cfa470af28b7">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b46548a1c9e4da6ade074b1560663d9_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTAtNC0xLTEtMTE1NjI3_de782d99-75a4-4a78-881a-784570630f9d">909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3cedda0d436f4730a24d2cce6e535f50_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTAtNi0xLTEtMTE1NjI3_9479af77-d193-429c-ac05-dc60e9badc93">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf3bbabc22fe40489b09d4860798d9fc_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTEtMi0xLTEtMTE1NjI3_e2403ab8-498f-4f2d-a90b-3d8d691887b6">2,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc26d7592994955bfeeae65142c46b8_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTEtNC0xLTEtMTE1NjI3_4f5d2533-12d8-4a56-9190-44243d77fa63">2,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idf3bbabc22fe40489b09d4860798d9fc_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTEtNi0xLTEtMTE1NjI3_be52200f-e01c-470e-97a5-d33f375a0120">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43daf65754947459d5aba53e5b92e81_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTMtMi0xLTEtMTE1NjI3_d06a10ff-d41e-45e2-9384-d874c9c1574a">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8a2811670fd4e388c4cff13e473d4c0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTMtNC0xLTEtMTE1NjI3_fbcccbd8-e972-4684-b4f1-89a2cd54f5bb">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic43daf65754947459d5aba53e5b92e81_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTMtNi0xLTEtMTE1NjI3_055717fc-e6d7-4de8-b4cf-0e7dca491def">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if25545d4d3224f2683d6c36402df6c2c_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTQtMi0xLTEtMTE1NjI3_013160d9-2cf4-4275-8b49-b79544a81866">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i583fb109cf304e3293199bb1d895aece_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTQtNC0xLTEtMTE1NjI3_59dd3981-2aa2-4063-92c0-a496475e5c9b">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if25545d4d3224f2683d6c36402df6c2c_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTQtNi0xLTEtMTE1NjI3_569781e2-8962-4344-a4ab-5e92c0d7e9a0">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d6adf3e8198442a90339cfc887ae4e4_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTUtMi0xLTEtMTE1NjI3_a481a3c1-e342-4fcd-b96c-06cd090d4f7b">640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63aa3f3d8b9249c185e61668767dfbf3_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTUtNC0xLTEtMTE1NjI3_68b67633-92e5-4276-8d5f-d6863f1e4774">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d6adf3e8198442a90339cfc887ae4e4_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTUtNi0xLTEtMTE1NjI3_299fae68-3919-4bb6-83d7-c61027adac44">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602b3a8f8c684e07855a432b44f877e7_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTctMi0xLTEtMTE1NjI3_b9f3c09c-ae93-4e69-8dc3-d9fc2c840b18">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i057cb94031764e83922e91e90e55ad2a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTctNC0xLTEtMTE1NjI3_afd960f0-c100-454d-8e34-94d913397782">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i602b3a8f8c684e07855a432b44f877e7_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTctNi0xLTEtMTE1NjI3_ab8d14b0-ddba-4cf2-8876-3844e6918b56">51.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f466a267f5244d987f9d84b05b1dd94_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTgtMi0xLTEtMTE1NjI3_c47ee0a0-2dd2-40bb-8b1c-908be00b3cd7">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69aa70e212f144c0a94a01e8c886be13_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTgtNC0xLTEtMTE1NjI3_1ec09296-9c62-4c1f-b32c-a41ac18ea70d">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f466a267f5244d987f9d84b05b1dd94_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTgtNi0xLTEtMTE1NjI3_cd4ee39b-1103-4d86-ab1d-9bdfea45012b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1581f8ac08c84383b20e0e6e3b0b3231_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTktMi0xLTEtMTE1NjI3_bec26739-3277-493f-a45e-5c0284c41384">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64ff97d1a3024cd4aa22d2ca000bb716_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTktNC0xLTEtMTE1NjI3_33ead4c6-3f86-44cb-8986-292379e35707">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1581f8ac08c84383b20e0e6e3b0b3231_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTktNi0xLTEtMTE1NjI3_75efabb7-1a91-41eb-b469-ddabac7b690a">51.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea40143a881c4e9fa30c030d13484367_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjItMi0xLTEtMTE1NjI3_6b7517d6-c815-4604-b681-d2b1797958ac">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26bdbd0a33904170961ee857f7f75ec2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjItNC0xLTEtMTE1NjI3_0bfd7e58-a098-4fe5-90b5-428357ce0370">461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iea40143a881c4e9fa30c030d13484367_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjItNi0xLTEtMTE1NjI3_d85e94ed-49b6-4b0c-bcd7-40da91d22070">14.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a944b7eb27347a88ca02d5d4d2a3ae3_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjMtMi0xLTEtMTE1NjI3_f1e951bc-d8d9-4ea8-9cf4-1b4a52ffca60">1,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a5cd0e89145489b9adb25e4375d33c2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjMtNC0xLTEtMTE1NjI3_fa8bd4a7-edf0-4e1a-8187-058a85178cec">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a944b7eb27347a88ca02d5d4d2a3ae3_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjMtNi0xLTEtMTE1NjI3_0c38c725-7779-49ed-b33c-4f5f01fbda9c">42.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1731aeb98946a7b4ae917d048b33e9_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjQtMi0xLTEtMTE1NjI3_aacb7645-bb65-476a-bcd0-cd035ad4b353">1,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if862ee47ff57402ab4003df617f3cbb7_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjQtNC0xLTEtMTE1NjI3_aacb27bc-5060-4d8c-bf41-100f3f67932e">1,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d1731aeb98946a7b4ae917d048b33e9_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjQtNi0xLTEtMTE1NjI3_ff899036-561c-4dd8-8ea4-67ab05821cdf">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic411e2d070f641dda19f24eba87d762f_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjYtMi0xLTEtMTE1NjI3_95c630d0-07a1-4619-9dbe-2b6d0e655e63">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i617fe07827554cea8265f01074aeb1a0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjYtNC0xLTEtMTE1NjI3_0b13a310-a3f2-49a3-9fd7-599dd888ec44">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1d744c7c8d14f1fb8fea48cff62dbdd_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjctMi0xLTEtMTE1NjI3_aea6bd5d-5459-4477-800c-cf1a29be751d">747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ae5dd1fae940ffb2cc4d896705c30c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjctNC0xLTEtMTE1NjI3_f517bc5e-7abf-408a-a1ce-287c1036e071">382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1d744c7c8d14f1fb8fea48cff62dbdd_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjctNi0xLTEtMTE1NjI3_1ec0e427-f50d-4bd4-8e2a-b3979719b30c">95.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a022c685c4343d79523d6f83bf6d043_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjgtMi0xLTEtMTE1NjI3_a32414c9-fd5d-47f9-a084-55e44d6ef42c">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadbb5deb5a1b4cc08f416461ce834cf6_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjgtNC0xLTEtMTE1NjI3_5c42cb46-1f32-4571-8c52-ce64ef2c7d88">457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a022c685c4343d79523d6f83bf6d043_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjgtNi0xLTEtMTE1NjI3_084dd332-6b5f-4417-a5be-5c3decbef04b">63.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4967a757b464053a991e793b0594a48_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzAtMi0xLTEtMTE1NjI3_402fc18f-24a7-40a5-bdd5-8c610f49ddeb">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0098733b5de24bea987487c0dc5edf73_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzAtNC0xLTEtMTE1NjI3_d5c08343-095e-4fc6-9f37-581590abe0c4">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia4967a757b464053a991e793b0594a48_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzAtNi0xLTEtMTE1NjI3_23131f35-d4be-4a9c-a30a-a583a0ea2987">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a690fd862144f769bca79051212a40a_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzEtMi0xLTEtMTE1NjI3_eed7cc67-c310-4935-a6c9-2088a56658bc">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i131a7455bdfa4e3e8cee654b964e7506_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzEtNC0xLTEtMTE1NjI3_df8fe1f1-19f5-485d-b987-fc2e0cee4c7d">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a690fd862144f769bca79051212a40a_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzEtNi0xLTEtMTE1NjI3_cb301065-3e77-42fd-ad12-e53b235090e4">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id11db793f4614fa5837a25d9b63156c9_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzItMi0xLTEtMTE1NjI3_c3b8957f-0c89-4786-a011-bf58e7136e82">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5573f6f5a5d9481c98d29c616f628da0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzItNC0xLTEtMTE1NjI3_94fe5511-7e66-4054-8b70-49f2dbebbf59">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id11db793f4614fa5837a25d9b63156c9_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzItNi0xLTEtMTE1NjI3_daf5a880-0054-4e21-8219-c3a6b5a3f952">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59a8dcb5bf443089bf51815435371fa_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzQtMi0xLTEtMTE1NjI3_06391918-2a9e-43cb-9fab-43fc6a4c1deb">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03761710c3c6468698fff19815667abe_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzQtNC0xLTEtMTE1NjI3_af8a9760-d08e-4d4a-90c6-3b6d1d23ae93">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib59a8dcb5bf443089bf51815435371fa_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzQtNi0xLTEtMTE1NjI3_1ea76afb-d97d-4638-af40-a08d719797ff">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6d4e5e284b940f0abc9192313e3810c_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzUtMi0xLTEtMTE1NjI3_b4f65edb-c339-447f-983f-009d4f4097eb">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db52f7f1f8f4820addc27c47eeb5cee_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzUtNC0xLTEtMTE1NjI3_8c07fbab-73b4-4bad-85af-eaf688277bfb">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id6d4e5e284b940f0abc9192313e3810c_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzUtNi0xLTEtMTE1NjI3_6ab5d367-eae7-47b3-9c82-24135519f95d">25.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629cb97dd9014b8a9866cd4d248ef278_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzYtMi0xLTEtMTE1NjI3_521762d8-4a05-4d9a-b81d-1f01d5a75a5a">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7fe9702d8b45e98e6fe37ca13068af_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzYtNC0xLTEtMTE1NjI3_3be665ad-1b47-4ba7-90cc-258e961d50e7">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i629cb97dd9014b8a9866cd4d248ef278_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzYtNi0xLTEtMTE1NjI3_245b9ed6-593a-4cf8-b1bd-97accd0ac684">4.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="id32ddee10dfa4f43af81e5429217dcee" continuedAt="i7dc04fc786c44b85a75d9b2db453404e"><ix:continuation id="i16e25211b3ef40c09d6390050540db6f" continuedAt="id7f3a46bcb9846f6b64e3fbec258448e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79e147a672e45f0884726eebc14855e_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODAtMi0xLTEtMTE1NjI3_f83ff730-e0ea-4104-b812-a04857da1304">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb5a5fc555d24f308104655c998bf305_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODAtNC0xLTEtMTE1NjI3_8b265651-f93d-4c09-92fb-2d7ed74f49c9">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if79e147a672e45f0884726eebc14855e_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODAtNi0xLTEtMTE1NjI3_d5feb270-8b2e-4a54-af2c-f47b26ae03e9">33.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2615b59268ff4c7d937c9cf5cf4ce170_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODEtMi0xLTEtMTE1NjI3_ab95a9c1-095e-4441-9236-c2ac8a7d80fd">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c978427d57f48948b5dca33ba9a8790_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODEtNC0xLTEtMTE1NjI3_7997566d-b3e0-43e2-bff6-f5dc86e0e5bb">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2615b59268ff4c7d937c9cf5cf4ce170_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODEtNi0xLTEtMTE1NjI3_cd59d200-2d2a-4663-aa98-b8ea9bda3bf5">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i785d0ef07e4f4fc6899d3084d7bde419_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODItMi0xLTEtMTE1NjI3_a556973c-f024-4bb6-9870-96661844198c">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c0840358a442fea238d7d4ecefdddf_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODItNC0xLTEtMTE1NjI3_95269ce7-abcf-4898-9303-96c65bf4d4db">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i785d0ef07e4f4fc6899d3084d7bde419_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODItNi0xLTEtMTE1NjI3_7ea8081c-cda5-4bfe-81f5-558e046da3e9">9.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcfcee01500e40b6a181c5d82cba6ce5_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODUtMi0xLTEtMTE1NjI3_cdd62a4b-9654-4621-b8b6-5e20097c03fa">978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i044647ef59d14e6ca30f9418a2cb334e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODUtNC0xLTEtMTE1NjI3_d56571dd-e51e-4e11-b507-3fe9e62d4611">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibcfcee01500e40b6a181c5d82cba6ce5_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODUtNi0xLTEtMTE1NjI3_8b14ae13-3065-440d-8cf8-a7ceeba29c7f">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab3e83e7566542ea969c626ac4818791_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODYtMi0xLTEtMTE1NjI3_934c4938-b6cd-4e61-a9fe-a570754ccba0">826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54ff8960370c41909dbf45d3630c3d78_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODYtNC0xLTEtMTE1NjI3_7c71ff9b-c601-434f-acf1-b2c0983984e4">898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iab3e83e7566542ea969c626ac4818791_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODYtNi0xLTEtMTE1NjI3_ee25d6e6-75ca-4466-a2e2-1f39e16ff0a8">8.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ff8415c7ec740b5af1069a9d5615847_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODctMi0xLTEtMTE1NjI3_ad841059-6a23-4230-9cdb-b05d631d90b4">1,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if178d1ce94e54a8b9f23398ad0e2c083_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODctNC0xLTEtMTE1NjI3_593b1255-9392-4b06-b443-85e5a9ca3422">1,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ff8415c7ec740b5af1069a9d5615847_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODctNi0xLTEtMTE1NjI3_f07293a9-813e-4a29-883e-2df6cb36c56e">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2f647ec067747e6b33e6c21b46b9acf_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODktMi0xLTEtMTE1NjI3_61cfd7a2-49ea-4a4a-b704-f66684355cd3">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01edf890de640d3ad17b53da34d46f7_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODktNC0xLTEtMTE1NjI3_875e44d3-fb22-496d-8b33-04140e0c9a28">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17723664c2b44d548c8c8e8627ed427d_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTAtMi0xLTEtMTE1NjI3_14ef14d7-4699-49aa-9b76-6daee0447960">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaea78f2bf0b45eb910fc188d04fbfbd_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTAtNC0xLTEtMTE1NjI3_10685c1e-0cc0-44f8-b145-d8b406de0819">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17723664c2b44d548c8c8e8627ed427d_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTAtNi0xLTEtMTE1NjI3_9099611a-7c54-40ec-aee9-565ae773fe64">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11798e595eff476180e4de36a00ef239_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTEtMi0xLTEtMTE1NjI3_d55f31a7-a8aa-4f4e-9fe7-5fb88002cf2a">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83d752ce08cf496391503b82c9f8093e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTEtNC0xLTEtMTE1NjI3_cf5828be-310c-4f3a-bddd-3d475050d460">157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11798e595eff476180e4de36a00ef239_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTEtNi0xLTEtMTE1NjI3_30376965-cf14-47ff-80b3-345eb4d54621">31.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f629283443f49d8aaad385960bb0673_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTMtMi0xLTEtMTE1NjI3_78f2658a-a646-46ca-a3c2-a6cf992107c9">713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i093f63f72e8e49ecb668d13b75d40bb2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTMtNC0xLTEtMTE1NjI3_7578357b-acf6-4b3a-99af-797288ea9a3e">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f629283443f49d8aaad385960bb0673_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTMtNi0xLTEtMTE1NjI3_4e03daac-6d20-4a2b-9719-b5b135b2430a">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686c8541b42b4c05a464ef7ee07f890d_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTQtMi0xLTEtMTE1NjI3_278ca092-cfa8-42d9-bb5b-68e67d1c4621">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae059ef9a71a4eb791f9e711bc7a3a8b_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTQtNC0xLTEtMTE1NjI3_562178b5-8320-4b2b-a8ce-96843b8ffe22">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i686c8541b42b4c05a464ef7ee07f890d_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTQtNi0xLTEtMTE1NjI3_d7a5e4be-000b-4b6b-b245-97979316cf01">14.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i540168e260374772b2846cd65772d665_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTUtMi0xLTEtMTE1NjI3_c2d80825-605f-4482-bac2-a77968b780a8">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eda79b80e2049239e63855bc02299d9_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTUtNC0xLTEtMTE1NjI3_3e7d96df-dc88-4178-a714-d884636dca6c">1,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i540168e260374772b2846cd65772d665_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTUtNi0xLTEtMTE1NjI3_763fd634-8c85-42d2-8b9f-c1f89c6d3472">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPRAVATO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7c7de0d76674b90ae3e372bc29d4f72_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTctMi0xLTEtMTE1NjI3_96c71ffc-291d-4249-81f5-d93e948cb7f0">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86f3e2bce1e74415a5032c634535117d_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTctNC0xLTEtMTE1NjI3_be86b7f2-cf36-4e81-a0b2-21d551ad0f6a">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7c7de0d76674b90ae3e372bc29d4f72_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTctNi0xLTEtMTE1NjI3_a10ddddc-6414-4bf6-8ec2-2e75c89b33a6">82.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a1a49f5edb04dcbbfd9179b3bc6605d_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTgtMi0xLTEtMTE1NjI3_704cd25e-233e-40f2-84b8-3af7329ed3b7">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eef9047d8b4024881a1e71e04644ab_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTgtNC0xLTEtMTE1NjI3_7c9a0270-7fa2-4a10-ae36-6dbb305bf922">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd5f7ebb194146fe824e76df773868ab_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTktMi0xLTEtMTE1NjI3_dfa3ec5a-9f97-4380-a26a-5a479fbb4104">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib75875ac7da34c28b177112493ce9e3b_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTktNC0xLTEtMTE1NjI3_ae91da3b-53f6-4cac-b288-570bf33ec298">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd5f7ebb194146fe824e76df773868ab_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTktNi0xLTEtMTE1NjI3_846f57dd-8312-4d81-9361-c705e5c9f91b">86.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5219d9e2234c1581c5cbbbc318e9ca_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAxLTItMS0xLTExNTYyNw_fa2c1e5f-2224-44cd-8e23-f4170aad9eaf">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3287ef468347f78f62d4695c0a6c33_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAxLTQtMS0xLTExNTYyNw_49eb5ad4-0db5-427a-81c3-a745f5615909">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4c5219d9e2234c1581c5cbbbc318e9ca_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAxLTYtMS0xLTExNTYyNw_b1fb7180-68a4-41b7-9db1-bdc20cab117a">3.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2dc3cc05679b42978b02eabd70ac7223_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAyLTItMS0xLTExNTYyNw_7ee1afc0-f69a-4268-afd2-233d40d38975">339</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if98063295c35488990378b212f03f0c0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAyLTQtMS0xLTExNTYyNw_1b55fefe-95de-4c3b-ae00-83f4d781785d">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2dc3cc05679b42978b02eabd70ac7223_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAyLTYtMS0xLTExNTYyNw_69b7b77e-54ca-4dc5-8392-e68b4b12f3f3">10.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied3b20670e8f435991a56e4ff15b778d_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAzLTItMS0xLTExNTYyNw_dff743ba-6c87-4b82-8048-e28d93ea8dca">423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac15c39db3b94e89978df479bba14ca0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAzLTQtMS0xLTExNTYyNw_2c7ca9a7-8318-4683-95fc-e7d52921f7b9">467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ied3b20670e8f435991a56e4ff15b778d_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAzLTYtMS0xLTExNTYyNw_cd4c9f3a-760b-4df8-a6f2-3d77eb6c6f93">9.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i333de10c5e194bb8a7cde19cd0859df9_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA2LTItMS0xLTExNTYyNw_7be3a41d-3749-4512-85df-b653c833d74e">1,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib525ff83930a455288c90417291f93fb_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA2LTQtMS0xLTExNTYyNw_a58c03f8-8d83-4ba2-84fd-6b73d11ce74c">1,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i333de10c5e194bb8a7cde19cd0859df9_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA2LTYtMS0xLTExNTYyNw_8033054f-7818-49a0-8bab-049f68c68c04">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68673ce635ab4895a3a71deec80d927b_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA3LTItMS0xLTExNTYyNw_43c863b9-0b1b-4852-b5b6-a587f1fbcbb5">2,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e28bea10b16493bb218d5f6672559a2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA3LTQtMS0xLTExNTYyNw_5f9d85f5-3e4d-4338-b2c3-809e3c3d0969">2,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i68673ce635ab4895a3a71deec80d927b_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA3LTYtMS0xLTExNTYyNw_0a4cc09e-ebb5-431a-839f-263818a5616e">6.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f2133a562294f9fad3ef124cc3f62af_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA4LTItMS0xLTExNTYyNw_528b8796-e564-4c1c-bf20-c05bab64c95e">4,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc0119131cf0458084a6a1dbfcc10ee5_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA4LTQtMS0xLTExNTYyNw_88c60ced-5ea7-46fe-899a-24c2dcb5d386">3,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f2133a562294f9fad3ef124cc3f62af_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA4LTYtMS0xLTExNTYyNw_d79451b3-29e9-486d-9500-2b0d30e85ac0">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CARVYKTI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60f30737549148d78386d683bd7971cf_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEwLTItMS0xLTExOTE2NQ_fbbe5be5-4c1f-4e80-bfc8-5229627b5733">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ec3b93d6a4485d9565624fd37520b1_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEwLTQtMS0xLTExOTE2NQ_fcef7db8-f4a2-4a39-b31a-7de2f96e4ef1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e2961eace9b41418fe529105d0a94b4_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTExLTItMS0xLTExOTE2NQ_486e0431-ae57-4246-86f1-d661711b26f8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dec4567146a4b51add1694785443d3f_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTExLTQtMS0xLTExOTE2NQ_85aa554c-5b4a-40ca-bbb6-0f464c84a871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c0955b8e0a143aca601efbe6babf21c_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEyLTItMS0xLTExOTE2NQ_e7d2fed5-be9d-4df5-ad76-7f71c4afd6d9">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib16a26859ccb46d6947b21484d429b1e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEyLTQtMS0xLTExOTE2NQ_1985657b-2f08-4855-8ea8-2b10c080f5ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee98c5cb0708407396e22087c411d285_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEwLTItMS0xLTExNTYyNw_0b62eb89-05c6-40b9-aa92-ea987c616311">1,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifab9674d8a57440385daec43e3b872b5_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEwLTQtMS0xLTExNTYyNw_c7ca98b4-6c8a-4534-9605-fe1c414e1dce">953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee98c5cb0708407396e22087c411d285_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEwLTYtMS0xLTExNTYyNw_9a316c55-9ad7-42c8-9940-5293179c2088">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd48985d52ea4f1693cc1042d3c8fdc3_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTExLTItMS0xLTExNTYyNw_2e45902f-b5d6-4851-bcb7-3d281f001b01">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c6fb890aee4700b7cabd1224a7a9f7_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTExLTQtMS0xLTExNTYyNw_318ca982-0d6e-4bae-87e1-33a0dad086e5">903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd48985d52ea4f1693cc1042d3c8fdc3_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTExLTYtMS0xLTExNTYyNw_39f9d7d1-1467-4c5c-b9a2-8e2f7b18d957">18.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3a9c49693c4528b8b24e19524f85c9_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEyLTItMS0xLTExNTYyNw_31ade336-5f9b-4ae8-a26a-ca087a482b42">2,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160565feac454261b5cf8029f03df1d1_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEyLTQtMS0xLTExNTYyNw_50c999a4-e81a-4727-bd1a-979a2a6dd18c">1,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d3a9c49693c4528b8b24e19524f85c9_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEyLTYtMS0xLTExNTYyNw_52ea4806-5401-4b1e-9fea-86930cea9158">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4815237e89d4db1b540f9d011fad6bd_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE0LTItMS0xLTExNTYyNw_43f7d9fa-e99c-4435-9f65-994ac2c123f5">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic942fa98d0f54d4abd3aa101ed8cfd4e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE0LTQtMS0xLTExNTYyNw_3287b670-dfe5-4316-a166-9aabf761d429">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4815237e89d4db1b540f9d011fad6bd_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE0LTYtMS0xLTExNTYyNw_32a7b897-3331-416c-9bb9-08699ebb51ec">21.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51623904c8e7456683c43cae3c239cbd_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE1LTItMS0xLTExNTYyNw_fe878576-f7f7-41f5-a713-addf6110ddc0">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d32e645ff894945ad0436a18173134f_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE1LTQtMS0xLTExNTYyNw_5fc38c44-0a9b-4c63-ae5d-a1274978be7d">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i51623904c8e7456683c43cae3c239cbd_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE1LTYtMS0xLTExNTYyNw_4b33a3b3-888c-439d-871e-b491fd16f425">50.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5f9f5c36c324901a0f9ef4ee74902fb_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE2LTItMS0xLTExNTYyNw_9e316544-625b-45bf-907e-07e044b7211e">542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ebd3fdfaab847999b1abbed0df2881e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE2LTQtMS0xLTExNTYyNw_def5b685-8008-42e0-8e0a-a4cf1210dce2">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5f9f5c36c324901a0f9ef4ee74902fb_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE2LTYtMS0xLTExNTYyNw_277be7d9-04e9-4307-ab55-f7536eb14585">35.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c5ac73df6614e86b2c68e2bb0b7b04c_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE4LTItMS0xLTExNTYyNw_512e5248-fdb8-4c70-a249-091e0bb96805">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076a0601ecf14a4288789888d685888e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE4LTQtMS0xLTExNTYyNw_fa2ce444-fc40-4d3d-b0f0-b5aaed600f42">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8c5ac73df6614e86b2c68e2bb0b7b04c_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE4LTYtMS0xLTExNTYyNw_aa8b751e-01ea-48a5-8258-1b46fd64f0c5">27.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8f0d46d42a41e097f8a42fea7efc04_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE5LTItMS0xLTExNTYyNw_0281393a-7425-4783-b1b0-ff6e75758894">557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6beee782dab74a55ae5b50d1a126075a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE5LTQtMS0xLTExNTYyNw_88fa61a6-b015-4f5e-aaef-3eb9f4986dd6">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1c8f0d46d42a41e097f8a42fea7efc04_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE5LTYtMS0xLTExNTYyNw_63682fe1-0131-4218-942b-d3e25290542c">16.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i652dff8c442f438c8266669ccab6b186_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIwLTItMS0xLTExNTYyNw_7904dee8-143e-42b8-9838-ca58cc7e1306">827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a7d9521630e4ed4a0f926999bb837f2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIwLTQtMS0xLTExNTYyNw_117e4b0d-81aa-4529-9150-9b6a2499ea99">1,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i652dff8c442f438c8266669ccab6b186_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIwLTYtMS0xLTExNTYyNw_51780a58-de23-44ee-9073-198493d2b490">20.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="i7dc04fc786c44b85a75d9b2db453404e" continuedAt="ie5b73e176e6949939a46801524bf5228"><ix:continuation id="id7f3a46bcb9846f6b64e3fbec258448e" continuedAt="i9dd0031a3bf14a5e9d76d9d02b29c16d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd82b4bf5fb40b3a12d708741b67d0f_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIyLTItMS0xLTExNTYyNw_4780763b-780b-4a05-a3d2-d5854fcf2b10">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35bd295b8c6c45a49ecf26261ae4958d_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIyLTQtMS0xLTExNTYyNw_ab0fba7f-e5e5-4774-bcbc-9654f8e86b1d">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6bd82b4bf5fb40b3a12d708741b67d0f_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIyLTYtMS0xLTExNTYyNw_8dd5705c-28eb-44f9-b90c-4f710ea5701a">14.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c53ac8f0c6c4ea2aaaf494a42d823c8_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIzLTItMS0xLTExNTYyNw_1401e872-3638-4214-bb49-25b59239201f">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88768a59c84946cc86069b6c72c10e17_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIzLTQtMS0xLTExNTYyNw_f9d79583-7465-4ee2-9abe-78a461341c83">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7c53ac8f0c6c4ea2aaaf494a42d823c8_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIzLTYtMS0xLTExNTYyNw_c53a4f3a-536b-44be-b2f8-7581146957e3">56.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie04f0afe64d04e5f81ea459941636bb7_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI0LTItMS0xLTExNTYyNw_a76dec07-7efe-4617-a490-c8ddc3686420">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4da66669adf2490a954dfa605b57620e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI0LTQtMS0xLTExNTYyNw_6421a0f4-599f-46ca-be9a-8a19453c4ae5">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie04f0afe64d04e5f81ea459941636bb7_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI0LTYtMS0xLTExNTYyNw_a99cf32d-4b87-4747-98a2-596eea26bca7">54.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i995cfb4d674e4f669792e3fcce3e446a_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI3LTItMS0xLTExNTYyNw_9e47ca91-9a8d-477b-a5f3-6d4506ad9877">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c00ddbe0f14783b81b783b0481b7d0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI3LTQtMS0xLTExNTYyNw_f0ff8d16-0460-41da-86c0-372ef97f99a0">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic70082fa2bd84d2abfaa197163d58036_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI4LTItMS0xLTExNTYyNw_ef63eb23-95c8-40d5-b502-fc2df3fb9827">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic93c8ff581fb4066a25be356733d40b9_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI4LTQtMS0xLTExNTYyNw_319262a1-1793-4da2-9788-860bfcb8599b">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic70082fa2bd84d2abfaa197163d58036_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI4LTYtMS0xLTExNTYyNw_40168817-df01-454d-8293-fc1cae619683">17.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ab9aaf299b94d139444f75057ae76ce_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI5LTItMS0xLTExNTYyNw_b68ffffc-7acb-48c6-9fec-dff8a6dd220f">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345f37b977dd4873a272254f2cd7b0b7_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI5LTQtMS0xLTExNTYyNw_b158966d-0173-4568-908a-4daa6e22301f">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ab9aaf299b94d139444f75057ae76ce_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI5LTYtMS0xLTExNTYyNw_030037c4-097e-4d29-9887-833fcd3797a8">37.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150f063107274f55809b1b424526240f_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMyLTItMS0xLTExNTYyNw_b1c124a5-f99f-4a5f-9983-b43833e10f59">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7326763483de473c80ee9447ae7d5874_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMyLTQtMS0xLTExNTYyNw_950595b3-cfab-472b-874f-562b274db19b">572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i150f063107274f55809b1b424526240f_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMyLTYtMS0xLTExNTYyNw_904e6be1-aca5-43a6-9e0a-ee2dcc9c54a8">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id31a5ffdbdb34a8da796905e5c398b22_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMzLTItMS0xLTExNTYyNw_84e612e4-ef24-44a3-a5bf-143f0a1e6621">272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505ae89dce3d4c318427fd4433c5ac85_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMzLTQtMS0xLTExNTYyNw_c30f3bb1-000c-439b-a253-6242d8ae0b56">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id31a5ffdbdb34a8da796905e5c398b22_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMzLTYtMS0xLTExNTYyNw_62323308-1765-427a-a354-30f270630213">2.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i136fdab820ca4a628cd28ba7b37ed9d6_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM0LTItMS0xLTExNTYyNw_f2c0d869-6455-46be-b33c-485b90acf206">872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1212b07b91c147ce8e0d1b45004d468c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM0LTQtMS0xLTExNTYyNw_7dca5700-ac95-4c68-8f54-c3e1f8e4bac7">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i136fdab820ca4a628cd28ba7b37ed9d6_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM0LTYtMS0xLTExNTYyNw_100a6394-33c4-4573-8972-b21827ef8434">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05688666a73b489f9d6fb95983420710_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM2LTItMS0xLTExNTYyNw_7bd54800-dd87-41a9-bf01-11e162eab35d">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37d4e70638d24648963bbcebc8758c59_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM2LTQtMS0xLTExNTYyNw_22b6bae2-c11e-4342-9d03-8d92a016e9e7">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i05688666a73b489f9d6fb95983420710_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM2LTYtMS0xLTExNTYyNw_ce0fd109-ba43-48aa-a4e2-8d5efd935703">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16171e8c53424225a58ffa109cbddc6f_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM3LTItMS0xLTExNTYyNw_dad89f79-453f-4059-b118-bd291ab21fa3">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad42b84534d649ba85fbccdcd13e9e92_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM3LTQtMS0xLTExNTYyNw_597eadf7-f973-4356-918a-45b049b811c6">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i16171e8c53424225a58ffa109cbddc6f_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM3LTYtMS0xLTExNTYyNw_83d07d74-d596-4440-ba58-b5b533b1b2aa">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6a67ff3e2c46c8b750cddad69dc4d3_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM4LTItMS0xLTExNTYyNw_8af18af2-fc87-4874-aa0a-c8d943b21263">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3581abfcda4f839a0c590c86c694a7_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM4LTQtMS0xLTExNTYyNw_6822e654-90a5-4651-a78c-907c28de9049">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibc6a67ff3e2c46c8b750cddad69dc4d3_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM4LTYtMS0xLTExNTYyNw_89ab3f46-5589-40b4-9632-3bfe3172b414">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67d976ab3276405b924504695f2c3e16_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQwLTItMS0xLTExNTYyNw_25a9ff45-12e8-4f4b-ada9-a2e58200b592">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fedce0cd42349b4ac489cf459d784b6_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQwLTQtMS0xLTExNTYyNw_d7a5c56d-9535-41e9-90d9-c2fb8db1e59e">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i67d976ab3276405b924504695f2c3e16_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQwLTYtMS0xLTExNTYyNw_7c947b69-3d54-4abe-b48c-b4ac488e16b0">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb91f2c98f843f3bf1a457a9e524b19_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQxLTItMS0xLTExNTYyNw_b175da58-ccf4-4c33-887d-a19a8a00233a">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6130edb225934eb28e1c70739f5d063d_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQxLTQtMS0xLTExNTYyNw_f431f2f5-87d3-4962-b789-166ccad0ba80">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifdb91f2c98f843f3bf1a457a9e524b19_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQxLTYtMS0xLTExNTYyNw_271d5941-c1aa-4e55-a3f6-461462dfbf61">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic918fc23c9474840bab3b6e74a8b4c59_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQyLTItMS0xLTExNTYyNw_8517dbf3-e627-4871-bff6-a6f8acc42d90">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5df37fa4b554bda930ce40e6cfe2580_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQyLTQtMS0xLTExNTYyNw_9ec75eea-9c66-4768-b3cb-86429e75cf3f">325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic918fc23c9474840bab3b6e74a8b4c59_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQyLTYtMS0xLTExNTYyNw_e7501122-d610-45ce-bcea-2ccab9e39d17">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c88a8d200f40b4bacde02a32dd9329_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ0LTItMS0xLTExNTYyNw_6acdab1a-edef-4519-9c87-ff2a660965c6">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa1ad776d62d468da5fc409a793fe0d2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ0LTQtMS0xLTExNTYyNw_607f34aa-aa5a-47c8-8d55-6525b64e734e">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib4c88a8d200f40b4bacde02a32dd9329_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ0LTYtMS0xLTExNTYyNw_60063f99-6bff-4aa6-8ec8-a5eeb2d858b3">22.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b4a5127e1b4328bc2a43a45710bde8_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ1LTItMS0xLTExNTYyNw_aa40bda5-504f-435b-be63-5da99f969e02">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id490f83accb14c9fa6698c9ccc80525a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ1LTQtMS0xLTExNTYyNw_3a43b4b0-1279-4705-a384-83161192bf50">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i43b4a5127e1b4328bc2a43a45710bde8_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ1LTYtMS0xLTExNTYyNw_34820b80-dbfe-49d4-bf78-0d10e8e3aee1">12.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb0bb69e2c4c4516a56e8f1e3dc2d643_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ2LTItMS0xLTExNTYyNw_e031aed3-bc5f-4347-aec8-8ab6837450ad">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6afd1882f62f4386a785d02f1a23bdb9_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ2LTQtMS0xLTExNTYyNw_5128c356-4db0-43a6-a3c0-b9f13756e4cb">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idb0bb69e2c4c4516a56e8f1e3dc2d643_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ2LTYtMS0xLTExNTYyNw_982129a2-f509-47ed-86c3-dd9827e9b8fe">16.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c3060e9d95943b589436fb77dc77a35_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ5LTItMS0xLTExNTYyNw_7f929d97-3229-4666-8ee7-4b25a41ce149">715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37be37c17b20438193f60193db94a428_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ5LTQtMS0xLTExNTYyNw_f5cf858c-1dfd-4103-a1ba-ddc0475dddc4">672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3c3060e9d95943b589436fb77dc77a35_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ5LTYtMS0xLTExNTYyNw_cfa9db4d-a569-4c9a-aeea-280c12911268">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21df6a06501347ef989f179b4cf7dd2a_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUwLTItMS0xLTExNTYyNw_a96585cf-f7c9-4fb1-b716-56ad2b928b15">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291cca6f20e64e3c8cebcfda2c8ccccb_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUwLTQtMS0xLTExNTYyNw_64f444b8-a943-4222-a202-3f5703566fe0">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i21df6a06501347ef989f179b4cf7dd2a_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUwLTYtMS0xLTExNTYyNw_11d2cddc-4f9c-4f86-8a84-109d8ebe3f49">10.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0152d0f99144507acb484aac822034c_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUxLTItMS0xLTExNTYyNw_5ff49416-08e0-44b0-987f-0c41452c233d">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04c171c0b08d4ba39f9cc175df531847_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUxLTQtMS0xLTExNTYyNw_6a6526c4-42f8-43c2-aa02-52b3c508f463">910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia0152d0f99144507acb484aac822034c_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUxLTYtMS0xLTExNTYyNw_218383a0-bd7f-492e-b11e-1dce22da08c2">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i236ad63ca35a41cd8f969b4e2938f2fc_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUzLTItMS0xLTExNTYyNw_75453ae3-9be3-4fca-8a4e-edadde19f06c">578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafc33bbf42804adb85ccdf725d2e83cc_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUzLTQtMS0xLTExNTYyNw_d63ce699-a3ef-454d-ac34-81fe1e4f86b1">508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i236ad63ca35a41cd8f969b4e2938f2fc_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUzLTYtMS0xLTExNTYyNw_b4369b82-9127-4fd9-b796-bd5c24338b4e">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01a03416efc042fba5eb7b5f63640595_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTU0LTItMS0xLTExNTYyNw_11c62279-5a3e-4dbd-9812-5953108e4888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id46b580cb2ea4c188253514d7ee59c8e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTU0LTQtMS0xLTExNTYyNw_eea5cb44-3968-4591-8f0d-127a2a3c38bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i01a03416efc042fba5eb7b5f63640595_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTU0LTYtMS0xLTExNTYyNw_d2f13e8e-59bd-4776-a629-b5e226f54469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e7f61f9e4f74352b9c8f412986189e3_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTU1LTItMS0xLTExNTYyNw_f99e79ec-cecb-4b85-85f8-8a66c99c1f24">578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5efb947632c47e19d68b8280af2e44d_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTU1LTQtMS0xLTExNTYyNw_2af2944d-ed09-4607-bf10-26ce0f450937">508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e7f61f9e4f74352b9c8f412986189e3_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTU1LTYtMS0xLTExNTYyNw_24038189-e961-4173-9536-1ced833fc0d9">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85bb32425f664497b088763671d4d454_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY1LTItMS0xLTExNTYyNw_11159f29-84f9-45b0-b574-c4de343dac05">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i098d2b32fc074e018e965ef42cd425b3_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY1LTQtMS0xLTExNTYyNw_864cfc10-7e2f-4567-94b8-e7311a3af460">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i85bb32425f664497b088763671d4d454_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY1LTYtMS0xLTExNTYyNw_b07bc0d5-df5d-4ac0-b38a-798b0dc4607f">16.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic47106d021b544a9b064a88a11f29db6_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY2LTItMS0xLTExNTYyNw_0f3fa259-42d7-4fdd-b612-a189e66072cb">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a6f8cd2d6443ff9d286090d2f06423_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY2LTQtMS0xLTExNTYyNw_7e703f41-552f-45be-b934-c45dd750748b">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic47106d021b544a9b064a88a11f29db6_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY2LTYtMS0xLTExNTYyNw_56db2a2e-614b-46c7-8785-a351b7d07c23">10.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b0c223e01d14534a29b703d9ffca9a1_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY3LTItMS0xLTExNTYyNw_08a52123-a53e-4d0b-a8bb-ea862b06551a">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569502cf2f0f4e4a8dfc490844775e54_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY3LTQtMS0xLTExNTYyNw_5cd50cd4-f4e8-46ed-9a0d-8d0ee318f3fa">402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3b0c223e01d14534a29b703d9ffca9a1_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY3LTYtMS0xLTExNTYyNw_b74bda9b-e4e4-43cf-b275-8487fa46d0c9">13.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if748627f3368423685d8be9fda1d9fe3_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcwLTItMS0xLTExNTYyNw_6ea480c8-3128-4dc0-956b-1f919c97cac5">7,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ac40786f71940aebc5e207db586eb04_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcwLTQtMS0xLTExNTYyNw_d4c8538b-2f23-4baa-a9db-18e111f3b736">6,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if748627f3368423685d8be9fda1d9fe3_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcwLTYtMS0xLTExNTYyNw_f7d2f5af-dd62-4100-ade0-8f0ce2f3e053">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac741c82fc14439fbb4cda5efa014094_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcxLTItMS0xLTExNTYyNw_820c9ccc-dc29-4f61-b469-3357f67fcae0">6,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6e46509ea6b444880c2eada1a0364ee_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcxLTQtMS0xLTExNTYyNw_ba593416-c9a4-4271-8c51-ac4f6a78dadd">6,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iac741c82fc14439fbb4cda5efa014094_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcxLTYtMS0xLTExNTYyNw_2079ab25-535c-4a3a-9917-e690484f5275">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f3967ed8804b3484a788194a6b55e2_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcyLTItMS0xLTExNTYyNw_1d222040-04ba-4d62-a78e-75c48931c44e">13,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12677390b1eb4de7a97ffc8bc444bbde_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcyLTQtMS0xLTExNTYyNw_daa23687-c50a-4077-8116-b378581f85dd">12,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id6f3967ed8804b3484a788194a6b55e2_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcyLTYtMS0xLTExNTYyNw_4d037c10-2e04-4deb-91be-c8dc2505d2f2">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:80pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="margin-top:5pt"><ix:continuation id="ie5b73e176e6949939a46801524bf5228" continuedAt="i7931c5d2e0ec4e40a2c9f7ee6eaa2c97"><ix:continuation id="i9dd0031a3bf14a5e9d76d9d02b29c16d" continuedAt="ic2c9d987e5bb44fcaab7f56f3e7f3baa"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDTECH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4b42c17ade64ae7ac0f6eb0f8faeda6_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg1LTItMS0xLTExNTYyNw_00dcfc5e-8585-4dbf-9cfb-7e9683c69f08">863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49526704b3f443cb8d37f9e340cec4a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg1LTQtMS0xLTExNTYyNw_895fc843-0c81-4361-bac1-50453b25b168">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4b42c17ade64ae7ac0f6eb0f8faeda6_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg1LTYtMS0xLTExNTYyNw_d9af4b0e-5ae0-40bb-9a48-0459db2aff2a">74.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e9f540147284f2b909c9bdcc3fa5530_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg2LTItMS0xLTExNTYyNw_25f4e520-076b-4ae2-921c-7e52de8e8b70">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e93949a9b44381a7f3701eee7f9ac8_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg2LTQtMS0xLTExNTYyNw_81c50a4e-b8e1-4f0c-a572-5de5864917cf">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e9f540147284f2b909c9bdcc3fa5530_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg2LTYtMS0xLTExNTYyNw_c532ad5a-88a3-451f-88c6-5b6fa3e31985">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91c597ec59014a40ae4281f9275dd4c1_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg3LTItMS0xLTExNTYyNw_cde8b17e-6480-4d45-940d-c848ae08744a">1,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f4fa75b8a74a9dac7059e98c19f5b6_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg3LTQtMS0xLTExNTYyNw_cde4c412-4f1d-4675-a1c7-8d635728da29">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91c597ec59014a40ae4281f9275dd4c1_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg3LTYtMS0xLTExNTYyNw_f0b15863-2f29-4b27-b65d-0dddf381fdd3">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ELECTROPHYSIOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588fd7f2edcb4507904e6ad2502e9f06_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkxLTItMS0xLTExOTgzMA_ce76a71f-0d4e-4e29-8565-adf8d28d089f">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd3f73f1f8144c4eba42b6ed8a810de7_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkxLTQtMS0xLTExOTg1Mw_d3254605-f121-4db8-ad95-b568c2bb57df">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i588fd7f2edcb4507904e6ad2502e9f06_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkxLTYtMS0xLTExOTg0NQ_348eb754-a2aa-4b1c-88e3-fbd8b8728a36">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ca28df51b6440c696c0314691bbe427_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkyLTItMS0xLTExOTgzMA_c8f38241-a44e-4a8e-97f4-c791a34d1d02">522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fa133450684e3dabae5a9de5d13ce8_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkyLTQtMS0xLTExOTg1Mw_ced92fbf-b95b-4f1a-b5b8-597588828931">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1ca28df51b6440c696c0314691bbe427_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkyLTYtMS0xLTExOTg0NQ_6fa63766-40dc-45b7-9ec1-c75b4bfef7af">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i238eddc286cc4e6ea38e56b95db65cf5_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkzLTItMS0xLTExOTgzMA_842f5462-1438-4a11-b1fb-616fcf1bf7cc">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7044bf88210248c884a8bef89b77d4eb_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkzLTQtMS0xLTExOTg1Mw_450cbf4f-715a-496b-bc8f-81580ea68abb">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i238eddc286cc4e6ea38e56b95db65cf5_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkzLTYtMS0xLTExOTg0NQ_d5747c7b-549a-4f3c-9ddc-9a6392f0e504">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ABIOMED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90c97bfc6a2b44d78898de9f3bff5d87_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk1LTItMS0xLTExOTgzMA_3e1eeaa4-7632-4bc6-91c0-de142ee47e04">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94dff6bcd4564c4eaddba70ccb2a8de2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk1LTQtMS0xLTExOTg1Mw_54593da3-a9b8-492f-a283-9f5ef78a88e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bfeff988ad0455782b5383e4bde3dac_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk2LTItMS0xLTExOTgzMA_279855c1-c217-4298-abfa-8d826506dad2">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccfe7ce7ecc24b40a8d287f61d0e19a3_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk2LTQtMS0xLTExOTg1Mw_ab66eacf-63b7-4f89-9003-3bec69a172cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e5e294252c54f9da688d735b42fe26f_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk3LTItMS0xLTExOTgzMA_8c390c29-97a1-4652-b592-8f1db2a560f7">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if98abe23095c49038b3e34d99b190cbb_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk3LTQtMS0xLTExOTg1Mw_6b94556a-3d48-46dd-b34b-48d0a28abb29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INTERVENTIONAL SOLUTIONS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9d23239da0148da8bb85076fc21c555_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk5LTItMS0xLTExOTgzMA_f6a339ce-b7c2-4f6e-9ddc-f9568e144af1">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifca62b1259c54fcba069f4a9034206b1_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk5LTQtMS0xLTExOTg1Mw_8aae6d80-f623-4057-abc9-90acf6d0becd">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9d23239da0148da8bb85076fc21c555_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk5LTYtMS0xLTExOTg0NQ_4cac1388-32ea-41bd-95c4-00b374f0940c">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87ea8359aa454362b30d54da0aab13a6_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAwLTItMS0xLTExOTgzMA_20930f00-7675-4a9f-8c00-fb73aa64eb8b">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e7e328557ce4073882ac9143166a882_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAwLTQtMS0xLTExOTg1Mw_3966fee0-dec6-419b-948e-7304051acf04">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i87ea8359aa454362b30d54da0aab13a6_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAwLTYtMS0xLTExOTg0NQ_49c9df62-606e-4e2e-8f3b-1e299c05c9f1">11.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42e4f8a3fab14e74a2530932f1029f2d_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAxLTItMS0xLTExOTgzMA_20587dc5-ad6a-4f9e-bdb0-4df513a13793">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42eb9f30337047a0b6994260a328fbdb_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAxLTQtMS0xLTExOTg1Mw_c198d376-cc89-4d9d-ac78-365362a4857c">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i42e4f8a3fab14e74a2530932f1029f2d_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAxLTYtMS0xLTExOTg0NQ_709dfb82-1d1a-48ec-9724-ef8e668c8222">3.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020c283a9b454f4c91205f8a5aecc950_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg5LTItMS0xLTExNTYyNw_f710653f-d415-48ad-9d60-c45bb455ea59">1,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12435a3d01c4f3c9b3518fa0cc67836_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg5LTQtMS0xLTExNTYyNw_b9719c6c-460a-4c0b-b558-13cb73582b16">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i020c283a9b454f4c91205f8a5aecc950_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg5LTYtMS0xLTExNTYyNw_505b8c07-39cc-4bfd-a9ed-7e17dafb4a21">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f9872cc99b44b5b1cccfb6c75db81a_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkwLTItMS0xLTExNTYyNw_32427562-9fb1-45ea-9785-4e4cb776366b">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e718713cf094373a8d40c5920af2f60_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkwLTQtMS0xLTExNTYyNw_5517e22a-5441-4e7e-b629-53d0f708a986">899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i29f9872cc99b44b5b1cccfb6c75db81a_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkwLTYtMS0xLTExNTYyNw_e4f112e3-e679-4644-9718-07d76a144a08">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib807084fc7c8485b9668410e22e4f2bf_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkxLTItMS0xLTExNTYyNw_42d2dab3-dd31-4ebb-8051-39967ad0c84d">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8e6ddf9e58e4f528caa4e6cce761163_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkxLTQtMS0xLTExNTYyNw_8c278600-2e3f-4104-aa72-d263183f72f4">2,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib807084fc7c8485b9668410e22e4f2bf_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkxLTYtMS0xLTExNTYyNw_3b38d32b-c1f9-4304-96d0-e535d027dcf5">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6901dd295b24125b4138f0b272f8777_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkzLTItMS0xLTExNTYyNw_6c33c445-501c-475b-ab49-ca45966aff5d">241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18df14d793b446acaebb489d09b54690_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkzLTQtMS0xLTExNTYyNw_0614dc90-14e6-4c13-9525-c5dcaf7716ef">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6901dd295b24125b4138f0b272f8777_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkzLTYtMS0xLTExNTYyNw_ee769b57-6810-48a7-8573-90d952a77500">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ccac7306a934e89a59dcc66dc558644_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk0LTItMS0xLTExNTYyNw_04f7d908-2690-44fb-945c-b6f3887cc9ea">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f491788cb63462fb654dbad9c0775b6_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk0LTQtMS0xLTExNTYyNw_406a7236-e4a0-4df1-b690-9554a4c1de10">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0ccac7306a934e89a59dcc66dc558644_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk0LTYtMS0xLTExNTYyNw_bf31b2be-4ac0-4ded-a357-9f21981a028d">9.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06411c6af6a74c35ac5cfad22270bc75_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk1LTItMS0xLTExNTYyNw_ec4586e9-d60f-431b-8455-9be022fcd529">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a5c0148e3e41e483ac0ea77b562ac2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk1LTQtMS0xLTExNTYyNw_d36e325a-8b19-41bb-bcb6-3fbeb23380f9">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06411c6af6a74c35ac5cfad22270bc75_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk1LTYtMS0xLTExNTYyNw_7f252590-ab7c-46d9-85ff-c67f8c50a236">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba51dfb57e344d5a0fea2a350310cc4_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk3LTItMS0xLTExNTYyNw_e35d9148-008b-4fc1-999b-65279a374f70">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fa3f9ddb7146f995f2f94806cfc5ec_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk3LTQtMS0xLTExNTYyNw_a64f1a82-4d88-4216-800f-14e24ed901b0">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ba51dfb57e344d5a0fea2a350310cc4_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk3LTYtMS0xLTExNTYyNw_bbe233ad-d8fc-424e-bce9-a57a71553c54">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabc10b6383d0489e8b8bb5a496eaf21a_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk4LTItMS0xLTExNTYyNw_374bfab8-c2c7-41b0-8659-e628bc1f80a3">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57664aba083e478a9546149bfc85f5c2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk4LTQtMS0xLTExNTYyNw_a55ad567-595f-46aa-aaa1-3ac83e77f82c">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iabc10b6383d0489e8b8bb5a496eaf21a_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk4LTYtMS0xLTExNTYyNw_73322f46-cb27-4718-b4d1-871610b2034f">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if29cd966f54442938b637f209a34b811_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk5LTItMS0xLTExNTYyNw_b0504b79-7e3c-445e-a484-30366b905699">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b174ade6ec43a9a47fa3978d28bd77_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk5LTQtMS0xLTExNTYyNw_cf94ab33-feea-4839-b8d4-30df785b93aa">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if29cd966f54442938b637f209a34b811_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk5LTYtMS0xLTExNTYyNw_a888060c-3edb-43f1-b91a-6b9c1748c1c9">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c27feb9bba3448a96cf3d833cc77e87_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAxLTItMS0xLTExNTYyNw_03ca418b-a776-4020-b359-3979349ef5c0">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec996af35e9d4904a9164c9042ba5927_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAxLTQtMS0xLTExNTYyNw_6158cb76-d4b1-4b72-90a6-c82196ce8df1">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9c27feb9bba3448a96cf3d833cc77e87_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAxLTYtMS0xLTExNTYyNw_9d2e1da6-b654-4e1c-ae63-8982f08420c4">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e256570168449b0bbdd5ac1802e0273_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAyLTItMS0xLTExNTYyNw_1bec8a21-65fe-408b-85c1-f4e4cfbf4cac">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8496c9c84c6f40d2b659a19f28f6f5b6_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAyLTQtMS0xLTExNTYyNw_6df39588-a092-4b99-aabd-0f1013829841">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4e256570168449b0bbdd5ac1802e0273_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAyLTYtMS0xLTExNTYyNw_7a937d1b-55bf-4226-ad9f-c9d68a062eeb">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i060b7639c5944fe3aa7774d6f5d6087d_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAzLTItMS0xLTExNTYyNw_51e0d608-b0d0-4781-90b8-59c90bf01de5">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b40c723a94457c91bbb0eb8f7292e6_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAzLTQtMS0xLTExNTYyNw_a03edad9-e6ac-43e9-854d-b426d3238749">748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i060b7639c5944fe3aa7774d6f5d6087d_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAzLTYtMS0xLTExNTYyNw_0d4920b3-8435-4ff9-b64a-65b8b3b6c578">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a4bd2851d954128945886c150131c9a_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA1LTItMS0xLTExNTYyNw_756f7897-fcd2-469d-b9f9-699ac87854ed">406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf832e226abb4c3b93f4a76b0876c785_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA1LTQtMS0xLTExNTYyNw_4e82ea4e-1fbb-404b-a333-5b86f18edee3">387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a4bd2851d954128945886c150131c9a_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA1LTYtMS0xLTExNTYyNw_47e74e15-9436-42ec-ae07-eff577e50cb3">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i341a9238ebd54b549ec9e2262b87e9dd_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA2LTItMS0xLTExNTYyNw_ab26d1f2-b786-46de-8be7-694889b73074">323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cf8369cc3964063aedd59972566936c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA2LTQtMS0xLTExNTYyNw_baabec8b-ed3b-41a6-8012-a894dd850b42">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i341a9238ebd54b549ec9e2262b87e9dd_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA2LTYtMS0xLTExNTYyNw_02f866ab-d141-4513-907a-16355743f83a">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i697f77c1d355434a9a8b15ca4ddad302_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA3LTItMS0xLTExNTYyNw_a5284b02-5251-4037-ab23-82370f1b387b">729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81e33ba2cabb410cb020c140d48b86f5_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA3LTQtMS0xLTExNTYyNw_099f89a3-4409-41e5-a8aa-64a7c9ef9f0a">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i697f77c1d355434a9a8b15ca4ddad302_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA3LTYtMS0xLTExNTYyNw_05779a7e-5461-4561-ac56-1e13fc7e7692">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e5596ec20ad4b459dfd9d49c8be8280_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA5LTItMS0xLTExNTYyNw_aa7c1bdd-09f3-4f81-b844-a4a02d165e2c">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie645a8f76fd04bdd9b7b72c99f5627e3_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA5LTQtMS0xLTExNTYyNw_a4c67fac-8d26-4290-8793-11fb033d0aba">921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9e5596ec20ad4b459dfd9d49c8be8280_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA5LTYtMS0xLTExNTYyNw_475dec6d-9ca6-4113-8490-5df04a3070b7">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8552e76d9d3b4733be32dc860982d8e4_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEwLTItMS0xLTExNTYyNw_cd4d7ea6-6b2b-4abc-822d-578076087552">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic807b109c8d14499aa4a84252589e37c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEwLTQtMS0xLTExNTYyNw_807f1fb9-4e67-4779-a43d-826d6a08beba">1,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8552e76d9d3b4733be32dc860982d8e4_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEwLTYtMS0xLTExNTYyNw_c65af9db-9889-400c-9151-c32258d3b0b3">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0dee0d184434eecb3b25dcaf1f98eba_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjExLTItMS0xLTExNTYyNw_50da989e-fb54-4394-8be4-69ba0c166f19">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90a5e69efde44189a532234286ccde39_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjExLTQtMS0xLTExNTYyNw_2df2ec7d-3b2b-449c-bd4f-6392d8505782">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0dee0d184434eecb3b25dcaf1f98eba_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjExLTYtMS0xLTExNTYyNw_0e56d612-9a57-481a-b98a-0ee717ea233a">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e384d939a2447cea4dadc0e5a0c2ba0_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEzLTItMS0xLTExNTYyNw_8e820185-a69a-460d-b964-98089edf1242">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed173f3390944eeb61ad6efe66a23f6_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEzLTQtMS0xLTExNTYyNw_9e6b7486-2fe9-4c72-b65a-e8c0316a6e70">417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7e384d939a2447cea4dadc0e5a0c2ba0_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEzLTYtMS0xLTExNTYyNw_63727faf-4188-4be7-8691-b6aede370763">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49de9bf99ea94180be433fa61b42ba88_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE0LTItMS0xLTExNTYyNw_68e33c71-5881-4f31-ae22-2db142d1761b">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f40102c79e405caf79b8aa335221bc_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE0LTQtMS0xLTExNTYyNw_92ad3040-cb76-499d-8580-5b78a51e084c">729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i49de9bf99ea94180be433fa61b42ba88_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE0LTYtMS0xLTExNTYyNw_37795a96-1d14-4d43-9bc5-55fc018b2989">7.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d75beb452e47f4893b94abbefb8bba_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE1LTItMS0xLTExNTYyNw_94475c0c-d96d-4385-a3dd-924785020542">1,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2400dc461764134b3d942c32d0168b5_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE1LTQtMS0xLTExNTYyNw_5e442c82-ab99-4be0-b9d3-50edbd4c0bc8">1,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia2d75beb452e47f4893b94abbefb8bba_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE1LTYtMS0xLTExNTYyNw_29116c94-0c01-4d38-8c27-c542825126c8">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8aa22293d2d40f6b58a4dec4c64b355_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE3LTItMS0xLTExNTYyNw_7e497558-6101-452d-91b5-4f30086a9a2d">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ba49a1061e421f816cbb74a729895b_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE3LTQtMS0xLTExNTYyNw_d6876674-4e72-42c9-831b-afcf5001b226">504</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8aa22293d2d40f6b58a4dec4c64b355_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE3LTYtMS0xLTExNTYyNw_5a88f99b-3456-4320-b9ea-26cd12ff4607">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i7931c5d2e0ec4e40a2c9f7ee6eaa2c97" continuedAt="i7287f03a31fb4ef1a6174ffd95bdd5a0"><ix:continuation id="ic2c9d987e5bb44fcaab7f56f3e7f3baa"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"></td><td style="width:49.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.777%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic05893454bf84c37b75cefbd3d5459a8_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE4LTItMS0xLTExNTYyNw_14af436f-67c0-4d0e-9842-bb5462e87433">785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce2e1faf70848a0bfcd29eeafb93a9c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE4LTQtMS0xLTExNTYyNw_241f4098-84bb-4a6e-88b6-b37d8a30bbe9">784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic05893454bf84c37b75cefbd3d5459a8_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE4LTYtMS0xLTExNTYyNw_c4015221-f618-4b0a-8a47-00dac4f5962c">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1677e46a9474356b3c9dfb976393db7_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE5LTItMS0xLTExNTYyNw_b7d1d6cc-c2ff-4e53-bf88-ac0ee785e76d">1,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i517534deb5ca4eb3aaae15c62790e025_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE5LTQtMS0xLTExNTYyNw_9f4dbfc0-ce13-44ae-a55b-da9831924847">1,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1677e46a9474356b3c9dfb976393db7_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE5LTYtMS0xLTExNTYyNw_e7924f0a-ba65-4e95-9e4b-198dd372ea7f">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd11491a92ce4672bdb3774057431a46_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIxLTItMS0xLTExNTYyNw_966e83fd-8364-4854-850d-28c1b5b7d029">558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339f955c262f45dfb4f389ca7e08c4a0_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIxLTQtMS0xLTExNTYyNw_8040379d-fc8f-4d6a-bb8a-5f888a75c164">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd11491a92ce4672bdb3774057431a46_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIxLTYtMS0xLTExNTYyNw_82acd4f3-b238-43b0-9375-f43389b2a014">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie597f3c11e0747f68e8d3493b85a2080_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIyLTItMS0xLTExNTYyNw_9e488ce0-cf63-4be4-bd70-220d9ddb84ab">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72679ec91b0f470ea17b2acaf9ad9344_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIyLTQtMS0xLTExNTYyNw_b258c685-2d56-4eb2-a839-723f9891a252">736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie597f3c11e0747f68e8d3493b85a2080_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIyLTYtMS0xLTExNTYyNw_7a31a3da-0b51-4083-b37b-46464f96756f">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1bb18c06f4c40b296683224f79a53f4_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIzLTItMS0xLTExNTYyNw_a45e82ab-03d1-453a-a3ad-877432cd1719">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade9c6803cc4447ca6535fa706f5fca2_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIzLTQtMS0xLTExNTYyNw_81abdb3c-42cb-4024-96df-784db94f51ba">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic1bb18c06f4c40b296683224f79a53f4_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIzLTYtMS0xLTExNTYyNw_a612d382-bbac-4328-80ba-0df925886772">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98b473235c7a47cf859add062d06101a_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI1LTItMS0xLTExNTYyNw_38348911-03ec-432e-9c67-2b81ae89ad3a">444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68cff8e717ca4f708d166109353460b5_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI1LTQtMS0xLTExNTYyNw_345bc71a-6f66-423f-9d13-8f0f30b2f7ba">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i98b473235c7a47cf859add062d06101a_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI1LTYtMS0xLTExNTYyNw_f636dbec-a6fb-405c-9675-d4824ddb32ea">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie56c32de3e2e41eba3b2b9cc344394db_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI2LTItMS0xLTExNTYyNw_153a7d6f-3309-409b-8c68-a40ec72d4721">509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d829554c2047b198f4d4504c6c4bad_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI2LTQtMS0xLTExNTYyNw_8c548e8e-26b1-45da-8c5f-c681d03ac2be">511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie56c32de3e2e41eba3b2b9cc344394db_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI2LTYtMS0xLTExNTYyNw_e78385a5-255e-4ff7-9c4a-02ad99667b19">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fa18e49624849a3bf980a89602d76c9_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI3LTItMS0xLTExNTYyNw_a4ca155e-e976-4fab-928e-4089256ee9d3">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i744e82d777a14f4dbc24cf9ac953202f_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI3LTQtMS0xLTExNTYyNw_99d5ac2f-3d29-4db8-a0ef-c624ea133c2d">910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3fa18e49624849a3bf980a89602d76c9_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI3LTYtMS0xLTExNTYyNw_46923183-0aef-4c84-8739-1a70b3f50886">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848d69207c1f4c90b5cc68c1f1eb7bf0_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMwLTItMS0xLTExNTYyNw_23be75fa-1645-4df6-b799-e0c01c4d554f">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74605a46308f4807bcd58248b6e0db65_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMwLTQtMS0xLTExNTYyNw_535e8850-6f6d-4047-a09a-2ece1bc5ef26">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i848d69207c1f4c90b5cc68c1f1eb7bf0_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMwLTYtMS0xLTExNTYyNw_9c0656ce-b509-4869-9e9c-daf00aa8f2c3">6.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i115ea6c058084298bd8bfd6a9c9d7b23_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMxLTItMS0xLTExNTYyNw_303b21ab-e2c9-4c40-ba35-a8155963c71a">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a59d2f00ca14a8fa8f0a3d5f5602967_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMxLTQtMS0xLTExNTYyNw_7215f7d5-29b1-4e1a-b7a6-e740649b83a4">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i115ea6c058084298bd8bfd6a9c9d7b23_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMxLTYtMS0xLTExNTYyNw_7005e4a2-4bba-451f-af32-d3aa7e2c4c96">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb91eb7b4af04d58ad7789571043edbf_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMyLTItMS0xLTExNTYyNw_06606158-aeea-44d6-88db-57e0ed1c1bc7">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a2a973165fa46a79af877784002fe9a_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMyLTQtMS0xLTExNTYyNw_53c5820a-6040-44e3-b66e-c3eb1b131eea">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifb91eb7b4af04d58ad7789571043edbf_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMyLTYtMS0xLTExNTYyNw_b3e4b7ff-571b-44c0-bb00-e65c2c11d637">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i787acd4164eb45deb0403c444006faf9_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM1LTItMS0xLTExNTYyNw_18e6258c-5634-42f4-ae5f-274803e51cc5">3,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf4ce4d283a4b7280171759a01baa0e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM1LTQtMS0xLTExNTYyNw_b1593d5e-c17d-4bd9-99aa-2aa16826d030">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i787acd4164eb45deb0403c444006faf9_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM1LTYtMS0xLTExNTYyNw_cfb1a448-0ab4-4cd3-a732-ba6397315811">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c64cc3fc6694b9495fdc5efad8fb4d4_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM2LTItMS0xLTExNTYyNw_2f8bf84f-659d-4a75-aec8-35258349712b">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib78785c8a47a4c63b2c807c981cf27ba_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM2LTQtMS0xLTExNTYyNw_c9282a52-045a-4b9b-9363-614272135b83">3,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0c64cc3fc6694b9495fdc5efad8fb4d4_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM2LTYtMS0xLTExNTYyNw_a31ffe83-be22-4381-a2cd-669c32121abb">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia44d907a039b4ea4b07c28589766bd8a_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM3LTItMS0xLTExNTYyNw_fd683a53-8cbb-45a7-b091-fb5641e1dcbd">7,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0b0bf9e3b4b4097ab7bdcaefa80578e_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM3LTQtMS0xLTExNTYyNw_3e758fd5-3d1e-49b5-9279-0c13bb0d2330">6,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia44d907a039b4ea4b07c28589766bd8a_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM3LTYtMS0xLTExNTYyNw_28880f45-bacd-4530-bd9a-9946b3db1a36">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18fd463fe944955b813ba83e60464c6_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQwLTItMS0xLTExNTYyNw_58dce6eb-6e23-422d-8602-6f28f538f6b3">12,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a29daeaf368468580d88ec00d701e07_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQwLTQtMS0xLTExNTYyNw_cea46835-dc3a-4788-9b00-3a58209feb2b">11,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib18fd463fe944955b813ba83e60464c6_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQwLTYtMS0xLTExNTYyNw_a953a6f5-7ade-48b8-be5c-51879dae9679">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf1fef094458495f8b29e9d3d2c96404_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQxLTItMS0xLTExNTYyNw_9387da4e-c518-42c4-909b-2b503ec45c03">12,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9092a20f7ec442c6abb4a5f03939e991_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQxLTQtMS0xLTExNTYyNw_95d6fe68-4227-4d3b-8251-33af1bb8db4c">12,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf1fef094458495f8b29e9d3d2c96404_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQxLTYtMS0xLTExNTYyNw_feb4d18b-598e-4236-96cc-33edc9413a98">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQyLTItMS0xLTExNTYyNw_22329c4d-7fb0-49e9-89c1-7491ff59399f">24,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQyLTQtMS0xLTExNTYyNw_debf6a3c-0546-4e92-891a-d3013ff56843">23,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQyLTYtMS0xLTExNTYyNw_538d9017-6948-49fa-b5b1-c92939d19c5b">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Inclusive of RISPERDAL CONSTA which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquired on December 22, 2022</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfNDIxOQ_5bd3e8da-591e-4258-a79c-4982f470db21" continuedAt="i023324dde7ea40bab764582116c97409" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS/(LOSS) BEFORE PROVISION FOR TAXES BY SEGMENT </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"></td><td style="width:55.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b70d99f03547bebaa68b9a5dfb0b6b_D20230102-20230402" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfMi0yLTEtMS0xMTU2Mjc_321afcca-701c-40c9-b84b-c798ed83baf5">776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e23b581651e49f0a5450b48eca550f3_D20220103-20220403" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfMi00LTEtMS0xMTU2Mjc_41cd561e-b1c1-411b-a859-f628c33bff27">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i76b70d99f03547bebaa68b9a5dfb0b6b_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfMi02LTEtMS0xMTU2Mjc_5c3ff826-4acc-4db2-bc3f-860a05be9db0">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i266ded4d880644b384a30db64ac42be7_D20230102-20230402" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfMy0yLTEtMS0xMTU2Mjc_efda2976-d65a-4717-89a6-89e8ce2f661b">4,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d86be298e0484a81aaed029e8f90b8_D20220103-20220403" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfMy00LTEtMS0xMTU2Mjc_7a1d9f99-c581-42ce-954e-00b86d24ea38">3,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i266ded4d880644b384a30db64ac42be7_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfMy02LTEtMS0xMTU2Mjc_892b5b2b-1614-4787-a09e-cbffd2837d3c">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e11113be4ef43419386891473e5f667_D20230102-20230402" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNC0yLTEtMS0xMTU2Mjc_2cf44a53-477c-4970-b144-1d1aac066592">1,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0748aae7984d91b72595fdb3674877_D20220103-20220403" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNC00LTEtMS0xMTU2Mjc_07814e55-25d6-4c0c-b8ac-4f6e65e075bb">1,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7e11113be4ef43419386891473e5f667_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNC02LTEtMS0xMTU2Mjc_1ab57af3-a953-48c1-94fd-6f66e5e09484">2.2</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i255efac904da4926972f85e5d3721be3_D20230102-20230402" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNS0yLTEtMS0xMTU2Mjc_a32b8dee-620d-44f0-a9ac-593aa38be64b">6,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6478dcb7f72f406bb51f1ce2d06bbe1d_D20220103-20220403" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNS00LTEtMS0xMTU2Mjc_0517837e-6423-4b0f-8e0e-2f31e01a7812">6,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i255efac904da4926972f85e5d3721be3_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInOperatingIncomeLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNS02LTEtMS0xMTU2Mjc_7f630a25-954f-4793-b96f-4cd693a2372d">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6422d8dc1a9349d8ad4352f323889e7e_D20230102-20230402" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNi0yLTEtMS0xMTU2Mjc_a38558b8-bd05-4600-86f7-9c280bfc0d77">7,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia33598a52aed4f398e20f2837c3224a6_D20220103-20220403" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNi00LTEtMS0xMTU2Mjc_70234d28-69b3-488c-a4da-a8c19d7a002f">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76b70d99f03547bebaa68b9a5dfb0b6b_D20230102-20230402" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNy0yLTEtMS0xMTU2Mjc_569b8157-03c1-409d-8e09-9732aa5bf916">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e23b581651e49f0a5450b48eca550f3_D20220103-20220403" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNy00LTEtMS0xMTU2Mjc_04e4b337-abdd-4a61-b381-c22e64d2f402">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income/(loss) before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfOC0yLTEtMS0xMTU2Mjc_d34f42cd-c19c-4ffc-ae9d-f7a81307fa4f">737</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfOC00LTEtMS0xMTU2Mjc_6b2a62c7-4bf4-4526-b17e-fc18a7ae915b">5,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i76b70d99f03547bebaa68b9a5dfb0b6b_D20230102-20230402" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfOTcy_64fb9c94-5130-4ce2-8e63-a9497abe2c2d">0.1</ix:nonFraction> billion in both the fiscal first quarter of 2023 and 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i266ded4d880644b384a30db64ac42be7_D20230102-20230402" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMTQxMQ_60fe7a59-0918-4044-a97e-d4273d37f543">0.7</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i32d86be298e0484a81aaed029e8f90b8_D20220103-20220403" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMTQxOA_7eab0076-b3ec-4c80-ab4e-dd2b16b17d56">0.8</ix:nonFraction>&#160;billion in the fiscal first quarter of 2023 and 2022, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine related exit costs of $<ix:nonFraction unitRef="usd" contextRef="i266ded4d880644b384a30db64ac42be7_D20230102-20230402" decimals="-8" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMjc0ODc3OTA3NjM5MQ_9a956ae9-18cb-4912-8e35-5ac54896164b">0.4</ix:nonFraction>&#160;billion in the fiscal first quarter of 2023.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="id0b0bf9e3b4b4097ab7bdcaefa80578e_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfODIwMg_0c0605cf-9031-4bc0-9296-5ce8e6e6b4f2"><ix:nonFraction unitRef="usd" contextRef="id0b0bf9e3b4b4097ab7bdcaefa80578e_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfODIwMg_42e04770-5122-4705-b6ff-cd2376ba7fa1">0.1</ix:nonFraction></ix:nonFraction> billion in the fiscal first quarter of 2023. </span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i7287f03a31fb4ef1a6174ffd95bdd5a0"><ix:continuation id="i023324dde7ea40bab764582116c97409" continuedAt="i146106f0fc4c48a39af04cb004872e51"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i2e99be17669548568e7cf2506dae3d92_D20220103-20220403" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMjc0ODc3OTA3NTUzNA_8419d72d-54d0-4d48-bb27-b9735c5c4404">0.6</ix:nonFraction>&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable changes in the fair value of securities in the fiscal first quarter of 2022 of $<ix:nonFraction unitRef="usd" contextRef="i32d86be298e0484a81aaed029e8f90b8_D20220103-20220403" decimals="-8" sign="-" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMjAzMg_2a208e91-6330-4669-b5e7-2167702335b3">0.4</ix:nonFraction>&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MedTech includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $<ix:nonFraction unitRef="usd" contextRef="i7e11113be4ef43419386891473e5f667_D20230102-20230402" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMjc0ODc3OTA3NzA4MA_73a5a1c7-7e49-40de-a388-c5139d2e46c5">0.4</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i0c0748aae7984d91b72595fdb3674877_D20220103-20220403" decimals="-8" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMzczNQ_da7a713e-ccdb-4de1-8cbc-08f6cf8efbb3">0.3</ix:nonFraction>&#160;billion in the fiscal first quarter of 2023 and 2022, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="id0b0bf9e3b4b4097ab7bdcaefa80578e_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfODIwNg_0c0605cf-9031-4bc0-9296-5ce8e6e6b4f2"><ix:nonFraction unitRef="usd" contextRef="id0b0bf9e3b4b4097ab7bdcaefa80578e_D20220103-20220403" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfODIwNg_42e04770-5122-4705-b6ff-cd2376ba7fa1">0.1</ix:nonFraction></ix:nonFraction> billion in the fiscal first quarter of 2022.</span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i146106f0fc4c48a39af04cb004872e51" continuedAt="ie3078dc297bd419cac0c5d92cadd4a53">(4)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ie3078dc297bd419cac0c5d92cadd4a53">Amounts not allocated to segments include interest income/expense and general corporate income/expense. The fiscal first quarter of 2023 includes the incremental $6.9 billion charge related to the talc settlement proposal. See Note 11, Legal Proceedings, for additional details.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfNDIzNA_8721b398-4830-4cd6-a03b-5672bf137009" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.736%"><tr><td style="width:1.0%"></td><td style="width:48.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.270%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18fd463fe944955b813ba83e60464c6_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfMi0yLTEtMS0xMTU2Mjc_0c0234a3-d559-4332-acd0-78deeaf1dd36">12,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a29daeaf368468580d88ec00d701e07_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfMi00LTEtMS0xMTU2Mjc_a1fbce51-9489-4572-a51b-87b85ee4aea4">11,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib18fd463fe944955b813ba83e60464c6_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfMi02LTEtMS0xMTU2Mjc_667fc5f8-1407-423f-908a-22ba9970819e">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e0a38cfc3b4adbbf4d6b479e3c1cb5_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfMy0yLTEtMS0xMTU2Mjc_a2b0f26d-43a2-4cf3-af47-2c61b80eca84">6,332</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6b9854fc844374a84fb9c3498a9aa8_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfMy00LTEtMS0xMTU2Mjc_3cd3dff7-a730-4016-9f0b-ada3bcb03ae5">6,024</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92e0a38cfc3b4adbbf4d6b479e3c1cb5_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfMy02LTEtMS0xMTU2Mjc_077a8ccd-6957-4c06-b309-3ce02a686e4e">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08a82343349b46cfa5a11eced6ece9f7_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNC0yLTEtMS0xMTU2Mjc_15b92f85-6e9e-4732-ac28-1154f785cdb4">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0468e2eece0f48cb874e2856e754bfea_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNC00LTEtMS0xMTU2Mjc_d4857f6b-4458-444f-87ac-e5a390874bc0">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i08a82343349b46cfa5a11eced6ece9f7_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNC02LTEtMS0xMTU2Mjc_7608a68a-b5fc-4b0f-a21d-e4cfbbf1beee">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60f2cfdf1f24ce795240fc4f13586e0_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNS0yLTEtMS0xMTU2Mjc_fbe652d5-2434-4fc5-8a12-9fee986bedcd">4,310</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65cb348676ea488598ee39d3f57d3991_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNS00LTEtMS0xMTU2Mjc_220ddf42-a212-46b5-94f8-05d6c20efde4">4,506</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id60f2cfdf1f24ce795240fc4f13586e0_D20230102-20230402" decimals="3" sign="-" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNS02LTEtMS0xMTU2Mjc_8352b959-12c7-424e-af21-e51127e448b1">4.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNi0yLTEtMS0xMTU2Mjc_19899fd3-80f4-4c62-8660-8904bcdfcdfd">24,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNi00LTEtMS0xMTU2Mjc_f04bd3c9-407b-45c9-bf6c-b475e936ae79">23,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="3" name="jnj:PercentageChangeInSalesByGeographicArea" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNi02LTEtMS0xMTU2Mjc_f580acbc-3e26-4c54-8b2c-36cb9106b436">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 10&#8212; <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfMzg0ODI5MDcwMjU3Mg_5795b250-4e47-41e4-addd-722c7d13361b" continuedAt="i75c92794523a447bbd2984bdac739de5" escape="true">ACQUISITIONS AND DIVESTITURES</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><ix:continuation id="i75c92794523a447bbd2984bdac739de5" continuedAt="i453bdc2bcf7145a18f7468f25455d2be"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no acquisitions or divestitures in the fiscal first quarter of 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Company&#8217;s position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcare&#8217;s largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE4OTIy_0420e0e1-08e9-4e00-a48e-29d400452dee">380.00</ix:nonFraction> per share in cash, amounting to $<ix:nonFraction unitRef="usd" contextRef="i36d5c84c5814468ba35bfdbf20ca360c_D20221222-20221222" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE4OTMx_478aee44-5c8b-436e-8804-308abd623db4">17.1</ix:nonFraction>&#160;billion, net of cash acquired, as well as a non-tradeable contingent value right (CVR) entitling the holder to receive up to $<ix:nonFraction unitRef="usdPerShare" contextRef="i81a2ab2c858b4a97bf160fe849e1cb84_D20221222-20221222" decimals="2" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE4OTQ2_59065da0-04ea-4e57-b779-3031bf31d3e2">35.00</ix:nonFraction> per share in cash (which with respect to the CVRs total approximately $<ix:nonFraction unitRef="usd" contextRef="i81a2ab2c858b4a97bf160fe849e1cb84_D20221222-20221222" decimals="-8" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE4OTU0_a6b3e5dd-df3a-4856-b877-b80830ee2ff9">1.6</ix:nonFraction>&#160;billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $<ix:nonFraction unitRef="usd" contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE4OTY4_360979b3-de89-4bf7-817b-412590f9d4bd">16.5</ix:nonFraction>&#160;billion includes cash, cash equivalents and marketable securities acquired. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The milestones of the CVR consist of:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">$<ix:nonFraction unitRef="usdPerShare" contextRef="icc8de83c4d3041d09bb523dcfd66b52e_I20221222" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfMzg0ODI5MDcwMjU2NQ_90a7d936-a871-497b-8f6d-5e96a47d9da9">17.50</ix:nonFraction> per share, payable if net sales for Abiomed products exceeds $<ix:nonFraction unitRef="usd" contextRef="i81a2ab2c858b4a97bf160fe849e1cb84_D20221222-20221222" decimals="-8" name="jnj:RevenuesContingentConsideration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE4OTg3_9783ea90-b93b-412e-be74-e3d9ca2b1526">3.7</ix:nonFraction>&#160;billion during Johnson &amp; Johnson&#8217;s fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson &amp; Johnson&#8217;s fiscal first quarter of 2029, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8836b8f3d5ba484189de37af4b30f820_I20221222" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDAw_625b375b-7c0e-49fe-bb2c-938ab6ecc78e">8.75</ix:nonFraction>per share;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">$<ix:nonFraction unitRef="usdPerShare" contextRef="i06197fa8dff142f592975553bd6a4d84_I20221222" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDE2_bbb1c0ac-8112-40f3-af96-08aa83b23462">7.50</ix:nonFraction> per share payable upon FDA premarket application approval of the use of Impella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0794a9f898cd4ed580c9795984a4df7d_I20221222" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDIz_8b37f012-71b6-464e-8975-2b9d21e0726f">10.00</ix:nonFraction> per share payable upon the first publication of a Class I recommendation for the use of Impella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the acquisition was initially allocated to assets acquired of $<ix:nonFraction unitRef="usd" contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDMx_bf925647-f58e-4e75-b9b8-b909aad19edf">19.9</ix:nonFraction>&#160;billion (net of $<ix:nonFraction unitRef="usd" contextRef="i36d5c84c5814468ba35bfdbf20ca360c_D20221222-20221222" decimals="-8" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDQ2_44f401a7-1f34-4541-8ab8-3c6384c511b3">0.3</ix:nonFraction>&#160;billion cash acquired), primarily to goodwill for $<ix:nonFraction unitRef="usd" contextRef="i36d5c84c5814468ba35bfdbf20ca360c_D20221222-20221222" decimals="-8" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDYw_c2c54c29-a2f3-4d01-8c52-d0b83ec2f680">10.9</ix:nonFraction>&#160;billion, amortizable intangible assets for $<ix:nonFraction unitRef="usd" contextRef="i36d5c84c5814468ba35bfdbf20ca360c_D20221222-20221222" decimals="-8" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDc1_6d2ba2ce-d85c-406c-a600-1572ea11ed85">6.6</ix:nonFraction>&#160;billion, IPR&amp;D for $<ix:nonFraction unitRef="usd" contextRef="i36d5c84c5814468ba35bfdbf20ca360c_D20221222-20221222" decimals="-8" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDg5_e4218fbd-b6ed-4725-a996-6f7868f7b6e9">1.1</ix:nonFraction>&#160;billion, marketable securities of $<ix:nonFraction unitRef="usd" contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTAz_b8a434c4-9205-420d-90f4-86b2d3576fed">0.6</ix:nonFraction>&#160;billion and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTE3_877b2b4a-d973-414f-885e-e38b4139bdcb">2.8</ix:nonFraction>&#160;billion, which includes the fair value of the contingent consideration mentioned above for $<ix:nonFraction unitRef="usd" contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222" decimals="-8" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTMx_a9c9e782-8199-4463-9130-b9331acd1680">0.7</ix:nonFraction>&#160;billion and deferred taxes of $<ix:nonFraction unitRef="usd" contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfMzg0ODI5MDcwMjU0MA_e261aaa1-7dd2-4029-a20b-8b5e1c1b3d95">1.8</ix:nonFraction>&#160;billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities on the Consolidated Balance Sheet.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i453bdc2bcf7145a18f7468f25455d2be" continuedAt="ia3bdf897ddea4d798a9e82aa7f83c0e1"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date. In the fiscal first quarter of 2023, there were purchase price allocation adjustments netting to approximately $<ix:nonFraction unitRef="usd" contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" decimals="-8" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE0NTE3OA_9c463800-b926-47a4-a1d5-df7369bc7586">0.1</ix:nonFraction>&#160;billion with an offsetting increase to goodwill.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortizable intangible assets were primarily comprised of already in-market products of the Impella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform with an average weighted life of <ix:nonNumeric contextRef="i814ccd0c40684dd8ae2ed1e023cd3b2a_D20221222-20221222" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfMzg0ODI5MDcwMjUzOA_3dceaca8-8f9d-45f9-bd5c-de4490ba1adc">14</ix:nonNumeric> years. The IPR&amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from <ix:nonFraction unitRef="number" contextRef="iccd1694ce0dc40e78004ae73676d4941_I20221222" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTgw_b375fa2a-2684-4551-b50d-11e8fb6e44a7">52</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia3a0b329d181434f981a08002ca2cd3b_I20221222" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTg1_9e33a591-0519-41ad-a652-5394f2c2eea4">70</ix:nonFraction>%. The discount rate applied was <ix:nonFraction unitRef="number" contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222" decimals="3" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTkw_4816f3da-09c0-4209-9853-958e7268a057">9.5</ix:nonFraction>%.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, the Company recorded acquisition related costs before tax of approximately $<ix:nonFraction unitRef="usd" contextRef="i74c08a50ff5f419b83ba7dba4d025c2a_D20220103-20230101" decimals="-8" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTk2_e8faefb9-376f-4a73-b37c-a52c1c986db4">0.3</ix:nonFraction>&#160;billion, which was recorded in Other (income)/expense. </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ia3bdf897ddea4d798a9e82aa7f83c0e1">There were no material acquisitions or divestitures in the fiscal first quarter of 2022.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE 11 &#8212; <ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfMzI5ODUzNTUwNTU4Ng_57d24819-f090-4dd3-b20d-0e6f38aea7e0" continuedAt="i3d883916280c44b2878303bcb6d4a2a2" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i3d883916280c44b2878303bcb6d4a2a2" continuedAt="i08cd939c59634b18b5c81d926d3d7472"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of April&#160;2, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">MATTERS CONCERNING TALC</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and the Company arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $<ix:nonFraction unitRef="usd" contextRef="ic4c5e1157e174c7b9992d3b947faa46d_D20200601-20200630" decimals="-8" name="us-gaap:LossContingencyReceivableProceeds" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NjAx_19e78b56-69e8-4a71-a746-ca51a7d997ad">4.7</ix:nonFraction>&#160;billion in Ingham v. Johnson &amp; Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $<ix:nonFraction unitRef="usd" contextRef="ic4c5e1157e174c7b9992d3b947faa46d_D20200601-20200630" decimals="-8" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NjE1_4d125f49-f7bf-49a1-96a0-70ae530f749c">2.1</ix:nonFraction>&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="ia9af996ed5624621b676a456a070b7db_D20210601-20210630" decimals="-8" name="us-gaap:LossContingencyDamagesPaidValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NjI5_9a5c0cad-c9d2-4712-b8be-8db2d602622c">2.5</ix:nonFraction>&#160;billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i08cd939c59634b18b5c81d926d3d7472" continuedAt="i9a8aa1d96d0b459093b27ceeb019e7dc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed, although LTL did agree to lift the stay on a small number of appeals where appeal bonds had been filed.   The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court&#8217;s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LTL filed a petition for rehearing of the Third Circuit&#8217;s decision, which was denied on March 22, 2023.  On the same day, LTL filed a motion in the Third Circuit to stay the mandate directing the New Jersey Bankruptcy Court to dismiss the LTL bankruptcy pending filing and disposition of a petition for writ of certiorari to the United States Supreme Court. On March 31, 2023, the Third Circuit denied the motion to stay the mandate and issued the mandate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 4, 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. Several hours later, also on April 4, 2023, LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case).  As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code.  Additionally, on April 5, 2023, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 20, 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction).  The LTL 2 Preliminary Injunction will remain in force and effect until June 15, 2023, subject to the New Jersey Bankruptcy Court revisiting its ruling at a hearing scheduled for May 22, 2023.  Under the LTL 2 Preliminary Injunction, except for in those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters is permitted to proceed. No trials may occur in any of the personal injury and wrongful death matters. On April 24, 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the original bankruptcy case, the Company agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $<ix:nonFraction unitRef="usd" contextRef="i5a2da6f47c794efc85b034ec75f9880b_D20211001-20211031" decimals="-8" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NzA0_cffa23af-7f00-4c9f-8d31-eeeb019c9960">2.0</ix:nonFraction>&#160;billion trust in furtherance of this purpose. The Company established a reserve for approximately $<ix:nonFraction unitRef="usd" contextRef="i5a2da6f47c794efc85b034ec75f9880b_D20211001-20211031" decimals="-8" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1OTUw_704fb037-e93e-4dfa-b8e9-7f33f8dd901b">2.0</ix:nonFraction>&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. In the LTL 2 Bankruptcy Case, the Company has agreed to contribute an additional $<ix:nonFraction unitRef="usd" contextRef="if6ec52a5f6d5422d88184d297ffc6e51_I20230424" decimals="-8" name="jnj:LossContingencyAdditionalContribution" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NjQz_17758453-2fbf-4a96-9e61-b88b2e9041c4">6.9</ix:nonFraction>&#160;billion which, when added to the prior $<ix:nonFraction unitRef="usd" contextRef="i5a2da6f47c794efc85b034ec75f9880b_D20211001-20211031" decimals="-8" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NjU3_cc97f1b1-55ac-416a-b6cb-ff3aa6a25115">2.0</ix:nonFraction>&#160;billion, will be a total reserve of present value of $<ix:nonFraction unitRef="usd" contextRef="i503d1efd449c494a99b00f5571fe65d2_I20211031" decimals="-8" name="jnj:LossContingencyReserveEstablishedWithinTrustTotal" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NjY5_b4575260-f360-47df-a89e-45ff2b517183">8.9</ix:nonFraction>&#160;billion payable over <ix:nonNumeric contextRef="i503d1efd449c494a99b00f5571fe65d2_I20211031" name="jnj:LossContingencyTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfMzI5ODUzNTUwNTYxOQ_f260c09e-d950-4b20-9c22-849efc5aa0c7">25</ix:nonNumeric> years (nominal value approximately $<ix:nonFraction unitRef="usd" contextRef="if6ec52a5f6d5422d88184d297ffc6e51_I20230424" decimals="-8" name="jnj:LossContingencyReserveEstablishedWithinTrustNominalValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1Njg0_042ead9c-af80-4dda-bb40-e7f5b48208b0">12.0</ix:nonFraction>&#160;billion discounted at a rate of <ix:nonFraction unitRef="number" contextRef="i304dd0295691432abf102897083e51f0_I20230424" decimals="4" name="jnj:BankruptcyLossContingencyDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1Njk3_06aada1e-2ec6-46c8-8032-f32abf45f836">4.41</ix:nonFraction>%), to resolve all the current and future talc claims. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The expected payment schedule provides that approximately $<ix:nonFraction unitRef="usd" contextRef="i5a2da6f47c794efc85b034ec75f9880b_D20211001-20211031" decimals="-8" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1OTY1_39e11d37-ee3c-4932-b162-4ad67976edcd">6.0</ix:nonFraction>&#160;billion is paid in the first two years, with the remainder paid over the remaining <ix:nonNumeric contextRef="i043b133272cb49e4ad4a3a90ff5a68b9_I20211031" name="jnj:LossContingencyRemainingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfMzI5ODUzNTUwNTYzNQ_b091d69c-d8eb-49af-85d2-46a2989da0d2">23</ix:nonNumeric> years. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Company&#8217;s then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i9a8aa1d96d0b459093b27ceeb019e7dc" continuedAt="i89317a5b8e424b40ac94fc4ebee2744f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jersey. In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC) (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the Tort Claimants&#8217; Committee (TCC) and Future Claimants&#8217; Representative (FCR) appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing &#8220;talc-related claims&#8221; against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023. The court subsequently extended the preliminary injunction through July 31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Imerys, the TCC, the FCR, certain of Imerys&#8217;s insurers, and certain parties in the Cyprus Mines chapter 11 case (collectively the Mediation Parties) have been engaged in mediation since October 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The Company filed a motion to dismiss the adversary proceeding. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, and that purchasers of the Company&#8217;s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In April 2021, briefing on Plaintiff&#8217;s motion for class certification was completed. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action and Plaintiff appealed the Bankruptcy Court&#8217;s order.  However, on March 31, 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case, which mooted the appeal, and on April 4, 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S Baby Powder. In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i89317a5b8e424b40ac94fc4ebee2744f" continuedAt="id4694b8ae5914c11b7d4a718ba68a7dd"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S Baby Powder and JOHNSON&#8217;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. In February 2022, the trial court set the case for trial to begin in February 2023. However, in October 2022, the LTL bankruptcy court issued an order staying the case. On March 31, 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and on April 4, 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. The trial court has indicated it will set a new trial date in this matter during the second fiscal quarter of 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Company&#8217;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#8217;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#8217;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexico&#8217;s discovery obligations. On March 31, 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and on April 4, 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Court&#8217;s stay until such time as the Supreme Court issues an order concerning the State of New Mexico&#8217;s discovery obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court.  In March 2023, the mediation was terminated.  The procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">MATTERS CONCERNING OPIOIDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to <ix:nonFraction unitRef="claimant" contextRef="i168a38aa9d2c44faab5619fe9ffe4231_I20230402" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1OTc5_229f580f-5676-4db7-a9e0-d25565264114">3,500</ix:nonFraction> lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned narcotic raw material and active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments, including 20 suits filed by state or territorial Attorneys General following a multi-state investigation of opioid marketing practices. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors. In August 2019, the Company received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The majority of the opioid marketing cases have been filed in federal courts and coordinated in a multi-district litigation proceeding in the United States District Court for the Northern District of Ohio (Ohio MDL), with most of the remainder in various state courts. To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal. In November 2021, the Oklahoma Supreme Court reversed a $<ix:nonFraction unitRef="usd" contextRef="i0ab721ca3d7d460192200182b3872c5a_D20191230-20210103" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MTA2_e49f2bd5-04ca-4277-a2b9-5233339f29a1">465</ix:nonFraction>&#160;million judgment entered against the Company and JPI on a public nuisance claim brought by the Oklahoma Attorney General, holding that the marketing of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="id4694b8ae5914c11b7d4a718ba68a7dd" continuedAt="iae0399bbc7de40ffbd017d27af4d0095"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">lawful products was not actionable under the State&#8217;s public nuisance law, and directing entry of judgment for the Company and JPI. In February 2022, the Superior Court of Orange County, California, entered judgment for the Company, JPI, and three other pharmaceutical manufacturers on public nuisance and deceptive marketing claims brought by four California local governments, holding that the plaintiffs had failed to prove that any defendant&#8217;s marketing was deceptive or that any defendant&#8217;s allegedly deceptive marketing led to medically inappropriate prescribing. The California plaintiffs appealed from that judgment, but abandoned their appeal after electing to participate in the Company&#8217;s national settlement agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, after settling an initial test case brought by two Ohio counties in the Ohio MDL, the Company announced a proposed agreement in principle with a negotiating committee of state Attorneys General to settle all remaining government opioid litigation claims nationwide. Under the final national settlement agreement, which was announced in July 2021, the Company agreed to pay up to $<ix:nonFraction unitRef="usd" contextRef="i0c6d0bc5404442dc9fbb22defa52977d_I20210704" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1OTg2_a9e5a95a-4e91-49d0-a3c9-5eae629356ff">5.0</ix:nonFraction>&#160;billion to resolve all opioid lawsuits and future opioid claims by states, cities, counties, local school districts and other special districts, and tribal governments, contingent on sufficient participation by eligible government entities, and with credits back for entities that declined or were ineligible to participate. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately half of the all-in settlement was paid by the first fiscal quarter of 2023. The expected payment schedule provides that approximately $<ix:nonFraction unitRef="usd" contextRef="ia97ebcbe40d746e3998c9afa253624ee_D20230102-20230402" decimals="-6" name="us-gaap:LossContingencyAccrualPayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MTMz_7cf2fa18-a296-43dd-8482-6212dfc18a7a">0.6</ix:nonFraction>&#160;billion of payments are to be paid by the end of the first fiscal quarter of 2024. The agreement is not an admission of liability or wrongdoing, and it provides for the release of all opioid-related claims against the Company, JPI, and their affiliates (including the Company&#8217;s former subsidiaries Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc.). By February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement. The Company confirmed that this level of participation was sufficient to proceed with the agreement, which became effective in April 2022. Also in 2022, the Company completed separate settlements with most of the government entities that had declined to participate in the national settlement agreement, including all federally-recognized tribes, the States of Alabama, New Hampshire, and West Virginia and their participating subdivisions, and litigating Oklahoma subdivisions. Consequently, by the end of the fiscal year 2022, the Company and JPI had settled or otherwise resolved the opioid claims advanced by all government entity claimants except the State of Washington and its subdivisions, the City of Baltimore, a number of school districts and other special district claimants, and a handful of others.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants, including NAS claimants, hospitals, and health insurers/payors. Counting the private litigant cases, there are approximately <ix:nonFraction unitRef="claim" contextRef="i168a38aa9d2c44faab5619fe9ffe4231_I20230402" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MTIw_aba43d09-8e0d-4656-a5fc-d23cc8124473">55</ix:nonFraction> remaining opioid cases against the Company and JPI in various state courts, <ix:nonFraction unitRef="claim" contextRef="i168a38aa9d2c44faab5619fe9ffe4231_I20230402" decimals="INF" name="jnj:LossContingencyPendingClaimsNumberRemaining" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MTI0_772e35a9-1c6c-45b6-ac33-b47b4ff6f7dd">545</ix:nonFraction> remaining cases in the Ohio MDL, and <ix:nonFraction unitRef="claim" contextRef="i168a38aa9d2c44faab5619fe9ffe4231_I20230402" decimals="INF" name="jnj:LossContingencyPendingClaimsNumberAdditional" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MTI5_a8373676-66d3-4398-89b6-e1b85d585b93">20</ix:nonFraction> additional cases in other federal courts. Several of these cases are scheduled for trial in 2023, 2024, or 2025. In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Company&#8217;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state court&#8217;s dismissal order.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="iae0399bbc7de40ffbd017d27af4d0095" continuedAt="i4d404588e26c4e3fba9bd3d3106d99d5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402" name="jnj:SummaryOfClaimsInPendingLawsuitsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfMzI5ODUzNTUwNTE2Nw_92dde397-fc24-42a5-8c36-ab75d75d980c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of April&#160;2, 2023:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"></td><td style="width:73.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product or product category</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Plaintiffs </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Body powders containing talc, primarily JOHNSON&#8217;S Baby Powder</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claimant" contextRef="i67bea373bcf745f8b39c99720a13df20_I20230402" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfMS0yLTEtMS0xMjYxMzY_48eb7a9f-6026-4607-b5dd-e657736d68c8">40,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claimant" contextRef="i4cf78e7db6fe424ca92d366884d15cc1_I20230402" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfMi0yLTEtMS0xMjYxMzY_2dfedd73-879c-438e-b2fd-081c021bd93a">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PINNACLE Acetabular Cup System</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claimant" contextRef="i3b4ceb386c184c2b93d06b92b82b2bbb_I20230402" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfMy0yLTEtMS0xMjYxMzY_132feade-03f8-4acc-b7fb-bbe3a7ed639f">940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pelvic meshes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claimant" contextRef="ifaeb7772b11c47759bd2f3879d60dc10_I20230402" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfNC0yLTEtMS0xMjYxMzY_fd36f5ac-f66c-4280-bd66-01812c6e6c19">8,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ETHICON PHYSIOMESH Flexible Composite Mesh</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claimant" contextRef="ib5a55c1aa53f481d8979dcf3332bb680_I20230402" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfNS0yLTEtMS0xMjYxMzY_a49159e6-bf14-4067-8483-46927bddfa40">2,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RISPERDAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claimant" contextRef="i51cf8df9cdd74871b6625778ba7d91de_I20230402" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfNi0yLTEtMS0xMjYxMzY_9c8caf95-6ed0-431f-adca-e691ec922cb9">520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELMIRON</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claimant" contextRef="i4790b713aa2844809fa453cd9fcb88bd_I20230402" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfNy0yLTEtMS0xMjYxMzY_986fca15-0290-47ec-9530-4ea3feab561d">2,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TYLENOL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claimant" contextRef="ibc7d93f749d74c228eda4c9d482b9c1a_I20230402" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfOC0yLTEtMS0xMjYxMzY_afeefee3-08cd-4769-9e7a-0d70d0354dc2">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">MedTech</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">DePuy ASR XL Acetabular System and ASR Hip Resurfacing System</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than <ix:nonFraction unitRef="claimant" contextRef="i77bc5b03664c43aea0c4d8e95bd4da26_I20230402" decimals="0" name="jnj:Numberofpatientsinsettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1OTk5_26d7ad04-f5f4-49ad-96fa-129fba8f3524">10,000</ix:nonFraction> claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">DePuy PINNACLE Acetabular Cup System</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i4d404588e26c4e3fba9bd3d3106d99d5" continuedAt="if6adedb743ff4e89aa0fdbb9583443a8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Ethicon Pelvic Mesh</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre- and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia and in March 2023 the Federal Court approved the settlement. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Ethicon Physiomesh</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately <ix:nonFraction unitRef="cases" contextRef="ic5638d3163f64eb384c2d26990c2bf2d_I20210531" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDA4_93ea5185-b61a-44b1-8050-4715309ffa58">3,600</ix:nonFraction> Physiomesh cases (covering approximately <ix:nonFraction unitRef="claimant" contextRef="ic5638d3163f64eb384c2d26990c2bf2d_I20210531" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDE1_1e00835f-f504-41ad-bd5e-5fce5840eb15">4,300</ix:nonFraction> plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes <ix:nonFraction unitRef="cases" contextRef="i8056c4aa7c884f9cb93c3477b3ab1519_I20210930" decimals="0" name="jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDIx_afc0a94d-94fc-4e53-be32-bf41ca70dbc6">3,729</ix:nonFraction> cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, <ix:nonFraction unitRef="cases" contextRef="i82887472019e4389baf706d14d575072_D20210901-20210930" decimals="0" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDIy_91af799f-f25b-42e1-b46e-9fd6da300b5d">2,308</ix:nonFraction> have been dismissed with prejudice. Ethicon has received releases from <ix:nonFraction unitRef="claimant" contextRef="i62a7dab5fc114de782c92d25060c9210_I20210531" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDI0_e237a340-5a2e-46a6-9fc4-2e2426f2d6fb">3,496</ix:nonFraction> plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of March 2023, there are approximately <ix:nonFraction unitRef="cases" contextRef="i28f2b9ddeb654daeb2f97d59eea0473d_I20230402" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDMx_bb705714-d863-4455-b440-ca66fe252275">225</ix:nonFraction> active cases subject to these orders which are being reviewed and evaluated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products.  All litigation activities in the two New Jersey MCLs are stayed pending resolution of the proposed settlement.  Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="if6adedb743ff4e89aa0fdbb9583443a8" continuedAt="id89c7a0c0dc54d9484d0d8d66f60108d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Pharmaceuticals</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">RISPERDAL</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $<ix:nonFraction unitRef="usd" contextRef="i7b5262aa703a4c79ad88ac4d66f46761_D20191001-20191031" decimals="-9" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDM2_77857015-1fef-4268-aa0b-4f79dd15c57d">8.0</ix:nonFraction>&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $<ix:nonFraction unitRef="usd" contextRef="i8420d4da9f3346f483112422335f21db_D20200101-20200131" decimals="-5" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDUw_fa6f27d2-f832-4300-babb-167a3ef03aad">6.8</ix:nonFraction>&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">ELMIRON</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Consumer Health</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">TYLENOL</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Johnson and Johnson Consumer Inc. (JJCI), arising out of the use of TYLENOL, an over-the-counter pain medication, alleging that prenatal exposure to acetaminophen is associated with the development of autism spectrum disorder and/or attention-deficit/hyperactivity disorder. In October 2022, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the Southern District of New York.  In addition, lawsuits have been filed in Canada against Johnson &amp; Johnson Inc. and the Company.  Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with TYLENOL related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Pharmaceuticals - Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDA&#8217;s publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations&#8221; (commonly known as the Orange Book). In each of these lawsuits, the Company&#8217;s subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company&#8217;s subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="id89c7a0c0dc54d9484d0d8d66f60108d" continuedAt="i9daa2e642b7e4582b8cc5fc8ef1a6989"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">XARELTO</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy&#8217;s Laboratories, Inc.; Dr. Reddy&#8217;s Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; USV Private Limited; Mankind Pharma Limited; Epic Pharma, LLC; Apotex Inc.; Apotex Corp.; Biocon Pharma Limited; Biocon Limited; Biocon Pharma, Inc.; and ScieGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218; and 10,828,310. In March 2023, the Company entered into a confidential settlement with Epic Pharma, LLC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. Patent No. 10,828,310 is also under consideration by the USPTO in an IPR proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">OPSUMIT</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; and Alembic Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in May 2020, Janssen Inc. and Actelion Pharmaceuticals Ltd initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against generic manufacturers who have filed ANDSs seeking approval to market generic versions of OPSUMIT before expiration of certain listed patents. The following entities are named defendants: Sandoz Canada Inc.; Apotex Inc.; and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Generic Medical Partners Inc. In March 2023, the Company entered into a confidential settlement agreement with Generic Medical Partners Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following Canadian patent is included in one or more cases: 2,659,770</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">INVEGA SUSTENNA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; and Accord Healthcare, Inc. The following U.S. patent is included in one or more cases: 9,439,906. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Teva Canada Limited; Pharmascience Inc.; and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">INVEGA TRINZA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">IMBRUVICA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in September 2021, Pharmacyclics LLC and Janssen Inc. initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of IMBRUVICA before expiration of certain listed patents. The following entities are named defendants: Natco Pharma (Canada) Inc.; and Sandoz Canada Inc. The following patents are included in one or more cases: 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i9daa2e642b7e4582b8cc5fc8ef1a6989" continuedAt="ibb9c31664dee49619f388cb59dbbf2c7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">SYMTUZA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp.  The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">ERLEADA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">UPTRAVI </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in November 2022, Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc.; Lupin Ltd.; Lupin Pharmaceuticals, Inc.; Cipla Limited; and Cipla USA Inc. The following U.S. patents are included in one or more cases: 8,791,122; 9,284,280; and 7,205,302. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Like other companies in the pharmaceutical, consumer health and medical devices industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">MedTech</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#8217;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#8217;s July 2021 ruling. In November 2021, the District Court granted DePuy&#8217;s motion for reconsideration and dismissed the case with prejudice. The District Court&#8217;s order was unsealed in December 2021. The relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court denied. Following the District Court&#8217;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#8217; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#8217;s dismissal of the case to the First Circuit. The briefing on the appeal is complete, the First Circuit held oral argument on December 6, 2022, and the First Circuit&#8217;s decision remains pending.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2012, the Company was contacted by the California Attorney General&#8217;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by the Company&#8217;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against the Company, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In October 2019, the Company and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. Between April 2019 and February </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="ibb9c31664dee49619f388cb59dbbf2c7" continuedAt="i16fb65089bd14d08a8233e6411a8b708"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023, the Company settled with Washington, West Virginia, Oregon, Mississippi and Kentucky. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $<ix:nonFraction unitRef="usd" contextRef="i7cec5795e9f24927925718a962fd322c_D20200101-20200131" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDY0_610a878f-b8a7-40c9-9807-ed99f66bc483">344</ix:nonFraction>&#160;million. In April 2020, the Court in California denied the Company&#8217;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $<ix:nonFraction unitRef="usd" contextRef="i7cec5795e9f24927925718a962fd322c_D20200101-20200131" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDky_0e41bdee-5f9b-4101-ae66-b308f5bb7f95">344</ix:nonFraction>&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $<ix:nonFraction unitRef="usd" contextRef="i2f8d53e5a09b495182048bc044c3b582_D20220401-20220430" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDc4_e3f13935-f128-4607-ae6d-46da85d41dc2">302</ix:nonFraction>&#160;million, but otherwise denied the appeal. In July 2022, the Supreme Court of California denied the Company&#8217;s petition to review the Court of Appeals decision, and the Company recorded a charge to reflect the judgment in the second quarter of 2022. In November 2022, the Company petitioned the United States Supreme Court for review. In February 2023, the Company&#8217;s petition to the United States Supreme Court was denied.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2017, the Company received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals.  The Company and DePuy fully cooperated with the government&#8217;s investigation. In January 2023, the Company, DePuy Synthes, Inc., and DePuy Synthes Sales Inc. entered into a settlement agreement with the United States resolving the matter for an immaterial amount. The only claim remaining before the United States District Court for the District of Massachusetts is the Relator&#8217;s employment retaliation claim.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Pharmaceuticals</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), the Company and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April and September 2017, the Company received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><ix:continuation id="i16fb65089bd14d08a8233e6411a8b708" continuedAt="i978919c9421b4cecbe26536621414d06"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company (subsequently substituted by Johnson &amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision. In February 2023, defendants petition for rehearing on the decision was denied. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">MedTech</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#8217;s motion for summary judgment. In April 2022, Innovative appealed this ruling to the United States Court of Appeals for the Ninth Circuit.  Oral argument has been set for June 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Pharmaceuticals</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against the Company and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> In re REMICADE Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022.  The Court issued final approval in March 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#8217;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands.  Janssen is in ongoing discussions with the FTC staff regarding the inquiry. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. Janssen filed its Notice of Defense in July 2022. Genmab and Janssen have cross-moved for early disposition of the arbitration.  In April 2023, the Arbitration Panel ruled in Janssen's favor and dismissed Genmab's claims. In April 2023, Genmab announced that it intends to appeal the award.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><ix:continuation id="i978919c9421b4cecbe26536621414d06"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In December 2021, several insurance companies and other payers filed individual &#8220;Opt-Out&#8221; complaints containing allegations similar to the original complaint. In September 2022, the Court granted in part and denied in part plaintiff&#8217;s motion for class certification. Trial was scheduled for May 2023; in March 2023, the Court issued an order dividing the matter into two separate trials.  The first trial, scheduled for May 2023, relates to claims that do not involve Janssen.  The court did not set a date for trial on the claims that do involve Janssen.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (EBSI) with the American Arbitration Association, alleging that EBSI breached the parties&#8217; Manufacturing Services Agreement for the Company&#8217;s COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In July 2022, Emergent filed its answering statement and counterclaims.  The hearing is scheduled for March 2024.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Merck Sharp &amp; Dohme Corp. with the American Arbitration Association pursuant to the Parties&#8217; agreements relating to production of drug substance and drug product for the Company&#8217;s COVID-19 vaccine. Also in October 2022, Merck filed its answer and counterclaims.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The hearing is scheduled for September 2023.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Consumer Health</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2019, the Company received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. In November 2022, Johnson &amp; Johnson received a demand for indemnification from GlaxoSmithKline LLC (GSK), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer, and certain 1993, 1998, and 2002 agreements between Glaxo Wellcome and Warner-Lambert entities. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in May 2021, multiple putative class actions were filed in state and federal courts (California, Florida, New York, and New Jersey) against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products and the affirmative promotion of those products as &#8220;safe&#8221;; and, in at least one case, alleging a strict liability manufacturing defect and failure to warn claims, asserting that the named plaintiffs suffered unspecified injuries as a result of alleged exposure to benzene. The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In December 2021, plaintiffs in the consolidated actions filed a motion for preliminary approval of a nationwide class settlement. The court issued an order granting final approval of the settlement in February 2023. A Notice of Appeal was filed in April 2023.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_103"></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span><br/></span></div><div style="padding-left:40.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;2 &#8212; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to Customers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Consolidated Sales</span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal first quarter of 2023, worldwide sales were $24.7 billion, a total increase of 5.6%, which included operational growth of 9.0% and a negative currency impact of 3.4% as compared to 2022 fiscal first quarter sales of $23.4 billion. In the fiscal first quarter of 2023, the net impact of acquisitions and divestitures on worldwide operational sales growth was a positive 1.4%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by U.S. companies were $12.5 billion in the fiscal first quarter of 2023, which represented an increase of 9.7% as compared to the prior year. In the fiscal first quarter of 2023, the net impact of acquisitions and divestitures on the U.S. operational sales growth was a positive 2.3%.  Sales by international companies were $12.2 billion, a total increase of 1.8%, which included operational growth of 8.3% and a negative currency impact of 6.5%. In the fiscal first quarter of 2023, the net impact of acquisitions and divestitures on the international operational sales growth was a positive 0.4%. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal first quarter of 2023, sales by companies in Europe achieved growth of 5.1%, which included operational growth of 10.0% and a negative currency impact of 4.9%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 7.1%, including operational growth of 14.3% and a negative currency impact of 7.2%. Sales by companies in the Asia-Pacific, Africa region experienced a decline of 4.3%, including operational growth of 4.1% offset by a negative currency impact of 8.4%.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20230402_g1.jpg" alt="3028" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/><img src="jnj-20230402_g2.jpg" alt="3029" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:310px"/></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:180pt"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: values may have been rounded</span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="padding-left:90pt;padding-right:90pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Analysis of Sales by Business Segments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:42.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Consumer Health segment sales in the fiscal first quarter of 2023 were $3.9 billion, an increase of 7.4% as compared to the same period a year ago, including operational growth of 11.3% and a negative currency impact of 3.9%. U.S. Consumer Health segment sales increased by 11.4%. International Consumer Health segment sales increased by 4.4% including operational growth of 11.3% and a negative currency impact of 6.9%. In the fiscal first quarter of 2023, the net impact of acquisitions and divestitures on the Consumer Health segment operational sales growth was negligible. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Major Consumer Health Franchise Sales &#8212; Fiscal First Quarter Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:43.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.380%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.567%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Consumer Health Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,586</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OTC franchise achieved operational growth of 15.8% as compared to the prior year fiscal first quarter. The growth was driven by price actions, exceptionally high Cough/Cold/Flu incidences primarily in Europe, and one-time supply replenishment reflected in TYLENOL, MOTRIN, NICORETTE and IMODIUM.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Skin Health/Beauty franchise achieved operational growth of 13.1% as compared to the prior year fiscal first quarter. The growth was driven by price actions, one-time supply replenishment and sun season pipeline fill, and e-commerce and club channel performance driven by new product innovations in NEUTROGENA and AVEENO. The growth was partially offset by U.S. portfolio simplification and competitive pressures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oral Care franchise achieved operational growth of 2.1% as compared to the prior year fiscal first quarter. The growth was driven by U.S. price actions, partially offset by category deceleration outside the U.S. and the negative impact from suspension of personal care sales in Russia. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Baby Care franchise achieved operational growth of 6.5% as compared to the prior year fiscal first quarter. The growth was driven by price actions, one-time supply replenishment and lapping of a prior year reserve true-up outside the U.S. The growth was partially offset by the negative impact from suspension of personal care sales in Russia. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Women&#8217;s Health franchise achieved operational growth of 4.1% as compared to the prior year fiscal first quarter primarily driven by price actions and strong performance in India partially offset by the negative impact from suspension of personal care sales in Russia.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Wound Care/Other franchise achieved operational growth of 2.5% as compared to the prior year fiscal first quarter primarily driven by price actions and strong demand in Canada.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business (Kenvue as the name for the planned New Consumer Health Company), with the intention to create a new, publicly traded company by the end of the fiscal year 2023, pending market conditions.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:48.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.749%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.017%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pharmaceutical segment sales in the fiscal first quarter of 2023 were $13.4 billion, an increase of 4.2% as compared to the same period a year ago, including an operational increase of 7.2% and a negative currency impact of 3.0%. U.S. Pharmaceutical sales increased 5.9% as compared to the same period a year ago. International Pharmaceutical sales increased by 2.4%, including operational growth of 8.6% and a negative currency impact of 6.2%. In the fiscal first quarter of 2023, the net impact of acquisitions and divestitures on the Pharmaceutical segment operational sales growth was negligible. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major Pharmaceutical Therapeutic Area Sales** &#8212; Fiscal First Quarter Ended</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:47.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.602%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,112</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SIMPONI/ SIMPONI ARIA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;STELARA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;TREMFYA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,586</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,297</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EDURANT/rilpivirine</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;PREZISTA/ PREZCOBIX/ REZOLSTA/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYMTUZA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,804</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,741</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CONCERTA/ methylphenidate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SPRAVATO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Neuroscience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,112</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,950</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CARVYKTI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;DARZALEX</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ERLEADA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IMBRUVICA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ZYTIGA/ abiraterone acetate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">872</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">852</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;OPSUMIT</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;UPTRAVI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">927</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">910</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;XARELTO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pharmaceutical Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,413</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,869</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Inclusive of  RISPERDAL CONSTA which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  INVOKANA </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunology products achieved operational growth of 2.5% as compared to the same period a year ago driven by market growth and share growth of STELARA (ustekinumab) in Crohn&#8217;s disease and Ulcerative Colitis partially offset by unfavorable patient mix and price. Additionally, strong growth of TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(guselkumab) was due to share gains in Psoriasis and Psoriatic Arthritis partially offset by unfavorable patient mix. Lower sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(infliximab) were due to biosimilar competition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The latest expiring United States composition of matter patent for STELARA (ustekinumab) expires in September 2023. STELARA (ustekinumab) U.S. sales in fiscal 2022 were approximately $6.4 billion. Third parties have filed abbreviated Biologics License Applications with the FDA seeking approval to market biosimilar versions of STELARA. In the event the Company is not successful in defending its patent claims in related lawsuits, biosimilar versions of STELARA may be introduced to the market, potentially resulting in substantial market share and revenue losses. There is also risk that one or more competitors could launch a biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Infectious disease products achieved operational growth of 26.4% as compared to the same period a year ago. Growth was primarily driven by COVID-19 vaccine revenue (which is now substantially complete) and EDURANT (rilpivirine) sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This was partially offset by lower sales of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and PREZCOBIX/REZOLSTA (darunavir/cobicistat) due to increased competition outside the U.S. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience products achieved operational sales growth of 6.1% as compared to the same period a year ago. Growth of SPRAVATO (esketamine) was driven by ongoing launches in the U.S. and Europe as well as increased patient demand. Paliperidone long-acting injectables growth was due to the strength of INVEGA SUSTENNA/XEPLION (paliperidone palmitate) and INVEGA TRINZA/TREVICTA driven by new patient starts and persistence of treatment as well as the launch of INVEGA HAFYERA/BYANNLI.  This was partially offset by the XEPLION loss of exclusivity in the European Union. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology products achieved operational sales growth of 7.7% as compared to the same period a year ago. Strong sales of DARZALEX (daratumumab) were driven by share gains in all regions, continued market growth, and strong FASPRO adoption. Growth of ERLEADA (apalutamide) was due to continued strong share gains, market growth, and increased penetration from new launches. Sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued market share gains and the ongoing phased launch. Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pulmonary Hypertension achieved operational sales growth of 5.0% as compared to the same period a year ago. Sales growth was due to market and volume growth from UPTRAVI (selexipag) and OPSUMIT (macitentan) partially offset by declines in Other Pulmonary Hypertension.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular / Metabolism / Other products achieved operational growth of 3.0% as compared to the same period a year ago. The growth of XARELTO (rivaroxaban) was primarily driven by favorable patient mix and market growth partially offset by share loss.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company maintains a policy that no end customer will be permitted direct delivery of product to a location other than the billing location. This policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Company&#8217;s drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities. This policy had discount implications which positively impacted sales to customers in the fiscal first quarter of 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:228.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:55.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment sales in the fiscal first quarter of 2023 were $7.5 billion, an increase of 7.3% as compared to the same period a year ago, which included operational growth of 11.0% and a negative currency impact of 3.7%. U.S. MedTech sales increased 16.6%. International MedTech sales decreased by 0.6%, including operational growth of 6.2% offset by a negative currency impact of 6.8%. In the fiscal first quarter of 2023, the net impact of acquisitions and divestitures on the MedTech segment operational sales growth was a positive 4.6%, related to the Abiomed acquisition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Major MedTech Franchise Sales** &#8212; Fiscal First Quarter Ended</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:45.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operations<br/>Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency<br/>Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,434</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Advanced</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,245</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,188</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Hips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Knees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trauma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Spine, Sports &amp; Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,092</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Electrophysiology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Abiomed</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Other Interventional Solutions</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,257</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contact Lenses/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total MedTech Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,481</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Surgery franchise achieved operational sales growth of 4.1% as compared to the prior year fiscal first quarter. The operational growth in Advanced Surgery was primarily driven by the following: Biosurgery global procedure recovery, the strength from new products and a differentiated portfolio; and Energy products double digit growth in the U.S. with improved procedure volumes and strength of new products partially offset by volume-based procurement in China and product supply challenges; partially offset by Endocutter decline primarily due to volume-based procurement in China, competitive pressures predominately in the U.S. and supply challenges partially offset by positive uptake from recently launched products. The operational growth in General Surgery was primarily driven by improved procedure volumes coupled with technology penetration and benefits from differentiated Wound Closure portfolio. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Orthopaedics franchise achieved operational sales growth of 5.1% as compared to the prior year fiscal first quarter. The operational growth in hips reflects global procedure recovery and strength across the portfolio. This was partially offset by impacts of volume-based procurement in China and supply challenges. The operational growth in knees was primarily driven by global procedure recovery, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. This was partially offset by impacts of volume-based procurement in China. The operational growth in Trauma was driven by the adoption of recently launched products. This was partially offset by softer procedure volumes compared to the prior year and impacts of volume-based procurement in China. The operational growth in Spine, Sports &amp; Other was primarily driven by market growth and positive new product performance in Digital Solutions, shoulders and spine. This was partially offset by impacts of volume-based procurement in China and continued competitive pressures in Spine. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Interventional Solutions franchise achieved operational sales growth of 41.9% as compared to the prior year fiscal first quarter which includes sales from Abiomed acquired on December 22, 2022. Electrophysiology grew by double digits in all regions except Asia Pacific which reflects the impacts of COVID-19 procedure disruption and volume-based procurement in China. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vision franchise achieved operational sales growth of 7.6% as compared to the prior year fiscal first quarter. The Contact Lenses/Other operational growth was primarily driven by the market recovery, continued strong performance in the ACUVUE OASYS 1-Day family (including recent launches) and effective commercial execution. This was partially offset by supply challenges. The Surgical operational growth was primarily driven by the strength in Monofocal IOLs partially offset by softer refractive and premium IOL markets and supply challenges.  </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANALYSIS OF CONSOLIDATED EARNINGS BEFORE PROVISION FOR TAXES ON INCOME </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated earnings/loss before provision for taxes on income for the fiscal first quarter of 2023 was a loss of $0.7 billion representing (3.0)% of sales as compared to earnings of $5.9 billion in the fiscal first quarter of 2022, representing 25.0% of sales primarily driven by the $6.9 billion charge related to the talc settlement proposal. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="text-align:center"><img src="jnj-20230402_g3.jpg" alt="17615" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q1 2023 versus Q1 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold increased as a percent to sales primarily driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">one-time COVID-19 vaccine manufacturing related exit costs and mix in the Pharmaceutical business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Commodity inflation and Abiomed amortization in the MedTech business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The intangible asset amortization expense included in cost of products sold for the fiscal first quarters of 2023 and 2022 was $1.2 billion and $1.1&#160;billion, respectively. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, Marketing and Administrative Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:72pt;padding-right:72pt;text-align:center"><img src="jnj-20230402_g4.jpg" alt="18630" style="height:178px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Q1 2023 versus Q1 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, Marketing and Administrative Expenses decreased as a percent to sales primarily driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">A reduction in brand marketing expenses in the Pharmaceutical business </span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research and Development Expense</span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center;text-indent:36pt"><img src="jnj-20230402_g5.jpg" alt="19128" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q1 2023 versus Q1 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a reduction in COVID-19 Vaccine related expenses </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">portfolio progression in the Pharmaceutical business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-Process Research and Development (IPR&amp;D)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fiscal first quarter of 2023, the Company recorded a charge of approximately $0.1 billion associated with the IPR&amp;D acquired with Pulsar Vascular in 2016. In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Interest (Income) Expense</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income in the fiscal first quarter of 2023 was $235 million as compared to $22 million in the fiscal first quarter of 2022 primarily due to higher rates of interest earned on cash balances. Interest expense in the fiscal first quarter of 2023 was $215 million as compared to interest expense of $10 million in the same period a year ago primarily due to a higher debt balance at higher interest rates. The balance of cash, cash equivalents, restricted cash and current marketable securities was $32.3&#160;billion ($24.6 billion unrestricted and $7.7 billion restricted) at the end of the fiscal first quarter of 2023 as compared to $30.4 billion at the end of the fiscal first quarter of 2022. The Company&#8217;s debt position was $52.9 billion ($7.7 billion related to Kenvue debt) as of April&#160;2, 2023, as compared to $33.1 billion the same period a year ago. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income) Expense, Net*</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Q1 2023 versus Q1 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income)&#160;expense, net for the fiscal first quarter of 2023 was unfavorable by $7.3 billion as compared to the prior year primarily due to the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:49.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal First Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID-19 Vaccine related exit costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the fair value of securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plan related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> Related to the talc settlement proposal</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, gains and losses on divestitures, gains and losses on sale of assets, certain transactional currency gains and losses, acquisition-related costs, litigation accruals and settlements, investment (income)/loss related to employee benefit plans, as well as royalty income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Income (loss) before tax by segment of business for the fiscal first quarters were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:31.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent of Segment Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,665&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,087&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,746&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,426&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expenses not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income/(loss) before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,862&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,746&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,426&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. The fiscal first quarter of 2023 includes the incremental $6.9 billion charge related to the talc settlement proposal.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consumer Health segment income before tax as a percent of sales in the fiscal first quarter of 2023 was 20.1% versus 19.1% for the same period a year ago. The increase in the income before tax as a percent of sales in the fiscal first quarter of 2023 as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pricing actions</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">commodity inflation</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pharmaceutical Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment income before tax as a percent of sales in the fiscal first quarter of 2023 was 33.1% versus 30.5% for the same period a year ago. The increase in the income before tax as a percent of sales for the fiscal first quarter as compared to the prior year was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An IPR&amp;D charge of $0.6 billion in 2022 related to bermekimab (JnJ-77474462), an investigational drug for the treatment of AD and Hidradenitis Suppurativa (HS) </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable changes in the fair value of securities in 2022 of $0.4 billion</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leveraging in selling and marketing expenses</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partially offset by </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine related exit costs of $0.4 billion in 2023</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restructuring charges of $0.1 billion in 2023</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable product mix</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment income before tax as a percent of sales in the fiscal first quarter of 2023 was 19.3% versus 21.2% for the same period a year ago. The decrease in the income before tax as a percent of sales for the fiscal first quarter was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Higher amortization expense of $0.1 billion in 2023 related to Abiomed</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">An IPR&amp;D charge in 2023 of approximately $0.1 billion related to the Pulsar Vascular acquisition</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Acquisition costs related to Abiomed</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Commodity inflation in 2023</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">No Restructuring charges in 2023 versus $0.1 billion in 2022</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Proactive management of costs </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">                                                     </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2023, the Company completed a prioritization of its research and development (R&amp;D) investment within the Pharmaceutical segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, HIV and hepatitis. The pre-tax restructuring charge of approximately $0.1 billion in the fiscal first quarter of 2023 includes the termination of partnered and non-partnered program costs and asset impairments. In the fiscal first quarter of 2022, the Company recorded a pre-tax charge of $0.1 billion related to a restructuring program of its Global Supply Chain. The Global Supply Chain program was announced in the second quarter of 2018 and was completed in the fiscal fourth quarter of 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Taxes on Income</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rate for the first fiscal three months of 2023 was 90.8% in 2023 and 12.2% in 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On December 15, 2022, the European Union (EU) Member States formally adopted the EU&#8217;s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. A significant number of other countries are also implementing similar legislation. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequent to April 2, 2023, as part of the planned separation of the Company&#8217;s Consumer Health business the Company anticipates the recognition of approximately $0.5 billion in incremental international tax costs due to the reorganization of certain international subsidiaries in the fiscal second quarter of 2023. During the fiscal year 2023, the Company is expected to incur additional tax costs related to the legal separation of the Consumer Health business. </span></div><div style="margin-top:2.7pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-top:2.7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For discussion related to the 2023 provision for taxes refer to Note&#160;5 to the Consolidated Financial Statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LIQUIDITY AND CAPITAL RESOURCES </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash Flows</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash were $26.9 billion at the end of the fiscal first quarter of 2023 as compared with $14.1 billion at the end of fiscal year 2022. The primary sources and uses of cash that contributed to the $12.8&#160;billion increase were:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:21.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2022 Cash and cash equivalents balance</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash generated from operating activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash generated from investing activities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash generated from financing activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">rounding</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q1 2023 Cash, cash equivalents and restricted cash balance</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company had $5.4 billion in marketable securities at the end of the fiscal first quarter of 2023 and $9.4 billion at the end of fiscal year 2022.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operations of $3.3&#160;billion was the result of:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs and credit losses and accounts receivable allowances partially offset by the deferred tax provision and net gain on sale of assets/businesses  </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in accounts receivable and inventories </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in accounts payable and accrued liabilities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in other current and non-current assets</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in other current and non-current liabilities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rounding</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow from operations</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from investing activities of $3.3 billion was primarily from:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">additions to property, plant and equipment</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net sales of investments</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">credit support agreements activity, net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash from investing activities</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from financing activities of $6.1 billion was primarily from: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">dividends to shareholders </span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">repurchase of common stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net proceeds from short term debt and repayment of long term debt</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from Kenvue long term debt, net of issuance cost</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other and rounding</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash from financing activities</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2022, the Company secured a new 364-day Credit Facility of $10&#160;billion, which expires on September&#160;7, 2023. In November 2022, the Company secured an additional 364-day revolving Credit Facility of $10 billion, which has an expiration of November 21, 2023. Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, Kenvue, a wholly owned subsidiary of the Company, priced an offering of senior unsecured notes in an aggregate principal amount of $7.75 billion (See Note 4 to the Consolidated Financial Statements for additional details). The senior unsecured notes (the Notes) will be senior unsecured obligations of Kenvue and will initially be fully and unconditionally guaranteed (the Guarantees) on a senior unsecured basis by the Company. The Guarantees will terminate upon (1) the completion in all material respects of the transfer of the assets and liabilities of Johnson &amp; Johnson&#8217;s Consumer Health Business to Kenvue and (2) Kenvue having registered equity securities. The Notes were issued in connection with Johnson &amp; Johnson&#8217;s separation of its Consumer Health Business. Kenvue intends to use the proceeds from the offering of the Notes as partial consideration to Johnson &amp; Johnson for the Consumer Health Business that Johnson &amp; Johnson will transfer to Kenvue. The proceeds of the Notes offering were placed in a segregated escrow account pending the transfer of the assets and liabilities of the Consumer Health Business to Kenvue and as such, classified as restricted cash as of the balance sheet date. On April 5, 2023, the net proceeds of the Notes were released from escrow upon completion of the Consumer Health Business transfer. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, in March 2023, Kenvue entered into a credit agreement providing for a five-year senior unsecured revolving credit facility (the Revolving Credit Facility) in an aggregate principal amount of $4.0 billion to be made available in U.S. dollars and Euros. The Revolving Credit Facility contains representations and warranties, covenants and events of default that are customary for this type of financing, including covenants restricting the incurrence of liens and the entry into certain merger transactions. In addition, Kenvue entered into a commercial paper program (the Commercial Paper Program) of up to $4.0 billion in aggregate principal amount of commercial paper under the Commercial Paper Program. The Commercial Paper Program contains representations and warranties, covenants and default that are customary for this type of financing.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequent to the fiscal first quarter, on April 24, 2023, the Company announced that Kenvue has launched a roadshow for the initial public offering (&#8220;IPO&#8221;) of 151,204,000 shares of its common stock. Kenvue expects to grant the underwriters a 30-day option to purchase up to an additional 22,680,600 shares of its common stock to cover over-allotments, if any. The IPO price is currently expected to be between $20.00 and $23.00 per share. Kenvue has applied to list its common stock on the New York Stock Exchange under the symbol &#8220;KVUE.&#8221; After the completion of the IPO, Johnson &amp; Johnson will own 1,716,160,000 shares of Kenvue&#8217;s common stock, representing 91.9% of the total outstanding shares of Kenvue&#8217;s common stock (or 90.8% if the underwriters exercise in full their over-allotment option).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of April&#160;2, 2023, the Company's cash, cash equivalents, restricted cash ($7.7 billion related to Kenvue) and marketable securities was approximately $32.3 billion and had approximately $52.9 billion of notes payable and long-term debt ($7.7 billion related to Kenvue) for a net debt position of $20.6 billion as compared to the prior year net debt position of $2.8 billion. Considering recent market conditions, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company&#8217;s remaining balance to be paid on the agreement to settle opioid litigation for approximately $2.5 billion and the establishment of the $8.9 billion reserve (present value) for the talc settlement proposal. (See Note 11 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Subsequent to April 2, 2023, the Company paid approximately $3.5 billion to the U.S. Treasury including $1.5 billion related to the current installment due on foreign undistributed earnings as part of the TCJA charge (see Note 1 to the Consolidated Financial Statements in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January 1, 2023), $1.4 billion in advance payments to resolve certain items under examination in its 2013 through 2016 U.S. IRS audit, and $0.6 billion primarily related to the normal estimated payment for the fiscal first quarter of 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company&#8217;s Common Stock. Any shares acquired will be available for general corporate purposes. As of April 2, 2023, $5.0 billion has been repurchased and the repurchase program was completed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividends</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2023, the Board of Directors declared a regular cash dividend of $1.13 per share, payable on March 7, 2023, to shareholders of record as of February 21, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 18, 2023, the Board of Directors declared a regular cash dividend of $1.19 per share, payable on June 6, 2023, to shareholders of record as of May 23, 2023. The Company expects to continue the practice of paying regular quarterly cash dividends.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OTHER INFORMATION</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New Accounting Pronouncements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 1 to the Consolidated Financial Statements for new accounting pronouncements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic and Market Factors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russia-Ukraine War</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the long-term implications of Russia&#8217;s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal first quarter of 2023, including accounts receivable or inventory reserves, was not material. As of both the fiscal first quarter ending April 2, 2023, and the 2022 fiscal year ending January 1, 2023, the business of the Company&#8217;s Ukraine subsidiaries represented less than 1% of the Company&#8217;s consolidated assets and revenues. As of both the fiscal first quarter ending April 2, 2023, and the 2022 fiscal year ending January 1, 2023, the business of the Company&#8217;s Russian subsidiaries represented less than 1% of the Company&#8217;s consolidated assets and represented 1% of revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early March of 2022, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. Additionally, at the end of March 2022, the Company made the decision to suspend supply of personal care products in Russia. The Company continues to supply its other products as patients rely on many of the products for healthcare purposes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates and currency exchange rates continue to have an effect on worldwide economies and, consequently, on the way the Company operates. The Company has accounted for operations in Venezuela, Argentina and Turkey (beginning in the fiscal second quarter of 2022) as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted.&#160;This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings.&#160; The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company faces various worldwide health care changes that may continue to result in pricing pressures that include health care cost containment and government legislation relating to sales, promotions and reimbursement of health care products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage, as a result of the current global economic downturn, may continue to impact the Company&#8217;s businesses.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces regular intellectual property challenges from third parties, including generic and biosimilar manufacturers, seeking to manufacture and market generic and biosimilar versions of key pharmaceutical products prior to the expiration of the applicable patents. These challengers file Abbreviated New Drug Applications or abbreviated Biologics License Applications with the FDA or otherwise challenged the coverage and/or validity of the Company&#8217;s patents. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue may be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;3 &#8212; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the Company&#8217;s assessment of its sensitivity to market risk since its presentation set forth in Item&#160;7A, &#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; in its Annual Report on Form 10-K for the fiscal year ended January&#160;1, 2023.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;4 &#8212; CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures. At the end of the period covered by this report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company&#8217;s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. Joaquin Duato, Chief Executive Officer; Chairman, Executive Committee and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs.&#160;Duato and Wolk concluded that, as of the end of the period covered by this report, the Company&#8217;s disclosure controls and procedures were effective.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Internal control. During the period covered by this report, there were no changes in the Company&#8217;s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part II &#8212; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;1 &#8212; LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to Note 11 included in Part&#160;I, Item&#160;1, Financial Statements (unaudited) &#8212; Notes to Consolidated Financial Statements.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i7c615dc7aec24dc98e6c850313251c4e_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;2 &#8212; UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's Common Stock. Share repurchases may be made at management&#8217;s discretion from time to time on the open market or through privately negotiated transactions. The repurchase program was completed during the fiscal first quarter of 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to Common Stock purchases by the Company during the fiscal first quarter of 2023. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company's compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal first quarter.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:503.25pt"><tr><td style="width:1.0pt"></td><td style="width:210.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:90.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:57pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal Month Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Avg. Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr style="height:18pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2023 through January 29, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,507,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 30, 2023 through February 26, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,143,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,852,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2023 through April 2, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,647,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,134,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;During the fiscal first quarter of 2023, the Company repurchased an aggregate of 21,647,317 shares of Johnson &amp; Johnson Common Stock in open-market transactions, of which 15,134,442 shares were purchased pursuant to the repurchase program that was publicly announced on September 14, 2022, and of which 6,512,875 shares were purchased as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;2, 2023, an aggregate of 30,546,218 shares were purchased for a total of $5.0 billion since the inception of the repurchase program announced on September 14, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="i7c615dc7aec24dc98e6c850313251c4e_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;6 &#8212; EXHIBITS</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit101-2022ltipxformps.htm">Exhibit 10.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Performance Share Unit Award Agreement</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit102-2022ltipformrsu.htm">Exhibit 10.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Restricted Share Unit Award Agreement</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit103-2022ltipformsto.htm">Exhibit 10.3</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global Nonqualified Stock Option Award Agreement</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20231qex311ceocertificati.htm">Exhibit&#160;31.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20231qex311ceocertificati.htm"> </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer under Rule&#160;13a-14(a) of the Securities Exchange Act pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 &#8212; Filed with this document.</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20231qex312cfocertificati.htm">Exhibit&#160;31.2 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Financial Officer under Rule&#160;13a-14(a) of the Securities Exchange Act pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 &#8212; Filed with this document.</span></div><div><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20231qex321ceocertificati.htm">Exhibit&#160;32.1 </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certification of Chief Executive Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 &#8212; Furnished with this document.</span></div><div style="text-indent:11.25pt"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="a20231qex322cfocertificati.htm">Exhibit&#160;32.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certification of Chief Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 &#8212; Furnished with this document.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 101: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.018%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i7c615dc7aec24dc98e6c850313251c4e_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Table of Content</span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:51.460%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JOHNSON &amp; JOHNSON<br/>(Registrant)&#160;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: April&#160;28, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By /s/ J. J. WOLK</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. J. WOLK</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer (Principal Financial Officer)&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: April&#160;28, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By /s/&#160;R. J. DECKER Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. J. DECKER Jr.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controller (Principal Accounting Officer)&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-2022ltipxformps.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id0b5d6569a7640c0864a0c7c172cb296_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT 10.1</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JOHNSON &#38; JOHNSON<br>2022 LONG-TERM INCENTIVE PLAN</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLOBAL PERFORMANCE SHARE UNIT AWARD AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Granted To&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.283%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WWID #</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Target Number of PSUs&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance Period&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Scheduled Vesting Date&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The third anniversary of the Grant Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Scheduled Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Certification Date&#58;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The date following the end of the Performance Period on which the Committee certifies the level of achievement of the performance-based vesting criteria set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:51.3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.205%"><tr><td style="width:1.0%"></td><td style="width:26.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.097%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Grant No.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Grant Type</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Target No. of PSUs</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance Share Units</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to such other conditions as may be established by the Committee in its sole discretion, in consideration of the granting of an award under the terms of the Johnson &#38; Johnson 2022 Long-Term Incentive Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you agree as follows&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Grant of Performance Share Units.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Global Performance Share Unit Award Agreement, including any country-specific terms in  Appendix B hereto and any other exhibits or addendums to these documents (collectively, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Plan, Johnson &#38; Johnson, a New Jersey corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), hereby grants you Performance Share Units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in the above-stated target number (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Target Number of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The actual number of PSUs that become vested (which may be more or less than the Target Number of PSUs) shall be determined as provided in accordance with the terms of this Agreement (including, without limitation, Section 2 of this Agreement and Appendix A). Each PSU that becomes vested in accordance with this Agreement will be settled in one share of Common Stock of the Corporation, par value $1.00 per share (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or cash in lieu thereof, in either case subject to and in accordance with the terms of Section 4 of this Agreement. Except where the context clearly indicates otherwise, each capitalized term used herein shall have the definition assigned to it by this Agreement or, to the extent that this Agreement does not define a capitalized term used herein, by the Plan. The PSUs granted herein are subject to all of the terms and conditions of the Plan, and the terms of the Plan are hereby incorporated herein by reference.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This grant of PSUs is conditioned on your (i) electronically accepting this grant on the website of the Plan recordkeeper (or in such other manner as the Corporation may establish or permit from time to time) and (ii) opening and maintaining a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">brokerage account that is permitted for use with respect to awards granted under the Plan, in each case by the deadline established by the Corporation and&#47;or set forth on the website of the Plan recordkeeper. By accepting this grant of PSUs, you will have confirmed your acceptance of all of the terms and conditions of this Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">If you do not accept this grant of PSUs by the applicable deadline, your grant will be cancelled.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Vesting of PSUs&#59; Competition with the Corporation Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Except as otherwise provided in this Section&#160;2, on the later of the above-stated Scheduled Vesting Date or the Certification Date you shall vest in a number of PSUs, if any, based upon the achievement of specified levels of performance during the Performance Period (as determined by the Committee in its sole discretion), as set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) you are Employed on the Scheduled Vesting Date and have been Employed at all times since the Grant Date and (ii) you have complied with and are in compliance with the terms of this Agreement, as determined by the Corporation in its sole discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Termination of Employment - General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If, prior to the Scheduled Vesting Date, you cease to be Employed for any reason, then except as otherwise provided in Section 2(c) (Certain Terminations&#59; Disability), the PSUs shall be forfeited for no consideration on the Date of Termination.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Certain Terminations&#59; Disability. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.69pt;text-decoration:underline">Termination of Employment due to Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If, prior to the Scheduled Vesting Date, you die while Employed, then, to the extent the PSUs are still outstanding, your estate, beneficiary or any person who acquires the PSUs by inheritance or devise, as applicable, shall (i) immediately become vested in the Target Number of PSUs on your date of death and (ii)&#160;be eligible to vest in the Top-Up Number of PSUs on the Certification Date based upon actual achievement relative to the Performance Goals during the Performance Period, and your estate, beneficiary or any person who acquires the PSUs by inheritance or devise, as applicable, shall receive a number of shares of Common Stock (or cash in lieu thereof), as provided in Section&#160;4 (Settlement of PSUs&#59; Tax Withholding&#59; Compliance With Securities Laws&#59; Compliance with Compensation Recoupment Policy).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:21.36pt;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If, prior to the Scheduled Vesting Date, you become Disabled while Employed, then, to the extent the PSUs are still outstanding, you shall (i) immediately become vested in the Target Number of PSUs on the date of Disability and (ii)&#160;be eligible to vest in the Top-Up Number of PSUs on the Certification Date based upon actual achievement relative to the Performance Goals during the Performance Period.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18.03pt;text-decoration:underline">Termination due to Specified Divestiture or Reduction in Force</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If, prior to the Scheduled Vesting Date, (A) your Employment terminates as a result of a Specified Divestiture or a Reduction in Force and (B) at the time of such termination of Employment, the conditions set forth in Section 2(c)(iv) (Qualifying Separation) are not satisfied with respect to the PSUs, then, a Pro Rata Number of PSUs shall remain outstanding and you shall be eligible to become vested in a number of PSUs (which may be more or less than the Pro Rata Number of PSUs) on the Certification Date in accordance with Section 2(a), based upon actual achievement relative to the Performance Goals during the Performance Period using the Pro Rata Number of PSUs (and not the Target Number of PSUs) as a base. For purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Pro Rata Number of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the number of PSUs equal to the result, rounded to the nearest whole number, of (I) the Target Number of PSUs, multiplied by (II) a fraction, the numerator of which is the number of days that elapsed from the Grant Date through and including the Date of Termination and the denominator of which is the total number of days in the period commencing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on the Grant Date and ending on (and including) the Scheduled Vesting Date. Notwithstanding this Section 2(c)(iii), you will be treated as having terminated Employment pursuant to Section 2(b) hereof (Termination of Employment &#8211; General) if, at any time prior to the Scheduled Vesting Date, the Corporation determines in its sole discretion that applying this Section 2(c)(iii) in a particular case (or cases) is not advisable or appropriate or consistent with the intent of this Section 2(c)(iii).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Qualifying Separation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If your Employment terminates prior to the Scheduled Vesting Date, but after the date that is six (6) months following the Grant Date&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">for any reason other than a termination of Employment pursuant to Section 2(c)(i) (Termination of Employment due to Death) or Section 2(c)(vi) (Termination for Cause), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">as of the Date of Termination, either (I) you have attained age fifty-five (55) and have at least ten (10) years of Service with at least five (5) consecutive years of Service immediately before your Date of Termination or (II) you have attained age sixty-two (62) (a termination of Employment that satisfies the conditions set forth in clauses (A) and (B) above, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Separation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then, subject to the terms of this Agreement, to the extent the PSUs are still outstanding, the PSUs shall remain outstanding and eligible to become vested on the Certification Date in accordance with Section 2(a) of this Agreement, based upon actual achievement relative to the Performance Goals during the Performance Period. For the avoidance of doubt, this Section 2(c)(iv) (Qualifying Separation) shall not apply if your Employment terminates on or prior to the date that is six (6) months following the Grant Date, as reflected in the records of the Corporation. If a termination of Employment satisfies the conditions set forth in Section 2(c)(iii) (Termination due to Specified Divestiture or Reduction in Force) and this Section 2(c)(iv) (Qualifying Separation), only this Section 2(c)(iv) (Qualifying Separation) shall apply. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, you will be treated as having terminated Employment pursuant to Section&#160;2(b) hereof (Termination of Employment &#8211; General) if, at any time prior to the Scheduled Vesting Date, the Corporation determines in its discretion that applying this Section&#160;2(c)(iv) (Qualifying Separation), (1) to employees based on age at the time of termination of Employment and not to all employees may violate any law or public policy applicable to you and&#47;or the PSUs (whether as applied to all holders of PSUs or only holders of PSUs in the jurisdiction where you are employed), or (2) in a particular case (or cases) is not advisable or appropriate or consistent with the intent of this Section 2(c)(iv).  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Death Following Certain Terminations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding the foregoing, if you die following (A) a termination of Employment pursuant to Section 2(c)(iv) (Qualifying Separation) or (B) a termination of Employment pursuant to Section 2(c)(iii) (Termination due to Specified Divestiture or Reduction in Force), but in either case prior to the Scheduled Vesting Date, then your estate, beneficiary or any person who acquires the PSUs by inheritance or devise, as applicable, shall (I)&#160;become vested in (x) the Target Number of PSUs on the date of your death following a termination of Employment pursuant to Section 2(c)(iv) (Qualifying Separation) or (y) the Pro Rata Number of PSUs on the date of your death following a termination of Employment pursuant to Section 2(c)(iii) (Termination due to Specified Divestiture or Reduction in Force), and (II) be eligible to vest in the Top-Up Number of PSUs on the Certification Date based upon actual achievement relative to the Performance Goals during the Performance Period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, in the event of your death following a termination of Employment pursuant to Section 2(c)(iii) (Termination due to Specified Divestiture or Reduction in Force), the Top-Up Number of PSUs shall be equal to the positive difference, if any, between the number of PSUs that would have vested based on actual achievement relative to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Performance Goals during the Performance Period (based on the Pro Rata Number of PSUs that remain outstanding following the Date of Termination), less the Pro Rata Number of PSUs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Pro Rata Top-Up Number of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18.69pt;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Without limiting the generality of Section 2(b), and notwithstanding any other provision of this Section 2(c), if you cease to be Employed for any reason (including, without limitation, as a result of your voluntary resignation) in connection with or following the occurrence of an event that constitutes Cause, then the PSUs and any other awards you hold under the Plan shall immediately be forfeited for no consideration as of the Date of Termination. If following your Date of Termination, the Corporation becomes aware of conduct or activity by you that occurred during or following your Employment that would have constituted Cause, then any PSUs (or portions thereof) or any other awards held by you under the Plan that are unvested or unexercised (and any payments or benefits in respect thereto) as of the date that the Corporation becomes aware of such conduct or activity shall be forfeited. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:15.36pt;text-decoration:underline">Corporation Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event of your termination of Employment, the determination of the reason for such termination and the applicable treatment under this Section 2 shall be made by the Corporation in its sole discretion. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Competition With the Corporation Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In order to protect the Corporation Group&#8217;s goodwill and investments in research and development and Customer and business relationships and to prevent the disclosure of the Corporation Group&#8217;s confidential and trade secret information, thereby promoting the long-term success of the Corporation Group&#8217;s business, you agree to the following&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">During your Employment, you will not, without the prior written consent of the Corporation, directly or indirectly engage in Competitive Activities.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">For a period of eighteen (18) months following your Date of Termination, you will not, without the prior written consent of the Corporation, directly or indirectly perform, or assist others to perform, work for a Competitor in a position or in any geographic location in which you could disadvantage the Corporation Group or advantage the Competitor through (a) your disclosure or use of the Corporation Group&#8217;s confidential or trade secret information  and&#47;or (b) your use of the Corporation Group&#8217;s Customer relationships and goodwill. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18.03pt">Rescission and Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand and agree that if the Corporation determines you have violated Section 2(d)(i) and&#47;or Section 2(d)(ii) and&#47;or any non-competition or non-solicitation agreement that you have with any member of the Corporation Group, then, in addition to injunctive relief, damages, and all other equitable and legal rights and remedies&#58;  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.36pt">the PSUs shall be forfeited for no consideration on the earliest date on which you are first in violation of Section 2(d)(i) and&#47;or <br>Section 2(d)(ii) or any non-competition or non-solicitation agreement that you have with any member of the Corporation Group&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:20.02pt">upon the Corporation&#8217;s demand, you shall immediately deliver to the Corporation (I) a number of shares of Common Stock equal to the number of PSUs that vested and were settled in the form of Common Stock (for the avoidance of doubt, without reduction for any shares of Common Stock that may have been withheld to satisfy applicable withholding taxes) and (II) the gross amount of cash paid to you (for the avoidance of doubt, without reduction for amounts withheld to satisfy applicable withholding taxes) for any PSUs </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that were settled in the form of cash, in each case in respect of any PSUs that vested within the twelve (12) month period of time immediately preceding the earliest date on which you are first in violation of Section 2(d)(i) and&#47;or Section 2(d)(ii) or any non-competition or non-solicitation agreement that you have with any member of the Corporation Group. To the extent that you do not, as of the date of the Corporation&#8217;s demand for repayment, hold a number of shares of Common Stock sufficient to satisfy your obligation set forth in clause (I) above, you shall pay the Corporation an amount in cash equal to the result of (x) (i) the number shares required to be delivered by you to the Corporation pursuant to clause (I) above, less (ii) the number of shares actually delivered by you to the Corporation pursuant to clause (I), multiplied by (y) the Fair Market Value per share of Common Stock as of the business day immediately preceding the date of the Corporation&#8217;s demand for repayment. You agree to deliver and execute such documents (including, if applicable, share certificates) as the Corporation may deem necessary to effect the repayment obligations referred to in this Section 2(d)(iii)(B). </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">You understand and agree that the remedies set forth in Section 2(d)(iii) shall not be the Corporation Group&#8217;s exclusive remedies in the event of a breach of the non-competition obligations set forth in Section 2(d)(i) and&#47;or Section 2(d)(ii) or in any other applicable non-competition or non-solicitation agreement that you have with any member of the Corporation Group, and that the Corporation Group reserves all other rights and remedies available to it at law or in equity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Conditions on Vesting upon or following Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Your eligibility to vest in any of the PSUs upon or following the date of your termination of Employment shall be subject to (i) your compliance with the non-competition obligations in Section 2(d)(i) and&#47;or Section 2(d)(ii) and&#47;or any other applicable non-competition or non-solicitation agreement with any member of the Corporation Group and (ii) if required by any member of the Corporation Group at the time of your termination of Employment, your execution of a separation agreement and&#47;or a general release of claims in favor of the Corporation and its subsidiaries and affiliates containing such provisions and in such form as required by the Corporation that becomes effective within sixty (60) days following the Date of Termination or such earlier date as the Corporation may require (but in no event later than the latest date for settlement under Section 4(a)). In the event a separation agreement and&#47;or a release of claims is required by the Corporation Group and (A) (I) the PSUs vest upon the Date of Termination or (II) the Vesting Date falls within the period that you have to provide such release of claims, and (B) the period in which the PSUs must be settled pursuant to Section 4(a) spans two calendar years, settlement of the vested PSUs will be made in the second calendar year.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Rights to Common Stock. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prior to the delivery of shares of Common Stock to you pursuant to Section 4(a) (if applicable), you shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> have any rights in, or with respect to, any of the shares of Common Stock underlying the PSUs, including, but not limited to, any voting rights and the right to receive any dividends (or dividend equivalents) that may be paid or any distributions that may be made with respect to such Common Stock.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Settlement of PSUs&#59; Tax Withholding&#59; Compliance With Securities Laws&#59; Compliance With Compensation Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">General.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the terms of this Agreement, within sixty (60) days following the Vesting Date (but in no event later than the first March 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to occur following the end of the Performance Period), you will receive from the Corporation one share of Common Stock for each PSU that becomes vested in accordance with the terms of this Agreement, or, at the discretion of the Committee, the cash equivalent of the Fair Market Value on the Vesting Date, reduced by any whole shares of Common Stock that are withheld or sold or any cash withheld to satisfy applicable Federal, state and local income taxes, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Plan and legally applicable or deemed applicable to you (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in the amount determined by the Corporation. In lieu of the foregoing, the Corporation or other applicable member of the Corporation Group may determine that withholding of Tax-Related Items shall be satisfied by any other method permitted under the Plan. Notwithstanding the foregoing, if you are a Section 16 officer of the Corporation under the Securities Exchange Act of 1934, as amended, then the Corporation will satisfy any applicable tax withholding obligations by withholding in shares of Common Stock upon the relevant taxable event (with such withholding obligations determined based on the applicable statutory withholding rates and without regard to Section 83(c)(3) of the Internal Revenue Code of 1986, as amended), unless otherwise determined by the Committee. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Registration and Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding Section 4(a), shares of Common Stock shall not be issued pursuant to this Agreement, unless, on the Vesting Date, there is in effect a current registration statement or amendment thereto under the Securities Act of 1933, as amended, covering the shares of Common Stock to be issued upon vesting of the PSUs, and such shares are authorized for listing on the New York Stock Exchange or another securities exchange as determined by the Corporation. Nothing herein shall be deemed to require the Corporation to apply for, to effect, or to obtain such registration or listing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Compensation Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You hereby acknowledge and agree that you and the PSUs, including any cash and&#47;or shares of Common Stock that may be delivered to you pursuant to the PSUs, are subject to the Corporation&#8217;s Compensation Recoupment Policy, as may be amended and&#47;or restated from time to time, a current copy of which can be found on the Corporation&#8217;s website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;www.investor.jnj.com&#47;gov&#47;compensation-recoupment-policy.cfm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The terms and conditions of the Compensation Recoupment Policy hereby are incorporated by reference into this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Nontransferability of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The PSUs and any rights granted hereunder may not be sold, transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise), other than by will or the laws of descent and distribution or in accordance with any beneficiary designation procedures that may be established by the Corporation. Nor shall any such rights be subject to execution, attachment or similar process, other than in accordance with the terms of the Plan. Upon any attempt to sell, transfer, assign, pledge, hypothecate, or otherwise dispose of the PSUs or of any rights granted herein contrary to the provisions of the Plan or this Agreement, or upon the levy of any attachment or similar process upon the PSUs or such rights, the PSUs and such rights shall, at the election of the Corporation, be forfeited for no consideration.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">No Special Employment Rights&#59; No Rights to Awards.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing contained in the Plan or this Agreement shall be construed or deemed by any person under any circumstances to bind any member of the Corporation Group to continue your employment for the vesting period, Performance Period or for any other period, to create a right to employment with the Corporation, to form or amend an employment or service contract with the Corporation or to interfere in any way with any right of a member of the Corporation Group to terminate your employment at any time.  You hereby acknowledge and agree that (i) the Plan is established voluntarily by the Corporation, is discretionary in nature and may be modified, amended, or terminated by the Corporation at any time, as provided in the Plan, (ii) your participation in the Plan is voluntary and you are voluntarily accepting the grant of PSUs, (iii) the PSUs and the shares of Common Stock subject to the PSUs, and the income and value of same, do not constitute part of your normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination indemnities, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement benefits or welfare benefits or similar payments, and in no event should be considered as compensation for, or in any way relating to, past services to the Corporation Group, (iv) the PSUs and shares of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Common Stock subject to the PSUs, and the income and value of same, are not intended to replace any pension rights or compensation, (v)&#160;the grant of the PSUs is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of PSUs, or benefits in lieu of PSUs, even if PSUs have been granted in the past, (vi) unless otherwise agreed with the Corporation, the PSUs and the shares of Common Stock subject to the PSUs, and the income and value of same, are not granted as consideration, or in connection with, the service you may provide as a director of a subsidiary of the Corporation, (vii) the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty, (viii) no claim or entitlement to compensation or damages shall arise from forfeiture or recoupment of the PSU resulting from the termination of your Employment or other service relationship (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), (ix)&#160;you shall seek all necessary approvals under, make all required notifications under, and comply with all laws, rules, and regulations applicable to the ownership of the PSUs and, if applicable, shares of Common Stock, including currency and exchange laws, rules, and regulations, (x) neither the Corporation nor any of its subsidiaries or affiliates shall be liable for any foreign exchange rate fluctuation between your local currency and the US dollar that may affect the value of the PSUs or of any amounts due to you pursuant to settlement of the PSUs or the subsequent sale of any shares of Common Stock acquired upon settlement, (xi) the determination of the form of awards granted under the Plan is made by the Committee in its sole discretion, and (xii) the Corporation is not providing any tax, legal, or financial advice, nor is the Corporation making any recommendations regarding your participation in the Plan or your acquisition or sale of the underlying shares of Common Stock, and you should consult your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the PSUs.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Notices. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Corporation notifies you otherwise in writing, all notices, designations, and payments to be submitted to the Corporation in connection with the PSUs shall be addressed to&#58;</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equity Compensation Resources <br>One Johnson &#38; Johnson Plaza <br>New Brunswick, NJ 08933<br>USA</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Adjustments  for Changes in the Corporation&#8217;s Corporate Structure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The PSUs granted hereunder shall be subject to the provisions of the Plan relating to adjustments for changes in the Corporation&#8217;s corporate structure.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following capitalized terms shall have the definitions set forth below for purposes of this Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) your conviction for or a plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the commission of a felony under federal or state law, or (ii) any act by you that, in the Corporation&#8217;s opinion, constitutes fraud, embezzlement, dishonesty, disclosure of confidential information, the willful and deliberate failure to perform your employment duties in any material respect, a conflict of interest, a violation of the non-competition obligations set forth in Section 2(d)(i) of this Agreement or any other applicable non-competition, non-solicitation, or confidentiality agreement or obligation that you have with any member of the Corporation Group, a violation of any standards of conduct policies or other policies of the Corporation Group to which you are subject, or any other event that is inimical or contrary to the best interests of the Corporation Group. Any determination of &#8220;Cause&#8221; shall be made by the Corporation in its sole discretion, and its determination shall be final and binding.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Certification Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;  means the Certification Date identified on the first page of this Agreement, which shall occur in the first February following the end of the Performance Period.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Compensation &#38; Benefits Committee of the Board of Directors of the Corporation (or any successor committee), or any person or persons to whom the Committee has delegated authority to administer, construe or interpret the terms of the Plan, pursuant to Section 3(d) of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any person or entity including, but not limited to, you or anyone acting on your behalf, that&#160;is engaged or preparing to be engaged in research, development, production, manufacturing, marketing or selling of, or consulting on, any product, process, technology, machine, invention or service in existence or under development that resembles, competes with, may now or in the future compete with, can be substituted for or can be marketed as a substitute for  any product, process, technology, machine, invention, or service of the Corporation Group that is in existence or that is, was, or is planned to be under development. The Corporation shall determine whether any individual or entity is a &#8220;Competitor&#8221; in its sole discretion, and its determination shall be final.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competitive Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all activities (including preparations) which compete with, are intended to compete with, or which otherwise may adversely affect or interfere with the Corporation Group&#8217;s business or advantage a Competitor whether immediately or in the future. The Corporation shall determine whether any conduct constitutes &#8220;Competitive Activities&#8221; in its sole discretion, and its determination shall be final.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Corporation Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;  means the Corporation and its subsidiaries and affiliates, as determined by the Corporation.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Customer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any entity, client, account, or person, including the employees, agents, or representatives of the foregoing, or any entity or person who participates, influences or has any responsibility in making purchasing decisions on behalf of such entities, clients, accounts, or persons, to whom or to which you contacted, solicited any business from, sold to, rendered any service to, were assigned to, had responsibilities for, received commissions or any compensation on, or promoted or marketed any products or services to during the eighteen (18) month period of time preceding your Date of Termination. The Corporation shall determine whether any individual or entity is a &#8220;Customer&#8221; in its sole discretion, and its determination shall be final.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date on which your Employment terminates.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disabled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that you have been determined to be unable to work because of a disability (i) that lasts for a period in excess of twenty-six (26) weeks and (ii) (A) that entitles you to long-term disability benefits under the long-term disability policy of the Corporation or its applicable affiliate under which you are covered, or (B) if there is no such policy, that you have been determined to be &#8220;disabled&#8221; (or of similar status) by the Corporation (or its applicable affiliate) in accordance with applicable procedures and policies. Notwithstanding the foregoing, (I) you will not be considered to have incurred a Disability unless you are identified as &#8220;disabled&#8221; (or of similar status) in accordance with the personnel and&#47;or human resources policies of the Corporation or its applicable affiliate, as in effect from time to time and (II) if the PSUs are subject to Section 409A (as determined by the Corporation), then you will not be considered to have incurred a Disability unless such condition also constitutes a &#8220;disability&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(4).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Divestiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the disposition of an organizational unit or business unit by the Corporation or one of its subsidiaries, whether pursuant to merger, reorganization, consolidation, spinoff, sale of assets, sale of stock, outsourcing arrangement, or asset transfer, in each case that (i) the Corporation determines constitutes a Divestiture and (ii) directly results in (A) the termination of your Employment and the employment of a group of employees of the Corporation Group and (B) you and such other employees becoming employed by an acquiring company or staffing firm.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any period of time during which you are an employee of the Corporation Group in good standing, as determined by the Corporation Group in accordance with its applicable practices, policies and records&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, during such period you are (i) in active employment status with the Corporation Group or (ii) on a Corporation Group-approved leave of absence (as determined by the Corporation Group in its sole discretion). For the avoidance of doubt, you shall not be considered to be Employed (x) for any period during which you are not considered to be an employee in good standing pursuant to the Corporation Group&#8217;s practices, policies and records, (y) during any notice period or salary continuation period required by contract, practice or local law (such as a &#8220;garden leave&#8221; or similar period) or any severance period (if you are covered by a severance agreement or arrangement) or (z) for any period of leave that is not approved by the Corporation Group (as determined by the Corporation Group in its sole discretion).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date on which the PSUs are granted, as identified on the first page of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the three-year performance period identified  on the first page of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reduction in Force</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a termination of Employment (i) due to a position elimination or (ii) in connection with a site closing or plant closing. The determination of whether there has been a position elimination for purposes of this Agreement, or whether a termination of Employment is otherwise in connection with a Reduction in Force, shall be made by the Corporation in its sole discretion and without regard to whether you are eligible to receive severance or other separation benefits from any member of the Corporation Group in connection with your termination of Employment.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Employment with the Corporation or one of its subsidiaries or affiliates, while that corporation or other legal entity was a subsidiary or affiliate of the Corporation, unless the Corporation has otherwise provided on or before the Grant Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Divestiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Divestiture in which the PSUs (or portion thereof) that would otherwise be forfeited hereunder as a result of a termination of Employment due to such Divestiture are not or would not be replaced (with cash-based compensation, equity-based compensation, or any other compensation or benefit) in whole or in part by the acquiring company, staffing firm, or other entity involved in such Divestiture, or any affiliate of the foregoing (as applicable, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Acquiring Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in the event that you accepted employment with the Acquiring Entity. The determination of whether any compensation or benefit is provided in replacement of forfeited PSUs, or whether a Divestiture constitutes a Specified Divestiture, shall be made by the Corporation in its sole discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(q)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Top-Up Number of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;  means the positive difference, if any, between (i)&#160;the number of PSUs that would have become vested based upon actual achievement relative to the Performance Goals during the Performance Period, less (ii)&#160;the Target Number of PSUs&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Top-up Number of PSUs shall not be less than zero.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(r)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;  means the earliest of (to the extent applicable)&#58; (i) the later of the Scheduled Vesting Date or the Certification Date&#59; or (ii) in the event of a termination of Employment pursuant to Section 2(c)(i) (Termination of Employment due to Death) or a Disability pursuant to Section 2(c)(ii) (Disability), (A) with respect to the Target Number of PSUs, the Date of Termination or the date you become Disabled, as applicable, and (B) with respect to the Top-Up Number of PSUs, the Certification Date&#59; or (iii) in the event of your death as described in Section 2(c)(v) (Death following Certain Terminations), (A)&#160;with respect to the Target Number of PSUs or Pro Rata Number of PSUs, as applicable, the date of death, and (B)&#160;with respect to the Top-Up Number of PSUs or the Pro Rata Top-Up Number of PSUs, as applicable, the Certification Date&#59; or (iv) the date the PSUs vest and become payable pursuant to any applicable provision of the Plan (provided, that, if the PSUs are subject to Section 409A (as determined by the Corporation), payment will occur on the earliest permissible date determined by the Corporation that would not result in accelerated taxation and&#47;or tax penalties under Section 409A).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">s. Except as provided herein, this Agreement may not be amended or otherwise modified unless evidenced in writing and signed by an authorized representative of the Corporation.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge and agree that all affiliates and subsidiaries of the Corporation have, or will as the result of a future acquisition, merger, assignment, or otherwise have, an interest in your Employment and your compliance with the obligations in Section 2(d) (Competition with the Corporation Group), and that those entities are each express, third-party beneficiaries of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, executors, administrators, successors and assigns.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that Section 2(d) (Competition with the Corporation Group) of this Agreement is invalidated or not enforced under applicable law, this shall not affect the validity or enforceability of the remaining provisions of this Agreement or the Plan. To the extent that Section 2(d) of this Agreement is unenforceable because it is deemed overbroad, the provision shall be applied and enforced in a more limited manner to the fullest extent permissible under the applicable law. You further understand and agree that, in the event Section 2(d) of this Agreement is declared invalid, void, overbroad, or unenforceable, in whole or in part, for any reason, you shall remain bound by any non-competition, confidentiality, non-solicitation, and&#47;or non-disclosure agreement previously entered between you and any member of the Corporation Group. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Appendix B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding any provisions in this Agreement, the PSUs shall be subject to any additional terms and conditions set forth in Appendix B for your country. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Moreover, if you relocate to one of the countries included in Appendix B, the additional terms and conditions for such country will apply to you, to the extent the Corporation determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appendix B constitutes part of this Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:24.03pt">Data Privacy Consent. By accepting this grant, you hereby unconditionally consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this document by and among, as applicable, your employing entity (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;) and the Corporation and the Corporation Group for the exclusive purpose of implementing, administering and managing any awards issued to you under the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan. You understand that the Corporation and your Employer may hold certain personal information about you, including, but not limited to, your name, home address, email address, telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, details of all PSUs or any other entitlement to shares of stock awarded, canceled, vested, unvested or outstanding in your favor (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;), for the purpose of implementing, administering and managing any grants issued to you under the Plan. You understand that Data may be transferred to any third parties, as may be selected by the Corporation, which are assisting in the implementation, administration and management of the Plan and the fulfillment of this Agreement. You understand that the  recipients of the Data may be located in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections from your country. You understand that if you reside outside of the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative. You authorize the recipients, which may assist the Corporation (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing grants under the Plan and the fulfillment of this Agreement. You understand the Data will be held only as long as is necessary to implement, administer and manage grants under the Plan and this Agreement. You understand that if you reside outside of the United States, you may, at any time, view Data, request information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your human resources representative. Further, you understand that your consent herein is being provided on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your Employment status or Service will not be affected&#59; the only consequence of refusing or withdrawing your consent is that the Corporation may not be able to grant PSUs or other equity awards to you or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement and the Plan constitute the entire agreement between the parties relating to the subject matter hereof, and any previous agreement or understanding between the parties with respect thereto is superseded by this Agreement and the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The intent of the parties is that payments and benefits under this Agreement are exempt from or comply with Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance issued thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), to the extent subject thereto, and accordingly, to the maximum extent permitted, this Agreement shall be interpreted and administered to be in compliance therewith or exempt therefrom, as applicable. Notwithstanding anything to the contrary in the Plan or this Agreement, the Corporation reserves the right to revise this Agreement as it deems necessary or advisable, in its sole discretion and without your consent, to comply with Section&#160;409A or to otherwise avoid imposition of any additional tax or income recognition under Section&#160;409A prior to the actual payment of cash or shares of Common Stock pursuant to the PSUs. However, the Corporation makes no representation that the PSUs are not subject to Section&#160;409A nor makes any undertaking to preclude Section&#160;409A from applying to the PSUs. The Corporation shall not have any liability under the Plan or this Agreement for any taxes, penalties or interest due on amounts paid or payable pursuant to the Plan or this Agreement, including any taxes, penalties or interest imposed under Section&#160;409A. For purposes of the Plan and this Agreement, to the extent the PSUs constitute &#8220;non-qualified deferred compensation&#8221; within the meaning of Section 409A and necessary to avoid accelerated taxation and&#47;or tax penalties under Section 409A, a termination of Employment shall not be deemed to have occurred for purposes of settlement of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any portion of the PSUs unless such termination constitutes a &#8220;separation from service&#8221; within the meaning of Section&#160;409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of Employment&#8221; or similar terms shall mean &#8220;separation from service.&#8221; Each amount to be paid under this Agreement shall be construed as a separately identified payment for purposes of Section 409A. In addition, notwithstanding anything herein to the contrary, if you are deemed on the Date of Termination to be a &#8220;specified employee&#8221; within the meaning of that term under Section&#160;409A and you are subject to U.S. federal taxation, then, to the extent the settlement of the PSUs following such termination of Employment is considered the payment of non-qualified deferred compensation under Section&#160;409A payable on account of a &#8220;separation from service&#8221; that is not exempt from Section&#160;409A, such settlement shall be delayed until the date that is the earlier of (i)&#160;the expiration of the six-month period measured from the date of such &#8220;separation from service&#8221; or (ii)&#160;the date of your death.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.69pt">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By electing to accept this Agreement, you acknowledge receipt of this Agreement and hereby confirm your understanding of the terms set forth in this Agreement. In the event of any conflict between the terms of the Plan and this Agreement, the terms of the Plan shall control. The Corporation may, in its sole discretion, decide to deliver any documents (including, without limitation, information required to be delivered to you pursuant to applicable securities laws) related to current or future participation in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Corporation or a third party designated by the Corporation. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.69pt">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge that you are proficient in the English language, or have consulted with an advisor who is proficient in the English language, so as to enable you to understand the provisions of this Agreement and the Plan. If you have received this Agreement or any other document related to the Plan translated into a language other than English, and the meaning of the translated version is different than the English version, the English version will control. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Corporation reserves the right to impose other requirements on your participation in the Plan, on the PSUs and on any shares of Common Stock acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan, to make any corrections or adjustments that it deems necessary or appropriate, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.69pt">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge that a waiver by the Corporation of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other grantee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18.69pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey without giving effect to conflict of laws principles, except to the extent superseded by federal law and as set forth in this Section 9(m). Provided that you primarily resided and worked in California during and in connection with your employment with the Corporation Group and at the time that you accepted this Agreement and participation in the Plan, (i) this Agreement shall be governed by and construed in accordance with the laws of the State of California&#59; and (ii) Section 2(d)(ii) shall not apply with respect to services you render in California that do not involve your use or disclosure of the Corporation Group&#8217;s confidential or trade secret information.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Submission to Jurisdiction&#59; Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any litigation brought against a party to this Agreement shall be brought in any U.S. federal or state court located in the State of New Jersey and each of the parties submits to the exclusive jurisdiction of such courts for the purpose of any such litigation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other matter provided by law. Each party agrees not to assert (A) any objection which it may have to venue in U.S. federal or state court located in the State of New Jersey, (B) any claim that litigation has been brought in an inconvenient forum and (C) any claim that such court does not have jurisdiction with respect to such litigation. Each party waives any right to a trial by jury with respect to any matters arising under this Agreement or any other awards granted under the Plan.</font></div><div style="margin-top:24pt;padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JOHNSON &#38; JOHNSON</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div style="padding-left:220.5pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carolyn Hoenisch</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Senior Finance Director</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Savings Plan, Pension, Equity Compensation Operations </font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Johnson &#38; Johnson </font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">One Johnson &#38; Johnson Plaza </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New Brunswick, NJ 08933<br>USA </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102-2022ltipformrsu.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic840008a3df549cea4c457c24aabe783_38"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT 10.2</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JOHNSON &#38; JOHNSON</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2022 LONG-TERM INCENTIVE PLAN</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLOBAL RESTRICTED SHARE UNIT AWARD AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Granted To&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.237%"><tr><td style="width:1.0%"></td><td style="width:20.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9eeff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WWID #</font></td><td colspan="3" style="background-color:#d9eeff;padding:0 1pt"></td><td colspan="3" style="background-color:#d9eeff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total Units&#58;</font></td></tr><tr><td colspan="3" style="background-color:#d9eeff;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Grant Date&#58;</font></td><td colspan="3" style="background-color:#d9eeff;padding:0 1pt"></td><td colspan="3" style="background-color:#d9eeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Scheduled Vesting Date(s)&#58; the date(s) set forth in the  table below (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Scheduled Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:15.404%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.055%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.200%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Grant No.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Grant Type</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No. of Units</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Scheduled Vesting Date</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted Share Units</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted Share Units</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted Share Units</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to such other conditions as may be established by the Committee in its sole discretion, in consideration of the granting of an award under the terms of the Johnson &#38; Johnson 2022 Long-Term Incentive Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you agree as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Grant of Restricted Share Units. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Global Restricted Share Unit Award Agreement, including any country-specific terms in Appendix A hereto and any other exhibits or addendums to these documents (collectively, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Plan, Johnson &#38; Johnson, a New Jersey corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), hereby grants you the above-stated number of Restricted Share Units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which will become vested subject to the terms and conditions of this Agreement. Upon vesting of each RSU, you will receive one share of Common Stock of the Corporation, par value $1.00 per share (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or cash in lieu thereof, in either case subject to and in accordance with the terms of Section 4 of this Agreement. Except where the context clearly indicates otherwise, each capitalized term used herein shall have the definition assigned to it by this Agreement or, to the extent that this Agreement does not define a capitalized term used herein, by the Plan. The RSUs granted herein are subject to all of the terms and conditions of the Plan, and the terms of the Plan are hereby incorporated herein by reference. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This grant of RSUs is conditioned on your (i) electronically accepting this grant on the website of the Plan recordkeeper (or in such other manner as the Corporation may establish or permit from time to time) and (ii) opening and maintaining a brokerage account that is permitted for use with respect to awards granted under the Plan, in each case by the deadline established by the Corporation and&#47;or set forth on the website of the Plan recordkeeper. By accepting this grant of RSUs, you will have confirmed your acceptance of all of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT 10.2</font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the terms and conditions of this Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">If you do not accept this grant of RSUs by the applicable deadline, your grant will be cancelled.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Vesting of RSUs&#59; Competition with the Corporation Group. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as otherwise provided in this Section 2, the RSUs granted herein shall become vested on the above-stated Scheduled Vesting Dates in accordance with the schedule set forth above, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, with respect to each RSU, (i) you are Employed on the applicable Scheduled Vesting Date and have been Employed at all times since the Grant Date and (ii) you have complied with and are in compliance with the terms of this Agreement, as determined by the Corporation in its sole discretion. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Termination of Employment - General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If, prior to the applicable Scheduled Vesting Date, you cease to be Employed for any reason, then except as otherwise provided in Section 2(c) (Certain Terminations&#59; Disability), the RSUs shall be forfeited for no consideration on the Date of Termination.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font></div><div style="margin-top:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Certain Terminations&#59; Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination of Employment due to Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you die while Employed, then the RSUs shall immediately become vested in full as of your date of death (to the extent still outstanding and not already vested), and your estate, beneficiary or any person who acquires the RSUs by inheritance or devise, as applicable, shall receive a number of shares of Common Stock (or cash in lieu thereof), as provided in Section&#160;4 (Settlement of RSUs&#59; Tax Withholding&#59; Compliance With Securities Laws&#59; Compliance with Compensation Recoupment Policy). </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you become Disabled while Employed, you shall immediately become vested in full in the RSUs (to the extent still outstanding and not already vested) on the date of Disability. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Qualifying Separation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If your Employment terminates after the date that is six (6) months following the Grant Date&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:132.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)for any reason other than a termination of Employment pursuant to Section 2(c)(i) (Termination of Employment due to Death) or Section 2(c)(v) (Termination for Cause), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:justify;text-indent:129.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)as of the Date of Termination either (I) you have attained age fifty-five (55) and have at least ten (10) years of Service with at least five (5) consecutive years of Service immediately before your Date of Termination or (II) you have attained age sixty-two (62) (a termination of Employment that satisfies the conditions set forth in clauses (A) and (B) above, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Separation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then, subject to the terms of this Agreement, you shall become vested in the RSUs (to the extent still outstanding and not already vested) on the applicable Scheduled Vesting Dates in accordance with the schedule set forth above. For the avoidance of doubt, this Section 2(c)(iii) (Qualifying Separation) shall not apply if your Employment terminates on or prior to the date that is six (6) months following the Grant Date, as reflected in the records of the Corporation. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, you will be treated as having terminated Employment pursuant to Section&#160;2(b) hereof (Termination of Employment &#8211; General) if, at any time prior to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.237%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT 10.2</font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable Scheduled Vesting Date, the Corporation determines in its sole discretion that applying this Section&#160;2(c)(iii) (Qualifying Separation), (1) to employees based on age at the time of termination of Employment and not to all employees may violate any law or public policy applicable to you and&#47;or the RSUs (whether as applied to all holders of RSUs or to only holders of RSUs in the jurisdiction where you are employed), or (2) in a particular case (or cases) is not advisable or appropriate or consistent with the intent of this Section 2(c)(iii).  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Death Following Qualifying Separation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding the foregoing, if you die following a termination of Employment pursuant to Section 2(c)(iii) (Qualifying Separation), but prior to any Scheduled Vesting Date that had not occurred as of the date of your death, then your estate, beneficiary or any person who acquires the RSUs (to the extent still outstanding) by inheritance or devise, as applicable, shall become fully vested in such RSUs  on the date of your death.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Without limiting the generality of Section 2(b), and notwithstanding any other provision of this Section 2(c), if you cease to be Employed for any reason (including, without limitation, as a result of your voluntary resignation) in connection with or following the occurrence of an event that constitutes Cause, then the RSUs and any other awards that you hold under the Plan shall immediately be forfeited for no consideration as of the Date of Termination. If following your Date of Termination, the Corporation becomes aware of conduct or activity by you that occurred during or following your Employment that would have constituted Cause, then any RSUs (or portions thereof) or any other awards held by you under the Plan that are unvested or unexercised (and any payments or benefits in respect thereto) as of the date that the Corporation becomes aware of such conduct or activity shall be forfeited.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Corporation Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event of your termination of Employment, the determination of the reason for such termination and the applicable treatment under this Section 2 shall be made by the Corporation in its sole discretion. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Competition With the Corporation Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In order to protect the Corporation Group&#8217;s goodwill and investments in research and development and Customer and business relationships and to prevent the disclosure of the Corporation Group&#8217;s confidential and trade secret information, thereby promoting the long-term success of the Corporation Group&#8217;s business, you agree to the following&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">During your Employment, you will not, without the prior written consent of the Corporation, directly or indirectly engage in Competitive Activities.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">For a period of eighteen (18) months following your Date of Termination, you will not, without the prior written consent of the Corporation, directly or indirectly perform, or assist others to perform, work for a Competitor in a position or in any geographic location in which you could disadvantage the Corporation Group or advantage the Competitor through (a) your disclosure or use of the Corporation Group&#8217;s confidential or trade secret information  and&#47;or (b) your use of the Corporation Group&#8217;s Customer relationships and goodwill. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Rescission and Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand and agree that if the Corporation determines you have violated Section 2(d)(i) and&#47;or Section 2(d)(ii) and&#47;or any non-competition or non-solicitation agreement that you have with any member of the Corporation Group, then, in addition to injunctive relief, damages, and all other equitable and legal rights and remedies&#58;  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.237%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT 10.2</font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:132.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)the RSUs shall be forfeited for no consideration on the earliest date on which you are first in violation of Section 2(d)(i) and&#47;or <br>Section 2(d)(ii) or any non-competition or non-solicitation agreement that you have with any member of the Corporation Group&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:129.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)upon the Corporation&#8217;s demand, you shall immediately deliver to the Corporation (I) a number of shares of Common Stock equal to the number of RSUs that vested and were settled in the form of Common Stock (for the avoidance of doubt, without reduction for any shares of Common Stock that may have been withheld and&#47;or sold to satisfy applicable withholding taxes) and (II) the gross amount of cash paid to you (for the avoidance of doubt, without reduction for amounts withheld to satisfy applicable withholding taxes) for any RSUs that were settled in the form of cash, in each case in respect of any RSUs that vested within the twelve (12) month period of time immediately preceding the earliest date on which you are first in violation of Section 2(d)(i) and&#47;or Section 2(d)(ii) or any non-competition or non-solicitation agreement that you have with any member of the Corporation Group. To the extent that you do not, as of the date of the Corporation&#8217;s demand for repayment, hold a number of shares of Common Stock sufficient to satisfy your obligation set forth in clause (I) above, you shall pay the Corporation an amount in cash equal to the result of (x) (i) the number shares required to be delivered by you to the Corporation pursuant to clause (I) above, less (ii) the number of shares actually delivered by you to the Corporation pursuant to clause (I), multiplied by (y) the Fair Market Value per share of Common Stock as of the business day immediately preceding the date of the Corporation&#8217;s demand for repayment. You agree to deliver and execute such documents (including, if applicable, share certificates) as the Corporation may deem necessary to effect the repayment obligations referred to in this Section 2(d)(iii)(B). </font></div><div style="margin-top:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">You understand and agree that the remedies set forth in Section 2(d)(iii) shall not be the Corporation Group&#8217;s exclusive remedies in the event of a breach of the non-competition obligations set forth in Section 2(d)(i) and&#47;or Section 2(d)(ii) or in any other applicable non-competition or non-solicitation agreement that you have with any member of the Corporation Group, and that the Corporation Group reserves all other rights and remedies available to it at law or in equity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Conditions on Vesting upon or following Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Your eligibility to vest in any of the RSUs upon or following the date of your termination of Employment shall be subject to (i) your compliance with the non-competition obligations in Section 2(d)(i) and&#47;or Section 2(d)(ii) and&#47;or any other applicable non-competition or non-solicitation agreement with any member of the Corporation Group and (ii) if required by any member of the Corporation Group at the time of your termination of Employment, your execution of a separation agreement and&#47;or a general release of claims in favor of the Corporation and its subsidiaries and affiliates containing such provisions and in such form as required by the Corporation Group that becomes effective prior to the latest date for settlement of the RSUs set forth in Section 4(a) (or such earlier date as the Corporation Group may require).  In the event a separation agreement and&#47;or a release of claims is required by the Corporation Group and (A) (I) the RSUs vest upon the Date of Termination or (II) the Vesting Date falls within the period that you have to provide such release of claims, and (B) the period in which the RSUs must be settled pursuant to Section 4(a) spans two calendar years, then settlement of the vested RSUs will be made in the second calendar year.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Rights to Common Stock. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Prior to the delivery of shares of Common Stock to you pursuant to Section 4(a) (if applicable), you shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> have any rights in, or with respect to, any of the shares of Common Stock underlying the RSUs, including, but not limited to, any voting rights and the right to receive any dividends (or dividend equivalents) that may be paid or any distributions that may be made with respect to such Common Stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.237%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT 10.2</font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Settlement of RSUs&#59; Tax Withholding&#59; Compliance With Securities Laws&#59; Compliance with Compensation Recoupment Policy.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms of this Agreement, within sixty (60) days following the Vesting Date (but in no event later than the first March 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> occurring thereafter), you will receive from the Corporation one share of Common Stock for each RSU that vested on that date, or, at the discretion of the Committee, the cash equivalent of the Fair Market Value on the Vesting Date, reduced by any whole shares of Common Stock that are withheld or sold or any cash withheld to satisfy applicable Federal, state and local income taxes, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable or deemed applicable to you (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in the amount determined by the Corporation. In lieu of the foregoing, the Corporation or other applicable member of the Corporation Group may determine that withholding of Tax-Related Items shall be satisfied by any other method permitted under the Plan. Notwithstanding the foregoing, if you are a Section 16 officer of the Corporation under the Securities Exchange Act of 1934, as amended, then the Corporation will satisfy any applicable tax withholding obligations by withholding in shares of Common Stock upon the relevant taxable event (with such withholding obligations determined based on the applicable statutory withholding rates and without regard to Section 83(c)(3) of the Internal Revenue Code of 1986, as amended), unless otherwise determined by the Committee. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Registration and Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding Section 4(a) hereof, shares of Common Stock shall not be issued pursuant to this Agreement unless, on the Vesting Date, there is in effect a current registration statement or amendment thereto under the Securities Act of 1933, as amended, covering the shares of Common Stock to be issued upon vesting of the RSUs, and such shares are authorized for listing on the New York Stock Exchange or another securities exchange as determined by the Corporation. Nothing herein shall be deemed to require the Corporation to apply for, to effect, or to obtain such registration or listing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Compensation Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You hereby acknowledge and agree that you and the RSUs, including any cash and&#47;or shares of Common Stock that may be delivered to you pursuant to the RSUs, are subject to the Corporation&#8217;s Compensation Recoupment Policy, as may be amended and&#47;or restated from time to time, a current copy of which can be found on the Corporation&#8217;s website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;www.investor.jnj.com&#47;gov&#47;compensation-recoupment-policy.cfm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The terms and conditions of the Compensation Recoupment Policy hereby are incorporated by reference into this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Nontransferability of RSUs. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The RSUs and any rights granted hereunder may not be sold, transferred, assigned, pledged, or hypothecated in any way (whether by operation of law or otherwise), other than by will or the laws of descent and distribution or in accordance with any beneficiary designation procedures that may be established by the Corporation. Nor shall any such rights be subject to execution, attachment, or similar process, other than in accordance with the terms of the Plan. Upon any attempt to sell, transfer, assign, pledge, hypothecate, or otherwise dispose of the RSUs or of any rights granted herein contrary to the provisions of the Plan or this Agreement, or upon the levy of any attachment or similar process upon the RSUs or such rights, the RSUs and such rights shall, at the election of the Corporation, be forfeited for no consideration.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">No Special Employment Rights&#59; No Rights to Awards. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Nothing contained in the Plan or this Agreement shall be construed or deemed by any person under any circumstances to bind any member of the Corporation Group to continue your employment for the vesting period or for any other period, to create a right to employment with the Corporation, to form or amend an employment or service contract with the Corporation or to interfere in any way with any right of a member of the Corporation Group to terminate your employment at any time. You </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.237%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT 10.2</font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">hereby acknowledge and agree that (i) the Plan is established voluntarily by the Corporation, is discretionary in nature and may be modified, amended, or terminated by the Corporation at any time, as provided in the Plan, (ii) your participation in the Plan is voluntary and you are voluntarily accepting the grant of RSUs, (iii) the RSUs and the shares of Common Stock subject to the RSUs, and the income and value of same, do not constitute part of your normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination indemnities, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement benefits or welfare benefits or similar payments, and in no event should be considered as compensation for, or in any way relating to, past services to the Corporation Group, (iv) the RSUs and shares of Common Stock subject to the RSUs, and the income and value of same, are not intended to replace any pension rights or compensation, (v) the grant of the RSUs is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of RSUs, or benefits in lieu of RSUs, even if RSUs have been granted in the past, (vi) unless otherwise agreed with the Corporation, the RSUs and the shares of Common Stock subject to the RSUs, and the income and value of same, are not granted as consideration, or in connection with, the service you may provide as a director of a subsidiary of the Corporation, (vii) the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty, (viii) no claim or entitlement to compensation or damages shall arise from forfeiture or recoupment of the RSU resulting from the termination of your Employment or other service relationship (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), (ix) you shall seek all necessary approvals under, make all required notifications under, and comply with all laws, rules, and regulations applicable to the ownership of the RSUs and, if applicable, shares of Common Stock, including currency and exchange laws, rules, and regulations, (x) neither the Corporation nor any of its subsidiaries or affiliates shall be liable for any foreign exchange rate fluctuation between your local currency and the US dollar that may affect the value of the RSUs or of any amounts due to you pursuant to settlement of the RSUs or the subsequent sale of any shares of Common Stock acquired upon settlement, (xi) the determination of the form of any award granted under the Plan is made by the Committee in its sole discretion and (xii) the Corporation is not providing any tax, legal, or financial advice, nor is the Corporation making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying shares of Common Stock, you should consult your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the RSUs.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Notices. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless the Corporation notifies you otherwise in writing, all notices, designations, and payments to be submitted to the Corporation in connection with the RSUs shall be addressed to&#58;</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equity Compensation Resources <br>One Johnson &#38; Johnson Plaza <br>New Brunswick, NJ 08933<br>USA</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Definitions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The following capitalized terms shall have the definitions set forth below for purposes of this Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) your conviction for or a plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the commission of a felony under federal or state law, or (ii) any act by you that, in the Corporation&#8217;s opinion, constitutes fraud, embezzlement, dishonesty, disclosure of confidential information, the willful and deliberate failure to perform your employment duties in any material respect, a conflict of interest, a violation of the non-competition obligations set forth in Section 2(d)(i) of this Agreement or any other applicable non-competition, non-solicitation, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.237%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT 10.2</font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">confidentiality agreement or obligation that you have with any member of the Corporation Group, a violation of any standards of conduct policies or other policies of the Corporation Group to which you are subject, or any other event that is inimical or contrary to the best interests of the Corporation Group. Any determination of &#8220;Cause&#8221; shall be made by the Corporation in its sole discretion, and its determination shall be final and binding.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Compensation &#38; Benefits Committee of the Board of Directors of the Corporation (or any successor committee), or any person or persons to whom the Committee has delegated authority to administer, construe or interpret the terms of the Plan, pursuant to Section 3(d) of the Plan. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any person or entity including, but not limited to, you or anyone acting on your behalf, that&#160;is engaged or preparing to be engaged in research, development, production, manufacturing, marketing or selling of, or consulting on, any product, process, technology, machine, invention or service in existence or under development that resembles, competes with, may now or in the future compete with, can be substituted for or can be marketed as a substitute for  any product, process, technology, machine, invention, or service of the Corporation Group that is in existence or that is, was, or is planned to be under development. The Corporation shall determine whether any individual or entity is a &#8220;Competitor&#8221; in its sole discretion, and its determination shall be final.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competitive Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all activities (including preparations) which compete with, are intended to compete with, or which otherwise may adversely affect or interfere with the Corporation Group&#8217;s business or advantage a Competitor whether immediately or in the future. The Corporation shall determine whether any conduct constitutes &#8220;Competitive Activities&#8221; in its sole discretion, and its determination shall be final.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Corporation Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Corporation and its subsidiaries and affiliates, as determined by the Corporation.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Customer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any entity, client, account, or person, including the employees, agents, or representatives of the foregoing, or any entity or person who participates, influences or has any responsibility in making purchasing decisions on behalf of such entities, clients, accounts, or persons, to whom or to which you contacted, solicited any business from, sold to, rendered any service to, were assigned to, had responsibilities for, received commissions or any compensation on, or promoted or marketed any products or services to during the eighteen (18) month period of time preceding your Date of Termination. The Corporation shall determine whether any individual or entity is a &#8220;Customer&#8221; in its sole discretion, and its determination shall be final.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date on which your Employment terminates. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disabled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that you have been determined to be unable to work because of a disability (i) that lasts for a period in excess of twenty-six (26) weeks and (ii) (A) that entitles you to long-term disability benefits under the long-term disability policy of the Corporation or its applicable affiliate under which you are covered, or (B) if there is no such policy, that you have been determined to be &#8220;disabled&#8221; (or of similar status) by the Corporation (or its applicable affiliate) in accordance with applicable procedures and policies. Notwithstanding the foregoing, (I) you will not be considered to have incurred a Disability unless you are identified as &#8220;disabled&#8221; (or of similar status) in accordance with the personnel and&#47;or human resources policies of the Corporation or its applicable affiliate, as in effect from time to time and (II) if the RSUs are subject to Section 409A (as determined by the Corporation), then </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.237%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT 10.2</font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">you will not be considered to have incurred a Disability unless such condition also constitutes a &#8220;disability&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(4).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any period of time during which you are an employee of the Corporation Group in good standing, as determined by the Corporation Group in accordance with its applicable practices, policies and records&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, during such period you are (i) in active employment status with the Corporation Group or (ii) on a Corporation Group-approved leave of absence (as determined by the Corporation Group in its sole discretion). For the avoidance of doubt, you shall not be considered to be Employed (x) for any period during which you are not considered to be an employee in good standing pursuant to the Corporation Group&#8217;s practices, policies and records, (y) during any notice period or salary continuation period required by contract, practice or local law (such as a &#8220;garden leave&#8221; or similar period) or any severance period (if you are covered by a severance agreement or arrangement) or (z) for any period of leave that is not approved by the Corporation Group (as determined by the Corporation Group in its sole discretion).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date on which the RSUs are granted, as identified on the first page of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Employment with the Corporation or one of its subsidiaries or affiliates, while that corporation or other legal entity was a subsidiary or affiliate of the Corporation, unless the Corporation has otherwise provided on or before the Grant Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, with respect to an RSU, the earliest of (to the extent applicable)&#58; (i) the applicable Scheduled Vesting Date&#59; or (ii) the date of death, in the event of a termination of Employment pursuant to Section 2(c)(i) (Termination Due to Death) or a death described in Section 2(c)(iv) (Death following Qualifying Separation)&#59; or (iii) the date you become Disabled, in the event of a Disability described in Section 2(c)(ii) (Disability)&#59; or (iv) the date the RSUs vest and become payable pursuant to any applicable provision of the Plan (provided, that, if the RSUs are subject to Section 409A (as determined by the Corporation), payment will occur on the earliest permissible date determined by the Corporation that would not result in accelerated taxation and&#47;or tax penalties under Section 409A).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Miscellaneous.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as provided herein, this Agreement may not be amended or otherwise modified unless evidenced in writing and signed by an authorized representative of the Corporation. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge and agree that all affiliates and subsidiaries of the Corporation have, or will as the result of a future acquisition, merger, assignment, or otherwise have, an interest in your Employment and your compliance with the obligations in Section 2(d) (Competition with the Corporation Group), and that those entities are each express, third-party beneficiaries of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, executors, administrators, successors and assigns.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that Section 2(d) (Competition with the Corporation Group) of this Agreement is invalidated or not enforced under applicable law, this shall not affect the validity or enforceability of the remaining provisions of this Agreement or the Plan. To the extent that Section 2(d) of this Agreement is unenforceable because it is deemed overbroad, the provision shall be applied and enforced in a more limited manner to the fullest </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.237%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT 10.2</font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extent permissible under the applicable law. You further understand and agree that, in the event Section 2(d) of this Agreement is declared invalid, void, overbroad, or unenforceable, in whole or in part, for any reason, you shall remain bound by any non-competition, confidentiality, non-solicitation, and&#47;or non-disclosure agreement previously entered between you and any member of the Corporation Group. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding any provisions in this Agreement, the RSUs shall be subject to any additional terms and conditions set forth in Appendix A for your country. Moreover, if you relocate to one of the countries included in Appendix A, the additional terms and conditions for such country will apply to you, to the extent the Corporation determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. Appendix A constitutes part of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:24.03pt">Data Privacy Consent. By accepting this grant, you hereby unconditionally consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this document by and among, as applicable, your employing entity (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;) and the Corporation and the Corporation Group for the exclusive purpose of implementing, administering and managing any awards issued to you under the Plan. You understand that the Corporation and your Employer may hold certain personal information about you, including, but not limited to, your name, home address, email address, telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, details of all RSUs or any other entitlement to shares of stock awarded, canceled, vested, unvested or outstanding in your favor (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;), for the purpose of implementing, administering and managing any grants issued to you under the Plan. You understand that Data may be transferred to any third parties, as may be selected by the Corporation, which are assisting in the implementation, administration and management of the Plan and the fulfillment of this Agreement. You understand that the  recipients of the Data may be located in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections from your country. You understand that if you reside outside of the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative. You authorize the recipients, which may assist the Corporation (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing grants under the Plan and the fulfillment of this Agreement. You understand the Data will be held only as long as is necessary to implement, administer and manage grants under the Plan and this Agreement. You understand that if you reside outside of the United States, you may, at any time, view Data, request information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your human resources representative. Further, you understand that your consent herein is being provided on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your Employment status or Service will not be affected&#59; the only consequence of refusing or withdrawing your consent is that the Corporation may not be able to grant RSUs or other equity awards to you or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement and the Plan constitute the entire agreement between the parties relating to the subject matter hereof, and any previous agreement or understanding between the parties with respect thereto is superseded by this Agreement and the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.237%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT 10.2</font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The intent of the parties is that payments and benefits under this Agreement comply with Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance issued thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), to the extent subject thereto, and accordingly, to the maximum extent permitted, this Agreement shall be interpreted and administered to be in compliance therewith. Notwithstanding anything to the contrary in the Plan or this Agreement, the Corporation reserves the right to revise this Agreement as it deems necessary or advisable, in its sole discretion and without your consent, to comply with Section&#160;409A or to otherwise avoid imposition of any additional tax or income recognition under Section&#160;409A prior to the actual payment of cash or shares of Common Stock pursuant to the RSUs. However, the Corporation makes no representation that the RSUs are not subject to Section&#160;409A nor makes any undertaking to preclude Section&#160;409A from applying to the RSUs. The Corporation shall not have any liability under the Plan or this Agreement for any taxes, penalties or interest due on amounts paid or payable pursuant to the Plan or this Agreement, including any taxes, penalties or interest imposed under Section&#160;409A. For purposes of the Plan and this Agreement, to the extent necessary to avoid accelerated taxation and&#47;or tax penalties under Section 409A, a termination of Employment shall not be deemed to have occurred for purposes of settlement of any portion of the RSUs unless such termination constitutes a &#8220;separation from service&#8221; within the meaning of Section&#160;409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of Employment&#8221; or similar terms shall mean &#8220;separation from service.&#8221; Each amount to be paid under this Agreement shall be construed as a separately identified payment for purposes of Section 409A. In addition, notwithstanding anything herein to the contrary, if you are deemed on the Date of Termination to be a &#8220;specified employee&#8221; within the meaning of that term under Section&#160;409A and you are subject to U.S. federal taxation, then, to the extent the settlement of the RSUs following such termination of Employment is considered the payment of &#8220;non-qualified deferred compensation&#8221; under Section&#160;409A payable on account of a &#8220;separation from service&#8221; that is not exempt from Section&#160;409A, such settlement shall be delayed until the date that is the earlier of (i)&#160;the expiration of the six-month period measured from the date of such &#8220;separation from service&#8221; or (ii)&#160;the date of your death.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.69pt">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By electing to accept this Agreement, you acknowledge receipt of this Agreement and hereby confirm your understanding of the terms set forth in this Agreement. In the event of any conflict between the terms of the Plan and this Agreement, the terms of the Plan shall control. The Corporation may, in its sole discretion, decide to deliver any documents (including, without limitation, information required to be delivered to you pursuant to applicable securities laws) related to current or future participation in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Corporation or a third party designated by the Corporation. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.69pt">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge that you are proficient in the English language, or have consulted with an advisor who is proficient in the English language, so as to enable you to understand the provisions of this Agreement and the Plan. If you have received this Agreement or any other document related to the Plan translated into a language other than English, and the meaning of the translated version is different than the English version, the English version will control. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Corporation reserves the right to impose other requirements on your participation in the Plan, on the RSUs and on any shares of Common Stock acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan, to make any corrections or adjustments that it deems necessary or appropriate, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.237%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT 10.2</font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.69pt">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge that a waiver by the Corporation of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other grantee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18.69pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey without giving effect to conflict of laws principles, except to the extent superseded by federal law and as set forth in this Section 9(m). Provided that you primarily resided and worked in California during and in connection with your employment with the Corporation Group and at the time that you accepted this Agreement and participation in the Plan, (i) this Agreement shall be governed by and construed in accordance with the laws of the State of California&#59; and (ii) Section 2(d)(ii) shall not apply with respect to services you render in California that do not involve your use or disclosure of the Corporation Group&#8217;s confidential or trade secret information.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Submission to Jurisdiction&#59; Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any litigation brought against a party to this Agreement shall be brought in any U.S. federal or state court located in the State of New Jersey and each of the parties submits to the exclusive jurisdiction of such courts for the purpose of any such litigation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other matter provided by law. Each party agrees not to assert (A) any objection which it may have to venue in U.S. federal or state court located in the State of New Jersey, (B) any claim that litigation has been brought in an inconvenient forum and (C) any claim that such court does not have jurisdiction with respect to such litigation. Each party waives any right to a trial by jury with respect to any matters arising under this Agreement or any other awards granted under the Plan.</font></div><div style="margin-top:24pt;padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JOHNSON &#38; JOHNSON</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><img alt="image_0a.jpg" src="image_0a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div style="padding-left:220.5pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carolyn Hoenisch</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Senior Finance Director</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Savings Plan, Pension, Equity Compensation Operations </font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Johnson &#38; Johnson </font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">One Johnson &#38; Johnson Plaza </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New Brunswick, NJ 08933<br>USA </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.237%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit103-2022ltipformsto.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i31c8744e6d424dc4850a73ae7cc99f5e_38"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">EXHIBIT 10.3</font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JOHNSON &#38; JOHNSON</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2022 LONG-TERM INCENTIVE PLAN</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">GLOBAL NONQUALIFIED STOCK OPTION AWARD AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Granted To&#58;&#160;&#160;&#160;&#160;Grant Date&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.500%"><tr><td style="width:1.0%"></td><td style="width:30.768%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.273%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WWID #</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Total Shares&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Scheduled Vesting Date(s)&#58; the date(s) set forth in the  table below (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Scheduled Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Purchase Price Per Share&#58;</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Grant No.</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Grant Type</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No. of Shares</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Scheduled Vesting Date</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NQSO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NQSO</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NQSO</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition to such other conditions as may be established by the Committee in its sole discretion, in consideration of the granting of an award under the terms of the Johnson &#38; Johnson 2022 Long-Term Incentive Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you agree as follows&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Grant of Nonqualified Stock Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the terms and conditions of this Global Nonqualified Stock Option Agreement, including any country-specific terms in  Appendix A hereto and any other exhibits or addendums to these documents (collectively, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and the Plan, Johnson &#38; Johnson, a New Jersey corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), hereby grants you a non-qualified stock option (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) to purchase from it the above-stated number of shares of common stock of the Corporation, par value $1.00 per share (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), at the above-stated price per share (such per share price, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which will become vested subject to the terms and conditions of this Agreement. This Option, and the exercise of this Option, is subject to all of the terms and conditions of the Plan, and the terms of the Plan are hereby incorporated herein by reference. Except where the context clearly indicates otherwise, each capitalized term used herein shall have the definition assigned to it by this Agreement or, to the extent that this Agreement does not define a capitalized term used herein, by the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Option grant is conditioned on your (i) electronically accepting this grant on the website of the Plan recordkeeper (or in such other manner as the Corporation may establish or permit from time to time) and (ii) opening and maintaining a brokerage account that is permitted for use with respect to awards granted under the Plan, in each case by the deadline established by the Corporation and&#47;or set forth on the website of the Plan recordkeeper. By accepting this Option grant, you will have confirmed your acceptance of all of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the terms and conditions of this Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">If you do not accept this Option grant by the applicable deadline, your grant will be cancelled.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Vesting of Option&#59; Competition with the Corporation Group.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Vesting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Except as otherwise provided in Section 3 (Termination of Employment&#59; Disability), the Option shall become vested on the above-stated Scheduled Vesting Dates in accordance with the schedule set forth above, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (i) you are Employed on the applicable Scheduled Vesting Date and have been Employed at all times since the Grant Date and (ii) you have complied with and are in compliance with the terms of this Agreement, as determined by the Corporation in its sole discretion. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Competition With the Corporation Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In order to protect the Corporation Group&#8217;s goodwill and investments in research and development and Customer and business relationships and to prevent the disclosure of the Corporation Group&#8217;s confidential and trade secret information, thereby promoting the long-term success of the Corporation Group&#8217;s business, you agree to the following&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During your Employment, you will not, without the prior written consent of the Corporation, directly or indirectly engage in Competitive Activities.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For a period of eighteen (18) months following your Date of Termination, you will not, without the prior written consent of the Corporation, directly or indirectly perform, or assist others to perform, work for a Competitor in a position or in any geographic location in which you could disadvantage the Corporation Group or advantage the Competitor through (A) your disclosure or use of the Corporation Group&#8217;s confidential or trade secret information  and&#47;or (B) your use of the Corporation Group&#8217;s Customer relationships and goodwill. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:90.03pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Rescission and Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You understand and agree that if the Corporation determines you have violated Section 2(b)(i) and&#47;or Section 2(b)(ii) and&#47;or any non-competition or non-solicitation agreement that you have with any member of the Corporation Group, then, in addition to injunctive relief, damages, and all other equitable and legal rights and remedies&#58;  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the Option (whether or not vested) shall be forfeited for no consideration on the earliest date on which you are first in violation of Section 2(b)(i) and&#47;or Section 2(b)(ii) or any non-competition or non-solicitation agreement that you have with any member of the Corporation Group&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">and</font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">upon the Corporation&#8217;s demand, you shall immediately deliver to the Corporation (I) a number of shares of Common Stock equal to the number of shares of Common Stock with respect to which you exercised the Option (for the avoidance of doubt, without reduction for any shares of Common Stock that may have been withheld and&#47;or sold to satisfy applicable withholding taxes) within the twelve (12) month period of time immediately preceding the earliest date on which you are first in violation of Section 2(b)(i) and&#47;or Section 2(b)(ii) or any non-competition or non-solicitation agreement that you have with any member of the Corporation Group, less (II) the number of shares of Common Stock withheld upon exercise to satisfy the Purchase Price (or, if you paid the Purchase Price in cash, the number of shares that would have been withheld had the purchase price been paid via cashless exercise). To the extent that you do not, as of the date of the Corporation&#8217;s demand for repayment, hold a number of shares of Common Stock sufficient to satisfy the obligation set forth in the preceding sentence, you shall pay the Corporation an amount in cash equal to (x) (i) the number shares required to be delivered by you to the Corporation pursuant to the preceding sentence, less (ii) the number of shares actually delivered by you to the Corporation pursuant to the preceding </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">sentence, multiplied by (y) the Fair Market Value per share of Common Stock as of the business day immediately preceding the date of the Corporation&#8217;s demand for repayment. You agree to deliver and execute such documents (including, if applicable, share certificates) as the Corporation may deem necessary to effect the repayment obligations referred to in this Section 2(b)(iii)(B). </font></div><div style="margin-top:12pt;text-align:justify;text-indent:90.69pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You understand and agree that the remedies set forth in Section 2(b)(iii) shall not be the Corporation Group&#8217;s exclusive remedies in the event of a breach of the non-competition obligations set forth in Section 2(b)(i) and&#47;or Section 2(b)(ii) or in any other applicable non-competition or non-solicitation agreement that you have with any member of the Corporation Group, and that the Corporation Group reserves all other rights and remedies available to it at law or in equity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Termination of Employment&#59; Disability.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">- General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you cease to be Employed for any reason, then, except as otherwise provided in this Section 3 (Termination of Employment&#59; Disability), (i) any portion of the Option that has not vested as of your Date of Termination shall be forfeited for no consideration on your Date of Termination&#59; and (ii) any portion of the Option that has vested as of your Date of Termination and that has not been exercised shall terminate in full on the earlier of (A) the date that is three (3) months after your Date of Termination or (B) the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Termination of Employment due to Death</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you die while Employed, then any portion of the Option that remains outstanding and that has not vested shall immediately become vested in full as of your date of death, and your estate, beneficiary or any person who acquires the Option by inheritance or devise, as applicable, shall have the right to exercise any unexercised portion of the Option until the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Disability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you become Disabled while Employed, then any portion of the Option that remains outstanding and that has not vested shall immediately become vested in full as of the date of Disability, and you (or should you die within said period, then by your estate, beneficiary or any person who acquires the Option by inheritance or devise, as applicable) shall have the right to exercise any unexercised portion of the Option until the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Certain other Terminations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Separation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If your Employment terminates after the date that is six (6) months following the Grant Date&#58; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">for any reason other than a termination of Employment pursuant to Section 3(b) (Termination of Employment due to Death) or Section 3(f) (Termination for Cause)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">as of the Date of Termination, either (I) you have attained age fifty-five (55) and have at least ten (10) years of Service, with at least five (5) consecutive years of Service immediately before your Date of Termination, or (II) you have attained age sixty-two (62) (a termination of Employment that satisfies the conditions set forth in clauses (A) and (B) immediately above, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Qualifying Separation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then, to the extent the Option remains outstanding as of the date of your Qualifying Separation, and subject to the terms of this Agreement, the Option shall become vested and exercisable on the applicable Scheduled Vesting Date in accordance with the schedule set forth above (to the extent not already vested and exercisable) and shall remain exercisable until the Expiration Date. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of doubt, this Section 3(d)(i) shall not apply if your Employment terminates on or prior to the date that is six (6) months following the Grant Date, as reflected in the records of the Corporation. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Non-Qualifying Separation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If, on or after a Scheduled Vesting Date, </font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">your Employment terminates for any reason other than a termination of Employment pursuant to Section 3(b) (Termination of Employment due to Death) or Section 3(f) (Termination for Cause), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:12pt;text-align:justify;text-indent:144pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">as of the Date of Termination, you have attained age fifty-five (55), but the conditions set forth in Section 3(d)(i) (Qualifying Separation) are not satisfied with respect to the Option (a termination that satisfies the conditions set forth in clauses (A) and (B) immediately above, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Qualifying Separation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then, subject to the terms of this Agreement, any vested portion of the Option that remains outstanding as of the date of your Non-Qualifying Separation shall terminate on the earlier of (A) the third (3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) anniversary of your Date of Termination or (B) the Expiration Date. For the avoidance of doubt, this Section 3(d)(ii) (Non-Qualifying Separation) shall not apply with respect to any portion of the Option that was not vested as of your Date of Termination. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding this Section 3(d), you will be treated as having terminated Employment pursuant to Section 3(a) hereof (Termination of Employment &#8211; General) if, at any time, the Corporation  determines in its sole discretion that applying Section 3(d)(i) (Qualifying Separation) or Section 3(d)(ii) (Non-Qualifying Separation) (1) to employees based on age at the time of termination of Employment and not to all employees may violate any law or public policy applicable to you and&#47;or the Option (whether as applied to all holders of options or to only holders of options in the jurisdiction where you are employed), or (2) in a particular case (or cases) is not advisable or appropriate or consistent with the intent of this Section 3(d). </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Death Following Qualifying Separation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding the foregoing, if you die following a termination of Employment pursuant to Section 3(d)(i) (Qualifying Separation), then, to the extent the Option (or portion thereof) remains outstanding as of the date of your death, your estate, beneficiary or any person who acquires the Option (or portion thereof) by inheritance or devise, as applicable, shall become vested in the Option (on the date of your death (to the extent unvested as of such date) and shall have the right to exercise any unexercised portion of the Option until the Expiration Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.03pt">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Without limiting the generality of Section 3(b), and notwithstanding any other provision of this Section 3, if you cease to be Employed for any reason (including without limitation, as a result of your voluntary resignation) in connection with or following the occurrence of an event that constitutes Cause, then the Option, whether or not vested, and any other award you hold under the Plan, shall immediately be forfeited for no consideration as of the Date of Termination. If following your Date of Termination, the Corporation becomes aware of conduct or activity by you that occurred during or following your Employment that would have constituted Cause, then any portion of the Option or any other awards held by you under the Plan that are unvested or unexercised (and any payments or benefits in respect thereto) as of the date that the Corporation becomes aware of such conduct or activity shall be forfeited.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Conditions on Vesting Upon or Following Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Your eligibility to vest in or exercise the Option (or any portion thereof) upon or following the date of your termination of Employment shall be subject to (i) your compliance with the non-competition obligations in Section 2(b)(i) and&#47;or Section 2(b)(ii) and&#47;or any other applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">non-competition or non-solicitation agreement with any member of the Corporation Group and (ii) if required by any member of the Corporation Group at the time of your termination of Employment, your execution of a separation agreement and&#47;or general release of claims in favor of the Corporation and its subsidiaries and affiliates containing such provisions and in such form as required by the Corporation Group that becomes effective within sixty (60) days following the date of termination (or such earlier date as the Corporation Group may require).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Corporation Determinations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event of your termination of Employment, the determination of the reason for such termination and the applicable treatment under this Section 3 (Termination of Employment&#59; Disability) shall be made by the Corporation in its sole discretion. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Exercise of Option&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Payment of Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Option may not be exercised until the Vesting Date. Once vested, the Option (or applicable vested portion thereof) shall be exercisable in accordance with the procedures established by the Corporation, subject to Section 4(c) of this Agreement. This Option shall terminate and shall not be exercisable after the closing of the New York Stock Exchange on the earlier of (i) the Expiration Date or (ii) the date on which the Option otherwise terminates pursuant to this Agreement (including, without limitation, pursuant to Section 2 (Vesting of the Option&#59; Competition with the Corporation Group) or Section 3 (Termination of Employment&#59; Disability)). If the New York Stock Exchange is not open on the date that the Option terminates, the Option shall no longer be exercisable after the closing of the New York Stock Exchange on the last day immediately preceding such date on which the New York Stock Exchange is open. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Exercise Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to the conditions set forth in this Agreement and the Plan, you must exercise the Option by providing notice of exercise in accordance with procedures established by the Corporation from time to time. This notice must be accompanied by payment in full of the aggregate Purchase Price and any applicable taxes required by law in accordance with the terms of this Agreement. You may purchase less than the number of shares of Common Stock covered by the Option. You may not exercise the Option for a fractional share.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:90.03pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Automatic Exercise Upon Expiration of the Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding any other provision of this Agreement, if, as of the close of trading on the last trading day on which all or a portion the outstanding Option may be exercised (such day, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Last Trading Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (x) the then-Fair Market Value of a share of Common Stock exceeds the Purchase Price by at least $0.01 and (y) the result of the option exercise would yield one or more shares of Common Stock  (such expiring portion of the Option that is so in-the-money, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Auto-Exercise Eligible Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), you will be deemed to have automatically exercised such Auto-Exercise Eligible Option (to the extent not previously been exercised or forfeited) as of the close of trading on the Last Trading Date in accordance with the provisions of this Section 4(a)(iii). In the event of an automatic exercise pursuant to this Section 4(a)(iii), the Corporation will reduce the number of shares of Common Stock issued to you upon such exercise in an amount necessary to satisfy (A) your aggregate Purchase Price obligation for the Auto-Exercise Eligible Option and (B) applicable Tax-Related Items (as defined below) arising upon the automatic exercise (unless the Corporation deems that a different method of satisfying such obligations is practicable and advisable), in each case, based on the closing price of the shares of Common Stock as of the close of trading on the Last Trading Date. In addition, this Section 4(a)(iii) shall not apply to any Option to the extent that this Section causes the Option to fail to qualify for favorable tax treatment under applicable law. The Corporation may, at any time in its discretion and for any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">reason, determine not to automatically exercise the Option. The automatic exercise procedure is provided as a convenience and as a protection against inadvertent expiration of an Option. Because any exercise of an Option is normally your responsibility, you hereby waive any claims against the Corporation or any of its affiliates, employees or agents if an automatic exercise does not occur for any reason and the Option expires. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Payment of Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Purchase Price payable upon exercise of the Option shall be paid in U.S. dollars or, unless otherwise determined by the Committee, (i) pursuant to any cashless exercise procedure through the use of a brokerage arrangement approved by the Corporation&#59; (ii) in Common Stock valued at Fair Market Value at the time of exercise&#59; (iii) a combination of such Common Stock and cash&#59; or (iv) such other method(s) as the Corporation may permit from time to time in its discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"> that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,&#58; (A) fractional shares of Common Stock shall not be accepted as payment of the Purchase Price&#59; (B) shares of Common Stock that you acquired within the six (6)&#160;month period immediately preceding the date of exercise may not be used to pay the Purchase Price&#59; (C) shares of Common Stock that were issued to you by the Corporation upon your exercise of an incentive stock option within the one (1) year period immediately preceding the exercise of the Option may not be used to pay the Purchase Price&#59; and (D) any shares of Common Stock used to pay the Purchase Price (or any portion thereof) must be owned by you free and clear of any liens, encumbrances or security interests. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Exercisability Subject to Administrative Processes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge and agree that your ability to exercise the Option on any specific date or during any specific period on or following the Vesting Date (whether the Vesting Date occurs during your Employment or upon or following your Date of Termination) is subject to and may be limited by the Corporation&#8217;s administrative practices under the Plan as in effect from time to time. These practices may include, without limitation, the imposition of blackout periods during which the Option may not be exercised, periods during which the Option may not be exercised as a result of updates, maintenance, errors or changes on or to the Plan recordkeeper&#8217;s electronic platform or otherwise, or such other limitations as the Corporation may deem necessary or advisable in its sole discretion. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Delivery of Shares&#59; Tax Withholding&#59; Compliance With Securities Laws&#59; Compensation Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Corporation shall, after receiving the aggregate Purchase Price for the shares of Common Stock purchased and paid for under the Option, make delivery of such shares to you, reduced by any whole shares of Common Stock that are withheld or sold or any cash withheld to satisfy applicable Federal, state and local income taxes, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable or deemed applicable to you (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in the amount determined by the Corporation. In lieu of the foregoing, the Corporation or other applicable member of the Corporation Group may determine that withholding of Tax-Related Items shall be satisfied by any other method permitted under the Plan. Notwithstanding the foregoing, if you are a Section 16 officer of the Corporation under the Securities Exchange Act of 1934, as amended, then, unless otherwise determined by the Committee, if the Purchase Price upon exercise of the Option is paid (i) in cash or shares of Common Stock held prior to the date of exercise, then any Tax-Related Items shall be satisfied in cash and (ii) pursuant to a cashless exercise procedure, then any Tax-Related Items shall be satisfied by the  disposition of shares pursuant to such cashless exercise (with such withholding obligations determined based on the applicable statutory withholding rates). </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Registration and Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Option shall not be exercisable unless at the time of exercise there is in effect a current registration statement or amendment thereto under the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Securities Act of 1933, as amended, covering the shares of Common Stock to be issued upon exercise of the Option and such shares are authorized for listing on the New York Stock Exchange or another securities exchange as determined by the Corporation. Nothing herein shall be deemed to require the Corporation to apply for, to effect or to obtain such registration or listing.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Compensation Recoupment Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You hereby acknowledge and agree that you and the Option, including any shares of Common Stock that may be delivered to you pursuant to this Option, are subject to the Corporation&#8217;s Compensation Recoupment Policy, as may be amended and&#47;or restated from time to time, a current copy of which can be found on the Corporation&#8217;s website at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">http&#58;&#47;&#47;www.investor.jnj.com&#47;gov&#47;compensation-recoupment-policy.cfm</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The terms and conditions of the Compensation Recoupment Policy hereby are incorporated by reference into this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Nontransferability of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Option is exercisable during your lifetime only by you, and no rights granted hereunder may be sold, transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise), other than by will or the laws of descent and distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or in accordance with any beneficiary designation procedures that may be established by the Corporation. Nor shall any such rights be subject to execution, attachment or similar process, other than in accordance with the terms of the Plan. Upon any attempt to sell, transfer, assign, pledge, hypothecate or otherwise dispose of the Option or of such rights contrary to the provisions of the Plan or this Agreement, or upon the levy of any attachment or similar process upon the Option or such rights, the Option and such rights shall, at the election of the Corporation, be forfeited for no consideration.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">No Special Employment Rights&#59; No Rights to Awards</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing contained in the Plan or this Agreement shall be construed or deemed by any person under any circumstances to bind any member of the Corporation Group to continue your employment for the period within which the Option may be exercised or for any other period, to create a right to employment with the Corporation, to form or amend an employment or service contract with the Corporation or to interfere in any way with any right of a member of the Corporation Group to terminate your employment at any time. You hereby acknowledge and agree that (i) the Plan is established voluntarily by the Corporation, is discretionary in nature and may be modified, amended, or terminated by the Corporation at any time, as provided in the Plan, (ii) your participation in the Plan is voluntary and you are voluntarily accepting the Option grant, (iii) the Option and shares of Common Stock subject to the Option, and the income and value of same, do not constitute part of your normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination indemnities, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement benefits or welfare benefits or similar payments, and in no event should be considered as compensation for, or in any way relating to, past services to the Corporation Group, (iv) the Option and shares of Common Stock subject to the Option, and the income and value of same, are not intended to replace any pension rights or compensation, (v) the grant of the Option is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted in the past, (vi) unless otherwise agreed with the Corporation, the Option and the shares of Common Stock subject to the Option, and the income and value of same, are not granted as consideration, or in connection with, the service you may provide as a director of a subsidiary of the Corporation, (vii) the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty, (viii) if the underlying shares of Common Stock do not increase in value, the Option will have no value, (ix) if you exercise the Option and acquire shares of Common Stock, the value of such shares of Common Stock may increase or decrease in value, even below the purchase price (x) no claim or entitlement to compensation or damages shall arise from forfeiture or recoupment of the Option resulting from the termination of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">your Employment or other service relationship (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where you are employed or the terms of your employment agreement, if any), (xi) you shall seek all necessary approvals under, make all required notifications under, and comply with all laws, rules, and regulations applicable to the ownership of the Option and, if applicable, shares of Common Stock, including currency and exchange laws, rules, and regulations, (xii) neither the Corporation nor any of its subsidiaries or affiliates shall be liable for any foreign exchange rate fluctuation between your local currency and the U.S. dollar that may affect the value of the Option or of any amounts due to you upon exercise of the Option or the subsequent sale of any shares of Common Stock acquired upon exercise, (xiii) the determination of the form of awards granted under the Plan is made by the Committee in its sole discretion, and (xiv) the Corporation is not providing any tax, legal, or financial advice, nor is the Corporation making any recommendations regarding your participation in the Plan, or your acquisition or sale of the underlying shares of Common Stock and you should consult your own personal tax, legal and financial advisors regarding your participation in the Plan before taking any action related to the Option.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Unless the Corporation notifies you otherwise in writing, all notices, designations, and payments to be submitted to the Corporation in connection with the Option shall be addressed to&#58;</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Equity Compensation Resources <br>One Johnson &#38; Johnson Plaza <br>New Brunswick, NJ 08933<br>USA</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The following capitalized terms shall have the definitions set forth below for purposes of this Agreement&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means (i) your conviction for or a plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the commission of a felony under federal or state law, or (ii) any act by you that, in the Corporation&#8217;s opinion, constitutes fraud, embezzlement, dishonesty, disclosure of confidential information, the willful and deliberate failure to perform your employment duties in any material respect, a conflict of interest, a violation of the non-competition obligations set forth in Section 2(b)(i) of this Agreement or any other applicable non-competition, non-solicitation, or confidentiality agreement or obligation that you have with any member of the Corporation Group, a violation of any standards of conduct policies or other policies of the Corporation Group to which you are subject, or any other event that is inimical or contrary to the best interests of the Corporation Group. Any determination of &#8220;Cause&#8221; shall be made by the Corporation in its sole discretion, and its determination shall be final and binding.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Compensation &#38; Benefits Committee of the Board of Directors of the Corporation (or any successor committee), or any person or persons to whom the Committee has delegated authority to administer, construe or interpret the terms of the Plan, pursuant to Section 3(d) of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any person or entity including, but not limited to, you or anyone acting on your behalf, that&#160;is engaged or preparing to be engaged in research, development, production, manufacturing, marketing or selling of, or consulting on, any product, process, technology, machine, invention or service in existence or under development that resembles, competes with, may now or in the future compete with, can be substituted for or can be marketed as a substitute for  any product, process, technology, machine, invention, or service of the Corporation Group that is in existence or that is, was, or is planned to be under </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">development. The Corporation shall determine whether any individual or entity is a &#8220;Competitor&#8221; in its sole discretion, and its determination shall be final.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Competitive Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any and all activities (including preparations) which compete with, are intended to compete with, or which otherwise may adversely affect or interfere with the Corporation Group&#8217;s business or advantage a Competitor whether immediately or in the future. The Corporation shall determine whether any conduct constitutes &#8220;Competitive Activities&#8221; in its sole discretion, and its determination shall be final.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Corporation Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Corporation and its subsidiaries and affiliates, as determined by the Corporation.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Customer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any entity, client, account, or person, including the employees, agents, or representatives of the foregoing, or any entity or person who participates, influences or has any responsibility in making purchasing decisions on behalf of such entities, clients, accounts, or persons, to whom or to which you contacted, solicited any business from, sold to, rendered any service to, were assigned to, had responsibilities for, received commissions or any compensation on, or promoted or marketed any products or services to during the eighteen (18) month period of time preceding your Date of Termination. The Corporation shall determine whether any individual or entity is a &#8220;Customer&#8221; in its sole discretion, and its determination shall be final. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date on which your Employment terminates. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disabled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means that you have been determined to be unable to work because of a disability (i) that lasts for a period in excess of twenty-six (26) weeks and (ii) (A) that entitles you to long-term disability benefits under the long-term disability policy of the Corporation or its applicable affiliate under which you are covered, or (B) if there is no such policy, that you have been determined to be &#8220;disabled&#8221; (or of similar status) by the Corporation (or its applicable affiliate) in accordance with applicable procedures and policies. Notwithstanding the foregoing, (I) you will not be considered to have incurred a Disability unless you are identified as &#8220;disabled&#8221; (or of similar status) in accordance with the personnel and&#47;or human resources policies of the Corporation or its applicable affiliate, as in effect from time to time and (II) if the Option is subject to Section 409A (as determined by the Corporation), then you will not be considered to have incurred a Disability unless such condition also constitutes a &#8220;disability&#8221; within the meaning of Treasury Regulation Section 1.409A-3(i)(4).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any period of time during which you are an employee of the Corporation Group in good standing, as determined by the Corporation Group in accordance with its applicable practices, policies and records&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, during such period you are (i) in active employment status with the Corporation Group or (ii) on a Corporation Group-approved leave of absence (as determined by the Corporation Group in its sole discretion). For the avoidance of doubt, you shall not be considered to be Employed (x) for any period during which you are not considered to be an employee in good standing pursuant to the Corporation Group&#8217;s practices, policies and records, (y) during any notice period or salary continuation period required by contract, practice or local law (such as a &#8220;garden leave&#8221; or similar period) or any severance period (if you are covered by a severance agreement or arrangement) or (z) for any period of leave that is not approved by the Corporation Group (as determined by the Corporation Group in its sole discretion).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the tenth anniversary of the Grant Date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date on which the Option is granted, as identified on the first page of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means Employment with the Corporation or one of its subsidiaries or affiliates, while that corporation or other legal entity was a subsidiary or affiliate of the Corporation, unless the Corporation has otherwise provided on or before the Grant Date.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the earliest of (to the extent applicable)&#58; (i) the applicable Scheduled Vesting Date&#59; or (ii) the date of death, in the event of a termination of Employment pursuant to Section&#160;3(b) (Termination Due to Death) or a death described in Section 3(e) (Death Following Qualifying Separation)&#59; or (iii) the date you become Disabled, in the event of a Disability described in Section 3(c) (Disability)&#59; or (iv) the date the Option (or any portion thereof) vests and becomes exercisable pursuant any applicable provision of the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as provided herein, this Agreement may not be amended or otherwise modified unless evidenced in writing and signed by an authorized representative of the Corporation. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge and agree that all affiliates and subsidiaries of the Corporation have, or will as the result of a future acquisition, merger, assignment, or otherwise have, an interest in your Employment and your compliance with the obligations in Section 2(b) (Competition with the Corporation Group), and that those entities are each express, third-party beneficiaries of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, executors, administrators, successors and assigns.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that Section 2(b) (Competition with the Corporation Group) of this Agreement is invalidated or not enforced under applicable law, this shall not affect the validity or enforceability of the remaining provisions of this Agreement or the Plan. To the extent that Section 2(b) of this Agreement is unenforceable because it is deemed overbroad, the provision shall be applied and enforced in a more limited manner to the fullest extent permissible under the applicable law. You further understand and agree that, in the event Section 2(b) of this Agreement is declared invalid, void, overbroad, or unenforceable, in whole or in part, for any reason, you shall remain bound by any non-competition, confidentiality, non-solicitation, and&#47;or non-disclosure agreement previously entered between you and any member of the Corporation Group. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.7pt">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding any provisions in this Agreement, the Option shall be subject to any additional terms and conditions set forth in Appendix A for your country. Moreover, if you relocate to one of the countries included in Appendix A, the additional terms and conditions for such country will apply to you, to the extent the Corporation determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons. Appendix A constitutes part of this Agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:24.03pt">Data Privacy Consent. By accepting this grant, you hereby unconditionally consent to the collection, use and transfer, in electronic or other form, of your personal data as described in this document by and among, as applicable, your employing entity (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;) and the Corporation and the Corporation Group for the exclusive purpose of implementing, administering and managing any awards issued to you under the Plan. You understand that the Corporation and your Employer may hold certain personal </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">information about you, including, but not limited to, your name, home address, email address, telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, details of all Options or any other entitlement to shares of stock awarded, canceled, vested, unvested or outstanding in your favor (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">&#8221;), for the purpose of implementing, administering and managing any grants issued to you under the Plan. You understand that Data may be transferred to any third parties, as may be selected by the Corporation, which are assisting in the implementation, administration and management of the Plan and the fulfillment of this Agreement. You understand that the  recipients of the Data may be located in the United States or elsewhere, and that the recipients&#8217; country may have different data privacy laws and protections from your country. You understand that if you reside outside of the United States, you may request a list with the names and addresses of any potential recipients of the Data by contacting your local human resources representative. You authorize the recipients, which may assist the Corporation (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing grants under the Plan and the fulfillment of this Agreement. You understand the Data will be held only as long as is necessary to implement, administer and manage grants under the Plan and this Agreement. You understand that if you reside outside of the United States, you may, at any time, view Data, request information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing your human resources representative. Further, you understand that your consent herein is being provided on a purely voluntary basis. If you do not consent, or if you later seek to revoke your consent, your Employment status or Service will not be affected&#59; the only consequence of refusing or withdrawing your consent is that the Corporation may not be able to grant options or other equity awards to you or administer or maintain such awards. Therefore, you understand that refusing or withdrawing your consent may affect your ability to participate in the Plan. For more information on the consequences of your refusal to consent or withdrawal of consent, you understand that you may contact your local human resources representative. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement and the Plan constitute the entire agreement between the parties relating to the subject matter hereof, and any previous agreement or understanding between the parties with respect thereto is superseded by this Agreement and the Plan.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The intent of the parties is that payments and benefits under this Agreement shall be exempt from or shall comply with Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance issued thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), to the extent subject thereto, and accordingly, to the maximum extent permitted, this Agreement shall be interpreted and administered to be in compliance therewith or exempt therefrom, as applicable. Notwithstanding anything to the contrary in the Plan or this Agreement, the Corporation reserves the right to revise this Agreement as it deems necessary or advisable, in its sole discretion and without your consent, to comply with Section&#160;409A or to otherwise avoid imposition of any additional tax or income recognition under Section&#160;409A. However, the Corporation makes no representation that the Option is not subject to Section&#160;409A nor makes any undertaking to preclude Section&#160;409A from applying to the Option. The Corporation shall not have any liability under the Plan or this Agreement for any taxes, penalties or interest due on amounts paid or payable pursuant to the Plan or this Agreement, including any taxes, penalties or interest imposed under Section&#160;409A. For purposes of the Plan and this Agreement, to the extent necessary to avoid accelerated taxation and&#47;or tax penalties under Section 409A, a termination of Employment shall not be deemed to have occurred for purposes of settlement of any portion of the Option unless such termination constitutes a &#8220;separation from service&#8221; within the meaning of Section&#160;409A and, for purposes of any such provision of this Agreement, references to a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;termination,&#8221; &#8220;termination of Employment&#8221; or similar terms shall mean &#8220;separation from service.&#8221; </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.69pt">Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. By electing to accept this Agreement, you acknowledge receipt of this Agreement and hereby confirm your understanding of the terms set forth in this Agreement. In the event of any conflict between the terms of the Plan and this Agreement, the terms of the Plan shall control. The Corporation may, in its sole discretion, decide to deliver any documents (including, without limitation, information required to be delivered to you pursuant to applicable securities laws) related to current or future participation in the Plan by electronic means. You hereby consent to receive such documents by electronic delivery and agree to participate in the Plan through an online or electronic system established and maintained by the Corporation or a third party designated by the Corporation. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.69pt">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge that you are proficient in the English language, or have consulted with an advisor who is proficient in the English language, so as to enable you to understand the provisions of this Agreement and the Plan. If you have received this Agreement or any other document related to the Plan translated into a language other than English, and the meaning of the translated version is different than the English version, the English version will control. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Corporation reserves the right to impose other requirements on your participation in the Plan, on the Option and on any shares of Common Stock acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or to facilitate the administration of the Plan, to make any corrections or adjustments that it deems necessary or appropriate, and to require you to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:24.69pt">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You acknowledge that a waiver by the Corporation of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by you or any other grantee.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:18.69pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement shall be governed by and construed in accordance with the laws of the State of New Jersey without giving effect to conflict of laws principles, except to the extent superseded by federal law and as set forth in this Section 9(m). Provided that you primarily resided and worked in California during and in connection with your employment with the Corporation Group and at the time that you accepted this Agreement and participation in the Plan, (i) this Agreement shall be governed by and construed in accordance with the laws of the State of California&#59; and (ii) Section 2(b)(ii) shall not apply with respect to services you render in California that do not involve your use or disclosure of the Corporation Group&#8217;s confidential or trade secret information.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#010000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%;padding-left:22.02pt">Submission to Jurisdiction&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Waiver of Jury Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Any litigation brought against a party to this Agreement shall be brought in any U.S. federal or state court located in the State of New Jersey and each of the parties submits to the exclusive jurisdiction of such courts for the purpose of any such litigation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, a final judgment in any such litigation shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other matter provided by law. Each party agrees not to assert (A) any objection which it may have to venue in U.S. federal or state court located in the State of New Jersey, (B) any claim that litigation has been brought in an inconvenient forum and (C) any claim that such court does not have jurisdiction with respect to such litigation. Each party waives any right to a trial by jury with respect to any matters arising under this Agreement or any other awards granted under the Plan. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:24pt;padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JOHNSON &#38; JOHNSON</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><img alt="image_01.jpg" src="image_01.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:206px"></div><div style="padding-left:220.5pt"><font><br></font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Carolyn Hoenisch</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Senior Finance Director</font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Savings Plan, Pension, Equity Compensation Operations </font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Johnson &#38; Johnson </font></div><div style="padding-left:144pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">One Johnson &#38; Johnson Plaza </font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New Brunswick, NJ 08933<br>USA </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>a20231qex311ceocertificati.htm
<DESCRIPTION>EX-31.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie313b920f0f049cebdecdb0505db3704_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joaquin Duato, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended April&#160;2, 2023 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#34;Company&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)  Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.  The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="padding-left:288pt"><font><br></font></div><div style="padding-left:288pt"><font><br></font></div><div style="padding-left:288pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Joaquin Duato</font></div><div style="padding-left:288pt"><font style="color:#7d7d7d;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">__________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joaquin Duato </font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;   April&#160;28, 2023</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>a20231qex312cfocertificati.htm
<DESCRIPTION>EX-31.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3de3c50a25d4449ebb624a5ca806c58a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph J. Wolk, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended April&#160;2, 2023 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#34;Company&#34;)&#59; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The Company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the Company and have&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)  Evaluated the effectiveness of the Company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)  Disclosed in this report any change in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter (the Company's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5.  The Company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company's auditors and the audit committee of the Company's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's internal control over financial reporting.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Joseph J. Wolk</font></div><div style="padding-left:252pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">______________________________</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joseph J. Wolk</font></div><div style="padding-left:252pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; April&#160;28, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>a20231qex321ceocertificati.htm
<DESCRIPTION>EX-32.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i56a5ae80ef754d799781a1ea11f67328_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-right:38.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 32.1</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:18pt;padding-left:19.12pt;padding-right:19.12pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned, Joaquin Duato, the Chief Executive Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:11pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company's Quarterly Report on Form 10-Q for the quarterly period ended April&#160;2, 2023 (the&#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joaquin Duato</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;padding-right:38.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58;  April&#160;28, 2023</font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification is being furnished to the SEC with this Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.</font></div><div style="margin-top:11.25pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>a20231qex322cfocertificati.htm
<DESCRIPTION>EX-32.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9701d41dea844592941c248ae9b1fc94_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;padding-right:38.25pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 32.2</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:18pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.327%"><tr><td style="width:1.0%"></td><td style="width:2.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.664%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Company's Quarterly Report on Form 10-Q for the quarterly period ended April&#160;2, 2023 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="21" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph J. Wolk</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:1pt;padding-left:22.5pt;padding-right:38.25pt;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;Dated&#58;  April&#160;28, 2023</font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-indent:-20.25pt"><font><br></font></div><div style="margin-top:6pt;padding-left:22.5pt;padding-right:38.25pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This certification is being furnished to the SEC with this Report pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.</font></div><div style="margin-top:11.25pt;padding-left:30.37pt;padding-right:30.37pt;text-align:center;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>jnj-20230402.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:58e186d7-ec31-41bf-b939-580d103359b5,g:2048fc28-099b-4a2a-a431-d29d26f24517-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20230402" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.jnj.com/20230402">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20230402_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20230402_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20230402_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20230402_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.jnj.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEarnings" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings">
        <link:definition>0000004 - Statement - Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000005 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>0000008 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000009 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.jnj.com/role/Inventories">
        <link:definition>0000011 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill">
        <link:definition>0000012 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.jnj.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.jnj.com/role/IncomeTaxes">
        <link:definition>0000014 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlans" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans">
        <link:definition>0000015 - Disclosure - Pensions and Other Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncome" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome">
        <link:definition>0000016 - Disclosure - Accumulated Other Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.jnj.com/role/EarningsPerShare">
        <link:definition>0000017 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreas" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas">
        <link:definition>0000018 - Disclosure - Segments of Business and Geographic Areas</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures">
        <link:definition>0000019 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.jnj.com/role/LegalProceedings">
        <link:definition>0000020 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.jnj.com/role/InventoriesTables">
        <link:definition>0000022 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>0000023 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.jnj.com/role/FairValueMeasurementsTables">
        <link:definition>0000024 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansTables" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables">
        <link:definition>0000025 - Disclosure - Pensions and Other Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeTables" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables">
        <link:definition>0000026 - Disclosure - Accumulated Other Comprehensive Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.jnj.com/role/EarningsPerShareTables">
        <link:definition>0000027 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasTables" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables">
        <link:definition>0000028 - Disclosure - Segments of Business and Geographic Areas (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesTables" roleURI="http://www.jnj.com/role/CommitmentandContingenciesTables">
        <link:definition>0000029 - Disclosure - Commitment and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000030 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.jnj.com/role/InventoriesDetails">
        <link:definition>0000031 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>0000032 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillGoodwillBySegmentDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails">
        <link:definition>0000033 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>0000034 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails">
        <link:definition>0000035 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>0000036 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofDerivativeActivityDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails">
        <link:definition>0000037 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDerivativesBalanceSheetLocationDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails">
        <link:definition>0000038 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
        <link:definition>0000039 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
        <link:definition>0000040 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
        <link:definition>0000041 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
        <link:definition>0000042 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails">
        <link:definition>0000043 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails">
        <link:definition>0000044 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails">
        <link:definition>0000045 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.jnj.com/role/IncomeTaxesDetails">
        <link:definition>0000046 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>0000047 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails">
        <link:definition>0000048 - Disclosure - Pensions and Other Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeDetails" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails">
        <link:definition>0000049 - Disclosure - Accumulated Other Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.jnj.com/role/EarningsPerShareDetails">
        <link:definition>0000050 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails">
        <link:definition>0000051 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails">
        <link:definition>0000052 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
        <link:definition>0000053 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresNarrativeDetails" roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails">
        <link:definition>0000054 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails">
        <link:definition>0000055 - Disclosure - Business Combinations and Divestitures - Schedule of Pro Forma Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsDetails" roleURI="http://www.jnj.com/role/LegalProceedingsDetails">
        <link:definition>0000056 - Disclosure - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jnj_WesternHemisphereExcludingUSMember" abstract="true" name="WesternHemisphereExcludingUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_MedicalDevicesMember" abstract="true" name="MedicalDevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EthiconMember" abstract="true" name="EthiconMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A0.650NotesDue2024Member" abstract="true" name="A0.650NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_HIPSMember" abstract="true" name="HIPSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BermekimabMember" abstract="true" name="BermekimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A550DebentureDue2025Member" abstract="true" name="A550DebentureDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InterestIncomeExpenseNetMember" abstract="true" name="InterestIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A1300NotesDue2030Member" abstract="true" name="A1300NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SPINEOTHERMember" abstract="true" name="SPINEOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_Restructuringchargepercenttosales" abstract="false" name="Restructuringchargepercenttosales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ImpellaMember" abstract="true" name="ImpellaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="jnj_CostOfGoodsSoldPercentToSales" abstract="false" name="CostOfGoodsSoldPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A5.85Debenturesdue2038Member" abstract="true" name="A5.85Debenturesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SellingGeneralAndAdministrativeExpensePercentToSales" abstract="false" name="SellingGeneralAndAdministrativeExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_VisionMember" abstract="true" name="VisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BusinessCombinationProbabilityOfSuccessFactor" abstract="false" name="BusinessCombinationProbabilityOfSuccessFactor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_NetIncomeAttributableToParentPercentToSales" abstract="false" name="NetIncomeAttributableToParentPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A4.95Debenturesdue2033Member" abstract="true" name="A4.95Debenturesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SimponiSimponiAriaMember" abstract="true" name="SimponiSimponiAriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ElectrophysiologyMember" abstract="true" name="ElectrophysiologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A510DebentureDue2043Member" abstract="true" name="A510DebentureDue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyReserveEstablishedWithinTrustTotal" abstract="false" name="LossContingencyReserveEstablishedWithinTrustTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BabyPowderMember" abstract="true" name="BabyPowderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CONCERTAMethylphenidateMember" abstract="true" name="CONCERTAMethylphenidateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.45Notesdue2026Member" abstract="true" name="A2.45Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.55Notesdue2036Member" abstract="true" name="A3.55Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesBySegmentOfBusiness" abstract="false" name="PercentageChangeInSalesBySegmentOfBusiness" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_UPTRAVIMember" abstract="true" name="UPTRAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A535DebentureDue2026Member" abstract="true" name="A535DebentureDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A500DebentureDue2030Member" abstract="true" name="A500DebentureDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InghamVsJohnsonJohnsonMember" abstract="true" name="InghamVsJohnsonJohnsonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithoutReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SurgicalMeshProductsMarketingMember" abstract="true" name="SurgicalMeshProductsMarketingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A5.95Notesdue2037Member" abstract="true" name="A5.95Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" abstract="false" name="SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_OtherInfectiousDiseasesMember" abstract="true" name="OtherInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ElmironMember" abstract="true" name="ElmironMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyAdditionalContribution" abstract="false" name="LossContingencyAdditionalContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A3.70Notesdue2046Member" abstract="true" name="A3.70Notesdue2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CardiovascularMetabolismOtherMember" abstract="true" name="CardiovascularMetabolismOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_DARZALEXMember" abstract="true" name="DARZALEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_KNEESMember" abstract="true" name="KNEESMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OPSUMITMember" abstract="true" name="OPSUMITMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInOperatingIncomeLoss" abstract="false" name="PercentageChangeInOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_InfectiousDiseasesMember" abstract="true" name="InfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SPRAVATOMember" abstract="true" name="SPRAVATOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" abstract="false" name="IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_LegalProceedingTextualsAbstract" abstract="true" name="LegalProceedingTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_PelvicMeshesMember" abstract="false" name="PelvicMeshesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A210NotesDue2040Member" abstract="true" name="A210NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A6.95Notesdue2029Member" abstract="true" name="A6.95Notesdue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NonTradeableContingentValueRightMember" abstract="true" name="NonTradeableContingentValueRightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyRemainingTerm" abstract="false" name="LossContingencyRemainingTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_ClassIRecommendationForImpellaMember" abstract="true" name="ClassIRecommendationForImpellaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.50Notesdue2043Member" abstract="true" name="A4.50Notesdue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.625Notesdue2037Member" abstract="true" name="A3.625Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OTHERNEUROSCIENCEMember" abstract="true" name="OTHERNEUROSCIENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" abstract="false" name="LossContingencyNumberOfClaimsWithinSettlementAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_WomensHealthMember" abstract="true" name="WomensHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.375Notesdue2033Member" abstract="true" name="A4.375Notesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TRAUMAMember" abstract="true" name="TRAUMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InvestmentIncomeInterestPercentToSales" abstract="false" name="InvestmentIncomeInterestPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesByGeographicArea" abstract="false" name="PercentageChangeInSalesByGeographicArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ADVANCEDMember" abstract="true" name="ADVANCEDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BankruptcyLossContingencyDiscountRate" abstract="false" name="BankruptcyLossContingencyDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A2.900Notesdue2028Member" abstract="true" name="A2.900Notesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.400Notesdue2038Member" abstract="true" name="A3.400Notesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_SalesBySegmentOfBusinessTableTextBlock" abstract="false" name="SalesBySegmentOfBusinessTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_AsrMember" abstract="false" name="AsrMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A1.650NotesDue2035Member" abstract="true" name="A1.650NotesDue2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.625Notesdue2025Member" abstract="true" name="A2.625Notesdue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AbiomedMember" abstract="true" name="AbiomedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CONTACTLENSESOTHERMember" abstract="true" name="CONTACTLENSESOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PhysiomeshMember" abstract="true" name="PhysiomeshMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.75Notesdue2047Member" abstract="true" name="A3.75Notesdue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OralCareMember" abstract="true" name="OralCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A505DebentureDue2028Member" abstract="true" name="A505DebentureDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConsumerMember" abstract="true" name="ConsumerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.95Notesdue2027Member" abstract="true" name="A2.95Notesdue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_GENERALMember" abstract="true" name="GENERALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.500Notesdue2048Member" abstract="true" name="A3.500Notesdue2048Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2450NotesDue2060Member" abstract="true" name="A2450NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EDURANTrilpivirineMember" abstract="true" name="EDURANTrilpivirineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" abstract="true" name="OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A0550NotesDue2025Member" abstract="true" name="A0550NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PulmonaryHypertensionMember" abstract="true" name="PulmonaryHypertensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SURGICALMember" abstract="true" name="SURGICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A1.150NotesDue2028Member" abstract="true" name="A1.150NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyReserveEstablishedWithinTrustNominalValue" abstract="false" name="LossContingencyReserveEstablishedWithinTrustNominalValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EquityInvestmentswithReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A095NotesDue2027Member" abstract="true" name="A095NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BusinessAcquisitionDiscountRate" abstract="false" name="BusinessAcquisitionDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ERLEADAMember" abstract="true" name="ERLEADAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentRollForward" abstract="true" name="EquityInvestmentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_LossContingencyTerm" abstract="false" name="LossContingencyTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock" abstract="false" name="SummaryOfClaimsInPendingLawsuitsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_SupplierFinanceProgramObligationCurrent" abstract="false" name="SupplierFinanceProgramObligationCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_WoundCareandOtherMember" abstract="true" name="WoundCareandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" abstract="false" name="ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" abstract="true" name="PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" abstract="false" name="EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_LossContingencyPendingClaimsNumberAdditional" abstract="false" name="LossContingencyPendingClaimsNumberAdditional" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_PatentsAndTrademarksMember" abstract="true" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AccountingStandardsUpdate202204Member" abstract="true" name="AccountingStandardsUpdate202204Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" abstract="false" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PinnacleAcetabularCupSystemMember" abstract="false" name="PinnacleAcetabularCupSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_GrossProfitPercentToSales" abstract="false" name="GrossProfitPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_RestrictedCashMember" abstract="true" name="RestrictedCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PurchasedInProcessResearchAndDevelopmentMember" abstract="true" name="PurchasedInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OpioidMember" abstract="true" name="OpioidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_IMBRUVICAMember" abstract="true" name="IMBRUVICAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DePuyASRU.S.Member" abstract="true" name="DePuyASRU.S.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ResearchAndDevelopmentInProcessPercentToSales" abstract="false" name="ResearchAndDevelopmentInProcessPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A490DebentureDue2033Member" abstract="true" name="A490DebentureDue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherIncomeExpenseNetMember" abstract="true" name="OtherIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AsiaPacificAfricaMember" abstract="true" name="AsiaPacificAfricaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_UnrecognizedTaxBenefitLiabilityPayment" abstract="false" name="UnrecognizedTaxBenefitLiabilityPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A4.50Debenturesdue2040Member" abstract="true" name="A4.50Debenturesdue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2250NotesDue2050Member" abstract="true" name="A2250NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InterventionalSolutionsMember" abstract="true" name="InterventionalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherInterventionalSolutionsMember" abstract="true" name="OtherInterventionalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_UNITEDSTATESExportsMember" abstract="true" name="UNITEDSTATESExportsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OTCMember" abstract="true" name="OTCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" abstract="true" name="INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_StelaraMember" abstract="true" name="StelaraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TalcMember" abstract="true" name="TalcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A520DebentureDue2063Member" abstract="true" name="A520DebentureDue2063Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_InterestExpensePercentToSales" abstract="false" name="InterestExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_BabyCareMember" abstract="true" name="BabyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RevenuesContingentConsideration" abstract="false" name="RevenuesContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CARVYKTIMember" abstract="true" name="CARVYKTIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.85Notesdue2041Member" abstract="true" name="A4.85Notesdue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BeautyMember" abstract="true" name="BeautyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherNonOperatingIncomeExpensePercentToSales" abstract="false" name="OtherNonOperatingIncomeExpensePercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ExcessOfCarryingValueOverFairValueOfDebt" abstract="false" name="ExcessOfCarryingValueOverFairValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_RisperdalMember" abstract="true" name="RisperdalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OrthopaedicsMember" abstract="true" name="OrthopaedicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyReserveEstablishedWithinTrust" abstract="false" name="LossContingencyReserveEstablishedWithinTrust" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A5.50NotesDue2024Member" abstract="true" name="A5.50NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A505DebentureDue2053Member" abstract="true" name="A505DebentureDue2053Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_XareltoMember" abstract="true" name="XareltoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SalesRevenueGoodsNetPercentToSales" abstract="false" name="SalesRevenueGoodsNetPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_AccruedRebatesReturnsAndPromotions" abstract="false" name="AccruedRebatesReturnsAndPromotions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SurgeryMember" abstract="true" name="SurgeryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NotesDuePeriodFifteenMember" abstract="true" name="NotesDuePeriodFifteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AccruedTaxesOnIncomeMember" abstract="true" name="AccruedTaxesOnIncomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AurisHealthMember" abstract="true" name="AurisHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ZYTIGAMember" abstract="true" name="ZYTIGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProductLiabilityContingencyNumberOfClaimant" abstract="false" name="ProductLiabilityContingencyNumberOfClaimant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_LossContingencyPendingClaimsNumberRemaining" abstract="false" name="LossContingencyPendingClaimsNumberRemaining" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_Numberofpatientsinsettlement" abstract="false" name="Numberofpatientsinsettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_IncomeTaxExpenseBenefitPercentToSales" abstract="false" name="IncomeTaxExpenseBenefitPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_TylenolMember" abstract="true" name="TylenolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>jnj-20230402_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:58e186d7-ec31-41bf-b939-580d103359b5,g:2048fc28-099b-4a2a-a431-d29d26f24517-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_028a40a4-f7e5-4cfb-858f-4fc949985557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_38031310-4089-4df8-a509-08bd0aaa2e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_028a40a4-f7e5-4cfb-858f-4fc949985557" xlink:to="loc_us-gaap_AssetsCurrent_38031310-4089-4df8-a509-08bd0aaa2e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_470535d6-d9fa-40a4-b51b-fc31f585c44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_028a40a4-f7e5-4cfb-858f-4fc949985557" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_470535d6-d9fa-40a4-b51b-fc31f585c44f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2c17f7b0-605b-417b-80fb-b923b8effcf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_028a40a4-f7e5-4cfb-858f-4fc949985557" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2c17f7b0-605b-417b-80fb-b923b8effcf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3d5a4a79-e1b8-4831-8ff1-5503f1cf9c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_028a40a4-f7e5-4cfb-858f-4fc949985557" xlink:to="loc_us-gaap_Goodwill_3d5a4a79-e1b8-4831-8ff1-5503f1cf9c0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_9e2cddac-5f6e-47e7-bd3b-00505c64352e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_028a40a4-f7e5-4cfb-858f-4fc949985557" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_9e2cddac-5f6e-47e7-bd3b-00505c64352e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4e072e79-76d5-4f32-b52a-8d9a4fb47dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_028a40a4-f7e5-4cfb-858f-4fc949985557" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4e072e79-76d5-4f32-b52a-8d9a4fb47dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa61d27b-8146-44bd-acc7-43c258b853e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6ea5d29b-63a7-417a-b2c5-44f0fc606f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa61d27b-8146-44bd-acc7-43c258b853e1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6ea5d29b-63a7-417a-b2c5-44f0fc606f5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f2f80eb8-b237-40e0-9aac-34d7b984c223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa61d27b-8146-44bd-acc7-43c258b853e1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f2f80eb8-b237-40e0-9aac-34d7b984c223" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_488a02e5-7b34-4a8f-a06a-126c003bf02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa61d27b-8146-44bd-acc7-43c258b853e1" xlink:to="loc_us-gaap_CommonStockValue_488a02e5-7b34-4a8f-a06a-126c003bf02a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_d0b9c093-2287-47d5-bcdf-516af0f2be95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fa61d27b-8146-44bd-acc7-43c258b853e1" xlink:to="loc_us-gaap_TreasuryStockCommonValue_d0b9c093-2287-47d5-bcdf-516af0f2be95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9bf450b2-2bc5-4e1f-94c3-4152a3477f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c1fbe7d6-ba37-4888-a521-93a29379b06f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9bf450b2-2bc5-4e1f-94c3-4152a3477f08" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c1fbe7d6-ba37-4888-a521-93a29379b06f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_1de9a4b0-26ca-4e79-93dd-c49a7d5c31ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9bf450b2-2bc5-4e1f-94c3-4152a3477f08" xlink:to="loc_us-gaap_RestrictedCash_1de9a4b0-26ca-4e79-93dd-c49a7d5c31ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_3ba021ed-527b-4c3b-988a-a2dc52815581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9bf450b2-2bc5-4e1f-94c3-4152a3477f08" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_3ba021ed-527b-4c3b-988a-a2dc52815581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9ad6aff1-f839-478f-8b56-dcd0ada4b5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9bf450b2-2bc5-4e1f-94c3-4152a3477f08" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9ad6aff1-f839-478f-8b56-dcd0ada4b5e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_67bc62e5-f45f-44f4-9ee8-d937e47b81ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9bf450b2-2bc5-4e1f-94c3-4152a3477f08" xlink:to="loc_us-gaap_InventoryNet_67bc62e5-f45f-44f4-9ee8-d937e47b81ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1949202f-a04d-4ea6-8eea-863ba76545c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9bf450b2-2bc5-4e1f-94c3-4152a3477f08" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1949202f-a04d-4ea6-8eea-863ba76545c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7a7e0162-439a-4fa5-af30-59bcc08b85b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_87c24281-901b-49bb-955a-40e5f771f6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7a7e0162-439a-4fa5-af30-59bcc08b85b3" xlink:to="loc_us-gaap_Liabilities_87c24281-901b-49bb-955a-40e5f771f6a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_89cc6229-ca48-4e1f-aa65-493306fd9605" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7a7e0162-439a-4fa5-af30-59bcc08b85b3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_89cc6229-ca48-4e1f-aa65-493306fd9605" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8b33dc4d-3870-4c0e-9516-3d1c24c01d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7a7e0162-439a-4fa5-af30-59bcc08b85b3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8b33dc4d-3870-4c0e-9516-3d1c24c01d29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_77d0ca1c-2a03-4eab-8343-ed72f38dd038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_157921de-ba7e-42eb-922c-f6d68335d64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77d0ca1c-2a03-4eab-8343-ed72f38dd038" xlink:to="loc_us-gaap_LiabilitiesCurrent_157921de-ba7e-42eb-922c-f6d68335d64e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_34251ea2-d868-411a-a1c7-51f2d51ace23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77d0ca1c-2a03-4eab-8343-ed72f38dd038" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_34251ea2-d868-411a-a1c7-51f2d51ace23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_70f83c40-fbf4-46be-8ad4-88ab124c6eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77d0ca1c-2a03-4eab-8343-ed72f38dd038" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_70f83c40-fbf4-46be-8ad4-88ab124c6eb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_01f56140-f114-4b1f-9fc4-ae7c01a30365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77d0ca1c-2a03-4eab-8343-ed72f38dd038" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_01f56140-f114-4b1f-9fc4-ae7c01a30365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1c81d99b-89f2-41ec-8c67-e2afbe9809a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77d0ca1c-2a03-4eab-8343-ed72f38dd038" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_1c81d99b-89f2-41ec-8c67-e2afbe9809a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8b0f3d36-334e-4f7d-964d-643111881d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_77d0ca1c-2a03-4eab-8343-ed72f38dd038" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8b0f3d36-334e-4f7d-964d-643111881d17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_93d8e50a-79f6-4e09-93aa-a11ceca12395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_14616a09-c8a0-4c37-8029-ef4e9bc4fb71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_93d8e50a-79f6-4e09-93aa-a11ceca12395" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_14616a09-c8a0-4c37-8029-ef4e9bc4fb71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_57337a35-722d-4abe-b45b-9d1db6dd3b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_93d8e50a-79f6-4e09-93aa-a11ceca12395" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_57337a35-722d-4abe-b45b-9d1db6dd3b87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2fe7de45-aeb1-432b-b6fe-bcb56a42cd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_219b0c7d-81ea-4cb4-82ae-b9d74cc44a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2fe7de45-aeb1-432b-b6fe-bcb56a42cd4f" xlink:to="loc_us-gaap_ShortTermBorrowings_219b0c7d-81ea-4cb4-82ae-b9d74cc44a3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_78e19ad4-4e45-4a3c-b905-98b206f67e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2fe7de45-aeb1-432b-b6fe-bcb56a42cd4f" xlink:to="loc_us-gaap_AccountsPayableCurrent_78e19ad4-4e45-4a3c-b905-98b206f67e81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4dd8c893-59ef-4077-bbe2-f8bad52b97ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2fe7de45-aeb1-432b-b6fe-bcb56a42cd4f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4dd8c893-59ef-4077-bbe2-f8bad52b97ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_d8fee7f7-929d-458b-8515-9b0c9f04fa80" xlink:href="jnj-20230402.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2fe7de45-aeb1-432b-b6fe-bcb56a42cd4f" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_d8fee7f7-929d-458b-8515-9b0c9f04fa80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5f9f948-c840-443b-875c-b11a315705dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2fe7de45-aeb1-432b-b6fe-bcb56a42cd4f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e5f9f948-c840-443b-875c-b11a315705dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_b58711d5-b14d-42ab-970d-23bfa01c021e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2fe7de45-aeb1-432b-b6fe-bcb56a42cd4f" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_b58711d5-b14d-42ab-970d-23bfa01c021e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_fecfb7d5-5fa8-4f43-8c76-a998645ce6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ea612f5-6b37-44d6-aaaa-502ca45d1382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_fecfb7d5-5fa8-4f43-8c76-a998645ce6ad" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ea612f5-6b37-44d6-aaaa-502ca45d1382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_86fe1e9d-c5dd-402e-b0d2-966122361214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_fecfb7d5-5fa8-4f43-8c76-a998645ce6ad" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_86fe1e9d-c5dd-402e-b0d2-966122361214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_615548a8-66b1-46de-8f5d-3f865731698a" xlink:href="jnj-20230402.xsd#jnj_GrossProfitPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales_97e2d11b-eeee-487c-bcc8-6ea3497819ec" xlink:href="jnj-20230402.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_GrossProfitPercentToSales_615548a8-66b1-46de-8f5d-3f865731698a" xlink:to="loc_jnj_CostOfGoodsSoldPercentToSales_97e2d11b-eeee-487c-bcc8-6ea3497819ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales_1eb50f1f-7f82-48ad-9124-d4a04fa9a6c5" xlink:href="jnj-20230402.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_GrossProfitPercentToSales_615548a8-66b1-46de-8f5d-3f865731698a" xlink:to="loc_jnj_SalesRevenueGoodsNetPercentToSales_1eb50f1f-7f82-48ad-9124-d4a04fa9a6c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales_93a4f150-d4bb-49a6-b806-791bd02cbacc" xlink:href="jnj-20230402.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_cf8e3aa3-3ec2-45c8-bf66-eaf1aa9ced45" xlink:href="jnj-20230402.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales_93a4f150-d4bb-49a6-b806-791bd02cbacc" xlink:to="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_cf8e3aa3-3ec2-45c8-bf66-eaf1aa9ced45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_c2c08e06-a6d5-4cd5-a5b6-9d93aaf6d3a9" xlink:href="jnj-20230402.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales_93a4f150-d4bb-49a6-b806-791bd02cbacc" xlink:to="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_c2c08e06-a6d5-4cd5-a5b6-9d93aaf6d3a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_22412063-99b6-4f02-9bad-22129c1e25a6" xlink:href="jnj-20230402.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_0fb07088-fd79-4c42-9636-415cf152caf5" xlink:href="jnj-20230402.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_22412063-99b6-4f02-9bad-22129c1e25a6" xlink:to="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_0fb07088-fd79-4c42-9636-415cf152caf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_d3cafc10-b2a4-4dba-b831-a1174afd8f59" xlink:href="jnj-20230402.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_22412063-99b6-4f02-9bad-22129c1e25a6" xlink:to="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_d3cafc10-b2a4-4dba-b831-a1174afd8f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales_e12ace28-8893-424d-a053-7bf4e57c527f" xlink:href="jnj-20230402.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_22412063-99b6-4f02-9bad-22129c1e25a6" xlink:to="loc_jnj_InvestmentIncomeInterestPercentToSales_e12ace28-8893-424d-a053-7bf4e57c527f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_4a302096-4d05-4038-b137-a6c8ca1903a5" xlink:href="jnj-20230402.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_22412063-99b6-4f02-9bad-22129c1e25a6" xlink:to="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_4a302096-4d05-4038-b137-a6c8ca1903a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales_489b6428-b84a-4ef9-936b-61dae977cee9" xlink:href="jnj-20230402.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_22412063-99b6-4f02-9bad-22129c1e25a6" xlink:to="loc_jnj_Restructuringchargepercenttosales_489b6428-b84a-4ef9-936b-61dae977cee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales_8b81fcfd-2454-4328-ab0a-604e567bfe13" xlink:href="jnj-20230402.xsd#jnj_InterestExpensePercentToSales"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_22412063-99b6-4f02-9bad-22129c1e25a6" xlink:to="loc_jnj_InterestExpensePercentToSales_8b81fcfd-2454-4328-ab0a-604e567bfe13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_4d66d87b-abc0-4192-9708-4ca9fd13ef5a" xlink:href="jnj-20230402.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_22412063-99b6-4f02-9bad-22129c1e25a6" xlink:to="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_4d66d87b-abc0-4192-9708-4ca9fd13ef5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_08f89fd6-b2f9-4d9c-8f89-c88567b7e775" xlink:href="jnj-20230402.xsd#jnj_GrossProfitPercentToSales"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_22412063-99b6-4f02-9bad-22129c1e25a6" xlink:to="loc_jnj_GrossProfitPercentToSales_08f89fd6-b2f9-4d9c-8f89-c88567b7e775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_64be1586-87d6-4d65-974f-6c8ce73323f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_73a9a214-d1fa-4c4e-bd93-9617c98f5e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_64be1586-87d6-4d65-974f-6c8ce73323f3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_73a9a214-d1fa-4c4e-bd93-9617c98f5e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e48f2fa6-7d9d-4ef7-abf3-5521e81feb68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_64be1586-87d6-4d65-974f-6c8ce73323f3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e48f2fa6-7d9d-4ef7-abf3-5521e81feb68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e9781091-2131-481b-9861-9f4ab71bd14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e35ca337-5ba8-4073-b1d6-999f2f7f3ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e9781091-2131-481b-9861-9f4ab71bd14c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e35ca337-5ba8-4073-b1d6-999f2f7f3ed4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f802e09f-9477-4d5c-b98a-6de19381b172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e9781091-2131-481b-9861-9f4ab71bd14c" xlink:to="loc_us-gaap_GrossProfit_f802e09f-9477-4d5c-b98a-6de19381b172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_289e5398-f369-450b-88b0-9aec932ab508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e9781091-2131-481b-9861-9f4ab71bd14c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_289e5398-f369-450b-88b0-9aec932ab508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ed9772fc-df09-4968-8ef5-e8de90d018e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e9781091-2131-481b-9861-9f4ab71bd14c" xlink:to="loc_us-gaap_RestructuringCharges_ed9772fc-df09-4968-8ef5-e8de90d018e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0c4d9935-7cbc-4b28-85cc-03b193fae4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e9781091-2131-481b-9861-9f4ab71bd14c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0c4d9935-7cbc-4b28-85cc-03b193fae4c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_17c02632-3f16-4e78-9a97-b8874e3d799c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e9781091-2131-481b-9861-9f4ab71bd14c" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_17c02632-3f16-4e78-9a97-b8874e3d799c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_ec574fb1-3d78-4cf3-8606-5204ca8c8df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e9781091-2131-481b-9861-9f4ab71bd14c" xlink:to="loc_us-gaap_InterestExpense_ec574fb1-3d78-4cf3-8606-5204ca8c8df3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_69758c35-ab6f-464d-b9d1-bd35eeef9fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e9781091-2131-481b-9861-9f4ab71bd14c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_69758c35-ab6f-464d-b9d1-bd35eeef9fa3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ee66aa57-4f5e-42d8-add6-97142159c20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_990b7dd3-3be9-499d-8565-eb239db3585b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ee66aa57-4f5e-42d8-add6-97142159c20b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_990b7dd3-3be9-499d-8565-eb239db3585b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e2c80fc6-19e7-4c76-8921-1d4ca099d536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ee66aa57-4f5e-42d8-add6-97142159c20b" xlink:to="loc_us-gaap_NetIncomeLoss_e2c80fc6-19e7-4c76-8921-1d4ca099d536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d8bf48ae-6457-4789-a920-5d404c35ed84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_1df69506-c381-4e18-a0ea-a76c419281a9" xlink:href="jnj-20230402.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d8bf48ae-6457-4789-a920-5d404c35ed84" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_1df69506-c381-4e18-a0ea-a76c419281a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_464be863-f639-4cfb-a470-1e6e38c49f3f" xlink:href="jnj-20230402.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d8bf48ae-6457-4789-a920-5d404c35ed84" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_464be863-f639-4cfb-a470-1e6e38c49f3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_57399cd5-9c3e-4694-8c76-0a86113d231d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_f3b6894c-37d5-4620-aef6-13acc9e17a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_57399cd5-9c3e-4694-8c76-0a86113d231d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_f3b6894c-37d5-4620-aef6-13acc9e17a17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_0812f008-26c2-40e8-89e1-a40ddf763ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_57399cd5-9c3e-4694-8c76-0a86113d231d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_0812f008-26c2-40e8-89e1-a40ddf763ac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3f6306ce-1f61-456f-a143-358c44ae59c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b8eb14aa-718b-4ae2-8751-cd95e439921f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3f6306ce-1f61-456f-a143-358c44ae59c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b8eb14aa-718b-4ae2-8751-cd95e439921f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9e417c5d-31f1-4aec-812d-06818b46ca32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3f6306ce-1f61-456f-a143-358c44ae59c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9e417c5d-31f1-4aec-812d-06818b46ca32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_e69b8e2b-71bd-4582-8335-1390cf5b78c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3f6306ce-1f61-456f-a143-358c44ae59c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_e69b8e2b-71bd-4582-8335-1390cf5b78c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f9f35aa9-f147-4185-b703-3b4f9316c970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3f6306ce-1f61-456f-a143-358c44ae59c2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f9f35aa9-f147-4185-b703-3b4f9316c970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f93edc37-8441-4138-9bcd-e14d5fd54179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_256fd065-35de-47ba-882d-e50a5d652ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f93edc37-8441-4138-9bcd-e14d5fd54179" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_256fd065-35de-47ba-882d-e50a5d652ef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_33ffd4f3-bd42-47cc-b046-c37490a1ae4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f93edc37-8441-4138-9bcd-e14d5fd54179" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_33ffd4f3-bd42-47cc-b046-c37490a1ae4a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_87203fd0-9871-490f-a6bf-a6301aec31a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_ea666377-9fb8-45e1-b94e-9727b234ca83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_87203fd0-9871-490f-a6bf-a6301aec31a9" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_ea666377-9fb8-45e1-b94e-9727b234ca83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_54858b26-2e65-48e5-9d56-3dff2fe52f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_87203fd0-9871-490f-a6bf-a6301aec31a9" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_54858b26-2e65-48e5-9d56-3dff2fe52f6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2e4050d7-7815-4d1e-8681-acb2021681b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:to="loc_us-gaap_NetIncomeLoss_2e4050d7-7815-4d1e-8681-acb2021681b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_627b9c7a-5ba0-4300-af78-1555772165f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_627b9c7a-5ba0-4300-af78-1555772165f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_47d3aeeb-fdef-45ca-91f8-293871b126a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:to="loc_us-gaap_ShareBasedCompensation_47d3aeeb-fdef-45ca-91f8-293871b126a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6927ae5a-051f-4ab4-8f69-89e062a8da30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:to="loc_us-gaap_AssetImpairmentCharges_6927ae5a-051f-4ab4-8f69-89e062a8da30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_857171be-5aab-4964-8306-644b564e291b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_857171be-5aab-4964-8306-644b564e291b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_438f1441-060e-4683-9100-51ccad00da0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_438f1441-060e-4683-9100-51ccad00da0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_c654956e-753f-4bb7-b83d-669f3ffa8240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_c654956e-753f-4bb7-b83d-669f3ffa8240" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d8accd1c-1715-4043-bd77-b24c0a98ddbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d8accd1c-1715-4043-bd77-b24c0a98ddbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_171e80bc-825c-4c21-bba1-2f734bb2db46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_171e80bc-825c-4c21-bba1-2f734bb2db46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1e9343ad-e93e-44fa-8c17-e468e626f431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1e9343ad-e93e-44fa-8c17-e468e626f431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5c0f03a6-9d0f-41da-8ba4-e0d39792dcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5c0f03a6-9d0f-41da-8ba4-e0d39792dcd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1523d58b-a877-4fc0-a949-0f71c5df9162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a55b0de3-97d3-43c3-a83d-d9693615d4f8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1523d58b-a877-4fc0-a949-0f71c5df9162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7974966-44f4-4f9f-a8b2-f589dd3fa165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d496711c-89c5-4f10-a5f2-5c0a422ec60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7974966-44f4-4f9f-a8b2-f589dd3fa165" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_d496711c-89c5-4f10-a5f2-5c0a422ec60d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_503ecaee-c845-4ca3-98e4-ac958c8ce729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7974966-44f4-4f9f-a8b2-f589dd3fa165" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_503ecaee-c845-4ca3-98e4-ac958c8ce729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_492eec2d-dfa0-4ff2-ba29-8a95821ca4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7974966-44f4-4f9f-a8b2-f589dd3fa165" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_492eec2d-dfa0-4ff2-ba29-8a95821ca4c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_7b774a22-6730-4984-b0de-5e919616a955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7974966-44f4-4f9f-a8b2-f589dd3fa165" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_7b774a22-6730-4984-b0de-5e919616a955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_ce181131-bda1-49b5-afbf-420ce9cdb4bb" xlink:href="jnj-20230402.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7974966-44f4-4f9f-a8b2-f589dd3fa165" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_ce181131-bda1-49b5-afbf-420ce9cdb4bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d4c0facd-a4d0-4111-a15c-41cfe98b6f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7974966-44f4-4f9f-a8b2-f589dd3fa165" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d4c0facd-a4d0-4111-a15c-41cfe98b6f7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_17c15c6a-515e-4610-8536-ac5f619b250b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7974966-44f4-4f9f-a8b2-f589dd3fa165" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_17c15c6a-515e-4610-8536-ac5f619b250b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3375f43a-13e8-4da2-ae1b-4b38212939be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_5f59ba65-bec7-4411-b846-8da402452ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3375f43a-13e8-4da2-ae1b-4b38212939be" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_5f59ba65-bec7-4411-b846-8da402452ec5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f5d5c22d-645f-499a-8aa7-e877eee7d1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3375f43a-13e8-4da2-ae1b-4b38212939be" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f5d5c22d-645f-499a-8aa7-e877eee7d1f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_a01dd020-2306-4d47-9017-99b8732c4b4f" xlink:href="jnj-20230402.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3375f43a-13e8-4da2-ae1b-4b38212939be" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_a01dd020-2306-4d47-9017-99b8732c4b4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_12f3c54e-f124-4e95-8cd5-2a8c31ae9a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3375f43a-13e8-4da2-ae1b-4b38212939be" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_12f3c54e-f124-4e95-8cd5-2a8c31ae9a2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_ce75813b-82f1-41ce-8986-cc0e325ca43a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3375f43a-13e8-4da2-ae1b-4b38212939be" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_ce75813b-82f1-41ce-8986-cc0e325ca43a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_59b17dac-df8d-4e11-8ff7-95e76cff48e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3375f43a-13e8-4da2-ae1b-4b38212939be" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_59b17dac-df8d-4e11-8ff7-95e76cff48e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_3a315f75-6e7e-41f6-aad1-cc438a719fd0" xlink:href="jnj-20230402.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3375f43a-13e8-4da2-ae1b-4b38212939be" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_3a315f75-6e7e-41f6-aad1-cc438a719fd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ac891b09-7980-45ab-913b-2c32235facad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3375f43a-13e8-4da2-ae1b-4b38212939be" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_ac891b09-7980-45ab-913b-2c32235facad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3a494ee2-b9dc-4e88-8bed-6c061fe15f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3375f43a-13e8-4da2-ae1b-4b38212939be" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3a494ee2-b9dc-4e88-8bed-6c061fe15f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a1e8450-0eae-4a10-9300-a4bdff9a1b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_585ff20a-d1a3-4979-ae46-5f9e2e823b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a1e8450-0eae-4a10-9300-a4bdff9a1b0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_585ff20a-d1a3-4979-ae46-5f9e2e823b25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5732940c-f030-4310-8a3d-26c41950a66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a1e8450-0eae-4a10-9300-a4bdff9a1b0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5732940c-f030-4310-8a3d-26c41950a66d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dd477be8-2a27-47a8-b055-b77e5b84c58b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a1e8450-0eae-4a10-9300-a4bdff9a1b0b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dd477be8-2a27-47a8-b055-b77e5b84c58b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3b41b31-7f38-49d0-8ecf-3edfe59b9c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a1e8450-0eae-4a10-9300-a4bdff9a1b0b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d3b41b31-7f38-49d0-8ecf-3edfe59b9c39" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_dde28cae-dba2-4185-bddd-f70c0e1af1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_eacd4f33-8c09-43c3-8a2e-7d05ddde70a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_dde28cae-dba2-4185-bddd-f70c0e1af1a4" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_eacd4f33-8c09-43c3-8a2e-7d05ddde70a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_243880ee-a3bd-4616-85f7-78ea0936753e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_dde28cae-dba2-4185-bddd-f70c0e1af1a4" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_243880ee-a3bd-4616-85f7-78ea0936753e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4fb97b14-f0f4-48b4-9a83-0956e9fb7a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_dde28cae-dba2-4185-bddd-f70c0e1af1a4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_4fb97b14-f0f4-48b4-9a83-0956e9fb7a8c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ba530f6e-7269-4a32-9347-0a7700704f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a1889c56-6c7a-4f5c-abe5-e15ec01fba1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ba530f6e-7269-4a32-9347-0a7700704f11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_a1889c56-6c7a-4f5c-abe5-e15ec01fba1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_10a2bfb0-23db-4ba1-b046-0fd8be924575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ba530f6e-7269-4a32-9347-0a7700704f11" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_10a2bfb0-23db-4ba1-b046-0fd8be924575" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_a53d4a4a-2368-455f-ae27-62ec8d6c34f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_ad3ff632-7538-4554-8be2-356574dd9b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_a53d4a4a-2368-455f-ae27-62ec8d6c34f4" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_ad3ff632-7538-4554-8be2-356574dd9b80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_9ef3c9dd-bce8-45f6-86a2-e187401d8c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_a53d4a4a-2368-455f-ae27-62ec8d6c34f4" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_9ef3c9dd-bce8-45f6-86a2-e187401d8c60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_e51d6c36-9d57-4899-a2ab-cb0b399b634a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_a344c59c-0682-4b89-84d6-369047302c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_e51d6c36-9d57-4899-a2ab-cb0b399b634a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_a344c59c-0682-4b89-84d6-369047302c4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_71a715b3-2f0c-4839-bbb2-d287f3f93604" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_e51d6c36-9d57-4899-a2ab-cb0b399b634a" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_71a715b3-2f0c-4839-bbb2-d287f3f93604" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5d512f7e-d9af-4376-9c68-63825f190ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_321f84fe-7d72-4a18-bf24-e1a029cf600a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5d512f7e-d9af-4376-9c68-63825f190ffc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_321f84fe-7d72-4a18-bf24-e1a029cf600a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c5a4630-3b75-4a95-89d0-062902749df5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5d512f7e-d9af-4376-9c68-63825f190ffc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7c5a4630-3b75-4a95-89d0-062902749df5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_4dc780f5-2e24-4f41-9cb4-5f0dfc1771cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_2e2556f7-74fb-40f5-9839-9c64a785179b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_4dc780f5-2e24-4f41-9cb4-5f0dfc1771cc" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_2e2556f7-74fb-40f5-9839-9c64a785179b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_655b1158-3cc7-443f-9849-690fe80472a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_4dc780f5-2e24-4f41-9cb4-5f0dfc1771cc" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_655b1158-3cc7-443f-9849-690fe80472a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_a3d3a6e7-2cba-45e1-a6fb-05926022070b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_94e5a6a3-e0eb-4198-a6d3-caf00f5223ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_a3d3a6e7-2cba-45e1-a6fb-05926022070b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_94e5a6a3-e0eb-4198-a6d3-caf00f5223ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_9cedeac7-be5a-48a9-9fdc-50d7b89b45f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_a3d3a6e7-2cba-45e1-a6fb-05926022070b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_9cedeac7-be5a-48a9-9fdc-50d7b89b45f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_f338b2c4-5b13-4712-bb19-3c72b117f16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_a3d3a6e7-2cba-45e1-a6fb-05926022070b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_f338b2c4-5b13-4712-bb19-3c72b117f16e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_5251edfc-9480-43d7-8d0d-52fe2b4046e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_e9c2b590-66b1-443b-9fde-19e6954fa0be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_5251edfc-9480-43d7-8d0d-52fe2b4046e0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_e9c2b590-66b1-443b-9fde-19e6954fa0be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b41adda6-4709-477f-88ad-3da1bac5e685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_5251edfc-9480-43d7-8d0d-52fe2b4046e0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_b41adda6-4709-477f-88ad-3da1bac5e685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_bd7e4f35-8be0-4acb-b904-ee8752db659f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_5251edfc-9480-43d7-8d0d-52fe2b4046e0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_bd7e4f35-8be0-4acb-b904-ee8752db659f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1a58c4a0-c7cb-4b85-9c52-2b59448fdc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_81e5c516-193a-4730-8e16-1d22130ef64d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1a58c4a0-c7cb-4b85-9c52-2b59448fdc5a" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_81e5c516-193a-4730-8e16-1d22130ef64d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_2c1fb138-583f-47e3-83b3-bdb10673d2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1a58c4a0-c7cb-4b85-9c52-2b59448fdc5a" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_2c1fb138-583f-47e3-83b3-bdb10673d2e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ccaf97c3-d7ad-4113-9218-f5d33d448df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1a58c4a0-c7cb-4b85-9c52-2b59448fdc5a" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_ccaf97c3-d7ad-4113-9218-f5d33d448df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_6eb3908f-c33d-418b-83a5-f79f6fcf7889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1a58c4a0-c7cb-4b85-9c52-2b59448fdc5a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_6eb3908f-c33d-418b-83a5-f79f6fcf7889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b9f67ddb-3814-4f2b-b385-caa280a0ae84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1a58c4a0-c7cb-4b85-9c52-2b59448fdc5a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_b9f67ddb-3814-4f2b-b385-caa280a0ae84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_7cb384a5-47cc-492d-a64f-ed25bb4faa00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1a58c4a0-c7cb-4b85-9c52-2b59448fdc5a" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_7cb384a5-47cc-492d-a64f-ed25bb4faa00" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d47043a7-7e05-4e4e-a03e-00cdccc86cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_334f9c20-7f4d-420f-b8f6-60e9d04b3a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d47043a7-7e05-4e4e-a03e-00cdccc86cdc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_334f9c20-7f4d-420f-b8f6-60e9d04b3a8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2009d1c3-f8c7-42c9-9705-e67512745be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d47043a7-7e05-4e4e-a03e-00cdccc86cdc" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2009d1c3-f8c7-42c9-9705-e67512745be1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_9637a4a6-59dc-4ecf-b835-30fe92dda90e" xlink:href="jnj-20230402.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d47043a7-7e05-4e4e-a03e-00cdccc86cdc" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_9637a4a6-59dc-4ecf-b835-30fe92dda90e" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>jnj-20230402_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:58e186d7-ec31-41bf-b939-580d103359b5,g:2048fc28-099b-4a2a-a431-d29d26f24517-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20230402.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended" id="i33aae0a223dd4c72944c4ee1a2b35115_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7e4f4870-593e-4c08-8a30-332123e2cf2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_DocumentType_7e4f4870-593e-4c08-8a30-332123e2cf2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_14585d8f-f9b2-4b05-bd65-d185d928395e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_DocumentQuarterlyReport_14585d8f-f9b2-4b05-bd65-d185d928395e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9e985839-7eaa-4517-8a26-82717ddfdc46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_DocumentPeriodEndDate_9e985839-7eaa-4517-8a26-82717ddfdc46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_bfa2a4ce-7ce3-4259-906f-df60e27cc22a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_DocumentTransitionReport_bfa2a4ce-7ce3-4259-906f-df60e27cc22a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_07a4cd55-ce2d-45e8-a092-3e6447a3b841" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityFileNumber_07a4cd55-ce2d-45e8-a092-3e6447a3b841" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1b58a2b4-baf2-46a3-ae77-6f24a1058a4d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityRegistrantName_1b58a2b4-baf2-46a3-ae77-6f24a1058a4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_83639321-e00e-4bf3-a2ae-e9f3dc9c1950" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityIncorporationStateCountryCode_83639321-e00e-4bf3-a2ae-e9f3dc9c1950" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e7f95a75-38eb-406d-a717-3cd08aa3c947" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityTaxIdentificationNumber_e7f95a75-38eb-406d-a717-3cd08aa3c947" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_29251397-2842-4a5b-bbe5-d598e09ec33d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityAddressAddressLine1_29251397-2842-4a5b-bbe5-d598e09ec33d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6566fe1c-fdf5-4d26-a880-02d7ef5a179e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityAddressCityOrTown_6566fe1c-fdf5-4d26-a880-02d7ef5a179e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_53249b5f-98f3-4cd2-8c76-bdcb42077bda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityAddressStateOrProvince_53249b5f-98f3-4cd2-8c76-bdcb42077bda" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_eac35b9c-fa1a-4468-a420-5309af641449" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityAddressPostalZipCode_eac35b9c-fa1a-4468-a420-5309af641449" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_27ec6599-9c46-4307-953d-d07a935af532" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_CityAreaCode_27ec6599-9c46-4307-953d-d07a935af532" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_21141d06-b272-40e2-8c51-a8c1dcf05e69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_LocalPhoneNumber_21141d06-b272-40e2-8c51-a8c1dcf05e69" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_63da714c-1177-412f-88c3-84ef7f14caba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityCurrentReportingStatus_63da714c-1177-412f-88c3-84ef7f14caba" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_72216035-c01f-46be-9323-d60949e0fe6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityInteractiveDataCurrent_72216035-c01f-46be-9323-d60949e0fe6c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_74f411f9-ae6c-45a2-af9f-a5b609802d25" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityFilerCategory_74f411f9-ae6c-45a2-af9f-a5b609802d25" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f75d0380-f1a1-4b8f-a4d2-116d97b735e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntitySmallBusiness_f75d0380-f1a1-4b8f-a4d2-116d97b735e1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a5b913c0-ddc2-4d45-a384-e76550959a9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityEmergingGrowthCompany_a5b913c0-ddc2-4d45-a384-e76550959a9c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d25c47b1-a2bc-46fe-afc3-fbc683586774" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityShellCompany_d25c47b1-a2bc-46fe-afc3-fbc683586774" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b65cfaa5-6e6e-4e96-98cd-900b5d4d0631" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_Security12bTitle_b65cfaa5-6e6e-4e96-98cd-900b5d4d0631" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8d38b88d-a095-4af1-8572-a4cd9ca75136" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_TradingSymbol_8d38b88d-a095-4af1-8572-a4cd9ca75136" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7fc6af40-9dca-4938-a499-548c664c67fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_SecurityExchangeName_7fc6af40-9dca-4938-a499-548c664c67fa" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f487ba49-9cc8-41d1-b859-fb29b3c161c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f487ba49-9cc8-41d1-b859-fb29b3c161c2" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5b2f0b2a-e129-4974-bb42-38a8cb0302ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityCentralIndexKey_5b2f0b2a-e129-4974-bb42-38a8cb0302ae" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_dea5fd89-040f-4e7f-941d-304ce71ceb28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_CurrentFiscalYearEndDate_dea5fd89-040f-4e7f-941d-304ce71ceb28" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3949b875-03e3-4f37-b701-319810f6237f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_DocumentFiscalYearFocus_3949b875-03e3-4f37-b701-319810f6237f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c10673b0-23bf-4a39-81db-e11b920f6146" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c10673b0-23bf-4a39-81db-e11b920f6146" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3626cc74-b93b-4ab5-a13f-3b8dc66d5199" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_AmendmentFlag_3626cc74-b93b-4ab5-a13f-3b8dc66d5199" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_6aee2c21-84f6-4f57-93a7-01f952c0ef6b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntitiesTable_6aee2c21-84f6-4f57-93a7-01f952c0ef6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_98639db2-a195-4de2-b4ba-394f230d5913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_6aee2c21-84f6-4f57-93a7-01f952c0ef6b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_98639db2-a195-4de2-b4ba-394f230d5913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_98639db2-a195-4de2-b4ba-394f230d5913_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_98639db2-a195-4de2-b4ba-394f230d5913" xlink:to="loc_us-gaap_ClassOfStockDomain_98639db2-a195-4de2-b4ba-394f230d5913_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_98639db2-a195-4de2-b4ba-394f230d5913" xlink:to="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e0e2c4c3-a545-49f4-9d61-dfd7d7a7be7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:to="loc_us-gaap_CommonStockMember_e0e2c4c3-a545-49f4-9d61-dfd7d7a7be7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_0c65d4ad-049f-493c-ac27-cc8111d74bf2" xlink:href="jnj-20230402.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:to="loc_jnj_A0.650NotesDue2024Member_0c65d4ad-049f-493c-ac27-cc8111d74bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_228bd5b7-769a-4f61-a6bd-f8a18ac5615d" xlink:href="jnj-20230402.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:to="loc_jnj_A5.50NotesDue2024Member_228bd5b7-769a-4f61-a6bd-f8a18ac5615d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_8ed3c1b8-33c3-48a4-b748-7b3d53800d57" xlink:href="jnj-20230402.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:to="loc_jnj_A1.150NotesDue2028Member_8ed3c1b8-33c3-48a4-b748-7b3d53800d57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_3a04b911-8d95-4c9b-9c12-18f58086938a" xlink:href="jnj-20230402.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:to="loc_jnj_A1.650NotesDue2035Member_3a04b911-8d95-4c9b-9c12-18f58086938a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="i54b8db2cd1cc4ef2b1fdbbcc619f868b_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_56bb7133-7a85-4058-8555-0febb16e4056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_56bb7133-7a85-4058-8555-0febb16e4056" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_285533d8-04a6-45b2-a31f-0022aa7794eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_NetIncomeLoss_285533d8-04a6-45b2-a31f-0022aa7794eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_90eeb6dc-40e3-4496-8e16-a8f379ee6f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_DividendsCommonStockCash_90eeb6dc-40e3-4496-8e16-a8f379ee6f92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_962899c3-1382-4617-a609-625aaf04ad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_962899c3-1382-4617-a609-625aaf04ad0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_cbe2f1ec-f261-4ae2-bb4b-5e7421786dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_cbe2f1ec-f261-4ae2-bb4b-5e7421786dca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_55efae6e-b14a-420e-af62-e2b6769a2cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_StockholdersEquityOther_55efae6e-b14a-420e-af62-e2b6769a2cb1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e38c46c-c81c-4771-9933-96edf5b615cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e38c46c-c81c-4771-9933-96edf5b615cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3d17549-e40b-4400-b7d0-e01d89b17971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_22f2b765-3e8a-416d-82ff-427f46ff1ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_StatementTable_22f2b765-3e8a-416d-82ff-427f46ff1ad0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8dc56b12-61df-4862-af77-871aa97bb743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_22f2b765-3e8a-416d-82ff-427f46ff1ad0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8dc56b12-61df-4862-af77-871aa97bb743" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8dc56b12-61df-4862-af77-871aa97bb743_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8dc56b12-61df-4862-af77-871aa97bb743" xlink:to="loc_us-gaap_EquityComponentDomain_8dc56b12-61df-4862-af77-871aa97bb743_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c387b8fa-1a9f-40a2-bf28-da68851ee573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8dc56b12-61df-4862-af77-871aa97bb743" xlink:to="loc_us-gaap_EquityComponentDomain_c387b8fa-1a9f-40a2-bf28-da68851ee573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c707c263-42bf-4b35-b6a3-51afd4980fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c387b8fa-1a9f-40a2-bf28-da68851ee573" xlink:to="loc_us-gaap_RetainedEarningsMember_c707c263-42bf-4b35-b6a3-51afd4980fe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4438c7fe-371e-44e9-96c8-63917218faad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c387b8fa-1a9f-40a2-bf28-da68851ee573" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4438c7fe-371e-44e9-96c8-63917218faad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cb178e43-068e-47e6-ab54-5bfc5c8c26f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c387b8fa-1a9f-40a2-bf28-da68851ee573" xlink:to="loc_us-gaap_CommonStockMember_cb178e43-068e-47e6-ab54-5bfc5c8c26f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_7780fbad-8dda-4495-84e8-8dff5a53254f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c387b8fa-1a9f-40a2-bf28-da68851ee573" xlink:to="loc_us-gaap_TreasuryStockCommonMember_7780fbad-8dda-4495-84e8-8dff5a53254f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="i8ef417cf405a4fe68ac54cf4b94210af_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1ba076fc-59f5-4aaa-b818-3f766cc9acc4" xlink:href="jnj-20230402.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3b62a7c1-0640-405a-9fd9-610f8e21099a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1ba076fc-59f5-4aaa-b818-3f766cc9acc4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3b62a7c1-0640-405a-9fd9-610f8e21099a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cab9b550-5cc4-44af-9866-354203f7d8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3b62a7c1-0640-405a-9fd9-610f8e21099a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cab9b550-5cc4-44af-9866-354203f7d8e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_29ff43c0-cad3-4fd7-ae92-e080358c66f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cab9b550-5cc4-44af-9866-354203f7d8e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_29ff43c0-cad3-4fd7-ae92-e080358c66f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0931b275-62e4-43cf-89ac-8a9617f137b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cab9b550-5cc4-44af-9866-354203f7d8e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0931b275-62e4-43cf-89ac-8a9617f137b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fff02d5c-5972-4d42-91d8-ee4431c31f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cab9b550-5cc4-44af-9866-354203f7d8e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fff02d5c-5972-4d42-91d8-ee4431c31f14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_1cf60cc5-464f-4f3d-8aac-ef0f50092c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3b62a7c1-0640-405a-9fd9-610f8e21099a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_1cf60cc5-464f-4f3d-8aac-ef0f50092c5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8a9cc938-6c4e-4469-b349-c098930fae8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_1cf60cc5-464f-4f3d-8aac-ef0f50092c5a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8a9cc938-6c4e-4469-b349-c098930fae8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f46c469b-b213-468e-a20d-3bcf7ad856d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_1cf60cc5-464f-4f3d-8aac-ef0f50092c5a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f46c469b-b213-468e-a20d-3bcf7ad856d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_f6c088ce-20b5-4fc8-9883-11c677ec1e30" xlink:href="jnj-20230402.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1ba076fc-59f5-4aaa-b818-3f766cc9acc4" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_f6c088ce-20b5-4fc8-9883-11c677ec1e30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b8165c42-8424-440e-b3d4-99073b3495a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_f6c088ce-20b5-4fc8-9883-11c677ec1e30" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b8165c42-8424-440e-b3d4-99073b3495a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b8165c42-8424-440e-b3d4-99073b3495a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b8165c42-8424-440e-b3d4-99073b3495a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b8165c42-8424-440e-b3d4-99073b3495a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_328463be-95db-43f6-80ad-7f3fb9fe692a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b8165c42-8424-440e-b3d4-99073b3495a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_328463be-95db-43f6-80ad-7f3fb9fe692a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_86db5364-496f-49ec-8f61-1850337e284e" xlink:href="jnj-20230402.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_328463be-95db-43f6-80ad-7f3fb9fe692a" xlink:to="loc_jnj_PatentsAndTrademarksMember_86db5364-496f-49ec-8f61-1850337e284e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_2c324ffe-b944-42af-a092-0753471d653b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_328463be-95db-43f6-80ad-7f3fb9fe692a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_2c324ffe-b944-42af-a092-0753471d653b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cddc8ff-8361-41af-879d-eafe92024318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_f6c088ce-20b5-4fc8-9883-11c677ec1e30" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cddc8ff-8361-41af-879d-eafe92024318" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4cddc8ff-8361-41af-879d-eafe92024318_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cddc8ff-8361-41af-879d-eafe92024318" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4cddc8ff-8361-41af-879d-eafe92024318_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1eb50d58-5173-4d34-b86e-eec49785f459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cddc8ff-8361-41af-879d-eafe92024318" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1eb50d58-5173-4d34-b86e-eec49785f459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_6651ff1e-f97a-46fd-a7e9-6da80c14abe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1eb50d58-5173-4d34-b86e-eec49785f459" xlink:to="loc_us-gaap_TrademarksMember_6651ff1e-f97a-46fd-a7e9-6da80c14abe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_114abced-f9f0-450a-bfb1-441fa927003b" xlink:href="jnj-20230402.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1eb50d58-5173-4d34-b86e-eec49785f459" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_114abced-f9f0-450a-bfb1-441fa927003b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_753d933f-f24d-4b26-8428-18436078a2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_f6c088ce-20b5-4fc8-9883-11c677ec1e30" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_753d933f-f24d-4b26-8428-18436078a2fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_753d933f-f24d-4b26-8428-18436078a2fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_753d933f-f24d-4b26-8428-18436078a2fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_753d933f-f24d-4b26-8428-18436078a2fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_09233844-6639-4061-bdcf-4248151347fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_753d933f-f24d-4b26-8428-18436078a2fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_09233844-6639-4061-bdcf-4248151347fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_9e7f2b5c-8c88-4f35-aa5f-b7a9b8cadafb" xlink:href="jnj-20230402.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_09233844-6639-4061-bdcf-4248151347fb" xlink:to="loc_jnj_BermekimabMember_9e7f2b5c-8c88-4f35-aa5f-b7a9b8cadafb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended" id="i193ad5dd9adc4194937ac3e92b93da1d_IntangibleAssetsandGoodwillGoodwillBySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_257572b4-7e9e-480a-ae80-c82d5dd4bc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_a8171720-c6ad-49d3-885b-c0527ea62be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_257572b4-7e9e-480a-ae80-c82d5dd4bc84" xlink:to="loc_us-gaap_GoodwillRollForward_a8171720-c6ad-49d3-885b-c0527ea62be3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bcf14a12-4f4e-4c37-8b83-820d3f6aa90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_a8171720-c6ad-49d3-885b-c0527ea62be3" xlink:to="loc_us-gaap_Goodwill_bcf14a12-4f4e-4c37-8b83-820d3f6aa90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_1345391c-1785-41f8-b811-ae51cfd80c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_a8171720-c6ad-49d3-885b-c0527ea62be3" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_1345391c-1785-41f8-b811-ae51cfd80c77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_f34d7e63-ab90-43b3-b234-3054e7d764a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_a8171720-c6ad-49d3-885b-c0527ea62be3" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_f34d7e63-ab90-43b3-b234-3054e7d764a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_46d7ac02-c1ef-4bfd-9d65-8fa30d02320b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_63630c74-6b1a-4131-93e4-5806c93b1d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_257572b4-7e9e-480a-ae80-c82d5dd4bc84" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_63630c74-6b1a-4131-93e4-5806c93b1d47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e6ddfbcb-6566-455c-bcdf-4c4298faaba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_63630c74-6b1a-4131-93e4-5806c93b1d47" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e6ddfbcb-6566-455c-bcdf-4c4298faaba9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e6ddfbcb-6566-455c-bcdf-4c4298faaba9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e6ddfbcb-6566-455c-bcdf-4c4298faaba9" xlink:to="loc_us-gaap_SegmentDomain_e6ddfbcb-6566-455c-bcdf-4c4298faaba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_49161981-dc44-4e03-8b08-e3dc50ca5018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e6ddfbcb-6566-455c-bcdf-4c4298faaba9" xlink:to="loc_us-gaap_SegmentDomain_49161981-dc44-4e03-8b08-e3dc50ca5018" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_22c2465e-2768-4fcc-a699-5a17f08a93e6" xlink:href="jnj-20230402.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_49161981-dc44-4e03-8b08-e3dc50ca5018" xlink:to="loc_jnj_ConsumerMember_22c2465e-2768-4fcc-a699-5a17f08a93e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_65717014-382f-4e37-8aaf-bbff16923b5d" xlink:href="jnj-20230402.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_49161981-dc44-4e03-8b08-e3dc50ca5018" xlink:to="loc_jnj_PharmaceuticalMember_65717014-382f-4e37-8aaf-bbff16923b5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_63496323-e68c-4778-b9a2-24a061ba9b5a" xlink:href="jnj-20230402.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_49161981-dc44-4e03-8b08-e3dc50ca5018" xlink:to="loc_jnj_MedicalDevicesMember_63496323-e68c-4778-b9a2-24a061ba9b5a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended" id="i65302d970a484d7d95ed9899359e2860_IntangibleAssetsandGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ae286194-964a-423f-8548-e3244994d002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b99e497d-b528-40fa-8107-b998599dd214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ae286194-964a-423f-8548-e3244994d002" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b99e497d-b528-40fa-8107-b998599dd214" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1f7a03ba-dde4-497c-b533-2b6fc3fb75a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ae286194-964a-423f-8548-e3244994d002" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1f7a03ba-dde4-497c-b533-2b6fc3fb75a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_26689460-fbbd-40d9-a5db-7874321d2e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ae286194-964a-423f-8548-e3244994d002" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_26689460-fbbd-40d9-a5db-7874321d2e89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e451b20a-cc60-44f6-bf01-7df84e70265c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_26689460-fbbd-40d9-a5db-7874321d2e89" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e451b20a-cc60-44f6-bf01-7df84e70265c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e451b20a-cc60-44f6-bf01-7df84e70265c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e451b20a-cc60-44f6-bf01-7df84e70265c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e451b20a-cc60-44f6-bf01-7df84e70265c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19fffbff-a1db-4f69-b521-0b8b49ef8037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e451b20a-cc60-44f6-bf01-7df84e70265c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19fffbff-a1db-4f69-b521-0b8b49ef8037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_ddda7dca-e7eb-4d92-98f2-0dd83cd3668a" xlink:href="jnj-20230402.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19fffbff-a1db-4f69-b521-0b8b49ef8037" xlink:to="loc_jnj_PatentsAndTrademarksMember_ddda7dca-e7eb-4d92-98f2-0dd83cd3668a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_8f2856be-af28-429c-a585-973667d65f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19fffbff-a1db-4f69-b521-0b8b49ef8037" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_8f2856be-af28-429c-a585-973667d65f62" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i5e712a487e78496695e02b569bd6774e_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_a7313b79-1040-4e28-a799-a0e35e31ea29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_a7313b79-1040-4e28-a799-a0e35e31ea29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_07136e7b-974c-416a-a0f5-8e21eae3f9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_DerivativeNotionalAmount_07136e7b-974c-416a-a0f5-8e21eae3f9f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_acd8523b-9449-4189-9aeb-ff59a5768d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_acd8523b-9449-4189-9aeb-ff59a5768d6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_9b652696-7817-4cc1-9ed4-3f70aa447fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_EquityFairValueAdjustment_9b652696-7817-4cc1-9ed4-3f70aa447fda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_7637fb25-6e41-4c59-8611-72be44b006de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_7637fb25-6e41-4c59-8611-72be44b006de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_143b0e3e-2716-4371-98a7-3e3161a23224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_ShortTermBorrowings_143b0e3e-2716-4371-98a7-3e3161a23224" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_142c9d6b-3550-42ef-8f38-21624635e55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_142c9d6b-3550-42ef-8f38-21624635e55d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_4f97589c-d4d2-430a-9fb0-f780b9e6cbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_DebtInstrumentTerm_4f97589c-d4d2-430a-9fb0-f780b9e6cbc6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_255479ac-0ec5-4ffc-a104-c04085cdcf38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_255479ac-0ec5-4ffc-a104-c04085cdcf38" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_b85af6f8-5b41-42cc-993d-ee5b949a5d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_b85af6f8-5b41-42cc-993d-ee5b949a5d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_b85af6f8-5b41-42cc-993d-ee5b949a5d9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_b85af6f8-5b41-42cc-993d-ee5b949a5d9a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_b85af6f8-5b41-42cc-993d-ee5b949a5d9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_b36fe316-c99e-46a6-bbbe-4e02bccfafe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_b85af6f8-5b41-42cc-993d-ee5b949a5d9a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_b36fe316-c99e-46a6-bbbe-4e02bccfafe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_60d26161-667c-43f8-94c9-51982cad9aaf" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_b36fe316-c99e-46a6-bbbe-4e02bccfafe5" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_60d26161-667c-43f8-94c9-51982cad9aaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_eeea4976-b2ba-4185-a4ce-27aafc4bda1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_eeea4976-b2ba-4185-a4ce-27aafc4bda1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_eeea4976-b2ba-4185-a4ce-27aafc4bda1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_eeea4976-b2ba-4185-a4ce-27aafc4bda1b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_eeea4976-b2ba-4185-a4ce-27aafc4bda1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c000a97-ee8b-47a0-9615-772acfd52ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_eeea4976-b2ba-4185-a4ce-27aafc4bda1b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c000a97-ee8b-47a0-9615-772acfd52ac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_ca27da10-6917-4b19-a4c5-aebdc5fbfec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c000a97-ee8b-47a0-9615-772acfd52ac6" xlink:to="loc_us-gaap_EquitySecuritiesMember_ca27da10-6917-4b19-a4c5-aebdc5fbfec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b2abe097-60e7-4cd0-94b9-843d115b91b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b2abe097-60e7-4cd0-94b9-843d115b91b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b2abe097-60e7-4cd0-94b9-843d115b91b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b2abe097-60e7-4cd0-94b9-843d115b91b8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b2abe097-60e7-4cd0-94b9-843d115b91b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7389c76d-71f8-4d0a-a10c-019e4b46a96f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b2abe097-60e7-4cd0-94b9-843d115b91b8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7389c76d-71f8-4d0a-a10c-019e4b46a96f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_83c55177-9178-4a77-83cc-4a88856c7262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7389c76d-71f8-4d0a-a10c-019e4b46a96f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_83c55177-9178-4a77-83cc-4a88856c7262" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_b5dcab46-12e9-47f1-9dcb-a1cc36e251e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7389c76d-71f8-4d0a-a10c-019e4b46a96f" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_b5dcab46-12e9-47f1-9dcb-a1cc36e251e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_aae16fd6-d51a-488f-a961-22044c7ece26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7389c76d-71f8-4d0a-a10c-019e4b46a96f" xlink:to="loc_us-gaap_InterestRateSwapMember_aae16fd6-d51a-488f-a961-22044c7ece26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_47ae6abe-2849-46cd-ba6a-771b210d3c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_47ae6abe-2849-46cd-ba6a-771b210d3c2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_47ae6abe-2849-46cd-ba6a-771b210d3c2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_47ae6abe-2849-46cd-ba6a-771b210d3c2a" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_47ae6abe-2849-46cd-ba6a-771b210d3c2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4ccf64c1-31e5-4cca-9b1e-39c7c2e18993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_47ae6abe-2849-46cd-ba6a-771b210d3c2a" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4ccf64c1-31e5-4cca-9b1e-39c7c2e18993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_290908a0-7fb3-4555-9ed6-5edb8ceec2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_4ccf64c1-31e5-4cca-9b1e-39c7c2e18993" xlink:to="loc_us-gaap_CommercialPaperMember_290908a0-7fb3-4555-9ed6-5edb8ceec2c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended" id="id465c99df6c24c3ebb705ada32c8bea2_FairValueMeasurementsSummaryofDerivativeActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_caa4be50-ff89-4314-8a8a-2134c669edae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_d7193574-42a0-4fed-8637-eddad54a2311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_caa4be50-ff89-4314-8a8a-2134c669edae" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_d7193574-42a0-4fed-8637-eddad54a2311" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_53299276-148c-4a3e-9f49-2252d4ca8397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_caa4be50-ff89-4314-8a8a-2134c669edae" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_53299276-148c-4a3e-9f49-2252d4ca8397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_88b89ec6-b456-47b8-b3cd-d87f68ec644b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_caa4be50-ff89-4314-8a8a-2134c669edae" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_88b89ec6-b456-47b8-b3cd-d87f68ec644b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b96b304a-8017-430b-8ff8-9e2f131c9e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_caa4be50-ff89-4314-8a8a-2134c669edae" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b96b304a-8017-430b-8ff8-9e2f131c9e00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea07925a-10f5-4e48-b803-178f4fd25371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b96b304a-8017-430b-8ff8-9e2f131c9e00" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea07925a-10f5-4e48-b803-178f4fd25371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ea07925a-10f5-4e48-b803-178f4fd25371_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea07925a-10f5-4e48-b803-178f4fd25371" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ea07925a-10f5-4e48-b803-178f4fd25371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_46c52dc5-07d3-4bfd-9d30-ce515856af27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea07925a-10f5-4e48-b803-178f4fd25371" xlink:to="loc_us-gaap_HedgingRelationshipDomain_46c52dc5-07d3-4bfd-9d30-ce515856af27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_c08a1bae-06c9-4c7e-9ec8-ab3d0ff93127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46c52dc5-07d3-4bfd-9d30-ce515856af27" xlink:to="loc_us-gaap_FairValueHedgingMember_c08a1bae-06c9-4c7e-9ec8-ab3d0ff93127" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1018750d-1a50-4109-ac0a-1e131d90c699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46c52dc5-07d3-4bfd-9d30-ce515856af27" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_1018750d-1a50-4109-ac0a-1e131d90c699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_7c45e2af-a192-4f18-8703-3e446dbb6efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46c52dc5-07d3-4bfd-9d30-ce515856af27" xlink:to="loc_us-gaap_CashFlowHedgingMember_7c45e2af-a192-4f18-8703-3e446dbb6efc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b917d6cd-2185-417b-89c9-88e610c9f6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b96b304a-8017-430b-8ff8-9e2f131c9e00" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b917d6cd-2185-417b-89c9-88e610c9f6cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b917d6cd-2185-417b-89c9-88e610c9f6cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b917d6cd-2185-417b-89c9-88e610c9f6cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b917d6cd-2185-417b-89c9-88e610c9f6cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b917d6cd-2185-417b-89c9-88e610c9f6cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_9e5ce4c0-fa29-4c71-b984-37d6728ba1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:to="loc_us-gaap_InterestRateContractMember_9e5ce4c0-fa29-4c71-b984-37d6728ba1c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_38df2bf2-4278-4f27-83e3-ceb1254d17fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:to="loc_us-gaap_ForeignExchangeContractMember_38df2bf2-4278-4f27-83e3-ceb1254d17fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_b400a74e-faa5-4477-b091-e00ddd719238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_b400a74e-faa5-4477-b091-e00ddd719238" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5a90838f-14a7-40df-b78e-d2a8e0762095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:to="loc_us-gaap_InterestRateSwapMember_5a90838f-14a7-40df-b78e-d2a8e0762095" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_c1867082-9156-48bb-b1be-ab365152bad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_c1867082-9156-48bb-b1be-ab365152bad0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ebd2474a-ae99-4b7a-8dd5-d499efbc73b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b96b304a-8017-430b-8ff8-9e2f131c9e00" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ebd2474a-ae99-4b7a-8dd5-d499efbc73b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ebd2474a-ae99-4b7a-8dd5-d499efbc73b2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ebd2474a-ae99-4b7a-8dd5-d499efbc73b2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ebd2474a-ae99-4b7a-8dd5-d499efbc73b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ebd2474a-ae99-4b7a-8dd5-d499efbc73b2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_d6fa7a66-9a20-43df-9eff-8aab1ec6e2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:to="loc_us-gaap_SalesMember_d6fa7a66-9a20-43df-9eff-8aab1ec6e2df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_0bc999ce-fc2b-49a5-b5d3-aa366b96afc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:to="loc_us-gaap_CostOfSalesMember_0bc999ce-fc2b-49a5-b5d3-aa366b96afc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d12db586-e55a-4fca-a58c-e529d65fc118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d12db586-e55a-4fca-a58c-e529d65fc118" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_74129526-28fa-4e38-a450-d6e7bd558e44" xlink:href="jnj-20230402.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_74129526-28fa-4e38-a450-d6e7bd558e44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_3c5947a8-ef5c-4596-90b4-48c1e059f93e" xlink:href="jnj-20230402.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_3c5947a8-ef5c-4596-90b4-48c1e059f93e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsDerivativesBalanceSheetLocationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="extended" id="ic76f7c4c2ecb4277a39959aeff0d1d1e_FairValueMeasurementsDerivativesBalanceSheetLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_43d4ed8f-5d63-4f3f-884e-55f08b96f147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_5b35b8de-9de6-44d3-aef0-0c3871098291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_43d4ed8f-5d63-4f3f-884e-55f08b96f147" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_5b35b8de-9de6-44d3-aef0-0c3871098291" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_f7eb8802-6593-420b-8269-02ab522dc555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_43d4ed8f-5d63-4f3f-884e-55f08b96f147" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_f7eb8802-6593-420b-8269-02ab522dc555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0f47a226-c459-41a4-8f39-8fce41586fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_43d4ed8f-5d63-4f3f-884e-55f08b96f147" xlink:to="loc_us-gaap_DerivativeTable_0f47a226-c459-41a4-8f39-8fce41586fec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4b3a165e-80f9-4712-b074-6436abe45603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0f47a226-c459-41a4-8f39-8fce41586fec" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4b3a165e-80f9-4712-b074-6436abe45603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4b3a165e-80f9-4712-b074-6436abe45603_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4b3a165e-80f9-4712-b074-6436abe45603" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4b3a165e-80f9-4712-b074-6436abe45603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4586a78b-bfdd-453c-904a-341c5ea595a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4b3a165e-80f9-4712-b074-6436abe45603" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4586a78b-bfdd-453c-904a-341c5ea595a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_58d6b36a-bcdf-4592-b2ea-851dde2f8a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4586a78b-bfdd-453c-904a-341c5ea595a4" xlink:to="loc_us-gaap_LongTermDebtMember_58d6b36a-bcdf-4592-b2ea-851dde2f8a85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c52adf19-bc93-429a-8f2c-b12e44ecfe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_0f47a226-c459-41a4-8f39-8fce41586fec" xlink:to="loc_us-gaap_HedgingDesignationAxis_c52adf19-bc93-429a-8f2c-b12e44ecfe7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c52adf19-bc93-429a-8f2c-b12e44ecfe7c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_c52adf19-bc93-429a-8f2c-b12e44ecfe7c" xlink:to="loc_us-gaap_HedgingDesignationDomain_c52adf19-bc93-429a-8f2c-b12e44ecfe7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a9193421-ca7c-4bbc-88de-664798087917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_c52adf19-bc93-429a-8f2c-b12e44ecfe7c" xlink:to="loc_us-gaap_HedgingDesignationDomain_a9193421-ca7c-4bbc-88de-664798087917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7f0f22c3-8f77-4c00-95cf-2f37578f2948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_a9193421-ca7c-4bbc-88de-664798087917" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7f0f22c3-8f77-4c00-95cf-2f37578f2948" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="i72491c534add4176980218c5296f5125_FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_376107ab-2e3a-46a7-b60a-1b5de25dc63b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ed0b2f4f-c290-4bed-8cf5-9b4ab41af2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_376107ab-2e3a-46a7-b60a-1b5de25dc63b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ed0b2f4f-c290-4bed-8cf5-9b4ab41af2f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_46ab0392-d74b-40ab-966a-9482cf2e7424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_376107ab-2e3a-46a7-b60a-1b5de25dc63b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_46ab0392-d74b-40ab-966a-9482cf2e7424" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_52501cee-38f4-4aa4-b664-7b936e274bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_46ab0392-d74b-40ab-966a-9482cf2e7424" xlink:to="loc_us-gaap_HedgingDesignationAxis_52501cee-38f4-4aa4-b664-7b936e274bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_52501cee-38f4-4aa4-b664-7b936e274bda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_52501cee-38f4-4aa4-b664-7b936e274bda" xlink:to="loc_us-gaap_HedgingDesignationDomain_52501cee-38f4-4aa4-b664-7b936e274bda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d344ecb9-9aa7-43f7-81f6-3a04b5b5e20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_52501cee-38f4-4aa4-b664-7b936e274bda" xlink:to="loc_us-gaap_HedgingDesignationDomain_d344ecb9-9aa7-43f7-81f6-3a04b5b5e20c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0a13ea55-ab03-4005-aa6a-18e71be9fe9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_d344ecb9-9aa7-43f7-81f6-3a04b5b5e20c" xlink:to="loc_us-gaap_NondesignatedMember_0a13ea55-ab03-4005-aa6a-18e71be9fe9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5a868573-845c-4a68-a380-a4722667b8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_46ab0392-d74b-40ab-966a-9482cf2e7424" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5a868573-845c-4a68-a380-a4722667b8eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_5a868573-845c-4a68-a380-a4722667b8eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5a868573-845c-4a68-a380-a4722667b8eb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_5a868573-845c-4a68-a380-a4722667b8eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4fbfb756-96d6-4ced-b8fb-209d2614db6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5a868573-845c-4a68-a380-a4722667b8eb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4fbfb756-96d6-4ced-b8fb-209d2614db6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_077dde4c-b2f0-47c0-873f-d1b2022ce9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4fbfb756-96d6-4ced-b8fb-209d2614db6c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_077dde4c-b2f0-47c0-873f-d1b2022ce9ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_54d4e8e2-9d4c-4469-9f94-c57afee60741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_46ab0392-d74b-40ab-966a-9482cf2e7424" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_54d4e8e2-9d4c-4469-9f94-c57afee60741" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_54d4e8e2-9d4c-4469-9f94-c57afee60741_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_54d4e8e2-9d4c-4469-9f94-c57afee60741" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_54d4e8e2-9d4c-4469-9f94-c57afee60741_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6e417fbe-298c-479d-8a77-bbeb02a22a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_54d4e8e2-9d4c-4469-9f94-c57afee60741" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6e417fbe-298c-479d-8a77-bbeb02a22a1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_2fe77cac-0370-4ea9-b52a-02f16c7d34f2" xlink:href="jnj-20230402.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e417fbe-298c-479d-8a77-bbeb02a22a1f" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_2fe77cac-0370-4ea9-b52a-02f16c7d34f2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="iea63bef9c53747c5ae46538515ab887a_FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3423bc80-c16d-42ea-b0b9-4b60e847902d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_db097666-be53-492b-a63a-47d0653023e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3423bc80-c16d-42ea-b0b9-4b60e847902d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_db097666-be53-492b-a63a-47d0653023e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_58a570b7-e9f8-4382-9e0f-67c47caac2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3423bc80-c16d-42ea-b0b9-4b60e847902d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_58a570b7-e9f8-4382-9e0f-67c47caac2b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1f24558b-f5e3-46c3-8f02-7ad53d18a978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3423bc80-c16d-42ea-b0b9-4b60e847902d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1f24558b-f5e3-46c3-8f02-7ad53d18a978" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_52dd0f75-6b75-44a1-92cc-b4217d7bc083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1f24558b-f5e3-46c3-8f02-7ad53d18a978" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_52dd0f75-6b75-44a1-92cc-b4217d7bc083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_52dd0f75-6b75-44a1-92cc-b4217d7bc083_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_52dd0f75-6b75-44a1-92cc-b4217d7bc083" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_52dd0f75-6b75-44a1-92cc-b4217d7bc083_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_adfd8ef8-a731-4936-9896-cbb593f47119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_52dd0f75-6b75-44a1-92cc-b4217d7bc083" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_adfd8ef8-a731-4936-9896-cbb593f47119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_fe023c7a-6be9-479f-ad1b-b8cc68ce049d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_adfd8ef8-a731-4936-9896-cbb593f47119" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_fe023c7a-6be9-479f-ad1b-b8cc68ce049d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_13b049aa-9267-4903-851f-2bd54b630753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1f24558b-f5e3-46c3-8f02-7ad53d18a978" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_13b049aa-9267-4903-851f-2bd54b630753" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_13b049aa-9267-4903-851f-2bd54b630753_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13b049aa-9267-4903-851f-2bd54b630753" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_13b049aa-9267-4903-851f-2bd54b630753_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_44fc56bf-6619-4b71-80ab-01712b14b0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13b049aa-9267-4903-851f-2bd54b630753" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_44fc56bf-6619-4b71-80ab-01712b14b0dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_9c12f771-3afa-4031-ac5a-b60be54b25db" xlink:href="jnj-20230402.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44fc56bf-6619-4b71-80ab-01712b14b0dc" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_9c12f771-3afa-4031-ac5a-b60be54b25db" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended" id="ib5a24b7411b540f88859f26efc1cc05d_FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_9585aaac-7d96-4000-86ba-25cd81778ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_9585aaac-7d96-4000-86ba-25cd81778ab4" xlink:to="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_15f17fd9-7008-4d58-9408-fd864f2d4270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_15f17fd9-7008-4d58-9408-fd864f2d4270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e25ab109-3faf-4a07-a5b8-a992a84bb78b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e25ab109-3faf-4a07-a5b8-a992a84bb78b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_60d87d3e-565e-48d4-b520-1d89c6754ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:to="loc_us-gaap_EquityFairValueAdjustment_60d87d3e-565e-48d4-b520-1d89c6754ab0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_3815b05e-b955-4f05-96cb-d710017c3b37" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_3815b05e-b955-4f05-96cb-d710017c3b37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_02f3949c-97e1-414a-8459-48bb0845d84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5ff3f15f-2af2-4c76-9009-211551f7222f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8722c07d-35ec-4dfd-8795-b667438cc8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8722c07d-35ec-4dfd-8795-b667438cc8e2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f5107573-8322-4917-a525-286336b79476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_9585aaac-7d96-4000-86ba-25cd81778ab4" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f5107573-8322-4917-a525-286336b79476" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_6d0bc776-6bb8-46ce-bae2-531c81fb2c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f5107573-8322-4917-a525-286336b79476" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_6d0bc776-6bb8-46ce-bae2-531c81fb2c80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6d0bc776-6bb8-46ce-bae2-531c81fb2c80_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6d0bc776-6bb8-46ce-bae2-531c81fb2c80" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6d0bc776-6bb8-46ce-bae2-531c81fb2c80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ca6f1e8a-d189-408c-8e30-d55f69a4e6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6d0bc776-6bb8-46ce-bae2-531c81fb2c80" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ca6f1e8a-d189-408c-8e30-d55f69a4e6e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_5b78d4b7-1396-400d-8205-5ef5f8d75668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ca6f1e8a-d189-408c-8e30-d55f69a4e6e7" xlink:to="loc_us-gaap_EquitySecuritiesMember_5b78d4b7-1396-400d-8205-5ef5f8d75668" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_f2a5e488-96c1-49eb-8edb-889c9c80ecaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f5107573-8322-4917-a525-286336b79476" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_f2a5e488-96c1-49eb-8edb-889c9c80ecaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f2a5e488-96c1-49eb-8edb-889c9c80ecaa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_f2a5e488-96c1-49eb-8edb-889c9c80ecaa" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_f2a5e488-96c1-49eb-8edb-889c9c80ecaa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_3988a5de-6528-417a-be92-88b6284b1c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_f2a5e488-96c1-49eb-8edb-889c9c80ecaa" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_3988a5de-6528-417a-be92-88b6284b1c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_5ebdb794-f482-40c0-9fed-79ef460374b7" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_3988a5de-6528-417a-be92-88b6284b1c14" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_5ebdb794-f482-40c0-9fed-79ef460374b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_9b5bb535-610f-4ac9-90be-f2cebcea8591" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_3988a5de-6528-417a-be92-88b6284b1c14" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_9b5bb535-610f-4ac9-90be-f2cebcea8591" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended" id="if4ab51cfb1a84a40bd83b22522f97035_FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_11a73a4a-dc0f-4537-a511-d3a6c7074f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_11a73a4a-dc0f-4537-a511-d3a6c7074f3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_eab8264b-f50a-411f-8b01-25f129524e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_eab8264b-f50a-411f-8b01-25f129524e08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_692ebbb4-8a14-48de-bc1a-d82a31baaca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_692ebbb4-8a14-48de-bc1a-d82a31baaca8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_96d69287-42e3-4f71-a27a-0118e94e69a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_96d69287-42e3-4f71-a27a-0118e94e69a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c6bc5f0a-112f-40ee-baa7-e2dce215e47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c6bc5f0a-112f-40ee-baa7-e2dce215e47b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8bbd9c2-de02-4cba-bdb9-9cdf524edab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8bbd9c2-de02-4cba-bdb9-9cdf524edab0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_986482da-f2d1-45ae-b86f-89e9b907c2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_986482da-f2d1-45ae-b86f-89e9b907c2b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_76cb2cec-9651-4e30-9693-2c07bcfa3778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_76cb2cec-9651-4e30-9693-2c07bcfa3778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_8c9f9e12-2e39-4372-a8e5-c261b38c0714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_8c9f9e12-2e39-4372-a8e5-c261b38c0714" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_72410b7e-30ac-49a0-b725-f2e506ae4004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeAssets_72410b7e-30ac-49a0-b725-f2e506ae4004" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_92b59bfe-423f-4b2a-8273-435a6e439e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_92b59bfe-423f-4b2a-8273-435a6e439e85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5cc9df2d-fad0-4a5c-8394-8c0e4eee84c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5cc9df2d-fad0-4a5c-8394-8c0e4eee84c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_89f98e25-1ba1-4585-bead-c3ccfa79badf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeLiabilities_89f98e25-1ba1-4585-bead-c3ccfa79badf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0bd91d13-623b-497a-8d93-540efb3072d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0bd91d13-623b-497a-8d93-540efb3072d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_f56c3bf9-6f5b-43a7-b79e-493a606c783a" xlink:href="jnj-20230402.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_f56c3bf9-6f5b-43a7-b79e-493a606c783a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2a1d9092-7157-4743-82a7-95feacfd7ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2a1d9092-7157-4743-82a7-95feacfd7ac1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_eae67a5f-5fd4-404b-9f0b-0af58b30c480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_eae67a5f-5fd4-404b-9f0b-0af58b30c480" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_77119a89-3155-41ff-98c3-f6573254742d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_a1427035-10da-484d-ac86-5b50520a6f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_a1427035-10da-484d-ac86-5b50520a6f7e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b824f5f6-9b8c-4e17-82a2-41c30d6da50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b824f5f6-9b8c-4e17-82a2-41c30d6da50f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b824f5f6-9b8c-4e17-82a2-41c30d6da50f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b824f5f6-9b8c-4e17-82a2-41c30d6da50f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b824f5f6-9b8c-4e17-82a2-41c30d6da50f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_24b9b9b0-2fce-41cd-a969-0dbfd37bf47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b824f5f6-9b8c-4e17-82a2-41c30d6da50f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_24b9b9b0-2fce-41cd-a969-0dbfd37bf47e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_69b6f258-1370-4aa2-a62a-776702ace23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24b9b9b0-2fce-41cd-a969-0dbfd37bf47e" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_69b6f258-1370-4aa2-a62a-776702ace23f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_51659068-c261-47bf-8563-a1e35d21bfdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24b9b9b0-2fce-41cd-a969-0dbfd37bf47e" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_51659068-c261-47bf-8563-a1e35d21bfdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_797f20d3-bc69-41dd-afe9-51721410b72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24b9b9b0-2fce-41cd-a969-0dbfd37bf47e" xlink:to="loc_us-gaap_LongTermDebtMember_797f20d3-bc69-41dd-afe9-51721410b72d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9fb0b197-9eab-435e-96c8-904b63472be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9fb0b197-9eab-435e-96c8-904b63472be6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9fb0b197-9eab-435e-96c8-904b63472be6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9fb0b197-9eab-435e-96c8-904b63472be6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9fb0b197-9eab-435e-96c8-904b63472be6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_780df89a-a15f-4424-92e9-4c481f7c5974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9fb0b197-9eab-435e-96c8-904b63472be6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_780df89a-a15f-4424-92e9-4c481f7c5974" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_b3632a5e-99a0-40e1-bc1e-5d62771b96c6" xlink:href="jnj-20230402.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_780df89a-a15f-4424-92e9-4c481f7c5974" xlink:to="loc_jnj_AurisHealthMember_b3632a5e-99a0-40e1-bc1e-5d62771b96c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4452e8d8-378d-4e80-98ee-d99995f925ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_InvestmentTypeAxis_4452e8d8-378d-4e80-98ee-d99995f925ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_4452e8d8-378d-4e80-98ee-d99995f925ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_4452e8d8-378d-4e80-98ee-d99995f925ee" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_4452e8d8-378d-4e80-98ee-d99995f925ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_230193c2-b232-4de0-a4c6-cc6b65e0ddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_4452e8d8-378d-4e80-98ee-d99995f925ee" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_230193c2-b232-4de0-a4c6-cc6b65e0ddd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_ea6dd485-7392-4125-afba-d039cbfe7df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_230193c2-b232-4de0-a4c6-cc6b65e0ddd6" xlink:to="loc_us-gaap_EquitySecuritiesMember_ea6dd485-7392-4125-afba-d039cbfe7df6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3b129dba-23cc-4411-a9e3-87106b84916a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3b129dba-23cc-4411-a9e3-87106b84916a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3b129dba-23cc-4411-a9e3-87106b84916a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3b129dba-23cc-4411-a9e3-87106b84916a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3b129dba-23cc-4411-a9e3-87106b84916a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c7cc18bf-bd8a-469e-a8f5-8486f9aa1803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3b129dba-23cc-4411-a9e3-87106b84916a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c7cc18bf-bd8a-469e-a8f5-8486f9aa1803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_de524015-80b8-44ea-ab94-111e7c6672a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7cc18bf-bd8a-469e-a8f5-8486f9aa1803" xlink:to="loc_us-gaap_InterestRateContractMember_de524015-80b8-44ea-ab94-111e7c6672a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ae2d593c-09f3-405c-a6f8-9fcf9f404609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7cc18bf-bd8a-469e-a8f5-8486f9aa1803" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ae2d593c-09f3-405c-a6f8-9fcf9f404609" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_25e942cf-79a4-4a0e-b337-ca944f471b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7cc18bf-bd8a-469e-a8f5-8486f9aa1803" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_25e942cf-79a4-4a0e-b337-ca944f471b0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_215c3c9d-20d6-419d-8c75-d217b52b2a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_215c3c9d-20d6-419d-8c75-d217b52b2a97" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_215c3c9d-20d6-419d-8c75-d217b52b2a97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_215c3c9d-20d6-419d-8c75-d217b52b2a97" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_215c3c9d-20d6-419d-8c75-d217b52b2a97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74036240-af18-4506-9f10-d9f3ae05f0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_215c3c9d-20d6-419d-8c75-d217b52b2a97" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74036240-af18-4506-9f10-d9f3ae05f0fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_813cf36c-1c55-49df-bd12-3aad91f83dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74036240-af18-4506-9f10-d9f3ae05f0fb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_813cf36c-1c55-49df-bd12-3aad91f83dd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_78a41022-6842-4373-9c8f-046c63289a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74036240-af18-4506-9f10-d9f3ae05f0fb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_78a41022-6842-4373-9c8f-046c63289a23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_64f21073-83d1-48da-bfc2-85a651bc7d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74036240-af18-4506-9f10-d9f3ae05f0fb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_64f21073-83d1-48da-bfc2-85a651bc7d82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da82e1b3-53ed-4a7b-9e8b-1e4e25835126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da82e1b3-53ed-4a7b-9e8b-1e4e25835126" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_da82e1b3-53ed-4a7b-9e8b-1e4e25835126_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da82e1b3-53ed-4a7b-9e8b-1e4e25835126" xlink:to="loc_us-gaap_HedgingRelationshipDomain_da82e1b3-53ed-4a7b-9e8b-1e4e25835126_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f76dbd7e-405a-4651-8864-58ddafeea3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da82e1b3-53ed-4a7b-9e8b-1e4e25835126" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f76dbd7e-405a-4651-8864-58ddafeea3e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_c065260f-5349-4ec5-8104-7dfbecd8e63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f76dbd7e-405a-4651-8864-58ddafeea3e1" xlink:to="loc_us-gaap_FairValueHedgingMember_c065260f-5349-4ec5-8104-7dfbecd8e63e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_22e16843-d373-4b70-8923-7acb1c87bd39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_22e16843-d373-4b70-8923-7acb1c87bd39" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_22e16843-d373-4b70-8923-7acb1c87bd39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_22e16843-d373-4b70-8923-7acb1c87bd39" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_22e16843-d373-4b70-8923-7acb1c87bd39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a99b1547-3dfb-4464-9979-f3010a4c124d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_22e16843-d373-4b70-8923-7acb1c87bd39" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a99b1547-3dfb-4464-9979-f3010a4c124d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_61c293b1-41a6-4628-be00-56a5eb7dc455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a99b1547-3dfb-4464-9979-f3010a4c124d" xlink:to="loc_us-gaap_EquitySecuritiesMember_61c293b1-41a6-4628-be00-56a5eb7dc455" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended" id="i69e2f3d163564b0180f4ff91d55eb0c2_FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_e626e798-952a-4a80-9861-5f5f3cfe19cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dfadffc1-b526-4b77-9fb8-e09dfd4b96a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e626e798-952a-4a80-9861-5f5f3cfe19cb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dfadffc1-b526-4b77-9fb8-e09dfd4b96a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_6fc02c94-cf25-4c54-abe7-0c17e7b81843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dfadffc1-b526-4b77-9fb8-e09dfd4b96a8" xlink:to="loc_us-gaap_HeldToMaturitySecurities_6fc02c94-cf25-4c54-abe7-0c17e7b81843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_39322599-1888-4bc7-9970-1d4884778a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dfadffc1-b526-4b77-9fb8-e09dfd4b96a8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_39322599-1888-4bc7-9970-1d4884778a89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_f8cb5c39-229e-43f0-9159-5d70fb77cbca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dfadffc1-b526-4b77-9fb8-e09dfd4b96a8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_f8cb5c39-229e-43f0-9159-5d70fb77cbca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939cadf1-5d33-4b37-a1cf-1724e274920e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e626e798-952a-4a80-9861-5f5f3cfe19cb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939cadf1-5d33-4b37-a1cf-1724e274920e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_595f3003-5865-4fa8-9379-6d5efecb4d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939cadf1-5d33-4b37-a1cf-1724e274920e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_595f3003-5865-4fa8-9379-6d5efecb4d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2ad28201-1724-4f04-aaf6-9ea4645ddebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939cadf1-5d33-4b37-a1cf-1724e274920e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2ad28201-1724-4f04-aaf6-9ea4645ddebb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f91537b7-52e6-448a-a63f-0e4a8ec3ee69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939cadf1-5d33-4b37-a1cf-1724e274920e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f91537b7-52e6-448a-a63f-0e4a8ec3ee69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f60fb7fd-68bd-4d2b-8534-3a70a8eceef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939cadf1-5d33-4b37-a1cf-1724e274920e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f60fb7fd-68bd-4d2b-8534-3a70a8eceef3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e626e798-952a-4a80-9861-5f5f3cfe19cb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_380a611b-2047-4dca-a86d-cc3473f656b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_380a611b-2047-4dca-a86d-cc3473f656b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ce86aeec-cf7f-4fe0-b5e7-d6b2d8359a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ce86aeec-cf7f-4fe0-b5e7-d6b2d8359a6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_6287ca8c-c5ff-47cc-aff3-406efb9dba84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_6287ca8c-c5ff-47cc-aff3-406efb9dba84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_0e69b72b-2789-4ecd-8227-4654d06979bd" xlink:href="jnj-20230402.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_0e69b72b-2789-4ecd-8227-4654d06979bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_eec3c842-71f3-46b0-9702-b1afdf3380df" xlink:href="jnj-20230402.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_eec3c842-71f3-46b0-9702-b1afdf3380df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_53b1c16b-19ea-4de4-9b51-fb8fb9e64739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e626e798-952a-4a80-9861-5f5f3cfe19cb" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_53b1c16b-19ea-4de4-9b51-fb8fb9e64739" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6a9a276c-9322-4cf2-8657-0c252b99a6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_53b1c16b-19ea-4de4-9b51-fb8fb9e64739" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6a9a276c-9322-4cf2-8657-0c252b99a6e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_6a9a276c-9322-4cf2-8657-0c252b99a6e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6a9a276c-9322-4cf2-8657-0c252b99a6e7" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_6a9a276c-9322-4cf2-8657-0c252b99a6e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_e9e0d1f0-6ab0-4cdb-9971-ecbfd1869244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6a9a276c-9322-4cf2-8657-0c252b99a6e7" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_e9e0d1f0-6ab0-4cdb-9971-ecbfd1869244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_20d55da7-aeb6-480a-9ea2-36e0fcd1a1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_e9e0d1f0-6ab0-4cdb-9971-ecbfd1869244" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_20d55da7-aeb6-480a-9ea2-36e0fcd1a1d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_14a9d1a5-9a53-4511-818f-b5e56830bb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_e9e0d1f0-6ab0-4cdb-9971-ecbfd1869244" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_14a9d1a5-9a53-4511-818f-b5e56830bb0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_7496816a-ee67-41d6-9b34-fd389cba08e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_53b1c16b-19ea-4de4-9b51-fb8fb9e64739" xlink:to="loc_us-gaap_InvestmentTypeAxis_7496816a-ee67-41d6-9b34-fd389cba08e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7496816a-ee67-41d6-9b34-fd389cba08e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_7496816a-ee67-41d6-9b34-fd389cba08e2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7496816a-ee67-41d6-9b34-fd389cba08e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_7496816a-ee67-41d6-9b34-fd389cba08e2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_1ea36578-3f17-446d-8c8d-d40a866870de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_CashMember_1ea36578-3f17-446d-8c8d-d40a866870de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestrictedCashMember_94c463f5-2436-4d18-8e00-773b02c2aa8a" xlink:href="jnj-20230402.xsd#jnj_RestrictedCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_jnj_RestrictedCashMember_94c463f5-2436-4d18-8e00-773b02c2aa8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_ef3bbbde-56ba-4860-a27b-5fbccb77e736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_ef3bbbde-56ba-4860-a27b-5fbccb77e736" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0296141e-1a9a-4b43-a91b-6e251f9dd916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0296141e-1a9a-4b43-a91b-6e251f9dd916" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2164a4d8-23f5-49e4-9b38-3165633960ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2164a4d8-23f5-49e4-9b38-3165633960ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_344b8561-8259-416f-8eaf-09dd4420de7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_BankTimeDepositsMember_344b8561-8259-416f-8eaf-09dd4420de7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_fc257e96-4abd-4172-9b89-eadeb75cc41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_fc257e96-4abd-4172-9b89-eadeb75cc41d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0e0a6f38-c4de-4de0-b404-45ba9caa40b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0e0a6f38-c4de-4de0-b404-45ba9caa40b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_caf23f5a-43c9-45af-a6b7-48c066f8f0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_53b1c16b-19ea-4de4-9b51-fb8fb9e64739" xlink:to="loc_us-gaap_FinancialInstrumentAxis_caf23f5a-43c9-45af-a6b7-48c066f8f0c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_caf23f5a-43c9-45af-a6b7-48c066f8f0c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_caf23f5a-43c9-45af-a6b7-48c066f8f0c3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_caf23f5a-43c9-45af-a6b7-48c066f8f0c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548203b5-380e-4b1e-9b21-8c0df809ad60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_caf23f5a-43c9-45af-a6b7-48c066f8f0c3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548203b5-380e-4b1e-9b21-8c0df809ad60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_f397034d-4b64-46a5-8626-f6d04d6e00ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548203b5-380e-4b1e-9b21-8c0df809ad60" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_f397034d-4b64-46a5-8626-f6d04d6e00ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_19545a37-1a04-47bf-a566-db1c905d185a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548203b5-380e-4b1e-9b21-8c0df809ad60" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_19545a37-1a04-47bf-a566-db1c905d185a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3792f1f2-6d56-4c6b-a774-4461f164d7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548203b5-380e-4b1e-9b21-8c0df809ad60" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3792f1f2-6d56-4c6b-a774-4461f164d7f3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended" id="i936b6e1f34e845eb840596366715fc51_FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_73fa31ff-77b9-4cd4-95fe-478d528be01f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_73fa31ff-77b9-4cd4-95fe-478d528be01f" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_df17daae-cf58-407f-b9a1-0935a9aa95ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_df17daae-cf58-407f-b9a1-0935a9aa95ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_afb53a14-9433-4a49-8212-8e7b57d61061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_df17daae-cf58-407f-b9a1-0935a9aa95ad" xlink:to="loc_us-gaap_ShortTermBorrowings_afb53a14-9433-4a49-8212-8e7b57d61061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_83c96a05-b604-424b-a7ea-779be3852a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_83c96a05-b604-424b-a7ea-779be3852a14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f54808e9-fc5d-4fa7-8530-45afcda8acb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_83c96a05-b604-424b-a7ea-779be3852a14" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f54808e9-fc5d-4fa7-8530-45afcda8acb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_afa233a7-a613-4511-8790-b48ae1bd9824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_afa233a7-a613-4511-8790-b48ae1bd9824" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e42fd80f-cb7c-467e-b5f9-9e2ec85dd9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e42fd80f-cb7c-467e-b5f9-9e2ec85dd9f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_f8cc6e6a-c85e-437d-a744-480da851d879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_f8cc6e6a-c85e-437d-a744-480da851d879" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt_21d63365-fa70-422a-bfdc-c0069ee1961c" xlink:href="jnj-20230402.xsd#jnj_ExcessOfCarryingValueOverFairValueOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_73fa31ff-77b9-4cd4-95fe-478d528be01f" xlink:to="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt_21d63365-fa70-422a-bfdc-c0069ee1961c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_09dc814d-fc8b-462e-aa4c-732a828592cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_73fa31ff-77b9-4cd4-95fe-478d528be01f" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_09dc814d-fc8b-462e-aa4c-732a828592cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_82d50322-f9e5-405f-bad8-9120c65fad38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_09dc814d-fc8b-462e-aa4c-732a828592cf" xlink:to="loc_us-gaap_DebtInstrumentAxis_82d50322-f9e5-405f-bad8-9120c65fad38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_82d50322-f9e5-405f-bad8-9120c65fad38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_82d50322-f9e5-405f-bad8-9120c65fad38" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_82d50322-f9e5-405f-bad8-9120c65fad38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_82d50322-f9e5-405f-bad8-9120c65fad38" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_4d21808d-f1fb-4b80-a484-75959bb8d719" xlink:href="jnj-20230402.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A0.650NotesDue2024Member_4d21808d-f1fb-4b80-a484-75959bb8d719" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_21767e0a-7237-4ec1-93ae-55dfa23258fd" xlink:href="jnj-20230402.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A5.50NotesDue2024Member_21767e0a-7237-4ec1-93ae-55dfa23258fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_f21b2cd8-da38-4035-9c55-66aa3fcd1aa7" xlink:href="jnj-20230402.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A2.625Notesdue2025Member_f21b2cd8-da38-4035-9c55-66aa3fcd1aa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member_4b4016de-1340-4ca4-ad84-5bb1c135cd3c" xlink:href="jnj-20230402.xsd#jnj_A0550NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A0550NotesDue2025Member_4b4016de-1340-4ca4-ad84-5bb1c135cd3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_50eda4da-e600-4477-ace3-a641cd187e43" xlink:href="jnj-20230402.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A2.45Notesdue2026Member_50eda4da-e600-4477-ace3-a641cd187e43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_c06c7f92-4d41-41f5-9ab5-e3e1f3cce7b6" xlink:href="jnj-20230402.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A2.95Notesdue2027Member_c06c7f92-4d41-41f5-9ab5-e3e1f3cce7b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_751339a0-66b2-4157-a7d0-6176ebc1ca24" xlink:href="jnj-20230402.xsd#jnj_A095NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A095NotesDue2027Member_751339a0-66b2-4157-a7d0-6176ebc1ca24" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_ff9473fe-75d1-4254-b293-f94eb6115a00" xlink:href="jnj-20230402.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A2.900Notesdue2028Member_ff9473fe-75d1-4254-b293-f94eb6115a00" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_deb4cfbb-5ff9-4379-a8ba-11e23cfd2e09" xlink:href="jnj-20230402.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A1.150NotesDue2028Member_deb4cfbb-5ff9-4379-a8ba-11e23cfd2e09" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_bf596a52-3096-4cf6-b58d-43d8afce8e1b" xlink:href="jnj-20230402.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A6.95Notesdue2029Member_bf596a52-3096-4cf6-b58d-43d8afce8e1b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member_99d9db44-ab4a-4b4d-a852-569eb86d12eb" xlink:href="jnj-20230402.xsd#jnj_A1300NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A1300NotesDue2030Member_99d9db44-ab4a-4b4d-a852-569eb86d12eb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_647c0276-5b2a-46d9-b52d-336aa1d14d20" xlink:href="jnj-20230402.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_647c0276-5b2a-46d9-b52d-336aa1d14d20" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_82cd649c-6121-4a84-8d9c-6ea1e094bb97" xlink:href="jnj-20230402.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A4.375Notesdue2033Member_82cd649c-6121-4a84-8d9c-6ea1e094bb97" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_dfedbbe8-1665-46f0-bbac-97ca3d5d69e6" xlink:href="jnj-20230402.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A1.650NotesDue2035Member_dfedbbe8-1665-46f0-bbac-97ca3d5d69e6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_34d97835-c416-4252-8dfa-28966b2f766e" xlink:href="jnj-20230402.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A3.55Notesdue2036Member_34d97835-c416-4252-8dfa-28966b2f766e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_3158ffa1-ebbb-446c-b5f6-9302aefeaefb" xlink:href="jnj-20230402.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A5.95Notesdue2037Member_3158ffa1-ebbb-446c-b5f6-9302aefeaefb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_14d9ec40-3ee8-4c6e-9d96-09ddd9b80d81" xlink:href="jnj-20230402.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A3.625Notesdue2037Member_14d9ec40-3ee8-4c6e-9d96-09ddd9b80d81" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_18b8ff3f-e6d4-444e-a95e-08c101bbf6fc" xlink:href="jnj-20230402.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A3.400Notesdue2038Member_18b8ff3f-e6d4-444e-a95e-08c101bbf6fc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_b010f3d9-c321-4ab3-8c3e-d09cf3c911ec" xlink:href="jnj-20230402.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_b010f3d9-c321-4ab3-8c3e-d09cf3c911ec" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_a577b88f-abd6-408e-aef8-9000ba228564" xlink:href="jnj-20230402.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_a577b88f-abd6-408e-aef8-9000ba228564" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_f419d02f-1f30-4a7b-923a-4200009528d5" xlink:href="jnj-20230402.xsd#jnj_A210NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A210NotesDue2040Member_f419d02f-1f30-4a7b-923a-4200009528d5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_63f440c6-052a-4db3-ac75-1397113673e9" xlink:href="jnj-20230402.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A4.85Notesdue2041Member_63f440c6-052a-4db3-ac75-1397113673e9" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_b7a157cd-c992-4253-a1c8-7737dc9a6229" xlink:href="jnj-20230402.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A4.50Notesdue2043Member_b7a157cd-c992-4253-a1c8-7737dc9a6229" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_b9c55776-60c4-4e17-ace4-6b6b127a8a80" xlink:href="jnj-20230402.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A3.70Notesdue2046Member_b9c55776-60c4-4e17-ace4-6b6b127a8a80" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_efc888d3-0b83-4d89-889c-179d17743188" xlink:href="jnj-20230402.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A3.75Notesdue2047Member_efc888d3-0b83-4d89-889c-179d17743188" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_ef3c30ba-a3ff-42f3-b78e-c24a356486b9" xlink:href="jnj-20230402.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A3.500Notesdue2048Member_ef3c30ba-a3ff-42f3-b78e-c24a356486b9" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_a5647b64-c5f5-4333-806d-34d1ba2cdb0d" xlink:href="jnj-20230402.xsd#jnj_A2250NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A2250NotesDue2050Member_a5647b64-c5f5-4333-806d-34d1ba2cdb0d" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_8cda95cd-58e9-471b-9a45-bee4393b1567" xlink:href="jnj-20230402.xsd#jnj_A2450NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A2450NotesDue2060Member_8cda95cd-58e9-471b-9a45-bee4393b1567" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A550DebentureDue2025Member_eca6eac4-9f93-47ff-94a4-fba832079925" xlink:href="jnj-20230402.xsd#jnj_A550DebentureDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A550DebentureDue2025Member_eca6eac4-9f93-47ff-94a4-fba832079925" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A535DebentureDue2026Member_81ec335b-fefa-47f5-8b03-29ea0f7fd86c" xlink:href="jnj-20230402.xsd#jnj_A535DebentureDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A535DebentureDue2026Member_81ec335b-fefa-47f5-8b03-29ea0f7fd86c" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A505DebentureDue2028Member_63702318-f6a7-4a57-a51f-4828456e01cc" xlink:href="jnj-20230402.xsd#jnj_A505DebentureDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A505DebentureDue2028Member_63702318-f6a7-4a57-a51f-4828456e01cc" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A500DebentureDue2030Member_dd0b202e-bf00-430d-b7bb-94fe68a1fb0c" xlink:href="jnj-20230402.xsd#jnj_A500DebentureDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A500DebentureDue2030Member_dd0b202e-bf00-430d-b7bb-94fe68a1fb0c" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A490DebentureDue2033Member_81d15e37-f09b-48d9-af0b-b2325f5ca977" xlink:href="jnj-20230402.xsd#jnj_A490DebentureDue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A490DebentureDue2033Member_81d15e37-f09b-48d9-af0b-b2325f5ca977" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A510DebentureDue2043Member_8999caa6-e9a2-4618-919a-c742ad367b69" xlink:href="jnj-20230402.xsd#jnj_A510DebentureDue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A510DebentureDue2043Member_8999caa6-e9a2-4618-919a-c742ad367b69" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A505DebentureDue2053Member_154b44c8-57ba-4d44-acd6-a39c17edb487" xlink:href="jnj-20230402.xsd#jnj_A505DebentureDue2053Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A505DebentureDue2053Member_154b44c8-57ba-4d44-acd6-a39c17edb487" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A520DebentureDue2063Member_1977a8a6-aafc-4cb8-9bc1-579b4d5d5af7" xlink:href="jnj-20230402.xsd#jnj_A520DebentureDue2063Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A520DebentureDue2063Member_1977a8a6-aafc-4cb8-9bc1-579b4d5d5af7" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember_338de418-4174-4c3a-97b2-33b89bdfd643" xlink:href="jnj-20230402.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_NotesDuePeriodFifteenMember_338de418-4174-4c3a-97b2-33b89bdfd643" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_926fb174-f04d-4a91-a5cc-2e50c90f5710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_09dc814d-fc8b-462e-aa4c-732a828592cf" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_926fb174-f04d-4a91-a5cc-2e50c90f5710" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_926fb174-f04d-4a91-a5cc-2e50c90f5710_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_926fb174-f04d-4a91-a5cc-2e50c90f5710" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_926fb174-f04d-4a91-a5cc-2e50c90f5710_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1c2a3159-e6ae-4eb6-a738-68baee11e1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_926fb174-f04d-4a91-a5cc-2e50c90f5710" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1c2a3159-e6ae-4eb6-a738-68baee11e1db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2a0408d-54a0-43b8-839e-378bfb047020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1c2a3159-e6ae-4eb6-a738-68baee11e1db" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2a0408d-54a0-43b8-839e-378bfb047020" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_283a68d9-2907-4a49-8b27-0f7975cf82f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2a0408d-54a0-43b8-839e-378bfb047020" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_283a68d9-2907-4a49-8b27-0f7975cf82f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7de3c3a2-5490-4898-9000-2fa70e2259ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2a0408d-54a0-43b8-839e-378bfb047020" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7de3c3a2-5490-4898-9000-2fa70e2259ef" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#IncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="extended" id="ia1077db2fcfc4305940589a73ddae1b7_IncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_7fa73424-5969-4f99-9256-1eb2468bd715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:to="loc_us-gaap_LitigationSettlementExpense_7fa73424-5969-4f99-9256-1eb2468bd715" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_4b4b0876-d65d-409f-8d7a-df1b08b31e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_4b4b0876-d65d-409f-8d7a-df1b08b31e87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6127eead-f010-4840-af75-6e69cd662e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6127eead-f010-4840-af75-6e69cd662e41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2251ebb4-0c13-44a4-ae82-383bbf0f0840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2251ebb4-0c13-44a4-ae82-383bbf0f0840" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_b5f9fb14-d337-4862-8caa-710d578d96c2" xlink:href="jnj-20230402.xsd#jnj_UnrecognizedTaxBenefitLiabilityPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:to="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_b5f9fb14-d337-4862-8caa-710d578d96c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e48c868b-0f48-4c6b-a5ca-717818d49fc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_srt_LitigationCaseAxis_e48c868b-0f48-4c6b-a5ca-717818d49fc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e48c868b-0f48-4c6b-a5ca-717818d49fc9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_e48c868b-0f48-4c6b-a5ca-717818d49fc9" xlink:to="loc_srt_LitigationCaseTypeDomain_e48c868b-0f48-4c6b-a5ca-717818d49fc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_00f92094-ac27-4e97-a874-0798a51f46cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_e48c868b-0f48-4c6b-a5ca-717818d49fc9" xlink:to="loc_srt_LitigationCaseTypeDomain_00f92094-ac27-4e97-a874-0798a51f46cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_5a313c74-5e92-4f66-93a8-45518c1c111d" xlink:href="jnj-20230402.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_00f92094-ac27-4e97-a874-0798a51f46cf" xlink:to="loc_jnj_TalcMember_5a313c74-5e92-4f66-93a8-45518c1c111d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_a4bcecaa-580d-431f-a00c-4d3cdc55b154" xlink:href="jnj-20230402.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_00f92094-ac27-4e97-a874-0798a51f46cf" xlink:to="loc_jnj_RisperdalMember_a4bcecaa-580d-431f-a00c-4d3cdc55b154" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_35891335-b4e8-4dda-adc8-734f7311e2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_35891335-b4e8-4dda-adc8-734f7311e2b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_35891335-b4e8-4dda-adc8-734f7311e2b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_35891335-b4e8-4dda-adc8-734f7311e2b4" xlink:to="loc_us-gaap_SegmentDomain_35891335-b4e8-4dda-adc8-734f7311e2b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8e197646-e49e-456d-8fb6-54d3a8d3ad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_35891335-b4e8-4dda-adc8-734f7311e2b4" xlink:to="loc_us-gaap_SegmentDomain_8e197646-e49e-456d-8fb6-54d3a8d3ad0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_5dd1037c-c8f3-4cca-861f-2e0740f1c171" xlink:href="jnj-20230402.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8e197646-e49e-456d-8fb6-54d3a8d3ad0c" xlink:to="loc_jnj_ConsumerMember_5dd1037c-c8f3-4cca-861f-2e0740f1c171" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_63573df2-4af6-4bef-b9f4-8d9f28793864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_63573df2-4af6-4bef-b9f4-8d9f28793864" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63573df2-4af6-4bef-b9f4-8d9f28793864_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63573df2-4af6-4bef-b9f4-8d9f28793864" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_63573df2-4af6-4bef-b9f4-8d9f28793864_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e220f637-ad9b-4e1e-a2ce-21d8c6aca348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63573df2-4af6-4bef-b9f4-8d9f28793864" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e220f637-ad9b-4e1e-a2ce-21d8c6aca348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_ccedf330-0298-45ca-991f-de3d05b70eb6" xlink:href="jnj-20230402.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e220f637-ad9b-4e1e-a2ce-21d8c6aca348" xlink:to="loc_jnj_AurisHealthMember_ccedf330-0298-45ca-991f-de3d05b70eb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_971db699-6a69-4a76-ab65-909bf03e707e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_971db699-6a69-4a76-ab65-909bf03e707e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_971db699-6a69-4a76-ab65-909bf03e707e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_971db699-6a69-4a76-ab65-909bf03e707e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_971db699-6a69-4a76-ab65-909bf03e707e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dac191cb-770f-404e-9393-a46d82527709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_971db699-6a69-4a76-ab65-909bf03e707e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dac191cb-770f-404e-9393-a46d82527709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_e9ec8157-859f-4bfe-8e62-398d78c4ff0d" xlink:href="jnj-20230402.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dac191cb-770f-404e-9393-a46d82527709" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_e9ec8157-859f-4bfe-8e62-398d78c4ff0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6a8731de-46c0-4443-94b2-e4f055fb859f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6a8731de-46c0-4443-94b2-e4f055fb859f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6a8731de-46c0-4443-94b2-e4f055fb859f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6a8731de-46c0-4443-94b2-e4f055fb859f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6a8731de-46c0-4443-94b2-e4f055fb859f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_96a447de-0937-476a-9d36-3d63bee42466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6a8731de-46c0-4443-94b2-e4f055fb859f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_96a447de-0937-476a-9d36-3d63bee42466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedTaxesOnIncomeMember_fd84bf8f-e935-4b63-b17e-30573ddf89c3" xlink:href="jnj-20230402.xsd#jnj_AccruedTaxesOnIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a447de-0937-476a-9d36-3d63bee42466" xlink:to="loc_jnj_AccruedTaxesOnIncomeMember_fd84bf8f-e935-4b63-b17e-30573ddf89c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_7e7c29af-e57d-45d0-aec0-0ab86de0b570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_7e7c29af-e57d-45d0-aec0-0ab86de0b570" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_7e7c29af-e57d-45d0-aec0-0ab86de0b570_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_7e7c29af-e57d-45d0-aec0-0ab86de0b570" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_7e7c29af-e57d-45d0-aec0-0ab86de0b570_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_d01c2c7d-e405-43c5-8d54-95ad353d2bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_7e7c29af-e57d-45d0-aec0-0ab86de0b570" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_d01c2c7d-e405-43c5-8d54-95ad353d2bd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_b420edb0-32bb-4346-8e2f-d674e822f7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_d01c2c7d-e405-43c5-8d54-95ad353d2bd9" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_b420edb0-32bb-4346-8e2f-d674e822f7a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a9425565-4009-4e4e-8c98-2e8cf6b46761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a9425565-4009-4e4e-8c98-2e8cf6b46761" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a9425565-4009-4e4e-8c98-2e8cf6b46761_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a9425565-4009-4e4e-8c98-2e8cf6b46761" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a9425565-4009-4e4e-8c98-2e8cf6b46761_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f930c15b-5aeb-405c-88de-2527077fb4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a9425565-4009-4e4e-8c98-2e8cf6b46761" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f930c15b-5aeb-405c-88de-2527077fb4fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_aa769771-1f35-4aec-a6a0-b0323a7d188a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f930c15b-5aeb-405c-88de-2527077fb4fb" xlink:to="loc_us-gaap_SubsequentEventMember_aa769771-1f35-4aec-a6a0-b0323a7d188a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="id3ec51478c2d4395b6b671c31282df4c_PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_895e87f6-7a6e-4cc7-8ad5-462f5e6e57a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_895e87f6-7a6e-4cc7-8ad5-462f5e6e57a9" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_5fdf9e1a-d9eb-4f43-94a1-bc3a6ad9c417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_5fdf9e1a-d9eb-4f43-94a1-bc3a6ad9c417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_2fa97ae9-a14f-4305-966d-a47f162bc6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_2fa97ae9-a14f-4305-966d-a47f162bc6b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_d0ca5e10-323f-478c-860d-a73a85c56eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_d0ca5e10-323f-478c-860d-a73a85c56eca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f60cdf4c-f9ff-4ea3-8718-51e73f077b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f60cdf4c-f9ff-4ea3-8718-51e73f077b4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2fcc4a04-9d55-4af9-b3df-e165ac90d0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2fcc4a04-9d55-4af9-b3df-e165ac90d0f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_05f5c3bd-74dc-432c-93fe-3f906a1338c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_05f5c3bd-74dc-432c-93fe-3f906a1338c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c8c3df39-ffe4-480c-85e9-72e4741f340a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c8c3df39-ffe4-480c-85e9-72e4741f340a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5c080222-f4ae-45d3-a8ae-043c7771f09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_895e87f6-7a6e-4cc7-8ad5-462f5e6e57a9" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5c080222-f4ae-45d3-a8ae-043c7771f09b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8c931144-405f-4e0a-a19e-b276e613044a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5c080222-f4ae-45d3-a8ae-043c7771f09b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8c931144-405f-4e0a-a19e-b276e613044a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8c931144-405f-4e0a-a19e-b276e613044a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8c931144-405f-4e0a-a19e-b276e613044a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8c931144-405f-4e0a-a19e-b276e613044a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_51b7a8b6-13e5-49e3-aaf2-a03348e9f62f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8c931144-405f-4e0a-a19e-b276e613044a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_51b7a8b6-13e5-49e3-aaf2-a03348e9f62f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_88326707-b78f-4d20-9b75-033a6c68c8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_51b7a8b6-13e5-49e3-aaf2-a03348e9f62f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_88326707-b78f-4d20-9b75-033a6c68c8a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0cc698cf-8bda-46cf-b467-f79c117eb77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_51b7a8b6-13e5-49e3-aaf2-a03348e9f62f" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0cc698cf-8bda-46cf-b467-f79c117eb77e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended" id="i4a3fd5fbc0f84356a216dcbe1d64f8cf_PensionsandOtherBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_be4f5d34-7f6f-45aa-bc16-11a30028a9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_e6261f36-7891-44bd-8ed0-202a1f14931b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_be4f5d34-7f6f-45aa-bc16-11a30028a9ac" xlink:to="loc_us-gaap_PensionContributions_e6261f36-7891-44bd-8ed0-202a1f14931b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8cece296-4bcd-49e3-b2dd-854b8e0ca38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_be4f5d34-7f6f-45aa-bc16-11a30028a9ac" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8cece296-4bcd-49e3-b2dd-854b8e0ca38a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3a4f43f-fb33-4e17-9311-8be38306019a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8cece296-4bcd-49e3-b2dd-854b8e0ca38a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3a4f43f-fb33-4e17-9311-8be38306019a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_e3a4f43f-fb33-4e17-9311-8be38306019a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3a4f43f-fb33-4e17-9311-8be38306019a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_e3a4f43f-fb33-4e17-9311-8be38306019a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2c5bae19-17be-439f-ad3c-4d6365db62a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3a4f43f-fb33-4e17-9311-8be38306019a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2c5bae19-17be-439f-ad3c-4d6365db62a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_fe784f69-50f6-46ba-81a6-cb69d0647739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2c5bae19-17be-439f-ad3c-4d6365db62a4" xlink:to="loc_us-gaap_DomesticPlanMember_fe784f69-50f6-46ba-81a6-cb69d0647739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_73980c4e-2116-421e-9a28-58c6cbffe792" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_fe784f69-50f6-46ba-81a6-cb69d0647739" xlink:to="loc_country_US_73980c4e-2116-421e-9a28-58c6cbffe792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_0e6082ed-5395-4ad4-bc79-38aecd8d2f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2c5bae19-17be-439f-ad3c-4d6365db62a4" xlink:to="loc_us-gaap_ForeignPlanMember_0e6082ed-5395-4ad4-bc79-38aecd8d2f41" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended" id="i63c30e359178430e96c852b47b15273b_AccumulatedOtherComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5bae52b1-1e1e-4669-b8da-2dbd4ca9fb51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5bae52b1-1e1e-4669-b8da-2dbd4ca9fb51" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7234f09f-6f6e-44cf-a1ca-b60dc48cdd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7234f09f-6f6e-44cf-a1ca-b60dc48cdd15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_70a2d430-de0f-4433-9051-570a105f6f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_70a2d430-de0f-4433-9051-570a105f6f21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_65529bd7-2d5f-4ea8-88b4-ecd5748ed3de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_65529bd7-2d5f-4ea8-88b4-ecd5748ed3de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_66ead5cc-a96c-47dd-a70f-dbc4ce0c3a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_66ead5cc-a96c-47dd-a70f-dbc4ce0c3a84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_47cafc38-07c0-4741-bba8-6b818fc5c943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_47cafc38-07c0-4741-bba8-6b818fc5c943" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2d7b2ca3-f6af-46f3-8d79-ebf8c2f8e5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2d7b2ca3-f6af-46f3-8d79-ebf8c2f8e5b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ba9c59f0-5e5b-4b33-bb36-f8102da3acde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_06cee861-916d-4056-a768-c7eb530d8be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5bae52b1-1e1e-4669-b8da-2dbd4ca9fb51" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_06cee861-916d-4056-a768-c7eb530d8be8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_67a735a5-f3c6-4505-aee4-245f267ae1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_06cee861-916d-4056-a768-c7eb530d8be8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_67a735a5-f3c6-4505-aee4-245f267ae1c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_67a735a5-f3c6-4505-aee4-245f267ae1c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_67a735a5-f3c6-4505-aee4-245f267ae1c6" xlink:to="loc_us-gaap_EquityComponentDomain_67a735a5-f3c6-4505-aee4-245f267ae1c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_67a735a5-f3c6-4505-aee4-245f267ae1c6" xlink:to="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5ca71f82-7939-46b2-aeeb-f0cf019f3526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5ca71f82-7939-46b2-aeeb-f0cf019f3526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d942bdd5-8f06-467c-9b12-cc6abba89c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d942bdd5-8f06-467c-9b12-cc6abba89c18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a37e45df-9d9b-468d-b73c-d14eb921a4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a37e45df-9d9b-468d-b73c-d14eb921a4b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_a332cf16-b709-4bcd-bb52-2684e83191e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_a332cf16-b709-4bcd-bb52-2684e83191e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_faf3756e-75b4-4425-a9c1-3f12572f91e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_faf3756e-75b4-4425-a9c1-3f12572f91e4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended" id="i839826af869046e79ee7ae88bd544a20_SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_edeeb68d-4f5e-405c-a51e-46559572b36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_b15ef415-9fd9-473c-8968-6c0beb0022a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_edeeb68d-4f5e-405c-a51e-46559572b36b" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_b15ef415-9fd9-473c-8968-6c0beb0022a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f3e8085c-f085-4047-95da-72b0b15e21ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_b15ef415-9fd9-473c-8968-6c0beb0022a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f3e8085c-f085-4047-95da-72b0b15e21ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_d5ca549a-3914-427a-933a-4cb5a532bade" xlink:href="jnj-20230402.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_b15ef415-9fd9-473c-8968-6c0beb0022a4" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_d5ca549a-3914-427a-933a-4cb5a532bade" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_edeeb68d-4f5e-405c-a51e-46559572b36b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3ac17d71-de3f-4c15-a55c-288896b79ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3ac17d71-de3f-4c15-a55c-288896b79ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ac17d71-de3f-4c15-a55c-288896b79ae7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3ac17d71-de3f-4c15-a55c-288896b79ae7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ac17d71-de3f-4c15-a55c-288896b79ae7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5845609-597e-45b5-ac0f-4429639fc737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3ac17d71-de3f-4c15-a55c-288896b79ae7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5845609-597e-45b5-ac0f-4429639fc737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_427e55c3-5eb9-446b-bf67-a3db114523de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_427e55c3-5eb9-446b-bf67-a3db114523de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_427e55c3-5eb9-446b-bf67-a3db114523de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_427e55c3-5eb9-446b-bf67-a3db114523de" xlink:to="loc_us-gaap_SegmentDomain_427e55c3-5eb9-446b-bf67-a3db114523de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dfa37a25-6af4-4e60-a3f3-2102ce676274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_427e55c3-5eb9-446b-bf67-a3db114523de" xlink:to="loc_us-gaap_SegmentDomain_dfa37a25-6af4-4e60-a3f3-2102ce676274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_aa17aab8-a4ff-4db6-a2de-4c1915c453fd" xlink:href="jnj-20230402.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dfa37a25-6af4-4e60-a3f3-2102ce676274" xlink:to="loc_jnj_ConsumerMember_aa17aab8-a4ff-4db6-a2de-4c1915c453fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_5aca5b96-7485-4a20-8c7d-3a6907bce937" xlink:href="jnj-20230402.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dfa37a25-6af4-4e60-a3f3-2102ce676274" xlink:to="loc_jnj_PharmaceuticalMember_5aca5b96-7485-4a20-8c7d-3a6907bce937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_b9d571ef-3ddf-42fd-bbf6-3256e7cdb298" xlink:href="jnj-20230402.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dfa37a25-6af4-4e60-a3f3-2102ce676274" xlink:to="loc_jnj_MedicalDevicesMember_b9d571ef-3ddf-42fd-bbf6-3256e7cdb298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_0715fcd6-e348-4e5a-95b0-d2c2d4a37c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:to="loc_us-gaap_SubsegmentsAxis_0715fcd6-e348-4e5a-95b0-d2c2d4a37c59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_0715fcd6-e348-4e5a-95b0-d2c2d4a37c59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_0715fcd6-e348-4e5a-95b0-d2c2d4a37c59" xlink:to="loc_us-gaap_SubsegmentsDomain_0715fcd6-e348-4e5a-95b0-d2c2d4a37c59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_0715fcd6-e348-4e5a-95b0-d2c2d4a37c59" xlink:to="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_4f459e77-cb55-4ce7-8b3d-ea1fcd16dc03" xlink:href="jnj-20230402.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_ImmunologyMember_4f459e77-cb55-4ce7-8b3d-ea1fcd16dc03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_0590dc18-9828-4a47-a851-cd9e6afd95a5" xlink:href="jnj-20230402.xsd#jnj_InfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_InfectiousDiseasesMember_0590dc18-9828-4a47-a851-cd9e6afd95a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_fb381a92-d873-4150-93e2-e475d34581df" xlink:href="jnj-20230402.xsd#jnj_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_NeuroscienceMember_fb381a92-d873-4150-93e2-e475d34581df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_3b0f5937-2a61-42f8-90cf-09b051699150" xlink:href="jnj-20230402.xsd#jnj_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_OncologyMember_3b0f5937-2a61-42f8-90cf-09b051699150" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_0eb42e5d-a7d1-4c6a-b60c-2d2ce9685a34" xlink:href="jnj-20230402.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_PulmonaryHypertensionMember_0eb42e5d-a7d1-4c6a-b60c-2d2ce9685a34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_b16c3277-d73b-4b0f-8382-caa0cbd241f8" xlink:href="jnj-20230402.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_b16c3277-d73b-4b0f-8382-caa0cbd241f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_3f8ecb90-1227-4771-b8fb-eb8aefbc3b60" xlink:href="jnj-20230402.xsd#jnj_InterventionalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_InterventionalSolutionsMember_3f8ecb90-1227-4771-b8fb-eb8aefbc3b60" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElectrophysiologyMember_1142c0c4-1483-4b10-8fdc-6c97eaa41916" xlink:href="jnj-20230402.xsd#jnj_ElectrophysiologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_ElectrophysiologyMember_1142c0c4-1483-4b10-8fdc-6c97eaa41916" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_ac5dfc81-5d14-44f1-a5ad-e2ccba22c025" xlink:href="jnj-20230402.xsd#jnj_AbiomedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_AbiomedMember_ac5dfc81-5d14-44f1-a5ad-e2ccba22c025" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInterventionalSolutionsMember_6bd70f6e-e35e-4921-9819-3f89f7cff3c7" xlink:href="jnj-20230402.xsd#jnj_OtherInterventionalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_OtherInterventionalSolutionsMember_6bd70f6e-e35e-4921-9819-3f89f7cff3c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_45f6e54d-47e6-4525-ac01-828c5a1c1cc7" xlink:href="jnj-20230402.xsd#jnj_OrthopaedicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_OrthopaedicsMember_45f6e54d-47e6-4525-ac01-828c5a1c1cc7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_0d119264-61e7-4397-9093-5f3252c6c390" xlink:href="jnj-20230402.xsd#jnj_SurgeryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_SurgeryMember_0d119264-61e7-4397-9093-5f3252c6c390" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_3fdbb4b7-deac-416c-9e15-b84594b838d2" xlink:href="jnj-20230402.xsd#jnj_VisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_VisionMember_3fdbb4b7-deac-416c-9e15-b84594b838d2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_287ad37a-c98d-4e8e-b815-978ac59a5788" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:to="loc_srt_ProductOrServiceAxis_287ad37a-c98d-4e8e-b815-978ac59a5788" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_287ad37a-c98d-4e8e-b815-978ac59a5788_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_287ad37a-c98d-4e8e-b815-978ac59a5788" xlink:to="loc_srt_ProductsAndServicesDomain_287ad37a-c98d-4e8e-b815-978ac59a5788_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_287ad37a-c98d-4e8e-b815-978ac59a5788" xlink:to="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_6aea7fa6-e1cf-44b7-9d11-3d109aedffe3" xlink:href="jnj-20230402.xsd#jnj_OTCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OTCMember_6aea7fa6-e1cf-44b7-9d11-3d109aedffe3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember_f65fd530-cec7-41cb-9914-6481b89ae732" xlink:href="jnj-20230402.xsd#jnj_BeautyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_BeautyMember_f65fd530-cec7-41cb-9914-6481b89ae732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_86efe0fb-c35e-4709-9e76-e35b168e11d8" xlink:href="jnj-20230402.xsd#jnj_OralCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OralCareMember_86efe0fb-c35e-4709-9e76-e35b168e11d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_9e8917e9-905f-4b55-8bf4-71a8d71cc40a" xlink:href="jnj-20230402.xsd#jnj_BabyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_BabyCareMember_9e8917e9-905f-4b55-8bf4-71a8d71cc40a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_b8ed41cc-e68c-4f65-b0fb-19143b292ac3" xlink:href="jnj-20230402.xsd#jnj_WomensHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_WomensHealthMember_b8ed41cc-e68c-4f65-b0fb-19143b292ac3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_ce32c146-e88c-47a9-bdf8-68e878aa6b64" xlink:href="jnj-20230402.xsd#jnj_WoundCareandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_WoundCareandOtherMember_ce32c146-e88c-47a9-bdf8-68e878aa6b64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_23a59356-2857-44ed-a875-6b74a8fffd85" xlink:href="jnj-20230402.xsd#jnj_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_RemicadeMember_23a59356-2857-44ed-a875-6b74a8fffd85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_a3ff8e0e-6211-4699-ac5a-2c89b92f4dad" xlink:href="jnj-20230402.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_SimponiSimponiAriaMember_a3ff8e0e-6211-4699-ac5a-2c89b92f4dad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_bc25dcfb-7823-4ca5-a481-a80071124b6b" xlink:href="jnj-20230402.xsd#jnj_StelaraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_StelaraMember_bc25dcfb-7823-4ca5-a481-a80071124b6b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_65bc6d77-c232-429b-9b59-7d6cf87a65ca" xlink:href="jnj-20230402.xsd#jnj_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_TremfyaMember_65bc6d77-c232-429b-9b59-7d6cf87a65ca" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_5443e1b1-bad5-414c-987f-beedccb8c941" xlink:href="jnj-20230402.xsd#jnj_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OtherImmunologyMember_5443e1b1-bad5-414c-987f-beedccb8c941" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_bca286a7-31ad-4266-97fc-21ac710ea4da" xlink:href="jnj-20230402.xsd#jnj_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_COVID19Member_bca286a7-31ad-4266-97fc-21ac710ea4da" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_9fc81f9e-1593-496d-8a4b-3c1832fff7d9" xlink:href="jnj-20230402.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_EDURANTrilpivirineMember_9fc81f9e-1593-496d-8a4b-3c1832fff7d9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_9b858065-b73f-488b-ae9a-715cb4cda15d" xlink:href="jnj-20230402.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_9b858065-b73f-488b-ae9a-715cb4cda15d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_ddca0460-713d-4728-ae45-c3c57af2c434" xlink:href="jnj-20230402.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_ddca0460-713d-4728-ae45-c3c57af2c434" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_5a9da27c-f485-4e3f-9abb-107879a6de96" xlink:href="jnj-20230402.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_5a9da27c-f485-4e3f-9abb-107879a6de96" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_6c512fca-5c6d-4447-8d2f-36325ed7a524" xlink:href="jnj-20230402.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_6c512fca-5c6d-4447-8d2f-36325ed7a524" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_a8e55e2b-aa61-4f6d-a112-bf7f79054240" xlink:href="jnj-20230402.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_a8e55e2b-aa61-4f6d-a112-bf7f79054240" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_e5334095-b428-47f5-9a1e-d8ca848b8cb8" xlink:href="jnj-20230402.xsd#jnj_DARZALEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_DARZALEXMember_e5334095-b428-47f5-9a1e-d8ca848b8cb8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember_f576e7d6-6a66-4f1c-8a97-81a30d47c8f5" xlink:href="jnj-20230402.xsd#jnj_ERLEADAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_ERLEADAMember_f576e7d6-6a66-4f1c-8a97-81a30d47c8f5" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_2b11fe7c-6d68-47d7-8971-168fbfcb18bb" xlink:href="jnj-20230402.xsd#jnj_IMBRUVICAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_IMBRUVICAMember_2b11fe7c-6d68-47d7-8971-168fbfcb18bb" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_bc28bde5-08a5-4ed3-8b3b-16249c5c7fbb" xlink:href="jnj-20230402.xsd#jnj_ZYTIGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_ZYTIGAMember_bc28bde5-08a5-4ed3-8b3b-16249c5c7fbb" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_31a5057e-60f0-43ee-a824-43013dd19107" xlink:href="jnj-20230402.xsd#jnj_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OtherOncologyMember_31a5057e-60f0-43ee-a824-43013dd19107" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_73e2c027-5c93-4be7-917d-714a13a71574" xlink:href="jnj-20230402.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OPSUMITMember_73e2c027-5c93-4be7-917d-714a13a71574" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_a6e98bcd-f17f-4021-80de-340c7c1580b8" xlink:href="jnj-20230402.xsd#jnj_UPTRAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_UPTRAVIMember_a6e98bcd-f17f-4021-80de-340c7c1580b8" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_17b55646-9718-473b-bc21-55c42c663a42" xlink:href="jnj-20230402.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_XareltoMember_17b55646-9718-473b-bc21-55c42c663a42" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_ba75f0b7-f9ab-4cfd-9f94-8008c60972f3" xlink:href="jnj-20230402.xsd#jnj_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OtherMember_ba75f0b7-f9ab-4cfd-9f94-8008c60972f3" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_dce424af-6715-4e78-af02-9b1912e1d498" xlink:href="jnj-20230402.xsd#jnj_HIPSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_HIPSMember_dce424af-6715-4e78-af02-9b1912e1d498" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_02ab7370-f494-4682-942d-852acd6064fa" xlink:href="jnj-20230402.xsd#jnj_KNEESMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_KNEESMember_02ab7370-f494-4682-942d-852acd6064fa" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_77470984-2243-4019-9e86-f9e0a0221912" xlink:href="jnj-20230402.xsd#jnj_TRAUMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_TRAUMAMember_77470984-2243-4019-9e86-f9e0a0221912" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_3c54a1d2-4c37-4072-bccc-ff595a79dcbb" xlink:href="jnj-20230402.xsd#jnj_SPINEOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_SPINEOTHERMember_3c54a1d2-4c37-4072-bccc-ff595a79dcbb" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_65cfb247-da4d-4a28-b34f-f2f0456c883a" xlink:href="jnj-20230402.xsd#jnj_ADVANCEDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_ADVANCEDMember_65cfb247-da4d-4a28-b34f-f2f0456c883a" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_596d4f48-d6e1-4c5b-ae3f-a8bbb21b5c6b" xlink:href="jnj-20230402.xsd#jnj_GENERALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_GENERALMember_596d4f48-d6e1-4c5b-ae3f-a8bbb21b5c6b" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_f8b1f979-58c0-462e-9706-24a31fc3b482" xlink:href="jnj-20230402.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_f8b1f979-58c0-462e-9706-24a31fc3b482" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_89c42042-cde8-4275-b7c3-b3965afecef4" xlink:href="jnj-20230402.xsd#jnj_SURGICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_SURGICALMember_89c42042-cde8-4275-b7c3-b3965afecef4" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CARVYKTIMember_63482946-572b-47aa-9e98-9fb25e430319" xlink:href="jnj-20230402.xsd#jnj_CARVYKTIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_CARVYKTIMember_63482946-572b-47aa-9e98-9fb25e430319" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPRAVATOMember_9369bce6-b29a-4559-b294-6bc7a0306517" xlink:href="jnj-20230402.xsd#jnj_SPRAVATOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_SPRAVATOMember_9369bce6-b29a-4559-b294-6bc7a0306517" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bf49ccba-efaf-42f1-b8fe-9aa10aee3185" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:to="loc_srt_StatementGeographicalAxis_bf49ccba-efaf-42f1-b8fe-9aa10aee3185" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bf49ccba-efaf-42f1-b8fe-9aa10aee3185_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bf49ccba-efaf-42f1-b8fe-9aa10aee3185" xlink:to="loc_srt_SegmentGeographicalDomain_bf49ccba-efaf-42f1-b8fe-9aa10aee3185_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8203c362-1af0-4269-8992-544b2dad9219" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bf49ccba-efaf-42f1-b8fe-9aa10aee3185" xlink:to="loc_srt_SegmentGeographicalDomain_8203c362-1af0-4269-8992-544b2dad9219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_eee4f7c2-9fe2-42f7-a722-69ceb8725ad3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8203c362-1af0-4269-8992-544b2dad9219" xlink:to="loc_country_US_eee4f7c2-9fe2-42f7-a722-69ceb8725ad3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_19ed6304-21f0-42da-a6b6-df4ea549f56d" xlink:href="jnj-20230402.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8203c362-1af0-4269-8992-544b2dad9219" xlink:to="loc_jnj_UNITEDSTATESExportsMember_19ed6304-21f0-42da-a6b6-df4ea549f56d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b0184925-ead9-408c-b4fb-fa8c640f2299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8203c362-1af0-4269-8992-544b2dad9219" xlink:to="loc_us-gaap_NonUsMember_b0184925-ead9-408c-b4fb-fa8c640f2299" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended" id="i8556ccb2be7f4400b2c78ab3922e4644_SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_80348220-e175-468c-8e93-385a7a102d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_OperatingIncomeLoss_80348220-e175-468c-8e93-385a7a102d32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_8a21d8cd-8925-4bda-b38e-44af0847cd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_BusinessExitCosts1_8a21d8cd-8925-4bda-b38e-44af0847cd4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71dc0e6e-fc34-41bd-842c-b9a4a87c0155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71dc0e6e-fc34-41bd-842c-b9a4a87c0155" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss_cbd8929f-fb20-49e2-8165-0032848d5377" xlink:href="jnj-20230402.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_jnj_PercentageChangeInOperatingIncomeLoss_cbd8929f-fb20-49e2-8165-0032848d5377" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_5cf63d4f-525f-46e4-a03c-39166c2eaaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_5cf63d4f-525f-46e4-a03c-39166c2eaaa2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_ec495847-a660-49e4-81ad-9ed481b04128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_SuppliesExpense_ec495847-a660-49e4-81ad-9ed481b04128" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_6edb7a90-6320-46be-8cd9-c17c56e931cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_RestructuringCharges_6edb7a90-6320-46be-8cd9-c17c56e931cd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_b98746da-14e7-4653-84ea-c6b5001da714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_b98746da-14e7-4653-84ea-c6b5001da714" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f18ddbee-6861-403c-bdaf-f411114d7b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f18ddbee-6861-403c-bdaf-f411114d7b4a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_6c203528-f037-4499-bc23-1018ed75d3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_AdjustmentForAmortization_6c203528-f037-4499-bc23-1018ed75d3a9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bcb3950e-749e-48e3-b6ae-ed0201bfc69c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c3a778fb-e32d-4dc1-a199-1d206c2c2b4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:to="loc_srt_ConsolidationItemsAxis_c3a778fb-e32d-4dc1-a199-1d206c2c2b4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c3a778fb-e32d-4dc1-a199-1d206c2c2b4e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_c3a778fb-e32d-4dc1-a199-1d206c2c2b4e" xlink:to="loc_srt_ConsolidationItemsDomain_c3a778fb-e32d-4dc1-a199-1d206c2c2b4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_19f859d8-230d-48e4-bf8f-124898feec8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_c3a778fb-e32d-4dc1-a199-1d206c2c2b4e" xlink:to="loc_srt_ConsolidationItemsDomain_19f859d8-230d-48e4-bf8f-124898feec8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_706656ed-4f18-4d77-9707-a7c84e271040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_19f859d8-230d-48e4-bf8f-124898feec8b" xlink:to="loc_us-gaap_OperatingSegmentsMember_706656ed-4f18-4d77-9707-a7c84e271040" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_099783fe-e94e-4a5e-ab9f-637145a32f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_19f859d8-230d-48e4-bf8f-124898feec8b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_099783fe-e94e-4a5e-ab9f-637145a32f68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ae21b6ae-8acf-4547-9af1-36067a8c0eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ae21b6ae-8acf-4547-9af1-36067a8c0eed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ae21b6ae-8acf-4547-9af1-36067a8c0eed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ae21b6ae-8acf-4547-9af1-36067a8c0eed" xlink:to="loc_us-gaap_SegmentDomain_ae21b6ae-8acf-4547-9af1-36067a8c0eed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8d735388-1890-4ed6-97ee-11f5805b8c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ae21b6ae-8acf-4547-9af1-36067a8c0eed" xlink:to="loc_us-gaap_SegmentDomain_8d735388-1890-4ed6-97ee-11f5805b8c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_badfe2cc-0250-45b6-8e68-d1f58177a430" xlink:href="jnj-20230402.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8d735388-1890-4ed6-97ee-11f5805b8c70" xlink:to="loc_jnj_ConsumerMember_badfe2cc-0250-45b6-8e68-d1f58177a430" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_17a12133-42a7-4846-8f32-cebbc295bad7" xlink:href="jnj-20230402.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8d735388-1890-4ed6-97ee-11f5805b8c70" xlink:to="loc_jnj_PharmaceuticalMember_17a12133-42a7-4846-8f32-cebbc295bad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_feb340b4-2adc-446b-a4c6-2a5e063267fb" xlink:href="jnj-20230402.xsd#jnj_MedicalDevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8d735388-1890-4ed6-97ee-11f5805b8c70" xlink:to="loc_jnj_MedicalDevicesMember_feb340b4-2adc-446b-a4c6-2a5e063267fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1a9dd970-36cf-4dc4-ad7b-290b7a0d4227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1a9dd970-36cf-4dc4-ad7b-290b7a0d4227" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a9dd970-36cf-4dc4-ad7b-290b7a0d4227_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1a9dd970-36cf-4dc4-ad7b-290b7a0d4227" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1a9dd970-36cf-4dc4-ad7b-290b7a0d4227_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8d20464-9b2c-4e59-8547-926a9c5709ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1a9dd970-36cf-4dc4-ad7b-290b7a0d4227" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8d20464-9b2c-4e59-8547-926a9c5709ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_21aea651-7620-48f6-804e-8930bf3c25df" xlink:href="jnj-20230402.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8d20464-9b2c-4e59-8547-926a9c5709ae" xlink:to="loc_jnj_BermekimabMember_21aea651-7620-48f6-804e-8930bf3c25df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e923f904-d2fd-4638-872b-2cbcebdc36ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:to="loc_srt_LitigationCaseAxis_e923f904-d2fd-4638-872b-2cbcebdc36ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e923f904-d2fd-4638-872b-2cbcebdc36ba_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_e923f904-d2fd-4638-872b-2cbcebdc36ba" xlink:to="loc_srt_LitigationCaseTypeDomain_e923f904-d2fd-4638-872b-2cbcebdc36ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1f290b95-1f09-4856-9ea6-a692188a115d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_e923f904-d2fd-4638-872b-2cbcebdc36ba" xlink:to="loc_srt_LitigationCaseTypeDomain_1f290b95-1f09-4856-9ea6-a692188a115d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_73547ba6-2595-4eab-9d3e-32159d1bfb5a" xlink:href="jnj-20230402.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1f290b95-1f09-4856-9ea6-a692188a115d" xlink:to="loc_jnj_RisperdalMember_73547ba6-2595-4eab-9d3e-32159d1bfb5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended" id="i34caf3e269ef472dbaf70e7b10e07340_SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6c554922-7489-4f6f-af18-2d71ad4dd9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_c3e731eb-eeec-4810-98fa-c7d0de7969ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6c554922-7489-4f6f-af18-2d71ad4dd9c5" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_c3e731eb-eeec-4810-98fa-c7d0de7969ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce4d78c0-56a3-46af-8915-ca5dbda1385d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_c3e731eb-eeec-4810-98fa-c7d0de7969ce" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce4d78c0-56a3-46af-8915-ca5dbda1385d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea_55c27ed8-b9a7-4c06-b8da-f6f8a6effd26" xlink:href="jnj-20230402.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_c3e731eb-eeec-4810-98fa-c7d0de7969ce" xlink:to="loc_jnj_PercentageChangeInSalesByGeographicArea_55c27ed8-b9a7-4c06-b8da-f6f8a6effd26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6bbdf5ac-ca6f-40f3-82e3-a3f0ee353de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6c554922-7489-4f6f-af18-2d71ad4dd9c5" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6bbdf5ac-ca6f-40f3-82e3-a3f0ee353de2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_faf147c7-b907-4653-8783-a123afcc1d0a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6bbdf5ac-ca6f-40f3-82e3-a3f0ee353de2" xlink:to="loc_srt_StatementGeographicalAxis_faf147c7-b907-4653-8783-a123afcc1d0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_faf147c7-b907-4653-8783-a123afcc1d0a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_faf147c7-b907-4653-8783-a123afcc1d0a" xlink:to="loc_srt_SegmentGeographicalDomain_faf147c7-b907-4653-8783-a123afcc1d0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f3ba1659-ef36-44ba-9925-7ff4d071b3da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_faf147c7-b907-4653-8783-a123afcc1d0a" xlink:to="loc_srt_SegmentGeographicalDomain_f3ba1659-ef36-44ba-9925-7ff4d071b3da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_dee51f55-4db4-4eff-a5f0-75f7869d3061" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f3ba1659-ef36-44ba-9925-7ff4d071b3da" xlink:to="loc_country_US_dee51f55-4db4-4eff-a5f0-75f7869d3061" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_17fad975-118a-4f97-887b-f3332d773db5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f3ba1659-ef36-44ba-9925-7ff4d071b3da" xlink:to="loc_srt_EuropeMember_17fad975-118a-4f97-887b-f3332d773db5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_e5222822-27ea-48fa-a377-d97c04ae33ef" xlink:href="jnj-20230402.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f3ba1659-ef36-44ba-9925-7ff4d071b3da" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_e5222822-27ea-48fa-a377-d97c04ae33ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_82e2e45b-dd61-4f7d-88a6-86006707be4a" xlink:href="jnj-20230402.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f3ba1659-ef36-44ba-9925-7ff4d071b3da" xlink:to="loc_jnj_AsiaPacificAfricaMember_82e2e45b-dd61-4f7d-88a6-86006707be4a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended" id="i493e163c42604e788b9e3bc8445dcaa4_AcquisitionsandDivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_cf6df50d-9e48-4c15-9159-48a8c2099688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_cf6df50d-9e48-4c15-9159-48a8c2099688" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7573961d-ed71-406b-a82f-7d49f352255d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7573961d-ed71-406b-a82f-7d49f352255d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_fb12ad9d-d329-4c48-99f2-cbfe04892848" xlink:href="jnj-20230402.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_fb12ad9d-d329-4c48-99f2-cbfe04892848" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_f4b2a46b-493f-468b-92af-c5a39be8f788" xlink:href="jnj-20230402.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_f4b2a46b-493f-468b-92af-c5a39be8f788" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a9e1fdf6-0412-400f-b2eb-0545b99e2c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a9e1fdf6-0412-400f-b2eb-0545b99e2c20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare_84eb99ff-bb7a-4161-93a0-6d48fa65c5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_DividendsPayableAmountPerShare_84eb99ff-bb7a-4161-93a0-6d48fa65c5f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RevenuesContingentConsideration_c326bb75-c346-4bed-ac31-2ff632797005" xlink:href="jnj-20230402.xsd#jnj_RevenuesContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_jnj_RevenuesContingentConsideration_c326bb75-c346-4bed-ac31-2ff632797005" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9095d54a-2f03-4116-a66e-5bd34adff365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9095d54a-2f03-4116-a66e-5bd34adff365" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_813e0995-db0b-42db-892d-a4270a2f86c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_813e0995-db0b-42db-892d-a4270a2f86c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_e77d8d3a-943e-4804-a1dc-fc117f418170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_e77d8d3a-943e-4804-a1dc-fc117f418170" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a576e1de-5dd7-4a7d-bb40-bb03e3c635cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a576e1de-5dd7-4a7d-bb40-bb03e3c635cc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_385dc79d-0c11-476c-91cc-f7cd7d8de722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_385dc79d-0c11-476c-91cc-f7cd7d8de722" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_63d306b3-f287-42e7-b8c0-3c99111e91c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_63d306b3-f287-42e7-b8c0-3c99111e91c8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b24fd1fc-8636-4900-becf-d1fd31328971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b24fd1fc-8636-4900-becf-d1fd31328971" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6217cff7-1899-4526-acea-3c59f147332d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6217cff7-1899-4526-acea-3c59f147332d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_3f5015de-ad89-43c2-b1f6-d78151397532" xlink:href="jnj-20230402.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_3f5015de-ad89-43c2-b1f6-d78151397532" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate_310e5b34-752f-431e-973b-1a0239695430" xlink:href="jnj-20230402.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_jnj_BusinessAcquisitionDiscountRate_310e5b34-752f-431e-973b-1a0239695430" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f1e44afd-5aac-4c61-bcd7-303d52b70035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f1e44afd-5aac-4c61-bcd7-303d52b70035" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_974e7d27-ae47-4af5-ae49-d65b2c05c8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_974e7d27-ae47-4af5-ae49-d65b2c05c8de" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_87551daa-dbf5-4060-afbd-5aa158807cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_87551daa-dbf5-4060-afbd-5aa158807cae" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_eb340584-9a72-4adb-a9d1-83495da24804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_eb340584-9a72-4adb-a9d1-83495da24804" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e44367ed-c2c9-42a4-9005-ee193066261b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e44367ed-c2c9-42a4-9005-ee193066261b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e44367ed-c2c9-42a4-9005-ee193066261b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e44367ed-c2c9-42a4-9005-ee193066261b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e44367ed-c2c9-42a4-9005-ee193066261b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07863a38-e375-471b-9bee-e45a4c8d452d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e44367ed-c2c9-42a4-9005-ee193066261b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07863a38-e375-471b-9bee-e45a4c8d452d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_69ac9e9e-4187-438b-b404-1749f8f1b223" xlink:href="jnj-20230402.xsd#jnj_AbiomedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07863a38-e375-471b-9bee-e45a4c8d452d" xlink:to="loc_jnj_AbiomedMember_69ac9e9e-4187-438b-b404-1749f8f1b223" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_806cf6ca-c903-4344-9244-d930d7e73acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:to="loc_us-gaap_AwardTypeAxis_806cf6ca-c903-4344-9244-d930d7e73acc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_806cf6ca-c903-4344-9244-d930d7e73acc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_806cf6ca-c903-4344-9244-d930d7e73acc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_806cf6ca-c903-4344-9244-d930d7e73acc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_762d42cd-74a5-4025-a72d-7023d35d66c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_806cf6ca-c903-4344-9244-d930d7e73acc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_762d42cd-74a5-4025-a72d-7023d35d66c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonTradeableContingentValueRightMember_0f6081ba-6c0f-4136-ad26-140fd20c1d0a" xlink:href="jnj-20230402.xsd#jnj_NonTradeableContingentValueRightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_762d42cd-74a5-4025-a72d-7023d35d66c6" xlink:to="loc_jnj_NonTradeableContingentValueRightMember_0f6081ba-6c0f-4136-ad26-140fd20c1d0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cceb929b-fb05-48d5-a906-82e88abe38ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:to="loc_srt_ProductOrServiceAxis_cceb929b-fb05-48d5-a906-82e88abe38ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cceb929b-fb05-48d5-a906-82e88abe38ec_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_cceb929b-fb05-48d5-a906-82e88abe38ec" xlink:to="loc_srt_ProductsAndServicesDomain_cceb929b-fb05-48d5-a906-82e88abe38ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b44471c7-37a6-43db-81e7-c130913c71e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_cceb929b-fb05-48d5-a906-82e88abe38ec" xlink:to="loc_srt_ProductsAndServicesDomain_b44471c7-37a6-43db-81e7-c130913c71e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImpellaMember_bfae4441-04a1-406b-a68f-dab1c6dfee05" xlink:href="jnj-20230402.xsd#jnj_ImpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b44471c7-37a6-43db-81e7-c130913c71e0" xlink:to="loc_jnj_ImpellaMember_bfae4441-04a1-406b-a68f-dab1c6dfee05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ClassIRecommendationForImpellaMember_aca2abfe-0e26-4095-9cb7-cddaf804a242" xlink:href="jnj-20230402.xsd#jnj_ClassIRecommendationForImpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b44471c7-37a6-43db-81e7-c130913c71e0" xlink:to="loc_jnj_ClassIRecommendationForImpellaMember_aca2abfe-0e26-4095-9cb7-cddaf804a242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dc8e1d83-87c6-4128-875a-912ada798f2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:to="loc_srt_RangeAxis_dc8e1d83-87c6-4128-875a-912ada798f2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dc8e1d83-87c6-4128-875a-912ada798f2f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dc8e1d83-87c6-4128-875a-912ada798f2f" xlink:to="loc_srt_RangeMember_dc8e1d83-87c6-4128-875a-912ada798f2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18a95865-cd39-4bea-86b9-97817a54b119" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dc8e1d83-87c6-4128-875a-912ada798f2f" xlink:to="loc_srt_RangeMember_18a95865-cd39-4bea-86b9-97817a54b119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7854050-737c-4c2f-a343-ecb179e3bf57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_18a95865-cd39-4bea-86b9-97817a54b119" xlink:to="loc_srt_MinimumMember_f7854050-737c-4c2f-a343-ecb179e3bf57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6046c877-9fba-49e6-9d8c-8d6fe21d9509" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_18a95865-cd39-4bea-86b9-97817a54b119" xlink:to="loc_srt_MaximumMember_6046c877-9fba-49e6-9d8c-8d6fe21d9509" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#LegalProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended" id="i94c91fa9b3cc42eaa9e7543411cab8b1_LegalProceedingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:href="jnj-20230402.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_c3d54d41-4601-4c8e-8c7c-fa23d4c94655" xlink:href="jnj-20230402.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_c3d54d41-4601-4c8e-8c7c-fa23d4c94655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_00997c2f-1681-4ce8-9030-84a967ba3cd8" xlink:href="jnj-20230402.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_jnj_Numberofpatientsinsettlement_00997c2f-1681-4ce8-9030-84a967ba3cd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_11e6d58d-dc24-4c3b-8306-f51c104cf65a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_11e6d58d-dc24-4c3b-8306-f51c104cf65a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_b788e29b-87db-46d6-b9df-fc2e15f8bbbd" xlink:href="jnj-20230402.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_b788e29b-87db-46d6-b9df-fc2e15f8bbbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_78174d00-07c8-44ed-a54c-3f1124ed8c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_78174d00-07c8-44ed-a54c-3f1124ed8c76" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_fb68776f-8f44-47d2-a40a-972748a5e1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_fb68776f-8f44-47d2-a40a-972748a5e1eb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_cdd39131-3378-46d2-a948-e93248cc89f1" xlink:href="jnj-20230402.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_cdd39131-3378-46d2-a948-e93248cc89f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPendingClaimsNumberRemaining_95d8264a-224c-4517-8a04-602074afd435" xlink:href="jnj-20230402.xsd#jnj_LossContingencyPendingClaimsNumberRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_jnj_LossContingencyPendingClaimsNumberRemaining_95d8264a-224c-4517-8a04-602074afd435" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPendingClaimsNumberAdditional_fcfc8607-e11b-45dd-bba9-1bcc93436b11" xlink:href="jnj-20230402.xsd#jnj_LossContingencyPendingClaimsNumberAdditional"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_jnj_LossContingencyPendingClaimsNumberAdditional_fcfc8607-e11b-45dd-bba9-1bcc93436b11" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4bdbf48d-d7e2-461a-8fa5-582b04fffe62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4bdbf48d-d7e2-461a-8fa5-582b04fffe62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableProceeds_a55ff98a-0ee3-4816-85a9-c5b5083aeea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_us-gaap_LossContingencyReceivableProceeds_a55ff98a-0ee3-4816-85a9-c5b5083aeea3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_d3cab608-069d-4a65-90f3-0a5e361b5a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_d3cab608-069d-4a65-90f3-0a5e361b5a5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyAdditionalContribution_8b58213a-3c39-4a98-9733-ba1ddddda610" xlink:href="jnj-20230402.xsd#jnj_LossContingencyAdditionalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_LossContingencyAdditionalContribution_8b58213a-3c39-4a98-9733-ba1ddddda610" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrustTotal_6e06d040-2511-49bc-b0a4-716181c56538" xlink:href="jnj-20230402.xsd#jnj_LossContingencyReserveEstablishedWithinTrustTotal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrustTotal_6e06d040-2511-49bc-b0a4-716181c56538" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue_f0c767ed-53ad-4597-9df7-63685fbb40b7" xlink:href="jnj-20230402.xsd#jnj_LossContingencyReserveEstablishedWithinTrustNominalValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue_f0c767ed-53ad-4597-9df7-63685fbb40b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BankruptcyLossContingencyDiscountRate_2b6450e0-45c7-4226-a40a-4592ac401432" xlink:href="jnj-20230402.xsd#jnj_BankruptcyLossContingencyDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_BankruptcyLossContingencyDiscountRate_2b6450e0-45c7-4226-a40a-4592ac401432" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyTerm_b77746ef-29a7-452b-a42f-bf0be5de6f1e" xlink:href="jnj-20230402.xsd#jnj_LossContingencyTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_LossContingencyTerm_b77746ef-29a7-452b-a42f-bf0be5de6f1e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_c70b0eef-1ba5-4227-86f9-bb33d58e7ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_c70b0eef-1ba5-4227-86f9-bb33d58e7ecd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyRemainingTerm_c8d269ec-5c30-4053-aadd-0ec5d8c1a435" xlink:href="jnj-20230402.xsd#jnj_LossContingencyRemainingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_LossContingencyRemainingTerm_c8d269ec-5c30-4053-aadd-0ec5d8c1a435" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d8d20e39-aeda-4e67-92ef-3c5662d7edde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:to="loc_srt_LitigationCaseAxis_d8d20e39-aeda-4e67-92ef-3c5662d7edde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_d8d20e39-aeda-4e67-92ef-3c5662d7edde_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_d8d20e39-aeda-4e67-92ef-3c5662d7edde" xlink:to="loc_srt_LitigationCaseTypeDomain_d8d20e39-aeda-4e67-92ef-3c5662d7edde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_d8d20e39-aeda-4e67-92ef-3c5662d7edde" xlink:to="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_535be347-ec33-44e6-8455-d44a9cc05b0d" xlink:href="jnj-20230402.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:to="loc_jnj_RisperdalMember_535be347-ec33-44e6-8455-d44a9cc05b0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_ddca4262-861c-4b55-9e13-1fead72a4b88" xlink:href="jnj-20230402.xsd#jnj_DePuyASRU.S.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:to="loc_jnj_DePuyASRU.S.Member_ddca4262-861c-4b55-9e13-1fead72a4b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_b8075d28-cf64-4226-899b-4abc15e4cff0" xlink:href="jnj-20230402.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:to="loc_jnj_BabyPowderMember_b8075d28-cf64-4226-899b-4abc15e4cff0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_9c2bdc28-e585-432b-955e-72497be858d3" xlink:href="jnj-20230402.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_9c2bdc28-e585-432b-955e-72497be858d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_0cb4e0e1-4767-4f7e-b74a-08b9544b4e69" xlink:href="jnj-20230402.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_0cb4e0e1-4767-4f7e-b74a-08b9544b4e69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InghamVsJohnsonJohnsonMember_7cc0cf3b-aa16-4c95-abe3-c7c1e41c1b3c" xlink:href="jnj-20230402.xsd#jnj_InghamVsJohnsonJohnsonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:to="loc_jnj_InghamVsJohnsonJohnsonMember_7cc0cf3b-aa16-4c95-abe3-c7c1e41c1b3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_639af253-8b4f-4656-83cd-9d649928a15b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:to="loc_srt_ProductOrServiceAxis_639af253-8b4f-4656-83cd-9d649928a15b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_639af253-8b4f-4656-83cd-9d649928a15b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_639af253-8b4f-4656-83cd-9d649928a15b" xlink:to="loc_srt_ProductsAndServicesDomain_639af253-8b4f-4656-83cd-9d649928a15b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_639af253-8b4f-4656-83cd-9d649928a15b" xlink:to="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_7cb67df2-5437-4a97-bde4-a41ad58d3a46" xlink:href="jnj-20230402.xsd#jnj_AsrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_AsrMember_7cb67df2-5437-4a97-bde4-a41ad58d3a46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_e9ca60c7-2bdb-4bf1-b191-183f7049e707" xlink:href="jnj-20230402.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_e9ca60c7-2bdb-4bf1-b191-183f7049e707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_0090a15d-f21f-4e30-a95d-bca35be24061" xlink:href="jnj-20230402.xsd#jnj_PelvicMeshesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_PelvicMeshesMember_0090a15d-f21f-4e30-a95d-bca35be24061" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_01539ac2-1c86-4b81-b379-52265e8a94a2" xlink:href="jnj-20230402.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_RisperdalMember_01539ac2-1c86-4b81-b379-52265e8a94a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_ed32730c-815a-4838-8514-998060be4e2d" xlink:href="jnj-20230402.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_TalcMember_ed32730c-815a-4838-8514-998060be4e2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_eb3cf4d8-3794-48e9-b741-408dd83be920" xlink:href="jnj-20230402.xsd#jnj_PhysiomeshMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_PhysiomeshMember_eb3cf4d8-3794-48e9-b741-408dd83be920" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember_1a6e2fc9-aa25-4c11-ad0d-5fa52387be86" xlink:href="jnj-20230402.xsd#jnj_ElmironMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_ElmironMember_1a6e2fc9-aa25-4c11-ad0d-5fa52387be86" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TylenolMember_6d388551-4f76-4e07-bd74-1af4848a3120" xlink:href="jnj-20230402.xsd#jnj_TylenolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_TylenolMember_6d388551-4f76-4e07-bd74-1af4848a3120" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_bb23f788-a934-456c-b7b5-af7910f78a30" xlink:href="jnj-20230402.xsd#jnj_OpioidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_OpioidMember_bb23f788-a934-456c-b7b5-af7910f78a30" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EthiconMember_4f79fecb-631a-44dd-9708-ebf941120f2e" xlink:href="jnj-20230402.xsd#jnj_EthiconMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_EthiconMember_4f79fecb-631a-44dd-9708-ebf941120f2e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_726ec1e2-41d0-4475-8922-bf3b8be1b366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:to="loc_us-gaap_LitigationStatusAxis_726ec1e2-41d0-4475-8922-bf3b8be1b366" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_726ec1e2-41d0-4475-8922-bf3b8be1b366_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_726ec1e2-41d0-4475-8922-bf3b8be1b366" xlink:to="loc_us-gaap_LitigationStatusDomain_726ec1e2-41d0-4475-8922-bf3b8be1b366_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a14bccf4-ffab-46e0-bba9-a469b3769eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_726ec1e2-41d0-4475-8922-bf3b8be1b366" xlink:to="loc_us-gaap_LitigationStatusDomain_a14bccf4-ffab-46e0-bba9-a469b3769eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_f055f97a-cf7b-4e46-81df-25ab76908245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a14bccf4-ffab-46e0-bba9-a469b3769eb8" xlink:to="loc_us-gaap_SettledLitigationMember_f055f97a-cf7b-4e46-81df-25ab76908245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_8fc26329-5567-4361-a685-454fad35b345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a14bccf4-ffab-46e0-bba9-a469b3769eb8" xlink:to="loc_us-gaap_PendingLitigationMember_8fc26329-5567-4361-a685-454fad35b345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_d6390c07-042c-45b6-8c00-73055922820b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_JudicialRulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_a14bccf4-ffab-46e0-bba9-a469b3769eb8" xlink:to="loc_us-gaap_JudicialRulingMember_d6390c07-042c-45b6-8c00-73055922820b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8d4bd25e-5c60-4bc0-b73f-66eea85c6391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8d4bd25e-5c60-4bc0-b73f-66eea85c6391" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8d4bd25e-5c60-4bc0-b73f-66eea85c6391_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8d4bd25e-5c60-4bc0-b73f-66eea85c6391" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8d4bd25e-5c60-4bc0-b73f-66eea85c6391_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_085d3c92-1d26-4e92-9aa4-8c04ef14fb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8d4bd25e-5c60-4bc0-b73f-66eea85c6391" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_085d3c92-1d26-4e92-9aa4-8c04ef14fb6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f3da91d5-5dea-4ab9-8feb-542ce4987637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_085d3c92-1d26-4e92-9aa4-8c04ef14fb6d" xlink:to="loc_us-gaap_SubsequentEventMember_f3da91d5-5dea-4ab9-8feb-542ce4987637" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccountingStandardsUpdate202204Member_06198201-b5ea-420a-845e-0421eb74fa1b" xlink:href="jnj-20230402.xsd#jnj_AccountingStandardsUpdate202204Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_jnj_AccountingStandardsUpdate202204Member_06198201-b5ea-420a-845e-0421eb74fa1b" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>jnj-20230402_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:58e186d7-ec31-41bf-b939-580d103359b5,g:2048fc28-099b-4a2a-a431-d29d26f24517-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f084565f-0081-4b35-a1b6-e5d06e40b7a1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_d8bf275e-b24b-4a49-822f-afdc74546694_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_57cfc328-db86-44b2-8168-8bc669c5fa06_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_f2d2c74e-29e5-4acd-be40-e100f2741ded_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit losses and accounts receivable allowances</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_d3bdc97a-ea72-4734-b383-5d15f6dffd8d_terseLabel_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_label_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_documentation_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:href="jnj-20230402.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:to="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyPowderMember_4941fb3b-e1b2-4d5e-9c3d-3483a9f830f5_terseLabel_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder</link:label>
    <link:label id="lab_jnj_BabyPowderMember_label_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:label id="lab_jnj_BabyPowderMember_documentation_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember" xlink:href="jnj-20230402.xsd#jnj_BabyPowderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyPowderMember" xlink:to="lab_jnj_BabyPowderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_2920f41f-5129-41c3-9868-9709a8d03cfe_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8b4f8e27-de3b-479c-8187-71c594ac7263_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_ecd16b66-4c4b-45c2-a954-8b7c19f947a2_terseLabel_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value (6)</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_label_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:href="jnj-20230402.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:to="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConsumerMember_fd441687-954a-48a6-b2bc-3ddd4cdf982d_terseLabel_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH</link:label>
    <link:label id="lab_jnj_ConsumerMember_label_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer [Member]</link:label>
    <link:label id="lab_jnj_ConsumerMember_documentation_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember" xlink:href="jnj-20230402.xsd#jnj_ConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConsumerMember" xlink:to="lab_jnj_ConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DARZALEXMember_39fa612c-53cc-49e6-9b60-fc85cdb6e508_terseLabel_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX</link:label>
    <link:label id="lab_jnj_DARZALEXMember_label_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:label id="lab_jnj_DARZALEXMember_documentation_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember" xlink:href="jnj-20230402.xsd#jnj_DARZALEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DARZALEXMember" xlink:to="lab_jnj_DARZALEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_81e397e8-c716-44cb-9b33-03eb25e6202f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ADVANCEDMember_929bef1e-fc85-4bd9-b27d-d7ee317ce0a2_terseLabel_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_label_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_documentation_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember" xlink:href="jnj-20230402.xsd#jnj_ADVANCEDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ADVANCEDMember" xlink:to="lab_jnj_ADVANCEDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_a198ef03-aba1-4c09-a43e-cb2f22d633f7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_446d2b2a-6715-4cf8-9128-6bb4ecf58e84_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_30dd755b-b431-4a87-b16d-c70255ed7c5f_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_fcd52e27-7656-4d95-b125-187acab2ed81_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_1b5f57af-ae03-432a-b54f-4bb4c982c10a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_0f5fdeec-7564-4076-9d16-03b9f235aef8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_1c087ba6-ef72-446b-81ee-222b8902534e_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change in Operating Income Loss</link:label>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_label_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change in Operating Income Loss</link:label>
    <link:label id="lab_jnj_PercentageChangeInOperatingIncomeLoss_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in operating income loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss" xlink:href="jnj-20230402.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInOperatingIncomeLoss" xlink:to="lab_jnj_PercentageChangeInOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_5f59d53b-686f-461e-a7fa-09f38df121a7_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_f3bcec0c-0c15-45b3-b006-b5528559548c_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply network costs</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_08816d3b-826c-4973-851d-4c3efa7ef253_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_77363785-9592-45f6-9c94-03817efb2cf7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63fd96c8-5e90-4e2a-9e21-52f62fb6933d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_05cc116e-3bfd-436f-b794-28b1ac7f825f_terseLabel_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_label_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_documentation_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member" xlink:href="jnj-20230402.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.75Notesdue2047Member" xlink:to="lab_jnj_A3.75Notesdue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f6249e0f-66db-48cc-b1d4-ed53de4df7a9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (primarily licenses and milestones)</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_225a89db-174e-4cc1-bc33-fa409295fed1_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_379a15da-8762-4813-bc51-ee8c676c0680_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyReceivableProceeds_94184edb-50b2-4a6b-b949-b78604598568_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Proceeds</link:label>
    <link:label id="lab_us-gaap_LossContingencyReceivableProceeds_label_en-US" xlink:label="lab_us-gaap_LossContingencyReceivableProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Receivable, Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableProceeds" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyReceivableProceeds" xlink:to="lab_us-gaap_LossContingencyReceivableProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionContributions_c6f86c60-bdb3-48fe-9b77-edb70f7fb021_terseLabel_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to pension plans</link:label>
    <link:label id="lab_us-gaap_PensionContributions_label_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionContributions" xlink:to="lab_us-gaap_PensionContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_08f850b3-11cf-46c4-b741-ab89776e3d7c_terseLabel_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES / OTHER</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_label_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_documentation_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember" xlink:href="jnj-20230402.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONTACTLENSESOTHERMember" xlink:to="lab_jnj_CONTACTLENSESOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_973384d3-c8ea-4937-92c9-d665a004f450_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_034d2257-c903-4024-be9c-dd294aab89fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_152f887d-7cce-4a52-a634-62b530c0be3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_22c9cd5c-3cc4-41a1-a348-d0bfabec1158_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivative Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_0a12c14e-ff5d-418f-88d3-c3132e3ee586_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_e09ec57b-a67a-44cf-92d4-23b9b1c3fba4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_485e6bf0-ab36-4bcc-91ec-9a06069cf905_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation, net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_849ad922-9dd4-4f6f-9f1e-0c8a9c27d635_negatedTerseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Unrecognized Loss</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:href="jnj-20230402.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:to="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_b26085b5-b749-48ae-a517-e3202a8bb46f_negatedTerseLabel_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: shares which could be repurchased under treasury stock method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_label_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Which Could Be Repurchased Under Treasury Stock Method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_documentation_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:href="jnj-20230402.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:to="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_3fe81de3-62fe-4cf0-913d-7ab60b3f9ef7_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost/(credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_HIPSMember_3be75a18-72fd-4dfc-ae5b-813ede9123f7_terseLabel_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS</link:label>
    <link:label id="lab_jnj_HIPSMember_label_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:label id="lab_jnj_HIPSMember_documentation_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember" xlink:href="jnj-20230402.xsd#jnj_HIPSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_HIPSMember" xlink:to="lab_jnj_HIPSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_30251f79-cae2-4ccc-b786-c18ce84e79e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_ea65c2b1-3762-44f7-b3cd-6e38a5474d90_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange rate</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7f481886-f2de-4cac-bb9c-ae18f64d75c4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4e9861f7-4594-4a6e-a5fc-2ae28e7ed672_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7c486a47-c296-41b6-b3a5-ec14c33f8249_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ee18dc66-9844-4246-a2fb-8c5eacf9b8a1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_2c52c39b-b64f-443a-8613-a09766ed7ab9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_d2486e1a-6498-4c8b-88c3-3bdc0c664373_verboseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due May 2035</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_0f619bc7-9e8f-43db-8f3d-59fa12da2742_terseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes due 2035 (1.5B Euro 1.0909)</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_label_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_documentation_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member" xlink:href="jnj-20230402.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.650NotesDue2035Member" xlink:to="lab_jnj_A1.650NotesDue2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NonTradeableContingentValueRightMember_0d5a07e9-41f1-4f08-921e-65b8a68b200b_terseLabel_en-US" xlink:label="lab_jnj_NonTradeableContingentValueRightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Tradeable Contingent Value Right</link:label>
    <link:label id="lab_jnj_NonTradeableContingentValueRightMember_label_en-US" xlink:label="lab_jnj_NonTradeableContingentValueRightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Tradeable Contingent Value Right [Member]</link:label>
    <link:label id="lab_jnj_NonTradeableContingentValueRightMember_documentation_en-US" xlink:label="lab_jnj_NonTradeableContingentValueRightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Tradeable Contingent Value Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonTradeableContingentValueRightMember" xlink:href="jnj-20230402.xsd#jnj_NonTradeableContingentValueRightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NonTradeableContingentValueRightMember" xlink:to="lab_jnj_NonTradeableContingentValueRightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_884d6821-2b75-44e9-baf7-8c0019ebef34_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost/(credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_505b4092-06e5-4863-8edf-9ecf125cb114_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_8fc18b19-83eb-4bd5-b545-93c6a6a3364f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherInterventionalSolutionsMember_3723257c-a668-4cca-8694-b0445a67c512_terseLabel_en-US" xlink:label="lab_jnj_OtherInterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER INTERVENTIONAL SOLUTIONS</link:label>
    <link:label id="lab_jnj_OtherInterventionalSolutionsMember_label_en-US" xlink:label="lab_jnj_OtherInterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Interventional Solutions [Member]</link:label>
    <link:label id="lab_jnj_OtherInterventionalSolutionsMember_documentation_en-US" xlink:label="lab_jnj_OtherInterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Interventional Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInterventionalSolutionsMember" xlink:href="jnj-20230402.xsd#jnj_OtherInterventionalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherInterventionalSolutionsMember" xlink:to="lab_jnj_OtherInterventionalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_84dc9cf8-7d66-4e28-8b3e-dbe977b8ef04_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right (in dollars per share)</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:href="jnj-20230402.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_143d09de-427e-4a0d-859e-9b2830e8d22c_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:href="jnj-20230402.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_4baf5dd6-4326-479b-bdc9-e25300db6b52_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_c04075ae-493d-4c57-abcf-48cdb420ceab_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims within settlement agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_label_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_documentation_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:href="jnj-20230402.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:to="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_9046affb-a127-4377-8f42-ef6fe8ed16fa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentRollForward_51f2058e-6c57-4add-94b1-24b2fb5234cb_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_label_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentRollForward" xlink:to="lab_jnj_EquityInvestmentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_9c3a5195-079c-4010-a63a-5ca6a3b7107c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of basic net earnings per share to diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_6c7b98f3-fad0-4abd-972e-3770cfb754d3_terseLabel_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_label_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_documentation_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember" xlink:href="jnj-20230402.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTHERNEUROSCIENCEMember" xlink:to="lab_jnj_OTHERNEUROSCIENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_bec8196a-6c3c-4c25-ab38-5434868dff72_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: common stock held in treasury, at cost (521,519,000 and 506,246,000 shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PhysiomeshMember_3ac62d16-56b0-492c-8a7b-939e15e5e308_terseLabel_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_label_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_documentation_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember" xlink:href="jnj-20230402.xsd#jnj_PhysiomeshMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PhysiomeshMember" xlink:to="lab_jnj_PhysiomeshMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_d67d9b76-f603-40f6-b9ef-5cb0a77a7936_terseLabel_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_label_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_documentation_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement" xlink:href="jnj-20230402.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Numberofpatientsinsettlement" xlink:to="lab_jnj_Numberofpatientsinsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_6d10aa9f-bb6d-4db8-a3fc-60b196fac291_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_967a3e52-574b-4af2-b890-13f3467e9e69_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2443da42-7e88-40bd-a2de-25c7e0918290_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities - Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_d00e02c1-a5ff-433e-92e3-cffc53b6d356_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_60b7fe87-dabf-4e6d-93e1-8f583cf28ea6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_d6043db8-1105-4be6-a995-7cc56118d55f_terseLabel_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_label_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_documentation_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member" xlink:href="jnj-20230402.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.95Notesdue2029Member" xlink:to="lab_jnj_A6.95Notesdue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_b2852be5-c28b-4616-8e43-d49b6640522a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with definite lives:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_47ef64e7-aa99-4808-a640-700a1315f209_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_3039dc72-7726-4ce4-a465-e84679515fe1_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information, Revenue for Reportable Segment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_6c945681-28be-4ff6-bb17-752db6f73e53_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AbiomedMember_e2d6d82c-6b3c-48a0-b845-4d357a7d44d5_terseLabel_en-US" xlink:label="lab_jnj_AbiomedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ABIOMED(3)</link:label>
    <link:label id="lab_jnj_AbiomedMember_label_en-US" xlink:label="lab_jnj_AbiomedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abiomed [Member]</link:label>
    <link:label id="lab_jnj_AbiomedMember_documentation_en-US" xlink:label="lab_jnj_AbiomedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abiomed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember" xlink:href="jnj-20230402.xsd#jnj_AbiomedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AbiomedMember" xlink:to="lab_jnj_AbiomedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_f1bef148-276a-4e85-9a90-c5891d8cc95b_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt_d8448f36-dcc3-44e0-93a4-484c8bb95a47_terseLabel_en-US" xlink:label="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Carrying Value Over Fair Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt_label_en-US" xlink:label="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Carrying Value Over Fair Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt_documentation_en-US" xlink:label="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Carrying Value Over Fair Value Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:href="jnj-20230402.xsd#jnj_ExcessOfCarryingValueOverFairValueOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:to="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_b963a368-dbf3-4345-8039-55b61ea6f907_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_1c314055-97d5-4ca6-95d4-75490efad92c_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_f3257f12-f2b1-4d8b-abbe-f28855391696_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0b287b2b-ab0a-42fd-9c1e-78db80513766_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_d7ab4c8a-d67a-4f68-b1a1-da76805679d7_terseLabel_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S.</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_label_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_documentation_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember" xlink:href="jnj-20230402.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WesternHemisphereExcludingUSMember" xlink:to="lab_jnj_WesternHemisphereExcludingUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_fa214787-d474-4df3-bb34-419a5cf3489b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted prices in active markets for identical assets and liabilities Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_9371692b-52a6-4242-bdf0-6a7a0d97f2d1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_116ee3e5-efcd-4f6f-8347-04eddde7cea7_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue_cf0975f1-5a15-45e3-ac38-66955811cd69_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established Within Trust, Nominal Value</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue_label_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established Within Trust, Nominal Value</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue_documentation_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established Within Trust, Nominal Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue" xlink:href="jnj-20230402.xsd#jnj_LossContingencyReserveEstablishedWithinTrustNominalValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue" xlink:to="lab_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_87282be8-a1f0-4c52-90d6-e46cb5e54745_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_24125dfa-4329-45d4-a01b-f5f17a044406_terseLabel_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income percent to sales</link:label>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_label_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income Interest Percent To Sales</link:label>
    <link:label id="lab_jnj_InvestmentIncomeInterestPercentToSales_documentation_en-US" xlink:label="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income interest percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales" xlink:href="jnj-20230402.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InvestmentIncomeInterestPercentToSales" xlink:to="lab_jnj_InvestmentIncomeInterestPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_af1dde1f-2a50-47d3-92b6-26d1f39d697f_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_4cd9cfc1-7d13-4359-b9d0-242c2511ea73_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available for Sale Securities Maturities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_4380f56f-a4cb-4f5a-ace1-e388aeed1f41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_939beaec-3621-4834-96c1-2f19c30aab34_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_f4f4e062-117a-4725-b0fc-4bbccf7b551a_terseLabel_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net percent to sales</link:label>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_label_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Operating Income Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non operating income expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:href="jnj-20230402.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:to="lab_jnj_OtherNonOperatingIncomeExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BeautyMember_437d38cb-da88-4db8-bbbd-5c956947d215_terseLabel_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin Health/Beauty</link:label>
    <link:label id="lab_jnj_BeautyMember_label_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty [Member]</link:label>
    <link:label id="lab_jnj_BeautyMember_documentation_en-US" xlink:label="lab_jnj_BeautyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beauty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember" xlink:href="jnj-20230402.xsd#jnj_BeautyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BeautyMember" xlink:to="lab_jnj_BeautyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_27007b70-3779-4bfc-b866-2d29993275b3_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note 4)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_8b18ec7c-adc5-4bfc-bcf5-880c9b34bf5d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyPendingClaimsNumberRemaining_9b69d580-e1c8-4286-a781-6918480f79de_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyPendingClaimsNumberRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number, Remaining</link:label>
    <link:label id="lab_jnj_LossContingencyPendingClaimsNumberRemaining_label_en-US" xlink:label="lab_jnj_LossContingencyPendingClaimsNumberRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number, Remaining</link:label>
    <link:label id="lab_jnj_LossContingencyPendingClaimsNumberRemaining_documentation_en-US" xlink:label="lab_jnj_LossContingencyPendingClaimsNumberRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number, Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPendingClaimsNumberRemaining" xlink:href="jnj-20230402.xsd#jnj_LossContingencyPendingClaimsNumberRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyPendingClaimsNumberRemaining" xlink:to="lab_jnj_LossContingencyPendingClaimsNumberRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_88c06fdc-e292-43cd-9674-c3a5bd0c34c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_5ec6125e-f13c-427d-8426-16ef7f0abb27_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_240322b1-be85-420e-bb3a-634180b3d138_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_COVID19Member_4fde8c2e-bc65-4db1-8485-5c50ab29cf4d_terseLabel_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_jnj_COVID19Member_label_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_jnj_COVID19Member_documentation_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member" xlink:href="jnj-20230402.xsd#jnj_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_COVID19Member" xlink:to="lab_jnj_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_6a9593cc-ae23-4748-b2de-ab7146d5fe26_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits(2)</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_1f8b31d2-18b8-4892-ae0d-5d123d269436_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposal of assets/businesses, net (Note 10)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_7c0b2537-c5e0-445f-8dbc-045893d963ca_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_92554cf7-90a0-44d6-886a-b5b6d27f0f92_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0087aee6-0dc1-447a-8a8f-0c7fe7241674_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_2dc1d24d-5ec1-4140-81d3-fc89f2832948_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and marketable securities acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_54bc6036-5241-47be-84ac-c453cd760dba_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7e7a240c-8e72-4d10-bcbb-c6fc2fe61f61_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_1a990710-49b5-45dd-8532-03d4970c8a0d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_043a51a4-a3ef-4dbf-b72a-7a9eaba4e807_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_bcafe963-720b-4ea3-8683-9edb82da1654_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DePuyASRU.S.Member_35a08076-3faa-4df3-967d-46bfd0059bbd_terseLabel_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S.</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_label_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_documentation_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member" xlink:href="jnj-20230402.xsd#jnj_DePuyASRU.S.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DePuyASRU.S.Member" xlink:to="lab_jnj_DePuyASRU.S.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A095NotesDue2027Member_6266dfd7-9fac-4657-aa2e-67e5d202b581_terseLabel_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_label_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_documentation_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member" xlink:href="jnj-20230402.xsd#jnj_A095NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A095NotesDue2027Member" xlink:to="lab_jnj_A095NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_7c559a44-edb5-4723-94c3-f92a609828b4_terseLabel_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_label_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_documentation_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:href="jnj-20230402.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:to="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_1bc01bc1-f386-4677-820e-a9da38c30f64_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_dee72b73-677f-4266-b39d-2f485ed7eaca_negatedLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities, Unrecognized Loss</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2c61468d-c899-4c26-ba0a-d7f34e307e20_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_95f9a71c-814c-4b95-8c24-e3aa4c002e01_terseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_label_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development in process percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales_documentation_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">research and development in process percent to sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:href="jnj-20230402.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:to="lab_jnj_ResearchAndDevelopmentInProcessPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_c4dae7b6-a443-4bd1-9558-dc0fef72551c_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Business Segments</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_8bbe7368-35d4-4158-b7e3-3d718a73137d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_885d9633-ff9e-4d45-a4ba-3b6a0393a8a2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_72e436a4-c1e7-4e8d-9d65-6b92d54082bf_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_e43240c1-28c6-4b3c-9017-109c139d3b42_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_0b3f457a-7e62-4cb2-b82a-2a030a91438f_terseLabel_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member" xlink:href="jnj-20230402.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.375Notesdue2033Member" xlink:to="lab_jnj_A4.375Notesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b31840cb-7f06-49e3-b536-133bf8ee7ef3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_d2a68922-ef25-4d82-ada3-7d3e44f8abac_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_5c6a32fa-d1b7-4117-ab98-fab6abe75b1f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_d606d98a-536b-4462-8b88-abc1636ae532_terseLabel_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_label_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing [Member]</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_documentation_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:href="jnj-20230402.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:to="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e646efce-8090-45cf-93a1-d3c50f56ed98_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_75174d10-04d0-414a-822f-dcd5df0b845d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Fair Value Reflected in Net Income</link:label>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueAdjustment" xlink:to="lab_us-gaap_EquityFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a05c4104-b853-4d44-b7b9-9290e316a9d0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_40e979e2-ecd9-49ee-b712-8158a6bafef0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_38ca5943-629b-49f6-8f13-001086ff5f8d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a3a23ad8-3b6e-474f-b756-fee231ce134d_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET EARNINGS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f4de5d9d-e006-4e12-ad47-51a3816b91d0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ff1ecdd2-8226-436a-9eef-43b89c4defb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1300NotesDue2030Member_ab63195f-7a12-47b2-b6e4-f6d93f11ff86_terseLabel_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:label id="lab_jnj_A1300NotesDue2030Member_label_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.300% Notes due 2030 [Member]</link:label>
    <link:label id="lab_jnj_A1300NotesDue2030Member_documentation_en-US" xlink:label="lab_jnj_A1300NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.300% Notes due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member" xlink:href="jnj-20230402.xsd#jnj_A1300NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1300NotesDue2030Member" xlink:to="lab_jnj_A1300NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_e73a1e4b-ca4c-4531-b40d-d3a605c68edb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit plans:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_e03deeac-9629-4743-abb9-3c2d645a6442_terseLabel_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_label_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Discount Rate</link:label>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_documentation_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate" xlink:href="jnj-20230402.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessAcquisitionDiscountRate" xlink:to="lab_jnj_BusinessAcquisitionDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_e8bb82df-346c-4b58-9869-b145d01f0532_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_24ca6b07-a2a7-4b85-a3aa-7240163fb148_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations (Note 6)</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_564e4699-2295-48dc-af7e-bb6a33cdc5e3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_86a478ac-6e16-4251-8a75-1ae41789e779_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_9c555724-0ca4-4434-aa12-435a9b60473e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_09525bea-40e0-4aae-a748-38d85fa28e17_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amortizable intangibles</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_914d69b0-3d7e-4023-b6ce-a4766e4d6dd7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH FROM/(USED BY) FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_08251dbc-ddc1-4593-94cd-4e0fa90095e7_totalLabel_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income percent to sales</link:label>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_label_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Percent To Sales</link:label>
    <link:label id="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_documentation_en-US" xlink:label="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:href="jnj-20230402.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:to="lab_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_8ea4456c-7f22-471e-86ce-5a10bb314e9a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5000a8f2-ae4d-44e3-b1e2-79408cf11df4_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee related obligations</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_aaba7069-4fd6-43ed-bf3d-08eccdb673de_terseLabel_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular / Metabolism / Other</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_label_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_documentation_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember" xlink:href="jnj-20230402.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CardiovascularMetabolismOtherMember" xlink:to="lab_jnj_CardiovascularMetabolismOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d7927adc-0046-4eb6-8a68-0abad1597587_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(Loss) before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1767f573-f3f0-4f3d-9890-532f321be545_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide income/(loss) before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_90e8a0ad-f2ef-4783-8ab0-29d4e2e717b5_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_dbf96b3f-ce55-4644-a67e-3601b4478ffc_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3e6e1135-6a87-45f9-ba0b-74c6cf00417d_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_133f28db-cb52-481b-8659-063e5702f466_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities - Carrying Amount</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_2c885eb9-92ea-42a9-9465-13a88ede43df_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_610f5f31-213f-4e5b-beea-d082a6775473_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_d474f13f-0279-48d7-9722-08627e90a119_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrustTotal_75d65ea9-52fd-4a9f-9053-41ae095df722_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrustTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established Within Trust, Total</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrustTotal_label_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrustTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established Within Trust, Total</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrustTotal_documentation_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrustTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established Within Trust, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrustTotal" xlink:href="jnj-20230402.xsd#jnj_LossContingencyReserveEstablishedWithinTrustTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyReserveEstablishedWithinTrustTotal" xlink:to="lab_jnj_LossContingencyReserveEstablishedWithinTrustTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_c0a15e9c-2a45-4a50-a54b-fe5fa9e8f0ba_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyRemainingTerm_1b2c912e-11bf-4e0b-bc84-1eb9ec950c4b_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyRemainingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Remaining Term</link:label>
    <link:label id="lab_jnj_LossContingencyRemainingTerm_label_en-US" xlink:label="lab_jnj_LossContingencyRemainingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Remaining Term</link:label>
    <link:label id="lab_jnj_LossContingencyRemainingTerm_documentation_en-US" xlink:label="lab_jnj_LossContingencyRemainingTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Remaining Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyRemainingTerm" xlink:href="jnj-20230402.xsd#jnj_LossContingencyRemainingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyRemainingTerm" xlink:to="lab_jnj_LossContingencyRemainingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_d852a7fa-b34d-4eec-aeab-c66aa84b7704_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_8723ea16-9c76-42d9-94c3-7819a419e62f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_ed46f183-25da-42de-80ac-623a783fe3b0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_87cf7359-7ff2-45af-b5e3-d222160419fc_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost amortization during period</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:href="jnj-20230402.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_d9928e7f-3424-4238-aa0a-58d7fc5fd3e5_terseLabel_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals)</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_label_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals) [Abstract]</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_documentation_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding Textuals Abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract" xlink:href="jnj-20230402.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalProceedingTextualsAbstract" xlink:to="lab_jnj_LegalProceedingTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_2c6675f2-1cfb-4c99-abd5-40717b0e7eac_terseLabel_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_label_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_documentation_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:href="jnj-20230402.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:to="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_a45d85f6-75dc-4fc3-ac9b-823f7ced4a0a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_982d70e4-c3cd-4ca2-9fab-93b1cfac912b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_c3b72744-725b-4bb9-b1dd-5b18d8aac2a1_verboseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates, returns and promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_label_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_documentation_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:href="jnj-20230402.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:to="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_b2f9a28b-fbe5-44ed-9a23-106ad51a08f9_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_136a97d3-90b9-41a3-8778-d3d0f0c7595e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c833022-98cc-44b1-aa8c-1982a8624df2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_31e6f299-5c8a-4fb3-aedb-8873ba00d098_terseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:href="jnj-20230402.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:to="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyCareMember_ece3d47c-ef51-4d06-8777-39175555275b_terseLabel_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care</link:label>
    <link:label id="lab_jnj_BabyCareMember_label_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:label id="lab_jnj_BabyCareMember_documentation_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember" xlink:href="jnj-20230402.xsd#jnj_BabyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyCareMember" xlink:to="lab_jnj_BabyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_5d2bb9be-9c3a-42e2-8738-90919d154f62_terseLabel_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_label_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System [Member]</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_documentation_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular cup system.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:href="jnj-20230402.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:to="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_ea12f38f-7694-4f3b-8eb5-df38a458e9cd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_bf83133e-2e86-421f-877b-5663bab38695_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_c6a5ee3c-9267-4bdd-824f-2e6f21b91c5d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities not Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_938961af-1ff9-4da9-b8c2-fdcd59ba6547_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_c269f29e-84af-4983-91da-cef8e9d92ce9_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_67976aca-203e-431c-b2f3-e43993567698_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_ce669f80-468e-4ddf-b721-37dc5e39e5bb_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_66cd2d79-f30e-4e91-8df7-82ccbafb505e_terseLabel_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_label_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_documentation_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member" xlink:href="jnj-20230402.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Debenturesdue2040Member" xlink:to="lab_jnj_A4.50Debenturesdue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_e14fa5d4-91d9-4aa7-ae52-c6c4b830c4b5_terseLabel_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_label_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_documentation_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member" xlink:href="jnj-20230402.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55Notesdue2036Member" xlink:to="lab_jnj_A3.55Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_c8df27bb-be19-4907-b89d-ce441e02ec78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income on derivatives, after tax</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TalcMember_de3afc88-73a4-46b8-886e-78f21759643b_terseLabel_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc</link:label>
    <link:label id="lab_jnj_TalcMember_label_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:label id="lab_jnj_TalcMember_documentation_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember" xlink:href="jnj-20230402.xsd#jnj_TalcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TalcMember" xlink:to="lab_jnj_TalcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_75f9af73-699c-473f-af32-49dca5def5f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_84cef426-0ccb-4227-9900-3050fbbc0f0e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3d9ed555-151c-4bc9-a770-051c0c9a7d88_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6ad24891-7d90-4035-99b3-ec057f4524d3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_38c0700f-8c8d-4efa-abfa-671238284544_terseLabel_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_label_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member" xlink:href="jnj-20230402.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.85Debenturesdue2038Member" xlink:to="lab_jnj_A5.85Debenturesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_fce8c105-a9b5-4067-ba31-c2f8bc8febf4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f4c1979e-c0c2-4297-9301-f4e48eb150e2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1839c2a6-7343-438c-bcc5-48dafdcf40f1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_727518e8-fe66-4758-8cc0-24fb9ad47308_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_bc4069c8-99ec-41ef-ada1-3ddb8f4a55d4_terseLabel_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIMPONI / SIMPONI ARIA</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_label_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_documentation_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember" xlink:href="jnj-20230402.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SimponiSimponiAriaMember" xlink:to="lab_jnj_SimponiSimponiAriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PelvicMeshesMember_1307371e-6563-4a53-b13d-67214945ede0_terseLabel_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_label_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes [Member]</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_documentation_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic meshes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember" xlink:href="jnj-20230402.xsd#jnj_PelvicMeshesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PelvicMeshesMember" xlink:to="lab_jnj_PelvicMeshesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_97c2e591-a848-4715-b56e-1d21b1945540_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a53c6704-1b5e-428a-a937-28a3f3ca2cf1_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_212c7469-7a74-4391-b024-f3357dc9ecd4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c7500be4-cd50-4335-a22a-3d714cd13560_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c4806c8e-5484-4fed-ace0-5a69e730d204_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_699763ff-d4e2-4b18-bb4f-c2e8f734560f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0bb75679-4fd3-4709-9168-4b8c2040a6a5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_XareltoMember_c8c4d656-3548-481e-aac3-54a3ea1f400a_terseLabel_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XARELTO</link:label>
    <link:label id="lab_jnj_XareltoMember_label_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:label id="lab_jnj_XareltoMember_documentation_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember" xlink:href="jnj-20230402.xsd#jnj_XareltoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_XareltoMember" xlink:to="lab_jnj_XareltoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_12134ea8-cdfb-4960-84b4-2d6a6fb05fb7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_905d13b9-df6c-4c36-88cb-8706e7de8dc2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9e8b4965-0dfc-4f5b-bc6b-21a510213ed6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_11ea1e49-943d-4bfd-b062-17fce835d541_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Amount</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_a508aac9-67a4-4b7d-8f57-b1e41afa76fd_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b082a074-8480-4836-bc47-bb2b86180a53_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_8be9e727-66b0-438a-b658-a684b2b7a95d_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0fe6e539-06a0-4ed6-9274-02281a73e1eb_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a5d70ff3-562d-4fd5-9e2b-c1d5edbddd6a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_e496bdf1-8645-42de-a86c-0670630f4832_terseLabel_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_label_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_documentation_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member" xlink:href="jnj-20230402.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.45Notesdue2026Member" xlink:to="lab_jnj_A2.45Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_8b9660c5-3870-432a-917f-cb393905b41f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyPendingClaimsNumberAdditional_634e4882-ea3f-43a6-b5bb-75ad0b75c152_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyPendingClaimsNumberAdditional" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Pending Claims, Number, Additional</link:label>
    <link:label id="lab_jnj_LossContingencyPendingClaimsNumberAdditional_label_en-US" xlink:label="lab_jnj_LossContingencyPendingClaimsNumberAdditional" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Pending Claims, Number, Additional</link:label>
    <link:label id="lab_jnj_LossContingencyPendingClaimsNumberAdditional_documentation_en-US" xlink:label="lab_jnj_LossContingencyPendingClaimsNumberAdditional" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Pending Claims, Number, Additional</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPendingClaimsNumberAdditional" xlink:href="jnj-20230402.xsd#jnj_LossContingencyPendingClaimsNumberAdditional"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyPendingClaimsNumberAdditional" xlink:to="lab_jnj_LossContingencyPendingClaimsNumberAdditional" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9514a22e-47c9-4f62-92ea-abd249ebb3c2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_14f41733-4f9e-4c7e-800b-7be36a8443d9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_dc974fb0-7071-4860-b1cd-95ff99c57662_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_9f4aff4f-0ee6-4765-b08e-ece05f2f25aa_terseLabel_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_label_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_documentation_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member" xlink:href="jnj-20230402.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Notesdue2043Member" xlink:to="lab_jnj_A4.50Notesdue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_f8d6d1e9-c233-4b6e-a5bc-d938eb149e34_terseLabel_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income percent to sales</link:label>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_label_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense Benefit Percent To Sales</link:label>
    <link:label id="lab_jnj_IncomeTaxExpenseBenefitPercentToSales_documentation_en-US" xlink:label="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense benefit percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:href="jnj-20230402.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:to="lab_jnj_IncomeTaxExpenseBenefitPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_91a3d934-5a9f-488f-8bca-3c8969e2bbed_terseLabel_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers percent to sales</link:label>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_label_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue Goods Net Percent To Sales</link:label>
    <link:label id="lab_jnj_SalesRevenueGoodsNetPercentToSales_documentation_en-US" xlink:label="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales revenue goods net percentage to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales" xlink:href="jnj-20230402.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesRevenueGoodsNetPercentToSales" xlink:to="lab_jnj_SalesRevenueGoodsNetPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_ef12d61f-fa6a-4925-b831-12689b1ff502_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a1ae8ae5-3494-4898-92ad-dd9f658bd924_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide effective income tax rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_6eeaabb5-b5be-4583-9730-c2e984712611_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales/ Purchases/Other</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_label_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:to="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_7de1e376-a118-44b7-bf1c-434f27c51677_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ZYTIGAMember_15fd0d45-a8d7-4ea4-8b32-e6fb38a4b39f_terseLabel_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA / abiraterone acetate</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_label_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_documentation_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember" xlink:href="jnj-20230402.xsd#jnj_ZYTIGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ZYTIGAMember" xlink:to="lab_jnj_ZYTIGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f917d2c2-bcd1-40e7-bf51-c9993ced9e9e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_12efd489-c1a0-46d3-80ac-3d3413c4a440_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_45ee4ee7-4cbc-40be-8d29-a5b2eac1d5f9_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_940a4de4-8951-49ba-a240-91b0038397b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) On Derivatives &amp; Hedges, net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_a14baa47-10d4-49ba-9c33-df3e94bbf5c0_verboseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:href="jnj-20230402.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:to="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_21d6627d-9edc-4cfa-b7d9-31a839d2ad4b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ae9f9778-a5a2-4bd6-9435-1efaf17da84c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_0ec40b07-96e3-4acd-af74-35d860053b13_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_50ecac2b-e392-497a-8756-84eb1e97fc9d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_9b59b498-88db-4c0b-9039-c2d432c251b6_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_378697fe-c89b-4a30-b18e-81c947f358df_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_0a2ac5b0-085b-4a2e-921f-0e19aa935b66_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b717d5e9-fd0b-4d61-bf4f-ec6bfd9115c5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_26a4700b-2406-47dd-94da-b52fbba1c240_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net earnings/(loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_ca5f0060-8f81-4823-8354-a03591f94a28_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_ffa85056-c15e-4975-ad0f-690971574280_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent value right</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:href="jnj-20230402.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_667305ca-b5e2-4a51-8ce2-8a9edd1a1445_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7dbfaf4d-c520-41ef-970e-00fad5eb3560_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PharmaceuticalMember_6502078d-8856-490a-8211-a947655069a3_terseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PHARMACEUTICAL</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_label_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_documentation_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember" xlink:href="jnj-20230402.xsd#jnj_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PharmaceuticalMember" xlink:to="lab_jnj_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_1def543d-a9f2-4135-84ce-97459fdbf62f_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_40c4ac4e-3afd-4516-942d-1e037178acb6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A535DebentureDue2026Member_3b885df1-44fe-46fe-8552-4cdef3c25a7a_terseLabel_en-US" xlink:label="lab_jnj_A535DebentureDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.35% Debentures due 2026*</link:label>
    <link:label id="lab_jnj_A535DebentureDue2026Member_label_en-US" xlink:label="lab_jnj_A535DebentureDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.35% Debenture Due 2026 [Member]</link:label>
    <link:label id="lab_jnj_A535DebentureDue2026Member_documentation_en-US" xlink:label="lab_jnj_A535DebentureDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.35% Debenture Due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A535DebentureDue2026Member" xlink:href="jnj-20230402.xsd#jnj_A535DebentureDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A535DebentureDue2026Member" xlink:to="lab_jnj_A535DebentureDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c0dcc4ee-5c2f-4415-a40d-ab20ed808305_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_bec6978f-a98e-424f-8ade-62380c67962c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_c159c2b6-8c86-4afc-a429-31beb7b37e0a_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Geographic Area</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Geographic Area</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesByGeographicArea_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by geographic area.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea" xlink:href="jnj-20230402.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesByGeographicArea" xlink:to="lab_jnj_PercentageChangeInSalesByGeographicArea" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgeryMember_cc3cede0-25d3-467f-af26-9a37e11ba435_terseLabel_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery</link:label>
    <link:label id="lab_jnj_SurgeryMember_label_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:label id="lab_jnj_SurgeryMember_documentation_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember" xlink:href="jnj-20230402.xsd#jnj_SurgeryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgeryMember" xlink:to="lab_jnj_SurgeryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_41d3404f-2444-4667-8af6-725833e1e6f7_terseLabel_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-Maturity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_c186b675-9ffd-4db5-be8f-486fb28d188c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e38026ea-6d83-4ba2-b3e5-87df69bec892_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_bd67c03c-78f1-42d4-acf7-2e8d308a262b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_82fe2e77-7998-4c07-8c78-e9eea0b40209_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RemicadeMember_37dfad70-f54d-4421-be37-d8e4aac09239_terseLabel_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REMICADE</link:label>
    <link:label id="lab_jnj_RemicadeMember_label_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_jnj_RemicadeMember_documentation_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember" xlink:href="jnj-20230402.xsd#jnj_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RemicadeMember" xlink:to="lab_jnj_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a5f2d62f-d8fe-4443-986e-e4691af0cf8d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b767056e-dee5-4cfe-b67f-2b658fa5424c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_3325b1f2-4503-448c-8765-52ae2c3db428_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_0d728ea4-8c28-4ca2-99d0-075689745b97_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TremfyaMember_39d061fc-711f-438a-ba70-6d8db542803d_terseLabel_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TREMFYA</link:label>
    <link:label id="lab_jnj_TremfyaMember_label_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_jnj_TremfyaMember_documentation_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfaya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember" xlink:href="jnj-20230402.xsd#jnj_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TremfyaMember" xlink:to="lab_jnj_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_ca6efda9-82a2-468c-a838-1e4a5773139b_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ef7abf2e-bc58-4732-a9ac-cb4c7c2ea723_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings and Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_d96b44c9-29e3-4a8f-a155-0568b54ab72b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_81c4a1cf-8efe-40b4-9ef7-e3fe6a1fe249_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_75d22e88-8f8b-4fe0-96dd-ba19df0014bd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_2017f7ec-0f51-4d36-8229-6d5285339063_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_333b7fe9-fd9f-4b2c-950f-0bc390c539bf_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ElmironMember_f59f91d6-9d37-46ac-8408-69bd24ddd650_terseLabel_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elmiron</link:label>
    <link:label id="lab_jnj_ElmironMember_label_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elmiron [Member]</link:label>
    <link:label id="lab_jnj_ElmironMember_documentation_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elmiron</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember" xlink:href="jnj-20230402.xsd#jnj_ElmironMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ElmironMember" xlink:to="lab_jnj_ElmironMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_97f089de-e765-4761-823d-952cf3778129_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par Value $1.00</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_0719f0a1-6bb2-4744-a124-2741eb4eaca4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued Amount</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NeuroscienceMember_b93ed4a9-1ca5-4c2a-a907-4798d10760c0_terseLabel_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_label_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_documentation_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember" xlink:href="jnj-20230402.xsd#jnj_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NeuroscienceMember" xlink:to="lab_jnj_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_5d65576d-903a-4d07-a109-08b65e480678_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_9313eba9-6e5b-4e80-9616-85d55111841b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_24ff77a7-1822-49d2-a28e-d85062a9b977_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_97b7423a-6ccb-4941-bc45-7864ae673a95_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_37ed1596-de3b-4c65-a44c-cf3184939fc4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_3e7a7ef4-227b-4c3b-86ac-3d34fd22e91d_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_42d23808-0182-4f2e-ac6d-f0ba467b7c0c_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_8b75246f-c358-4b1b-a3d5-5a3a529c17da_periodStartLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning of period</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_7fe62b01-dba0-4f0a-9742-12cc0cef1ee7_periodEndLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, end of period</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_7f323309-46a1-414e-8f4c-e2171e85c033_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_0355db7e-cc3e-4065-80bf-2478b12d4fce_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_85326dad-469f-4d02-b2a2-dc2f80037618_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0fe345cc-ab13-47ac-9acf-afb8949ed30a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a22977d2-f82f-4580-bb5b-b42aad0f7fa8_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_491df121-6d35-43eb-a136-7b66d536f719_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Accumulated OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_4c01d61e-4bc2-4e15-bd90-eda6ccd929c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e05c8f2b-b606-4d9e-a3fe-cf58c5dca803_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets with indefinite lives</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock_702c8825-83fe-4f41-a667-394c626e72c3_terseLabel_en-US" xlink:label="lab_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Claims In Pending Lawsuits</link:label>
    <link:label id="lab_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock_label_en-US" xlink:label="lab_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Claims In Pending Lawsuits [Table Text Block]</link:label>
    <link:label id="lab_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Claims In Pending Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock" xlink:href="jnj-20230402.xsd#jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock" xlink:to="lab_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_8977c273-6aec-447e-b602-d9c10f802681_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings and Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0f9bdcce-bdb5-4b4c-8de0-ffa9a14c8673_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, trade, less allowances $207 (2022, $203)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8a96b86b-8591-44c4-ad85-87541bf4a39c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_862207f1-92bc-4aec-a74c-cf4abf4ec41e_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Gov&#8217;t securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_43ed3e63-6ae2-434e-8530-9f7a357daa90_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VisionMember_8344a96e-62a7-4317-a39e-830ecef920ff_terseLabel_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision</link:label>
    <link:label id="lab_jnj_VisionMember_label_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision [Member]</link:label>
    <link:label id="lab_jnj_VisionMember_documentation_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember" xlink:href="jnj-20230402.xsd#jnj_VisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VisionMember" xlink:to="lab_jnj_VisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_461a4d3e-b860-470e-bb6c-d838136552e1_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccruedTaxesOnIncomeMember_bbb60c69-657c-4b79-b3ec-da5c07161431_terseLabel_en-US" xlink:label="lab_jnj_AccruedTaxesOnIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Taxes On Income</link:label>
    <link:label id="lab_jnj_AccruedTaxesOnIncomeMember_label_en-US" xlink:label="lab_jnj_AccruedTaxesOnIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Taxes On Income [Member]</link:label>
    <link:label id="lab_jnj_AccruedTaxesOnIncomeMember_documentation_en-US" xlink:label="lab_jnj_AccruedTaxesOnIncomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Taxes On Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedTaxesOnIncomeMember" xlink:href="jnj-20230402.xsd#jnj_AccruedTaxesOnIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccruedTaxesOnIncomeMember" xlink:to="lab_jnj_AccruedTaxesOnIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_975b3721-3e13-407a-a96a-c95b32d5c1f8_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_84997dcb-d0d3-450a-94f8-d2e63177f8f5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_a98cdc48-60db-4587-97bb-a0bdc200fa49_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_dfda84f0-e91d-4c6f-8f13-4b87ea4fbfc5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2c214d9-edc0-48aa-8e9e-ac5a266e5a3a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_fa00e158-8b19-4938-bbee-0aaaf773824d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_3b2ca699-1a62-42e8-815e-af5e76001865_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets/businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InghamVsJohnsonJohnsonMember_05d9ffaa-d016-4074-970f-f381db56f4a2_terseLabel_en-US" xlink:label="lab_jnj_InghamVsJohnsonJohnsonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ingham v. Johnson &amp; Johnson</link:label>
    <link:label id="lab_jnj_InghamVsJohnsonJohnsonMember_label_en-US" xlink:label="lab_jnj_InghamVsJohnsonJohnsonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ingham vs. Johnson &amp; Johnson [Member]</link:label>
    <link:label id="lab_jnj_InghamVsJohnsonJohnsonMember_documentation_en-US" xlink:label="lab_jnj_InghamVsJohnsonJohnsonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ingham vs. Johnson &amp; Johnson</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InghamVsJohnsonJohnsonMember" xlink:href="jnj-20230402.xsd#jnj_InghamVsJohnsonJohnsonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InghamVsJohnsonJohnsonMember" xlink:to="lab_jnj_InghamVsJohnsonJohnsonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GENERALMember_ad24ce4c-a067-4e53-a5be-601fcbf0b586_terseLabel_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL</link:label>
    <link:label id="lab_jnj_GENERALMember_label_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:label id="lab_jnj_GENERALMember_documentation_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember" xlink:href="jnj-20230402.xsd#jnj_GENERALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GENERALMember" xlink:to="lab_jnj_GENERALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_9b7a3fd8-9bd1-4727-85a3-7e9b62cb97dc_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_cc856bc0-a637-4f30-8ffe-8ad6950a4a89_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ccecdc20-9bd8-40c3-b91c-dec3318786b7_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, marketing and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_f68771dd-c15c-42d4-b5c0-109254c98009_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_6231c3bd-d280-4952-8bf6-fa733631419d_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6a66c539-7ab1-432f-82f5-7915a4d56108_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Unrecognized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_12b9f517-23a2-4f65-9af3-74a83b57a514_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f577aed9-d5ae-4e78-a676-ee0f0f60a6de_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d2ba221-f01b-405d-9527-5ed163a637cb_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_71543eb2-ab81-4f74-af01-ed5c55d57fbb_terseLabel_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.50% Notes due 2048</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_label_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_documentation_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member" xlink:href="jnj-20230402.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.500Notesdue2048Member" xlink:to="lab_jnj_A3.500Notesdue2048Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_9a31d795-a8b8-4044-8a36-60004be205f9_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0550NotesDue2025Member_d6641b3c-995c-43ef-8c02-0c499aa82782_terseLabel_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:label id="lab_jnj_A0550NotesDue2025Member_label_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.550 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A0550NotesDue2025Member_documentation_en-US" xlink:label="lab_jnj_A0550NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.550 Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member" xlink:href="jnj-20230402.xsd#jnj_A0550NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0550NotesDue2025Member" xlink:to="lab_jnj_A0550NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A550DebentureDue2025Member_72046782-a4d1-499a-91a5-8028f49e7d87_terseLabel_en-US" xlink:label="lab_jnj_A550DebentureDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Debentures due 2025*</link:label>
    <link:label id="lab_jnj_A550DebentureDue2025Member_label_en-US" xlink:label="lab_jnj_A550DebentureDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Debenture Due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A550DebentureDue2025Member_documentation_en-US" xlink:label="lab_jnj_A550DebentureDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Debenture Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A550DebentureDue2025Member" xlink:href="jnj-20230402.xsd#jnj_A550DebentureDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A550DebentureDue2025Member" xlink:to="lab_jnj_A550DebentureDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_946536c4-9853-43da-a97e-87bcfd30d52c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e846b329-6d0d-4162-860b-d58ab9fa5cca_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_022734d5-564c-4f2f-bee6-665db1f4bc74_terseLabel_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_label_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:label id="lab_jnj_Restructuringchargepercenttosales_documentation_en-US" xlink:label="lab_jnj_Restructuringchargepercenttosales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge percent to sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales" xlink:href="jnj-20230402.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Restructuringchargepercenttosales" xlink:to="lab_jnj_Restructuringchargepercenttosales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3ee368cd-9284-4180-b03e-2ecfa8bfa653_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Segment Operating Income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_452e6916-f944-4082-81d9-a90dc74c3efa_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_5c048c46-5de4-43ee-b9ce-a7d3a616e28c_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9ea50551-9d82-4a8a-ae22-ea0658ae24d0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New and Recently Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_43305d0e-c487-4a78-ad2f-b27b3746f2ed_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_00dde41c-d15b-4b11-854a-09db2b74c8cf_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, beginning of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_cad3d2c5-b1f2-4c2f-a071-906e3ab5fa0b_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value, end of period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_dfdc5503-b421-47a8-bef2-8d231f7beba8_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Note 3)</link:label>
    <link:label id="lab_us-gaap_Goodwill_af1e911c-20ba-4fe9-a4d9-2e0aaf4c9130_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Beginning of Period</link:label>
    <link:label id="lab_us-gaap_Goodwill_27486dc3-dc97-4f1a-996c-99964876ea0f_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill End of Period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_46c07501-6724-4aa9-bbbb-393f3b91d4bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SPINEOTHERMember_e76424e5-3222-4787-8d47-5bbffb53dd04_terseLabel_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE, SPORTS &amp; OTHER</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_label_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:label id="lab_jnj_SPINEOTHERMember_documentation_en-US" xlink:label="lab_jnj_SPINEOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember" xlink:href="jnj-20230402.xsd#jnj_SPINEOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SPINEOTHERMember" xlink:to="lab_jnj_SPINEOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_145adca5-aaf0-43eb-8ea7-f1a8245810ef_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) amortization during period</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:href="jnj-20230402.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_e249cdc3-3fc9-4d4f-b964-c12cd4784078_terseLabel_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold percent to sales</link:label>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_label_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Goods Sold Percent To Sales</link:label>
    <link:label id="lab_jnj_CostOfGoodsSoldPercentToSales_documentation_en-US" xlink:label="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales" xlink:href="jnj-20230402.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CostOfGoodsSoldPercentToSales" xlink:to="lab_jnj_CostOfGoodsSoldPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a01298a6-ed13-4a87-85fb-198587543779_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_98712b91-30c6-4dfe-a3c5-a71b53d80bd5_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b1c3f2a1-f458-4d1b-abe9-b03e5a49ec34_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for/(Benefit from) taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_2a45df44-4db5-4e15-99e2-7a685574d121_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_d598dc2f-a3ef-4672-85f7-74cd6f899f3b_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_9168fbeb-2cfd-429a-a617-c11a20b3b789_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_feec37ef-633e-46fe-857d-cc909c9d36f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_193b71d6-f2c7-4d07-b5b9-c9636c5a3888_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_617b7285-11cc-481c-8429-d43c55b2c544_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_3d4d1c04-e6e1-42ba-8f84-12cb77e5fb40_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImmunologyMember_effec26c-a6cb-4ead-b6e5-274183350468_terseLabel_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_jnj_ImmunologyMember_label_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_jnj_ImmunologyMember_documentation_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember" xlink:href="jnj-20230402.xsd#jnj_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImmunologyMember" xlink:to="lab_jnj_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_82902e5d-7ab1-496e-8164-ec385352bc96_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_9d930b52-866a-46dd-b352-3b7ae407d6f2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f5429519-5ec4-4065-95b2-8606d72fbe6b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ec9fc97f-0ded-4dca-9588-db169109b762_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding &#8212; basic/diluted*</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_5a3be35b-b04c-46a2-9cfd-81afb1ad1a98_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_29dd63db-6659-4ecd-a8f1-96452f68e233_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_916c40de-4b50-409c-a4fe-8c13071a2272_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_fc9aa70d-1e25-4da8-bfc8-626dc897894b_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_371bab84-33e5-4594-8466-923bd904d7e3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_752a7e6c-ef24-4966-a729-2d6d066e104c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7bb62386-64fa-49cb-82b8-6c9e4ce5d8d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Equity Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_8f6b9b78-e760-4c20-9706-f47dd584f37f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_7a31de77-e4b0-43d5-b40f-653ddcc4f0f9_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:href="jnj-20230402.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_62ed3d89-fd93-4b64-a617-ed2bec2862c0_terseLabel_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="jnj-20230402.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_3a294a3b-c40e-4897-a363-8574f44d1fc5_verboseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_dcfca42c-25ae-4bc6-b3f5-c48acea8d300_terseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes due 2028 (750MM Euro 1.0909)</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_label_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_documentation_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member" xlink:href="jnj-20230402.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.150NotesDue2028Member" xlink:to="lab_jnj_A1.150NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6557c163-952a-4fb3-b612-13dad915e656_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock &#8212; par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_605daa17-a30f-4273-a68d-b475437ff1d7_verboseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_23313ea7-7c21-4d04-b5a4-9ea825555174_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_35352b35-1396-4791-9079-102931cdbd06_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_7fc33d74-cfa9-4e2c-afdd-b617f91d6662_terseLabel_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT / rilpivirine</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_label_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_documentation_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember" xlink:href="jnj-20230402.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EDURANTrilpivirineMember" xlink:to="lab_jnj_EDURANTrilpivirineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_93c376c2-af6c-4c0d-9f1a-dfb4ffa95fa2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_9ed98f22-49ef-4954-87e1-05babdb0875b_verboseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due May 2024</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_993f80a9-7ea0-49ea-ae0d-0f3d8241f29c_terseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes due 2024 (750MM Euro 1.0909)</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member" xlink:href="jnj-20230402.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.650NotesDue2024Member" xlink:to="lab_jnj_A0.650NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a8647aa2-43a7-49c7-95c6-5d7576c835ac_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash equivalents beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_628825c8-40bf-45c3-96b3-9eed5104b7ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WomensHealthMember_461117cf-396b-421a-acff-d2671d55e721_terseLabel_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women&#8217;s Health</link:label>
    <link:label id="lab_jnj_WomensHealthMember_label_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:label id="lab_jnj_WomensHealthMember_documentation_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember" xlink:href="jnj-20230402.xsd#jnj_WomensHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WomensHealthMember" xlink:to="lab_jnj_WomensHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0d910c94-c7ee-49dc-bab5-930a943a1457_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1e346b6b-3e63-4a33-bd8e-c326eddcecd1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs (Note 4)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b44390eb-96b6-405d-a8ca-356104b65e62_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_e94a3740-015a-4bd3-ba9e-429c8e311a75_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IMBRUVICAMember_3a1b4ead-355b-4a34-a38a-e79b5cf52830_terseLabel_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_label_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_documentation_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember" xlink:href="jnj-20230402.xsd#jnj_IMBRUVICAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IMBRUVICAMember" xlink:to="lab_jnj_IMBRUVICAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_c3a59fda-56ee-4226-bd70-b7f974846c1c_terseLabel_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of success factor</link:label>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_label_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Probability Of Success Factor</link:label>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_documentation_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Probability Of Success Factor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:href="jnj-20230402.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:to="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_e499181b-0d96-44b0-b196-15c472bbcb18_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; Hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2250NotesDue2050Member_f64963f4-1687-4d01-8220-6bee948dbbae_terseLabel_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2050</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_label_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050 [Member]</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_documentation_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member" xlink:href="jnj-20230402.xsd#jnj_A2250NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2250NotesDue2050Member" xlink:to="lab_jnj_A2250NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_0cd0c708-2dfa-4bb0-b946-df5dae728d8e_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_41002905-dfa8-482e-975e-01116579c8f1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a12dee53-6ef9-437d-8c11-8de91ff9e1dc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ec7d4d24-a80c-48c1-8fe3-9d48c91cdbd7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_2b18cc78-17d1-4687-8a6f-96b8cc829a45_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f497f3f0-5b6a-4b29-beae-969e7b0b88bb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_876408cb-0efc-495e-9a8c-39883eacb8f1_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Weighted-Average Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ee61d3fb-5541-4cb4-babb-85148e32f35d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_60f3a25e-4759-413e-8ea7-c29da5f17f7a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH FROM/(USED BY) INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_6886b6fa-7f01-4fcd-a95a-375e6a544a9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_19781aa0-4906-4f54-8740-622e0992343d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_d0b9e737-3938-4350-b11b-0d8df942d8ed_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_dfb22d54-e0a5-4364-81e1-d5868b5b22f2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1b50dce6-bf8b-4fc4-8429-051f793528a7_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_19dbeabd-cc20-4fd8-ac11-5715c2dfcf35_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_472e3d68-37f8-4b22-b738-30dcbb5b5b78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accumulated Other Comprehensive Income (Loss), net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_d0404a47-445c-491a-8304-9f03786182f5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OralCareMember_f3454684-fd82-4917-a2bd-b32aeea2ce0d_terseLabel_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care</link:label>
    <link:label id="lab_jnj_OralCareMember_label_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:label id="lab_jnj_OralCareMember_documentation_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember" xlink:href="jnj-20230402.xsd#jnj_OralCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OralCareMember" xlink:to="lab_jnj_OralCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_3a8f9a1c-68a8-4a7d-b127-cf5cd5024a03_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_789e50cc-56ef-4bc0-99b6-ad07022bc0c7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, related to acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OPSUMITMember_3d79a9ea-0a89-42da-9dd1-7b62206b0168_terseLabel_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT</link:label>
    <link:label id="lab_jnj_OPSUMITMember_label_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:label id="lab_jnj_OPSUMITMember_documentation_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember" xlink:href="jnj-20230402.xsd#jnj_OPSUMITMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OPSUMITMember" xlink:to="lab_jnj_OPSUMITMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_d1409451-d2ff-4e78-a3d3-e6f4d7e50e16_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:href="jnj-20230402.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_c5be55ff-1e96-4dfa-95cf-6bf55632bf28_verboseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_15c7e465-f9a6-44c8-b36f-cccc9b9f1bf7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9cff6273-da2c-4fa0-97a1-fb56309f000a_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Profit by Segment of Business</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_da30992a-e1cb-4b7a-b893-b7e3f342a535_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_612313e9-df47-4972-850f-f89a6a3485aa_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ec327549-2c08-4b41-880e-b1dbd21ae5dc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b2ae8ef9-84a5-4a4a-8ab9-5a5b38cef3b7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a260aa76-cf7c-4e76-be4b-f7bce12e0f4a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f5921c64-e1ef-4152-8314-f3e846a1cba5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Current Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BankruptcyLossContingencyDiscountRate_2246cf93-2a2e-4d8b-a3d0-9fb4719ca8b3_terseLabel_en-US" xlink:label="lab_jnj_BankruptcyLossContingencyDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bankruptcy Loss Contingency, Discount Rate</link:label>
    <link:label id="lab_jnj_BankruptcyLossContingencyDiscountRate_label_en-US" xlink:label="lab_jnj_BankruptcyLossContingencyDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bankruptcy Loss Contingency, Discount Rate</link:label>
    <link:label id="lab_jnj_BankruptcyLossContingencyDiscountRate_documentation_en-US" xlink:label="lab_jnj_BankruptcyLossContingencyDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bankruptcy Loss Contingency, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BankruptcyLossContingencyDiscountRate" xlink:href="jnj-20230402.xsd#jnj_BankruptcyLossContingencyDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BankruptcyLossContingencyDiscountRate" xlink:to="lab_jnj_BankruptcyLossContingencyDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_ff53201d-a787-4648-9c90-695a923623b6_verboseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_ffc3cfb7-c1a9-42de-b204-d109fc423669_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_49ce731a-50d2-4b48-9173-33eade13dfc1_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of property and intangibles</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_b9af4f7f-cc6f-4013-945a-2f1c5623e551_terseLabel_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90%&#160;Notes due 2028</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_label_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_documentation_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member" xlink:href="jnj-20230402.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.900Notesdue2028Member" xlink:to="lab_jnj_A2.900Notesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_3b31081a-a1d8-42e1-922f-49af9d6429c1_terseLabel_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Exports</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_label_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_documentation_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember" xlink:href="jnj-20230402.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UNITEDSTATESExportsMember" xlink:to="lab_jnj_UNITEDSTATESExportsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableAmountPerShare_5e4cea30-39d9-405d-a4f2-ef8f0c61f898_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DividendsPayableAmountPerShare_label_en-US" xlink:label="lab_us-gaap_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableAmountPerShare" xlink:to="lab_us-gaap_DividendsPayableAmountPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_35f02c30-8f8b-40b5-9326-86d58e3ee66b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_990afbd8-7b38-4f18-baf8-3c7340c70a33_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A490DebentureDue2033Member_ea06aa79-2f80-4655-a48c-36a866ce6f31_terseLabel_en-US" xlink:label="lab_jnj_A490DebentureDue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.90% Debentures due 2033*</link:label>
    <link:label id="lab_jnj_A490DebentureDue2033Member_label_en-US" xlink:label="lab_jnj_A490DebentureDue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.90% Debenture Due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A490DebentureDue2033Member_documentation_en-US" xlink:label="lab_jnj_A490DebentureDue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.90% Debenture Due 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A490DebentureDue2033Member" xlink:href="jnj-20230402.xsd#jnj_A490DebentureDue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A490DebentureDue2033Member" xlink:to="lab_jnj_A490DebentureDue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_88011e63-912e-4487-926b-3932497059ec_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsrMember_f1647b1b-b283-4cc5-ae75-4305fe3ccb09_terseLabel_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR</link:label>
    <link:label id="lab_jnj_AsrMember_label_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR [Member]</link:label>
    <link:label id="lab_jnj_AsrMember_documentation_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember" xlink:href="jnj-20230402.xsd#jnj_AsrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsrMember" xlink:to="lab_jnj_AsrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_2533e1db-7e65-4122-a7d1-9628a4c28b6a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RestrictedCashMember_714e62de-853d-4dca-88e0-8e6a2e681500_terseLabel_en-US" xlink:label="lab_jnj_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_jnj_RestrictedCashMember_label_en-US" xlink:label="lab_jnj_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Member]</link:label>
    <link:label id="lab_jnj_RestrictedCashMember_documentation_en-US" xlink:label="lab_jnj_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestrictedCashMember" xlink:href="jnj-20230402.xsd#jnj_RestrictedCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RestrictedCashMember" xlink:to="lab_jnj_RestrictedCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ba690aa9-0c25-44f3-9aa3-27a0e1b13f84_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_3f3a2ad3-0e87-4886-882b-d24a21db1870_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GrossProfitPercentToSales_0b50a9f7-ace9-4bf6-9529-72de95e1d09c_totalLabel_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit Percent To Sales</link:label>
    <link:label id="lab_jnj_GrossProfitPercentToSales_label_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit Percent To Sales</link:label>
    <link:label id="lab_jnj_GrossProfitPercentToSales_documentation_en-US" xlink:label="lab_jnj_GrossProfitPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales" xlink:href="jnj-20230402.xsd#jnj_GrossProfitPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GrossProfitPercentToSales" xlink:to="lab_jnj_GrossProfitPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_409bfd7c-770d-4506-b630-7abd61783ad1_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_0d378b08-4ca1-4721-a221-10bff59371ee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_af78b1e2-b62c-480e-ba07-3ad1f1431814_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_980d470b-fb3f-4abd-bb3f-0ab7ed3bfc6d_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve established</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_label_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_documentation_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:href="jnj-20230402.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:to="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_f057249f-9986-4fab-97eb-48a2432cd401_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_152fc7bb-febc-470f-8e33-2b0fd77cd27d_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_0ce3d4fb-8604-4cd9-a611-fa5b6b4b9ebc_terseLabel_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member" xlink:href="jnj-20230402.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.95Debenturesdue2033Member" xlink:to="lab_jnj_A4.95Debenturesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_KNEESMember_06527da4-508e-4ffb-8316-66c2558b48c5_terseLabel_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES</link:label>
    <link:label id="lab_jnj_KNEESMember_label_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:label id="lab_jnj_KNEESMember_documentation_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember" xlink:href="jnj-20230402.xsd#jnj_KNEESMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_KNEESMember" xlink:to="lab_jnj_KNEESMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_c16c7252-304a-49db-8b50-1da2ce60d9f1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_c3474635-9a3e-439f-b86c-f0c4e54716fd_terseLabel_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling marketing and administrative expenses percent to sales</link:label>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_label_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General And Administrative Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling general and administrative expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:href="jnj-20230402.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:to="lab_jnj_SellingGeneralAndAdministrativeExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_9e78e3e0-a8af-4ffc-a181-2b96c1179707_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_46425c07-cfd7-4062-be60-1206e7855de9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_68f913c0-4486-44b1-8d5b-c426fcda23ef_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e7e748b3-82bc-433b-aad6-0e29a1ee3773_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans, net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_9a482a7c-b472-4d2a-baa4-855c9b033c2d_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A505DebentureDue2028Member_5fc892c3-816b-4896-98b6-6488fc17280e_terseLabel_en-US" xlink:label="lab_jnj_A505DebentureDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.05% Debentures due 2028*</link:label>
    <link:label id="lab_jnj_A505DebentureDue2028Member_label_en-US" xlink:label="lab_jnj_A505DebentureDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.05% Debenture Due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A505DebentureDue2028Member_documentation_en-US" xlink:label="lab_jnj_A505DebentureDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.05% Debenture Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A505DebentureDue2028Member" xlink:href="jnj-20230402.xsd#jnj_A505DebentureDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A505DebentureDue2028Member" xlink:to="lab_jnj_A505DebentureDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f1c5e3ad-f0e0-4666-a1c0-8af219583103_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e27e4efc-107f-4d44-a053-e56725d2878e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_8ed068b4-75d0-465b-a230-1cf4aa6ac3dd_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_cc404b9c-af88-48ed-8733-8003f1fed954_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_71e1bc81-898f-4c3b-b40d-a796c8e4dc28_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) On Securities, net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_467207be-58a3-435a-b975-a5d8aa3ce513_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ba772988-cee6-411d-8095-04cb74a0ab99_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_bbc9c242-2474-4854-80d2-f0751769b7c2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes on income (Note 5)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CARVYKTIMember_5c264d16-10ca-4b9b-bf82-60793e121fe9_terseLabel_en-US" xlink:label="lab_jnj_CARVYKTIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARVYKTI</link:label>
    <link:label id="lab_jnj_CARVYKTIMember_label_en-US" xlink:label="lab_jnj_CARVYKTIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARVYKTI [Member]</link:label>
    <link:label id="lab_jnj_CARVYKTIMember_documentation_en-US" xlink:label="lab_jnj_CARVYKTIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARVYKTI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CARVYKTIMember" xlink:href="jnj-20230402.xsd#jnj_CARVYKTIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CARVYKTIMember" xlink:to="lab_jnj_CARVYKTIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_086c5cb2-349a-49fe-8f28-a617a7235f50_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d1b1052d-0cc4-4ad1-90d5-c70e7b492753_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss) (Note 7)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a2e40c01-663f-4172-95f2-c23fa6c9a85a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_c71a1e66-fa5a-4db1-b1e4-b7fa1fb271c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Derivatives not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1f3bc1d1-d7d2-4506-adee-987376e2f098_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (Note 4)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_418a5423-9f27-4beb-9ff7-aa0b4835b7ab_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4f68fb66-7f32-446a-9440-5c9dbb1eef7b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_caa0b094-aad5-46b0-955b-c60641c56241_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_e17d3359-ecf5-4a4b-822e-5c7a28d89e68_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency, number of claimants</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_label_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingency Number Of Claimant</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency number of claimant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:href="jnj-20230402.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:to="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_86caade4-4f14-4232-94e2-99bbc9a0bedc_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_937a6474-379f-482a-abc1-6709a4c4a78a_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_7c305484-1bbd-4c50-8cc4-084a981c955f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_20a563b4-9368-4dd3-8c1b-d797f2db53d5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation/Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9bc1060c-aa46-40af-b537-32f2ec98af6a_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_53aa8943-c157-477b-9faf-683bf183a6a3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ClassIRecommendationForImpellaMember_d3344a46-04e8-46f3-bafc-f4fc3c82b1a3_terseLabel_en-US" xlink:label="lab_jnj_ClassIRecommendationForImpellaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class I Recommendation For Impella</link:label>
    <link:label id="lab_jnj_ClassIRecommendationForImpellaMember_label_en-US" xlink:label="lab_jnj_ClassIRecommendationForImpellaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class I Recommendation For Impella [Member]</link:label>
    <link:label id="lab_jnj_ClassIRecommendationForImpellaMember_documentation_en-US" xlink:label="lab_jnj_ClassIRecommendationForImpellaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class I Recommendation For Impella</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ClassIRecommendationForImpellaMember" xlink:href="jnj-20230402.xsd#jnj_ClassIRecommendationForImpellaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ClassIRecommendationForImpellaMember" xlink:to="lab_jnj_ClassIRecommendationForImpellaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_bc06dbe3-bea5-43b2-9c77-f80e2aad7d35_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SPRAVATOMember_6584a774-41c0-4184-9d5b-6d3ff3d24a91_terseLabel_en-US" xlink:label="lab_jnj_SPRAVATOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPRAVATO</link:label>
    <link:label id="lab_jnj_SPRAVATOMember_label_en-US" xlink:label="lab_jnj_SPRAVATOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPRAVATO [Member]</link:label>
    <link:label id="lab_jnj_SPRAVATOMember_documentation_en-US" xlink:label="lab_jnj_SPRAVATOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPRAVATO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPRAVATOMember" xlink:href="jnj-20230402.xsd#jnj_SPRAVATOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SPRAVATOMember" xlink:to="lab_jnj_SPRAVATOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_92f11958-2f1b-4a39-a6f2-154a3bbed2c2_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_45994309-5eeb-498a-9402-9d5db17202f2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash (Note 4)</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_80fc88e4-a587-48e1-8474-a90db73c3863_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by geographic area</link:label>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments, Geographical Areas [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract" xlink:to="lab_us-gaap_SegmentsGeographicalAreasAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_82fa1866-dc54-4746-a499-f3600602d152_terseLabel_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.40%&#160;Notes due 2038</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_label_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member" xlink:href="jnj-20230402.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.400Notesdue2038Member" xlink:to="lab_jnj_A3.400Notesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_379beb40-cad8-497a-9cd6-0ab5056feb70_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A505DebentureDue2053Member_c3ea5d67-1fcb-4448-a4ea-f9c0eee2a80c_terseLabel_en-US" xlink:label="lab_jnj_A505DebentureDue2053Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.05% Debentures due 2053*</link:label>
    <link:label id="lab_jnj_A505DebentureDue2053Member_label_en-US" xlink:label="lab_jnj_A505DebentureDue2053Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.05% Debenture Due 2053 [Member]</link:label>
    <link:label id="lab_jnj_A505DebentureDue2053Member_documentation_en-US" xlink:label="lab_jnj_A505DebentureDue2053Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.05% Debenture Due 2053</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A505DebentureDue2053Member" xlink:href="jnj-20230402.xsd#jnj_A505DebentureDue2053Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A505DebentureDue2053Member" xlink:to="lab_jnj_A505DebentureDue2053Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AurisHealthMember_bac06499-d9ef-4dc9-bed1-23211a554fa0_terseLabel_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:label id="lab_jnj_AurisHealthMember_label_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health [Member]</link:label>
    <link:label id="lab_jnj_AurisHealthMember_documentation_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember" xlink:href="jnj-20230402.xsd#jnj_AurisHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AurisHealthMember" xlink:to="lab_jnj_AurisHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_57203af9-de1f-4594-88a2-f5e4b50a3e00_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_d8af2bdb-20f2-4902-bb49-aa8c0047e630_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and notes payable</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_72520429-e3fd-4395-8a8d-a3276084c05c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3c14cd9b-98a5-4e0e-adbb-ac8426e9b916_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_b572796f-0a96-4b8a-b481-04748bf36f44_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_27212961-666a-44ce-bf49-01764f05b30a_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_8ccebf37-3d7c-4fc7-ad99-19b3d515c4d5_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_01a19ef0-b2bf-462f-85a4-9c9cae0bb796_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_label_en-US" xlink:label="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Loaned or Sold under Agreements to Repurchase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:to="lab_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_303b4cda-b2ab-482c-b92f-b87fa562d457_terseLabel_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_label_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Due Period Fifteen Member</link:label>
    <link:label id="lab_jnj_NotesDuePeriodFifteenMember_documentation_en-US" xlink:label="lab_jnj_NotesDuePeriodFifteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes due period fifteen.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember" xlink:href="jnj-20230402.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NotesDuePeriodFifteenMember" xlink:to="lab_jnj_NotesDuePeriodFifteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyAdditionalContribution_5ad939be-4551-4989-a534-c4bc1a9cb4da_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyAdditionalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Additional Contribution</link:label>
    <link:label id="lab_jnj_LossContingencyAdditionalContribution_label_en-US" xlink:label="lab_jnj_LossContingencyAdditionalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Additional Contribution</link:label>
    <link:label id="lab_jnj_LossContingencyAdditionalContribution_documentation_en-US" xlink:label="lab_jnj_LossContingencyAdditionalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Additional Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyAdditionalContribution" xlink:href="jnj-20230402.xsd#jnj_LossContingencyAdditionalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyAdditionalContribution" xlink:to="lab_jnj_LossContingencyAdditionalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_49ce4fe5-c712-4503-9d22-54b74273df5a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_281e270d-8832-472b-8232-ef435d7b85bc_terseLabel_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_label_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business [Table Text Block]</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_documentation_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:href="jnj-20230402.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:to="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_07a974c4-7e3a-402e-8a8d-f99f29c38c0f_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_98c7f4c5-df16-455e-aede-f0a9620e9db6_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments of Business and Geographic Areas</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_af8a613e-35c8-4c0a-a671-d741c9a1a66b_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_43174214-d1a9-4f8c-8988-0998b5a69895_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_9b8d7d96-3f4c-46da-a516-f0561583dfc7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Income on Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_73d5d57e-8c59-4747-9d08-b4af1d2d5f1b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_a32fbc24-b8ea-431a-9f6a-468a39d2437b_verboseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due November 2024</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_dbf3b21a-ffed-4e55-9dd2-66e025589e3c_terseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes due 2024 (500MM GBP 1.2359)</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member" xlink:href="jnj-20230402.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.50NotesDue2024Member" xlink:to="lab_jnj_A5.50NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4a249490-6e96-4e5f-bed7-74a20813901b_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_0b8eee11-8e0e-4498-bb43-bcb5af34d092_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_27f3d55c-51d2-47ac-81bc-6006c2a2f5a8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7042c860-a5ad-4dcd-a0f2-6d9c62625ba1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities - Carrying Amount</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RisperdalMember_217e10be-a8a4-43da-9962-1f07a290f0e9_terseLabel_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal</link:label>
    <link:label id="lab_jnj_RisperdalMember_label_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal [Member]</link:label>
    <link:label id="lab_jnj_RisperdalMember_documentation_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember" xlink:href="jnj-20230402.xsd#jnj_RisperdalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RisperdalMember" xlink:to="lab_jnj_RisperdalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_86298396-a288-4b32-bfe0-cda4a1938404_terseLabel_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_label_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_documentation_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member" xlink:href="jnj-20230402.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.70Notesdue2046Member" xlink:to="lab_jnj_A3.70Notesdue2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_9776112f-583c-488f-809a-c30984cc0dcf_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVG. SHARES OUTSTANDING</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_23ef70df-7afb-4741-bb8f-a9d8904d867a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (Note 2)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_70563309-5bc2-47d2-9800-60a855b13153_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EthiconMember_721df5e8-0d79-4db8-876e-05d0408af454_terseLabel_en-US" xlink:label="lab_jnj_EthiconMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ethicon</link:label>
    <link:label id="lab_jnj_EthiconMember_label_en-US" xlink:label="lab_jnj_EthiconMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ethicon [Member]</link:label>
    <link:label id="lab_jnj_EthiconMember_documentation_en-US" xlink:label="lab_jnj_EthiconMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ethicon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EthiconMember" xlink:href="jnj-20230402.xsd#jnj_EthiconMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EthiconMember" xlink:to="lab_jnj_EthiconMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f73333db-79cb-49be-93cc-498cfdb798b3_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_e998d597-85af-42bd-a2b4-bfadb18d6464_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_e3554a80-4665-4046-90b3-b8229fcf5248_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MedicalDevicesMember_3418c751-aa45-486d-aaf8-586836a1fb8e_verboseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MedTech</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_d02848a2-aeb3-4fd2-916f-66f7dd2d0d68_terseLabel_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEDTECH</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_label_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:label id="lab_jnj_MedicalDevicesMember_documentation_en-US" xlink:label="lab_jnj_MedicalDevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember" xlink:href="jnj-20230402.xsd#jnj_MedicalDevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MedicalDevicesMember" xlink:to="lab_jnj_MedicalDevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b3a13c26-dff2-42e5-98ed-cf2ffd29cd24_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase)/Decrease in other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_2c424c2f-a4bd-42c9-b89d-77d03837e980_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherOncologyMember_4bdbbb94-2cb9-4e6d-9307-5b5617084c7b_terseLabel_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER ONCOLOGY</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_label_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_documentation_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember" xlink:href="jnj-20230402.xsd#jnj_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherOncologyMember" xlink:to="lab_jnj_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_efc9f73b-b0c1-4b77-8a64-99739fdd48cb_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_99089a25-b582-4def-8549-26027b5d2465_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_91f45abb-d56a-41df-9cf7-ada59d2bdf48_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_27b2b346-b013-4f04-b213-d8c2e3915a2e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Liability Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_99f91020-d4ca-486b-b9d5-4a5d5a95a6e3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9ceb74b5-0dc1-40c5-b1b5-6c32c12dedd1_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding &#8212; basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_bdc325fa-8923-406f-9c40-86a4165c316e_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_13339564-23c6-4651-906b-1b365c128ddf_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ERLEADAMember_a2dc557c-3152-4b24-8000-e0a4fb2ddfac_terseLabel_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:label id="lab_jnj_ERLEADAMember_label_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA [Member]</link:label>
    <link:label id="lab_jnj_ERLEADAMember_documentation_en-US" xlink:label="lab_jnj_ERLEADAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember" xlink:href="jnj-20230402.xsd#jnj_ERLEADAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ERLEADAMember" xlink:to="lab_jnj_ERLEADAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_47c81ddd-8cc1-43e2-a514-07d861f64a71_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_a6ab7ac3-1223-400a-b333-0f23450e46dd_terseLabel_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_label_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_documentation_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember" xlink:href="jnj-20230402.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PatentsAndTrademarksMember" xlink:to="lab_jnj_PatentsAndTrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_d70ce42b-894e-46e8-89cf-887d349c071c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_eec3d79d-0584-4085-8b0a-dc4959cf65cb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_6b2dcb10-371f-44fa-80b2-a8fce131dcd2_terseLabel_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member" xlink:href="jnj-20230402.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.625Notesdue2037Member" xlink:to="lab_jnj_A3.625Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_3da8de7d-d552-4f00-9d0d-9fc88bee95a5_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with indefinite lives:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7dbd8d34-050e-41ae-8b92-e374980a2dfd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_6785a9f5-c957-45f0-aa8c-c52e75aeb362_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherImmunologyMember_6ffdb488-6023-4811-bbb3-01c8eabecc8f_terseLabel_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER IMMUNOLOGY</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_label_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_documentation_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember" xlink:href="jnj-20230402.xsd#jnj_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherImmunologyMember" xlink:to="lab_jnj_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_36bd76ca-a0fe-4d92-87ff-410674f8be45_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BermekimabMember_c08044c2-976a-4913-b8aa-39e52e9c861f_terseLabel_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab</link:label>
    <link:label id="lab_jnj_BermekimabMember_label_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:label id="lab_jnj_BermekimabMember_documentation_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember" xlink:href="jnj-20230402.xsd#jnj_BermekimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BermekimabMember" xlink:to="lab_jnj_BermekimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_3867fb86-8d58-4c18-a286-1f05bbc17c45_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_efc1b3c0-820a-49c1-8e9c-6358835de1e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_377fdc8c-a65c-4147-a8c7-cbd2e6e9ae85_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8c28e4a0-ca32-4575-bfe1-1ac742ea2e12_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d53252c1-3127-4104-9c63-84f143fc1c4f_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_705ffd0e-c999-43c9-add9-c6eb349eb90e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_c585a613-59ec-4010-8e53-35e44e12c50d_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_12aac8ce-3219-4b27-9020-dd04637a9399_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Paid, Value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesPaidValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Paid, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesPaidValue" xlink:to="lab_us-gaap_LossContingencyDamagesPaidValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_119bd848-8199-4538-b607-50b77053b26b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_64d9609b-ccae-44e4-878a-7fbb62e7afd4_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_15a46f03-aff0-4195-9485-3b255763c4d9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_65e34e73-9df1-43c4-9876-239809e39e17_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities - Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_4fcaa527-f128-4111-8234-532a73b0c72b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goods in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_de6f7664-3179-4b9b-ba68-759e7692db36_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_8f577b5d-974b-42a2-9352-c80024c348b1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired from acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_14c53857-bbcd-4332-8b8a-452a8a0db875_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterventionalSolutionsMember_79f41460-0fe6-430a-9b58-a015a18693d7_verboseLabel_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_label_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_documentation_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember" xlink:href="jnj-20230402.xsd#jnj_InterventionalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterventionalSolutionsMember" xlink:to="lab_jnj_InterventionalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_85712d1c-9d22-4844-9f66-072179b5ad84_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RevenuesContingentConsideration_ef3b80c0-f698-4ba1-97fd-a9e178daf17a_terseLabel_en-US" xlink:label="lab_jnj_RevenuesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_jnj_RevenuesContingentConsideration_label_en-US" xlink:label="lab_jnj_RevenuesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Contingent Consideration</link:label>
    <link:label id="lab_jnj_RevenuesContingentConsideration_documentation_en-US" xlink:label="lab_jnj_RevenuesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RevenuesContingentConsideration" xlink:href="jnj-20230402.xsd#jnj_RevenuesContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RevenuesContingentConsideration" xlink:to="lab_jnj_RevenuesContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_259b55d8-cc6b-4f1c-88db-03c3c91399cb_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial (gains) losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f36fa58b-c5a6-4195-b487-0fc5210064dc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_6abafe4a-b9aa-486b-b93a-f672a71e1d78_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestExpensePercentToSales_95e1324e-a78a-4cf2-8512-7c4173351294_terseLabel_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized percent to sales</link:label>
    <link:label id="lab_jnj_InterestExpensePercentToSales_label_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense Percent To Sales</link:label>
    <link:label id="lab_jnj_InterestExpensePercentToSales_documentation_en-US" xlink:label="lab_jnj_InterestExpensePercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales" xlink:href="jnj-20230402.xsd#jnj_InterestExpensePercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestExpensePercentToSales" xlink:to="lab_jnj_InterestExpensePercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_e4184696-d938-4fac-8999-31779329bb87_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_c965cda7-c308-4bdd-b984-426254d129de_verboseLabel_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_label_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_documentation_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:href="jnj-20230402.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:to="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_a46c574f-4a2a-4d58-8dfc-e714c3ba6b7c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d8a4a2b5-0cd7-43a5-9fb2-f7e68a44dc14_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential shares exercisable under stock option plans</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_3f88ec58-2285-4eac-8253-cc9e43d82f2f_verboseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_b51f15c4-4915-43fb-abd9-fea9b320b60e_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_73dc18d1-4697-494f-9117-4428c265b05c_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_5d607472-130c-4dc8-b1a1-50f9f4051d05_terseLabel_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_label_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_documentation_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member" xlink:href="jnj-20230402.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.95Notesdue2027Member" xlink:to="lab_jnj_A2.95Notesdue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_eed56c80-4d50-49ca-bf10-4a9a7b432e2a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired (Note 10)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_a2ca81ca-ffa9-4615-8d06-62d83105c136_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant other observable inputs Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_f43c959d-859a-4378-bdc9-d36775a7f4a7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_22a67e30-b2e2-4590-8e05-09ab38ce2052_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_b06933fe-e7ab-45b2-bf9e-50e108a339c3_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_5109a02a-00fb-454a-bbba-2bf4ba9cb782_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c8fc274b-07a5-427c-be4d-a69359f47bbd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_08020789-550a-4b06-9a4a-705460ef74c3_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss) per share (basic/diluted)*</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_3f1a7ed9-9fe3-4b1d-bbe4-548d72bf2105_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net (Note 3)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_47e01dbc-533b-4eb1-ae0e-a4742a284a99_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets &#8212; net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OpioidMember_dc3c8e07-d6f0-4c27-aa23-0495e4831a1b_terseLabel_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:label id="lab_jnj_OpioidMember_label_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">opioid [Member]</link:label>
    <link:label id="lab_jnj_OpioidMember_documentation_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember" xlink:href="jnj-20230402.xsd#jnj_OpioidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OpioidMember" xlink:to="lab_jnj_OpioidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2450NotesDue2060Member_736470cb-360c-464f-81b0-81d648787d87_terseLabel_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2060</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_label_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060 [Member]</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_documentation_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member" xlink:href="jnj-20230402.xsd#jnj_A2450NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2450NotesDue2060Member" xlink:to="lab_jnj_A2450NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_7b324b2e-9809-44b6-b3da-a3a6b84285a1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_2aaee1b6-ea56-43cd-85d6-5436074756e3_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_b195bcaa-93e8-4fec-ae72-63109fcbcaa0_terseLabel_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_label_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_documentation_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member" xlink:href="jnj-20230402.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.85Notesdue2041Member" xlink:to="lab_jnj_A4.85Notesdue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e8d26722-ba76-417a-b371-242f498f5952_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_7a040e3d-9eaa-4923-8f0e-d51e6b66a403_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term taxes payable (Note 5)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherMember_6ca09f7a-f2c0-4983-bb58-b04933322882_terseLabel_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_OtherMember_label_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_jnj_OtherMember_documentation_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember" xlink:href="jnj-20230402.xsd#jnj_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherMember" xlink:to="lab_jnj_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_5cf2c331-6467-4348-b485-e4fe3a882651_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_3f9d3718-7849-4ae5-86b1-ffb1e20a07b2_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_a89ef04a-6e7a-4f9e-a613-8b9d9b40d577_verboseLabel_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (income)/Interest expense, net</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember" xlink:href="jnj-20230402.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestIncomeExpenseNetMember" xlink:to="lab_jnj_InterestIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_d36be880-124e-41ae-a47f-52c134642544_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities(2)</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_d4c6fe53-5079-4909-8ffe-fb33cef3b227_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_e681a1f0-cb91-4208-b202-455341942df3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Asset Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_a64234a3-8d42-4e73-9058-4c6f9851cef4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TRAUMAMember_1b2d81e9-fe68-4074-bd5b-43e73d663367_terseLabel_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA</link:label>
    <link:label id="lab_jnj_TRAUMAMember_label_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:label id="lab_jnj_TRAUMAMember_documentation_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember" xlink:href="jnj-20230402.xsd#jnj_TRAUMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TRAUMAMember" xlink:to="lab_jnj_TRAUMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_b7f21b7c-3621-46dc-96a8-a2e54c6699dc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_f856c4a4-e266-4508-a04b-5839c8ba7897_terseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_041060e0-9bcd-4f8f-963d-bebfae5da22a_verboseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember" xlink:href="jnj-20230402.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherIncomeExpenseNetMember" xlink:to="lab_jnj_OtherIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_581b210c-2a0e-44d0-a14a-7edf6cce63d4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_18568f8c-f6e9-400e-b53f-45d3d50e21b0_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral already posted, aggregate fair value</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8dc6ec0e-e9da-4fbd-85cb-9249465da2e9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TylenolMember_2109c641-cef0-4985-b2bb-7372e5728582_terseLabel_en-US" xlink:label="lab_jnj_TylenolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tylenol</link:label>
    <link:label id="lab_jnj_TylenolMember_label_en-US" xlink:label="lab_jnj_TylenolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tylenol [Member]</link:label>
    <link:label id="lab_jnj_TylenolMember_documentation_en-US" xlink:label="lab_jnj_TylenolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tylenol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TylenolMember" xlink:href="jnj-20230402.xsd#jnj_TylenolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TylenolMember" xlink:to="lab_jnj_TylenolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_ddfcc57d-3ea8-47ed-9291-ba0bc27067fd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Current Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A500DebentureDue2030Member_86ea7e22-064e-4d7d-b121-8ee2121602d0_terseLabel_en-US" xlink:label="lab_jnj_A500DebentureDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Debentures due 2030*</link:label>
    <link:label id="lab_jnj_A500DebentureDue2030Member_label_en-US" xlink:label="lab_jnj_A500DebentureDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Debenture Due 2030 [Member]</link:label>
    <link:label id="lab_jnj_A500DebentureDue2030Member_documentation_en-US" xlink:label="lab_jnj_A500DebentureDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Debenture Due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A500DebentureDue2030Member" xlink:href="jnj-20230402.xsd#jnj_A500DebentureDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A500DebentureDue2030Member" xlink:to="lab_jnj_A500DebentureDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_b060a235-5515-4bb2-9d73-62dda2008801_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OncologyMember_392786d0-e3d6-4262-b8da-9c44a5024fbb_terseLabel_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_jnj_OncologyMember_label_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_jnj_OncologyMember_documentation_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember" xlink:href="jnj-20230402.xsd#jnj_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OncologyMember" xlink:to="lab_jnj_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_e440c216-3595-4f06-b11b-90643819ee0f_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities at fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument Detail [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_b263f9cb-b5f2-4314-8f6d-2649870afce2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_914d4699-7f5c-4568-8d36-f479760c5b37_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_aba63bfa-c64c-46e9-8466-e245da56ae26_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_42a0c4fd-8f6d-4dbc-b924-474fe45eee6d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_37a67628-029e-403a-bafe-e1444ab647e6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_8f791930-ce28-4abe-96e1-7de729d338ca_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTCMember_14a16be5-4377-4c4a-8400-8fab163bbec3_terseLabel_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_label_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_documentation_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember" xlink:href="jnj-20230402.xsd#jnj_OTCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTCMember" xlink:to="lab_jnj_OTCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_62d58cdd-44d6-43c2-b719-89bad94fd636_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_78090092-fcea-4990-9b36-1d2da9d8ecc6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_64993a0c-c786-40fc-a34f-51c4328a05d8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_0b7c4381-86aa-4810-8f96-7ca3b415b3f5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) reclassified from AOCI into income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_0f2e6e1c-c1b0-4291-85e1-0da0fce35af5_terseLabel_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense percent to sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_label_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense Excluding Acquired In Process Cost Percent To Sales</link:label>
    <link:label id="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_documentation_en-US" xlink:label="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense excluding acquired in process cost percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:href="jnj-20230402.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:to="lab_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b97dbbac-d6b9-4d5d-8a16-ac0b75e15b1f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImpellaMember_943b84f5-2065-48ab-afb2-8011041092b9_terseLabel_en-US" xlink:label="lab_jnj_ImpellaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impella</link:label>
    <link:label id="lab_jnj_ImpellaMember_label_en-US" xlink:label="lab_jnj_ImpellaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impella [Member]</link:label>
    <link:label id="lab_jnj_ImpellaMember_documentation_en-US" xlink:label="lab_jnj_ImpellaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impella</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImpellaMember" xlink:href="jnj-20230402.xsd#jnj_ImpellaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImpellaMember" xlink:to="lab_jnj_ImpellaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_4a3db01e-d8ab-4d13-a431-4f178ad51fd0_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_ae290338-7cc9-410d-85d9-a67486ebe9d7_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_250401a8-5741-4880-8c88-205e7c140c19_terseLabel_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and current marketable securities, Estimated Fair Value</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_label_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value</link:label>
    <link:label id="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:href="jnj-20230402.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:to="lab_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_a027f0d9-e43e-42c2-8192-2bee05167491_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_c287ce08-81bf-4b8e-967b-a98dd6a5cbc1_terseLabel_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member" xlink:href="jnj-20230402.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.95Notesdue2037Member" xlink:to="lab_jnj_A5.95Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment_47a125bc-6667-49a6-b836-1dbb27226614_terseLabel_en-US" xlink:label="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefit Liability, Payment</link:label>
    <link:label id="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment_label_en-US" xlink:label="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefit Liability, Payment</link:label>
    <link:label id="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment_documentation_en-US" xlink:label="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefit Liability, Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:href="jnj-20230402.xsd#jnj_UnrecognizedTaxBenefitLiabilityPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:to="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_50be1e27-00dd-4d0a-b2da-bb68579528d8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c7527365-9d80-4a0d-b21e-08ac8449daad_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_cfbe2902-72ed-42c4-ab8b-6e9813f284d8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyTerm_8fab05e4-693e-4e3e-87f8-c95d5d921050_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Term</link:label>
    <link:label id="lab_jnj_LossContingencyTerm_label_en-US" xlink:label="lab_jnj_LossContingencyTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Term</link:label>
    <link:label id="lab_jnj_LossContingencyTerm_documentation_en-US" xlink:label="lab_jnj_LossContingencyTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyTerm" xlink:href="jnj-20230402.xsd#jnj_LossContingencyTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyTerm" xlink:to="lab_jnj_LossContingencyTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_55f192d5-7b6a-4928-a7e2-59cb91d17f2a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_3962195c-dca7-4eb8-9279-72ac0b026928_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d4dd0126-9ba7-47c2-b544-bdbb7223aafc_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_185ca538-dcbb-4af3-9ad7-5cf75a9ebb6d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_94a7d6dd-c690-45fc-97f2-131abdd5e8b0_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A210NotesDue2040Member_f6e9a533-e301-49a4-a4d1-7c8a1c03d710_terseLabel_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_label_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_documentation_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member" xlink:href="jnj-20230402.xsd#jnj_A210NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A210NotesDue2040Member" xlink:to="lab_jnj_A210NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_ead5fd52-ad73-43a9-a0c5-35683b85e0b9_terseLabel_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA / methylphenidate</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_label_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_documentation_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember" xlink:href="jnj-20230402.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONCERTAMethylphenidateMember" xlink:to="lab_jnj_CONCERTAMethylphenidateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_834042d6-7d75-486a-8592-a8d4f13db631_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StelaraMember_88b007d7-cf4c-415d-9a51-b9a2d534c310_terseLabel_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STELARA</link:label>
    <link:label id="lab_jnj_StelaraMember_label_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:label id="lab_jnj_StelaraMember_documentation_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember" xlink:href="jnj-20230402.xsd#jnj_StelaraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StelaraMember" xlink:to="lab_jnj_StelaraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SURGICALMember_330d76ff-0787-4a5a-be4a-84c99f845036_terseLabel_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL</link:label>
    <link:label id="lab_jnj_SURGICALMember_label_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:label id="lab_jnj_SURGICALMember_documentation_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember" xlink:href="jnj-20230402.xsd#jnj_SURGICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SURGICALMember" xlink:to="lab_jnj_SURGICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_81173f30-efec-4406-ab95-2019c927498a_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments and settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_0bd55d58-84db-44f2-b6a8-38e6de56e49c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_410e31f8-f8b2-4fb1-a42a-2d6f34099a98_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase/(Decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_2dd19739-34cc-42d7-84d5-fde14287d80e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OrthopaedicsMember_f6952400-b4e7-42cf-b25f-5abe5b4c9ffa_terseLabel_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_label_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_documentation_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember" xlink:href="jnj-20230402.xsd#jnj_OrthopaedicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OrthopaedicsMember" xlink:to="lab_jnj_OrthopaedicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A510DebentureDue2043Member_29a9bc3c-2148-413c-8319-29fe4f1dc805_terseLabel_en-US" xlink:label="lab_jnj_A510DebentureDue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.10% Debentures due 2043*</link:label>
    <link:label id="lab_jnj_A510DebentureDue2043Member_label_en-US" xlink:label="lab_jnj_A510DebentureDue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.10% Debenture Due 2043 [Member]</link:label>
    <link:label id="lab_jnj_A510DebentureDue2043Member_documentation_en-US" xlink:label="lab_jnj_A510DebentureDue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.10% Debenture Due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A510DebentureDue2043Member" xlink:href="jnj-20230402.xsd#jnj_A510DebentureDue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A510DebentureDue2043Member" xlink:to="lab_jnj_A510DebentureDue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_af2abc52-7a68-4545-abf0-bae17536ce63_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SupplierFinanceProgramObligationCurrent_e707bef5-1847-4f08-80d6-9a6f5d80c512_terseLabel_en-US" xlink:label="lab_jnj_SupplierFinanceProgramObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier finance program, obligation</link:label>
    <link:label id="lab_jnj_SupplierFinanceProgramObligationCurrent_label_en-US" xlink:label="lab_jnj_SupplierFinanceProgramObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Finance Program, Obligation, Current</link:label>
    <link:label id="lab_jnj_SupplierFinanceProgramObligationCurrent_documentation_en-US" xlink:label="lab_jnj_SupplierFinanceProgramObligationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Finance Program, Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplierFinanceProgramObligationCurrent" xlink:href="jnj-20230402.xsd#jnj_SupplierFinanceProgramObligationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SupplierFinanceProgramObligationCurrent" xlink:to="lab_jnj_SupplierFinanceProgramObligationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7977a17d-6e7a-46f8-acac-873eed283ef1_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InfectiousDiseasesMember_28fc39fe-2921-48fd-8eb7-685f45f37707_terseLabel_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember" xlink:href="jnj-20230402.xsd#jnj_InfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InfectiousDiseasesMember" xlink:to="lab_jnj_InfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_f982d7e3-0386-4781-8e91-58c9e88fe8f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_0727e419-2b13-4e80-a063-015b13a37da7_terseLabel_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_label_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_documentation_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember" xlink:href="jnj-20230402.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PulmonaryHypertensionMember" xlink:to="lab_jnj_PulmonaryHypertensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b1c83fe2-5e5f-4a27-8995-3753ce3644da_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ElectrophysiologyMember_46c57ae7-d12d-43a4-8355-0c568d64c939_terseLabel_en-US" xlink:label="lab_jnj_ElectrophysiologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ELECTROPHYSIOLOGY</link:label>
    <link:label id="lab_jnj_ElectrophysiologyMember_label_en-US" xlink:label="lab_jnj_ElectrophysiologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electrophysiology [Member]</link:label>
    <link:label id="lab_jnj_ElectrophysiologyMember_documentation_en-US" xlink:label="lab_jnj_ElectrophysiologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electrophysiology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElectrophysiologyMember" xlink:href="jnj-20230402.xsd#jnj_ElectrophysiologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ElectrophysiologyMember" xlink:to="lab_jnj_ElectrophysiologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8b70a3e1-3e4c-4020-86e4-e37026f8369e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_183638e9-7458-46e9-81d5-ea5eeec5459d_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_4123ddb5-1ef7-473c-b380-60ca7aaed50f_totalLabel_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings percent to sales</link:label>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_label_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Parent Percent to Sales</link:label>
    <link:label id="lab_jnj_NetIncomeAttributableToParentPercentToSales_documentation_en-US" xlink:label="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Attributable to Parent Percent to Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales" xlink:href="jnj-20230402.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NetIncomeAttributableToParentPercentToSales" xlink:to="lab_jnj_NetIncomeAttributableToParentPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_921d6f26-b261-45bb-9a17-59a523ba47a4_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_b0ab7e9e-c374-45d2-a90f-5c207757e3df_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_63aa1d43-ff77-4f45-93f5-c6d8ed9f5a83_totalLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_a692963e-a728-4cb6-ac72-e428bc340b55_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_55c5d919-b810-4a08-9e32-b5dbcdc5ab2c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A520DebentureDue2063Member_b4bf8e7e-d4b5-424e-afe3-75561149407c_terseLabel_en-US" xlink:label="lab_jnj_A520DebentureDue2063Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.20% Debentures due 2063*</link:label>
    <link:label id="lab_jnj_A520DebentureDue2063Member_label_en-US" xlink:label="lab_jnj_A520DebentureDue2063Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.20% Debenture Due 2063 [Member]</link:label>
    <link:label id="lab_jnj_A520DebentureDue2063Member_documentation_en-US" xlink:label="lab_jnj_A520DebentureDue2063Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.20% Debenture Due 2063</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A520DebentureDue2063Member" xlink:href="jnj-20230402.xsd#jnj_A520DebentureDue2063Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A520DebentureDue2063Member" xlink:to="lab_jnj_A520DebentureDue2063Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_7a92c780-2fb4-4f11-aa87-4d8e9c762954_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent Change (as a percent)</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:href="jnj-20230402.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:to="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_5d7a1f2a-acfd-4c92-8dea-35724cb4da83_terseLabel_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625% Notes due 2025</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_label_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_documentation_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member" xlink:href="jnj-20230402.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.625Notesdue2025Member" xlink:to="lab_jnj_A2.625Notesdue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_79f5eb75-d2dc-4ecc-b745-5ed02a33da68_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_48d39405-2bfc-4867-9ca7-1bc17678d287_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_20748b1c-b7b2-46bb-875b-dc72ff3f806e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate on non-current debt</link:label>
    <link:label id="lab_us-gaap_LongtermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_LongtermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_4b0e3e0b-9612-4b96-947f-7ae2c565a665_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JudicialRulingMember_e5f2aac1-f232-43c6-b60a-79ea12c83383_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_JudicialRulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember" xlink:to="lab_us-gaap_JudicialRulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_0cada06c-6202-41bc-be72-813402e84b73_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_532cee59-f018-475d-af72-cde423cd46ee_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_adc5782f-91f1-4eef-99da-ff9f951a0e40_terseLabel_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_label_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_documentation_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember" xlink:href="jnj-20230402.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsiaPacificAfricaMember" xlink:to="lab_jnj_AsiaPacificAfricaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4c8cdc1d-bb90-4fab-92e9-9c315bc95192_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_b8db697c-ddc6-4266-bcfe-f92b95212c72_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UPTRAVIMember_9701bb61-beff-47ec-8e0e-9714cda100d1_terseLabel_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_label_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_documentation_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember" xlink:href="jnj-20230402.xsd#jnj_UPTRAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UPTRAVIMember" xlink:to="lab_jnj_UPTRAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_9afc1f0c-0853-4900-91fe-69548eefaccd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualPayments" xlink:to="lab_us-gaap_LossContingencyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e3d49b2a-eed9-496b-a130-a0fabe9d5c5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in other current and non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WoundCareandOtherMember_0f4b95cb-cdaf-4f81-918e-da90568e8382_terseLabel_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care/Other</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_label_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_documentation_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember" xlink:href="jnj-20230402.xsd#jnj_WoundCareandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WoundCareandOtherMember" xlink:to="lab_jnj_WoundCareandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_00382aa1-10f5-4a80-930f-a5ac76daea50_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_c535ceb7-e2c6-4aad-80b0-71d1f1298810_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c4da1de4-7791-4fec-a4f7-d22b0012777b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_5169f5b7-ac39-446d-893e-3fb856228676_terseLabel_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER INFECTIOUS DISEASES(</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember" xlink:href="jnj-20230402.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherInfectiousDiseasesMember" xlink:to="lab_jnj_OtherInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_151e2fd1-fc97-4ccd-9981-f72a3fe2d25c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_369ba577-2b16-47f7-8b94-906a0081021e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_6ff1a230-cead-4651-90b6-792d1299db68_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_4965fcbd-6d04-4e90-8996-40647385a9ed_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9085fa54-3b05-40b7-b54c-380b55f410a0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_5a2af4d8-02bc-494b-b0c3-3894a941a9be_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccountingStandardsUpdate202204Member_label_en-US" xlink:label="lab_jnj_AccountingStandardsUpdate202204Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2022-04 [Member]</link:label>
    <link:label id="lab_jnj_AccountingStandardsUpdate202204Member_documentation_en-US" xlink:label="lab_jnj_AccountingStandardsUpdate202204Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2022-04</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccountingStandardsUpdate202204Member" xlink:href="jnj-20230402.xsd#jnj_AccountingStandardsUpdate202204Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccountingStandardsUpdate202204Member" xlink:to="lab_jnj_AccountingStandardsUpdate202204Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>jnj-20230402_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:58e186d7-ec31-41bf-b939-580d103359b5,g:2048fc28-099b-4a2a-a431-d29d26f24517-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/Cover" xlink:type="simple" xlink:href="jnj-20230402.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_127eae55-ceb3-47bf-95ac-373cd66dacf1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_6aee2c21-84f6-4f57-93a7-01f952c0ef6b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_127eae55-ceb3-47bf-95ac-373cd66dacf1" xlink:to="loc_dei_EntitiesTable_6aee2c21-84f6-4f57-93a7-01f952c0ef6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_98639db2-a195-4de2-b4ba-394f230d5913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_6aee2c21-84f6-4f57-93a7-01f952c0ef6b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_98639db2-a195-4de2-b4ba-394f230d5913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_98639db2-a195-4de2-b4ba-394f230d5913" xlink:to="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e0e2c4c3-a545-49f4-9d61-dfd7d7a7be7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:to="loc_us-gaap_CommonStockMember_e0e2c4c3-a545-49f4-9d61-dfd7d7a7be7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_0c65d4ad-049f-493c-ac27-cc8111d74bf2" xlink:href="jnj-20230402.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:to="loc_jnj_A0.650NotesDue2024Member_0c65d4ad-049f-493c-ac27-cc8111d74bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_228bd5b7-769a-4f61-a6bd-f8a18ac5615d" xlink:href="jnj-20230402.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:to="loc_jnj_A5.50NotesDue2024Member_228bd5b7-769a-4f61-a6bd-f8a18ac5615d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_8ed3c1b8-33c3-48a4-b748-7b3d53800d57" xlink:href="jnj-20230402.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:to="loc_jnj_A1.150NotesDue2028Member_8ed3c1b8-33c3-48a4-b748-7b3d53800d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_3a04b911-8d95-4c9b-9c12-18f58086938a" xlink:href="jnj-20230402.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_eb6abd8d-5845-4464-ba11-4c4fb2f9a032" xlink:to="loc_jnj_A1.650NotesDue2035Member_3a04b911-8d95-4c9b-9c12-18f58086938a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_6aee2c21-84f6-4f57-93a7-01f952c0ef6b" xlink:to="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7e4f4870-593e-4c08-8a30-332123e2cf2e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_DocumentType_7e4f4870-593e-4c08-8a30-332123e2cf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_14585d8f-f9b2-4b05-bd65-d185d928395e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_DocumentQuarterlyReport_14585d8f-f9b2-4b05-bd65-d185d928395e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_9e985839-7eaa-4517-8a26-82717ddfdc46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_DocumentPeriodEndDate_9e985839-7eaa-4517-8a26-82717ddfdc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_bfa2a4ce-7ce3-4259-906f-df60e27cc22a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_DocumentTransitionReport_bfa2a4ce-7ce3-4259-906f-df60e27cc22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_07a4cd55-ce2d-45e8-a092-3e6447a3b841" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityFileNumber_07a4cd55-ce2d-45e8-a092-3e6447a3b841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1b58a2b4-baf2-46a3-ae77-6f24a1058a4d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityRegistrantName_1b58a2b4-baf2-46a3-ae77-6f24a1058a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_83639321-e00e-4bf3-a2ae-e9f3dc9c1950" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityIncorporationStateCountryCode_83639321-e00e-4bf3-a2ae-e9f3dc9c1950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e7f95a75-38eb-406d-a717-3cd08aa3c947" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityTaxIdentificationNumber_e7f95a75-38eb-406d-a717-3cd08aa3c947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_29251397-2842-4a5b-bbe5-d598e09ec33d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityAddressAddressLine1_29251397-2842-4a5b-bbe5-d598e09ec33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6566fe1c-fdf5-4d26-a880-02d7ef5a179e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityAddressCityOrTown_6566fe1c-fdf5-4d26-a880-02d7ef5a179e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_53249b5f-98f3-4cd2-8c76-bdcb42077bda" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityAddressStateOrProvince_53249b5f-98f3-4cd2-8c76-bdcb42077bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_eac35b9c-fa1a-4468-a420-5309af641449" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityAddressPostalZipCode_eac35b9c-fa1a-4468-a420-5309af641449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_27ec6599-9c46-4307-953d-d07a935af532" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_CityAreaCode_27ec6599-9c46-4307-953d-d07a935af532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_21141d06-b272-40e2-8c51-a8c1dcf05e69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_LocalPhoneNumber_21141d06-b272-40e2-8c51-a8c1dcf05e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_63da714c-1177-412f-88c3-84ef7f14caba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityCurrentReportingStatus_63da714c-1177-412f-88c3-84ef7f14caba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_72216035-c01f-46be-9323-d60949e0fe6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityInteractiveDataCurrent_72216035-c01f-46be-9323-d60949e0fe6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_74f411f9-ae6c-45a2-af9f-a5b609802d25" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityFilerCategory_74f411f9-ae6c-45a2-af9f-a5b609802d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f75d0380-f1a1-4b8f-a4d2-116d97b735e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntitySmallBusiness_f75d0380-f1a1-4b8f-a4d2-116d97b735e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a5b913c0-ddc2-4d45-a384-e76550959a9c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityEmergingGrowthCompany_a5b913c0-ddc2-4d45-a384-e76550959a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d25c47b1-a2bc-46fe-afc3-fbc683586774" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityShellCompany_d25c47b1-a2bc-46fe-afc3-fbc683586774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b65cfaa5-6e6e-4e96-98cd-900b5d4d0631" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_Security12bTitle_b65cfaa5-6e6e-4e96-98cd-900b5d4d0631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8d38b88d-a095-4af1-8572-a4cd9ca75136" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_TradingSymbol_8d38b88d-a095-4af1-8572-a4cd9ca75136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7fc6af40-9dca-4938-a499-548c664c67fa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_SecurityExchangeName_7fc6af40-9dca-4938-a499-548c664c67fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f487ba49-9cc8-41d1-b859-fb29b3c161c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f487ba49-9cc8-41d1-b859-fb29b3c161c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5b2f0b2a-e129-4974-bb42-38a8cb0302ae" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_EntityCentralIndexKey_5b2f0b2a-e129-4974-bb42-38a8cb0302ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_dea5fd89-040f-4e7f-941d-304ce71ceb28" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_CurrentFiscalYearEndDate_dea5fd89-040f-4e7f-941d-304ce71ceb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3949b875-03e3-4f37-b701-319810f6237f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_DocumentFiscalYearFocus_3949b875-03e3-4f37-b701-319810f6237f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c10673b0-23bf-4a39-81db-e11b920f6146" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c10673b0-23bf-4a39-81db-e11b920f6146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3626cc74-b93b-4ab5-a13f-3b8dc66d5199" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_e2de8a90-2b28-4b7b-a192-8c399634ee24" xlink:to="loc_dei_AmendmentFlag_3626cc74-b93b-4ab5-a13f-3b8dc66d5199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_295a1b22-c784-40a4-956a-0c75a0c95b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_6e7e0166-6b54-47d3-b3c2-0f6bceb88aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_295a1b22-c784-40a4-956a-0c75a0c95b01" xlink:to="loc_us-gaap_AssetsAbstract_6e7e0166-6b54-47d3-b3c2-0f6bceb88aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3b47ccbc-08f4-4712-ac1e-5174367e6ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e7e0166-6b54-47d3-b3c2-0f6bceb88aeb" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3b47ccbc-08f4-4712-ac1e-5174367e6ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d016c48c-f726-4478-86d6-3a9625aeccbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b47ccbc-08f4-4712-ac1e-5174367e6ddc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d016c48c-f726-4478-86d6-3a9625aeccbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_ad64b4cc-111d-4a43-b717-d854513b2f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b47ccbc-08f4-4712-ac1e-5174367e6ddc" xlink:to="loc_us-gaap_RestrictedCash_ad64b4cc-111d-4a43-b717-d854513b2f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_3abdf88c-a507-4be6-8d9a-a3e72c536d60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b47ccbc-08f4-4712-ac1e-5174367e6ddc" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_3abdf88c-a507-4be6-8d9a-a3e72c536d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5889a98a-655f-4880-8b03-50dfd9cec108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b47ccbc-08f4-4712-ac1e-5174367e6ddc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5889a98a-655f-4880-8b03-50dfd9cec108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d4a36adc-6ba1-4d32-a3ea-c620cf30fe43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b47ccbc-08f4-4712-ac1e-5174367e6ddc" xlink:to="loc_us-gaap_InventoryNet_d4a36adc-6ba1-4d32-a3ea-c620cf30fe43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1294c3fe-17c0-4762-b9b7-54d4e696a5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b47ccbc-08f4-4712-ac1e-5174367e6ddc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1294c3fe-17c0-4762-b9b7-54d4e696a5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6ea0c46e-b8d7-4dda-866d-f5d1bbc15695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3b47ccbc-08f4-4712-ac1e-5174367e6ddc" xlink:to="loc_us-gaap_AssetsCurrent_6ea0c46e-b8d7-4dda-866d-f5d1bbc15695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_0b9ffd30-1549-49eb-8e0f-5e2eb4de2071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e7e0166-6b54-47d3-b3c2-0f6bceb88aeb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_0b9ffd30-1549-49eb-8e0f-5e2eb4de2071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_80098dab-ec12-432c-bb01-41e8d93522e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e7e0166-6b54-47d3-b3c2-0f6bceb88aeb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_80098dab-ec12-432c-bb01-41e8d93522e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_abf3dfaf-dd22-4b58-8bdb-76957b10c6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e7e0166-6b54-47d3-b3c2-0f6bceb88aeb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_abf3dfaf-dd22-4b58-8bdb-76957b10c6c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f1def0eb-5881-4306-9ecc-6511f70e9e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e7e0166-6b54-47d3-b3c2-0f6bceb88aeb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f1def0eb-5881-4306-9ecc-6511f70e9e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e3ac73d8-bb39-4b60-beb1-f98de30fa705" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e7e0166-6b54-47d3-b3c2-0f6bceb88aeb" xlink:to="loc_us-gaap_Goodwill_e3ac73d8-bb39-4b60-beb1-f98de30fa705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_86167750-6beb-4fb6-8d8b-674672ea64aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e7e0166-6b54-47d3-b3c2-0f6bceb88aeb" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_86167750-6beb-4fb6-8d8b-674672ea64aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f4093d4a-a884-4a71-866e-14a04b07f1f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e7e0166-6b54-47d3-b3c2-0f6bceb88aeb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f4093d4a-a884-4a71-866e-14a04b07f1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5e6cbbb9-4509-4b7f-8703-553f99ffaf99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_6e7e0166-6b54-47d3-b3c2-0f6bceb88aeb" xlink:to="loc_us-gaap_Assets_5e6cbbb9-4509-4b7f-8703-553f99ffaf99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74daa983-6e48-4464-9ef4-40a6a793fb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_295a1b22-c784-40a4-956a-0c75a0c95b01" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74daa983-6e48-4464-9ef4-40a6a793fb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a5dcab7c-bef1-417c-81fb-a80fe3cbd0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74daa983-6e48-4464-9ef4-40a6a793fb5f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a5dcab7c-bef1-417c-81fb-a80fe3cbd0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_4eb8d8a6-ab5e-4a85-8119-39d0972af363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5dcab7c-bef1-417c-81fb-a80fe3cbd0fa" xlink:to="loc_us-gaap_ShortTermBorrowings_4eb8d8a6-ab5e-4a85-8119-39d0972af363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_de5b2421-7f88-4203-85d5-e3da53d966ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5dcab7c-bef1-417c-81fb-a80fe3cbd0fa" xlink:to="loc_us-gaap_AccountsPayableCurrent_de5b2421-7f88-4203-85d5-e3da53d966ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4bea1c4e-9c2e-4072-be69-45e68d3ff0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5dcab7c-bef1-417c-81fb-a80fe3cbd0fa" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4bea1c4e-9c2e-4072-be69-45e68d3ff0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_7bfc720c-e9f9-420b-bc6c-cce9223c9f59" xlink:href="jnj-20230402.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5dcab7c-bef1-417c-81fb-a80fe3cbd0fa" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_7bfc720c-e9f9-420b-bc6c-cce9223c9f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_052e313f-5e8b-4eb7-bdfd-bb81030d820b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5dcab7c-bef1-417c-81fb-a80fe3cbd0fa" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_052e313f-5e8b-4eb7-bdfd-bb81030d820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_01d5bfe4-d9f9-4383-a37c-d1bca67e1f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5dcab7c-bef1-417c-81fb-a80fe3cbd0fa" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_01d5bfe4-d9f9-4383-a37c-d1bca67e1f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_36ee4e93-5870-4a6e-89a4-b0f7542c3358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5dcab7c-bef1-417c-81fb-a80fe3cbd0fa" xlink:to="loc_us-gaap_LiabilitiesCurrent_36ee4e93-5870-4a6e-89a4-b0f7542c3358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0e6f83f9-45f6-46a3-8890-4eda997edbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74daa983-6e48-4464-9ef4-40a6a793fb5f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0e6f83f9-45f6-46a3-8890-4eda997edbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d69bd411-7730-474a-aa08-77dab1330d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74daa983-6e48-4464-9ef4-40a6a793fb5f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_d69bd411-7730-474a-aa08-77dab1330d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_f723ade4-4ae1-46e4-bb13-fa12b7a04e63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74daa983-6e48-4464-9ef4-40a6a793fb5f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_f723ade4-4ae1-46e4-bb13-fa12b7a04e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_44f9a3f3-91d6-4f77-9c76-6b1907ea742d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74daa983-6e48-4464-9ef4-40a6a793fb5f" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_44f9a3f3-91d6-4f77-9c76-6b1907ea742d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b0e0ecef-1b02-482f-af7d-62e55f5a9259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74daa983-6e48-4464-9ef4-40a6a793fb5f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b0e0ecef-1b02-482f-af7d-62e55f5a9259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_72b8a07e-3652-4c04-85e7-7fb86731f0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74daa983-6e48-4464-9ef4-40a6a793fb5f" xlink:to="loc_us-gaap_Liabilities_72b8a07e-3652-4c04-85e7-7fb86731f0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f48e3f0a-62e5-45b4-8b65-deb9cebf7d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74daa983-6e48-4464-9ef4-40a6a793fb5f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f48e3f0a-62e5-45b4-8b65-deb9cebf7d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_50d1db7a-25ce-4a7c-ac84-fcadf5cc33fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74daa983-6e48-4464-9ef4-40a6a793fb5f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_50d1db7a-25ce-4a7c-ac84-fcadf5cc33fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0c753bce-9795-4abf-8028-8d1278a2f5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50d1db7a-25ce-4a7c-ac84-fcadf5cc33fe" xlink:to="loc_us-gaap_CommonStockValue_0c753bce-9795-4abf-8028-8d1278a2f5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_afd4b102-7cc2-4db7-890f-347e5fd5e21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50d1db7a-25ce-4a7c-ac84-fcadf5cc33fe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_afd4b102-7cc2-4db7-890f-347e5fd5e21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15823f03-c853-4716-9dfc-f3278775bcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50d1db7a-25ce-4a7c-ac84-fcadf5cc33fe" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15823f03-c853-4716-9dfc-f3278775bcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_78036031-e1a4-4b3d-a4e3-5dca47d8dd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50d1db7a-25ce-4a7c-ac84-fcadf5cc33fe" xlink:to="loc_us-gaap_TreasuryStockCommonValue_78036031-e1a4-4b3d-a4e3-5dca47d8dd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4501ff24-b6f6-415d-80b6-bf374eb12ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50d1db7a-25ce-4a7c-ac84-fcadf5cc33fe" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4501ff24-b6f6-415d-80b6-bf374eb12ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_98ae7f8e-1938-4f9f-8e8d-674e281a43a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74daa983-6e48-4464-9ef4-40a6a793fb5f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_98ae7f8e-1938-4f9f-8e8d-674e281a43a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_61cebc98-d7bf-4cd5-af7a-752c082e8c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_44672ce7-960a-4973-bad7-9325a303db17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61cebc98-d7bf-4cd5-af7a-752c082e8c15" xlink:to="loc_us-gaap_AssetsCurrentAbstract_44672ce7-960a-4973-bad7-9325a303db17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_e91d3e7e-609d-4b92-99f2-efe69532bd69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_44672ce7-960a-4973-bad7-9325a303db17" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_e91d3e7e-609d-4b92-99f2-efe69532bd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_da839663-a382-495f-9f0f-80c375f4c390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_61cebc98-d7bf-4cd5-af7a-752c082e8c15" xlink:to="loc_us-gaap_StockholdersEquityAbstract_da839663-a382-495f-9f0f-80c375f4c390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_261cbc9c-5d2e-438c-b3a1-57818a18d982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_da839663-a382-495f-9f0f-80c375f4c390" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_261cbc9c-5d2e-438c-b3a1-57818a18d982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_72470985-7173-4771-9d96-6b1b718da64d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_da839663-a382-495f-9f0f-80c375f4c390" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_72470985-7173-4771-9d96-6b1b718da64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8e5994c9-4e42-4735-87cd-73ad22cdc04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_da839663-a382-495f-9f0f-80c375f4c390" xlink:to="loc_us-gaap_CommonStockSharesIssued_8e5994c9-4e42-4735-87cd-73ad22cdc04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_40a633ec-16ed-40da-af31-fd428bac3749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_da839663-a382-495f-9f0f-80c375f4c390" xlink:to="loc_us-gaap_TreasuryStockCommonShares_40a633ec-16ed-40da-af31-fd428bac3749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce5b826b-00da-4129-ac27-d1d9ec1a9d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce5b826b-00da-4129-ac27-d1d9ec1a9d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesRevenueGoodsNetPercentToSales_d23b7d76-7091-46a1-8664-5f494af61d86" xlink:href="jnj-20230402.xsd#jnj_SalesRevenueGoodsNetPercentToSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_SalesRevenueGoodsNetPercentToSales_d23b7d76-7091-46a1-8664-5f494af61d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_925dff15-14ac-4397-a962-a3babdc11ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_925dff15-14ac-4397-a962-a3babdc11ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CostOfGoodsSoldPercentToSales_675418e2-42a4-4846-8d57-8d7a61587a6c" xlink:href="jnj-20230402.xsd#jnj_CostOfGoodsSoldPercentToSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_CostOfGoodsSoldPercentToSales_675418e2-42a4-4846-8d57-8d7a61587a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_d95fef52-c2ff-4bfb-9620-b75c9e300fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_GrossProfit_d95fef52-c2ff-4bfb-9620-b75c9e300fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GrossProfitPercentToSales_669bc5a1-4407-477b-838f-6781788da82f" xlink:href="jnj-20230402.xsd#jnj_GrossProfitPercentToSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_GrossProfitPercentToSales_669bc5a1-4407-477b-838f-6781788da82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b820589f-8dec-4a0f-bdb2-3630f5de5d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b820589f-8dec-4a0f-bdb2-3630f5de5d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_2da4b856-bb9f-4ba6-851d-0c57f4ef9c7e" xlink:href="jnj-20230402.xsd#jnj_SellingGeneralAndAdministrativeExpensePercentToSales"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_SellingGeneralAndAdministrativeExpensePercentToSales_2da4b856-bb9f-4ba6-851d-0c57f4ef9c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0b67f5c1-928e-4458-8597-80b75e3ae89e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0b67f5c1-928e-4458-8597-80b75e3ae89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_39d0c34e-722c-4117-a055-999676efadc3" xlink:href="jnj-20230402.xsd#jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales_39d0c34e-722c-4117-a055-999676efadc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_b93bda9b-5364-4279-b65a-ca5acb931bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_b93bda9b-5364-4279-b65a-ca5acb931bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_034f8908-cef4-459e-bd98-7a0ed74990ef" xlink:href="jnj-20230402.xsd#jnj_ResearchAndDevelopmentInProcessPercentToSales"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_ResearchAndDevelopmentInProcessPercentToSales_034f8908-cef4-459e-bd98-7a0ed74990ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_e2089a73-81d3-4c7d-be3d-cfe956c2ef27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_e2089a73-81d3-4c7d-be3d-cfe956c2ef27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InvestmentIncomeInterestPercentToSales_cf3ce3f3-74da-40ba-b7d7-8f42e7f30585" xlink:href="jnj-20230402.xsd#jnj_InvestmentIncomeInterestPercentToSales"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_InvestmentIncomeInterestPercentToSales_cf3ce3f3-74da-40ba-b7d7-8f42e7f30585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bd798da6-9bdc-4177-81f1-a1db50f77af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_InterestExpense_bd798da6-9bdc-4177-81f1-a1db50f77af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestExpensePercentToSales_08aeb19c-153d-4f95-8775-f5c39ec1e334" xlink:href="jnj-20230402.xsd#jnj_InterestExpensePercentToSales"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_InterestExpensePercentToSales_08aeb19c-153d-4f95-8775-f5c39ec1e334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d32efe06-06b4-4752-9c4f-f94848a42d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d32efe06-06b4-4752-9c4f-f94848a42d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_17f861c4-941f-4edf-940f-73b79e067730" xlink:href="jnj-20230402.xsd#jnj_OtherNonOperatingIncomeExpensePercentToSales"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_OtherNonOperatingIncomeExpensePercentToSales_17f861c4-941f-4edf-940f-73b79e067730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_7edbc6c3-89ca-4aeb-a7ab-ce63de184c61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_RestructuringCharges_7edbc6c3-89ca-4aeb-a7ab-ce63de184c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Restructuringchargepercenttosales_ebc2ae10-d1ed-45a7-9c5c-ff8996fbb0ca" xlink:href="jnj-20230402.xsd#jnj_Restructuringchargepercenttosales"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_Restructuringchargepercenttosales_ebc2ae10-d1ed-45a7-9c5c-ff8996fbb0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f709e516-7e6f-46fb-82a5-2f66bd0e92a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f709e516-7e6f-46fb-82a5-2f66bd0e92a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_19325218-f00d-4aff-9e01-593aee47844c" xlink:href="jnj-20230402.xsd#jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales_19325218-f00d-4aff-9e01-593aee47844c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7ce1529d-f5ce-4581-baf6-0ae60636b540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7ce1529d-f5ce-4581-baf6-0ae60636b540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_6e7f9489-5aaf-4815-8323-4bf6648dac6f" xlink:href="jnj-20230402.xsd#jnj_IncomeTaxExpenseBenefitPercentToSales"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_IncomeTaxExpenseBenefitPercentToSales_6e7f9489-5aaf-4815-8323-4bf6648dac6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8621e38e-1451-4bdf-bfa9-13f4b2fb5396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_NetIncomeLoss_8621e38e-1451-4bdf-bfa9-13f4b2fb5396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NetIncomeAttributableToParentPercentToSales_5b500eb2-fa25-41c0-915c-ab45348a6495" xlink:href="jnj-20230402.xsd#jnj_NetIncomeAttributableToParentPercentToSales"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_jnj_NetIncomeAttributableToParentPercentToSales_5b500eb2-fa25-41c0-915c-ab45348a6495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5f6fbfc5-3a0d-479f-9db1-b69a0cd8210e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_EarningsPerShareAbstract_5f6fbfc5-3a0d-479f-9db1-b69a0cd8210e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c62f44e2-33df-4cff-a441-49d06f40e31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5f6fbfc5-3a0d-479f-9db1-b69a0cd8210e" xlink:to="loc_us-gaap_EarningsPerShareBasic_c62f44e2-33df-4cff-a441-49d06f40e31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_be2a03b2-95f6-4e5f-9935-b7aedc795be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5f6fbfc5-3a0d-479f-9db1-b69a0cd8210e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_be2a03b2-95f6-4e5f-9935-b7aedc795be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2f2c09ae-8786-4844-86ff-ecb5f734e17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_77596a05-59a2-41da-87a3-e749d16647e9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2f2c09ae-8786-4844-86ff-ecb5f734e17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cee02ac8-090c-4a3c-b895-c7adfab0739a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2f2c09ae-8786-4844-86ff-ecb5f734e17a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cee02ac8-090c-4a3c-b895-c7adfab0739a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7dfca5e-0d16-4922-b950-86288871b052" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2f2c09ae-8786-4844-86ff-ecb5f734e17a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7dfca5e-0d16-4922-b950-86288871b052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d3be614b-5339-47da-8f0a-1399c02a066e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_01dad961-6c14-4f96-977f-fd6651fbf9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d3be614b-5339-47da-8f0a-1399c02a066e" xlink:to="loc_us-gaap_NetIncomeLoss_01dad961-6c14-4f96-977f-fd6651fbf9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_07d39e2b-aa46-44ef-8bf4-0d57b8b7610c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d3be614b-5339-47da-8f0a-1399c02a066e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_07d39e2b-aa46-44ef-8bf4-0d57b8b7610c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_5ab66220-5051-4e79-baf1-8a80eb1079ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_07d39e2b-aa46-44ef-8bf4-0d57b8b7610c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_5ab66220-5051-4e79-baf1-8a80eb1079ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_c72ebcc0-675f-42d9-977b-f46dd16059bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_07d39e2b-aa46-44ef-8bf4-0d57b8b7610c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_c72ebcc0-675f-42d9-977b-f46dd16059bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1c298efb-43c5-4d71-aec3-62f1badcf709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_c72ebcc0-675f-42d9-977b-f46dd16059bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1c298efb-43c5-4d71-aec3-62f1badcf709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_9af5ef4e-f6f4-4464-9f2a-765a60e0a6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_c72ebcc0-675f-42d9-977b-f46dd16059bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_9af5ef4e-f6f4-4464-9f2a-765a60e0a6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_477909c9-658e-4553-8072-3797c9ec91ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_c72ebcc0-675f-42d9-977b-f46dd16059bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_477909c9-658e-4553-8072-3797c9ec91ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_f754fb3b-1fc5-446a-b23e-a98dcfe041c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_07d39e2b-aa46-44ef-8bf4-0d57b8b7610c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_f754fb3b-1fc5-446a-b23e-a98dcfe041c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_f4aee063-806c-4017-8eab-302d3b9593f0" xlink:href="jnj-20230402.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_f754fb3b-1fc5-446a-b23e-a98dcfe041c3" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_f4aee063-806c-4017-8eab-302d3b9593f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_dcd94397-74a2-46a3-8636-a1b8b46ba351" xlink:href="jnj-20230402.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_f754fb3b-1fc5-446a-b23e-a98dcfe041c3" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_dcd94397-74a2-46a3-8636-a1b8b46ba351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f3fb304f-88cc-4a79-96e5-421d32bd5545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_f754fb3b-1fc5-446a-b23e-a98dcfe041c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_f3fb304f-88cc-4a79-96e5-421d32bd5545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_5192c50e-8356-4493-a468-c1f43a677700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_07d39e2b-aa46-44ef-8bf4-0d57b8b7610c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_5192c50e-8356-4493-a468-c1f43a677700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_8014140e-a715-4183-9909-0515351d88c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_5192c50e-8356-4493-a468-c1f43a677700" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_8014140e-a715-4183-9909-0515351d88c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_e6adc21c-64e6-4c48-8371-0971dda0607b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_5192c50e-8356-4493-a468-c1f43a677700" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_e6adc21c-64e6-4c48-8371-0971dda0607b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_59bb31a0-aadd-455b-aa22-495ad9f3443d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_5192c50e-8356-4493-a468-c1f43a677700" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_59bb31a0-aadd-455b-aa22-495ad9f3443d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_97ba4d2b-92c6-4e1e-87dd-34a68ecfea23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d3be614b-5339-47da-8f0a-1399c02a066e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_97ba4d2b-92c6-4e1e-87dd-34a68ecfea23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_571b02b0-cae6-4873-a396-3b2a3ff8ee6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_d3be614b-5339-47da-8f0a-1399c02a066e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_571b02b0-cae6-4873-a396-3b2a3ff8ee6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_53e0c1ad-b3b7-4c64-a22d-c08630247a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_84e79cdc-67a5-4fc5-baa0-d97a224bc9e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_53e0c1ad-b3b7-4c64-a22d-c08630247a3a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_84e79cdc-67a5-4fc5-baa0-d97a224bc9e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_e16c1c21-6c95-418b-ad3d-90e457f16272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_53e0c1ad-b3b7-4c64-a22d-c08630247a3a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_e16c1c21-6c95-418b-ad3d-90e457f16272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_064ff11b-b70e-4009-a045-04133de9b18a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_53e0c1ad-b3b7-4c64-a22d-c08630247a3a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_064ff11b-b70e-4009-a045-04133de9b18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_33be7725-b275-4af1-b2b4-89ef1a396a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_53e0c1ad-b3b7-4c64-a22d-c08630247a3a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_33be7725-b275-4af1-b2b4-89ef1a396a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3db937d6-a413-4bb4-8caa-0caacde84e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_22f2b765-3e8a-416d-82ff-427f46ff1ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3db937d6-a413-4bb4-8caa-0caacde84e68" xlink:to="loc_us-gaap_StatementTable_22f2b765-3e8a-416d-82ff-427f46ff1ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8dc56b12-61df-4862-af77-871aa97bb743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22f2b765-3e8a-416d-82ff-427f46ff1ad0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8dc56b12-61df-4862-af77-871aa97bb743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c387b8fa-1a9f-40a2-bf28-da68851ee573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8dc56b12-61df-4862-af77-871aa97bb743" xlink:to="loc_us-gaap_EquityComponentDomain_c387b8fa-1a9f-40a2-bf28-da68851ee573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_c707c263-42bf-4b35-b6a3-51afd4980fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c387b8fa-1a9f-40a2-bf28-da68851ee573" xlink:to="loc_us-gaap_RetainedEarningsMember_c707c263-42bf-4b35-b6a3-51afd4980fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4438c7fe-371e-44e9-96c8-63917218faad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c387b8fa-1a9f-40a2-bf28-da68851ee573" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4438c7fe-371e-44e9-96c8-63917218faad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cb178e43-068e-47e6-ab54-5bfc5c8c26f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c387b8fa-1a9f-40a2-bf28-da68851ee573" xlink:to="loc_us-gaap_CommonStockMember_cb178e43-068e-47e6-ab54-5bfc5c8c26f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_7780fbad-8dda-4495-84e8-8dff5a53254f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c387b8fa-1a9f-40a2-bf28-da68851ee573" xlink:to="loc_us-gaap_TreasuryStockCommonMember_7780fbad-8dda-4495-84e8-8dff5a53254f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22f2b765-3e8a-416d-82ff-427f46ff1ad0" xlink:to="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_56bb7133-7a85-4058-8555-0febb16e4056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_56bb7133-7a85-4058-8555-0febb16e4056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_285533d8-04a6-45b2-a31f-0022aa7794eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_NetIncomeLoss_285533d8-04a6-45b2-a31f-0022aa7794eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_90eeb6dc-40e3-4496-8e16-a8f379ee6f92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_DividendsCommonStockCash_90eeb6dc-40e3-4496-8e16-a8f379ee6f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_962899c3-1382-4617-a609-625aaf04ad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_962899c3-1382-4617-a609-625aaf04ad0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_cbe2f1ec-f261-4ae2-bb4b-5e7421786dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_cbe2f1ec-f261-4ae2-bb4b-5e7421786dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_55efae6e-b14a-420e-af62-e2b6769a2cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_StockholdersEquityOther_55efae6e-b14a-420e-af62-e2b6769a2cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e38c46c-c81c-4771-9933-96edf5b615cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3e38c46c-c81c-4771-9933-96edf5b615cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3d17549-e40b-4400-b7d0-e01d89b17971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f0c96f7d-1425-4a6b-9447-01bcf9b09741" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3d17549-e40b-4400-b7d0-e01d89b17971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f07210d9-7319-4866-8145-644d3318766a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_8eedeb37-d307-4072-a34d-e462209e0e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f07210d9-7319-4866-8145-644d3318766a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_8eedeb37-d307-4072-a34d-e462209e0e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20230402.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2d48e257-72ff-4a99-91a9-0b8a72edf96b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7aaf46e8-717b-4aba-b641-7b860721b4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2d48e257-72ff-4a99-91a9-0b8a72edf96b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7aaf46e8-717b-4aba-b641-7b860721b4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1f43cc67-7bb9-4b69-98e7-4baccd26b91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7aaf46e8-717b-4aba-b641-7b860721b4ef" xlink:to="loc_us-gaap_NetIncomeLoss_1f43cc67-7bb9-4b69-98e7-4baccd26b91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2918e57f-030a-454e-b356-21111032b837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7aaf46e8-717b-4aba-b641-7b860721b4ef" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2918e57f-030a-454e-b356-21111032b837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_98e3f8df-4037-4f26-a4a8-bb7d62acd9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2918e57f-030a-454e-b356-21111032b837" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_98e3f8df-4037-4f26-a4a8-bb7d62acd9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_91426bed-d17b-48dd-9fe7-cbb1132f2b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2918e57f-030a-454e-b356-21111032b837" xlink:to="loc_us-gaap_ShareBasedCompensation_91426bed-d17b-48dd-9fe7-cbb1132f2b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c6803b6b-6873-4063-bf72-20a8124b3727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2918e57f-030a-454e-b356-21111032b837" xlink:to="loc_us-gaap_AssetImpairmentCharges_c6803b6b-6873-4063-bf72-20a8124b3727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b3827973-c2a7-4db5-907a-09de6d4357c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2918e57f-030a-454e-b356-21111032b837" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_b3827973-c2a7-4db5-907a-09de6d4357c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bc92e705-40e7-4df2-af99-a9a5ec33ae96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2918e57f-030a-454e-b356-21111032b837" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bc92e705-40e7-4df2-af99-a9a5ec33ae96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_6cfe801a-0a73-4c1b-9106-087dc241aeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2918e57f-030a-454e-b356-21111032b837" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_6cfe801a-0a73-4c1b-9106-087dc241aeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ab5b276-9343-4808-b530-e0962fcc1288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7aaf46e8-717b-4aba-b641-7b860721b4ef" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ab5b276-9343-4808-b530-e0962fcc1288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_16efcfda-1355-4d80-8dfe-39b91e4572ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ab5b276-9343-4808-b530-e0962fcc1288" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_16efcfda-1355-4d80-8dfe-39b91e4572ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c19f4eca-5b23-4f27-90cc-78ff818d19dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ab5b276-9343-4808-b530-e0962fcc1288" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c19f4eca-5b23-4f27-90cc-78ff818d19dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_538af1a5-bec0-45e8-9ba3-3c69f7ea56ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ab5b276-9343-4808-b530-e0962fcc1288" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_538af1a5-bec0-45e8-9ba3-3c69f7ea56ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5ae36af1-8201-487e-bb33-c7f19d4b13a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ab5b276-9343-4808-b530-e0962fcc1288" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5ae36af1-8201-487e-bb33-c7f19d4b13a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9c010e30-d582-4e62-ae7c-9b4cdce2a0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0ab5b276-9343-4808-b530-e0962fcc1288" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9c010e30-d582-4e62-ae7c-9b4cdce2a0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ef8072e-0b4e-4e4d-bdff-d4f5be8fd94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7aaf46e8-717b-4aba-b641-7b860721b4ef" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9ef8072e-0b4e-4e4d-bdff-d4f5be8fd94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5923023-9e51-4488-b4a0-c2a67249bda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2d48e257-72ff-4a99-91a9-0b8a72edf96b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5923023-9e51-4488-b4a0-c2a67249bda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7296752-48e9-4959-b713-f605ee0c51f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5923023-9e51-4488-b4a0-c2a67249bda6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7296752-48e9-4959-b713-f605ee0c51f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_e39045fb-748a-44c1-9fbf-4fcb97e78570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5923023-9e51-4488-b4a0-c2a67249bda6" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_e39045fb-748a-44c1-9fbf-4fcb97e78570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_426f88ad-2b2d-4981-83ff-824c63c226d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5923023-9e51-4488-b4a0-c2a67249bda6" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_426f88ad-2b2d-4981-83ff-824c63c226d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_1eae0d9b-fe7d-4981-ba01-c56aaa1083ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5923023-9e51-4488-b4a0-c2a67249bda6" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_1eae0d9b-fe7d-4981-ba01-c56aaa1083ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_2dbb9950-6fa7-49b4-9e4b-b1d259eeb11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5923023-9e51-4488-b4a0-c2a67249bda6" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_2dbb9950-6fa7-49b4-9e4b-b1d259eeb11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_7ee4da8d-9594-4472-9cbd-9742925d1210" xlink:href="jnj-20230402.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5923023-9e51-4488-b4a0-c2a67249bda6" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_7ee4da8d-9594-4472-9cbd-9742925d1210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ea593dd9-d821-4961-86db-c668e5003fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5923023-9e51-4488-b4a0-c2a67249bda6" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ea593dd9-d821-4961-86db-c668e5003fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d79640bb-da5e-4488-859f-e3ed72f6437a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a5923023-9e51-4488-b4a0-c2a67249bda6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d79640bb-da5e-4488-859f-e3ed72f6437a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb3791d-0cfe-4793-a7c2-4f9e97c4f17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2d48e257-72ff-4a99-91a9-0b8a72edf96b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb3791d-0cfe-4793-a7c2-4f9e97c4f17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_be2c3184-54df-4c21-8ec5-649967e337f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb3791d-0cfe-4793-a7c2-4f9e97c4f17a" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_be2c3184-54df-4c21-8ec5-649967e337f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_72cc8c8e-a089-4b68-8467-8b9ef25257a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb3791d-0cfe-4793-a7c2-4f9e97c4f17a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_72cc8c8e-a089-4b68-8467-8b9ef25257a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_5adfca61-6230-45d3-a05d-d3a45dab87d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb3791d-0cfe-4793-a7c2-4f9e97c4f17a" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_5adfca61-6230-45d3-a05d-d3a45dab87d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_7caf4810-2b21-4b13-94a5-680c04a0e9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb3791d-0cfe-4793-a7c2-4f9e97c4f17a" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_7caf4810-2b21-4b13-94a5-680c04a0e9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_27f8c517-c81d-44b3-bc3d-88271a2981df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb3791d-0cfe-4793-a7c2-4f9e97c4f17a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_27f8c517-c81d-44b3-bc3d-88271a2981df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_6321a476-c24e-48d9-898a-95d831f7b9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb3791d-0cfe-4793-a7c2-4f9e97c4f17a" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_6321a476-c24e-48d9-898a-95d831f7b9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_c0ed0a6d-f52b-4e72-9b90-11e4ccedda02" xlink:href="jnj-20230402.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb3791d-0cfe-4793-a7c2-4f9e97c4f17a" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_c0ed0a6d-f52b-4e72-9b90-11e4ccedda02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_da7bdd23-2c8f-4b08-913f-1a65dd140f5b" xlink:href="jnj-20230402.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb3791d-0cfe-4793-a7c2-4f9e97c4f17a" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_da7bdd23-2c8f-4b08-913f-1a65dd140f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_103f01ab-1c4f-4224-ac97-37c77c5f146a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb3791d-0cfe-4793-a7c2-4f9e97c4f17a" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_103f01ab-1c4f-4224-ac97-37c77c5f146a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0f5b786-247e-4bab-8f32-98fe1f3ab31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bfb3791d-0cfe-4793-a7c2-4f9e97c4f17a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a0f5b786-247e-4bab-8f32-98fe1f3ab31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc802216-c2c7-4caa-a187-708eaee3544c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2d48e257-72ff-4a99-91a9-0b8a72edf96b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fc802216-c2c7-4caa-a187-708eaee3544c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_94b7117b-68d0-4b42-9b13-e0dbc854715b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2d48e257-72ff-4a99-91a9-0b8a72edf96b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_94b7117b-68d0-4b42-9b13-e0dbc854715b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_442d1a08-0c36-4253-85b6-37509f3feff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2d48e257-72ff-4a99-91a9-0b8a72edf96b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_442d1a08-0c36-4253-85b6-37509f3feff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_208485ca-3cc3-4490-b88a-2783db11a6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2d48e257-72ff-4a99-91a9-0b8a72edf96b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_208485ca-3cc3-4490-b88a-2783db11a6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_a6bfefae-6edc-4dcd-9e74-1808e57f49e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2d48e257-72ff-4a99-91a9-0b8a72edf96b" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_a6bfefae-6edc-4dcd-9e74-1808e57f49e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_9cc6dd55-aa34-44a6-b246-b24f8ef9db69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_a6bfefae-6edc-4dcd-9e74-1808e57f49e9" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_9cc6dd55-aa34-44a6-b246-b24f8ef9db69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_7a3b98c7-ad85-4acf-8af9-d8c6b90ef26f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_a6bfefae-6edc-4dcd-9e74-1808e57f49e9" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_7a3b98c7-ad85-4acf-8af9-d8c6b90ef26f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_8f0da5c7-705f-4516-bdb8-5f94a65b41c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_a6bfefae-6edc-4dcd-9e74-1808e57f49e9" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_8f0da5c7-705f-4516-bdb8-5f94a65b41c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20230402.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_76281834-4404-46f8-a224-d328e69212ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_325b39c6-9b87-416b-8c1c-78e8a7a45430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_76281834-4404-46f8-a224-d328e69212ab" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_325b39c6-9b87-416b-8c1c-78e8a7a45430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20230402.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6da90536-47f7-409e-8741-49f2b39ce948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_6448ff4d-978a-4898-900b-176e4513b431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6da90536-47f7-409e-8741-49f2b39ce948" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_6448ff4d-978a-4898-900b-176e4513b431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20230402.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e7e6b4dc-3ac8-44a9-a3d5-d4bf961e3d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_da3a0305-1003-40d3-bb63-fa77a00798e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e7e6b4dc-3ac8-44a9-a3d5-d4bf961e3d3a" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_da3a0305-1003-40d3-bb63-fa77a00798e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c53b4abb-1a46-4f3f-a5cd-1b55bb4115b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_dc038dc2-0d66-49eb-9900-f597df71b5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c53b4abb-1a46-4f3f-a5cd-1b55bb4115b9" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_dc038dc2-0d66-49eb-9900-f597df71b5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20230402.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e9803520-ee8a-41de-9502-504f45a8431a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3e3dd63c-7d7f-421f-9cb1-43e54cad7b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e9803520-ee8a-41de-9502-504f45a8431a" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3e3dd63c-7d7f-421f-9cb1-43e54cad7b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20230402.xsd#PensionsandOtherBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_81242dd1-1c88-472d-9489-82cd2633dd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_8449c6fa-2bca-462a-8aad-67bb2729a1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_81242dd1-1c88-472d-9489-82cd2633dd1b" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_8449c6fa-2bca-462a-8aad-67bb2729a1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20230402.xsd#AccumulatedOtherComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_224e417e-b301-4bfc-b11d-987708c1a54e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_bf449eec-221b-4bff-aa7f-fa11638f790b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_224e417e-b301-4bfc-b11d-987708c1a54e" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_bf449eec-221b-4bff-aa7f-fa11638f790b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20230402.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5d375646-bea6-4714-b89b-02e5c90bbdec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ccdb7eb5-cd74-4b4d-8e77-9d5b3bc7f949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5d375646-bea6-4714-b89b-02e5c90bbdec" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ccdb7eb5-cd74-4b4d-8e77-9d5b3bc7f949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20230402.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7ecc6fa2-7cd1-4ddb-847b-932234521292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_fd33ce0a-b837-40c8-a16c-148cda4f16f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7ecc6fa2-7cd1-4ddb-847b-932234521292" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_fd33ce0a-b837-40c8-a16c-148cda4f16f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20230402.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3c478d81-e274-4da9-883f-8fb8a494a9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_e3e13060-56f9-4f90-a303-4fab7e17a0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3c478d81-e274-4da9-883f-8fb8a494a9e5" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_e3e13060-56f9-4f90-a303-4fab7e17a0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20230402.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_948a0589-ff99-46ad-b22b-928dcb330c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1a1b5a9e-fb08-4f9c-a14d-a40db4d7c0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_948a0589-ff99-46ad-b22b-928dcb330c46" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_1a1b5a9e-fb08-4f9c-a14d-a40db4d7c0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20230402.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2ab8c6af-efef-4c1e-bdc8-d8ae60e39601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6e56dea2-62a6-4e0e-b2fc-564fd9353dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ab8c6af-efef-4c1e-bdc8-d8ae60e39601" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6e56dea2-62a6-4e0e-b2fc-564fd9353dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_56c58902-dc08-4dfd-a10d-0526891dce60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ab8c6af-efef-4c1e-bdc8-d8ae60e39601" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_56c58902-dc08-4dfd-a10d-0526891dce60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_947e18b1-cda8-415b-b1b2-847365082b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2ab8c6af-efef-4c1e-bdc8-d8ae60e39601" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_947e18b1-cda8-415b-b1b2-847365082b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20230402.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_fcb15fb7-c93a-44d8-b6cb-f8f1153b9445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4fe751e4-9496-47cf-af3d-c28b41dad5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fcb15fb7-c93a-44d8-b6cb-f8f1153b9445" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_4fe751e4-9496-47cf-af3d-c28b41dad5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20230402.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e0629efc-c4d0-41b1-938e-0920ed08a386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_1f7f096a-c442-41e6-aa63-a83c553d244e" xlink:href="jnj-20230402.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e0629efc-c4d0-41b1-938e-0920ed08a386" xlink:to="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_1f7f096a-c442-41e6-aa63-a83c553d244e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_deb442da-6271-4178-af9f-585140492862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e0629efc-c4d0-41b1-938e-0920ed08a386" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_deb442da-6271-4178-af9f-585140492862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_335dcd2f-b61a-4e32-abe9-9e653b10b1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e0629efc-c4d0-41b1-938e-0920ed08a386" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_335dcd2f-b61a-4e32-abe9-9e653b10b1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_baf8f207-a3e8-4e81-b540-874465135f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_4f9282f6-044a-4635-a6e1-0c02015bf9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baf8f207-a3e8-4e81-b540-874465135f57" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_4f9282f6-044a-4635-a6e1-0c02015bf9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f7486f9e-f0d3-4c4d-91ae-95802c439902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baf8f207-a3e8-4e81-b540-874465135f57" xlink:to="loc_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_f7486f9e-f0d3-4c4d-91ae-95802c439902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_d96dfd96-4c8a-4ab6-8875-4de837e4c952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baf8f207-a3e8-4e81-b540-874465135f57" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_d96dfd96-4c8a-4ab6-8875-4de837e4c952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_129b2752-340a-4aba-9fae-c3b44b74a8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baf8f207-a3e8-4e81-b540-874465135f57" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_129b2752-340a-4aba-9fae-c3b44b74a8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_a0422259-5628-4f01-a1e7-7031d77dfd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baf8f207-a3e8-4e81-b540-874465135f57" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_a0422259-5628-4f01-a1e7-7031d77dfd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2186c6e6-8c17-4c1f-baec-c7eac90a85b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baf8f207-a3e8-4e81-b540-874465135f57" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2186c6e6-8c17-4c1f-baec-c7eac90a85b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_234794ca-1879-4e56-95d7-1d731885c2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baf8f207-a3e8-4e81-b540-874465135f57" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_234794ca-1879-4e56-95d7-1d731885c2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_ec562bb4-e79b-43db-b8f4-d4072edb9c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baf8f207-a3e8-4e81-b540-874465135f57" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_ec562bb4-e79b-43db-b8f4-d4072edb9c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20230402.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5e1bdb18-efd1-41fe-89ae-6f9045d37f01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_27f269ba-ece0-46d3-a031-167fa76e2b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5e1bdb18-efd1-41fe-89ae-6f9045d37f01" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_27f269ba-ece0-46d3-a031-167fa76e2b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="simple" xlink:href="jnj-20230402.xsd#AccumulatedOtherComprehensiveIncomeTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_800b0edc-f071-4a26-abc4-a61610f11204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3aa5e676-95db-4442-90b5-0c03356a2c73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_800b0edc-f071-4a26-abc4-a61610f11204" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_3aa5e676-95db-4442-90b5-0c03356a2c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20230402.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f74c2b3c-1245-4338-b06e-f02a5455dea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_85133401-59d9-43cf-8527-b93b8cdec286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f74c2b3c-1245-4338-b06e-f02a5455dea2" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_85133401-59d9-43cf-8527-b93b8cdec286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20230402.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_24ff28ef-2004-450e-8630-aa191edd5ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_b95cc9c0-802b-4031-8406-cf31fd3d8b45" xlink:href="jnj-20230402.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_24ff28ef-2004-450e-8630-aa191edd5ffe" xlink:to="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_b95cc9c0-802b-4031-8406-cf31fd3d8b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d9bf404e-052d-4ff7-8608-58d9ab42ffb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_24ff28ef-2004-450e-8630-aa191edd5ffe" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_d9bf404e-052d-4ff7-8608-58d9ab42ffb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_9657530d-ee66-4293-89dd-5d9625146e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_24ff28ef-2004-450e-8630-aa191edd5ffe" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_9657530d-ee66-4293-89dd-5d9625146e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommitmentandContingenciesTables" xlink:type="simple" xlink:href="jnj-20230402.xsd#CommitmentandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommitmentandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e23892c1-5762-4d7a-b7ff-9d5ea8c8d438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock_7a6ff329-0c79-4f2d-ba2d-e09d3cb6cd87" xlink:href="jnj-20230402.xsd#jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e23892c1-5762-4d7a-b7ff-9d5ea8c8d438" xlink:to="loc_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock_7a6ff329-0c79-4f2d-ba2d-e09d3cb6cd87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_49080051-aa67-422c-82b3-44279126fc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_46c3f3e0-8ccc-4b8f-8775-af655e3d274b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49080051-aa67-422c-82b3-44279126fc9d" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_46c3f3e0-8ccc-4b8f-8775-af655e3d274b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplierFinanceProgramObligationCurrent_cdfbd03d-d236-4ed6-95e5-e89fc8d90c8a" xlink:href="jnj-20230402.xsd#jnj_SupplierFinanceProgramObligationCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_49080051-aa67-422c-82b3-44279126fc9d" xlink:to="loc_jnj_SupplierFinanceProgramObligationCurrent_cdfbd03d-d236-4ed6-95e5-e89fc8d90c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_e2daafe6-df84-44f1-b0b1-2655bce5b134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_10d0969f-cd6a-4d8b-ad5a-5774572fec74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e2daafe6-df84-44f1-b0b1-2655bce5b134" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_10d0969f-cd6a-4d8b-ad5a-5774572fec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c2cbec00-66b2-4198-b4ad-b4d581b15721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e2daafe6-df84-44f1-b0b1-2655bce5b134" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c2cbec00-66b2-4198-b4ad-b4d581b15721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f3fbc755-9521-4c7e-ad92-da9c345412ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e2daafe6-df84-44f1-b0b1-2655bce5b134" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f3fbc755-9521-4c7e-ad92-da9c345412ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2164d8bd-9a7f-4d46-b15a-d1ea2b9e30ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_e2daafe6-df84-44f1-b0b1-2655bce5b134" xlink:to="loc_us-gaap_InventoryNet_2164d8bd-9a7f-4d46-b15a-d1ea2b9e30ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_658b4a66-83ff-45f2-bc75-9c558580cf22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_f6c088ce-20b5-4fc8-9883-11c677ec1e30" xlink:href="jnj-20230402.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_658b4a66-83ff-45f2-bc75-9c558580cf22" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_f6c088ce-20b5-4fc8-9883-11c677ec1e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b8165c42-8424-440e-b3d4-99073b3495a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_f6c088ce-20b5-4fc8-9883-11c677ec1e30" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b8165c42-8424-440e-b3d4-99073b3495a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_328463be-95db-43f6-80ad-7f3fb9fe692a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_b8165c42-8424-440e-b3d4-99073b3495a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_328463be-95db-43f6-80ad-7f3fb9fe692a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_86db5364-496f-49ec-8f61-1850337e284e" xlink:href="jnj-20230402.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_328463be-95db-43f6-80ad-7f3fb9fe692a" xlink:to="loc_jnj_PatentsAndTrademarksMember_86db5364-496f-49ec-8f61-1850337e284e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_2c324ffe-b944-42af-a092-0753471d653b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_328463be-95db-43f6-80ad-7f3fb9fe692a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_2c324ffe-b944-42af-a092-0753471d653b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cddc8ff-8361-41af-879d-eafe92024318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_f6c088ce-20b5-4fc8-9883-11c677ec1e30" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cddc8ff-8361-41af-879d-eafe92024318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1eb50d58-5173-4d34-b86e-eec49785f459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4cddc8ff-8361-41af-879d-eafe92024318" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1eb50d58-5173-4d34-b86e-eec49785f459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_6651ff1e-f97a-46fd-a7e9-6da80c14abe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1eb50d58-5173-4d34-b86e-eec49785f459" xlink:to="loc_us-gaap_TrademarksMember_6651ff1e-f97a-46fd-a7e9-6da80c14abe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_114abced-f9f0-450a-bfb1-441fa927003b" xlink:href="jnj-20230402.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1eb50d58-5173-4d34-b86e-eec49785f459" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_114abced-f9f0-450a-bfb1-441fa927003b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_753d933f-f24d-4b26-8428-18436078a2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_f6c088ce-20b5-4fc8-9883-11c677ec1e30" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_753d933f-f24d-4b26-8428-18436078a2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_09233844-6639-4061-bdcf-4248151347fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_753d933f-f24d-4b26-8428-18436078a2fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_09233844-6639-4061-bdcf-4248151347fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_9e7f2b5c-8c88-4f35-aa5f-b7a9b8cadafb" xlink:href="jnj-20230402.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_09233844-6639-4061-bdcf-4248151347fb" xlink:to="loc_jnj_BermekimabMember_9e7f2b5c-8c88-4f35-aa5f-b7a9b8cadafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1ba076fc-59f5-4aaa-b818-3f766cc9acc4" xlink:href="jnj-20230402.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_f6c088ce-20b5-4fc8-9883-11c677ec1e30" xlink:to="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1ba076fc-59f5-4aaa-b818-3f766cc9acc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3b62a7c1-0640-405a-9fd9-610f8e21099a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_1ba076fc-59f5-4aaa-b818-3f766cc9acc4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3b62a7c1-0640-405a-9fd9-610f8e21099a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cab9b550-5cc4-44af-9866-354203f7d8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3b62a7c1-0640-405a-9fd9-610f8e21099a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cab9b550-5cc4-44af-9866-354203f7d8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_29ff43c0-cad3-4fd7-ae92-e080358c66f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cab9b550-5cc4-44af-9866-354203f7d8e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_29ff43c0-cad3-4fd7-ae92-e080358c66f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0931b275-62e4-43cf-89ac-8a9617f137b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cab9b550-5cc4-44af-9866-354203f7d8e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0931b275-62e4-43cf-89ac-8a9617f137b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fff02d5c-5972-4d42-91d8-ee4431c31f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cab9b550-5cc4-44af-9866-354203f7d8e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fff02d5c-5972-4d42-91d8-ee4431c31f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_1cf60cc5-464f-4f3d-8aac-ef0f50092c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3b62a7c1-0640-405a-9fd9-610f8e21099a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_1cf60cc5-464f-4f3d-8aac-ef0f50092c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8a9cc938-6c4e-4469-b349-c098930fae8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_1cf60cc5-464f-4f3d-8aac-ef0f50092c5a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_8a9cc938-6c4e-4469-b349-c098930fae8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f46c469b-b213-468e-a20d-3bcf7ad856d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_1cf60cc5-464f-4f3d-8aac-ef0f50092c5a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f46c469b-b213-468e-a20d-3bcf7ad856d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#IntangibleAssetsandGoodwillGoodwillBySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c323d828-050c-4738-a4a3-779611bb0f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_63630c74-6b1a-4131-93e4-5806c93b1d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c323d828-050c-4738-a4a3-779611bb0f98" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_63630c74-6b1a-4131-93e4-5806c93b1d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e6ddfbcb-6566-455c-bcdf-4c4298faaba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_63630c74-6b1a-4131-93e4-5806c93b1d47" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e6ddfbcb-6566-455c-bcdf-4c4298faaba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_49161981-dc44-4e03-8b08-e3dc50ca5018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e6ddfbcb-6566-455c-bcdf-4c4298faaba9" xlink:to="loc_us-gaap_SegmentDomain_49161981-dc44-4e03-8b08-e3dc50ca5018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_22c2465e-2768-4fcc-a699-5a17f08a93e6" xlink:href="jnj-20230402.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_49161981-dc44-4e03-8b08-e3dc50ca5018" xlink:to="loc_jnj_ConsumerMember_22c2465e-2768-4fcc-a699-5a17f08a93e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_65717014-382f-4e37-8aaf-bbff16923b5d" xlink:href="jnj-20230402.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_49161981-dc44-4e03-8b08-e3dc50ca5018" xlink:to="loc_jnj_PharmaceuticalMember_65717014-382f-4e37-8aaf-bbff16923b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_63496323-e68c-4778-b9a2-24a061ba9b5a" xlink:href="jnj-20230402.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_49161981-dc44-4e03-8b08-e3dc50ca5018" xlink:to="loc_jnj_MedicalDevicesMember_63496323-e68c-4778-b9a2-24a061ba9b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_257572b4-7e9e-480a-ae80-c82d5dd4bc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_63630c74-6b1a-4131-93e4-5806c93b1d47" xlink:to="loc_us-gaap_GoodwillLineItems_257572b4-7e9e-480a-ae80-c82d5dd4bc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_a8171720-c6ad-49d3-885b-c0527ea62be3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_257572b4-7e9e-480a-ae80-c82d5dd4bc84" xlink:to="loc_us-gaap_GoodwillRollForward_a8171720-c6ad-49d3-885b-c0527ea62be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bcf14a12-4f4e-4c37-8b83-820d3f6aa90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a8171720-c6ad-49d3-885b-c0527ea62be3" xlink:to="loc_us-gaap_Goodwill_bcf14a12-4f4e-4c37-8b83-820d3f6aa90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_1345391c-1785-41f8-b811-ae51cfd80c77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a8171720-c6ad-49d3-885b-c0527ea62be3" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_1345391c-1785-41f8-b811-ae51cfd80c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_f34d7e63-ab90-43b3-b234-3054e7d764a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a8171720-c6ad-49d3-885b-c0527ea62be3" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_f34d7e63-ab90-43b3-b234-3054e7d764a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_46d7ac02-c1ef-4bfd-9d65-8fa30d02320b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_a8171720-c6ad-49d3-885b-c0527ea62be3" xlink:to="loc_us-gaap_Goodwill_46d7ac02-c1ef-4bfd-9d65-8fa30d02320b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a148eb9-68ac-45c4-959c-ba6cd93c43eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_26689460-fbbd-40d9-a5db-7874321d2e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a148eb9-68ac-45c4-959c-ba6cd93c43eb" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_26689460-fbbd-40d9-a5db-7874321d2e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e451b20a-cc60-44f6-bf01-7df84e70265c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_26689460-fbbd-40d9-a5db-7874321d2e89" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e451b20a-cc60-44f6-bf01-7df84e70265c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19fffbff-a1db-4f69-b521-0b8b49ef8037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e451b20a-cc60-44f6-bf01-7df84e70265c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19fffbff-a1db-4f69-b521-0b8b49ef8037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_ddda7dca-e7eb-4d92-98f2-0dd83cd3668a" xlink:href="jnj-20230402.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19fffbff-a1db-4f69-b521-0b8b49ef8037" xlink:to="loc_jnj_PatentsAndTrademarksMember_ddda7dca-e7eb-4d92-98f2-0dd83cd3668a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_8f2856be-af28-429c-a585-973667d65f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_19fffbff-a1db-4f69-b521-0b8b49ef8037" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_8f2856be-af28-429c-a585-973667d65f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ae286194-964a-423f-8548-e3244994d002" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_26689460-fbbd-40d9-a5db-7874321d2e89" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ae286194-964a-423f-8548-e3244994d002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b99e497d-b528-40fa-8107-b998599dd214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ae286194-964a-423f-8548-e3244994d002" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b99e497d-b528-40fa-8107-b998599dd214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1f7a03ba-dde4-497c-b533-2b6fc3fb75a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ae286194-964a-423f-8548-e3244994d002" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1f7a03ba-dde4-497c-b533-2b6fc3fb75a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50e08ab4-ce92-4943-a58d-612a57ea9b03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d2136cd1-3d21-426a-ab4f-3119c852bb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50e08ab4-ce92-4943-a58d-612a57ea9b03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d2136cd1-3d21-426a-ab4f-3119c852bb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7252c048-d53c-421a-babf-3adc726cbf86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50e08ab4-ce92-4943-a58d-612a57ea9b03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7252c048-d53c-421a-babf-3adc726cbf86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e847272d-a137-42cf-aa36-0413a53ace51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50e08ab4-ce92-4943-a58d-612a57ea9b03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e847272d-a137-42cf-aa36-0413a53ace51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_34e129b0-ac53-440c-8569-a238823c114c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50e08ab4-ce92-4943-a58d-612a57ea9b03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_34e129b0-ac53-440c-8569-a238823c114c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7f23e7f7-df45-432f-a73e-a533bb6de465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_50e08ab4-ce92-4943-a58d-612a57ea9b03" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7f23e7f7-df45-432f-a73e-a533bb6de465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_fd39c637-1fcd-465e-afb0-089e859bf124" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_fd39c637-1fcd-465e-afb0-089e859bf124" xlink:to="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_b85af6f8-5b41-42cc-993d-ee5b949a5d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_b85af6f8-5b41-42cc-993d-ee5b949a5d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_b36fe316-c99e-46a6-bbbe-4e02bccfafe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_b85af6f8-5b41-42cc-993d-ee5b949a5d9a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_b36fe316-c99e-46a6-bbbe-4e02bccfafe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_60d26161-667c-43f8-94c9-51982cad9aaf" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_b36fe316-c99e-46a6-bbbe-4e02bccfafe5" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_60d26161-667c-43f8-94c9-51982cad9aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_eeea4976-b2ba-4185-a4ce-27aafc4bda1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_eeea4976-b2ba-4185-a4ce-27aafc4bda1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c000a97-ee8b-47a0-9615-772acfd52ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_eeea4976-b2ba-4185-a4ce-27aafc4bda1b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c000a97-ee8b-47a0-9615-772acfd52ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_ca27da10-6917-4b19-a4c5-aebdc5fbfec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4c000a97-ee8b-47a0-9615-772acfd52ac6" xlink:to="loc_us-gaap_EquitySecuritiesMember_ca27da10-6917-4b19-a4c5-aebdc5fbfec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b2abe097-60e7-4cd0-94b9-843d115b91b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b2abe097-60e7-4cd0-94b9-843d115b91b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7389c76d-71f8-4d0a-a10c-019e4b46a96f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b2abe097-60e7-4cd0-94b9-843d115b91b8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7389c76d-71f8-4d0a-a10c-019e4b46a96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_83c55177-9178-4a77-83cc-4a88856c7262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7389c76d-71f8-4d0a-a10c-019e4b46a96f" xlink:to="loc_us-gaap_ForeignExchangeContractMember_83c55177-9178-4a77-83cc-4a88856c7262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_b5dcab46-12e9-47f1-9dcb-a1cc36e251e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7389c76d-71f8-4d0a-a10c-019e4b46a96f" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_b5dcab46-12e9-47f1-9dcb-a1cc36e251e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_aae16fd6-d51a-488f-a961-22044c7ece26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7389c76d-71f8-4d0a-a10c-019e4b46a96f" xlink:to="loc_us-gaap_InterestRateSwapMember_aae16fd6-d51a-488f-a961-22044c7ece26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_47ae6abe-2849-46cd-ba6a-771b210d3c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_47ae6abe-2849-46cd-ba6a-771b210d3c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4ccf64c1-31e5-4cca-9b1e-39c7c2e18993" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_47ae6abe-2849-46cd-ba6a-771b210d3c2a" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4ccf64c1-31e5-4cca-9b1e-39c7c2e18993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_290908a0-7fb3-4555-9ed6-5edb8ceec2c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_4ccf64c1-31e5-4cca-9b1e-39c7c2e18993" xlink:to="loc_us-gaap_CommercialPaperMember_290908a0-7fb3-4555-9ed6-5edb8ceec2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_781f5b63-f93a-4285-abdd-d540148caafe" xlink:to="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_a7313b79-1040-4e28-a799-a0e35e31ea29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_a7313b79-1040-4e28-a799-a0e35e31ea29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_07136e7b-974c-416a-a0f5-8e21eae3f9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_DerivativeNotionalAmount_07136e7b-974c-416a-a0f5-8e21eae3f9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_acd8523b-9449-4189-9aeb-ff59a5768d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_acd8523b-9449-4189-9aeb-ff59a5768d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_9b652696-7817-4cc1-9ed4-3f70aa447fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_EquityFairValueAdjustment_9b652696-7817-4cc1-9ed4-3f70aa447fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_7637fb25-6e41-4c59-8611-72be44b006de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_LongtermDebtWeightedAverageInterestRate_7637fb25-6e41-4c59-8611-72be44b006de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_143b0e3e-2716-4371-98a7-3e3161a23224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_ShortTermBorrowings_143b0e3e-2716-4371-98a7-3e3161a23224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_142c9d6b-3550-42ef-8f38-21624635e55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_142c9d6b-3550-42ef-8f38-21624635e55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_4f97589c-d4d2-430a-9fb0-f780b9e6cbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_DebtInstrumentTerm_4f97589c-d4d2-430a-9fb0-f780b9e6cbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_255479ac-0ec5-4ffc-a104-c04085cdcf38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_da284166-e7c0-435f-9689-45e21f8e1306" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_255479ac-0ec5-4ffc-a104-c04085cdcf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9a4752bd-0baa-486f-9a21-b086069d74ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b96b304a-8017-430b-8ff8-9e2f131c9e00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9a4752bd-0baa-486f-9a21-b086069d74ad" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b96b304a-8017-430b-8ff8-9e2f131c9e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea07925a-10f5-4e48-b803-178f4fd25371" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b96b304a-8017-430b-8ff8-9e2f131c9e00" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea07925a-10f5-4e48-b803-178f4fd25371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_46c52dc5-07d3-4bfd-9d30-ce515856af27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea07925a-10f5-4e48-b803-178f4fd25371" xlink:to="loc_us-gaap_HedgingRelationshipDomain_46c52dc5-07d3-4bfd-9d30-ce515856af27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_c08a1bae-06c9-4c7e-9ec8-ab3d0ff93127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46c52dc5-07d3-4bfd-9d30-ce515856af27" xlink:to="loc_us-gaap_FairValueHedgingMember_c08a1bae-06c9-4c7e-9ec8-ab3d0ff93127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_1018750d-1a50-4109-ac0a-1e131d90c699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46c52dc5-07d3-4bfd-9d30-ce515856af27" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_1018750d-1a50-4109-ac0a-1e131d90c699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_7c45e2af-a192-4f18-8703-3e446dbb6efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_46c52dc5-07d3-4bfd-9d30-ce515856af27" xlink:to="loc_us-gaap_CashFlowHedgingMember_7c45e2af-a192-4f18-8703-3e446dbb6efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b917d6cd-2185-417b-89c9-88e610c9f6cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b96b304a-8017-430b-8ff8-9e2f131c9e00" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b917d6cd-2185-417b-89c9-88e610c9f6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b917d6cd-2185-417b-89c9-88e610c9f6cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_9e5ce4c0-fa29-4c71-b984-37d6728ba1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:to="loc_us-gaap_InterestRateContractMember_9e5ce4c0-fa29-4c71-b984-37d6728ba1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_38df2bf2-4278-4f27-83e3-ceb1254d17fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:to="loc_us-gaap_ForeignExchangeContractMember_38df2bf2-4278-4f27-83e3-ceb1254d17fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_b400a74e-faa5-4477-b091-e00ddd719238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_b400a74e-faa5-4477-b091-e00ddd719238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5a90838f-14a7-40df-b78e-d2a8e0762095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:to="loc_us-gaap_InterestRateSwapMember_5a90838f-14a7-40df-b78e-d2a8e0762095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_c1867082-9156-48bb-b1be-ab365152bad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_63aa22a8-0afc-4a10-be17-58039aaaa356" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_c1867082-9156-48bb-b1be-ab365152bad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_ebd2474a-ae99-4b7a-8dd5-d499efbc73b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b96b304a-8017-430b-8ff8-9e2f131c9e00" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_ebd2474a-ae99-4b7a-8dd5-d499efbc73b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_ebd2474a-ae99-4b7a-8dd5-d499efbc73b2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_d6fa7a66-9a20-43df-9eff-8aab1ec6e2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:to="loc_us-gaap_SalesMember_d6fa7a66-9a20-43df-9eff-8aab1ec6e2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_0bc999ce-fc2b-49a5-b5d3-aa366b96afc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:to="loc_us-gaap_CostOfSalesMember_0bc999ce-fc2b-49a5-b5d3-aa366b96afc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d12db586-e55a-4fca-a58c-e529d65fc118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d12db586-e55a-4fca-a58c-e529d65fc118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_74129526-28fa-4e38-a450-d6e7bd558e44" xlink:href="jnj-20230402.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_74129526-28fa-4e38-a450-d6e7bd558e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_3c5947a8-ef5c-4596-90b4-48c1e059f93e" xlink:href="jnj-20230402.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6c6a1e14-14c8-4b7a-822c-cafa46aaf483" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_3c5947a8-ef5c-4596-90b4-48c1e059f93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_caa4be50-ff89-4314-8a8a-2134c669edae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_b96b304a-8017-430b-8ff8-9e2f131c9e00" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_caa4be50-ff89-4314-8a8a-2134c669edae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_d7193574-42a0-4fed-8637-eddad54a2311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_caa4be50-ff89-4314-8a8a-2134c669edae" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_d7193574-42a0-4fed-8637-eddad54a2311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_53299276-148c-4a3e-9f49-2252d4ca8397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_caa4be50-ff89-4314-8a8a-2134c669edae" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_53299276-148c-4a3e-9f49-2252d4ca8397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_88b89ec6-b456-47b8-b3cd-d87f68ec644b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_caa4be50-ff89-4314-8a8a-2134c669edae" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_88b89ec6-b456-47b8-b3cd-d87f68ec644b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsDerivativesBalanceSheetLocationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_93d17d0e-9a8e-42db-8b7d-1c83ac77f6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_0f47a226-c459-41a4-8f39-8fce41586fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_93d17d0e-9a8e-42db-8b7d-1c83ac77f6b0" xlink:to="loc_us-gaap_DerivativeTable_0f47a226-c459-41a4-8f39-8fce41586fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4b3a165e-80f9-4712-b074-6436abe45603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0f47a226-c459-41a4-8f39-8fce41586fec" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4b3a165e-80f9-4712-b074-6436abe45603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4586a78b-bfdd-453c-904a-341c5ea595a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4b3a165e-80f9-4712-b074-6436abe45603" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4586a78b-bfdd-453c-904a-341c5ea595a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_58d6b36a-bcdf-4592-b2ea-851dde2f8a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4586a78b-bfdd-453c-904a-341c5ea595a4" xlink:to="loc_us-gaap_LongTermDebtMember_58d6b36a-bcdf-4592-b2ea-851dde2f8a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c52adf19-bc93-429a-8f2c-b12e44ecfe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0f47a226-c459-41a4-8f39-8fce41586fec" xlink:to="loc_us-gaap_HedgingDesignationAxis_c52adf19-bc93-429a-8f2c-b12e44ecfe7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a9193421-ca7c-4bbc-88de-664798087917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_c52adf19-bc93-429a-8f2c-b12e44ecfe7c" xlink:to="loc_us-gaap_HedgingDesignationDomain_a9193421-ca7c-4bbc-88de-664798087917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7f0f22c3-8f77-4c00-95cf-2f37578f2948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_a9193421-ca7c-4bbc-88de-664798087917" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7f0f22c3-8f77-4c00-95cf-2f37578f2948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_43d4ed8f-5d63-4f3f-884e-55f08b96f147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_0f47a226-c459-41a4-8f39-8fce41586fec" xlink:to="loc_us-gaap_DerivativeLineItems_43d4ed8f-5d63-4f3f-884e-55f08b96f147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_5b35b8de-9de6-44d3-aef0-0c3871098291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_43d4ed8f-5d63-4f3f-884e-55f08b96f147" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_5b35b8de-9de6-44d3-aef0-0c3871098291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_f7eb8802-6593-420b-8269-02ab522dc555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_43d4ed8f-5d63-4f3f-884e-55f08b96f147" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_f7eb8802-6593-420b-8269-02ab522dc555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_83fd2819-0bdd-40bb-a808-990649466340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_46ab0392-d74b-40ab-966a-9482cf2e7424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_83fd2819-0bdd-40bb-a808-990649466340" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_46ab0392-d74b-40ab-966a-9482cf2e7424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_52501cee-38f4-4aa4-b664-7b936e274bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_46ab0392-d74b-40ab-966a-9482cf2e7424" xlink:to="loc_us-gaap_HedgingDesignationAxis_52501cee-38f4-4aa4-b664-7b936e274bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d344ecb9-9aa7-43f7-81f6-3a04b5b5e20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_52501cee-38f4-4aa4-b664-7b936e274bda" xlink:to="loc_us-gaap_HedgingDesignationDomain_d344ecb9-9aa7-43f7-81f6-3a04b5b5e20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_0a13ea55-ab03-4005-aa6a-18e71be9fe9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_d344ecb9-9aa7-43f7-81f6-3a04b5b5e20c" xlink:to="loc_us-gaap_NondesignatedMember_0a13ea55-ab03-4005-aa6a-18e71be9fe9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_5a868573-845c-4a68-a380-a4722667b8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_46ab0392-d74b-40ab-966a-9482cf2e7424" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_5a868573-845c-4a68-a380-a4722667b8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4fbfb756-96d6-4ced-b8fb-209d2614db6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_5a868573-845c-4a68-a380-a4722667b8eb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4fbfb756-96d6-4ced-b8fb-209d2614db6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_077dde4c-b2f0-47c0-873f-d1b2022ce9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4fbfb756-96d6-4ced-b8fb-209d2614db6c" xlink:to="loc_us-gaap_ForeignExchangeContractMember_077dde4c-b2f0-47c0-873f-d1b2022ce9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_54d4e8e2-9d4c-4469-9f94-c57afee60741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_46ab0392-d74b-40ab-966a-9482cf2e7424" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_54d4e8e2-9d4c-4469-9f94-c57afee60741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6e417fbe-298c-479d-8a77-bbeb02a22a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_54d4e8e2-9d4c-4469-9f94-c57afee60741" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6e417fbe-298c-479d-8a77-bbeb02a22a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_2fe77cac-0370-4ea9-b52a-02f16c7d34f2" xlink:href="jnj-20230402.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e417fbe-298c-479d-8a77-bbeb02a22a1f" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_2fe77cac-0370-4ea9-b52a-02f16c7d34f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_376107ab-2e3a-46a7-b60a-1b5de25dc63b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_46ab0392-d74b-40ab-966a-9482cf2e7424" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_376107ab-2e3a-46a7-b60a-1b5de25dc63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ed0b2f4f-c290-4bed-8cf5-9b4ab41af2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_376107ab-2e3a-46a7-b60a-1b5de25dc63b" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_ed0b2f4f-c290-4bed-8cf5-9b4ab41af2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cf4194cf-c123-4535-ba78-2b75bbf7beb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1f24558b-f5e3-46c3-8f02-7ad53d18a978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cf4194cf-c123-4535-ba78-2b75bbf7beb5" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1f24558b-f5e3-46c3-8f02-7ad53d18a978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_52dd0f75-6b75-44a1-92cc-b4217d7bc083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1f24558b-f5e3-46c3-8f02-7ad53d18a978" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_52dd0f75-6b75-44a1-92cc-b4217d7bc083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_adfd8ef8-a731-4936-9896-cbb593f47119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_52dd0f75-6b75-44a1-92cc-b4217d7bc083" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_adfd8ef8-a731-4936-9896-cbb593f47119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_fe023c7a-6be9-479f-ad1b-b8cc68ce049d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_adfd8ef8-a731-4936-9896-cbb593f47119" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_fe023c7a-6be9-479f-ad1b-b8cc68ce049d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_13b049aa-9267-4903-851f-2bd54b630753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1f24558b-f5e3-46c3-8f02-7ad53d18a978" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_13b049aa-9267-4903-851f-2bd54b630753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_44fc56bf-6619-4b71-80ab-01712b14b0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_13b049aa-9267-4903-851f-2bd54b630753" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_44fc56bf-6619-4b71-80ab-01712b14b0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_9c12f771-3afa-4031-ac5a-b60be54b25db" xlink:href="jnj-20230402.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_44fc56bf-6619-4b71-80ab-01712b14b0dc" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_9c12f771-3afa-4031-ac5a-b60be54b25db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3423bc80-c16d-42ea-b0b9-4b60e847902d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_1f24558b-f5e3-46c3-8f02-7ad53d18a978" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3423bc80-c16d-42ea-b0b9-4b60e847902d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_db097666-be53-492b-a63a-47d0653023e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3423bc80-c16d-42ea-b0b9-4b60e847902d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_db097666-be53-492b-a63a-47d0653023e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_58a570b7-e9f8-4382-9e0f-67c47caac2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_3423bc80-c16d-42ea-b0b9-4b60e847902d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_58a570b7-e9f8-4382-9e0f-67c47caac2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f9872dc3-0afd-46be-9a97-33425e671963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f5107573-8322-4917-a525-286336b79476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f9872dc3-0afd-46be-9a97-33425e671963" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f5107573-8322-4917-a525-286336b79476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_6d0bc776-6bb8-46ce-bae2-531c81fb2c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f5107573-8322-4917-a525-286336b79476" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_6d0bc776-6bb8-46ce-bae2-531c81fb2c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ca6f1e8a-d189-408c-8e30-d55f69a4e6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6d0bc776-6bb8-46ce-bae2-531c81fb2c80" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ca6f1e8a-d189-408c-8e30-d55f69a4e6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_5b78d4b7-1396-400d-8205-5ef5f8d75668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ca6f1e8a-d189-408c-8e30-d55f69a4e6e7" xlink:to="loc_us-gaap_EquitySecuritiesMember_5b78d4b7-1396-400d-8205-5ef5f8d75668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_f2a5e488-96c1-49eb-8edb-889c9c80ecaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f5107573-8322-4917-a525-286336b79476" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_f2a5e488-96c1-49eb-8edb-889c9c80ecaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_3988a5de-6528-417a-be92-88b6284b1c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_f2a5e488-96c1-49eb-8edb-889c9c80ecaa" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_3988a5de-6528-417a-be92-88b6284b1c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_5ebdb794-f482-40c0-9fed-79ef460374b7" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_3988a5de-6528-417a-be92-88b6284b1c14" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_5ebdb794-f482-40c0-9fed-79ef460374b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_9b5bb535-610f-4ac9-90be-f2cebcea8591" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_3988a5de-6528-417a-be92-88b6284b1c14" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_9b5bb535-610f-4ac9-90be-f2cebcea8591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_9585aaac-7d96-4000-86ba-25cd81778ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_f5107573-8322-4917-a525-286336b79476" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_9585aaac-7d96-4000-86ba-25cd81778ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_9585aaac-7d96-4000-86ba-25cd81778ab4" xlink:to="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_15f17fd9-7008-4d58-9408-fd864f2d4270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_15f17fd9-7008-4d58-9408-fd864f2d4270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e25ab109-3faf-4a07-a5b8-a992a84bb78b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e25ab109-3faf-4a07-a5b8-a992a84bb78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_60d87d3e-565e-48d4-b520-1d89c6754ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:to="loc_us-gaap_EquityFairValueAdjustment_60d87d3e-565e-48d4-b520-1d89c6754ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_3815b05e-b955-4f05-96cb-d710017c3b37" xlink:href="jnj-20230402.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_3815b05e-b955-4f05-96cb-d710017c3b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_02f3949c-97e1-414a-8459-48bb0845d84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_02f3949c-97e1-414a-8459-48bb0845d84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5ff3f15f-2af2-4c76-9009-211551f7222f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5ff3f15f-2af2-4c76-9009-211551f7222f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8722c07d-35ec-4dfd-8795-b667438cc8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_e0889eae-4d4d-4767-be50-fc2a84a17562" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8722c07d-35ec-4dfd-8795-b667438cc8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_14da833f-7112-478f-a383-946b2d49e5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_14da833f-7112-478f-a383-946b2d49e5fa" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b824f5f6-9b8c-4e17-82a2-41c30d6da50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b824f5f6-9b8c-4e17-82a2-41c30d6da50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_24b9b9b0-2fce-41cd-a969-0dbfd37bf47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b824f5f6-9b8c-4e17-82a2-41c30d6da50f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_24b9b9b0-2fce-41cd-a969-0dbfd37bf47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_69b6f258-1370-4aa2-a62a-776702ace23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24b9b9b0-2fce-41cd-a969-0dbfd37bf47e" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_69b6f258-1370-4aa2-a62a-776702ace23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_51659068-c261-47bf-8563-a1e35d21bfdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24b9b9b0-2fce-41cd-a969-0dbfd37bf47e" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_51659068-c261-47bf-8563-a1e35d21bfdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_797f20d3-bc69-41dd-afe9-51721410b72d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_24b9b9b0-2fce-41cd-a969-0dbfd37bf47e" xlink:to="loc_us-gaap_LongTermDebtMember_797f20d3-bc69-41dd-afe9-51721410b72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9fb0b197-9eab-435e-96c8-904b63472be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9fb0b197-9eab-435e-96c8-904b63472be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_780df89a-a15f-4424-92e9-4c481f7c5974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9fb0b197-9eab-435e-96c8-904b63472be6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_780df89a-a15f-4424-92e9-4c481f7c5974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_b3632a5e-99a0-40e1-bc1e-5d62771b96c6" xlink:href="jnj-20230402.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_780df89a-a15f-4424-92e9-4c481f7c5974" xlink:to="loc_jnj_AurisHealthMember_b3632a5e-99a0-40e1-bc1e-5d62771b96c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_4452e8d8-378d-4e80-98ee-d99995f925ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_InvestmentTypeAxis_4452e8d8-378d-4e80-98ee-d99995f925ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_230193c2-b232-4de0-a4c6-cc6b65e0ddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_4452e8d8-378d-4e80-98ee-d99995f925ee" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_230193c2-b232-4de0-a4c6-cc6b65e0ddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_ea6dd485-7392-4125-afba-d039cbfe7df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_230193c2-b232-4de0-a4c6-cc6b65e0ddd6" xlink:to="loc_us-gaap_EquitySecuritiesMember_ea6dd485-7392-4125-afba-d039cbfe7df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3b129dba-23cc-4411-a9e3-87106b84916a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3b129dba-23cc-4411-a9e3-87106b84916a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c7cc18bf-bd8a-469e-a8f5-8486f9aa1803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3b129dba-23cc-4411-a9e3-87106b84916a" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c7cc18bf-bd8a-469e-a8f5-8486f9aa1803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_de524015-80b8-44ea-ab94-111e7c6672a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7cc18bf-bd8a-469e-a8f5-8486f9aa1803" xlink:to="loc_us-gaap_InterestRateContractMember_de524015-80b8-44ea-ab94-111e7c6672a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ae2d593c-09f3-405c-a6f8-9fcf9f404609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7cc18bf-bd8a-469e-a8f5-8486f9aa1803" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ae2d593c-09f3-405c-a6f8-9fcf9f404609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_25e942cf-79a4-4a0e-b337-ca944f471b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c7cc18bf-bd8a-469e-a8f5-8486f9aa1803" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_25e942cf-79a4-4a0e-b337-ca944f471b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_215c3c9d-20d6-419d-8c75-d217b52b2a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_215c3c9d-20d6-419d-8c75-d217b52b2a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74036240-af18-4506-9f10-d9f3ae05f0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_215c3c9d-20d6-419d-8c75-d217b52b2a97" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74036240-af18-4506-9f10-d9f3ae05f0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_813cf36c-1c55-49df-bd12-3aad91f83dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74036240-af18-4506-9f10-d9f3ae05f0fb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_813cf36c-1c55-49df-bd12-3aad91f83dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_78a41022-6842-4373-9c8f-046c63289a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74036240-af18-4506-9f10-d9f3ae05f0fb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_78a41022-6842-4373-9c8f-046c63289a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_64f21073-83d1-48da-bfc2-85a651bc7d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_74036240-af18-4506-9f10-d9f3ae05f0fb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_64f21073-83d1-48da-bfc2-85a651bc7d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da82e1b3-53ed-4a7b-9e8b-1e4e25835126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da82e1b3-53ed-4a7b-9e8b-1e4e25835126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f76dbd7e-405a-4651-8864-58ddafeea3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_da82e1b3-53ed-4a7b-9e8b-1e4e25835126" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f76dbd7e-405a-4651-8864-58ddafeea3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_c065260f-5349-4ec5-8104-7dfbecd8e63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f76dbd7e-405a-4651-8864-58ddafeea3e1" xlink:to="loc_us-gaap_FairValueHedgingMember_c065260f-5349-4ec5-8104-7dfbecd8e63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_22e16843-d373-4b70-8923-7acb1c87bd39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_22e16843-d373-4b70-8923-7acb1c87bd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a99b1547-3dfb-4464-9979-f3010a4c124d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_22e16843-d373-4b70-8923-7acb1c87bd39" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a99b1547-3dfb-4464-9979-f3010a4c124d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_61c293b1-41a6-4628-be00-56a5eb7dc455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_a99b1547-3dfb-4464-9979-f3010a4c124d" xlink:to="loc_us-gaap_EquitySecuritiesMember_61c293b1-41a6-4628-be00-56a5eb7dc455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_25e701e5-edff-44dc-ae76-7b7e4e58e0f7" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_11a73a4a-dc0f-4537-a511-d3a6c7074f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_11a73a4a-dc0f-4537-a511-d3a6c7074f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_eab8264b-f50a-411f-8b01-25f129524e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_eab8264b-f50a-411f-8b01-25f129524e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_692ebbb4-8a14-48de-bc1a-d82a31baaca8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_692ebbb4-8a14-48de-bc1a-d82a31baaca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_96d69287-42e3-4f71-a27a-0118e94e69a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_96d69287-42e3-4f71-a27a-0118e94e69a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c6bc5f0a-112f-40ee-baa7-e2dce215e47b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c6bc5f0a-112f-40ee-baa7-e2dce215e47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8bbd9c2-de02-4cba-bdb9-9cdf524edab0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8bbd9c2-de02-4cba-bdb9-9cdf524edab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_986482da-f2d1-45ae-b86f-89e9b907c2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_9ed1cbee-f44e-494b-b7b1-e756a9a592f0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_986482da-f2d1-45ae-b86f-89e9b907c2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_76cb2cec-9651-4e30-9693-2c07bcfa3778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_76cb2cec-9651-4e30-9693-2c07bcfa3778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_8c9f9e12-2e39-4372-a8e5-c261b38c0714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_8c9f9e12-2e39-4372-a8e5-c261b38c0714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_72410b7e-30ac-49a0-b725-f2e506ae4004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeAssets_72410b7e-30ac-49a0-b725-f2e506ae4004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_92b59bfe-423f-4b2a-8273-435a6e439e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_92b59bfe-423f-4b2a-8273-435a6e439e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5cc9df2d-fad0-4a5c-8394-8c0e4eee84c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_5cc9df2d-fad0-4a5c-8394-8c0e4eee84c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_89f98e25-1ba1-4585-bead-c3ccfa79badf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_DerivativeLiabilities_89f98e25-1ba1-4585-bead-c3ccfa79badf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0bd91d13-623b-497a-8d93-540efb3072d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0bd91d13-623b-497a-8d93-540efb3072d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_f56c3bf9-6f5b-43a7-b79e-493a606c783a" xlink:href="jnj-20230402.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_f56c3bf9-6f5b-43a7-b79e-493a606c783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2a1d9092-7157-4743-82a7-95feacfd7ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_2a1d9092-7157-4743-82a7-95feacfd7ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_eae67a5f-5fd4-404b-9f0b-0af58b30c480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_eae67a5f-5fd4-404b-9f0b-0af58b30c480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_77119a89-3155-41ff-98c3-f6573254742d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_77119a89-3155-41ff-98c3-f6573254742d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_a1427035-10da-484d-ac86-5b50520a6f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_f3326b33-02b9-48e6-989a-188e38683c1f" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_a1427035-10da-484d-ac86-5b50520a6f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e5202a9b-855f-4eac-881b-06fc49381da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_53b1c16b-19ea-4de4-9b51-fb8fb9e64739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5202a9b-855f-4eac-881b-06fc49381da5" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_53b1c16b-19ea-4de4-9b51-fb8fb9e64739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6a9a276c-9322-4cf2-8657-0c252b99a6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_53b1c16b-19ea-4de4-9b51-fb8fb9e64739" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6a9a276c-9322-4cf2-8657-0c252b99a6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_e9e0d1f0-6ab0-4cdb-9971-ecbfd1869244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_6a9a276c-9322-4cf2-8657-0c252b99a6e7" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_e9e0d1f0-6ab0-4cdb-9971-ecbfd1869244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_20d55da7-aeb6-480a-9ea2-36e0fcd1a1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_e9e0d1f0-6ab0-4cdb-9971-ecbfd1869244" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_20d55da7-aeb6-480a-9ea2-36e0fcd1a1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_14a9d1a5-9a53-4511-818f-b5e56830bb0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_e9e0d1f0-6ab0-4cdb-9971-ecbfd1869244" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_14a9d1a5-9a53-4511-818f-b5e56830bb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_7496816a-ee67-41d6-9b34-fd389cba08e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_53b1c16b-19ea-4de4-9b51-fb8fb9e64739" xlink:to="loc_us-gaap_InvestmentTypeAxis_7496816a-ee67-41d6-9b34-fd389cba08e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_7496816a-ee67-41d6-9b34-fd389cba08e2" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_1ea36578-3f17-446d-8c8d-d40a866870de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_CashMember_1ea36578-3f17-446d-8c8d-d40a866870de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RestrictedCashMember_94c463f5-2436-4d18-8e00-773b02c2aa8a" xlink:href="jnj-20230402.xsd#jnj_RestrictedCashMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_jnj_RestrictedCashMember_94c463f5-2436-4d18-8e00-773b02c2aa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_ef3bbbde-56ba-4860-a27b-5fbccb77e736" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember_ef3bbbde-56ba-4860-a27b-5fbccb77e736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_0296141e-1a9a-4b43-a91b-6e251f9dd916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_0296141e-1a9a-4b43-a91b-6e251f9dd916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2164a4d8-23f5-49e4-9b38-3165633960ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2164a4d8-23f5-49e4-9b38-3165633960ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_344b8561-8259-416f-8eaf-09dd4420de7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_BankTimeDepositsMember_344b8561-8259-416f-8eaf-09dd4420de7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_fc257e96-4abd-4172-9b89-eadeb75cc41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_fc257e96-4abd-4172-9b89-eadeb75cc41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0e0a6f38-c4de-4de0-b404-45ba9caa40b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_30b1024b-4907-44e7-98dd-a55cd03ddfbb" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0e0a6f38-c4de-4de0-b404-45ba9caa40b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_caf23f5a-43c9-45af-a6b7-48c066f8f0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_53b1c16b-19ea-4de4-9b51-fb8fb9e64739" xlink:to="loc_us-gaap_FinancialInstrumentAxis_caf23f5a-43c9-45af-a6b7-48c066f8f0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548203b5-380e-4b1e-9b21-8c0df809ad60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_caf23f5a-43c9-45af-a6b7-48c066f8f0c3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548203b5-380e-4b1e-9b21-8c0df809ad60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_f397034d-4b64-46a5-8626-f6d04d6e00ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548203b5-380e-4b1e-9b21-8c0df809ad60" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_f397034d-4b64-46a5-8626-f6d04d6e00ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_19545a37-1a04-47bf-a566-db1c905d185a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548203b5-380e-4b1e-9b21-8c0df809ad60" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_19545a37-1a04-47bf-a566-db1c905d185a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3792f1f2-6d56-4c6b-a774-4461f164d7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_548203b5-380e-4b1e-9b21-8c0df809ad60" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_3792f1f2-6d56-4c6b-a774-4461f164d7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_e626e798-952a-4a80-9861-5f5f3cfe19cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_53b1c16b-19ea-4de4-9b51-fb8fb9e64739" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_e626e798-952a-4a80-9861-5f5f3cfe19cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dfadffc1-b526-4b77-9fb8-e09dfd4b96a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e626e798-952a-4a80-9861-5f5f3cfe19cb" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dfadffc1-b526-4b77-9fb8-e09dfd4b96a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_6fc02c94-cf25-4c54-abe7-0c17e7b81843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dfadffc1-b526-4b77-9fb8-e09dfd4b96a8" xlink:to="loc_us-gaap_HeldToMaturitySecurities_6fc02c94-cf25-4c54-abe7-0c17e7b81843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_39322599-1888-4bc7-9970-1d4884778a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dfadffc1-b526-4b77-9fb8-e09dfd4b96a8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_39322599-1888-4bc7-9970-1d4884778a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_f8cb5c39-229e-43f0-9159-5d70fb77cbca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_dfadffc1-b526-4b77-9fb8-e09dfd4b96a8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_f8cb5c39-229e-43f0-9159-5d70fb77cbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939cadf1-5d33-4b37-a1cf-1724e274920e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e626e798-952a-4a80-9861-5f5f3cfe19cb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939cadf1-5d33-4b37-a1cf-1724e274920e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_595f3003-5865-4fa8-9379-6d5efecb4d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939cadf1-5d33-4b37-a1cf-1724e274920e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_595f3003-5865-4fa8-9379-6d5efecb4d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2ad28201-1724-4f04-aaf6-9ea4645ddebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939cadf1-5d33-4b37-a1cf-1724e274920e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2ad28201-1724-4f04-aaf6-9ea4645ddebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f91537b7-52e6-448a-a63f-0e4a8ec3ee69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939cadf1-5d33-4b37-a1cf-1724e274920e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f91537b7-52e6-448a-a63f-0e4a8ec3ee69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f60fb7fd-68bd-4d2b-8534-3a70a8eceef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_939cadf1-5d33-4b37-a1cf-1724e274920e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_f60fb7fd-68bd-4d2b-8534-3a70a8eceef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_e626e798-952a-4a80-9861-5f5f3cfe19cb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_380a611b-2047-4dca-a86d-cc3473f656b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_380a611b-2047-4dca-a86d-cc3473f656b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ce86aeec-cf7f-4fe0-b5e7-d6b2d8359a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ce86aeec-cf7f-4fe0-b5e7-d6b2d8359a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_6287ca8c-c5ff-47cc-aff3-406efb9dba84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_6287ca8c-c5ff-47cc-aff3-406efb9dba84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_0e69b72b-2789-4ecd-8227-4654d06979bd" xlink:href="jnj-20230402.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss_0e69b72b-2789-4ecd-8227-4654d06979bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_eec3c842-71f3-46b0-9702-b1afdf3380df" xlink:href="jnj-20230402.xsd#jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract_7c0e230c-23de-4f09-ab3d-2522d7cf69ed" xlink:to="loc_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue_eec3c842-71f3-46b0-9702-b1afdf3380df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_847c07c0-d87e-41e5-a5b0-06bf1b5bef9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_bfc1e831-7703-4f5b-ba73-669b5111cb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_847c07c0-d87e-41e5-a5b0-06bf1b5bef9e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_bfc1e831-7703-4f5b-ba73-669b5111cb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_dfffb1aa-014f-4c11-a970-542ef49481a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_bfc1e831-7703-4f5b-ba73-669b5111cb2a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_dfffb1aa-014f-4c11-a970-542ef49481a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_81e00291-6848-4df5-8217-711f118b8675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_bfc1e831-7703-4f5b-ba73-669b5111cb2a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_81e00291-6848-4df5-8217-711f118b8675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_01d7b440-c815-4dd8-881f-af2c909aa70d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_bfc1e831-7703-4f5b-ba73-669b5111cb2a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_01d7b440-c815-4dd8-881f-af2c909aa70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_73e48524-4575-49de-9bb1-78b887a33183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_bfc1e831-7703-4f5b-ba73-669b5111cb2a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_73e48524-4575-49de-9bb1-78b887a33183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_97b39842-d658-425e-b387-d684b8ee79b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_847c07c0-d87e-41e5-a5b0-06bf1b5bef9e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_97b39842-d658-425e-b387-d684b8ee79b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_56e3e11e-a9a7-4f49-876c-f65f296152d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_97b39842-d658-425e-b387-d684b8ee79b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_56e3e11e-a9a7-4f49-876c-f65f296152d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_98e15649-f5e5-46ad-ae08-334f28d75ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_97b39842-d658-425e-b387-d684b8ee79b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_98e15649-f5e5-46ad-ae08-334f28d75ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_9be0ab8b-a57f-47b5-bbc6-9f94231328d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_97b39842-d658-425e-b387-d684b8ee79b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_9be0ab8b-a57f-47b5-bbc6-9f94231328d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_069fb8a9-bc0e-47ed-bd9c-ddfc692d821d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_97b39842-d658-425e-b387-d684b8ee79b6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_069fb8a9-bc0e-47ed-bd9c-ddfc692d821d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4ec2e395-4280-48ff-af3f-60edc3943afd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_09dc814d-fc8b-462e-aa4c-732a828592cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4ec2e395-4280-48ff-af3f-60edc3943afd" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_09dc814d-fc8b-462e-aa4c-732a828592cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_82d50322-f9e5-405f-bad8-9120c65fad38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_09dc814d-fc8b-462e-aa4c-732a828592cf" xlink:to="loc_us-gaap_DebtInstrumentAxis_82d50322-f9e5-405f-bad8-9120c65fad38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_82d50322-f9e5-405f-bad8-9120c65fad38" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_4d21808d-f1fb-4b80-a484-75959bb8d719" xlink:href="jnj-20230402.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A0.650NotesDue2024Member_4d21808d-f1fb-4b80-a484-75959bb8d719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_21767e0a-7237-4ec1-93ae-55dfa23258fd" xlink:href="jnj-20230402.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A5.50NotesDue2024Member_21767e0a-7237-4ec1-93ae-55dfa23258fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_f21b2cd8-da38-4035-9c55-66aa3fcd1aa7" xlink:href="jnj-20230402.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A2.625Notesdue2025Member_f21b2cd8-da38-4035-9c55-66aa3fcd1aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0550NotesDue2025Member_4b4016de-1340-4ca4-ad84-5bb1c135cd3c" xlink:href="jnj-20230402.xsd#jnj_A0550NotesDue2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A0550NotesDue2025Member_4b4016de-1340-4ca4-ad84-5bb1c135cd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_50eda4da-e600-4477-ace3-a641cd187e43" xlink:href="jnj-20230402.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A2.45Notesdue2026Member_50eda4da-e600-4477-ace3-a641cd187e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_c06c7f92-4d41-41f5-9ab5-e3e1f3cce7b6" xlink:href="jnj-20230402.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A2.95Notesdue2027Member_c06c7f92-4d41-41f5-9ab5-e3e1f3cce7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_751339a0-66b2-4157-a7d0-6176ebc1ca24" xlink:href="jnj-20230402.xsd#jnj_A095NotesDue2027Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A095NotesDue2027Member_751339a0-66b2-4157-a7d0-6176ebc1ca24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_ff9473fe-75d1-4254-b293-f94eb6115a00" xlink:href="jnj-20230402.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A2.900Notesdue2028Member_ff9473fe-75d1-4254-b293-f94eb6115a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_deb4cfbb-5ff9-4379-a8ba-11e23cfd2e09" xlink:href="jnj-20230402.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A1.150NotesDue2028Member_deb4cfbb-5ff9-4379-a8ba-11e23cfd2e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_bf596a52-3096-4cf6-b58d-43d8afce8e1b" xlink:href="jnj-20230402.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A6.95Notesdue2029Member_bf596a52-3096-4cf6-b58d-43d8afce8e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1300NotesDue2030Member_99d9db44-ab4a-4b4d-a852-569eb86d12eb" xlink:href="jnj-20230402.xsd#jnj_A1300NotesDue2030Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A1300NotesDue2030Member_99d9db44-ab4a-4b4d-a852-569eb86d12eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_647c0276-5b2a-46d9-b52d-336aa1d14d20" xlink:href="jnj-20230402.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_647c0276-5b2a-46d9-b52d-336aa1d14d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_82cd649c-6121-4a84-8d9c-6ea1e094bb97" xlink:href="jnj-20230402.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A4.375Notesdue2033Member_82cd649c-6121-4a84-8d9c-6ea1e094bb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_dfedbbe8-1665-46f0-bbac-97ca3d5d69e6" xlink:href="jnj-20230402.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A1.650NotesDue2035Member_dfedbbe8-1665-46f0-bbac-97ca3d5d69e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_34d97835-c416-4252-8dfa-28966b2f766e" xlink:href="jnj-20230402.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A3.55Notesdue2036Member_34d97835-c416-4252-8dfa-28966b2f766e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_3158ffa1-ebbb-446c-b5f6-9302aefeaefb" xlink:href="jnj-20230402.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A5.95Notesdue2037Member_3158ffa1-ebbb-446c-b5f6-9302aefeaefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_14d9ec40-3ee8-4c6e-9d96-09ddd9b80d81" xlink:href="jnj-20230402.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A3.625Notesdue2037Member_14d9ec40-3ee8-4c6e-9d96-09ddd9b80d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_18b8ff3f-e6d4-444e-a95e-08c101bbf6fc" xlink:href="jnj-20230402.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A3.400Notesdue2038Member_18b8ff3f-e6d4-444e-a95e-08c101bbf6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_b010f3d9-c321-4ab3-8c3e-d09cf3c911ec" xlink:href="jnj-20230402.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_b010f3d9-c321-4ab3-8c3e-d09cf3c911ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_a577b88f-abd6-408e-aef8-9000ba228564" xlink:href="jnj-20230402.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_a577b88f-abd6-408e-aef8-9000ba228564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_f419d02f-1f30-4a7b-923a-4200009528d5" xlink:href="jnj-20230402.xsd#jnj_A210NotesDue2040Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A210NotesDue2040Member_f419d02f-1f30-4a7b-923a-4200009528d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_63f440c6-052a-4db3-ac75-1397113673e9" xlink:href="jnj-20230402.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A4.85Notesdue2041Member_63f440c6-052a-4db3-ac75-1397113673e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_b7a157cd-c992-4253-a1c8-7737dc9a6229" xlink:href="jnj-20230402.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A4.50Notesdue2043Member_b7a157cd-c992-4253-a1c8-7737dc9a6229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_b9c55776-60c4-4e17-ace4-6b6b127a8a80" xlink:href="jnj-20230402.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A3.70Notesdue2046Member_b9c55776-60c4-4e17-ace4-6b6b127a8a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_efc888d3-0b83-4d89-889c-179d17743188" xlink:href="jnj-20230402.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A3.75Notesdue2047Member_efc888d3-0b83-4d89-889c-179d17743188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_ef3c30ba-a3ff-42f3-b78e-c24a356486b9" xlink:href="jnj-20230402.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A3.500Notesdue2048Member_ef3c30ba-a3ff-42f3-b78e-c24a356486b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_a5647b64-c5f5-4333-806d-34d1ba2cdb0d" xlink:href="jnj-20230402.xsd#jnj_A2250NotesDue2050Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A2250NotesDue2050Member_a5647b64-c5f5-4333-806d-34d1ba2cdb0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_8cda95cd-58e9-471b-9a45-bee4393b1567" xlink:href="jnj-20230402.xsd#jnj_A2450NotesDue2060Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A2450NotesDue2060Member_8cda95cd-58e9-471b-9a45-bee4393b1567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A550DebentureDue2025Member_eca6eac4-9f93-47ff-94a4-fba832079925" xlink:href="jnj-20230402.xsd#jnj_A550DebentureDue2025Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A550DebentureDue2025Member_eca6eac4-9f93-47ff-94a4-fba832079925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A535DebentureDue2026Member_81ec335b-fefa-47f5-8b03-29ea0f7fd86c" xlink:href="jnj-20230402.xsd#jnj_A535DebentureDue2026Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A535DebentureDue2026Member_81ec335b-fefa-47f5-8b03-29ea0f7fd86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A505DebentureDue2028Member_63702318-f6a7-4a57-a51f-4828456e01cc" xlink:href="jnj-20230402.xsd#jnj_A505DebentureDue2028Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A505DebentureDue2028Member_63702318-f6a7-4a57-a51f-4828456e01cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A500DebentureDue2030Member_dd0b202e-bf00-430d-b7bb-94fe68a1fb0c" xlink:href="jnj-20230402.xsd#jnj_A500DebentureDue2030Member"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A500DebentureDue2030Member_dd0b202e-bf00-430d-b7bb-94fe68a1fb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A490DebentureDue2033Member_81d15e37-f09b-48d9-af0b-b2325f5ca977" xlink:href="jnj-20230402.xsd#jnj_A490DebentureDue2033Member"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A490DebentureDue2033Member_81d15e37-f09b-48d9-af0b-b2325f5ca977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A510DebentureDue2043Member_8999caa6-e9a2-4618-919a-c742ad367b69" xlink:href="jnj-20230402.xsd#jnj_A510DebentureDue2043Member"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A510DebentureDue2043Member_8999caa6-e9a2-4618-919a-c742ad367b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A505DebentureDue2053Member_154b44c8-57ba-4d44-acd6-a39c17edb487" xlink:href="jnj-20230402.xsd#jnj_A505DebentureDue2053Member"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A505DebentureDue2053Member_154b44c8-57ba-4d44-acd6-a39c17edb487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A520DebentureDue2063Member_1977a8a6-aafc-4cb8-9bc1-579b4d5d5af7" xlink:href="jnj-20230402.xsd#jnj_A520DebentureDue2063Member"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_A520DebentureDue2063Member_1977a8a6-aafc-4cb8-9bc1-579b4d5d5af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NotesDuePeriodFifteenMember_338de418-4174-4c3a-97b2-33b89bdfd643" xlink:href="jnj-20230402.xsd#jnj_NotesDuePeriodFifteenMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b96e1a16-f114-4598-a340-2eaed6840db5" xlink:to="loc_jnj_NotesDuePeriodFifteenMember_338de418-4174-4c3a-97b2-33b89bdfd643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_926fb174-f04d-4a91-a5cc-2e50c90f5710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_09dc814d-fc8b-462e-aa4c-732a828592cf" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_926fb174-f04d-4a91-a5cc-2e50c90f5710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1c2a3159-e6ae-4eb6-a738-68baee11e1db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_926fb174-f04d-4a91-a5cc-2e50c90f5710" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1c2a3159-e6ae-4eb6-a738-68baee11e1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2a0408d-54a0-43b8-839e-378bfb047020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_1c2a3159-e6ae-4eb6-a738-68baee11e1db" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2a0408d-54a0-43b8-839e-378bfb047020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_283a68d9-2907-4a49-8b27-0f7975cf82f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2a0408d-54a0-43b8-839e-378bfb047020" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_283a68d9-2907-4a49-8b27-0f7975cf82f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7de3c3a2-5490-4898-9000-2fa70e2259ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_b2a0408d-54a0-43b8-839e-378bfb047020" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7de3c3a2-5490-4898-9000-2fa70e2259ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_73fa31ff-77b9-4cd4-95fe-478d528be01f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_09dc814d-fc8b-462e-aa4c-732a828592cf" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_73fa31ff-77b9-4cd4-95fe-478d528be01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_73fa31ff-77b9-4cd4-95fe-478d528be01f" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_df17daae-cf58-407f-b9a1-0935a9aa95ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_df17daae-cf58-407f-b9a1-0935a9aa95ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_afb53a14-9433-4a49-8212-8e7b57d61061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract_df17daae-cf58-407f-b9a1-0935a9aa95ad" xlink:to="loc_us-gaap_ShortTermBorrowings_afb53a14-9433-4a49-8212-8e7b57d61061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_83c96a05-b604-424b-a7ea-779be3852a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_83c96a05-b604-424b-a7ea-779be3852a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f54808e9-fc5d-4fa7-8530-45afcda8acb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_83c96a05-b604-424b-a7ea-779be3852a14" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f54808e9-fc5d-4fa7-8530-45afcda8acb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_afa233a7-a613-4511-8790-b48ae1bd9824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_afa233a7-a613-4511-8790-b48ae1bd9824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_e42fd80f-cb7c-467e-b5f9-9e2ec85dd9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_e42fd80f-cb7c-467e-b5f9-9e2ec85dd9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_f8cc6e6a-c85e-437d-a744-480da851d879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d8a85649-ac42-48ff-9922-7d72dd04651e" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_f8cc6e6a-c85e-437d-a744-480da851d879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt_21d63365-fa70-422a-bfdc-c0069ee1961c" xlink:href="jnj-20230402.xsd#jnj_ExcessOfCarryingValueOverFairValueOfDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_73fa31ff-77b9-4cd4-95fe-478d528be01f" xlink:to="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt_21d63365-fa70-422a-bfdc-c0069ee1961c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0bdf818b-ab30-4f66-937b-e7024c8e74cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0bdf818b-ab30-4f66-937b-e7024c8e74cc" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e48c868b-0f48-4c6b-a5ca-717818d49fc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_srt_LitigationCaseAxis_e48c868b-0f48-4c6b-a5ca-717818d49fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_00f92094-ac27-4e97-a874-0798a51f46cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_e48c868b-0f48-4c6b-a5ca-717818d49fc9" xlink:to="loc_srt_LitigationCaseTypeDomain_00f92094-ac27-4e97-a874-0798a51f46cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_5a313c74-5e92-4f66-93a8-45518c1c111d" xlink:href="jnj-20230402.xsd#jnj_TalcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_00f92094-ac27-4e97-a874-0798a51f46cf" xlink:to="loc_jnj_TalcMember_5a313c74-5e92-4f66-93a8-45518c1c111d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_a4bcecaa-580d-431f-a00c-4d3cdc55b154" xlink:href="jnj-20230402.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_00f92094-ac27-4e97-a874-0798a51f46cf" xlink:to="loc_jnj_RisperdalMember_a4bcecaa-580d-431f-a00c-4d3cdc55b154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_35891335-b4e8-4dda-adc8-734f7311e2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_35891335-b4e8-4dda-adc8-734f7311e2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8e197646-e49e-456d-8fb6-54d3a8d3ad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_35891335-b4e8-4dda-adc8-734f7311e2b4" xlink:to="loc_us-gaap_SegmentDomain_8e197646-e49e-456d-8fb6-54d3a8d3ad0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_5dd1037c-c8f3-4cca-861f-2e0740f1c171" xlink:href="jnj-20230402.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8e197646-e49e-456d-8fb6-54d3a8d3ad0c" xlink:to="loc_jnj_ConsumerMember_5dd1037c-c8f3-4cca-861f-2e0740f1c171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_63573df2-4af6-4bef-b9f4-8d9f28793864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_63573df2-4af6-4bef-b9f4-8d9f28793864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e220f637-ad9b-4e1e-a2ce-21d8c6aca348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_63573df2-4af6-4bef-b9f4-8d9f28793864" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e220f637-ad9b-4e1e-a2ce-21d8c6aca348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_ccedf330-0298-45ca-991f-de3d05b70eb6" xlink:href="jnj-20230402.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e220f637-ad9b-4e1e-a2ce-21d8c6aca348" xlink:to="loc_jnj_AurisHealthMember_ccedf330-0298-45ca-991f-de3d05b70eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_971db699-6a69-4a76-ab65-909bf03e707e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_971db699-6a69-4a76-ab65-909bf03e707e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dac191cb-770f-404e-9393-a46d82527709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_971db699-6a69-4a76-ab65-909bf03e707e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dac191cb-770f-404e-9393-a46d82527709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_e9ec8157-859f-4bfe-8e62-398d78c4ff0d" xlink:href="jnj-20230402.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dac191cb-770f-404e-9393-a46d82527709" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_e9ec8157-859f-4bfe-8e62-398d78c4ff0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6a8731de-46c0-4443-94b2-e4f055fb859f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6a8731de-46c0-4443-94b2-e4f055fb859f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_96a447de-0937-476a-9d36-3d63bee42466" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6a8731de-46c0-4443-94b2-e4f055fb859f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_96a447de-0937-476a-9d36-3d63bee42466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedTaxesOnIncomeMember_fd84bf8f-e935-4b63-b17e-30573ddf89c3" xlink:href="jnj-20230402.xsd#jnj_AccruedTaxesOnIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_96a447de-0937-476a-9d36-3d63bee42466" xlink:to="loc_jnj_AccruedTaxesOnIncomeMember_fd84bf8f-e935-4b63-b17e-30573ddf89c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_7e7c29af-e57d-45d0-aec0-0ab86de0b570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_7e7c29af-e57d-45d0-aec0-0ab86de0b570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_d01c2c7d-e405-43c5-8d54-95ad353d2bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_7e7c29af-e57d-45d0-aec0-0ab86de0b570" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_d01c2c7d-e405-43c5-8d54-95ad353d2bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_b420edb0-32bb-4346-8e2f-d674e822f7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_d01c2c7d-e405-43c5-8d54-95ad353d2bd9" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_b420edb0-32bb-4346-8e2f-d674e822f7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a9425565-4009-4e4e-8c98-2e8cf6b46761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a9425565-4009-4e4e-8c98-2e8cf6b46761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f930c15b-5aeb-405c-88de-2527077fb4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a9425565-4009-4e4e-8c98-2e8cf6b46761" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f930c15b-5aeb-405c-88de-2527077fb4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_aa769771-1f35-4aec-a6a0-b0323a7d188a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_f930c15b-5aeb-405c-88de-2527077fb4fb" xlink:to="loc_us-gaap_SubsequentEventMember_aa769771-1f35-4aec-a6a0-b0323a7d188a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_f7b56c51-e95c-4f3d-9537-c07394c72ec5" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_7fa73424-5969-4f99-9256-1eb2468bd715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:to="loc_us-gaap_LitigationSettlementExpense_7fa73424-5969-4f99-9256-1eb2468bd715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_4b4b0876-d65d-409f-8d7a-df1b08b31e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_4b4b0876-d65d-409f-8d7a-df1b08b31e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6127eead-f010-4840-af75-6e69cd662e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6127eead-f010-4840-af75-6e69cd662e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2251ebb4-0c13-44a4-ae82-383bbf0f0840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2251ebb4-0c13-44a4-ae82-383bbf0f0840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_b5f9fb14-d337-4862-8caa-710d578d96c2" xlink:href="jnj-20230402.xsd#jnj_UnrecognizedTaxBenefitLiabilityPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_cb99b070-ce19-43bc-ba4f-c29d28f7fd2a" xlink:to="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_b5f9fb14-d337-4862-8caa-710d578d96c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a229533-823d-4722-a8bb-ff34139128f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5c080222-f4ae-45d3-a8ae-043c7771f09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3a229533-823d-4722-a8bb-ff34139128f1" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5c080222-f4ae-45d3-a8ae-043c7771f09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8c931144-405f-4e0a-a19e-b276e613044a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5c080222-f4ae-45d3-a8ae-043c7771f09b" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8c931144-405f-4e0a-a19e-b276e613044a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_51b7a8b6-13e5-49e3-aaf2-a03348e9f62f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8c931144-405f-4e0a-a19e-b276e613044a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_51b7a8b6-13e5-49e3-aaf2-a03348e9f62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_88326707-b78f-4d20-9b75-033a6c68c8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_51b7a8b6-13e5-49e3-aaf2-a03348e9f62f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_88326707-b78f-4d20-9b75-033a6c68c8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0cc698cf-8bda-46cf-b467-f79c117eb77e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_51b7a8b6-13e5-49e3-aaf2-a03348e9f62f" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_0cc698cf-8bda-46cf-b467-f79c117eb77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_895e87f6-7a6e-4cc7-8ad5-462f5e6e57a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_5c080222-f4ae-45d3-a8ae-043c7771f09b" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_895e87f6-7a6e-4cc7-8ad5-462f5e6e57a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_895e87f6-7a6e-4cc7-8ad5-462f5e6e57a9" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_5fdf9e1a-d9eb-4f43-94a1-bc3a6ad9c417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_5fdf9e1a-d9eb-4f43-94a1-bc3a6ad9c417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_2fa97ae9-a14f-4305-966d-a47f162bc6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_2fa97ae9-a14f-4305-966d-a47f162bc6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_d0ca5e10-323f-478c-860d-a73a85c56eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_d0ca5e10-323f-478c-860d-a73a85c56eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f60cdf4c-f9ff-4ea3-8718-51e73f077b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_f60cdf4c-f9ff-4ea3-8718-51e73f077b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2fcc4a04-9d55-4af9-b3df-e165ac90d0f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_2fcc4a04-9d55-4af9-b3df-e165ac90d0f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_05f5c3bd-74dc-432c-93fe-3f906a1338c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_05f5c3bd-74dc-432c-93fe-3f906a1338c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c8c3df39-ffe4-480c-85e9-72e4741f340a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract_deccf99e-32ec-49b6-93a5-d89c8fa53397" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_c8c3df39-ffe4-480c-85e9-72e4741f340a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#PensionsandOtherBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_16e204b8-97d0-4f3e-b308-eb3cb36e8542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8cece296-4bcd-49e3-b2dd-854b8e0ca38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_16e204b8-97d0-4f3e-b308-eb3cb36e8542" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8cece296-4bcd-49e3-b2dd-854b8e0ca38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3a4f43f-fb33-4e17-9311-8be38306019a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8cece296-4bcd-49e3-b2dd-854b8e0ca38a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3a4f43f-fb33-4e17-9311-8be38306019a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2c5bae19-17be-439f-ad3c-4d6365db62a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_e3a4f43f-fb33-4e17-9311-8be38306019a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2c5bae19-17be-439f-ad3c-4d6365db62a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_fe784f69-50f6-46ba-81a6-cb69d0647739" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2c5bae19-17be-439f-ad3c-4d6365db62a4" xlink:to="loc_us-gaap_DomesticPlanMember_fe784f69-50f6-46ba-81a6-cb69d0647739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_73980c4e-2116-421e-9a28-58c6cbffe792" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_fe784f69-50f6-46ba-81a6-cb69d0647739" xlink:to="loc_country_US_73980c4e-2116-421e-9a28-58c6cbffe792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_0e6082ed-5395-4ad4-bc79-38aecd8d2f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_2c5bae19-17be-439f-ad3c-4d6365db62a4" xlink:to="loc_us-gaap_ForeignPlanMember_0e6082ed-5395-4ad4-bc79-38aecd8d2f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_be4f5d34-7f6f-45aa-bc16-11a30028a9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_8cece296-4bcd-49e3-b2dd-854b8e0ca38a" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_be4f5d34-7f6f-45aa-bc16-11a30028a9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_e6261f36-7891-44bd-8ed0-202a1f14931b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_be4f5d34-7f6f-45aa-bc16-11a30028a9ac" xlink:to="loc_us-gaap_PensionContributions_e6261f36-7891-44bd-8ed0-202a1f14931b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#AccumulatedOtherComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_981a91c2-cbf1-4e69-bc81-1f3476b952fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_06cee861-916d-4056-a768-c7eb530d8be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_981a91c2-cbf1-4e69-bc81-1f3476b952fb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_06cee861-916d-4056-a768-c7eb530d8be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_67a735a5-f3c6-4505-aee4-245f267ae1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_06cee861-916d-4056-a768-c7eb530d8be8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_67a735a5-f3c6-4505-aee4-245f267ae1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_67a735a5-f3c6-4505-aee4-245f267ae1c6" xlink:to="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5ca71f82-7939-46b2-aeeb-f0cf019f3526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5ca71f82-7939-46b2-aeeb-f0cf019f3526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d942bdd5-8f06-467c-9b12-cc6abba89c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_d942bdd5-8f06-467c-9b12-cc6abba89c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a37e45df-9d9b-468d-b73c-d14eb921a4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a37e45df-9d9b-468d-b73c-d14eb921a4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_a332cf16-b709-4bcd-bb52-2684e83191e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_a332cf16-b709-4bcd-bb52-2684e83191e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_faf3756e-75b4-4425-a9c1-3f12572f91e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c4e10c5e-6590-40ef-9dec-5afdcc9bdf66" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_faf3756e-75b4-4425-a9c1-3f12572f91e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5bae52b1-1e1e-4669-b8da-2dbd4ca9fb51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_06cee861-916d-4056-a768-c7eb530d8be8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5bae52b1-1e1e-4669-b8da-2dbd4ca9fb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_5bae52b1-1e1e-4669-b8da-2dbd4ca9fb51" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7234f09f-6f6e-44cf-a1ca-b60dc48cdd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7234f09f-6f6e-44cf-a1ca-b60dc48cdd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_70a2d430-de0f-4433-9051-570a105f6f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_70a2d430-de0f-4433-9051-570a105f6f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_65529bd7-2d5f-4ea8-88b4-ecd5748ed3de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_65529bd7-2d5f-4ea8-88b4-ecd5748ed3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_66ead5cc-a96c-47dd-a70f-dbc4ce0c3a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_66ead5cc-a96c-47dd-a70f-dbc4ce0c3a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_47cafc38-07c0-4741-bba8-6b818fc5c943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_47cafc38-07c0-4741-bba8-6b818fc5c943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2d7b2ca3-f6af-46f3-8d79-ebf8c2f8e5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_2d7b2ca3-f6af-46f3-8d79-ebf8c2f8e5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ba9c59f0-5e5b-4b33-bb36-f8102da3acde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_293ef21b-59fc-4c43-bace-aff6d5b4169e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ba9c59f0-5e5b-4b33-bb36-f8102da3acde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f932f68a-058c-4e4c-9f30-c069b7dfd33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_d8034c23-7c5e-4e3a-8aec-fea58f45dd2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f932f68a-058c-4e4c-9f30-c069b7dfd33f" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_d8034c23-7c5e-4e3a-8aec-fea58f45dd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_482bb474-adeb-45cb-80cb-47825300c5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_d8034c23-7c5e-4e3a-8aec-fea58f45dd2d" xlink:to="loc_us-gaap_EarningsPerShareBasic_482bb474-adeb-45cb-80cb-47825300c5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5e3a0255-d33d-41ef-a6fa-2ef3b24a9e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_d8034c23-7c5e-4e3a-8aec-fea58f45dd2d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5e3a0255-d33d-41ef-a6fa-2ef3b24a9e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3d366bdf-cf07-4646-bcf6-7dfdf7eef140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_d8034c23-7c5e-4e3a-8aec-fea58f45dd2d" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_3d366bdf-cf07-4646-bcf6-7dfdf7eef140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_722bbb6a-3c7e-46e3-a2a7-5eb3b7eeea6f" xlink:href="jnj-20230402.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_d8034c23-7c5e-4e3a-8aec-fea58f45dd2d" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_722bbb6a-3c7e-46e3-a2a7-5eb3b7eeea6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4d032398-1a08-43c9-ace2-323fe2a57cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_d8034c23-7c5e-4e3a-8aec-fea58f45dd2d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4d032398-1a08-43c9-ace2-323fe2a57cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2dab0c37-3c55-42e9-a65a-4786bbdd258e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_d8034c23-7c5e-4e3a-8aec-fea58f45dd2d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2dab0c37-3c55-42e9-a65a-4786bbdd258e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_34fd76cc-6150-4316-a51e-41f18eda9006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_34fd76cc-6150-4316-a51e-41f18eda9006" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3ac17d71-de3f-4c15-a55c-288896b79ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3ac17d71-de3f-4c15-a55c-288896b79ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5845609-597e-45b5-ac0f-4429639fc737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3ac17d71-de3f-4c15-a55c-288896b79ae7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5845609-597e-45b5-ac0f-4429639fc737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_427e55c3-5eb9-446b-bf67-a3db114523de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_427e55c3-5eb9-446b-bf67-a3db114523de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dfa37a25-6af4-4e60-a3f3-2102ce676274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_427e55c3-5eb9-446b-bf67-a3db114523de" xlink:to="loc_us-gaap_SegmentDomain_dfa37a25-6af4-4e60-a3f3-2102ce676274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_aa17aab8-a4ff-4db6-a2de-4c1915c453fd" xlink:href="jnj-20230402.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dfa37a25-6af4-4e60-a3f3-2102ce676274" xlink:to="loc_jnj_ConsumerMember_aa17aab8-a4ff-4db6-a2de-4c1915c453fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_5aca5b96-7485-4a20-8c7d-3a6907bce937" xlink:href="jnj-20230402.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dfa37a25-6af4-4e60-a3f3-2102ce676274" xlink:to="loc_jnj_PharmaceuticalMember_5aca5b96-7485-4a20-8c7d-3a6907bce937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_b9d571ef-3ddf-42fd-bbf6-3256e7cdb298" xlink:href="jnj-20230402.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dfa37a25-6af4-4e60-a3f3-2102ce676274" xlink:to="loc_jnj_MedicalDevicesMember_b9d571ef-3ddf-42fd-bbf6-3256e7cdb298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_0715fcd6-e348-4e5a-95b0-d2c2d4a37c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:to="loc_us-gaap_SubsegmentsAxis_0715fcd6-e348-4e5a-95b0-d2c2d4a37c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_0715fcd6-e348-4e5a-95b0-d2c2d4a37c59" xlink:to="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_4f459e77-cb55-4ce7-8b3d-ea1fcd16dc03" xlink:href="jnj-20230402.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_ImmunologyMember_4f459e77-cb55-4ce7-8b3d-ea1fcd16dc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_0590dc18-9828-4a47-a851-cd9e6afd95a5" xlink:href="jnj-20230402.xsd#jnj_InfectiousDiseasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_InfectiousDiseasesMember_0590dc18-9828-4a47-a851-cd9e6afd95a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_fb381a92-d873-4150-93e2-e475d34581df" xlink:href="jnj-20230402.xsd#jnj_NeuroscienceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_NeuroscienceMember_fb381a92-d873-4150-93e2-e475d34581df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_3b0f5937-2a61-42f8-90cf-09b051699150" xlink:href="jnj-20230402.xsd#jnj_OncologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_OncologyMember_3b0f5937-2a61-42f8-90cf-09b051699150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_0eb42e5d-a7d1-4c6a-b60c-2d2ce9685a34" xlink:href="jnj-20230402.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_PulmonaryHypertensionMember_0eb42e5d-a7d1-4c6a-b60c-2d2ce9685a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_b16c3277-d73b-4b0f-8382-caa0cbd241f8" xlink:href="jnj-20230402.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_b16c3277-d73b-4b0f-8382-caa0cbd241f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_3f8ecb90-1227-4771-b8fb-eb8aefbc3b60" xlink:href="jnj-20230402.xsd#jnj_InterventionalSolutionsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_InterventionalSolutionsMember_3f8ecb90-1227-4771-b8fb-eb8aefbc3b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElectrophysiologyMember_1142c0c4-1483-4b10-8fdc-6c97eaa41916" xlink:href="jnj-20230402.xsd#jnj_ElectrophysiologyMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_ElectrophysiologyMember_1142c0c4-1483-4b10-8fdc-6c97eaa41916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_ac5dfc81-5d14-44f1-a5ad-e2ccba22c025" xlink:href="jnj-20230402.xsd#jnj_AbiomedMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_AbiomedMember_ac5dfc81-5d14-44f1-a5ad-e2ccba22c025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInterventionalSolutionsMember_6bd70f6e-e35e-4921-9819-3f89f7cff3c7" xlink:href="jnj-20230402.xsd#jnj_OtherInterventionalSolutionsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_OtherInterventionalSolutionsMember_6bd70f6e-e35e-4921-9819-3f89f7cff3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_45f6e54d-47e6-4525-ac01-828c5a1c1cc7" xlink:href="jnj-20230402.xsd#jnj_OrthopaedicsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_OrthopaedicsMember_45f6e54d-47e6-4525-ac01-828c5a1c1cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_0d119264-61e7-4397-9093-5f3252c6c390" xlink:href="jnj-20230402.xsd#jnj_SurgeryMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_SurgeryMember_0d119264-61e7-4397-9093-5f3252c6c390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_3fdbb4b7-deac-416c-9e15-b84594b838d2" xlink:href="jnj-20230402.xsd#jnj_VisionMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_219e6212-d43b-47d3-a3a3-c9d7e5972f6a" xlink:to="loc_jnj_VisionMember_3fdbb4b7-deac-416c-9e15-b84594b838d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_287ad37a-c98d-4e8e-b815-978ac59a5788" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:to="loc_srt_ProductOrServiceAxis_287ad37a-c98d-4e8e-b815-978ac59a5788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_287ad37a-c98d-4e8e-b815-978ac59a5788" xlink:to="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_6aea7fa6-e1cf-44b7-9d11-3d109aedffe3" xlink:href="jnj-20230402.xsd#jnj_OTCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OTCMember_6aea7fa6-e1cf-44b7-9d11-3d109aedffe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BeautyMember_f65fd530-cec7-41cb-9914-6481b89ae732" xlink:href="jnj-20230402.xsd#jnj_BeautyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_BeautyMember_f65fd530-cec7-41cb-9914-6481b89ae732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_86efe0fb-c35e-4709-9e76-e35b168e11d8" xlink:href="jnj-20230402.xsd#jnj_OralCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OralCareMember_86efe0fb-c35e-4709-9e76-e35b168e11d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_9e8917e9-905f-4b55-8bf4-71a8d71cc40a" xlink:href="jnj-20230402.xsd#jnj_BabyCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_BabyCareMember_9e8917e9-905f-4b55-8bf4-71a8d71cc40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_b8ed41cc-e68c-4f65-b0fb-19143b292ac3" xlink:href="jnj-20230402.xsd#jnj_WomensHealthMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_WomensHealthMember_b8ed41cc-e68c-4f65-b0fb-19143b292ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_ce32c146-e88c-47a9-bdf8-68e878aa6b64" xlink:href="jnj-20230402.xsd#jnj_WoundCareandOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_WoundCareandOtherMember_ce32c146-e88c-47a9-bdf8-68e878aa6b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_23a59356-2857-44ed-a875-6b74a8fffd85" xlink:href="jnj-20230402.xsd#jnj_RemicadeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_RemicadeMember_23a59356-2857-44ed-a875-6b74a8fffd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_a3ff8e0e-6211-4699-ac5a-2c89b92f4dad" xlink:href="jnj-20230402.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_SimponiSimponiAriaMember_a3ff8e0e-6211-4699-ac5a-2c89b92f4dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_bc25dcfb-7823-4ca5-a481-a80071124b6b" xlink:href="jnj-20230402.xsd#jnj_StelaraMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_StelaraMember_bc25dcfb-7823-4ca5-a481-a80071124b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_65bc6d77-c232-429b-9b59-7d6cf87a65ca" xlink:href="jnj-20230402.xsd#jnj_TremfyaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_TremfyaMember_65bc6d77-c232-429b-9b59-7d6cf87a65ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_5443e1b1-bad5-414c-987f-beedccb8c941" xlink:href="jnj-20230402.xsd#jnj_OtherImmunologyMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OtherImmunologyMember_5443e1b1-bad5-414c-987f-beedccb8c941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_bca286a7-31ad-4266-97fc-21ac710ea4da" xlink:href="jnj-20230402.xsd#jnj_COVID19Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_COVID19Member_bca286a7-31ad-4266-97fc-21ac710ea4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_9fc81f9e-1593-496d-8a4b-3c1832fff7d9" xlink:href="jnj-20230402.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_EDURANTrilpivirineMember_9fc81f9e-1593-496d-8a4b-3c1832fff7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_9b858065-b73f-488b-ae9a-715cb4cda15d" xlink:href="jnj-20230402.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_9b858065-b73f-488b-ae9a-715cb4cda15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_ddca0460-713d-4728-ae45-c3c57af2c434" xlink:href="jnj-20230402.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_ddca0460-713d-4728-ae45-c3c57af2c434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_5a9da27c-f485-4e3f-9abb-107879a6de96" xlink:href="jnj-20230402.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_5a9da27c-f485-4e3f-9abb-107879a6de96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_6c512fca-5c6d-4447-8d2f-36325ed7a524" xlink:href="jnj-20230402.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_6c512fca-5c6d-4447-8d2f-36325ed7a524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_a8e55e2b-aa61-4f6d-a112-bf7f79054240" xlink:href="jnj-20230402.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_a8e55e2b-aa61-4f6d-a112-bf7f79054240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_e5334095-b428-47f5-9a1e-d8ca848b8cb8" xlink:href="jnj-20230402.xsd#jnj_DARZALEXMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_DARZALEXMember_e5334095-b428-47f5-9a1e-d8ca848b8cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ERLEADAMember_f576e7d6-6a66-4f1c-8a97-81a30d47c8f5" xlink:href="jnj-20230402.xsd#jnj_ERLEADAMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_ERLEADAMember_f576e7d6-6a66-4f1c-8a97-81a30d47c8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_2b11fe7c-6d68-47d7-8971-168fbfcb18bb" xlink:href="jnj-20230402.xsd#jnj_IMBRUVICAMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_IMBRUVICAMember_2b11fe7c-6d68-47d7-8971-168fbfcb18bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_bc28bde5-08a5-4ed3-8b3b-16249c5c7fbb" xlink:href="jnj-20230402.xsd#jnj_ZYTIGAMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_ZYTIGAMember_bc28bde5-08a5-4ed3-8b3b-16249c5c7fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_31a5057e-60f0-43ee-a824-43013dd19107" xlink:href="jnj-20230402.xsd#jnj_OtherOncologyMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OtherOncologyMember_31a5057e-60f0-43ee-a824-43013dd19107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_73e2c027-5c93-4be7-917d-714a13a71574" xlink:href="jnj-20230402.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OPSUMITMember_73e2c027-5c93-4be7-917d-714a13a71574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_a6e98bcd-f17f-4021-80de-340c7c1580b8" xlink:href="jnj-20230402.xsd#jnj_UPTRAVIMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_UPTRAVIMember_a6e98bcd-f17f-4021-80de-340c7c1580b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_17b55646-9718-473b-bc21-55c42c663a42" xlink:href="jnj-20230402.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_XareltoMember_17b55646-9718-473b-bc21-55c42c663a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_ba75f0b7-f9ab-4cfd-9f94-8008c60972f3" xlink:href="jnj-20230402.xsd#jnj_OtherMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_OtherMember_ba75f0b7-f9ab-4cfd-9f94-8008c60972f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_dce424af-6715-4e78-af02-9b1912e1d498" xlink:href="jnj-20230402.xsd#jnj_HIPSMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_HIPSMember_dce424af-6715-4e78-af02-9b1912e1d498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_02ab7370-f494-4682-942d-852acd6064fa" xlink:href="jnj-20230402.xsd#jnj_KNEESMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_KNEESMember_02ab7370-f494-4682-942d-852acd6064fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_77470984-2243-4019-9e86-f9e0a0221912" xlink:href="jnj-20230402.xsd#jnj_TRAUMAMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_TRAUMAMember_77470984-2243-4019-9e86-f9e0a0221912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINEOTHERMember_3c54a1d2-4c37-4072-bccc-ff595a79dcbb" xlink:href="jnj-20230402.xsd#jnj_SPINEOTHERMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_SPINEOTHERMember_3c54a1d2-4c37-4072-bccc-ff595a79dcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_65cfb247-da4d-4a28-b34f-f2f0456c883a" xlink:href="jnj-20230402.xsd#jnj_ADVANCEDMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_ADVANCEDMember_65cfb247-da4d-4a28-b34f-f2f0456c883a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_596d4f48-d6e1-4c5b-ae3f-a8bbb21b5c6b" xlink:href="jnj-20230402.xsd#jnj_GENERALMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_GENERALMember_596d4f48-d6e1-4c5b-ae3f-a8bbb21b5c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_f8b1f979-58c0-462e-9706-24a31fc3b482" xlink:href="jnj-20230402.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_f8b1f979-58c0-462e-9706-24a31fc3b482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_89c42042-cde8-4275-b7c3-b3965afecef4" xlink:href="jnj-20230402.xsd#jnj_SURGICALMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_SURGICALMember_89c42042-cde8-4275-b7c3-b3965afecef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CARVYKTIMember_63482946-572b-47aa-9e98-9fb25e430319" xlink:href="jnj-20230402.xsd#jnj_CARVYKTIMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_CARVYKTIMember_63482946-572b-47aa-9e98-9fb25e430319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPRAVATOMember_9369bce6-b29a-4559-b294-6bc7a0306517" xlink:href="jnj-20230402.xsd#jnj_SPRAVATOMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e1c56ee3-3c96-4f27-8b2d-01f31814727c" xlink:to="loc_jnj_SPRAVATOMember_9369bce6-b29a-4559-b294-6bc7a0306517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bf49ccba-efaf-42f1-b8fe-9aa10aee3185" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:to="loc_srt_StatementGeographicalAxis_bf49ccba-efaf-42f1-b8fe-9aa10aee3185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8203c362-1af0-4269-8992-544b2dad9219" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bf49ccba-efaf-42f1-b8fe-9aa10aee3185" xlink:to="loc_srt_SegmentGeographicalDomain_8203c362-1af0-4269-8992-544b2dad9219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_eee4f7c2-9fe2-42f7-a722-69ceb8725ad3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8203c362-1af0-4269-8992-544b2dad9219" xlink:to="loc_country_US_eee4f7c2-9fe2-42f7-a722-69ceb8725ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_19ed6304-21f0-42da-a6b6-df4ea549f56d" xlink:href="jnj-20230402.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8203c362-1af0-4269-8992-544b2dad9219" xlink:to="loc_jnj_UNITEDSTATESExportsMember_19ed6304-21f0-42da-a6b6-df4ea549f56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_b0184925-ead9-408c-b4fb-fa8c640f2299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8203c362-1af0-4269-8992-544b2dad9219" xlink:to="loc_us-gaap_NonUsMember_b0184925-ead9-408c-b4fb-fa8c640f2299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_edeeb68d-4f5e-405c-a51e-46559572b36b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_36c99e74-542c-4a8d-887c-8b03996609a1" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_edeeb68d-4f5e-405c-a51e-46559572b36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationRevenueAbstract_b15ef415-9fd9-473c-8968-6c0beb0022a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationRevenueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_edeeb68d-4f5e-405c-a51e-46559572b36b" xlink:to="loc_us-gaap_SegmentReportingInformationRevenueAbstract_b15ef415-9fd9-473c-8968-6c0beb0022a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f3e8085c-f085-4047-95da-72b0b15e21ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_b15ef415-9fd9-473c-8968-6c0beb0022a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f3e8085c-f085-4047-95da-72b0b15e21ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_d5ca549a-3914-427a-933a-4cb5a532bade" xlink:href="jnj-20230402.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationRevenueAbstract_b15ef415-9fd9-473c-8968-6c0beb0022a4" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_d5ca549a-3914-427a-933a-4cb5a532bade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6f020f8f-825c-4002-948b-c11535103e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6f020f8f-825c-4002-948b-c11535103e98" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c3a778fb-e32d-4dc1-a199-1d206c2c2b4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:to="loc_srt_ConsolidationItemsAxis_c3a778fb-e32d-4dc1-a199-1d206c2c2b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_19f859d8-230d-48e4-bf8f-124898feec8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_c3a778fb-e32d-4dc1-a199-1d206c2c2b4e" xlink:to="loc_srt_ConsolidationItemsDomain_19f859d8-230d-48e4-bf8f-124898feec8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_706656ed-4f18-4d77-9707-a7c84e271040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_19f859d8-230d-48e4-bf8f-124898feec8b" xlink:to="loc_us-gaap_OperatingSegmentsMember_706656ed-4f18-4d77-9707-a7c84e271040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_099783fe-e94e-4a5e-ab9f-637145a32f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_19f859d8-230d-48e4-bf8f-124898feec8b" xlink:to="loc_us-gaap_CorporateNonSegmentMember_099783fe-e94e-4a5e-ab9f-637145a32f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_ae21b6ae-8acf-4547-9af1-36067a8c0eed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_ae21b6ae-8acf-4547-9af1-36067a8c0eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8d735388-1890-4ed6-97ee-11f5805b8c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_ae21b6ae-8acf-4547-9af1-36067a8c0eed" xlink:to="loc_us-gaap_SegmentDomain_8d735388-1890-4ed6-97ee-11f5805b8c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_badfe2cc-0250-45b6-8e68-d1f58177a430" xlink:href="jnj-20230402.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8d735388-1890-4ed6-97ee-11f5805b8c70" xlink:to="loc_jnj_ConsumerMember_badfe2cc-0250-45b6-8e68-d1f58177a430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_17a12133-42a7-4846-8f32-cebbc295bad7" xlink:href="jnj-20230402.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8d735388-1890-4ed6-97ee-11f5805b8c70" xlink:to="loc_jnj_PharmaceuticalMember_17a12133-42a7-4846-8f32-cebbc295bad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedicalDevicesMember_feb340b4-2adc-446b-a4c6-2a5e063267fb" xlink:href="jnj-20230402.xsd#jnj_MedicalDevicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8d735388-1890-4ed6-97ee-11f5805b8c70" xlink:to="loc_jnj_MedicalDevicesMember_feb340b4-2adc-446b-a4c6-2a5e063267fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1a9dd970-36cf-4dc4-ad7b-290b7a0d4227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1a9dd970-36cf-4dc4-ad7b-290b7a0d4227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8d20464-9b2c-4e59-8547-926a9c5709ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1a9dd970-36cf-4dc4-ad7b-290b7a0d4227" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8d20464-9b2c-4e59-8547-926a9c5709ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_21aea651-7620-48f6-804e-8930bf3c25df" xlink:href="jnj-20230402.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f8d20464-9b2c-4e59-8547-926a9c5709ae" xlink:to="loc_jnj_BermekimabMember_21aea651-7620-48f6-804e-8930bf3c25df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_e923f904-d2fd-4638-872b-2cbcebdc36ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:to="loc_srt_LitigationCaseAxis_e923f904-d2fd-4638-872b-2cbcebdc36ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1f290b95-1f09-4856-9ea6-a692188a115d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_e923f904-d2fd-4638-872b-2cbcebdc36ba" xlink:to="loc_srt_LitigationCaseTypeDomain_1f290b95-1f09-4856-9ea6-a692188a115d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_73547ba6-2595-4eab-9d3e-32159d1bfb5a" xlink:href="jnj-20230402.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1f290b95-1f09-4856-9ea6-a692188a115d" xlink:to="loc_jnj_RisperdalMember_73547ba6-2595-4eab-9d3e-32159d1bfb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a9c67f4c-08f4-41f8-9360-d0bd9bf5dc11" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_80348220-e175-468c-8e93-385a7a102d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_OperatingIncomeLoss_80348220-e175-468c-8e93-385a7a102d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_8a21d8cd-8925-4bda-b38e-44af0847cd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_BusinessExitCosts1_8a21d8cd-8925-4bda-b38e-44af0847cd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71dc0e6e-fc34-41bd-842c-b9a4a87c0155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_71dc0e6e-fc34-41bd-842c-b9a4a87c0155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInOperatingIncomeLoss_cbd8929f-fb20-49e2-8165-0032848d5377" xlink:href="jnj-20230402.xsd#jnj_PercentageChangeInOperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_jnj_PercentageChangeInOperatingIncomeLoss_cbd8929f-fb20-49e2-8165-0032848d5377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_5cf63d4f-525f-46e4-a03c-39166c2eaaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_5cf63d4f-525f-46e4-a03c-39166c2eaaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_ec495847-a660-49e4-81ad-9ed481b04128" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_SuppliesExpense_ec495847-a660-49e4-81ad-9ed481b04128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_6edb7a90-6320-46be-8cd9-c17c56e931cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_RestructuringCharges_6edb7a90-6320-46be-8cd9-c17c56e931cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_b98746da-14e7-4653-84ea-c6b5001da714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_b98746da-14e7-4653-84ea-c6b5001da714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f18ddbee-6861-403c-bdaf-f411114d7b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f18ddbee-6861-403c-bdaf-f411114d7b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_6c203528-f037-4499-bc23-1018ed75d3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_1fd766c9-09ad-4503-92bb-ea8ead020ea9" xlink:to="loc_us-gaap_AdjustmentForAmortization_6c203528-f037-4499-bc23-1018ed75d3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bcb3950e-749e-48e3-b6ae-ed0201bfc69c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a5ecd848-9179-49f6-9832-f0e2c642c154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6bbdf5ac-ca6f-40f3-82e3-a3f0ee353de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a5ecd848-9179-49f6-9832-f0e2c642c154" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6bbdf5ac-ca6f-40f3-82e3-a3f0ee353de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_faf147c7-b907-4653-8783-a123afcc1d0a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6bbdf5ac-ca6f-40f3-82e3-a3f0ee353de2" xlink:to="loc_srt_StatementGeographicalAxis_faf147c7-b907-4653-8783-a123afcc1d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f3ba1659-ef36-44ba-9925-7ff4d071b3da" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_faf147c7-b907-4653-8783-a123afcc1d0a" xlink:to="loc_srt_SegmentGeographicalDomain_f3ba1659-ef36-44ba-9925-7ff4d071b3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_dee51f55-4db4-4eff-a5f0-75f7869d3061" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f3ba1659-ef36-44ba-9925-7ff4d071b3da" xlink:to="loc_country_US_dee51f55-4db4-4eff-a5f0-75f7869d3061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_17fad975-118a-4f97-887b-f3332d773db5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f3ba1659-ef36-44ba-9925-7ff4d071b3da" xlink:to="loc_srt_EuropeMember_17fad975-118a-4f97-887b-f3332d773db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_e5222822-27ea-48fa-a377-d97c04ae33ef" xlink:href="jnj-20230402.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f3ba1659-ef36-44ba-9925-7ff4d071b3da" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_e5222822-27ea-48fa-a377-d97c04ae33ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_82e2e45b-dd61-4f7d-88a6-86006707be4a" xlink:href="jnj-20230402.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f3ba1659-ef36-44ba-9925-7ff4d071b3da" xlink:to="loc_jnj_AsiaPacificAfricaMember_82e2e45b-dd61-4f7d-88a6-86006707be4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6c554922-7489-4f6f-af18-2d71ad4dd9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6bbdf5ac-ca6f-40f3-82e3-a3f0ee353de2" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6c554922-7489-4f6f-af18-2d71ad4dd9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_c3e731eb-eeec-4810-98fa-c7d0de7969ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentsGeographicalAreasAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6c554922-7489-4f6f-af18-2d71ad4dd9c5" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_c3e731eb-eeec-4810-98fa-c7d0de7969ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce4d78c0-56a3-46af-8915-ca5dbda1385d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_c3e731eb-eeec-4810-98fa-c7d0de7969ce" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ce4d78c0-56a3-46af-8915-ca5dbda1385d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesByGeographicArea_55c27ed8-b9a7-4c06-b8da-f6f8a6effd26" xlink:href="jnj-20230402.xsd#jnj_PercentageChangeInSalesByGeographicArea"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_c3e731eb-eeec-4810-98fa-c7d0de7969ce" xlink:to="loc_jnj_PercentageChangeInSalesByGeographicArea_55c27ed8-b9a7-4c06-b8da-f6f8a6effd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_082e8537-d6d5-4d46-b908-cfd46889b0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_082e8537-d6d5-4d46-b908-cfd46889b0a3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e44367ed-c2c9-42a4-9005-ee193066261b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e44367ed-c2c9-42a4-9005-ee193066261b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07863a38-e375-471b-9bee-e45a4c8d452d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e44367ed-c2c9-42a4-9005-ee193066261b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07863a38-e375-471b-9bee-e45a4c8d452d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_69ac9e9e-4187-438b-b404-1749f8f1b223" xlink:href="jnj-20230402.xsd#jnj_AbiomedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_07863a38-e375-471b-9bee-e45a4c8d452d" xlink:to="loc_jnj_AbiomedMember_69ac9e9e-4187-438b-b404-1749f8f1b223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_806cf6ca-c903-4344-9244-d930d7e73acc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:to="loc_us-gaap_AwardTypeAxis_806cf6ca-c903-4344-9244-d930d7e73acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_762d42cd-74a5-4025-a72d-7023d35d66c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_806cf6ca-c903-4344-9244-d930d7e73acc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_762d42cd-74a5-4025-a72d-7023d35d66c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonTradeableContingentValueRightMember_0f6081ba-6c0f-4136-ad26-140fd20c1d0a" xlink:href="jnj-20230402.xsd#jnj_NonTradeableContingentValueRightMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_762d42cd-74a5-4025-a72d-7023d35d66c6" xlink:to="loc_jnj_NonTradeableContingentValueRightMember_0f6081ba-6c0f-4136-ad26-140fd20c1d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_cceb929b-fb05-48d5-a906-82e88abe38ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:to="loc_srt_ProductOrServiceAxis_cceb929b-fb05-48d5-a906-82e88abe38ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b44471c7-37a6-43db-81e7-c130913c71e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_cceb929b-fb05-48d5-a906-82e88abe38ec" xlink:to="loc_srt_ProductsAndServicesDomain_b44471c7-37a6-43db-81e7-c130913c71e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImpellaMember_bfae4441-04a1-406b-a68f-dab1c6dfee05" xlink:href="jnj-20230402.xsd#jnj_ImpellaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b44471c7-37a6-43db-81e7-c130913c71e0" xlink:to="loc_jnj_ImpellaMember_bfae4441-04a1-406b-a68f-dab1c6dfee05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ClassIRecommendationForImpellaMember_aca2abfe-0e26-4095-9cb7-cddaf804a242" xlink:href="jnj-20230402.xsd#jnj_ClassIRecommendationForImpellaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b44471c7-37a6-43db-81e7-c130913c71e0" xlink:to="loc_jnj_ClassIRecommendationForImpellaMember_aca2abfe-0e26-4095-9cb7-cddaf804a242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dc8e1d83-87c6-4128-875a-912ada798f2f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:to="loc_srt_RangeAxis_dc8e1d83-87c6-4128-875a-912ada798f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_18a95865-cd39-4bea-86b9-97817a54b119" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dc8e1d83-87c6-4128-875a-912ada798f2f" xlink:to="loc_srt_RangeMember_18a95865-cd39-4bea-86b9-97817a54b119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7854050-737c-4c2f-a343-ecb179e3bf57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_18a95865-cd39-4bea-86b9-97817a54b119" xlink:to="loc_srt_MinimumMember_f7854050-737c-4c2f-a343-ecb179e3bf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6046c877-9fba-49e6-9d8c-8d6fe21d9509" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_18a95865-cd39-4bea-86b9-97817a54b119" xlink:to="loc_srt_MaximumMember_6046c877-9fba-49e6-9d8c-8d6fe21d9509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b4caea-8476-4349-ab04-4f57f0e43cf2" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_cf6df50d-9e48-4c15-9159-48a8c2099688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_cf6df50d-9e48-4c15-9159-48a8c2099688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7573961d-ed71-406b-a82f-7d49f352255d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_7573961d-ed71-406b-a82f-7d49f352255d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_fb12ad9d-d329-4c48-99f2-cbfe04892848" xlink:href="jnj-20230402.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_fb12ad9d-d329-4c48-99f2-cbfe04892848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_f4b2a46b-493f-468b-92af-c5a39be8f788" xlink:href="jnj-20230402.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_f4b2a46b-493f-468b-92af-c5a39be8f788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a9e1fdf6-0412-400f-b2eb-0545b99e2c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a9e1fdf6-0412-400f-b2eb-0545b99e2c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare_84eb99ff-bb7a-4161-93a0-6d48fa65c5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_DividendsPayableAmountPerShare_84eb99ff-bb7a-4161-93a0-6d48fa65c5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RevenuesContingentConsideration_c326bb75-c346-4bed-ac31-2ff632797005" xlink:href="jnj-20230402.xsd#jnj_RevenuesContingentConsideration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_jnj_RevenuesContingentConsideration_c326bb75-c346-4bed-ac31-2ff632797005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9095d54a-2f03-4116-a66e-5bd34adff365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_9095d54a-2f03-4116-a66e-5bd34adff365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_813e0995-db0b-42db-892d-a4270a2f86c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_813e0995-db0b-42db-892d-a4270a2f86c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_e77d8d3a-943e-4804-a1dc-fc117f418170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_e77d8d3a-943e-4804-a1dc-fc117f418170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_a576e1de-5dd7-4a7d-bb40-bb03e3c635cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_a576e1de-5dd7-4a7d-bb40-bb03e3c635cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_385dc79d-0c11-476c-91cc-f7cd7d8de722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_385dc79d-0c11-476c-91cc-f7cd7d8de722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_63d306b3-f287-42e7-b8c0-3c99111e91c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_63d306b3-f287-42e7-b8c0-3c99111e91c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b24fd1fc-8636-4900-becf-d1fd31328971" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b24fd1fc-8636-4900-becf-d1fd31328971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6217cff7-1899-4526-acea-3c59f147332d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_6217cff7-1899-4526-acea-3c59f147332d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_3f5015de-ad89-43c2-b1f6-d78151397532" xlink:href="jnj-20230402.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_3f5015de-ad89-43c2-b1f6-d78151397532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate_310e5b34-752f-431e-973b-1a0239695430" xlink:href="jnj-20230402.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_jnj_BusinessAcquisitionDiscountRate_310e5b34-752f-431e-973b-1a0239695430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f1e44afd-5aac-4c61-bcd7-303d52b70035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_f1e44afd-5aac-4c61-bcd7-303d52b70035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_974e7d27-ae47-4af5-ae49-d65b2c05c8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_974e7d27-ae47-4af5-ae49-d65b2c05c8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_87551daa-dbf5-4060-afbd-5aa158807cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_87551daa-dbf5-4060-afbd-5aa158807cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_eb340584-9a72-4adb-a9d1-83495da24804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0a4e9fb2-8d3c-42e0-b4e3-bfee34ccac36" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_eb340584-9a72-4adb-a9d1-83495da24804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BusinessCombinationsandDivestituresScheduleofProFormaResultsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20230402.xsd#LegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_deda7f69-9096-46b3-9dfd-db896260903e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_deda7f69-9096-46b3-9dfd-db896260903e" xlink:to="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_d8d20e39-aeda-4e67-92ef-3c5662d7edde" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:to="loc_srt_LitigationCaseAxis_d8d20e39-aeda-4e67-92ef-3c5662d7edde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_d8d20e39-aeda-4e67-92ef-3c5662d7edde" xlink:to="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_535be347-ec33-44e6-8455-d44a9cc05b0d" xlink:href="jnj-20230402.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:to="loc_jnj_RisperdalMember_535be347-ec33-44e6-8455-d44a9cc05b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_ddca4262-861c-4b55-9e13-1fead72a4b88" xlink:href="jnj-20230402.xsd#jnj_DePuyASRU.S.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:to="loc_jnj_DePuyASRU.S.Member_ddca4262-861c-4b55-9e13-1fead72a4b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_b8075d28-cf64-4226-899b-4abc15e4cff0" xlink:href="jnj-20230402.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:to="loc_jnj_BabyPowderMember_b8075d28-cf64-4226-899b-4abc15e4cff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_9c2bdc28-e585-432b-955e-72497be858d3" xlink:href="jnj-20230402.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_9c2bdc28-e585-432b-955e-72497be858d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_0cb4e0e1-4767-4f7e-b74a-08b9544b4e69" xlink:href="jnj-20230402.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_0cb4e0e1-4767-4f7e-b74a-08b9544b4e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InghamVsJohnsonJohnsonMember_7cc0cf3b-aa16-4c95-abe3-c7c1e41c1b3c" xlink:href="jnj-20230402.xsd#jnj_InghamVsJohnsonJohnsonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_13467a08-ebb2-4871-af9e-2bcee7565461" xlink:to="loc_jnj_InghamVsJohnsonJohnsonMember_7cc0cf3b-aa16-4c95-abe3-c7c1e41c1b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_639af253-8b4f-4656-83cd-9d649928a15b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:to="loc_srt_ProductOrServiceAxis_639af253-8b4f-4656-83cd-9d649928a15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_639af253-8b4f-4656-83cd-9d649928a15b" xlink:to="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_7cb67df2-5437-4a97-bde4-a41ad58d3a46" xlink:href="jnj-20230402.xsd#jnj_AsrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_AsrMember_7cb67df2-5437-4a97-bde4-a41ad58d3a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_e9ca60c7-2bdb-4bf1-b191-183f7049e707" xlink:href="jnj-20230402.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_e9ca60c7-2bdb-4bf1-b191-183f7049e707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_0090a15d-f21f-4e30-a95d-bca35be24061" xlink:href="jnj-20230402.xsd#jnj_PelvicMeshesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_PelvicMeshesMember_0090a15d-f21f-4e30-a95d-bca35be24061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_01539ac2-1c86-4b81-b379-52265e8a94a2" xlink:href="jnj-20230402.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_RisperdalMember_01539ac2-1c86-4b81-b379-52265e8a94a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_ed32730c-815a-4838-8514-998060be4e2d" xlink:href="jnj-20230402.xsd#jnj_TalcMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_TalcMember_ed32730c-815a-4838-8514-998060be4e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_eb3cf4d8-3794-48e9-b741-408dd83be920" xlink:href="jnj-20230402.xsd#jnj_PhysiomeshMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_PhysiomeshMember_eb3cf4d8-3794-48e9-b741-408dd83be920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember_1a6e2fc9-aa25-4c11-ad0d-5fa52387be86" xlink:href="jnj-20230402.xsd#jnj_ElmironMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_ElmironMember_1a6e2fc9-aa25-4c11-ad0d-5fa52387be86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TylenolMember_6d388551-4f76-4e07-bd74-1af4848a3120" xlink:href="jnj-20230402.xsd#jnj_TylenolMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_TylenolMember_6d388551-4f76-4e07-bd74-1af4848a3120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_bb23f788-a934-456c-b7b5-af7910f78a30" xlink:href="jnj-20230402.xsd#jnj_OpioidMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_OpioidMember_bb23f788-a934-456c-b7b5-af7910f78a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EthiconMember_4f79fecb-631a-44dd-9708-ebf941120f2e" xlink:href="jnj-20230402.xsd#jnj_EthiconMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_67534354-93ec-4561-bc1d-c3b6b2fa1eea" xlink:to="loc_jnj_EthiconMember_4f79fecb-631a-44dd-9708-ebf941120f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_726ec1e2-41d0-4475-8922-bf3b8be1b366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:to="loc_us-gaap_LitigationStatusAxis_726ec1e2-41d0-4475-8922-bf3b8be1b366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_a14bccf4-ffab-46e0-bba9-a469b3769eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_726ec1e2-41d0-4475-8922-bf3b8be1b366" xlink:to="loc_us-gaap_LitigationStatusDomain_a14bccf4-ffab-46e0-bba9-a469b3769eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_f055f97a-cf7b-4e46-81df-25ab76908245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a14bccf4-ffab-46e0-bba9-a469b3769eb8" xlink:to="loc_us-gaap_SettledLitigationMember_f055f97a-cf7b-4e46-81df-25ab76908245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_8fc26329-5567-4361-a685-454fad35b345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a14bccf4-ffab-46e0-bba9-a469b3769eb8" xlink:to="loc_us-gaap_PendingLitigationMember_8fc26329-5567-4361-a685-454fad35b345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_d6390c07-042c-45b6-8c00-73055922820b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_JudicialRulingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_a14bccf4-ffab-46e0-bba9-a469b3769eb8" xlink:to="loc_us-gaap_JudicialRulingMember_d6390c07-042c-45b6-8c00-73055922820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8d4bd25e-5c60-4bc0-b73f-66eea85c6391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8d4bd25e-5c60-4bc0-b73f-66eea85c6391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_085d3c92-1d26-4e92-9aa4-8c04ef14fb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8d4bd25e-5c60-4bc0-b73f-66eea85c6391" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_085d3c92-1d26-4e92-9aa4-8c04ef14fb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f3da91d5-5dea-4ab9-8feb-542ce4987637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_085d3c92-1d26-4e92-9aa4-8c04ef14fb6d" xlink:to="loc_us-gaap_SubsequentEventMember_f3da91d5-5dea-4ab9-8feb-542ce4987637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_41e800f9-6418-4ad0-9dba-83f885953a4f" xlink:to="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:href="jnj-20230402.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_c3d54d41-4601-4c8e-8c7c-fa23d4c94655" xlink:href="jnj-20230402.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_c3d54d41-4601-4c8e-8c7c-fa23d4c94655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_00997c2f-1681-4ce8-9030-84a967ba3cd8" xlink:href="jnj-20230402.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_jnj_Numberofpatientsinsettlement_00997c2f-1681-4ce8-9030-84a967ba3cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_11e6d58d-dc24-4c3b-8306-f51c104cf65a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_11e6d58d-dc24-4c3b-8306-f51c104cf65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_b788e29b-87db-46d6-b9df-fc2e15f8bbbd" xlink:href="jnj-20230402.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_b788e29b-87db-46d6-b9df-fc2e15f8bbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_78174d00-07c8-44ed-a54c-3f1124ed8c76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_78174d00-07c8-44ed-a54c-3f1124ed8c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_fb68776f-8f44-47d2-a40a-972748a5e1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_fb68776f-8f44-47d2-a40a-972748a5e1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_cdd39131-3378-46d2-a948-e93248cc89f1" xlink:href="jnj-20230402.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_cdd39131-3378-46d2-a948-e93248cc89f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPendingClaimsNumberRemaining_95d8264a-224c-4517-8a04-602074afd435" xlink:href="jnj-20230402.xsd#jnj_LossContingencyPendingClaimsNumberRemaining"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_jnj_LossContingencyPendingClaimsNumberRemaining_95d8264a-224c-4517-8a04-602074afd435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPendingClaimsNumberAdditional_fcfc8607-e11b-45dd-bba9-1bcc93436b11" xlink:href="jnj-20230402.xsd#jnj_LossContingencyPendingClaimsNumberAdditional"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_d1d7fe88-e3d7-4073-b4b5-67a91030b614" xlink:to="loc_jnj_LossContingencyPendingClaimsNumberAdditional_fcfc8607-e11b-45dd-bba9-1bcc93436b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4bdbf48d-d7e2-461a-8fa5-582b04fffe62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_4bdbf48d-d7e2-461a-8fa5-582b04fffe62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyReceivableProceeds_a55ff98a-0ee3-4816-85a9-c5b5083aeea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyReceivableProceeds"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_us-gaap_LossContingencyReceivableProceeds_a55ff98a-0ee3-4816-85a9-c5b5083aeea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesPaidValue_d3cab608-069d-4a65-90f3-0a5e361b5a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesPaidValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_us-gaap_LossContingencyDamagesPaidValue_d3cab608-069d-4a65-90f3-0a5e361b5a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyAdditionalContribution_8b58213a-3c39-4a98-9733-ba1ddddda610" xlink:href="jnj-20230402.xsd#jnj_LossContingencyAdditionalContribution"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_LossContingencyAdditionalContribution_8b58213a-3c39-4a98-9733-ba1ddddda610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrustTotal_6e06d040-2511-49bc-b0a4-716181c56538" xlink:href="jnj-20230402.xsd#jnj_LossContingencyReserveEstablishedWithinTrustTotal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrustTotal_6e06d040-2511-49bc-b0a4-716181c56538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue_f0c767ed-53ad-4597-9df7-63685fbb40b7" xlink:href="jnj-20230402.xsd#jnj_LossContingencyReserveEstablishedWithinTrustNominalValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue_f0c767ed-53ad-4597-9df7-63685fbb40b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BankruptcyLossContingencyDiscountRate_2b6450e0-45c7-4226-a40a-4592ac401432" xlink:href="jnj-20230402.xsd#jnj_BankruptcyLossContingencyDiscountRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_BankruptcyLossContingencyDiscountRate_2b6450e0-45c7-4226-a40a-4592ac401432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyTerm_b77746ef-29a7-452b-a42f-bf0be5de6f1e" xlink:href="jnj-20230402.xsd#jnj_LossContingencyTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_LossContingencyTerm_b77746ef-29a7-452b-a42f-bf0be5de6f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualPayments_c70b0eef-1ba5-4227-86f9-bb33d58e7ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualPayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_us-gaap_LossContingencyAccrualPayments_c70b0eef-1ba5-4227-86f9-bb33d58e7ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyRemainingTerm_c8d269ec-5c30-4053-aadd-0ec5d8c1a435" xlink:href="jnj-20230402.xsd#jnj_LossContingencyRemainingTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b1ba02cf-7b88-4507-9509-8fb154f99476" xlink:to="loc_jnj_LossContingencyRemainingTerm_c8d269ec-5c30-4053-aadd-0ec5d8c1a435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $S!"P# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %)D[L8X]:6CZ5,IJ"NP"F33QPE0[@%VPH)ZFHKB_ALV*
MSL1A"V0,_P J_,G_ (+5_P#!:KQK^S-XID_8G_8Q\)ZCK'QJU464FD:A:6=O
M?6EHSS1LT,D)?<)&BWXW*%!YR"!77EN78O-*BI0T;Z]EW'LKGV+^V]_P4!^
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M%)_$7_!<S1?V6_B%^TS')X<T[18_$/B3PYHFA0FRDMW5D^R-(59T99.K;AG
MQWS^Q$:JB@G/3K7YK?\ ! ?]BL>'/AY?_M[?&GP19Q?$_P")5_--;WMQIV+O
M3]%8ATMMS@%2[G>Y7A@L?7''Z4LZJ &%>MQCC,*LPC"G3C35-*,N5:.2W?WA
M9I6[CZ***^:W)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH *Y?XH>*/#'PQ\(:I\3O%^IQ6>F:/837-[<R$ 1(%RS9_P"
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M/3@<=JW%AB20RJF&(P36&<YK/-LTG4EI%?"NR6PE"PZBBBO.+"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D#K3)[F.W4-(&Y( V
MJ3R?I1N[#LQTS,L9*$ ^K#BL;Q-XQTCPEHMUKOB;4[73[6UC=Y+JYE 147)+
M$]J\Z_;&_;2^"?[%'P/U+XS_ !R\41Z1;6L16QLW(:XO[D\)! BY,KL<<+G
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MVE9)+OK^B$_AU/K&BBBO.,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***BFN5B8)MRS-A5W $_3/7CG\*(^\] M<2_94M'9@2 .0!R>:_&+_@K?\3_
M !3_ ,%5O^"@GAG_ ((Y? 'QD1X4TBZCU7XK:Q9Q_.LJ$2F L/W>(H?+"C;G
M>&#9QBOTR_X*&_M4Z5^R'^QC\0/VA)X;R>3P_P"'YY;&.P53(\Y*QH4+$*2&
M<-@G)"MC.*^+_P#@VM_91O/"G[+U[^V7\3&>?X@_&O6K[7M9N[ZSVSPVYNI
MB@L,^7)(KW"]OW]?49'1C@\)4S6:^!\L;_S-7_!:C23=C]$?A/\ !KP-\'O
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M[ W[+4/B[QYI=]_PLWX@Q1:CX[NM1NA(T;*TC16L8 "K&HD9^F[=*V6("@?
M_P#P1]^!?B[_ (+ ?\%)?$7_  5%_:$N)&\/>!M=ED\,^%+Q3<PM,VY88E>3
MY1';9\Q6!W;XDXZD?O7 C&S2.)50>@Z8K['B&=/AJA#(J7\2RG.W=I:>BT,J
M>KYUMT'V\4,>]HSEF;+MCJ?_ -6!4E-CC6-=J_C3J^,45S<Q844450!1110
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M^:W4?+LR?]TG\:]452,LQY/:M\7RTFJ<>A<]$+1117(8A1110 4444 %%%%
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M0!^I%/R!U-17;1"$F< QCER3TQR#^>*T;5Q"7$L4EO(BOR 1@=<CTS7X:?\
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M(@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO7E9E6RCF]C@FWR[M[OY=$-[:EFBBBO))"BBB@ HHHH **** "BBB@ HHHH
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M"3DXKSS]HS]I3X??LS_ GQ+^T)\1[J:#0/#&ASZE>RPQ%W=(E9BB*H)=CC@
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M"Y'3-%)\I(.?I1N7^\/SK)3E%OG0"T445JFFKH HHHH **** "BBB@ HHHH
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MU*D[NXNAZ-IVBPR0:;81PH[AF=  9C@?,WJ>W/I5Z@  Y ZT5;=Q!1114O0
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M- OX+?Q%JL(TKPPK.P=KRZ81F1 .IC@:6;ZQBOEK_@V+_P"":]Q\*OA->_\
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MU^2?_!:S]H[Q]^UW^TAX,_X(X_L_D+=^+M0L[OXB:F [MIUCN4BW:)&!1#&
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M4=M;V\NGX&5&,H.UA(B3G/K3Z15VBEKD>K-Y--A1112$%%%% !1110 4444
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M+B.%%4>86 VND:?+@D'.:_HP^!/PPMOA!\/M+\#IJ,VH2V5FL<]_/&!)<.
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M6[(C_=21N4&UHB4*;2#G-?O1X0T30?"VD6WA'PO91VECI5JEO!91)M6)0!M
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M_@H')X=TS1OA]\,+^]U#PWX<U&$+_9;R%G2>4@>4%B@\U@<_*P5AC&1^G_\
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MC+!$J]78N>5 S@=QDCHP>&EB:ZI1U;=OO&E<_-;_ (*:VUE_P5Q_X*U?#_\
MX)O:+X:EU#P7\'KL>(/B/K9EG9726))9K19(LJK-%MB7)!$BL.,5^M.@Q:5X
M:\%6\6B1V\%I86Z1VD=O)MB6-5P"?]C'('7CCG%?F/\ \&QW[,?BS_A3'CO]
MOCX_Z&D/C?XR^+;N^M]20NCK9+(>/+;E%-R)V3!(*,I!P:]D_P""MG_!6FP_
M8\T_3OV6_P!F_P ":GXS^-GCRS%IX)\+:/&F+"5V5%DN&W'9LW;PI&&VX9D!
M+K[^<4JU>4<J?PT=--K[MOY@NYQG_!7;_@KY\0?@5XXT+_@G_P#L2:1<:O\
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MK_X*A?';3VO?#NDPS:'\%(M:P\\5M%(Z%H^,*@'!/)WA_8U^TL,SQJRPQJV
MH0ANI/7'L*^KXLSNK6I4<K6BHK7Y?Y?JQQ=W<XC]JCXL:'\"?V>O&?Q?\2>)
M;32+70/#US<_VC?L!##($(B+9XP9"@_&OR/_ .#63X':EX^\4?%O_@H5\3.?
M$.O^*+K3X9VTCRH"7;[5=7<$FT AVG>,D'&4([5]._\ !SM\8_$'PD_X)<Z_
MIVB12W*^-/$>G^'K^".0*4@D2>=V!/O;K7M?_!'G]GGP/^SU_P $[OA/X.\(
M02&#4/"=IK<MQ,07>2_07S*Q[X-P5^@K;!5?[.X Q2B[/&24+_W8J[_%I,Y:
M7^\ZGU7U3KGBJ\TQMDD=B&*X9 >Q/%6!@C ]*\4_;H_:C\.?L8?LT^-?VD/%
MHE^Q>&-,-PEM^[+WDS'9'%&&=<G>RG'H&/-?"X7"2Q&-C2COHOT.E+4_-3_@
MX>^-GB3]L_\ :)^'7_!(?]GU;S4M3\0ZE;W?CV733OCM8=X,0DQT,?\ K3G@
M*XK]3?V2_@%X6_9:_9\\*_L^>#(&33O">AVVGP%A]\(@7.?PK\J?^#=']F#7
M?VI?C)X\_P""O'[0E_JTOBKQ+XEO[+0X[Q1Y0MW0(_DLI.8TYMP?2$?6OV8M
M8D!"DMNC380W<>M?5\4U/JF%IY5'3V7Q><GO]P_-DZ]!2T45\I!<L$B0KS?]
MKK5ET?\ 9C\?:A'#YS1>$=2 C7KDVL@_K7I%>"?\%*/B1H_P@_8<^*7C[7-:
MBTJWM/"EVOVMXB_S2)Y8/'KN KIPR7MXWVN3)V1^>?\ P9LZ-K%A^P1\1==U
M'29+:QU?XG-+8M(O$R1Z99PLX]O,C<?4&O5?^#E;_@H9>?LI_L0/\&_A[?Y\
M9_%)CI$,<#(TEKI[J3<R%&/(>,- , G=,M2?\&OFD?\ "._\$@O"6M7&I8@O
M]2UBYMY2N 0M[.K-CN,J>*^'?"-EJ7_!=+_@NQ=_$ :Q,?A7\)+M=2TZ6,[X
MY+"PF7R#$I "R7%P("Z-_"7ZXQ7V608"EB,WJ9G5C>G07/+_ -M7S?Y&3@YQ
MY5U/T3_X( ?\$[X?V#OV,]%?Q)8+#XT\<11:SXINV:+SEBVG[+8ED)+11K)(
MX'0-.W<FOOEL,I<'&!S6-I=NMA:&UTFT")'"C6T<K;%P>J< XP /SKX$_P""
MQO\ P7!^'?[ '@?7? ?PJ\3Z7JWQ<L#;,O@Z_:53%;RMGS&*HRD["'QN!V%>
M_%>#]5S/B;.V\/'FE)W=OZV12E'#Z'3G_@JGX2\+?\%8W_X)N:EX?U;7K_Q'
M$MYI>JZ;;6L=CHJQV4MS,ERS$/N+1[NA^90.]?=6F.TEC&[@@D=VSGWS7Y"?
M\&XW["'Q+TZUUW_@IM^US;7]_P#$#X@M(WA^74R3)%9SN&>:12,JTA*[?[J%
M@17ZD?$?XY_"WX1*DWQ-^*6@^';:9 T<NL:K';'=T.P2%?,4<9"Y(R..:.(,
M'A,#C_88=W:LF^\NIMTN=T!BBN;^'_Q0^'WQ,TK_ (2+X>^.M,\16F &N=%U
M"*XBSZ@QL1^&>.E;\+(KB)9&?<I<%CT&>E>-*,HNTMQ$M(% Z4R\E$-L\ID*
M8'W@F['X=ZA#R6T8-S.Q3RANF([_ $K&4ZBGRQ0%JBOGG]H[_@J?_P $_P#]
MDB:VMOCY^U=X2T0WEPUM;A+YKV5;A028Y([59&C/!^\!TQ7HO[/'[2GP?_:I
M^%]C\:/@%\0;+Q1X>U97^P:C8*PC!0X(8. RG/9E!]JV=*K&//):,#T&BHK-
MKAK9&N]GFE<N(SP#[5+4@%%([%4+#' S\QXK&\6^*]#\(>&;KQ3K^M+8V-I;
MM<WFHW$BB&UB49,CDD80 $T6OH!JRA<;7..:RM1U$:;.US+,!$"=A +'<!E@
MQZ(H 'IWKP_]D+_@H?\ LR_MU^$O$/Q"_9S^+\.L:-X5UA]/U:X:S>(0%=Q2
M9S)M/ERHK%2!D9!(&,5^8?\ P6"_X*\^*/VZ?$ME_P $SO\ @F7<S>(M5\7Z
MR++6O$.G7#PG$999+=&*@J@/S/(< !%"[RQQ[&3\.YIFV,G14+4Z:O)]$EW,
MFTC];O@?^UO^SK^T;XG\0>%?@M\5-$U[4?#-T8?$=G978EELR&*E9,=#N! [
M8Q7IUN^;EWCBD"\JVYN,@XX%?(G_  2"_P""3WP0_P"":WP=GD\-6TVH>._%
MEG;'Q[X@NKXSBXNHXU62* X!6W$BNRAOF.XDX)VCZUUM_P"S[)[N B/8&=V8
MX7H3\S?PKG&3@\5Y^8PHNLZ>%=XIV3-5JD7_ +R\4*-HQ7Y1?MM_\'2_[-G[
M,7QSD^"'PQ^'^M>,9-)\06]AXK\18$.FV".#YOE.-S3.N!A2J @L=W%?IS\,
MOB9X:^+7@3P_\1_!EZ9M+\0Z+;ZK8NZ[6>">,21G'8X89%15RS%851JUE:ZT
M"]T=+1117+%\U1L J.XB$JC)Q@YIMW<0VYC>69U)8A=JD@_7%<Q\0_B/X7^&
M?A"Y\;>-O%EKINB6:K+-J=[<K%&D?=G9B,#.!W)SC'-=$(5:DU&FKR>PGL:'
MC?Q+I/@WPMJ'B?6[[[/;6%H]Q<3DG$:(-S-QSP 37YI_!7_@JU^T+^W'_P %
M;8_@M^QCXS\/W7P-\%Z#;3>/=3N!#,FHB2,3O/!*FZ2.4&0P@#";HN3UKR7_
M (*!_ML_%7_@H/\ !SXE_$KX<?$2\T']F?X>V,UMKTOA\-#KGCB]#*@AM@X"
MK9AY(]S[B21PM?0__!NU_P $Z? O[(G['&E?%G6?#=J/&GQ!L5O]5OTC(DAM
M'D:6WM&)^]L# G@<DU]E#(<!D?#U7&XIKVK:2CV;5[OSMKY>IG=MJQ^C:_=!
MSGBEH^E%?%7N:D;M^^">U1SL25$*$ON.WDX!QW]J6Z,JOB&1 [1GR@W=AZ^U
M?.W[?G_!23]F;_@GY\-5\9_&_P =QV5_J,,IT#0P";G49E4L(T SL#8V[FP
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M0'B36M,6;3=&F70--OKD1_;=2*'R;<'J6=\+QZU\0?\ !#/]A7Q;J&K^*/\
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M@W_!6G_@HK>)XC^(?C.U%[X*\-WT(:W\/:<Q/D%(NBL8]I .2#R<L2Q^9_\
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M,[ZIXDU>!RGB/5BVZ HY. -IC8Q#Y44A0 !7MO\ P5Z\267B;XI?#7_@A/\
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MHHH *#P,T44 4%U>1H9Y$02-$,A8AN.#]WBOQ&_X*NZKXD_X*_\ _!8/P/\
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M(V2Y &.IK]#HM^'F&ABX-3K5T^22=U&SL[=S.5.,])+0\#_X)I_\$>?V;O\
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M(^&?%_P?\7W^@^,?!MS.^G7^FX\R2VF4).J\9\U5&Z(YP'.2#TKPCX\>'?\
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MU[I7A_6/"&FF#P'XQU"Y^SQ:_IB2ND#(S#:"(U4$LPY&.U?J)J$GE6<CC?\
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M#)\/.,N3>WVI/^9>2V\B$[ZGV1;2P0QF(-A0WRL3][//]:G9U3EC7P;\-_\
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M&W_!)O\ X)P.^N^.OB);3W?CJ[LI8Y9+4WL+R75JY$?$$<9D#,>0!UK]R/\
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MF,JWZ]?\$T?^":WP@_X)6?L\W>@:+J\.HZC,/M_B_P 57-H ]W,HRS*G)15
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MM.  Z"BG&52VJ07&() WS'BGT455V]Q/4**** "BBB@ HHHH **** "BBB@
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MX52C)]!\K-ZBLWPQXC7Q)H$6O?V?+:K,,B&?&X?E6E4B"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLOV:K_Q9\7[J\U&&V;3/AQX;EDGMP^6$LIO?L\:Q$#!.XGYAQ6%X"_X-YO\
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M,AC[Y_7ZU9J&R5$MAL;()+#\23_6I$D+,1BOS36M/VB>@M7J.HHHJQ!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $S!"P# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]^**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI&!
M92H;!(X/I5>SE,[<^>I@.QP^ '_VJ +-%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,N
MX8]Z6H[D.0K1L00<X#XS[=#1=K8"0#' I&4-4231HV9)3N;^#=D#]*E5U;H:
MS4:T9<S'JA:***T$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %)D[L8X]:6CZ5,IJ"NP"F33QPE0[@%VPH)ZFHKB_ALV*
MSL1A"V0,_P J_,G_ (+5_P#!:KQK^S-XID_8G_8Q\)ZCK'QJU464FD:A:6=O
M?6EHSS1LT,D)?<)&BWXW*%!YR"!77EN78O-*BI0T;Z]EW'LKGV+^V]_P4!^
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M%)_$7_!<S1?V6_B%^TS')X<T[18_$/B3PYHFA0FRDMW5D^R-(59T99.K;AG
MQWS^Q$:JB@G/3K7YK?\ ! ?]BL>'/AY?_M[?&GP19Q?$_P")5_--;WMQIV+O
M3]%8ATMMS@%2[G>Y7A@L?7''Z4LZJ &%>MQCC,*LPC"G3C35-*,N5:.2W?WA
M9I6[CZ***^:W)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH *Y?XH>*/#'PQ\(:I\3O%^IQ6>F:/837-[<R$ 1(%RS9_P"
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M/3@<=JW%AB20RJF&(P36&<YK/-LTG4EI%?"NR6PE"PZBBBO.+"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D#K3)[F.W4-(&Y( V
MJ3R?I1N[#LQTS,L9*$ ^K#BL;Q-XQTCPEHMUKOB;4[73[6UC=Y+JYE 147)+
M$]J\Z_;&_;2^"?[%'P/U+XS_ !R\41Z1;6L16QLW(:XO[D\)! BY,KL<<+G
MY-?#?[,?PG_X*"_\%/?CG:_M3?M>V4WP_P#@L^G26VA_"EKIA/J\$N3'<W"#
MY5#*P)!.?:O0P>"C4O5JOEBNO?T-(*SU/;+C_@I'XS_:C^(5Y\%OV"O!#ZC:
M/:%KOXNZI;23Z)I_JH5"I=^RX?&>QKK/@C_P2[^'_ASXC3_'3]H7XC:_\4/&
M-Y\XN?$-YBPL=P'F1V]M$$0Q-A?EE#XV\'DY^A?A]\+O"_PH\.0>$OA[HECI
M.D64 BT_2;"T6&"W4>@05T4$8AA$>YFP.K')-88G,*-&;A0T_-_,IR70PH/#
M6C^%-.MM'T'2X[2U@8&&WLK9%544Y\I(E "@#CY0/SYKX$_X)H>"OA[=_P#!
M8_\ :X^)_@>UGG>VNK;2-1U"W5(+:.Y,BR36[11*JO*KQ_ZU@7(4[F.2:^]O
MB=XPT_P#X2U/QIKM]Y&G:7I[7%Y,(F8PQKDO(-@+$A>P':OG7_@DQ\ _$GPJ
M^$GB#XH^-KS2;O7/B9XENO$>IZAI,$RB\\Z1FBE<SHDF[:_<=ZZ,,XRP-2=5
MVE9)+OK^B$_AU/K&BBBO.,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***BFN5B8)MRS-A5W $_3/7CG\*(^\] M<2_94M'9@2 .0!R>:_&+_@K?\3_
M !3_ ,%5O^"@GAG_ ((Y? 'QD1X4TBZCU7XK:Q9Q_.LJ$2F L/W>(H?+"C;G
M>&#9QBOTR_X*&_M4Z5^R'^QC\0/VA)X;R>3P_P"'YY;&.P53(\Y*QH4+$*2&
M<-@G)"MC.*^+_P#@VM_91O/"G[+U[^V7\3&>?X@_&O6K[7M9N[ZSVSPVYNI
MB@L,^7)(KW"]OW]?49'1C@\)4S6:^!\L;_S-7_!:C23=C]$?A/\ !KP-\'O
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M[ W[+4/B[QYI=]_PLWX@Q1:CX[NM1NA(T;*TC16L8 "K&HD9^F[=*V6("@?
M_P#P1]^!?B[_ (+ ?\%)?$7_  5%_:$N)&\/>!M=ED\,^%+Q3<PM,VY88E>3
MY1';9\Q6!W;XDXZD?O7 C&S2.)50>@Z8K['B&=/AJA#(J7\2RG.W=I:>BT,J
M>KYUMT'V\4,>]HSEF;+MCJ?_ -6!4E-CC6-=J_C3J^,45S<Q844450!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%%%F 4444; %%5K_5+33QB5P7X)C4Y8 G 8CLN>YXHL-2BOWD
M5$*[&(&6!SCZ=/H::BY1YEL%F6:***0!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444$@=30!%<75O;L!-*
M%)Z UY-^UW^U_P#!C]CWX3:A\4_C!XB>WM[9?+LM.M8R]SJ%PPQ'!$@!+,S8
M'H,\UUOQR^)?A7X1?#W4OB)XON56TTFT>X,2INDE(!PJJ.7)Q@*.M?)O[,W[
M/OC+]KSXI1_MF?M;^&[_ .SQ[W^'_@75 'MM(AW;EFP !-.<#]XV5;)**HXK
MT\#AJ,DZM5VBOO?DC>"5CS/]C[]D[XV?\%!_C.G[??\ P47\'W%MI.GWW_%I
M/A%>@-#I5MU6_G7.'G<$  X  -?HY;:/'IRQ!;56$491!#\HB0?<55Z=,"ET
MJQ2VEC:"'(,1$KR#:RX^Z-HX Z]JTJY\5C?;U7R:16ENQ$VKZ"$@#)J-[F%)
M!$7 8Y(J6O&/BI^VK\"OAK\9X/V=M3\96'_"87^E/?V>BL^7E0''8\<UA2H+
M$U/=5VA02;,[]H_4+#XXZO8? #P1\2%TZ_DO$FU=H(3)_HZD%H7! !#C(Z]Z
M]H\/V TNTCTZ"V$4,$01%$80 #H% /  KSKX >%;2^6Y^*5WHUNE[K$[2!8T
M^:W4?+LR?]TG\:]452,LQY/:M\7RTFJ<>A<]$+1117(8A1110 4444 %%%%
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M0!^I%/R!U-17;1"$F< QCER3TQR#^>*T;5Q"7$L4EO(BOR 1@=<CTS7X:?\
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M(@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO7E9E6RCF]C@FWR[M[OY=$-[:EFBBBO))"BBB@ HHHH **** "BBB@ HHHH
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M"3DXKSS]HS]I3X??LS_ GQ+^T)\1[J:#0/#&ASZE>RPQ%W=(E9BB*H)=CC@
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M"Y'3-%)\I(.?I1N7^\/SK)3E%OG0"T445JFFKH HHHH **** "BBB@ HHHH
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MU*D[NXNAZ-IVBPR0:;81PH[AF=  9C@?,WJ>W/I5Z@  Y ZT5;=Q!1114O0
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M- OX+?Q%JL(TKPPK.P=KRZ81F1 .IC@:6;ZQBOEK_@V+_P"":]Q\*OA->_\
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MU^2?_!:S]H[Q]^UW^TAX,_X(X_L_D+=^+M0L[OXB:F [MIUCN4BW:)&!1#&
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M4=M;V\NGX&5&,H.UA(B3G/K3Z15VBEKD>K-Y--A1112$%%%% !1110 4444
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M+B.%%4>86 VND:?+@D'.:_HP^!/PPMOA!\/M+\#IJ,VH2V5FL<]_/&!)<.
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M6[(C_=21N4&UHB4*;2#G-?O1X0T30?"VD6WA'PO91VECI5JEO!91)M6)0!M
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M_@H')X=TS1OA]\,+^]U#PWX<U&$+_9;R%G2>4@>4%B@\U@<_*P5AC&1^G_\
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MC+!$J]78N>5 S@=QDCHP>&EB:ZI1U;=OO&E<_-;_ (*:VUE_P5Q_X*U?#_\
MX)O:+X:EU#P7\'KL>(/B/K9EG9726))9K19(LJK-%MB7)!$BL.,5^M.@Q:5X
M:\%6\6B1V\%I86Z1VD=O)MB6-5P"?]C'('7CCG%?F/\ \&QW[,?BS_A3'CO]
MOCX_Z&D/C?XR^+;N^M]20NCK9+(>/+;E%-R)V3!(*,I!P:]D_P""MG_!6FP_
M8\T_3OV6_P!F_P ":GXS^-GCRS%IX)\+:/&F+"5V5%DN&W'9LW;PI&&VX9D!
M+K[^<4JU>4<J?PT=--K[MOY@NYQG_!7;_@KY\0?@5XXT+_@G_P#L2:1<:O\
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MK_X*A?';3VO?#NDPS:'\%(M:P\\5M%(Z%H^,*@'!/)WA_8U^TL,SQJRPQJV
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M?.W[?G_!23]F;_@GY\-5\9_&_P =QV5_J,,IT#0P";G49E4L(T SL#8V[FP
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M0'B36M,6;3=&F70--OKD1_;=2*'R;<'J6=\+QZU\0?\ !#/]A7Q;J&K^*/\
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M@W_!6G_@HK>)XC^(?C.U%[X*\-WT(:W\/:<Q/D%(NBL8]I .2#R<L2Q^9_\
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M,[ZIXDU>!RGB/5BVZ HY. -IC8Q#Y44A0 !7MO\ P5Z\267B;XI?#7_@A/\
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MHHH *#P,T44 4%U>1H9Y$02-$,A8AN.#]WBOQ&_X*NZKXD_X*_\ _!8/P/\
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M(V2Y &.IK]#HM^'F&ABX-3K5T^22=U&SL[=S.5.,])+0\#_X)I_\$>?V;O\
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M(^&?%_P?\7W^@^,?!MS.^G7^FX\R2VF4).J\9\U5&Z(YP'.2#TKPCX\>'?\
M@N5^UMXI\+_!WX7:W8_!+P=+ ?\ A-?&7E13:G/'Y+(]O$DR,"CDALIL=2 P
M; (/V.+HX?.,LPLX5(QE2IN$DW;[3::[W3*W/M_XH?M&^'?^$D/P:^%.MV&L
M>.+@%7L[9Q,NGK_?GP<*/]G.[VKF?AG^P7\*?A=XKU+XS:EX:L]8\;ZZLD^N
M>(;L9D68IC;%D';&  @&1\J@]>*L?L:?L8_#C]D;PY8^%_#-E+J6JR6S-K'B
MG4Y_-O-1G&-TCLX+L"2>2W'05[[+$LJE' ((P01P:\+VM++J<:&#FVDK-]6_
MT7E]X7LT?G5_P1X^(/[*7[)?["$D'B+XEZ/X<M-'UO5'U9-;UN"2XF>.X)^T
M!4.Z4%0S*J@L>@!-=/J__!6>+XY_$F+X,?\ !/GX-^(/B+JTUI'/)XJU;1+C
M2-!L8BY#2>?.GFRR '(018/]ZOH+5/V _P!DC5O$$OB+4_V=O"DMV\T,J)_8
MT1@A:(@J4AV[%W8YXKTSPWX6T/PY9+INA:5!%;Q'Y6MPD6W'1 J*  /2NS%9
MEE]2O+%5KSJ2_F>G3MJ_O07.'\#?!+POI6J_\+&\86R7_BC4[6,:SJLRDK(4
M0 PQ*QVH@8$<\GKWKP/_ (+'?\% O!G_  3A_8P\2^+=(\36$7C[4[5K'P+H
M,;&"6[NYOW?GHJA_EMT9YR2 I,(7(+ 5],?&OXB^#?A!X+U;XI?%/Q=8:1X7
MT6PEOM6U*]E$<-E%$FYVD8Y&S ZX!'/-?R^?\%./V@/C/_P5$_:X3XX>&+K;
MX5U[Q?\ \(O\'-/G@>.66":7RQ(J.S'+<-*0=JO@  &OH.!N'X<2YK&>+DX4
M(^])JVW1:Z:_D9R=HW6Y^@'_  :Z_LM_$GXS_$[QQ_P5)^.WB/6=6US7I;C1
M["ZU,8^W-((7N;ELC.X>7 J$<8W\U^UIL;BW0&,2(JQ^7$D1!V_[1SCFO)?V
M /V=-%_9%_9.\$?LZZ,;A8_#>BPV]P]TJ[IKAP9)&) &X[F8?117MQ&1BOF>
M(\PAF6?5*D/@CI'T6BO\M0Y$M&,\U40,YQD54GOH4NO-N7$:1(P9F.!@XP<_
M@?RJTZ[8\N V.E?DU_P<!_\ !5OQ!\*],_X8=_9-\5:@?C!XCU"!9!H$*SM9
M6;+(H@8$'9+*S'!QP(_>N7)LIQ>;YG[.+2AW[+JWZ&GNI79\M?\ !5>^^*7[
M6_\ P6KNOB5X.T,WW@+]G==$B\2:O!;-<""!MEVQ1$!+MNF<8 (&,G YK]S?
M@1\8OA;\8O!-EXL^%_BBQO\ 39( N+6=':)\9*OL)"D8/&:^:_\ @D=_P3[L
M/V.OV1[32O&L6I:KXO\ 'D5MK/Q#N?$C"6]-Y+;QB2VE9A]R-0(]F!@+ZG-<
M+#^P]\1_^"<?Q4UWX]?LARZQK/@V:]FFUKX8VR^89(9Y-[)"#G#*^UE;J$5A
MSFOKLXQ>"S?#QRQ5;QPZY:;Z-:7OV;>QFJ45)R?4_0AKFW^202<,,K@$YIT=
M[:ROY:2\^A4CL#_(BOGOX8_\%&/V8_&^GE/%7C&W\,ZU9 ?;] U5S%<6(8?=
MDSC)S7=^'_VH?V;O&,G_ !(?BKHEVQYQ'J8S]XQ],_[-?%SP6)I-QE%Z;%O4
M]-,D8&[S%QZ@TM<EI_QG^%&HV4-]IGC32Y8;A@L6R96R3]#73VM[:W4:M#=Q
M29&?W;"N>4*D'[R))J"0.M%(Q4$ GDGBHES6]W<!#*BYRW3KQ4-SJEC:PR3S
MS;4C8*[;3@$CZ4ZX=((7E]L]:_.C_@X/_P""GT_["'[+D_@#X5^(HK?XC^-[
M8V^CVX<,]A;OE9;G'JOS8SQD5W91EV+SK.*>#PZWW?;_ (9:C]U*[/S)_P""
MPW_!67PE^U7_ ,%$-(T3^V+S7?@W\+_$'G:)H&GV,:MJ6L6VX)<JY<_NY9@J
M"1@-L,DAV,V%/W%_P2A_X):_'KX]_&BU_P""FG_!1N!9=>N8BO@CP!>HLUOI
M%EPUO*,':CH&.S .?,<G' KSS_@@;_P1!\+ZEX,T;]M7]KSX;V-W>ZSI$5SX
M,\-W2LR1I)AAJ-TCYWS%3_JV_=#<<)D C]JM%L[?3]*@L;2!8HH8@D<:*%"J
M!@  < 8'05^B\89]E>"P4,HRE>Y3T<^K?75=WNS-4[^]+J)H\,UM;FWEB*!"
M @//&/7O^G/YU;HH) ZFORYOFES-:EC+AD6!FDV[0.=QP*\G_:^_:M^$W[%7
MP!U[]HSXP:RMKH7A^T\T00./,N)B,K&H.-S,< #WKTWQ)>06.AW5W<7*1)%$
M7DDD8!44<DDG@#%?A-_P4<^)7Q"_X+]_MW6/_!-?]F+6XM+^'_PVN)+W7_'E
MH[WL.H7"@>>SQHRJ8X]IAB0Y?S8G._D =^"P57$\U5K]W#=]O^''LKGF?[/?
MPX^)?_!9[XZ?%7_@L%^U/X<N=(\$?"O3_P"VO"7AFQNY%:8Z?$US;Q([Q[94
M"0X<@*)&QT!R/KW_ (-2OAC9:M\%/BQ^UM>O,+SXC>/Y(&R $B@LE,D8!S_T
M^D8_V*^U/V@_@G\./V9O^"9?Q(^!WP6\,6>E:%H/P>UFSCMX(]K11+I4XWN>
MKM@=3SS7SC_P:V6#:3_P2YTG3Y_#=[IT5UXMU*<?;3E+P&.V EC/93MP!Z@U
M]A+-,7B>$ZT()>S4HQ7>VK_-$RI1DD?I1:.&9L'[IPW%2S1K/&8F&0RD'\J9
M9OOBR8RGHC=@.*D5U8D+VK\TP\E"DHRW=RE[NQXY^W1^RMX1_;+_ &6?%/[.
M7C5YH+/Q%I_D)>6Z!I+652&CD7/HP_(FOAK_ ()B?MW?$K]E;XHR?\$N?^"A
MU[I7A_6/"&FF#P'XQU"Y^SQ:_IB2ND#(S#:"(U4$LPY&.U?J)J$GE6<CC?\
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M#)\/.,N3>WVI/^9>2V\B$[ZGV1;2P0QF(-A0WRL3][//]:G9U3EC7P;\-_\
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M&W_!)O\ X)P.^N^.OB);3W?CJ[LI8Y9+4WL+R75JY$?$$<9D#,>0!UK]R/\
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MF,JWZ]?\$T?^":WP@_X)6?L\W>@:+J\.HZC,/M_B_P 57-H ]W,HRS*G)15
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MM.  Z"BG&52VJ07&() WS'BGT455V]Q/4**** "BBB@ HHHH **** "BBB@
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MX52C)]!\K-ZBLWPQXC7Q)H$6O?V?+:K,,B&?&X?E6E4B"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLOV:K_Q9\7[J\U&&V;3/AQX;EDGMP^6$LIO?L\:Q$#!.XGYAQ6%X"_X-YO\
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M,AC[Y_7ZU9J&R5$MAL;()+#\23_6I$D+,1BOS36M/VB>@M7J.HHHJQ!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $S!"P# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %)D[L8X]:6CZ5,IJ"NP"F33QPE0[@%VPH)ZFHKB_ALV*
MSL1A"V0,_P J_,G_ (+5_P#!:KQK^S-XID_8G_8Q\)ZCK'QJU464FD:A:6=O
M?6EHSS1LT,D)?<)&BWXW*%!YR"!77EN78O-*BI0T;Z]EW'LKGV+^V]_P4!^
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M%)_$7_!<S1?V6_B%^TS')X<T[18_$/B3PYHFA0FRDMW5D^R-(59T99.K;AG
MQWS^Q$:JB@G/3K7YK?\ ! ?]BL>'/AY?_M[?&GP19Q?$_P")5_--;WMQIV+O
M3]%8ATMMS@%2[G>Y7A@L?7''Z4LZJ &%>MQCC,*LPC"G3C35-*,N5:.2W?WA
M9I6[CZ***^:W)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH ****EN28!4-SJ%G9LJ7%PJLYPJD\FI'D5.IK\IO^"S7_  5\\8>'
MOB>__!.3_@GKILOB'XV>*)/[+U36;5/,7PRC@;EC'(-P58$D\1KAF!)0KW8#
M+\3F%=0IK1:OR7<=NK-O_@LC_P %?O%?@_5(/V)?^"<^K+XH^,?B"X?3M0N-
M$B-Q)X=+*,';@(\AW8R7 BQD[SE1W_\ P1]_X) :+^R1HK?M!_M+74WB_P"-
M?BVQBG\3ZSK+B?\ LV1L.UO"3UPX&9.-V. H.*?_ ,$;O^"./@O_ ()U^")O
MB!\5-=;Q;\7M?8W/B3Q'<R&>6UDD4,]M&6)+8)+-)R79F;."!7WGIP>21IIH
ME5E&U "<A?\ :]Z]K,LTP> H?4<M;:?Q3>[].T?Z]:O;7^D/$"13!TM<,>-Z
MGM[U.<\?+FEHKY54VY\TW?U)N%%%%:""BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH "0.M,:XA1F5GP5 +>P-.(SCZUFW<Q.
MH/()</;PL#$.C!OND_\ ?)K.3G[O+NQZ&DLB/G8P..N#TI:\>_9(_:_^$/[6
MB^-A\*]0:>;P-XOF\.>(PQ_U=_#&A=1^#"O8:Z:]&="JZ<E9H3"BBBL@"HDO
M+:3?ME'R2;&R#PV,XJ6J-\I+M(N]RA^5&'R@GO655M+W?BZ>HF[%;Q'KND:/
M9RZEJ5VL,$=NSW$TK!8DC7.<DD =Z_"/P)X:\<_\'&G_  4AU/QC+J=[IWP(
M^$-^GV&U6 ,;Q$E5E@Y?'FS;>O01[QG->M?\'*G_  4 \2>)7\,?\$POV1]0
MNM8^(7C34[<>(K?P_+<BZBB$F8+2)H)% :5R5D5@3L*]*^[_ /@D#_P3V\(?
M\$Y_V0=!^$5CH$,/BB[M([KQSJ49)^VZF5_>LI))\L,6"CH!7WV58JMPKE;Q
MOPXFJK0_NKK)>NR_X(N>[Y3Z,\&^&;?PUH&GZ!:6 @AT^VC@A2-=BJB+M0 <
M_P . ?<5MG<S;73CL:?17P*ISDYNM)SYG?7H:.5PHHHK78D**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH *Y?XH>*/#'PQ\(:I\3O%^IQ6>F:/837-[<R$ 1(%RS9_P"
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M/3@<=JW%AB20RJF&(P36&<YK/-LTG4EI%?"NR6PE"PZBBBO.+"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0D#K3)[F.W4-(&Y( V
MJ3R?I1N[#LQTS,L9*$ ^K#BL;Q-XQTCPEHMUKOB;4[73[6UC=Y+JYE 147)+
M$]J\Z_;&_;2^"?[%'P/U+XS_ !R\41Z1;6L16QLW(:XO[D\)! BY,KL<<+G
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MVE9)+OK^B$_AU/K&BBBO.,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***BFN5B8)MRS-A5W $_3/7CG\*(^\] M<2_94M'9@2 .0!R>:_&+_@K?\3_
M !3_ ,%5O^"@GAG_ ((Y? 'QD1X4TBZCU7XK:Q9Q_.LJ$2F L/W>(H?+"C;G
M>&#9QBOTR_X*&_M4Z5^R'^QC\0/VA)X;R>3P_P"'YY;&.P53(\Y*QH4+$*2&
M<-@G)"MC.*^+_P#@VM_91O/"G[+U[^V7\3&>?X@_&O6K[7M9N[ZSVSPVYNI
MB@L,^7)(KW"]OW]?49'1C@\)4S6:^!\L;_S-7_!:C23=C]$?A/\ !KP-\'O
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M[ W[+4/B[QYI=]_PLWX@Q1:CX[NM1NA(T;*TC16L8 "K&HD9^F[=*V6("@?
M_P#P1]^!?B[_ (+ ?\%)?$7_  5%_:$N)&\/>!M=ED\,^%+Q3<PM,VY88E>3
MY1';9\Q6!W;XDXZD?O7 C&S2.)50>@Z8K['B&=/AJA#(J7\2RG.W=I:>BT,J
M>KYUMT'V\4,>]HSEF;+MCJ?_ -6!4E-CC6-=J_C3J^,45S<Q844450!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%%%F 4444; %%5K_5+33QB5P7X)C4Y8 G 8CLN>YXHL-2BOWD
M5$*[&(&6!SCZ=/H::BY1YEL%F6:***0!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444$@=30!%<75O;L!-*
M%)Z UY-^UW^U_P#!C]CWX3:A\4_C!XB>WM[9?+LM.M8R]SJ%PPQ'!$@!+,S8
M'H,\UUOQR^)?A7X1?#W4OB)XON56TTFT>X,2INDE(!PJJ.7)Q@*.M?)O[,W[
M/OC+]KSXI1_MF?M;^&[_ .SQ[W^'_@75 'MM(AW;EFP !-.<#]XV5;)**HXK
MT\#AJ,DZM5VBOO?DC>"5CS/]C[]D[XV?\%!_C.G[??\ P47\'W%MI.GWW_%I
M/A%>@-#I5MU6_G7.'G<$  X  -?HY;:/'IRQ!;56$491!#\HB0?<55Z=,"ET
MJQ2VEC:"'(,1$KR#:RX^Z-HX Z]JTJY\5C?;U7R:16ENQ$VKZ"$@#)J-[F%)
M!$7 8Y(J6O&/BI^VK\"OAK\9X/V=M3\96'_"87^E/?V>BL^7E0''8\<UA2H+
M$U/=5VA02;,[]H_4+#XXZO8? #P1\2%TZ_DO$FU=H(3)_HZD%H7! !#C(Z]Z
M]H\/V TNTCTZ"V$4,$01%$80 #H% /  KSKX >%;2^6Y^*5WHUNE[K$[2!8T
M^:W4?+LR?]TG\:]452,LQY/:M\7RTFJ<>A<]$+1117(8A1110 4444 %%%%
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M0!^I%/R!U-17;1"$F< QCER3TQR#^>*T;5Q"7$L4EO(BOR 1@=<CTS7X:?\
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M(@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO7E9E6RCF]C@FWR[M[OY=$-[:EFBBBO))"BBB@ HHHH **** "BBB@ HHHH
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M"3DXKSS]HS]I3X??LS_ GQ+^T)\1[J:#0/#&ASZE>RPQ%W=(E9BB*H)=CC@
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M"Y'3-%)\I(.?I1N7^\/SK)3E%OG0"T445JFFKH HHHH **** "BBB@ HHHH
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MU*D[NXNAZ-IVBPR0:;81PH[AF=  9C@?,WJ>W/I5Z@  Y ZT5;=Q!1114O0
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M- OX+?Q%JL(TKPPK.P=KRZ81F1 .IC@:6;ZQBOEK_@V+_P"":]Q\*OA->_\
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MU^2?_!:S]H[Q]^UW^TAX,_X(X_L_D+=^+M0L[OXB:F [MIUCN4BW:)&!1#&
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M4=M;V\NGX&5&,H.UA(B3G/K3Z15VBEKD>K-Y--A1112$%%%% !1110 4444
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M+B.%%4>86 VND:?+@D'.:_HP^!/PPMOA!\/M+\#IJ,VH2V5FL<]_/&!)<.
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M6[(C_=21N4&UHB4*;2#G-?O1X0T30?"VD6WA'PO91VECI5JEO!91)M6)0!M
M[< 5QW[*?[-?PJ_9*^!>A? +X.>'8=-T'0+016T"J [LQ+O)+US([LSL>[,2
M, @#T..!(7)B0 'KCO7G9[G=7.\1:;]V&W^8+8DI&("DD4VYD>*!I(^JC/-?
MG3_P6X_X+B>#_P#@G7X*/PM^"UQ8>*?B_P")+3_B2Z ) T.CQ-\OVF[VDY.<
ME8A\SX .U2&/F9?@,9F-=4:,;MAYL^6/^#D+_@HE\!/']O)^PCX7^*NIZ]X@
ML->MEUKP+X=DD>.^O]V(;.[=/EN?+8B7R,MB>&)"N3BO1_\ @@W_ ,$(-#_9
M9T^W_:Q_:;TC3=0\<ZA"LN@:7>60":%;2<A]K#Y+@GCCE0 .*Y7_ (($_P#!
M&'XA>%/'FL_M[_\ !0/P"3XVUV>1O#&E:X%N9[9YLL][*PR!*1G!_P!H]#7[
M,V-E#%;1Q?9%0*!\F.X&*^QS/B%9%EKR?+Y7@_BDEN^O]?(2WYFCEOB;XFT;
MP9X+U?7]8NR;72=,DDO7:<)M4)EF=G(0?+SR>]?@G_P;^?LN_LT?M(?MV_%G
M_@H')X=TS1OA]\,+^]U#PWX<U&$+_9;R%G2>4@>4%B@\U@<_*P5AC&1^G_\
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MC+!$J]78N>5 S@=QDCHP>&EB:ZI1U;=OO&E<_-;_ (*:VUE_P5Q_X*U?#_\
MX)O:+X:EU#P7\'KL>(/B/K9EG9726))9K19(LJK-%MB7)!$BL.,5^M.@Q:5X
M:\%6\6B1V\%I86Z1VD=O)MB6-5P"?]C'('7CCG%?F/\ \&QW[,?BS_A3'CO]
MOCX_Z&D/C?XR^+;N^M]20NCK9+(>/+;E%-R)V3!(*,I!P:]D_P""MG_!6FP_
M8\T_3OV6_P!F_P ":GXS^-GCRS%IX)\+:/&F+"5V5%DN&W'9LW;PI&&VX9D!
M+K[^<4JU>4<J?PT=--K[MOY@NYQG_!7;_@KY\0?@5XXT+_@G_P#L2:1<:O\
M'GQKY,EL[Z;YUOX=M)2RHX^4K<3R;)&51N*+&Y?;\N?7_P#@E+_P3*C_ &+-
M-U[XT?%OQ./&?QJ\>7(N_'?BFXNVDD!< ^2FX_NU48  P/PKG_\ @DM_P28?
M]EVP'[3?[8.H6/C7]H3Q6YOO$GBJY)EDTKS>180,W\"@<O@<Y4#"Y;[Q>SM7
M=7:!<JVX$#'/K7FXS%T*.%6%PVW5]W_D#\R0?*,L:H:K#L5[@7*P[E^:0C&X
M#) )] -W7CFK[KO7&:^8?^"GO[9'@[]CKX$2^(_$5ZPN-<G;3HA" '@@\IVE
MFR2!A?D4GUE6N' 8"IC*\*%+638(_*W_ (*S:_\ \+"_:FT6:SN;F?XT_%#Q
M/+X9^%%HNJDQ^%],24V27,,(;Y9I98Y)HI@.#("&&*_7_P#X)Z?L??#[]A7]
MEGPK^S=X @7;H>G[=4O$79]OOFP9[EEXRSOEBWO7Y?\ _!OG\!OC9^UU^T=X
MK_X*A?';3VO?#NDPS:'\%(M:P\\5M%(Z%H^,*@'!/)WA_8U^TL,SQJRPQJV
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M?.W[?G_!23]F;_@GY\-5\9_&_P =QV5_J,,IT#0P";G49E4L(T SL#8V[FP
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M0'B36M,6;3=&F70--OKD1_;=2*'R;<'J6=\+QZU\0?\ !#/]A7Q;J&K^*/\
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M@W_!6G_@HK>)XC^(?C.U%[X*\-WT(:W\/:<Q/D%(NBL8]I .2#R<L2Q^9_\
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M,[ZIXDU>!RGB/5BVZ HY. -IC8Q#Y44A0 !7MO\ P5Z\267B;XI?#7_@A/\
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MHHH *#P,T44 4%U>1H9Y$02-$,A8AN.#]WBOQ&_X*NZKXD_X*_\ _!8/P/\
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M(V2Y &.IK]#HM^'F&ABX-3K5T^22=U&SL[=S.5.,])+0\#_X)I_\$>?V;O\
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M(^&?%_P?\7W^@^,?!MS.^G7^FX\R2VF4).J\9\U5&Z(YP'.2#TKPCX\>'?\
M@N5^UMXI\+_!WX7:W8_!+P=+ ?\ A-?&7E13:G/'Y+(]O$DR,"CDALIL=2 P
M; (/V.+HX?.,LPLX5(QE2IN$DW;[3::[W3*W/M_XH?M&^'?^$D/P:^%.MV&L
M>.+@%7L[9Q,NGK_?GP<*/]G.[VKF?AG^P7\*?A=XKU+XS:EX:L]8\;ZZLD^N
M>(;L9D68IC;%D';&  @&1\J@]>*L?L:?L8_#C]D;PY8^%_#-E+J6JR6S-K'B
MG4Y_-O-1G&-TCLX+L"2>2W'05[[+$LJE' ((P01P:\+VM++J<:&#FVDK-]6_
MT7E]X7LT?G5_P1X^(/[*7[)?["$D'B+XEZ/X<M-'UO5'U9-;UN"2XF>.X)^T
M!4.Z4%0S*J@L>@!-=/J__!6>+XY_$F+X,?\ !/GX-^(/B+JTUI'/)XJU;1+C
M2-!L8BY#2>?.GFRR '(018/]ZOH+5/V _P!DC5O$$OB+4_V=O"DMV\T,J)_8
MT1@A:(@J4AV[%W8YXKTSPWX6T/PY9+INA:5!%;Q'Y6MPD6W'1 J*  /2NS%9
MEE]2O+%5KSJ2_F>G3MJ_O07.'\#?!+POI6J_\+&\86R7_BC4[6,:SJLRDK(4
M0 PQ*QVH@8$<\GKWKP/_ (+'?\% O!G_  3A_8P\2^+=(\36$7C[4[5K'P+H
M,;&"6[NYOW?GHJA_EMT9YR2 I,(7(+ 5],?&OXB^#?A!X+U;XI?%/Q=8:1X7
MT6PEOM6U*]E$<-E%$FYVD8Y&S ZX!'/-?R^?\%./V@/C/_P5$_:X3XX>&+K;
MX5U[Q?\ \(O\'-/G@>.66":7RQ(J.S'+<-*0=JO@  &OH.!N'X<2YK&>+DX4
M(^])JVW1:Z:_D9R=HW6Y^@'_  :Z_LM_$GXS_$[QQ_P5)^.WB/6=6US7I;C1
M["ZU,8^W-((7N;ELC.X>7 J$<8W\U^UIL;BW0&,2(JQ^7$D1!V_[1SCFO)?V
M /V=-%_9%_9.\$?LZZ,;A8_#>BPV]P]TJ[IKAP9)&) &X[F8?117MQ&1BOF>
M(\PAF6?5*D/@CI'T6BO\M0Y$M&,\U40,YQD54GOH4NO-N7$:1(P9F.!@XP<_
M@?RJTZ[8\N V.E?DU_P<!_\ !5OQ!\*],_X8=_9-\5:@?C!XCU"!9!H$*SM9
M6;+(H@8$'9+*S'!QP(_>N7)LIQ>;YG[.+2AW[+JWZ&GNI79\M?\ !5>^^*7[
M6_\ P6KNOB5X.T,WW@+]G==$B\2:O!;-<""!MEVQ1$!+MNF<8 (&,G YK]S?
M@1\8OA;\8O!-EXL^%_BBQO\ 39( N+6=':)\9*OL)"D8/&:^:_\ @D=_P3[L
M/V.OV1[32O&L6I:KXO\ 'D5MK/Q#N?$C"6]-Y+;QB2VE9A]R-0(]F!@+ZG-<
M+#^P]\1_^"<?Q4UWX]?LARZQK/@V:]FFUKX8VR^89(9Y-[)"#G#*^UE;J$5A
MSFOKLXQ>"S?#QRQ5;QPZY:;Z-:7OV;>QFJ45)R?4_0AKFW^202<,,K@$YIT=
M[:ROY:2\^A4CL#_(BOGOX8_\%&/V8_&^GE/%7C&W\,ZU9 ?;] U5S%<6(8?=
MDSC)S7=^'_VH?V;O&,G_ !(?BKHEVQYQ'J8S]XQ],_[-?%SP6)I-QE%Z;%O4
M]-,D8&[S%QZ@TM<EI_QG^%&HV4-]IGC32Y8;A@L6R96R3]#73VM[:W4:M#=Q
M29&?W;"N>4*D'[R))J"0.M%(Q4$ GDGBHES6]W<!#*BYRW3KQ4-SJEC:PR3S
MS;4C8*[;3@$CZ4ZX=((7E]L]:_.C_@X/_P""GT_["'[+D_@#X5^(HK?XC^-[
M8V^CVX<,]A;OE9;G'JOS8SQD5W91EV+SK.*>#PZWW?;_ (9:C]U*[/S)_P""
MPW_!67PE^U7_ ,%$-(T3^V+S7?@W\+_$'G:)H&GV,:MJ6L6VX)<JY<_NY9@J
M"1@-L,DAV,V%/W%_P2A_X):_'KX]_&BU_P""FG_!1N!9=>N8BO@CP!>HLUOI
M%EPUO*,':CH&.S .?,<G' KSS_@@;_P1!\+ZEX,T;]M7]KSX;V-W>ZSI$5SX
M,\-W2LR1I)AAJ-TCYWS%3_JV_=#<<)D C]JM%L[?3]*@L;2!8HH8@D<:*%"J
M!@  < 8'05^B\89]E>"P4,HRE>Y3T<^K?75=WNS-4[^]+J)H\,UM;FWEB*!"
M @//&/7O^G/YU;HH) ZFORYOFES-:EC+AD6!FDV[0.=QP*\G_:^_:M^$W[%7
MP!U[]HSXP:RMKH7A^T\T00./,N)B,K&H.-S,< #WKTWQ)>06.AW5W<7*1)%$
M7DDD8!44<DDG@#%?A-_P4<^)7Q"_X+]_MW6/_!-?]F+6XM+^'_PVN)+W7_'E
MH[WL.H7"@>>SQHRJ8X]IAB0Y?S8G._D =^"P57$\U5K]W#=]O^''LKGF?[/?
MPX^)?_!9[XZ?%7_@L%^U/X<N=(\$?"O3_P"VO"7AFQNY%:8Z?$US;Q([Q[94
M"0X<@*)&QT!R/KW_ (-2OAC9:M\%/BQ^UM>O,+SXC>/Y(&R $B@LE,D8!S_T
M^D8_V*^U/V@_@G\./V9O^"9?Q(^!WP6\,6>E:%H/P>UFSCMX(]K11+I4XWN>
MKM@=3SS7SC_P:V6#:3_P2YTG3Y_#=[IT5UXMU*<?;3E+P&.V EC/93MP!Z@U
M]A+-,7B>$ZT()>S4HQ7>VK_-$RI1DD?I1:.&9L'[IPW%2S1K/&8F&0RD'\J9
M9OOBR8RGHC=@.*D5U8D+VK\TP\E"DHRW=RE[NQXY^W1^RMX1_;+_ &6?%/[.
M7C5YH+/Q%I_D)>6Z!I+652&CD7/HP_(FOAK_ ()B?MW?$K]E;XHR?\$N?^"A
MU[I7A_6/"&FF#P'XQU"Y^SQ:_IB2ND#(S#:"(U4$LPY&.U?J)J$GE6<CC?\
M=_Y9KD_E7QS_ ,%4/^"47P#_ ."DWPV$'Q%CFT;Q7H^GM'X;\::9*3-;CE]K
M)T,6XDD'GD\U]/D.,PLL+'+<9)JDG>ZU<7:U_3NBT^;U/DC_ (.0/'?B#]I7
MXK_!?_@F#\(;R9]4^(/BR"^U^72[@.D5E&"A^T+D$>7O%PHZ'R>QQ7Z>_LY?
M CP)^S#\$/#7P.^'%I;V6E^'-,AM_D38LSA<-)]6;<?QK\)?^#=7]GO]J/Q[
M^U#>?M^>(K2_\:^']#LIM$35?$<TE[?W$P.W?;@D%#A2.2V :_5#XK?\%5?V
M=?V>?#%YHGCKQQKB:W:QR7]SIFL>'3<36\7G)'Y6V(("1NR.^#7T7%.75<#[
M#)\/.,N3>WVI/^9>2V\B$[ZGV1;2P0QF(-A0WRL3][//]:G9U3EC7P;\-_\
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M&W_!)O\ X)P.^N^.OB);3W?CJ[LI8Y9+4WL+R75JY$?$$<9D#,>0!UK]R/\
M@F9^PA\)/^";G[)N@_!KPE8&"YMHTNO%&JW*?Z1J&HNHWRLPP"@^X  !A<XR
M23]KQ>X83.*^(J1M4J65.'2$5I=+I>VBZ'+3?.DCWCX6>#?"'PT\%:?X \$Z
M+!IFE:/90V=A8V\6Q(H8XU10!Z84?UYJ3XEZ_8>'_!FHZ_>WRI!I]C+=W"[]
MN^.-"Q!;^%>.3@\9KGO&7QF\(>"=$NM3'B"R$5M*T:-*WFL9R-YC"!@68AA@
M9'45^0?_  7I_P""B_[=%KX#3]G?X>>#-,\"^%OBEK$.A>&;P22W.MZK:2-D
MS)(KHMLDC*L30LCMB4_/QS\ADF0YAG69QC:W5M_>_G8U<N1^AY__ ,$ROVJ_
MV>?V=KWXL?MZ?%_1-<^)?QM\9?$/4-.\.:!HT*7%]):1F-8)2 VV*-RP0R,P
MXA7CK7TW\$_^":G[;'_!3/XLZ;^TM_P5^O(M&\':3K$UYX*^!FG3;HK>,N?+
M&H,I*$E0I(7=N!_@)('N?_!)'_@D[\&/V&?@9H.JZU\/-(O?B#K6GPR>)_$@
MMYI"[L-Z1A9)&5%3YMQ R6<9Z"ON66".++F7: XEFE[<=OR%>QG^?8*GF$HX
M%MN*Y>9ZM6_EZ)6Z[]2XO34P_!/PV\)_#[2(O#7@WPS;Z1ID<!CCT[3U"0Q]
M#N  '/'6MVTO+>*W2.X9(7R5$;OSD?7K5D$8R#7E7[2O[5G[//[)7AI_B-^T
MU\4M!\):(THAL+[6[Y(Q+* 6*(",[L8_.OS]4YRK)SYJDYOXMVO7R"4G8[CQ
M]XV\+>"/#5QXC\5:Y9V%C!#(TMUJ-P(;=0HR=[GH*_(']KG_ (*;?'K_ (*P
M>-=2_8"_X)!>?+HNH K\0/BCJHDM[2RL,C?# ^W>B2'"8*[V1BNT EUE^-WC
M?]L3_@X=2S^%GPET+6OA7^SE9>);D>(O&AN49_%5M:RGRI+8F,%4<J0N"5[L
M&'%)_P %(?C7\#O^" '[&VF?LF_L'^$H+3XC>.8VC36YPUQ?M$B$O?3C/[R8
MD!57 0>9N"[5*G[W*,NH8.M"-5<]:37*EK&/G/TWLF2I7>NQ\H^-M/\ #_P6
MOM!_X)7?L(_#VZ\:>+[C4IH/$WBIK2*1=9U678D]Y&QDW1VUI&2 KX65IB0R
MF,JWZ]?\$T?^":WP@_X)6?L\W>@:+J\.HZC,/M_B_P 57-H ]W,HRS*G)15
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MM.  Z"BG&52VJ07&() WS'BGT455V]Q/4**** "BBB@ HHHH **** "BBB@
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MX52C)]!\K-ZBLWPQXC7Q)H$6O?V?+:K,,B&?&X?E6E4B"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLOV:K_Q9\7[J\U&&V;3/AQX;EDGMP^6$LIO?L\:Q$#!.XGYAQ6%X"_X-YO\
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M,AC[Y_7ZU9J&R5$MAL;()+#\23_6I$D+,1BOS36M/VB>@M7J.HHHJQ!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>jnj-20230402_g1.jpg
<TEXT>
begin 644 jnj-20230402_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(!^N]%?@A_P3A_;3_P""Y/\ P48^,?[4W[&GPJ_;CT_3K_P1=20^&OB#XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \9_:+_;/\&_!'XH^#_V;_"?AZ;QA\5?'XFE\+>!]/NU@
M*64 S<:G?7#!A96,71IBKN[8CABFD^2O'O&'_!6Z7PC_ ,%@/#'_  2?D_9/
M\671\1>%&UAOB5#<_P"A6Y%K+<<0>3^\MAY7DM<>:NV9@GEGK7Q]_P $-OB_
MK/[9_P#P71_;@_:H\:7+75QX3EMO!/A+S3D66BIJ5U#%%&.B!QI<4K@<&1W;
MDL2=+QC^WW^V]X _X.FO"'_!/6T_:6U>^^#OB/3IM3N_!M_HNF%8B_AZ^O!"
MEPEJMP(TN(4=<R%L#:689! /UVHK\7/$7[:?_!33Q3_P<K>,O^"6OPT_;EU'
M0_APVF_:[/\ M/P;I%]/I,4WAVWU*3[,WV5"\J2S.L)F:1$&PR)/L*/V?_!O
M)^W_ /ME?%_]MS]J+]@K]JSX[WWQ+M?A+XGNXO#'BG6K""&]"VVJ7-A,KF%%
M#))LBD"G/ED,%.TX !^G'[2_Q:UOX"?L_>,OCAH'@N'Q%-X/\.7>M2Z++JOV
M(W<%K$TTR)-Y4@60QH^P%=K-M!9 2P\._P""0?\ P5(\(_\ !7']F/5OVE_!
M?PDU+P9::5XUNO#CZ5JFIQW<DDD%K:7!F#QHH"D787;C.4)SS7J7[>?_ "8U
M\9_^R3^(O_39<5^#W_!$+X=?M=2?\&_7QW_:'_9I_;;\5?#2]^&GC+Q)XCT/
MP_X9T?3F@U2\L=#TV[G%]-<P2RRI)#&L4<430JC9>3S@P5 #]T_^"A'[71_8
M-_8T\>_M<K\)]6\<'P1I4=Y_PB^B2^7/>;[B*')DV/Y42>;YLDFQMD4<C[6V
MX/S'\:/^"ZK_  7_ ."47P^_X*N:Y^QWKG]@>,9(8M8\&WOB1;74M(>:>2"&
M2,O;;;J"1HF=9/W3&.6%PA#L$^6]'_X++_M>?M0_\&T?C?\ X*%>#_BQ<^"O
MC+\*?$EOH.LZ]H&D6+6VK72WVFQM(]M<P2QJLEGJ,;,L80+,"5VIB.O/?^"D
MW[1/QE_:R_X-%? G[0O[0?C63Q%XQ\2^)=/FUO6I;."W:Z>/7+R%"8X$2-<1
MQHORJ/NYZDF@#[?_ &T/^"]NB?L;_L ?!C_@HGJ_[+.H:]X0^,-IIQ@TRT\6
MQ07VDW=Y8R7T4+JUN4E3RH909%8'<H&S!S71?\%'O^"U4/\ P3^^ _P/^.=A
M^R%XN^(D/QGO+..+3O#]Z$;25GMH)Q&7$,@GNG$^V&#"><8I/G3;S^8W_!<'
M_E5B_8J_Z_\ P=_ZBVIU[!_P76_;\_;>_P"">'[%_P"R%X]_8[_:6U?P=_PE
M_@FVT[7]*CT73+RVG6WTW3Y(Y5^UVLLB2?OG4X?:1M^4$9(!^WL3^;&LFQEW
M*#M88(]C3J_,#_@K)_P4X^.^@_\ !4K]GW_@D3^S/X_N?!3_ !%U&PU'XE^-
M]*M8)=2ATN>YE06-DUQ')';RM%;3NTVQF'F0[2,.&J_LM?\ !1_X\? 3_@O9
MXV_X(R_&KXJ:GX_\%ZMHL>I_"[Q)XEC@;6M+N/['BU.6RGN(8XQ=0^6+O:\B
MF0>5&-Q!(H _4FBOQ$_8H_:R_P""J/[8'_!93]IG_@F[#_P46UK0O!/@*U\0
M#1=:F\#:+=:KI\%MJ]K;0&W=;6)//Q,$:659!Y?F;461DECZ7_@@'_P5H_;N
M_:3_ .";G[3/BSXNZK+\4?B'\$-.N[[P1/=V2_:M8E;3;N>WL91 J&;_ $BT
M(!QYC";;DX7 !^RU>,?"K]L_P?XQ_:2\1?L<?$GP])X.^)VA:6NM66@W=XL\
M'B#0WE:./5-.N J?:(@ZF*5&1)895*LA4I(_Y:?\$7O^"H?Q$_X*&P_#O2;'
M_@HMXQA^-VG>-X[SXQ?"?QM;Z3%IGB[1//D,LFB,EHC6_D0M'(T$,BN4@F5X
MW!24]9_P=*_%W5_V+_CI^QY_P4$\!7#V>O> OB/J-G>SVYVM?:9-':R7-G(1
MRT;PQ3QD>EP^,$YH _8:B@$$9!R#T-% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ?D-_P1\^"FJ_L&?\ !?7]
ML/\ 9?\ &=JUI!\5=/A^(7P_N)AMCU+2SJ5Q*RPL?OF%]2>%AUS;2'H,U'\6
MOV!OV_M>_P"#G7PC_P %*]!_8_UR[^$/ANU&E77B!/%WAY)IU.B7>GF[CM7U
M(3>4);A6PR+*44GR\X4_I9^T-^R3\,/VB==\+?$+5[C4- \<> [^2\\#>/?#
MLD<6J:+)*GESQHTB/'-;S1YCEMIDDBD7&4W*C+Z@@94"N^Y@.6QC)]: /R$\
M+?L!_M^:=_P=#:]_P4RO?V0]:3X/:G:?V5!XA_X2[P^9PJ>'(-,%T;4:CYWE
M-/"2!M\SRV4E <J)/^"(?_!/W]OC]E;_ (*R_M,?M/?M'_LG:MX3\$_&75=9
MU#PSK$WBS0;TVPGUF6^BCN8;/4)I49HI ,HCJ&&"0/FK]>** /.OVP?"'B3X
M@_LD_%+P%X-TF2_UC7/ASK>GZ58Q$![FYFL)HXHU+$#+.R@9('-?D=^P#^Q5
M_P %*?\ @G]_P1Q^.'_!-SQ3^Q'K_B+XA_%J/5IO!VJ^%_$&E3Z/;?VUHUKI
MLL5[<RW<?V66T,4DCY5HWRHB>3DC]MJ* /R$\5_\$6OVC/V8O^#;WQ1_P3.^
M!'PZ?XC?%SX@:A:ZKXE71-9L+*RBU)]2L;B8^=J%Q;J88K6RC@##+R/&&V*'
M.SA/C9_P35_X*0^.?^#:GX=_\$T-!_8NUQ_BQHGB5?[7TJ3QIX;6UM[>+5+J
M\%S]I.I^6Z.DZ*JJ2X</N55 9OVVHH _$?\ X*9_\$T_^"D7[4W_  0M_9C_
M &#OA3^Q=KDWQ#^'%WHS^,+*]\:>&X;>R73]'N[!BLQU/9+YLEPCIL+?(K;]
MAPI=_P %U_\ @FQ_P4B_;Z_8[_95^$'[/'[%FN7>O?#;PVQ\;6VI^-/#=JFG
MW'V.SMA;AVU/$S%K:1]T>Y-C)\VXLB_MM10!^6O_  4U_P"";G[1'CW_ (*5
M_LY?\%D/V>_@OJNMWW@273[+XH_"\:C81ZS'I\4TS_:;8FY^RW$\<=U.CQ+/
M\WEP["V6(7]ES_@FE\??CE_P7P\=?\%F/CI\,=1\ >#])TN/3?A9X8\07-LV
ML:G/_8T6E2WL\-O+*MM#L^UE4D82$S1G: I)_4FB@#\>O^"8_P"PE_P4&_9I
M_P""Y'[2?[>WQ>_8J\1V'P]^)^E^)?\ A%;BW\8>&KB[>2;5;6^MHI((]4)C
M::.V9 2=JR2('9%W.N%_P;_?\$^O^"H__!-K]G#]JG1?BE^S#>>$?''B_P .
M#5OA7??\)+H6JV]QJ]M9WZP6[I;7LI#^?/ 1YB")@&#,. ?VBHH _%'XN_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2*V/F.(MTKK&9 RJ[%30!^77_!QU^U#^R5\9OVU_"O["G[1?_!0?Q5\!]!\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWNF7DNG:E9RV]Q!(8YX)XRCQN#@JRGD$'@@U%7UJ::NCY!IIV84444 %%%%
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MG!^QKX^E_8,_8]O9OB^NCK_P@L4GQ)U$*UWYT><_;[X6W^K\S_6G;^.*N?L
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!H\D-^K[O^MD?G^.QU;'5N>>W1=E_6["BBBNPXPHHHH **** "BBB@ HHHH
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M3SA3^D7PR^&/@KX0>#;3P)X!T6.RT^T7Y47EY7/WI)&ZN[=V/TZ "OR_COQ
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MQ.;M59K507P+UZR]-(]U(K:/HVD^'M*M]#T'3(+.RM(A%;6MK$$CB0<!54<
M59HHK\=E*4I.4G=L_9HQC"*C%62"BBBD,**** "BBB@ HHHH **** "BBB@
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M>);[P[XB^(EII5G#8B9H(3]MEC(>>YD2011K%L!BE\R2(*K, ?25%?$^E?\
M!9[1?B1HWP7N_P!G_P#8^^(7B_4/CIX/\1:QX.TN:\T[372\T;:MYIMPUQ<
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MOBEK6M/\.997;R_"FE_:Y]0T.P3Y<B.SU"XGN>,_//)@\C'W_6%X8^)GP_\
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MHY8.!R'7[0JO:Z3I=A=W5_8Z;;PSWLBR7DT4*J\[J@16<@9<A5503G 4#H*
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M$KX<^+[^W;PMH/BCQ?=6$]A;G2;.UNK.YB.G74$MK)<Q7$N%^91,^4EWX3Z
MHH ^5_V'_P!C_P#:#_X)_P#[+GP;_95^$NH>"=;TC1/$&IS_ !+NM5N+V#[#
M8WL][?&#1D57W"&YN(X4$Y4&%"QP[?+%X>^%.H_&3_@L!J7[4MC&6\+?"GX,
MOX&M;['R7FOZCJ2WM['$?XQ:VUM:(YZ"2\9/OQ.%^K:KZ5I&E:%I\6DZ'IEO
M9VL((AMK2%8XXP3G"JH '))X]: +%%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"MZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>jnj-20230402_g2.jpg
<TEXT>
begin 644 jnj-20230402_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI^*M/\#V,J:?X<M&4LAOKY8)A%,Z R+ D<DGE R,$0H7D_X(\?\ !87X*_\
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MQ#S1(JO"H!^3_B;_ ,%3OVC/V5?^"R7[-7P"^%O[7FO?$+PE\6TT'1/B_P"
MO&&L:7K*^'==OKX6=S;QW=A;1)#<6YEC9HX2%#H05".$ !]M_M/_ /!:C3OV
M4_\ @J-\-?\ @F3X[_9LO;R^^*9TR7PYXRTSQ3&UO':WEW/:+)/;O K(Z2VT
MN8U9@5VD/\Q ^Y:_"_\ X+0_\K5W[%__ & ?"_\ ZD6KU[I\6O\ @J[J?Q^_
MX+5>-?\ @G;J?[26K?"#X2?"/P-/=:[KGA6-%U7Q-X@;[&@B^T-!,UO;P?;6
M(1%7>]JV]G1U10#]7**_#K5_^"UW_!3;1?\ @A5\6?C#?^&=2B^+_P ,_B-;
M>$W^)-YX.^S"YT.YD41:]]FDB$/FGF D)Y09XY"N217U9_P1M_;$TO\ ;A^(
MVF_%[]G?]N_QAX_^'%M\-;RV\;_"SXG/IQ\1>$O%#WFG-;SO);VT,MU;S0)?
MA7S)$C(P1AYACB /M_\ :;^+NM_ #]GOQG\=-!\%P^(I?!WAN\UJ;19=5^Q&
M[@M86GF1)?*D"R>6C[ 5VLVT%D!+#Q+_ ()#?\%1?"7_  5O_9AU3]IGP9\)
M=1\&6FF>-+KP\^E:IJ<=W)))!;6MP9@\:* I%T%QC/R'GFO3/V_?^3$?C7_V
M23Q)_P"FNXK\(_\ @B9\//VNQ_P;Y_'/]HS]FG]MSQ5\-+WX9^+_ !)XCT/P
M]X9T;3FM]4NK#1=.NYQ?2W,$LLJ20QB*.*)H41LO)YP8*@!_1O17X]_!'_@H
MI_P43_X*9_\ !OSX@_;,_9K^,]YX+^//PEO]1M_$$GA[0-/GM?%1T^&"ZG4V
MUU;S+&\EC<)(JPA/](4JH",$&U_P3H_X*+?M"?\ !0+_ ((KZ%XE\+_M9^(K
M3]H?4OBA;^"KOQ'#IFDM/!JD]\CAQ:FS\AK./2G>\<>5NVVLX#EDS0!^M5?*
MWC;_ (*0^(/%G[:/B/\ 8'_8P^"&E_$7QWX#T&VU;XC:GXG\;-X?T/PZMSM-
MM:O<PV5]//=2(P?RX[8HJGYI 0RK]-^&='NO#WAVQT*^\17VKS6=I'#+JNI^
M5]IO&50#++Y21Q[V(W'8BKDG"@<5^$__  5__8,_X*O_ /!/K_@HWXM_X+"_
M\$JM1U?Q%HOC)$F\;Z+H%H-0N+)TCCCN;>[T\AC>V;M )0\:L\+;L^48TE8
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MN]#^'OBS36O4T_6?!^E7Z:4DF@75[+Y!^S)*[1M"SP"61U$@C\T2QAHVY_\
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M=X/\0> /A_I?@WQ3\2]9\8ZAI]MY5UXG\0PVD=[J+9)\R5;.&" -@@?NXD7
M'&<F@#?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_""]^"7@C_A#-0^,/C/QQ*;IICKGCK4H;J^.41?+WPPPH$&S( 3JS$DYKLZ
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MNVNHKAO#NDQ<A;B: M%)>7,O[^<1-)$C!5223YF/VI10!\]_\%3_  )^T?\
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M:_\ $^*;XF:IX3W>?X1C#&>*STB\=5>&Z>-FMDOF5/,%O(=D33H(_%OV!_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$A,T9V@*2>#_ ."8_P"PE_P4&_9I_P""Y'[2?[>WQ>_8J\1V'P]^)^E^)?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !6/\0?'WA'X6>!]6^(_CW6HM.T;1+"2\U*]F/RQ1(I9CZD\8"CDD@
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M\GGEM5WE0=X_X)=/^W7?Y-(UJ***_(S]A"BBB@ HHHH **** "BBB@ HHHH
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MBEJNC>*- ^(?B;5Y[_7_ !;X=\<75S.FH3?O"7MKR2>!%^8'R51 $(5-@VX
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MX.0/$[S>)/A1X,28A;>QU:]EC!ZF1[6-2?IY3X^IK[CPWPBQG&N$B]HMR_\
M 8RDOQ2/A/$S%O!\$8R2WDE'_P "E&+_  ;/S)HHHK^Q#^,@HHHH **** "B
MBB@ K]X/^"0O[(UK^RU^R7I>IZUI@B\5>-XHM9\0R.N)(T=<VUL>X$<3 E3T
MDDEK\>?V$_@G!^T1^U[X ^$5_:^?8ZGXABDU6$KD/9P W%POXQ1./QK^BU55
M5"JH  P !TK\)\:<\J4J%#*:;MS^_/S2=HKTNF_6*/WSP1R&G5KU\WJ*_)^[
MAY-J\GZV:7I)BT445_/)_1@4444 %%%% !1110 4$ C!&0>H-%% 'Y??MR_
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M^(=8U*[>YO\ 6=0D55DN[J=R6EE*HB#HJ1QQQQJD<:(O9444 %%%% !1110
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MKRJ=/,</F,5[LX\C]8MM?>F[?X3^D_ _-X5,MQ.6R?O0ESK_  R23MZ-*_\
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M****S-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(HK^Q*5.G1I1ITU:,4DDMDELD?QE5JU*U652H[RDVVWNV]6V%%%%69A1110
M4444 %>O_L(>"F\;_M3^%;5HMT.G7;ZE.V/NB!&D0_\ ?P1C\:\@K[(_X)*_
M#DS:QXI^+%U!\MO;QZ59.1P6<B6;\0$A_P"^S7RW&V8K*^%L56O9N#BO6?NK
M[KW^1]7P-EKS7BS"4+72FI/TA[S^^UOF?;E%%%?QX?V:%%%% !1110 4444
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M#\'_ -G3P]X=NK7RK^]M_P"T=4!7#>?/A]K>ZIL3_@%? O[%WP5?XX?'W1]
MO;,RZ5ITG]HZUE<J8(B"$/L[E$^C$]J_4VOPGQCSM/V&54W_ -/)_BHK_P!*
M=O1G[YX+Y$U[?-JB_P"G</P<G_Z2K^J"BBBOPD_? HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &SP074#VUS"DD<B%9
M(Y%!5E(P00>H(K^?O_@IC^R)=?L=?M4:UX(TS3I(_#&L.=4\(S%3L-G*Q/D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$WB32IQ-HFI>*%?4O[(E  \RRCNFDCLFX^] L9)))Y)SZ)110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M],?%^^\5?&3_ (*=?LN_&?P7\*/B#9>'K;X:_$"WU'7=2^'VI6R:/+J TD6
MO/-@ M))?LD[B*?9(F )%C9@M?;%% 'YU?\ !+SQ5XJT;X%_"C]@7]IG]@3Q
MG+\5?@KK?V>Z\4>)O CR>&[5[:29/^$DL=;F0P2RSVTLA3R6-RTUPZE5C\R9
M?(_!=]\</&/CC]EWQ]K?['?Q5\+7W@/]I+Q _C+X=^'?A3=6'A_P7#=V>NQ0
MM:LL"+?QW$EQ#/+J8DFMP\\C-):K*(C^N-% 'R/_ ,$U_#_C#P_^T1^UI?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>jnj-20230402_g3.jpg
<TEXT>
begin 644 jnj-20230402_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (!'_(/[<SO_ *"JG_@<O\ST;_AK/]H'_H?_ /RE6G_QJC_AK/\ :!_Z'_\
M\I5I_P#&J\YHH_L3)?\ H&I_^ 1_R#^W,[_Z"JG_ ('+_,]&_P"&L_V@?^A_
M_P#*5:?_ !JC_AK/]H'_ *'_ /\ *5:?_&J\YHH_L3)?^@:G_P" 1_R#^W,[
M_P"@JI_X'+_,]&_X:S_:!_Z'_P#\I5I_\:H_X:S_ &@?^A__ /*5:?\ QJO.
M:*/[$R7_ *!J?_@$?\@_MS._^@JI_P"!R_S/1O\ AK/]H'_H?_\ RE6G_P :
MH_X:S_:!_P"A_P#_ "E6G_QJO.:*/[$R7_H&I_\ @$?\@_MS._\ H*J?^!R_
MS/1O^&L_V@?^A_\ _*5:?_&J]I_9!^+7Q!^*/_"0_P#"=^(/MWV'[)]E_P!$
MBBV;_.W?ZM%SG8O7/2OE"OHS]@'_ )FW_MP_]N*^<XLRO+,-P_6J4J$(R7+9
MJ,4U[\5ND?2<(YKFF)XAHTZU><HOFNG*33]R3V;MN?1E%%%?C)^V!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\6_M:?\G ^
M(/\ MT_])(:\YKT;]K3_ ).!\0?]NG_I)#7G-?T3DG_(EPW_ %[A_P"DH_F_
M//\ D=XK_KY/_P!*84445Z9Y85G^+?$NF^"_"NI^,=9$GV/2=/FO+KR4W/Y<
M49=MH[G"G K0IEQ;P7<#VMU DL4J%)(Y%#*ZD8((/4$=J3O;0<;<ROL?%GP+
M_:#_ &O?VN)OA]\:_AK\7?"7ANV\;^ O%.LZ'X0F\.RW^GVPL]3TJWA@OI5N
M8Y)Y\3.'EC$7E%G58VY+>A_'/]M7QY\%OV._ /QC\3>$-)TCQGX^U70=!-IJ
M;R'3-#U+4"%EFN"&5VMX,2L0&4ML"[EW;A\N_%K]F+XX_P#!+']J"R^,G[ 6
MFS^,?!M]X7\0ZUKWP>U:Z8IINGQ76D_;_P"S),DAW,EHX4*7 M<'SAA*]_\
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M_P!F'X'ZKXK\(: NM^+[C3;UO"N@EN)Y;>VDN)KB7D;;>"*-I9&R,A0@.^1
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MJO.:*_1?[$R7_H&I_P#@$?\ (_-_[<SO_H*J?^!R_P ST;_AK/\ :!_Z'_\
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M <D N"0/2L#]D'X(:K^S9^S%X'^ NN:Y;ZG=^%/#T&G7%_:1LD<[1C!=5;D
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M6T6I]OT445[Y\\%%%% 'VE^R7_R;]X?_ .WO_P!*YJ]&KSG]DO\ Y-^\/_\
M;W_Z5S5Z-7\[YW_R.L3_ -?)_P#I3/Z/R/\ Y$F%_P"O</\ TE!1117EGJA1
M110 4444 %%%% !1110 4444 %%%% !1110!\6_M:?\ )P/B#_MT_P#22&O.
M:]&_:T_Y.!\0?]NG_I)#7G-?T3DG_(EPW_7N'_I*/YOSS_D=XK_KY/\ ]*84
M445Z9Y84444 %%%% !1110 4444 %%%% !1110 5]&?L _\ ,V_]N'_MQ7SG
M7T9^P#_S-O\ VX?^W%?,<9?\DW7_ .W?_2XGU/!7_)34/^WO_2)'T91117X4
M?O84444 %%%% !1110 4444 %?G/7Z,5^<]?IWAQ_P Q7_;G_MY^6^)7_,+_
M -Q/_; HHHK]./RT**** "BBB@ HHHH **** "BBB@ HHHH **** /M+]DO_
M )-^\/\ _;W_ .E<U>C5YS^R7_R;]X?_ .WO_P!*YJ]&K^=\[_Y'6)_Z^3_]
M*9_1^1_\B3"_]>X?^DH****\L]4**** "BBB@ HHHH **** "BBB@ HHHH *
M*** /BW]K3_DX'Q!_P!NG_I)#7G->C?M:?\ )P/B#_MT_P#22&O.:_HG)/\
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M_P"3?O#_ /V]_P#I7-7HU?SOG?\ R.L3_P!?)_\ I3/Z/R/_ )$F%_Z]P_\
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M31L_:9_Z,:^*?_@OLO\ Y)K],J*/]<N)/^?_ /Y+#_Y$/]2N&?\ GQ_Y-/\
M^2/S-V?M,_\ 1C7Q3_\ !?9?_)-&S]IG_HQKXI_^"^R_^2:_3*BC_7+B3_G_
M /\ DL/_ )$/]2N&?^?'_DT__DC\S=G[3/\ T8U\4_\ P7V7_P DT;/VF?\
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MLO\ XJOJ:B@#Y9_X;[_:9_Z1@_%/_P #K+_XJC_AOO\ :9_Z1@_%/_P.LO\
MXJOJ:B@#Y9_X;[_:9_Z1@_%/_P #K+_XJC_AOO\ :9_Z1@_%/_P.LO\ XJOJ
M:B@#Y9_X;[_:9_Z1@_%/_P #K+_XJC_AOO\ :9_Z1@_%/_P.LO\ XJOJ:B@#
MY9_X;[_:9_Z1@_%/_P #K+_XJOG/9^TS_P!&-?%/_P %]E_\DU^F5%>IEN<Y
MEE'/]4J<O-:^B=[7MNGW9Y69Y+EF<<GUNGS<M[:R5KVOLUV6Y^9NS]IG_HQK
MXI_^"^R_^2:-G[3/_1C7Q3_\%]E_\DU^F5%>G_KEQ)_S_P#_ "6'_P B>7_J
M5PS_ ,^/_)I__)'YF[/VF?\ HQKXI_\ @OLO_DFC9^TS_P!&-?%/_P %]E_\
MDU^F5%'^N7$G_/\ _P#)8?\ R(?ZE<,_\^/_ ":?_P D?F;L_:9_Z,:^*?\
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M3/\ T8U\4_\ P7V7_P DU^F5%'^N7$G_ #__ /)8?_(A_J5PS_SX_P#)I_\
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MS7,Z0Q-(R11CEY"%(51R20.] &M17Y@?ME_M*?\ !P?^R%\(=4_X*":]X>^
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M'\+^$=&GU37=2F!(AMX4+,0HY=CC"HH+,Q"@$D"@#JJ*^+OV2_C'_P % O\
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M%\&O#-Q<R^'/#=QK4NG>+/!=A(S2^0SQ6]PNL6<3LVTI%%/$K;2'C3?'UO\
MP2>\ ?"O]N#Q3:?\%JO'_P 7]+^(7Q&\6>%UT#0=.TJP-KI_PSL4):XT.""2
M2247@EDD^T7,K!I-Y\M8XI,. 8W_  =&_P#*)O5_^RC>%?\ TZP5^B5?(W_!
M9']A/X]_\%(/V6Q^RU\'_&'A+PQ:W?B#3=6U#Q#XC:ZFD1K.X$Z0QV\,>"&9
M4S(9!@9&SD,/J3P3-XVN/"UG+\1M-TJTUHQD7\&B7TEQ:A@Q ,;RQ1N05PV"
MHVDE<MC<0#5KY ^*?PPLO^"AW[<7P^UA8%N/A3^S7XKN->N-4(W1>(O',<;6
M]M:VQ_BBTP/-)-*I*_:GC@&6M[A4],_X*$_"G]L[XX_L]WOPI_8C^-OAOX=>
M(]:E^SZIXNUVSN9YK2Q*GS%L_L[*8IWX7SL[HU+%,2;'3Y?^'O[#O_!=3PWX
M;T#X-2_\%!_@QX9^']C]ET^^LOA_\*GL;^VTE659HK*5V98)C#O5)<;E<A@0
MPW4 <M\![/4+3_@['^-TWB0,'NOV6--D\.>:/O60O=)279GM]H23..X-.^,"
MZEJ?_!VA\*$\-AF73?V2+R3Q"T71;9M4U18P^.WG/">>[+ZBOJG]J#]B'Q'X
MU_:K^'G[?7[.NN:1I?Q1\ :1>>'[ZS\0^:NG>*_#MUEI-,NIH5>6W:*8BX@G
M1)-DFX-%(K_+7_9Y_8C\=_#W]H#XH?MY?%G7O#NM?&GXB:#;Z+I=O8).NB^&
M-(M$S;:7!(X\^='G GN+AE0R/C9%$$"D U?^"AGCGQKKOPDO?V0_@$\,_P 4
M/BWH]YHN@^8I:+0=.E007VO76/N6]I%-N7/^NN'MX%YEX])_9@_9X^'O[)7[
M._@O]F?X56LD7A[P/X=M=(TPSD&65(8PIFD( !DD;=(Y &6=CWKX2\&?L)_\
M%^O ?CWQ9\3="_X*!_ 9]=\9ZD+G6-3OOA;=W$PACW"VL8F>4F*TMU=EBA7Y
M07DD.Z6661_8?B!^RU_P59UK]@MO@;X6_;@\+?\ "Y?$VK74WC?XI7^AW$-O
M:V4KL%M=(M;8I]B*P+!") 0RD32KB:02* 6/BG\,++_@H=^W%\/M86!;CX4_
MLU^*[C7KC5"-T7B+QS'&UO;6ML?XHM,#S232J2OVIXX!EK>X5/K^OSL^'O[#
MO_!=3PWX;T#X-2_\%!_@QX9^']C]ET^^LOA_\*GL;^VTE659HK*5V98)C#O5
M)<;E<A@0PW5^B8 4!1G@=S0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Q7Q)_9R^!GQ>\1:;XT^(7POTF_\ $&B@
MC0_$RV_D:KI@.=WV:]B*W%OG)SY<BYR<]:["PLH=-L8=.MWE:.")8T:>=Y9"
M%  +.Y+.W'+,22>22:EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "N%LOV9?@-H_Q+N?C'X9^&6G:'XHU
M"9)=8UOPZ'TZ?5F4Y7[<UJT?VX#)PMQY@&3Q7=44 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>jnj-20230402_g4.jpg
<TEXT>
begin 644 jnj-20230402_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HKQ;XM?M??\ "KOB#J'@3_A7GV[[#Y7^E?VMY6_?$DGW?*;&
M-^.IZ9KG/^&_O^J3?^5[_P"T5]%0X3X@Q-&-6G1O&233YH:IJZWD?-U^+N'L
M-7E1J5K2BVFN6>C3L]HVW/HRBOG/_AO[_JDW_E>_^T4?\-_?]4F_\KW_ -HK
M7_4WB3_GQ_Y-#_Y(R_UUX9_Y_P#_ )+/_P"1/HRBOG/_ (;^_P"J3?\ E>_^
MT4?\-_?]4F_\KW_VBC_4WB3_ )\?^30_^2#_ %UX9_Y__P#DL_\ Y$^C**^<
M_P#AO[_JDW_E>_\ M%'_  W]_P!4F_\ *]_]HH_U-XD_Y\?^30_^2#_77AG_
M )__ /DL_P#Y$^C**^<_^&_O^J3?^5[_ .T4?\-_?]4F_P#*]_\ :*/]3>)/
M^?'_ )-#_P"2#_77AG_G_P#^2S_^1/HRBOG/_AO[_JDW_E>_^T4?\-_?]4F_
M\KW_ -HH_P!3>)/^?'_DT/\ Y(/]=>&?^?\ _P"2S_\ D3Z,HKYS_P"&_O\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\6_M:?\G ^(/\
MMT_])(:\YKT;]K3_ ).!\0?]NG_I)#7G-?T3DG_(EPW_ %[A_P"DH_F_//\
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M10 5^<]?HQ7YSU^G>''_ #%?]N?^WGY;XE?\PO\ W$_]L"BBBOTX_+0HHHH
M***AMM1T^]GN+:SOH9I+.80W<<4H9H)"BR!' ^ZVQT;!YVNIZ$4 34444 %%
M%% !1110 4444 %%%% 'VE^R7_R;]X?_ .WO_P!*YJ]&KSG]DO\ Y-^\/_\
M;W_Z5S5Z-7\[YW_R.L3_ -?)_P#I3/Z/R/\ Y$F%_P"O</\ TE!1117EGJA1
M110 4444 %%%% !1110 4444 %%%% !1110!\6_M:?\ )P/B#_MT_P#22&O.
M:]&_:T_Y.!\0?]NG_I)#7G-?T3DG_(EPW_7N'_I*/YOSS_D=XK_KY/\ ]*84
M445Z9Y850\5>&]+\9>&-2\(:Y&SV6JV$UG>(C;6:*5"C@'L=K'FK]8OQ(/C$
M?#O7S\.P#X@_L6Z_L(-LQ]L\EO)SYGR?ZS;][Y?7BIG90=U<J%^=6=O,_,[X
M?_$;XQ_\$:_C]X+^$G[7WG>)_@UI?A[7]+^'WQ#T*R,MQIMC>7^E2R?VA"I+
M*D$D5NG )'VK"-* L:^O?\%=?BY<6W['OPW_ &>?V5M:M1;?'+Q=I?A;1;_1
MKT"&32;@ E89AD!)=T,9/(,<CBMWXD?'_6/BGXR\-:'\0OV/O'=SXIU'X->+
M=+U;X=7WAIF@N[R>ZT &);TDV;6I9'!N/-VHI0L%9T5N:UW_ ()I?&GPG_P3
MA^"_PR\):E9ZQ\5?@7XFL_&&C6SW@2WU"\CO);N735F? 5,3>6CL "8(\[58
MD?%NCB8X?$87"MRI\NFCYHJT+POUO&]E\2Y;.]T?;*MAI8G#XK%I1J\VNJY9
M:SM.RVM*SD_A?-=6LSL?&'[4?Q8_X)Y>)_A9\+OC'\$?!FG_  A\27]KX2T3
M5O!.KW4LGABZV!;:*Y%Q#&+B)E4GS$5&Q'(Q7*A7^Q*^3?VIO ^M_P#!1+1_
MAK\*-)^%OBKP]HNF>/=.\3^.]0\6Z#+IQTZ"S21C81"8#[3<3/((Q)!YD**)
M&,A^16]H_P"%U?$__AJW_A0G_#.VM?\ ")?\(C_:W_"SOMJ_8?M?G;/L'E;/
MO[?FSOW?],]OSU[^#JSHU9QE)NG>*@[=6M5HMEIJ]$VU?2R\#&TH5J,)1BE5
M2DYJ_1/1ZOXGKHM6DG;6YX%_P66 /@[]G[(Z?M2>$O\ T&\K['KY!_X*S>%O
MB1\2]+^#_AOX5_";Q/XGNO"WQNT#Q7KG]C:0\D=OIMH+D2MYC81Y,R+B-26[
MD#C/UKH^J6^MZ7!JUK!<Q1W$8=([RTD@E4'LT<BJZ'V8 U6$O_:F(??D_!._
MW=2,7;^RL,NW/^+5OOZ%FBBBO5/)"BBB@ KZ,_8!_P"9M_[</_;BOG.OHS]@
M'_F;?^W#_P!N*^8XR_Y)NO\ ]N_^EQ/J>"O^2FH?]O?^D2/HRBBBOPH_>PHH
MHH **** "BBB@ HHHH *_.>OT8K\YZ_3O#C_ )BO^W/_ &\_+?$K_F%_[B?^
MV!1117Z<?EH4444 ?-O_  5C^-GQ4_9^_8HU_P")'PGGU&TN(=2T^WUK5]'C
M#7>F:9+<HEU<09!"R",E%<CY#)OX*@CSG]GOX,?"_P",J^,?C9^QQ\6M=B^Q
M_%O0KO1M?TOQO?SPZQIBZ1X?EO;6]6>9Q=;T:Z5O/!E27C*E2M?8/C#5_!=I
M;VGAGQN]HUOXDNFTJ"SOH/,BO9'AE<P,I!4AHXY.&X;&WDD _F3\6OA=XX_X
M)<?$WXE?MA?L9^(&T[X?^'OBII>B>-?@W(SOI^H6=YIFD3>=: DF.X%Q?N%Q
M]U64+^[1HF^9S=/#XI8FHN>DM))?%"RD^:/E9W?7W4U?8^HR9QQ&%>%IODJ[
MQ;^&=W!<LO.ZM'[/O-.VY]&?\%8OVO?A/\$]'\'? /XG?&?Q5X TWQ[J,C^)
M/&/@J.7^TM)TRW7?^XDBCD,4DUQY,6[:W[H7& 2 *['_ ()[_ 7X+>"_#EU\
M;/@C^V9\3?C#HWBBSCAL]0\<^/SK%M:"-B7$,:Q1B&4D@.'4NNP+\OS _0^K
MZ/I'B#2Y]$U[2[:^LKJ(QW-I>0++%,AZJR,"&!]",5\C?L8_L]:/^S!_P4,^
M-?PY^!=M]A^&VJ>%M#UZ[T"V/^AZ-KEQ)<HT$"](]\$/G%%^ZLD(P%$8'56H
M5J6;0KS2G&3Y5NI0]UONU).SOHFK]4CEHUZ%7)YT(-PE%<SV<9^\EV3BU=6U
M:=K:-GNG[:/QWOOV8_V4O'WQ[TG38[N^\,>&[B[TZWF!,;W.-D.\#DIYC(6Q
MSM!KYJ^(/PC\06'_  3.M_VQO ?Q8\2+\6](^&]OX];QV^OW#MJ%PMHM_<V\
ML!?R'LY$\R);4IY2*4"J"H-?8?Q5^&/@WXT_#37OA)\0]+^VZ'XDTJ?3M5MM
MY4O#*A1MK#E6 .0PY! (Y%?G]^UU\%_VA?V./V&C^Q7X&_:JN?&__"=R'P;\
M*_!@\%P1:U<6UP=LUM->F>19+6"U:3?*+>(H"B^9&I7&6<JM3<ZLHN5/V;2L
MU>,[Z-7:=WHDU=IK3<UR5T:BA2A)1J>T3=T[2A;5-I-66KDG9-/78^X?V4_C
MA#^TI^S9X'^/4>GI:/XK\-6FH7-G&25MYWC'FQJ3R563>H)Z@ UZ!7!?LM?!
M.W_9P_9P\$? BWO5N3X4\,V>G7%T@(6XFCB42R@'H&DWL!V#5WM>UAO;?5H>
MU^*ROZVU_$\/%>Q^LS]C\%W;TOI^ 4445N8!1110!]I?LE_\F_>'_P#M[_\
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M/Q/::0FESW/@OQ?+817UHKNZQ3Q896 9V/ 4\@GD CT?X9_"OP/\(?#[^'/
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MM8OX[?6_$NE.JW^GZ?M=YFM"P*K<.52%9"#Y8F:0 L@!^)_C/^SSX\_X)O\
M[3OP1^(_[,WQW\?ZSHGQ%^)EEX0\;^"?&'B:;5(;Z.ZW,;Q/,Y1XT25R_)4A
M""%+JWZ#:WK>C^&]'N_$7B+5;:PL+"V>XO;V\G6.*WB12SR.[$!550223@ 9
MKQ7PMX5A^.'Q:L/VP/BE;G2_#'@[3KL?#33-77[.T,<R8NM=NE?'E/)"OEPQ
MO@Q0%W?:\[)%X^98.GB91<?XETT[_"DTV_2U[_S-I/3;V<LQE7#0DI:TK--6
M7O-II+UO9K^5)M:[]_\ 'GXOI\'/!"ZIIFBG6/$.K7B:9X1\/1R['U74Y0WE
M0[L'9& KRRR8(BABED(PAKYF_P""1^L_%B_\;?M&Z-\9?B1<^*-;TCXS7%E<
MZE*66'=' BLL$3,1!"",)&#A5 '.,UH_%CQ9^W]X:_:[USXE>"_V ;7XD^']
M*T^/3?AYJS_%S3=)CM+:6..2\G%O-%(_GS2@(TC;<101HH :1I/*/^"1/Q0_
M:4U;]J'X]:/XH_99BTG2-;^+VI7GC+61X[M;@^&=1$.18"%8PUZ"P5?/C*J-
MV<<5PUL:JF<4$U-6E**7)-+X6KWY;.[ZW:4==+L[Z.!]GDM=IP;<8R;YX-_$
MG:W-=672R;EIK9'WI\6M5\9Z#\*_$VN?#C2%U#Q#9>'[V?0;!UR+F]2!V@B(
M[AI JX]Z_/CP+\:/@_\ %'_@F!/^T#X%^*GB*\^/=O816DM]%KMRWB$^-7)\
MJQ6V#Y:"6=6"6HC,!M@PV;4?;^@7QH^)=A\&/@]XL^,.J:9->VWA3PU?:Q<6
M=M_K)X[6W>=HU_VF"$#W-?G-XS_8_P#BL?@3HG_!9K]G+QI8Z%\:[KPX?'7B
M?1K.RC31=6TRXMEN9-.$*@8=+7"F0LSS2"1F8.ZNE9W*LJJ]DN:T)<RZI77O
MQU7O+HNNMFGO.11HND_:OEO./++HY6?N2T?NOJ^CM=-;?0?QZ\4_%#QE^UM^
MS/\ LW_%Y6M=#\4^'=;U?QUI.GW+QVNKZK9Z=&RVCLC R012R/+Y1)5R$+ A
M15K_ ()S?'&]T7X%_&(?%WQK._A;X2?&3Q5H&A^(-9NWF=="L9$DBWS.2\PB
M$CQAB6)6-5&<8KUSP;IGPV_;0^ OPY^,WCOP--;S:GH>G^)M%\C4)[2^T:XN
MK-7/D75N\<T3;)GC8HR[U)!R#BN+\&?"WX?^//'%K\"_A9X6MM,^$OPKU<3Z
MO:VVYHM?\2+(+A+=G8EITM9&%S.[%C)=M$K,6@F4ZJA6ABUB(3YE+X;WNTXQ
M23_NKE<WZZ*[UR=>A4PCPU2'*X?%:UDU.3;7]Y\R@M.FKLM.W_9V\-^-/$-Y
MJG[1'Q4L;NPUOQ;%&FD^';MB/^$?T:,LUM:,F<+<ON,]P>OF2"+++!&:]2K\
M]O$O[>OQ_L?V:?'7_!0"W\;W$>E^$/C<= M?A\+"V^QW'A^*_@T]XG)B,_VQ
MS,T_FB3"LJJ%V;E;]":[<NQ=#$1<*=]$I7?52;M+YM/32W9'#F6#Q&'FIU+:
MMQLNCBHWC\E):ZW[L****](\P*^C/V ?^9M_[</_ &XKYSKZ,_8!_P"9M_[<
M/_;BOF.,O^2;K_\ ;O\ Z7$^IX*_Y*:A_P!O?^D2/HRBBBOPH_>PHHHH ***
M* "BBB@ HHHH *_.>OT8K\YZ_3O#C_F*_P"W/_;S\M\2O^87_N)_[8%%%%?I
MQ^6A7"^,_P!G;X6?$KXGV7Q0^)GA6Q\17&CZ2;+0;'6K*.YMM,:21FN+B*-P
M5$TH$*,^-P6 !2 SANZKP/\ ;4_;Y^"W[)(TKP'XD^)WAW2/&'B?*Z/'KUR1
M;:=!R'U"[5#O\E,':BX:9P(U*C?)'RXRIA:-!SQ#7*K;[7Z;^>WF=6#I8NM7
M5/#IN3OMO;KMTMOY'D7[-?P!\-_##_@L5\5]=_9^T*#1/!*?"S38_&^E:5$(
M;$>)+FY$T*K$N$5Q:1F4[1\IN22!YN3Q7[<?C;XN_#;]IWQ'\<_VHO\ @F)8
M_%SX+:3IMKIVA:S*^G:K/H-G'NDO+]+"19=C2R/EW<1?N[>$,Z[6S[G^R%^U
MI^PK<ZUIW[/G[.7QPA\>>*?$%Y>:KKVH6$+S7-[<F,RW6IWLNQ4C#,J1@# 7
M=#%&@10%[S2_V\OV+?$L?B*RM_VCO"1E\-:E/IFOZ;?:DL%S!<1.8WB^SR[9
M)<N"B[%82-PFX\5X4</@JN!Y(5XPO.4M'!QN]>6SNFDFF[6UUT/?EB<;2Q_/
M4P\IVA&+NIJ5E9<UU9IMII-WTTU-S]E/Q+^SOXT^ 'ASQC^RGHVAZ?X#U6T:
MZT.S\.Z3'8VT.^1C*OD1JJQ2"7S ZX!#AL\YK:^,WQ8T+X*_#^[\=:U9W%[(
MCQVVEZ18@-<ZI?3.([>S@4\-++*RHN< 9+,0JL1X7^P_X0\+_L._L6:]XS^*
MBR>#_"R>(M?\6)IM_;2!_#^C7%W)-:V[Q("ZR+;>46B"EE=V3!85:^-WP@\>
M_MPVWPS_ &C_ -DO]M-O!.E:9I]SJ.A7L/@.VUB*_-Y$B)="*^*B&5(O-C!*
M;U$\J_+N<'T88JNLOARP7M>5/D5DU>R;2DUHMTFUVO<\VIA:#S&?--^R4FN>
M5VG:[2;BGJ]FTGWM8\.^'OPT\6> O^"U/@O7OB;K*:AXQ\4_ [4M6\53V\K-
M;07#7Q1+2V#?=MX(DCA3@%_+,C#?(Y.?\>HY?AKXM_;A\,_&&%WU7XH^"].3
MX8VTD1>7Q$K:1<65O:V*8)GEANW5&C0%D9PY&&#'D_$?[/7[;6G?\%<_ _@O
M7/\ @H;<:CXKE^$-W>V_C4_"O28FAT];]A)I_P!D4^4P=@6\X_.N[ X%?H[\
M6OBCX9^#/P^U'XB^+#.]K8(HBM+.+S+B]N)'6."U@3_EI-+*Z11I_$[J.]>-
M@\*L31KJ2=-0J2=Y<KWI\KO:3NTFVW?=[O4]K&XIX6O0<6JKG3BK1YEM4YE:
M\59-I)*VRV6AXAX=U'XQ^'/V<OA-^Q]9:Y<6OQ/UCX?:9;>*]:CD$DOARSM[
M2&*_U%FY!G\S,$&<[YY ^&2*7'N_P[\*>"/A_P"#K#X>?#RRMK72= MDL+2R
MM9-PMUC4 (QR26QR2QW$DDY)S7SI\=O"/QQ^$?["GQE^.-G(Y^,'B7P?>:EJ
M=SI4ID;2A' XAL;-QR8[.!I-C+C?-YLV TS"O+/@E::+\-OVN?V4-&_9YL[:
MWTWQ?\"=0E^(::4BA;ZPBLK::RO;G;_K)#>2.!,^6+32#=\[9]".+>#K0A*+
M=U!:O5*4E!+;5W]Z>UO.R//EA%C*$YQFE9S;LM'*,7-O?16]V&]]7I=GWS11
M17OGSP4444 ?:7[)?_)OWA__ +>__2N:O1J\Y_9+_P"3?O#_ /V]_P#I7-7H
MU?SOG?\ R.L3_P!?)_\ I3/Z/R/_ )$F%_Z]P_\ 24%%%%>6>J%%%% !1110
M 4444 %%%% !1110 4444 %%%% 'Q;^UI_R<#X@_[=/_ $DAKSFO1OVM/^3@
M?$'_ &Z?^DD-><U_1.2?\B7#?]>X?^DH_F_//^1WBO\ KY/_ -*84445Z9Y9
MYO\ M1?LN_#_ /:Y^&__  J?XHZ[XBM=#>\CN;NV\/:T]B;MDY1)609= V&V
M=-RJ3RHQXKI?_!&;]D:PUFQU74?$GQ)U>*QOX;K^S=:^(-Y<VEPT4BR*DL3G
M;(A*@%3U&17UE17%7R[ 8FK[2K34I=VK['=0S+,,-2]G2JN,>R=MPK@?@O\
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M-^\/_P#;W_Z5S5Z-7G/[)?\ R;]X?_[>_P#TKFKT:OYWSO\ Y'6)_P"OD_\
MTIG]'Y'_ ,B3"_\ 7N'_ *2@HHHKRSU0HHHH **** "BBB@ HHHH \V_:1_9
M;^'G[4FB:;H'Q#USQ)8PZ5=/<6[^&]?FL'9F7:0[1'+C'8]Z\B_X=#_LS?\
M0_\ Q3_\./>_XU]344 ?+/\ PZ'_ &9O^A_^*?\ X<>]_P :/^'0_P"S-_T/
M_P 4_P#PX][_ (U]344 ?+/_  Z'_9F_Z'_XI_\ AQ[W_&C_ (=#_LS?]#_\
M4_\ PX][_C7U-10!\L_\.A_V9O\ H?\ XI_^''O?\:/^'0_[,W_0_P#Q3_\
M#CWO^-?4U% 'RS_PZ'_9F_Z'_P"*?_AQ[W_&C_AT/^S-_P!#_P#%/_PX][_C
M7U-10!\L_P##H?\ 9F_Z'_XI_P#AQ[W_ !H_X=#_ +,W_0__ !3_ /#CWO\
MC7U-10!\L_\ #H?]F;_H?_BG_P"''O?\:/\ AT/^S-_T/_Q3_P##CWO^-?4U
M% 'RS_PZ'_9F_P"A_P#BG_X<>]_QH_X=#_LS?]#_ /%/_P ./>_XU]344 ?+
M/_#H?]F;_H?_ (I_^''O?\:/^'0_[,W_ $/_ ,4__#CWO^-?4U% 'RS_ ,.A
M_P!F;_H?_BG_ .''O?\ &C_AT/\ LS?]#_\ %/\ \./>_P"-?4U% 'RS_P .
MA_V9O^A_^*?_ (<>]_QH_P"'0_[,W_0__%/_ ,./>_XU]344 ?+/_#H?]F;_
M *'_ .*?_AQ[W_&C_AT/^S-_T/\ \4__  X][_C7U-10!\L_\.A_V9O^A_\
MBG_X<>]_QH_X=#_LS?\ 0_\ Q3_\./>_XU]344 ?+/\ PZ'_ &9O^A_^*?\
MX<>]_P :/^'0_P"S-_T/_P 4_P#PX][_ (U]344 ?+/_  Z'_9F_Z'_XI_\
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M_#CWO^-?4U% 'RS_ ,.A_P!F;_H?_BG_ .''O?\ &C_AT/\ LS?]#_\ %/\
M\./>_P"-?4U% 'RS_P .A_V9O^A_^*?_ (<>]_QH_P"'0_[,W_0__%/_ ,./
M>_XU]344 ?+/_#H?]F;_ *'_ .*?_AQ[W_&C_AT/^S-_T/\ \4__  X][_C7
MU-10!\L_\.A_V9O^A_\ BG_X<>]_QH_X=#_LS?\ 0_\ Q3_\./>_XU]344 ?
M+/\ PZ'_ &9O^A_^*?\ X<>]_P :/^'0_P"S-_T/_P 4_P#PX][_ (U]344
M?+/_  Z'_9F_Z'_XI_\ AQ[W_&C_ (=#_LS?]#_\4_\ PX][_C7U-10!\L_\
M.A_V9O\ H?\ XI_^''O?\:/^'0_[,W_0_P#Q3_\ #CWO^-?4U% 'RS_PZ'_9
MF_Z'_P"*?_AQ[W_&C_AT/^S-_P!#_P#%/_PX][_C7U-10!5T+1[7P]HEGH%E
M)*\-C:QV\+SR%W944*"S'EC@<D]35JBB@ HHHH **** "BBB@ HHHH ****
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M*;&RO9$BMEMD:VU":QDSD0K/MMXY5)YL3R2N:\^_X+T^$?\ @E';_L[>"O\
M@F:_C;X6?"_X@Z_XUT*#P9JIBB@F\#VR7<,]WJ=Q-&N^W$EH)8E,SJ9Y;J-F
M;&^5 #]9:*BL8D@LH88[EYE2)56:1]S2 #[Q/<GKFI: "BBB@ HHHH ****
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M/AAHO@_XKK\:!/JUYX1TN*P:Y\&6,'VC6#="!5#Q+&8H%+_\_IC!_>X/Z=T
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M_P#QJNVTS1='T31[?P]HVDVUII]I;+;VMC:P+'##"JA5C1% 54"@ *!@ 8H
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M\(_#;0]%\07PF\S[1?6MA!!/)O\ XLR(QW=\YKTJBB@ HHHH **** "BBB@
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MK;>'_B)X>\)6T>D^$OB3X0>/3[J33H_EB_M33;@JL4L:  RVTUP9<99 ^YG
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MFN>&K#P7K?P?\+7FCZ6S-IFDW7A^VDMK,G.3%$R%(\Y.=H&<F@#\_P#X!_\
M!7G_ ()8:1XUU3]ISXJ_MG^#_&/QG\:6<&D:;X7\%BYU&72K(RYM/#>E+Y2F
M5GG=3+.VS[3<OO?RHHX8X/TI!) )!''0]JX?2?V9/V;=!U2VUS0_V?/ ]E>V
M5PD]G>6GA.SCE@E1@R2(ZQ@JRL 0P(((!%=Q0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>jnj-20230402_g5.jpg
<TEXT>
begin 644 jnj-20230402_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "OAG]H3_DMGB7_ +"C_P!*^YJ^&?VA/^2V>)?^PH_]*_0/#S_D95O\'_MR
M/SOQ&_Y%E'_'_P"VLXVBBBOUP_'PHHHH ***AMM1T^]GN+:SOH9I+.80W<<4
MH9H)"BR!' ^ZVQT;!YVNIZ$4 34444 %%%% !1110 4444 %%%% 'Z">!_\
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MK3_XU1_PUG^T#_T/_P#Y2K3_ .-5YS11_8F2_P#0-3_\ C_D']N9W_T%5/\
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MCX4444 %%%% &?XK\5^&_ WAN]\7^+]:M].TS3K=I[V]NI L<,:CDD_TZDX
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M_P#R/G_@E^:/6J***_%S]M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO[*RU>;Q)IOV-[B:X$[#RX6/F*@$.<R!2=X^4#D^R5\<?L! #_@HK^V, /\
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M/[X__$K5?C!\7OV>+;6?$>MRI+JFIOK^HPF=UC6-3LBN51<(BCY5'3UKQ?\
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M+_M^/Y,^W\/_ /D?/_!+\T>M4445^+G[:%%%% !1110 4444 %%%% !1110
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M_P##CWO^-'_#H?\ 9F_Z'_XI_P#AQ[W_ !H ^IJ*^6?^'0_[,W_0_P#Q3_\
M#CWO^-'_  Z'_9F_Z'_XI_\ AQ[W_&@";]O/_D=-"_[!;_\ HPUX/7N7_#H?
M]F;_ *'_ .*?_AQ[W_&C_AT/^S-_T/\ \4__  X][_C7WV5<<?V9E]/"_5^;
MD5K\]KZM[<K_ #/S[-^!?[5S&IBOK'+SN]N2]M$M^9=NQX;17N7_  Z'_9F_
MZ'_XI_\ AQ[W_&C_ (=#_LS?]#_\4_\ PX][_C7H?\1'_P"H7_R?_P"T/._X
MAK_U%?\ DG_VYX;17N7_  Z'_9F_Z'_XI_\ AQ[W_&C_ (=#_LS?]#_\4_\
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M/_Q3_P##CWO^-'_$1_\ J%_\G_\ M _XAK_U%?\ DG_VYX;7U]^Q9_R1./\
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M[=\6>+?"W@+POJ/C?QOXCL='T;2+*6\U75=3ND@M[.WC4O)++(Y"HBJ"2Q(
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MC;46.E2QW%[X06^6*]U&& CS#&4MH+A<J&^SLTC*NT@ '0_\' _CZ[_9)O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440985360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr.  02,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Johnson & Johnson<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1024240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Johnson & Johnson Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Brunswick<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">524-0400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,598,734,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000200406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, Par Value $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes Due May 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.650% Notes Due May 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes Due November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">5.50% Notes Due November 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24BP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes Due November 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.150% Notes Due November 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes Due May 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.650% Notes Due May 2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756437592624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Note 4)</a></td>
<td class="nump">$ 19,170<span></span>
</td>
<td class="nump">$ 14,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash (Note 4)</a></td>
<td class="nump">7,695<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">5,443<span></span>
</td>
<td class="nump">9,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, trade, less allowances $207 (2022, $203)</a></td>
<td class="nump">16,350<span></span>
</td>
<td class="nump">16,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Note 2)</a></td>
<td class="nump">12,809<span></span>
</td>
<td class="nump">12,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">2,921<span></span>
</td>
<td class="nump">3,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">64,388<span></span>
</td>
<td class="nump">55,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment at cost</a></td>
<td class="nump">50,367<span></span>
</td>
<td class="nump">49,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(30,193)<span></span>
</td>
<td class="num">(29,450)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">20,174<span></span>
</td>
<td class="nump">19,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (Note 3)</a></td>
<td class="nump">47,448<span></span>
</td>
<td class="nump">48,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Note 3)</a></td>
<td class="nump">45,575<span></span>
</td>
<td class="nump">45,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred taxes on income (Note 5)</a></td>
<td class="nump">8,817<span></span>
</td>
<td class="nump">9,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">9,567<span></span>
</td>
<td class="nump">9,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">195,969<span></span>
</td>
<td class="nump">187,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">17,979<span></span>
</td>
<td class="nump">12,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,909<span></span>
</td>
<td class="nump">11,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">11,204<span></span>
</td>
<td class="nump">11,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued rebates, returns and promotions</a></td>
<td class="nump">14,784<span></span>
</td>
<td class="nump">14,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee related obligations</a></td>
<td class="nump">2,231<span></span>
</td>
<td class="nump">3,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes on income (Note 5)</a></td>
<td class="nump">4,266<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">60,373<span></span>
</td>
<td class="nump">55,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note 4)</a></td>
<td class="nump">34,928<span></span>
</td>
<td class="nump">26,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred taxes on income (Note 5)</a></td>
<td class="nump">4,417<span></span>
</td>
<td class="nump">6,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Employee related obligations (Note 6)</a></td>
<td class="nump">6,665<span></span>
</td>
<td class="nump">6,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term taxes payable (Note 5)</a></td>
<td class="nump">4,296<span></span>
</td>
<td class="nump">4,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">14,421<span></span>
</td>
<td class="nump">10,437<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">125,100<span></span>
</td>
<td class="nump">110,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock &#8212; par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)</a></td>
<td class="nump">3,120<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss) (Note 7)</a></td>
<td class="num">(12,626)<span></span>
</td>
<td class="num">(12,967)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings and Additional paid-in capital</a></td>
<td class="nump">124,558<span></span>
</td>
<td class="nump">128,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Less: common stock held in treasury, at cost (521,519,000 and 506,246,000 shares)</a></td>
<td class="nump">44,183<span></span>
</td>
<td class="nump">41,694<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">70,869<span></span>
</td>
<td class="nump">76,804<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 195,969<span></span>
</td>
<td class="nump">$ 187,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440245888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 207<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">4,320,000,000<span></span>
</td>
<td class="nump">4,320,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,119,843,000<span></span>
</td>
<td class="nump">3,119,843,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">521,519,000<span></span>
</td>
<td class="nump">506,246,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756437512224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 24,746<span></span>
</td>
<td class="nump">$ 23,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SalesRevenueGoodsNetPercentToSales', window );">Sales to customers percent to sales</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">$ 8,395<span></span>
</td>
<td class="nump">$ 7,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CostOfGoodsSoldPercentToSales', window );">Cost of products sold percent to sales</a></td>
<td class="nump">33.90%<span></span>
</td>
<td class="nump">32.40%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 16,351<span></span>
</td>
<td class="nump">$ 15,828<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_GrossProfitPercentToSales', window );">Gross Profit Percent To Sales</a></td>
<td class="nump">66.10%<span></span>
</td>
<td class="nump">67.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">$ 6,138<span></span>
</td>
<td class="nump">$ 5,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SellingGeneralAndAdministrativeExpensePercentToSales', window );">Selling marketing and administrative expenses percent to sales</a></td>
<td class="nump">24.80%<span></span>
</td>
<td class="nump">25.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">$ 3,563<span></span>
</td>
<td class="nump">$ 3,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales', window );">Research and development expense percent to sales</a></td>
<td class="nump">14.40%<span></span>
</td>
<td class="nump">14.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ResearchAndDevelopmentInProcessPercentToSales', window );">In-process research and development percent to sales</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (235)<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_InvestmentIncomeInterestPercentToSales', window );">Interest income percent to sales</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net of portion capitalized</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_InterestExpensePercentToSales', window );">Interest expense, net of portion capitalized percent to sales</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">$ 7,228<span></span>
</td>
<td class="num">$ (102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherNonOperatingIncomeExpensePercentToSales', window );">Other (income) expense, net percent to sales</a></td>
<td class="nump">29.20%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_Restructuringchargepercenttosales', window );">Restructuring charge percent to sales</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings/(Loss) before provision for taxes on income</a></td>
<td class="num">$ (737)<span></span>
</td>
<td class="nump">$ 5,862<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales', window );">Earnings before provision for taxes on income percent to sales</a></td>
<td class="num">(3.00%)<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for/(Benefit from) taxes on income (Note 5)</a></td>
<td class="num">$ (669)<span></span>
</td>
<td class="nump">$ 713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_IncomeTaxExpenseBenefitPercentToSales', window );">Provision for taxes on income percent to sales</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="num">$ (68)<span></span>
</td>
<td class="nump">$ 5,149<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_NetIncomeAttributableToParentPercentToSales', window );">Net earnings percent to sales</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET EARNINGS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 1.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>AVG. SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">2,605.5<span></span>
</td>
<td class="nump">2,629.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">2,605.5<span></span>
</td>
<td class="nump">2,666.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CostOfGoodsSoldPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of goods sold percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CostOfGoodsSoldPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_GrossProfitPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross profit percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_GrossProfitPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncomeTaxExpenseBenefitPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax expense benefit percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncomeTaxExpenseBenefitPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InterestExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InterestExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InvestmentIncomeInterestPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment income interest percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InvestmentIncomeInterestPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NetIncomeAttributableToParentPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income Attributable to Parent Percent to Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NetIncomeAttributableToParentPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherNonOperatingIncomeExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other non operating income expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherNonOperatingIncomeExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense excluding acquired in process cost percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ResearchAndDevelopmentInProcessPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>research and development in process percent to sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ResearchAndDevelopmentInProcessPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Restructuringchargepercenttosales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring charge percent to sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Restructuringchargepercenttosales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesRevenueGoodsNetPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales revenue goods net percentage to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesRevenueGoodsNetPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SellingGeneralAndAdministrativeExpensePercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Selling general and administrative expense percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SellingGeneralAndAdministrativeExpensePercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440934528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings/(loss)</a></td>
<td class="num">$ (68)<span></span>
</td>
<td class="nump">$ 5,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(554)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) arising during period</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Employee benefit plans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax', window );">Prior service cost amortization during period</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax', window );">Gain (loss) amortization during period</a></td>
<td class="num">(33)<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change</a></td>
<td class="num">(68)<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Derivatives &amp; hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) arising during period</a></td>
<td class="nump">570<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to earnings</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="nump">573<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">341<span></span>
</td>
<td class="num">(699)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">$ 4,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756638208000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign Currency Translation</a></td>
<td class="num">$ (234)<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Securities</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Employee Benefit Plans</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives &amp; Hedges</a></td>
<td class="num">$ (154)<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440637744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Retained Earnings and Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Common Stock Issued Amount</div></th>
<th class="th"><div>Treasury Stock Amount</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jan. 02, 2022</a></td>
<td class="nump">$ 74,023<span></span>
</td>
<td class="nump">$ 123,060<span></span>
</td>
<td class="num">$ (13,058)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (39,099)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">5,149<span></span>
</td>
<td class="nump">5,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(2,787)<span></span>
</td>
<td class="num">(2,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">600<span></span>
</td>
<td class="num">(1,042)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(1,577)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,577)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Apr. 03, 2022</a></td>
<td class="nump">74,709<span></span>
</td>
<td class="nump">124,380<span></span>
</td>
<td class="num">(13,757)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(39,034)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jan. 01, 2023</a></td>
<td class="nump">76,804<span></span>
</td>
<td class="nump">128,345<span></span>
</td>
<td class="num">(12,967)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(41,694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="num">(68)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(2,942)<span></span>
</td>
<td class="num">(2,942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Employee compensation and stock option plans</a></td>
<td class="nump">295<span></span>
</td>
<td class="num">(777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(3,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,537)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Apr. 02, 2023</a></td>
<td class="nump">$ 70,869<span></span>
</td>
<td class="nump">$ 124,558<span></span>
</td>
<td class="num">$ (12,626)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (44,183)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756441434480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756443616992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="num">$ (68)<span></span>
</td>
<td class="nump">$ 5,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and intangibles</a></td>
<td class="nump">1,880<span></span>
</td>
<td class="nump">1,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">306<span></span>
</td>
<td class="nump">278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset write-downs</a></td>
<td class="nump">426<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Net gain on sale of assets/businesses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision</a></td>
<td class="num">(1,543)<span></span>
</td>
<td class="num">(926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit losses and accounts receivable allowances</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(524)<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accrued liabilities</a></td>
<td class="num">(2,572)<span></span>
</td>
<td class="num">(2,817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">(Increase)/Decrease in other current and non-current assets</a></td>
<td class="num">(915)<span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Increase in other current and non-current liabilities</a></td>
<td class="nump">6,328<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH FLOWS FROM OPERATING ACTIVITIES</a></td>
<td class="nump">3,257<span></span>
</td>
<td class="nump">3,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="num">(863)<span></span>
</td>
<td class="num">(607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from the disposal of assets/businesses, net (Note 10)</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired (Note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(3,774)<span></span>
</td>
<td class="num">(9,018)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales of investments</a></td>
<td class="nump">7,766<span></span>
</td>
<td class="nump">6,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities', window );">Credit support agreements activity, net</a></td>
<td class="nump">158<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other (primarily licenses and milestones)</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH FROM/(USED BY) INVESTING ACTIVITIES</a></td>
<td class="nump">3,315<span></span>
</td>
<td class="num">(3,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Dividends to shareholders</a></td>
<td class="num">(2,942)<span></span>
</td>
<td class="num">(2,787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(3,537)<span></span>
</td>
<td class="num">(1,577)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term debt</a></td>
<td class="nump">11,094<span></span>
</td>
<td class="nump">3,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term debt</a></td>
<td class="num">(5,388)<span></span>
</td>
<td class="num">(856)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs (Note 4)</a></td>
<td class="nump">7,674<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(2,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits', window );">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities', window );">Credit support agreements activity, net</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(239)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH FROM/(USED BY) FINANCING ACTIVITIES</a></td>
<td class="nump">6,138<span></span>
</td>
<td class="num">(4,385)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase/(Decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">12,738<span></span>
</td>
<td class="num">(4,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash equivalents beginning of period</a></td>
<td class="nump">14,127<span></span>
</td>
<td class="nump">14,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD</a></td>
<td class="nump">26,865<span></span>
</td>
<td class="nump">10,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of assets acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net cash paid for acquisitions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442151872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;1, 2023. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;1, 2023. </span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzI5ODUzNDg5MzQ2NA_6b98e8e9-0203-4faa-b7c5-6f9e7ebf5ed3">ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50)</span> &#8211; Disclosure of Supplier Finance Program Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company adopted the standard as of the beginning of fiscal year 2023, which requires that a buyer in a supplier finance program disclose additional information about the program for financial statement users. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company&#8217;s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier&#8217;s decision to participate in the program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of April 2, 2023, and January 1, 2023, $0.9&#160;billion and $1.0&#160;billion, respectively, were valid obligations under the program. The obligations are presented as Accounts payable on the Consolidated Balance Sheets. </span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Not Adopted as of April 2, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no new material accounting standards issued in fiscal first quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442254672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">INVENTORIES <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"/><td style="width:51.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442191056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2022. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:61.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,636&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,211)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,901)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,684&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,686&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,448&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The majority is comprised of customer relationships</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of April&#160;2, 2023 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:37.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.967%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.982%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January&#160;1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at April&#160;2, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Includes purchase price allocation adjustment for Abiomed </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.2 billion and $1.1&#160;billion for the fiscal first quarters ended April&#160;2, 2023 and April&#160;3, 2022, respectively.  Intangible asset write-downs are included in Other (income) expense, net. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442073104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of April&#160;2, 2023, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $0.7 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April&#160;2, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $44.3&#160;billion, $36.5&#160;billion and $10.0&#160;billion, respectively. As of January&#160;1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $43.3 billion,  $36.2 billion and $12.4 billion respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;2, 2023, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $343&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and </span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net investment hedge</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2023 and 2022, net of tax:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(929)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;2, 2023, and January&#160;1, 2023, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2023 and 2022: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"/><td style="width:34.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal first quarters ended in 2023 and 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:24.725%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.758%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.001%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.265%"/><td style="width:0.1%"/></tr><tr style="height:9pt"><td colspan="33" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:26.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8212; Significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8212; Significant unobservable inputs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of April&#160;2, 2023 and January&#160;1, 2023 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration for the fiscal first quarters ended 2023 and 2022 is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"/><td style="width:41.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2022 assets and liabilities are all classified as Level 2 with the exception of equity investments of $576 million, which are classified as Level 1 and contingent consideration of $1,120 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $1,138 million and $1,116 million, classified as non-current other liabilities as of April&#160;2, 2023 and January&#160;1, 2023, respectively.  Includes $4 million and $4 million classified as current liabilities as of April&#160;2, 2023 and January&#160;1, 2023, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents, restricted cash and current marketable securities as of April&#160;2, 2023 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"/><td style="width:33.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.201%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.513%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.589%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov&#8217;t securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov&#8217;t Agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and current marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relates to the Kenvue Inc. (Kenvue) debt offering. See debt schedule below for additional details.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the fiscal year ended January&#160;1, 2023, the carrying amount was approximately the same as the estimated fair value.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of April&#160;2, 2023 are as follows:  </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"/><td style="width:43.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;2, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:78.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 (750MM Euro 1.0909)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Notes due 2024 (500MM GBP 1.2359)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028 (750MM Euro 1.0909)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035 (1.5B Euro 1.0909)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Debentures due 2025*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35% Debentures due 2026*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05% Debentures due 2028*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Debentures due 2030*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90% Debentures due 2033*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10% Debentures due 2043*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05% Debentures due 2053*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20% Debentures due 2063*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average effective interest rate on non-current debt is 3.47%.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The excess of the carrying value over the estimated fair value of debt was $1.6 billion at January 1, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2023, Kenvue, a wholly owned subsidiary of the Company, priced an offering of senior unsecured notes in an aggregate principal amount of $7.75&#160;billion (tranches with an * in the above table). The senior unsecured notes (the Notes) will be senior unsecured obligations of Kenvue and will initially be fully and unconditionally guaranteed (the Guarantees) on a senior unsecured basis by the Company. The Guarantees will terminate upon (1) the completion in all material respects of the transfer of the assets and liabilities of Johnson &amp; Johnson&#8217;s Consumer Health Business to Kenvue and (2) Kenvue having registered equity securities. The Notes were issued in connection with Johnson &amp; Johnson&#8217;s separation of its Consumer Health Business. The proceeds of the Notes offering were placed in a segregated escrow account pending the transfer of the assets and liabilities of the Consumer Health Business to Kenvue and as such, classified as restricted cash as of the balance sheet date. On April 5, 2023, the net proceeds of the Notes were released from escrow upon completion of the Consumer Health Business transfer. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The current debt balance as of April&#160;2, 2023 includes $16.9&#160;billion of commercial paper which has a weighted average interest rate of 4.85% and a weighted average maturity of approximately three months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442073104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The worldwide effective income tax rates for the fiscal first quarters of 2023 and 2022 were 90.8% and 12.2%, respectively. This increase in the consolidated tax rate as compared to the prior year fiscal first quarter is primarily due to a $6.9&#160;billion charge related to the talc settlement proposal at an effective tax rate of 23.5% (for further information see Note 11 to the Consolidated Financial Statements).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the first fiscal quarter of 2022, there were favorable tax benefits due to income mix for mark to market adjustments to the Company&#8217;s investment portfolio and the impairment of the bermekimab AD IPR&amp;D, both at the U.S. statutory rate. Additionally, the prior year&#8217;s effective tax rate benefited from the impact of certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in 2022. These benefits were partially offset by incremental tax costs directly related to the planned separation of the Company&#8217;s Consumer Health business in the first fiscal quarter of 2022 as compared to the first fiscal quarter of 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company also received tax benefits from stock-based compensation that were either exercised or vested during each of the fiscal first quarters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of April&#160;2, 2023, the Company had approximately $3.8 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities in the next 12 months. As a result, the Company has classified approximately $1.7&#160;billion of unrecognized tax benefits and associated interest as a current liability on the &#8220;Accrued taxes on Income&#8221; line of the Consolidated Balance Sheet as of the end of the first fiscal quarter of 2023 in anticipation of final settlement. Subsequent to April 2, 2023, the Company made a payment for approximately $1.4&#160;billion to the U.S. Treasury for the estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Company&#8217;s unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442098832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pensions and Other Benefit Plans</a></td>
<td class="text">PENSIONS AND OTHER BENEFIT PLANS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.877%"><tr><td style="width:1.0%"/><td style="width:54.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.574%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(668)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial (gains) losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company Contributions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal three months ended April&#160;2, 2023, the Company contributed $27 million and $6 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442348752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE INCOME<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:34.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.991%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,813)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(965)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,626)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756441382528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">EARNINGS/(LOSS) PER SHARE<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings/(loss) per share to diluted net earnings/(loss) per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.454%"><tr><td style="width:1.0%"/><td style="width:69.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.065%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.789%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.068%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings/(loss) per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic/diluted*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,666.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings/(loss) per share (basic/diluted)*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>The diluted net earnings per share calculation for the fiscal first quarter ended April&#160;3, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#8217;s stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756446340800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments of Business and Geographic Areas</a></td>
<td class="text">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPRAVATO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CARVYKTI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:80pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDTECH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ELECTROPHYSIOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ABIOMED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INTERVENTIONAL SOLUTIONS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Inclusive of RISPERDAL CONSTA which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquired on December 22, 2022</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS/(LOSS) BEFORE PROVISION FOR TAXES BY SEGMENT </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"/><td style="width:55.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.818%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income/(loss) before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2023 and 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.7&#160;billion and $0.8&#160;billion in the fiscal first quarter of 2023 and 2022, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine related exit costs of $0.4&#160;billion in the fiscal first quarter of 2023.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.1 billion in the fiscal first quarter of 2023. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable changes in the fair value of securities in the fiscal first quarter of 2022 of $0.4&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MedTech includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.4&#160;billion and $0.3&#160;billion in the fiscal first quarter of 2023 and 2022, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.1 billion in the fiscal first quarter of 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Amounts not allocated to segments include interest income/expense and general corporate income/expense. The fiscal first quarter of 2023 includes the incremental $6.9 billion charge related to the talc settlement proposal. See Note 11, Legal Proceedings, for additional details. </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.736%"><tr><td style="width:1.0%"/><td style="width:48.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,024&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442191872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">ACQUISITIONS AND DIVESTITURES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no acquisitions or divestitures in the fiscal first quarter of 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Company&#8217;s position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcare&#8217;s largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $380.00 per share in cash, amounting to $17.1&#160;billion, net of cash acquired, as well as a non-tradeable contingent value right (CVR) entitling the holder to receive up to $35.00 per share in cash (which with respect to the CVRs total approximately $1.6&#160;billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $16.5&#160;billion includes cash, cash equivalents and marketable securities acquired. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The milestones of the CVR consist of:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">$17.50 per share, payable if net sales for Abiomed products exceeds $3.7&#160;billion during Johnson &amp; Johnson&#8217;s fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson &amp; Johnson&#8217;s fiscal first quarter of 2029, $8.75per share;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">$7.50 per share payable upon FDA premarket application approval of the use of Impella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">$10.00 per share payable upon the first publication of a Class I recommendation for the use of Impella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the acquisition was initially allocated to assets acquired of $19.9&#160;billion (net of $0.3&#160;billion cash acquired), primarily to goodwill for $10.9&#160;billion, amortizable intangible assets for $6.6&#160;billion, IPR&amp;D for $1.1&#160;billion, marketable securities of $0.6&#160;billion and liabilities assumed of $2.8&#160;billion, which includes the fair value of the contingent consideration mentioned above for $0.7&#160;billion and deferred taxes of $1.8&#160;billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities on the Consolidated Balance Sheet.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date. In the fiscal first quarter of 2023, there were purchase price allocation adjustments netting to approximately $0.1&#160;billion with an offsetting increase to goodwill.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortizable intangible assets were primarily comprised of already in-market products of the Impella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform with an average weighted life of 14 years. The IPR&amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52% to 70%. The discount rate applied was 9.5%.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, the Company recorded acquisition related costs before tax of approximately $0.3&#160;billion, which was recorded in Other (income)/expense. </span></div>There were no material acquisitions or divestitures in the fiscal first quarter of 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442191872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text">LEGAL PROCEEDINGS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of April&#160;2, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">MATTERS CONCERNING TALC</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and the Company arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in Ingham v. Johnson &amp; Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed, although LTL did agree to lift the stay on a small number of appeals where appeal bonds had been filed.   The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court&#8217;s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LTL filed a petition for rehearing of the Third Circuit&#8217;s decision, which was denied on March 22, 2023.  On the same day, LTL filed a motion in the Third Circuit to stay the mandate directing the New Jersey Bankruptcy Court to dismiss the LTL bankruptcy pending filing and disposition of a petition for writ of certiorari to the United States Supreme Court. On March 31, 2023, the Third Circuit denied the motion to stay the mandate and issued the mandate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 4, 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. Several hours later, also on April 4, 2023, LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case).  As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code.  Additionally, on April 5, 2023, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 20, 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction).  The LTL 2 Preliminary Injunction will remain in force and effect until June 15, 2023, subject to the New Jersey Bankruptcy Court revisiting its ruling at a hearing scheduled for May 22, 2023.  Under the LTL 2 Preliminary Injunction, except for in those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters is permitted to proceed. No trials may occur in any of the personal injury and wrongful death matters. On April 24, 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the original bankruptcy case, the Company agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2.0&#160;billion trust in furtherance of this purpose. The Company established a reserve for approximately $2.0&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. In the LTL 2 Bankruptcy Case, the Company has agreed to contribute an additional $6.9&#160;billion which, when added to the prior $2.0&#160;billion, will be a total reserve of present value of $8.9&#160;billion payable over 25 years (nominal value approximately $12.0&#160;billion discounted at a rate of 4.41%), to resolve all the current and future talc claims. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The expected payment schedule provides that approximately $6.0&#160;billion is paid in the first two years, with the remainder paid over the remaining 23 years. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Company&#8217;s then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jersey. In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC) (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the Tort Claimants&#8217; Committee (TCC) and Future Claimants&#8217; Representative (FCR) appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing &#8220;talc-related claims&#8221; against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023. The court subsequently extended the preliminary injunction through July 31, 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Imerys, the TCC, the FCR, certain of Imerys&#8217;s insurers, and certain parties in the Cyprus Mines chapter 11 case (collectively the Mediation Parties) have been engaged in mediation since October 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The Company filed a motion to dismiss the adversary proceeding. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, and that purchasers of the Company&#8217;s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In April 2021, briefing on Plaintiff&#8217;s motion for class certification was completed. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action and Plaintiff appealed the Bankruptcy Court&#8217;s order.  However, on March 31, 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case, which mooted the appeal, and on April 4, 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S Baby Powder. In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S Baby Powder and JOHNSON&#8217;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. In February 2022, the trial court set the case for trial to begin in February 2023. However, in October 2022, the LTL bankruptcy court issued an order staying the case. On March 31, 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and on April 4, 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. The trial court has indicated it will set a new trial date in this matter during the second fiscal quarter of 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Company&#8217;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#8217;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#8217;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexico&#8217;s discovery obligations. On March 31, 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and on April 4, 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Court&#8217;s stay until such time as the Supreme Court issues an order concerning the State of New Mexico&#8217;s discovery obligations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court.  In March 2023, the mediation was terminated.  The procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">MATTERS CONCERNING OPIOIDS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned narcotic raw material and active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments, including 20 suits filed by state or territorial Attorneys General following a multi-state investigation of opioid marketing practices. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors. In August 2019, the Company received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The majority of the opioid marketing cases have been filed in federal courts and coordinated in a multi-district litigation proceeding in the United States District Court for the Northern District of Ohio (Ohio MDL), with most of the remainder in various state courts. To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal. In November 2021, the Oklahoma Supreme Court reversed a $465&#160;million judgment entered against the Company and JPI on a public nuisance claim brought by the Oklahoma Attorney General, holding that the marketing of </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">lawful products was not actionable under the State&#8217;s public nuisance law, and directing entry of judgment for the Company and JPI. In February 2022, the Superior Court of Orange County, California, entered judgment for the Company, JPI, and three other pharmaceutical manufacturers on public nuisance and deceptive marketing claims brought by four California local governments, holding that the plaintiffs had failed to prove that any defendant&#8217;s marketing was deceptive or that any defendant&#8217;s allegedly deceptive marketing led to medically inappropriate prescribing. The California plaintiffs appealed from that judgment, but abandoned their appeal after electing to participate in the Company&#8217;s national settlement agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, after settling an initial test case brought by two Ohio counties in the Ohio MDL, the Company announced a proposed agreement in principle with a negotiating committee of state Attorneys General to settle all remaining government opioid litigation claims nationwide. Under the final national settlement agreement, which was announced in July 2021, the Company agreed to pay up to $5.0&#160;billion to resolve all opioid lawsuits and future opioid claims by states, cities, counties, local school districts and other special districts, and tribal governments, contingent on sufficient participation by eligible government entities, and with credits back for entities that declined or were ineligible to participate. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately half of the all-in settlement was paid by the first fiscal quarter of 2023. The expected payment schedule provides that approximately $0.6&#160;billion of payments are to be paid by the end of the first fiscal quarter of 2024. The agreement is not an admission of liability or wrongdoing, and it provides for the release of all opioid-related claims against the Company, JPI, and their affiliates (including the Company&#8217;s former subsidiaries Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc.). By February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement. The Company confirmed that this level of participation was sufficient to proceed with the agreement, which became effective in April 2022. Also in 2022, the Company completed separate settlements with most of the government entities that had declined to participate in the national settlement agreement, including all federally-recognized tribes, the States of Alabama, New Hampshire, and West Virginia and their participating subdivisions, and litigating Oklahoma subdivisions. Consequently, by the end of the fiscal year 2022, the Company and JPI had settled or otherwise resolved the opioid claims advanced by all government entity claimants except the State of Washington and its subdivisions, the City of Baltimore, a number of school districts and other special district claimants, and a handful of others.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants, including NAS claimants, hospitals, and health insurers/payors. Counting the private litigant cases, there are approximately 55 remaining opioid cases against the Company and JPI in various state courts, 545 remaining cases in the Ohio MDL, and 20 additional cases in other federal courts. Several of these cases are scheduled for trial in 2023, 2024, or 2025. In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Company&#8217;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state court&#8217;s dismissal order.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of April&#160;2, 2023:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"/><td style="width:73.479%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product or product category</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Plaintiffs </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Body powders containing talc, primarily JOHNSON&#8217;S Baby Powder</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PINNACLE Acetabular Cup System</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pelvic meshes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ETHICON PHYSIOMESH Flexible Composite Mesh</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RISPERDAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELMIRON</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TYLENOL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">MedTech</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">DePuy ASR XL Acetabular System and ASR Hip Resurfacing System</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">DePuy PINNACLE Acetabular Cup System</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Ethicon Pelvic Mesh</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre- and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia and in March 2023 the Federal Court approved the settlement. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Ethicon Physiomesh</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 2,308 have been dismissed with prejudice. Ethicon has received releases from 3,496 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of March 2023, there are approximately 225 active cases subject to these orders which are being reviewed and evaluated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products.  All litigation activities in the two New Jersey MCLs are stayed pending resolution of the proposed settlement.  Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Pharmaceuticals</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">RISPERDAL</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">ELMIRON</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Consumer Health</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">TYLENOL</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Claims for personal injury have been made against Johnson and Johnson Consumer Inc. (JJCI), arising out of the use of TYLENOL, an over-the-counter pain medication, alleging that prenatal exposure to acetaminophen is associated with the development of autism spectrum disorder and/or attention-deficit/hyperactivity disorder. In October 2022, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the Southern District of New York.  In addition, lawsuits have been filed in Canada against Johnson &amp; Johnson Inc. and the Company.  Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with TYLENOL related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Pharmaceuticals - Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDA&#8217;s publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations&#8221; (commonly known as the Orange Book). In each of these lawsuits, the Company&#8217;s subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company&#8217;s subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">XARELTO</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy&#8217;s Laboratories, Inc.; Dr. Reddy&#8217;s Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; USV Private Limited; Mankind Pharma Limited; Epic Pharma, LLC; Apotex Inc.; Apotex Corp.; Biocon Pharma Limited; Biocon Limited; Biocon Pharma, Inc.; and ScieGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218; and 10,828,310. In March 2023, the Company entered into a confidential settlement with Epic Pharma, LLC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. Patent No. 10,828,310 is also under consideration by the USPTO in an IPR proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">OPSUMIT</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; and Alembic Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in May 2020, Janssen Inc. and Actelion Pharmaceuticals Ltd initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against generic manufacturers who have filed ANDSs seeking approval to market generic versions of OPSUMIT before expiration of certain listed patents. The following entities are named defendants: Sandoz Canada Inc.; Apotex Inc.; and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Generic Medical Partners Inc. In March 2023, the Company entered into a confidential settlement agreement with Generic Medical Partners Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following Canadian patent is included in one or more cases: 2,659,770</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">INVEGA SUSTENNA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; and Accord Healthcare, Inc. The following U.S. patent is included in one or more cases: 9,439,906. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Teva Canada Limited; Pharmascience Inc.; and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">INVEGA TRINZA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">IMBRUVICA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in September 2021, Pharmacyclics LLC and Janssen Inc. initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of IMBRUVICA before expiration of certain listed patents. The following entities are named defendants: Natco Pharma (Canada) Inc.; and Sandoz Canada Inc. The following patents are included in one or more cases: 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">SYMTUZA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp.  The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">ERLEADA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">UPTRAVI </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in November 2022, Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc.; Lupin Ltd.; Lupin Pharmaceuticals, Inc.; Cipla Limited; and Cipla USA Inc. The following U.S. patents are included in one or more cases: 8,791,122; 9,284,280; and 7,205,302. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Like other companies in the pharmaceutical, consumer health and medical devices industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">MedTech</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#8217;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#8217;s July 2021 ruling. In November 2021, the District Court granted DePuy&#8217;s motion for reconsideration and dismissed the case with prejudice. The District Court&#8217;s order was unsealed in December 2021. The relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court denied. Following the District Court&#8217;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#8217; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#8217;s dismissal of the case to the First Circuit. The briefing on the appeal is complete, the First Circuit held oral argument on December 6, 2022, and the First Circuit&#8217;s decision remains pending.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2012, the Company was contacted by the California Attorney General&#8217;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by the Company&#8217;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against the Company, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In October 2019, the Company and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. Between April 2019 and February </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023, the Company settled with Washington, West Virginia, Oregon, Mississippi and Kentucky. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company&#8217;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $302&#160;million, but otherwise denied the appeal. In July 2022, the Supreme Court of California denied the Company&#8217;s petition to review the Court of Appeals decision, and the Company recorded a charge to reflect the judgment in the second quarter of 2022. In November 2022, the Company petitioned the United States Supreme Court for review. In February 2023, the Company&#8217;s petition to the United States Supreme Court was denied.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2017, the Company received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals.  The Company and DePuy fully cooperated with the government&#8217;s investigation. In January 2023, the Company, DePuy Synthes, Inc., and DePuy Synthes Sales Inc. entered into a settlement agreement with the United States resolving the matter for an immaterial amount. The only claim remaining before the United States District Court for the District of Massachusetts is the Relator&#8217;s employment retaliation claim.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Pharmaceuticals</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), the Company and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April and September 2017, the Company received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company (subsequently substituted by Johnson &amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision. In February 2023, defendants petition for rehearing on the decision was denied. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">MedTech</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#8217;s motion for summary judgment. In April 2022, Innovative appealed this ruling to the United States Court of Appeals for the Ninth Circuit.  Oral argument has been set for June 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Pharmaceuticals</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against the Company and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> In re REMICADE Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022.  The Court issued final approval in March 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#8217;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands.  Janssen is in ongoing discussions with the FTC staff regarding the inquiry. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. Janssen filed its Notice of Defense in July 2022. Genmab and Janssen have cross-moved for early disposition of the arbitration.  In April 2023, the Arbitration Panel ruled in Janssen's favor and dismissed Genmab's claims. In April 2023, Genmab announced that it intends to appeal the award.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In December 2021, several insurance companies and other payers filed individual &#8220;Opt-Out&#8221; complaints containing allegations similar to the original complaint. In September 2022, the Court granted in part and denied in part plaintiff&#8217;s motion for class certification. Trial was scheduled for May 2023; in March 2023, the Court issued an order dividing the matter into two separate trials.  The first trial, scheduled for May 2023, relates to claims that do not involve Janssen.  The court did not set a date for trial on the claims that do involve Janssen.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (EBSI) with the American Arbitration Association, alleging that EBSI breached the parties&#8217; Manufacturing Services Agreement for the Company&#8217;s COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> In July 2022, Emergent filed its answering statement and counterclaims.  The hearing is scheduled for March 2024.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Merck Sharp &amp; Dohme Corp. with the American Arbitration Association pursuant to the Parties&#8217; agreements relating to production of drug substance and drug product for the Company&#8217;s COVID-19 vaccine. Also in October 2022, Merck filed its answer and counterclaims.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The hearing is scheduled for September 2023.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Consumer Health</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2019, the Company received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. In November 2022, Johnson &amp; Johnson received a demand for indemnification from GlaxoSmithKline LLC (GSK), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer, and certain 1993, 1998, and 2002 agreements between Glaxo Wellcome and Warner-Lambert entities. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.  </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Beginning in May 2021, multiple putative class actions were filed in state and federal courts (California, Florida, New York, and New Jersey) against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products and the affirmative promotion of those products as &#8220;safe&#8221;; and, in at least one case, alleging a strict liability manufacturing defect and failure to warn claims, asserting that the named plaintiffs suffered unspecified injuries as a result of alleged exposure to benzene. The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In December 2021, plaintiffs in the consolidated actions filed a motion for preliminary approval of a nationwide class settlement. The court issued an order granting final approval of the settlement in February 2023. A Notice of Appeal was filed in April 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756436377920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New and Recently Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;1, 2023. </span></div><div><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recently Adopted Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzI5ODUzNDg5MzQ2NA_6b98e8e9-0203-4faa-b7c5-6f9e7ebf5ed3">ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50)</span> &#8211; Disclosure of Supplier Finance Program Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company adopted the standard as of the beginning of fiscal year 2023, which requires that a buyer in a supplier finance program disclose additional information about the program for financial statement users. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company&#8217;s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier&#8217;s decision to participate in the program. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of April 2, 2023, and January 1, 2023, $0.9&#160;billion and $1.0&#160;billion, respectively, were valid obligations under the program. The obligations are presented as Accounts payable on the Consolidated Balance Sheets. </span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Not Adopted as of April 2, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were no new material accounting standards issued in fiscal first quarter of 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442151872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"><tr><td style="width:1.0%"/><td style="width:51.896%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440243168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:61.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.325%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.587%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; gross</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,636&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,012&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles &#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,211)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,901)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,086&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,684&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,686&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets &#8212; net</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,448&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,325&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The majority is comprised of customer relationships</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of April&#160;2, 2023 was allocated by segment of business as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:37.585%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.967%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.814%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.399%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.982%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January&#160;1, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at April&#160;2, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>*Includes purchase price allocation adjustment for Abiomed<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Intangible Asset Amortization Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440710064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivative Activity</a></td>
<td class="text">The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2023 and 2022, net of tax:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.102%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.125%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.836%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income)  Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(929)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(531)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of net investment hedges for the fiscal first quarters ended in 2023 and 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.363%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.814%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.610%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.524%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated<br/>OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of April&#160;2, 2023, and January&#160;1, 2023, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges </span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,214)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Effect of Derivatives not Designated as Hedging Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2023 and 2022: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"><tr><td style="width:1.0%"/><td style="width:34.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.628%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.634%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Activity Related to Equity Investments</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:26.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.871%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.311%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales/ Purchases/Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Financial Assets and Liabilities at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of April&#160;2, 2023 and January&#160;1, 2023 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:48.229%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.202%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.904%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.850%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.905%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration for the fiscal first quarters ended 2023 and 2022 is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"><tr><td style="width:1.0%"/><td style="width:41.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.410%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 3, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2022 assets and liabilities are all classified as Level 2 with the exception of equity investments of $576 million, which are classified as Level 1 and contingent consideration of $1,120 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes cross currency interest rate swaps and interest rate swaps.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">           (3)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Classified as non-current other assets. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Includes $1,138 million and $1,116 million, classified as non-current other liabilities as of April&#160;2, 2023 and January&#160;1, 2023, respectively.  Includes $4 million and $4 million classified as current liabilities as of April&#160;2, 2023 and January&#160;1, 2023, respectively.</span></div>           (6)    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash, cash equivalents, restricted cash and current marketable securities as of April&#160;2, 2023 comprised:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"/><td style="width:33.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.201%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.513%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.589%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. reverse repurchase agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov&#8217;t securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov&#8217;t Agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Subtotal available for sale debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash and current marketable securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relates to the Kenvue Inc. (Kenvue) debt offering. See debt schedule below for additional details.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available for Sale Securities Maturities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale securities as of April&#160;2, 2023 are as follows:  </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"><tr><td style="width:1.0%"/><td style="width:43.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.279%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,942&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Financial Liabilities not Measured at Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments not measured at Fair Value:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;2, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"/><td style="width:78.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 (750MM Euro 1.0909)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Notes due 2024 (500MM GBP 1.2359)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,924&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028 (750MM Euro 1.0909)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95% Notes due 2029</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95% Debentures due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035 (1.5B Euro 1.0909)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85% Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Debentures due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50% Notes due 2048</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2050</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2060</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50% Debentures due 2025*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.35% Debentures due 2026*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05% Debentures due 2028*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.00% Debentures due 2030*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90% Debentures due 2033*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10% Debentures due 2043*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.05% Debentures due 2053*</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20% Debentures due 2063*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Non-Current Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442201632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of Net Periodic Benefit Cost</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans include the following components:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.877%"><tr><td style="width:1.0%"/><td style="width:54.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.763%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.574%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(668)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost/(credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial (gains) losses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost/(credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442081280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"/><td style="width:34.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.914%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.662%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.846%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.719%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.306%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.991%"/><td style="width:0.1%"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Accumulated</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">On Derivatives</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Comprehensive</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,813)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(965)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,626)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756446340800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings/(loss) per share to diluted net earnings/(loss) per share:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.454%"><tr><td style="width:1.0%"/><td style="width:69.605%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.065%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.789%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.919%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.068%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Shares in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings/(loss) per share </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,629.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares which could be repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(102.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding &#8212; basic/diluted*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,605.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,666.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings/(loss) per share (basic/diluted)*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.03)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756441974736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SalesBySegmentOfBusinessTableTextBlock', window );">Sales By Segment Of Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY SEGMENT OF BUSINESS </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:168pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,586&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX /</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">                                    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">            REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,048&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPRAVATO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CARVYKTI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,191&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> / </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">852&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER PULMONARY HYPERTENSION</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:80pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MEDTECH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ELECTROPHYSIOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ABIOMED</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;OTHER INTERVENTIONAL SOLUTIONS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"><tr><td style="width:1.0%"/><td style="width:49.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.102%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.777%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Inclusive of RISPERDAL CONSTA which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of INVOKANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Operating Profit by Segment of Business</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EARNINGS/(LOSS) BEFORE PROVISION FOR TAXES BY SEGMENT </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"><tr><td style="width:1.0%"/><td style="width:55.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.095%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.818%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">776&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before provision for taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,087&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income/(loss) before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(737)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consumer Health includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2023 and 2022. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pharmaceutical includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.7&#160;billion and $0.8&#160;billion in the fiscal first quarter of 2023 and 2022, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">COVID-19 Vaccine related exit costs of $0.4&#160;billion in the fiscal first quarter of 2023.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.1 billion in the fiscal first quarter of 2023. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable changes in the fair value of securities in the fiscal first quarter of 2022 of $0.4&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MedTech includes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intangible amortization expense of $0.4&#160;billion and $0.3&#160;billion in the fiscal first quarter of 2023 and 2022, respectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.1 billion in the fiscal first quarter of 2022.</span></div>(4)Amounts not allocated to segments include interest income/expense and general corporate income/expense. The fiscal first quarter of 2023 includes the incremental $6.9 billion charge related to the talc settlement proposal. See Note 11, Legal Proceedings, for additional details.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SALES BY GEOGRAPHIC AREA</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.736%"><tr><td style="width:1.0%"/><td style="width:48.166%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.994%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.270%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fiscal First Quarter Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 3, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Percent<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,414&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,332&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,024&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,506&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesBySegmentOfBusinessTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesBySegmentOfBusinessTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756442126784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Apr. 02, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock', window );">Summary Of Claims In Pending Lawsuits</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of April&#160;2, 2023:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"><tr><td style="width:1.0%"/><td style="width:73.479%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product or product category</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Plaintiffs </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Body powders containing talc, primarily JOHNSON&#8217;S Baby Powder</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PINNACLE Acetabular Cup System</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pelvic meshes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ETHICON PHYSIOMESH Flexible Composite Mesh</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RISPERDAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ELMIRON</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TYLENOL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Claims In Pending Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756443742352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Accounting Standards Update 2022-04 [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SupplierFinanceProgramObligationCurrent', window );">Supplier finance program, obligation</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SupplierFinanceProgramObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplier Finance Program, Obligation, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SupplierFinanceProgramObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440325104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 2,267<span></span>
</td>
<td class="nump">$ 2,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Goods in process</a></td>
<td class="nump">1,866<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">8,676<span></span>
</td>
<td class="nump">8,713<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 12,809<span></span>
</td>
<td class="nump">$ 12,483<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756437774784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total intangible assets with indefinite lives</a></td>
<td class="nump">$ 16,527<span></span>
</td>
<td class="nump">$ 16,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets &#8212; net</a></td>
<td class="nump">47,448<span></span>
</td>
<td class="nump">48,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total intangible assets with indefinite lives</a></td>
<td class="nump">6,843<span></span>
</td>
<td class="nump">6,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember', window );">Purchased In-Process Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total intangible assets with indefinite lives</a></td>
<td class="nump">9,684<span></span>
</td>
<td class="nump">9,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">44,636<span></span>
</td>
<td class="nump">44,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(23,512)<span></span>
</td>
<td class="num">(22,266)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">21,124<span></span>
</td>
<td class="nump">21,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">23,008<span></span>
</td>
<td class="nump">22,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(13,211)<span></span>
</td>
<td class="num">(12,901)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 9,797<span></span>
</td>
<td class="nump">$ 10,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756441295088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Goodwill By Segment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 02, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">$ 45,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">45,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">9,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">9,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">10,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">10,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill Beginning of Period</a></td>
<td class="nump">25,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/Other</a></td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill End of Period</a></td>
<td class="nump">$ 26,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756436450528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Assets, Weighted-Average Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756441400928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 02, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 4,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">4,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">3,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756433089968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">Accumulated other comprehensive income on derivatives, after tax</a></td>
<td class="nump">$ 343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtWeightedAverageInterestRate', window );">Weighted average interest rate on non-current debt</a></td>
<td class="nump">3.47%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 17,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 16,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral already posted, aggregate fair value</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">44,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">36,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember', window );">Equity Investments without readily determinable value | Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of long-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756432958912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedging | Interest Rate Swap | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="num">(929)<span></span>
</td>
<td class="num">(531)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">929<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging [Member] | Net Investment Hedging [Member] | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">12<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">145<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">417<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061172-113977<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440260224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Derivatives, Balance Sheet Location (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">$ 2,958<span></span>
</td>
<td class="nump">$ 3,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term Debt | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">8,860<span></span>
</td>
<td class="nump">8,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability</a></td>
<td class="num">$ (1,214)<span></span>
</td>
<td class="num">$ (1,435)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440623520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain/(Loss) Recognized In Income on Derivative</a></td>
<td class="num">$ (31)<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440357552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="num">$ (77)<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross Currency Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="nump">690<span></span>
</td>
<td class="nump">560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross Currency Interest Rate Contract | Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756441439616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">$ 9,567<span></span>
</td>
<td class="nump">$ 9,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Equity Investments with readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, beginning of period</a></td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Sales/ Purchases/Other</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Carrying value, end of period</a></td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Equity Investments without readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying value, beginning of period</a></td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Changes in Fair Value Reflected in Net Income</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Sales/ Purchases/Other</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Carrying value, end of period</a></td>
<td class="nump">724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non Current Other Assets</a></td>
<td class="nump">$ 724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Investment [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756441191808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">$ 2,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">2,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">8,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total Gross Assets</a></td>
<td class="nump">2,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(2,028)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,176)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total Net Asset</a></td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total Gross Liabilities</a></td>
<td class="nump">2,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">(2,729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,023)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total Net Liabilities</a></td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">$ 533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue', window );">Changes in estimated fair value (6)</a></td>
<td class="nump">23<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">$ 486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">2,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">2,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">8,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Available-for-sale Securities, Equity Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">2,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,534<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">2,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest Rate Contract | Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Significant other observable inputs Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts | Significant unobservable inputs Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440154432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">$ 8,942<span></span>
</td>
<td class="nump">$ 10,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current</a></td>
<td class="nump">26,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">19,170<span></span>
</td>
<td class="nump">14,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">5,443<span></span>
</td>
<td class="nump">$ 9,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and current marketable securities, Carrying Amount</a></td>
<td class="nump">32,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss', window );">Total cash, cash equivalents and current marketable securities, Unrecognized Loss</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue', window );">Total cash, cash equivalents and current marketable securities, Estimated Fair Value</a></td>
<td class="nump">32,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">23,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">23,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">22,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">4,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">4,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">4,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">7,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">7,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">7,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | U.S. reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">6,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">6,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">6,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Corporate debt securities(2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">3,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">3,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">3,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Time deposits(2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Debt Securities, Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity Securities - Carrying Amount</a></td>
<td class="nump">675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity Securities, Unrecognized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity Securities - Estimated Fair Value</a></td>
<td class="nump">675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">8,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">8,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">3,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">5,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov&#8217;t securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">8,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">8,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Corporate debt securities(2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | US Government Agencies Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale Securities - Carrying Amount</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale Securities, Unrecognized Loss</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale Securities - Estimated Fair Value</a></td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Corporate debt securities(2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov&#8217;t securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">3,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">4,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | US Government Agencies Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract', window );"><strong>Debt Securities, Available-for-sale and Held-to-maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">$ 182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=jnj_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=jnj_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756446521456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 02, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Cost Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 8,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total debt securities</a></td>
<td class="nump">8,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">8,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total debt securities</a></td>
<td class="nump">$ 8,942<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756428225312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 02, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 02, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Apr. 02, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">$ 17,979,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,771,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">34,928,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,888,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ExcessOfCarryingValueOverFairValueOfDebt', window );">Excess Of Carrying Value Over Fair Value Of Debt</a></td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">17,979,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">34,928,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract', window );"><strong>Financial Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Current Debt</a></td>
<td class="nump">17,982,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 34,232,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.0909)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="nump">1.0909<span></span>
</td>
<td class="nump">1.0909<span></span>
</td>
<td class="nump">1.0909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.0909) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 812,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.0909) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 796,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500MM GBP 1.2359)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="nump">1.2359<span></span>
</td>
<td class="nump">1.2359<span></span>
</td>
<td class="nump">1.2359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500MM GBP 1.2359) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 617,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes due 2024 (500MM GBP 1.2359) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 626,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 749,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 732,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.55%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 936,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member', window );">0.55% Notes due 2025 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 920,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,997,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,924,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 896,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 968,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,412,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,329,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,496,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,438,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.0909)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="nump">1.0909<span></span>
</td>
<td class="nump">1.0909<span></span>
</td>
<td class="nump">1.0909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.0909) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 814,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.0909) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 737,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.95%<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 298,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95% Notes due 2029 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 368,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,628,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member', window );">1.30% Notes due 2030 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,469,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 498,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95% Debentures due 2033 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 543,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 854,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">879,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.0909) | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,629,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign exchange rate</a></td>
<td class="nump">1.0909<span></span>
</td>
<td class="nump">1.0909<span></span>
</td>
<td class="nump">1.0909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.0909) | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,369,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 864,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 933,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 993,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95% Notes due 2037 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,161,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,359,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,389,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 992,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.40%&#160;Notes due 2038 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 896,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 697,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85% Debentures due 2038 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 806,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50% Debentures due 2040 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 551,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 852,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 726,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 297,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 311,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 496,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 501,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,976,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,785,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 837,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 899,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 743,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.50% Notes due 2048 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 651,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 834,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.25% Notes due 2050 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 667,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,080,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.45% Notes due 2060 | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 819,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A550DebentureDue2025Member', window );">5.50% Debentures due 2025*</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A550DebentureDue2025Member', window );">5.50% Debentures due 2025* | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 748,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A550DebentureDue2025Member', window );">5.50% Debentures due 2025* | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 775,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A535DebentureDue2026Member', window );">5.35% Debentures due 2026*</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.35%<span></span>
</td>
<td class="nump">5.35%<span></span>
</td>
<td class="nump">5.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A535DebentureDue2026Member', window );">5.35% Debentures due 2026* | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 747,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A535DebentureDue2026Member', window );">5.35% Debentures due 2026* | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 776,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A505DebentureDue2028Member', window );">5.05% Debentures due 2028*</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.05%<span></span>
</td>
<td class="nump">5.05%<span></span>
</td>
<td class="nump">5.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A505DebentureDue2028Member', window );">5.05% Debentures due 2028* | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 993,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A505DebentureDue2028Member', window );">5.05% Debentures due 2028* | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,038,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A500DebentureDue2030Member', window );">5.00% Debentures due 2030*</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A500DebentureDue2030Member', window );">5.00% Debentures due 2030* | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 992,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A500DebentureDue2030Member', window );">5.00% Debentures due 2030* | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,033,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A490DebentureDue2033Member', window );">4.90% Debentures due 2033*</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A490DebentureDue2033Member', window );">4.90% Debentures due 2033* | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A490DebentureDue2033Member', window );">4.90% Debentures due 2033* | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,271,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A510DebentureDue2043Member', window );">5.10% Debentures due 2043*</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A510DebentureDue2043Member', window );">5.10% Debentures due 2043* | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 741,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A510DebentureDue2043Member', window );">5.10% Debentures due 2043* | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 774,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A505DebentureDue2053Member', window );">5.05% Debentures due 2053*</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.05%<span></span>
</td>
<td class="nump">5.05%<span></span>
</td>
<td class="nump">5.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A505DebentureDue2053Member', window );">5.05% Debentures due 2053* | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,476,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A505DebentureDue2053Member', window );">5.05% Debentures due 2053* | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 1,540,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A520DebentureDue2063Member', window );">5.20% Debentures due 2063*</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A520DebentureDue2063Member', window );">5.20% Debentures due 2063* | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 738,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A520DebentureDue2063Member', window );">5.20% Debentures due 2063* | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">776,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember', window );">Other | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember', window );">Other | Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-Current Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-Current Debt</a></td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExcessOfCarryingValueOverFairValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excess Of Carrying Value Over Fair Value Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExcessOfCarryingValueOverFairValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0550NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1300NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A550DebentureDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A550DebentureDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A535DebentureDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A535DebentureDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A505DebentureDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A505DebentureDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A500DebentureDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A500DebentureDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A490DebentureDue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A490DebentureDue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A510DebentureDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A510DebentureDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A505DebentureDue2053Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A505DebentureDue2053Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A520DebentureDue2063Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A520DebentureDue2063Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_NotesDuePeriodFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756437293664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2023</div></th>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Worldwide effective income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.80%<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_UnrecognizedTaxBenefitLiabilityPayment', window );">Unrecognized Tax Benefit Liability, Payment</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=jnj_AccruedTaxesOnIncomeMember', window );">Accrued Taxes On Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_TalcMember', window );">Talc | CONSUMER HEALTH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_UnrecognizedTaxBenefitLiabilityPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefit Liability, Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_UnrecognizedTaxBenefitLiabilityPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=jnj_AccruedTaxesOnIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=jnj_AccruedTaxesOnIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440650160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">354<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(668)<span></span>
</td>
<td class="num">(699)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost/(credit)</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial (gains) losses</a></td>
<td class="num">(50)<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost/(credit)</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract', window );"><strong>Components of net periodic benefit cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost/(credit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial (gains) losses</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost/(credit)</a></td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756436519184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 02, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756437847168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="nump">$ 76,804<span></span>
</td>
<td class="nump">$ 74,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign Currency Translation, net change</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Gain/(Loss) On Securities, net change</a></td>
<td class="nump">17<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Employee Benefit Plans, net change</a></td>
<td class="num">(68)<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Gain/(Loss) On Derivatives &amp; Hedges, net change</a></td>
<td class="nump">573<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total Accumulated Other Comprehensive Income (Loss), net change</a></td>
<td class="nump">341<span></span>
</td>
<td class="num">(699)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">70,869<span></span>
</td>
<td class="nump">74,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Accumulated Foreign Currency Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(11,813)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(11,994)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Accumulated Net Investment Gain (Loss) Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Accumulated Defined Benefit Plans Adjustment Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(965)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(12,967)<span></span>
</td>
<td class="num">(13,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total Accumulated Other Comprehensive Income (Loss), net change</a></td>
<td class="nump">341<span></span>
</td>
<td class="num">(699)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">$ (12,626)<span></span>
</td>
<td class="num">$ (13,757)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756441389664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Reconciliation of basic net earnings per share to diluted net earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net earnings/(loss) per share</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 1.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average shares outstanding &#8212; basic</a></td>
<td class="nump">2,605.5<span></span>
</td>
<td class="nump">2,629.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Potential shares exercisable under stock option plans</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">140.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod', window );">Less: shares which could be repurchased under treasury stock method</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(102.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average shares outstanding &#8212; basic/diluted*</a></td>
<td class="nump">2,605.5<span></span>
</td>
<td class="nump">2,666.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net earnings/(loss) per share (basic/diluted)*</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756423653968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 24,746<span></span>
</td>
<td class="nump">$ 23,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 12,517<span></span>
</td>
<td class="nump">11,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 12,229<span></span>
</td>
<td class="nump">12,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,852<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,735<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,117<span></span>
</td>
<td class="nump">2,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | OTC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,642<span></span>
</td>
<td class="nump">1,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | OTC [Member] | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | OTC [Member] | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 897<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Skin Health/Beauty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Skin Health/Beauty | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Skin Health/Beauty | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 493<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Oral Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Oral Care | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Oral Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Baby Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 359<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Baby Care | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Baby Care | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 263<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Women&#8217;s Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Women&#8217;s Health | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Women&#8217;s Health | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Wound Care/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Wound Care/Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">CONSUMER HEALTH | Wound Care/Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 13,413<span></span>
</td>
<td class="nump">12,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 7,023<span></span>
</td>
<td class="nump">6,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 6,390<span></span>
</td>
<td class="nump">6,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 4,112<span></span>
</td>
<td class="nump">4,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,448<span></span>
</td>
<td class="nump">2,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,664<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 487<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(26.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(22.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE | U.S. Exports</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(48.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | REMICADE | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(24.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 537<span></span>
</td>
<td class="nump">571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(5.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | STELARA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,444<span></span>
</td>
<td class="nump">2,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | STELARA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,451<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | STELARA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | TREMFYA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 640<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | TREMFYA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 406<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | TREMFYA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 234<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(51.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(51.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,586<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">22.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,193<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">42.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 747<span></span>
</td>
<td class="nump">457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">63.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | COVID-19 | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | COVID-19 | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 747<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">95.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 280<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | EDURANT / rilpivirine | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 477<span></span>
</td>
<td class="nump">501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(4.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(25.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES(</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(33.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES( | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,804<span></span>
</td>
<td class="nump">1,741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 978<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(8.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">31.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | CONCERTA / methylphenidate | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,044<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 713<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 331<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 339<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(10.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | SPRAVATO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">86.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | SPRAVATO | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">82.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Neuroscience | SPRAVATO | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 4,112<span></span>
</td>
<td class="nump">3,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,889<span></span>
</td>
<td class="nump">1,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">19.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,223<span></span>
</td>
<td class="nump">2,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | DARZALEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,264<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | DARZALEX | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,191<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | DARZALEX | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,072<span></span>
</td>
<td class="nump">903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">18.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ERLEADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 542<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">35.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ERLEADA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 249<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">21.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ERLEADA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 293<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">50.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | IMBRUVICA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 827<span></span>
</td>
<td class="nump">1,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(20.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | IMBRUVICA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 270<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(27.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | IMBRUVICA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 557<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(16.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(54.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(14.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | ZYTIGA / abiraterone acetate | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(56.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | OTHER ONCOLOGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">37.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(17.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | CARVYKTI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | CARVYKTI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Oncology | CARVYKTI | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 440<span></span>
</td>
<td class="nump">443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 273<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 167<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 362<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(16.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(22.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Pulmonary Hypertension | Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(12.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 927<span></span>
</td>
<td class="nump">910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(10.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 578<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 578<span></span>
</td>
<td class="nump">508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(13.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(16.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">PHARMACEUTICAL | Cardiovascular / Metabolism / Other | Other | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 212<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(10.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 7,481<span></span>
</td>
<td class="nump">6,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,759<span></span>
</td>
<td class="nump">3,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">16.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 3,722<span></span>
</td>
<td class="nump">3,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,503<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">37.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Interventional Solutions | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 863<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">74.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Interventional Solutions | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 640<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | ELECTROPHYSIOLOGY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">9.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | ELECTROPHYSIOLOGY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">21.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | ELECTROPHYSIOLOGY | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | ABIOMED(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 324<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | ABIOMED(3) | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | ABIOMED(3) | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | OTHER INTERVENTIONAL SOLUTIONS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | OTHER INTERVENTIONAL SOLUTIONS | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">17.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | OTHER INTERVENTIONAL SOLUTIONS | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(11.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,245<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,363<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 881<span></span>
</td>
<td class="nump">899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | HIPS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | HIPS | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | HIPS | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | KNEES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 368<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">8.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | KNEES | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | KNEES | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | TRAUMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 757<span></span>
</td>
<td class="nump">748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | TRAUMA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 491<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | TRAUMA | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 267<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | SPINE, SPORTS &amp; OTHER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 729<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | SPINE, SPORTS &amp; OTHER | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 406<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Orthopaedics | SPINE, SPORTS &amp; OTHER | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 323<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 2,434<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Surgery | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 975<span></span>
</td>
<td class="nump">921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Surgery | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,459<span></span>
</td>
<td class="nump">1,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(3.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Surgery | ADVANCED</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,118<span></span>
</td>
<td class="nump">1,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(2.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Surgery | ADVANCED | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Surgery | ADVANCED | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 673<span></span>
</td>
<td class="nump">729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(7.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Surgery | GENERAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,316<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Surgery | GENERAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 531<span></span>
</td>
<td class="nump">504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Surgery | GENERAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 785<span></span>
</td>
<td class="nump">784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Vision | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 558<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Vision | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Vision | CONTACT LENSES / OTHER</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 953<span></span>
</td>
<td class="nump">910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">4.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Vision | CONTACT LENSES / OTHER | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">11.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Vision | CONTACT LENSES / OTHER | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 509<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Vision | SURGICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 347<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Vision | SURGICAL | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MEDTECH | Vision | SURGICAL | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationRevenueAbstract', window );"><strong>Sales by segment of business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percent Change (as a percent)</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesBySegmentOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesBySegmentOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BeautyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BeautyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OralCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OralCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BabyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BabyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WomensHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WomensHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_StelaraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_StelaraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SPRAVATOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SPRAVATOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_DARZALEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ERLEADAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ERLEADAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_IMBRUVICAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ZYTIGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CARVYKTIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CARVYKTIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_UPTRAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ElectrophysiologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ElectrophysiologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_AbiomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_AbiomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OtherInterventionalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OtherInterventionalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_HIPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_HIPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_KNEESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_KNEESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TRAUMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SPINEOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SPINEOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_SurgeryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_SurgeryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ADVANCEDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_GENERALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_GENERALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_VisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_VisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SURGICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SURGICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756423494128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Worldwide income/(loss) before tax</a></td>
<td class="num">$ (737)<span></span>
</td>
<td class="nump">$ 5,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember', window );">bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">In-process research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember', window );">MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 6,665<span></span>
</td>
<td class="nump">6,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CONSUMER HEALTH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 776<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business Exit Costs</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 4,444<span></span>
</td>
<td class="nump">3,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="nump">13.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Unrealized gain (loss) on securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supply network costs</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | MedTech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 1,445<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInOperatingIncomeLoss', window );">Percentage Change in Operating Income Loss</a></td>
<td class="num">(2.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total Segment Operating Income</a></td>
<td class="nump">$ 7,102<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage change in operating income loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedicalDevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756440338496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 24,746<span></span>
</td>
<td class="nump">$ 23,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 12,517<span></span>
</td>
<td class="nump">11,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 6,332<span></span>
</td>
<td class="nump">6,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember', window );">Western Hemisphere, excluding U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 1,587<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember', window );">Asia-Pacific, Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Sales by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 4,310<span></span>
</td>
<td class="nump">$ 4,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesByGeographicArea', window );">Percentage Change In Sales By Geographic Area</a></td>
<td class="num">(4.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesByGeographicArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by geographic area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesByGeographicArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentsGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentsGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756428181696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Apr. 02, 2023</div></th>
<th class="th"><div>Apr. 03, 2022</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill, Purchase Accounting Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=jnj_NonTradeableContingentValueRightMember', window );">Non-Tradeable Contingent Value Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends payable (in dollars per share)</a></td>
<td class="nump">$ 8.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=jnj_NonTradeableContingentValueRightMember', window );">Non-Tradeable Contingent Value Right | Class I Recommendation For Impella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends payable (in dollars per share)</a></td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">ABIOMED(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 380.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Consideration transferred</a></td>
<td class="nump">$ 17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash, cash equivalents, and marketable securities acquired</a></td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Assets acquired</a></td>
<td class="nump">19,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired from acquisition</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Total amortizable intangibles</a></td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable securities</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">ABIOMED(3) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">ABIOMED(3) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">ABIOMED(3) | Non-Tradeable Contingent Value Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight', window );">Contingent value right (in dollars per share)</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight', window );">Contingent value right</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends payable (in dollars per share)</a></td>
<td class="nump">$ 17.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_RevenuesContingentConsideration', window );">Revenues</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">ABIOMED(3) | Non-Tradeable Contingent Value Right | Impella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends payable (in dollars per share)</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessAcquisitionDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessAcquisitionDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessCombinationProbabilityOfSuccessFactor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Probability Of Success Factor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessCombinationProbabilityOfSuccessFactor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RevenuesContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RevenuesContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=jnj_NonTradeableContingentValueRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=jnj_NonTradeableContingentValueRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ClassIRecommendationForImpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ClassIRecommendationForImpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ImpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ImpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139756435880704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>cases</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 02, 2023 </div>
<div>USD ($) </div>
<div>cases </div>
<div>claim </div>
<div>claimant</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 24, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>claimant </div>
<div>cases</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyRemainingTerm', window );">Loss Contingency Remaining Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BankruptcyLossContingencyDiscountRate', window );">Bankruptcy Loss Contingency, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.41%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_AsrMember', window );">ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember', window );">Pinnacle Acetabular Cup System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember', window );">Pelvic Meshes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RisperdalMember', window );">Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember', window );">Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember', window );">Physiomesh | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement', window );">Number of claims within settlement agreement | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Loss Contingency, Claims Dismissed, Number | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ElmironMember', window );">Elmiron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TylenolMember', window );">Tylenol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OpioidMember', window );">Opioid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyPendingClaimsNumberRemaining', window );">Loss Contingency, Pending Claims, Number, Remaining | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyPendingClaimsNumberAdditional', window );">Loss Contingency Pending Claims, Number, Additional | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss Contingency Accrual, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_EthiconMember', window );">Ethicon | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member', window );">DePuy ASR U.S. | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_Numberofpatientsinsettlement', window );">Number of patients in settlement | claimant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyReserveEstablishedWithinTrust', window );">Reserve established</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyReserveEstablishedWithinTrustTotal', window );">Loss Contingency, Reserve Established Within Trust, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyTerm', window );">Loss Contingency, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualPayments', window );">Loss Contingency Accrual, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Talc | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyAdditionalContribution', window );">Loss Contingency, Additional Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue', window );">Loss Contingency, Reserve Established Within Trust, Nominal Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember', window );">Surgical Mesh Products Marketing | Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="nump">$ 302.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember', window );">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_InghamVsJohnsonJohnsonMember', window );">Ingham v. Johnson &amp; Johnson</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableProceeds', window );">Loss Contingency, Receivable, Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Loss Contingency, Damages Paid, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BankruptcyLossContingencyDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bankruptcy Loss Contingency, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BankruptcyLossContingencyDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalProceedingTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Proceeding Textuals Abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalProceedingTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyAdditionalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Additional Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyAdditionalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Claims within Settlement Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyPendingClaimsNumberAdditional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency Pending Claims, Number, Additional</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyPendingClaimsNumberAdditional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyPendingClaimsNumberRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Pending Claims, Number, Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyPendingClaimsNumberRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyRemainingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency Remaining Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyRemainingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyReserveEstablishedWithinTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Reserve Established within Trust</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyReserveEstablishedWithinTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyReserveEstablishedWithinTrustNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Reserve Established Within Trust, Nominal Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyReserveEstablishedWithinTrustNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyReserveEstablishedWithinTrustTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Reserve Established Within Trust, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyReserveEstablishedWithinTrustTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Numberofpatientsinsettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patients in settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Numberofpatientsinsettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityContingencyNumberOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product liability contingency number of claimant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityContingencyNumberOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow reducing loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivableProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the collection of receivables related to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12053-110248<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivableProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_AsrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_AsrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PelvicMeshesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PhysiomeshMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ElmironMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ElmironMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TylenolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TylenolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OpioidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OpioidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_EthiconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_EthiconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_BabyPowderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_BabyPowderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_InghamVsJohnsonJohnsonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_InghamVsJohnsonJohnsonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>jnj-20230402_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jnj="http://www.jnj.com/20230402"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jnj-20230402.xsd" xlink:type="simple"/>
    <context id="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ie4185cc0226f40acb9724055d3655952_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i5cd2bfae49cc471b8e8f8f061eeb877b_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i5985eba1fdd445c088f418dadd94f1c6_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ie611e2d28014400cb2d7774070bd6ea5_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i56880e9c6bfe4b0985d48f5d5f70bb4f_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib8cdf2a1534245f6aaf14d9138fb6495_I20230421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="ie7987f4710274da781b044c04aa38be0_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="if241137260614532b6020bfeda156ac3_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2188b6c0f7514c949842cbb0fdfabbab_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i77ff9cf53ba540b9a5e6aeca7ca5804f_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i2e69e8dd1c3d465ea6435891bf59621c_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="idb53f128b06d4aba845d354b0be0e42a_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i0b3fd2b8861e424999c7010d105bfd21_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ia6a21dc14a504f8ea99bb332930384c0_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="if4da4c2095b244be8c3cc67e88df5d15_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i5578ef4542b444f5ac1a50c33d446bb1_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i455ec88d396c41248d806ba599269e74_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i09e8821bbba242a6923019b0a460d64e_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ifab9bbc2a1a94a03a0a926fea40d151c_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="iae6ce94080c14bf3947a9c53d1a7596d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i2d9051e5238a4ac9baecaaf4941dc3a4_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3e2d68ed978242baaa348359c8c9ca9a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i78fcc13d384f4330aec9188cab3a6947_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i96bae56901ee43a5b70044963ee0eb2f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if5ba501b50bc44c68b5053ecd96d9a08_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3f1e92fdb7cb435b85c3f0ef4f00add4_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iaae68b8ec38442eab92d9dc3b0260cd9_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i047e4a043e444bcba72ba4e9efc5393a_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i8919e9f61f8f44749d28698f8da6d82c_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ie5c9ee590fe74fbea7151627b39b194d_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="i06bfeb1f5de646c1882f0ac3995b15aa_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ib1a577429d7543cb917887d15b2934a5_I20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-03</instant>
        </period>
    </context>
    <context id="ibba084db76814e3ea3789881d3aff00a_D20230402-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2023-04-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="icfde879145bf49229de003973cc34868_D20230101-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i38228c4f861c4d53b47d4201d723003c_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="if3e842812a5248e0bef37aa2b2e9b2fa_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ib7b4546281ac435aa92aec6c7e41c91b_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id3230083ab32476fb09c3bc58c85a4ba_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i26813cf41e0b40518f5acdbd9c90332b_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i197e0943ce2a43d7936e32486da181f8_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i4cfc80b6878c4f6f932fc48b92669884_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ib0507cd24d2e4b288dd7a9b0753017af_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i0799f3dd7e1443109b9ff412c554094d_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i54a01f5eb53d4ab89d3cbe7a3ba985c1_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ie416bf3f26e54604b272b38173898aa1_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i26cdc03025f14afa93aeea4d2797344e_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="id6f3967ed8804b3484a788194a6b55e2_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ia44d907a039b4ea4b07c28589766bd8a_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i580a3adc3cf744379ba4cf5f599f7937_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i621fb40d2bb940e1b24bdcca1e4136e8_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i5ee98f9e7d6a4590b9ac7b2d9cdb9144_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ibcd0d6c747a149e19fbcded0d930ca35_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i882e2c7e02fc4e118e5a1079393bf3a8_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="if54031088777474188c6dca64d2fb710_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="idf8c231701af4202b803070c0de9def8_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i2ad211fc0f6c4a23b3511340169453c0_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ia0c30aae843c488795f8e7c12bdf070d_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i82b6d9a04c804ccfa99f995cf671dd34_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i68677eb45407447cb144946c0f01f334_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i41f4633d6ab6401e9804fb1a385a3531_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i5588691f505049b895ad7d374a5c3a41_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i3b45f400dac942d296156e124dc1e9b9_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ieaff6b065b8f45f384f79c9289dacd25_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i831a75e27b404331b68d0e1d0c6dd089_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i95ad3c15d3724acf827b842d7dbf0f89_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ifebd08ff3dce4721a4b99e42c41bef26_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia39a02e3ee104b9ba558b07af3c8b6f4_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic7b9d91b169a40358401cf82127d3e79_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ice47da4dbb604bc89bb47d0c82573768_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9068df14ebfc48e38d180f60734ca507_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ic52c17526572465e9e1b5a35d8831216_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="icb38841a93344de99840a565926c66a5_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i4779df903b7b429d8d7c7bd175fed19d_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="iee79a709871d48e79e9780dda18549cf_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i7667c30e53b74e189bee49ab6ab578aa_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic67e218f34d2463381b9461693780c78_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i39a3c4d59b0242d5872c4a78d9b2f266_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1b8e5036b85e4f42ab00ba31e3cc72e0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i61ab5b9880cd4f64ada5ab99bbe01129_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i968b152e9828408dbcfff2d958bb2ffa_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i3f8f4aec6be94d6fbddc3da727226560_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i518fab6babc2450f8b8bfc59a05e3df0_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i4d1e2c54d6bb479292b9652c120a6541_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ia0c6b0431ad94e9aaac1f8408e9e643f_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i2cc8515d00ca476a938ce6b49ef1d594_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie051977e19b94b39a0ddaa23a4b507b3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i53b711721e994f5fac5c2f261e490da8_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ibf1da9ad33c847a19893c85c250bba48_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iba41bab8774e437ea305e80eaf3595db_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ife40f1a43412473da55b7933c850ee6c_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i13f98824188a4648a8a09d1453d2780b_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i2f10659432f044afbd1fba6198533009_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="iece4bb18d3dc46fc9364b46a20d5f69d_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="id81ca34bf19c4617889e951ac6dfbc59_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i28d280475a264030901bece015a4dc31_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="icff16d560d4c47149af82242e78d7c81_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i18eb2772b356408db2d5bed81f211a2c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ibf982a48aaff440bb1776f320d637a69_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i4443adb601eb4729914e2ba1f143557c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1a044beb1efb4064b0c24daf2024f934_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="if77451a376c4461ebd92a6a553653653_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i06741010c1a64e268867848027daba0c_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="if6330ab077ff46f38183eaaac192c351_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i530924810ee74f0498a5b576273161b3_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ia1c1b995a63246e89358347d16f7c60e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i075611e2f1c34545856ee1fb67001c5b_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i8ca12285d2874df69fab0b80f4e166fc_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3c4f8bd9f0f44566948524fae883de74_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i652d6068f154428ba681e62b55ce5132_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3f485b1f7c7942f49f325dd462771cde_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ifd652ec5aec24fbfa5838b3c7c1bc608_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i307781a0dd6f4fee83ba5f3b83bacf6a_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ic8fce605d8bf42a4809c31f01fea678e_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ie4c4f1b4529e4b4e94c51763f2b03fee_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i205b08e0d52a41018c1f1aac759297b4_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ief14a8d3f839490ea2f5004d02e9ea85_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i6eecc4b339cc4793b846af6357408a8a_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="idfb9204df17c4b71bb33876248a6fc03_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i8d229fdf0aac48939a630ab1e339fe6a_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i93b2a01d5e1942d0934133917a0b41c4_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id75635b8099d4b48b2cd2669062d8331_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ia81349c4bdf242e682e3fd1ce2fbe13d_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id7a1713ee90b4874b872f2aa9e7ff7cb_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i3c27bfe420f54e1ca9c1eeb355beb0b2_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i7f03697427554f22b26c5738cd4a66e3_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i8dd646702260408ea267396967e28f41_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i2bdc0608d83a46fca52c9bb31b17d8bf_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ibd3150f03c284a7c8af03baa7bea76ca_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="iecf72c1b6f094918ab2d8aac314f3e7b_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i7f05b2c736c746f9bbb497d86e2362a0_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i47f2667d72af493883f17ca87070a398_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i3c83227b39104d4d82056ac6bfea554b_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i4c31014b15774921a5f30a4880f42786_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i92e0aa803ceb4db2aff7a0bbab1124fc_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i5cbc0e3c61c34bc3bdcd6deaea9d806b_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i99ffa091217a4323bc5c0aed611527aa_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">jnj:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i3a3200f710ae4ab696b549ce19c468e9_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ie33a79c5f8cb4a83813ae704160ed98f_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="iaf23f95e6fb14d838dd8f888af18a5dc_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i54377ee71ddc46f195fb7d79c03086c4_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ia7e10a1fefa741b8b65c1bc8d547367e_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i5115b43c247a46cb8480efe59a9a01e2_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i4af82efbb61a401e9e04b30f3cd374c2_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i8b85c7849ee2491c98f1a6384d52b0b3_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ia22c34150afa480cbfb032861aa89f53_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ica912cc5502e4edfac4509644a475663_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i28b97484a76e4109b1cc8fb5d4f35ca3_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ib55fd172e7b345698937c728fa47ea35_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i76cf9f7d43b546acb7b030654e84376e_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i38b034ded43b4398ab07f2c8eb4df69c_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ia8fb8551fca949dea98f62de1af8e1fb_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i74fbc3262ac245c6b06dbfaa60a35912_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id2c5ffc25a414b4eb02918f1226b594b_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id7901b5b213e45cfad73dbf6c939e3a1_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i201ea42815f84447b0563ee2d6978dbf_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ifc07e47d11a24f3d84ea26db566510ba_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ic7899493f2a04f03b8d3a44ba0c57ce8_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id55a3b7fc5a045b8b30ed7f0edeef623_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i00240ca013be4736a3577b6e2e4e6e8f_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i4d061251a667491cb3ccfb55f7e0fdf1_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i27aece83874544b59d6a3aeaf4140c57_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ib72ea9d48ff044b48b8f3531137328b3_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0550NotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id2d24b4e1a0d4ff0b2f3b876efb8f98d_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id922d848f11649e8bb4d6a787425f3d9_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i8d10576f649d4fcaa6628e37339ed7d7_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ie6efd100445841fd9e4073832291ac05_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="if128e6a98f974c349bec0f4b8249d2e9_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id8830cb3725a43db940330000abf4afe_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i368a811b66144aceb4879d90f93ca849_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i1212e32453564047b7f1d38ae4b843e4_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i79e9145f348e4338a78e8f59378476ae_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i48f4f2f5d47242ce9696a233b88c95d8_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i909ade28c6444d4abeff119bf7fda238_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i2867cf9e16e54b48951692ded48ddfec_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ib925ed2921f044c7b6a52dcd57f43461_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ib1f4ccd1b3ab4f02bad67727e76ccb50_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i0a544d1c051b4c1a82b7d2c87b858546_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i227ac8f50abd4fa982cb5d05a9110d6e_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i3b249c5b4e484ae4a30c7aece7e87a09_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i1a6f9a852e704a75b988ca1c5efcda90_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ia133568690864c2c80040ff64a3bd09d_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i57ad96c98de046ca96f7fb7c74dca343_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ib27758560e174afab9810f4bf86f5335_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1300NotesDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i4e6d8ba2689941f9b382cef18e8e510d_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i6539619b042047df93391dc561673fce_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="iee5802a254024b95b747bbfcf78a55d8_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i3725ff0a163f4284b203c37c1a364bb1_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ief4a308916ec45049d576f86d454ed54_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i94f8018599af4e97a1cf4a42f83a48c3_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i4e731198db6248e18229839dfbbb9b60_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ia7ecfe4e547b48e2bf37c8b07270def0_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i7d3943f6e0ae4e0587c9c4d74a075a18_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i53b67cb6ca9a44edaab52a8871fcc3df_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id4f9ebffba3147cf8d00c064683c36e2_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i6c63abc9f5cf4a73a4a82c7b3a2282c6_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i9fa813e2d18f4d07a5ba47a2be3612d2_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i8c8bd52c349746b1881e96b11ce47bf6_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ief71832a9018470cb79070bc07ffdec0_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="idb5347aa05834f46ac9daf1613e272ca_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i816cf20f9e104bf6b19a363b6ba3c457_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i2a7bfa3080844dec82b6603a0abd071c_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ia1aeff3a19174fbaa6c309a6a87828c3_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i4a929f2577cd41d8b9bb8a882be4e1b4_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i3946c9afdf54418086ade08e21fa3a2b_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i82f6eaa7f0c74d57aafe2c652a9c905b_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ib652901c5fce4f24af8075006cd9aa10_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i7bec9abf70944616ba30c3702874dcfa_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i339a1d20f63346cb832562ac3c78a237_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="iaacba4e8463a4d2e83aee15b14146669_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i8cfb0968d3344cd78090b4f6ead3bd76_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="if0a4b17867e147fcbe4c359e1afbd038_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i724b3a0e6f5147afb4e0ba7665d6ef80_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ib37fac857ce1416bbf734b81d98d767b_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="if3e1a1289b7d4dc7817b8a11b9bdba25_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i89ee2bcaaa4345b49e22759f9172507a_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i93d5e74486b449e89b3a9220a64520f0_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id9923a50e9724fc481bdd65773cf31a0_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id6a612e6189440309a78a24f6aaabefb_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i2e60148e6e194dce942bd04838e31cbc_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ia4c126d2c7894910adb1770911c549ed_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ie24382cee4f042c7954a6d0aa1419fb4_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ib3f1f5aa22a94cdbb91e0e86cd25fcaa_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i24b45cbd53644d79afe96aa1ef132108_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i022de5a785f24bcd9f3083e4891f2ccc_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i6862fde9a77c43f0bd130d62e09598e6_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ia86125a3d772402db1a30fdce3dcd466_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i5b0b8630278f405ba64f234c38a4a3ae_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ie533216722654c1e9ba1846224e6ec14_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i74486a5277344ce59312540a7f416cbe_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i7a9fa797383949bba12905735e92ed19_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i5f065931abb84eccba21550140a470ca_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i8bb4ca4a34d6461dbc0d107842b6a046_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ic6552612946f41819e903a05f07bf91c_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i918f92a298af41bda8fe834dd3b26150_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A550DebentureDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i9f501e2baabd405c810574367101a19d_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A550DebentureDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i1a69ae7c0f5d41bf986a42afdbbfb628_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A550DebentureDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="if0a6b938d37244aa8e09a786396d444a_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A535DebentureDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id3a99eecd02148a2a368b8096810c2b5_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A535DebentureDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i03eb671135b6424d97690216188682fa_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A535DebentureDue2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="if08f43d66b2b4b1789c28c89f773bcd9_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A505DebentureDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i92360a98889d40b2bee328fb5755cfb0_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A505DebentureDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i741825ad780746bea2f2c6a35aed64c1_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A505DebentureDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id3fb8e7a45764351bb0b176fcbcb6e26_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A500DebentureDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ieedfdd205ab143638b2c4e0babcb3bcc_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A500DebentureDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i7e9541bc07fa4ed8a81ca1e22b84a82a_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A500DebentureDue2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id69efa8053fb47178e9e37e201313747_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A490DebentureDue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ia0cf278aad3544b68d1287619e1ff5db_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A490DebentureDue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i66beed51389f4daebb6d2d780254c5d2_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A490DebentureDue2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i51d9ee539efe4210a650dbc237af95c4_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A510DebentureDue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i638e9c268a244ef0bdd12369ee16af36_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A510DebentureDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i4e2c136ed07a4293bbc96e175b9bbdfe_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A510DebentureDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i21e0e43d753d451b9ac7010d74e12a35_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A505DebentureDue2053Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i0b160e5cf382471abfa01a07b6979dcd_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A505DebentureDue2053Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i6091369129b642cfa7e758e78afae422_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A505DebentureDue2053Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i024e2dfb671f4922b572b41f106efb1e_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A520DebentureDue2063Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i89b252fa9afc4f6895a65928a3dc4679_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A520DebentureDue2063Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ie6b6aef384bf4a9b80ea47648fea1fee_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A520DebentureDue2063Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="id967b50670d04639aa79dfa133928a7b_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="if123e4fc41a748d3a7f0c30e5548e9dd_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:NotesDuePeriodFifteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i30b84b721a8a47b89119d6e1923faac2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i61afdda999f44da2a95e6ba9519c4fa0_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i3e12ceb17aec40709533c417fa7976aa_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ia2a87b5a064e4c7a899475e0dbadc527_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i50e2318413734df39c6c543008cbcb21_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">jnj:AccruedTaxesOnIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i3ec8770b399d406faad6d9a6b24fac59_D20230403-20230701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-03</startDate>
            <endDate>2023-07-01</endDate>
        </period>
    </context>
    <context id="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i6a79593849c348e791c81a2228ea6405_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i7b50bef376d94029914fd830a153b7aa_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i6b6f17374cb84625bb4b63c7a5d62e2c_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ia51b75ec8ed24459b26207e74f51ad4d_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i39da497bc9a345169e8c633fc9ccb4c8_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i8f8ef72c3cba4a74a4cbe42bd9004f33_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i2b26df561bd946948e1a78379354d9b5_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i03d933225100466a8dad732be7b062f9_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i99a10cb23bf04c2a9aefd04cd01d1d5b_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i248120dc95c44c078c9b33b2c6c60b4d_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="iaaf739bb046840338e03bd31a098d3ec_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib70396f99f564ac9938bee2564160961_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if52ae96f4fc946d0926968e3c2defc87_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i41317b52070e4c52a074c754ab815d1c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9c740c593a5e49d1a9b8f5e7e616b946_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i984d66aa451f4fddafb447e2b3a07b38_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ieaa2e564e1714834a088812e21dfe9e7_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i85292bb163e24d1a8b532b0152757469_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iff776c204ddd4fe4af24bb0222ea1874_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i07b3f305984a48ad85f9a74e74005373_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i25ae31c7c436415cacd6f0634ac5e358_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i2a06685196204a4799f887412650fe40_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i15733073985a4ce5959e11ca5f252bf1_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i9e96376a42a04152b58e3882a9b14ef3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i579190aae8a9475783a0704c6aa14097_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i7c3a3dafb62444ad8218b38dd1ed838e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9a8851c22232454e975ee3658a578864_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i2c3fc8b5552e4871a6f2db9f1a367083_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1c9625e879e043e09db9ba52fa49c414_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i77d45dffb4d24df982e0a69a2edb48b5_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i37a140c2966c4d39be0eb69abb0cd291_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="if081b963d9144c09a6d20b20d26d3d66_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i01f0cdd79a5d41e2b78a6bf7fcb0b94f_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="id17d813e9a0a41f89c0e446fdf68e56a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i8f0aee6f09e5488091b12bba39e31ee2_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib4c384167ae1453abbb9d0b6c0c04854_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i736ac00e11af42359794eaeaddc3a97a_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="icacbe869dfec46a8be4b9c12f04f7cc6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9f04259b9e384d4386a146f306a64433_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="id4456f20d70b4883b575d2169dd71544_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie2627fcecbe54a53bd26bd35bb03ae37_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib7f08dd82e14407f93f9374ec1c64bba_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i63462697f7cb451f9132abc3d2242368_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i3e48079566be4bc3891e3fe4dd109037_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i29728a150c174ada8da66efe8fb411d7_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i262a53f9ec2547dc9bc3e7376b7a007a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i4510efc748d54bb7930912ba6509e096_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i767c65868b3d4650833e3270ece3465a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i6b25c8c23a664e359b78c1353fbb6375_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i9e4c728c6f644bf29493a4b4e9dad170_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id0598fae3f054742badc9b82185f5c04_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i18dc481a2ecf4435be42bac0b2119b30_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i4623992e0dd14d1a9e9f595afd28bd4a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i4e5f74d7507448aa8240b9c69285bd57_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="id0ee1a5c112245ef922eeb1907bc70a7_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i29c3c1f4c5bf4928852da60e04089160_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i89d74a9d646040ac8bda4a109e5316d2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib1e47778732e44aea0320f24635c55e6_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i000088d3af5046b2921cb4af5f6fc205_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ide60c30a5fc749e0b67837f69ae698e5_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i53b79714bdfb42359807a488bf5a74ec_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i359821ae58ad4ff8a87eaa12e4efdb78_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i10d2670c3b13416fb7a206927fd88687_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1cd662d1267e49139b46c4a297215a54_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i3ef2ee88e44043efbb8a96f8b9d8c89d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie188724cc3dd4a949ef2fbaa68fca7b1_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i31b8c4e7570d486f9a67881129d6fa3a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i339e5f7a0cc1453d976a0dc292d89c27_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ifb2ce733a0ef4e72980327ed5e0107f8_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i0b9072482295465bb3ae5b67b3338abb_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="iec663daee5fb47d4a96c14b56bbddb1c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1dba4cd103d24bc9b66b596eab786d18_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i68917d7a1b8842be98f382c714c21a1e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3cedda0d436f4730a24d2cce6e535f50_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i9b46548a1c9e4da6ade074b1560663d9_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="idf3bbabc22fe40489b09d4860798d9fc_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i0dc26d7592994955bfeeae65142c46b8_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic43daf65754947459d5aba53e5b92e81_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ic8a2811670fd4e388c4cff13e473d4c0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if25545d4d3224f2683d6c36402df6c2c_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i583fb109cf304e3293199bb1d895aece_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9d6adf3e8198442a90339cfc887ae4e4_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i63aa3f3d8b9249c185e61668767dfbf3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i602b3a8f8c684e07855a432b44f877e7_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i057cb94031764e83922e91e90e55ad2a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i0f466a267f5244d987f9d84b05b1dd94_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i69aa70e212f144c0a94a01e8c886be13_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1581f8ac08c84383b20e0e6e3b0b3231_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i64ff97d1a3024cd4aa22d2ca000bb716_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iea40143a881c4e9fa30c030d13484367_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i26bdbd0a33904170961ee857f7f75ec2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i5a944b7eb27347a88ca02d5d4d2a3ae3_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i9a5cd0e89145489b9adb25e4375d33c2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3d1731aeb98946a7b4ae917d048b33e9_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="if862ee47ff57402ab4003df617f3cbb7_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic411e2d070f641dda19f24eba87d762f_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i617fe07827554cea8265f01074aeb1a0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia1d744c7c8d14f1fb8fea48cff62dbdd_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i52ae5dd1fae940ffb2cc4d896705c30c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i8a022c685c4343d79523d6f83bf6d043_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="iadbb5deb5a1b4cc08f416461ce834cf6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia4967a757b464053a991e793b0594a48_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i0098733b5de24bea987487c0dc5edf73_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i0a690fd862144f769bca79051212a40a_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i131a7455bdfa4e3e8cee654b964e7506_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id11db793f4614fa5837a25d9b63156c9_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i5573f6f5a5d9481c98d29c616f628da0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib59a8dcb5bf443089bf51815435371fa_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i03761710c3c6468698fff19815667abe_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id6d4e5e284b940f0abc9192313e3810c_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i7db52f7f1f8f4820addc27c47eeb5cee_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i629cb97dd9014b8a9866cd4d248ef278_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ica7fe9702d8b45e98e6fe37ca13068af_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if79e147a672e45f0884726eebc14855e_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ieb5a5fc555d24f308104655c998bf305_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2615b59268ff4c7d937c9cf5cf4ce170_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i7c978427d57f48948b5dca33ba9a8790_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i785d0ef07e4f4fc6899d3084d7bde419_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ic3c0840358a442fea238d7d4ecefdddf_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ibcfcee01500e40b6a181c5d82cba6ce5_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i044647ef59d14e6ca30f9418a2cb334e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iab3e83e7566542ea969c626ac4818791_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i54ff8960370c41909dbf45d3630c3d78_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i4ff8415c7ec740b5af1069a9d5615847_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="if178d1ce94e54a8b9f23398ad0e2c083_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id2f647ec067747e6b33e6c21b46b9acf_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="id01edf890de640d3ad17b53da34d46f7_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i17723664c2b44d548c8c8e8627ed427d_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="idaea78f2bf0b45eb910fc188d04fbfbd_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i11798e595eff476180e4de36a00ef239_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i83d752ce08cf496391503b82c9f8093e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3f629283443f49d8aaad385960bb0673_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i093f63f72e8e49ecb668d13b75d40bb2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i686c8541b42b4c05a464ef7ee07f890d_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="iae059ef9a71a4eb791f9e711bc7a3a8b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i540168e260374772b2846cd65772d665_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i4eda79b80e2049239e63855bc02299d9_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie7c7de0d76674b90ae3e372bc29d4f72_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i86f3e2bce1e74415a5032c634535117d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i4a1a49f5edb04dcbbfd9179b3bc6605d_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i64eef9047d8b4024881a1e71e04644ab_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ifd5f7ebb194146fe824e76df773868ab_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib75875ac7da34c28b177112493ce9e3b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPRAVATOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i4c5219d9e2234c1581c5cbbbc318e9ca_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i7f3287ef468347f78f62d4695c0a6c33_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2dc3cc05679b42978b02eabd70ac7223_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="if98063295c35488990378b212f03f0c0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ied3b20670e8f435991a56e4ff15b778d_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="iac15c39db3b94e89978df479bba14ca0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i333de10c5e194bb8a7cde19cd0859df9_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib525ff83930a455288c90417291f93fb_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i68673ce635ab4895a3a71deec80d927b_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i8e28bea10b16493bb218d5f6672559a2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3f2133a562294f9fad3ef124cc3f62af_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ifc0119131cf0458084a6a1dbfcc10ee5_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i60f30737549148d78386d683bd7971cf_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i22ec3b93d6a4485d9565624fd37520b1_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3e2961eace9b41418fe529105d0a94b4_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i0dec4567146a4b51add1694785443d3f_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i6c0955b8e0a143aca601efbe6babf21c_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib16a26859ccb46d6947b21484d429b1e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CARVYKTIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iee98c5cb0708407396e22087c411d285_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ifab9674d8a57440385daec43e3b872b5_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="icd48985d52ea4f1693cc1042d3c8fdc3_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i45c6fb890aee4700b7cabd1224a7a9f7_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9d3a9c49693c4528b8b24e19524f85c9_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i160565feac454261b5cf8029f03df1d1_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic4815237e89d4db1b540f9d011fad6bd_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ic942fa98d0f54d4abd3aa101ed8cfd4e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i51623904c8e7456683c43cae3c239cbd_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i2d32e645ff894945ad0436a18173134f_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id5f9f5c36c324901a0f9ef4ee74902fb_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i4ebd3fdfaab847999b1abbed0df2881e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ERLEADAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i8c5ac73df6614e86b2c68e2bb0b7b04c_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i076a0601ecf14a4288789888d685888e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1c8f0d46d42a41e097f8a42fea7efc04_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i6beee782dab74a55ae5b50d1a126075a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i652dff8c442f438c8266669ccab6b186_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i6a7d9521630e4ed4a0f926999bb837f2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i6bd82b4bf5fb40b3a12d708741b67d0f_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i35bd295b8c6c45a49ecf26261ae4958d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7c53ac8f0c6c4ea2aaaf494a42d823c8_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i88768a59c84946cc86069b6c72c10e17_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie04f0afe64d04e5f81ea459941636bb7_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i4da66669adf2490a954dfa605b57620e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i995cfb4d674e4f669792e3fcce3e446a_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="if0c00ddbe0f14783b81b783b0481b7d0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic70082fa2bd84d2abfaa197163d58036_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ic93c8ff581fb4066a25be356733d40b9_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2ab9aaf299b94d139444f75057ae76ce_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i345f37b977dd4873a272254f2cd7b0b7_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i150f063107274f55809b1b424526240f_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i7326763483de473c80ee9447ae7d5874_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id31a5ffdbdb34a8da796905e5c398b22_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i505ae89dce3d4c318427fd4433c5ac85_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i136fdab820ca4a628cd28ba7b37ed9d6_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i1212b07b91c147ce8e0d1b45004d468c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i05688666a73b489f9d6fb95983420710_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i37d4e70638d24648963bbcebc8758c59_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i16171e8c53424225a58ffa109cbddc6f_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="iad42b84534d649ba85fbccdcd13e9e92_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ibc6a67ff3e2c46c8b750cddad69dc4d3_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i9b3581abfcda4f839a0c590c86c694a7_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i67d976ab3276405b924504695f2c3e16_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i9fedce0cd42349b4ac489cf459d784b6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ifdb91f2c98f843f3bf1a457a9e524b19_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i6130edb225934eb28e1c70739f5d063d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic918fc23c9474840bab3b6e74a8b4c59_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib5df37fa4b554bda930ce40e6cfe2580_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib4c88a8d200f40b4bacde02a32dd9329_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ifa1ad776d62d468da5fc409a793fe0d2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i43b4a5127e1b4328bc2a43a45710bde8_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="id490f83accb14c9fa6698c9ccc80525a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="idb0bb69e2c4c4516a56e8f1e3dc2d643_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i6afd1882f62f4386a785d02f1a23bdb9_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3c3060e9d95943b589436fb77dc77a35_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i37be37c17b20438193f60193db94a428_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i21df6a06501347ef989f179b4cf7dd2a_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i291cca6f20e64e3c8cebcfda2c8ccccb_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia0152d0f99144507acb484aac822034c_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i04c171c0b08d4ba39f9cc175df531847_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i236ad63ca35a41cd8f969b4e2938f2fc_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="iafc33bbf42804adb85ccdf725d2e83cc_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i01a03416efc042fba5eb7b5f63640595_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="id46b580cb2ea4c188253514d7ee59c8e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9e7f61f9e4f74352b9c8f412986189e3_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="id5efb947632c47e19d68b8280af2e44d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i85bb32425f664497b088763671d4d454_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i098d2b32fc074e018e965ef42cd425b3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic47106d021b544a9b064a88a11f29db6_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib6a6f8cd2d6443ff9d286090d2f06423_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3b0c223e01d14534a29b703d9ffca9a1_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i569502cf2f0f4e4a8dfc490844775e54_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if748627f3368423685d8be9fda1d9fe3_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i2ac40786f71940aebc5e207db586eb04_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iac741c82fc14439fbb4cda5efa014094_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ie6e46509ea6b444880c2eada1a0364ee_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i12677390b1eb4de7a97ffc8bc444bbde_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia4b42c17ade64ae7ac0f6eb0f8faeda6_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ie49526704b3f443cb8d37f9e340cec4a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9e9f540147284f2b909c9bdcc3fa5530_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib2e93949a9b44381a7f3701eee7f9ac8_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i91c597ec59014a40ae4281f9275dd4c1_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ic6f4fa75b8a74a9dac7059e98c19f5b6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i588fd7f2edcb4507904e6ad2502e9f06_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="idd3f73f1f8144c4eba42b6ed8a810de7_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i1ca28df51b6440c696c0314691bbe427_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="if2fa133450684e3dabae5a9de5d13ce8_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i238eddc286cc4e6ea38e56b95db65cf5_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i7044bf88210248c884a8bef89b77d4eb_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ElectrophysiologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i90c97bfc6a2b44d78898de9f3bff5d87_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i94dff6bcd4564c4eaddba70ccb2a8de2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i4bfeff988ad0455782b5383e4bde3dac_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="iccfe7ce7ecc24b40a8d287f61d0e19a3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i6e5e294252c54f9da688d735b42fe26f_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="if98abe23095c49038b3e34d99b190cbb_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id9d23239da0148da8bb85076fc21c555_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OtherInterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ifca62b1259c54fcba069f4a9034206b1_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OtherInterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i87ea8359aa454362b30d54da0aab13a6_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OtherInterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i5e7e328557ce4073882ac9143166a882_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OtherInterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i42e4f8a3fab14e74a2530932f1029f2d_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OtherInterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i42eb9f30337047a0b6994260a328fbdb_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OtherInterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i020c283a9b454f4c91205f8a5aecc950_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="id12435a3d01c4f3c9b3518fa0cc67836_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i29f9872cc99b44b5b1cccfb6c75db81a_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i8e718713cf094373a8d40c5920af2f60_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib807084fc7c8485b9668410e22e4f2bf_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="id8e6ddf9e58e4f528caa4e6cce761163_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic6901dd295b24125b4138f0b272f8777_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i18df14d793b446acaebb489d09b54690_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i0ccac7306a934e89a59dcc66dc558644_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i1f491788cb63462fb654dbad9c0775b6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i06411c6af6a74c35ac5cfad22270bc75_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i16a5c0148e3e41e483ac0ea77b562ac2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7ba51dfb57e344d5a0fea2a350310cc4_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib6fa3f9ddb7146f995f2f94806cfc5ec_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="iabc10b6383d0489e8b8bb5a496eaf21a_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i57664aba083e478a9546149bfc85f5c2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if29cd966f54442938b637f209a34b811_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="if5b174ade6ec43a9a47fa3978d28bd77_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9c27feb9bba3448a96cf3d833cc77e87_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="iec996af35e9d4904a9164c9042ba5927_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i4e256570168449b0bbdd5ac1802e0273_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i8496c9c84c6f40d2b659a19f28f6f5b6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i060b7639c5944fe3aa7774d6f5d6087d_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i60b40c723a94457c91bbb0eb8f7292e6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i5a4bd2851d954128945886c150131c9a_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="icf832e226abb4c3b93f4a76b0876c785_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i341a9238ebd54b549ec9e2262b87e9dd_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i5cf8369cc3964063aedd59972566936c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i697f77c1d355434a9a8b15ca4ddad302_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i81e33ba2cabb410cb020c140d48b86f5_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINEOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i9e5596ec20ad4b459dfd9d49c8be8280_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ie645a8f76fd04bdd9b7b72c99f5627e3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i8552e76d9d3b4733be32dc860982d8e4_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ic807b109c8d14499aa4a84252589e37c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="if0dee0d184434eecb3b25dcaf1f98eba_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i90a5e69efde44189a532234286ccde39_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7e384d939a2447cea4dadc0e5a0c2ba0_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="iaed173f3390944eeb61ad6efe66a23f6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i49de9bf99ea94180be433fa61b42ba88_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i14f40102c79e405caf79b8aa335221bc_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia2d75beb452e47f4893b94abbefb8bba_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ic2400dc461764134b3d942c32d0168b5_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic8aa22293d2d40f6b58a4dec4c64b355_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ic8ba49a1061e421f816cbb74a729895b_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic05893454bf84c37b75cefbd3d5459a8_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i9ce2e1faf70848a0bfcd29eeafb93a9c_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ia1677e46a9474356b3c9dfb976393db7_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i517534deb5ca4eb3aaae15c62790e025_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ibd11491a92ce4672bdb3774057431a46_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i339f955c262f45dfb4f389ca7e08c4a0_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie597f3c11e0747f68e8d3493b85a2080_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i72679ec91b0f470ea17b2acaf9ad9344_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ic1bb18c06f4c40b296683224f79a53f4_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="iade9c6803cc4447ca6535fa706f5fca2_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i98b473235c7a47cf859add062d06101a_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i68cff8e717ca4f708d166109353460b5_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie56c32de3e2e41eba3b2b9cc344394db_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib0d829554c2047b198f4d4504c6c4bad_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i3fa18e49624849a3bf980a89602d76c9_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i744e82d777a14f4dbc24cf9ac953202f_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i848d69207c1f4c90b5cc68c1f1eb7bf0_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i74605a46308f4807bcd58248b6e0db65_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i115ea6c058084298bd8bfd6a9c9d7b23_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i5a59d2f00ca14a8fa8f0a3d5f5602967_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ifb91eb7b4af04d58ad7789571043edbf_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i9a2a973165fa46a79af877784002fe9a_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i787acd4164eb45deb0403c444006faf9_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ibaf4ce4d283a4b7280171759a01baa0e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i0c64cc3fc6694b9495fdc5efad8fb4d4_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ib78785c8a47a4c63b2c807c981cf27ba_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id0b0bf9e3b4b4097ab7bdcaefa80578e_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ib18fd463fe944955b813ba83e60464c6_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i4a29daeaf368468580d88ec00d701e07_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ibf1fef094458495f8b29e9d3d2c96404_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i9092a20f7ec442c6abb4a5f03939e991_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i76b70d99f03547bebaa68b9a5dfb0b6b_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i3e23b581651e49f0a5450b48eca550f3_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i266ded4d880644b384a30db64ac42be7_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i32d86be298e0484a81aaed029e8f90b8_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i7e11113be4ef43419386891473e5f667_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i0c0748aae7984d91b72595fdb3674877_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedicalDevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i255efac904da4926972f85e5d3721be3_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i6478dcb7f72f406bb51f1ce2d06bbe1d_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i6422d8dc1a9349d8ad4352f323889e7e_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="ia33598a52aed4f398e20f2837c3224a6_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i2e99be17669548568e7cf2506dae3d92_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i92e0a38cfc3b4adbbf4d6b479e3c1cb5_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i1b6b9854fc844374a84fb9c3498a9aa8_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="i08a82343349b46cfa5a11eced6ece9f7_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i0468e2eece0f48cb874e2856e754bfea_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="id60f2cfdf1f24ce795240fc4f13586e0_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i65cb348676ea488598ee39d3f57d3991_D20220103-20220403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-04-03</endDate>
        </period>
    </context>
    <context id="ie51821e4cdcc40f9935183e51ba866a3_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i36d5c84c5814468ba35bfdbf20ca360c_D20221222-20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="i81a2ab2c858b4a97bf160fe849e1cb84_D20221222-20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="icc8de83c4d3041d09bb523dcfd66b52e_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i8836b8f3d5ba484189de37af4b30f820_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i06197fa8dff142f592975553bd6a4d84_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ImpellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i0794a9f898cd4ed580c9795984a4df7d_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ClassIRecommendationForImpellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i814ccd0c40684dd8ae2ed1e023cd3b2a_D20221222-20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="iccd1694ce0dc40e78004ae73676d4941_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="ia3a0b329d181434f981a08002ca2cd3b_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i74c08a50ff5f419b83ba7dba4d025c2a_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ic4c5e1157e174c7b9992d3b947faa46d_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:InghamVsJohnsonJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia9af996ed5624621b676a456a070b7db_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:InghamVsJohnsonJohnsonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5a2da6f47c794efc85b034ec75f9880b_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="if6ec52a5f6d5422d88184d297ffc6e51_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i503d1efd449c494a99b00f5571fe65d2_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i304dd0295691432abf102897083e51f0_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="i043b133272cb49e4ad4a3a90ff5a68b9_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i168a38aa9d2c44faab5619fe9ffe4231_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i0ab721ca3d7d460192200182b3872c5a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0c6d0bc5404442dc9fbb22defa52977d_I20210704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-04</instant>
        </period>
    </context>
    <context id="ia97ebcbe40d746e3998c9afa253624ee_D20230102-20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-02</startDate>
            <endDate>2023-04-02</endDate>
        </period>
    </context>
    <context id="i67bea373bcf745f8b39c99720a13df20_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i4cf78e7db6fe424ca92d366884d15cc1_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i3b4ceb386c184c2b93d06b92b82b2bbb_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ifaeb7772b11c47759bd2f3879d60dc10_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ib5a55c1aa53f481d8979dcf3332bb680_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i51cf8df9cdd74871b6625778ba7d91de_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i4790b713aa2844809fa453cd9fcb88bd_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ElmironMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ibc7d93f749d74c228eda4c9d482b9c1a_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TylenolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i77bc5b03664c43aea0c4d8e95bd4da26_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="ic5638d3163f64eb384c2d26990c2bf2d_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i8056c4aa7c884f9cb93c3477b3ab1519_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i82887472019e4389baf706d14d575072_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i62a7dab5fc114de782c92d25060c9210_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EthiconMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i28f2b9ddeb654daeb2f97d59eea0473d_I20230402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-02</instant>
        </period>
    </context>
    <context id="i7b5262aa703a4c79ad88ac4d66f46761_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i8420d4da9f3346f483112422335f21db_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i7cec5795e9f24927925718a962fd322c_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i2f8d53e5a09b495182048bc044c3b582_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="claimant">
        <measure>jnj:claimant</measure>
    </unit>
    <unit id="claim">
        <measure>jnj:claim</measure>
    </unit>
    <unit id="cases">
        <measure>jnj:cases</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80L2ZyYWc6YTMyZmRjNzg3NDNkNDcxOWE0YzAyOTYxMmQ2MmI1MDEvdGFibGU6M2FhNTAwNzQ0NGM0NGZkMWEzZTFhZThiMjcxNTIxOGMvdGFibGVyYW5nZTozYWE1MDA3NDQ0YzQ0ZmQxYTNlMWFlOGIyNzE1MjE4Y180LTEtMS0xLTExNTYyNw_a2fd08dc-f508-4493-994b-2549d06b28c1">0000200406</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80L2ZyYWc6YTMyZmRjNzg3NDNkNDcxOWE0YzAyOTYxMmQ2MmI1MDEvdGFibGU6M2FhNTAwNzQ0NGM0NGZkMWEzZTFhZThiMjcxNTIxOGMvdGFibGVyYW5nZTozYWE1MDA3NDQ0YzQ0ZmQxYTNlMWFlOGIyNzE1MjE4Y181LTEtMS0xLTExNTYyNw_c06ce72c-cbbc-4d00-98ea-c088f2b37cbb">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80L2ZyYWc6YTMyZmRjNzg3NDNkNDcxOWE0YzAyOTYxMmQ2MmI1MDEvdGFibGU6M2FhNTAwNzQ0NGM0NGZkMWEzZTFhZThiMjcxNTIxOGMvdGFibGVyYW5nZTozYWE1MDA3NDQ0YzQ0ZmQxYTNlMWFlOGIyNzE1MjE4Y185LTEtMS0xLTExNTYyNw_49b91b1d-77b7-4453-881a-74984e3a5cd5">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80L2ZyYWc6YTMyZmRjNzg3NDNkNDcxOWE0YzAyOTYxMmQ2MmI1MDEvdGFibGU6M2FhNTAwNzQ0NGM0NGZkMWEzZTFhZThiMjcxNTIxOGMvdGFibGVyYW5nZTozYWE1MDA3NDQ0YzQ0ZmQxYTNlMWFlOGIyNzE1MjE4Y18xMC0xLTEtMS0xMTU2Mjc_79717867-df6d-4ab0-b61c-46b2cab481ed">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80L2ZyYWc6YTMyZmRjNzg3NDNkNDcxOWE0YzAyOTYxMmQ2MmI1MDEvdGFibGU6M2FhNTAwNzQ0NGM0NGZkMWEzZTFhZThiMjcxNTIxOGMvdGFibGVyYW5nZTozYWE1MDA3NDQ0YzQ0ZmQxYTNlMWFlOGIyNzE1MjE4Y18xMS0xLTEtMS0xMTU2Mjc_83ebaa88-cda5-408f-bf70-8644f1898bf1">false</dei:AmendmentFlag>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzI5ODUzNDg5MzQ2NA_6b98e8e9-0203-4faa-b7c5-6f9e7ebf5ed3">http://www.jnj.com/20230402#AccountingStandardsUpdate202204Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <dei:DocumentType
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDY5_1a82dd62-06e8-4e8a-9e6c-23691f11f02a">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6ZTQzZDU0MmZhOTE3NDU5NWFjYzI5Zjk0MTFiYmY3YzAvdGFibGVyYW5nZTplNDNkNTQyZmE5MTc0NTk1YWNjMjlmOTQxMWJiZjdjMF8xLTAtMS0xLTExNTYyNw_5f418fb6-0154-4a63-9168-5ab70288ee2d">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8xMjQ_8b9bbf80-c516-453b-a8a9-80086dd7775b">2023-04-02</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6NjdmMDQ1NzU4ZjM3NGQzMzgyZGExNjUwYTdlMDc4ZmQvdGFibGVyYW5nZTo2N2YwNDU3NThmMzc0ZDMzODJkYTE2NTBhN2UwNzhmZF8xLTAtMS0xLTExNTYyNw_1a7f536f-16a9-4246-9c63-51bf120986fc">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDYz_c0e68cc8-7279-47e7-9d84-d031ce425127">1-3215</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDY0_af451115-b668-448d-ba7b-5533a11701b4">Johnson &amp; Johnson</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6MWZkNDZlOWI3Nzc5NDY5ODk3ZTAwMmRlYzRiNzg4MzcvdGFibGVyYW5nZToxZmQ0NmU5Yjc3Nzk0Njk4OTdlMDAyZGVjNGI3ODgzN18wLTAtMS0xLTExNTYyNw_4b70211d-0815-48b2-80ac-79356314e472">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6MWZkNDZlOWI3Nzc5NDY5ODk3ZTAwMmRlYzRiNzg4MzcvdGFibGVyYW5nZToxZmQ0NmU5Yjc3Nzk0Njk4OTdlMDAyZGVjNGI3ODgzN18wLTItMS0xLTExNTYyNw_cff8468c-4a46-4185-9807-820ca7f33932">22-1024240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDY1_c721b047-b3b6-46e6-8d3c-89ca879999b7">One Johnson &amp; Johnson Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDcw_8ef5415c-8cc2-4c6f-be94-1e23c109aa93">New Brunswick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDY2_1e804ab2-57dd-49d2-a202-00d7b277fbe4">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDY3_ea9c3a89-41d0-41b0-9311-83b909849ffa">08933</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDcx_7557421d-5846-45d4-a4c2-1e978310f603">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDcy_d8196b03-0cf5-4a1f-893b-be7acdf31506">524-0400</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDcz_95eff410-101a-4805-8ab4-5a1869b160ac">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDY4_cd4b25d1-7405-456b-8607-cf07bc9c328f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6OTQ2MjU1Njk4NDUyNDk3Yzk0YzU2MGE2MTlkNjIyOWEvdGFibGVyYW5nZTo5NDYyNTU2OTg0NTI0OTdjOTRjNTYwYTYxOWQ2MjI5YV8wLTEtMS0xLTExNTYyNw_56706e8d-2c7d-45ee-82ac-7107b2753d9c">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6OTQ2MjU1Njk4NDUyNDk3Yzk0YzU2MGE2MTlkNjIyOWEvdGFibGVyYW5nZTo5NDYyNTU2OTg0NTI0OTdjOTRjNTYwYTYxOWQ2MjI5YV8xLTQtMS0xLTExNTYyNw_2b84da8a-8294-49a7-b453-5feab6efd563">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6OTQ2MjU1Njk4NDUyNDk3Yzk0YzU2MGE2MTlkNjIyOWEvdGFibGVyYW5nZTo5NDYyNTU2OTg0NTI0OTdjOTRjNTYwYTYxOWQ2MjI5YV8yLTItMS0xLTExNTYyNw_7ef6c9c1-bda6-4372-a0db-f79229325fbf">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDYy_d13d4d78-e9ea-4cc7-b4f1-44513a3ec03a">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="ie4185cc0226f40acb9724055d3655952_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18xLTAtMS0xLTExNTYyNw_d14728b9-e62d-4849-aef5-acb68fec3f4f">Common Stock, Par Value $1.00</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie4185cc0226f40acb9724055d3655952_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18xLTEtMS0xLTExNTYyNw_778c9a27-2be5-4373-bb87-910ddf9a88f3">JNJ</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie4185cc0226f40acb9724055d3655952_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18xLTItMS0xLTExNTYyNw_df46d161-4983-413f-84d0-85bea80b014f">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i5cd2bfae49cc471b8e8f8f061eeb877b_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18yLTAtMS0xLTExNTYyNw_68184dd3-55f9-40fc-8055-0f12b0b04d7a">0.650% Notes Due May 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5cd2bfae49cc471b8e8f8f061eeb877b_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18yLTEtMS0xLTExNTYyNw_bec1f400-4204-4663-879e-dabb2a70f379">JNJ24C</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5cd2bfae49cc471b8e8f8f061eeb877b_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18yLTItMS0xLTExNTYyNw_a1240378-aef9-4b4c-974e-e53d7aa714d0">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i5985eba1fdd445c088f418dadd94f1c6_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18zLTAtMS0xLTExNTYyNw_a4a6fbd3-9a70-44d5-925e-d6a2732cf2b3">5.50% Notes Due November 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5985eba1fdd445c088f418dadd94f1c6_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18zLTEtMS0xLTExNTYyNw_a4bea152-ef6b-4282-a5e0-4fd9f828d0da">JNJ24BP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5985eba1fdd445c088f418dadd94f1c6_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y18zLTItMS0xLTExNTYyNw_6d27c089-5ce0-4b9e-871b-004dcac21205">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ie611e2d28014400cb2d7774070bd6ea5_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y180LTAtMS0xLTExNTYyNw_1e7f60b9-57fc-45f6-82f8-65087c8c9538">1.150% Notes Due November 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ie611e2d28014400cb2d7774070bd6ea5_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y180LTEtMS0xLTExNTYyNw_25eda0a7-bedf-4004-8002-ed09a69c3425">JNJ28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ie611e2d28014400cb2d7774070bd6ea5_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y180LTItMS0xLTExNTYyNw_f5c0b587-b4ca-45af-9a45-37be3553b72a">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i56880e9c6bfe4b0985d48f5d5f70bb4f_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y181LTAtMS0xLTExNTYyNw_58021816-de76-4b2b-9fcb-133b69a25d74">1.650% Notes Due May 2035</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i56880e9c6bfe4b0985d48f5d5f70bb4f_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y181LTEtMS0xLTExNTYyNw_c7d58c82-68ea-49a0-ba5c-aa14e994885c">JNJ35</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i56880e9c6bfe4b0985d48f5d5f70bb4f_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGFibGU6YmViN2RiYzJiNzZjNDM0MTk1NmU4ZjJiMzcxYjk1NWMvdGFibGVyYW5nZTpiZWI3ZGJjMmI3NmM0MzQxOTU2ZThmMmIzNzFiOTU1Y181LTItMS0xLTExNTYyNw_68166a06-cada-4c56-8d53-de7181d532d1">NYSE</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib8cdf2a1534245f6aaf14d9138fb6495_I20230421"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xL2ZyYWc6OWY1YzcwM2ExOWY1NDIyOTgzYTZmYTQxNzVkN2FlN2QvdGV4dHJlZ2lvbjo5ZjVjNzAzYTE5ZjU0MjI5ODNhNmZhNDE3NWQ3YWU3ZF8yMDAx_32ec39ff-1ee3-4fc7-8db9-45c27de232a6"
      unitRef="shares">2598734075</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMy0yLTEtMS0xMTU2Mjc_5aad73a8-b90a-42ba-a44c-20c5fae1e24d"
      unitRef="usd">19170000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMy00LTEtMS0xMTU2Mjc_145874ab-ae6d-497a-a419-e9dc015a48b7"
      unitRef="usd">14127000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNC0yLTEtMS0xMjQyMDA_ecf5e242-e382-4e52-8310-e9e9e6569f0a"
      unitRef="usd">7695000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNC00LTEtMS0xMjcwMzc_a46ecc80-223b-4221-bc00-c3ecc7724ac2"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNC0yLTEtMS0xMTU2Mjc_0a00285c-bd7a-489e-b4bd-483333177105"
      unitRef="usd">5443000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNC00LTEtMS0xMTU2Mjc_de8e4270-2fa5-4a87-a3ba-38eafb0b7d3a"
      unitRef="usd">9392000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNS0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjpiMDQ5MTA2NTE5YjM0MzNiYWU4Mjc3MDI1NTFkMTE5M180OA_55b216c1-27b8-49ed-8413-eb46124e338e"
      unitRef="usd">207000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNS0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjpiMDQ5MTA2NTE5YjM0MzNiYWU4Mjc3MDI1NTFkMTE5M181OA_56943255-a018-413f-8f0a-67fb3bbfaf26"
      unitRef="usd">203000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNS0yLTEtMS0xMTU2Mjc_814dc276-451a-4806-9e4e-4fe8bc22885b"
      unitRef="usd">16350000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNS00LTEtMS0xMTU2Mjc_1050177d-90e5-4285-ae5e-6540a9d859c6"
      unitRef="usd">16160000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNi0yLTEtMS0xMTU2Mjc_b345ff66-3893-4771-8305-006e8a33e369"
      unitRef="usd">12809000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNi00LTEtMS0xMTU2Mjc_e28701ca-b580-4661-8024-b63acf8f662a"
      unitRef="usd">12483000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNy0yLTEtMS0xMTU2Mjc_d942afd9-14b0-4680-acc2-b312a95c916c"
      unitRef="usd">2921000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNy00LTEtMS0xMTU2Mjc_906a2075-af82-4900-a79c-9f197d5617de"
      unitRef="usd">3132000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfOS0yLTEtMS0xMTU2Mjc_564e9bbf-d492-4d39-a483-55d142527423"
      unitRef="usd">64388000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfOS00LTEtMS0xMTU2Mjc_c3b67f49-d536-473b-8145-b1760d437c89"
      unitRef="usd">55294000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTAtMi0xLTEtMTE1NjI3_de657ac4-b8ec-4f3f-9997-685054e8952c"
      unitRef="usd">50367000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTAtNC0xLTEtMTE1NjI3_31224f38-8aa9-4c57-b123-14e9dd6dcd22"
      unitRef="usd">49253000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTEtMi0xLTEtMTE1NjI3_5c90e248-e631-4d3c-ae84-22a0af203c9d"
      unitRef="usd">30193000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTEtNC0xLTEtMTE1NjI3_07900aba-a393-416c-83f5-0bbd4478d4c8"
      unitRef="usd">29450000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTItMi0xLTEtMTE1NjI3_a1bdf784-47de-46c7-a2b3-d7556a93aebf"
      unitRef="usd">20174000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTItNC0xLTEtMTE1NjI3_a629aebc-b851-40a5-b31f-6032ece8a158"
      unitRef="usd">19803000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTMtMi0xLTEtMTE1NjI3_8a8474dd-73ba-47d1-8832-e95f86b66e2c"
      unitRef="usd">47448000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTMtNC0xLTEtMTE1NjI3_9947635d-c313-478c-acdd-88ebcf262c97"
      unitRef="usd">48325000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTQtMi0xLTEtMTE1NjI3_608eaf9f-698b-4ceb-8db5-3c9d12d0a60f"
      unitRef="usd">45575000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTQtNC0xLTEtMTE1NjI3_dd3c8591-09e0-4598-9738-0c9d69a215ab"
      unitRef="usd">45231000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTUtMi0xLTEtMTE1NjI3_27276647-346d-49ff-951b-e97d83927823"
      unitRef="usd">8817000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTUtNC0xLTEtMTE1NjI3_15e8ad4a-1a9f-4d25-ad28-6de0f1a9062a"
      unitRef="usd">9123000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTYtMi0xLTEtMTE1NjI3_77e13e3a-286a-48b3-a55d-fefa1e47591d"
      unitRef="usd">9567000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTYtNC0xLTEtMTE1NjI3_dd79c3b9-0825-4971-b56a-7400711cc183"
      unitRef="usd">9602000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTctMi0xLTEtMTE1NjI3_91bda055-a32b-46a9-a5a2-5f826d9d94d1"
      unitRef="usd">195969000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMTctNC0xLTEtMTE1NjI3_f8d6f0bd-0871-4edf-a8e2-1a6de1207a7a"
      unitRef="usd">187378000000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjAtMi0xLTEtMTE1NjI3_e7ec3fb0-10f4-4ccd-a8f8-471939f9d8e8"
      unitRef="usd">17979000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjAtNC0xLTEtMTE1NjI3_454990ca-5198-4c8a-acea-6ae064e1287f"
      unitRef="usd">12771000000</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjEtMi0xLTEtMTE1NjI3_b4fbef45-1ef8-4db9-ad8e-c12421946fc7"
      unitRef="usd">9909000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjEtNC0xLTEtMTE1NjI3_f6530810-9ce9-4205-a7ad-81e23cb9b339"
      unitRef="usd">11703000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjItMi0xLTEtMTE1NjI3_7e18d627-8009-4d68-a181-391e934ee8e5"
      unitRef="usd">11204000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjItNC0xLTEtMTE1NjI3_54f4c8f9-9d3a-4da2-a1bd-fcee027cba0e"
      unitRef="usd">11456000000</us-gaap:AccruedLiabilitiesCurrent>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjMtMi0xLTEtMTE1NjI3_8dada9af-7c51-4aba-9e0a-09605e550260"
      unitRef="usd">14784000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjMtNC0xLTEtMTE1NjI3_6ff8d247-8804-459b-b081-f9c79f8b8da7"
      unitRef="usd">14417000000</jnj:AccruedRebatesReturnsAndPromotions>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjQtMi0xLTEtMTE1NjI3_92ae07e9-9838-4d39-bbc2-6ffd922380e5"
      unitRef="usd">2231000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjQtNC0xLTEtMTE1NjI3_a7339738-74cf-45e3-abec-a911c903d9e7"
      unitRef="usd">3328000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjUtMi0xLTEtMTE1NjI3_2f9f30dc-0852-485c-a82a-86d2727a9787"
      unitRef="usd">4266000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjUtNC0xLTEtMTE1NjI3_6c8427c5-bc58-4218-96c8-9a03e55a40d3"
      unitRef="usd">2127000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjYtMi0xLTEtMTE1NjI3_9ac6dddc-a517-420f-a2e6-ef81e291cb42"
      unitRef="usd">60373000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjYtNC0xLTEtMTE1NjI3_a98a4bbe-e0ff-4e7f-9ec7-43b21ac36c45"
      unitRef="usd">55802000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjctMi0xLTEtMTE1NjI3_0af59aa7-1ac8-42ce-a658-4e7eecd8d641"
      unitRef="usd">34928000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjctNC0xLTEtMTE1NjI3_078eb6ac-558d-4fbd-b209-5a8aa332c0d7"
      unitRef="usd">26888000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjgtMi0xLTEtMTE1NjI3_af54a401-5216-451b-98aa-e76935d28876"
      unitRef="usd">4417000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjgtNC0xLTEtMTE1NjI3_9458ccfb-7fe9-4d1c-a521-a08c719ef8aa"
      unitRef="usd">6374000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjktMi0xLTEtMTE1NjI3_8a8a9148-0ef4-4db3-8c9d-d8bd3a26ca6c"
      unitRef="usd">6665000000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMjktNC0xLTEtMTE1NjI3_df5e0aa4-fff2-453d-8cca-34a984661819"
      unitRef="usd">6767000000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzAtMi0xLTEtMTE1NjI3_281d3b4a-313a-4123-8a6d-8bb70a32a539"
      unitRef="usd">4296000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzAtNC0xLTEtMTE1NjI3_c023e2e6-ad98-442c-82b1-fdd108af85e7"
      unitRef="usd">4306000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzEtMi0xLTEtMTE1NjI3_578d5885-05e7-41e4-8a22-e91ca16bb927"
      unitRef="usd">14421000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzEtNC0xLTEtMTE1NjI3_c34dbe7a-4a4b-436e-9643-860831481c96"
      unitRef="usd">10437000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzItMi0xLTEtMTE1NjI3_3dad61ae-4a6f-46c1-a8bc-7fdfd7a07666"
      unitRef="usd">125100000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzItNC0xLTEtMTE1NjI3_e0f51d97-278d-4276-bf3c-9adf55bd6ae5"
      unitRef="usd">110574000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzMtMi0xLTEtMTE1NjI3_3ba747e3-df38-450d-98b6-47509d9ce5da"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzMtNC0xLTEtMTE1NjI3_76c636b6-b045-402b-8dcc-ea2621a13c8a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzVlOThhMDQzNGNhNDU0Mzg0MDNhZTkxODY1N2QwMTJfMjk_44b92829-ec6b-4f84-93e4-3a224711e25d"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzVlOThhMDQzNGNhNDU0Mzg0MDNhZTkxODY1N2QwMTJfMjk_5f1c6257-4638-43f0-bff9-a0efeb5bc492"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzVlOThhMDQzNGNhNDU0Mzg0MDNhZTkxODY1N2QwMTJfNTQ_532d13be-e601-4ec0-bfce-b751e130bf64"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzVlOThhMDQzNGNhNDU0Mzg0MDNhZTkxODY1N2QwMTJfNTQ_89d134f1-e716-45b3-878c-33e6a984ea03"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzVlOThhMDQzNGNhNDU0Mzg0MDNhZTkxODY1N2QwMTJfNzI_27b2816f-24ff-4ed0-ae6b-51c651476e16"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzVlOThhMDQzNGNhNDU0Mzg0MDNhZTkxODY1N2QwMTJfNzI_a496a3ba-5462-45a4-b8db-dce11eceea4c"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtMi0xLTEtMTE1NjI3_a6c6acb3-a4e0-45f4-8926-a9651443982a"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzUtNC0xLTEtMTE1NjI3_a257f877-5db9-4a6c-ab97-9e3111cc4fe7"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzYtMi0xLTEtMTE1NjI3_d36221d9-d1d6-4d6a-a2fc-df1feb0aa019"
      unitRef="usd">-12626000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzYtNC0xLTEtMTE1NjI3_bbad7828-7ec0-4276-9f51-cfecc17f0e0c"
      unitRef="usd">-12967000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzctMi0xLTEtMTE1NjI3_0f62f0af-4572-4b05-9e86-203d51a1e510"
      unitRef="usd">124558000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzctNC0xLTEtMTE1NjI3_c36424bf-456a-40e4-b5fd-b259d3e16263"
      unitRef="usd">128345000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzgtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZmYyM2Y3MzM4NGI5NDAyZWI5Mzk2ZDlkNTI5YzU5NGJfNTA_6081d911-df64-4b47-8c0b-b1bdffb70639"
      unitRef="shares">521519000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzgtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZmYyM2Y3MzM4NGI5NDAyZWI5Mzk2ZDlkNTI5YzU5NGJfNTc_cb7c8671-04f5-4300-bf0a-f85870ce9d7a"
      unitRef="shares">506246000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzgtMi0xLTEtMTE1NjI3_20b7e6ea-8f6e-4eaa-bbe5-6804262319d4"
      unitRef="usd">44183000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzgtNC0xLTEtMTE1NjI3_84e970d5-0575-4f05-b499-f0f7c1d9e820"
      unitRef="usd">41694000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzktMi0xLTEtMTE1NjI3_95431654-4209-4cbb-aa09-c62c15c148be"
      unitRef="usd">70869000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfMzktNC0xLTEtMTE1NjI3_1b93f708-4d5f-4673-982a-0cff89eebfa6"
      unitRef="usd">76804000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNDAtMi0xLTEtMTE1NjI3_3722aa7a-776e-4e6b-a610-424833edf066"
      unitRef="usd">195969000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8xOS9mcmFnOmM0MWMzODI5ZjU0YzQxZDU4ODk4Mjc5YmZjMTRmNDAyL3RhYmxlOjAwYzAxY2ZiYzc2ZTQ0YjRhY2UxNjkwN2NjYzZlMzk2L3RhYmxlcmFuZ2U6MDBjMDFjZmJjNzZlNDRiNGFjZTE2OTA3Y2NjNmUzOTZfNDAtNC0xLTEtMTE1NjI3_b42e0c7d-884a-4600-92cc-7a080932ce90"
      unitRef="usd">187378000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMi0yLTEtMS0xMTU2Mjc_a1fd8204-3d8d-47e2-a1a0-a0871772ba71"
      unitRef="usd">24746000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMi00LTEtMS0xMTU2Mjc_8dc0f6ab-2334-41a5-93ad-1776e71495b0"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMi02LTEtMS0xMTU2Mjc_0a892fea-f6c8-4379-897e-462f7d89dcd1"
      unitRef="usd">23426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:SalesRevenueGoodsNetPercentToSales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMi04LTEtMS0xMTU2Mjc_99a9c4e7-ff53-467c-9e70-c796f48e973c"
      unitRef="number">1.000</jnj:SalesRevenueGoodsNetPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMy0yLTEtMS0xMTU2Mjc_c0c5f715-2673-4e1e-8281-c609d890aeaf"
      unitRef="usd">8395000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMy00LTEtMS0xMTU2Mjc_568b0478-efd4-4fe2-9ee0-e2143e5396d2"
      unitRef="number">0.339</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMy02LTEtMS0xMTU2Mjc_ae41a72a-d421-446d-9e61-9c1558fef673"
      unitRef="usd">7598000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:CostOfGoodsSoldPercentToSales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMy04LTEtMS0xMTU2Mjc_546a037e-b455-4706-89ba-bc9ef6b7ec22"
      unitRef="number">0.324</jnj:CostOfGoodsSoldPercentToSales>
    <us-gaap:GrossProfit
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNC0yLTEtMS0xMTU2Mjc_1cac9543-e8f4-4307-ad48-c8ebe64c47d5"
      unitRef="usd">16351000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNC00LTEtMS0xMTU2Mjc_f7476e01-c7b9-47b3-b251-abc9f9015733"
      unitRef="number">0.661</jnj:GrossProfitPercentToSales>
    <us-gaap:GrossProfit
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNC02LTEtMS0xMTU2Mjc_2fbc5f2a-24e3-49ec-8302-cbd072ee126a"
      unitRef="usd">15828000000</us-gaap:GrossProfit>
    <jnj:GrossProfitPercentToSales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNC04LTEtMS0xMTU2Mjc_d7a10c85-4c4b-4e4a-81f1-4b6eb9365aeb"
      unitRef="number">0.676</jnj:GrossProfitPercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNS0yLTEtMS0xMTU2Mjc_91d2e874-f85b-4503-9a97-7ab28c041cab"
      unitRef="usd">6138000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNS00LTEtMS0xMTU2Mjc_4c304f41-0f40-45bf-b546-e5180d030673"
      unitRef="number">0.248</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNS02LTEtMS0xMTU2Mjc_516d39ec-2be8-42d3-8548-cedafd03ffac"
      unitRef="usd">5938000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <jnj:SellingGeneralAndAdministrativeExpensePercentToSales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNS04LTEtMS0xMTU2Mjc_842044d4-cbdd-4748-a543-1f50bbc11759"
      unitRef="number">0.254</jnj:SellingGeneralAndAdministrativeExpensePercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNi0yLTEtMS0xMTU2Mjc_7cfc36da-1a63-4f4a-a7a2-3ec9686a861a"
      unitRef="usd">3563000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNi00LTEtMS0xMTU2Mjc_f4f01882-f233-4e43-8b4b-913011f4390b"
      unitRef="number">0.144</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNi02LTEtMS0xMTU2Mjc_84879e78-9332-4a24-9a7b-b6997f280afb"
      unitRef="usd">3462000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNi04LTEtMS0xMTU2Mjc_c61735e9-2584-439d-86e2-f2a658ff16cc"
      unitRef="number">0.148</jnj:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNy0yLTEtMS0xMTU2Mjc_192c5ca0-5ed0-444d-975d-44325f7a918e"
      unitRef="usd">49000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNy00LTEtMS0xMTU2Mjc_94e7cc2d-736d-4652-812a-7ce6c8635dd5"
      unitRef="number">0.002</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNy02LTEtMS0xMTU2Mjc_5cdae3a7-ad61-4b66-88e8-343598a3ee24"
      unitRef="usd">610000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:ResearchAndDevelopmentInProcessPercentToSales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfNy04LTEtMS0xMTU2Mjc_daa3b9d0-f22d-4f69-8f27-9153a553b66d"
      unitRef="number">0.026</jnj:ResearchAndDevelopmentInProcessPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOC0yLTEtMS0xMTU2Mjc_db573efd-6a09-4de0-b95d-b4b820fa6305"
      unitRef="usd">235000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOC00LTEtMS0xMTU2Mjc_1332e234-5814-4694-a7d2-b65befdf9043"
      unitRef="number">-0.010</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOC02LTEtMS0xMTU2Mjc_34d9ef9d-3c19-45cc-a998-912aff7f8e1c"
      unitRef="usd">22000000</us-gaap:InvestmentIncomeInterest>
    <jnj:InvestmentIncomeInterestPercentToSales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOC04LTEtMS0xMTU2Mjc_a4afe8a4-db2f-48b5-b473-34a2141ee286"
      unitRef="number">-0.001</jnj:InvestmentIncomeInterestPercentToSales>
    <us-gaap:InterestExpense
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOS0yLTEtMS0xMTU2Mjc_933dd26c-fd62-47b2-b6fc-0e73e761e171"
      unitRef="usd">215000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOS00LTEtMS0xMTU2Mjc_cbb441ec-04d6-4ced-b466-c63577d74271"
      unitRef="number">0.009</jnj:InterestExpensePercentToSales>
    <us-gaap:InterestExpense
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOS02LTEtMS0xMTU2Mjc_3ec1f080-f776-4fa0-b805-03c911b7270a"
      unitRef="usd">10000000</us-gaap:InterestExpense>
    <jnj:InterestExpensePercentToSales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfOS04LTEtMS0xMTU2Mjc_adff735d-3745-432c-80a4-b4ea03c2fb77"
      unitRef="number">0.000</jnj:InterestExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTAtMi0xLTEtMTE1NjI3_831b4190-cbc5-4aef-879f-51e78900b517"
      unitRef="usd">-7228000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTAtNC0xLTEtMTE1NjI3_a37b069c-363a-4aa4-b8bf-38852ca4aa2c"
      unitRef="number">0.292</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTAtNi0xLTEtMTE1NjI3_b10e0fb1-ed6e-43d6-8bb8-0a99ae6b5619"
      unitRef="usd">102000000</us-gaap:OtherNonoperatingIncomeExpense>
    <jnj:OtherNonOperatingIncomeExpensePercentToSales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTAtOC0xLTEtMTE1NjI3_bff76057-59ba-45c7-9b85-9f955f7b9c30"
      unitRef="number">-0.004</jnj:OtherNonOperatingIncomeExpensePercentToSales>
    <us-gaap:RestructuringCharges
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTEtMi0xLTEtMTE1NjI3_65ae8550-7005-4070-a809-b587628fbb77"
      unitRef="usd">130000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTEtNC0xLTEtMTE1NjI3_c67c786d-347a-49fc-a1da-d7385af3486a"
      unitRef="number">0.006</jnj:Restructuringchargepercenttosales>
    <us-gaap:RestructuringCharges
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTEtNi0xLTEtMTE1NjI3_ab4bdb4f-4058-4fbf-9cfd-d05b0c7fce0d"
      unitRef="usd">70000000</us-gaap:RestructuringCharges>
    <jnj:Restructuringchargepercenttosales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTEtOC0xLTEtMTE1NjI3_87d5a81f-cdf7-41a2-a618-6ff02d7db57c"
      unitRef="number">0.003</jnj:Restructuringchargepercenttosales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTItMi0xLTEtMTE1NjI3_f3fd8102-dce4-4af5-820a-653c43045475"
      unitRef="usd">-737000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTItNC0xLTEtMTE1NjI3_4b57a49c-b829-41f3-aa4e-f4ebc19a2b5a"
      unitRef="number">-0.030</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTItNi0xLTEtMTE1NjI3_9fefaae0-a771-43b8-b83d-cccacf960d54"
      unitRef="usd">5862000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTItOC0xLTEtMTE1NjI3_09e83d52-58ff-45cb-8dfe-873e2c6d8356"
      unitRef="number">0.250</jnj:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTMtMi0xLTEtMTE1NjI3_94e51dbb-682f-47a7-a4f0-55a5ac14c44e"
      unitRef="usd">-669000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTMtNC0xLTEtMTE1NjI3_a29bff19-bcb1-474c-b5e7-552ef7f4c2ab"
      unitRef="number">-0.027</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTMtNi0xLTEtMTE1NjI3_7562326d-e330-44fb-a4a6-068c8d8a1eeb"
      unitRef="usd">713000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:IncomeTaxExpenseBenefitPercentToSales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTMtOC0xLTEtMTE1NjI3_80e6372d-22be-470b-841a-4c4c8f06d7f3"
      unitRef="number">0.030</jnj:IncomeTaxExpenseBenefitPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTQtMi0xLTEtMTE1NjI3_da6c6efd-d385-41f9-b96e-ebd0677c6aab"
      unitRef="usd">-68000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTQtNC0xLTEtMTE1NjI3_44657d72-ac0a-4ef7-a927-0718e0b9a506"
      unitRef="number">-0.003</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:NetIncomeLoss
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTQtNi0xLTEtMTE1NjI3_8ba2a07a-d61d-4d36-8fa1-af09ea87f4b5"
      unitRef="usd">5149000000</us-gaap:NetIncomeLoss>
    <jnj:NetIncomeAttributableToParentPercentToSales
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTQtOC0xLTEtMTE1NjI3_01f102af-72d6-41b9-8d4f-cf8d2fcbc2b5"
      unitRef="number">0.220</jnj:NetIncomeAttributableToParentPercentToSales>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTctMi0xLTEtMTE1NjI3_e53e200b-326e-44d6-bafd-0989b8dfccc2"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTctNi0xLTEtMTE1NjI3_60788230-2698-43d8-9b77-656a05e5be1f"
      unitRef="usdPerShare">1.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTgtMi0xLTEtMTE1NjI3_588cbd4f-dd03-44a2-a253-ca05e0f716ce"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMTgtNi0xLTEtMTE1NjI3_7065b02f-c48b-4714-87dd-4cbc57559917"
      unitRef="usdPerShare">1.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMjEtMi0xLTEtMTE1NjI3_dc565ae9-f6cf-4068-92b6-b532ae9d482f"
      unitRef="shares">2605500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMjEtNi0xLTEtMTE1NjI3_9c75adca-2a1c-474e-82d3-876cbbec29b1"
      unitRef="shares">2629200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMjItMi0xLTEtMTE1NjI3_2122c920-d92c-4823-b6da-68fa325de703"
      unitRef="shares">2605500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8yNS9mcmFnOmQ2ZmQzMzVjZTlmYjQ3NjJiZmU4YjRmNjYxYWFhMjFkL3RhYmxlOjg5MTVkODQzNjBjMjQ0YjA5ZTMyZjNhODRmOTQ5NzBiL3RhYmxlcmFuZ2U6ODkxNWQ4NDM2MGMyNDRiMDllMzJmM2E4NGY5NDk3MGJfMjItNi0xLTEtMTE1NjI3_ff5f9fc3-3d05-4975-9611-2ce7c649b974"
      unitRef="shares">2666500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMy0xLTEtMS0xMTU2Mjc_13a2f8e0-70c8-47f9-a8be-02db92ca6d46"
      unitRef="usd">-68000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMy0zLTEtMS0xMTU2Mjc_aa6e6b29-5428-47ab-a7d0-633ba97d6a45"
      unitRef="usd">5149000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfNi0xLTEtMS0xMTU2Mjc_94ac46ef-8bd9-41bb-8953-ad9005602a79"
      unitRef="usd">-181000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfNi0zLTEtMS0xMTU2Mjc_b2017a4e-0d1b-4ad0-873f-480b4657850e"
      unitRef="usd">-554000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfOS0xLTEtMS0xMTU2Mjc_8792324b-b659-475f-8009-df48008dd4ab"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfOS0zLTEtMS0xMTU2Mjc_d6e28a5b-cba4-433b-ac37-051f919bd4ed"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTAtMS0xLTEtMTE1NjI3_ec85537c-9021-4f44-bf14-eaa6a20017ab"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTAtMy0xLTEtMTE1NjI3_276a932c-3f5e-4fc9-bf69-21e509cdd705"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTItMS0xLTEtMTE1NjI3_a9ad79fd-5b0a-4da0-9754-6a7507a0527a"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTItMy0xLTEtMTE1NjI3_6bc8c2e9-b389-494a-93aa-a6dfc977bbb8"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTUtMS0xLTEtMTE1NjI3_802df04b-368a-44d1-8c3d-ae1b416c48a1"
      unitRef="usd">35000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTUtMy0xLTEtMTE1NjI3_c58067b1-d76f-4300-aafa-8cdc8cbdff90"
      unitRef="usd">53000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTYtMS0xLTEtMTE1NjI3_6c217c72-ed6e-4a0c-bb24-512d09091cde"
      unitRef="usd">33000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTYtMy0xLTEtMTE1NjI3_3475b006-03a2-4f8f-adff-54b0ae36b62b"
      unitRef="usd">-217000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTgtMS0xLTEtMTE1NjI3_c037d64f-9385-48c5-9cb3-58be85dbc72c"
      unitRef="usd">68000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMTgtMy0xLTEtMTE1NjI3_407b3a20-af8c-49af-9321-8060d8459dd5"
      unitRef="usd">-164000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjEtMS0xLTEtMTE1NjI3_001ceda9-b261-46c8-b383-b78a17f16882"
      unitRef="usd">570000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjEtMy0xLTEtMTE1NjI3_65e41ba1-39de-43c2-b13b-c981052d5455"
      unitRef="usd">-195000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjItMS0xLTEtMTE1NjI3_9a402cef-4f5c-4eff-9736-93c1a1653761"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjItMy0xLTEtMTE1NjI3_ab53f1e3-3c4e-4eb0-bf58-154a0589af12"
      unitRef="usd">101000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjMtMS0xLTEtMTE1NjI3_e19e26f0-e907-489b-a258-69cf6f2ab6dd"
      unitRef="usd">573000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjMtMy0xLTEtMTE1NjI3_9ae03bc5-085d-4c7b-a37a-21a5755ff220"
      unitRef="usd">-296000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjUtMS0xLTEtMTE1NjI3_bb505917-eb7c-4683-a909-df2e4f3a7854"
      unitRef="usd">341000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjUtMy0xLTEtMTE1NjI3_fa507cdb-bc36-451d-8c18-a4ed0c86a4e9"
      unitRef="usd">-699000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjctMS0xLTEtMTE1NjI3_341669c3-0b7d-4210-9b5c-43bf172d842e"
      unitRef="usd">273000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjMzZTYzOTdlYjU2MjRhMzdhMDJjZDhlNDMxODU0YmVkL3RhYmxlcmFuZ2U6MzNlNjM5N2ViNTYyNGEzN2EwMmNkOGU0MzE4NTRiZWRfMjctMy0xLTEtMTE1NjI3_3c89cd55-d5fb-4d95-a261-5b739505011d"
      unitRef="usd">4450000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8xNTk_19ca06ad-ffe7-4a28-968c-cb15913ce49e"
      unitRef="usd">-234000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8xNzQ_3af7c6e0-2018-4849-bf5f-65b69453813a"
      unitRef="usd">145000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8yMTk5MDIzMjU1ODc0_2d97c914-0286-4fe8-aed2-dcdee223bbf6"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8yMTk5MDIzMjU1ODgy_9b9c6fc9-c557-4cd6-8f24-712224403c6c"
      unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8yMTE_17f95772-5a5b-4636-ab24-3104e629f396"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8yMjc_167cf3d8-1fa6-4a71-b912-df122a625d44"
      unitRef="usd">19000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8yNjI_6090b566-a4ba-4f7f-b02f-06db84d01c5d"
      unitRef="usd">-154000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zMS9mcmFnOmJlYmVjNTNjNTVkYzQxNTJiMjVmYmYwOWE0NTdkY2I4L3RhYmxlOjE3NWQyYTQ4ZjQ4NDQ3MjFiZGNjYzA2Yzk5ODlhZGY4L3RhYmxlcmFuZ2U6MTc1ZDJhNDhmNDg0NDcyMWJkY2NjMDZjOTk4OWFkZjhfMC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo2ZjQ4NGRhZDlkZTM0MmYwYWM2NDkxZDk3MjZmYjI0MF8yNzg_4fa27d37-c233-49cc-957c-cd54ecd8d421"
      unitRef="usd">78000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMS0xLTEtMS0xMTU2Mjc_2b758979-3206-47c6-8ab1-a974cc05ee7c"
      unitRef="usd">76804000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2188b6c0f7514c949842cbb0fdfabbab_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMS0zLTEtMS0xMTU2Mjc_0b9aa358-76f7-4608-a597-ea5f324002f7"
      unitRef="usd">128345000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i77ff9cf53ba540b9a5e6aeca7ca5804f_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMS01LTEtMS0xMTU2Mjc_0bf36ed3-c1b4-4b0a-8899-4e38524fb6d7"
      unitRef="usd">-12967000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e69e8dd1c3d465ea6435891bf59621c_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMS03LTEtMS0xMTU2Mjc_59b55e12-514d-4384-9ede-c67f82d26b6b"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idb53f128b06d4aba845d354b0be0e42a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMS05LTEtMS0xMTU2Mjc_0a6b8149-5e0c-44fe-b290-e2167ac7f8a4"
      unitRef="usd">-41694000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMi0xLTEtMS0xMTU2Mjc_aee416cf-ea64-4597-9572-c84ace4bfb27"
      unitRef="usd">-68000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b3fd2b8861e424999c7010d105bfd21_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMi0zLTEtMS0xMTU2Mjc_5e56f31c-3dc1-448c-8bee-a90488c3a563"
      unitRef="usd">-68000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMy0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjo3NDg2YWVmMTM4NWU0ZTgyOWE5ODc2ZDJhNTcwYTU2NV8yNg_d35dcb9a-18b4-44b9-bad9-bc916cd53252"
      unitRef="usdPerShare">1.13</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMy0xLTEtMS0xMTU2Mjc_f9d8c029-694e-46b3-84fb-1e3018c3ef69"
      unitRef="usd">2942000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0b3fd2b8861e424999c7010d105bfd21_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfMy0zLTEtMS0xMTU2Mjc_273576c3-fd8f-411c-9434-73558488bc2f"
      unitRef="usd">2942000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNC0xLTEtMS0xMTU2Mjc_78ff70eb-c666-4cb8-82ce-88778a905bb7"
      unitRef="usd">295000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i0b3fd2b8861e424999c7010d105bfd21_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNC0zLTEtMS0xMTU2Mjc_44f147be-813e-4209-ade3-f7fe775c7f35"
      unitRef="usd">-777000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ia6a21dc14a504f8ea99bb332930384c0_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNC05LTEtMS0xMTU2Mjc_58750e59-f13e-4470-accf-3a6a4bb4c7f1"
      unitRef="usd">1072000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNS0xLTEtMS0xMTU2Mjc_eeaa95d5-3949-4f67-8594-8232d8622f8c"
      unitRef="usd">3537000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia6a21dc14a504f8ea99bb332930384c0_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNS05LTEtMS0xMTU2Mjc_fa305c1d-f5ee-4e40-8797-0ccce7e0c260"
      unitRef="usd">3537000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNi0xLTEtMS0xMTU2Mjc_98051648-49df-4932-b47b-ed00e6e9b4c9"
      unitRef="usd">24000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ia6a21dc14a504f8ea99bb332930384c0_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNi05LTEtMS0xMTU2Mjc_602e5468-efd7-4082-951e-45fd0432c5ed"
      unitRef="usd">24000000</us-gaap:StockholdersEquityOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNy0xLTEtMS0xMTU2Mjc_0cbf2311-d9bb-49ea-8fc7-9952170d527e"
      unitRef="usd">341000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if4da4c2095b244be8c3cc67e88df5d15_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfNy01LTEtMS0xMTU2Mjc_3588fc4f-a5a5-4278-ae65-fffc7747f53c"
      unitRef="usd">341000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfOC0xLTEtMS0xMTU2Mjc_e6ff43b4-c2f1-43b7-a3ef-ad660dcc525e"
      unitRef="usd">70869000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5578ef4542b444f5ac1a50c33d446bb1_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfOC0zLTEtMS0xMTU2Mjc_7025d2b4-7981-485f-a40b-f1d16ca80028"
      unitRef="usd">124558000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i455ec88d396c41248d806ba599269e74_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfOC01LTEtMS0xMTU2Mjc_01c1e336-9f5b-4318-a7b4-6a7058946eb9"
      unitRef="usd">-12626000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09e8821bbba242a6923019b0a460d64e_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfOC03LTEtMS0xMTU2Mjc_caf137e9-9369-48fe-a396-4d110101816b"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifab9bbc2a1a94a03a0a926fea40d151c_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjczNmFiZTZkYTJhNjQ0ZDVhYWI4ZTdiOWI1NjQ5M2YzL3RhYmxlcmFuZ2U6NzM2YWJlNmRhMmE2NDRkNWFhYjhlN2I5YjU2NDkzZjNfOC05LTEtMS0xMTU2Mjc_c8d8cae7-ae91-40dc-859a-372068d9e825"
      unitRef="usd">-44183000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae6ce94080c14bf3947a9c53d1a7596d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMS0xLTEtMS0xMTU2Mjc_fd34f429-a521-4e86-9188-0800ada848fe"
      unitRef="usd">74023000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d9051e5238a4ac9baecaaf4941dc3a4_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMS0zLTEtMS0xMTU2Mjc_3ff579d7-d036-401d-8759-e89905f110a3"
      unitRef="usd">123060000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e2d68ed978242baaa348359c8c9ca9a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMS01LTEtMS0xMTU2Mjc_9d32dc00-65a1-4feb-8025-a546f208b59b"
      unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78fcc13d384f4330aec9188cab3a6947_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMS03LTEtMS0xMTU2Mjc_d7706a05-6d6a-4a6a-93a3-19be71d4ed2c"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i96bae56901ee43a5b70044963ee0eb2f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMS05LTEtMS0xMTU2Mjc_01249eb9-950b-4211-818e-27930eea0234"
      unitRef="usd">-39099000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMy0xLTEtMS0xMTU2Mjc_3edbe23e-65dc-489a-8e4d-ed9bbebcd9af"
      unitRef="usd">5149000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if5ba501b50bc44c68b5053ecd96d9a08_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfMy0zLTEtMS0xMTU2Mjc_5a59831a-8f45-4b15-a8c0-37fc2d222277"
      unitRef="usd">5149000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNC0wLTEtMS0xMTU2MjcvdGV4dHJlZ2lvbjoxNTUwYWRiYTM1MmI0OTRlYjJhNjcwMWUyMDFhOWZjZF8yNg_85a3d7dc-7b1d-41ab-8484-7bb7f76fac51"
      unitRef="usdPerShare">1.06</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNC0xLTEtMS0xMTU2Mjc_ca25697b-88d2-4619-bcaa-429a3e0868ea"
      unitRef="usd">2787000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="if5ba501b50bc44c68b5053ecd96d9a08_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNC0zLTEtMS0xMTU2Mjc_9de2080d-7177-4211-9203-37daacc03eb6"
      unitRef="usd">2787000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNS0xLTEtMS0xMTU2Mjc_2bcab640-b0ee-4078-82d9-0616a085bc28"
      unitRef="usd">600000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="if5ba501b50bc44c68b5053ecd96d9a08_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNS0zLTEtMS0xMTU2Mjc_f4c99356-c0a7-4557-8361-168b0764ae58"
      unitRef="usd">-1042000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i3f1e92fdb7cb435b85c3f0ef4f00add4_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNS05LTEtMS0xMTU2Mjc_8438ab4b-4015-4647-a786-042e7ec1245f"
      unitRef="usd">1642000000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNi0xLTEtMS0xMTU2Mjc_87179f73-a8f4-4f03-877b-8c8b4969eb30"
      unitRef="usd">1577000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3f1e92fdb7cb435b85c3f0ef4f00add4_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfNi05LTEtMS0xMTU2Mjc_5528a6c9-b457-4819-b14d-4d72b185839c"
      unitRef="usd">1577000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOC0xLTEtMS0xMTU2Mjc_9df71788-a69c-4736-9bcd-cd961f41c824"
      unitRef="usd">-699000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iaae68b8ec38442eab92d9dc3b0260cd9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOC01LTEtMS0xMTU2Mjc_b698e049-84f1-4575-848c-dcf130c4e935"
      unitRef="usd">-699000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i047e4a043e444bcba72ba4e9efc5393a_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOS0xLTEtMS0xMTU2Mjc_e0a279d3-5040-4826-829c-b2f82f52c231"
      unitRef="usd">74709000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8919e9f61f8f44749d28698f8da6d82c_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOS0zLTEtMS0xMTU2Mjc_bff2e78f-7a7a-48df-bf7b-83a50bb04540"
      unitRef="usd">124380000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie5c9ee590fe74fbea7151627b39b194d_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOS01LTEtMS0xMTU2Mjc_ede161d6-533d-4428-b061-39ced556515e"
      unitRef="usd">-13757000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i06bfeb1f5de646c1882f0ac3995b15aa_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOS03LTEtMS0xMTU2Mjc_d2fb9334-ea99-48c6-8693-2b82a28ad1ac"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1a577429d7543cb917887d15b2934a5_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV8zNy9mcmFnOjZjYTdkZDliYmMyZDQxZjM5N2FjZWI5MTRhYWZhNDRmL3RhYmxlOjE3OWZlNDYxYmU1YTQwODFhYmVlMTY2MjQxZmFkM2I3L3RhYmxlcmFuZ2U6MTc5ZmU0NjFiZTVhNDA4MWFiZWUxNjYyNDFmYWQzYjdfOS05LTEtMS0xMTU2Mjc_f26a0dc9-7c8f-4c62-9b4f-2019b3cf4eab"
      unitRef="usd">-39034000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMy0yLTEtMS0xMTU2Mjc_8d239e29-58d3-42b1-a1b8-6ddb0c8a5457"
      unitRef="usd">-68000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMy00LTEtMS0xMTU2Mjc_a49e197e-fd32-4d20-ac33-cc5b33f348bf"
      unitRef="usd">5149000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNS0yLTEtMS0xMTU2Mjc_089e4661-6de0-4d2f-85a4-307616850cdb"
      unitRef="usd">1880000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNS00LTEtMS0xMTU2Mjc_754aad8e-917d-4fa7-9824-d6ded2606ad1"
      unitRef="usd">1769000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNi0yLTEtMS0xMTU2Mjc_693bf459-b92d-443c-aa38-a72f19b346da"
      unitRef="usd">306000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNi00LTEtMS0xMTU2Mjc_e3c14f5c-a12d-4362-8585-59de61939179"
      unitRef="usd">278000000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfOS0yLTEtMS0xMTU2Mjc_1cefa27a-d032-44fb-b940-7f427c17f8b7"
      unitRef="usd">426000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfOS00LTEtMS0xMTU2Mjc_f486c9fc-df8a-49e6-8f53-3c25bab93afd"
      unitRef="usd">610000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTEtMi0xLTEtMTE1NjI3_c4bd34c6-84d8-440d-86c5-a1da64bc84b4"
      unitRef="usd">8000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTEtNC0xLTEtMTE1NjI3_e4380841-2d4e-4bd8-85db-e4db5cd99444"
      unitRef="usd">168000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTMtMi0xLTEtMTE1NjI3_9e1f190b-09e4-4bd3-8787-9ff8971b63d4"
      unitRef="usd">-1543000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTMtNC0xLTEtMTE1NjI3_08fcaf0a-208c-4905-9d02-874ebbeaf6bb"
      unitRef="usd">-926000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTQtMi0xLTEtMTE1NjI3_6e59e9d5-2fed-4b02-b273-885da34e9ac7"
      unitRef="usd">1000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTQtNC0xLTEtMTE1NjI3_8e0e8325-585a-4f69-886d-979cb4127761"
      unitRef="usd">6000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTYtMi0xLTEtMTE1NjI3_84e5c9f1-25d2-4042-a2ad-af95f6b35b60"
      unitRef="usd">54000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTYtNC0xLTEtMTE1NjI3_c56a6ce9-afe1-4b0a-bf53-19660e963c60"
      unitRef="usd">427000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTctMi0xLTEtMTE1NjI3_f3374c9b-67b7-4d40-912d-b28e2293a7b4"
      unitRef="usd">524000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTctNC0xLTEtMTE1NjI3_49686c4a-be33-4f26-a8d3-41b7bd25c8b6"
      unitRef="usd">600000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTgtMi0xLTEtMTE1NjI3_1e30deac-27c2-4ddc-9ab7-afbf0e9d28f1"
      unitRef="usd">-2572000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTgtNC0xLTEtMTE1NjI3_760a1f60-15ae-415a-a7c3-5a8624ac821e"
      unitRef="usd">-2817000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTktMi0xLTEtMTE1NjI3_bfe91b1b-d8e2-4e13-8d6f-a024f2777791"
      unitRef="usd">915000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMTktNC0xLTEtMTE1NjI3_a71b24ce-1d4e-41e0-b21f-503cb556710f"
      unitRef="usd">-995000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjAtMi0xLTEtMTE1NjI3_e6f3c7de-3c6e-4a32-9a9f-005636ad7f56"
      unitRef="usd">6328000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjAtNC0xLTEtMTE1NjI3_ef397aa4-7523-4d35-8189-db68ff0ea1e7"
      unitRef="usd">110000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjItMi0xLTEtMTE1NjI3_88aa319b-9e56-4a2b-86bc-41c18287f26f"
      unitRef="usd">3257000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjItNC0xLTEtMTE1NjI3_46a2de79-78c7-4919-99eb-6de642ec40d2"
      unitRef="usd">3979000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjUtMi0xLTEtMTE1NjI3_d97c8c36-7e75-4853-8f47-91bcc55d1a26"
      unitRef="usd">863000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjUtNC0xLTEtMTE1NjI3_cf9adfee-a46b-4c61-82bd-1ab3614342c8"
      unitRef="usd">607000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjYtMi0xLTEtMTE1NjI3_1b4cbc2c-1f99-40fb-8984-13f5895677e4"
      unitRef="usd">40000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjYtNC0xLTEtMTE1NjI3_2ae2b647-b668-4fca-abe1-6dce4d10686a"
      unitRef="usd">248000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjctMi0xLTEtMTE1NjI3_b95ce2e8-b6af-45b6-bec9-5f15fe5472f6"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjctNC0xLTEtMTE1NjI3_0679aa95-6c1a-4b5c-8c77-f2c1d3ef0414"
      unitRef="usd">252000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjgtMi0xLTEtMTE1NjI3_1d18be87-ab65-4dda-818b-45ff15c0f211"
      unitRef="usd">3774000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjgtNC0xLTEtMTE1NjI3_59479393-4b2a-4103-b846-99a9fb08f589"
      unitRef="usd">9018000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjktMi0xLTEtMTE1NjI3_82d501e7-904b-4ea2-b370-f8c5afb357d1"
      unitRef="usd">7766000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMjktNC0xLTEtMTE1NjI3_9ea04da5-1995-4f63-b9ee-77dd7000e413"
      unitRef="usd">6303000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzAtMi0xLTEtMTE1NjI3_7c6adeb4-28f7-4aaf-8408-1efba8385e16"
      unitRef="usd">158000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzAtNC0xLTEtMTE1NjI3_1c4aa5b6-ebbd-4044-8fcb-804c4e8cea79"
      unitRef="usd">-249000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzEtMi0xLTEtMTE1NjI3_c4349d4a-50af-4d9b-a874-8b7e3da40bc0"
      unitRef="usd">12000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzEtNC0xLTEtMTE1NjI3_dce94209-f5c5-4423-aeb2-effc1049d4be"
      unitRef="usd">59000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzMtMi0xLTEtMTE1NjI3_9faf80ff-a278-4e66-8041-948dc1ef8581"
      unitRef="usd">3315000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzMtNC0xLTEtMTE1NjI3_b450d352-bb9b-4984-a23d-b6113fb88a27"
      unitRef="usd">-3634000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzYtMi0xLTEtMTE1NjI3_a2f2a6da-527d-4df4-9291-83179c1fe497"
      unitRef="usd">2942000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzYtNC0xLTEtMTE1NjI3_496250ec-d533-458d-92e1-b4dc169f05db"
      unitRef="usd">2787000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzctMi0xLTEtMTE1NjI3_bb054f93-178f-492e-bd25-98ed5b3abffe"
      unitRef="usd">3537000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzctNC0xLTEtMTE1NjI3_2263a5b3-f0e6-4233-a18e-db45cd9e5a84"
      unitRef="usd">1577000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzgtMi0xLTEtMTE1NjI3_a97edcbe-95b9-46a8-a434-42cb6a3b55c4"
      unitRef="usd">11094000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzgtNC0xLTEtMTE1NjI3_cb59832e-cdc4-4e9b-8bc9-30268ec7d25b"
      unitRef="usd">3019000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzktMi0xLTEtMTE1NjI3_441779ee-1d17-4ea5-8675-306a3b41d64b"
      unitRef="usd">5388000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfMzktNC0xLTEtMTE1NjI3_09014788-572d-475f-b6e9-f619bcc760e2"
      unitRef="usd">856000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDAtMi0xLTEtMTE1NjI3_9f594440-9d19-48e6-b14f-bd01125aac82"
      unitRef="usd">7674000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDAtNC0xLTEtMTE1NjI3_4a947199-2d61-40e8-a050-c4643df468bb"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDEtMi0xLTEtMTE1NjI3_435461a8-f7f0-414e-aef2-ecd618d6d1d3"
      unitRef="usd">500000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDEtNC0xLTEtMTE1NjI3_490d539d-bea7-4acb-a073-07936da410c7"
      unitRef="usd">2132000000</us-gaap:RepaymentsOfLongTermDebt>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDItMi0xLTEtMTE1NjI3_c25d2c12-8c10-45c8-b1cb-7cafa1b91d0e"
      unitRef="usd">-11000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDItNC0xLTEtMTE1NjI3_fa86ffb4-416d-489e-9ba8-8bd06789ce79"
      unitRef="usd">321000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDMtMi0xLTEtMTE1NjI3_fab8289e-ad5f-492d-9a95-b51b51d4db10"
      unitRef="usd">-13000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDMtNC0xLTEtMTE1NjI3_45c74bea-e047-498a-9a2e-0b6245655b97"
      unitRef="usd">-235000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDQtMi0xLTEtMTE1NjI3_9662d9fd-1c4b-415c-b9d9-66c5d298d5f7"
      unitRef="usd">-239000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDQtNC0xLTEtMTE1NjI3_ec720cb5-7efa-482f-885b-0afadcf51e18"
      unitRef="usd">-138000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDYtMi0xLTEtMTE1NjI3_a47e8732-0149-408c-a6ce-99b0e96b6761"
      unitRef="usd">6138000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDYtNC0xLTEtMTE1NjI3_2542d0fd-2fe5-4aa5-89b4-3add55cc4917"
      unitRef="usd">-4385000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDgtMi0xLTEtMTE1NjI3_6fb725b2-af0c-4205-9f39-6d4b74870419"
      unitRef="usd">28000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDgtNC0xLTEtMTE1NjI3_bb8bbcb5-8d6c-402f-87fe-3576d1ca3dc7"
      unitRef="usd">16000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDktMi0xLTEtMTE1NjI3_864eedcf-993a-4664-abef-1cf8afc73a7e"
      unitRef="usd">12738000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNDktNC0xLTEtMTE1NjI3_802b3bc7-c14f-4f54-9bb7-4f295dc1c9e0"
      unitRef="usd">-4024000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTAtMi0xLTEtMTE1NjI3_17756112-1954-4f59-9fb6-846ed5428943"
      unitRef="usd">14127000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iae6ce94080c14bf3947a9c53d1a7596d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTAtNC0xLTEtMTE1NjI3_23b3a87e-fe63-4226-b551-3bccf6e87c5c"
      unitRef="usd">14487000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTEtMi0xLTEtMTE1NjI3_df6529a7-9ed5-4fc0-aef8-c064648c3dc5"
      unitRef="usd">26865000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i047e4a043e444bcba72ba4e9efc5393a_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTEtNC0xLTEtMTE1NjI3_daf0b347-dacc-464e-b009-aeda2d223448"
      unitRef="usd">10463000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTgtMi0xLTEtMTE1NjI3_3212d9dc-e163-4d57-9d43-7777f126a891"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTgtNC0xLTEtMTE1NjI3_4c8ff6f5-43fb-436b-a2ea-fe7f853aa2e2"
      unitRef="usd">255000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTktMi0xLTEtMTE1NjI3_fd92359f-3db4-4858-a8c2-56dbe6744c89"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNTktNC0xLTEtMTE1NjI3_7fe1b999-4923-48a1-ba6f-396b38f23259"
      unitRef="usd">3000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNjAtMi0xLTEtMTE1NjI3_7223e21e-c245-43f4-bec7-00c3c3548f2f"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80My9mcmFnOjY0NWI4YmIyMjExMTQxYTA5ZTM3YjY3YWY2YzA1ZWFhL3RhYmxlOmUxYjlkMWNmMjdkOTRlNThhMWVlM2Y3OWQwZTFhZTVlL3RhYmxlcmFuZ2U6ZTFiOWQxY2YyN2Q5NGU1OGExZWUzZjc5ZDBlMWFlNWVfNjAtNC0xLTEtMTE1NjI3_587cd7e7-9ab5-469f-b088-4ab901314dcb"
      unitRef="usd">252000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzM5OQ_d752334b-6151-4986-a59e-8691c8126d16">The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson &amp;amp; Johnson and its subsidiaries (the Company) and related notes as contained in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;1, 2023. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented.&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;1, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzI5ODUzNDg5MzQ2NA_6b98e8e9-0203-4faa-b7c5-6f9e7ebf5ed3"&gt;ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50)&lt;/span&gt; &#x2013; Disclosure of Supplier Finance Program Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company adopted the standard as of the beginning of fiscal year 2023, which requires that a buyer in a supplier finance program disclose additional information about the program for financial statement users. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company&#x2019;s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier&#x2019;s decision to participate in the program. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of April 2, 2023, and January 1, 2023, $0.9&#160;billion and $1.0&#160;billion, respectively, were valid obligations under the program. The obligations are presented as Accounts payable on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Not Adopted as of April 2, 2023&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There were no new material accounting standards issued in fiscal first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzI5ODUzNDg5MzQ2Mg_b1eea87b-2fc6-4327-8c03-bcb0c09cef6d">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company assesses the adoption impacts of recently issued accounting standards by the Financial Accounting Standards Board on the Company's financial statements as well as material updates to previous assessments, if any, from the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended January&#160;1, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzI5ODUzNDg5MzQ2NA_6b98e8e9-0203-4faa-b7c5-6f9e7ebf5ed3"&gt;ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50)&lt;/span&gt; &#x2013; Disclosure of Supplier Finance Program Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company adopted the standard as of the beginning of fiscal year 2023, which requires that a buyer in a supplier finance program disclose additional information about the program for financial statement users. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has agreements for supplier finance programs with third-party financial institutions. These programs provide participating suppliers the ability to finance payment obligations from the Company with the third-party financial institutions. The Company is not a party to the arrangements between the suppliers and the third-party financial institutions. The Company&#x2019;s obligations to its suppliers, including amounts due, and scheduled payment dates (which have general payment terms of 90 days), are not affected by a participating supplier&#x2019;s decision to participate in the program. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of April 2, 2023, and January 1, 2023, $0.9&#160;billion and $1.0&#160;billion, respectively, were valid obligations under the program. The obligations are presented as Accounts payable on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Not Adopted as of April 2, 2023&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There were no new material accounting standards issued in fiscal first quarter of 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <jnj:SupplierFinanceProgramObligationCurrent
      contextRef="ibba084db76814e3ea3789881d3aff00a_D20230402-20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfNTQ5NzU1ODIzOTk0_e708fea9-2780-42ee-8219-c28b29addb22"
      unitRef="usd">900000000</jnj:SupplierFinanceProgramObligationCurrent>
    <jnj:SupplierFinanceProgramObligationCurrent
      contextRef="icfde879145bf49229de003973cc34868_D20230101-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfNTQ5NzU1ODI0MDA4_65db5a3d-3871-48af-ba9a-b0bdcaec7f09"
      unitRef="usd">1000000000</jnj:SupplierFinanceProgramObligationCurrent>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV80OS9mcmFnOjEzMjZmYmVlYTRlZTRkN2E5Y2IwMGY4NzJmMjEzYzQwL3RleHRyZWdpb246MTMyNmZiZWVhNGVlNGQ3YTljYjAwZjg3MmYyMTNjNDBfMzM5NQ_d2b0da32-8ca8-411a-ad0a-ebf5284c5c4e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RleHRyZWdpb246Yjg4YzcwNzczOTFiNDA3NjhkZWI1YTU0ZDM3MWM3ODRfNDM_f2c6a8d7-eea2-4441-bcb9-a2ea36426798">INVENTORIES &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RleHRyZWdpb246Yjg4YzcwNzczOTFiNDA3NjhkZWI1YTU0ZDM3MWM3ODRfMzE_2cf5360e-dc4b-4c1a-9126-1117852339df">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.070%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.896%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.310%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfMS0yLTEtMS0xMTU2Mjc_16475834-f3c2-498c-936d-85418a0908f8"
      unitRef="usd">2267000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfMS00LTEtMS0xMTU2Mjc_cd151aa5-732e-4ca2-89bf-3333c51b91ff"
      unitRef="usd">2070000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfMi0yLTEtMS0xMTU2Mjc_ece27d95-d813-403f-873a-78815d7e12d3"
      unitRef="usd">1866000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfMi00LTEtMS0xMTU2Mjc_94d7e961-0c18-4dc3-abdf-7893d2c3983a"
      unitRef="usd">1700000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfMy0yLTEtMS0xMTU2Mjc_05d49fa6-f1cd-4399-8e0b-71ea2f67c9fe"
      unitRef="usd">8676000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfMy00LTEtMS0xMTU2Mjc_00fd7a1f-61f9-4957-9964-4a9a13f4ad5f"
      unitRef="usd">8713000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfNC0yLTEtMS0xMTU2Mjc_fd89acea-5189-41c7-b6cd-58694ce0ab62"
      unitRef="usd">12809000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81Mi9mcmFnOmI4OGM3MDc3MzkxYjQwNzY4ZGViNWE1NGQzNzFjNzg0L3RhYmxlOmI2MzgyMjY5ZjAxNzRmOWU5NDFhNGY1YThlMGFjMWM4L3RhYmxlcmFuZ2U6YjYzODIyNjlmMDE3NGY5ZTk0MWE0ZjVhOGUwYWMxYzhfNC00LTEtMS0xMTU2Mjc_1375e671-3861-4baa-b5fe-9f38d4c5b385"
      unitRef="usd">12483000000</us-gaap:InventoryNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMjUyNQ_7421352d-cc9a-46f7-bbd1-356a19006982">INTANGIBLE ASSETS AND GOODWILL&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2022. Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of April&#160;2, 2023 was allocated by segment of business as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.967%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at April&#160;2, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Includes purchase price allocation adjustment for Abiomed &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.2 billion and $1.1&#160;billion for the fiscal first quarters ended April&#160;2, 2023 and April&#160;3, 2022, respectively.  Intangible asset write-downs are included in Other (income) expense, net. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMjUyMw_7da67e74-7da9-41fc-98ae-f057365a26ca">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles &#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,211)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets &#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;</jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i38228c4f861c4d53b47d4201d723003c_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMi0yLTEtMS0xMTU2Mjc_e47f5bed-558e-4f29-994f-da0c516a559f"
      unitRef="usd">44636000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if3e842812a5248e0bef37aa2b2e9b2fa_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMi00LTEtMS0xMTU2Mjc_661a1ca1-cc29-4cab-b571-080f945c2c33"
      unitRef="usd">44012000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i38228c4f861c4d53b47d4201d723003c_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMy0yLTEtMS0xMTU2Mjc_77ce5853-5993-4c6d-b27f-7d242c4324ba"
      unitRef="usd">23512000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if3e842812a5248e0bef37aa2b2e9b2fa_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMy00LTEtMS0xMTU2Mjc_c3038b37-5197-498e-ad32-37d103084137"
      unitRef="usd">22266000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i38228c4f861c4d53b47d4201d723003c_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNC0yLTEtMS0xMTU2Mjc_e7cbab84-fdba-4109-b3e9-70034b4c9ada"
      unitRef="usd">21124000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if3e842812a5248e0bef37aa2b2e9b2fa_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNC00LTEtMS0xMTU2Mjc_216fc4e0-6a1c-49d5-8472-2d04fda56ed9"
      unitRef="usd">21746000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib7b4546281ac435aa92aec6c7e41c91b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNS0yLTEtMS0xMTU2Mjc_ee69e3a1-43ae-4632-94a3-990ab0be26b2"
      unitRef="usd">23008000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id3230083ab32476fb09c3bc58c85a4ba_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNS00LTEtMS0xMTU2Mjc_9656bb13-6c1a-44ed-892b-60a32ac5bfd0"
      unitRef="usd">22987000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib7b4546281ac435aa92aec6c7e41c91b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNi0yLTEtMS0xMTU2Mjc_eacfe685-4399-458f-8924-719e922252ec"
      unitRef="usd">13211000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id3230083ab32476fb09c3bc58c85a4ba_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNi00LTEtMS0xMTU2Mjc_632f24ff-b7a8-4317-bf02-d52151233911"
      unitRef="usd">12901000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib7b4546281ac435aa92aec6c7e41c91b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNy0yLTEtMS0xMTU2Mjc_c8a1441c-d02f-4ca2-91cd-4d5f800ece8e"
      unitRef="usd">9797000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id3230083ab32476fb09c3bc58c85a4ba_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfNy00LTEtMS0xMTU2Mjc_7c758051-2954-4268-91ae-115bb70806d6"
      unitRef="usd">10086000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i26813cf41e0b40518f5acdbd9c90332b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfOS0yLTEtMS0xMTU2Mjc_ee4c3c45-bff3-4cac-aacb-4d53b05ab733"
      unitRef="usd">6843000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i197e0943ce2a43d7936e32486da181f8_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfOS00LTEtMS0xMTU2Mjc_b64828be-ac6a-4061-933a-72b5af44ea0c"
      unitRef="usd">6807000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4cfc80b6878c4f6f932fc48b92669884_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMTAtMi0xLTEtMTE1NjI3_8d01234e-051c-441f-8362-a40fe5ffc2ee"
      unitRef="usd">9684000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib0507cd24d2e4b288dd7a9b0753017af_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMTAtNC0xLTEtMTE1NjI3_84a57246-508c-4c5e-9a13-2da48add8854"
      unitRef="usd">9686000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMTEtMi0xLTEtMTE1NjI3_06cbb657-2c3c-4836-9121-6f0444a4fa01"
      unitRef="usd">16527000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMTEtNC0xLTEtMTE1NjI3_00aa9fc1-ec12-44be-aae9-2c2982e0c8d8"
      unitRef="usd">16493000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMTItMi0xLTEtMTE1NjI3_6bb2de62-a54b-43a2-91b1-43e624e793ca"
      unitRef="usd">47448000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmY1Y2M1ZDRjM2Q5MDQzMDBiNDM4MGI1NzUxNjVjMzE2L3RhYmxlcmFuZ2U6ZjVjYzVkNGMzZDkwNDMwMGI0MzgwYjU3NTE2NWMzMTZfMTItNC0xLTEtMTE1NjI3_47c34571-aca9-4713-a83a-bc24f3c7936b"
      unitRef="usd">48325000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMjUxMg_58aeffe9-681c-4e21-a42a-dab384cc76e1">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of April&#160;2, 2023 was allocated by segment of business as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.585%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.967%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.399%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.982%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January&#160;1, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at April&#160;2, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;*Includes purchase price allocation adjustment for Abiomed</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i0799f3dd7e1443109b9ff412c554094d_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMS0yLTEtMS0xMTU2Mjc_865137e8-d261-4a7b-aa03-c7195bf53d0b"
      unitRef="usd">9184000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i54a01f5eb53d4ab89d3cbe7a3ba985c1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMS00LTEtMS0xMTU2Mjc_ae2527a5-c54d-4a00-9a65-090685ad7219"
      unitRef="usd">10184000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie416bf3f26e54604b272b38173898aa1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMS02LTEtMS0xMTU2Mjc_a2e044ce-49d5-4b0c-9767-fffc2f1e61a4"
      unitRef="usd">25863000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMS04LTEtMS0xMTU2Mjc_86105be6-4202-4ed1-8ca2-66382cbd7dd5"
      unitRef="usd">45231000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i26cdc03025f14afa93aeea4d2797344e_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMi0yLTEtMS0xMTU2Mjc_0e25f99d-b5b9-4aa6-b3d8-90bf2c141a33"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="id6f3967ed8804b3484a788194a6b55e2_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMi00LTEtMS0xMTU2Mjc_da0d5059-c450-450f-8ef4-d867ab6e6bae"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ia44d907a039b4ea4b07c28589766bd8a_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMi02LTEtMS0xMTU2Mjc_cff2abbe-2315-4698-a7e6-964a5a515b48"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfMi04LTEtMS0xMTU2Mjc_a1ced11f-dcdf-44b8-a7e5-2d9de477a3ea"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i26cdc03025f14afa93aeea4d2797344e_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNC0yLTEtMS0xMTU2Mjc_433e71cd-f9de-4f55-96fc-26b13b4ac11c"
      unitRef="usd">49000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="id6f3967ed8804b3484a788194a6b55e2_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNC00LTEtMS0xMTU2Mjc_870aab87-bd2b-4650-ae77-e11590c85bfb"
      unitRef="usd">124000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ia44d907a039b4ea4b07c28589766bd8a_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNC02LTEtMS0xMTU2Mjc_775715d8-25b9-4000-afb2-a66c93d2e1b8"
      unitRef="usd">171000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNC04LTEtMS0xMTU2Mjc_f68ecaa8-2397-4566-ad5d-b91ae50c0e33"
      unitRef="usd">344000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i580a3adc3cf744379ba4cf5f599f7937_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNS0yLTEtMS0xMTU2Mjc_db16236c-902b-4e95-8d37-5b0b6f652e06"
      unitRef="usd">9233000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i621fb40d2bb940e1b24bdcca1e4136e8_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNS00LTEtMS0xMTU2Mjc_6b14a4d9-5b51-4858-90d6-5b23b3b12a72"
      unitRef="usd">10308000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5ee98f9e7d6a4590b9ac7b2d9cdb9144_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNS02LTEtMS0xMTU2Mjc_5339e6fa-b5a6-487e-964e-e81aa70848fc"
      unitRef="usd">26034000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOjQwZDg3YTFhZTIzZTQ0MGVhZTc3OWNlNWNjMGU2MzcxL3RhYmxlcmFuZ2U6NDBkODdhMWFlMjNlNDQwZWFlNzc5Y2U1Y2MwZTYzNzFfNS04LTEtMS0xMTU2Mjc_519882b7-56f2-4679-814b-2ade429d0fb9"
      unitRef="usd">45575000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ibcd0d6c747a149e19fbcded0d930ca35_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMTc4OA_7b7695f2-1333-4135-a91b-6c2385f053da">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i882e2c7e02fc4e118e5a1079393bf3a8_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMTg5Nw_51295037-54ca-4141-9d75-7b6c35535430">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMjAwMw_365b75bb-d5a2-4dfe-846f-5e80a809061f"
      unitRef="usd">1200000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMjAxMA_b62eebe7-ef5f-446c-b86d-f8cc18e725d4"
      unitRef="usd">1100000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RleHRyZWdpb246MDkwOTJkYTg2MzljNDRlMGFlZGVhYzcxYTZjM2E5MjBfMjUyMA_ff3e4514-51d2-4319-8376-04b0568ecb19">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,800&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,200&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmQxZTI5N2M0MjA0OTRhN2Y4ODA0OTYwZGRmZmQxZjM3L3RhYmxlcmFuZ2U6ZDFlMjk3YzQyMDQ5NGE3Zjg4MDQ5NjBkZGZmZDFmMzdfMi0wLTEtMS0xMTU2Mjc_6322f116-fba7-4864-b346-8e4eaeba6757"
      unitRef="usd">4800000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmQxZTI5N2M0MjA0OTRhN2Y4ODA0OTYwZGRmZmQxZjM3L3RhYmxlcmFuZ2U6ZDFlMjk3YzQyMDQ5NGE3Zjg4MDQ5NjBkZGZmZDFmMzdfMi0yLTEtMS0xMTU2Mjc_19065162-5753-43a2-97f9-99333b10dba3"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmQxZTI5N2M0MjA0OTRhN2Y4ODA0OTYwZGRmZmQxZjM3L3RhYmxlcmFuZ2U6ZDFlMjk3YzQyMDQ5NGE3Zjg4MDQ5NjBkZGZmZDFmMzdfMi00LTEtMS0xMTU2Mjc_09e658ea-031a-4141-94d5-74c754ba35f7"
      unitRef="usd">3800000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmQxZTI5N2M0MjA0OTRhN2Y4ODA0OTYwZGRmZmQxZjM3L3RhYmxlcmFuZ2U6ZDFlMjk3YzQyMDQ5NGE3Zjg4MDQ5NjBkZGZmZDFmMzdfMi02LTEtMS0xMTU2Mjc_1ed20e9b-1682-4e58-a099-736f61d9690c"
      unitRef="usd">3200000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV81NS9mcmFnOjA5MDkyZGE4NjM5YzQ0ZTBhZWRlYWM3MWE2YzNhOTIwL3RhYmxlOmQxZTI5N2M0MjA0OTRhN2Y4ODA0OTYwZGRmZmQxZjM3L3RhYmxlcmFuZ2U6ZDFlMjk3YzQyMDQ5NGE3Zjg4MDQ5NjBkZGZmZDFmMzdfMi04LTEtMS0xMTU2Mjc_15148941-695d-446d-87ac-c1a98f3d93f3"
      unitRef="usd">2600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE2OTM_30ac4094-154d-46d2-8774-5c062a24eab5">FAIR VALUE MEASUREMENTS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings.  These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of April&#160;2, 2023, the cumulative amount of cash collateral paid by the Company under the CSA amounted to $0.7 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating.  Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of April&#160;2, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $44.3&#160;billion, $36.5&#160;billion and $10.0&#160;billion, respectively. As of January&#160;1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $43.3 billion,  $36.2 billion and $12.4 billion respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur.  Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April&#160;2, 2023, the balance of deferred net gain on derivatives included in accumulated other comprehensive income was $343&#160;million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;net investment hedge&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2023 and 2022, net of tax:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April&#160;2, 2023, and January&#160;1, 2023, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal first quarters ended in 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated&lt;br/&gt;OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.725%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.758%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.080%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.001%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="33" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values.  The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#x2019;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following three levels of inputs are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2014; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2014; Significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2014; Significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of April&#160;2, 2023 and January&#160;1, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration for the fiscal first quarters ended 2023 and 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2022 assets and liabilities are all classified as Level 2 with the exception of equity investments of $576 million, which are classified as Level 1 and contingent consideration of $1,120 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classified as non-current other assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Includes $1,138 million and $1,116 million, classified as non-current other liabilities as of April&#160;2, 2023 and January&#160;1, 2023, respectively.  Includes $4 million and $4 million classified as current liabilities as of April&#160;2, 2023 and January&#160;1, 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash, cash equivalents, restricted cash and current marketable securities as of April&#160;2, 2023 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov&#x2019;t securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov&#x2019;t Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Relates to the Kenvue Inc. (Kenvue) debt offering. See debt schedule below for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the fiscal year ended January&#160;1, 2023, the carrying amount was approximately the same as the estimated fair value.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale securities as of April&#160;2, 2023 are as follows:  &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments not measured at Fair Value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;2, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 (750MM Euro 1.0909)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Notes due 2024 (500MM GBP 1.2359)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028 (750MM Euro 1.0909)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035 (1.5B Euro 1.0909)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Debentures due 2025*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.35% Debentures due 2026*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.05% Debentures due 2028*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Debentures due 2030*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90% Debentures due 2033*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.10% Debentures due 2043*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.05% Debentures due 2053*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20% Debentures due 2063*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average effective interest rate on non-current debt is 3.47%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The excess of the carrying value over the estimated fair value of debt was $1.6 billion at January 1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2023, Kenvue, a wholly owned subsidiary of the Company, priced an offering of senior unsecured notes in an aggregate principal amount of $7.75&#160;billion (tranches with an * in the above table). The senior unsecured notes (the Notes) will be senior unsecured obligations of Kenvue and will initially be fully and unconditionally guaranteed (the Guarantees) on a senior unsecured basis by the Company. The Guarantees will terminate upon (1) the completion in all material respects of the transfer of the assets and liabilities of Johnson &amp;amp; Johnson&#x2019;s Consumer Health Business to Kenvue and (2) Kenvue having registered equity securities. The Notes were issued in connection with Johnson &amp;amp; Johnson&#x2019;s separation of its Consumer Health Business. The proceeds of the Notes offering were placed in a segregated escrow account pending the transfer of the assets and liabilities of the Consumer Health Business to Kenvue and as such, classified as restricted cash as of the balance sheet date. On April 5, 2023, the net proceeds of the Notes were released from escrow upon completion of the Consumer Health Business transfer. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The current debt balance as of April&#160;2, 2023 includes $16.9&#160;billion of commercial paper which has a weighted average interest rate of 4.85% and a weighted average maturity of approximately three months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="if54031088777474188c6dca64d2fb710_I20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTY1MQ_857ee5d2-cfd1-4dab-8513-c62e67fdc7f7"
      unitRef="usd">700000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if54031088777474188c6dca64d2fb710_I20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMjMxNg_b622c3e9-192b-431c-8f14-e3b07df4712a"
      unitRef="usd">44300000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="idf8c231701af4202b803070c0de9def8_I20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMjMyMA_a784e0de-722c-40a2-8862-d5b82dc4fcf8"
      unitRef="usd">36500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i2ad211fc0f6c4a23b3511340169453c0_I20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMjMyNw_3d7346cb-cbe3-46fa-bf61-cb8fca6deb79"
      unitRef="usd">10000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia0c30aae843c488795f8e7c12bdf070d_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMjUwMg_2039b403-250c-465a-b8f6-c3c6a1178488"
      unitRef="usd">43300000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i82b6d9a04c804ccfa99f995cf671dd34_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMjUwNw_ccb200d1-4933-42e7-86dc-385ec7fbf725"
      unitRef="usd">36200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i68677eb45407447cb144946c0f01f334_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMjUxNA_c89269dd-ac2e-41da-9076-68b6e3aa3d56"
      unitRef="usd">12400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfNDY0NA_dcdc4291-bdcb-4f5c-9ef9-cb898e344775"
      unitRef="usd">-343000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3NDE_86b7c1ba-79d9-4bec-917e-c8fc5177c4dd">The following table is a summary of the activity related to derivatives and hedges for the fiscal first quarters ended in 2023 and 2022, net of tax:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.259%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.125%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.836%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income)  Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(531)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of net investment hedges for the fiscal first quarters ended in 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.363%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.814%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.610%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.959%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.769%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated&lt;br/&gt;OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)                                                                                                                                                                                                                                  Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i41f4633d6ab6401e9804fb1a385a3531_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy0xLTEtMS0xMTU2Mjc_92b1b253-c483-41e6-b3f6-db952aa49a13"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i5588691f505049b895ad7d374a5c3a41_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy0yLTEtMS0xMTU2Mjc_97004675-58d5-497b-9daf-0baaa694306e"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i3b45f400dac942d296156e124dc1e9b9_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy0zLTEtMS0xMTU2Mjc_d3fba935-c7d1-4054-8a0c-e1616dd64487"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ieaff6b065b8f45f384f79c9289dacd25_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy00LTEtMS0xMTU2Mjc_a9b343b3-3469-4991-9be5-b8a75b41b02e"
      unitRef="usd">-929000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i831a75e27b404331b68d0e1d0c6dd089_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy01LTEtMS0xMTU2Mjc_c27853d4-817f-4d5f-bc14-b0158161b1a3"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i95ad3c15d3724acf827b842d7dbf0f89_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy02LTEtMS0xMTU2Mjc_1e98a9b3-3cc6-4f9c-9ccf-8cfd94874423"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ifebd08ff3dce4721a4b99e42c41bef26_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy03LTEtMS0xMTU2Mjc_9c6f6ba0-f052-4e73-bb02-52fd74e67b24"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ia39a02e3ee104b9ba558b07af3c8b6f4_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy04LTEtMS0xMTU2Mjc_dc56c68d-75a3-48f7-abe7-ab34d183d977"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ic7b9d91b169a40358401cf82127d3e79_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy05LTEtMS0xMTU2Mjc_5287e70e-b833-44c8-8ed6-eaee8457f449"
      unitRef="usd">-531000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ice47da4dbb604bc89bb47d0c82573768_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfNy0xMC0xLTEtMTE1NjI3_b77f778b-6188-4f7f-a196-23d99679dc1d"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i41f4633d6ab6401e9804fb1a385a3531_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC0xLTEtMS0xMTU2Mjc_94eee325-ecaa-4dde-b059-2cac07fa4b5b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i5588691f505049b895ad7d374a5c3a41_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC0yLTEtMS0xMTU2Mjc_3086c6ab-f973-4571-ae7b-bb2ed2cf9ee8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i3b45f400dac942d296156e124dc1e9b9_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC0zLTEtMS0xMTU2Mjc_3f11b213-c88b-4d53-9a21-30c8e5d24d79"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ieaff6b065b8f45f384f79c9289dacd25_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC00LTEtMS0xMTU2Mjc_eec08004-0830-4844-b858-2d1c05f87735"
      unitRef="usd">929000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i831a75e27b404331b68d0e1d0c6dd089_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC01LTEtMS0xMTU2Mjc_410f07e2-8e18-4fd4-97fb-823bcca0e3b1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i95ad3c15d3724acf827b842d7dbf0f89_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC02LTEtMS0xMTU2Mjc_69adf4cd-e800-49e2-80fb-cc05f22f99cb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ifebd08ff3dce4721a4b99e42c41bef26_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC03LTEtMS0xMTU2Mjc_ee7c1421-ff8f-4fb4-8e10-4bf995331a7b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ia39a02e3ee104b9ba558b07af3c8b6f4_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC04LTEtMS0xMTU2Mjc_a0be054b-6fa2-4b0d-a2f5-048b0df7ea33"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ic7b9d91b169a40358401cf82127d3e79_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC05LTEtMS0xMTU2Mjc_bd7af7b3-579e-4373-b26f-8a5fabfda72e"
      unitRef="usd">531000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ice47da4dbb604bc89bb47d0c82573768_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfOC0xMC0xLTEtMTE1NjI3_35e0a974-9492-4054-96e1-cd38c7e885c4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i9068df14ebfc48e38d180f60734ca507_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItMS0xLTEtMTE1NjI3_3a08bd47-8856-4323-b7b8-d8481baf4ecc"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ic52c17526572465e9e1b5a35d8831216_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItMi0xLTEtMTE1NjI3_051b1bbf-18f0-4e0e-9324-fcd474efef3c"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="icb38841a93344de99840a565926c66a5_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItMy0xLTEtMTE1NjI3_e2216f95-eca2-4cb9-b01b-5b1313ed7e69"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i4779df903b7b429d8d7c7bd175fed19d_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItNC0xLTEtMTE1NjI3_f2db5037-ee7f-41d5-9656-7642ff029a31"
      unitRef="usd">34000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="iee79a709871d48e79e9780dda18549cf_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItNS0xLTEtMTE1NjI3_a3aa22b8-cb23-4cd1-8679-cd4f137d11f7"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i7667c30e53b74e189bee49ab6ab578aa_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItNi0xLTEtMTE1NjI3_d5f7cc7f-2831-41f7-97e6-78229646c09a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ic67e218f34d2463381b9461693780c78_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItNy0xLTEtMTE1NjI3_9f1073e3-8a9a-47a6-810f-1c9723870a3e"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i39a3c4d59b0242d5872c4a78d9b2f266_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItOC0xLTEtMTE1NjI3_300eba11-0800-48db-b510-fdc913e95d63"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i1b8e5036b85e4f42ab00ba31e3cc72e0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItOS0xLTEtMTE1NjI3_603c34b7-75e8-46c6-b40d-175db47273da"
      unitRef="usd">45000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i61ab5b9880cd4f64ada5ab99bbe01129_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTItMTAtMS0xLTExNTYyNw_563aa724-cb30-48b9-921d-e194aca27c29"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9068df14ebfc48e38d180f60734ca507_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtMS0xLTEtMTE1NjI3_6ec52655-8a30-4e96-bcd1-622ba104e4a0"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ic52c17526572465e9e1b5a35d8831216_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtMi0xLTEtMTE1NjI3_04c7fae3-450f-4b1d-ba23-301a45fba11c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="icb38841a93344de99840a565926c66a5_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtMy0xLTEtMTE1NjI3_aab2e00e-594f-4b8c-a848-d46966550d21"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4779df903b7b429d8d7c7bd175fed19d_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtNC0xLTEtMTE1NjI3_11b04895-e124-430f-b26f-45448c9c26e7"
      unitRef="usd">34000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iee79a709871d48e79e9780dda18549cf_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtNS0xLTEtMTE1NjI3_e5db70c0-5087-4a0c-ba92-5b89f0439b37"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7667c30e53b74e189bee49ab6ab578aa_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtNi0xLTEtMTE1NjI3_24108b67-198e-4306-a99a-a83d3c950af9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ic67e218f34d2463381b9461693780c78_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtNy0xLTEtMTE1NjI3_3f733cf3-5259-4c78-b819-2bea71d33d01"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i39a3c4d59b0242d5872c4a78d9b2f266_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtOC0xLTEtMTE1NjI3_561f70c7-79d4-40bb-8c63-f28b7910e500"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1b8e5036b85e4f42ab00ba31e3cc72e0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtOS0xLTEtMTE1NjI3_ae03b1ca-14f3-4f8e-824c-ffdc582a496f"
      unitRef="usd">45000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i61ab5b9880cd4f64ada5ab99bbe01129_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTMtMTAtMS0xLTExNTYyNw_3be7fa0f-5ef7-44c7-baac-663e1360bb2d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i968b152e9828408dbcfff2d958bb2ffa_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctMS0xLTEtMTE1NjI3_b3073e8b-a21a-48ac-ba18-22c263a96a74"
      unitRef="usd">12000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i3f8f4aec6be94d6fbddc3da727226560_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctMi0xLTEtMTE1NjI3_7fc2f528-46e0-4d22-9f1e-911c8afe950e"
      unitRef="usd">-146000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i518fab6babc2450f8b8bfc59a05e3df0_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctMy0xLTEtMTE1NjI3_df7a4554-8a1a-4a1d-9147-eebd387d5c9e"
      unitRef="usd">-13000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i4d1e2c54d6bb479292b9652c120a6541_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctNC0xLTEtMTE1NjI3_725e7ea3-8b46-4cf3-8d23-3e36b85ea788"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ia0c6b0431ad94e9aaac1f8408e9e643f_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctNS0xLTEtMTE1NjI3_7eafd66d-acc6-4421-bf98-30443af7fd8f"
      unitRef="usd">2000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i2cc8515d00ca476a938ce6b49ef1d594_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctNi0xLTEtMTE1NjI3_419f4f07-5221-4a18-9de7-8e53671c18f0"
      unitRef="usd">-17000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ie051977e19b94b39a0ddaa23a4b507b3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctNy0xLTEtMTE1NjI3_ce4cdaea-3ecd-4f92-8b4c-a4633f12cb78"
      unitRef="usd">-52000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i53b711721e994f5fac5c2f261e490da8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctOC0xLTEtMTE1NjI3_0b6a3ef0-b4a3-4613-bece-db50659c5f13"
      unitRef="usd">23000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ibf1da9ad33c847a19893c85c250bba48_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctOS0xLTEtMTE1NjI3_0a49b7e5-1487-4ca4-b9b9-a2d738be017a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iba41bab8774e437ea305e80eaf3595db_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMTctMTAtMS0xLTExNTYyNw_2e976bc8-d4cf-471f-a9c9-bc01a0709ba8"
      unitRef="usd">-18000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i968b152e9828408dbcfff2d958bb2ffa_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtMS0xLTEtMTE1NjI3_4bfc0842-3613-4a6e-a028-a835f64ddba9"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i3f8f4aec6be94d6fbddc3da727226560_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtMi0xLTEtMTE1NjI3_e8cec205-a3e4-47d1-89e3-334fbefdd8d0"
      unitRef="usd">145000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i518fab6babc2450f8b8bfc59a05e3df0_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtMy0xLTEtMTE1NjI3_163d6f95-33eb-4524-bc00-cb74990b028a"
      unitRef="usd">-36000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4d1e2c54d6bb479292b9652c120a6541_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtNC0xLTEtMTE1NjI3_fd5b332f-f2e6-4dbb-9f5f-20e46766da96"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ia0c6b0431ad94e9aaac1f8408e9e643f_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtNS0xLTEtMTE1NjI3_ee04a7d8-fbff-40af-9671-a34e58cda0d0"
      unitRef="usd">-14000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i2cc8515d00ca476a938ce6b49ef1d594_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtNi0xLTEtMTE1NjI3_87371cbe-4711-4b6b-bcab-34d72df615bb"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ie051977e19b94b39a0ddaa23a4b507b3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtNy0xLTEtMTE1NjI3_48f1ed26-a718-40c6-8454-f09e06af53ad"
      unitRef="usd">-94000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i53b711721e994f5fac5c2f261e490da8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtOC0xLTEtMTE1NjI3_a493f98d-ff70-4d2c-bacd-3b63ec4ea3de"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ibf1da9ad33c847a19893c85c250bba48_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtOS0xLTEtMTE1NjI3_8242f42c-6004-4624-bda0-a551da4b95ae"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iba41bab8774e437ea305e80eaf3595db_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjEtMTAtMS0xLTExNTYyNw_1c4552bd-d4ec-4ed1-af9b-b66218680d08"
      unitRef="usd">-73000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ife40f1a43412473da55b7933c850ee6c_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtMS0xLTEtMTE1NjI3_2c0a0839-c4e9-424f-a68d-fcf8e61dd37c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i13f98824188a4648a8a09d1453d2780b_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtMi0xLTEtMTE1NjI3_5593c757-0ddd-482c-980d-8cb4f4ee3484"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i2f10659432f044afbd1fba6198533009_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtMy0xLTEtMTE1NjI3_ccff3eb7-d2e2-48f5-8dcd-2c538c5d01b1"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="iece4bb18d3dc46fc9364b46a20d5f69d_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtNC0xLTEtMTE1NjI3_e00aa282-fbad-4277-ab96-bd125ea57da2"
      unitRef="usd">108000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="id81ca34bf19c4617889e951ac6dfbc59_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtNS0xLTEtMTE1NjI3_a57b3760-7504-4df9-97fa-e2539599f241"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i28d280475a264030901bece015a4dc31_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtNi0xLTEtMTE1NjI3_6b1e2e23-6f6d-4d29-bdca-9732ce762c06"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="icff16d560d4c47149af82242e78d7c81_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtNy0xLTEtMTE1NjI3_cecc60fd-9880-4a20-9174-37e9db55a9f6"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i18eb2772b356408db2d5bed81f211a2c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtOC0xLTEtMTE1NjI3_2e8aed29-3190-4839-8349-6fef882d0dca"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ibf982a48aaff440bb1776f320d637a69_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtOS0xLTEtMTE1NjI3_202355ca-9f1b-411a-8ecb-bf759750443f"
      unitRef="usd">120000000</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i4443adb601eb4729914e2ba1f143557c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjQtMTAtMS0xLTExNTYyNw_7e9cd0a7-6369-4226-a782-c6ae71150dfb"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ife40f1a43412473da55b7933c850ee6c_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtMS0xLTEtMTE1NjI3_04f38af8-555e-4c9c-b04d-44540bfa2a78"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i13f98824188a4648a8a09d1453d2780b_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtMi0xLTEtMTE1NjI3_dfce6a30-5312-43c7-9558-e39351717f3f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i2f10659432f044afbd1fba6198533009_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtMy0xLTEtMTE1NjI3_f3e7fdd2-c1bd-4d3a-a7d5-a59802506b04"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iece4bb18d3dc46fc9364b46a20d5f69d_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtNC0xLTEtMTE1NjI3_80c02646-3a58-44f6-af24-bd604161b63d"
      unitRef="usd">417000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id81ca34bf19c4617889e951ac6dfbc59_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtNS0xLTEtMTE1NjI3_f4018615-9e7c-49a3-a6f6-726cdc1ac68f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i28d280475a264030901bece015a4dc31_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtNi0xLTEtMTE1NjI3_77cf27ca-3733-45a1-8a94-e1e96a3b8ea3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="icff16d560d4c47149af82242e78d7c81_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtNy0xLTEtMTE1NjI3_b2022e65-440f-4488-81c0-5f878ecb16de"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i18eb2772b356408db2d5bed81f211a2c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtOC0xLTEtMTE1NjI3_baeaade5-064e-46e5-b4ac-15c946b8910a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ibf982a48aaff440bb1776f320d637a69_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtOS0xLTEtMTE1NjI3_0a0636d3-04a1-4472-80ad-886dd522dc07"
      unitRef="usd">-128000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i4443adb601eb4729914e2ba1f143557c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1MjZjNTY5YWY2YjRhNzE4MDMwMmU5NDFjNzYwNzI2L3RhYmxlcmFuZ2U6MzUyNmM1NjlhZjZiNGE3MTgwMzAyZTk0MWM3NjA3MjZfMjYtMTAtMS0xLTExNTYyNw_62112581-959a-4a66-b315-ed0b7abff6cf"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3NTU_8b98f557-dede-4d79-be8b-b3cdc32f148b">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of April&#160;2, 2023, and January&#160;1, 2023, the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Gain/ (Loss)  Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,214)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i1a044beb1efb4064b0c24daf2024f934_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjNlODUzZDNhNzE3ZjQ3MmZhMWI4ODVhNDM2YmU4NjVlL3RhYmxlcmFuZ2U6M2U4NTNkM2E3MTdmNDcyZmExYjg4NWE0MzZiZTg2NWVfNC0yLTEtMS0xMTU2Mjc_e8e479c6-3c2a-4b2e-865d-59c5312f2d08"
      unitRef="usd">8860000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="if77451a376c4461ebd92a6a553653653_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjNlODUzZDNhNzE3ZjQ3MmZhMWI4ODVhNDM2YmU4NjVlL3RhYmxlcmFuZ2U6M2U4NTNkM2E3MTdmNDcyZmExYjg4NWE0MzZiZTg2NWVfNC00LTEtMS0xMTU2Mjc_7d7e1d4b-4d68-4892-851b-968e6114b3bb"
      unitRef="usd">8665000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i1a044beb1efb4064b0c24daf2024f934_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjNlODUzZDNhNzE3ZjQ3MmZhMWI4ODVhNDM2YmU4NjVlL3RhYmxlcmFuZ2U6M2U4NTNkM2E3MTdmNDcyZmExYjg4NWE0MzZiZTg2NWVfNC02LTEtMS0xMTU2Mjc_e0b9541f-40cd-43f6-9fab-93bef5f944df"
      unitRef="usd">-1214000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="if77451a376c4461ebd92a6a553653653_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjNlODUzZDNhNzE3ZjQ3MmZhMWI4ODVhNDM2YmU4NjVlL3RhYmxlcmFuZ2U6M2U4NTNkM2E3MTdmNDcyZmExYjg4NWE0MzZiZTg2NWVfNC04LTEtMS0xMTU2Mjc_9acf362e-c381-4a16-baf3-ba2643be0e13"
      unitRef="usd">-1435000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE2OTE_bb4fa461-76c3-4309-b53b-4cac762fbcef">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is the effect of derivatives not designated as hedging instruments for the fiscal first quarters ended 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.284%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.634%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i06741010c1a64e268867848027daba0c_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOmE2ODg1ZDM1MWNiMjRjZTViZGY1N2I5ZTdlYTI5ZDYyL3RhYmxlcmFuZ2U6YTY4ODVkMzUxY2IyNGNlNWJkZjU3YjllN2VhMjlkNjJfNC00LTEtMS0xMTU2Mjc_394d5689-cec9-4895-8be0-44752645c7b7"
      unitRef="usd">-31000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="if6330ab077ff46f38183eaaac192c351_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOmE2ODg1ZDM1MWNiMjRjZTViZGY1N2I5ZTdlYTI5ZDYyL3RhYmxlcmFuZ2U6YTY4ODVkMzUxY2IyNGNlNWJkZjU3YjllN2VhMjlkNjJfNC02LTEtMS0xMTU2Mjc_3f2a41f7-9656-49b5-90dc-7298f39f724b"
      unitRef="usd">29000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfMy0yLTEtMS0xMTU2Mjc_42e521fc-d3ae-4b5b-943f-ecfeff0666a3"
      unitRef="usd">-77000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfMy00LTEtMS0xMTU2Mjc_1de65132-c355-4eac-aeb5-53641c148251"
      unitRef="usd">68000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i530924810ee74f0498a5b576273161b3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfMy04LTEtMS0xMTU2Mjc_8432521d-ed26-405d-a4ff-33a01842febb"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ia1c1b995a63246e89358347d16f7c60e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfMy0xMC0xLTEtMTE1NjI3_06d63eae-f34e-4088-bb00-89c0b7e015be"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i075611e2f1c34545856ee1fb67001c5b_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfNC0yLTEtMS0xMTU2Mjc_bcc2459b-cca1-4fc6-959f-598f32eb2969"
      unitRef="usd">690000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i8ca12285d2874df69fab0b80f4e166fc_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfNC00LTEtMS0xMTU2Mjc_af2f8649-8de6-4500-b3c6-d42858121ef9"
      unitRef="usd">560000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i3c4f8bd9f0f44566948524fae883de74_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfNC04LTEtMS0xMTU2Mjc_690a69a3-9227-466d-8cfe-db1c47ddbf81"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i652d6068f154428ba681e62b55ce5132_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM3ZTZkN2E5ZjA1MjQ1Nzk4YTE3MzBmNjM5NDU3YTA0L3RhYmxlcmFuZ2U6MzdlNmQ3YTlmMDUyNDU3OThhMTczMGY2Mzk0NTdhMDRfNC0xMC0xLTEtMTE1NjI3_df22596c-a8cb-4467-9d1b-07c5cca06469"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3MDU_899abed1-879d-43bb-8728-00452f7eb9b9">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.871%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i3f485b1f7c7942f49f325dd462771cde_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfMi0yLTEtMS0xMTU2Mjc_7b368ea3-4565-4b97-9252-c56a4c6e0969"
      unitRef="usd">576000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment
      contextRef="ifd652ec5aec24fbfa5838b3c7c1bc608_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfMi00LTEtMS0xMTU2Mjc_d13c402b-aad6-4497-95e0-b1b7d863d41a"
      unitRef="usd">-73000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="ifd652ec5aec24fbfa5838b3c7c1bc608_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfMi02LTEtMS0xMTU2Mjc_1388fb99-94b6-478a-a891-331c44cd69bf"
      unitRef="usd">2000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i307781a0dd6f4fee83ba5f3b83bacf6a_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfMi04LTEtMS0xMTU2Mjc_531a0771-c887-422f-9e37-57b2b813f702"
      unitRef="usd">505000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i307781a0dd6f4fee83ba5f3b83bacf6a_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfMi0xMC0xLTEtMTE1NjI3_21018c38-7d26-45d5-87a6-e6c0444ce448"
      unitRef="usd">505000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ic8fce605d8bf42a4809c31f01fea678e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfNC0yLTEtMS0xMTU2Mjc_dec7dd38-1484-40ad-9cda-05f8e60b5c08"
      unitRef="usd">698000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment
      contextRef="ie4c4f1b4529e4b4e94c51763f2b03fee_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfNC00LTEtMS0xMTU2Mjc_752ab98f-e03b-4bb4-a586-7097f81d8cf7"
      unitRef="usd">-1000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="ie4c4f1b4529e4b4e94c51763f2b03fee_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfNC02LTEtMS0xMTU2Mjc_4e32b4e3-fb93-47e4-bbae-a7480dc3f22d"
      unitRef="usd">27000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i205b08e0d52a41018c1f1aac759297b4_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfNC04LTEtMS0xMTU2Mjc_65705391-d6e9-469a-b4c5-89546db24b5f"
      unitRef="usd">724000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i205b08e0d52a41018c1f1aac759297b4_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjFjYmJmZmQ3MGM0ODRlZGFiOGUwNzJiN2ZhYzQ3YWNlL3RhYmxlcmFuZ2U6MWNiYmZmZDcwYzQ4NGVkYWI4ZTA3MmI3ZmFjNDdhY2VfNC0xMC0xLTEtMTE1NjI3_7b6c5b17-9039-4448-ad5c-9257bd1718c1"
      unitRef="usd">724000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3MzY_d654ddc5-4d6a-4ce7-9f93-bf3e2f4bb6fc">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of April&#160;2, 2023 and January&#160;1, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.904%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration for the fiscal first quarters ended 2023 and 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.269%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.410%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.609%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2022 assets and liabilities are all classified as Level 2 with the exception of equity investments of $576 million, which are classified as Level 1 and contingent consideration of $1,120 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;           (3)&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Classified as non-current other assets. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Classified within cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Includes $1,138 million and $1,116 million, classified as non-current other liabilities as of April&#160;2, 2023 and January&#160;1, 2023, respectively.  Includes $4 million and $4 million classified as current liabilities as of April&#160;2, 2023 and January&#160;1, 2023, respectively.&lt;/span&gt;&lt;/div&gt;           (6)    Ongoing fair value adjustment amounts are primarily recorded in Research and Development expense.</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ief14a8d3f839490ea2f5004d02e9ea85_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNC0yLTEtMS0xMTU2Mjc_0f6cbd78-f727-4fe4-bda8-34ce40d874fc"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i6eecc4b339cc4793b846af6357408a8a_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNC00LTEtMS0xMTU2Mjc_e984a8dc-5485-4f72-82e7-a981cb221a9b"
      unitRef="usd">661000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="idfb9204df17c4b71bb33876248a6fc03_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNC02LTEtMS0xMTU2Mjc_b8e830d6-094c-4da1-9b87-8f6dc77ff55b"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="if54031088777474188c6dca64d2fb710_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNC04LTEtMS0xMTU2Mjc_592de3f1-eb19-4289-b220-a4851810e5d7"
      unitRef="usd">661000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i8d229fdf0aac48939a630ab1e339fe6a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNC0xMC0xLTEtMTE1NjI3_ef31248f-99d5-479c-9540-a8a4114bf246"
      unitRef="usd">629000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i93b2a01d5e1942d0934133917a0b41c4_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNS0yLTEtMS0xMTU2Mjc_31ae1da8-ec41-46e3-9b4a-73f5a430b18a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="id75635b8099d4b48b2cd2669062d8331_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNS00LTEtMS0xMTU2Mjc_d7453ccc-9cd3-4862-a2b6-9b6e13a906b1"
      unitRef="usd">1399000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ia81349c4bdf242e682e3fd1ce2fbe13d_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNS02LTEtMS0xMTU2Mjc_57b0e62a-b554-4de7-8bed-37780a6b0a74"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="id7a1713ee90b4874b872f2aa9e7ff7cb_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNS04LTEtMS0xMTU2Mjc_e27e2492-0598-4933-a797-e56e2bf7215a"
      unitRef="usd">1399000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i3c27bfe420f54e1ca9c1eeb355beb0b2_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNS0xMC0xLTEtMTE1NjI3_6fa97844-9365-4037-8a37-7850906393f8"
      unitRef="usd">1534000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i7f03697427554f22b26c5738cd4a66e3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNy0yLTEtMS0xMTU2Mjc_5ff5c871-16d7-49f5-9d3b-2df3bc2873a8"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i8dd646702260408ea267396967e28f41_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNy00LTEtMS0xMTU2Mjc_3d671100-5e83-43c7-ae05-2302d2edb53d"
      unitRef="usd">2060000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i2bdc0608d83a46fca52c9bb31b17d8bf_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNy02LTEtMS0xMTU2Mjc_beb07daa-a17c-498c-9c7a-89d8cbb0299b"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNy04LTEtMS0xMTU2Mjc_fa973007-9a86-49cf-9116-4a45543b77c8"
      unitRef="usd">2060000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ibd3150f03c284a7c8af03baa7bea76ca_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfNy0xMC0xLTEtMTE1NjI3_d3cc40da-c5bf-4e41-8170-36db72bdd115"
      unitRef="usd">2163000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ief14a8d3f839490ea2f5004d02e9ea85_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfOS0yLTEtMS0xMTU2Mjc_47fc3804-f248-411c-b8d9-422c5dd59828"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i6eecc4b339cc4793b846af6357408a8a_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfOS00LTEtMS0xMTU2Mjc_1ac95945-f7e7-4d15-ab3b-0c0154114197"
      unitRef="usd">349000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="idfb9204df17c4b71bb33876248a6fc03_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfOS02LTEtMS0xMTU2Mjc_b3c65afa-56e9-4a95-b2d7-8d5bb9c213b3"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="if54031088777474188c6dca64d2fb710_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfOS04LTEtMS0xMTU2Mjc_fe3f111e-c2bc-4d32-8e70-00dac149056c"
      unitRef="usd">349000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i8d229fdf0aac48939a630ab1e339fe6a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfOS0xMC0xLTEtMTE1NjI3_313681f1-91df-4af9-8003-606e1408b1d8"
      unitRef="usd">511000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i93b2a01d5e1942d0934133917a0b41c4_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTAtMi0xLTEtMTE1NjI3_f097dd1f-a3b2-4a0e-9220-614efa4b0aa9"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="id75635b8099d4b48b2cd2669062d8331_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTAtNC0xLTEtMTE1NjI3_d9b7db45-83d7-4dcd-8cff-bfa83274ffda"
      unitRef="usd">2553000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ia81349c4bdf242e682e3fd1ce2fbe13d_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTAtNi0xLTEtMTE1NjI3_5a24ceb4-125a-4051-b79c-1a17348624e4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="id7a1713ee90b4874b872f2aa9e7ff7cb_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTAtOC0xLTEtMTE1NjI3_26b2e750-2e9e-469c-990e-ac7309d6562f"
      unitRef="usd">2553000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i3c27bfe420f54e1ca9c1eeb355beb0b2_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTAtMTAtMS0xLTExNTYyNw_4d6f579c-c673-454a-974e-13331eaabc42"
      unitRef="usd">2778000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7f03697427554f22b26c5738cd4a66e3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTItMi0xLTEtMTE1NjI3_c504f524-82e3-42c8-8c69-835583eb6ddf"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i8dd646702260408ea267396967e28f41_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTItNC0xLTEtMTE1NjI3_28c46505-46f2-4a1c-8592-3bd4f022b99a"
      unitRef="usd">2902000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i2bdc0608d83a46fca52c9bb31b17d8bf_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTItNi0xLTEtMTE1NjI3_251da0a6-74a4-461f-ac6a-15d2099effad"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTItOC0xLTEtMTE1NjI3_7d19e758-9492-432e-a81f-26ba297cd449"
      unitRef="usd">2902000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ibd3150f03c284a7c8af03baa7bea76ca_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTItMTAtMS0xLTExNTYyNw_59bdb42b-8308-44c4-8883-58211384e894"
      unitRef="usd">3289000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ief14a8d3f839490ea2f5004d02e9ea85_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTUtMi0xLTEtMTE1NjI3_6c31f7d5-4a74-487e-bd51-0e8a0638f4ec"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i6eecc4b339cc4793b846af6357408a8a_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTUtNC0xLTEtMTE1NjI3_615b52bc-5d40-4081-9e89-bc2458bdbd8e"
      unitRef="usd">32000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="idfb9204df17c4b71bb33876248a6fc03_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTUtNi0xLTEtMTE1NjI3_37c3de38-c0fe-419c-9712-78f7936ab03c"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="if54031088777474188c6dca64d2fb710_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTUtOC0xLTEtMTE1NjI3_ec99fd7d-f915-4051-aa58-4a8998bfa243"
      unitRef="usd">32000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i8d229fdf0aac48939a630ab1e339fe6a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTUtMTAtMS0xLTExNTYyNw_da65f4fb-7236-4087-9b2a-e79453712887"
      unitRef="usd">38000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ief14a8d3f839490ea2f5004d02e9ea85_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTctMi0xLTEtMTE1NjI3_d00906b3-8d17-4d89-8605-a08d8775f195"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i6eecc4b339cc4793b846af6357408a8a_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTctNC0xLTEtMTE1NjI3_66c74fdd-3ea1-45bf-90ed-393ae721e9a2"
      unitRef="usd">56000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="idfb9204df17c4b71bb33876248a6fc03_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTctNi0xLTEtMTE1NjI3_6f59c1a3-83b3-4004-bbda-60c33a181537"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="if54031088777474188c6dca64d2fb710_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTctOC0xLTEtMTE1NjI3_2510eb7d-4027-4cb8-b1ff-d854134982ce"
      unitRef="usd">56000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i8d229fdf0aac48939a630ab1e339fe6a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTctMTAtMS0xLTExNTYyNw_83b9f70c-2691-4c53-b34f-3829ef30988d"
      unitRef="usd">68000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7f03697427554f22b26c5738cd4a66e3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTktMi0xLTEtMTE1NjI3_584ff95d-497d-49fc-9421-154615bcf8b9"
      unitRef="usd">505000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i8dd646702260408ea267396967e28f41_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTktNC0xLTEtMTE1NjI3_0b68bbe7-77b7-4ce6-a930-1f86a7c4db2f"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2bdc0608d83a46fca52c9bb31b17d8bf_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTktNi0xLTEtMTE1NjI3_fac61fb5-d6e8-4f86-a25b-1b7af92e17a8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTktOC0xLTEtMTE1NjI3_ac948f61-88c2-41e8-847a-e8911f51f6cd"
      unitRef="usd">505000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMTktMTAtMS0xLTExNTYyNw_3a959351-ebb2-406d-9838-0be9508d280e"
      unitRef="usd">576000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f03697427554f22b26c5738cd4a66e3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjAtMi0xLTEtMTE1NjI3_ea95ecd2-daf0-4f8b-a6ea-5aff533ccb81"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8dd646702260408ea267396967e28f41_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjAtNC0xLTEtMTE1NjI3_a936b173-12eb-4685-975c-a491d5a0791a"
      unitRef="usd">8942000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2bdc0608d83a46fca52c9bb31b17d8bf_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjAtNi0xLTEtMTE1NjI3_09728e2d-0bc5-43c8-8897-33e8a1bf8dbf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjAtOC0xLTEtMTE1NjI3_777b8699-b124-4408-9458-d9fbef0d992a"
      unitRef="usd">8942000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjAtMTAtMS0xLTExNTYyNw_d9ffb273-94b2-4ddf-b3ad-b31197819a5f"
      unitRef="usd">10487000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7f03697427554f22b26c5738cd4a66e3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjItMi0xLTEtMTE1NjI3_49b64911-837d-4279-8b10-48a3f1de5449"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8dd646702260408ea267396967e28f41_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjItNC0xLTEtMTE1NjI3_df52a0d7-6331-42d6-8800-5850ccdacac7"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2bdc0608d83a46fca52c9bb31b17d8bf_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjItNi0xLTEtMTE1NjI3_cba45723-2d7e-4f38-9cd8-6d9d039b003a"
      unitRef="usd">1142000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjItOC0xLTEtMTE1NjI3_f2a988ee-e5be-42de-9d1e-3d2f5a06a8c0"
      unitRef="usd">1142000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY1ODY2YTY3Y2EzMTRlNTc5Y2Q1Nzc4YjUyMDE5M2Q4L3RhYmxlcmFuZ2U6NjU4NjZhNjdjYTMxNGU1NzljZDU3NzhiNTIwMTkzZDhfMjItMTAtMS0xLTExNTYyNw_fbd9ab25-de85-4ce5-b758-7d1dfe4465eb"
      unitRef="usd">1120000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfMi0yLTEtMS0xMTU2Mjc_bbc7fc75-0d3c-4ac4-9d0f-505caf1a9e40"
      unitRef="usd">2092000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfMi00LTEtMS0xMTU2Mjc_d27ad9ac-1de5-479e-9175-3b81eb796125"
      unitRef="usd">2201000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfMy0yLTEtMS0xMTU2Mjc_e7287ca8-bab0-48cb-8b73-42822a1fc2e8"
      unitRef="usd">2028000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfMy00LTEtMS0xMTU2Mjc_8af42a83-a117-4d94-9275-9225409dde94"
      unitRef="usd">2176000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssets
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfNC0yLTEtMS0xMTU2Mjc_8f6ae478-4a04-4603-834e-a304e3ecc7fa"
      unitRef="usd">64000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfNC00LTEtMS0xMTU2Mjc_4a3cc1ff-843b-4a10-9583-d1f978228730"
      unitRef="usd">25000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfNi0yLTEtMS0xMTU2Mjc_ad642cef-ade1-4624-852e-737a359c1790"
      unitRef="usd">2958000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfNi00LTEtMS0xMTU2Mjc_bbd39295-a612-4edd-85b9-1a085b54ef44"
      unitRef="usd">3357000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfNy0yLTEtMS0xMTU2Mjc_37547fb5-05ec-4e80-8170-11e6d9e2f394"
      unitRef="usd">2729000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfNy00LTEtMS0xMTU2Mjc_0a0e520a-c963-4d63-aae4-755ad885ebfa"
      unitRef="usd">3023000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfOC0yLTEtMS0xMTU2Mjc_1262a5f0-23aa-4006-ab32-89d5db7a6fa0"
      unitRef="usd">229000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjBkNzU0Njk3OGY4MDRkZjJhZThjNzk4OGZlZWM4YTAyL3RhYmxlcmFuZ2U6MGQ3NTQ2OTc4ZjgwNGRmMmFlOGM3OTg4ZmVlYzhhMDJfOC00LTEtMS0xMTU2Mjc_45cb4b74-921f-4dfe-9177-72ab57be936c"
      unitRef="usd">334000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="if241137260614532b6020bfeda156ac3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfMy0yLTEtMS0xMTU2Mjc_75cd5072-e3b5-43fc-8c51-1b932718e760"
      unitRef="usd">1120000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iae6ce94080c14bf3947a9c53d1a7596d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfMy00LTEtMS0xMTU2Mjc_0f8130a1-0554-4570-ae11-8fe5f9a88b04"
      unitRef="usd">533000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNC0yLTEtMS0xMTU2Mjc_1fb4c6e2-add2-4de7-a9e4-04aeb623ddc0"
      unitRef="usd">23000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNC00LTEtMS0xMTU2Mjc_ee4d4bd9-ee07-4aba-8f56-dabdaaec2055"
      unitRef="usd">-47000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNS0yLTEtMS0xMTU2Mjc_40d888c7-dccd-451a-b410-45c851a4cb44"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNS00LTEtMS0xMTU2Mjc_fd9729e4-a286-4fc5-8b0a-72438864185f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNi0yLTEtMS0xMTU2Mjc_fc2f445d-0389-4f76-9225-957f25e71ed2"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNi00LTEtMS0xMTU2Mjc_937a8e19-44e7-4ca8-8d02-636a5eb7d445"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNy0yLTEtMS0xMTU2Mjc_d4062a23-6d4c-474a-b4b5-b2a8a7313b3c"
      unitRef="usd">1142000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i047e4a043e444bcba72ba4e9efc5393a_I20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjY3YTJlZWE5Yzk1ODQ0N2M4ZWQ1Y2NlMWExODFhZjkwL3RhYmxlcmFuZ2U6NjdhMmVlYTljOTU4NDQ3YzhlZDVjY2UxYTE4MWFmOTBfNy00LTEtMS0xMTU2Mjc_1633283d-c8cd-4a67-87c2-aa0078e1d4f2"
      unitRef="usd">486000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iecf72c1b6f094918ab2d8aac314f3e7b_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfOTEzMQ_94cca867-e738-41e7-ac26-edfcf98d8e52"
      unitRef="usd">576000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7f05b2c736c746f9bbb497d86e2362a0_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfOTE5OQ_3923d3a4-2170-4dd6-95d5-a769bc459f38"
      unitRef="usd">1120000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i47f2667d72af493883f17ca87070a398_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfOTQ1NQ_ba4bddf6-a28e-4c54-b5d1-a9a1d31f24a3"
      unitRef="usd">1138000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3c83227b39104d4d82056ac6bfea554b_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfOTQ3MA_0fecc2c6-82a5-4af1-bf57-8cebbf83bba3"
      unitRef="usd">1116000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4c31014b15774921a5f30a4880f42786_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfOTU2Nw_86f57747-bd3e-4f2f-ac92-4c74c81629a7"
      unitRef="usd">4000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i92e0aa803ceb4db2aff7a0bbab1124fc_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfOTU4Mg_e0ba53af-88cc-486a-a150-b605ff49ad00"
      unitRef="usd">4000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3Mzc_35455523-340e-4e3f-9501-521655f6cdfc">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash, cash equivalents, restricted cash and current marketable securities as of April&#160;2, 2023 comprised:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.513%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov&#x2019;t securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov&#x2019;t Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Relates to the Kenvue Inc. (Kenvue) debt offering. See debt schedule below for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i5cbc0e3c61c34bc3bdcd6deaea9d806b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMS0xLTEtMS0xMTU2Mjc_acd12e39-fdcf-4346-9223-3340dbc22a0d"
      unitRef="usd">4674000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i5cbc0e3c61c34bc3bdcd6deaea9d806b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMS01LTEtMS0xMTU2Mjc_7a3aa3de-39b6-49c3-b1fa-44613b7629be"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i5cbc0e3c61c34bc3bdcd6deaea9d806b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMS03LTEtMS0xMTU2Mjc_3096a03e-d802-49e7-a1e5-fa2d962884fb"
      unitRef="usd">4674000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5cbc0e3c61c34bc3bdcd6deaea9d806b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMS05LTEtMS0xMTU2Mjc_45b7ec9a-f6f0-4a4f-b289-98b8691af183"
      unitRef="usd">4674000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i5cbc0e3c61c34bc3bdcd6deaea9d806b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMS0xMS0xLTEtMTE1NjI3_b621cbe4-ad3a-4f6f-88b2-d8625167e63c"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i99ffa091217a4323bc5c0aed611527aa_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMi0xLTEtMS0xMTU2Mjc_1a855f08-dce0-4a0c-8b6a-a1b52a0cc8c2"
      unitRef="usd">7695000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i99ffa091217a4323bc5c0aed611527aa_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMi01LTEtMS0xMTU2Mjc_56dd15ff-c85a-4b58-a44b-2fc24c92a72a"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i99ffa091217a4323bc5c0aed611527aa_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMi03LTEtMS0xMTU2Mjc_caba33a0-2a86-47ed-80f0-72ff8e9d851c"
      unitRef="usd">7695000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i99ffa091217a4323bc5c0aed611527aa_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMi05LTEtMS0xMTU2Mjc_d5505a4b-5ff1-439c-af4e-90b0de7a437d"
      unitRef="usd">7695000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i99ffa091217a4323bc5c0aed611527aa_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMi0xMS0xLTEtMTE1NjI3_f6838282-b648-4db3-8556-aa510b403690"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i3a3200f710ae4ab696b549ce19c468e9_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNC0xLTEtMS0xMTU2Mjc_4c2fd1aa-03e8-45df-9f75-918c0c5cb5c4"
      unitRef="usd">6286000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i3a3200f710ae4ab696b549ce19c468e9_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNC01LTEtMS0xMTU2Mjc_5743caef-a0d7-452a-8035-086681cefb15"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i3a3200f710ae4ab696b549ce19c468e9_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNC03LTEtMS0xMTU2Mjc_a7345620-7b09-4814-ae78-ff3b64b633a4"
      unitRef="usd">6286000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3a3200f710ae4ab696b549ce19c468e9_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNC05LTEtMS0xMTU2Mjc_876a29b8-b78c-42db-b425-eff93db6ca08"
      unitRef="usd">6286000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3a3200f710ae4ab696b549ce19c468e9_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNC0xMS0xLTEtMTE1NjI3_935f8c9d-3cfc-4eef-a654-07f6be882a47"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ie33a79c5f8cb4a83813ae704160ed98f_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNi0xLTEtMS0xMTU2Mjc_cb096b81-3d54-4260-a3cb-ea7fcb109c1d"
      unitRef="usd">672000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ie33a79c5f8cb4a83813ae704160ed98f_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNi01LTEtMS0xMTU2Mjc_223496bf-b141-4c8a-870e-9e539dfcc48b"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ie33a79c5f8cb4a83813ae704160ed98f_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNi03LTEtMS0xMTU2Mjc_18d90571-ac93-44de-9569-6a756a0f42c8"
      unitRef="usd">672000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie33a79c5f8cb4a83813ae704160ed98f_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNi05LTEtMS0xMTU2Mjc_b7fb828b-5953-4198-8e03-476ba4efd589"
      unitRef="usd">300000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie33a79c5f8cb4a83813ae704160ed98f_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNi0xMS0xLTEtMTE1NjI3_0485a9ee-eafa-4ff4-a6bc-4e8bba5c595b"
      unitRef="usd">372000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="iaf23f95e6fb14d838dd8f888af18a5dc_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNy0xLTEtMS0xMTU2Mjc_cd7916de-098e-45ee-8ac9-c8141612fc0c"
      unitRef="usd">3364000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="iaf23f95e6fb14d838dd8f888af18a5dc_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNy01LTEtMS0xMTU2Mjc_6a30a225-9d27-44a1-9e65-ba1d852552bd"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="iaf23f95e6fb14d838dd8f888af18a5dc_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNy03LTEtMS0xMTU2Mjc_b52a2d3f-7952-479b-8e78-0cacdc510645"
      unitRef="usd">3364000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iaf23f95e6fb14d838dd8f888af18a5dc_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNy05LTEtMS0xMTU2Mjc_fec8f58a-bdf2-4da6-b159-7460a1d05b8a"
      unitRef="usd">3364000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iaf23f95e6fb14d838dd8f888af18a5dc_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfNy0xMS0xLTEtMTE1NjI3_7c450266-3503-4102-b3e2-419a28318b24"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i54377ee71ddc46f195fb7d79c03086c4_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOC0xLTEtMS0xMTU2Mjc_3c9c2ce0-225f-4fbe-ba4b-8754baf7b5c0"
      unitRef="usd">675000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i54377ee71ddc46f195fb7d79c03086c4_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOC01LTEtMS0xMTU2Mjc_c4dd94ad-f604-4b9d-8ce3-6a7e18d9a77f"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i54377ee71ddc46f195fb7d79c03086c4_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOC03LTEtMS0xMTU2Mjc_b6895172-bedc-4029-b6ce-2f2332a4cc52"
      unitRef="usd">675000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i54377ee71ddc46f195fb7d79c03086c4_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOC05LTEtMS0xMTU2Mjc_f6d9eeae-6b2b-45f3-972d-0fee676f037a"
      unitRef="usd">675000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i54377ee71ddc46f195fb7d79c03086c4_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOC0xMS0xLTEtMTE1NjI3_48784723-4624-494b-89d2-4a1de3373697"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ia7e10a1fefa741b8b65c1bc8d547367e_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOS0xLTEtMS0xMTU2Mjc_f81a07e0-7136-4a48-9c1a-bca5e4cd8437"
      unitRef="usd">23366000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ia7e10a1fefa741b8b65c1bc8d547367e_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOS01LTEtMS0xMTU2Mjc_001f6cde-33ec-49bd-b6b1-fe8bf48f93a1"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ia7e10a1fefa741b8b65c1bc8d547367e_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOS03LTEtMS0xMTU2Mjc_12e033cd-4877-410e-8026-0ce7e8b2b063"
      unitRef="usd">23366000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia7e10a1fefa741b8b65c1bc8d547367e_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOS05LTEtMS0xMTU2Mjc_919f9327-b98b-4833-91a5-a10e67d280ca"
      unitRef="usd">22994000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ia7e10a1fefa741b8b65c1bc8d547367e_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfOS0xMS0xLTEtMTE1NjI3_999a3bc6-8bb9-4bd9-a856-a1a18de5397e"
      unitRef="usd">372000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5115b43c247a46cb8480efe59a9a01e2_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTItMS0xLTEtMTE1NjI3_97564c61-2827-41fa-8f2d-b54f8453fe28"
      unitRef="usd">8462000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5115b43c247a46cb8480efe59a9a01e2_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTItNS0xLTEtMTE1NjI3_0a9bb659-70fc-413e-ad96-7f293f06a81f"
      unitRef="usd">9000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5115b43c247a46cb8480efe59a9a01e2_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTItNy0xLTEtMTE1NjI3_2c9f5feb-6d5c-4b49-bdfc-fc951050da48"
      unitRef="usd">8453000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4af82efbb61a401e9e04b30f3cd374c2_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTItOS0xLTEtMTE1NjI3_406a8bb8-9c78-4394-91a2-ac392fecf758"
      unitRef="usd">3804000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i4af82efbb61a401e9e04b30f3cd374c2_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTItMTEtMS0xLTExNTYyNw_29a332cc-61f9-415e-8c3a-69561983a45d"
      unitRef="usd">4649000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8b85c7849ee2491c98f1a6384d52b0b3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTMtMS0xLTEtMTE1NjI3_5fc50286-6d8f-4922-9ff3-34ce96338848"
      unitRef="usd">185000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8b85c7849ee2491c98f1a6384d52b0b3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTMtNS0xLTEtMTE1NjI3_5ac7f793-b70f-4b4b-ab53-0848a4fc6823"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b85c7849ee2491c98f1a6384d52b0b3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTMtNy0xLTEtMTE1NjI3_5128cb93-78dc-49a5-860c-2dc4cc21d56d"
      unitRef="usd">182000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia22c34150afa480cbfb032861aa89f53_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTMtOS0xLTEtMTE1NjI3_0689c96c-ea8d-4fd1-806c-80e311db8ef9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ia22c34150afa480cbfb032861aa89f53_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTMtMTEtMS0xLTExNTYyNw_8d4cf730-75aa-40dc-999f-c012569b32f7"
      unitRef="usd">182000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ia22c34150afa480cbfb032861aa89f53_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTMtMTEtMS0xLTExNTYyNw_c63ac2c9-5b40-49c5-8af1-6356931e6a14"
      unitRef="usd">182000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ica912cc5502e4edfac4509644a475663_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTQtMS0xLTEtMTE1NjI3_d836d16b-840f-4468-9215-9d33e334251b"
      unitRef="usd">308000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ica912cc5502e4edfac4509644a475663_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTQtNS0xLTEtMTE1NjI3_45b8d3bb-79c3-4d56-9acd-d02ea4bdeae6"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ica912cc5502e4edfac4509644a475663_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTQtNy0xLTEtMTE1NjI3_1ba86279-84d9-4ae0-96d0-39594d839714"
      unitRef="usd">307000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i28b97484a76e4109b1cc8fb5d4f35ca3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTQtOS0xLTEtMTE1NjI3_2aa641e4-05f3-40d1-b548-14e6369bf534"
      unitRef="usd">67000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i28b97484a76e4109b1cc8fb5d4f35ca3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTQtMTEtMS0xLTExNTYyNw_7fc15e8a-c248-40d6-959d-b9df7f3d74e5"
      unitRef="usd">240000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib55fd172e7b345698937c728fa47ea35_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTUtMS0xLTEtMTE1NjI3_c190078c-d30e-4b99-a411-fce745325019"
      unitRef="usd">8955000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib55fd172e7b345698937c728fa47ea35_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTUtNS0xLTEtMTE1NjI3_bc7ad87f-cfd8-4795-87f7-e46c0ccb797c"
      unitRef="usd">13000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib55fd172e7b345698937c728fa47ea35_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTUtNy0xLTEtMTE1NjI3_2ac8aef7-2bcb-4366-877e-87d6c34d318f"
      unitRef="usd">8942000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib55fd172e7b345698937c728fa47ea35_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTUtOS0xLTEtMTE1NjI3_da8380ae-8445-43ee-8ff2-2d3e80b50a46"
      unitRef="usd">3871000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib55fd172e7b345698937c728fa47ea35_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTUtMTEtMS0xLTExNTYyNw_f44fde4d-e4e3-41be-be79-4649cffc5d23"
      unitRef="usd">5071000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTYtMS0xLTEtMTE1NjI3_78c3b5e3-9703-412d-8436-8df2d28a1f9e"
      unitRef="usd">32321000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTYtNS0xLTEtMTE1NjI3_08f215ec-7436-4633-ba47-7219e2a0eac7"
      unitRef="usd">13000000</jnj:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss>
    <jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTYtNy0xLTEtMTE1NjI3_8117f494-2e00-460e-8793-b27f630d2e8c"
      unitRef="usd">32308000000</jnj:CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTYtOS0xLTEtMTE1NjI3_5f5421eb-a722-4e90-83f0-1c2f8ccf75b0"
      unitRef="usd">26865000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjM1YTY5ZjVmZmQ5NDQzM2NiMjk1YjE4ZWUyODNjNjg2L3RhYmxlcmFuZ2U6MzVhNjlmNWZmZDk0NDMzY2IyOTViMThlZTI4M2M2ODZfMTYtMTEtMS0xLTExNTYyNw_f623ddd2-7f3a-4cff-8410-3d409d02c62f"
      unitRef="usd">5443000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3MjA_fc598bfd-7fd6-44c0-81d5-ef75ecc228e6">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE2NzE_67a4a660-0751-4c79-b39a-76afbe7eb41f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale securities as of April&#160;2, 2023 are as follows:  &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.279%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.031%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfMS0yLTEtMS0xMTU2Mjc_a4aa386e-abd8-4f1f-8b64-e5b55893dc67"
      unitRef="usd">8901000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfMS00LTEtMS0xMTU2Mjc_0d6e8141-bc9d-4a44-87bd-631795299d3c"
      unitRef="usd">8889000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfMi0yLTEtMS0xMTU2Mjc_d39e4d90-6d60-4a08-a4f6-3f4daff5a447"
      unitRef="usd">54000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfMi00LTEtMS0xMTU2Mjc_56df7ef6-d246-4cc0-bb1f-413381fe07b8"
      unitRef="usd">53000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfMy0yLTEtMS0xMTU2Mjc_34450bb8-e41e-4b9f-ae28-5979358488cf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfMy00LTEtMS0xMTU2Mjc_5329fea1-a452-4971-a2bb-437c572693c4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfNC0yLTEtMS0xMTU2Mjc_990709f4-60bb-44c7-a890-a028059df2f1"
      unitRef="usd">8955000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjk5YmEwNjVkZjM4ZTRmNGNiNjM4ZGQ3YTEwMmFjZTc3L3RhYmxlcmFuZ2U6OTliYTA2NWRmMzhlNGY0Y2I2MzhkZDdhMTAyYWNlNzdfNC00LTEtMS0xMTU2Mjc_1e2b7be7-af84-4205-9bd7-1e9c03400239"
      unitRef="usd">8942000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE3MDg_755898fb-8496-49d9-999d-e8cbea628112">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments not measured at Fair Value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following financial liabilities are held at carrying amount on the consolidated balance sheet as of April&#160;2, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.793%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Financial Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 (750MM Euro 1.0909)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Notes due 2024 (500MM GBP 1.2359)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028 (750MM Euro 1.0909)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95% Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95% Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035 (1.5B Euro 1.0909)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.40%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85% Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50% Debentures due 2025*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.35% Debentures due 2026*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.05% Debentures due 2028*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.00% Debentures due 2030*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90% Debentures due 2033*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.10% Debentures due 2043*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.05% Debentures due 2053*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20% Debentures due 2063*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Non-Current Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="i76cf9f7d43b546acb7b030654e84376e_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNC0yLTEtMS0xMTU2Mjc_38cbda2d-856a-4059-a1c6-c24c2b664688"
      unitRef="usd">17979000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i38b034ded43b4398ab07f2c8eb4df69c_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNC00LTEtMS0xMTU2Mjc_45379b81-dbc5-4f96-a859-64c8f89f0009"
      unitRef="usd">17982000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia8fb8551fca949dea98f62de1af8e1fb_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZTUxNTMzYTc5MDRiNDhjMWFlODdkMGZjYWU2NzJiZmRfNA_b54256b2-d4df-461a-a0e8-59d59fa4ccb6"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia8fb8551fca949dea98f62de1af8e1fb_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZTUxNTMzYTc5MDRiNDhjMWFlODdkMGZjYWU2NzJiZmRfMjM_8d3b2363-7f7b-406b-863d-53b87b53e34e"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="ia8fb8551fca949dea98f62de1af8e1fb_I20230402"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZTUxNTMzYTc5MDRiNDhjMWFlODdkMGZjYWU2NzJiZmRfNTQ5NzU1ODEzOTM4_aaf5dbf1-6c9a-47f8-85dc-a75a97e403ea"
      unitRef="number">1.0909</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i74fbc3262ac245c6b06dbfaa60a35912_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTAtMi0xLTEtMTE1NjI3_f9adbd31-907c-42dc-a03e-c6835e90cfaf"
      unitRef="usd">812000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id2c5ffc25a414b4eb02918f1226b594b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTAtNC0xLTEtMTE1NjI3_6fe66ade-d9b7-4459-91a4-6d6dbd26d6f2"
      unitRef="usd">796000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id7901b5b213e45cfad73dbf6c939e3a1_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTEtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NDJiOTlmY2FlODU2NGE3NjlmZDYxNGFkN2JmOTAyYzVfNA_97bbdd8e-e03f-44c5-b128-4d4b018f1db1"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id7901b5b213e45cfad73dbf6c939e3a1_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTEtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NDJiOTlmY2FlODU2NGE3NjlmZDYxNGFkN2JmOTAyYzVfMjM_7f5b15c6-273e-4e1a-839b-85d315b15048"
      unitRef="gbp">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="id7901b5b213e45cfad73dbf6c939e3a1_I20230402"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTEtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NDJiOTlmY2FlODU2NGE3NjlmZDYxNGFkN2JmOTAyYzVfMzI_1d737324-4a5c-4a7e-9f10-3d06e8e538da"
      unitRef="number">1.2359</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i201ea42815f84447b0563ee2d6978dbf_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTEtMi0xLTEtMTE1NjI3_f1c44195-8d5c-4d81-a470-ef4b3c33386d"
      unitRef="usd">617000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifc07e47d11a24f3d84ea26db566510ba_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTEtNC0xLTEtMTE1NjI3_dc103db4-3367-412b-8531-d7cac20fbaac"
      unitRef="usd">626000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic7899493f2a04f03b8d3a44ba0c57ce8_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTItMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NmYxMjA0Yjk3MWM0NDhhMTk3ODg0ZGUzMmM4ODU1MTFfNA_26e7de16-48d1-4e27-a473-92a7dee1a92c"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id55a3b7fc5a045b8b30ed7f0edeef623_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTItMi0xLTEtMTE1NjI3_1845f623-aaec-420f-bb0c-61f7699f4820"
      unitRef="usd">749000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i00240ca013be4736a3577b6e2e4e6e8f_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTItNC0xLTEtMTE1NjI3_2b6ae2cc-613d-4841-8c5e-f29ed8a7b169"
      unitRef="usd">732000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d061251a667491cb3ccfb55f7e0fdf1_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTMtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YmVmYzA2NjA4YzRjNDUyOTkwYzljZjdkMTI1ZjNiYTRfNTQ5NzU1ODEzODkwNQ_47e5874a-d471-4c00-b442-1ddae62f9921"
      unitRef="number">0.0055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i27aece83874544b59d6a3aeaf4140c57_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTMtMi0xLTEtMTE1NjI3_8c40ef3b-24dc-4845-816b-62d6529ffc50"
      unitRef="usd">936000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib72ea9d48ff044b48b8f3531137328b3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTMtNC0xLTEtMTE1NjI3_30a5acf4-484f-42d9-a11a-9bab6de088aa"
      unitRef="usd">920000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id2d24b4e1a0d4ff0b2f3b876efb8f98d_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YzdiZjc5MjQ5MTQ1NGRlY2I0NTM1YjAxODMwNDc2ZWRfNA_bf829c3f-2775-4224-84d5-b3ba15e57d63"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id922d848f11649e8bb4d6a787425f3d9_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTUtMi0xLTEtMTE1NjI3_25f362b0-196c-4ece-99fb-d577f6d29969"
      unitRef="usd">1997000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8d10576f649d4fcaa6628e37339ed7d7_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTUtNC0xLTEtMTE1NjI3_61b4a4f4-844b-42c8-94c7-509545cf89f1"
      unitRef="usd">1924000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie6efd100445841fd9e4073832291ac05_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTYtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ODBiMTA2OGEwODU4NDQ1NWFmYzkxNzA2MTBjYzNkZDJfNA_9d8411d2-2225-449b-b281-ad16bee861b9"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if128e6a98f974c349bec0f4b8249d2e9_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTYtMi0xLTEtMTE1NjI3_da79a071-6979-4768-b35c-33264a908532"
      unitRef="usd">896000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id8830cb3725a43db940330000abf4afe_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTYtNC0xLTEtMTE1NjI3_63f62180-56d3-4a35-a3b8-7be1135359a8"
      unitRef="usd">968000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i368a811b66144aceb4879d90f93ca849_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTgtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246M2IxMTk1MDAwNGU2NDE1Mjg0YTY1YmIyMTQ3MjM1MTNfNA_f76d4aa9-a461-431d-8cc2-51f061227a5b"
      unitRef="number">0.0095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1212e32453564047b7f1d38ae4b843e4_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTgtMi0xLTEtMTE1NjI3_00957f1a-2f9f-4329-922d-f1adf965f35e"
      unitRef="usd">1412000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i79e9145f348e4338a78e8f59378476ae_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTgtNC0xLTEtMTE1NjI3_9f54a076-5741-4a17-a293-7b14dd7daebf"
      unitRef="usd">1329000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i48f4f2f5d47242ce9696a233b88c95d8_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTktMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NzM5NGYwMGMwODRmNGJiOTkyMGFmMThlYWU4NDRiM2JfNA_e143266b-e68b-4b53-822d-30d6abddf9b2"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i909ade28c6444d4abeff119bf7fda238_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTktMi0xLTEtMTE1NjI3_e038e75e-0e9e-4de0-8f0e-345658209372"
      unitRef="usd">1496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i2867cf9e16e54b48951692ded48ddfec_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMTktNC0xLTEtMTE1NjI3_021c436d-56ec-4c70-bf1f-76ef60a31467"
      unitRef="usd">1438000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib925ed2921f044c7b6a52dcd57f43461_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YjY5ZTUzOTU4MDRkNGIzZDhlNTAzNzllZDI1OGFlOGNfNA_fd74bf39-823c-4314-8452-a5f7f3a7b2e5"
      unitRef="number">0.01150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib925ed2921f044c7b6a52dcd57f43461_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YjY5ZTUzOTU4MDRkNGIzZDhlNTAzNzllZDI1OGFlOGNfMjM_890306d5-04b1-4135-aa29-f281ca7896a0"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="ib925ed2921f044c7b6a52dcd57f43461_I20230402"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YjY5ZTUzOTU4MDRkNGIzZDhlNTAzNzllZDI1OGFlOGNfMzM_f4a94813-3787-45de-a90d-0a6f47dc6f5c"
      unitRef="number">1.0909</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib1f4ccd1b3ab4f02bad67727e76ccb50_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjAtMi0xLTEtMTE1NjI3_d730ff87-154d-4e40-ae69-9e0144fd2ea2"
      unitRef="usd">814000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0a544d1c051b4c1a82b7d2c87b858546_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjAtNC0xLTEtMTE1NjI3_fc350081-bbed-402d-a712-03ef88b6f4f4"
      unitRef="usd">737000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i227ac8f50abd4fa982cb5d05a9110d6e_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjEtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YTBkODZkZWIzN2IzNDMzODhjMTRkYzk3MGYxZjUzYTlfNA_430c5bdd-6231-4a67-844f-f2db34ab5837"
      unitRef="number">0.0695</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3b249c5b4e484ae4a30c7aece7e87a09_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjEtMi0xLTEtMTE1NjI3_76d8159f-f115-4a4e-b8bb-5f7acd2d3b43"
      unitRef="usd">298000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1a6f9a852e704a75b988ca1c5efcda90_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjEtNC0xLTEtMTE1NjI3_567464ac-e413-4f98-90ea-bbf730102699"
      unitRef="usd">368000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia133568690864c2c80040ff64a3bd09d_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjItMC0xLTEtMTE1NjI3L3RleHRyZWdpb246OGRhNjdiOTdjMjVjNDc4NjgxMDY0YmIyYzU2YjM1MmFfNA_13c02670-fe66-4b26-b3ca-56ba1196a0b4"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i57ad96c98de046ca96f7fb7c74dca343_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjItMi0xLTEtMTE1NjI3_c57defdf-b2bf-4367-83eb-0caa21af67b8"
      unitRef="usd">1628000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib27758560e174afab9810f4bf86f5335_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjItNC0xLTEtMTE1NjI3_87231ce3-5874-4e7c-afb0-b74513fa1cf7"
      unitRef="usd">1469000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4e6d8ba2689941f9b382cef18e8e510d_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjMtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ODYyYTkzMWU1OTczNDAxMjhjYWNkNTY2YzAxMzE3YzFfNA_1f49ff4b-4c3c-46d1-9d91-b2c2a6f7b4e7"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6539619b042047df93391dc561673fce_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjMtMi0xLTEtMTE1NjI3_fce72d7c-9c17-49f3-bbd6-7521578e75cf"
      unitRef="usd">498000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iee5802a254024b95b747bbfcf78a55d8_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjMtNC0xLTEtMTE1NjI3_1a1fe730-a561-4dfd-ae55-b423c94a03f4"
      unitRef="usd">543000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3725ff0a163f4284b203c37c1a364bb1_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjQtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZjBlMzEwZTJlNTYxNDhkNjg5OTNiMDA3M2Y5MTM2ZTZfNA_700ae797-5125-48b5-8eec-be8f4584a006"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ief4a308916ec45049d576f86d454ed54_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjQtMi0xLTEtMTE1NjI3_7375f65f-fede-43ce-8c63-244b796bfab5"
      unitRef="usd">854000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i94f8018599af4e97a1cf4a42f83a48c3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjQtNC0xLTEtMTE1NjI3_eca0a400-9968-4e08-8794-4173a3750771"
      unitRef="usd">879000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4e731198db6248e18229839dfbbb9b60_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YmNhMDc3ZWQxNTVhNDU2NzllNmNlYTJmYjU5NjE3MDNfNA_0e82565b-12b9-445b-8c5a-8b719d9599fb"
      unitRef="number">0.01650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4e731198db6248e18229839dfbbb9b60_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YmNhMDc3ZWQxNTVhNDU2NzllNmNlYTJmYjU5NjE3MDNfMjM_5e646982-944a-43fd-a9d0-724d1499eabb"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i4e731198db6248e18229839dfbbb9b60_I20230402"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246YmNhMDc3ZWQxNTVhNDU2NzllNmNlYTJmYjU5NjE3MDNfMzI_7c962cc3-61d9-4029-b27e-eb73e8aa111b"
      unitRef="number">1.0909</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4e731198db6248e18229839dfbbb9b60_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjUtMi0xLTEtMTE1NjI3_fe28838f-d328-4597-ac28-84954d77f821"
      unitRef="usd">1629000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia7ecfe4e547b48e2bf37c8b07270def0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjUtNC0xLTEtMTE1NjI3_d0a2276a-79cf-4f0d-acae-a898b91f5f41"
      unitRef="usd">1369000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7d3943f6e0ae4e0587c9c4d74a075a18_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjYtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246M2U4N2Y2NTNjZTFmNGViOWE5YzkwYjg0YmQ5ZDAzMDlfNA_ad97ce0f-efb1-4816-82f6-66f9ae1f1b21"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i53b67cb6ca9a44edaab52a8871fcc3df_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjYtMi0xLTEtMTE1NjI3_dda81be4-8c2b-4cf4-9c57-f1756d97d2f7"
      unitRef="usd">864000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id4f9ebffba3147cf8d00c064683c36e2_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjYtNC0xLTEtMTE1NjI3_3994a79c-061d-45b6-8f10-5047fa217a38"
      unitRef="usd">933000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6c63abc9f5cf4a73a4a82c7b3a2282c6_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjctMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NTgzOGQ4M2UxNzQzNDIwYzhmM2VkNjdlYjYxNTlmNWVfNA_f2ffe2a0-6432-45c4-b39d-2ca1a8bb201e"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9fa813e2d18f4d07a5ba47a2be3612d2_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjctMi0xLTEtMTE1NjI3_8748be9a-e046-4fc1-989e-f3a4cf331f79"
      unitRef="usd">993000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8c8bd52c349746b1881e96b11ce47bf6_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjctNC0xLTEtMTE1NjI3_0f8f61da-94ff-4f30-be32-a75975adfa8d"
      unitRef="usd">1161000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ief71832a9018470cb79070bc07ffdec0_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjgtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NzA5ZGY2MGI4ODdiNGFmOTlhYTI1ZWIyNTllOGU3Y2VfNA_2077abe8-8bfb-4394-9b5e-10f983e938a3"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="idb5347aa05834f46ac9daf1613e272ca_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjgtMi0xLTEtMTE1NjI3_437916cc-39a6-4290-ab76-850c8e094d1a"
      unitRef="usd">1359000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i816cf20f9e104bf6b19a363b6ba3c457_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjgtNC0xLTEtMTE1NjI3_5db69d77-998e-4f10-ab0c-4805c72f02f7"
      unitRef="usd">1389000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2a7bfa3080844dec82b6603a0abd071c_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjktMC0xLTEtMTE1NjI3L3RleHRyZWdpb246N2M0ZmQ5MzYyNzkyNDhhNzlkNmE0NGQ2ZDY2NmU4M2VfNA_00313c4f-a55e-41df-b580-251c28bdb49b"
      unitRef="number">0.0340</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia1aeff3a19174fbaa6c309a6a87828c3_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjktMi0xLTEtMTE1NjI3_30f69494-2c89-4cc8-858f-1cd69f88de3f"
      unitRef="usd">992000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4a929f2577cd41d8b9bb8a882be4e1b4_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMjktNC0xLTEtMTE1NjI3_6ce74297-c926-4a83-8666-8944aa782795"
      unitRef="usd">896000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i3946c9afdf54418086ade08e21fa3a2b_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzAtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NzUyNWQzYjUwYzdkNDM1YmI5NGYzNzRkMzYyMDQ2NmRfNA_916b240a-7271-4a32-a55e-58e4a7fc87ad"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i82f6eaa7f0c74d57aafe2c652a9c905b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzAtMi0xLTEtMTE1NjI3_12af8237-f39a-41a2-b3f1-f6180b8c9f34"
      unitRef="usd">697000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ib652901c5fce4f24af8075006cd9aa10_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzAtNC0xLTEtMTE1NjI3_0b6a48c1-02e8-4f09-834c-674f7cc86a1b"
      unitRef="usd">806000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7bec9abf70944616ba30c3702874dcfa_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzEtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246MWJhMjBiNGEzYjc5NDA4ZTlmNTNmZjFjYzFhOTQ1NDZfNA_8f065251-0158-46e9-8355-de5d8697d11a"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i339a1d20f63346cb832562ac3c78a237_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzEtMi0xLTEtMTE1NjI3_59d211c6-e474-4f82-8eb6-a061058ebfb6"
      unitRef="usd">540000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iaacba4e8463a4d2e83aee15b14146669_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzEtNC0xLTEtMTE1NjI3_2bee42bd-2eb7-492c-85aa-60a63fcc40a7"
      unitRef="usd">551000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8cfb0968d3344cd78090b4f6ead3bd76_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzItMC0xLTEtMTE1NjI3L3RleHRyZWdpb246ZmUxNjUzZDA1N2VkNGMwM2I2NWRlZDU3Y2QzY2M2NGVfNA_c67da85b-73f3-4509-bf23-334d84824e46"
      unitRef="number">0.0210</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if0a4b17867e147fcbe4c359e1afbd038_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzItMi0xLTEtMTE1NjI3_b93673c0-2b29-487d-bcd9-c6089ad4ee28"
      unitRef="usd">852000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i724b3a0e6f5147afb4e0ba7665d6ef80_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzItNC0xLTEtMTE1NjI3_07b5b8c5-66c0-41f3-8aa5-cf5606c508a9"
      unitRef="usd">726000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib37fac857ce1416bbf734b81d98d767b_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzMtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246MzQxZjc2YzM5MjZjNGZmYjg4MDg4OTgyYTg4OTgxZGNfNA_61dc91f4-2c61-4128-b642-cb29dc5e50d4"
      unitRef="number">0.0485</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if3e1a1289b7d4dc7817b8a11b9bdba25_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzMtMi0xLTEtMTE1NjI3_abce8e94-5258-4fd0-b15a-22f56ac422f3"
      unitRef="usd">297000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i89ee2bcaaa4345b49e22759f9172507a_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzMtNC0xLTEtMTE1NjI3_abf3b59e-ccf2-4c57-9c40-098527cb58f7"
      unitRef="usd">311000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i93d5e74486b449e89b3a9220a64520f0_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzQtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246MjQwODRmZjA3MWI4NGZjNmI1MmRiYWI1OTdlYTRkODFfNA_876b4da4-7e11-4e2d-90a4-1c906c76003b"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id9923a50e9724fc481bdd65773cf31a0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzQtMi0xLTEtMTE1NjI3_2b559c8d-b712-43bb-a1b5-ab72baf633b3"
      unitRef="usd">496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id6a612e6189440309a78a24f6aaabefb_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzQtNC0xLTEtMTE1NjI3_defc0fd0-7ac7-449a-8a58-a4a578d40853"
      unitRef="usd">501000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2e60148e6e194dce942bd04838e31cbc_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzUtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246MmM1NGFlNTY3ZTlhNDEzMmIxZTI1ZjMzODY3ZDg1MzhfNA_b25b0978-73b5-4a03-8603-5b5d18cd981c"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia4c126d2c7894910adb1770911c549ed_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzUtMi0xLTEtMTE1NjI3_4860611a-cfa3-440e-8097-59c255e4cff5"
      unitRef="usd">1976000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie24382cee4f042c7954a6d0aa1419fb4_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzUtNC0xLTEtMTE1NjI3_5507dfca-30df-4de9-8e54-c0473e4d7bb6"
      unitRef="usd">1785000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3f1f5aa22a94cdbb91e0e86cd25fcaa_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzYtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246OTlhNGJhZDNiNmU2NDJhOWFjNjBmNjhmNjQ5ZWE4MzhfNA_9aba9499-78a7-461c-b888-8331d523883d"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i24b45cbd53644d79afe96aa1ef132108_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzYtMi0xLTEtMTE1NjI3_3bffbbbe-55a6-467c-8a95-a7c88ea860fa"
      unitRef="usd">837000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i022de5a785f24bcd9f3083e4891f2ccc_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzYtNC0xLTEtMTE1NjI3_127ba633-ddc3-48dd-bf7f-b6f835c633b5"
      unitRef="usd">899000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6862fde9a77c43f0bd130d62e09598e6_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzctMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NGE1YWI1MTg3YjRmNDJhMTk3OTc2MzYyMTdhODNmMzdfNA_20d50236-acbf-4fa2-bbf6-406434bebffd"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia86125a3d772402db1a30fdce3dcd466_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzctMi0xLTEtMTE1NjI3_96d0152e-25ea-4ed9-8120-cd58898be151"
      unitRef="usd">743000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5b0b8630278f405ba64f234c38a4a3ae_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzctNC0xLTEtMTE1NjI3_b3dffdc8-ff33-4aaf-aeeb-4c108ea5de59"
      unitRef="usd">651000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie533216722654c1e9ba1846224e6ec14_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzgtMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NjUwNzI1NGRhNTIwNGVlNzg1ZGZjOGRlYjEwMDY3N2JfNA_75fd749c-3948-4338-a191-47eb087b3b20"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i74486a5277344ce59312540a7f416cbe_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzgtMi0xLTEtMTE1NjI3_adaabf10-6ba7-4880-9c12-17dadb64c809"
      unitRef="usd">834000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7a9fa797383949bba12905735e92ed19_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzgtNC0xLTEtMTE1NjI3_ae68323a-c69f-424f-92ed-ca938b81a784"
      unitRef="usd">667000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5f065931abb84eccba21550140a470ca_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzktMC0xLTEtMTE1NjI3L3RleHRyZWdpb246NmNkOGEyMzVmMDNiNDMxYTgxZDEwMjk2NmNhNjNiYTZfNA_ed3fca3a-cb0b-41a1-8127-043a9cc92f7e"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i8bb4ca4a34d6461dbc0d107842b6a046_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzktMi0xLTEtMTE1NjI3_4d21e9ba-e876-4dba-a6ef-0432cae938f0"
      unitRef="usd">1080000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic6552612946f41819e903a05f07bf91c_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzktNC0xLTEtMTE1NjI3_321c8c08-d6cd-4b48-8883-dbbac3c966f8"
      unitRef="usd">819000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i918f92a298af41bda8fe834dd3b26150_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzgtMC0xLTEtMTI1OTIzL3RleHRyZWdpb246ODBmYTE4ZDlkMzE4NGUzM2FhMmEyY2Y3NmI5YWRjNzdfNTQ5NzU1ODEzODkwOQ_630f3299-3b0f-4a3c-bd23-271c53becd66"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i9f501e2baabd405c810574367101a19d_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzgtMi0xLTEtMTI1Njk0_15402734-d281-420d-9702-4015feb2d9ba"
      unitRef="usd">748000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1a69ae7c0f5d41bf986a42afdbbfb628_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzgtNC0xLTEtMTI1NzAz_8087da38-4363-4478-9558-0605df791b25"
      unitRef="usd">775000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if0a6b938d37244aa8e09a786396d444a_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzktMC0xLTEtMTI1OTMxL3RleHRyZWdpb246MWY5OGU2Y2YxZGJjNGNhNWI4YTBkZThiZTdiNGIxMjVfNTQ5NzU1ODEzODkwOQ_4dc35ef1-386d-456d-8b90-a6b5ed50655f"
      unitRef="number">0.0535</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id3a99eecd02148a2a368b8096810c2b5_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzktMi0xLTEtMTI1Njk0_f715a8d8-c839-438a-9001-1264eb8b711e"
      unitRef="usd">747000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i03eb671135b6424d97690216188682fa_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfMzktNC0xLTEtMTI1NzAz_7d2bc623-53e4-40ed-bdcc-ba24dac0ad39"
      unitRef="usd">776000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if08f43d66b2b4b1789c28c89f773bcd9_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDAtMC0xLTEtMTI1OTMzL3RleHRyZWdpb246OTAzMTY1MTViMzQxNGY1NjlmMWVjOWZmNWFhNjQ5NDRfNTQ5NzU1ODEzODkwOQ_3d49aeb6-be56-41a3-8e88-e15a924cd3c8"
      unitRef="number">0.0505</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i92360a98889d40b2bee328fb5755cfb0_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDAtMi0xLTEtMTI1Njk0_5ba9e760-6526-4627-9b3a-5cd35404c2fd"
      unitRef="usd">993000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i741825ad780746bea2f2c6a35aed64c1_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDAtNC0xLTEtMTI1NzAz_bd93e914-e9b1-44ff-b2be-787153735b62"
      unitRef="usd">1038000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id3fb8e7a45764351bb0b176fcbcb6e26_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDEtMC0xLTEtMTI1OTQwL3RleHRyZWdpb246ZTU3ZWFjNzA4YTQ3NDRhN2EyNGVmNDY0MzEwOTA0NTBfNTQ5NzU1ODEzODkwOQ_e2572d76-0bd9-48a2-a65a-5472699a9786"
      unitRef="number">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ieedfdd205ab143638b2c4e0babcb3bcc_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDEtMi0xLTEtMTI1Njk0_cb6557ca-2181-450e-812a-b999562ebf3c"
      unitRef="usd">992000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i7e9541bc07fa4ed8a81ca1e22b84a82a_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDEtNC0xLTEtMTI1NzAz_59b5a31d-e5ba-41ec-bbca-ab8e8a33d000"
      unitRef="usd">1033000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id69efa8053fb47178e9e37e201313747_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDItMC0xLTEtMTI1OTM4L3RleHRyZWdpb246Y2EyZDQyNzI5ZmU2NGMxYTlmZjU1Y2ZiMjRhNDg0MjhfNTQ5NzU1ODEzODkwOQ_6e37a396-992a-4f54-a040-b1a09606b363"
      unitRef="number">0.0490</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia0cf278aad3544b68d1287619e1ff5db_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDItMi0xLTEtMTI1Njk0_0b2970a7-b3c0-4d04-8c8f-44e89f3aa51f"
      unitRef="usd">1240000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i66beed51389f4daebb6d2d780254c5d2_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDItNC0xLTEtMTI1NzAz_ee570e46-a750-434c-960c-4864e33c5e92"
      unitRef="usd">1271000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i51d9ee539efe4210a650dbc237af95c4_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDMtMC0xLTEtMTI1OTQyL3RleHRyZWdpb246ZjRlNWIzZTcxNDQyNDg5Y2FjMjYxMTcyZDU2ZWRlMmJfNTQ5NzU1ODEzODkwOQ_52216086-75b9-4b9c-8756-c182358abfcc"
      unitRef="number">0.0510</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i638e9c268a244ef0bdd12369ee16af36_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDMtMi0xLTEtMTI1Njk0_4837e41d-1e7f-4803-9579-44ff4f7fab95"
      unitRef="usd">741000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4e2c136ed07a4293bbc96e175b9bbdfe_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDMtNC0xLTEtMTI1NzAz_6a5388bc-7a2d-4138-9f68-e10acb94bf33"
      unitRef="usd">774000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i21e0e43d753d451b9ac7010d74e12a35_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDQtMC0xLTEtMTI1OTQ0L3RleHRyZWdpb246OWZiYjM3OWQzMTI0NDlkMjgwMWYwNjkzMDczMTM2ODZfNTQ5NzU1ODEzODkwOQ_0606598a-4184-4c7d-9a71-495e4a087732"
      unitRef="number">0.0505</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i0b160e5cf382471abfa01a07b6979dcd_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDQtMi0xLTEtMTI1Njk0_6f64708f-dea4-4470-8fba-ec530a7be028"
      unitRef="usd">1476000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6091369129b642cfa7e758e78afae422_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDQtNC0xLTEtMTI1NzAz_685fb7f8-3945-4e18-a468-bafdcecae4c3"
      unitRef="usd">1540000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i024e2dfb671f4922b572b41f106efb1e_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDUtMC0xLTEtMTI1OTQ2L3RleHRyZWdpb246YjE5Y2JkODBkMTJjNDU0Y2I3ZDc1YWZlZWZkNjUwODNfNTQ5NzU1ODEzODkxNA_2a3351ff-bea8-4cf2-a78f-4ae04eddbaea"
      unitRef="number">0.0520</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i89b252fa9afc4f6895a65928a3dc4679_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDUtMi0xLTEtMTI1Njk0_73798644-671b-4f7d-a538-b8396f35abf1"
      unitRef="usd">738000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ie6b6aef384bf4a9b80ea47648fea1fee_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDUtNC0xLTEtMTI1NzAz_bffd218e-0f79-47d6-8d55-9146db4dc126"
      unitRef="usd">776000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id967b50670d04639aa79dfa133928a7b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDAtMi0xLTEtMTE1NjI3_9039a571-4287-47a4-8fa7-e2f4b9cb4690"
      unitRef="usd">57000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="if123e4fc41a748d3a7f0c30e5548e9dd_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDAtNC0xLTEtMTE1NjI3_7ba9aaf4-43e4-4480-a195-76bd88aafe8a"
      unitRef="usd">56000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i76cf9f7d43b546acb7b030654e84376e_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDEtMi0xLTEtMTE1NjI3_f8f8d217-c317-4d12-a55c-6e81ae8ea2d4"
      unitRef="usd">34928000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i38b034ded43b4398ab07f2c8eb4df69c_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RhYmxlOjQxNTRhYWE3ZDAzMTQwYmFhNzkzNjY0MzcxZDM2ODNjL3RhYmxlcmFuZ2U6NDE1NGFhYTdkMDMxNDBiYWE3OTM2NjQzNzFkMzY4M2NfNDEtNC0xLTEtMTE1NjI3_4ba2935f-97e9-4a68-b22c-1527f25f5241"
      unitRef="usd">34232000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongtermDebtWeightedAverageInterestRate
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTEyMzg_1bbd998b-af18-49f8-9f2e-d40fae0dbf62"
      unitRef="number">0.0347</us-gaap:LongtermDebtWeightedAverageInterestRate>
    <jnj:ExcessOfCarryingValueOverFairValueOfDebt
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTEzMTg_25eb046b-7ffd-40ef-b847-788f15bc2d11"
      unitRef="usd">1600000000</jnj:ExcessOfCarryingValueOverFairValueOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i30b84b721a8a47b89119d6e1923faac2_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfNTQ5NzU1ODM2NjY1_d969074d-d220-4127-886e-adf40259c15a"
      unitRef="usd">7750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ShortTermBorrowings
      contextRef="i61afdda999f44da2a95e6ba9519c4fa0_I20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTEzODU_6811fb0b-a788-41d7-8650-7152ca84f6cc"
      unitRef="usd">16900000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i61afdda999f44da2a95e6ba9519c4fa0_I20230402"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE0NTQ_200c8738-8388-4adf-be46-9ce8ba7b2451"
      unitRef="number">0.0485</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentTerm
      contextRef="i3e12ceb17aec40709533c417fa7976aa_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82MS9mcmFnOjU2MDhmNWZmMWFlYzQxMjVhZWY4MmYyYjkzZGM3ODlkL3RleHRyZWdpb246NTYwOGY1ZmYxYWVjNDEyNWFlZjgyZjJiOTNkYzc4OWRfMTE1MDY_21c83a68-67e6-4d7c-9c94-230a585dcc58">P3M</us-gaap:DebtInstrumentTerm>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfMzUxMw_7fb6b2bc-6574-4980-922b-7b11d5cc1103">INCOME TAXES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The worldwide effective income tax rates for the fiscal first quarters of 2023 and 2022 were 90.8% and 12.2%, respectively. This increase in the consolidated tax rate as compared to the prior year fiscal first quarter is primarily due to a $6.9&#160;billion charge related to the talc settlement proposal at an effective tax rate of 23.5% (for further information see Note 11 to the Consolidated Financial Statements).  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In the first fiscal quarter of 2022, there were favorable tax benefits due to income mix for mark to market adjustments to the Company&#x2019;s investment portfolio and the impairment of the bermekimab AD IPR&amp;amp;D, both at the U.S. statutory rate. Additionally, the prior year&#x2019;s effective tax rate benefited from the impact of certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in 2022. These benefits were partially offset by incremental tax costs directly related to the planned separation of the Company&#x2019;s Consumer Health business in the first fiscal quarter of 2022 as compared to the first fiscal quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company also received tax benefits from stock-based compensation that were either exercised or vested during each of the fiscal first quarters.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of April&#160;2, 2023, the Company had approximately $3.8 billion of liabilities from unrecognized tax benefits. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress in a number of jurisdictions. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. The Company currently expects completion of this audit and settlement of the related tax liabilities in the next 12 months. As a result, the Company has classified approximately $1.7&#160;billion of unrecognized tax benefits and associated interest as a current liability on the &#x201c;Accrued taxes on Income&#x201d; line of the Consolidated Balance Sheet as of the end of the first fiscal quarter of 2023 in anticipation of final settlement. Subsequent to April 2, 2023, the Company made a payment for approximately $1.4&#160;billion to the U.S. Treasury for the estimated liability of the 2013-2016 IRS Audit. The completion of this tax audit may result in additional adjustments to the Company&#x2019;s unrecognized tax benefit liability. In other major jurisdictions where the Company conducts business, the years that remain open to tax audit go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments relating to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfMTE1_5f287730-668d-41d0-94e6-90f90789c531"
      unitRef="number">0.908</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfMTIy_d3ee8309-8ae5-425a-928d-976ae786159b"
      unitRef="number">0.122</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:LitigationSettlementExpense
      contextRef="ia2a87b5a064e4c7a899475e0dbadc527_D20230102-20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfNTQ5NzU1ODI1MzUy_3573de1e-c6f1-4035-9d87-cfa18a81171b"
      unitRef="usd">6900000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="ia2a87b5a064e4c7a899475e0dbadc527_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfNTQ5NzU1ODE4MDAw_3aa79f01-d353-476f-832e-4aaffc5e75f4"
      unitRef="number">0.235</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i50e2318413734df39c6c543008cbcb21_I20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfMjY5Mw_ce1f02e4-9aba-4edc-812f-1031364563d0"
      unitRef="usd">3800000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ie7987f4710274da781b044c04aa38be0_I20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfMzI5ODUzNDg5NDg3MQ_24b7b4e4-61ae-424a-9982-aa6912915ac9"
      unitRef="usd">1700000000</us-gaap:UnrecognizedTaxBenefits>
    <jnj:UnrecognizedTaxBenefitLiabilityPayment
      contextRef="i3ec8770b399d406faad6d9a6b24fac59_D20230403-20230701"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV82Ny9mcmFnOjdiMTZiNWMzNzZhMTQ5NTRiMDE3ZTM4NTBiM2IwMDEyL3RleHRyZWdpb246N2IxNmI1YzM3NmExNDk1NGIwMTdlMzg1MGIzYjAwMTJfNTQ5NzU1ODI1NDQ2_e9f65f99-23ae-4b99-bad2-16a47ec88973"
      unitRef="usd">1400000000</jnj:UnrecognizedTaxBenefitLiabilityPayment>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RleHRyZWdpb246NmEyYjU2YjZjNzhkNDE5Njk2YjE2MmZhNzhiYWFmMTJfMTAwMg_f7d63153-a70a-4a7c-ac5f-9025c98f5880">PENSIONS AND OTHER BENEFIT PLANS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of Net Periodic Benefit Cost&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.877%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial (gains) losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Company Contributions&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the fiscal three months ended April&#160;2, 2023, the Company contributed $27 million and $6 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RleHRyZWdpb246NmEyYjU2YjZjNzhkNDE5Njk2YjE2MmZhNzhiYWFmMTJfMTAwNg_c2f0bfee-4e38-4b9f-8cc2-58ee42218402">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of Net Periodic Benefit Cost&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans include the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.877%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.574%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial (gains) losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost/(credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMy0yLTEtMS0xMTU2Mjc_b1b8f5fa-7e4f-429d-ad80-a79f750828ec"
      unitRef="usd">212000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMy00LTEtMS0xMTU2Mjc_2c534e4a-81f3-42ee-8c7b-b4a833599e14"
      unitRef="usd">321000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMy02LTEtMS0xMTU2Mjc_25b5e637-1b85-4cbe-8ec4-b2b9afafe4fa"
      unitRef="usd">68000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMy04LTEtMS0xMTU2Mjc_f2d9d74e-2358-4ef2-99b9-159a7d90f502"
      unitRef="usd">80000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNC0yLTEtMS0xMTU2Mjc_a5135c6b-4ebe-4f62-9400-46c04e7d5a5f"
      unitRef="usd">354000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNC00LTEtMS0xMTU2Mjc_93e227f3-9f7d-4c3e-be86-c62d47f00992"
      unitRef="usd">230000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNC02LTEtMS0xMTU2Mjc_550c8788-6a21-4c68-a6be-560bfbd74ac8"
      unitRef="usd">54000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNC04LTEtMS0xMTU2Mjc_500c6408-9832-422b-b08a-be0816b8dae8"
      unitRef="usd">26000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNS0yLTEtMS0xMTU2Mjc_4df40baa-ea5b-4d65-bd9a-e872e4ad7dc2"
      unitRef="usd">668000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNS00LTEtMS0xMTU2Mjc_eabc71b0-7d72-4816-ac26-0509806adbde"
      unitRef="usd">699000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNS02LTEtMS0xMTU2Mjc_88f8debe-b1a7-4d9e-8bf8-648ce922aa55"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNS04LTEtMS0xMTU2Mjc_20f54a12-fcca-4490-8bb7-c4b045cbdbdb"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNi0yLTEtMS0xMTU2Mjc_95b8e18e-bea7-45b0-ac65-9e48ba4cdd29"
      unitRef="usd">-46000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNi00LTEtMS0xMTU2Mjc_d6cc2d09-f067-43ab-ae43-edd514001760"
      unitRef="usd">-46000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNi02LTEtMS0xMTU2Mjc_de5ba8b5-d10b-455c-b8f0-d863b8d20126"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfNi04LTEtMS0xMTU2Mjc_51955ed1-5fbb-493d-b03c-b092bdbdb3a6"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOC0yLTEtMS0xMTU2Mjc_dad724dc-6128-4332-a4ef-8fb1964cba2b"
      unitRef="usd">50000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOC00LTEtMS0xMTU2Mjc_0d1e960c-220d-489f-bf22-dcf568dff429"
      unitRef="usd">-162000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOC02LTEtMS0xMTU2Mjc_17b9c0e1-2941-4556-9abb-ee545aebaacd"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOC04LTEtMS0xMTU2Mjc_9a1fde3a-234c-4a66-9aa8-eca20372f0b0"
      unitRef="usd">-30000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOS0yLTEtMS0xMTU2Mjc_48e3feda-9ee2-49fa-9a92-41010275f8c8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOS00LTEtMS0xMTU2Mjc_349e5c86-43cd-43cb-ba68-bb2fd84d9397"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOS02LTEtMS0xMTU2Mjc_0607a308-955f-43b3-882c-dcc632379af8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfOS04LTEtMS0xMTU2Mjc_aef6bc9f-ac04-4329-82a4-16dc1d95e062"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMTAtMi0xLTEtMTE1NjI3_a1fb9b2d-eec4-4049-8574-576b6d37df7a"
      unitRef="usd">-198000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i267bbdbe4d2e406f85767fab38b7213b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMTAtNC0xLTEtMTE1NjI3_6f6060fa-f1a5-4b4e-8a77-acd3fff1e500"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i2026d97980794e2188d7f6ba9ee4e136_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMTAtNi0xLTEtMTE1NjI3_00c741b6-e436-4bc1-8fc6-738d724916ef"
      unitRef="usd">127000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i16183d22fa544d2885b66e083d9b4ab8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RhYmxlOjBiM2YzNWIwMGRiNTQ4MTY5YWJjODczYTgxNTYyNjU5L3RhYmxlcmFuZ2U6MGIzZjM1YjAwZGI1NDgxNjlhYmM4NzNhODE1NjI2NTlfMTAtOC0xLTEtMTE1NjI3_9d0dc196-fa6e-4d75-a4c1-594468500455"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:PensionContributions
      contextRef="i6a79593849c348e791c81a2228ea6405_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RleHRyZWdpb246NmEyYjU2YjZjNzhkNDE5Njk2YjE2MmZhNzhiYWFmMTJfNzQy_807469ac-7d9b-4260-a31b-b2efcdc4c526"
      unitRef="usd">27000000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="i7b50bef376d94029914fd830a153b7aa_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83MC9mcmFnOjZhMmI1NmI2Yzc4ZDQxOTY5NmIxNjJmYTc4YmFhZjEyL3RleHRyZWdpb246NmEyYjU2YjZjNzhkNDE5Njk2YjE2MmZhNzhiYWFmMTJfNzQ5_21cc35be-a64f-4807-b269-beda9f5fd5a9"
      unitRef="usd">6000000</us-gaap:PensionContributions>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RleHRyZWdpb246ZGExZjNiYjIxNDIwNDJlY2I3NmIwNDVjNzdjNGQ3ZmVfOTI5_99e2387e-fafe-4c76-9b2f-8d778525c669">ACCUMULATED OTHER COMPREHENSIVE INCOME&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Accumulated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Comprehensive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts in accumulated other comprehensive income are presented net of the related tax impact.  Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries.  For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details on reclassifications out of Accumulated Other Comprehensive Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Derivatives &amp;amp; Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RleHRyZWdpb246ZGExZjNiYjIxNDIwNDJlY2I3NmIwNDVjNzdjNGQ3ZmVfOTM2_ccef692f-5ad7-45d9-b178-7b4e0084d003">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.774%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.662%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.719%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.306%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.547%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain/(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Accumulated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;On Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other Comprehensive&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,994)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b6f17374cb84625bb4b63c7a5d62e2c_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNC0yLTEtMS0xMTU2Mjc_175169a6-166d-4a11-9d2e-1163c3e9a8c0"
      unitRef="usd">-11813000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia51b75ec8ed24459b26207e74f51ad4d_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNC00LTEtMS0xMTU2Mjc_67ece337-51e5-4fb7-ae5f-e5ebffc6216e"
      unitRef="usd">-27000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i39da497bc9a345169e8c633fc9ccb4c8_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNC02LTEtMS0xMTU2Mjc_80d3f77e-2ad9-44ef-9a77-d82c3f3488aa"
      unitRef="usd">-897000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f8ef72c3cba4a74a4cbe42bd9004f33_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNC04LTEtMS0xMTU2Mjc_4aadc106-7089-44b7-ae7f-300b75c1bed1"
      unitRef="usd">-230000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i77ff9cf53ba540b9a5e6aeca7ca5804f_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNC0xMC0xLTEtMTE1NjI3_54c1c48c-f526-49c9-bbf0-99259af9f19a"
      unitRef="usd">-12967000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNS0yLTEtMS0xMTU2Mjc_9cd28387-fc27-4a64-8187-c29f08fd5d1f"
      unitRef="usd">-181000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNS00LTEtMS0xMTU2Mjc_df17b72d-66be-4ae8-806e-592e9b2be9d1"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNS02LTEtMS0xMTU2Mjc_6b19ecd1-6da5-4006-883c-c15b9c90ac48"
      unitRef="usd">68000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNS04LTEtMS0xMTU2Mjc_e9a1f846-30b2-4338-869c-97a02953536e"
      unitRef="usd">573000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNS0xMC0xLTEtMTE1NjI3_973eb5f5-a216-4161-b947-722a78d3ef74"
      unitRef="usd">341000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b26df561bd946948e1a78379354d9b5_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNy0yLTEtMS0xMTU2Mjc_1e35fb8f-8bf1-4ab3-b0f2-eefcef916a1a"
      unitRef="usd">-11994000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i03d933225100466a8dad732be7b062f9_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNy00LTEtMS0xMTU2Mjc_2f07e1e5-5269-4d8b-855c-1262d55d7cb6"
      unitRef="usd">-10000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99a10cb23bf04c2a9aefd04cd01d1d5b_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNy02LTEtMS0xMTU2Mjc_f6f09361-602f-487d-90a0-26eebd72061c"
      unitRef="usd">-965000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i248120dc95c44c078c9b33b2c6c60b4d_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNy04LTEtMS0xMTU2Mjc_b8656267-9d90-4482-b603-5eadac34e046"
      unitRef="usd">343000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i455ec88d396c41248d806ba599269e74_I20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83My9mcmFnOmRhMWYzYmIyMTQyMDQyZWNiNzZiMDQ1Yzc3YzRkN2ZlL3RhYmxlOjYwMTRjZWMyNzBmZDQ4MzJiNDhhMTM4MGNkMmRjMmZjL3RhYmxlcmFuZ2U6NjAxNGNlYzI3MGZkNDgzMmI0OGExMzgwY2QyZGMyZmNfNy0xMC0xLTEtMTE1NjI3_e29cee0d-c11a-41d1-aaf2-c0e67f628de3"
      unitRef="usd">-12626000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RleHRyZWdpb246ZmQ3YTY4MzNhZTE2NDU3Njg0NDU3YWUwMGNjODJlNGNfNjEz_8f730cb3-d686-46b2-bf8c-e62c6afaad40">EARNINGS/(LOSS) PER SHARE&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings/(loss) per share to diluted net earnings/(loss) per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.068%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings/(loss) per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares which could be repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic/diluted*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,666.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net earnings/(loss) per share (basic/diluted)*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The diluted net earnings per share calculation for the fiscal first quarter ended April&#160;3, 2022 included all shares related to stock options, as the exercise price of all options was less than the average market value of the Company&#x2019;s stock.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RleHRyZWdpb246ZmQ3YTY4MzNhZTE2NDU3Njg0NDU3YWUwMGNjODJlNGNfNjAy_95702610-5be1-4caa-9e50-46667f677d6f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings/(loss) per share to diluted net earnings/(loss) per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.454%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.605%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.654%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.919%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.068%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Shares in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings/(loss) per share &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,629.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares which could be repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(102.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding &#x2014; basic/diluted*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,605.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,666.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net earnings/(loss) per share (basic/diluted)*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.03)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfMi0yLTEtMS0xMTU2Mjc_e53e200b-326e-44d6-bafd-0989b8dfccc2"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfMi00LTEtMS0xMTU2Mjc_bfda86c1-fbe1-4d7a-874d-d058059fc8c8"
      unitRef="usdPerShare">1.96</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfMy0yLTEtMS0xMTU2Mjc_dc565ae9-f6cf-4068-92b6-b532ae9d482f"
      unitRef="shares">2605500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfMy00LTEtMS0xMTU2Mjc_ca263a88-a897-4b52-8f6b-5b54f84ff1d1"
      unitRef="shares">2629200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfNC0yLTEtMS0xMTU2Mjc_936639ed-c76d-4679-aad8-b9e9022c582e"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfNC00LTEtMS0xMTU2Mjc_266698a9-2ce8-434a-b375-9a266f6b227b"
      unitRef="shares">140100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfNS0yLTEtMS0xMTU2Mjc_f69a5f77-0763-45ea-9702-8230d6ea5b34"
      unitRef="shares">0</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfNS00LTEtMS0xMTU2Mjc_8be35c6d-93dd-4694-85cb-0a1119722e91"
      unitRef="shares">102800000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfNy0yLTEtMS0xMTU2Mjc_2122c920-d92c-4823-b6da-68fa325de703"
      unitRef="shares">2605500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfNy00LTEtMS0xMTU2Mjc_2faa52ce-c359-461a-8d04-1b14715d6af4"
      unitRef="shares">2666500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfOC0yLTEtMS0xMTU2Mjc_588cbd4f-dd03-44a2-a253-ca05e0f716ce"
      unitRef="usdPerShare">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83Ni9mcmFnOmZkN2E2ODMzYWUxNjQ1NzY4NDQ1N2FlMDBjYzgyZTRjL3RhYmxlOjk3Mzg1MzkwMTE3MTRjMTU4ZTQ1MzZiMTM0YjdhOGYzL3RhYmxlcmFuZ2U6OTczODUzOTAxMTcxNGMxNThlNDUzNmIxMzRiN2E4ZjNfOC00LTEtMS0xMTU2Mjc_c10140f6-4fe3-4b13-a379-bce6e8400bba"
      unitRef="usdPerShare">1.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfNDIxNQ_751c933b-bdf4-40d8-9377-2048cbbf6dad">SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY SEGMENT OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 2,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women&#x2019;s Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:168pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;REMICADE  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA / PREZCOBIX /&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;                                    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;            REZOLSTA / SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPRAVATO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CARVYKTI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; / &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:80pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ELECTROPHYSIOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ABIOMED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;OTHER INTERVENTIONAL SOLUTIONS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Inclusive of RISPERDAL CONSTA which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inclusive of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Acquired on December 22, 2022&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS/(LOSS) BEFORE PROVISION FOR TAXES BY SEGMENT &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 2,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Consumer Health separation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income/(loss) before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.7&#160;billion and $0.8&#160;billion in the fiscal first quarter of 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;COVID-19 Vaccine related exit costs of $0.4&#160;billion in the fiscal first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1 billion in the fiscal first quarter of 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Unfavorable changes in the fair value of securities in the fiscal first quarter of 2022 of $0.4&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.4&#160;billion and $0.3&#160;billion in the fiscal first quarter of 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1 billion in the fiscal first quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Amounts not allocated to segments include interest income/expense and general corporate income/expense. The fiscal first quarter of 2023 includes the incremental $6.9 billion charge related to the talc settlement proposal. See Note 11, Legal Proceedings, for additional details. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY GEOGRAPHIC AREA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere, excluding U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <jnj:SalesBySegmentOfBusinessTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfNDIwNA_52ef2f98-9612-4488-bf5f-0a5d07459eba">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY SEGMENT OF BUSINESS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 2,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women&#x2019;s Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:168pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;REMICADE  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA / PREZCOBIX /&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;                                    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;            REZOLSTA / SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA / XEPLION / INVEGA   TRINZA / TREVICTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPRAVATO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CARVYKTI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; / &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER PULMONARY HYPERTENSION&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:80pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ELECTROPHYSIOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ABIOMED&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 19pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;OTHER INTERVENTIONAL SOLUTIONS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;504&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.146%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.102%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Inclusive of RISPERDAL CONSTA which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inclusive of INVOKANA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;</jnj:SalesBySegmentOfBusinessTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaaf739bb046840338e03bd31a098d3ec_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNS0yLTEtMS0xMTU2Mjc_d4d5fef9-b41f-41fb-a476-28c100ad1bda"
      unitRef="usd">745000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib70396f99f564ac9938bee2564160961_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNS00LTEtMS0xMTU2Mjc_9806183b-760e-4f02-91f2-93582d3911c5"
      unitRef="usd">670000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaaf739bb046840338e03bd31a098d3ec_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNS02LTEtMS0xMTU2Mjc_7a16b98a-8776-471a-b020-0d112d814acd"
      unitRef="number">0.110</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if52ae96f4fc946d0926968e3c2defc87_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNi0yLTEtMS0xMTU2Mjc_a4966656-cff8-4fc8-ae7d-759e4e7ae61e"
      unitRef="usd">897000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41317b52070e4c52a074c754ab815d1c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNi00LTEtMS0xMTU2Mjc_d34460b4-fc8f-4099-a7a4-c5d222787a85"
      unitRef="usd">791000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if52ae96f4fc946d0926968e3c2defc87_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNi02LTEtMS0xMTU2Mjc_6edb572f-76f6-46ec-ab3e-d02d42d59594"
      unitRef="number">0.135</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c740c593a5e49d1a9b8f5e7e616b946_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNy0yLTEtMS0xMTU2Mjc_efb74bc6-ed94-4ba0-9d64-348f70dfbb8a"
      unitRef="usd">1642000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i984d66aa451f4fddafb447e2b3a07b38_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNy00LTEtMS0xMTU2Mjc_28e9910e-fcd5-4d46-bc5a-c0bb990d2640"
      unitRef="usd">1461000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9c740c593a5e49d1a9b8f5e7e616b946_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNy02LTEtMS0xMTU2Mjc_61c26106-72ff-467c-bb05-e6186365892a"
      unitRef="number">0.124</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaa2e564e1714834a088812e21dfe9e7_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOS0yLTEtMS0xMTU2Mjc_052493f5-d80f-47a4-aba3-df16f6a2a3fc"
      unitRef="usd">617000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85292bb163e24d1a8b532b0152757469_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOS00LTEtMS0xMTU2Mjc_5aed0654-62ed-481b-b557-efc664999626"
      unitRef="usd">544000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieaa2e564e1714834a088812e21dfe9e7_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOS02LTEtMS0xMTU2Mjc_7eddff93-c512-4bc6-927c-659887ee0220"
      unitRef="number">0.134</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff776c204ddd4fe4af24bb0222ea1874_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAtMi0xLTEtMTE1NjI3_2c8b01b7-da78-4ee3-84c7-710e20e29715"
      unitRef="usd">493000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07b3f305984a48ad85f9a74e74005373_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAtNC0xLTEtMTE1NjI3_9f6c3e1b-3fb5-4b06-a119-80791afbe2d3"
      unitRef="usd">468000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iff776c204ddd4fe4af24bb0222ea1874_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAtNi0xLTEtMTE1NjI3_fcf2c36b-faf4-4297-b29c-6cadea5813d2"
      unitRef="number">0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25ae31c7c436415cacd6f0634ac5e358_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEtMi0xLTEtMTE1NjI3_92794257-273e-41b6-9738-9b2b69a5c7fb"
      unitRef="usd">1110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a06685196204a4799f887412650fe40_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEtNC0xLTEtMTE1NjI3_79ed43cf-00bf-42c4-894b-0e3fa72dfc98"
      unitRef="usd">1012000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i25ae31c7c436415cacd6f0634ac5e358_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEtNi0xLTEtMTE1NjI3_7912db33-fbc2-455b-9289-d34c7d892487"
      unitRef="number">0.097</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15733073985a4ce5959e11ca5f252bf1_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMtMi0xLTEtMTE1NjI3_cdf62cbe-d2f5-4304-b1e0-b99b7c55ccb3"
      unitRef="usd">159000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e96376a42a04152b58e3882a9b14ef3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMtNC0xLTEtMTE1NjI3_ebc16545-a2a5-4cac-b031-daa818f111cc"
      unitRef="usd">143000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i15733073985a4ce5959e11ca5f252bf1_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMtNi0xLTEtMTE1NjI3_f6fe2664-d715-4588-8905-6b004b0fec13"
      unitRef="number">0.116</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i579190aae8a9475783a0704c6aa14097_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQtMi0xLTEtMTE1NjI3_2428aef2-37d5-4470-a242-41c32a608cca"
      unitRef="usd">202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c3a3dafb62444ad8218b38dd1ed838e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQtNC0xLTEtMTE1NjI3_edecf5f8-a849-4f8d-afab-04b9153223b2"
      unitRef="usd">223000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i579190aae8a9475783a0704c6aa14097_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQtNi0xLTEtMTE1NjI3_d634a0b5-09c8-4b10-b5dd-4f3d61d01dc3"
      unitRef="number">-0.096</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a8851c22232454e975ee3658a578864_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUtMi0xLTEtMTE1NjI3_44c60ca4-4082-4734-8e2a-7e9d74aa5f6c"
      unitRef="usd">361000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c3fc8b5552e4871a6f2db9f1a367083_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUtNC0xLTEtMTE1NjI3_fffd25c3-2b41-41e5-9fb8-75ab0d1a728f"
      unitRef="usd">366000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9a8851c22232454e975ee3658a578864_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUtNi0xLTEtMTE1NjI3_bd6767e6-c857-4d8e-a37d-cfc873b998d2"
      unitRef="number">-0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c9625e879e043e09db9ba52fa49c414_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTctMi0xLTEtMTE1NjI3_e10a5d46-3ed1-4a2c-9995-fa1055e51f0f"
      unitRef="usd">96000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77d45dffb4d24df982e0a69a2edb48b5_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTctNC0xLTEtMTE1NjI3_85767dbf-0a81-4651-9d25-42655f74e132"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1c9625e879e043e09db9ba52fa49c414_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTctNi0xLTEtMTE1NjI3_787fba13-d986-42c9-9be3-496ece12d07d"
      unitRef="number">0.130</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37a140c2966c4d39be0eb69abb0cd291_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTgtMi0xLTEtMTE1NjI3_b90c6485-88b8-4dc4-b45b-c0c27ca7384d"
      unitRef="usd">263000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if081b963d9144c09a6d20b20d26d3d66_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTgtNC0xLTEtMTE1NjI3_1e1ffca3-842e-4381-b51b-f7fb2d0fd903"
      unitRef="usd">270000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i37a140c2966c4d39be0eb69abb0cd291_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTgtNi0xLTEtMTE1NjI3_2de1810a-5b47-45c9-b02b-58e6c2b5ef1e"
      unitRef="number">-0.028</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01f0cdd79a5d41e2b78a6bf7fcb0b94f_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTktMi0xLTEtMTE1NjI3_a6ede553-a9f8-4cab-b259-2ba092407e3b"
      unitRef="usd">359000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id17d813e9a0a41f89c0e446fdf68e56a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTktNC0xLTEtMTE1NjI3_2b6bf766-1ad0-4ced-b996-8449e7c5b414"
      unitRef="usd">355000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i01f0cdd79a5d41e2b78a6bf7fcb0b94f_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTktNi0xLTEtMTE1NjI3_959e02ad-ae5e-4ea0-8572-ef617df3bb83"
      unitRef="number">0.010</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f0aee6f09e5488091b12bba39e31ee2_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEtMi0xLTEtMTE1NjI3_481cb609-6cac-4d75-8899-631f45b6082d"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4c384167ae1453abbb9d0b6c0c04854_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEtNC0xLTEtMTE1NjI3_c1251064-9488-4ca8-8b34-1b96b894f246"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8f0aee6f09e5488091b12bba39e31ee2_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEtNi0xLTEtMTE1NjI3_5a02a9ea-1654-4561-a3e3-6b3eedb73fdb"
      unitRef="number">0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i736ac00e11af42359794eaeaddc3a97a_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjItMi0xLTEtMTE1NjI3_cb9c5454-65d7-41c1-b89d-27f8ac6964b6"
      unitRef="usd">214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icacbe869dfec46a8be4b9c12f04f7cc6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjItNC0xLTEtMTE1NjI3_2944edbf-b6e9-4716-9f21-8a1a2af0005f"
      unitRef="usd">224000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i736ac00e11af42359794eaeaddc3a97a_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjItNi0xLTEtMTE1NjI3_42d71047-ace2-4006-a9f3-8b917222e915"
      unitRef="number">-0.049</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f04259b9e384d4386a146f306a64433_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMtMi0xLTEtMTE1NjI3_a1640853-4c2b-4443-95b0-8ddddbd522a9"
      unitRef="usd">217000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4456f20d70b4883b575d2169dd71544_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMtNC0xLTEtMTE1NjI3_a5d421cc-8957-4918-b1ba-efc25364d7ff"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9f04259b9e384d4386a146f306a64433_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMtNi0xLTEtMTE1NjI3_a81c1eab-172e-4dd3-9f19-9a81ddd9d40d"
      unitRef="number">-0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2627fcecbe54a53bd26bd35bb03ae37_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjUtMi0xLTEtMTE1NjI3_0d46fc0d-34e4-41b5-8811-57deee2ace5b"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7f08dd82e14407f93f9374ec1c64bba_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjUtNC0xLTEtMTE1NjI3_20fa074d-e4a1-4fac-9d9b-b359ff60cc8a"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie2627fcecbe54a53bd26bd35bb03ae37_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjUtNi0xLTEtMTE1NjI3_f6ad2d1d-19dc-4f3e-9465-30d69ffa66f8"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63462697f7cb451f9132abc3d2242368_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjYtMi0xLTEtMTE1NjI3_9f9155a6-dada-486e-ac04-645fbdf0111c"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e48079566be4bc3891e3fe4dd109037_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjYtNC0xLTEtMTE1NjI3_4a74ea9c-8c08-4cc8-8b4e-79000fee4ac7"
      unitRef="usd">52000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i63462697f7cb451f9132abc3d2242368_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjYtNi0xLTEtMTE1NjI3_3a0ddad3-6fe2-4193-8b8a-64687e9946e4"
      unitRef="number">-0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29728a150c174ada8da66efe8fb411d7_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjctMi0xLTEtMTE1NjI3_41430659-843e-44ea-a083-26682ebfb206"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i262a53f9ec2547dc9bc3e7376b7a007a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjctNC0xLTEtMTE1NjI3_deb3906d-a27b-4578-a195-d208cfaf900c"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29728a150c174ada8da66efe8fb411d7_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjctNi0xLTEtMTE1NjI3_5330d7bd-da46-4385-8b4c-ae3c785f7ecd"
      unitRef="number">-0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4510efc748d54bb7930912ba6509e096_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjktMi0xLTEtMTE1NjI3_f2d9fb92-b8a7-42cc-835e-46d0cc69cb05"
      unitRef="usd">1735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i767c65868b3d4650833e3270ece3465a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjktNC0xLTEtMTE1NjI3_f3cc47d3-3b4a-4337-863e-268ee65695b5"
      unitRef="usd">1557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4510efc748d54bb7930912ba6509e096_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjktNi0xLTEtMTE1NjI3_5e036ded-6f0e-4b75-895a-ad3b4d33d6ce"
      unitRef="number">0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b25c8c23a664e359b78c1353fbb6375_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzAtMi0xLTEtMTE1NjI3_34541deb-92bb-48ce-9c1a-7d4a377bed61"
      unitRef="usd">2117000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e4c728c6f644bf29493a4b4e9dad170_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzAtNC0xLTEtMTE1NjI3_08c16e9f-cdc5-49e4-8fcc-b71aeb67dd62"
      unitRef="usd">2029000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6b25c8c23a664e359b78c1353fbb6375_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzAtNi0xLTEtMTE1NjI3_a7b2b5b0-4e04-425e-8670-d1312d4ef780"
      unitRef="number">0.044</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26cdc03025f14afa93aeea4d2797344e_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzEtMi0xLTEtMTE1NjI3_e1d8257b-7185-418f-82fb-78d599dcf91f"
      unitRef="usd">3852000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0598fae3f054742badc9b82185f5c04_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzEtNC0xLTEtMTE1NjI3_bd7cd5ce-75eb-41a4-be4f-6f7ddf1c5ee4"
      unitRef="usd">3586000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i26cdc03025f14afa93aeea4d2797344e_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzEtNi0xLTEtMTE1NjI3_b028e2f7-a4c7-4335-8ce0-05e97ebc7bd4"
      unitRef="number">0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18dc481a2ecf4435be42bac0b2119b30_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzYtMi0xLTEtMTE1NjI3_70c96096-91c1-48bf-8e76-3dda0384f86b"
      unitRef="usd">2448000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4623992e0dd14d1a9e9f595afd28bd4a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzYtNC0xLTEtMTE1NjI3_2d2ef260-64e9-4fd7-abc2-01c87c32a75b"
      unitRef="usd">2501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i18dc481a2ecf4435be42bac0b2119b30_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzYtNi0xLTEtMTE1NjI3_c9c1d94f-f30f-4706-b0d3-463da4012d1d"
      unitRef="number">-0.021</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e5f74d7507448aa8240b9c69285bd57_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzctMi0xLTEtMTE1NjI3_1c4ba8e1-3d7f-4c25-a664-5772fd2b0d45"
      unitRef="usd">1664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0ee1a5c112245ef922eeb1907bc70a7_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzctNC0xLTEtMTE1NjI3_87fae189-9322-4824-83a6-9c5360821ab3"
      unitRef="usd">1617000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4e5f74d7507448aa8240b9c69285bd57_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzctNi0xLTEtMTE1NjI3_09c5a6c0-0e94-41c4-a6e1-b9d5cc9db82e"
      unitRef="number">0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29c3c1f4c5bf4928852da60e04089160_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzgtMi0xLTEtMTE1NjI3_bac3e36d-3f3c-418f-91f6-a8d09a8a5e72"
      unitRef="usd">4112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89d74a9d646040ac8bda4a109e5316d2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzgtNC0xLTEtMTE1NjI3_1231c53f-2635-40d8-a466-2655d4b13174"
      unitRef="usd">4119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29c3c1f4c5bf4928852da60e04089160_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMzgtNi0xLTEtMTE1NjI3_79cff87d-0b0b-47ab-aa3e-a186fb055865"
      unitRef="number">-0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1e47778732e44aea0320f24635c55e6_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDAtMi0xLTEtMTE1NjI3_09bff553-57d4-4272-a8f5-39571f831c20"
      unitRef="usd">276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i000088d3af5046b2921cb4af5f6fc205_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDAtNC0xLTEtMTE1NjI3_c89697d7-e94d-4038-852b-3480f1cc70d3"
      unitRef="usd">358000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib1e47778732e44aea0320f24635c55e6_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDAtNi0xLTEtMTE1NjI3_596e92b7-71df-4593-ace3-41388e741496"
      unitRef="number">-0.228</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide60c30a5fc749e0b67837f69ae698e5_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDEtMi0xLTEtMTE1NjI3_803fdb68-1818-402f-ae22-930bada23b0e"
      unitRef="usd">41000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i53b79714bdfb42359807a488bf5a74ec_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDEtNC0xLTEtMTE1NjI3_87112034-54cd-4821-805f-66835eb014d1"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ide60c30a5fc749e0b67837f69ae698e5_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDEtNi0xLTEtMTE1NjI3_a4d51fc3-9141-4efc-a031-fdc9efa1c860"
      unitRef="number">-0.488</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i359821ae58ad4ff8a87eaa12e4efdb78_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDItMi0xLTEtMTE1NjI3_d3a7d674-1522-4bdd-9baf-76883ab40441"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10d2670c3b13416fb7a206927fd88687_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDItNC0xLTEtMTE1NjI3_38efce56-ceb5-4b58-9ea5-42cad29266ac"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i359821ae58ad4ff8a87eaa12e4efdb78_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDItNi0xLTEtMTE1NjI3_7a876792-845c-4ee3-86c6-637837a5df3d"
      unitRef="number">-0.244</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cd662d1267e49139b46c4a297215a54_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDMtMi0xLTEtMTE1NjI3_96f767a4-944f-47fb-b8e5-7dc90b698af4"
      unitRef="usd">487000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ef2ee88e44043efbb8a96f8b9d8c89d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDMtNC0xLTEtMTE1NjI3_ffc1dddb-8084-4f03-a46c-6c1306aab0e2"
      unitRef="usd">663000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1cd662d1267e49139b46c4a297215a54_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDMtNi0xLTEtMTE1NjI3_4a758182-fbd9-4a84-b419-c072dff74d9f"
      unitRef="number">-0.265</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie188724cc3dd4a949ef2fbaa68fca7b1_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDUtMi0xLTEtMTE1NjI3_db67127a-f0f2-44ce-b6a4-747b4f1bbe43"
      unitRef="usd">271000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31b8c4e7570d486f9a67881129d6fa3a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDUtNC0xLTEtMTE1NjI3_92b86d89-3ef1-42cd-8b8b-8687b8edb075"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie188724cc3dd4a949ef2fbaa68fca7b1_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDUtNi0xLTEtMTE1NjI3_16700b05-d8e0-463d-8672-f169fbe9b794"
      unitRef="number">-0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i339e5f7a0cc1453d976a0dc292d89c27_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDYtMi0xLTEtMTE1NjI3_bff3c634-3177-4eaa-87cf-ac62b34b1c0c"
      unitRef="usd">266000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb2ce733a0ef4e72980327ed5e0107f8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDYtNC0xLTEtMTE1NjI3_b19259fd-8bea-43b5-85c8-fba7a9938f6f"
      unitRef="usd">283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i339e5f7a0cc1453d976a0dc292d89c27_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDYtNi0xLTEtMTE1NjI3_29343a1d-4088-444b-aca7-5bf468928880"
      unitRef="number">-0.061</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b9072482295465bb3ae5b67b3338abb_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDctMi0xLTEtMTE1NjI3_b4672c3d-8fef-4542-a63e-21c1107b966e"
      unitRef="usd">537000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec663daee5fb47d4a96c14b56bbddb1c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDctNC0xLTEtMTE1NjI3_2d6093c1-5971-4b4f-8c39-14350738318d"
      unitRef="usd">571000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0b9072482295465bb3ae5b67b3338abb_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDctNi0xLTEtMTE1NjI3_470cb763-f7e8-4340-9959-08f16c0f546f"
      unitRef="number">-0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dba4cd103d24bc9b66b596eab786d18_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDktMi0xLTEtMTE1NjI3_11f4df22-2bac-4ef1-a2fb-40e6563cbffa"
      unitRef="usd">1451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68917d7a1b8842be98f382c714c21a1e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDktNC0xLTEtMTE1NjI3_ed33ff26-742e-4225-936d-aba0e031a1c2"
      unitRef="usd">1379000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1dba4cd103d24bc9b66b596eab786d18_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNDktNi0xLTEtMTE1NjI3_1ca4af57-5807-422b-9dd1-e0f12c7e6676"
      unitRef="number">0.052</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3cedda0d436f4730a24d2cce6e535f50_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTAtMi0xLTEtMTE1NjI3_befffdd0-ca88-4ef4-851e-cfa470af28b7"
      unitRef="usd">993000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b46548a1c9e4da6ade074b1560663d9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTAtNC0xLTEtMTE1NjI3_de782d99-75a4-4a78-881a-784570630f9d"
      unitRef="usd">909000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3cedda0d436f4730a24d2cce6e535f50_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTAtNi0xLTEtMTE1NjI3_9479af77-d193-429c-ac05-dc60e9badc93"
      unitRef="number">0.093</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf3bbabc22fe40489b09d4860798d9fc_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTEtMi0xLTEtMTE1NjI3_e2403ab8-498f-4f2d-a90b-3d8d691887b6"
      unitRef="usd">2444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dc26d7592994955bfeeae65142c46b8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTEtNC0xLTEtMTE1NjI3_4f5d2533-12d8-4a56-9190-44243d77fa63"
      unitRef="usd">2288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idf3bbabc22fe40489b09d4860798d9fc_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTEtNi0xLTEtMTE1NjI3_be52200f-e01c-470e-97a5-d33f375a0120"
      unitRef="number">0.068</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic43daf65754947459d5aba53e5b92e81_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTMtMi0xLTEtMTE1NjI3_d06a10ff-d41e-45e2-9384-d874c9c1574a"
      unitRef="usd">406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8a2811670fd4e388c4cff13e473d4c0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTMtNC0xLTEtMTE1NjI3_fbcccbd8-e972-4684-b4f1-89a2cd54f5bb"
      unitRef="usd">391000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic43daf65754947459d5aba53e5b92e81_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTMtNi0xLTEtMTE1NjI3_055717fc-e6d7-4de8-b4cf-0e7dca491def"
      unitRef="number">0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if25545d4d3224f2683d6c36402df6c2c_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTQtMi0xLTEtMTE1NjI3_013160d9-2cf4-4275-8b49-b79544a81866"
      unitRef="usd">234000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i583fb109cf304e3293199bb1d895aece_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTQtNC0xLTEtMTE1NjI3_59dd3981-2aa2-4063-92c0-a496475e5c9b"
      unitRef="usd">199000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if25545d4d3224f2683d6c36402df6c2c_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTQtNi0xLTEtMTE1NjI3_569781e2-8962-4344-a4ab-5e92c0d7e9a0"
      unitRef="number">0.173</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d6adf3e8198442a90339cfc887ae4e4_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTUtMi0xLTEtMTE1NjI3_a481a3c1-e342-4fcd-b96c-06cd090d4f7b"
      unitRef="usd">640000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i63aa3f3d8b9249c185e61668767dfbf3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTUtNC0xLTEtMTE1NjI3_68b67633-92e5-4276-8d5f-d6863f1e4774"
      unitRef="usd">590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9d6adf3e8198442a90339cfc887ae4e4_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTUtNi0xLTEtMTE1NjI3_299fae68-3919-4bb6-83d7-c61027adac44"
      unitRef="number">0.084</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i602b3a8f8c684e07855a432b44f877e7_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTctMi0xLTEtMTE1NjI3_b9f3c09c-ae93-4e69-8dc3-d9fc2c840b18"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i057cb94031764e83922e91e90e55ad2a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTctNC0xLTEtMTE1NjI3_afd960f0-c100-454d-8e34-94d913397782"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i602b3a8f8c684e07855a432b44f877e7_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTctNi0xLTEtMTE1NjI3_ab8d14b0-ddba-4cf2-8876-3844e6918b56"
      unitRef="number">-0.512</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f466a267f5244d987f9d84b05b1dd94_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTgtMi0xLTEtMTE1NjI3_c47ee0a0-2dd2-40bb-8b1c-908be00b3cd7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69aa70e212f144c0a94a01e8c886be13_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTgtNC0xLTEtMTE1NjI3_1ec09296-9c62-4c1f-b32c-a41ac18ea70d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0f466a267f5244d987f9d84b05b1dd94_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTgtNi0xLTEtMTE1NjI3_cd4ee39b-1103-4d86-ab1d-9bdfea45012b"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1581f8ac08c84383b20e0e6e3b0b3231_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTktMi0xLTEtMTE1NjI3_bec26739-3277-493f-a45e-5c0284c41384"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64ff97d1a3024cd4aa22d2ca000bb716_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTktNC0xLTEtMTE1NjI3_33ead4c6-3f86-44cb-8986-292379e35707"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1581f8ac08c84383b20e0e6e3b0b3231_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNTktNi0xLTEtMTE1NjI3_75efabb7-1a91-41eb-b469-ddabac7b690a"
      unitRef="number">-0.513</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea40143a881c4e9fa30c030d13484367_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjItMi0xLTEtMTE1NjI3_6b7517d6-c815-4604-b681-d2b1797958ac"
      unitRef="usd">392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26bdbd0a33904170961ee857f7f75ec2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjItNC0xLTEtMTE1NjI3_0bfd7e58-a098-4fe5-90b5-428357ce0370"
      unitRef="usd">461000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iea40143a881c4e9fa30c030d13484367_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjItNi0xLTEtMTE1NjI3_d85e94ed-49b6-4b0c-bcd7-40da91d22070"
      unitRef="number">-0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a944b7eb27347a88ca02d5d4d2a3ae3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjMtMi0xLTEtMTE1NjI3_f1e951bc-d8d9-4ea8-9cf4-1b4a52ffca60"
      unitRef="usd">1193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a5cd0e89145489b9adb25e4375d33c2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjMtNC0xLTEtMTE1NjI3_fa8bd4a7-edf0-4e1a-8187-058a85178cec"
      unitRef="usd">836000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5a944b7eb27347a88ca02d5d4d2a3ae3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjMtNi0xLTEtMTE1NjI3_0c38c725-7779-49ed-b33c-4f5f01fbda9c"
      unitRef="number">0.428</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d1731aeb98946a7b4ae917d048b33e9_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjQtMi0xLTEtMTE1NjI3_aacb7645-bb65-476a-bcd0-cd035ad4b353"
      unitRef="usd">1586000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if862ee47ff57402ab4003df617f3cbb7_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjQtNC0xLTEtMTE1NjI3_aacb27bc-5060-4d8c-bf41-100f3f67932e"
      unitRef="usd">1297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3d1731aeb98946a7b4ae917d048b33e9_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjQtNi0xLTEtMTE1NjI3_ff899036-561c-4dd8-8ea4-67ab05821cdf"
      unitRef="number">0.223</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic411e2d070f641dda19f24eba87d762f_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjYtMi0xLTEtMTE1NjI3_95c630d0-07a1-4619-9dbe-2b6d0e655e63"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i617fe07827554cea8265f01074aeb1a0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjYtNC0xLTEtMTE1NjI3_0b13a310-a3f2-49a3-9fd7-599dd888ec44"
      unitRef="usd">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1d744c7c8d14f1fb8fea48cff62dbdd_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjctMi0xLTEtMTE1NjI3_aea6bd5d-5459-4477-800c-cf1a29be751d"
      unitRef="usd">747000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52ae5dd1fae940ffb2cc4d896705c30c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjctNC0xLTEtMTE1NjI3_f517bc5e-7abf-408a-a1ce-287c1036e071"
      unitRef="usd">382000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia1d744c7c8d14f1fb8fea48cff62dbdd_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjctNi0xLTEtMTE1NjI3_1ec0e427-f50d-4bd4-8e2a-b3979719b30c"
      unitRef="number">0.956</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a022c685c4343d79523d6f83bf6d043_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjgtMi0xLTEtMTE1NjI3_a32414c9-fd5d-47f9-a084-55e44d6ef42c"
      unitRef="usd">747000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iadbb5deb5a1b4cc08f416461ce834cf6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjgtNC0xLTEtMTE1NjI3_5c42cb46-1f32-4571-8c52-ce64ef2c7d88"
      unitRef="usd">457000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8a022c685c4343d79523d6f83bf6d043_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNjgtNi0xLTEtMTE1NjI3_084dd332-6b5f-4417-a5be-5c3decbef04b"
      unitRef="number">0.634</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4967a757b464053a991e793b0594a48_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzAtMi0xLTEtMTE1NjI3_402fc18f-24a7-40a5-bdd5-8c610f49ddeb"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0098733b5de24bea987487c0dc5edf73_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzAtNC0xLTEtMTE1NjI3_d5c08343-095e-4fc6-9f37-581590abe0c4"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia4967a757b464053a991e793b0594a48_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzAtNi0xLTEtMTE1NjI3_23131f35-d4be-4a9c-a30a-a583a0ea2987"
      unitRef="number">-0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a690fd862144f769bca79051212a40a_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzEtMi0xLTEtMTE1NjI3_eed7cc67-c310-4935-a6c9-2088a56658bc"
      unitRef="usd">271000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i131a7455bdfa4e3e8cee654b964e7506_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzEtNC0xLTEtMTE1NjI3_df8fe1f1-19f5-485d-b987-fc2e0cee4c7d"
      unitRef="usd">239000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0a690fd862144f769bca79051212a40a_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzEtNi0xLTEtMTE1NjI3_cb301065-3e77-42fd-ad12-e53b235090e4"
      unitRef="number">0.134</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id11db793f4614fa5837a25d9b63156c9_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzItMi0xLTEtMTE1NjI3_c3b8957f-0c89-4786-a011-bf58e7136e82"
      unitRef="usd">280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5573f6f5a5d9481c98d29c616f628da0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzItNC0xLTEtMTE1NjI3_94fe5511-7e66-4054-8b70-49f2dbebbf59"
      unitRef="usd">248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id11db793f4614fa5837a25d9b63156c9_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzItNi0xLTEtMTE1NjI3_daf5a880-0054-4e21-8219-c3a6b5a3f952"
      unitRef="number">0.128</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib59a8dcb5bf443089bf51815435371fa_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzQtMi0xLTEtMTE1NjI3_06391918-2a9e-43cb-9fab-43fc6a4c1deb"
      unitRef="usd">378000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03761710c3c6468698fff19815667abe_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzQtNC0xLTEtMTE1NjI3_af8a9760-d08e-4d4a-90c6-3b6d1d23ae93"
      unitRef="usd">369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib59a8dcb5bf443089bf51815435371fa_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzQtNi0xLTEtMTE1NjI3_1ea76afb-d97d-4638-af40-a08d719797ff"
      unitRef="number">0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6d4e5e284b940f0abc9192313e3810c_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzUtMi0xLTEtMTE1NjI3_b4f65edb-c339-447f-983f-009d4f4097eb"
      unitRef="usd">99000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7db52f7f1f8f4820addc27c47eeb5cee_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzUtNC0xLTEtMTE1NjI3_8c07fbab-73b4-4bad-85af-eaf688277bfb"
      unitRef="usd">132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id6d4e5e284b940f0abc9192313e3810c_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzUtNi0xLTEtMTE1NjI3_6ab5d367-eae7-47b3-9c82-24135519f95d"
      unitRef="number">-0.252</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i629cb97dd9014b8a9866cd4d248ef278_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzYtMi0xLTEtMTE1NjI3_521762d8-4a05-4d9a-b81d-1f01d5a75a5a"
      unitRef="usd">477000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica7fe9702d8b45e98e6fe37ca13068af_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzYtNC0xLTEtMTE1NjI3_3be665ad-1b47-4ba7-90cc-258e961d50e7"
      unitRef="usd">501000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i629cb97dd9014b8a9866cd4d248ef278_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfNzYtNi0xLTEtMTE1NjI3_245b9ed6-593a-4cf8-b1bd-97accd0ac684"
      unitRef="number">-0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if79e147a672e45f0884726eebc14855e_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODAtMi0xLTEtMTE1NjI3_f83ff730-e0ea-4104-b812-a04857da1304"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb5a5fc555d24f308104655c998bf305_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODAtNC0xLTEtMTE1NjI3_8b265651-f93d-4c09-92fb-2d7ed74f49c9"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if79e147a672e45f0884726eebc14855e_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODAtNi0xLTEtMTE1NjI3_d5feb270-8b2e-4a54-af2c-f47b26ae03e9"
      unitRef="number">-0.331</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2615b59268ff4c7d937c9cf5cf4ce170_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODEtMi0xLTEtMTE1NjI3_ab95a9c1-095e-4441-9236-c2ac8a7d80fd"
      unitRef="usd">77000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c978427d57f48948b5dca33ba9a8790_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODEtNC0xLTEtMTE1NjI3_7997566d-b3e0-43e2-bff6-f5dc86e0e5bb"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2615b59268ff4c7d937c9cf5cf4ce170_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODEtNi0xLTEtMTE1NjI3_cd59d200-2d2a-4663-aa98-b8ea9bda3bf5"
      unitRef="number">-0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i785d0ef07e4f4fc6899d3084d7bde419_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODItMi0xLTEtMTE1NjI3_a556973c-f024-4bb6-9870-96661844198c"
      unitRef="usd">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3c0840358a442fea238d7d4ecefdddf_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODItNC0xLTEtMTE1NjI3_95269ce7-abcf-4898-9303-96c65bf4d4db"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i785d0ef07e4f4fc6899d3084d7bde419_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODItNi0xLTEtMTE1NjI3_7ea8081c-cda5-4bfe-81f5-558e046da3e9"
      unitRef="number">-0.098</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcfcee01500e40b6a181c5d82cba6ce5_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODUtMi0xLTEtMTE1NjI3_cdd62a4b-9654-4621-b8b6-5e20097c03fa"
      unitRef="usd">978000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i044647ef59d14e6ca30f9418a2cb334e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODUtNC0xLTEtMTE1NjI3_d56571dd-e51e-4e11-b507-3fe9e62d4611"
      unitRef="usd">843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibcfcee01500e40b6a181c5d82cba6ce5_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODUtNi0xLTEtMTE1NjI3_8b14ae13-3065-440d-8cf8-a7ceeba29c7f"
      unitRef="number">0.160</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab3e83e7566542ea969c626ac4818791_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODYtMi0xLTEtMTE1NjI3_934c4938-b6cd-4e61-a9fe-a570754ccba0"
      unitRef="usd">826000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54ff8960370c41909dbf45d3630c3d78_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODYtNC0xLTEtMTE1NjI3_7c71ff9b-c601-434f-acf1-b2c0983984e4"
      unitRef="usd">898000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iab3e83e7566542ea969c626ac4818791_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODYtNi0xLTEtMTE1NjI3_ee25d6e6-75ca-4466-a2e2-1f39e16ff0a8"
      unitRef="number">-0.081</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ff8415c7ec740b5af1069a9d5615847_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODctMi0xLTEtMTE1NjI3_ad841059-6a23-4230-9cdb-b05d631d90b4"
      unitRef="usd">1804000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if178d1ce94e54a8b9f23398ad0e2c083_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODctNC0xLTEtMTE1NjI3_593b1255-9392-4b06-b443-85e5a9ca3422"
      unitRef="usd">1741000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4ff8415c7ec740b5af1069a9d5615847_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODctNi0xLTEtMTE1NjI3_f07293a9-813e-4a29-883e-2df6cb36c56e"
      unitRef="number">0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2f647ec067747e6b33e6c21b46b9acf_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODktMi0xLTEtMTE1NjI3_61cfd7a2-49ea-4a4a-b704-f66684355cd3"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id01edf890de640d3ad17b53da34d46f7_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfODktNC0xLTEtMTE1NjI3_875e44d3-fb22-496d-8b33-04140e0c9a28"
      unitRef="usd">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17723664c2b44d548c8c8e8627ed427d_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTAtMi0xLTEtMTE1NjI3_14ef14d7-4699-49aa-9b76-6daee0447960"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idaea78f2bf0b45eb910fc188d04fbfbd_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTAtNC0xLTEtMTE1NjI3_10685c1e-0cc0-44f8-b145-d8b406de0819"
      unitRef="usd">122000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i17723664c2b44d548c8c8e8627ed427d_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTAtNi0xLTEtMTE1NjI3_9099611a-7c54-40ec-aee9-565ae773fe64"
      unitRef="number">0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11798e595eff476180e4de36a00ef239_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTEtMi0xLTEtMTE1NjI3_d55f31a7-a8aa-4f4e-9fe7-5fb88002cf2a"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83d752ce08cf496391503b82c9f8093e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTEtNC0xLTEtMTE1NjI3_cf5828be-310c-4f3a-bddd-3d475050d460"
      unitRef="usd">157000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i11798e595eff476180e4de36a00ef239_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTEtNi0xLTEtMTE1NjI3_30376965-cf14-47ff-80b3-345eb4d54621"
      unitRef="number">0.314</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f629283443f49d8aaad385960bb0673_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTMtMi0xLTEtMTE1NjI3_78f2658a-a646-46ca-a3c2-a6cf992107c9"
      unitRef="usd">713000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i093f63f72e8e49ecb668d13b75d40bb2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTMtNC0xLTEtMTE1NjI3_7578357b-acf6-4b3a-99af-797288ea9a3e"
      unitRef="usd">661000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3f629283443f49d8aaad385960bb0673_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTMtNi0xLTEtMTE1NjI3_4e03daac-6d20-4a2b-9719-b5b135b2430a"
      unitRef="number">0.079</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i686c8541b42b4c05a464ef7ee07f890d_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTQtMi0xLTEtMTE1NjI3_278ca092-cfa8-42d9-bb5b-68e67d1c4621"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae059ef9a71a4eb791f9e711bc7a3a8b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTQtNC0xLTEtMTE1NjI3_562178b5-8320-4b2b-a8ce-96843b8ffe22"
      unitRef="usd">387000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i686c8541b42b4c05a464ef7ee07f890d_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTQtNi0xLTEtMTE1NjI3_d7a5e4be-000b-4b6b-b245-97979316cf01"
      unitRef="number">-0.146</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i540168e260374772b2846cd65772d665_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTUtMi0xLTEtMTE1NjI3_c2d80825-605f-4482-bac2-a77968b780a8"
      unitRef="usd">1044000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4eda79b80e2049239e63855bc02299d9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTUtNC0xLTEtMTE1NjI3_3e7d96df-dc88-4178-a714-d884636dca6c"
      unitRef="usd">1048000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i540168e260374772b2846cd65772d665_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTUtNi0xLTEtMTE1NjI3_763fd634-8c85-42d2-8b9f-c1f89c6d3472"
      unitRef="number">-0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7c7de0d76674b90ae3e372bc29d4f72_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTctMi0xLTEtMTE1NjI3_96c71ffc-291d-4249-81f5-d93e948cb7f0"
      unitRef="usd">111000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i86f3e2bce1e74415a5032c634535117d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTctNC0xLTEtMTE1NjI3_be86b7f2-cf36-4e81-a0b2-21d551ad0f6a"
      unitRef="usd">61000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie7c7de0d76674b90ae3e372bc29d4f72_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTctNi0xLTEtMTE1NjI3_a10ddddc-6414-4bf6-8ec2-2e75c89b33a6"
      unitRef="number">0.824</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a1a49f5edb04dcbbfd9179b3bc6605d_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTgtMi0xLTEtMTE1NjI3_704cd25e-233e-40f2-84b8-3af7329ed3b7"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64eef9047d8b4024881a1e71e04644ab_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTgtNC0xLTEtMTE1NjI3_7c9a0270-7fa2-4a10-ae36-6dbb305bf922"
      unitRef="usd">9000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd5f7ebb194146fe824e76df773868ab_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTktMi0xLTEtMTE1NjI3_dfa3ec5a-9f97-4380-a26a-5a479fbb4104"
      unitRef="usd">131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib75875ac7da34c28b177112493ce9e3b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTktNC0xLTEtMTE1NjI3_ae91da3b-53f6-4cac-b288-570bf33ec298"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifd5f7ebb194146fe824e76df773868ab_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfOTktNi0xLTEtMTE1NjI3_846f57dd-8312-4d81-9361-c705e5c9f91b"
      unitRef="number">0.869</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c5219d9e2234c1581c5cbbbc318e9ca_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAxLTItMS0xLTExNTYyNw_fa2c1e5f-2224-44cd-8e23-f4170aad9eaf"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f3287ef468347f78f62d4695c0a6c33_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAxLTQtMS0xLTExNTYyNw_49eb5ad4-0db5-427a-81c3-a745f5615909"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4c5219d9e2234c1581c5cbbbc318e9ca_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAxLTYtMS0xLTExNTYyNw_b1fb7180-68a4-41b7-9db1-bdc20cab117a"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2dc3cc05679b42978b02eabd70ac7223_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAyLTItMS0xLTExNTYyNw_7ee1afc0-f69a-4268-afd2-233d40d38975"
      unitRef="usd">339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if98063295c35488990378b212f03f0c0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAyLTQtMS0xLTExNTYyNw_1b55fefe-95de-4c3b-ae00-83f4d781785d"
      unitRef="usd">380000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2dc3cc05679b42978b02eabd70ac7223_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAyLTYtMS0xLTExNTYyNw_69b7b77e-54ca-4dc5-8392-e68b4b12f3f3"
      unitRef="number">-0.107</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied3b20670e8f435991a56e4ff15b778d_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAzLTItMS0xLTExNTYyNw_dff743ba-6c87-4b82-8048-e28d93ea8dca"
      unitRef="usd">423000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac15c39db3b94e89978df479bba14ca0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAzLTQtMS0xLTExNTYyNw_2c7ca9a7-8318-4683-95fc-e7d52921f7b9"
      unitRef="usd">467000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ied3b20670e8f435991a56e4ff15b778d_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTAzLTYtMS0xLTExNTYyNw_cd4c9f3a-760b-4df8-a6f2-3d77eb6c6f93"
      unitRef="number">-0.094</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i333de10c5e194bb8a7cde19cd0859df9_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA2LTItMS0xLTExNTYyNw_7be3a41d-3749-4512-85df-b653c833d74e"
      unitRef="usd">1889000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib525ff83930a455288c90417291f93fb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA2LTQtMS0xLTExNTYyNw_a58c03f8-8d83-4ba2-84fd-6b73d11ce74c"
      unitRef="usd">1582000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i333de10c5e194bb8a7cde19cd0859df9_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA2LTYtMS0xLTExNTYyNw_8033054f-7818-49a0-8bab-049f68c68c04"
      unitRef="number">0.194</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68673ce635ab4895a3a71deec80d927b_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA3LTItMS0xLTExNTYyNw_43c863b9-0b1b-4852-b5b6-a587f1fbcbb5"
      unitRef="usd">2223000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e28bea10b16493bb218d5f6672559a2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA3LTQtMS0xLTExNTYyNw_5f9d85f5-3e4d-4338-b2c3-809e3c3d0969"
      unitRef="usd">2369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i68673ce635ab4895a3a71deec80d927b_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA3LTYtMS0xLTExNTYyNw_0a4cc09e-ebb5-431a-839f-263818a5616e"
      unitRef="number">-0.061</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f2133a562294f9fad3ef124cc3f62af_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA4LTItMS0xLTExNTYyNw_528b8796-e564-4c1c-bf20-c05bab64c95e"
      unitRef="usd">4112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifc0119131cf0458084a6a1dbfcc10ee5_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA4LTQtMS0xLTExNTYyNw_88c60ced-5ea7-46fe-899a-24c2dcb5d386"
      unitRef="usd">3950000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3f2133a562294f9fad3ef124cc3f62af_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTA4LTYtMS0xLTExNTYyNw_d79451b3-29e9-486d-9500-2b0d30e85ac0"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60f30737549148d78386d683bd7971cf_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEwLTItMS0xLTExOTE2NQ_fbbe5be5-4c1f-4e80-bfc8-5229627b5733"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22ec3b93d6a4485d9565624fd37520b1_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEwLTQtMS0xLTExOTE2NQ_fcef7db8-f4a2-4a39-b31a-7de2f96e4ef1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e2961eace9b41418fe529105d0a94b4_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTExLTItMS0xLTExOTE2NQ_486e0431-ae57-4246-86f1-d661711b26f8"
      unitRef="usd">2000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dec4567146a4b51add1694785443d3f_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTExLTQtMS0xLTExOTE2NQ_85aa554c-5b4a-40ca-bbb6-0f464c84a871"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c0955b8e0a143aca601efbe6babf21c_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEyLTItMS0xLTExOTE2NQ_e7d2fed5-be9d-4df5-ad76-7f71c4afd6d9"
      unitRef="usd">72000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib16a26859ccb46d6947b21484d429b1e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEyLTQtMS0xLTExOTE2NQ_1985657b-2f08-4855-8ea8-2b10c080f5ec"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee98c5cb0708407396e22087c411d285_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEwLTItMS0xLTExNTYyNw_0b62eb89-05c6-40b9-aa92-ea987c616311"
      unitRef="usd">1191000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifab9674d8a57440385daec43e3b872b5_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEwLTQtMS0xLTExNTYyNw_c7ca98b4-6c8a-4534-9605-fe1c414e1dce"
      unitRef="usd">953000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iee98c5cb0708407396e22087c411d285_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEwLTYtMS0xLTExNTYyNw_9a316c55-9ad7-42c8-9940-5293179c2088"
      unitRef="number">0.250</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd48985d52ea4f1693cc1042d3c8fdc3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTExLTItMS0xLTExNTYyNw_2e45902f-b5d6-4851-bcb7-3d281f001b01"
      unitRef="usd">1072000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45c6fb890aee4700b7cabd1224a7a9f7_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTExLTQtMS0xLTExNTYyNw_318ca982-0d6e-4bae-87e1-33a0dad086e5"
      unitRef="usd">903000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icd48985d52ea4f1693cc1042d3c8fdc3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTExLTYtMS0xLTExNTYyNw_39f9d7d1-1467-4c5c-b9a2-8e2f7b18d957"
      unitRef="number">0.188</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d3a9c49693c4528b8b24e19524f85c9_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEyLTItMS0xLTExNTYyNw_31ade336-5f9b-4ae8-a26a-ca087a482b42"
      unitRef="usd">2264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i160565feac454261b5cf8029f03df1d1_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEyLTQtMS0xLTExNTYyNw_50c999a4-e81a-4727-bd1a-979a2a6dd18c"
      unitRef="usd">1856000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9d3a9c49693c4528b8b24e19524f85c9_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTEyLTYtMS0xLTExNTYyNw_52ea4806-5401-4b1e-9fea-86930cea9158"
      unitRef="number">0.220</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4815237e89d4db1b540f9d011fad6bd_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE0LTItMS0xLTExNTYyNw_43f7d9fa-e99c-4435-9f65-994ac2c123f5"
      unitRef="usd">249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic942fa98d0f54d4abd3aa101ed8cfd4e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE0LTQtMS0xLTExNTYyNw_3287b670-dfe5-4316-a166-9aabf761d429"
      unitRef="usd">206000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic4815237e89d4db1b540f9d011fad6bd_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE0LTYtMS0xLTExNTYyNw_32a7b897-3331-416c-9bb9-08699ebb51ec"
      unitRef="number">0.212</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i51623904c8e7456683c43cae3c239cbd_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE1LTItMS0xLTExNTYyNw_fe878576-f7f7-41f5-a713-addf6110ddc0"
      unitRef="usd">293000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d32e645ff894945ad0436a18173134f_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE1LTQtMS0xLTExNTYyNw_5fc38c44-0a9b-4c63-ae5d-a1274978be7d"
      unitRef="usd">194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i51623904c8e7456683c43cae3c239cbd_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE1LTYtMS0xLTExNTYyNw_4b33a3b3-888c-439d-871e-b491fd16f425"
      unitRef="number">0.509</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5f9f5c36c324901a0f9ef4ee74902fb_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE2LTItMS0xLTExNTYyNw_9e316544-625b-45bf-907e-07e044b7211e"
      unitRef="usd">542000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ebd3fdfaab847999b1abbed0df2881e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE2LTQtMS0xLTExNTYyNw_def5b685-8008-42e0-8e0a-a4cf1210dce2"
      unitRef="usd">400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id5f9f5c36c324901a0f9ef4ee74902fb_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE2LTYtMS0xLTExNTYyNw_277be7d9-04e9-4307-ab55-f7536eb14585"
      unitRef="number">0.356</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c5ac73df6614e86b2c68e2bb0b7b04c_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE4LTItMS0xLTExNTYyNw_512e5248-fdb8-4c70-a249-091e0bb96805"
      unitRef="usd">270000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i076a0601ecf14a4288789888d685888e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE4LTQtMS0xLTExNTYyNw_fa2ce444-fc40-4d3d-b0f0-b5aaed600f42"
      unitRef="usd">370000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8c5ac73df6614e86b2c68e2bb0b7b04c_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE4LTYtMS0xLTExNTYyNw_aa8b751e-01ea-48a5-8258-1b46fd64f0c5"
      unitRef="number">-0.271</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c8f0d46d42a41e097f8a42fea7efc04_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE5LTItMS0xLTExNTYyNw_0281393a-7425-4783-b1b0-ff6e75758894"
      unitRef="usd">557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6beee782dab74a55ae5b50d1a126075a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE5LTQtMS0xLTExNTYyNw_88fa61a6-b015-4f5e-aaef-3eb9f4986dd6"
      unitRef="usd">668000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1c8f0d46d42a41e097f8a42fea7efc04_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTE5LTYtMS0xLTExNTYyNw_63682fe1-0131-4218-942b-d3e25290542c"
      unitRef="number">-0.166</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i652dff8c442f438c8266669ccab6b186_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIwLTItMS0xLTExNTYyNw_7904dee8-143e-42b8-9838-ca58cc7e1306"
      unitRef="usd">827000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a7d9521630e4ed4a0f926999bb837f2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIwLTQtMS0xLTExNTYyNw_117e4b0d-81aa-4529-9150-9b6a2499ea99"
      unitRef="usd">1038000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i652dff8c442f438c8266669ccab6b186_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIwLTYtMS0xLTExNTYyNw_51780a58-de23-44ee-9073-198493d2b490"
      unitRef="number">-0.203</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bd82b4bf5fb40b3a12d708741b67d0f_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIyLTItMS0xLTExNTYyNw_4780763b-780b-4a05-a3d2-d5854fcf2b10"
      unitRef="usd">16000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35bd295b8c6c45a49ecf26261ae4958d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIyLTQtMS0xLTExNTYyNw_ab0fba7f-e5e5-4774-bcbc-9654f8e86b1d"
      unitRef="usd">19000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6bd82b4bf5fb40b3a12d708741b67d0f_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIyLTYtMS0xLTExNTYyNw_8dd5705c-28eb-44f9-b90c-4f710ea5701a"
      unitRef="number">-0.140</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c53ac8f0c6c4ea2aaaf494a42d823c8_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIzLTItMS0xLTExNTYyNw_1401e872-3638-4214-bb49-25b59239201f"
      unitRef="usd">229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88768a59c84946cc86069b6c72c10e17_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIzLTQtMS0xLTExNTYyNw_f9d79583-7465-4ee2-9abe-78a461341c83"
      unitRef="usd">520000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7c53ac8f0c6c4ea2aaaf494a42d823c8_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTIzLTYtMS0xLTExNTYyNw_c53a4f3a-536b-44be-b2f8-7581146957e3"
      unitRef="number">-0.560</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie04f0afe64d04e5f81ea459941636bb7_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI0LTItMS0xLTExNTYyNw_a76dec07-7efe-4617-a490-c8ddc3686420"
      unitRef="usd">245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4da66669adf2490a954dfa605b57620e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI0LTQtMS0xLTExNTYyNw_6421a0f4-599f-46ca-be9a-8a19453c4ae5"
      unitRef="usd">539000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie04f0afe64d04e5f81ea459941636bb7_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI0LTYtMS0xLTExNTYyNw_a99cf32d-4b87-4747-98a2-596eea26bca7"
      unitRef="number">-0.545</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i995cfb4d674e4f669792e3fcce3e446a_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI3LTItMS0xLTExNTYyNw_9e47ca91-9a8d-477b-a5f3-6d4506ad9877"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0c00ddbe0f14783b81b783b0481b7d0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI3LTQtMS0xLTExNTYyNw_f0ff8d16-0460-41da-86c0-372ef97f99a0"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic70082fa2bd84d2abfaa197163d58036_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI4LTItMS0xLTExNTYyNw_ef63eb23-95c8-40d5-b502-fc2df3fb9827"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic93c8ff581fb4066a25be356733d40b9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI4LTQtMS0xLTExNTYyNw_319262a1-1793-4da2-9788-860bfcb8599b"
      unitRef="usd">84000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic70082fa2bd84d2abfaa197163d58036_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI4LTYtMS0xLTExNTYyNw_40168817-df01-454d-8293-fc1cae619683"
      unitRef="number">-0.172</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ab9aaf299b94d139444f75057ae76ce_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI5LTItMS0xLTExNTYyNw_b68ffffc-7acb-48c6-9fec-dff8a6dd220f"
      unitRef="usd">162000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i345f37b977dd4873a272254f2cd7b0b7_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI5LTQtMS0xLTExNTYyNw_b158966d-0173-4568-908a-4daa6e22301f"
      unitRef="usd">118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2ab9aaf299b94d139444f75057ae76ce_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTI5LTYtMS0xLTExNTYyNw_030037c4-097e-4d29-9887-833fcd3797a8"
      unitRef="number">0.374</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i150f063107274f55809b1b424526240f_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMyLTItMS0xLTExNTYyNw_b1c124a5-f99f-4a5f-9983-b43833e10f59"
      unitRef="usd">600000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7326763483de473c80ee9447ae7d5874_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMyLTQtMS0xLTExNTYyNw_950595b3-cfab-472b-874f-562b274db19b"
      unitRef="usd">572000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i150f063107274f55809b1b424526240f_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMyLTYtMS0xLTExNTYyNw_904e6be1-aca5-43a6-9e0a-ee2dcc9c54a8"
      unitRef="number">0.049</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id31a5ffdbdb34a8da796905e5c398b22_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMzLTItMS0xLTExNTYyNw_84e612e4-ef24-44a3-a5bf-143f0a1e6621"
      unitRef="usd">272000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i505ae89dce3d4c318427fd4433c5ac85_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMzLTQtMS0xLTExNTYyNw_c30f3bb1-000c-439b-a253-6242d8ae0b56"
      unitRef="usd">279000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id31a5ffdbdb34a8da796905e5c398b22_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTMzLTYtMS0xLTExNTYyNw_62323308-1765-427a-a354-30f270630213"
      unitRef="number">-0.027</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i136fdab820ca4a628cd28ba7b37ed9d6_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM0LTItMS0xLTExNTYyNw_f2c0d869-6455-46be-b33c-485b90acf206"
      unitRef="usd">872000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1212b07b91c147ce8e0d1b45004d468c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM0LTQtMS0xLTExNTYyNw_7dca5700-ac95-4c68-8f54-c3e1f8e4bac7"
      unitRef="usd">852000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i136fdab820ca4a628cd28ba7b37ed9d6_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM0LTYtMS0xLTExNTYyNw_100a6394-33c4-4573-8972-b21827ef8434"
      unitRef="number">0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05688666a73b489f9d6fb95983420710_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM2LTItMS0xLTExNTYyNw_7bd54800-dd87-41a9-bf01-11e162eab35d"
      unitRef="usd">273000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37d4e70638d24648963bbcebc8758c59_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM2LTQtMS0xLTExNTYyNw_22b6bae2-c11e-4342-9d03-8d92a016e9e7"
      unitRef="usd">273000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i05688666a73b489f9d6fb95983420710_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM2LTYtMS0xLTExNTYyNw_ce0fd109-ba43-48aa-a4e2-8d5efd935703"
      unitRef="number">-0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16171e8c53424225a58ffa109cbddc6f_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM3LTItMS0xLTExNTYyNw_dad89f79-453f-4059-b118-bd291ab21fa3"
      unitRef="usd">167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad42b84534d649ba85fbccdcd13e9e92_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM3LTQtMS0xLTExNTYyNw_597eadf7-f973-4356-918a-45b049b811c6"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i16171e8c53424225a58ffa109cbddc6f_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM3LTYtMS0xLTExNTYyNw_83d07d74-d596-4440-ba58-b5b533b1b2aa"
      unitRef="number">-0.016</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc6a67ff3e2c46c8b750cddad69dc4d3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM4LTItMS0xLTExNTYyNw_8af18af2-fc87-4874-aa0a-c8d943b21263"
      unitRef="usd">440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b3581abfcda4f839a0c590c86c694a7_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM4LTQtMS0xLTExNTYyNw_6822e654-90a5-4651-a78c-907c28de9049"
      unitRef="usd">443000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibc6a67ff3e2c46c8b750cddad69dc4d3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTM4LTYtMS0xLTExNTYyNw_89ab3f46-5589-40b4-9632-3bfe3172b414"
      unitRef="number">-0.007</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67d976ab3276405b924504695f2c3e16_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQwLTItMS0xLTExNTYyNw_25a9ff45-12e8-4f4b-ada9-a2e58200b592"
      unitRef="usd">304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fedce0cd42349b4ac489cf459d784b6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQwLTQtMS0xLTExNTYyNw_d7a5c56d-9535-41e9-90d9-c2fb8db1e59e"
      unitRef="usd">269000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i67d976ab3276405b924504695f2c3e16_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQwLTYtMS0xLTExNTYyNw_7c947b69-3d54-4abe-b48c-b4ac488e16b0"
      unitRef="number">0.131</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifdb91f2c98f843f3bf1a457a9e524b19_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQxLTItMS0xLTExNTYyNw_b175da58-ccf4-4c33-887d-a19a8a00233a"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6130edb225934eb28e1c70739f5d063d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQxLTQtMS0xLTExNTYyNw_f431f2f5-87d3-4962-b789-166ccad0ba80"
      unitRef="usd">56000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifdb91f2c98f843f3bf1a457a9e524b19_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQxLTYtMS0xLTExNTYyNw_271d5941-c1aa-4e55-a3f6-461462dfbf61"
      unitRef="number">0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic918fc23c9474840bab3b6e74a8b4c59_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQyLTItMS0xLTExNTYyNw_8517dbf3-e627-4871-bff6-a6f8acc42d90"
      unitRef="usd">362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5df37fa4b554bda930ce40e6cfe2580_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQyLTQtMS0xLTExNTYyNw_9ec75eea-9c66-4768-b3cb-86429e75cf3f"
      unitRef="usd">325000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic918fc23c9474840bab3b6e74a8b4c59_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQyLTYtMS0xLTExNTYyNw_e7501122-d610-45ce-bcea-2ccab9e39d17"
      unitRef="number">0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4c88a8d200f40b4bacde02a32dd9329_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ0LTItMS0xLTExNTYyNw_6acdab1a-edef-4519-9c87-ff2a660965c6"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifa1ad776d62d468da5fc409a793fe0d2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ0LTQtMS0xLTExNTYyNw_607f34aa-aa5a-47c8-8d55-6525b64e734e"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib4c88a8d200f40b4bacde02a32dd9329_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ0LTYtMS0xLTExNTYyNw_60063f99-6bff-4aa6-8ec8-a5eeb2d858b3"
      unitRef="number">-0.224</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43b4a5127e1b4328bc2a43a45710bde8_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ1LTItMS0xLTExNTYyNw_aa40bda5-504f-435b-be63-5da99f969e02"
      unitRef="usd">47000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id490f83accb14c9fa6698c9ccc80525a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ1LTQtMS0xLTExNTYyNw_3a43b4b0-1279-4705-a384-83161192bf50"
      unitRef="usd">53000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i43b4a5127e1b4328bc2a43a45710bde8_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ1LTYtMS0xLTExNTYyNw_34820b80-dbfe-49d4-bf78-0d10e8e3aee1"
      unitRef="number">-0.126</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb0bb69e2c4c4516a56e8f1e3dc2d643_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ2LTItMS0xLTExNTYyNw_e031aed3-bc5f-4347-aec8-8ab6837450ad"
      unitRef="usd">70000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6afd1882f62f4386a785d02f1a23bdb9_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ2LTQtMS0xLTExNTYyNw_5128c356-4db0-43a6-a3c0-b9f13756e4cb"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idb0bb69e2c4c4516a56e8f1e3dc2d643_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ2LTYtMS0xLTExNTYyNw_982129a2-f509-47ed-86c3-dd9827e9b8fe"
      unitRef="number">-0.161</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c3060e9d95943b589436fb77dc77a35_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ5LTItMS0xLTExNTYyNw_7f929d97-3229-4666-8ee7-4b25a41ce149"
      unitRef="usd">715000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37be37c17b20438193f60193db94a428_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ5LTQtMS0xLTExNTYyNw_f5cf858c-1dfd-4103-a1ba-ddc0475dddc4"
      unitRef="usd">672000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3c3060e9d95943b589436fb77dc77a35_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTQ5LTYtMS0xLTExNTYyNw_cfa9db4d-a569-4c9a-aeea-280c12911268"
      unitRef="number">0.063</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21df6a06501347ef989f179b4cf7dd2a_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUwLTItMS0xLTExNTYyNw_a96585cf-f7c9-4fb1-b716-56ad2b928b15"
      unitRef="usd">212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i291cca6f20e64e3c8cebcfda2c8ccccb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUwLTQtMS0xLTExNTYyNw_64f444b8-a943-4222-a202-3f5703566fe0"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i21df6a06501347ef989f179b4cf7dd2a_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUwLTYtMS0xLTExNTYyNw_11d2cddc-4f9c-4f86-8a84-109d8ebe3f49"
      unitRef="number">-0.108</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0152d0f99144507acb484aac822034c_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUxLTItMS0xLTExNTYyNw_5ff49416-08e0-44b0-987f-0c41452c233d"
      unitRef="usd">927000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i04c171c0b08d4ba39f9cc175df531847_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUxLTQtMS0xLTExNTYyNw_6a6526c4-42f8-43c2-aa02-52b3c508f463"
      unitRef="usd">910000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia0152d0f99144507acb484aac822034c_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUxLTYtMS0xLTExNTYyNw_218383a0-bd7f-492e-b11e-1dce22da08c2"
      unitRef="number">0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i236ad63ca35a41cd8f969b4e2938f2fc_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUzLTItMS0xLTExNTYyNw_75453ae3-9be3-4fca-8a4e-edadde19f06c"
      unitRef="usd">578000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafc33bbf42804adb85ccdf725d2e83cc_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUzLTQtMS0xLTExNTYyNw_d63ce699-a3ef-454d-ac34-81fe1e4f86b1"
      unitRef="usd">508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i236ad63ca35a41cd8f969b4e2938f2fc_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTUzLTYtMS0xLTExNTYyNw_b4369b82-9127-4fd9-b796-bd5c24338b4e"
      unitRef="number">0.137</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01a03416efc042fba5eb7b5f63640595_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTU0LTItMS0xLTExNTYyNw_11c62279-5a3e-4dbd-9812-5953108e4888"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id46b580cb2ea4c188253514d7ee59c8e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTU0LTQtMS0xLTExNTYyNw_eea5cb44-3968-4591-8f0d-127a2a3c38bc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i01a03416efc042fba5eb7b5f63640595_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTU0LTYtMS0xLTExNTYyNw_d2f13e8e-59bd-4776-a629-b5e226f54469"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e7f61f9e4f74352b9c8f412986189e3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTU1LTItMS0xLTExNTYyNw_f99e79ec-cecb-4b85-85f8-8a66c99c1f24"
      unitRef="usd">578000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5efb947632c47e19d68b8280af2e44d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTU1LTQtMS0xLTExNTYyNw_2af2944d-ed09-4607-bf10-26ce0f450937"
      unitRef="usd">508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9e7f61f9e4f74352b9c8f412986189e3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTU1LTYtMS0xLTExNTYyNw_24038189-e961-4173-9536-1ced833fc0d9"
      unitRef="number">0.137</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85bb32425f664497b088763671d4d454_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY1LTItMS0xLTExNTYyNw_11159f29-84f9-45b0-b574-c4de343dac05"
      unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i098d2b32fc074e018e965ef42cd425b3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY1LTQtMS0xLTExNTYyNw_864cfc10-7e2f-4567-94b8-e7311a3af460"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i85bb32425f664497b088763671d4d454_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY1LTYtMS0xLTExNTYyNw_b07bc0d5-df5d-4ac0-b38a-798b0dc4607f"
      unitRef="number">-0.167</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic47106d021b544a9b064a88a11f29db6_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY2LTItMS0xLTExNTYyNw_0f3fa259-42d7-4fdd-b612-a189e66072cb"
      unitRef="usd">212000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6a6f8cd2d6443ff9d286090d2f06423_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY2LTQtMS0xLTExNTYyNw_7e703f41-552f-45be-b934-c45dd750748b"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic47106d021b544a9b064a88a11f29db6_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY2LTYtMS0xLTExNTYyNw_56db2a2e-614b-46c7-8785-a351b7d07c23"
      unitRef="number">-0.108</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b0c223e01d14534a29b703d9ffca9a1_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY3LTItMS0xLTExNTYyNw_08a52123-a53e-4d0b-a8bb-ea862b06551a"
      unitRef="usd">349000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i569502cf2f0f4e4a8dfc490844775e54_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY3LTQtMS0xLTExNTYyNw_5cd50cd4-f4e8-46ed-9a0d-8d0ee318f3fa"
      unitRef="usd">402000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3b0c223e01d14534a29b703d9ffca9a1_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTY3LTYtMS0xLTExNTYyNw_b74bda9b-e4e4-43cf-b275-8487fa46d0c9"
      unitRef="number">-0.132</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if748627f3368423685d8be9fda1d9fe3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcwLTItMS0xLTExNTYyNw_6ea480c8-3128-4dc0-956b-1f919c97cac5"
      unitRef="usd">7023000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2ac40786f71940aebc5e207db586eb04_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcwLTQtMS0xLTExNTYyNw_d4c8538b-2f23-4baa-a9db-18e111f3b736"
      unitRef="usd">6632000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if748627f3368423685d8be9fda1d9fe3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcwLTYtMS0xLTExNTYyNw_f7d2f5af-dd62-4100-ade0-8f0ce2f3e053"
      unitRef="number">0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac741c82fc14439fbb4cda5efa014094_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcxLTItMS0xLTExNTYyNw_820c9ccc-dc29-4f61-b469-3357f67fcae0"
      unitRef="usd">6390000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6e46509ea6b444880c2eada1a0364ee_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcxLTQtMS0xLTExNTYyNw_ba593416-c9a4-4271-8c51-ac4f6a78dadd"
      unitRef="usd">6237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iac741c82fc14439fbb4cda5efa014094_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcxLTYtMS0xLTExNTYyNw_2079ab25-535c-4a3a-9917-e690484f5275"
      unitRef="number">0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6f3967ed8804b3484a788194a6b55e2_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcyLTItMS0xLTExNTYyNw_1d222040-04ba-4d62-a78e-75c48931c44e"
      unitRef="usd">13413000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12677390b1eb4de7a97ffc8bc444bbde_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcyLTQtMS0xLTExNTYyNw_daa23687-c50a-4077-8116-b378581f85dd"
      unitRef="usd">12869000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id6f3967ed8804b3484a788194a6b55e2_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTcyLTYtMS0xLTExNTYyNw_4d037c10-2e04-4deb-91be-c8dc2505d2f2"
      unitRef="number">0.042</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4b42c17ade64ae7ac0f6eb0f8faeda6_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg1LTItMS0xLTExNTYyNw_00dcfc5e-8585-4dbf-9cfb-7e9683c69f08"
      unitRef="usd">863000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie49526704b3f443cb8d37f9e340cec4a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg1LTQtMS0xLTExNTYyNw_895fc843-0c81-4361-bac1-50453b25b168"
      unitRef="usd">494000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia4b42c17ade64ae7ac0f6eb0f8faeda6_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg1LTYtMS0xLTExNTYyNw_d9af4b0e-5ae0-40bb-9a48-0459db2aff2a"
      unitRef="number">0.745</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e9f540147284f2b909c9bdcc3fa5530_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg2LTItMS0xLTExNTYyNw_25f4e520-076b-4ae2-921c-7e52de8e8b70"
      unitRef="usd">640000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2e93949a9b44381a7f3701eee7f9ac8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg2LTQtMS0xLTExNTYyNw_81c50a4e-b8e1-4f0c-a572-5de5864917cf"
      unitRef="usd">597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9e9f540147284f2b909c9bdcc3fa5530_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg2LTYtMS0xLTExNTYyNw_c532ad5a-88a3-451f-88c6-5b6fa3e31985"
      unitRef="number">0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91c597ec59014a40ae4281f9275dd4c1_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg3LTItMS0xLTExNTYyNw_cde8b17e-6480-4d45-940d-c848ae08744a"
      unitRef="usd">1503000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6f4fa75b8a74a9dac7059e98c19f5b6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg3LTQtMS0xLTExNTYyNw_cde4c412-4f1d-4675-a1c7-8d635728da29"
      unitRef="usd">1092000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i91c597ec59014a40ae4281f9275dd4c1_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg3LTYtMS0xLTExNTYyNw_f0b15863-2f29-4b27-b65d-0dddf381fdd3"
      unitRef="number">0.376</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i588fd7f2edcb4507904e6ad2502e9f06_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkxLTItMS0xLTExOTgzMA_ce76a71f-0d4e-4e29-8565-adf8d28d089f"
      unitRef="usd">571000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd3f73f1f8144c4eba42b6ed8a810de7_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkxLTQtMS0xLTExOTg1Mw_d3254605-f121-4db8-ad95-b568c2bb57df"
      unitRef="usd">470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i588fd7f2edcb4507904e6ad2502e9f06_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkxLTYtMS0xLTExOTg0NQ_348eb754-a2aa-4b1c-88e3-fbd8b8728a36"
      unitRef="number">0.214</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ca28df51b6440c696c0314691bbe427_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkyLTItMS0xLTExOTgzMA_c8f38241-a44e-4a8e-97f4-c791a34d1d02"
      unitRef="usd">522000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2fa133450684e3dabae5a9de5d13ce8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkyLTQtMS0xLTExOTg1Mw_ced92fbf-b95b-4f1a-b5b8-597588828931"
      unitRef="usd">532000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1ca28df51b6440c696c0314691bbe427_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkyLTYtMS0xLTExOTg0NQ_6fa63766-40dc-45b7-9ec1-c75b4bfef7af"
      unitRef="number">-0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i238eddc286cc4e6ea38e56b95db65cf5_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkzLTItMS0xLTExOTgzMA_842f5462-1438-4a11-b1fb-616fcf1bf7cc"
      unitRef="usd">1092000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7044bf88210248c884a8bef89b77d4eb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkzLTQtMS0xLTExOTg1Mw_450cbf4f-715a-496b-bc8f-81580ea68abb"
      unitRef="usd">1002000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i238eddc286cc4e6ea38e56b95db65cf5_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkzLTYtMS0xLTExOTg0NQ_d5747c7b-549a-4f3c-9ddc-9a6392f0e504"
      unitRef="number">0.091</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90c97bfc6a2b44d78898de9f3bff5d87_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk1LTItMS0xLTExOTgzMA_3e1eeaa4-7632-4bc6-91c0-de142ee47e04"
      unitRef="usd">264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94dff6bcd4564c4eaddba70ccb2a8de2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk1LTQtMS0xLTExOTg1Mw_54593da3-a9b8-492f-a283-9f5ef78a88e4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4bfeff988ad0455782b5383e4bde3dac_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk2LTItMS0xLTExOTgzMA_279855c1-c217-4298-abfa-8d826506dad2"
      unitRef="usd">60000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccfe7ce7ecc24b40a8d287f61d0e19a3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk2LTQtMS0xLTExOTg1Mw_ab66eacf-63b7-4f89-9003-3bec69a172cc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e5e294252c54f9da688d735b42fe26f_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk3LTItMS0xLTExOTgzMA_8c390c29-97a1-4652-b592-8f1db2a560f7"
      unitRef="usd">324000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if98abe23095c49038b3e34d99b190cbb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk3LTQtMS0xLTExOTg1Mw_6b94556a-3d48-46dd-b34b-48d0a28abb29"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9d23239da0148da8bb85076fc21c555_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk5LTItMS0xLTExOTgzMA_f6a339ce-b7c2-4f6e-9ddc-f9568e144af1"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifca62b1259c54fcba069f4a9034206b1_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk5LTQtMS0xLTExOTg1Mw_8aae6d80-f623-4057-abc9-90acf6d0becd"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id9d23239da0148da8bb85076fc21c555_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk5LTYtMS0xLTExOTg0NQ_4cac1388-32ea-41bd-95c4-00b374f0940c"
      unitRef="number">0.174</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87ea8359aa454362b30d54da0aab13a6_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAwLTItMS0xLTExOTgzMA_20930f00-7675-4a9f-8c00-fb73aa64eb8b"
      unitRef="usd">58000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e7e328557ce4073882ac9143166a882_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAwLTQtMS0xLTExOTg1Mw_3966fee0-dec6-419b-948e-7304051acf04"
      unitRef="usd">65000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i87ea8359aa454362b30d54da0aab13a6_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAwLTYtMS0xLTExOTg0NQ_49c9df62-606e-4e2e-8f3b-1e299c05c9f1"
      unitRef="number">-0.117</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42e4f8a3fab14e74a2530932f1029f2d_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAxLTItMS0xLTExOTgzMA_20587dc5-ad6a-4f9e-bdb0-4df513a13793"
      unitRef="usd">87000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42eb9f30337047a0b6994260a328fbdb_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAxLTQtMS0xLTExOTg1Mw_c198d376-cc89-4d9d-ac78-365362a4857c"
      unitRef="usd">90000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i42e4f8a3fab14e74a2530932f1029f2d_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAxLTYtMS0xLTExOTg0NQ_709dfb82-1d1a-48ec-9724-ef8e668c8222"
      unitRef="number">-0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i020c283a9b454f4c91205f8a5aecc950_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg5LTItMS0xLTExNTYyNw_f710653f-d415-48ad-9d60-c45bb455ea59"
      unitRef="usd">1363000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id12435a3d01c4f3c9b3518fa0cc67836_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg5LTQtMS0xLTExNTYyNw_b9719c6c-460a-4c0b-b558-13cb73582b16"
      unitRef="usd">1289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i020c283a9b454f4c91205f8a5aecc950_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTg5LTYtMS0xLTExNTYyNw_505b8c07-39cc-4bfd-a9ed-7e17dafb4a21"
      unitRef="number">0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29f9872cc99b44b5b1cccfb6c75db81a_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkwLTItMS0xLTExNTYyNw_32427562-9fb1-45ea-9785-4e4cb776366b"
      unitRef="usd">881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e718713cf094373a8d40c5920af2f60_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkwLTQtMS0xLTExNTYyNw_5517e22a-5441-4e7e-b629-53d0f708a986"
      unitRef="usd">899000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i29f9872cc99b44b5b1cccfb6c75db81a_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkwLTYtMS0xLTExNTYyNw_e4f112e3-e679-4644-9718-07d76a144a08"
      unitRef="number">-0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib807084fc7c8485b9668410e22e4f2bf_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkxLTItMS0xLTExNTYyNw_42d2dab3-dd31-4ebb-8051-39967ad0c84d"
      unitRef="usd">2245000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8e6ddf9e58e4f528caa4e6cce761163_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkxLTQtMS0xLTExNTYyNw_8c278600-2e3f-4104-aa72-d263183f72f4"
      unitRef="usd">2188000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib807084fc7c8485b9668410e22e4f2bf_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkxLTYtMS0xLTExNTYyNw_3b38d32b-c1f9-4304-96d0-e535d027dcf5"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6901dd295b24125b4138f0b272f8777_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkzLTItMS0xLTExNTYyNw_6c33c445-501c-475b-ab49-ca45966aff5d"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i18df14d793b446acaebb489d09b54690_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkzLTQtMS0xLTExNTYyNw_0614dc90-14e6-4c13-9525-c5dcaf7716ef"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic6901dd295b24125b4138f0b272f8777_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTkzLTYtMS0xLTExNTYyNw_ee769b57-6810-48a7-8573-90d952a77500"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ccac7306a934e89a59dcc66dc558644_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk0LTItMS0xLTExNTYyNw_04f7d908-2690-44fb-945c-b6f3887cc9ea"
      unitRef="usd">149000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f491788cb63462fb654dbad9c0775b6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk0LTQtMS0xLTExNTYyNw_406a7236-e4a0-4df1-b690-9554a4c1de10"
      unitRef="usd">164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0ccac7306a934e89a59dcc66dc558644_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk0LTYtMS0xLTExNTYyNw_bf31b2be-4ac0-4ded-a357-9f21981a028d"
      unitRef="number">-0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06411c6af6a74c35ac5cfad22270bc75_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk1LTItMS0xLTExNTYyNw_ec4586e9-d60f-431b-8455-9be022fcd529"
      unitRef="usd">390000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16a5c0148e3e41e483ac0ea77b562ac2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk1LTQtMS0xLTExNTYyNw_d36e325a-8b19-41bb-bcb6-3fbeb23380f9"
      unitRef="usd">389000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i06411c6af6a74c35ac5cfad22270bc75_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk1LTYtMS0xLTExNTYyNw_7f252590-ab7c-46d9-85ff-c67f8c50a236"
      unitRef="number">0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ba51dfb57e344d5a0fea2a350310cc4_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk3LTItMS0xLTExNTYyNw_e35d9148-008b-4fc1-999b-65279a374f70"
      unitRef="usd">226000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6fa3f9ddb7146f995f2f94806cfc5ec_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk3LTQtMS0xLTExNTYyNw_a64f1a82-4d88-4216-800f-14e24ed901b0"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7ba51dfb57e344d5a0fea2a350310cc4_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk3LTYtMS0xLTExNTYyNw_bbe233ad-d8fc-424e-bce9-a57a71553c54"
      unitRef="number">0.124</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabc10b6383d0489e8b8bb5a496eaf21a_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk4LTItMS0xLTExNTYyNw_374bfab8-c2c7-41b0-8659-e628bc1f80a3"
      unitRef="usd">142000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57664aba083e478a9546149bfc85f5c2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk4LTQtMS0xLTExNTYyNw_a55ad567-595f-46aa-aaa1-3ac83e77f82c"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iabc10b6383d0489e8b8bb5a496eaf21a_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk4LTYtMS0xLTExNTYyNw_73322f46-cb27-4718-b4d1-871610b2034f"
      unitRef="number">0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if29cd966f54442938b637f209a34b811_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk5LTItMS0xLTExNTYyNw_b0504b79-7e3c-445e-a484-30366b905699"
      unitRef="usd">368000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5b174ade6ec43a9a47fa3978d28bd77_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk5LTQtMS0xLTExNTYyNw_cf94ab33-feea-4839-b8d4-30df785b93aa"
      unitRef="usd">339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if29cd966f54442938b637f209a34b811_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMTk5LTYtMS0xLTExNTYyNw_a888060c-3edb-43f1-b91a-6b9c1748c1c9"
      unitRef="number">0.087</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c27feb9bba3448a96cf3d833cc77e87_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAxLTItMS0xLTExNTYyNw_03ca418b-a776-4020-b359-3979349ef5c0"
      unitRef="usd">491000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec996af35e9d4904a9164c9042ba5927_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAxLTQtMS0xLTExNTYyNw_6158cb76-d4b1-4b72-90a6-c82196ce8df1"
      unitRef="usd">475000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9c27feb9bba3448a96cf3d833cc77e87_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAxLTYtMS0xLTExNTYyNw_9d2e1da6-b654-4e1c-ae63-8982f08420c4"
      unitRef="number">0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e256570168449b0bbdd5ac1802e0273_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAyLTItMS0xLTExNTYyNw_1bec8a21-65fe-408b-85c1-f4e4cfbf4cac"
      unitRef="usd">267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8496c9c84c6f40d2b659a19f28f6f5b6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAyLTQtMS0xLTExNTYyNw_6df39588-a092-4b99-aabd-0f1013829841"
      unitRef="usd">273000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4e256570168449b0bbdd5ac1802e0273_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAyLTYtMS0xLTExNTYyNw_7a937d1b-55bf-4226-ad9f-c9d68a062eeb"
      unitRef="number">-0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i060b7639c5944fe3aa7774d6f5d6087d_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAzLTItMS0xLTExNTYyNw_51e0d608-b0d0-4781-90b8-59c90bf01de5"
      unitRef="usd">757000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60b40c723a94457c91bbb0eb8f7292e6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAzLTQtMS0xLTExNTYyNw_a03edad9-e6ac-43e9-854d-b426d3238749"
      unitRef="usd">748000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i060b7639c5944fe3aa7774d6f5d6087d_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjAzLTYtMS0xLTExNTYyNw_0d4920b3-8435-4ff9-b64a-65b8b3b6c578"
      unitRef="number">0.012</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a4bd2851d954128945886c150131c9a_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA1LTItMS0xLTExNTYyNw_756f7897-fcd2-469d-b9f9-699ac87854ed"
      unitRef="usd">406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icf832e226abb4c3b93f4a76b0876c785_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA1LTQtMS0xLTExNTYyNw_4e82ea4e-1fbb-404b-a333-5b86f18edee3"
      unitRef="usd">387000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5a4bd2851d954128945886c150131c9a_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA1LTYtMS0xLTExNTYyNw_47e74e15-9436-42ec-ae07-eff577e50cb3"
      unitRef="number">0.047</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i341a9238ebd54b549ec9e2262b87e9dd_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA2LTItMS0xLTExNTYyNw_ab26d1f2-b786-46de-8be7-694889b73074"
      unitRef="usd">323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cf8369cc3964063aedd59972566936c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA2LTQtMS0xLTExNTYyNw_baabec8b-ed3b-41a6-8012-a894dd850b42"
      unitRef="usd">324000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i341a9238ebd54b549ec9e2262b87e9dd_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA2LTYtMS0xLTExNTYyNw_02f866ab-d141-4513-907a-16355743f83a"
      unitRef="number">-0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i697f77c1d355434a9a8b15ca4ddad302_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA3LTItMS0xLTExNTYyNw_a5284b02-5251-4037-ab23-82370f1b387b"
      unitRef="usd">729000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81e33ba2cabb410cb020c140d48b86f5_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA3LTQtMS0xLTExNTYyNw_099f89a3-4409-41e5-a8aa-64a7c9ef9f0a"
      unitRef="usd">712000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i697f77c1d355434a9a8b15ca4ddad302_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA3LTYtMS0xLTExNTYyNw_05779a7e-5461-4561-ac56-1e13fc7e7692"
      unitRef="number">0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9e5596ec20ad4b459dfd9d49c8be8280_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA5LTItMS0xLTExNTYyNw_aa7c1bdd-09f3-4f81-b844-a4a02d165e2c"
      unitRef="usd">975000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie645a8f76fd04bdd9b7b72c99f5627e3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA5LTQtMS0xLTExNTYyNw_a4c67fac-8d26-4290-8793-11fb033d0aba"
      unitRef="usd">921000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9e5596ec20ad4b459dfd9d49c8be8280_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjA5LTYtMS0xLTExNTYyNw_475dec6d-9ca6-4113-8490-5df04a3070b7"
      unitRef="number">0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8552e76d9d3b4733be32dc860982d8e4_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEwLTItMS0xLTExNTYyNw_cd4d7ea6-6b2b-4abc-822d-578076087552"
      unitRef="usd">1459000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic807b109c8d14499aa4a84252589e37c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEwLTQtMS0xLTExNTYyNw_807f1fb9-4e67-4779-a43d-826d6a08beba"
      unitRef="usd">1513000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8552e76d9d3b4733be32dc860982d8e4_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEwLTYtMS0xLTExNTYyNw_c65af9db-9889-400c-9151-c32258d3b0b3"
      unitRef="number">-0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0dee0d184434eecb3b25dcaf1f98eba_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjExLTItMS0xLTExNTYyNw_50da989e-fb54-4394-8be4-69ba0c166f19"
      unitRef="usd">2434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90a5e69efde44189a532234286ccde39_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjExLTQtMS0xLTExNTYyNw_2df2ec7d-3b2b-449c-bd4f-6392d8505782"
      unitRef="usd">2434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if0dee0d184434eecb3b25dcaf1f98eba_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjExLTYtMS0xLTExNTYyNw_0e56d612-9a57-481a-b98a-0ee717ea233a"
      unitRef="number">0.000</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e384d939a2447cea4dadc0e5a0c2ba0_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEzLTItMS0xLTExNTYyNw_8e820185-a69a-460d-b964-98089edf1242"
      unitRef="usd">444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaed173f3390944eeb61ad6efe66a23f6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEzLTQtMS0xLTExNTYyNw_9e6b7486-2fe9-4c72-b65a-e8c0316a6e70"
      unitRef="usd">417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7e384d939a2447cea4dadc0e5a0c2ba0_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjEzLTYtMS0xLTExNTYyNw_63727faf-4188-4be7-8691-b6aede370763"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i49de9bf99ea94180be433fa61b42ba88_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE0LTItMS0xLTExNTYyNw_68e33c71-5881-4f31-ae22-2db142d1761b"
      unitRef="usd">673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14f40102c79e405caf79b8aa335221bc_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE0LTQtMS0xLTExNTYyNw_92ad3040-cb76-499d-8580-5b78a51e084c"
      unitRef="usd">729000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i49de9bf99ea94180be433fa61b42ba88_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE0LTYtMS0xLTExNTYyNw_37795a96-1d14-4d43-9bc5-55fc018b2989"
      unitRef="number">-0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2d75beb452e47f4893b94abbefb8bba_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE1LTItMS0xLTExNTYyNw_94475c0c-d96d-4385-a3dd-924785020542"
      unitRef="usd">1118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic2400dc461764134b3d942c32d0168b5_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE1LTQtMS0xLTExNTYyNw_5e442c82-ab99-4be0-b9d3-50edbd4c0bc8"
      unitRef="usd">1146000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia2d75beb452e47f4893b94abbefb8bba_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE1LTYtMS0xLTExNTYyNw_29116c94-0c01-4d38-8c27-c542825126c8"
      unitRef="number">-0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8aa22293d2d40f6b58a4dec4c64b355_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE3LTItMS0xLTExNTYyNw_7e497558-6101-452d-91b5-4f30086a9a2d"
      unitRef="usd">531000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8ba49a1061e421f816cbb74a729895b_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE3LTQtMS0xLTExNTYyNw_d6876674-4e72-42c9-831b-afcf5001b226"
      unitRef="usd">504000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic8aa22293d2d40f6b58a4dec4c64b355_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE3LTYtMS0xLTExNTYyNw_5a88f99b-3456-4320-b9ea-26cd12ff4607"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic05893454bf84c37b75cefbd3d5459a8_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE4LTItMS0xLTExNTYyNw_14af436f-67c0-4d0e-9842-bb5462e87433"
      unitRef="usd">785000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ce2e1faf70848a0bfcd29eeafb93a9c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE4LTQtMS0xLTExNTYyNw_241f4098-84bb-4a6e-88b6-b37d8a30bbe9"
      unitRef="usd">784000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic05893454bf84c37b75cefbd3d5459a8_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE4LTYtMS0xLTExNTYyNw_c4015221-f618-4b0a-8a47-00dac4f5962c"
      unitRef="number">0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1677e46a9474356b3c9dfb976393db7_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE5LTItMS0xLTExNTYyNw_b7d1d6cc-c2ff-4e53-bf88-ac0ee785e76d"
      unitRef="usd">1316000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i517534deb5ca4eb3aaae15c62790e025_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE5LTQtMS0xLTExNTYyNw_9f4dbfc0-ce13-44ae-a55b-da9831924847"
      unitRef="usd">1288000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia1677e46a9474356b3c9dfb976393db7_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjE5LTYtMS0xLTExNTYyNw_e7924f0a-ba65-4e95-9e4b-198dd372ea7f"
      unitRef="number">0.022</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd11491a92ce4672bdb3774057431a46_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIxLTItMS0xLTExNTYyNw_966e83fd-8364-4854-850d-28c1b5b7d029"
      unitRef="usd">558000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i339f955c262f45dfb4f389ca7e08c4a0_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIxLTQtMS0xLTExNTYyNw_8040379d-fc8f-4d6a-bb8a-5f888a75c164"
      unitRef="usd">521000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibd11491a92ce4672bdb3774057431a46_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIxLTYtMS0xLTExNTYyNw_82acd4f3-b238-43b0-9375-f43389b2a014"
      unitRef="number">0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie597f3c11e0747f68e8d3493b85a2080_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIyLTItMS0xLTExNTYyNw_9e488ce0-cf63-4be4-bd70-220d9ddb84ab"
      unitRef="usd">743000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72679ec91b0f470ea17b2acaf9ad9344_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIyLTQtMS0xLTExNTYyNw_b258c685-2d56-4eb2-a839-723f9891a252"
      unitRef="usd">736000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie597f3c11e0747f68e8d3493b85a2080_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIyLTYtMS0xLTExNTYyNw_7a31a3da-0b51-4083-b37b-46464f96756f"
      unitRef="number">0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1bb18c06f4c40b296683224f79a53f4_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIzLTItMS0xLTExNTYyNw_a45e82ab-03d1-453a-a3ad-877432cd1719"
      unitRef="usd">1300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iade9c6803cc4447ca6535fa706f5fca2_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIzLTQtMS0xLTExNTYyNw_81abdb3c-42cb-4024-96df-784db94f51ba"
      unitRef="usd">1257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic1bb18c06f4c40b296683224f79a53f4_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjIzLTYtMS0xLTExNTYyNw_a612d382-bbac-4328-80ba-0df925886772"
      unitRef="number">0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98b473235c7a47cf859add062d06101a_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI1LTItMS0xLTExNTYyNw_38348911-03ec-432e-9c67-2b81ae89ad3a"
      unitRef="usd">444000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68cff8e717ca4f708d166109353460b5_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI1LTQtMS0xLTExNTYyNw_345bc71a-6f66-423f-9d13-8f0f30b2f7ba"
      unitRef="usd">400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i98b473235c7a47cf859add062d06101a_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI1LTYtMS0xLTExNTYyNw_f636dbec-a6fb-405c-9675-d4824ddb32ea"
      unitRef="number">0.111</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie56c32de3e2e41eba3b2b9cc344394db_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI2LTItMS0xLTExNTYyNw_153a7d6f-3309-409b-8c68-a40ec72d4721"
      unitRef="usd">509000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib0d829554c2047b198f4d4504c6c4bad_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI2LTQtMS0xLTExNTYyNw_8c548e8e-26b1-45da-8c5f-c681d03ac2be"
      unitRef="usd">511000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie56c32de3e2e41eba3b2b9cc344394db_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI2LTYtMS0xLTExNTYyNw_e78385a5-255e-4ff7-9c4a-02ad99667b19"
      unitRef="number">-0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fa18e49624849a3bf980a89602d76c9_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI3LTItMS0xLTExNTYyNw_a4ca155e-e976-4fab-928e-4089256ee9d3"
      unitRef="usd">953000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i744e82d777a14f4dbc24cf9ac953202f_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI3LTQtMS0xLTExNTYyNw_99d5ac2f-3d29-4db8-a0ef-c624ea133c2d"
      unitRef="usd">910000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3fa18e49624849a3bf980a89602d76c9_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjI3LTYtMS0xLTExNTYyNw_46923183-0aef-4c84-8739-1a70b3f50886"
      unitRef="number">0.047</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i848d69207c1f4c90b5cc68c1f1eb7bf0_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMwLTItMS0xLTExNTYyNw_23be75fa-1645-4df6-b799-e0c01c4d554f"
      unitRef="usd">114000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74605a46308f4807bcd58248b6e0db65_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMwLTQtMS0xLTExNTYyNw_535e8850-6f6d-4047-a09a-2ece1bc5ef26"
      unitRef="usd">121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i848d69207c1f4c90b5cc68c1f1eb7bf0_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMwLTYtMS0xLTExNTYyNw_9c0656ce-b509-4869-9e9c-daf00aa8f2c3"
      unitRef="number">-0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i115ea6c058084298bd8bfd6a9c9d7b23_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMxLTItMS0xLTExNTYyNw_303b21ab-e2c9-4c40-ba35-a8155963c71a"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a59d2f00ca14a8fa8f0a3d5f5602967_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMxLTQtMS0xLTExNTYyNw_7215f7d5-29b1-4e1a-b7a6-e740649b83a4"
      unitRef="usd">226000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i115ea6c058084298bd8bfd6a9c9d7b23_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMxLTYtMS0xLTExNTYyNw_7005e4a2-4bba-451f-af32-d3aa7e2c4c96"
      unitRef="number">0.033</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb91eb7b4af04d58ad7789571043edbf_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMyLTItMS0xLTExNTYyNw_06606158-aeea-44d6-88db-57e0ed1c1bc7"
      unitRef="usd">347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9a2a973165fa46a79af877784002fe9a_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMyLTQtMS0xLTExNTYyNw_53c5820a-6040-44e3-b66e-c3eb1b131eea"
      unitRef="usd">347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifb91eb7b4af04d58ad7789571043edbf_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjMyLTYtMS0xLTExNTYyNw_b3e4b7ff-571b-44c0-bb00-e65c2c11d637"
      unitRef="number">0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i787acd4164eb45deb0403c444006faf9_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM1LTItMS0xLTExNTYyNw_18e6258c-5634-42f4-ae5f-274803e51cc5"
      unitRef="usd">3759000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibaf4ce4d283a4b7280171759a01baa0e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM1LTQtMS0xLTExNTYyNw_b1593d5e-c17d-4bd9-99aa-2aa16826d030"
      unitRef="usd">3225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i787acd4164eb45deb0403c444006faf9_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM1LTYtMS0xLTExNTYyNw_cfb1a448-0ab4-4cd3-a732-ba6397315811"
      unitRef="number">0.166</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c64cc3fc6694b9495fdc5efad8fb4d4_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM2LTItMS0xLTExNTYyNw_2f8bf84f-659d-4a75-aec8-35258349712b"
      unitRef="usd">3722000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib78785c8a47a4c63b2c807c981cf27ba_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM2LTQtMS0xLTExNTYyNw_c9282a52-045a-4b9b-9363-614272135b83"
      unitRef="usd">3746000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0c64cc3fc6694b9495fdc5efad8fb4d4_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM2LTYtMS0xLTExNTYyNw_a31ffe83-be22-4381-a2cd-669c32121abb"
      unitRef="number">-0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia44d907a039b4ea4b07c28589766bd8a_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM3LTItMS0xLTExNTYyNw_fd683a53-8cbb-45a7-b091-fb5641e1dcbd"
      unitRef="usd">7481000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0b0bf9e3b4b4097ab7bdcaefa80578e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM3LTQtMS0xLTExNTYyNw_3e758fd5-3d1e-49b5-9279-0c13bb0d2330"
      unitRef="usd">6971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia44d907a039b4ea4b07c28589766bd8a_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjM3LTYtMS0xLTExNTYyNw_28880f45-bacd-4530-bd9a-9946b3db1a36"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib18fd463fe944955b813ba83e60464c6_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQwLTItMS0xLTExNTYyNw_58dce6eb-6e23-422d-8602-6f28f538f6b3"
      unitRef="usd">12517000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a29daeaf368468580d88ec00d701e07_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQwLTQtMS0xLTExNTYyNw_cea46835-dc3a-4788-9b00-3a58209feb2b"
      unitRef="usd">11414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib18fd463fe944955b813ba83e60464c6_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQwLTYtMS0xLTExNTYyNw_a953a6f5-7ade-48b8-be5c-51879dae9679"
      unitRef="number">0.097</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf1fef094458495f8b29e9d3d2c96404_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQxLTItMS0xLTExNTYyNw_9387da4e-c518-42c4-909b-2b503ec45c03"
      unitRef="usd">12229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9092a20f7ec442c6abb4a5f03939e991_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQxLTQtMS0xLTExNTYyNw_95d6fe68-4227-4d3b-8251-33af1bb8db4c"
      unitRef="usd">12012000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibf1fef094458495f8b29e9d3d2c96404_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQxLTYtMS0xLTExNTYyNw_feb4d18b-598e-4236-96cc-33edc9413a98"
      unitRef="number">0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQyLTItMS0xLTExNTYyNw_22329c4d-7fb0-49e9-89c1-7491ff59399f"
      unitRef="usd">24746000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQyLTQtMS0xLTExNTYyNw_debf6a3c-0546-4e92-891a-d3013ff56843"
      unitRef="usd">23426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmJmZTk2YWZhMDY2YTQ2YjVhZmUzNDAwNTZiYzc1M2Y1L3RhYmxlcmFuZ2U6YmZlOTZhZmEwNjZhNDZiNWFmZTM0MDA1NmJjNzUzZjVfMjQyLTYtMS0xLTExNTYyNw_538d9017-6948-49fa-b5b1-c92939d19c5b"
      unitRef="number">0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfNDIxOQ_5bd3e8da-591e-4258-a79c-4982f470db21">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;EARNINGS/(LOSS) BEFORE PROVISION FOR TAXES BY SEGMENT &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.818%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 2,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings before provision for taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Consumer Health separation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide income/(loss) before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.7&#160;billion and $0.8&#160;billion in the fiscal first quarter of 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;COVID-19 Vaccine related exit costs of $0.4&#160;billion in the fiscal first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1 billion in the fiscal first quarter of 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Unfavorable changes in the fair value of securities in the fiscal first quarter of 2022 of $0.4&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Intangible amortization expense of $0.4&#160;billion and $0.3&#160;billion in the fiscal first quarter of 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1 billion in the fiscal first quarter of 2022.&lt;/span&gt;&lt;/div&gt;(4)Amounts not allocated to segments include interest income/expense and general corporate income/expense. The fiscal first quarter of 2023 includes the incremental $6.9 billion charge related to the talc settlement proposal. See Note 11, Legal Proceedings, for additional details.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="i76b70d99f03547bebaa68b9a5dfb0b6b_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfMi0yLTEtMS0xMTU2Mjc_321afcca-701c-40c9-b84b-c798ed83baf5"
      unitRef="usd">776000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3e23b581651e49f0a5450b48eca550f3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfMi00LTEtMS0xMTU2Mjc_41cd561e-b1c1-411b-a859-f628c33bff27"
      unitRef="usd">686000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i76b70d99f03547bebaa68b9a5dfb0b6b_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfMi02LTEtMS0xMTU2Mjc_5c3ff826-4acc-4db2-bc3f-860a05be9db0"
      unitRef="number">0.131</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i266ded4d880644b384a30db64ac42be7_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfMy0yLTEtMS0xMTU2Mjc_efda2976-d65a-4717-89a6-89e8ce2f661b"
      unitRef="usd">4444000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i32d86be298e0484a81aaed029e8f90b8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfMy00LTEtMS0xMTU2Mjc_7a1d9f99-c581-42ce-954e-00b86d24ea38"
      unitRef="usd">3924000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i266ded4d880644b384a30db64ac42be7_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfMy02LTEtMS0xMTU2Mjc_892b5b2b-1614-4787-a09e-cbffd2837d3c"
      unitRef="number">0.133</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7e11113be4ef43419386891473e5f667_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNC0yLTEtMS0xMTU2Mjc_2cf44a53-477c-4970-b144-1d1aac066592"
      unitRef="usd">1445000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0c0748aae7984d91b72595fdb3674877_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNC00LTEtMS0xMTU2Mjc_07814e55-25d6-4c0c-b8ac-4f6e65e075bb"
      unitRef="usd">1477000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i7e11113be4ef43419386891473e5f667_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNC02LTEtMS0xMTU2Mjc_1ab57af3-a953-48c1-94fd-6f66e5e09484"
      unitRef="number">-0.022</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i255efac904da4926972f85e5d3721be3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNS0yLTEtMS0xMTU2Mjc_a32b8dee-620d-44f0-a9ac-593aa38be64b"
      unitRef="usd">6665000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6478dcb7f72f406bb51f1ce2d06bbe1d_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNS00LTEtMS0xMTU2Mjc_0517837e-6423-4b0f-8e0e-2f31e01a7812"
      unitRef="usd">6087000000</us-gaap:OperatingIncomeLoss>
    <jnj:PercentageChangeInOperatingIncomeLoss
      contextRef="i255efac904da4926972f85e5d3721be3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNS02LTEtMS0xMTU2Mjc_7f630a25-954f-4793-b96f-4cd693a2372d"
      unitRef="number">0.095</jnj:PercentageChangeInOperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6422d8dc1a9349d8ad4352f323889e7e_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNi0yLTEtMS0xMTU2Mjc_a38558b8-bd05-4600-86f7-9c280bfc0d77"
      unitRef="usd">7102000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia33598a52aed4f398e20f2837c3224a6_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNi00LTEtMS0xMTU2Mjc_70234d28-69b3-488c-a4da-a8c19d7a002f"
      unitRef="usd">123000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:BusinessExitCosts1
      contextRef="i76b70d99f03547bebaa68b9a5dfb0b6b_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNy0yLTEtMS0xMTU2Mjc_569b8157-03c1-409d-8e09-9732aa5bf916"
      unitRef="usd">300000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="i3e23b581651e49f0a5450b48eca550f3_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfNy00LTEtMS0xMTU2Mjc_04e4b337-abdd-4a61-b381-c22e64d2f402"
      unitRef="usd">102000000</us-gaap:BusinessExitCosts1>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfOC0yLTEtMS0xMTU2Mjc_d34f42cd-c19c-4ffc-ae9d-f7a81307fa4f"
      unitRef="usd">-737000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOmQ1ZTQxODA0YTliZDRhYTk5NDU3ZTk3ZDg0ODE1NTdhL3RhYmxlcmFuZ2U6ZDVlNDE4MDRhOWJkNGFhOTk0NTdlOTdkODQ4MTU1N2FfOC00LTEtMS0xMTU2Mjc_6b2a62c7-4bf4-4526-b17e-fc18a7ae915b"
      unitRef="usd">5862000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:AdjustmentForAmortization
      contextRef="i76b70d99f03547bebaa68b9a5dfb0b6b_D20230102-20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfOTcy_64fb9c94-5130-4ce2-8e63-a9497abe2c2d"
      unitRef="usd">100000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i266ded4d880644b384a30db64ac42be7_D20230102-20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMTQxMQ_60fe7a59-0918-4044-a97e-d4273d37f543"
      unitRef="usd">700000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i32d86be298e0484a81aaed029e8f90b8_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMTQxOA_7eab0076-b3ec-4c80-ab4e-dd2b16b17d56"
      unitRef="usd">800000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:SuppliesExpense
      contextRef="i266ded4d880644b384a30db64ac42be7_D20230102-20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMjc0ODc3OTA3NjM5MQ_9a956ae9-18cb-4912-8e35-5ac54896164b"
      unitRef="usd">400000000</us-gaap:SuppliesExpense>
    <us-gaap:RestructuringCharges
      contextRef="id0b0bf9e3b4b4097ab7bdcaefa80578e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfODIwMg_0c0605cf-9031-4bc0-9296-5ce8e6e6b4f2"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="id0b0bf9e3b4b4097ab7bdcaefa80578e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfODIwMg_42e04770-5122-4705-b6ff-cd2376ba7fa1"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2e99be17669548568e7cf2506dae3d92_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMjc0ODc3OTA3NTUzNA_8419d72d-54d0-4d48-bb27-b9735c5c4404"
      unitRef="usd">600000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i32d86be298e0484a81aaed029e8f90b8_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMjAzMg_2a208e91-6330-4669-b5e7-2167702335b3"
      unitRef="usd">-400000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:AdjustmentForAmortization
      contextRef="i7e11113be4ef43419386891473e5f667_D20230102-20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMjc0ODc3OTA3NzA4MA_73a5a1c7-7e49-40de-a388-c5139d2e46c5"
      unitRef="usd">400000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i0c0748aae7984d91b72595fdb3674877_D20220103-20220403"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfMzczNQ_da7a713e-ccdb-4de1-8cbc-08f6cf8efbb3"
      unitRef="usd">300000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:RestructuringCharges
      contextRef="id0b0bf9e3b4b4097ab7bdcaefa80578e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfODIwNg_0c0605cf-9031-4bc0-9296-5ce8e6e6b4f2"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="id0b0bf9e3b4b4097ab7bdcaefa80578e_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfODIwNg_42e04770-5122-4705-b6ff-cd2376ba7fa1"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RleHRyZWdpb246YjQ5OWMyMTM5YTFiNDg2MjhmYWJkNGRjYTdiNjFhMzVfNDIzNA_8721b398-4830-4cd6-a03b-5672bf137009">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SALES BY GEOGRAPHIC AREA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:69.736%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.166%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.270%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fiscal First Quarter Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 2, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;April 3, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Percent&lt;br/&gt;Change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere, excluding U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib18fd463fe944955b813ba83e60464c6_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfMi0yLTEtMS0xMTU2Mjc_0c0234a3-d559-4332-acd0-78deeaf1dd36"
      unitRef="usd">12517000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a29daeaf368468580d88ec00d701e07_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfMi00LTEtMS0xMTU2Mjc_a1fbce51-9489-4572-a51b-87b85ee4aea4"
      unitRef="usd">11414000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ib18fd463fe944955b813ba83e60464c6_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfMi02LTEtMS0xMTU2Mjc_667fc5f8-1407-423f-908a-22ba9970819e"
      unitRef="number">0.097</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92e0a38cfc3b4adbbf4d6b479e3c1cb5_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfMy0yLTEtMS0xMTU2Mjc_a2b0f26d-43a2-4cf3-af47-2c61b80eca84"
      unitRef="usd">6332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b6b9854fc844374a84fb9c3498a9aa8_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfMy00LTEtMS0xMTU2Mjc_3cd3dff7-a730-4016-9f0b-ada3bcb03ae5"
      unitRef="usd">6024000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i92e0a38cfc3b4adbbf4d6b479e3c1cb5_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfMy02LTEtMS0xMTU2Mjc_077a8ccd-6957-4c06-b309-3ce02a686e4e"
      unitRef="number">0.051</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08a82343349b46cfa5a11eced6ece9f7_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNC0yLTEtMS0xMTU2Mjc_15b92f85-6e9e-4732-ac28-1154f785cdb4"
      unitRef="usd">1587000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0468e2eece0f48cb874e2856e754bfea_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNC00LTEtMS0xMTU2Mjc_d4857f6b-4458-444f-87ac-e5a390874bc0"
      unitRef="usd">1482000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="i08a82343349b46cfa5a11eced6ece9f7_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNC02LTEtMS0xMTU2Mjc_7608a68a-b5fc-4b0f-a21d-e4cfbbf1beee"
      unitRef="number">0.071</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id60f2cfdf1f24ce795240fc4f13586e0_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNS0yLTEtMS0xMTU2Mjc_fbe652d5-2434-4fc5-8a12-9fee986bedcd"
      unitRef="usd">4310000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65cb348676ea488598ee39d3f57d3991_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNS00LTEtMS0xMTU2Mjc_220ddf42-a212-46b5-94f8-05d6c20efde4"
      unitRef="usd">4506000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="id60f2cfdf1f24ce795240fc4f13586e0_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNS02LTEtMS0xMTU2Mjc_8352b959-12c7-424e-af21-e51127e448b1"
      unitRef="number">-0.043</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNi0yLTEtMS0xMTU2Mjc_19899fd3-80f4-4c62-8660-8904bcdfcdfd"
      unitRef="usd">24746000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic125ef32f97a407ea27574960fb3f14c_D20220103-20220403"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNi00LTEtMS0xMTU2Mjc_f04bd3c9-407b-45c9-bf6c-b475e936ae79"
      unitRef="usd">23426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesByGeographicArea
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV83OS9mcmFnOmI0OTljMjEzOWExYjQ4NjI4ZmFiZDRkY2E3YjYxYTM1L3RhYmxlOjFlNGJkNjM0ZmJkZjRiNTNhYTk4ZDFlMDJiOWVjNjI4L3RhYmxlcmFuZ2U6MWU0YmQ2MzRmYmRmNGI1M2FhOThkMWUwMmI5ZWM2MjhfNi02LTEtMS0xMTU2Mjc_f580acbc-3e26-4c54-8b2c-36cb9106b436"
      unitRef="number">0.056</jnj:PercentageChangeInSalesByGeographicArea>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfMzg0ODI5MDcwMjU3Mg_5795b250-4e47-41e4-addd-722c7d13361b">ACQUISITIONS AND DIVESTITURES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;There were no acquisitions or divestitures in the fiscal first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Company&#x2019;s position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcare&#x2019;s largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $380.00 per share in cash, amounting to $17.1&#160;billion, net of cash acquired, as well as a non-tradeable contingent value right (CVR) entitling the holder to receive up to $35.00 per share in cash (which with respect to the CVRs total approximately $1.6&#160;billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $16.5&#160;billion includes cash, cash equivalents and marketable securities acquired. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The milestones of the CVR consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt"&gt;$17.50 per share, payable if net sales for Abiomed products exceeds $3.7&#160;billion during Johnson &amp;amp; Johnson&#x2019;s fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson &amp;amp; Johnson&#x2019;s fiscal first quarter of 2029, $8.75per share;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt"&gt;$7.50 per share payable upon FDA premarket application approval of the use of Impella&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt"&gt;$10.00 per share payable upon the first publication of a Class I recommendation for the use of Impella&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the acquisition was initially allocated to assets acquired of $19.9&#160;billion (net of $0.3&#160;billion cash acquired), primarily to goodwill for $10.9&#160;billion, amortizable intangible assets for $6.6&#160;billion, IPR&amp;amp;D for $1.1&#160;billion, marketable securities of $0.6&#160;billion and liabilities assumed of $2.8&#160;billion, which includes the fair value of the contingent consideration mentioned above for $0.7&#160;billion and deferred taxes of $1.8&#160;billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities on the Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date. In the fiscal first quarter of 2023, there were purchase price allocation adjustments netting to approximately $0.1&#160;billion with an offsetting increase to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortizable intangible assets were primarily comprised of already in-market products of the Impella&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; platform with an average weighted life of 14 years. The IPR&amp;amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;amp;D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52% to 70%. The discount rate applied was 9.5%.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2022, the Company recorded acquisition related costs before tax of approximately $0.3&#160;billion, which was recorded in Other (income)/expense. &lt;/span&gt;&lt;/div&gt;There were no material acquisitions or divestitures in the fiscal first quarter of 2022.</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE4OTIy_0420e0e1-08e9-4e00-a48e-29d400452dee"
      unitRef="usdPerShare">380.00</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i36d5c84c5814468ba35bfdbf20ca360c_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE4OTMx_478aee44-5c8b-436e-8804-308abd623db4"
      unitRef="usd">17100000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight
      contextRef="i81a2ab2c858b4a97bf160fe849e1cb84_D20221222-20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE4OTQ2_59065da0-04ea-4e57-b779-3031bf31d3e2"
      unitRef="usdPerShare">35.00</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight
      contextRef="i81a2ab2c858b4a97bf160fe849e1cb84_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE4OTU0_a6b3e5dd-df3a-4856-b877-b80830ee2ff9"
      unitRef="usd">1600000000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE4OTY4_360979b3-de89-4bf7-817b-412590f9d4bd"
      unitRef="usd">16500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="icc8de83c4d3041d09bb523dcfd66b52e_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfMzg0ODI5MDcwMjU2NQ_90a7d936-a871-497b-8f6d-5e96a47d9da9"
      unitRef="usdPerShare">17.50</us-gaap:DividendsPayableAmountPerShare>
    <jnj:RevenuesContingentConsideration
      contextRef="i81a2ab2c858b4a97bf160fe849e1cb84_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE4OTg3_9783ea90-b93b-412e-be74-e3d9ca2b1526"
      unitRef="usd">3700000000</jnj:RevenuesContingentConsideration>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i8836b8f3d5ba484189de37af4b30f820_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDAw_625b375b-7c0e-49fe-bb2c-938ab6ecc78e"
      unitRef="usdPerShare">8.75</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i06197fa8dff142f592975553bd6a4d84_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDE2_bbb1c0ac-8112-40f3-af96-08aa83b23462"
      unitRef="usdPerShare">7.50</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i0794a9f898cd4ed580c9795984a4df7d_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDIz_8b37f012-71b6-464e-8975-2b9d21e0726f"
      unitRef="usdPerShare">10.00</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDMx_bf925647-f58e-4e75-b9b8-b909aad19edf"
      unitRef="usd">19900000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="i36d5c84c5814468ba35bfdbf20ca360c_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDQ2_44f401a7-1f34-4541-8ab8-3c6384c511b3"
      unitRef="usd">300000000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i36d5c84c5814468ba35bfdbf20ca360c_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDYw_c2c54c29-a2f3-4d01-8c52-d0b83ec2f680"
      unitRef="usd">10900000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i36d5c84c5814468ba35bfdbf20ca360c_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDc1_6d2ba2ce-d85c-406c-a600-1572ea11ed85"
      unitRef="usd">6600000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i36d5c84c5814468ba35bfdbf20ca360c_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MDg5_e4218fbd-b6ed-4725-a996-6f7868f7b6e9"
      unitRef="usd">1100000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTAz_b8a434c4-9205-420d-90f4-86b2d3576fed"
      unitRef="usd">600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTE3_877b2b4a-d973-414f-885e-e38b4139bdcb"
      unitRef="usd">2800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTMx_a9c9e782-8199-4463-9130-b9331acd1680"
      unitRef="usd">700000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfMzg0ODI5MDcwMjU0MA_e261aaa1-7dd2-4029-a20b-8b5e1c1b3d95"
      unitRef="usd">1800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE0NTE3OA_9c463800-b926-47a4-a1d5-df7369bc7586"
      unitRef="usd">100000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i814ccd0c40684dd8ae2ed1e023cd3b2a_D20221222-20221222"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfMzg0ODI5MDcwMjUzOA_3dceaca8-8f9d-45f9-bd5c-de4490ba1adc">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="iccd1694ce0dc40e78004ae73676d4941_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTgw_b375fa2a-2684-4551-b50d-11e8fb6e44a7"
      unitRef="number">0.52</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="ia3a0b329d181434f981a08002ca2cd3b_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTg1_9e33a591-0519-41ad-a652-5394f2c2eea4"
      unitRef="number">0.70</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="ie51821e4cdcc40f9935183e51ba866a3_I20221222"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTkw_4816f3da-09c0-4209-9853-958e7268a057"
      unitRef="number">0.095</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i74c08a50ff5f419b83ba7dba4d025c2a_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84Mi9mcmFnOjNiYTc4YjcwOGNhMjQxYmI5YmYwMWQwNWM1NDU1Mjk4L3RleHRyZWdpb246M2JhNzhiNzA4Y2EyNDFiYjliZjAxZDA1YzU0NTUyOThfNTQ5NzU1ODE5MTk2_e8faefb9-376f-4a73-b37c-a52c1c986db4"
      unitRef="usd">300000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfMzI5ODUzNTUwNTU4Ng_57d24819-f090-4dd3-b20d-0e6f38aea7e0">LEGAL PROCEEDINGS&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of April&#160;2, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the Company&#x2019;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#x2019;s balance sheet, is not expected to have a material adverse effect on the Company&#x2019;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#x2019;s results of operations and cash flows for that period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;MATTERS CONCERNING TALC&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp;amp; Johnson Consumer Inc. and the Company arising out of the use of body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in Ingham v. Johnson &amp;amp; Johnson, et al., No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the Ingham decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the Ingham decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#x2019;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, Johnson &amp;amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#x2019;s direct parent, Johnson &amp;amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#x2019;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#x2019; compensation statute or act (the Talc-Related Liabilities). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, notwithstanding the Company&#x2019;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). All litigation against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties) was stayed, although LTL did agree to lift the stay on a small number of appeals where appeal bonds had been filed.   The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions in March 2022. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss the LTL Bankruptcy Case and the extension of the stay to the Protected Parties. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court&#x2019;s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;LTL filed a petition for rehearing of the Third Circuit&#x2019;s decision, which was denied on March 22, 2023.  On the same day, LTL filed a motion in the Third Circuit to stay the mandate directing the New Jersey Bankruptcy Court to dismiss the LTL bankruptcy pending filing and disposition of a petition for writ of certiorari to the United States Supreme Court. On March 31, 2023, the Third Circuit denied the motion to stay the mandate and issued the mandate.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 4, 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to all parties and returning the talc litigation to the tort system. Several hours later, also on April 4, 2023, LTL re-filed in the United States Bankruptcy Court for the District of New Jersey seeking relief under chapter 11 of the Bankruptcy Code (the LTL 2 Bankruptcy Case).  As a result of the new filing, all talc claims against LTL were again automatically stayed pursuant to section 362 of the Bankruptcy Code.  Additionally, on April 5, 2023, the New Jersey Bankruptcy Court issued a temporary restraining order staying all litigation as to LTL, Old JJCI, New JJCI, the Company, identified retailers, and certain other parties (the New Protected Parties). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 20, 2023, the New Jersey Bankruptcy Court issued a decision that granted limited injunctive relief to the Company and the New Protected Parties (the LTL 2 Preliminary Injunction).  The LTL 2 Preliminary Injunction will remain in force and effect until June 15, 2023, subject to the New Jersey Bankruptcy Court revisiting its ruling at a hearing scheduled for May 22, 2023.  Under the LTL 2 Preliminary Injunction, except for in those cases filed in the federal court ovarian cancer multi-district litigation, discovery in all personal injury and wrongful death matters is permitted to proceed. No trials may occur in any of the personal injury and wrongful death matters. On April 24, 2023, the Talc Claimants' Committee filed a motion to dismiss the LTL 2 Bankruptcy.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In the original bankruptcy case, the Company agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2.0&#160;billion trust in furtherance of this purpose. The Company established a reserve for approximately $2.0&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. In the LTL 2 Bankruptcy Case, the Company has agreed to contribute an additional $6.9&#160;billion which, when added to the prior $2.0&#160;billion, will be a total reserve of present value of $8.9&#160;billion payable over 25 years (nominal value approximately $12.0&#160;billion discounted at a rate of 4.41%), to resolve all the current and future talc claims. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The expected payment schedule provides that approximately $6.0&#160;billion is paid in the first two years, with the remainder paid over the remaining 23 years. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Company&#x2019;s then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Jersey. In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2019, the Company&#x2019;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#x2019;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC) (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the Tort Claimants&#x2019; Committee (TCC) and Future Claimants&#x2019; Representative (FCR) appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing &#x201c;talc-related claims&#x201d; against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023. The court subsequently extended the preliminary injunction through July 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Imerys, the TCC, the FCR, certain of Imerys&#x2019;s insurers, and certain parties in the Cyprus Mines chapter 11 case (collectively the Mediation Parties) have been engaged in mediation since October 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The Company filed a motion to dismiss the adversary proceeding. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2021, several of the Company&#x2019;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder, and that purchasers of the Company&#x2019;s shares suffered losses as a result. In April 2019, the Company moved to dismiss the complaint. In December 2019, the Court denied, in part, the motion to dismiss. In April 2021, briefing on Plaintiff&#x2019;s motion for class certification was completed. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action and Plaintiff appealed the Bankruptcy Court&#x2019;s order.  However, on March 31, 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case, which mooted the appeal, and on April 4, 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#x2019;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#x2019;S Baby Powder. In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#x2019;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson &amp;amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp;amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#x2019; use of talc contained in JOHNSON&#x2019;S Baby Powder and JOHNSON&#x2019;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. In February 2022, the trial court set the case for trial to begin in February 2023. However, in October 2022, the LTL bankruptcy court issued an order staying the case. On March 31, 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and on April 4, 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. The trial court has indicated it will set a new trial date in this matter during the second fiscal quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. In March 2022, the New Mexico court denied the Company&#x2019;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#x2019;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#x2019;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexico&#x2019;s discovery obligations. On March 31, 2023, the Third Circuit issued the mandate to dismiss the LTL Bankruptcy Case and on April 4, 2023, the New Jersey Bankruptcy Court dismissed the LTL Bankruptcy Case, effectively lifting the stay as to this matter. However, this case remains stayed as a result of the New Mexico Supreme Court&#x2019;s stay until such time as the Supreme Court issues an order concerning the State of New Mexico&#x2019;s discovery obligations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Forty-two states and the District of Columbia (including Mississippi and New Mexico) have commenced a joint investigation into the Company&#x2019;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court.  In March 2023, the mediation was terminated.  The procedural history and status of the New Mexico and Mississippi matters specifically have been discussed above.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;MATTERS CONCERNING OPIOIDS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned narcotic raw material and active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments, including 20 suits filed by state or territorial Attorneys General following a multi-state investigation of opioid marketing practices. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome (NAS); hospitals; and health insurers/payors. In August 2019, the Company received a grand jury subpoena from the United States Attorney&#x2019;s Office for the Eastern District of New York for documents related to the Company&#x2019;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#x2019; and distributors&#x2019; monitoring programs and reporting under the Controlled Substances Act. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The majority of the opioid marketing cases have been filed in federal courts and coordinated in a multi-district litigation proceeding in the United States District Court for the Northern District of Ohio (Ohio MDL), with most of the remainder in various state courts. To date, the Company and JPI have litigated two of the cases to judgment and have prevailed in both, either at trial or on appeal. In November 2021, the Oklahoma Supreme Court reversed a $465&#160;million judgment entered against the Company and JPI on a public nuisance claim brought by the Oklahoma Attorney General, holding that the marketing of &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;lawful products was not actionable under the State&#x2019;s public nuisance law, and directing entry of judgment for the Company and JPI. In February 2022, the Superior Court of Orange County, California, entered judgment for the Company, JPI, and three other pharmaceutical manufacturers on public nuisance and deceptive marketing claims brought by four California local governments, holding that the plaintiffs had failed to prove that any defendant&#x2019;s marketing was deceptive or that any defendant&#x2019;s allegedly deceptive marketing led to medically inappropriate prescribing. The California plaintiffs appealed from that judgment, but abandoned their appeal after electing to participate in the Company&#x2019;s national settlement agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2019, after settling an initial test case brought by two Ohio counties in the Ohio MDL, the Company announced a proposed agreement in principle with a negotiating committee of state Attorneys General to settle all remaining government opioid litigation claims nationwide. Under the final national settlement agreement, which was announced in July 2021, the Company agreed to pay up to $5.0&#160;billion to resolve all opioid lawsuits and future opioid claims by states, cities, counties, local school districts and other special districts, and tribal governments, contingent on sufficient participation by eligible government entities, and with credits back for entities that declined or were ineligible to participate. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately half of the all-in settlement was paid by the first fiscal quarter of 2023. The expected payment schedule provides that approximately $0.6&#160;billion of payments are to be paid by the end of the first fiscal quarter of 2024. The agreement is not an admission of liability or wrongdoing, and it provides for the release of all opioid-related claims against the Company, JPI, and their affiliates (including the Company&#x2019;s former subsidiaries Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc.). By February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement. The Company confirmed that this level of participation was sufficient to proceed with the agreement, which became effective in April 2022. Also in 2022, the Company completed separate settlements with most of the government entities that had declined to participate in the national settlement agreement, including all federally-recognized tribes, the States of Alabama, New Hampshire, and West Virginia and their participating subdivisions, and litigating Oklahoma subdivisions. Consequently, by the end of the fiscal year 2022, the Company and JPI had settled or otherwise resolved the opioid claims advanced by all government entity claimants except the State of Washington and its subdivisions, the City of Baltimore, a number of school districts and other special district claimants, and a handful of others.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company and JPI continue to defend the cases brought by the remaining government entity litigants as well as the cases brought by private litigants, including NAS claimants, hospitals, and health insurers/payors. Counting the private litigant cases, there are approximately 55 remaining opioid cases against the Company and JPI in various state courts, 545 remaining cases in the Ohio MDL, and 20 additional cases in other federal courts. Several of these cases are scheduled for trial in 2023, 2024, or 2025. In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;From June 2017 through December 2019, the Company&#x2019;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Company&#x2019;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state court&#x2019;s dismissal order.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;PRODUCT LIABILITY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of April&#160;2, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.479%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Product or product category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Plaintiffs &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PINNACLE Acetabular Cup System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pelvic meshes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ETHICON PHYSIOMESH Flexible Composite Mesh&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RISPERDAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ELMIRON&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TYLENOL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;MedTech&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;DePuy ASR XL Acetabular System and ASR Hip Resurfacing System&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;DePuy PINNACLE Acetabular Cup System&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Ethicon Pelvic Mesh&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon&#x2019;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#x2019;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#x2019;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre- and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia and in March 2023 the Federal Court approved the settlement. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon&#x2019;s pelvic mesh products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;Ethicon Physiomesh&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Following a June 2016 worldwide market withdrawal of Ethicon Physiomesh Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 2,308 have been dismissed with prejudice. Ethicon has received releases from 3,496 plaintiffs, and releases continue to be submitted as part of the settlement process. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of March 2023, there are approximately 225 active cases subject to these orders which are being reviewed and evaluated. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products.  All litigation activities in the two New Jersey MCLs are stayed pending resolution of the proposed settlement.  Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has established accruals with respect to product liability litigation associated with Ethicon Physiomesh Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;Pharmaceuticals&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;RISPERDAL&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#x2019;s accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;ELMIRON&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;Consumer Health&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;TYLENOL&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Claims for personal injury have been made against Johnson and Johnson Consumer Inc. (JJCI), arising out of the use of TYLENOL, an over-the-counter pain medication, alleging that prenatal exposure to acetaminophen is associated with the development of autism spectrum disorder and/or attention-deficit/hyperactivity disorder. In October 2022, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the Southern District of New York.  In addition, lawsuits have been filed in Canada against Johnson &amp;amp; Johnson Inc. and the Company.  Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with TYLENOL related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;INTELLECTUAL PROPERTY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#x2019;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;Pharmaceuticals - Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company&#x2019;s subsidiaries have brought lawsuits against generic companies that have filed ANDAs with the U.S. FDA (or similar lawsuits outside of the United States) seeking to market generic versions of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These lawsuits typically include allegations of non-infringement and/or invalidity of patents listed in FDA&#x2019;s publication &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations&#x201d; (commonly known as the Orange Book). In each of these lawsuits, the Company&#x2019;s subsidiaries are seeking an order enjoining the defendant from marketing a generic version of a product before the expiration of the relevant patents (Orange Book Listed Patents). In the event the Company&#x2019;s subsidiaries are not successful in an action, or any automatic statutory stay expires before the court rulings are obtained, the generic companies involved would have the ability, upon regulatory approval, to introduce generic versions of their products to the market, resulting in the potential for substantial &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#x2019;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Inter Partes Review (IPR) process with the United States Patent and Trademark Office (USPTO), created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits to challenge the applicable patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in March 2021, Janssen Pharmaceuticals, Inc.; Bayer Pharma AG; Bayer AG; and Bayer Intellectual Property GmbH filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of XARELTO before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Dr. Reddy&#x2019;s Laboratories, Inc.; Dr. Reddy&#x2019;s Laboratories, Ltd.; Lupin Limited; Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd.; Taro Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Mylan Inc.; USV Private Limited; Mankind Pharma Limited; Epic Pharma, LLC; Apotex Inc.; Apotex Corp.; Biocon Pharma Limited; Biocon Limited; Biocon Pharma, Inc.; and ScieGen Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 9,539,218; and 10,828,310. In March 2023, the Company entered into a confidential settlement with Epic Pharma, LLC.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;U.S. Patent No. 10,828,310 is also under consideration by the USPTO in an IPR proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in January 2023 Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of OPSUMIT before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Sun Pharmaceutical Industries Limited; Sun Pharmaceutical Industries, Inc.; Alembic Pharmaceuticals Ltd.; and Alembic Pharmaceuticals, Inc. The following U.S. patents are included in one or more cases: 7,094,781; and 10,946,015.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in May 2020, Janssen Inc. and Actelion Pharmaceuticals Ltd initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against generic manufacturers who have filed ANDSs seeking approval to market generic versions of OPSUMIT before expiration of certain listed patents. The following entities are named defendants: Sandoz Canada Inc.; Apotex Inc.; and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Generic Medical Partners Inc. In March 2023, the Company entered into a confidential settlement agreement with Generic Medical Partners Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following Canadian patent is included in one or more cases: 2,659,770&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Teva Pharmaceuticals USA, Inc.; Mylan Laboratories Limited; Pharmascience Inc.; Mallinckrodt PLC; Specgx LLC; Tolmar, Inc.; and Accord Healthcare, Inc. The following U.S. patent is included in one or more cases: 9,439,906. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in February 2018, Janssen Inc. and Janssen Pharmaceutica NV initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of INVEGA SUSTENNA before expiration of the listed patent. The following entities are named defendants: Teva Canada Limited; Pharmascience Inc.; and Apotex Inc. The following Canadian patent is included in one or more cases: 2,655,335. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;INVEGA TRINZA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp;amp; Development, LLC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of INVEGA TRINZA before expiration of the Orange Book Listed Patent. The following entities are named defendants: Mylan Laboratories Limited; Mylan Pharmaceuticals Inc.; and Mylan Institutional LLC. The following U.S. patent is included in one or more cases: 10,143,693. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in September 2021, Pharmacyclics LLC and Janssen Inc. initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against generic manufacturers who have filed ANDSs seeking approval to market generic versions of IMBRUVICA before expiration of certain listed patents. The following entities are named defendants: Natco Pharma (Canada) Inc.; and Sandoz Canada Inc. The following patents are included in one or more cases: 2,663,116; 2,928,721; 2,800,913; 3,007,787; 3,007,788; 2,875,986; and 3,022,256. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in November 2021, Janssen Products, L.P., Janssen Sciences Ireland Unlimited Company, Gilead Sciences, Inc. and Gilead Sciences Ireland UC filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of SYMTUZA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; MSN Laboratories Private Ltd.; MSN Life Sciences Private Ltd.; MSN Pharmaceuticals Inc.; Apotex Inc.; and Apotex Corp.  The following U.S. patents are included in one or more cases: 10,039,718 and 10,786,518. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in May 2022, Aragon Pharmaceuticals, Inc., Janssen Biotech, Inc., Sloan Kettering Institute for Cancer Research and The Regents of the University of California filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of ERLEADA before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Lupin Limited; Lupin Pharmaceuticals, Inc.; Zydus Worldwide DMCC; Zydus Pharmaceuticals (USA), Inc.; Zydus Lifesciences Limited; Sandoz Inc.; Eugia Pharma Specialities Limited; Aurobindo Pharma USA, Inc.; Auromedics Pharma LLC; Hetero Labs Limited Unit V; and Hetero USA, Inc. The following U.S. patents are included in one or more cases: 9,481,663; 9,884,054; 10,052,314; 10,702,508; 10,849,888; 8,445,507; 8,802,689; 9,388,159; 9,987,261; and RE49,353.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"&gt;UPTRAVI &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in November 2022, Actelion Pharmaceuticals US Inc., Actelion Pharmaceuticals Ltd and Nippon Shinyaku Co., Ltd. filed patent infringement lawsuits in United States district courts against generic manufacturers who have filed ANDAs seeking approval to market generic versions of UPTRAVI before expiration of certain Orange Book Listed Patents. The following entities are named defendants: Alembic Pharmaceuticals Limited, Alembic Pharmaceuticals Inc.; Lupin Ltd.; Lupin Pharmaceuticals, Inc.; Cipla Limited; and Cipla USA Inc. The following U.S. patents are included in one or more cases: 8,791,122; 9,284,280; and 7,205,302. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;GOVERNMENT PROCEEDINGS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Like other companies in the pharmaceutical, consumer health and medical devices industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;MedTech&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp;amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#x2019;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#x2019; motion to dismiss with prejudice, unsealed the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; complaint, and denied the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; relators&#x2019; request for leave to file a further amended complaint. The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#x2019;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#x2019; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#x2019; second amended complaint; the District Court denied DePuy&#x2019;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#x2019;s July 2021 ruling. In November 2021, the District Court granted DePuy&#x2019;s motion for reconsideration and dismissed the case with prejudice. The District Court&#x2019;s order was unsealed in December 2021. The relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court denied. Following the District Court&#x2019;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#x2019; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#x2019;s dismissal of the case to the First Circuit. The briefing on the appeal is complete, the First Circuit held oral argument on December 6, 2022, and the First Circuit&#x2019;s decision remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2012, the Company was contacted by the California Attorney General&#x2019;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by the Company&#x2019;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against the Company, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In October 2019, the Company and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. Between April 2019 and February &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2023, the Company settled with Washington, West Virginia, Oregon, Mississippi and Kentucky. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company&#x2019;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#x2019;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $302&#160;million, but otherwise denied the appeal. In July 2022, the Supreme Court of California denied the Company&#x2019;s petition to review the Court of Appeals decision, and the Company recorded a charge to reflect the judgment in the second quarter of 2022. In November 2022, the Company petitioned the United States Supreme Court for review. In February 2023, the Company&#x2019;s petition to the United States Supreme Court was denied.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2017, the Company received a subpoena from the United States Attorney&#x2019;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals.  The Company and DePuy fully cooperated with the government&#x2019;s investigation. In January 2023, the Company, DePuy Synthes, Inc., and DePuy Synthes Sales Inc. entered into a settlement agreement with the United States resolving the matter for an immaterial amount. The only claim remaining before the United States District Court for the District of Massachusetts is the Relator&#x2019;s employment retaliation claim.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp;amp; Johnson do Brasil Ind&#xfa;stria e Com&#xe9;rcio de Produtos para Sa&#xfa;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;Pharmaceuticals&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company and several of its pharmaceutical subsidiaries (the J&amp;amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;amp;J AWP Defendants were ultimately dismissed. The J&amp;amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), the Company and ALZA Corporation. All other cases have been resolved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April and September 2017, the Company received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp;amp; Johnson to cooperate with these inquiries by producing the requested information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;GENERAL LITIGATION&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company (subsequently substituted by Johnson &amp;amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp;amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#x2019;s decision. In February 2023, defendants petition for rehearing on the decision was denied. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;MedTech&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#x2019;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#x2019; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#x2019;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#x2019;s motion for summary judgment. In April 2022, Innovative appealed this ruling to the United States Court of Appeals for the Ninth Circuit.  Oral argument has been set for June 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;Pharmaceuticals&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against the Company and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; In re REMICADE Antitrust Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022.  The Court issued final approval in March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#x2019;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands.  Janssen is in ongoing discussions with the FTC staff regarding the inquiry. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. Janssen filed its Notice of Defense in July 2022. Genmab and Janssen have cross-moved for early disposition of the arbitration.  In April 2023, the Arbitration Panel ruled in Janssen's favor and dismissed Genmab's claims. In April 2023, Genmab announced that it intends to appeal the award.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the U.S. Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2019, a class action antitrust complaint was filed against Janssen R&amp;amp;D Ireland (Janssen) and Johnson &amp;amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In December 2021, several insurance companies and other payers filed individual &#x201c;Opt-Out&#x201d; complaints containing allegations similar to the original complaint. In September 2022, the Court granted in part and denied in part plaintiff&#x2019;s motion for class certification. Trial was scheduled for May 2023; in March 2023, the Court issued an order dividing the matter into two separate trials.  The first trial, scheduled for May 2023, relates to claims that do not involve Janssen.  The court did not set a date for trial on the claims that do involve Janssen.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (EBSI) with the American Arbitration Association, alleging that EBSI breached the parties&#x2019; Manufacturing Services Agreement for the Company&#x2019;s COVID-19 vaccine.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; In July 2022, Emergent filed its answering statement and counterclaims.  The hearing is scheduled for March 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Merck Sharp &amp;amp; Dohme Corp. with the American Arbitration Association pursuant to the Parties&#x2019; agreements relating to production of drug substance and drug product for the Company&#x2019;s COVID-19 vaccine. Also in October 2022, Merck filed its answer and counterclaims.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The hearing is scheduled for September 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline"&gt;Consumer Health&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2019, the Company received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp;amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp;amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp;amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. In November 2022, Johnson &amp;amp; Johnson received a demand for indemnification from GlaxoSmithKline LLC (GSK), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer, and certain 1993, 1998, and 2002 agreements between Glaxo Wellcome and Warner-Lambert entities. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp;amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp;amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp;amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Beginning in May 2021, multiple putative class actions were filed in state and federal courts (California, Florida, New York, and New Jersey) against various Johnson &amp;amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products and the affirmative promotion of those products as &#x201c;safe&#x201d;; and, in at least one case, alleging a strict liability manufacturing defect and failure to warn claims, asserting that the named plaintiffs suffered unspecified injuries as a result of alleged exposure to benzene. The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In December 2021, plaintiffs in the consolidated actions filed a motion for preliminary approval of a nationwide class settlement. The court issued an order granting final approval of the settlement in February 2023. A Notice of Appeal was filed in April 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyReceivableProceeds
      contextRef="ic4c5e1157e174c7b9992d3b947faa46d_D20200601-20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NjAx_19e78b56-69e8-4a71-a746-ca51a7d997ad"
      unitRef="usd">4700000000</us-gaap:LossContingencyReceivableProceeds>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ic4c5e1157e174c7b9992d3b947faa46d_D20200601-20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NjE1_4d125f49-f7bf-49a1-96a0-70ae530f749c"
      unitRef="usd">2100000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="ia9af996ed5624621b676a456a070b7db_D20210601-20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NjI5_9a5c0cad-c9d2-4712-b8be-8db2d602622c"
      unitRef="usd">2500000000</us-gaap:LossContingencyDamagesPaidValue>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="i5a2da6f47c794efc85b034ec75f9880b_D20211001-20211031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NzA0_cffa23af-7f00-4c9f-8d31-eeeb019c9960"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="i5a2da6f47c794efc85b034ec75f9880b_D20211001-20211031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1OTUw_704fb037-e93e-4dfa-b8e9-7f33f8dd901b"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <jnj:LossContingencyAdditionalContribution
      contextRef="if6ec52a5f6d5422d88184d297ffc6e51_I20230424"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NjQz_17758453-2fbf-4a96-9e61-b88b2e9041c4"
      unitRef="usd">6900000000</jnj:LossContingencyAdditionalContribution>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="i5a2da6f47c794efc85b034ec75f9880b_D20211001-20211031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NjU3_cc97f1b1-55ac-416a-b6cb-ff3aa6a25115"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <jnj:LossContingencyReserveEstablishedWithinTrustTotal
      contextRef="i503d1efd449c494a99b00f5571fe65d2_I20211031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1NjY5_b4575260-f360-47df-a89e-45ff2b517183"
      unitRef="usd">8900000000</jnj:LossContingencyReserveEstablishedWithinTrustTotal>
    <jnj:LossContingencyTerm
      contextRef="i503d1efd449c494a99b00f5571fe65d2_I20211031"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfMzI5ODUzNTUwNTYxOQ_f260c09e-d950-4b20-9c22-849efc5aa0c7">P25Y</jnj:LossContingencyTerm>
    <jnj:LossContingencyReserveEstablishedWithinTrustNominalValue
      contextRef="if6ec52a5f6d5422d88184d297ffc6e51_I20230424"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1Njg0_042ead9c-af80-4dda-bb40-e7f5b48208b0"
      unitRef="usd">12000000000</jnj:LossContingencyReserveEstablishedWithinTrustNominalValue>
    <jnj:BankruptcyLossContingencyDiscountRate
      contextRef="i304dd0295691432abf102897083e51f0_I20230424"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1Njk3_06aada1e-2ec6-46c8-8032-f32abf45f836"
      unitRef="number">0.0441</jnj:BankruptcyLossContingencyDiscountRate>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="i5a2da6f47c794efc85b034ec75f9880b_D20211001-20211031"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1OTY1_39e11d37-ee3c-4932-b162-4ad67976edcd"
      unitRef="usd">6000000000</us-gaap:LossContingencyAccrualPayments>
    <jnj:LossContingencyRemainingTerm
      contextRef="i043b133272cb49e4ad4a3a90ff5a68b9_I20211031"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfMzI5ODUzNTUwNTYzNQ_b091d69c-d8eb-49af-85d2-46a2989da0d2">P23Y</jnj:LossContingencyRemainingTerm>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i168a38aa9d2c44faab5619fe9ffe4231_I20230402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1OTc5_229f580f-5676-4db7-a9e0-d25565264114"
      unitRef="claimant">3500</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i0ab721ca3d7d460192200182b3872c5a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MTA2_e49f2bd5-04ca-4277-a2b9-5233339f29a1"
      unitRef="usd">465000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i0c6d0bc5404442dc9fbb22defa52977d_I20210704"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1OTg2_a9e5a95a-4e91-49d0-a3c9-5eae629356ff"
      unitRef="usd">5000000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualPayments
      contextRef="ia97ebcbe40d746e3998c9afa253624ee_D20230102-20230402"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MTMz_7cf2fa18-a296-43dd-8482-6212dfc18a7a"
      unitRef="usd">600000000</us-gaap:LossContingencyAccrualPayments>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i168a38aa9d2c44faab5619fe9ffe4231_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MTIw_aba43d09-8e0d-4656-a5fc-d23cc8124473"
      unitRef="claim">55</us-gaap:LossContingencyPendingClaimsNumber>
    <jnj:LossContingencyPendingClaimsNumberRemaining
      contextRef="i168a38aa9d2c44faab5619fe9ffe4231_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MTI0_772e35a9-1c6c-45b6-ac33-b47b4ff6f7dd"
      unitRef="claim">545</jnj:LossContingencyPendingClaimsNumberRemaining>
    <jnj:LossContingencyPendingClaimsNumberAdditional
      contextRef="i168a38aa9d2c44faab5619fe9ffe4231_I20230402"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MTI5_a8373676-66d3-4398-89b6-e1b85d585b93"
      unitRef="claim">20</jnj:LossContingencyPendingClaimsNumberAdditional>
    <jnj:SummaryOfClaimsInPendingLawsuitsTableTextBlock
      contextRef="ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfMzI5ODUzNTUwNTE2Nw_92dde397-fc24-42a5-8c36-ab75d75d980c">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The table below contains the most significant of these cases and provides the approximate number of plaintiffs in the United States with direct claims in pending lawsuits regarding injuries allegedly due to the relevant product or product category as of April&#160;2, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.842%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.479%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Product or product category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Plaintiffs &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PINNACLE Acetabular Cup System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pelvic meshes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ETHICON PHYSIOMESH Flexible Composite Mesh&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RISPERDAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ELMIRON&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;TYLENOL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:SummaryOfClaimsInPendingLawsuitsTableTextBlock>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i67bea373bcf745f8b39c99720a13df20_I20230402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfMS0yLTEtMS0xMjYxMzY_48eb7a9f-6026-4607-b5dd-e657736d68c8"
      unitRef="claimant">40330</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i4cf78e7db6fe424ca92d366884d15cc1_I20230402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfMi0yLTEtMS0xMjYxMzY_2dfedd73-879c-438e-b2fd-081c021bd93a"
      unitRef="claimant">160</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i3b4ceb386c184c2b93d06b92b82b2bbb_I20230402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfMy0yLTEtMS0xMjYxMzY_132feade-03f8-4acc-b7fb-bbe3a7ed639f"
      unitRef="claimant">940</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ifaeb7772b11c47759bd2f3879d60dc10_I20230402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfNC0yLTEtMS0xMjYxMzY_fd36f5ac-f66c-4280-bd66-01812c6e6c19"
      unitRef="claimant">8780</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ib5a55c1aa53f481d8979dcf3332bb680_I20230402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfNS0yLTEtMS0xMjYxMzY_a49159e6-bf14-4067-8483-46927bddfa40"
      unitRef="claimant">2070</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i51cf8df9cdd74871b6625778ba7d91de_I20230402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfNi0yLTEtMS0xMjYxMzY_9c8caf95-6ed0-431f-adca-e691ec922cb9"
      unitRef="claimant">520</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i4790b713aa2844809fa453cd9fcb88bd_I20230402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfNy0yLTEtMS0xMjYxMzY_986fca15-0290-47ec-9530-4ea3feab561d"
      unitRef="claimant">2070</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ibc7d93f749d74c228eda4c9d482b9c1a_I20230402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RhYmxlOmI1YmMwNGVmYmYyZDQ3ZTFiNjhmZjY4M2IyNTYyMWIxL3RhYmxlcmFuZ2U6YjViYzA0ZWZiZjJkNDdlMWI2OGZmNjgzYjI1NjIxYjFfOC0yLTEtMS0xMjYxMzY_afeefee3-08cd-4769-9e7a-0d70d0354dc2"
      unitRef="claimant">200</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:Numberofpatientsinsettlement
      contextRef="i77bc5b03664c43aea0c4d8e95bd4da26_I20230402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM1OTk5_26d7ad04-f5f4-49ad-96fa-129fba8f3524"
      unitRef="claimant">10000</jnj:Numberofpatientsinsettlement>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ic5638d3163f64eb384c2d26990c2bf2d_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDA4_93ea5185-b61a-44b1-8050-4715309ffa58"
      unitRef="cases">3600</us-gaap:LossContingencyPendingClaimsNumber>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ic5638d3163f64eb384c2d26990c2bf2d_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDE1_1e00835f-f504-41ad-bd5e-5fce5840eb15"
      unitRef="claimant">4300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement
      contextRef="i8056c4aa7c884f9cb93c3477b3ab1519_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDIx_afc0a94d-94fc-4e53-be32-bf41ca70dbc6"
      unitRef="cases">3729</jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i82887472019e4389baf706d14d575072_D20210901-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDIy_91af799f-f25b-42e1-b46e-9fd6da300b5d"
      unitRef="cases">2308</us-gaap:LossContingencyClaimsDismissedNumber>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i62a7dab5fc114de782c92d25060c9210_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDI0_e237a340-5a2e-46a6-9fc4-2e2426f2d6fb"
      unitRef="claimant">3496</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i28f2b9ddeb654daeb2f97d59eea0473d_I20230402"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDMx_bb705714-d863-4455-b440-ca66fe252275"
      unitRef="cases">225</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i7b5262aa703a4c79ad88ac4d66f46761_D20191001-20191031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDM2_77857015-1fef-4268-aa0b-4f79dd15c57d"
      unitRef="usd">8000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i8420d4da9f3346f483112422335f21db_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDUw_fa6f27d2-f832-4300-babb-167a3ef03aad"
      unitRef="usd">6800000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i7cec5795e9f24927925718a962fd322c_D20200101-20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDY0_610a878f-b8a7-40c9-9807-ed99f66bc483"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i7cec5795e9f24927925718a962fd322c_D20200101-20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDky_0e41bdee-5f9b-4101-ae66-b308f5bb7f95"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i2f8d53e5a09b495182048bc044c3b582_D20220401-20220430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjdjNjE1ZGM3YWVjMjRkYzk4ZTZjODUwMzEzMjUxYzRlL3NlYzo3YzYxNWRjN2FlYzI0ZGM5OGU2Yzg1MDMxMzI1MWM0ZV84NS9mcmFnOmQzZjRmZTBiNjJjZjQyYjlhNGNjODUyNWM1Yjc2OGRjL3RleHRyZWdpb246ZDNmNGZlMGI2MmNmNDJiOWE0Y2M4NTI1YzViNzY4ZGNfNTQ5NzU2NDM2MDc4_e3f13935-f128-4607-ae6d-46da85d41dc2"
      unitRef="usd">302000000</us-gaap:LossContingencyDamagesAwardedValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MWVI7-0%RHJH Z\.M'.563E=N51-4-5'!98?RC7:>>LAN+></@R3(RWY163P
ML7UW^\#)9?Z8Q4BM7CRM\H%D=Z83%-*Y+#6.3J0%\>(!D&)!L%7^#,4#$X)%
M^<LE)3[EV0KR\SF3/;=<R+Y@^QC.^#]02P,$%     @ VH"<5I;N"8%A!P
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M,!#]5ZRLVEJI:WX2*(-(+=6T3:J$RKI]-LE!K#IV:CO0[J_?.:$1E)2V4OD
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M!)0-P.<+*<W3Q/:Y]K4F^0]02P,$%     @ VH"<5G2]X\]&!@  ?AP  !@
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MM59PI!<]KD2/K:(_4L*8E+Q)N$[:N)4HUT=>L[<U5MX8&O(YJ:1-.DA;Y=+
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M[3ZDS223]J'3!P6.C69!HI)L)_OK*R[A8@3N=OQB0#[GXSL7S@=:'KGX)B,
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M@?Y_R[EZN\AN4&W.K/\%4$L#!!0    ( -J G%:60-=XV@(  *X'   8
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&ULK57);MLP$/T50@V"!&@B6?*2)K8
MVTF1' (8<=,>BAYH:6P1H4B5I.WD[SND9-6+;/30B[AHWN.;&7*FOY;J36<
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ME=3-RN_:.IP B*<?D+: ]#%@] 0@:P%9$-ID%F1]YLCSB34'9GTTL?E-J$U
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M+U7X5&$E=^QH?3H',;3EX>$(MT?A,AN'/G<WL V[:7ORZN\/@\,1";5A$C8
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M>G4R8#9^R\0;;YKP_; R'E\CX;+"-B<L">!]:;!,I1MRT'U0SO\"4$L#!!0
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M>-5CO'6)88>5:?7[,*YW10D!2//[:BS>%/5:U$];!><24#[$9)TJ$0/3I:P
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MLP"^EPY'Q.Z!'0R7[I/_ %!+ P04    " #:@)Q69("Z*+<$  "9"@  &0
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M7\6T&J9OXM4OR0W3:TY."5R1:K=S=AJ KL9\M;"J\*-UJ2P-:O^YH3\CU$Z
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M]5D NBFW36!5Y4O<5EDJF+Y;T!\*M5M \SM%Y]8&;H/NGS?["U!+ P04
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MR>.5*-=CDKUE$F?RE3T6SQK\C"T/69YLR\'P8!OMBK_AUS(.M0&.^IT!O!S
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M?EWCS0=HW\$!++Q[*8J:AS=-\04L!&[X=5XKMDVLI@==#=Y,&B+Q^$6!URP
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MY7MJZ&RBY :4O8W:[,*YZJ01'*]M4KX:A5\YRIG9Y]K0>LV7@L%<:V8TT+J
MGZ0L-EP(.+VE^$F?30*#QJQ(D.\47W6*R1'%,=S(VI0:/M0%*Y[*!PBR1TH>
MD%Z1087S1IU#2'P@(8D'],6]Y['3%Q_1U_MH'7X9AO=<YT+J5C'X<[[41F']
M_'4H#)V5Y+ 5RZE+W="<33TDC6;JCGFSMV^B+'PWX$/2^Y ,:7\E>X?0#NL[
M?2^%H$H#K^$&-2!O]!E@Y+F 7>3A9UJW2%^(=OL]#+3#L.&FM,S@-3<,!+).
M7\*"&E;O &(P"^PMV'?@[9LQB<@[6"NI-9Q DOA9G-DIC C\PO"0YGE;M0+E
M"Z"55(;_0QVC3TGLIQ$YPP7Q29:=O6:DQB9'(C\BB9U&20;7CF%,87\13JDN
M>=/)2U/B.>^]>XX5C8?A&-#TQ7CT&M(H]DD4(=((KX>X^%^&+?Y3%+[P1Q<C
MB$(_'&?'XL_KYQFX?0Q(YH^3V([A"!:MRDOL:P6*_-@HF5M/;*E2/'> "G:'
MS;O!5FS0=#9.W)C!K314[ $=M ]1YJ=D9*?D(CXJN^\J5L/(3Y(Q)&,_)JES
M_;9DV/[^EHJ;+7 -N:RP.BUZN=KUR^=!'>!9VO,L'>3%$*,&)0_S_['U: O[
M*;\V>$B%D+DKH^46-%N[T./-9:M1OZTT#2NDJMQ@7@^3]AK'UL;B$Z,"\[$H
M*?[$<M8:GF/D;UAQRS"_71X> 9D7_#[!;$>8<RPW.Y'4'V<Q)*E/XJ@7]+N0
M(V CD0;?6ZZY2T"?T&/S=:L4J_.MY6NMN[0%OSH*)!=@J1J-(O@!XB1Y O-I
MT"Q($L<69&Q)F?EAG%B0Z2B%@0+(^@+(_E.CA?D^O3_<XQM)LT/5,:S65C/3
MAE<O6P;K=&*:%= &>7F'-W JVMQH'Y8,/S P]-YW5S!@L$*>X>LJSQDK>+V&
M+7-5H3OY>V=%;(\5C(LC#HD=4CMD=AC!28)](@1LS#C&;HW=#$=B3PX%-]A[
MCV )KMVKRW*UK4WW-.E/^X?=O'O//%[O7H4W5*TYEI%@*Q0-ST=(-]6]M+J-
MD8U[W2RE0>Z[98F/4Z;L!?R^DM(\;*R!_KD[^Q=02P,$%     @ VH"<5EA8
MOWNJ#0  DBT  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULM5K9<MO(
M%?V5+HTRH5P8"OLBVZJ2*-E68GD<RS-Y2.4! ILD8A#@ *!DY>MS;G=C(0!"
MM,=Y(+%UWWT'7CUF^9=BQ7G)OJZ3M'A]M"K+S=GI:1&M^#HLIMF&IWBRR/)U
M6.(R7YX6FYR'<[%IG9R:NNZ>KL,X/3I_)>Y]S,]?9=LRB5/^,6?%=KT.\Z=+
MGF2/KX^,H^K&IWBY*NG&Z?FK3;CD=[S\;?,QQ]5I#64>KWE:Q%G*<KYX?71A
MG%T:8H-8\7O,'XO6.2-6[K/L"UW<S%\?Z4013WA4$H@0AP<^XTE"D$#''PKH
M48V3-K;/*^AO!/-@YCXL^"Q+_AG/R]7K(_^(S?DBW";EI^SQ'5<,.00ORI)"
M_+-'M58_8M&V*+.UV@P*UG$JC^%7)8A#-IAJ@RGHEH@$E5=A&9Z_RK-'EM-J
M0*,3P:K8#>+BE+1R5^9X&F-?>?XFC'/V>YAL.;OE8;'-.41>%FSR.;Q/>''R
MZK0$%EI[&BF(EQ*BN0>BQ6ZSM%P5[#J=\_GN_E-05Y-H5B1>FJ, +S;YE.FF
MQDS=M$;@637+EH!G/<_R55Q$249<%^Q?%_=%F<-*_CW$LP1I#X,DUSDK-F'$
M7Q_!-PJ>/_"C\Y]_,ES]Y0C!=DVP/0;]_$YZ#,L6[(KG\4-(ALPNR)[C\FF(
MVE%XP]1^7G&VR!)X:9PN64G:9W'!PLI?"7N)-:%""Y=,PI+/69G!"RJJL"&=
MLQ6?+W&*F"&V+"#E,,$A+TKVQS;,2YX7C)-YL#@5:A7;< (MIPA%A"O\>L:@
M^CAA2O7JRA)7)IM<@=H0@ #B-DX2^'AQPNY"6"V;984 \C'/YML(YGR7)7/V
MZ>=PO7EYQ:Z_(J85G-VD((1CY>0FC;(U/ZF?_ JR\_[M_RMP4@!?+#A!!/0%
M6>D#6:D429Q"NB4YIY!5%!8KMH"VA+"ALC/V%C&83=YG!<2 >-< J)9(E9&<
M5O'FK*$PAQY9\1AN"A;!=<D'BC/VCI0(!95\7;!C]O-/OFF8+WO'26 &)WN?
MUJL<RVA67;7L9<Z+>)D*2PJ+FM(XA2]N92C:!Q.(G\4+M/5Y1SX=H0[+:)9C
M.>)PGO,T>L+Z49%=K+-M*FQC2;A@_I-$H,MYE"W3^+_2X&.A>:*A<1P6RKW\
M:Y1LR3$6>;96]H#'*0<9)3 3B?N8M>QGY6$[]>F!Q%[\.KOY01@["NB9<$?V
MR+J/83ZG,(+<FI)H5F&ZY(=*/ F+(E[$E2P%(U!@5LG?0 PQ;/<$_U9CFW33
MPSW'/&&(.;4!&_[)-XG,M)D!WB>6>]("8@,H, 0X6BW@'@CX<:;V'./[5&7H
M_K/J-$S]NRQH?P"Q#>_Y\&&8?B/&/:FJK ,HD33@WM^9DF1D/56&^SZ+A(T2
MCK<5V_+1I[[HHVB[WLH\*</^+%LCYZZHK'V@)"$4<D/*4>=M7#L WQ# X:0W
MEB;'GEWQ^Q*:F7@P>-=OI:Q8Y2:N<E-7'])69V.V>LS<0&>.JW\#V)%:R:EK
M)6>\5D+;,M_"(':+I3=Q&J91#)7?M#(+:7BF)%QI-86*TB)+XKG0VF688"-2
M/U780Z76.#D7(I?OZ$ 3:/\6IENJJHSJ9KECU#(;%.P1DA/NE)-E@CA:MI_
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M=J'RJ3D$R25(EB^XD^,^QZ/1HYI)=:,>2DP; <2G@VD-I[K3UF>R:YXOQ<?
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M1;3M&%DU=6@A#5:UIKG&=P>4#<#YI93FN6-+6_^297\ 4$L#!!0    ( -J
MG%:5NCH'%P0  *L3   9    >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;+58
M[W.;.!#]5S2TTVEGFH $QG9J,Y,FTUXZ;<>37.\^*R#;F@+R2;+=N[_^5D
MVS)-//A+PH_=Q]O':OW$9"OD3[5D3*-?69JKJ;/4>G7ENBI>LHRJ2[%B.=R9
M"YE1#:=RX:J59#0IDK+4)9X7NAGEN1--BFLS&4W$6J<\9S.)U#K+J/SW(TO%
M=NI@Y^G"/5\LM;G@1I,57; 'IG^L9A+.W!HEX1G+%1<YDFP^=:[QU0WQ3$(1
M\1=G6]4Z1J:41R%^FI.[9.IXAA%+6:P-!(5_&W;#TM0@ 8]_*E"G?J9);!\_
MH7\JBH=B'JEB-R+]FR=Z.75&#DK8G*Y3?2^V?["JH('!BT6JBK]H6\:& P?%
M:Z5%5B4#@XSGY7_ZJQ*BE8"#(PFD2B#/3?"K!+\HM&16E'5+-8TF4FR1--&
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M:=A!T.X^K/;!32Y@36(SMBG3?[_.1Q,Z)!Y [ NQD]QSS[7O.8KI[X3\JM8
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M^^YS#8F@)!$<1>*C46U,-41("Z.^;UNFF&[JDQPRV&/BU;-HERS:5A:3K93
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M;KHT2%M@]C="Z./$=HZV[R=_ 5!+ P04    " #:@)Q6:&$E"V8%  #1'P
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MX.H"_'[%F'P]4 GJ7?S%OU!+ P04    " #:@)Q6(BPB:"()  "X5@  &0
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MZ<9NJ(D:=>5_/'$EIF/<>P,Y/);!#6X"R#D@Z1SS0,[1"N1T>5,+ FK1>:E
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M4PL"DL[7PL_:1MBO$R[Y07;:^0U&05OK@[KRQX.P,3-<IUZGHKK!Y,P*6_(
M4>3CHFCT"#^!A^$A#6YA$SS,KSQM:IZ'^7H?,C7!PWQ0>+X6'M8ZTW5@=8J(
M41,U:E!7_K,^$.IW/Q&*FJA9@"3RAP.N7L]#]P-<^-D']ZD)P!6 "@O, ZY
M*^#2Y4TM"*BYP"C@"KKO.4--U*A!4P7/BK>"[GO04!,U"Q!"P7"VU6MP>[,M
M/(#!K6J";06@O@+S;"O0RK9T>5,+ C(N,,JV@NZ[QU 3-6K03L&S<JV@^VXR
MU$3-HK*OQG"DU6MVQR M/);!76L":04@N@+S2"O0BK1T>5,+ OHM,(JT@N[[
MP% 3=2L54%+AL_*LL/N^,-1$S0+D3S@<9FG>2PB/8&BOZO*FU@N$5V@>9H5:
M898N;VI!0,.%1F%6V'U'%VJB1@U2*GQ6D!5VW^&%FJA9@/X)AV.L7L/[!(R%
MAS2X>4U@K!"D6&@>8X5:,98N;VI!0-6%1C%6V'#?5>46B$.*#4]>6G8+TPTK
M>YL][^9F^[-5M^BS9N%I*@U&]NE83RM[@*:4K\NM4>6(%N'N=\P\'CUNOWI=
M;CIZ<OR]]6Z^WT05W.SW=+V-N!S_G"1T)5W.WA9?6_A^F]3]"\&VY4ZC7Y@0
M+"U_W=!H27EA(/^^8DP\OBA.<-RL]NK_4$L#!!0    ( -J G%:]_L2^Y@(
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M.B2%*<VYN9.K:ZC\A)8OD5P73[*J8CV')+DV,JO J"!CHGS3IRH/&X!6^QV
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MB2BLM*EWU=?K(HJ+C:*A^":_&UARI7B:/R:Z]( P _3[%>?JJ6$<5-=+D_\
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M8:#^?8?*V[LX+8R$WU;FS=/ZWDV^_\6$_9,RVS8_.G"3E66V:1[>\VC-\_J
MZOW;+"N_/JE_Q^#PPQ47_P)02P,$%     @ VH"<5O3,7<:] @  @@@  !D
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M>__V]3AB;KVUH_5V_.(F#_6-^<6DYD7"A(0I!!LDVGU+M+/O0<XY_F%V"9J
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M37\72H3(<2YRG-A'DWKN*=KPW/<"IUGJ!!OOFG$2P0:G+C:4YE":H#2E:,/
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MV#9I;F>.5Q%L91.*<RQ.6)QBN&'ZI2>C2J!UKF1E$XIS+$Y8G&*X(&%/-I5
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MKF8=$XIS+$Y8G&*X8<*-YY@:NY#I4@-QPH:^8/P,RLB!+G:@+!Q1<@04+HC
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MA\/Y-T\3_/:P__OSE_WZOP%02P,$%     @ VH"<5EEU2@P)!   ,Q0  !D
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MEIU/9A><+M,COBGEG$;ISP5&/F:)@7@^HY2_720.BE/BX?]02P,$%     @
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MTR8T$R,K=]-NI,%[VPT+[*Q 60/\OI58ANW$;M#U:NF_4$L#!!0    ( -J
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M8(Q/U2%?YJW:-ORETF\V7N>=HKP;0OHV>93V#!VJ*-FR"XV<<."Y5X PO(W
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MV+8%P[8M%K8-*Q<T@%@P"&S;1F#;KF&&,@+;=JND;HD/0L.V^X+ATU1FVJN
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M&4Y^;GK_CO@1/('VKV^UO=0'CR#%(\C\U.9[$PEJ/GMI3H9EH]J*VSJ1*#Y
M9CY84"8'$1;D'?A D^.RDK1.&H4.'C<=J=7#5IR!W#ZGD(X HDQ%'SB"%(X@
M,X[\P!3B-??)NSO,,JQF*P>BO7JU=A[,QX2M\_<5N,2&;2**9]75U>J=B'G^
M)L#>]7/G=%&\V:!DBA<M;C!;APD'$5E)2?O$DY7'BG<7BA-!T_SQ_Y(*0>/\
M<$-P0%C60'Z_HE2\GF0_4+U!,OL/4$L#!!0    ( -J G%:[%>-K/ 0  )P4
M   9    >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;+58VV[C-A#]%4+=%@F0
M6"(EWU+;@.UDNPML "-&NL^,-+:)E4B7I.WD[TM=HMO*:I-5\A#=9H[F#'G$
M8TY.0OY0.P"-GJ.0JZFUTWI_8]O*WT%$54_L@9LG&R$CJLVEW-IJ+X$&25(4
MVL1Q!G9$&;=FD^3>2LXFXJ!#QF$ED3I$$94O"PC%:6IAZ_7& ]ON='S#GDWV
M= MKT(_[E317=HX2L BX8H(C"9NI-<<W2Y(D)!%_,SBITCF*J3P)\2.^^!I,
M+2>N"$+P=0Q!S>$(2PC#&,G4\4\&:N7OC!/+YZ_HGQ/RALP35; 4X7<6Z-W4
M&EDH@ T]A/I!G+Y 1J@?X_DB5,E_=,IB'0OY!Z5%E"6;"B+&TR-]SAI12C X
MS0DD2R#U!.],@ILEN G1M+*$UBW5=#:1XH1D'&W0XI.D-TFV8<-X/(QK+<U3
M9O+T; U;,RA:(;%!BX,R3Y5"E ?H+Q!;2?<[YJ.YF1\*7:.UF4/!(80X]@&.
MP ^ -E)$Z.Y9@^0T1,ND8) IQ#?!M]??S"@%:*X4:'6%GEY*P"8AA;ZX!4U9
MJ"[-2Q[7M^CBTR7ZA!A']RP,S6"KB:T-U[ABV\]X+5)>Y PO%]T+KG<*W?$
M@FJ^;7J4-XJ\-FI!6@'G>]E##KE"Q"%N0SW+_Y/N)NFDI1PW'S<WP7//C1L-
M0<7MW!;C1$TSFSJ5(GG-2/%WXD;MJ0]3RWP(%,@C6+,_?L,#Y\\FFAV!54A[
M.6FO#3TEW<0P31LD:?&'ZS@CWM ;3.QCN?2&*-<C152EIGY>4[^UIA5(WPC(
M?/+0<D>Y.7SE*!V=Q4M=14VUI_"C4E5.S^G7:V\MXIUM'^04!ZT4'SG31L-K
M375S^UO3WSK!.@*K,!WF3(>=J6K8)>F.P"JD1SGIT?M4-?I)+YCT\; V,].H
M?CD*>]AK5M4XKVG\L:H:-ZEJ7*^]M8AWMAT[Q=+KM)*\.TACQQK7MM;$MTZN
MKM"J-$L. W<FJ@RJ*^(=H56)DX(X>9^PLKRRL@:N2VJ3,XLJ*VO@D#/"PH5Q
MP*U+]*]+*\.OKUBX7OY'. 5<6 7<[A6^@XI-*?H"$5/['4BX0O#LAX> \2UZ
M[*U[C=Q:0=\\_SI"J[:@<":XWYWP.C(8&?&/L"NX\"NXW;"<%][@YR6M/ZJO
M"EE494GS1N2,\ IO@5M7\0Z$-VP2WM 95_[J9#["6N#"6^!V<S%7C%ZOJ,\V
MS+]"\XTT/_L:N;7"O'G^=816)5V8%SSN3G@=>9",^$<X&E(X&M+N:,X*+\LK
M"\]SL5.;JTU1?>?,#S12&!#2NL[_NO#^ __"Z[G.[Y>-FP*=.A"[M,\3@=PF
MVU\*^>+ =;J3D=_-M]CFR<92[?X"WRS3C;(")MVWNZ=RR[A"(6P,I-,;FJ^@
M3+?"T@LM]LENTI/06D3)Z0YH #(.,,\W0NC7B_@%^8;D[%]02P,$%     @
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M\^@>?J@F4"U M1#5)*HI5(M0+4:U!-4TI=G-H\[\#="K\@[0X!^J^:@F4"U
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M-OGJ!M7W?RP6Y<LGJPD>%_G/]6&?_P=02P,$%     @ VH"<5F4YJY]\ P
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MXK):&Q8^AG_]BC)LR6\[*6]]V2?U0?/Z^$K.\76B=_\ 4$L#!!0    ( -J
MG%:\ =;!X $  .P@   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-
MVCM.PT 4A>&M1%X D_N8\%!"14.+V( 5)@^1Q)9G$,GNB4(1CD5!@^94UMCR
M]=_XDV5[_I)V;=EVA[S9]GERW.\.>=%L2ND?0LC+3=JW^:;KT^%\9-4-^[:<
ME\,Z].WRO5VGH-/I+ P_9S2/\Y\S)Z^G/OUE8K=:;9?IJ5M^[-.A_#(X?';#
M>]ZD5)K):SNL4UDTX;B[[L[ALI&;\^1F\ORV:(;G-VE"[2"%(*T?9!!D]8,<
M@KQ^4(2@6#]H!D&S^D&W$'1;/^@.@N[J!]U#T'W]()FBC%."I!'6!%H+<BT$
M7@N"+01B"Y(M!&8+HBT$:@NR+01N"\(M!'(+TBT$=@OB+01Z*^JM!'HKZJT$
M>NOH89M ;T6]E4!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 ;T6]E4!O0[V-
M0&]#O8U ;T.]C4!O&[TL(=#;4&\CT-M0;R/0VU!O(]#;4&\CT-M0;R/0VU!O
M(]#;46\GT-M1;R?0VU%O)]#;46\GT-M'+[L)]';4VPGT=M3;"?1VU-L)]';4
MVPGT=M3;"?2.J'<DT#NBWI% [XAZ1P*](^H="?2.J'<DT#N./E;^I]ZYG'8I
M7WN^UWC]_Z2ZG,]-U\M?EM\[1S?4!>< /S<\?@%02P,$%     @ VH"<5A34
M<>30 0  K2   !,   !;0V]N=&5N=%]4>7!E<UTN>&ULS=K);L(P% 707T'9
M5L1X"!T$;-IN6Q;] 3=Y0$026[:A\/=UPB"UHJB(2KT;(F+[W1=;.IMD]+:U
MY'N;NFK\.%F$8!\8\_F":NU38ZF)(S/C:AWB7S=G5N=+/2<F!H,ARTT3J G]
MT-9()J,GFNE5%7K/FWC;EZ89)XXJG_0>=Q/;K'&BK:W*7(<XSM9-\2VEOT](
MX\INCE^4UM_$"0D[F="._!RP7_>Z)N?*@GI3[<*+KN,LMJF8#]N*?'J^Q(D>
MS6Q6YE28?%7'):FWCG3A%T2AKM)=T9OSR2'N,.U^^=7Y79ES@7'FU!GKXXDY
MNCSN<"3MZKZ-A<B%\OPC'A-CZ:N?C]K3+JCX97;<W@_CEMUY>-9=KM_CKV=\
MK']A'P*D#PG2AP+I(P/I8PC2QRU('W<@?=R#],$'*(V@B,I12.4HIG(45#F*
MJAR%58[B*D>!E:/(*E!D%2BR"A19!8JL D56@2*K0)%5H,@J4&05*+)*%%DE
MBJP215:)(JM$D56BR"I19)4HLDH4626*K I%5H4BJT*15:'(JE!D52BR*A19
M%8JL"D56A2)KAB)KAB)KAB)KAB)KAB)K]I^ROANS_.L7Z.TUK779'/)9]Y7"
MY!-02P$"% ,4    " #:@)Q6!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -J G%;@7<79[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( -J G%:97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ VH"<5HN/[8I,!P  DC,  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( -J G%:6[@F!80<  !8?   8              " @8\/  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #:@)Q6E[U=YN8"  #B"
M&               @($F%P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ VH"<5G2]X\]&!@  ?AP  !@              ("!0AH  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( -J G%;/Y&DU7P0
M *@1   8              " @;X@  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    " #:@)Q6ED#7>-H"  "N!P  &               @(%3
M)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ VH"<5H2#
MIJ09!0  E1H  !@              ("!8R@  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( -J G%;L'[>S< (  ,\%   8
M  " @;(M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #:
M@)Q62)>"P\0(  "()0  &               @(%8,   >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ VH"<5K055&SF!0  7 X  !D
M         ("!4CD  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    " #:@)Q6M?B@L'<"  !;!0  &0              @(%O/P  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( -J G%:@/?]%U 4  /T-
M   9              " @1U"  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ VH"<5M:'D;ZR&   Q%   !D              ("!*$@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #:@)Q6K$VS
M7'X&  " #P  &0              @($180  >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( -J G%9D@+HHMP0  )D*   9
M  " @<9G  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
MVH"<5B%1E&@I!   =PD  !D              ("!M&P  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    " #:@)Q6LBB*C@L#  #_!@  &0
M            @($4<0  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( -J G%8C*:[V5 X  ,DA   9              " @59T  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ VH"<5GXV]?Y["0
MNA8  !D              ("!X8(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    " #:@)Q6G0P!S$\J  #ZA0  &0              @(&3
MC   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( -J G%9W
M1X)#I 4  *T.   9              " @1FW  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ VH"<5HTO9 YZ @  8P4  !D
M     ("!]+P  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -J G%9T,8WS" ,  "P'   9              "
M@=+8  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ VH"<
M5C@D:)8U#@  Q2$  !D              ("!$=P  'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    " #:@)Q65)*I<X0#  !!!P  &0
M        @(%]Z@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( -J G%;A!E^YOP(  "<(   9              " @3CN  !X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ VH"<5@198?"+ @  U08
M !D              ("!+O$  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    " #:@)Q6E;HZ!Q<$  "K$P  &0              @('P\P
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( -J G%8)C8:S
MS0,  &<0   9              " @3[X  !X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ VH"<5EB@(&US P  .Q   !D
M ("!0OP  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " #:
M@)Q6DY8;9E8"   #!@  &0              @('L_P  >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( -J G%9H824+9@4  -$?   9
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M970T,"YX;6Q02P$"% ,4    " #:@)Q65HF< ?P#  !J$@  &0
M    @(%A&P$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M -J G%9^1+L:^@H  /)I   9              " @90? 0!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ VH"<5OSX!*L;"@  Q&(  !D
M             ("!Q2H! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    " #:@)Q6],Q=QKT"  """   &0              @($7-0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( -J G%9KO:VGJR8
M (&( @ 9              " @0LX 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ VH"<5EEU2@P)!   ,Q0  !D              ("!
M[5X! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #:@)Q6
MA]#I:2 $  !>$0  &0              @($M8P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( -J G%:A)!$R?@(  #8'   9
M      " @81G 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ VH"<5N4/1\)O!0  ,1X  !D              ("!.6H! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #:@)Q6S+[MXTL#  "W"0
M&0              @('?;P$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( -J G%:D?49'8C(  *]/ @ 9              " @6%S 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ VH"<5@P9^%OK
M!0  32(  !D              ("!^J4! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    " #:@)Q6NQ7C:SP$  "<%   &0
M@($<K $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( -J
MG%:^BGMR+ @  -1%   9              " @8^P 0!X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ VH"<5F[49H&X$0  D2L! !D
M         ("!\K@! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
M    " #:@)Q693FKGWP#  #G%@  #0              @ 'AR@$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( -J G%:7BKL<P    !,"   +
M  "  8C. 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( -J G%99O+2M1 0  -(D
M   /              "  7'/ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #:@)Q6O '6P> !  #L(   &@              @ 'BTP$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #:@)Q6%-1QY- !  "M(
M$P              @ 'ZU0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
../P _ # 1  #[UP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>665</ContextCount>
  <ElementCount>321</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>189</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEarnings</Role>
      <ShortName>Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Pensions and Other Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlans</Role>
      <ShortName>Pensions and Other Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Accumulated Other Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome</Role>
      <ShortName>Accumulated Other Comprehensive Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Segments of Business and Geographic Areas</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</Role>
      <ShortName>Segments of Business and Geographic Areas</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Inventories</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Pensions and Other Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</Role>
      <ShortName>Pensions and Other Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlans</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Accumulated Other Comprehensive Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Segments of Business and Geographic Areas (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables</Role>
      <ShortName>Segments of Business and Geographic Areas (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Commitment and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommitmentandContingenciesTables</Role>
      <ShortName>Commitment and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/InventoriesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Goodwill By Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Derivative Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails</Role>
      <ShortName>Fair Value Measurements - Derivatives, Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IncomeTaxes</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Pensions and Other Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails</Role>
      <ShortName>Pensions and Other Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Accumulated Other Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShareTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="jnj-20230402.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedingsDetails</Role>
      <ShortName>Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/LegalProceedings</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept ResearchAndDevelopmentInProcess in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. jnj-20230402.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="jnj-20230402.htm">jnj-20230402.htm</File>
    <File>a20231qex311ceocertificati.htm</File>
    <File>a20231qex312cfocertificati.htm</File>
    <File>a20231qex321ceocertificati.htm</File>
    <File>a20231qex322cfocertificati.htm</File>
    <File>exhibit101-2022ltipxformps.htm</File>
    <File>exhibit102-2022ltipformrsu.htm</File>
    <File>exhibit103-2022ltipformsto.htm</File>
    <File>jnj-20230402.xsd</File>
    <File>jnj-20230402_cal.xml</File>
    <File>jnj-20230402_def.xml</File>
    <File>jnj-20230402_lab.xml</File>
    <File>jnj-20230402_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>jnj-20230402_g1.jpg</File>
    <File>jnj-20230402_g2.jpg</File>
    <File>jnj-20230402_g3.jpg</File>
    <File>jnj-20230402_g4.jpg</File>
    <File>jnj-20230402_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1191">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="41">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>84
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "jnj-20230402.htm": {
   "axisCustom": 0,
   "axisStandard": 32,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1191,
    "http://xbrl.sec.gov/dei/2022": 41
   },
   "contextCount": 665,
   "dts": {
    "calculationLink": {
     "local": [
      "jnj-20230402_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "jnj-20230402_def.xml"
     ]
    },
    "inline": {
     "local": [
      "jnj-20230402.htm"
     ]
    },
    "labelLink": {
     "local": [
      "jnj-20230402_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jnj-20230402_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "jnj-20230402.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 653,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 50,
   "keyStandard": 271,
   "memberCustom": 121,
   "memberStandard": 56,
   "nsprefix": "jnj",
   "nsuri": "http://www.jnj.com/20230402",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.jnj.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.jnj.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Intangible Assets and Goodwill",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.jnj.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.jnj.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Pensions and Other Benefit Plans",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlans",
     "shortName": "Pensions and Other Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Accumulated Other Comprehensive Income",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome",
     "shortName": "Accumulated Other Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Earnings Per Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.jnj.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Segments of Business and Geographic Areas",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas",
     "shortName": "Segments of Business and Geographic Areas",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Acquisitions and Divestitures",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestitures",
     "shortName": "Acquisitions and Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Legal Proceedings",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.jnj.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.jnj.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.jnj.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Pensions and Other Benefit Plans (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables",
     "shortName": "Pensions and Other Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Accumulated Other Comprehensive Income (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables",
     "shortName": "Accumulated Other Comprehensive Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Earnings Per Share (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.jnj.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Segments of Business and Geographic Areas (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables",
     "shortName": "Segments of Business and Geographic Areas (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SummaryOfClaimsInPendingLawsuitsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Commitment and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.jnj.com/role/CommitmentandContingenciesTables",
     "shortName": "Commitment and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SummaryOfClaimsInPendingLawsuitsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ibba084db76814e3ea3789881d3aff00a_D20230402-20230402",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "jnj:SupplierFinanceProgramObligationCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ibba084db76814e3ea3789881d3aff00a_D20230402-20230402",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "jnj:SupplierFinanceProgramObligationCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.jnj.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Intangible Assets and Goodwill (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "if241137260614532b6020bfeda156ac3_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Intangible Assets and Goodwill - Goodwill By Segment (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
     "shortName": "Intangible Assets and Goodwill - Goodwill By Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i814ccd0c40684dd8ae2ed1e023cd3b2a_D20221222-20221222",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails",
     "shortName": "Intangible Assets and Goodwill - Intangible Asset Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i530924810ee74f0498a5b576273161b3_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
     "shortName": "Fair Value Measurements - Summary of Derivative Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i41f4633d6ab6401e9804fb1a385a3531_D20230102-20230402",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Fair Value Measurements - Derivatives, Balance Sheet Location (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
     "shortName": "Fair Value Measurements - Derivatives, Balance Sheet Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i1a044beb1efb4064b0c24daf2024f934_I20230402",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i06741010c1a64e268867848027daba0c_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i06741010c1a64e268867848027daba0c_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Earnings",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
     "shortName": "Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:SalesRevenueGoodsNetPercentToSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
     "shortName": "Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i3f485b1f7c7942f49f325dd462771cde_I20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
     "shortName": "Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails",
     "shortName": "Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-8",
      "lang": "en-US",
      "name": "jnj:ExcessOfCarryingValueOverFairValueOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.jnj.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ie7987f4710274da781b044c04aa38be0_I20230402",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i8835d6dda8df4e5bb049a67defcdc043_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i6a79593849c348e791c81a2228ea6405_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Pensions and Other Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails",
     "shortName": "Pensions and Other Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i6a79593849c348e791c81a2228ea6405_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionContributions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "if241137260614532b6020bfeda156ac3_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Accumulated Other Comprehensive Income (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
     "shortName": "Accumulated Other Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i6b6f17374cb84625bb4b63c7a5d62e2c_I20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.jnj.com/role/EarningsPerShareDetails",
     "shortName": "Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Sales By Segment Of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesBySegmentOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i2e99be17669548568e7cf2506dae3d92_D20220103-20220403",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails",
     "shortName": "Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesByGeographicArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Acquisitions and Divestitures - Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
     "shortName": "Acquisitions and Divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i74c08a50ff5f419b83ba7dba4d025c2a_D20220103-20230101",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i043b133272cb49e4ad4a3a90ff5a68b9_I20211031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:LossContingencyRemainingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Legal Proceedings (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.jnj.com/role/LegalProceedingsDetails",
     "shortName": "Legal Proceedings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i043b133272cb49e4ad4a3a90ff5a68b9_I20211031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:LossContingencyRemainingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "iae6ce94080c14bf3947a9c53d1a7596d_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "i2d9051e5238a4ac9baecaaf4941dc3a4_I20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230402.htm",
      "contextRef": "ia1dc7f763e8442a582291278de4fd0a3_D20230102-20230402",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 189,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r804"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "jnj_A0.650NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.650% Notes Due 2024 [Member]",
        "label": "0.650% Notes Due 2024 [Member]",
        "terseLabel": "0.650% Notes due 2024 (750MM Euro 1.0909)",
        "verboseLabel": "0.650% Notes Due May 2024"
       }
      }
     },
     "localname": "A0.650NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A0550NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.550 Notes due 2025",
        "label": "0.550 Notes due 2025 [Member]",
        "terseLabel": "0.55% Notes due 2025"
       }
      }
     },
     "localname": "A0550NotesDue2025Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A095NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.95% Notes due 2027",
        "label": "0.95% Notes due 2027 [Member]",
        "terseLabel": "0.95% Notes due 2027"
       }
      }
     },
     "localname": "A095NotesDue2027Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.150NotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.150% Notes Due 2028 [Member]",
        "label": "1.150% Notes Due 2028 [Member]",
        "terseLabel": "1.150% Notes due 2028 (750MM Euro 1.0909)",
        "verboseLabel": "1.150% Notes Due November 2028"
       }
      }
     },
     "localname": "A1.150NotesDue2028Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.650NotesDue2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.650% Notes Due 2035 [Member]",
        "label": "1.650% Notes Due 2035 [Member]",
        "terseLabel": "1.650% Notes due 2035 (1.5B Euro 1.0909)",
        "verboseLabel": "1.650% Notes Due May 2035"
       }
      }
     },
     "localname": "A1.650NotesDue2035Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1300NotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.300% Notes due 2030",
        "label": "1.300% Notes due 2030 [Member]",
        "terseLabel": "1.30% Notes due 2030"
       }
      }
     },
     "localname": "A1300NotesDue2030Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.45Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes due 2026 [Member]",
        "label": "2.45% Notes due 2026 [Member]",
        "terseLabel": "2.45% Notes due 2026"
       }
      }
     },
     "localname": "A2.45Notesdue2026Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.625Notesdue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.625 Notes due 2025 [Member]",
        "label": "2.625 Notes due 2025 [Member]",
        "terseLabel": "2.625% Notes due 2025"
       }
      }
     },
     "localname": "A2.625Notesdue2025Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.900Notesdue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.900% Notes due 2028 [Member]",
        "label": "2.900% Notes due 2028 [Member]",
        "terseLabel": "2.90%\u00a0Notes due 2028"
       }
      }
     },
     "localname": "A2.900Notesdue2028Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.95Notesdue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Notes due 2027 [Member]",
        "label": "2.95% Notes due 2027 [Member]",
        "terseLabel": "2.95% Notes due 2027"
       }
      }
     },
     "localname": "A2.95Notesdue2027Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A210NotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.10% Notes due 2040",
        "label": "2.10% Notes due 2040 [Member]",
        "terseLabel": "2.10% Notes due 2040"
       }
      }
     },
     "localname": "A210NotesDue2040Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2250NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.250% Notes due 2050",
        "label": "2.250% Notes due 2050 [Member]",
        "terseLabel": "2.25% Notes due 2050"
       }
      }
     },
     "localname": "A2250NotesDue2050Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2450NotesDue2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.450% Notes due 2060",
        "label": "2.450% Notes due 2060 [Member]",
        "terseLabel": "2.45% Notes due 2060"
       }
      }
     },
     "localname": "A2450NotesDue2060Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.400Notesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.400% Notes due 2038 [Member]",
        "label": "3.400% Notes due 2038 [Member]",
        "terseLabel": "3.40%\u00a0Notes due 2038"
       }
      }
     },
     "localname": "A3.400Notesdue2038Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.500Notesdue2048Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.500% Notes due 2048 [Member]",
        "label": "3.500% Notes due 2048 [Member]",
        "terseLabel": "3.50% Notes due 2048"
       }
      }
     },
     "localname": "A3.500Notesdue2048Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.55Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.55% Notes due 2036 [Member]",
        "label": "3.55% Notes due 2036 [Member]",
        "terseLabel": "3.55% Notes due 2036"
       }
      }
     },
     "localname": "A3.55Notesdue2036Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.625Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.625% Notes due 2037 [Member]",
        "label": "3.625% Notes due 2037 [Member]",
        "terseLabel": "3.625% Notes due 2037"
       }
      }
     },
     "localname": "A3.625Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.70Notesdue2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Notes due 2046 [Member]",
        "label": "3.70% Notes due 2046 [Member]",
        "terseLabel": "3.70% Notes due 2046"
       }
      }
     },
     "localname": "A3.70Notesdue2046Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.75Notesdue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.75% Notes due 2047 [Member]",
        "label": "3.75% Notes due 2047 [Member]",
        "terseLabel": "3.75% Notes due 2047"
       }
      }
     },
     "localname": "A3.75Notesdue2047Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.375Notesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Notes due 2033 [Member]",
        "label": "4.375% Notes due 2033 [Member]",
        "terseLabel": "4.375% Notes due 2033"
       }
      }
     },
     "localname": "A4.375Notesdue2033Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Debenturesdue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Debentures due 2040 [Member]",
        "label": "4.50% Debentures due 2040 [Member]",
        "terseLabel": "4.50% Debentures due 2040"
       }
      }
     },
     "localname": "A4.50Debenturesdue2040Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Notesdue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Notes due 2043 [Member]",
        "label": "4.50% Notes due 2043 [Member]",
        "terseLabel": "4.50% Notes due 2043"
       }
      }
     },
     "localname": "A4.50Notesdue2043Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.85Notesdue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.85% Notes due 2041 [Member]",
        "label": "4.85% Notes due 2041 [Member]",
        "terseLabel": "4.85% Notes due 2041"
       }
      }
     },
     "localname": "A4.85Notesdue2041Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.95Debenturesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.95% Debentures due 2033 [Member]",
        "label": "4.95% Debentures due 2033 [Member]",
        "terseLabel": "4.95% Debentures due 2033"
       }
      }
     },
     "localname": "A4.95Debenturesdue2033Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A490DebentureDue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.90% Debenture Due 2033",
        "label": "4.90% Debenture Due 2033 [Member]",
        "terseLabel": "4.90% Debentures due 2033*"
       }
      }
     },
     "localname": "A490DebentureDue2033Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.50NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Notes Due 2024 [Member]",
        "label": "5.50% Notes Due 2024 [Member]",
        "terseLabel": "5.50% Notes due 2024 (500MM GBP 1.2359)",
        "verboseLabel": "5.50% Notes Due November 2024"
       }
      }
     },
     "localname": "A5.50NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/Cover",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.85Debenturesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.85% Debentures due 2038 [Member]",
        "label": "5.85% Debentures due 2038 [Member]",
        "terseLabel": "5.85% Debentures due 2038"
       }
      }
     },
     "localname": "A5.85Debenturesdue2038Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.95Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.95% Notes due 2037 [Member]",
        "label": "5.95% Notes due 2037 [Member]",
        "terseLabel": "5.95% Notes due 2037"
       }
      }
     },
     "localname": "A5.95Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A500DebentureDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.00% Debenture Due 2030",
        "label": "5.00% Debenture Due 2030 [Member]",
        "terseLabel": "5.00% Debentures due 2030*"
       }
      }
     },
     "localname": "A500DebentureDue2030Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A505DebentureDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.05% Debenture Due 2028",
        "label": "5.05% Debenture Due 2028 [Member]",
        "terseLabel": "5.05% Debentures due 2028*"
       }
      }
     },
     "localname": "A505DebentureDue2028Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A505DebentureDue2053Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.05% Debenture Due 2053",
        "label": "5.05% Debenture Due 2053 [Member]",
        "terseLabel": "5.05% Debentures due 2053*"
       }
      }
     },
     "localname": "A505DebentureDue2053Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A510DebentureDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.10% Debenture Due 2043",
        "label": "5.10% Debenture Due 2043 [Member]",
        "terseLabel": "5.10% Debentures due 2043*"
       }
      }
     },
     "localname": "A510DebentureDue2043Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A520DebentureDue2063Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.20% Debenture Due 2063",
        "label": "5.20% Debenture Due 2063 [Member]",
        "terseLabel": "5.20% Debentures due 2063*"
       }
      }
     },
     "localname": "A520DebentureDue2063Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A535DebentureDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.35% Debenture Due 2026",
        "label": "5.35% Debenture Due 2026 [Member]",
        "terseLabel": "5.35% Debentures due 2026*"
       }
      }
     },
     "localname": "A535DebentureDue2026Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A550DebentureDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Debenture Due 2025",
        "label": "5.50% Debenture Due 2025 [Member]",
        "terseLabel": "5.50% Debentures due 2025*"
       }
      }
     },
     "localname": "A550DebentureDue2025Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.95Notesdue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.95% Notes due 2029 [Member]",
        "label": "6.95% Notes due 2029 [Member]",
        "terseLabel": "6.95% Notes due 2029"
       }
      }
     },
     "localname": "A6.95Notesdue2029Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ADVANCEDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADVANCED [Member]",
        "label": "ADVANCED [Member]",
        "terseLabel": "ADVANCED"
       }
      }
     },
     "localname": "ADVANCEDMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AbiomedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abiomed",
        "label": "Abiomed [Member]",
        "terseLabel": "ABIOMED(3)"
       }
      }
     },
     "localname": "AbiomedMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AccruedRebatesReturnsAndPromotions": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.",
        "label": "Accrued Rebates Returns And Promotions",
        "verboseLabel": "Accrued rebates, returns and promotions"
       }
      }
     },
     "localname": "AccruedRebatesReturnsAndPromotions",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AccruedTaxesOnIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Taxes On Income",
        "label": "Accrued Taxes On Income [Member]",
        "terseLabel": "Accrued Taxes On Income"
       }
      }
     },
     "localname": "AccruedTaxesOnIncomeMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AsiaPacificAfricaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asia-Pacific, Africa [Member]",
        "label": "Asia-Pacific, Africa [Member]",
        "terseLabel": "Asia-Pacific, Africa"
       }
      }
     },
     "localname": "AsiaPacificAfricaMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AsrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASR.",
        "label": "ASR [Member]",
        "terseLabel": "ASR"
       }
      }
     },
     "localname": "AsrMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AurisHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auris Health",
        "label": "Auris Health [Member]",
        "terseLabel": "Auris Health"
       }
      }
     },
     "localname": "AurisHealthMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Care [Member]",
        "label": "Baby Care [Member]",
        "terseLabel": "Baby Care"
       }
      }
     },
     "localname": "BabyCareMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyPowderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Powder [Member]",
        "label": "Baby Powder [Member]",
        "terseLabel": "Baby Powder"
       }
      }
     },
     "localname": "BabyPowderMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BankruptcyLossContingencyDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bankruptcy Loss Contingency, Discount Rate",
        "label": "Bankruptcy Loss Contingency, Discount Rate",
        "terseLabel": "Bankruptcy Loss Contingency, Discount Rate"
       }
      }
     },
     "localname": "BankruptcyLossContingencyDiscountRate",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_BeautyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beauty [Member]",
        "label": "Beauty [Member]",
        "terseLabel": "Skin Health/Beauty"
       }
      }
     },
     "localname": "BeautyMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BermekimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bermekimab [Member]",
        "label": "bermekimab [Member]",
        "terseLabel": "bermekimab"
       }
      }
     },
     "localname": "BermekimabMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BusinessAcquisitionDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Discount Rate",
        "label": "Business Acquisition, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "BusinessAcquisitionDiscountRate",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_BusinessCombinationProbabilityOfSuccessFactor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Probability Of Success Factor",
        "label": "Business Combination, Probability Of Success Factor",
        "terseLabel": "Probability of success factor"
       }
      }
     },
     "localname": "BusinessCombinationProbabilityOfSuccessFactor",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_CARVYKTIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARVYKTI",
        "label": "CARVYKTI [Member]",
        "terseLabel": "CARVYKTI"
       }
      }
     },
     "localname": "CARVYKTIMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONCERTAMethylphenidateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONCERTA/Methylphenidate [Member]",
        "label": "CONCERTA/Methylphenidate [Member]",
        "terseLabel": "CONCERTA / methylphenidate"
       }
      }
     },
     "localname": "CONCERTAMethylphenidateMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONTACTLENSESOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONTACT LENSES/OTHER [Member]",
        "label": "CONTACT LENSES/OTHER [Member]",
        "terseLabel": "CONTACT LENSES / OTHER"
       }
      }
     },
     "localname": "CONTACTLENSESOTHERMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CardiovascularMetabolismOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular/Metabolism/Other [Member]",
        "label": "Cardiovascular/Metabolism/Other [Member]",
        "terseLabel": "Cardiovascular / Metabolism / Other"
       }
      }
     },
     "localname": "CardiovascularMetabolismOtherMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, And Short-Term Investments, Accumulated Gross Unrealized Loss",
        "negatedTerseLabel": "Total cash, cash equivalents and current marketable securities, Unrecognized Loss"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Short-term Investments, Estimated Fair Value",
        "label": "Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Estimated Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ClassIRecommendationForImpellaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class I Recommendation For Impella",
        "label": "Class I Recommendation For Impella [Member]",
        "terseLabel": "Class I Recommendation For Impella"
       }
      }
     },
     "localname": "ClassIRecommendationForImpellaMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ConsumerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer.",
        "label": "Consumer [Member]",
        "terseLabel": "CONSUMER HEALTH"
       }
      }
     },
     "localname": "ConsumerMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CostOfGoodsSoldPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_GrossProfitPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of goods sold percent to sales.",
        "label": "Cost Of Goods Sold Percent To Sales",
        "terseLabel": "Cost of products sold percent to sales"
       }
      }
     },
     "localname": "CostOfGoodsSoldPercentToSales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_DARZALEXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DARZALEX [Member]",
        "label": "DARZALEX [Member]",
        "terseLabel": "DARZALEX"
       }
      }
     },
     "localname": "DARZALEXMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DePuyASRU.S.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DePuy ASR U.S. [Member]",
        "label": "DePuy ASR U.S. [Member]",
        "terseLabel": "DePuy ASR U.S."
       }
      }
     },
     "localname": "DePuyASRU.S.Member",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EDURANTrilpivirineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EDURANT/rilpivirine [Member]",
        "label": "EDURANT/rilpivirine [Member]",
        "terseLabel": "EDURANT / rilpivirine"
       }
      }
     },
     "localname": "EDURANTrilpivirineMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ERLEADAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ERLEADA",
        "label": "ERLEADA [Member]",
        "terseLabel": "ERLEADA"
       }
      }
     },
     "localname": "ERLEADAMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ElectrophysiologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Electrophysiology",
        "label": "Electrophysiology [Member]",
        "terseLabel": "ELECTROPHYSIOLOGY"
       }
      }
     },
     "localname": "ElectrophysiologyMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ElmironMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elmiron",
        "label": "Elmiron [Member]",
        "terseLabel": "Elmiron"
       }
      }
     },
     "localname": "ElmironMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityInvestmentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment [Roll Forward]",
        "label": "Equity Investment [Roll Forward]",
        "terseLabel": "Equity Investment [Roll Forward]"
       }
      }
     },
     "localname": "EquityInvestmentRollForward",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "label": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "terseLabel": "Sales/ Purchases/Other"
       }
      }
     },
     "localname": "EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentswithReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments with Readily Determinable Value [Member]",
        "label": "Equity Investments with Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments with readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityInvestmentswithoutReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments without Readily Determinable Value [Member]",
        "label": "Equity Investments without Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments without readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithoutReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EthiconMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ethicon",
        "label": "Ethicon [Member]",
        "terseLabel": "Ethicon"
       }
      }
     },
     "localname": "EthiconMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExcessOfCarryingValueOverFairValueOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess Of Carrying Value Over Fair Value Of Debt",
        "label": "Excess Of Carrying Value Over Fair Value Of Debt",
        "terseLabel": "Excess Of Carrying Value Over Fair Value Of Debt"
       }
      }
     },
     "localname": "ExcessOfCarryingValueOverFairValueOfDebt",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "terseLabel": "Changes in estimated fair value (6)"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_GENERALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GENERAL [Member]",
        "label": "GENERAL [Member]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "GENERALMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_GrossProfitPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross profit percent to sales.",
        "label": "Gross Profit Percent To Sales",
        "totalLabel": "Gross Profit Percent To Sales"
       }
      }
     },
     "localname": "GrossProfitPercentToSales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_HIPSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIPS [Member]",
        "label": "HIPS [Member]",
        "terseLabel": "HIPS"
       }
      }
     },
     "localname": "HIPSMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IMBRUVICAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMBRUVICA [Member]",
        "label": "IMBRUVICA [Member]",
        "terseLabel": "IMBRUVICA"
       }
      }
     },
     "localname": "IMBRUVICAMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "label": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "terseLabel": "INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA"
       }
      }
     },
     "localname": "INVEGASUSTENNAXEPLIONTRINZATREVICTAMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ImpellaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impella",
        "label": "Impella [Member]",
        "terseLabel": "Impella"
       }
      }
     },
     "localname": "ImpellaMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_NetIncomeAttributableToParentPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income loss from continuing operations before income taxes minority interest and income loss from equity method investments percent to sales.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Percent To Sales",
        "totalLabel": "Earnings before provision for taxes on income percent to sales"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_IncomeTaxExpenseBenefitPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_NetIncomeAttributableToParentPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax expense benefit percent to sales.",
        "label": "Income Tax Expense Benefit Percent To Sales",
        "terseLabel": "Provision for taxes on income percent to sales"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitPercentToSales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infectious Diseases [Member]",
        "label": "Infectious Diseases [Member]",
        "terseLabel": "Infectious Diseases"
       }
      }
     },
     "localname": "InfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InghamVsJohnsonJohnsonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ingham vs. Johnson &amp; Johnson",
        "label": "Ingham vs. Johnson &amp; Johnson [Member]",
        "terseLabel": "Ingham v. Johnson &amp; Johnson"
       }
      }
     },
     "localname": "InghamVsJohnsonJohnsonMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterestExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest expense percent to sales.",
        "label": "Interest Expense Percent To Sales",
        "terseLabel": "Interest expense, net of portion capitalized percent to sales"
       }
      }
     },
     "localname": "InterestExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_InterestIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Income Expense Net Member.",
        "label": "Interest Income Expense Net Member",
        "verboseLabel": "Interest (income)/Interest expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterventionalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interventional Solutions [Member]",
        "label": "Interventional Solutions [Member]",
        "verboseLabel": "Interventional Solutions"
       }
      }
     },
     "localname": "InterventionalSolutionsMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InvestmentIncomeInterestPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment income interest percent to sales.",
        "label": "Investment Income Interest Percent To Sales",
        "terseLabel": "Interest income percent to sales"
       }
      }
     },
     "localname": "InvestmentIncomeInterestPercentToSales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_KNEESMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KNEES [Member]",
        "label": "KNEES [Member]",
        "terseLabel": "KNEES"
       }
      }
     },
     "localname": "KNEESMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LegalProceedingTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Proceeding Textuals Abstract.",
        "label": "Legal Proceeding (Textuals) [Abstract]",
        "terseLabel": "Legal Proceeding (Textuals)"
       }
      }
     },
     "localname": "LegalProceedingTextualsAbstract",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LossContingencyAdditionalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Additional Contribution",
        "label": "Loss Contingency, Additional Contribution",
        "terseLabel": "Loss Contingency, Additional Contribution"
       }
      }
     },
     "localname": "LossContingencyAdditionalContribution",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Claims within Settlement Agreement",
        "label": "Loss Contingency, Number of Claims within Settlement Agreement",
        "terseLabel": "Number of claims within settlement agreement"
       }
      }
     },
     "localname": "LossContingencyNumberOfClaimsWithinSettlementAgreement",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_LossContingencyPendingClaimsNumberAdditional": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Pending Claims, Number, Additional",
        "label": "Loss Contingency Pending Claims, Number, Additional",
        "terseLabel": "Loss Contingency Pending Claims, Number, Additional"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumberAdditional",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_LossContingencyPendingClaimsNumberRemaining": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Pending Claims, Number, Remaining",
        "label": "Loss Contingency, Pending Claims, Number, Remaining",
        "terseLabel": "Loss Contingency, Pending Claims, Number, Remaining"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumberRemaining",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_LossContingencyRemainingTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Remaining Term",
        "label": "Loss Contingency Remaining Term",
        "terseLabel": "Loss Contingency Remaining Term"
       }
      }
     },
     "localname": "LossContingencyRemainingTerm",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "jnj_LossContingencyReserveEstablishedWithinTrust": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Reserve Established within Trust",
        "label": "Loss Contingency, Reserve Established within Trust",
        "terseLabel": "Reserve established"
       }
      }
     },
     "localname": "LossContingencyReserveEstablishedWithinTrust",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LossContingencyReserveEstablishedWithinTrustNominalValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Reserve Established Within Trust, Nominal Value",
        "label": "Loss Contingency, Reserve Established Within Trust, Nominal Value",
        "terseLabel": "Loss Contingency, Reserve Established Within Trust, Nominal Value"
       }
      }
     },
     "localname": "LossContingencyReserveEstablishedWithinTrustNominalValue",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LossContingencyReserveEstablishedWithinTrustTotal": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Reserve Established Within Trust, Total",
        "label": "Loss Contingency, Reserve Established Within Trust, Total",
        "terseLabel": "Loss Contingency, Reserve Established Within Trust, Total"
       }
      }
     },
     "localname": "LossContingencyReserveEstablishedWithinTrustTotal",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LossContingencyTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Term",
        "label": "Loss Contingency, Term",
        "terseLabel": "Loss Contingency, Term"
       }
      }
     },
     "localname": "LossContingencyTerm",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "jnj_MedicalDevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Devices [Member]",
        "label": "Medical Devices [Member]",
        "terseLabel": "MEDTECH",
        "verboseLabel": "MedTech"
       }
      }
     },
     "localname": "MedicalDevicesMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NetIncomeAttributableToParentPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income Attributable to Parent Percent to Sales",
        "label": "Net Income Attributable to Parent Percent to Sales",
        "totalLabel": "Net earnings percent to sales"
       }
      }
     },
     "localname": "NetIncomeAttributableToParentPercentToSales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neuroscience [Member]",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NonTradeableContingentValueRightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Tradeable Contingent Value Right",
        "label": "Non-Tradeable Contingent Value Right [Member]",
        "terseLabel": "Non-Tradeable Contingent Value Right"
       }
      }
     },
     "localname": "NonTradeableContingentValueRightMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NotesDuePeriodFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes due period fifteen.",
        "label": "Notes Due Period Fifteen Member",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "NotesDuePeriodFifteenMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Numberofpatientsinsettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients in settlement",
        "label": "Number of patients in settlement",
        "terseLabel": "Number of patients in settlement"
       }
      }
     },
     "localname": "Numberofpatientsinsettlement",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_OPSUMITMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPSUMIT [Member]",
        "label": "OPSUMIT [Member]",
        "terseLabel": "OPSUMIT"
       }
      }
     },
     "localname": "OPSUMITMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTC [Member]",
        "label": "OTC [Member]",
        "terseLabel": "OTC [Member]"
       }
      }
     },
     "localname": "OTCMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTHERNEUROSCIENCEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTHER NEUROSCIENCE [Member]",
        "label": "OTHER NEUROSCIENCE [Member]",
        "terseLabel": "OTHER NEUROSCIENCE"
       }
      }
     },
     "localname": "OTHERNEUROSCIENCEMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "label": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "terseLabel": "Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI"
       }
      }
     },
     "localname": "OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OpioidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid",
        "label": "opioid [Member]",
        "terseLabel": "Opioid"
       }
      }
     },
     "localname": "OpioidMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OralCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Care [Member]",
        "label": "Oral Care [Member]",
        "terseLabel": "Oral Care"
       }
      }
     },
     "localname": "OralCareMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OrthopaedicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orthopaedics [Member]",
        "label": "Orthopaedics [Member]",
        "terseLabel": "Orthopaedics"
       }
      }
     },
     "localname": "OrthopaedicsMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "negatedTerseLabel": "Prior service cost amortization during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "negatedTerseLabel": "Gain (loss) amortization during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "OTHER IMMUNOLOGY"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Expense Net [Member]",
        "label": "Other Income Expense Net [Member]",
        "terseLabel": "Other (income) expense",
        "verboseLabel": "Other Income Expense Net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Infectious Diseases [Member]",
        "label": "Other Infectious Diseases [Member]",
        "terseLabel": "OTHER INFECTIOUS DISEASES("
       }
      }
     },
     "localname": "OtherInfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherInterventionalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Interventional Solutions",
        "label": "Other Interventional Solutions [Member]",
        "terseLabel": "OTHER INTERVENTIONAL SOLUTIONS"
       }
      }
     },
     "localname": "OtherInterventionalSolutionsMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherNonOperatingIncomeExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non operating income expense percent to sales.",
        "label": "Other Non Operating Income Expense Percent To Sales",
        "terseLabel": "Other (income) expense, net percent to sales"
       }
      }
     },
     "localname": "OtherNonOperatingIncomeExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "OTHER ONCOLOGY"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "label": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "terseLabel": "PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA"
       }
      }
     },
     "localname": "PREZISTAPREZCOBIXREZOLSTASYMTUZAMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents And Trademarks [Member]",
        "label": "Patents And Trademarks [Member]",
        "terseLabel": "Patents And Trademarks"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PelvicMeshesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pelvic meshes.",
        "label": "Pelvic Meshes [Member]",
        "terseLabel": "Pelvic Meshes"
       }
      }
     },
     "localname": "PelvicMeshesMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PercentageChangeInOperatingIncomeLoss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in operating income loss.",
        "label": "Percentage Change in Operating Income Loss",
        "terseLabel": "Percentage Change in Operating Income Loss"
       }
      }
     },
     "localname": "PercentageChangeInOperatingIncomeLoss",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageChangeInSalesByGeographicArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by geographic area.",
        "label": "Percentage Change In Sales By Geographic Area",
        "terseLabel": "Percentage Change In Sales By Geographic Area"
       }
      }
     },
     "localname": "PercentageChangeInSalesByGeographicArea",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageChangeInSalesBySegmentOfBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by segment of business.",
        "label": "Percentage Change In Sales By Segment Of Business",
        "terseLabel": "Percent Change (as a percent)"
       }
      }
     },
     "localname": "PercentageChangeInSalesBySegmentOfBusiness",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical.",
        "label": "Pharmaceutical [Member]",
        "terseLabel": "PHARMACEUTICAL"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PhysiomeshMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physiomesh [Member]",
        "label": "Physiomesh [Member]",
        "terseLabel": "Physiomesh"
       }
      }
     },
     "localname": "PhysiomeshMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PinnacleAcetabularCupSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Acetabular cup system.",
        "label": "Pinnacle Acetabular Cup System [Member]",
        "terseLabel": "Pinnacle Acetabular Cup System"
       }
      }
     },
     "localname": "PinnacleAcetabularCupSystemMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "label": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "verboseLabel": "Proceeds from the exercise of stock options/employee withholding tax on stock awards, net"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProductLiabilityContingencyNumberOfClaimant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability contingency number of claimant.",
        "label": "Product Liability Contingency Number Of Claimant",
        "terseLabel": "Product liability contingency, number of claimants"
       }
      }
     },
     "localname": "ProductLiabilityContingencyNumberOfClaimant",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_PulmonaryHypertensionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pulmonary Hypertension [Member]",
        "label": "Pulmonary Hypertension [Member]",
        "terseLabel": "Pulmonary Hypertension"
       }
      }
     },
     "localname": "PulmonaryHypertensionMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PurchasedInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased In-Process Research And Development [Member]",
        "label": "Purchased In-Process Research And Development [Member]",
        "terseLabel": "Purchased In-Process Research And Development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member]",
        "label": "Remicade [Member]",
        "terseLabel": "REMICADE"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense excluding acquired in process cost percent to sales.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost Percent To Sales",
        "terseLabel": "Research and development expense percent to sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostPercentToSales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ResearchAndDevelopmentInProcessPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "research and development in process percent to sales",
        "label": "Research and development in process percent to sales",
        "terseLabel": "In-process research and development percent to sales"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcessPercentToSales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_RestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash",
        "label": "Restricted Cash [Member]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Restructuringchargepercenttosales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring charge percent to sales",
        "label": "Restructuring charge percent to sales",
        "terseLabel": "Restructuring charge percent to sales"
       }
      }
     },
     "localname": "Restructuringchargepercenttosales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_RevenuesContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues, Contingent Consideration",
        "label": "Revenues, Contingent Consideration",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesContingentConsideration",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_RisperdalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risperdal.",
        "label": "Risperdal [Member]",
        "terseLabel": "Risperdal"
       }
      }
     },
     "localname": "RisperdalMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SPINEOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINE &amp; OTHER [Member]",
        "label": "SPINE &amp; OTHER [Member]",
        "terseLabel": "SPINE, SPORTS &amp; OTHER"
       }
      }
     },
     "localname": "SPINEOTHERMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SPRAVATOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPRAVATO",
        "label": "SPRAVATO [Member]",
        "terseLabel": "SPRAVATO"
       }
      }
     },
     "localname": "SPRAVATOMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SURGICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SURGICAL [Member]",
        "label": "SURGICAL [Member]",
        "terseLabel": "SURGICAL"
       }
      }
     },
     "localname": "SURGICALMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SalesBySegmentOfBusinessTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales by segment of business.",
        "label": "Sales By Segment Of Business [Table Text Block]",
        "terseLabel": "Sales By Segment Of Business"
       }
      }
     },
     "localname": "SalesBySegmentOfBusinessTableTextBlock",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_SalesRevenueGoodsNetPercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "jnj_GrossProfitPercentToSales",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales revenue goods net percentage to sales.",
        "label": "Sales Revenue Goods Net Percent To Sales",
        "terseLabel": "Sales to customers percent to sales"
       }
      }
     },
     "localname": "SalesRevenueGoodsNetPercentToSales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "label": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "label": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "terseLabel": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_SellingGeneralAndAdministrativeExpensePercentToSales": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "jnj_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterestPercentToSales",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling general and administrative expense percent to sales.",
        "label": "Selling General And Administrative Expense Percent To Sales",
        "terseLabel": "Selling marketing and administrative expenses percent to sales"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensePercentToSales",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right",
        "terseLabel": "Contingent value right"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right",
        "terseLabel": "Contingent value right (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.",
        "label": "Shares Which Could Be Repurchased Under Treasury Stock Method",
        "negatedTerseLabel": "Less: shares which could be repurchased under treasury stock method"
       }
      }
     },
     "localname": "SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_SimponiSimponiAriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi/Simponi Aria [Member]",
        "label": "Simponi/Simponi Aria [Member]",
        "terseLabel": "SIMPONI / SIMPONI ARIA"
       }
      }
     },
     "localname": "SimponiSimponiAriaMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_StelaraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stelara [Member]",
        "label": "Stelara [Member]",
        "terseLabel": "STELARA"
       }
      }
     },
     "localname": "StelaraMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SummaryOfClaimsInPendingLawsuitsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Claims In Pending Lawsuits",
        "label": "Summary Of Claims In Pending Lawsuits [Table Text Block]",
        "terseLabel": "Summary Of Claims In Pending Lawsuits"
       }
      }
     },
     "localname": "SummaryOfClaimsInPendingLawsuitsTableTextBlock",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/CommitmentandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_SupplierFinanceProgramObligationCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplier Finance Program, Obligation, Current",
        "label": "Supplier Finance Program, Obligation, Current",
        "terseLabel": "Supplier finance program, obligation"
       }
      }
     },
     "localname": "SupplierFinanceProgramObligationCurrent",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_SurgeryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgery [Member]",
        "label": "Surgery [Member]",
        "terseLabel": "Surgery"
       }
      }
     },
     "localname": "SurgeryMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgicalMeshProductsMarketingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Mesh Products Marketing",
        "label": "Surgical Mesh Products Marketing [Member]",
        "terseLabel": "Surgical Mesh Products Marketing"
       }
      }
     },
     "localname": "SurgicalMeshProductsMarketingMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TRAUMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRAUMA [Member]",
        "label": "TRAUMA [Member]",
        "terseLabel": "TRAUMA"
       }
      }
     },
     "localname": "TRAUMAMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TalcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Talc [Member]",
        "label": "Talc [Member]",
        "terseLabel": "Talc"
       }
      }
     },
     "localname": "TalcMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TremfyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tremfaya",
        "label": "Tremfya [Member]",
        "terseLabel": "TREMFYA"
       }
      }
     },
     "localname": "TremfyaMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TylenolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tylenol",
        "label": "Tylenol [Member]",
        "terseLabel": "Tylenol"
       }
      }
     },
     "localname": "TylenolMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UNITEDSTATESExportsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UNITED STATES Exports [Member]",
        "label": "UNITED STATES Exports [Member]",
        "terseLabel": "U.S. Exports"
       }
      }
     },
     "localname": "UNITEDSTATESExportsMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UPTRAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPTRAVI [Member]",
        "label": "UPTRAVI [Member]",
        "terseLabel": "UPTRAVI"
       }
      }
     },
     "localname": "UPTRAVIMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UnrecognizedTaxBenefitLiabilityPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefit Liability, Payment",
        "label": "Unrecognized Tax Benefit Liability, Payment",
        "terseLabel": "Unrecognized Tax Benefit Liability, Payment"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitLiabilityPayment",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_VisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision[Member]",
        "label": "Vision [Member]",
        "terseLabel": "Vision"
       }
      }
     },
     "localname": "VisionMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WesternHemisphereExcludingUSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Western Hemisphere, excluding U.S. [Member]",
        "label": "Western Hemisphere, excluding U.S. [Member]",
        "terseLabel": "Western Hemisphere, excluding U.S."
       }
      }
     },
     "localname": "WesternHemisphereExcludingUSMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WomensHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Women's Health [Member]",
        "label": "Women's Health [Member]",
        "terseLabel": "Women\u2019s Health"
       }
      }
     },
     "localname": "WomensHealthMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WoundCareandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wound Care and Other [Member]",
        "label": "Wound Care and Other [Member]",
        "terseLabel": "Wound Care/Other"
       }
      }
     },
     "localname": "WoundCareandOtherMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_XareltoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xarelto [Member]",
        "label": "Xarelto [Member]",
        "terseLabel": "XARELTO"
       }
      }
     },
     "localname": "XareltoMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ZYTIGAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZYTIGA [Member]",
        "label": "ZYTIGA [Member]",
        "terseLabel": "ZYTIGA / abiraterone acetate"
       }
      }
     },
     "localname": "ZYTIGAMember",
     "nsuri": "http://www.jnj.com/20230402",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r265",
      "r309",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r331",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415",
      "r416",
      "r418",
      "r420",
      "r421",
      "r861",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r265",
      "r309",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r331",
      "r410",
      "r411",
      "r412",
      "r413",
      "r415",
      "r416",
      "r418",
      "r420",
      "r421",
      "r861",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r524",
      "r695",
      "r718",
      "r756",
      "r757",
      "r778",
      "r791",
      "r797",
      "r863",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r524",
      "r695",
      "r718",
      "r756",
      "r757",
      "r778",
      "r791",
      "r797",
      "r863",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r333",
      "r696",
      "r779",
      "r795",
      "r858",
      "r859",
      "r864",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r333",
      "r696",
      "r779",
      "r795",
      "r858",
      "r859",
      "r864",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r472",
      "r524",
      "r550",
      "r551",
      "r552",
      "r671",
      "r695",
      "r718",
      "r756",
      "r757",
      "r778",
      "r791",
      "r797",
      "r853",
      "r863",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r472",
      "r524",
      "r550",
      "r551",
      "r552",
      "r671",
      "r695",
      "r718",
      "r756",
      "r757",
      "r778",
      "r791",
      "r797",
      "r853",
      "r863",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r334",
      "r335",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r780",
      "r796",
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r334",
      "r335",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r780",
      "r796",
      "r864"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r271",
      "r272",
      "r273",
      "r343",
      "r344",
      "r359",
      "r360",
      "r361",
      "r362",
      "r365",
      "r366",
      "r554",
      "r555",
      "r556",
      "r567",
      "r568",
      "r582",
      "r583",
      "r584",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r630",
      "r631",
      "r647",
      "r648",
      "r651",
      "r652",
      "r653",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r14",
      "r794"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r339",
      "r340"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, trade, less allowances $207 (2022, $203)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r4",
      "r185",
      "r199"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Accrued taxes on income (Note 5)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r6",
      "r185",
      "r199"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term taxes payable (Note 5)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r30",
      "r36",
      "r142",
      "r813",
      "r814",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r103",
      "r221"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r245",
      "r254",
      "r255",
      "r588",
      "r766",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r245",
      "r254",
      "r255",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Accumulated Net Investment Gain (Loss) Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r33",
      "r35",
      "r36",
      "r231",
      "r713",
      "r726",
      "r730"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss) (Note 7)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r253",
      "r254",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r32",
      "r36",
      "r142",
      "r662",
      "r721",
      "r722",
      "r813",
      "r814",
      "r815",
      "r827",
      "r828",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r29",
      "r36",
      "r142",
      "r254",
      "r255",
      "r638",
      "r639",
      "r640",
      "r641",
      "r644",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r63",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net earnings to cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r232",
      "r341",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r63",
      "r91",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense of amortizable intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "negatedTerseLabel": "Accumulated other comprehensive income on derivatives, after tax"
       }
      }
     },
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r63",
      "r101"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset write-downs"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r183",
      "r198",
      "r225",
      "r262",
      "r317",
      "r323",
      "r329",
      "r358",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r417",
      "r419",
      "r421",
      "r422",
      "r586",
      "r589",
      "r620",
      "r794",
      "r861",
      "r862",
      "r884"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r217",
      "r234",
      "r262",
      "r358",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r417",
      "r419",
      "r421",
      "r422",
      "r586",
      "r589",
      "r620",
      "r794",
      "r861",
      "r862",
      "r884"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale Securities, Unrecognized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r348",
      "r374"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Available-for-sale Securities - Carrying Amount"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r78",
      "r351",
      "r711"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r78",
      "r350",
      "r710"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r834",
      "r835",
      "r896"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r834",
      "r835",
      "r895"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "totalLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r78",
      "r349",
      "r709"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofAvailableforSaleSecuritiesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r76",
      "r347",
      "r374",
      "r703"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Available-for-sale Securities",
        "verboseLabel": "Available-for-sale Securities - Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-Sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r152",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits(2)"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r581",
      "r785",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r130",
      "r131",
      "r581",
      "r785",
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r134",
      "r137",
      "r585"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash, cash equivalents, and marketable securities acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "terseLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Business Exit Costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "verboseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash acquired from acquisition"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r65",
      "r219",
      "r759"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents (Note 4)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r812"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Total cash, cash equivalents and current marketable securities, Carrying Amount"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r59",
      "r65",
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD",
        "periodStartLabel": "Cash and Cash equivalents beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r59",
      "r176"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase/(Decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r262",
      "r288",
      "r292",
      "r294",
      "r296",
      "r303",
      "r304",
      "r358",
      "r410",
      "r413",
      "r414",
      "r415",
      "r421",
      "r422",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r620",
      "r758",
      "r807",
      "r823",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral already posted, aggregate fair value"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r22",
      "r190",
      "r204"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r827",
      "r828",
      "r880"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock Issued Amount",
        "verboseLabel": "Common Stock, Par Value $1.00"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value per share (per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r794"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock \u2014 par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r38",
      "r250",
      "r252",
      "r258",
      "r705",
      "r715"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r49",
      "r257",
      "r704",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "verboseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r781",
      "r783",
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities(2)"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r74",
      "r322",
      "r323",
      "r324",
      "r325",
      "r331",
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate, Non-Segment"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r45",
      "r696"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r866",
      "r879"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross Currency Interest Rate Contract",
        "verboseLabel": "Cross currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r184",
      "r186",
      "r196",
      "r265",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r650",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r177",
      "r179",
      "r423",
      "r650",
      "r774",
      "r775"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r19",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r20",
      "r265",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r650",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale and Held-to-Maturity, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale and Held-to-maturity [Abstract]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Available for Sale Securities Maturities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r558",
      "r559"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred taxes on income (Note 5)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r63",
      "r127",
      "r566",
      "r574",
      "r575",
      "r826"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r558",
      "r559"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred taxes on income (Note 5)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r450",
      "r488",
      "r513",
      "r783",
      "r784"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Recognized actuarial (gains) losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r450",
      "r489",
      "r514",
      "r783",
      "r784"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Amortization of prior service cost/(credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r450",
      "r487",
      "r512",
      "r783",
      "r784"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r450",
      "r454",
      "r486",
      "r511",
      "r783",
      "r784"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "verboseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r484",
      "r509",
      "r783",
      "r784"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic benefit cost/(credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]",
        "verboseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": {
     "auth_ref": [
      "r865",
      "r867",
      "r868"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment",
        "negatedLabel": "Curtailments and settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r452",
      "r485",
      "r510",
      "r783",
      "r784"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r63",
      "r312"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization of property and intangibles"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r25",
      "r27",
      "r155"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r236",
      "r237",
      "r619",
      "r765"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "totalLabel": "Total Net Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "auth_ref": [
      "r595",
      "r877"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "terseLabel": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r26",
      "r155",
      "r180",
      "r235",
      "r765"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Total Gross Assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r26",
      "r155",
      "r180",
      "r235",
      "r765"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Total Gross Liabilities",
        "verboseLabel": "Carrying Amount of the Hedged Liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r876"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Gain/(Loss) Recognized In Income on Derivative"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Detail [Abstract]",
        "verboseLabel": "Financial assets and liabilities at fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentDetailAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r153",
      "r156",
      "r161",
      "r163",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r150",
      "r153",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r150",
      "r153",
      "r161",
      "r163",
      "r167",
      "r168",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r597"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "terseLabel": "Amount of gain or (loss) reclassified from AOCI into income"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Assets, at Fair Value",
        "verboseLabel": "Derivatives designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value",
        "verboseLabel": "Derivatives designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r236",
      "r237",
      "r619",
      "r765"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "totalLabel": "Total Net Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r25",
      "r27",
      "r155",
      "r764"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r874",
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r150",
      "r151",
      "r159",
      "r161",
      "r165",
      "r166",
      "r168",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.",
        "label": "Dividends Payable, Amount Per Share",
        "terseLabel": "Dividends payable (in dollars per share)"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r869",
      "r870",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "NET EARNINGS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r259",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r286",
      "r288",
      "r294",
      "r295",
      "r296",
      "r300",
      "r609",
      "r610",
      "r706",
      "r716",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (per share)",
        "verboseLabel": "Basic net earnings/(loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r259",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r288",
      "r294",
      "r295",
      "r296",
      "r300",
      "r609",
      "r610",
      "r706",
      "r716",
      "r768"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (per share)",
        "verboseLabel": "Net earnings/(loss) per share (basic/diluted)*"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "verboseLabel": "Reconciliation of basic net earnings per share to diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Worldwide effective income tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r872",
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and employee related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r189",
      "r205"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Employee-related Liabilities",
        "verboseLabel": "Employee related obligations (Note 6)"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r109",
      "r211",
      "r253",
      "r254",
      "r255",
      "r266",
      "r267",
      "r268",
      "r272",
      "r280",
      "r282",
      "r302",
      "r362",
      "r446",
      "r554",
      "r555",
      "r556",
      "r567",
      "r568",
      "r608",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r644",
      "r662",
      "r721",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.",
        "label": "Equity, Fair Value Adjustment",
        "terseLabel": "Changes in Fair Value Reflected in Net Income"
       }
      }
     },
     "localname": "EquityFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r226",
      "r617",
      "r761"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Available-for-sale Securities, Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r87",
      "r197",
      "r798",
      "r799",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "periodEndLabel": "Carrying value, end of period",
        "periodStartLabel": "Carrying value, beginning of period"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r431",
      "r619",
      "r774",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r169",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r169",
      "r174",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r169",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "verboseLabel": "Financial Liabilities not Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r431",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r615",
      "r668",
      "r669",
      "r670",
      "r774",
      "r775",
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Fair Value, Hierarchy"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r169",
      "r173",
      "r431",
      "r774",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r431",
      "r774",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r431",
      "r475",
      "r480",
      "r615",
      "r668",
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted prices in active markets for identical assets and liabilities Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r431",
      "r475",
      "r480",
      "r615",
      "r669",
      "r774",
      "r775",
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant other observable inputs Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r431",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r615",
      "r670",
      "r774",
      "r775",
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant unobservable inputs Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r431",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r668",
      "r669",
      "r670",
      "r774",
      "r775",
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r152",
      "r159",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r352",
      "r355",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r439",
      "r444",
      "r598",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r771",
      "r837",
      "r838",
      "r839",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Liabilities, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Financial Liabilities"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialLiabilitiesBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life (in years)",
        "verboseLabel": "Finite-Lived Intangible Assets, Weighted-Average Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r223",
      "r395"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Intangible Asset Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillIntangibleAssetAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r391",
      "r394",
      "r395",
      "r397",
      "r697",
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r96",
      "r701"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r92",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r96",
      "r697"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Intangible assets with definite lives:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Total amortizable intangibles"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value",
        "verboseLabel": "Derivatives not designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value",
        "verboseLabel": "Derivatives not designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "Foreign exchange rate"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r765",
      "r781",
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Forward foreign exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r869",
      "r870",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r821"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Net gain on sale of assets/businesses"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r222",
      "r379",
      "r702",
      "r772",
      "r794",
      "r842",
      "r849"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill End of Period",
        "periodStartLabel": "Goodwill Beginning of Period",
        "terseLabel": "Goodwill (Note 3)"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r381",
      "r772"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, related to acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Currency translation/Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r128",
      "r848"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Goodwill, Purchase Accounting Adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r44",
      "r262",
      "r317",
      "r322",
      "r328",
      "r331",
      "r358",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r417",
      "r419",
      "r421",
      "r422",
      "r620",
      "r770",
      "r861"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Gain/ (Loss) Included in the Carrying Amount of the Hedged Liability"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r150",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r82",
      "r342",
      "r371",
      "r841"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "totalLabel": "Held-to-maturity Securities - Carrying Amount"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r84",
      "r354"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss",
        "negatedLabel": "Held-to-maturity Securities, Unrecognized Loss"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesClassifiedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesClassifiedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r83",
      "r353",
      "r703"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "terseLabel": "Held-to-maturity Securities - Estimated Fair Value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldtomaturitySecuritiesMember": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as held-to-maturity.",
        "label": "Held-to-Maturity Securities [Member]",
        "terseLabel": "Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r41",
      "r181",
      "r191",
      "r207",
      "r317",
      "r322",
      "r328",
      "r331",
      "r707",
      "r770"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings/(Loss) before provision for taxes on income",
        "verboseLabel": "Worldwide income/(loss) before tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r398",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "verboseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r263",
      "r562",
      "r564",
      "r565",
      "r572",
      "r576",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r264",
      "r281",
      "r282",
      "r315",
      "r560",
      "r573",
      "r577",
      "r717"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for/(Benefit from) taxes on income (Note 5)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Decrease in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "(Increase)/Decrease in other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Increase in other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r289",
      "r290",
      "r291",
      "r296",
      "r527"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Potential shares exercisable under stock option plans"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r393",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Total intangible assets with indefinite lives"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets with indefinite lives:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r93",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r90",
      "r94"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Total intangible assets \u2014 net",
        "verboseLabel": "Intangible assets, net (Note 3)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets and Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r178",
      "r194",
      "r256",
      "r311",
      "r649"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net of portion capitalized"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r765",
      "r781",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest Rate Contract"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r88",
      "r762"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r233",
      "r760",
      "r794"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories (Note 2)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r88",
      "r811"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "verboseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r88",
      "r763"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Goods in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r47",
      "r310"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_JudicialRulingMember": {
     "auth_ref": [
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.",
        "label": "Judicial Ruling [Member]",
        "terseLabel": "Judicial Ruling"
       }
      }
     },
     "localname": "JudicialRulingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r262",
      "r358",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r417",
      "r419",
      "r421",
      "r422",
      "r587",
      "r589",
      "r590",
      "r620",
      "r769",
      "r861",
      "r884",
      "r885"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r187",
      "r202",
      "r794",
      "r825",
      "r840",
      "r881"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r218",
      "r262",
      "r358",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r417",
      "r419",
      "r421",
      "r422",
      "r587",
      "r589",
      "r590",
      "r620",
      "r794",
      "r861",
      "r884",
      "r885"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsDerivativesBalanceSheetLocationDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r227"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Non-Current Debt",
        "verboseLabel": "Long-term debt (Note 4)"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Excluding Current Maturities [Abstract]",
        "terseLabel": "Non-Current Debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.",
        "label": "Long-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Weighted average interest rate on non-current debt"
       }
      }
     },
     "localname": "LongtermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r106",
      "r107",
      "r405",
      "r406",
      "r407",
      "r856",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "verboseLabel": "Product Liability Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r405",
      "r808"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss Contingency Accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualPayments": {
     "auth_ref": [
      "r855"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow reducing loss contingency liability.",
        "label": "Loss Contingency Accrual, Payments",
        "terseLabel": "Loss Contingency Accrual, Payments"
       }
      }
     },
     "localname": "LossContingencyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [
      "r856",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Loss Contingency, Claims Dismissed, Number"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r855",
      "r856",
      "r857"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesPaidValue": {
     "auth_ref": [
      "r855",
      "r856",
      "r857"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages paid to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Paid, Value",
        "terseLabel": "Loss Contingency, Damages Paid, Value"
       }
      }
     },
     "localname": "LossContingencyDamagesPaidValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r856",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyReceivableProceeds": {
     "auth_ref": [
      "r820",
      "r860"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the collection of receivables related to a loss contingency.",
        "label": "Loss Contingency, Receivable, Proceeds",
        "terseLabel": "Loss Contingency, Receivable, Proceeds"
       }
      }
     },
     "localname": "LossContingencyReceivableProceeds",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "periodEndLabel": "Carrying value, end of period",
        "periodStartLabel": "Carrying value, beginning of period",
        "terseLabel": "Marketable Securities, Noncurrent"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on securities"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r0",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "verboseLabel": "Acquisitions and Divestitures"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "NET CASH FROM/(USED BY) FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "NET CASH FROM/(USED BY) INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r59",
      "r61",
      "r64"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "NET CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r42",
      "r64",
      "r192",
      "r206",
      "r216",
      "r248",
      "r251",
      "r255",
      "r262",
      "r271",
      "r275",
      "r276",
      "r277",
      "r278",
      "r281",
      "r282",
      "r293",
      "r317",
      "r322",
      "r328",
      "r331",
      "r358",
      "r410",
      "r411",
      "r413",
      "r414",
      "r415",
      "r417",
      "r419",
      "r421",
      "r422",
      "r610",
      "r620",
      "r770",
      "r861"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net earnings/(loss)",
        "terseLabel": "Net earnings",
        "totalLabel": "Net earnings"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r214",
      "r269",
      "r270",
      "r273",
      "r274",
      "r283",
      "r284",
      "r285",
      "r345",
      "r346",
      "r363",
      "r364",
      "r569",
      "r570",
      "r571",
      "r606",
      "r612",
      "r613",
      "r614",
      "r627",
      "r628",
      "r629",
      "r654",
      "r655",
      "r657",
      "r663",
      "r698",
      "r699",
      "r700",
      "r725",
      "r726",
      "r727",
      "r728",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New and Recently Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "verboseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r67",
      "r68",
      "r69"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "totalLabel": "Net cash paid for acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r67",
      "r68",
      "r69"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "verboseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r67",
      "r68",
      "r69"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedLabel": "Fair value of liabilities assumed"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r317",
      "r322",
      "r328",
      "r331",
      "r770"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "verboseLabel": "Total Segment Operating Income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Non Current Other Assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]",
        "terseLabel": "Employee benefit plans:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]",
        "terseLabel": "Derivatives &amp; hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r28",
      "r33",
      "r632",
      "r633",
      "r636"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation",
        "verboseLabel": "Foreign Currency Translation, net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r240",
      "r241",
      "r243"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Gain/(Loss) On Securities, net change",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r238",
      "r243"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Gain/(Loss) On Derivatives &amp; Hedges, net change",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Derivatives &amp; Hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r238",
      "r243"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Unrealized gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r243",
      "r246"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": {
     "auth_ref": [
      "r239",
      "r243",
      "r591",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax",
        "verboseLabel": "Amount of gain or (loss) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r239",
      "r243",
      "r591",
      "r592",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain/(Loss) Recognized In Accumulated OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r28",
      "r34",
      "r634",
      "r643"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r39",
      "r109",
      "r249",
      "r252",
      "r257",
      "r637",
      "r642",
      "r644",
      "r704",
      "r714",
      "r813",
      "r814"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Total Accumulated Other Comprehensive Income (Loss), net change",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r31",
      "r33"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTerseLabel": "Employee Benefit Plans, net change",
        "negatedTotalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r31",
      "r34",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r33",
      "r37",
      "r86",
      "r247"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r240",
      "r243"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r34",
      "r241"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Customer relationships and other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableAxis": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group of items that represent other investments not readily marketable, including description of investment, fair value, and value as measured by quoted value method.",
        "label": "Other Investment Not Readily Marketable [Axis]",
        "terseLabel": "Other Investment Not Readily Marketable [Axis]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Investment Not Readily Marketable [Line Items]",
        "terseLabel": "Other Investment Not Readily Marketable [Line Items]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the investment category or actual investment title.",
        "label": "Other Investment Not Readily Marketable, Name [Domain]",
        "terseLabel": "Other Investment Not Readily Marketable, Name [Domain]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableTable": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the information about other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price.",
        "label": "Other Investment Not Readily Marketable [Table]",
        "terseLabel": "Other Investment Not Readily Marketable [Table]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r114",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r497",
      "r499",
      "r502",
      "r505",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r521",
      "r522",
      "r523",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "verboseLabel": "Other Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r816",
      "r817"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other (primarily licenses and milestones)"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash acquired (Note 10)"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r472",
      "r474",
      "r480",
      "r498",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r519",
      "r520",
      "r521",
      "r526",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Pensions and Other Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Payment for Pension Benefits",
        "terseLabel": "Contribution to pension plans"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r113",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r497",
      "r499",
      "r502",
      "r505",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r521",
      "r522",
      "r525",
      "r783",
      "r784",
      "r788",
      "r789",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "verboseLabel": "Retirement Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r812"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from long-term debt, net of issuance costs (Note 4)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r818",
      "r819"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "verboseLabel": "Proceeds from the disposal of assets/businesses, net (Note 10)"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "verboseLabel": "Proceeds from short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r102",
      "r220"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r104",
      "r203",
      "r712",
      "r794"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r260",
      "r369"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "verboseLabel": "Credit losses and accounts receivable allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Repayment of short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r121",
      "r208",
      "r892"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "In-process research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r810",
      "r822",
      "r893",
      "r897"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash (Note 4)"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r65",
      "r70",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted Cash and Cash Equivalents, Current"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r63",
      "r402",
      "r403",
      "r854"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring",
        "verboseLabel": "Restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r110",
      "r201",
      "r725",
      "r730",
      "r794"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings and Additional paid-in capital"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r211",
      "r266",
      "r267",
      "r268",
      "r272",
      "r280",
      "r282",
      "r362",
      "r554",
      "r555",
      "r556",
      "r567",
      "r568",
      "r608",
      "r721",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings and Additional paid-in capital"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r502",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r869",
      "r870",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r502",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r869",
      "r870",
      "r871"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r497",
      "r499",
      "r502",
      "r505",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r521",
      "r522",
      "r523",
      "r525",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r113",
      "r114",
      "r449",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r496",
      "r497",
      "r499",
      "r502",
      "r505",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r521",
      "r522",
      "r523",
      "r525",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r308",
      "r309",
      "r321",
      "r326",
      "r327",
      "r333",
      "r334",
      "r337",
      "r447",
      "r448",
      "r696"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Sales",
        "terseLabel": "Sales to customers",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r36",
      "r882",
      "r883"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Components of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Equity Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r130",
      "r131",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r153",
      "r161",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Derivative Activity"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Financial Assets and Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Derivative Financial Instruments and Classification on Consolidated Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r92",
      "r95",
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r772",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r11",
      "r12",
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "verboseLabel": "Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r160",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule of Effect of Derivatives not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r43",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r40",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Operating Profit by Segment of Business"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of securities that an institution sells and agrees to repurchase at a specified date for a specified price, net of any reductions or offsets.",
        "label": "Securities Loaned or Sold under Agreements to Repurchase [Member]",
        "terseLabel": "U.S. reverse repurchase agreements"
       }
      }
     },
     "localname": "SecuritiesLoanedOrSoldUnderAgreementsToRepurchaseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r337",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r401",
      "r404",
      "r772",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]",
        "verboseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r305",
      "r306",
      "r307",
      "r317",
      "r320",
      "r325",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segments of Business and Geographic Areas"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingInformationRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information, Revenue for Reportable Segment [Abstract]",
        "verboseLabel": "Sales by segment of business"
       }
      }
     },
     "localname": "SegmentReportingInformationRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentsGeographicalAreasAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments, Geographical Areas [Abstract]",
        "verboseLabel": "Sales by geographic area"
       }
      }
     },
     "localname": "SegmentsGeographicalAreasAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofRevenuefromExternalCustomersandLongLivedAssetsbyGeographicalAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, marketing and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r2",
      "r184",
      "r200",
      "r794"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Current Debt",
        "verboseLabel": "Loans and notes payable"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialLiabilitiesnotMeasuredatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r215",
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r337",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r399",
      "r401",
      "r404",
      "r772",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Statement, Business Segments"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillBySegmentDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r262",
      "r288",
      "r292",
      "r294",
      "r296",
      "r303",
      "r304",
      "r358",
      "r410",
      "r413",
      "r414",
      "r415",
      "r421",
      "r422",
      "r440",
      "r441",
      "r442",
      "r443",
      "r445",
      "r620",
      "r758",
      "r807",
      "r823",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r23",
      "r109",
      "r211",
      "r253",
      "r254",
      "r255",
      "r266",
      "r267",
      "r268",
      "r272",
      "r280",
      "r282",
      "r302",
      "r362",
      "r446",
      "r554",
      "r555",
      "r556",
      "r567",
      "r568",
      "r608",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r644",
      "r662",
      "r721",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r302",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r7",
      "r8",
      "r109",
      "r110",
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Employee compensation and stock option plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:",
        "verboseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r139",
      "r140",
      "r143",
      "r211",
      "r212",
      "r254",
      "r266",
      "r267",
      "r268",
      "r272",
      "r280",
      "r362",
      "r446",
      "r554",
      "r555",
      "r556",
      "r567",
      "r568",
      "r608",
      "r637",
      "r638",
      "r644",
      "r662",
      "r722",
      "r723",
      "r825",
      "r840",
      "r881"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesBySegmentOfBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r645",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r645",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r645",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Supply network costs"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasOperatingProfitbySegmentofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r352",
      "r355",
      "r439",
      "r444",
      "r598",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r837",
      "r838",
      "r839",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock Amount"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r24",
      "r111",
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "verboseLabel": "Less: common stock held in treasury, at cost (521,519,000 and 506,246,000 shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r109",
      "r110",
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r767",
      "r781",
      "r894"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Agencies Debt Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r708",
      "r781",
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Gov\u2019t securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsCashCashEquivalentsandMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r557",
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r287",
      "r296"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (shares)",
        "totalLabel": "Average shares outstanding \u2014 basic/diluted*"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "AVG. SHARES OUTSTANDING"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r286",
      "r296"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (shares)",
        "verboseLabel": "Average shares outstanding \u2014 basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "820",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6284393-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r801": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r802": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r803": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r804": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r805": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r806": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0000200406-23-000056-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000200406-23-000056-xbrl.zip
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MIS\Z&.;%THJ#8$/*[;*&$E]X$(+P1.J=+DENCF>\:U#E4?"6?/5K]V&)MP?
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M[H8'.5/8>IV^4(RT<SKK-E<J/+):%6Y;Y0MOX,O/\/\ _C\3^O\%4$L#!!0
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M"D^=5L#?H2QH56.*-^:ZBO 0;N5CA@A<!#HIU^@I$V?N=(T C9S2KY)%(=$
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MT;O=FR>491JJ,O27$9]R!77/<D]+? 598Q8BA:[E>FL**$=/*"# ?679+]=
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MY]L2,L5/TKE:7_*=ZVC%,[\<9Z[I#?\#4$L#!!0    ( -J G%88#VX] @8
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MG(NU\TQXGK5Z$__]-I.*!XN'V:;+W+K27UYRUYSN73TG(0,3&22*RV@5/F+
M3T/X:&&D%@=54 @P##D+8(/')/8Y$; 3!-QG&20!@H>Q3&)87JJWNN5;%8B1
M]B.B90O $)0640C>:'S+2RW/<[K#)$I)O#!O;O=M%=)9)F<$5:H2<%NP9XVM
MH05N?=5!C!((35*=9DZ#C9FO\>;":&M%GC2),<FF)&:RMG,DD(6!K_2,YSA>
M%4*6L2FRQ3+<6XX[HT*BJAJ;7CEETL!&"SB(D[E@=)\M+ZVVNE<:VGV8MR)3
MP4H"TR3#':JAA0F22M8I_W0IEZD@BPZ/C9V81=W"[J>)4DG4T09]J"7UB2@H
M&Y+Y=)$+6VVK[C5U.E3H4(J6A(M,:9E,:2MZ<<ZS6OG"2V<=R[UR[CJL#<NM
M_QK6ZRFZ3OO.><4]6UN[>Q5XB+7Q2+ V'*N]YMTY6K=I.<VKIT^CM8W=YK:+
MWB$QKKRKU"OG/+3CI4?@GG5#[;3G'23WC=\?WYV3^'X<; K);R\4YL$'DNB-
M^_8GQ'&T,)5+0-W5VXE^*F)?S/ /I!J37?,TN"+A\XQDF!/$ G899DQ,0S%L
M)%D$KE/[#$&2F03U_1@J1:()!8;9@\(@S;C(C0=SG#EKG4ZV.<8RUT(P$T)G
MYB@5.@/.N0H-\HQ]G_&,Z>.8U%FPR*^8A-^0M\?)E?FS#,^0N'!TY(<DWF=E
MAG7;]09FRW872$S/G::>EZ-Z[O6F_7PT\1A#EO<;0U9YR/ACI-<^SF.,-U'^
MT>[C"H)0%$=- "C"4T"X"4,9DSI>5/4T$0)P&1+&@P).I!A 9'Z,"(X/$(B0
MFAJ4CA(::B;R<)-@2#,T91EKBNAHG=F.2WW']7[5SB).J6!/S'E>A'H1ZD6H
MYQ@RVD]1J&=GB%=^5)QL;U$7*BH]" XR$9Q"*=?C^H9L-+O2/,_5(%],XI&+
M=ZWQFB;!;2WW024^:ZTO8>Q)B/?X\^D539MG;9]>XTF)9YN&SP\:L#_?^GP,
M?<YU?>'$M.7@3.6SE9<^[ZDI_-*&OK<V-)=E0];/BTXX,&7Z/E$PRV(N0T;+
M#NUX-"P+U@A4U*)NUQ0V=2@9ZN)5G*@JL".?I:HDB%K7UYR*VCB%Z0+DS \U
M@BHR"92Q"(<#+O+)4W4K4[5'WE+\2#A=4,]Y<ULW+*GG_>_(5/JK@"@37)3-
MN63(R?0;XM2\"DZF7'"UR+$2-(J<FG6CJQIN;G=__GT6]T86"KF.X8+L-_':
M<U?&</M,O;*3,8'F><@N7"([^:PUAS'G9 F9XK?M3%U<\H-[9\4SOP5G[N/U
M_P=02P,$%     @ VH"<5N%=R)J'/P  .Z8! !X   !E>&AI8FET,3 Q+3(P
M,C)L=&EP>&9O<FUP<RYH=&WM?>ESVT:V[_?W5^ Z[^52512MQ;LSKI*7)$XE
MCI^7\9M/MYI 4T0, APLE)B__IVM%RQ<)$LFI-&MNA.+!!N]G#[[^9V?_NOU
MGZ\^_>O]FV!:SI+@_>>7O[]]%=S;OW__R_&K^_=??WH=_/KIC]^#!Z.#P^!3
MKM(B+N,L5<G]^V_>W0ON3<MR_NS^_;.SL]'9\2C+3^]_^G ?AWIP/\FR0H^B
M,KKWXB?\!/Y7J^C%__KIO_;W@]=96,UT6@9AKE6IHZ JXO0T^!+IXFNPOR]/
MO<KFRSP^G9;!T<'1<? ER[_&"\7?EW&9Z!=FG)_N\]\_W:>7_#3.HN6+GZ)X
M$<31/^[%T<'X8?3HX:.GZO&C!P?AP9-'#]1!^#@\?'P4CH^>/OJ?0YCD?7B<
M?U.4RT3_X]XL3O>G&M__[/'1O'Q^%D?E]-GAP<'_N5=[KM3GY;Y*XM/T&<T6
MOIUDL#;Y.LR2+'_VPP']WW/\9G^B9G&R?/;?G^*9+H)W^BSXD,U4^M_# G9X
MO]!Y/.$'B_AO_>P07TY_GO%L'L X29QJ,SN>TIO_]^O;EV\_!8<'H\.?[N/S
M9DWME:G\%!979G,>W%M!"+NI\VM?PN/.)?SVYZ_O/O[Y+OCQA^,GSP/YZZ=Q
M_@+._RCX_<]WO^Q_>O/AC^#MNU=OWGUZ^\\WP?O?3][5%WL#EOG+[W^^//D]
M>/_FP\]_?OCC!!83?/SUY,.;X/,[.+^3+R<?7@<GOWQX\^8/6.5E5O=7593Q
M9+FKY0&?P#O]*?OQAX=/GK<6\.*G4HT3;:8USO)(Y_LPNT3-"_W,_.-Y%!?S
M1"V?Q2F]@W[T7%8]SLHRFSU["!-:Z+R,0Y7(VFD;^&MW8T<'?&O+'/X_,F^6
MKT?TU?TRZOCN\>CXR?'*K^&FK?[IFF&/CD8/GSZZ^F&?C(ZN8[:P"<=/MAKV
M/FTP;S*<8S%7Z3_N'=\S/YBK* (^_^QH?AX<=I)LZS2S^8[8Z9<O;U\'/UCB
ME96O6=0!+NG>5H_>A/5_@HNFR^!=-1OK/,@FP?N/GXOZA;[@GMPBXB 6%[P&
MU>6;=N3F;\1[G4^R'(8)=0#_CK/HCD1X9SZ&4QU5"<C!?VJ8&FBWF\GEZ38K
M3?2D+?1HF6N4 QEO'W_\[&CT^*'W&2FMYL,=:!$K^,]4!^4TSJ- I6D,ZRU4
MOD0^5,(7[OX% _S[QQ^>'!T=V(W]_O/E?8MTF.4*+:1G50I*#3ZUBA)V-]=[
M+VB[#I_O-<R$6W8#7^%$)C 5/)"[VW?AVQ?A]9J -IZ=(='B/=-I9*Y@F_,'
ML,MGTSB<TO>OLMDL+DNM@Y#/ 2:'GR=ZH1,<1(73&/Y-;@ 9<^[&W!^K F[,
M0FY,F,=@K\4J*$ G@6?*:1"G03_O^\E\#OL4G__XP^&C@^<GN[SHP53GNLQ6
MW?/[9%/53+/=L"/<J/;_KC1]:_?IX>'HF#2([VM5/@9CZ^#A98S*HT>CXX=/
MK]Q,.X8)/7AP]<,>C0Z>/KX*ZT^.A [M8 2;'!19$D>!(3#Y'KEFU]<-IAS@
M?X]'CQ]ORY]WY@H)WF6C+13B_]CM^;2<ZZO;'Y:G_R$;:(ST;&0L]-I&;G<A
MA>NMV;)OI<DMC-[O-I>;=+R^CO5QJG(=?$[CLMC^LGS[=G[S=6K;]S=5Z^BP
M=>BC&%2_M'QV_&B^J]#/VS3 W28[I\R"H@(=/ .%.@?22/GS(E!%,%/+8 Q:
M?($G$!=@E@;C94-;![4:2 P/$RR N A!?X2?#_%S&*R(X<S9H!*=_11Y.*KH
MJ-+#/,X4F.RD#=/7H+7/"O/L;]DT+>"G$M^1OSBXDX$^]PD>#MZF&)P!BS]X
MGRAX,<Q;@9$0P60G>38+2M@Y7"7]M__6/RZB#[;^,%AF5:!.<SACV%*VZXKN
M",W:$--F<C^\9K9X./H^&]KU]H8M_Q@W@=48%,#=_'H4!-\0Q:OM.@:BKWW7
MNPEIH/:N>=MIQ&=Q"<L/-]^Y^D$<C>@H3I#][/*ZC8*/U?@O'9;$HBP#5&GD
M\V+BAW$1_))D8Y6LH)N %A.<X)5%+PGRX#"I<-$PWA+&J](R7^X7<QVBGTM>
M!8PZ,"Z(X*5X &@"^",6"_I\&H^1S6<Y2@YXMH)?\HP+X/N25E$$ [2;837
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MIJKY$HB;B=G&4=6CH9$:H NQ9Z+E5^I.E$5EC<B]E<Y);)3M-/06D!W9<*.
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M6<,-_L;%&5T0LQA 2KG)Y%2%DU3(3ND=IDD(G2:GF=66@7/Z_!$8<X):EG5
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M=[D+G[8(_"Q2@1U)_EB'^=?1P\&R,\N<80/AZA0TPJ4ACW=JN+TA;(!FC*^
M6XIF,5I2?Z8Z^"V;IJB^_/C#\9/G]B^XL7\K>@8G\S*OTN(L1L[Q[K?@X,G3
MXV/\ZO/'DUMP3Y_T[)Z>1+A!3,S<VH6T :O^=4?])38+##Y'?2'7NRTY<6'!
M=ARP"QQ@3:S'<^W I71[@UL3;MX:&[8.BM;6;$>UNR?1ISTCT==@HZ><2;#;
MX#.1F2N."=6<\I,P>8U-'Z8U+E0GI=).W,.5&6OX/=&3<<>VBUBN%/7^5E?-
M73@KK-=% #OOJR6)_\%,(^R!!Z*2+F('4LE(\HE6ON_ZFJ9[H41 +#)/.'2(
M#LO=HF@;28.VET!\D]=L @P [!$63Q.NZ"*KBFJZ$G7&/=0978;L%K^5U7"=
M^,GFP'#0QO0;?TUR547# (.(?_]M+%\P2*=9JHN2 S1>GY :"GVS\0=EM$PJ
M<<GJ)!YK]ANH.,'?.YC^EA,HJDH!YZ( ,/JE8@*(H4)T2OF#-\,ID\5/P5%=
MT.<UT$:<Q*4!O%J,MM&D:R5NS["%VC.4#O5VKU#[5?ZX'D;BI3&]ZFLG'P>F
MH),_(G-MSR@#4'P_$NBVGZR)&M=!,D5!&M;WQ.LF1\GG\0QK5V7QM>R9,6,[
M\;FM?O$H.$F7;8>+\&7B@(8+7;)1T]#B"-7?XG#!8Q-5P(2$M3G9_W$!N,>W
M+@#7&V7HVNMO+EYMTV]MJ-4]O@^JD>A&Q(K:[>U9&E"E8>:C$N"MZ$1!(!;,
MG(FK[V/_9S_K<5YQ"L?6-?EW!2;_@8:#B3KTX89X%\3W!K+/[Z6)N;M B5#R
MRPRK.^&/UQ)D[M0A!@;EG[O,<<X!#[1G51?)1,QR^5?!VH[%I3!OGE*I&$8<
M*$S.Q6B,5*DBD%%Q46(PT>0\<LP4/IIC1Z;.M.9A)V#7,>B?M>3GVW!%K[V3
MY&T39[9;6'\N:?VR4&K$<E-R($5-Z)XAJ N&U;ABDPR^L091-AF2P<#A?<SR
MH:9_E"<P1_3N7!RL6*L@7WDM,(=^_\LA.FJE008&_]-J@@D_.<UN1@@MTL\9
M2P>XYM289B87@RV"I1EIZ.H62AU.T6-PNL3!PBGLUI Z<Z8VU"EI&5AU>X[L
M@)IXY&*]^XTZR43"-<S&%,]GZU$7DEK#]2@&2=E+BI'GY#$I<,, MVDY+1X7
M^8;7S$D]RGN.'KO4,H?^.E>;B]8"K&^$? Z:C.*D*GAF#BPNM8C\K:WB,A[_
M%:S_.'0'D\2"RT$+;1%'DN-E2!07;TQ&>Z\,;7^+67@K6/.UHUO?.NVIHQ5I
MO[BTZ3BG[/R\7@O"5MD%MF=J96N,A<LJ71YG_5M,H:8?N7 XY?)$"Q .V$M"
MLGJ, D1E"YVU#=TM?NN],VM].\U=]SM7-)GDQ3B&\8KY3M &KZB?]!W?$+XQ
MZ0_?>" -,GO..'K4DKS+07$Q;/7A9NB,VT#EI_VA<F.X]!N;S'0-[@-U.XG(
MJB"HS$E,AH+ %@Z=V>]GX)+;C!.6B=!/N22(NQVAVIZ6Y-,OO.Q/ _,E7@71
M/>WPZ%'P4A"YKFJ25)K*';&@7!62?UG,,?]>*NECFYPYK\#>407^$W;>I*.D
M8D510C_U$\ 74UT5K[6PBRV\U19#Z^7@ D._Q36L#A/D$1N28EB:ZS"M?,9\
M]2'C4:*-EW/X-)+J+[8-\ MJ &>JY^F3J8KJ"T2^0D534H 1>1'0PJ)=UM+N
MV08!>V66E6PG.C/'632%9ZB01R>J+#01D4J]FWFS>YQKA[6JM_E5&R9R;>[4
M"V&\T_XQWE[SW0X2[0\+I@RG9K?%6FV++>>]N@SK75+OM?>3OXARS!W7^DV]
M<2'8,7T@6F#1_=^M1$=]V"MSP?VD%:I_]&P#X]LS%5-GB-,WUB'UN*0\I\B>
MOP *4"^Y0I)IE=><!ZM I<+M#&[Y$B9]'@R.'NV!NJ&_%J[;%38<HG&DB*\P
M?3>I;!SGYK_5EG>ZBIW.YQ@_J\OUB7Z(LE8;9HTE&;2>0D-HB0)F@#V(8AJ2
M<1M3Z;0Q%VRT;;97*#82VC#G,^ R*E/@3OBIQ5Y7@LQ@S0KV.N&&W(,>NA#5
M/$A&T4907.P(94'AI4+3JZ^'E=&*036OJ&&G"ARG,'6T9D.]<+HJ+K@=*Y"(
M6%E.=>)CT4VK&25_FWJ%=>E3:[:4#&@'T-D"M@ML__#8+RFL@^U9;-&#IR?!
M8)-%OB?8P-^ZXT2;%K,M4$F1U1QHJK;[]%.S_U[3+N0<!HT9*U6K?!E\L$6-
M#B)YA(O;/P:^,'BP=Y=]Y<I#[K*OKDM]^^M.?;N@0D( 2^A^[Y-.8I#>8I<4
M"QSY%-C.WXJ!)("CQ12IL,X-^J!#.J+<2'57$?706OI^.@?8\J>:'!O^&SD_
M! 1&)'\6\SC-)I.AJTTN"HVN&O-WP76Q6562O*$*U3S'XB*++D<_\8#P4*@H
M D M&B!-_H*LI"@:O-L[3*=-,9A#LA38 I)<K&%MA"TP]=\^^A7J?*<4*[9H
M GI= K)IU&A0;DD"2=*Q_37U@L$-LF #!#8F-=V,8#:;4[HR27Z0Q(B^$.>S
M6V%S?NT/T[H1'I,W0B5]X%A]MSC[T2>Z,Q_)=]N*D[=N:%G@/;TF9078V6D&
M(QE#97-XR_VP:3DT-/XYP@YQ=;@U%1C  W\FJ(_]/'8#F[?+0Q_V=&]0L.YV
M7X3:V5/ %\'0/ I\HDS*7O D+QN\:](Q;#T9&G;MK_<99$=C5R6T$U&2CPM*
M\-IH?KH;TQ':V!L%/PMBBUID,5\GA$#.JG'I-ZSMM%GA \/."0O'HACRMG3R
M!8.76!O%9Q9-GM#"OU^=R[+AS@^#P7+/S KGR?@1EIU9-$8!-A4(9_[6[[=M
M4,V&]HW4/8( >!!Q>D#$H3R3'#%1=,JGYTD?"X#(K?I,Z,V".9J7#[PV1N+!
M(BW+>[)6V.;IJC3HX._6X2 XMN8Z:$X;Q(.Q9+:2C+Z5W&Z#RI?T1^6[$7;J
M+X0KV)?JH%6QL9JS3U JV%MXH8*A6T'AL]Y0^.&3FT#A[1*O?E%Z.07JW%]J
M%C5VJB:^XPC\/X;"T]Y0^,TPVS]H*?% R0XJ8]@C7JZ:OC#/#88JN0 8JL Z
M)356RZ36Q4B:=P<*&.A7V*((H1>DA 7K)DKS 2<CM>KDC5^2XXJ884:APQ6O
M7P\S(WG?DM*T9IUQ4<=):R^E?8+#RY;OK^CY:.9IT4?AYL<2?#90OTYA]7!5
M36*\BP=37&Z;-@0=2R5/Z,J=NA7<*[OC7A?B7A\Y);$_+.O-^D86:^(>=?!8
M*D]/Q(@+&P/0[6*P3LE]/+,E:084VANL$R&ZZ@9H1*[F^(WM\\ O-LB>\!NG
M^M^*>S>_NW<7NW?8=(<4RU[&*NM1M[AE"6+:"I"\  2!-,\FDMUT1CBY[@;4
MNCHY:$.Z;AR[X^C;:@$N2@IYCFJQ0/&9H1Y +Q5/G*#\1]+A&1M-[G/[YCK"
MOR;4S\ZO:BA"391U$<5[O"U9(J7UW.!$-(56B&]8#_"Y!F"N<'F1)0NN)FXN
MU4ZHQ9%LZA*YGWQ<;_RVUS?@Q&[1&]J!'A"_[1GO 4>1RD;M=.!LNKHL-=>Q
M0?=M%Q!8BJ+R8Z\QD!"RB5"[:V2;0#C]U[\8]?!Y)Z>YM()[*X35O^^$U86N
MZJ=LOO]Y'KRKC,6QZV::'>6";$(ND%8GTG#5=&P8VG8 8/.ZIBYI;3F^])*L
M5FI1@E<&W?DD)0B$7YJV(!8!\(D9]S#GM#Z+S.ZYDG[)L .$5^[3=HDA<'Q1
MD+'MIO<)[I,N&YM^%YR]"\Y>;E^(I. >5\U[7 ]CBDVCTN!OG6=WV:UV!Y_>
M9;=>ESC.^R..;T3E_C^E>6A?XH:>%-8*YHA8JL!<!B(,82&4=FF-DSV""+=)
MH-SF20R:C^%41U4"LM9?I>F=TP8M9('H>:J=^K[!K.S".CL:A(2U._BTR1I]
MK54YY;0$OR!A]: XJGL0FTB=[+$1(2C"1G?HE/O,OSMJ*LW.1-(_U:@MIB2+
MXK2^76@R5SM?W:7G#;?8^8ZM)U]SA+O$F6M@0,1CMFMJ&[/ ?:'''$SD*VZ"
MYJ^SX!UC]6CK;</IO<^SX(,J56M9'09S)!M,\[9[M>:E71MFCL2^>,6V=KQ_
M[2Y+"TZ:HW7$H'K*:,!\[G.UY"0_CQ#)<U"KC>+N$;7F$0.CO@T-5/<55OE(
MSQGI*4]0H1).M0QCC@,4!45%:(GK<VD\;1TU%_$D<?*C3@C8.\*>3!8_Q%1+
MP6?8^U$E5.O/SBA_/5>7B+/#-AB'!_WI@W&(N_!'7,"Q )WIK-IM)XS;X+^X
M]LX4%VI<T V:=H(]VW:=H%V,@C?4I;76<QN]T#'U!*C!Z3/*(5E!TMC;.FD9
M5$SZ?IO(C\;1TI!EFG3?XF(0!AB18@\&9L5&*W6PEHZ@TJT@SFM'"O\VXF1W
MVZ=IG$?[[U4..ANC^H8<1-QMEYY_D;-Y96][PM!S[3&Y\,@/@+9S ="5Q:YB
M%+V*M70_[B)(GEZ7Q*&M%6.L')MMX:X"CXH-)*5E EZ!KCHKZ< "'\;U2F:_
M[46CV44P>.7UQUB=&;YGV@DK=-5GA;980YQC@25G^ARO'.FP>.!S.O"Q?^"W
M-(OKVC'(KT!$O.0&%L$;JCC?>7^LFC!@IUB<2F.8DGJ$<)2&ZC91X38=.-@M
M3$YH!-2"::&$(<6;*@WCW-@-R/;Q;^S2?:[#"H'"AQ:N&XB;_K;PX()Q1[?P
M=N#07#ON]E4(AX^4B;5[^)=1\+85CKP4H^SH'41HR-1,6PEJ&:H^&ELFA;9/
ML&<T4FLG&L.YB^O=DD$*,<"<#&)<(K;W]PQ,>L9[K7<O;/8TLD#S8#C[#J3V
M^CN75:5V HFVJ"X<78WP,5@MG.\XSU3$5K<SB%U/4UPY(;A%;E/0N@0M,-<6
M4GR&6-&Y81"3*DE0%LI\?8O6H;C4]Y1%_J3**8Q+3U%U3T/R#^ONE<V;$.DP
M43G-F8YF&& -T]!?.0&!>ULU[,IG&-KB&.[=[A<^\8D&8^K/3LKNLMUZJM%E
MJJL7E6><XY=>1R]7N0-2?!&#Z9@0DB%7^;@6W[Q;FW,B74??F\Q#KQT@^RJL
MO_D<+*CX/'BY6P;:A/L11$;#?^A6U;.*K<^KJ_DJ>=(BAIG!GM_400.)SX+/
M-)JXN7V@BR3J<)66^;*[O?08U'\$(DBC?=FE"?W?\^^U9W\ ?T,N00Y O%NY
MQO*]DM0@R;PLJ3,@KH*[XB%.*?-'MU[>R4V;A9LBZ#VT*6*F (^D1B;P_F%0
M-J3 2M@(L00LCS7>>WI!Y^NQN$^CKF4R/K%7._%FG!@GB-+'5D%##8Y9X8[[
M@WN4Y>?[4!):VZ2Y%8SOVA&^5S*^+=R<)G+X&CW^[_-XH4+L*)X6M/TOEY)$
MQDD@L71[9G&*UL(8P:PL90+GH5K:0KOB7EAGHJ67"&HT9%S4,%;PZSQ+X] E
M%V*BR="&8Q@^#&@ZPDDVPS(TK2@+*Y*X8X'MGV4"/N#'*KS^F(1OPBF,@^^7
M<WBQD]H,NG'=\- 7FJ^7CVBP:II@Z-TE'Q/1GO4Y<.0"6974SU"Z/*R4F &C
M2=@64<9K"<M0IT9&JC-JTPGJ:\6EZ$BG3HF]2PMQD99;EQ=R?3MYP5O 1N"_
M#.6Q862%?/-*>.Y'G9,S?XJ(X*'$DBWO\]H"!VJ,=5JD96QN' 7FB9H!\YMB
MG!5X/SL6T0A*W)\E<.$Y=B>6],*AC2F/XQQCRD46<G-BL'#()6K2$ W+-C6G
MHK^881B  >PG00HC8^JO;!P0F"CVG8)E)F12H]YJ M%>,UR&'9V)2 'U-F?O
M)R%Z\8W'Z&^(LZ+, 4Y]Q$H728+$.5:E5::-SW>B%AB@OF&<'P5UG^;JN/[0
M,O++LF]2+E:S[]47B[07O#M@]QCE0L!(<%SRHALO)VD%\FQ!RD=GJ-[T"54"
MOL]9/>+/L*LRO@!/TY9[30NS2? V7\%(P4F53,!F<-_7]=Y5W /++N,Y-20P
MP_IK9Y,G,M/\G!(C^%A2W 5]7$FASU!OJ\4@M#>J0*]8PX88DO+RDTO6PN:B
M*B;J3+!J\ZQD/4^*/>M&8]>"K*6&V#%T1>F_D_;<6>'$N2!J"^6. )LKO'(&
MY''B=V:>QDR"#.>LE-;J*S9/ &"DK1[-FZ%?FA"U]4BHQ+U,H+2QD89^J*<3
MT4^+_0]DM([N2Y+HM/7ML?3E*G,1,@>WH2"]&Q$42:#X^K?=@@V*>.->%Q>Z
MV'*IZ]?XTO= CHSL[3%&);!J*\5N604A31.^AV\>PX;8J?KS]"[IVBENOI>7
M(&.82,F<*4;1O(B!-_,Y&/INBWL<#61>KB3 *JT&!?K7_3HFK+:EMP7*Y#10
M!P_:/^K!,B'<\)Q(+<K5F=AK9+X5-MV :&;)*)BF1#S,"MC,^KWQL@GH"FVZ
M/#^S]WCHF+RWI\(\V)+DF>"QCK7UQ$MUJD*BQ/YE"U"\86Q8[EC!;1L%;_E8
MHLPB5)F L!P8)W 66G_E6[/(ONK:BX>MV+# ?F68>\4-6GS\9PXL($@V)K]1
MN#@U!O&_*RU(7+3O@CY@=MYNFEER[+F%?);A)WM((3X1KU6<1&FB&D%C#HD@
M]3Q"K+BA'YQX J-;T<-4!I93O6_WR6PU?6)Z'&:ASTU0I:PU[S$LC^4ZPI91
ME,(G?0E0>EM86+< S00]=)E]KS<G=(%-:B?9160T4R'B"W#^V^"6NO:67%<1
MT\3:1" )RX%WZY9O!-N-1")IX;R9[,O@B;M0D(G[^/%V]C!P8UYB[^*R!^+'
M*\H%RD,;)C+1I#HTG*-J'*GK-?448 GR8TBT0NM21T;_7;FX6T'OU]X)Z6IB
M^"ZE=]>T+LU+K?UBR,G()LF.+B2MI-'XHTY,F-ATKF=S:="027;5DFFSEI@M
M;WN+WC%T?'S X'&%8I"UJL.G3QZQ9Y>S'8>65'/;]8#G=%H)_J4Q*%T=_W>R
M^B^-;M(/*G"6?3V894.+S$N$0Q%\+Y!TLK3/S]1Y/*MFM=2"LN1D_8Z\I3&3
M7 Z,KI0L!J>Q6&Q10@BRJ7DT!Z(BM&^9QN@S;J]7BP!T!E:QD<:IBU8@$&B^
M]%433NYHAUM]O0R5@WRA)4\1MU!TRIBPX^N7H<"T#LSI6!7&&VX#TU375*6]
M<.-&<0D(7RO*]W"YD(0.BZ91#=>_'B=6YVR84HD&8JZ>IOQLK?[ >\D\CS.;
M5R(%QZ:( K4Q5= Q.2?>JVPVPR8EY,MKXL*B3CL*?LW.- 5VV[KP5TT]?GSE
MS-18U&I 4&-NUX%X\TY)&_ZJ&0V;5E=RNTC46&'E&"GN^!VC6F'8UZ,AGO:G
MQFQ=_A&Y4_ ]0,&V(4S-\FP1G$UG@2,A,%Q;"6*Z0Z/-B#5>2"0S:E,)&Q^3
M[[.KMF8=;;L&GAO?2.1C\ZY:^\-*?1T,;:5QW14QIQ/T-"OAVIAO\V^@+<YK
MC[1X^WQ\BO6-<FH"!Z=2\Q?PU?C6BISAVC*^6O6RY'>9ID%4:80+:D+)%;HT
MKG#XZRZ:9:-9AW?1K*O92?:7YH9@[1WT.U;Y1-W9KLK#_R,&*?UCM[J2'G.%
MNS9L70%"TR:D]GHY8)V3Y%JP- K&B92)>3,?FMFTOZK?U YP;\[)X1N,*]BP
M[I$9X@VF]C-W%E6&6'2GQFP5(MKAO.)N;,I@*Z+'RT-Y-3*VN5L^/Z*T7"/=
M,:%QA28DWK:&0F3SJE">FGS4U#AD6^6]@@)O=\:"^1A4^/7$P"(<>P:NTC0D
M=-HL\?P\^C@*)F#2YJR_2'P&AD^[Y$N=H5IJ=R6]+8)O@73ZT/=D)%EM9PLI
MM5J1$IF=I:;M-)>];'?#? 1XW^QJO6?("_2VP=)=!/)B2:*]C)/ J^!5XITT
M1;"4MUI#J-'G\SA7/@\IXO/]6H/H&36J0Q%'_?J\&F::T';+E/)Y]V(SABOB
MOA6>BVOO@OLMG@L#6'_BZK]V[ZA[N>1HEFCEG,/6DA++1MD:!<[F'7$HXC:2
M[D:9X;F$-^N^-R%V$0]^/FTSC/2V"?B0\L"P_W5/(8^U47'N?)*O,C'P+&D;
M)!2&6M4?/0)^'5%X ?@ :(UL?9@L.\1\<GDGQB"EO!-AN+X/WS;:8*$@ [H
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MB@:1*/)HLJ-9+-X"RD4V@(RE^()PFK]AFLO2&JJG\8+*OP0'('.F-_90Q$&
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MOP4'3YX>'R,[^_SQY"ZIV+D?CB_G?K@_SJ(E_&=:SI(7_Q]02P,$%     @
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M-0O]-H67I<"G/N+X*ERM6/&"GCWV%Q1$1Y52-H-K7])&W<+9OTF!YJUKB7<
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MO&=E5VZQ@7@ HTJP!XR+"64A#^8;^0&O7?FY&UON?'WUV)\->K)R(2H+0:<
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MO^S(/01_XNFCZS]R#R;/GSZY]ML>/)\\>W[])_G1T>3H\=/K.,GE59,^WI_
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M".-.(+IO XRG]XT, L0UA'5[\/V>]Z-*51XD.TYHLZ<5JH ]LZD#]M!N-QP
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M39:K/S-O%L34.^/?##JE%T]I46TNM](QSLL&VQD-]Q:Q?PV"KW,L#L!>-R#
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M.W.-5 HG7;XSE8Y"F7A$R^AU>53P^"%2#K8,93,42GTFDA0+X>52MB 1R+5
MWKACN]3&($72+ X%(2&7<41Y89K8X2]P1F (58D2RP,6MDHTHK@&\,*98'%&
M3F^@E8OD*=3;]'1J(9MRD<X??#:;=..V(='RP/JDH!0T3-ZU8M)Z%6V-F9OZ
M0!MB;N,UPM\X06U](NP(=H,=#@;0O5E2H4E SYBJ<HWG-<=("<17FPB.R:F#
MM-&R@%.;-2W<BA]1E(=P8(7N7&S(''H2P1HX"9.%]T\F8Y H?;,^^@%=1E6[
M,Z^O9A+LHFEFQW*FFW]H"Z !_H^+!IFRH*5Z$.?\GN'18MG5R)<+X?_0-&/D
M72'PD<")9&K,8@3>8W $L>WH * @Q%V ^,_Z%GB8+-"K$V%GC6*"W[UN&3V0
MZT-P"0O#DZ\7_7*&@/;GQ+I'\PE+"NC&L,LD8A$DSE29$:$VU0++#"X[<I!<
ME&ZXHUD$+N9S0:%6KNY"&._9X,)X5.RRX_3/;]VD*7QHP)-0+JVS@1&LG!I4
M^9[ HW .OIL=$$UMNOCPB0H:20"?'0YG1W,H1Z<9]0QKF&.]&-Z#DKU?(I68
M^U'YCBR;8] 2Y::9N2U@JZ(KCC;:^U1Y/V?S%.V7;[\Y>O;2_ 7;]L^ KL'!
MO,ZKM%C'>(B^^]G;?_;\Z B_^NW3JSNP59\/;*N^138B3KX/(%MKJ_K"8$DX
M'L1XL6'9Z%(8V8$[-)_LJLVHMRO'U]IL?E^\OX:&I[KQRITKHZ<&712Q\V:(
M4@CA+13<Q&U>E:[$P4+!99K(1 6N0S\$P!RV34HX+80!S=VR_EJRWP4&M,5T
M#[P9* #J5HJ&^HS+D<ALI8(D<+I\0R,NEJ';:-#7AF074BQ;@L)!*]YMV#C+
M@RI"\J*I^O//1+Q<,/GG6:J*DB/NR'Q6F4:'LQ@5!]<_H9OAQ#,Q(C:K)&JK
MDGBJV"T+XH1X8#*TE\DU:;K8445@5HF++]#KCZG3$_45])D\:@9OF6)*FCD
M/^>VV([KLZUO6HU/N=E!K:5H&WT4K9O=>(3?:K[E2Y-JLU9H6@3N?1U^/H-Z
MI+/ALLVZ6G,G+Q)+<\CCRVQ32@+-B6LM>4OSR98D(.=#=;!$@M!^?4V<+J $
MJX\7R!@FDZ^!*J;<<T\8'WH?//%>I9NV2RMZF32@UD)?V _(-PW!ZD^Q/29C
MG7C 9/-=P2[?>.7)U>M,AGW8ZEC(< [<%K"4G9#7.H]EPS>RNUYGV$\7_G@K
MZ9K.?:>I7HHJQ- EY_'X1F.SW069D>7RKX(UA$3Q[9/G5(604.EPI.L<F)Q#
M,U)@C%-C0#B*"Q\M87-V@\*Z.UA@@_4:=.PN[-$;KR^XLCT\["IAW:@DRX>S
M2>N;A1)J&^\"A 0%<FB?(5D4!ONX&(B,I*F"@VGFTR'+S%F8/$_/ D'FPLY9
M!ERM1-$<_15W959!'LXQ!K0"NW+)UMTRS] NB+D,/ZUFF$?/:70+8LZ3#M4(
MO.1B8FW.Z/0=GZ(;?2??HCY+%<[1RC[;X,W".:P6VJ1H)NCXJR2*L ;O'-4!
M]137% '.0-FLP#DLII1D8(L+7APGJ9GW92V)(">]+-?)95)'@6%WW41;O!3Y
MAN>L.6/L=739%TW3=^?9;V(9JZF^$/*Y[ZT#!BI@'3*HN%3I%!@OU7VN]):5
M'CJRW69:9O/3EO3K/"C*'YJAJS@2K(O6*2BMVBXVBE KH[]B^]Z)LS0:TEEZ
M.^Q==F=7Q+L \H8.^;#.50+/(/+$C,_I?B8'(3OZ8UU$5SL*N-[*HMGJWR+R
MCWYD<RJ4#D8JZ@*9&@-3\VJQMOW]T4S895H5,+>B$$XO,&2)]-:SF]9L=I<7
MLGFL74UE:-_?#?4TE$7]3=\K#E$<:DB*XQ8$I9MR/QR5T8)\7]P(WK^XBOXN
MR/AL.#+^2/J4#5O(X?UE"S4P-Y,-0?!PD&@78^%,*^;;*(V+XJ*",=VBP)<&
M!3[C-9?H9:4E.0B% R'2S$X2!!++T]P> T .CH5K 69)I335+T:#&,3C-E[
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MB_9,F3FXU&S=R<)PUD;<4TLCQS:COE/V?(UN,>VB/8UKZU$A(45*/:MVH":
MW"V3I/^]^<R,$;8@=7RV?W'Z\@Y$>/E&SY_Y?7?@['#OV9]_\DA'BOWR+SMP
M/3D[]D^?&^#\R1=O\>*Y%X^7]_AUQBO"I8]4),1"30N#!:(:2!79/+RXHUN1
MC/_RCOZ,J3]Y1\_.M<WKM^SY)M(G7]^[_H?O9H\$@"7FD=%1PFAY_,&#>]J
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M$]WWZ3!#R[$CWLTR* V0B <R#!UKPT)U LR\*1:L<+GH$A?C5 N3N$<2J$.
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MO**WIF%\[\NZ#0MD7T93DK2E6)ISHT3>TEI]\RZT^:Q@$>H<@).(=G(I"G7
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M"00E2 9W3J6/_R2O,QSJL"+T?2%T(QR:AA@C*VZQ()5!I2/$Q[:4A$1%=9R
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M#UP2Q2*Q&FFGK7>.1L,YK=4NNDN H3IY<_.9'B-!4\VTT1 (4(6-C%0B'$(
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MRYB72FGE(1:F-D;N5>W]N37;Z9\$WX09]2(US7R,PCK/N$AQL/'>&HF<L\0
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M!>\U?\))SY53I"54JE37!K6LX:YE#&9!:Z84=X4_T0#U$8BV\2<>$<O7,Q1
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M3E FGZK $+#!6XM$@![:$N)J2AF41X'X4T@[?>M'.K[H"J\'O3CH<?+I=GR
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ME7(+)1GNAU)QIB0^/_C2L7YX$ 69V=#<5.I%U?MCH65!( 9P.E)!/?) 8HF
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MP+R#@%+J@!+,Q;\(9D%HA:3?V*+Y-/7:@/:1/ ]7D,UD9"8$5[P+BGIA+79
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M,<+/U_B\[)-7!G-/R\K*H/;*X.)F91'!M2+8 A*8C\K JJ@,N (8>0:5=4Y
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M,HX2%Y]$QB9?/'X7;98T_89&&[]'Y":"XM:WX2:Z];U?W59N2LD>=-=??Z.
M\DF/%:%-B?&*#%9M0K)*8[T;#&[9K.DO-NM[Z-Q\Z1(O_4TNP:5VCOS0S_"1
M?.5C79F%M4)79F&MT)596"MT91;6"EV9A;5"5V9AK="565@K=&46U@I=F86U
M0E>NL9_^\GV[^%0!G%R)+SLI5%N\[ R&H^+-N1[$H12[/>?=^.3&.)6 E,<W
M<+&680?,5?*,WCOL(#857D38@8J%>)P1G;\K'VY*K%9EL&A3\MO?KM=@Y282
M#XL0/,98Z1W'^IM-]@&^\"GI/F-%LIQ\'W6G=)]V?Z2[MQ8*6?_G?^M'.K[H
MRKU@5P]Z<>3#LJG>=GR*E+,2=Z SW7&@TRNL/NL\[>G:MO;\]+RK1Y,9&Q?B
M3'_]=#2_?&5\/O\)3]:X3W-1)K6-9Z1LCE)LG_;/>Z,G/#&758W+2?DQ/5/F
M9;UJ.OWF./(_NA=)[L7D0#*>Y?CWNAU(GO:(]<ZCO4\U*L^M5Q1*:!$U@2@J
MM+*,.*0%4]R5:;0XU4K):?OSR9[=)?L?CKJMG<-OAZ?OT&'[S=?]G9?QO??=
M9OL0-T_B/4Y??F[B/7(S>[;9MNSH]!ULG:3LV_?QOMNT^2'^_>'=M];)X45K
MY^7IX8<WWP]/7&A.Z8P2'*&!8@4TPPA0+SE02$H0A0^UTS(E\F]L"=HH*Q*L
M;MY^KAQ27WV#G8(,>8:)U%1;9;2W6@>J*'*6:)KUS<KJF\J!9!("$\H)X"#A
M@$+D@(R;"O!2Q440$(*:I%.!I 'Y2A\4R@IGR0KG/@>%B,>.2^^4D)ABH[4F
M5!*FK+3*:J5OUSCYH-"JJ)[*@63E"'860L"9CE0G> ,DQ"PR'\H#AM(P9:+J
MB9IG2BF$W 6NML"_!^Z%#-8BXHB,I)<0&(E&8KM6&Z)Y-',RTUA9N%<.)#LA
M(->0 >ZX!E3''XIH I R7B!'O<-V#0XD9W538YZA>+1E&%<0>4^)9B;>DE+%
MB??0&QPRSUA]Q5,YD P1ILH;!12#!E",$)!(>H"%(M![#3&A4?&H!E35&F]U
M;-%6OZ26IWSE>E5$G;X'MORH\)/@YQ-KJW>/W<4BS'P@."BA*11>8\%$W%U@
M,"0@:LN:YFEW(:#\@T+R:UH;I_U'$?.\2<QMDYC2.X)X9SPF/AJCS@(JE0;2
M4P=\ZB7AC75*AXTMUD"TND?DDC5K ^' C&80F<@4+*66R_@7(SZ*G\<5 &6&
M<&T@7'%E,\V4)"@U?:$,4(,8T-)"0$2PV.'XGQ 9PJL)X=SE+XLIBVEMQ+3L
MM*TR=_\Q9OJ%'AX7\=L[SO?<L$P4+?[XGU\1DM=^<'"L!WZ^M@6^R4O&N8>E
M^VKG<GB77YT&_3J.](J1P,Q(?LM(6B_@UQN,Y(M[]9ZZO__I'N'N%W/2_]9J
MO_MZ^.%MY[#=1,W3/;C??ML]/$GE^>S7YH=W%\TXKCC6DZ.7\J+UZ:-DFC@1
MS1%AD ,4:0,DE33^TZ3FA$%;AC:VT":LUNLMSOR@&"9A_N?G RQKYQ2>O=WL
MW,WV*T!= UG"5*;_<P1;Q8*W&C.N1,2(=!A0CA0P5FM L=+$0\FEUQM;N"&D
MJ(>7-X=WYHWDN5OO&<E+0'+%D%?.8RBA P(),0[8*!QE1H33VEI(O.$9R2N'
MY$?O79?%E,64Q90[0=Y]DG=/S[K]"^_C YZ>^=Y0EPPDG?X<)BI0],_*%\ZZ
M\3MR7'1I!E;)P\:')7?.!RG7)CY#W[W7W7-_>7:PO.:M[Y1794IV'THVY5@2
MCJ:4X10" [T'48@22.P4@!SQ2*R9L:EO&8?5U+WL"ZXWCI=L7_TJC^Y^B,X6
MV-S@7K'  K5*$<:!A3I:8(P)( E' $610\&I]BRU*6Q BNO1PF-Q6%]!2-^%
M&M9[TM=)P3YZL"V+:<Y\-I)6KW!P1EA#"3.261*@#S2D,]J.+H//YMUO;KM?
M)6%<4B*UH28=AV6 <BJ %I*#N-MYX:,U0UE(NQ^?LOL]G9CZ8X#TK3\[']AC
M/?1%/R2C/-7/*4WQ!UG?J^O]>=3XYD\JJ512V_:_YYV!=R_ZPU'3CX[[64/-
M3T-UJN:X%$BH( C0,E 0]QT"I$BA3RM-E*SRAL"DH9C($9(50O6C^W2SF+*8
MLIBRF.I*9>9N>64JLV0J4S&V&,-2<ZN H4P *E/:%J(.4">P09))HFRMJ$P^
MG+M"5SZ%('598[>,4%_5URTZY9FSXH]N?SC\3Z/H^5$RF$?ZVQ.+4B_93KXE
MNE5*Z*<"R#_.!+;\:#^T];>\D=QC(]F?DO^K7(A6L91 <V4!%80#96Q<PTYQ
M%"BR$M.-+3Y3C8?LE5\)#I_%5&,UJ[7GTDAOB:04>VT4=LI98B#F,((UJ]DZ
MJ=E*U3[#E?20*B!I0"!R=I8.)5G@;$ $6NH585G-KAA^LYK-8GIZ,<;?M%LH
M>X@5)#=;>%+-%B 5GFI(B:>4&FNTP$;'7<T'RX@BEZ6([Y;3D2L#UH?+3,EJ
M]C#:^,H1P*(\ 968 XFC\6APD#@P;#%!9;,% :MT)M<DS3&-.>@;J9#R*G 4
M9*!44.6PC!0[2*>YD]AF?;.R^J:25FU"P%[( (06.NH;%X )*6V#: :-@931
ME+:!:8/(7 0Y*YS%%$'VS"KOF8+!"QJ,UP(QQ+$P1!FDJ+M=X^0BR*NB>BIN
M&^\\XLAQP AQ@%(L@8$< :*L=XQQAI@OFRT(5I,X:P;^O"T;;H(W*##G.>46
MR<AQH;9$*680T]FR65VX5YLMX& 4(11XK51D&C9:-EP1@(W$&DOMD,[-%K*Z
M62C/,$@S(2A63C!*K%$I.BL<8@8K0C7+/&/U%4\EG2M@KJ&S"@@;[1QJ.0;*
MT  P1,H0&ZC79MQL@=!Z\(R<S[5"5Y;"^K/$]V5%P_CC\A.5IM83+;E5MH_^
MN1#BXCZVQ#T3)YU<%&O[9/<:8;DJKE1&?Q"WB:0NNOILZ)]=_O'\<E5U>N7W
ME1]Z?JH'GSH],%8,S]A91664WS=^^_G7CAL=I_UP$XXI^$1Y3+YY\O9F^=8-
M139^CXA-3O&M;\--=.M[O[JMW.2*/>BNO_Y& 6__SH>/5=*'C6?Y8T7XP>)Z
MC(E54JS.6!6YTUTG>_3E!9=*8DR]I^\>OR7H^=)'N?0!="LSM!6Z,@MKA:[,
MPEJA*[.P5NC*+*P5NC(+:X6NS,):H2NSL%;HRBRL%;HR"VN%KLS"6J$KZQ1C
MF@0F1OVS9XC\G!SPJ)&9 ^^+5G\4;SCJ%R_ZO6&_VW%ZY%WQLM/3/=O1W>)@
M%%\XC:,<WOIXDWM2O"E2T.6L/^RD0/"S@>_J4>>+_Q%K2:[@:Q^<1&K@CX]H
M$\=P/KK](W69.GJC(=NUGVFT9=:!L!PQ9X7V%E-GE?3<2@8)(I@A2_U'2C8N
M/W1\Y18_TY\\, .O/P,=X@,^T]VO^F*X\>?/2RJNI\F L(@COCE?CS,K[3)X
MUP]I,8VB>*9-4@V%^<_^WZV#_5;QO_KT['EQ^:_MUDYQ\.ZO@[V=O>VW>[L'
MM0^TOMB/X_YW;V>[O1M'WHZ_FKNM]D&Q_[)XL7WP=_'RW_T/]7^*/][U]+GK
M1"WTO-A)\=[!L.CTBF:GVXT:8OB?NVA9=HN276YP6:E- <LPWGUCRX)O$J0>
M%*K[]7N,W"U4=Y_!JDW*YA^L7-Q8Y9WN^ANR5XNSL'*&;,R'! 7571Y_#+8Z
M3<#+3DH'+-K'@\AWFO'RXV&QVW/>_30G=Q3X8H*K*S&/XZ/4N%&270PQF<>:
M6NFY(%=S@>^SEE;LA/TM3;&O*$7Q\NU^L]A_O?MVN[W7>E5LOVCOO=]K7Z=,
MMTO]X;G9:S:?=U;3><9NG[&G4"FPY4>3DH!_>CWHQ6$/BP<MF]^48;G/G-6M
M.,;TF;M[<8QICUB7,QUS*-Z%G$V]YXE/Q;LTDQ@KA(5TG@8'-2F+=Q&(( ;E
M'Q3B.Q[NB&OS1[6NC9H<PX#-JV,8A[#U88\>GNY=-$]VOS7;;[X=MK?943M^
M[\EA_.[#^/EM=/3AY?'5,8S3^+TGW<_-#ZW3YHG[O-]^VVVUCX^;']YWF_B0
M[']X\_6H_?+XJ/V^>_,81GR]$]__%N]ZT<)O6.O5.[3_:O?;T8=WWX].+#O:
M^:O;_/"RV_KP/C0OX$6E08##1'FL ).. (H- AH9";AS!EJI632\-K:XS$6Z
MZGCVJGX=-V^@<P5.4*T*=.%-Z&JJ/%+"@^ (!M1A"+0E!%C+#"&!4&G"QA9K
M(%JM29,K@RT2@-ONY'PX*B,:*>PQ\!%SMM/U97GE*T(5W[%Z>%R$;O_KL B#
M_FG1/_,#/8KO%DE.7SJCCA\^RWP]6SBK:.&4ZD&, W9UGH$=?Q81VOG1LEN?
MID/"W\<O]$-Q-DBX'%V4;W9Z(]W[U#%=?WLC[TQ-YD!-YF!!_$Q-KLLY_MWU
MY4'PGMN^)N[,6.;%6%H'56,#2N4IYRA:%QXFQA* 9)H" @5'7#)HG4DM/.24
MHE:YY.S:('ON1D=&]I*17;%%!*-:.^F!0L(!&K0 2F(*7$2ZPQQR[5!"MN!K
M:(NL"M$IRZ(41@]]>MS3,]\;EM!8*%U>]?(V]>,Q!\=ZX/]*4GQQ38A9A=U'
MA76JY(0K8@)E"J0^$X!28H'61 (M<$@E:2AW>F.+0#ZK LNUJ.H+UKE3DPS6
M>8"UPC<\L8@&%B&*$E@)Q]&2D PPY3Q'BD0:HC:VHI:M$5C7.+?_Z3[:NCG#
MMH=#/RJ^#CHC'PVDK[WLY%HM<EC*;^_T3'<&*?[P(FX_GWP.D]]GO]F?XKE"
MUH?(!31P,,7::#"1)E((1*!86"2"-&)CB^*9R6'V6]47K',GAQFL\P!KA1P&
M*KE5P0(7I 94>0YD8 00BYG11A$=W,861W5R,F<&M2Y>MI0[^4EW>D54)D,]
M/JNF$]"'?YKS8;P\_OTP5O6TK?@E9Q_^K*E?18&FC*;]WD$4Z7 _E*I[F&(,
M68?/G-R4]'=GTG6KO8M:)WODHZ7&$9K*T5,G(^."#D2MSJ+![S2GQDIJZ,;6
M+'F)V0]78P3/G6ME!"\8P:T7-Q#L*9%04@2PHQY$.$L@F3/ 4V>8=4I1&A&,
M9LHMSNZY[,.:DM 5_&#@73'2WU+RUI?.\*%1SJ=M&]?CP,>E.,=YY6W];?=;
M"J3XOWS/A\YJM.E8$2W>K/(PY5% "AH E:=)BQ,@A11 A2"50(83E[1X@U&2
MSXBL)[3GP,4>"NV,WGNAM\+!H Q6!ZBC8*0%5$$&E(LJ6 KJC?$Z<&,VMM04
MO_6C8/>)N8I>Q*7?&17IH&V\:9EZ;FU\O-$PG1GQG2]E+1G=[?:_ID[S#SR#
M^[2-SL?T&KV^Y)XO^X.=_KD9A?/N]D3"6;?=2[>]J3(3[IGRRC& @W>1F42Q
M&"PB/8E6IB;4*VU%9"8UR@#)B*U[1"XC=HZ(K; 1Z:&7!#/ )-. !JXB6+D#
M2BAK:%2U@J.-K3HE6#Z%8A\OCG7ODR\KX(WC5"43Z7:TZ73+$ZB-\MQJ/Q1Q
M5KT=3<ZJ:OO?\\ZXIN;X$Z[SQ0]'G='YX*&'5N]JDJV9 &8XM)IG;,[UL%;%
M=(@6\\#KH2]16S4:LJ%0=V?GS[SC4IP[?OQ[KW?).MY>R33SCWOQC\.JQ2"I
M9U8%!#!S&%!(,=!8.Z"#8H$;P@R'&UNL)OV&,VQKZ,C,L%TX;"MF@V5<<^M5
MQ*E'R=#7P*1\/J0XAUYQ8A-L*1;UP.T3B[9>9R*=WA??&_4'G5P<8_49R-X/
M868==B\=9JO4(Q BJ%4&<&$$H(Y"H-+1-8.ECZ(C6J1T-H9GX1XYB%ICP"Z!
M>V3 /ARP%=(112.YI9%J>$( #9@#79;(1$88AYF5AF]L<5@]1) CI\M(\9KB
M_CC3%^. Z3B0.CCW/[DQLT^D[HSDEBR1VZVLUV.)IR3>L;S__2'NG!<V/_WX
MJ4IHD"?0>6T!%C95'W46*!VIC0XF1*/,81G0QA9N,('K899EQ->0TF3$UQ;Q
M%48D.-0H< @0TS[R(*:!%I8 IB7'5%N)D4^(ER@[8AX%NI>H^<^?U^E1?W3L
M!X4]'PRB<5!RHR@8</7O,N*;G35UIT:_TX_[2<K[E^6CQV>;LLJ[E\K[7"4Y
M)GB%##+ 21])CD<$2,<#T!!'BU#$_U0D.0JQ>AB!&;GURR^[,\/)")X#@BND
M10MD,+4>H/(0(O(0&(P"8)!8PQ@7"(:(8%5%<&UK0:R;+^=Z .G79"4[<U8U
M$_YWZBY;<8M0B"?;54KC>2!6. ^(Y5$A:H*!TBH "!DG7#L16/)K-PBN4^W$
MC/#Z,9L9$)Y!?"\05TLK!!+EIBD0#!- '6% (JF ,UR& +U&/AU]F;W"U?R]
M,9??-5FXI,3G(Z8[K^T]GD*CK=9NNWCT)L%/?B^9.UML^=$+/3PN#V,Y[_ZZ
M>#=,9\1_&,=7S=$R69S?/K,W)6%::DV0,D!YQB-9Q 9(;FRTHRV26(J >;2>
M20.SJLL_D\6U ?@BNH1F@#\"P*M93EQCYX4"_Q][7][4UK'M^U54U'WOY;RB
M2<]#<HLJ8G NYP5(;)(4_L?5(P@+B2.)8/SIW^J])09)V& DV!*=<^+(4N_>
M/?W6U&M0VBO$#3'(F.AR@2[):?0<!YH!;M23Z_8447)I^W@-HN2D&+F[_]?.
M^^<4(U=L/4LEUI<(:EW"6-XM&&H=1#[L79=:76^==^SH!B#^YZ)]GC-S%B^%
MY?)2^-U>536P#WM;.5= /_X^VMW?\]YN=</.>&>+(/<H0>[/:4TM&.6U9Q*I
MJ 3B6C"D$U?($.>]$(%8*M<VM2Q)^E84O?-/A5/0NRCT3D>X)F-#BA%9+AWB
M7A*DJ0N(6,<DX8Q3KW.PR5,<*YOGH-!HL01..PPZC)+=#$]B*V=6[@UL9V9!
MASI'S@_[O6%L$3RU*\4>U6B#\WBSW\)>Y_3P!PF^"1?9"A6+)]9WT+@9R3>(
MX]YYZA%)QB .? EIHSDB+ EMA%0J\K5-WJ0KRP+<IAN2"W#G#MPIX83:2)T$
M7<))J1%/WB+K(D$R^,@#P5)+N[9)>9/\A5Z%X>16 K[K%'W>#D[JU'RY ,+3
MY)'7K7PURG+RR[6@N1^'!RE?GHU^"7=OR%+[<PSH2^SW"N%[%.&;D;/#&>$C
MC1H(GTV("R>1B]X@D8A(47!%D\QF6TT)_;E!_N,%W\MG7/DJP N0'P7DZ2H(
M4AEKC4#2$XNX$QYIKQ1*U)/ 8L*<@.I!Q5,BU8MYY7'FE8N^/[&Y[ $(+3EM
MV&!8 :(83I;\CF?W9B^+[\[\J-JL#!R!:!>U FU,BIR!PV8G< >"2@(!Q>-$
M"<F^.TJ5A*8K"N?%RR4%S@N"\Y20(@Q7AAD&\@D%(27OF=-<(I/#LQS6V4JZ
MMFG6,5F.@IDK86.I:L7.0T1YW;I6D^YV]NSPHM\>7FUUPYM>IQ.K$0T.4J%T
M"Z%T,[)J:!H$)E$A@SF(*\"UD&,*HZ2]L,"YA H@N*AU)9]<"J9859J+](5?
M!A6D/S/2IV0:$RWFP0I$C!&YX!/(-"9&I%0("@YBY(15P>9XVB]MZ?-O-%JP
M&96>'%R<G_?ZPY8][L=8(:)EZ]B;J^I*J9ACED+6.>V>7E._L0J7J>!AK][G
M]_4V;UWO<DT")R*M"K5[.+7[,B.UAO+2AN@XHCHIQ*U-2'.L$8G)6<VTB$2N
M;1+1I(OR@ND&VF0F<H85=+\ NJ=D&>(!T?D..#H7<O$HCG3R#FG,/8_:1ZM,
M=H.9#I0LUID%P;+*,-/ZX;P/V.E#]ZU.V^?R\74]2G@AH*#7C8/B_K*DMTIO
M>_W;2EVUWX6X/96X[4R++IXS;@*W2.#LZA*,0U8KH'!.11: CSF/071IR 5Y
M07 #A9:"X.=$\)1X$GPTG&*#DO " 1EFR$9'$<@3GN ,;A?7-L53I)/YFUB>
ME,%A 6'B*]O':Y &;Y*!O3O8^_&'/]_O;+=^.?K7_#(YO&YVTL"$8#,923'H
MSXO+[$W+B2;9I'%*" 0$C7B4,NN_!!FN@R<Q::$KGR,V(R5^N;IK-L";4?JG
M0/UEH#XE4#HN<&""(N= &^0Y5--2%I"3A+#DM(8]SU"7K"$U2XM,663*16<%
M>[N[O[7_YAEER15;SR=D!2LK]MU9P9;0/V&[G=E_-U19P08GMA]/>IT0^R5
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MT'F<LV-IY+'DDFO/@A=KFU2N:SGMR%*,8"N#=<Q5Y!9S%CGGSCNKJ+,\FIA
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M1E:!,F(DM\(*(AS7!<ZO <[?X\=9X/RR<)XR)ECB8R DH>!#RM%N%9P%HL'
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MVQZ<Y+%7[I_P(TQO> +O/NEUPJ#E@#&$%G#R&T?NZ\';875(\K9W1Z?H9B2
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MLQTGDT]@4Q%(%+RP[O'<7M5_J699L[9[YOHM,C->T!,;,F6O#4 UT8#G+H9
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M\U>!:Y(MI9IRHK7EDFNK+3:!<,$"51J[@NN5Q_7D3;40AGDE%,(A!,0U]<B
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MA#_@E( "]"4&^OW5=P'ZT@*=WP2ZL3XQ"1:Z9YH@;HE$SB8&/ZCD '8<"<M
MYZRIUA\%Z"68]>B?G%"U^-NU2J6'4/,OJN2I/OCD2MU3JS?<BEERY=SLYF"<
M*"O54#.IAJ([NZ\^.<>3!4V"0*,PL"FP04XP<"B\]4K2Y'Q,DZJA'JD,\%K]
MTJ@ZJ#VH\Z @RJ*OLZ+A<O]4W=X0?C_?094=U%G\_.7VY2:J*Y7JTJAV5ESP
M3W\PK/Y[:OO#V!]4L9NSL'GSUI55^0B?WV\O8YI4%;K8,B:%UR7A]ZEB8GR=
MX?O5&_WX/4FGJS.Y4\D57Q?W/'K@Q[?D0LZ^UD:N@UB<^6#I.M5\+B57;.K+
M/JYVO,LF9-/MEKD:,U.60BQ71\0*U.#4M36CTIK:OGD??>^@"]\/U=MN_9?1
M$6NY_/72 )DB7S;]=KB]V>2IYB#G6S-S_SC!P^9O^3;ON<6:K9N\D:OQ3JZN
M[&+XZSUW\/WGV3S9>9Z\4U^/[+_7M?WW;F3_5:^ZTQ5Y3B\([C;A=Y80XT,!
MQW;FL'?R>W;KZQ+7ZI83 Q]'?$RW^:^X@Q7X@]76-7/^O';RBD]XKRU_8U[N
M)5J6]!I/ GIWK1DK,W=]YE@]<W2F<FH>G[S;NMW7.EH5V?>ZUX=?N]6K;_[0
M=@_J7H5ACO3>3\@MQGY:NGJN.JI8_=*NS:-?J_CM)'8'<[&,2BW<4ZJ%NTOB
M#4O%"2;8$RMYI%)KJ337F*I@G<5^8IA[J@S<I7V33?MLU^]T+__6BL/52*<=
MOZ([6P=D?VL;KM=JP]B.]G?_;N^_V2,M^E;L[X;.WB[\N[5W=C.=MK>[EU-N
MG[>_P]CIV[/6FU:G]<^?G_>//K*]HTZG1?\^W#[J?&X=_3FQ2H89'H34!OGH
M3:Z2$4B[B!'G2E#)A5=.K6TPLARYM)(TGW7)FV0,6X>52HG+Q#31+%IK/3'4
M,T%JZ%* +D/U"X[9M+5O!;$S06RCTH4E:CE)"ADI).+&"61P\$A1HQ,S25'N
MUC:H6?JBMF4SMG\::)AC!KE)SH$]H]Q$Y83&7'!CO!=!42F$C50EL_2IQF[=
M(_PECAD/QA0'TZ03V]T;&<6?\2)D7T9,\D47GE]\"$T"66=R'@E&06>?!C/K
MZIY\!JLS5DUF/U:JUR6Y'YW!3^@GQ.SI)Y[8)E#3D4_<(\6YP,3ERJ88-_V8
M+R>&^O>=EV]7LCWVGEDM4)N7>:V.'0S:J0V3E_J]X^K*U%6C>,[+WO%)/Q[&
M[B 3*XQS7V^[P][X]3,FG+BR$ZN5_^_:7GD->^4FU*H,LU&&?_+F*/043U_$
M/%<F@OGDB):F#.D)S6[99;?OLM7-XTT9KBSD"R7A=+>$T[WZ*J9*.-7F\S7K
M>60397OQ,HS]ZMN(?BQ_$-S [O!F"]@?,?7Z<?."[W.PV0V[]MMJQ+Z/MAF,
MXW.+OA+[1YMD^^@=:<'8]G9?L>WO?QRWCK9%:^LCV]O=Q(WFK^^ATSI^!^]U
MCK>W/I[ES^WL'AYN[_KOVV_VZ/;WS[BU&PZWM]ZG[;,F40.G45"2/ K,1L2=
M<,APEE#T";8[EE):MK:A5,E6K62VRA,J8F(T&64Y5M%2)10W$B?'$N'^SMFJ
M O=E@GLC.4U"E((PBCP3 O%H/;+1"228Y,03KJD@:QM2+WVJJY0;C<'^-MOE
M<3!<2,51$9SG@E,P;"C7!,>H>,+<:"N<4)(J1B1QTQA,MZ7YKQ07GV?\+Z-.
MHR!F#CQ=B3GMO'R[VQO)V5>#(=P"_M:*PQ%UZV[OC[C;AUE)L=^/X7HO?6I_
MBP%]C_U>$:UW$ZV--GK-&053*J 8J$0<BX L3PDQ9C'1G*:8V7'^S_^C*:'_
M6F'Y^NQ%@P5%ZHP15C+*9=2&"<VX"D0FY26.#Z@ *J+A*8B&;]LO\;=:/.R^
M(JVCM^P3E@%<:W"P$N/@96&MD7,8(VT\=BIB(EQ<1MGP%'(54P+X91_ 4KT\
MA8W>]6=5^]QLZ@,BJL%7>S)-D?M/ F.K$_]Z0F&NNY15*R$)B301S[C@0@L9
M(TE.*HR)%^[.1EOQ=I=&[DYB(77>4RZ,0]Y;@GCR$AEA$A*YKI-&1XTTX.V:
M.W*0SL_JNH-QM=HVE(8%HU2+0+7B(<G,/(>=QHE'(F4J<:FGC=1&7,HFFK3D
M!ND0P7D28!LY!G -'#:!)I3$7)\K[LH6_(A(O;>5=-P.H1.?8#2I"*^Q\&*>
M)^V"22"NN)#2<"TH3S9JS4)4O,2&5ER\-6)#8&)8:2Q#AE*%N)0!:9\B"HYX
MKD)P29-[^G_%&)D[GJ6@06*I$Q$<])&S4I,HJ1/"QYQ,*0&=%<=S,Z 3$J7"
M2(^L]@YQ+A4R@3B$E1?@;&#)LV?Q:(">?)2\+"?)K_)';^FHN]H(M]RM7D:M
M,ZGOU>G%UQ6=QX&X0LS^)%2UKL3]""I_TCTE[LM!>?M8];J\9YO3XL=*S3K6
ML^_T@EOBV0_6K).Y=*7-8\.:=2KOU.EU0^^8IMYY&$_A\O%A/^XGRW2MY"?+
MLJ[D)\NRKN0G)YC?36-[; ZK6M4M..QQ0321LQNV>U8=]CIA4,7_GK:'9U>(
M)0;5U_;PL.I'&^#^58CY0,]VMW8%4CY'_$L^LF50DTG<\N7>Z?"GWU^OJFN#
ML3"43O2YA7+8JXZC'9SVXZ0;# _ML J]FFW_T'Z)4XQT"(LX&%;PWNF@:L,-
MV_U\K1=5.\%CG+VH3CKP1J\__L2(_FX %QZ<=H:9D:/N"NXYF/0O]=5/^FT?
M+SY7=Q.#;P1C&.;HR\C-OZ3F: >X679]\BUL-6C#PMK^52Z/\?'J WN<>3\&
MI[&__CAG8FQ^L3 V>,37O?X'VXD?HC_MMX?MF.-2O:YO=]KE.(OM'&+:^OA)
M&V-=# 1I9?(16<[!*ZH1QES0I*(SSDPZSF(9A<($]AG8J:?'Q_E(Z?'VS/OZ
M2X9C/XYZG0&H38 ^(7(9(]:Y5/>*.$AP"V<?<8!;WC..\<,C%MBZ$O=C /F)
M&Z]F[QG/;;!B2B?V3H,EZVHN%$-SF5FR;LC]3AMYE)EE9+H!/84JQ<*H<*\L
MW9^V>YH5$)EGN_M3^NC36+8%<!3<B;E[FL;^Y[Q>+VV_?Y9MO_HTSH4)G!^*
MWY^<<O8HTW3I[^6C2T>S58$7-O9;X>^M.#QGASJ?QIF.5*Z+*8;ZKY/QZ8._
MUY9Z^TO\5][\B*U/,(N='<1\ 5 _Y-?KMGO9 3=V0':)![]5_SGM@^\_@)<C
M=K GN-1TT4M=Q-X2ST2KUQWWQ@S'A'>;@T&\<?##DSX];,J)>#4*9[R=*AKZ
M9<IM4XAV5IIHYRZEP8EKX4A27AE.$S>)41$"EU0IXD.\_43UZP';;=O_'.NP
MUV6 %C#L1Q!>D?J^UT=[QW\>[Q^_8]MOMO'.UOO._IO7;;C7U];W/]LMNG\(
MUX%QMYI'HO_3:N_!-_>W_%?X#&^]^?OSWC]OX;DVV?;Q6[9__/JHM14.]^C?
M:;O=;!Q2CDD=+4-<2(&X,PH9*BCR0EKN9<1UXY!0<HEZ-6<D>E:\C_LNI%@I
M2$&C%S9ZRI-+5FBF'?/*$^<EUO<GQ1IIF>Q#U);'93]10>[=D-MH) J$>5@'
MAZP-$G&>D2LB1HXX%;1D@1.[MJ%8X;-Z.IA=+&1'2#WJ'HU1>L44O-D-F.K2
M?/C4R /+SN$6*./NP7_@07NA@/EN8&X<S$*8ULD9@PQW &:E+;+:$,08\9S[
M((U+:QNT*.'5!33#2FEB<0@R\12C9LZ*Q%S^UR=IQP;S3UOHBL$\2Z0V&MP$
M@S4"%P9YK17BE"9D(E-(*$>=)BPI6* -@47!:L'J5*P:H_A3@>A](=KL6:,$
M$^V91JHF*!-!(*VL1%%ZS$&=1L[ULF&T-+(]PX\^XSCSK86S)=1<0LUWT\9>
M)Q\E%D&[Q*GE&AO/2,(D12N5GCK4/-JIEU;S/Z-M^GZT2[>N;-++>%;=C%XT
M]ATT]B3Z*E@5%0(H;,(U1QS;@(P/%F&1-*RL$Q[K3%^URFS-JVE4WR4*';GG
MB3@NJ(G<\6BX%T1)EJC##*SL$H5^=.0VHM!*4.N,3BABYA!WCB,KM$0*&Y4T
M"=HGM;91C@!_0I!=+&)+$/JQL-P(0O/(*"PB0\D9AKB*'#EG([(*3*K@855I
M6-N@S1-2BA)>&413+!S6$0>13XK/8122B+5>"4.-<GS:R%:QI1>$XB8#FU!8
M,$-0D-$@+HU%#L0RTD9P&1SE3J2U#45Y@7&!<0E0+P"BS0"U<M(+1Q0RF %&
M.=?(!N%SZ95R@:B\7LN&T<E=_X_3QOMH9>AT%AT'JS-C/SV_M+YW[J?OAU'7
MR*CD>M0W\MNK&XR[-[NHQ]L6Y<#K[TR>R^=V-[,,P(S+V?>1SW4/5%=Z$9[;
M)A@M?+M;TXZ/J"E\S0;AQP=5W&C2N$8#L3&9WV_T(!OU(>2-332G-V\DZ#A=
M5WG-FQMBW-P[TMQ7OCCNVL>77[%NT.N<#F__RA+T!-5K2/"-1;KR\[!_B=J#
MB!QX[)^133#8WVWGJST;K/UVG2&AW44WYO#FXS\2142=A8*-^3(;5-WAI$?^
MX2:YL5-')I(.&D=AE0"]SX5W5GOLB#9&6R*UCR/[#;X3PV9FL0W8@:LD-9%>
M<:*X,4;*Y+S/Y+S>^\><H=<7A#.9.R/39<1O[>&8*:;FK/G:.^V$RF7"&A\!
M##5_!DC!3@6CM=F<S/PP)[9=OS$<\_A6MNJTK6MWP'-<KZ[?Q5;'=5T3RM(T
MG)/FU(PRY]E#^//I(/<XP0U.CT]&Q#3U<$9?A?MEN=R&&<LYR'J(IX.8M5(>
M>OW-*Z.[,I2W\&>?=9CMPA/673*;'UY6FN(7,+#A83]&T%%?8J<Z;,>^[?O#
ML^IK9OD99'.I/3@<30#<I9>]X>]QQ)73/3F%@9P.1IIQ]$@U!<_%DZ_7Q$'U
MI4=94_A<_NKE;6P_P@0,?+_M8I[Q3N_K:(!_U>,AYW<YM%]JQI/ZRP>'F?A^
M/)RSFMYH]'$VX>-P1?CT^GU$Z,*A>WB5#2ECV,+DG#-05ZG=A05LVPX\Y3D9
M=?5+>SVNO\@$1E]M/^1_X8I=V-$CRJ,:EMGX'KRX<9+2Q1N_GJ/ 'ASTX\$(
M].[L0K'5XX"MGTZ'F>?)V\%AE6!6!U5H#WR.>8RV1QOF_02NGT<U>@#8NOFZ
M\,?,59079+R3KXUDQ$\U.'6#^-]3^'+G+(\M&R&CZ^9+?%S_L%Z-*!?.KSIV
MYJK!26_8?.Q\X?5KM%6A!W?*3%2PR=JP6T;0NDH^->+.&<2K<WXYTX,J,WCW
M8?ISQK^=,N!KLJEZZNK8SQBN_E)Z@-+[GG%] E,*N!QV1I#/_%5VF$-+9R^J
MFGKJ_*$N^Y:O;(2O;9C^FD#+7@RB K\H9@MDA*CQ4]8\UNI?YX18]3/U3@!L
MM31Y<77QX+:7&^I<EU^?,G"J>S_@'CML^\,:P.<TZ/"D(#7.D9M7-40'*W01
M1?O)=^CUVX_N;"\CYA=L1B-=<Y"G\ES,Y:N/9&L]V1ZVCVWG;QQD-O9>?R0F
MP&P'@ZQ^9+AC-Z/BQT-B^0.]0;P@**OEU0V!?04'%Q,,\G!XV L@.0[RT&"V
MS\G$AM$?=MO_S5?+M&.C^^<UO"@CJ9\55N[*%NCG!8!%K3.$->,\//O1:3@X
MWT]Q1#&?E_GIR+I+)JNL@\X5!3SY6(SGV:[URQ6>N<M):=)7+>%SGJ-AS#!?
MO3OMY7U2&QLUSFNJKCB6C*,M<<E"5VOSD8"\LM%O6^#'>39Z\6P?KNS-7NTO
M72'B&RWI<@V=31SZ:7?J8=]B/R^$ '#BV11ONQ^&("+SZYWT^ER^_V<LWB]R
M%<^:#_#[WJ<@!0_!"\2#M(C[J)!)AB&76*2).R>3O^G2Y+.NK#;4),:Y-,0E
M@ZD*222BM>5T$G_@HU.'7A@$5_7&I=Z?+%_.96VHKEE(62N";*XI@T9QW#%O
M4/W],0'4Z(TQ"U3U%<R\_+61I)^:<'#Q]()Z'1MS'WI!KM<!Q/.@:N.SIVI3
MZ_2>5UW\6.4Z[* G,E:Q;O!<B!"?^1X@?%U/>4S"ZE +3DZ1W:=ZGXAE([FY
M&6M7CT5*]ZSVP=)Q'4VW#7Y$*;DZ<'\^3*+3K?K887[V,T"?_0PL3O0OWPSL
M]H:VLQRJ;Y&)W'M,SDSO+\#>G&((M]=/D'O0=JY6%^7D);L,5@URO@_&4P?R
M[: ZC.$@AX"O9%I^GV+CW[^X<HIK3*8A'D_2<D[[ VW(,IUE.LMTENDLT_FC
MZ;RSIK[!7+]<CWU+\*5."=Q/!=^=J/^)3=G,@5=FK,Q8F;$R8\LZ8ZOEFTY^
M[-<_K9VLYF%4/;C#;^DFLO#YC%@%$N%6!Y8T,]S@:&D2&/. :331:C%M\^(M
M!3[_CN$@#D9FVN;PHJ1G+>_?8YLK5;X-?T_M;S&@[['?6Y%NQSVRL[5']W;W
MV!Z%<>R^[[1VO=BC[TCKN^=[1Q_/MK=>B6WZCM_L=FP=?>2MH_W#%CS?WN[V
MM]:;C_"=SM'^UD?6^G[8;NV^_;J]"_?<.IQ([H.3]"XHC9*B"O&4:06"U8AE
M(CX<M.+)9]E9%Y(M4<-C:4J>,:YEC-YSQYB!?Y1A3G-IDV1"<:RMGIHU\ZZX
M+OB]"WX;%#_1Z"R./1)<"\"OHDC3J) UFGA'*;'&K6U(V23Y*=A=&>R&Y P%
M'9R( @@KX@#&6DG*M97)8U9T\C)CND'UXW34# >)L.$>\6 ),DXKI),,7JF4
MA'!%)S\#7"?!,2-8:Z445YQH[6$'6,D#30!S7'3R,N"WR4)O:(@L$10=,8A3
M;1!H8HPLJ&BB"8XBJ**35QR[.E!J4DC86L^U8<9*AJTC$2SL%"]8Z'_*>UNP
M.T_L-ME_8F($#*>$C E@4"OCD0$QC, %XH1PERB7 %YJE@B\B\[</4;O3XV_
MMY.;O%?\X-O[A_!_)(4G[('5D\*&.6HQ"2(2PVG AG$" I@HBQTG?FJJM>(9
M+5XZ?VA&*QFQD>3P9/2<("XC \^(6Z18$I:S3-IB9^8931:2<[6N"JZGC7@H
M(9EP&H.6YHYK1WV@4AHL:=",D47@NGMZC$)OB,;7+^"^&[B;9V8J+ICW/I\N
MP!#7DB)+G02$RTB8A;5U9&V#O&#FP;97@?;R0MMJPKCQW 4PM6F4FH(O'8B/
M-#G8!Z&H[&5&=2.8*93#45*+G! <\1 5T@XFERFEL94.6\6+RGX&N [*$D58
MC 9,;ZVXTXHF:JV)*B7E75'92P_N1J0S4A4I-Q1A833BAC%DE5$H"AFI2XH2
M88O*7GEH,T^52Y%3G 2/Q%OC28R.">&BPX[.*]99H#TS:#<#H3)9HS3GR# I
M$,<,%+>%'TH+#+8X,RSIC&W!'DR$/D-L_R04>DZI X.-/Q8'Y9/+],G5JM3]
M0>/O7(IQ2U;N7%.IA)DTBE,%WDBBU%'IA6+:!VZEC*529HF5U%DS'BQ2$EXK
M@H@,"NS/)) )S"$:$G.>:L6L+I4RSP#7.@3)I<*42@"OCI9*Q8PT$OP3G7B)
M!R\_N!OQ8!:D(K 3D(B:(<Z\0C9B@6 =:: Q.,'RB7<OL,0%VJL+;>J"AR76
M03/+9?)64&^<8\01E0^5+BI[F5'=+&Z-#JM@+;)$>5#9.N=[E$7:!.V=P]28
M4MSZ'' =E=$J<44P53Q8I8G#G'O,K67:Q;D5MQ:5/3-P-^+!.63$,%;(6"T!
MW#XA0PB\LAS\+>:4\KJH[)6'M@N," RN-KA@W,*:6WCMK%4N6B7]W&I?"[1G
M!NUF/#@P[SD.%GGA$N*1$Z2)PHC)X!08:8$0D;%-)%LB;#\'4IN_+LGM"[--
MX= H,U9FK,S8\YZQU<J7+16S33'S%TH%<\6X*>&YV9KY.Q,Z++A*GFG,4:)<
M(TZ(1TZ'W,5*O0A!&$U+1NTY@'LA?#"W@;N ^"X@;F3.B/5&&"Y04E$A'HA
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M/-KY)(3,B2P9[UR0E%"'MJ0)7MER'DNPVLNZ2CA;2%F=B"H9*:WV$G&&>E&
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MA0!,,RM-?WC*#=8K;G I"\'D.R77A6-7?DW7?_0[E#8_=.??-=:N.^;JMCY
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M19"VNJWSO2Z^9@AL?.Z[@Q;?ZU\&\=[VUBG"M]OI(> W=TY:F[_W.WQ'H #
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M3AF;]O>U:(J] Q5K. S=?G>R8%%.^S+'%>^:T8M_3JO:( ]KC,LR*-PC3I;
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MR9285I\3)I @ \J#'X.ZZ*&)D*?NAW&N \IX<*UL07D6*._-DQSHF%>>Y%@
MWBEVYVXA9X16_ !P(@)BER"K<ZBN6_7Q>MAR/F$$STRKSC51LF3'$]G\W? M
M%?;L1(R$L:1"V^0=AS6+>'2\NC_GL_Y_V",[QD!B/4 LVY0=+&X$<A@ ?8U!
MLJ-:Y6+;X'S"4J>SAW*I4>(V0BL'1)1&P9-&:LU;HTBVF-B$4-YE8N..]-0)
MA) !.S60+@HCBF.?8@A1PX!R.&75XFE"^7_=CHH=Z)FW^S#>\L#UXF1'@O)-
MK]PV?8'3!(XK :IWH*FU >K8LF_.MQJWVO4N)?O?IX#BF3G6*H<M[?%T 1P+
M4?(U#.<>,*%Q26;;A#T9UI_R:@&=S^I_M,O%<+AH5P4!'0T&5B("61 HQJV@
M2.JY7ES%->_TE*$<:NR5-*44#*EXR3TTY>XEYN)H5<5FA/(.%QMA3@NICGND
MZ &])>"N!"6)NN:E!.H;E$\YIWZ:4+XE%SO0,R\N=G0HW_3*VG+)Q3)42@6P
MD8'$,I[D;7M05&;:FD']GF;0-^=B$Z-X9H9UKI6Q_1+B7XM^MR3$ZQSSH6_E
M3):$>!Z&Y2OGD(P*F\-HC@>]4DFA"W)%OY(E\X5E=3=98MY)VI;"1&N#84FH
MP,QI/%W>I63)=S<8%B^"=<)(+J5A:KTKMH"M,P5SDEF"-472M'(E$R)Y)U<R
M:%4N33LXH8'DG#QP"PDPY)1Z0?-Q$"PZ>,_G0O(L2-XO(#[,+2\!\;'PN]-H
M3:6K^ B-*6^S$AA8+0)RMFH^-%?:]=SB4QZ*,C.I.M<TR1(03V3S=Z.W6#8Y
M4@V<<\46A\UPMHU14G6U!5ZMG/-9_S_O\C!E5S-2 B(EP%81%)-"'7>V5"F1
M<%C_D)?J\(2AW!UYY1P;>\3J6'(+3L.VI+7%EO,B8A-">8>(>?.]5]D&CP<#
MC(.-:?(*?<1W(XKKC<=MNPKEX#AN07GNHO6!GGD5K8\.Y9VVGF:>O!-(B@4P
M#4ZF+B@DLER#)NM^!/WA<G<$^1(03W/D*H8M ?&Q%D_X/DQ[*[S55+P%+219
MA^.OZI2Q+RXVG=7_ZRX7DVS-4HH@W&F;Q:&@(3$$%<<!7;&H%U=QC=4Y92@W
M7QKY:"Q.T'?BZ@PQ]]8S6<JRN-B$4-[A8D$W\YLS>&EN0-G:-APK#VJ&;*6.
ML,[C!N55%3L9*.^E8@<ZYE45.Q: =W8%)#87I(%8,D 3!Y1* .MY&.@>56D;
MJ[.*8M,?>5I%L?W:X3\-3_[%__-_4?#EO:_O?6CRV:M/EXSXK,\Q'Q!7YF3)
MB.?A6=2=F.7NV!(2.?;J@ZI$MNC-PDJ9S!:F_67/2B<D7S4[WG;[5<!6MD(V
MCV^C[YC&*Q3:X%DG'*2=/9 5:R3TN8AY3%%4E9O37%UU2 E7PF1"(.\D3*H/
MR;N,P,,8;[E/ M*(L.D2E 93#I@7D$\(R'O3)0<ZY94N.19\;_KA)"X(F\ V
M3!PP90\2+4+6:-:TQ-ZVU8I["M:G ^"9&=6YIDN6AG@BD[^G RQFJ<Z9]](Q
MQ,2%T<3&>ZY1N,@B8=,9_X=[UL$HUX3#[N?4RC9ZV,,(V1J$TDEJYHPZ8K?@
M<0D/3Q?*@W^K4>;6K6(64L/Q6/C0'?92Z](0SPCEW;HU(]K6S*G9&+#X#-R#
M!Q(O0?IXVE+?AA O*-\U*-]20WR@9UX:XJ-#>2<U&EKQ#@M(M0#CH<B;KBP"
M*?L20C#VZ>(*+W?59$M#/,V1JQ*V-,3'&D(\(K606-FVGC^,E,5C[M%ER8@Q
M+BXVG=7?LYI3?$9'*0+6H(#CQ@$G=4!M_*4MA2"\<;%37IM^]E!NB"GWX%IQ
MBD114TDM^$'.MB5QN$IB,T)YAXMMDM'@:P7B;7(I>P+U*F"]AA0SMM*ON=@I
MY]1/$\JW'4)\F&=>7.SH4-[QRN2K-U$8S,L 6QM>N7L&'B\,O\P-7=NXV"']
MG!.C>&:&=:Z5L9\2$H_KOYY"_*LGKSZUETM$?-;GF ^$*W6R1,3S$"T+.91>
MK:HEE!2UA:PM)E47Q>):HCM?=+9G<9-K(YJNKD%$0T"OFXC8>TBEF5F0:FD3
M+_G5K'G"4-;2';5&P3RB*YWC^*>@55\SJJZ^ZQFAO%N_=EU<P0:&X@&[5.#&
M"AH3]YY=K20;E _>A[V@/ N4]Z9,#G3,2TA\+ #?],4]2PO--_#<ZK8PUX Q
M)XBNY8%@R;G3-OGJE!<#S,RJSC5=LH3$$YG\W>@M1\PA<^FE*B;?V<<@6F,+
M 4/,M(C8=,;_XUTBQN.^I209FC0!I&P@U2%D3%U;=][[>G&%!\^_FEBV=/9(
MCH;D"J><-P5QC<3>8C=LS3MVKR.WQ</F0O(.#T,9U%FX E6WM7/6K9T3#0J/
M!ZW;8&>U7%RE@VG80O+<I>L#_?(J71\=R3=]<A37ACN.D/LF(_:\*8A)AD_.
M5(P'.3.\N,I[!F$M&?$T1ZY:V)(1'RE^"UP"B4^N^H(CC*<F.5LWZHK>MU42
MF\_J[UG/B1ZCRXF!,!K@B.5 '(V0.V<*IEV#RQ=7/A_<!S9Q&FY!.0=)L;/5
MD+"TRB-PLQ)+UB+.E542FQ'*.U2LF49VN8&$HH"I$(CG!"TXJEWZ8&1U0?DN
M0OF67.Q S[RXV-&AO#-E)T;7BC9H@GG;\)2VK$H%L5@+I5ZLMHLK=^F7C'C>
M(^]T78S?2$7\_,GS^[^[]_Z3Q\\^>O3@Z;T/']S_W?,/EY3XK,\Q'Q!7^F1)
MB><A6YB\LUX+4DNH6C@Z]D$E)\?F.!\G;]*_?/FYO!J7\^VK=T<0">W+5_#Z
MERPF=JOP;<]^IQX:=^4 2E*V3>L5*&[;)7)SM6:NZM)@8N^4N)3&)XSTDDO-
MB3)I;#C@33%:#,59M3B^/U):92'][2%])^?28ZU86H2H*(.HQ0*4HT'(9)93
MYJ372$]IS6$X&:3O3;H<Z-:7$/E8$-[)M9B+N5F#W-UPT;IM%N D(&U@NL78
M<K6MD^#RE/.F,Y.R,\FX+"7R!)_N;93(&E*E&J+DC!83:Z'J8XI=-<>2%H^[
M4Z[A'_=W>5S$A+Z9 @=50*H&7+U :2BQ%+66_<55>,<?/F5K8F74V2.=#6L)
M5'//B-H#(T=!1>,FS1>W>-Q=0_H.CW/#=&?C#K75!#CN.%"O%;1X,<VEM1PV
MI+NP>A).!NG[A<R'N?7%XXX%X9W16T6#;A,PT1P"AF1 N3AH/OK0T'HAMXW>
M.N6)YC.3LU6%6R+FZ4*[D(?#=]&%U#U*EQ'8F0FV4+A$1%LD[F[YA3V;0\TW
M"JDH%$\CM//4@4(?WU)+S*UV]OWB*KY#AS>I39S@.WND-Y>8NECL+F'!H++I
MG"F,AZ*GZHXT*GDA_>TA?8?$:2NUI6I0DNE NB"H88?<!W_KOB;;.MCB.XE.
M>:C(F2%]OP+Z,+>^2-RQ('S36:L+9*$7$*QEJZ<GH&H.7#(NIK5H&Q NJQ8W
M_9&O2=P/A_P YG3]GN=6L*YSS'F.^1[R@^&0Z;_!PRT^FG7H.3U'OWHE^IF-
M_[87?[OZP1,^_F:PCA?U^^^W:.C%%]]<"P&N_M]QV(T'#\-E&:;XO:^^_/K%
M=LR[+^VS<?#?[+V_OVBO/OTAZ/K1#W[O\]YU__DCHE]_^=DWKW[Z1W[D1K<(
M:D1I1X\=PW9-GOX9%GS_@?WHST]?_N<#]&<#?6GR5Y ^+O9=^>SO\MW7%[_Z
M+^_I\Q=?P(W/\.;;_V7>Y//MD;CW9;^WD='Q:>][RS]^'_+RS^.MO/KRJW>_
M=\DW'IKOXU?J(W[VC@.UAI2%J];<*&"/WE#R]V'W^!EK]U]=Q[NA-3/O6A?L
M&*63MX2!@R]MA#\_]7MZ"5N7HG$* 86[>#-GXQQ8$IOM_!Z?+:3@O4;KZ*KC
MEB,[EP:U=TUSWTSJ]>?QSX?W9;.7F^?Y3+[ZVM[]X8OW?H#8BR^N/]'K'WKO
M]6?S^HG?;O&-^._ZP?[^Y==WOZ1+CWE[ %[GK5__XM?/QN7ULW$C*/W^->3+
M7.@G7W:7_E]\K93P+_WD?W>Q/EX2_?3+DUULNG18[LK%QLO!1G^6BWWCC^!.
M., S40.^6?_E[S^\__31_?<??/3\X?OW?[<:+\_Z'/,A\%Q+OOO!^O#SS[_Y
M8ORN/W_WL]9TUSEF/\=\\#L3I_K+=D@O%=X;EFH]M8KD)5CMB#&I;>7:ZG0P
M/M;HEBCC;M5Y]@P +ZYR=IR!??6 I!W(2H;8FKA(V"GKIK=%/'CI[<1RO;-'
M.N80F8.YUCPV+VS<$R?I+9 V7!W2=P[INXN:6K >LH.,QH"]%1"M 9RO5&H,
M4M(UTI/;'6:UD#XWTF\YE^Y O[[FTAT=S#?==N7J&V.''ET'+"Z#NA8!<VR"
MSF\+G;:E38?,I9L8Q3,3LW/-M?PR7=)+C/>F$9ZE7K"5Y,J(Y44HH%.NF0,E
M;>E(4\)7A/>VG,*>$>*^H@J9'^2M#*=00X*M=PY2*6$$\L-!X/4,G+PF#Y\R
MTILS\Y*J]R%@LLXAF*EG5[06)T?:Y[20_O:0OL/EJ'0Q3PP<0P <MAPH2@:N
M*69'P8O&:Z0?/@]A(7T6I.^?=G686U\"^V-!^*:S=@.KDJL#9XR PW</9SU\
MMW)+M7)3"K8QN(/''$P,X)G)V:K$':]+^KR3=[=:]51C]1UKTH[#Q%,*3;*S
M8=:)QYU8).YN^84_[Y*X\61'B[E![+%^WR7-OF<0:HZ%)%D)%U?XSHCN5YK^
M=)%.W H*MXQYH%@J:1,4[]A2]+F%1>+N&M)W2)P/T0^^UB'DF !=(Q#,>7R;
M4D/UT1?\'NEKU-5=0_JM%T4=Y-=70>[H8-[1T7#MG4H#ITX!BRB(1 /QE+NZ
ME"BG;5'4KM->!;EICKS3!;F;C0K_"I%[^N#1P_?O?_#@9YYVM<XQ^SGFP^;*
MQRQE]#ST3+UA*85*#(8H)BX&UP..2+ZF9$?:';48V!L';>-<N[D6Q]I[2A%2
M:=NDTA) J">(G(KO-.A9<!=7H1P\I6KBR.WLH;Q="5&+TI/#K%N+?%4<W_7<
MQ_U/:^?VA%#>2:94XLRE%3#&!N,>$0P2K1"17/>U%M?BQ55,JXOAKD'YEJF4
M SWS2J4<'<H[>Z X&P<M4'SK@(DC2+4(Z".1%?3(>7CE<+F+Y95+F>;(.YU+
M>6LL[-Z#;[_Z\N6KKY>V^6=5/%IV-3I)V]H_-J>Y4"P]LUAFLB-M@%HAW"WL
M_I[YX.1B;YH)/'D:(5SH(!8"<'0J34)4-ZP+'MR=-K$@ZNR1G*(6+AZU=<40
M$Y,K@D3:DQ2TNLC8A$C>(T_V/KB(D+"V39[L@5SJD/.V?5O=UF)\<45N(?F.
M(?F67.Q O[RXV-&1O+/+"5ORO49@CQ[0>H5!J#WT5MFZ^$IYV^5$!W&QB6$\
M,\-:%;&UCG?"$&X+VH(72R0->R>A8B(^V+ >30LM,C:=X7^X2\9:E-)R0?!I
MZS#3UH!5.I1,%$71(8X0SI>#8[B)$W%G#V7O6LAEA'#J(_K<M4APF4/IC2C3
MD3I)%Y1O!>4=-A9IA&V6,E33-*"<"-AD?!6JM, A9ZE;/CTM*-\Q*-^2CAWH
MF1<=.SJ4=U3&XY;EP@$(4QUTS")0KAERW(BUI-;C-O9GWV[=51J;YLA5&EMK
M=8\5P=66<VA^A'&&[",KYHH2N 2?).$B8].9_4>[9(QS'V9?$!AQF_;6%90L
M06F5G68FZ5NG&*UA'R<,Y6@]F!$9#O(]OE$E&0\&*3>JQ&V1L0FAO$/&>J^^
MM:9 CA"PC[LEPR1#KCZZ+*+.PL55SG%!^8Y!^;8S6 _SS(N,'1W*-[TR2DGD
M*4#7QH R\*SH&:HKH?5M*A/W0<;RY6YB9=7&ICGRV+6QM[^7\&TT?O[P/![]
MPK[_W(9=^_+E=77NW?%)V\OMJ(NK9P\?_?[)XX?W?G7OAZ_N/WUX_\8^Q9\W
MS;#.,><YYK,C*_USA/[4\XXP;T$6S1.5@+7&UE 8>9#'KB*9>I6B?N5]IHLP
M/]I3A-=<?"@"W?4 B-5 LR 4+(K=JQK&K3]U2:)/&,K1*U6TDHK;5C]WEER(
MO _<<I=XI-4\"\JW@O).WH>#4F[$$*W[K?3>@)04-AF%DC5U)0THKQ3NG8/R
M+?,^!WKFE?<Y.I1WUBSDXIRZ!(W,76_<&2@N ;K/W-58"^/%5;K<G1JQTC[3
M'+DDT4L2?;P0+O(VIE]<K1Y3;%RRN%8#AQ$1U'"DW3LKA+N%W=^S*E5[CS5'
MA.A+ 301H%([2,U!(ZJO;M-1YC4MZ(2AW#54*S&*LSY(66!R,11KR09\2Z?%
MQB:$\@X;4\\A<=\XF E@U 24*L$(Q(LP1^IY*]W1P57X!>6YV=B!GGFQL:-#
M^:97#APQBM]F?A$!(NIPR%)@FZ2=:9NE3>[B*J]-J#,?N4IB2Q%]K'&/RJX$
MI! X84ZJ42QI+AIC)%%=7&PZJ[]GU:EB+J%NF;=NVXPX#" Y&@1?_8C#E7,>
MQB7%E4X_82A;S=NZ<QL1G&+9LNEY1'&:LFIK@XXO+C8AE'>X6&C9<:P>$A</
MJ-B!:F3P&),KD:*G-J"\BMQW#LJWY&('>N;%Q8X.Y1U%='%52X[0BPTN%M$!
M<V)PU'VNKH_;VK?*V!H6-/&12Q ]KR#Z^8/?W7^Z%-#K'#,:CI7N60KH><BA
M;RI8VR!_+:!6UIQUFRPO6B@W?Z0Q9&N!ZML*-_^ZFP3ROF/K8=S \8QOPRD]
M2.@*Z"RG'*OV+A=7_AU,BSN>,-(SL2^MB%<B#&I,/5*HQ6,-7KRM5<EW#>D[
M.2)K,?8>,A0,!AA" MYVI(N*,Q?'7:YA0WHL!Z]*7DB?!>G[V^8/<^MQY8:.
M!.$=9UUE6ZI6()$K&X05N#4/YKH?QMIR+GG+#>TN2#X= ,_,R>9-$,W'WI9T
M^GC2Z6JMB6L8<\<2G01L8> M6XJI)[?*];,9_^=[%JWJ,(^]-0=5-I&6=01*
MWJ!VP>*D!])R<<6\])8G#.5MPE%"&K$Z&S;)TLP55)^RV^KXO,KU$T)YAXHU
M*Q0:,Y0D""B%@,@+%,)47(ZN<QM0=@<3L07E6:"\7SE]F&->1.Q8 -X9)HJ%
MI9<"S7,<1(PK2-VZ66MVQBJM<AP OCQE7SPSO5IEM*6:GBYV:SVJBM80NJ%#
M8G6\32-QA:EQKZN:=K?\PI[UJQ9&P"TZZ!E3!^RA@;!3B(U:YFUJA6YKM]]!
MW%TN<#HINK-'^M;]EEM)')B14])N)I:3QU QZY$:7!?2WQ[2=R@<]M1"BA%\
M: /NDC*P9P>( 6,KI4O>QHJ]$VA7J+F0?D>1OG]!ZV%N?9&X8T%X-Z&:ANUU
M'<SY"EB< 1<9)"[&'DL2Y\-UU^LI WAF:C9O-6W)K=]8;OW\Z8-'O_EXR:W7
M.68T'"M/M.36\]#&.IB#])Q*0L:"B5L2E10M*0>C-7!ZOK!RSZ*QYK)XUSLT
M] :8+ !'0FA4L'+UJ:!<7*$[>,39Q&'E@C))(+]-.>T-+1)5K+W[:%ABP^I6
MG7Y"*.\N&M-:JS8"XQ( \_5VHNZ!6$)M"7M2O;B*O%HC3@;*>U,\!SKFE>(Y
M%H!O^F*74O&E5[#<"F S&@"N'9R55@79-^L#P)>GW/$P,ZN:-\4S'_]:@NGC
M#:@-*6%JV&((V$.FV'*->9CUUG,-1ZK4K^CM%L;_#[M$S/DX<-,80NT(&$H"
M4F30P@E1R%/>BO'QX%+\Q"*MLX=RHMC5.ZY]P-1BX.B957TC3F+U2(VM"\JW
M@O(.$1L1=XM,'H+((&(N1^!0'8P0+F-)EBH/(C;N[(+RJ4!Y+Q$[T#$O(G8L
M -_TQ2ES(6\!B'/8IIKAP*XH)-MPW(JQN '@LA33TQ^Y*F%+,7VL;K>6I?5H
MY)D0@["+<41RE:B(H>'B8=/9_CT;6 7)RS:<UB(.V]]K ^5<P>7:'+N&O8S@
M;3CQ$T["G3V4<Q2)/392#LC54[+L<Z:22^O:X^)A$T)YAX=ETEQRW-B7I2VE
MDH%:ZM RY=B]82G;VD9>4#X9*._E80<ZYL7#C@7@W4T_W,4R063/@*H#P+$5
MJ'G<JR)-*@X T^4IMR?-3*[F+8@MS?,;:YZ?//_PP=-[#Q\]^NCQD]\]^>W'
M2_R\SC&A!5DIGR5^GH@@NJ!1J%/-A.8*I208@R)V*L76?N?YXLM].\6XQ^JV
M<2BV#4:QS(,@U@A;(V2HA$X]75P=G.2?.+H\>R"[5*HRNNA+1J/((1A[8V<#
MT2W(RO1,".2=3(_TQMEU!W4\ -MRP 9D$8&QL1]DOQ0*%U>KA^&N ?F6^\0.
M],K;?5C[Q(X*Y)WJBU+SJ Y:4P&L/0!1R1 )-_?L2=,V,]KO&1J]%HI-<^22
M/Q]/_GS8QSJ?R;]-[-8Q9PFY]!1P>'HJG1L-ZY'4M\:KX#Z?R?_S+@FK6,R<
M. BM;6I)52#U%=B1FG,::RL75[LUNH6JGRFUP2+%6?"A>\3JA%&<-ZI$6<VO
MVO>,J-IA1-ZJX\ 9N&X2QNH[: P5!+U43S9N<3LZJI8H^&"G]2\7HW\\7Z^_
M^-8:_,->?KDHRZV1MN._&II%5O";2<1&&63<2F!MW023\T&W<)&&17UOZ84G
M/W(5CY9>^%C[2A/Y3E+="*TP4M3@S%FVJ"/H#7$-T)G/_.]92:I6AS./##&4
M LBQCQ@K&:3J F%%'PE7#>FD@9RQ=R[-2W0!1S@@$D(+5<8%JA:?%V.:$,@[
MC"E&DX8U0^PCA!O,5X%X?!4XQ,(64W%EU9#N'I!O64,ZT"NO&M+1@7S3(Y=D
M78;A!2_L ;TI*&:&UF0\UT4S.[FN(>TZY55#FN;(UT3LAT-^@#1>O^>YQ9/K
M''.>8[Z'_%SS$F6OIW[X1;?-#G_S];T/7GQM,H+;GS4#L<XQ^SGFP^$201Q!
MAK[J26^8>3!!YS$*D:]HW"6ZZJ)K/N(@+WG)T*<C+']YN)M"S%J2+RU#)9\
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MEJW0L+/&/BP\MHP:*([(/O1AY*6'NNG8>F;_V!:[X(AS+7-M79ISO:2!57.
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M/.NQL"VB/E]';"E:<G1))6)C49):2DJU$'%"W'1L/?/OCM QASU7<0QAN'!
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MF _(6.DR.'6,T%M30(X"QG6"N?8\1P)'U0'FN#70%P/FHV3L1.>\R=C9('Q
MQI2977(%8JL&&&=CN7B%X8O+L-%<?!G^F*_S!4-X98JU;FUL:Z#?60/][//'
MO_OT\19![W,L:#=VNF>+H->AAE)"[LW$;,2.R"JI]%@YQE)R;KR'02\75_[O
MQ\=V@KE8%#T;:,X)QEUR8)$$!LN7B-(Z%7=U@[)UDQ<,YE9$DO9(32J*0Q6?
ML(QO@BE)V'F>-<%\D.=)GKC8P''%N8_=<@!QFJ!P\,- MSGS>X Y[V'0%P/F
MHWF>$YWSSO.<#<('>1ZIH?DZ,#LG0 (V7T!;BL#"H3O&X K.HOO)(KB%(;PR
MMUHWS[,>"]L:Z+-%<-@")<K.)T84<V:UDA;/+C07<MQT;#WS__T1.N:M%=;@
M(5%O@XX-8L94/'1L6+IU+%JN;D(Z.<V_L.;JP8.9<01L4AA+ZNAJ&*& J)<>
MN*>^AT&O"N9#.E9[%&(&=1(&'1,!5:O@NG<^<A#&0<>&==Y@OF=@ON,PZ!.]
M\QX&?7XP'ZJA56*NWH#(.F (";1*AR(UL;H46K.YB_E0#;V'02]SY*Z,;2'T
MV89!.\LI2B%!["VJYIRQC@"N)L>Y;D:VGMT_MBV5?'/SCH&YZ@ S>Q!G#"1E
M_-F=KXVN;C)=LO#JP8-Y8!E=R2'J #/E(M[,7#/N.4AHFY&M">;#KE076QUA
M&[2D!3"V.4D6*QB&5&.(G%$&F'%W-5P,F']D&/1)SGD7R,X&X0,>YBI*<!:!
M,1)@[P*64"&1L45+A3)?W?A=(%O^R,L30O\SA&Q)(?07O_WXLR?O/?KBMT\_
M?_;%H_];__SU!X^>/OOHR>=;&[W/L: IV1F@K8U>ARV2HM7 Y*L0^L""Q)R*
M)^>C+[('DBT8:A[; Y8I]<R2H9<: ),,HB@CWDPB6C@/YMCJU0VZ/2#Z@L%<
M.L?00DAJAB6:Q(Z:DPV:F,IX!G;J9TDP'VYF;AR:8@/?S0 =&FB,$09M3-US
MJZW%N0=LYW$O!LQ'4S\G.N>=^CD;A ]2/YA;QN8)!&,"#&UJHUV&\=Q2SHU<
ML0%AW#WPRQ^YM=%;&WVV""ZB5PF1FU5"(Y169 9TP3@WJ;L2OZ#Y#T?HF%I(
MU?< ECG--9 -V%H>= R9Q7)T>;;&A"VGO& PT^1C24J)D@;SCMIJ)9$<*"6)
M:>_K61/,!W3,5&>K@T&K<= QKW-?CP^@(R"OE<D9A@GF2QXN>YE@OJ,V^D3O
MO+71YP?S84T^=$Y)#:I'#T@^@KBLX%,DRAB'R=:YH/G0,V]M]#)'[LK8UD:?
M2TXIN>=<?!WF 2.J*)NGHL/S:XTN;$:VGMT_MD%5*3#:N$L4:-A]%S,,DA:!
M0\RN>XN<[>HFASU7]H+!S+[%:!K*+)!Y5\;SX(I'5Y%G:647R-8$\P$C<R*=
M12,@.AF,K-$@8ZJ04/,(R;MT-X*X["]96/G P'R4D)WHG'>![&P0/N1AE+-H
M;C"7I@T>-KYHH02^^=A+;CE).-ZC>CD07IEB/=0"V?$!T5_\Y>4?V\OO?];B
MUS['ZN=8#WL[9;+%Q.O0*VE$DEH)3BL:DM1>YY36PM8XL-NYDO5BLV,+M72P
M*&^U@I,^.%9G#\:(H*@N5)^HS86HLF>S7C*86T)2[CGUZG \#&+9<BB#>5,*
MN<6=*UD2S(=]Y%A2[EJ :YA*1'' 62)XW\W%6)V:#C"'/37]8L!\?-#R:<YY
MYTK.!N$C8F(:-R)5D*(#PM[/CO*!8ZK=H4:7G>6K&[J^Y-K%RMSJH>9*MIAX
M(:-_I-I%%%I.P\I'PQRCM1AJX>2$0^6&YZ%C_<7+/^NWXW+^]NW[PS%!?7';
MR3]_R0[O[N0;GGQWA*N5BC6WX1:2!0-4&X%>"!4HL\MS0,QX"*YN_'O#X6]Y
MXN5BO8R[;=Z-:*YZ1!$=7)TQ4""6%O.9M,8;ZS\EU@^HW+C'?; V 6PI ^8L
MH!CK 'RJ2=T(Y">5\^^1WWT%]PWK=Y0BG^C;MQ3Y_' ^H'4ED7:I!L(\,.U<
M ?'DH<0PS/:XL6[VB,;KPYD-6XJ\S)&[KK:ER&>*\;JKK;GJ&3%B:\6B!:I%
M1TP@/%S_YG/WS"D<6W)*KJJ,F!VZS:5J47!VCB(D,77%I]2]7-V$]\8C<,'9
MO@>/=7%*+4GKM2%Z%J41%$0,G$JI+<KF<_</ZP=\+M0>6LD5XFWN!J6 5>R0
MHH395TJ9P\;ZA6']*)T[T;7OXMS90'PH9&Z4:O(!AHW.@.P53%C!M99];AKB
MJX92=\$07IF@K5N<VT.>WWG(\^/?_/[Q9Q\^^<V>Z;S/L:#EV.FB+<->ASOF
M%AFK1-& F$M3K%K+B%/4E6"Z9=@+1I;'UGEQX\'PF4"3*&!R<Z9S0A!V+*UV
M'^;<(<1-#B\8S-JJS[''*$YP4$-+7FMJO:4TJ$7?Z[S6!/-!KD=:LHR<(/0F
M@"4'L$0*C8N+/FEJV0TP^TL>"/O P'PTTW.B<]Z9GK-!^"#3DV(.N6L'],R
M<YXG)_$#Q\-(MYA=3O'J)EU?<EO4RMQJW4S/>BQLR[#/%L&AU";619K*L!S.
M&L;8-7G#8?"9-QU;S_R[(W0L<8NQ9 _$[ %[]* MC)M6S6,84?JXH\/\YZV]
MO& P>^PXH5JR-'14M&<Q5HV10O"V9SJO">9#.A;F@"AT4"PG0)$*3.R ++/.
M/>J,Y2<9![C!O+:0^D3OO(74YP?S 3&+.0NI)/#5(V#%"&*%@*@7Y]F"\%R5
MOH74*Q^Y*V-;2'VNG'JHF:P94FB8.[)$$U2SUHUM"ZGOG5,XMA%5$#,55Z!*
MJH!QUM%BK2 !,Y,+CO"V,=9[ON!\W8/'>@GC%+5@&OP<?42+53"4&*KSB>U,
M(Y\WUG]*K!^P.6HX[BD'4!.9F7D')C4"N5:M8G%6^!;KN/<?WS>LWY'/G>C;
M-Y\[/YP/^%P0[U,1!#?HV^!SD8%+R%"&R^9 /J0)YW"DT/;N?&YA'*_,TM:M
ML?WT:FJZ9GH7W?+7+[YY?BM8?MF^U&^?_[5]\.V+K]^'>.WGR]^^7OVFO=(T
MWT,9]K\^^>S)YX\_V2KL?8X%+<[.-6T5]D+$DU5#"!)KJ.AZ,F+%85:QI$%"
MB7;9?[U@]-CBL-Q0,A%#\C,8I5!!O-$4 #C'264PCJL;BGM^[D6#V11%O4N^
M8?"=!S\QRZAYUI;(=ME_23 ?)(IJXIQ21L"6 V H AR]@?;2R3EO(:0!9K=;
M*BX&S$>S1"<ZYZW"/AN$#Y)#I,Q=Q" B)< 89JZW*814J@^]8W*WP[ O&<(K
M<ZL[LK!??ZOV9;NYO5D3HL^_^LMMVN'HO]SF&\:7-V=];0$P7.>9:CE,Q'SW
MO'[[IS<6X@<O?'5[WG?_]1*U;UY\^9=O?_PE/[CC$^[#I)S=T(5Y32&\E7[Y
MP=<_O7QS-5\/<P3VLNE_#-\V+O9]_?([_?Z;JU__PWOZ\_.OX*W/\.VW_\N\
MR6?SH7CTHC^:P='XM(^]Y;<>CU<&-4OTA6IH;ACSADZ'B^^YM=1T?IM?^8'Q
MFE8?SWI<#IR[BQI]-VS=:_(9>Z\CIJN5U%W]R.\IXV15.#<R0^Q%U7*GU&/+
M/9KJ/SX[?]:7?QP?]4P+TBVB;Q_Z_WH87];V<MJ +_7K;]K[;[[YX UHGG]U
M^PG=ONB#U^=Z_00?R3#>/JBO?OSZ;F:Z]ICF#7V=\WC]BU_?Z^O;>_V6/7SU
M,Y3KE/E'?^RN_3_YLYS#/_7*_^YB?;QF_O$?+W:Q=.TPWY>+C=<C%/I9+O:=
M/X)[X=+6+8^LEX+<+4CG2U\X8AGQ,EIG+#%;IM*ZU5@)272W("W(??!(+M*C
M=HRI0\K% 5;70!@#F!&FT#ACC%<WF4_N0%U8[?S@P2REA>:[]NP869WU4H.T
MIMTDJNP6I#7!?#C]$WU')PR,-C>WI ;,EL!BKJS1F;79M< G)S(VF%<!\_%<
MY&G.>><BSP;APPT.Z/SL^X2>_)P(X118,8-S50MVDC07Y;KK<,$07IED;47(
M[CY:+GY3GW)NF%1PQ.N4+!:I(W;+*4JLEG?WT3WS#,=6J%NNOJ92H(3> 1M%
M&.Z=0<N<"\TT=S?-CH3H=T?"!6.=?*:(M1D5Q69159NGDD(6UUS8W4?W$.N'
MLR0ZUD'"'93F(R!J R4RF(M<HI> C'EB/?#N-+P8K!]O/CK-M6\J=S80'U"Y
ME@=0^R!PIHF&PQ8":6C@A6N-.33-??8<G4SE%H;PR@3MH5;6\E&S]/OGWXQ'
M[V<MFNUSK'Z.]:"W\RV[ V<=\F75>Q2O$LJ(R7*P:C%G=#1B,Z^8=M5[N=#L
MXV,K,26EQK%7X)@0D F!R54(7+R1Y>J"7-T0;79UP6".4;H0E9!"1QJD"GMD
M*9J;XX*OYZ;OJO=J8#Y(EO"\,UDJ],(=L*;!N(P5J#.S9BH^X0!SV.UT%P/F
MHZF2$YWS3I6<#<('J1(.6NHPOV A,F T!Q(S0<<X3+(%=1[GN,U+AO#*W.JA
MIDJV"'DAHW\8P362W&/QOKF,N2=N7"-*-"8-CO=:N@7-__?'Z%A#YM(<E)[B
M'+:'8#4[&$%WE5J-46V8?]Q[$"X8S#FD+*V(-]<QNZ8^#\=?M(M6B8B;CBT)
MY@,Z9H&X)"8(=793-PN@' 5RB%UXQ.>!P@!S/%FELL&\"IB/TK$3G?.F8V>#
M\ $=RSH(<ZP*SL@#.HZSA<  T_AOEY0I]2E"/CD]NC"$5R99NRBV1<C+Q6_%
MFWDN+G4LZ"Q(2AQ#P)Y%*7;<(N1[YAF.+1!7I,9!#5RL<W1=5-"H%3@/=A9*
M]=G+K0C9N0M.U3UXK&MM,F)\%TO!N7-8$T7JF@?XJ1<-6X1\_[!^6%?S.DLH
M90ZU&[&?"PB2:H?,6$VPDS>]%2'3WC!^,5@_WD]ZFFO?5.YL(#Z@<II\J)'G
M0 <M<[8= SL;S*YV"<2<<@Y7-W'/MEO^R+W]X/*V'WSX]+-GCS]\]NB3)Y]]
M\>2+1[]^]/391T\^W\L0]CD6-$ [Z[2EV.M04&'#'$.DDG4PT,XDX_VZ%,;_
MO?-GVKBY6>9= M1C2S4C1V3Q'EQLMP%J RDI0[#!/QN/FQH'RT2\Y #UP8,Y
M<>F=6_:Y*,XI9-6G@6*)%#&Y<ZW4W&"^(Y@/4D81R4KV"JFG!!AB!ZD^ G?7
MH[/0\TP9X4X.7PZ8CR:,3G3..V%T-@@?)(QZBJG:<,6:^LSZ4H%9\(>*'+!6
M&PYZ9GW]UF(O?^368F\M]AFUV&FN0&^QA8:^F48+)J5$Q"A8;?.Q]>Q_.#80
MFJ+FFCK$Z&38?S&8<DY0=*WD4#$'/_=9R05KOQX\F,U5#D*$97"M;%ZX8T5R
M6%)!T[KYV))@/BSA%T)NW" DFW*=J@/,U&$ VE<7M00;T0+YDV.Y#>8S@_E7
M=Q5CG^2=YWT8;WD@>S.S<X'YR#PQCDQ*$(@:8.\9I*"""UI%4IIV>JJR#[ND
M_N42<+PRT]JEL2W(7BZ(BUT]-Y0TQX7*L/A=V"E+<J'F5&0SLO7L_K%UX8I%
M_33Y37(:=E\-)(R8#AU+H-2:U'AU(W1R=^S"";D'#^:,V'C@-F?U.*<#EX"E
MBY9QWP=Z^V9D2X+Y<+*S5!JTJT.L06#<1P9U;3*R@$U]C"74 6:_*V07 ^:C
MA.Q$Y[PK9&>#\ $/PR0A>H[@=  7"R-PC@)>L[/8R3&GJQN\ON2NB)4IUKH%
MLBVI_ODEU5_\[O-__?C#QY]L$?4^QX(F9V>*MHAZ'5;)R'5$,RX7W[&(,RHE
M\?B+;Y:M[P%JZX6DGWYW)$44HK5,7<$GI,$J>P++(M!<<;Y@)<(^15M;1'W!
M8,Z8'"FFZ+@CNVRE$@]Z::FY:FF+J-<$\T&*B"(U9G)31%T!'690)PJAE>:M
M4.MA\$N_YUG?.S#?L6A_HG?>1?OS@_D@623%)4JE@=&4TW$2D"8%JG;G5+F'
M$J]NTO5AOO?=B_8+XWAE@K5NGF@]*K:%U&<+X[RGIJDX8L<8A*VR]9I4BM1L
M(6Y.MI[E/[9C*+IHP:M!"V58_H(.3".!LB>2%&>?W-5-B'NH]06#F92DAN'J
MBWH<WG[\SVFLU"FY("EO3K8DF \X60Z>>JX$0::0NGD%RYJ@970)Q3@J#C"'
M/=3Z8L!\E)*=Z)QWV?YL$#X<:NT<-=0 :*: Y#MHCP%J5,W#1P^&G>8DM$OV
MQRN3K%T9VQKJY>*W;G*;;$/M#BNQUIQ9*'N'L57KFXRM9_R/;1AR*;GDB4%;
M&\8?:P+F:D"YN59]\5;R,/YXR9JM!P]FT:"2HT_4%9-FT<YYX'F<./0FNLG8
MDF ^4B KQ,$II'&+!IA;!$NI08G-O/GHVQQ1LL%\06 ^2L9.=,Z;C)T-P@=D
MS&)#R[T/!^QM0+@X,',.6J(2BO<UQ3Q[62^YQKTRQ;HS&7MSR!LXA]OWO+8Z
M=)]CS7.L]Y _D-S$V]K[?-1)/WOZ[/$GCSY]\IMG3S[\Z&=-/]R7S^U..9W]
MB=W73^Q,YUC/J&VES!F:%G89[EUUSIRU5/0)FR'59C-1,_>0.9>Z]C/-M=C+
MQWXR@GAL++SGEN8B:: 4$3!T!&W4(61D%QOY4NCJ)KZ7:0\BO&"LFW8L#6N8
M @O+@9W/?MQS==Y47=N+!N\?U@\WQGN26*E!\;D"6A40486@ZA.'5%UT$^LA
MT,;ZI6#]:$;W1->^,[IG _%!1K=T\XK(X-2&PRXU@N88P#3%670C]O[JQJ?K
M2Y;(K4S-'D@.:Y%VAUW'>\<(SY6$I<1>4A(T0:%>9X^C5NZ&=:^-OV_.X=A0
M^=#9.F.'1#(B/,TTV%QAB#0X7D3)/M@MFPOA@@M^#Q[K-N([IL**6;&D:*&P
MRT78EQZRG4F L['^4V+]@,T5"1R4 C@D'6Q.#"2F",ECR,%',HZW6,>3(\&-
M];4;V$_T[;N!_?QP/EP@'WWOC2-8"P$PL@<-I<*XI24&/SL<;2IU#L&\&]B7
M.7*7Y4[MF-A9O'>,\12QBLOJHA@V11L!7F!BR2E9Y3/M9=XQWD_F%(Z-I.\U
M<52*P,4,1IR7P9QXZ$8)??.U6+VZR>\A[\U"%XSUZLQ9EQ8-#9UDM6RUZ CP
MV%'F79V[AU@_W.G<,G&O!+'Z!BA&("$+N.*CF:LASNI<>D_RQOK%8/THG3O1
MM>_JW-E ?,#B C.[C@3CZ:W#84<'5D5!!)/%:EYC&@Y[-[\O?^3Q?@N^4[O%
M_=7&[G/LQ,;%)#;>K=WB?SW]_)/?_*^/?_/D9\U;W)?/[.=O'-B?V/[$UOO$
MUC.]6T^T-UFLDXHRS[UBBKT)HA 9^VC*L26'"4O::>?[Q6+_[=B:"^):6FH&
MJ84(&$(%3N..IAZX4^0^N.R<C/\>^3W[XX+!CAJD:M,>$V-B8E>96W&N9N>;
M.]-4U0WVGQ+LASJBIN/>1H):H@)F9I Y(B3J'/XCO=G4#'K_'NZU-I<#]J.)
MYQ.=^TX\GPW%A_(AH:BI$V2M#9"-P1H5(,]YVG!)6:YN9"]+7?[(>YUJ6Z0K
M9%<;WY7.==];=\/<$T_9*%N0)C764"2AVUTA]\TW'-N0(9%S56Q0AC<8=*X@
MB!.#8.1B*TC%O:)S(>PF_PL&^[CI08/K>=SS\10D-4.E[J+$ 7KQF\[=/[ ?
MT#FAFGI+$^<A ]9HP($\Q*C=FW$U++=@=_[D'K -]E7 ?IS.G>;<-YT[&XH/
MZ%QOAM6S 0D/.A=B DFE#!2W6@1]5.&!XFN^8 BO3-)V46Z9)1HG9^V6^SC_
MKU.2,7= [5(>[$B'BZ\E]YQBXQ&NSFQT$!\RUX:].CW3@L8=KOYDCN[8PI 0
M8I""%7(W!SCB$V I'O+_S]Z7-L6-=&O^%85CWAE[HD1+J=36ON,(#-A-CP&W
MH;O'_D+D)I!=5:HK58'QKY]S,E-;+108VX!=-][K!DHEI3+/OCR'IGZ6A>"9
MI-F3%X1NVIA_)G-UD=F%3T*5!21+8T:]6#$2AT #D9?Q(/.IV/BFCX_9%WQ3
MJ7@6L4"X7D@CEZJ4 +/[S)4@Q0/@]BBA 8YJ'="[#WC<,/M#8?;E/2YW4^X;
MW_2'<?&";QH&B4P]/W:CE":@LC/F\I#[KD@)J&OIIR+D3UZ$=P>@^S8L?!^\
M\)\?!*7^\-S=6SK&OTT9'RKXK\PO7OR7_N>[EOXO'!?!X_K?K01QSDK%IJIT
MIB!*'#Q-IRB=<3%U1HJ-X5BR69N2O-=%-\[T-WUVM!7>X.G/)T65(TO_7JHA
MF^87ZOFTF/SN!OK;\YS(*H4W>/+BJ?_LNRSZAANV/P:;KX+%.D7FO-L_?KOW
M;G?[C;-S='A\LNU<GN?BW+EDE3,IU45>S*KAE0.$*X8%F(=.I2:L!,H87FV.
M_VN/GWR?XP^WDKNMVK]VV=]GIV]VRCV2W3_\Y^C_;A]N;S;Q=IOXE9R-U@O:
MK/EXIFM1-KQ^&UX/-KQ^RU/>%O\]RTL@2'">=I50Z#4YA P<#'BL4#HO_HN7
MO[WH?VB,[L/9"%8AOH'7U8^K'(MS)6=#=919[^J=FA2PF^.S_;$)G\"N-Z[7
M"3SZY; 0GQZGNS54?[R[^O"OG'!"([@V//KWX.K@Y"!\?_(J/]P](P<?ST?O
M__WST^'K=Q_?G\C\\..K\X,O_V2'N_N?C_XZ#;F$K9;,#5/$]" X&#E.!3A-
M"<EH[$E.?.,8@Y!1<AM#3[#O :%2JE@QZG'&XXC"0?E^)-*8>ND31X$3.X$C
MF98SM*:_O51:[^5H@MW;?G>X?_CZ^+>G;XZ.CY\Y+_=>';W;<]Z^._IG_WC_
MZ-"!7YV3[?^W=^R\?.\<[[T^V#L\<18HN5[VB)5G^=A%/@U-FSWZ!HV[5)12
ME>@J#=FD4K_7/SRO?8M\K%>HO_3<WLLX@;\O87GM/IJ/GU_F<GK^>^QO@0.+
M@0R;K;,/-I_Z6SK&,>>SFL]"\'6]>.7'WI;_E9\E?O15W[QNL3Y\F(:/9;$$
MSH0^EL4" 7G)=UGLC>_Z*#S_7_G*->4 #R+KGWS;MNRU\2P_O,G[8X!&E0]I
M!U[E&$UV7N5E-77^FK$2XT9[8ZGDM]B533_!C0_BZ2X: V7EY&/G(!\.P0*M
M%E!QOU-MTM?LW\,CY>U)F0\=,M#N!)K^F]V[]>X%S>Z1S>[=8O=L\%UOGDG@
M;; ^?L$K?W2AY'VXS9K>=T [87#&^4.QX?3\OF)[WK=(X]A(Z::<<U/.N7:<
M<,1C3Z9IY@4AC;GBC$4)3UDH,^[QB-^ZG/-HHDIF H^B&*DW1:>^XW$7:?WE
M?SCYZ_/1[K;W_F2(UYV_/_D4'N[^'7PX^11\V#WSCG;W_,,3>3Y?WO%A]Y_A
MX>X>/8#O'.FXY*OSHY-/'EP[/#J1GXYV_Z(')W_[\ [90>Y=O3G9T^4=\#=R
M\%&<!L1GF1#,C3U?N-03J<L3RET1IXF22<!9%CYY$<</I+9C4Y[U/3@U4"3@
M8>)'H:\H\"L+:>AQFBC!PM#+@EO78FXX]<Z<ZLUS*O6%#"-?N=P7ODM]G[LL
M"5,WBT@B@H!G&8F?O(B2#:?^-)RZ?)3OW=3JFD+*ZSCWD==0_C#6)?.L&XH@
MRQ(2N90)4+*2$Y?#GQ!CC7DA5ZGDWI,7?K!U9Z#_307E)@;PF*[\3MF1>W/U
MWYZS<L2$FNEE/4)/G]S%T]_TZM_0X"91))6D,DF\B%(>))0%GN01Z =*N(J_
MC6O\\S<W_2"5?K7H-ZM,,I+&D2LC',8:^[&;I"R"?U0B%,FBR.=/7M !I7?&
M4'S '?N_/",'1"815R1-E$>!BQ.?,24] E20I1Y/OHWGO&'D;\;("VYUS'R9
M9FGJBC#Q$2M+N6E(E>O!Z4624,6"!*<JIV3#R#\-(R]UK.^HE#>.]7=GW@7'
M.DD)#SGAKA_Y%*&,8Y=YJ7(%SS))DB"6@=".]6;\UN;*!^;;_CSY[0,E3Y1X
MC'GMX#OFM7_5H/621+#RX?\"KJC*:$#]-$BB)/5I'*@0'*6-M_N@].SASJ*W
M2T1&*8ZEIG&,S2RQYW*?4M>7X.\(+XK"E(">!6\W?!@1[ TC?P]&]H07TP0\
MW#A-J$Q]'I,P#3/)@PC^'M]^/,B&D;\O(R]XNUZ<^%2%H4M"&;E4>,+E"0.6
MSB(5A<J+0\XU(\>_QMR FRT[L.M^\+S\]):IY+LI9MQ&>&5@[(WK^[TY><'U
M]1D/8Y8%+@X"<6DB?#>EF70C.#@%G)S2A#YY0;86,9^_KE%BDVE]W%<^ZJZ@
M&XH_VX/N*%8B<D_E< 7&A'(F97&15R@/X5=GRCZK:C-EY+OF-\-094RD'I6,
MIB1*8Y(EH0IE$!.?J]LCN6X,Q>^I7HX7/3X6$)Y(I=R(>-*E-/- T8"A&*8!
M8T'"543!4(P&X/K]Q*'57YZ1(QHG4O X P:F7L1YZ&>^4$3BS\J7&X_O@3'R
MHL<7^G$2Q,#(%$>[<B]S$^4IEV2!KSR?@4-(D)&]Y,X>WX:1'PHC+\]OWDTI
M;_*;WYUY%YR\.(L"CY$02Q(RE\9IX/(T@I^$C$ 1$S@YB4,>?V8=_)"=JE_Y
MRE\FO?E&5=7OSM[GB1I72B/#LN&P$&RJI#,MG,HXG=7C2W\Z3^DF__E#C&A"
M))C1/DL#FLJ$21J$8'^1($E2%:N--_R@]/"2+EGP>,-0CUB67NC2R//<),IB
M-Q4D\7@F/!G'3U[$ SC"GSAM\LLS,@N",$U82)B2- O21!$OPS(S$1!"6;3I
MD_WQO+I8T LBE$J2N%'*,3&2")>!Q^.R1/BIC)GGD0SG8=ZY)/ !<^K=S+"'
MQZ,WAI[;Y*U^MBM_A;R5\3#F8()JF'+42:*HIM77#5/<1,CN"ZZFGD&T]SF?
M[N !^AO=?AO=OJ3K+@2=GOAA['H!8F!XJ<1@=NJF<4 8"WF6^M&3%X'G_<3Q
ML%^>4;\Y6LV&4>_*J(M9)ZHH#X+895Q*%UPCW^5!XKN"$!6!=9ZA]'SQ#=SE
M!\RH#^\>#\^Z^Y6O_!4&A;>CP',=X?CMZ;"HJF=U8=:4?=Y,"/_5(257%RU_
MEQ'A<R7+M1'01N#J"<+Y> 8[:$-TX)N]U#1KKCO!&L*]S].2%27L,RNO]J=J
M5!T68UQN60R'.J@W5:6JIAMKXA;6Q-&2]B,9T(P2 33NXRR=+!,N4V#[9S%+
M_,"+,T:S)R_B8+&"9:'6^3%&\W[YN/LWGQ7^79E]DXC[9I)@P:^(.&$1$;%+
M>49=&I+(Y7ZLW$SX"8M!*/AZ%/$@B7[F1-Q/V[_TOS<A_E_PRA\R&/J[#K]\
M8/.D'^5,YQO.(%Q(D^0X,5>JZO>5<P:M8'#1J_L]B&HAF(\E'-GOKI]H<?&#
M7\8/=5X3')CH^3WM)RSA>6]O?+JE!S&"+</&9SD.8V0CG/7YQ:2AE*V!*S+G
M?_S S$HR;[YMRX^S:HI5=Z^*<KNSPIL97^GC-+Z^>C;IT8FX.HUHQE.14C<$
MC\FE0A$W41&VCU*PJKDB DN)O240Q XW$[9PV!98!^<@V923F5%HF1Z%]M]V
M%!K0!1Z@P\92S[#=6IS]N7J*[6,3@]]IMOE-Q6 ?:?:Q2D'BW;L4U"3P Z3@
M73%?-U+P;E+P %S6@[].(R]3,0M3UTO]Q*4>I2 "P8.4E,2!#.(LI '*P57=
M4+4P1!EWF^._*U+HYOCO?OQ'VZ>Q8MSSXLCE@1*@!A//99S"\4O"_8C[L0PC
M//YDS?&#+KRQ&APXI:HF2J!N&5YM;23TMY+0.T?_[.^Z?NK\PX2 ;SA:@RL)
M(CJ?VJ*I^Y;2Q[/)9)AC_%!KC0US+F7.C\([VA7!T<EV</CQ( 0YG;(TC)A*
M@>P%=VGJH[T:A&[(1$B3-/)U [JWM0J5]Q:,NN'(;\:1VRCJIN5,3&<E?-@P
MI !K]>S6)I/TP#_,4A5PRJF';DK,I6 J8XD7QHFZ==S_77=Q.WI--^R<^=4X
M\FAW__+@[-037N2%(G-3+_!=RH7GIB2-W% H\!Y5Q&E&;I7*V1SI?1\I)6"
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M\K+.>6 BK8DTPTE.BGS</W$L8J@&#I_AW'1=@"!@I] '<G"$.1XYZY3?!$8
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M;IQYGDM%FKF)#'Q7F12 2-/(P_SC(GY OW9DBGNN1;/IG-#1D,*.8+4XDW.
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M;U@\4/)$B?.']1++SONZE[A!*<T-BFCNO9>^'4+E#6SMSU$Y/2\F#%L-FX&
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MR.KW!RG1+'<S(G3]0(!/X2F)9,RD1]TLS*A+4R;=-,J8ZY,TXRS)@I#0)R]
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ME$Y.]33B?^,A. A+9>6)4+2<*8<]J(6?@W'*M5M_VJSGLA$(> L(A_?ZMC,
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MX"P,(@W<1<!%OS1G6)(_4N"4=4#69G%(U^>EN)^\"'"R[T4.N- E-=-KS%^
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M)E*%UU./SO)TU+*W("&3!UX)1_%[P_@G,$3J?(7EXJ0:_-]TZC6,WU%Y?O$
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MWWFRM;(_@8_N1&H[+/B<!T%\[]\"!X&./B/NPD?/CEH5%J2@2!HT)>9@B,2
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MJXJ+R;(/?<^AUU>'RRGO7)X59?X &JU9['AT+]>39\#3%DEG9NNKF:NX=J.
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M5D<96'.7&!Y^)\8_YHT2A1; "O%(>9M$[BII9.ZT-^/<]M93<B$1XZF(^03
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MG\@3(D7QE\M_/AO)EO,,K<$ ;';XMR^^AW?810VHGD7+-'[GO@_^#Y=M^J.
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M0<7FEOV/?4 O\P)C&GFPR'O.(H--@%J2V+AAM]P8<1X8$7=\%L?>V..ND83
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M./8,O+)P2NYK@94/+XX/AV!<[S @^Q19V>6E\$7^?/FPPF(:5>\L<#$/>")
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M!_K],.#1]7U^C[2?7>_:2PK[P#=]-B]-X\[#+R9P/4(S7]1MZ*>(17QFMB2
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M:<-+TMR+&Y(DYBYXS%GDB./F PX6<#BE<)Z4]ZM);MS=C/5&7\W1](<*5;W
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M+L"5Q^,I#L%P.P.L;I>63JP\&D4>C6;ET7AAFLL(O*R99EA7H>#:/ JO@UH
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MC/M9(7=> 3&O<$W@81\;<'E8^"!A(_\=&+%9HZVM<R&H&9+17KD/$G?3R[:
M(V++]:)M;O2R9&A;^&K\4+1MW,#'C6'!K<$0)&)6U$H:>]3_$A]QL7<8E5.
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M""MJ.P\$!%2!5Y4MRL)[:KF.$K@96$9_M(ACM!2F;N#BRL72O\3LF.?YIM:
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MPH4X#0-6*OF*$B6> *5 ((\]%#JAQL$\%2N;_30W^XU@NCYLK6#BVJ3IOC'
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MB2U\@K<K2!$G2V>KS75Y39,&YH9(T7=N+F1S.R%MI%@PB;H0(2R/Z,LV*A8
M)4YBLZ]'?5R'V0I;RVG32\@W3IF@Z=/D>8I=P;H"/X0.03_-9DQO1%PTICP>
M_KPRP4N.ABA^J].%W=:<<:F<4Z0K2<#>C#')B=9,(2C-+YKWD;//6(\3V&-8
M=N%?J6R\PK60/EW\2 1*S8T3+;X>6S\$^V9 Q5!N;I9Z,/+89<;#IZY6G-"
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M#;T_T<'TB2>W,Q),^3[;V[7,BTWE&R)NR"1_)Q8/9W)4B;\^,1JNWY]$X"3
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M(*?,0B;R:E3MDP:WXAE?_KT%)9I)H.&&W&=Z]J+[5K/"QL9DJC]/(RPUFZ#
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MO078KKOS5EFV"4LJ>U^;5J280,6Z%:E3 B8C*<\24*76[4FV0S:*39RQTVT
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M\SU^&LWFI&7S7\,I'O&H:=>("F(H=$:8("&@M5!=_\ 9_:'*#2B]^=8#H76
M*&]3JX=3^V:<)E/:-!:+_#"G0^+5Y&P\GWY]-<EXY*21GJP[0,;(XHN%X(F
M@+[(G'SB7K,F!O\=( Z$^':"OJT'9K@>? Q_OLETEHS*Z#S =;'WH"U>!ZM!
M.HR@F,D0R%8 F3)S(<CDE6V@ 1M>?R#<MQ#N;=;M<-9?Y#S%V>SB?^IR^9'P
M0G/I+0BG:$L*.D*,2!Z ]@Z9QR1EB]U]S:L/A.VA0KW-M&O&]"OZY;OIQ\D?
MXR.CC2G($Y1<-*A,;D!PC@$3V6+1@5L_S'7>\.+#8OF! KW-L6_&\>)P>3?]
M;3KY,AHG/-)2*!]U >_H6"%+LB[1&O+K4U2"61OS, ?KKK<?%MM#1+LF6C(H
M)'8#V&^3V3R<_'^CSPMK D.2.GK2Q,#)S5>&' :" UHR'XI17"G?CO$;[SXL
MOA\NUC5L#PJ.U7WFQ13# HBPF(SVY-4G94!)9L%KF2&3I^BE#H7T<A"_U]_V
M[!E]L.C6<#@H!%;OCD]^.YZ,EXZ]X%SQS&B_$):L H9U,9K3L9%X3H5I-,.^
MT]4W/GLN!XEP#9\-8EVOSJ93LNW/0V^C\:=Z1IS-CHS,9,NK!)R3/Z^X*.!H
M=> 4%EOH#T)L<>JN?_NSY[F9:-=PWB @]F8\QVE(\]$7?!WFX0+GD16"&R8U
M),8+*!,1R*F7D WSRB,K:%*3<,FZMQ\(YPU$NX;S!I&R&I"=OB+[[]-D^O7(
MJJ(X+QX"O1B4#@)"\07(LR-$CFQ^H1N%M2]?>B ,/UR0:XAM$/KZ<!I.3EZ>
MS6AYL]E1L3HS26Y;X8'3VAQ!(5^.]AJ3O8U6:FQQ7W'CI0="[,,%N8;8!M&M
MGTYQ^HF.C7],)W_,CU]-3C^'\=<C4BS/96*0<R*+(2L-03H%:(W6S&L??(M-
M>NW+#X3HX8)=0WB#(->'8SPY6<*A?2,I&\D4%)$V%E.0-A:R$DI,QDGMC+4M
MDI6NO_- Z'VP&->P.BBL]0'3V90 <1$_CN8G>!2-3B4$#08-@D)OP+N4P3,6
M=5;D!\AAF_/J&Y\]HX-$N"8%9%#(ZN,TU%SV#U]/X^3DR&7IHG.Y7F9K4*%P
M<)J<N'K9[5.PFLMAF3TW7O?LF7RX\-;0."@6M=2IG_Y,QV'\"1<WV;8D$XIB
MX',*H+RLP3'O02N7C%')V#+,WUWWUF=/ZF!1KN%V4(SJPO&>G)[66^I)^OW#
M<9CB[-W9O)9-5 4\JCF@D0"!3XG6RC.'Z+2G$T'X*!,W/ V+/MZ/X=GSWEC,
M:[2@162+'.]I.'DSSOCG_\*O1SJ*PJ((@%QXTDNK($8E0+K@4F22B=#BQG#E
MM8?"]0!AKJ%W4!#K(JCR\VB6PLG_BV&ZS _-&'3)S@-3K)!Q8 MXTCR03"6T
M/"&M?-C%PH8W/WN2FXAT#<^# E?+!-$K5#_33V9'TBL?G=7 9,T/+=)"M(R#
MY-YQ5HR0MC1)N5UY\;-GN85 UY \*(AU$]-YOO<YJL29L3+2*F4DU0O2@^,Y
MTH[#HQ<$BS=*G;_UZ@,C^J%"74/UH+#6"X*4%[!.PJ<C:81)J9X;7M8RW*AI
M;;* C"Z3G9@U]\-N#V^\[ME3^G#AK:%Q>+!JA+./(9)#;@(A3H+\-U4,[1W:
M@I?! N/%:Y$8%A.'6U7+US6D\5J=\7YLJ >);%V1TG?G1:-_2R>3&>:_?S^?
MGN'5#R?C.?XY_^D$J[+\_?L9?CJ]=;VV/>%G,_@4PN>C1>I0?="KDS";O2L+
MJ__%GZ/9D7=&^AQ%E43-&T,!4<4 =*@4(5G6GLL[%*"$65SP<_&F<RW D_EL
M^9,K=;@73$/UN*/D>XVZ/(S;20\9-RQK6P*[CN?U8O?;"M'12N%Y(_9OHVFY
MN6^JFK\BO3%=DRZRWH\68#0A9I=!.Z5K2EFM!.$<5%+DYQ<?V)V97$^9_1L]
M"!Z1_%U$W(/TJQC/+WB>]<]H@U-)0M 5D"\*?#8<<LDVVV CVKL2[!_$^2J(
M_5ESK9A9)7J06!M6I_]K_*^C%^P'H]FODSG.7I\A25]=8&+)Z*Q")N??EQK)
M31"2L)"2XYQGJV)9^;QO=96XZ_G/EL5F0FOXP2XPZ1_60A+"Q:RC!6M\(*.$
MU"J8F*&XP%U(VG"=M^%Q_>.?-XT-1-:PU'P!B?_ ;V!R%Y@<9IEX=" E[1/*
M!5JC50YLE%E+Q^ALL=O0N.'YSYO'%D)K6$Q^@>G&%B'U!289F(J>5N5R-1&2
MC^ 3%\!=T8XYXZ4+VQ&Y]OG/G<CA0MM81OYO/Z[(A'S[WQ_49&D\FYR,<FU;
M=VD*SB;EI_\Z&\V_WH2Q9?>E.Q\XM"W3]FA7^C5I%1T9LRGSE!06$7G),:9D
MN"_.N'ATS[,;11VN0C"%)6^*S<"5J)D#AM1 J>I@QU1\9-[>V9!A4+CA$L7P
M: I]*,>3$U+-V;F@WHS3R5F]./VMYHK3MSJ?3T?Q;%Z#"A\GOT[&-:Y#9-(3
M/RURC'$V/](F1LNE!!L<R8)I!TYK#:Q@C-P@_>2N"/G#9-$"^?YWJ(&:=#M4
MLW<"&QK]RU7\BO-:UW^*;R>SV9&@5TN9'1FNP8#2U865O  C'0C!6J_PKDCN
M0[3I!H!GKQ0/%V<'Q_WUZ,LHTTX^N^9JO@JSXR//D,[FG&JU$1E$RAMPR&NQ
M;Y'6(YKB6\=L-F%Y]HPW$7)#]^'&]O1F-CO#_/IL6C>EQ17@_Q-.SO#C%,/L
M;/IU\7?>XVCQMXZ\$<Y[LI"Y=+63"[?D[S /1N@0"JEP9G>EE3_X*-D%Y+-7
ME[ZT-/1>EH!O@%K ?)'HM)MB?C69S7_!^?$D'Z6(HG!,4 1YR2K4@&=4$31:
M);AU]!G<E3KY$-79!M>SUY;FPF_87&NS'?1N?DS.FM980LW0CEP%4(+5M'LC
M $4T-:(B4FQOI:^%\NS5H(6(&_;>6L):@*A5%E,\KG<F7_#*]B%#Z%WY&/X\
MDBA=4B9!<IS.0FLY>$_FKC>8BXZ&Z]3:I-P&U[/7B>;";]B4J[&+E&3F5BL/
MY Q%LJ08@V@S V0\.Q^Y];;_3C+<QQT0^SA/+!"BB&B-!HF./G=N,CA1"GWX
MMBA3"B=3H%?<8R^I-]VVSP>+\<GEWIPK8_WN)^,:95O<-[N<M(E<@.&9UN%,
MK4"V%ISE(7@;HU7=\F_6 =IW#DX+HC?IS&"!=W#L5S!=A-NW =4I'V<MH$=.
MR1E.W*27U/>F$DDZ&UT)P$.]B&:!7(,B'.1@G-,<4=O6&\,>56';_)P]:<(N
MPNZ@ >]Q3B@P_Q2F8[)!9A=W9LDRFX2I3;1KMG>4&F)MTJMY*%EY5_N.-%:!
M]4CV;W$WH&G27,8=8O@O4CH[/3NIUV^;O((+H$J1/V +@K0<R9)&3ZY <F"D
MYU9PDDIHG;BU-;A#T(\^3.PEIR^1'^5026#&$2"+!D+4"G0L22='ZEWN:@?T
M3'/ZVJO ,,EVN BX$4,\1W<!S%K:F6(@JSCGV@W2Z]J S-%O2]%!2Z'5745T
M@Z.VU\$< O5M)+TQAM\J<>7->![&GT;D(;V8S7 ^"^/\C\DD_S$Z.7E=S[>3
MV0.25[9XZ+ $EEU1KR2Q."R*VU04TT'1<5P3^!3]-GHE. OE:(OG/SP-[.>Z
M6GQ+AT!^,<ZU@KI<_63US5=!#QX#LZ8DT+[V8PXA0'3<@2S6F)1\2$G=P\O#
MWSYTWUE]\*\X_^G/BQC:4K(O8ITDD>9',AH1;.*T1RI6LR "^)(]&>>L."2&
MO&]]@;0+OOWM3GO2EM6MJQM9'<S=GS<+@V!?HDPA^J@U TWKICTWU![7QH#4
M2C"2279WML%[B$IMAVS_1UT_=B?=J>E@_-Z!\A_31=Z.+T75/G IY%H,GRT$
M] *0.29U;6%36@?:[\.T?Z7IP>7VZK([$?M5E&N>WHO3>B/TWXLZX2/F)8_"
M:C "21PR%7"T\X(+WG!;N+2Q=;AE=Y3?FC*U(*N#9W:W4(Y**4QD7<]SN^A&
M*<#S[ !1*<F3Y(7?U?ZQ_0'VK:G-KB1TR+ZZQ_C;?(KS5 Q+B>Q HTKMYT*^
M9R#5QL**9LR+I-L;U _#>L#VT%[HZ[ S[8K[B'9,\C"D Y-4#6<:#U$J#XEY
MYR4K 5WKW-%=,3Z&FNV#_8$JMQ-U'6RL;;[%HZ((G/$1HN!D!]8X:A L@XRI
MV)"=-OFNKFZ]P@/?C$HUIJAQM>R'=(SY[ 3?E9TB)R^__A+^-9DN"A?/$T:*
M2<RYA*0-D215DB,[PDG@/!EK,7&4*W[?VGA;*SR]TZWV'&MZ-*J>2A+7':;F
M]04NTA-(FD8GLC:=$M6D94B[<E;@/;.R[L\Z[-&/7(6W[P2OQU.=[;V%013N
M-WAQ!;1V:[ZX^=H&;J?TL1VA/DYB63?JMU>Q9KP] 763PBDCZQ DG2,H60PX
M%C+8(DOT!8T7K1W4)Z%F]R2M/54MVX6NQBUM?@OS1=;>.-<! G@:IK\O$Z^<
MR5%+0XOWIC;:P02N]FGA3C,I+1+H^RZN[W[#DPIY#2=FTERJ'>[W%IE3M]9^
MT9,G2:%*(47WBO")4.KX" ',:JDLST;++M5$Z^$<IG:TYJ%+T&!KFV^Q4ZJ4
M<W*E@).U1)(37&=]!@P%?6WY)'G[^,%.$+]9B[HGE?N/C*[]"+>!W,FR?@#<
MQ[&NNZK!;BK7C,/];WQKH7.,FF7M0',K066I(#J#@)B4MTX7I>_JLOZLU>X>
M:_NI:]TNU'70MEN6H3&:E\(1BK>ACM++$"QZ,#DXEKBB1]C&JO3X%GEWXFZE
M$0^0>N.^L+^=3=-QF-55_S:=))S-WN,,Z?''9">\QB]X,OE<0Z,72'D%DS 3
MTL) :18@EDA?BN(E>&$96S7/U_MC.[WU<#6B,P,==HSE[-Q%FY+9.0UUXR2W
M('LI"Q2A,J@H3 U:.'(IE33,NB!*:[]M Y1OUM!N04V'#)=UL,Y[W"R_G&T
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M_;!?PRE>W,%N@ZM38N(F3(^39#B4LSM58*# ]ZD0T1OD@1LHG-?T:^\@2,5
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M&DF]@\'S4RF8YJ,O>+GZ.F[@/:;).(U.1@O0],,KW+/:DRXR9PUD4T?L,%_
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M(LE2)"/1&3J,!#*K6"'#P6[3"O+F4_<?%QL@WDD3V72XAEOJX(OT7V>CV;D
MJQH:J:W,A:R\4 RHB 6B+XL.SD4XZZ5;[1XW^,O< .6PSN46\FX8]+X+5OWE
M%)<VZ38 .YW2]X)[G).["95;J,=P'CJ<X_<#12%8,?19A%S+-)$C!)$0!,\N
MF9""5*TG7S^2HMQSWC^.GNPB_L:G_XNSZ6CV'QA.YL<7AUQ*F(N4#)CP-5Q
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MS:^_S]"<'M_-_M&IN0XRC5$[&S.Q(?GR""B3DH]#LG&1,0/!5"\TL0/,-Z)
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MO%"S&C+0'$B<^["E) W:!26W006F+3"6FH3-'X]ZZ%RUD%'E2\=W/MP\0.+
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MN)%QA4A4T,2"MB05),P8+T63,LF/1WVU:.HNXAU5D4WE%Q5G5QX/G@BS:<E
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MG@G;S-K;?G%M _/5;@=JD?WDH4NW3%6V(9^^!;_P YB\NWE\YO24BMQ LJ4
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M?,H7LU@L\)]]Q#%Z(BO*%-KA/I7'7B)R$EC6)!G+%!/.*+%BF:XOK+7-1]^
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MSE=5C! <=X'D@.Z#M FGZZ@N94>MQ?]>6&ADIKU0ZFW=M]^TA59%X!7?=S_
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ML;YMI<$.2-]"KK4;-DS&=\=*T"9E3I04I4^?,R0DD,1+YLOC4MR\=(-3^6[
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M#:MY\>/RC^ G\'__U_\'4$L#!!0    ( -N G%9.:(>$X(L  !Z?   3
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MH'S8 92\?*M/4$I%GZK*^*?:?VCVWZ;8O?];FOVOBOUO>HTCA+?SP,[;+H9
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M(8,79(\3U!6IB '[9@;B86+)JLM$&_-JH?**3O#KS !*]9G1[FUH:S0E$Z\
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MOLBI7SKSB(=E;C_]\6?8K68"K\/DSB<M$OU/^L@H]2N"'2>.?!&\.<+_&N^
M.X"!=';4%' [,;78)3ICPA$J?<%V_K$VY<Q,!5<2RO2C/35M*P>=ANE^U7?,
MA29*##>D]>X'>]DR*X)=C2I)"QP$_KH-#-IY(!A9%VU@0&M3(Z98[@HMY>,:
ML\^CBZ$CT5\D-A_T/C+)>(Q?<+CX0W"R(4WB3F!-)E>(!'915NC?7L"F,@."
MB6-M'< .7 !MJ,9L]_!*C8VV\XDAOJ\I(O7N/>'"]ZS37PGW(<H*K7P6,3GY
M: :7"%9QD>>'N?NN8@39UC.!S_?/S86 I =2?36:ZRBDRZ&)TMF.)IV%UX3
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M_<ZC> 2L8\8]FI8.VF/'!.C!^0&[Z5.-/?3&V6(T>!$+*9'H5#"0*QA V4)
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ML*?E*>C&.'9\"5[?,.+$V!5V&,4%K6N8?27[G5PMK#K6>B5 ;$>;DEUY 1,
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M2V<P[L%*Z&V@>,&NUCCZ<76ZEVI=]5U5?A$"?1<_/\H6KOH(@))'KJI;(KV
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M.?TEJ/8YD%VFYW,RYL>SGM5NB%KYY O,J#,^'#G0'<FKN-- ,N9:0''!3]F
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M+>> CG91]:]$_<@F:]&PA@\^,U,E1;]-G@QU2H39+">K.RS*=CYGY2..=T(
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MT-R>)X6R[NR2D?=BQX3BBI=_*.FX>FQUWWR'KTGQT,2K[W/R,,C8$\XTCXD
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MM#8GLGW 0Q,I?/]X=)- R>I+*RSW@^1%LRHWB1&OC]:Q;E)-7\.D=V[8W?P
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M.T(0&5W]ZZE"MI(KTRQ-=3%H+]O*TLB+3&*-[9%QCY^J9UV/MH9QO8N)VP@
MJ!?+D2=;0Q(4$CS #H#VY+1^)A\FR5/WPCCR-&8PQQ;;YZT:<T]Y;DR6IEE]
M?WI10^N?';-WJ^T5U@,Y,@VLSB$^+ *>-H7N6IZDL):9J3C>3J\$DY9Z)K%]
M('V@'"Z#<>B2CBLW:5G6;*TSG/;JWX)*3NB5-3QDHW8I9[=T Q\63,QLHKR7
MGESN!G89PX4[Z/L3=M&:^T/"%7W<%VU^2USPC,O57"F5T,K'O5&8ZJ]3/.$@
M+0MI; 60G!(TH5F*YCZ(1DX%DHK$HN%;/8.?&C<Q5A<\R\IW?<VS%R:\)CTP
M#WJV7\DR,HN3^C1T&(&F_#& 9P,L>W-[/JRL.8.C#@G;EV#.K>[AJ,XS!UA9
MW$(@?$ AP;@5#(2&6A:#LV)LI%P//_)ZW:%22NEL\V.40Y10S<<\*^6,P\5!
M3JKZ6H^5#\  FS7W60H)#FJ7<^21/'&H FSE@$FL3]Q"GM$,1G]VH-V+:T/I
ME,7$GQB>)S"=AFF)/Z--Q]U6==&:V>UVE:+(M>0#S]2%5%&,LSA0NV%)##)N
M"Z2<S@]?309Q*9"N@YR".X//T=1*HDQ'6;">N4KIQ@=:5T7MBLKGX_MGF#WW
MF\.KJ$?\^V%8@OO'&5/HWKM@4E=1/2X-"A]@HH.:4L!4ZL$*?@DGH-.FBM(Y
M83/P+YRC#<<<"95?.P)NFF\XJXNLS-9KO\(&"TA6KE%2KL?CI3$Q/2?;F HL
MO,F3TJM]KWYBW:?0.\X+ZK8YVZJQU",G,AJUQ$440"2D+L!-0E KH;!'XD%M
M2B9 ?4-DG'YMZ\Y4S)S5L&]!%_]03#KWKN9ZSN'?X;_75I1G)IM/:$JKU+:3
M:^>4A]Q@7 ]0F!T'-M#12X$5V"ZX$A!0))N 8-8G4^/,D2]G9D+J-Z9,N.53
MU/KDM;YW;\9S:^T/KNJZK9P:% Y*3\ /$OY %51HT_(_"<K0]0W')XDVWX-,
MBL&*<)\EF-".@;J!P]]SZ[BACGFA'FBW$;LN6J0FH9G04F;CFE9CU]$O0543
M@>[\G!#);>.I\$91=0,=RU.S*# RGC'W(I45"D;1]-1V=+]DY3I>K4653'U"
MS[5.2EHXO,E!&+0?7*J&(:*"\)UH,IDGT<J.LF=OYWTPX.@RUBAB+3?9MB$-
MGBB<N6,TC>/XK,_OI=?"N$Z@\$_#SBMY5YYX6E_)T7MDK]=Z@S+EP,KCM@&!
M<% ?:)<&H4!OIX#:TITF()H))[%N?.7#IK"J7TQ:3P]1I4Z=QD7&EM>]%BJ:
M;"[:5F9P=?&.D,0)^-M_W&>UEJ38$+@E.>@2J7.M<)Y8$<.=-=3\A:<&UCJ&
MC@RO%XDLN"^\T"@4'EULLV0;GEY2/3D R[=UVHWKE^U6,84PYT745 ]//)L)
M :-U]@F !%^GD-FN(YSCM _XY44+C5]M<L/5)MP#4U/Q_F1_(8>PVM/Z>]V,
MK'7M]E[)T?#+@'&;BXF[$=09- 1"ENR9ZET  ?U^@)PT>W,95[=\J_#13/#3
M@R-A>W) #RO3YPI#B']>:7A[E*9M.YT?_=4]"*7(0' 4_5A-W*K-,,X"&.<H
M6[ CA904K,X/A*QZ*G7Y/47JA\', FHB?V7BH5X$C:W3RAGNB(IJ<\OU.",Z
M&'=BZ9GT3(8.4Y GT0N%:2RW!2N*[0)J*$OWV <24.,\^1"B8MT17%;+#D3J
M&COM=43>U%2@8P,K[PQN9TV_6BSLP\O32;T_@& TV84G;LG> I 2B('X22)=
M9.E>%%."Q(>I+*Z5,E%WKC"ZGN3<+^\#7GI/&,?(=)==F$TNR;";GHM[%.SA
M>^+L"81GFR'V"R#&VX)(?MVFA:G>93'?W7;P+6,@N0IG%'+T_O!2CO)X17MJ
M[H"UW73S1=9]4 '2N88QWRT%\+:%<0O:MI<OV<[&'T=XUGY91TOVANDJ8RSB
MGSCSQJS*.S0KW]LK.AV)3YN/\4NY8ITMM^%%BTWB6%*E4_^BDA)<F/H>S)SG
MY>0X=U\MIJ1I[LQ/O;R$7K?/RKNE$D5^TZW?[PS<=\OL1W$&3/L_L'.@H4M\
M"L6A,B)(Z%]Y294G801-5?)P7;8['9%""#V&WY5@,DHP'A[N9'8H33Y9BBCE
MCACU!3FV))Y,.^$AB):$/^!60Q6QQA"2X\93!>=Y8EJ0B.^@%@3K9LNSKX=;
MG6!V%70NZ-8YH$6#%W;7CXX%FAT<CWIUK'-OO8=7:$O)WKWEZS_;$%P\0$TM
M>C.P=)/)1G)?HZO,O1B_Z)^?F$?9,G5HMNE>-J,!>283.'4A3.E=K=[O#SCM
M#TYVG3@G$,43DX$>V<Y <F3AK .I5.2=P(*NI]HM[PJ\F-6U ?*1]E4_LU7P
M!;"'H\X:=D/:]Z=MA2<J<G_1D+>);Z#*D$D"&-?@60#UI=H^;I(Y4J2=(IM)
MU@DN81*3G_*T'YU.^;Q_YFL()1K"E>>Z$M\=_K"7Z&4AS-G="FI2<:"5B726
MA1&SLVRA[.A\#D$[ I_CI-1'D3STS+)VM]#/3_9'JC_?DE&NV>I_P*[7)0L7
MH;."XTD SP#2=6(0>DJZ_2F,FX*XV*K4"64CP0KR+^>O8$]7H5@-,Z;FEKEL
M?X!IN61V>- WX\@SS\P7OA\]E".+< ]Z)CT @)HV#Z$PK ,GF2(]?P<XBDFT
M^G0:2DHK:7;07)V&D [Q#,OWK/4]W7_3?.%2W+4SN3UHH9"AFB6OAT)^W_\9
M[T5M0U#_(38H+5JS8=@1(L,>EP*OG:F=9:,SVPYY%=VA;%\T\;'8I<4^NA!^
M\>&Z62%-LS9_1N+<YV*MU9UTO=E";FOQ+<31!'NV+G:&PC@#!]6U[@"7BD!-
M/(D(7B JT(;V#2^W>&QK+0NN;S*9'NZ- E[A6=F?]@6NEN7JE0C4TU3.JD_P
M83J\#I040%V I[H#4H#_@"*VER<*>C$\*5U'PRQ,F2+)A&DQ@IWQO?B=3?=[
MBM1>'^]L<"E_['L5?ZREBMWPI(/U-P,&YJRR(%F)E1PM;G.+'Z.2/L"1.\CN
M!@3GFRP9LSU\F+A)Z/YHA<S+JX#4.L>._/A-F$24XO!MP[OK?CRQMU 044>Q
M KRQ(C@4TL\I\BTZ:-J $@?#E'7THS:'OJQ6[6@ZXYW\KG#+H'U<E/[RO(QQ
MKKKP^3SD0]S4/^=$!@#&>3YL"W800BB(2X RQIUE^99MVSG[,L@=*[;U>O9E
M8OU8583?P^D/KG:<$G792((J_O0*?DJ)3NFA3!UCF3'=%X?9$,\G[><$5F-^
M=:G)O1OZW6(0&%\R U[Y_=>NWC9*L5*37J7X2T?WU4IIK$'8Q\[/K[R6"K4%
MF?A9B"T+\L2=V'LA :V%6HM2;%&PY1<@'PU7SG:A5V%5Q^60\;\D7CR>GICX
MZFV.VGNXQJ9O3^'A,JJ8I&T/%D*MI .0X54SZMQGQ$NX*?4.! .)% DJ1+^O
M!*0O_()+<U29>TEDI(^^2P;+*[-Q?GLG[GK"@H% TP0ILT_GW< R05X Y$(A
M>9A[>].%J#H1CE(!"\-MQLIC>SRK"8Q5VME'M%\H^9!ZK/&7O4;VZ%<S,]Z$
M4G=W1K]N\*XAF'_.OAB;]MN)5R&* )_0X8F[0J,"24S\]A/!<$-,J+/"T5F^
M(N#]B^$MT=1F*>S8Q[\32$FQZ(CNP)W&K"_3MH8Z+P,,WIT31"PNR0NLV':A
MU2"[;!(NL0]9,A4W6,9?UG=%>3-CBM"5V('AT+_AO^QIP3+/1_3PT1)/ZO-\
MCC;W$T23$]Y=UMMM6/!'D"=V#U+@YA@BD +JB:03P_DP"%7',0M(\$0$XY;C
MY9EMS++G@:PG5I[- 4934Z30Z*O.[7JYGU1LW]_?TM5TR!3;['1"#<WV!X]U
M4F00_OH91&F.4JG]R]"CRQTWHY!#87MV'^__-)7 [)+-W[WE\\<2C6VA*[8L
M<6X&0'V!>*/%D<'/QG+DW+O@;]6(=/VT(D6_T:)VE884<ZO2@1)R-:%D:F&H
M)SY*<P0(R/_2I=/F6@+\<VI%,I<=;@U+R(6T=X3<%]8/O8"@?2(  BQ_YEE"
MX"NP>(4W[\WLFDOQ'',\^V-O2V0$K"ZR0WY[RF[T2B8M-AR^&4@J /7N5,.B
M%S2H&&XYQZD\),=" 73WKBF <HU4]R^[=:FS0PYWR0)_#NJ&Z;^H%7[3K7>B
M80\)3X "H!+%<'RBSA//9!]>*!+ \XZ F;2YF=19';CL@MH>QN)E-X=FU_M.
M 7>:Q,[%=;W_^L(_QTQDCL32GV13JP!!<S&M5#S'+YX>'GM^9'XTP97^^JQH
M<>-8](ZT5:WKZ:[JYRIW&G27R%A).B6>W'+B6 88Q;H!0I$GO)5;P(<%26>/
M%2DC_!$RF [J?!IV_T_/GHZ;\:0;+Y(_ORZSTL9]ME];J-Z;NZ3YT#_?+#/A
M^;>[=0&[?+"S4$XS 0*EP7V!:5AMR ?H:#RH\_TUVV* D=0^%7A'U8'!AZ40
MK((*&S+6*ZCY,[\\FQOJ\B\LJ1\Z,R@4N_HB:,CVO$;2JBU'KI*U"7QK(2&B
MB'#IC")Q"Q%>1P-\5YL(Y_2H7U''C>KT64?$F7@YR3QNOH?G A]V]9=D]_[!
M+SKRMCDV8JE<$J2,!H+Z#9G%TP<=V-L3%%!D.,MUJ 4H">7#Y.B/Z%<J:,=G
M@#M^DH$9 W8MT>XI"[-7ZAV^GU\5;DGU=SPJRO%B;8+G%8"DZLZB#"4 L_#)
MI%G3;*9##\*?T574Q8=EW"C^->Q!?GOA4L.J?].5VEOY E,SNF^O#?DK7OI;
MQ(9X$\EB;7FJ=A;>#DQYM1-W$'!""2=!_8H0,ZS$Z)YAZDC=O-(7O=9/L3%&
MM"M2*K>J<?+I>:XDDC<Q PX1CQV\T;_$I%ENH\6Q!0LSQOQM#BJ8?E.]':L(
M8@LU7WPO#WU'MH_3V(BM[54Q4EPISE.X!KMW(\(&!J;2W1>%V3=_P1G7I9.)
MU!>%9HO955\Y\"]ZQ)J(!)LV/<;?O@.FMZ/+'M41PD\AOZ57*[PY=]KI0MK&
MI3.H-\1%I4W"!N[GPT0D.=#<34Q)L.5F$]CZ*?#MUY^$=)P<]6,"J?O>N6B,
M&5IJY"]4/%3P5PP3$:K(-1-6S>"]=SH!SX:HD]7 )MI?(C#D6!7<*A,X&<%R
M&C/?0\5-;9EA&K>Z\&27Q-<ZA,9C/S/.Y+NOVN49NR<).]TU-+6;-1_GR+!9
M-Z!'?X&\*-<2RQ1D:1*XB2ZS9AUH6?#ESYGMS.[[L[^D]G7/?.O.7XH]=L8_
M3_M%BK+YARQL6+C 1"U:E1@.E?L>(G@DB2?6 1FT!Y*6GJ &*C$H4+R+$K<G
M6--VF$@Y]*BP"O +*C8/=_5WGM.ZAU9[?E/^6T3V1T[5EK"OBW-O*. !U"($
MSX3%N"^AV4E U6HM#3)B65K,71NWVA3(X!5 <2!J%BYE&:W:4=D'1$N>ZWTE
MJ-.QDR3VP3976=TP/(:; L6C)D"%BB7C+)&<!!55AH?T9"5//)QMP-ERC^Z>
MBH5[!'O&9IB;E&$RVMMY$Y,_"PI2SLSTRX?A=RVX'NC<>B=E:H<]]SQ#;SZ+
M !=9F,)UZLGVG1G[K>?F@W0<QDM],KWVIC?YRH$RGX?D[^'GYAR$SUTU>?EL
M2X;V__>])9"5R:WEJ#)LZ;@D/NP*'R8&WD K)[@RP4*4! :.;+X@[G'"*+*"
MXGWH4H"?DLV#RN9Z]93]I7]T)BN9%)YH.!/PX$+SG=J$:!!9<IIUR&]ZQWA<
M/R/&*"B\IEMW?J3Z>89VSZEMQN]>7#UL>*Q!,WTW_"+8P1.?UK\#<7.U38:,
M[&5K@34_P,SV["JSSI<1P)?7'PCYLVGF13->TCJ]H3B3F$\D\]JQMA[\AR)E
M'@6HW[B%H"[@10'2\7!$<+@OF[J<MK9 .$;<2OG1=.E")GCC+^-D@5A(PQ;C
M=\F[HO:$2;UXX*_FT(FJ+^+(#W<A&-<:LHC4?*(4(L+'U@J\.H6>6N3#ZCBJ
MI2AD:9=9:OCZ?HM/E("3*Z6U1]NO!,ML[=B+?%-R"SLX+LUVX'B.\;9@!V8,
M0=HSS$&XC".5#]OF\\OY1\U/XF6SJYZ=PV?2S>[O]I ,8@OX5)$M_87><*"P
M28I#0"28K$.')E8CVPE+0A$">^*7TV.(8@G(6*44<Y?7%RRE?GB%.W]O#X@2
MU_:_Y^\L?&3EP\7RX/?<'=P6/NQ;=QM$5R:UF$J\1P>U!?N@2@4A,-SFEQ7>
MP)7C7JP"!JK=T8&47^B>'=%R^*];145/K$:>96CPU2O2*MKBUA,^[SZ?>[SJ
MFPY-"5%N-6Y1E:V"V6 UHN[\;<B13C1^N8R@*0UJKLRW4"+ECQB& 0<T5A,F
M-2;(>W-LI\A7 0D$-0VUC1A:@:!2\#F0PQ 0? L'*VDOECN0.S#W.F_ 4SE&
M)0O]6ROB_)XO-$1E+E1?S/=PMO.[4)*Q+]FI9B6.E%@^= .BTBA6"_<E0)U"
MJ$+:GVR!,R_/DU [L/)@'L5R+'I)T.YM:+CG KIN8LJVOC'QPJA_[8C?E0OM
MP@]DFUUDOHB,%*D@J$UX!HHG9LU@\\0;J[$]-^99(EG^*7I^I(8V#2\?![NX
M\CQ1_ZS6>O)+C:"'8\AI@YP+WGNVD79SZQ#4UB:M130;]J\%FO2??%C-Y^=X
MC-6L5-GCB\-ZYE[R2E..TW-9!8,G?X[-:2(/[+#,O;#KX]9/.\<[X0QG])36
MK/Y2 !^V-0.48R5SGW%"M=):_.@HV875T!LC]5>]",,]U;XG[_1LT0A-F[7^
M<_[FUW6-<6G([1!)OW^!>!G_%\HCL;SBJ2<P[&/( [9$*N$<]!O1)LB1!N<O
ML?=@FND:B!W+NK.99QG<'S9#;O%!6C(%VS]H-45:3%QLC^O>;W&=// U%_%(
MI?=MP;4D0HHHRP1,AAXQQB4BPI=!K=1%%"1F@W6,^X( B #M*.JC\&.HH9+!
MZWU]P6,4Q^%O.:YLGZH:C:*VZ,,W2\/_6.Y G !('@AJ.7S7&AP\X+[(AD!4
M.O<A!XBBEH.9+R="$+(<] M/TL$7VPJ.?WJI&U9(/Z+><+^X_LE4>%;'I]1@
MY:OOX>5K[G,-BQ <$H:#3(8<3V)R%@VJZW?C,PJ+<!RERJ"W/P&)%GOZ!6IX
MJ,,[7D^F2_['^#2_+!^KN<Q6_-Z'(O>5OUKN;3%C:7.KB-17B'H1CJ(+"R)^
MB1&;Q4!QK$Y?"!0?[Q2T'BMCF&9&OUI@>(6PZK^HQGI=N#?025+Q<+.<^_/(
MR=\__Y TN4F'6<X3A0"!<!"WF1B, /?-+QG1!S*;JHCRV#V<[</5RRTRQZ?S
MN)47[M>1&Y<6 [8?V$$<TA,54?,3J_]&BTR%?. +/?PYY]1F/>U@+-M#Q2 Q
M$],-SYZ*S9YM ;L81=UC?\]X!F;6(2VL= O5-8M-B+D2MNJ6DAESNQ_ZF@EK
M[H97 .+$,*@L@SVL/*;28B13JV,(<XP>D_RBFA#P;'I&EX%)LHKS/+SN>)1Z
MX&;Q[I^7[^^0O1#@7)5\VHXW@,(A&-?Q7=,HECZXP%8#2);FPE=9-Z JIO[3
M-+:6_.3US3+'754%IM=D^FP87>;^-[PM#IT-92EOM['\<%P*)N]D_;^D*_R1
M@MR7 .Y_Q2,5,5 HLC0+Q7Q2Z6G)=$>FTI4ZV.DI$^MZNC_=96O:>Y8?H)PQ
M%Z+[ZU*?]6-;Q@NP7R@UR [I*2T?1D.GGN_LN2_FD=1C?_3-I68IVWIW>I9E
M:E3,#:@8IS'[T<9Q.5[!>7:EW@%F!PQO88,YGMS;1/12/&];- /'D<=;<G'K
M?<0[%JH$%=?Q-+FN&37[<I=BGX7OOX^YC]R9.9=/\Y+,W&^MU?=9'I],O(@@
MKYZ%4O9SPC*X__[R8NIK+=+2V6'V >GM?%B[#VWU\'G&-Y6+3:8E3JLM94]E
M3Y"_QX65/COB])=U^_Z6YM\7CX3Y:8WEWT) R(6:!C"0%/(LRPV*FAK>,+QN
M8PG.U@J9D6,@NWW</4;,C:H<Z?U;U\ABZP_1Q3G?58^?#'8JW _[J/[R4N*)
M/Y5K RP2(S7=8C>O%R'?(DR=WN? ]?,&HUXO_'7-.B72V%C8'D3/=MAN^/GC
M5KN=X\6#)^#IB#?2BQ"3%-Z_R8  TD[L88!D9N["EOG%VPNF,D..>Z)%0MJ4
MF%OO6^#"N802SX6:KO@HO:__HE0:N/M!E -[XXZH-S-1')E05A;W 9%*IL@#
M)*,VH82C0!I%R6)WB&(3/MW]U%B8;E7Q2)'SVW</_DPE=S4]N$RHR8%UZ*MW
MJUY./8;P_?%,NK,HNXCAB +W2^= &;\H%6 X2HFP#H[#Z=WI=%?>^% ILSQE
M;&QF1L_Y)\.;6_H3ZU52^N/5*X=4Z4;7$U?0'/D!GE@Y9,U>;@61FDRLA2_N
M8I1# O:!J0SZL@V@[.$+#G=<)4\>+"J9GC#PR"FO09DZW+D^X?7-C?*&AESJ
M@F@ZQ&N%QS>9(4"R(Z+Q$\LL5]"2;8[M*IR;:660.\(2PL,K(#$Q%>5?;^9\
MGO!*#4?*&80&PZ_'W_/3ZG]7HU\/D!P!ZJ.B.EL<1%6!V@*.HA4K'M1_]2MV
M1J@ 60.6,%I"3&5^&2PP'8VX91./BFJ^(G?&NI1TUG)FO(])!*1Q3T-H4H\8
M, #N*^BAY* 8*.E= .F*Q=$$@Y$$ 2I7RP'G"'K0<-N]R:9O*P:XV8KW]189
MY+X#9*O:I0!G&UDYX\ @<7L(<% ?\&%O"CCRJJS@S<4"[!#0T-"U/%'9&0.7
MQFHM8"'X?L>-3NE64WG7'+=O-!S]NCA/=/VD7W!)O;_0DTJ-M%VYL4=Y[5"L
M9!(9Z V.W"^>. Z:JE/<QXB0)TKT@L6..!I\)X;8D>0&NM^$8.'!Y%?DKR&L
ML=A?PLTO"(NEB")SH;BTO1>5C;8)E#-C>6(B3&E6,:1,/F\ J(>3X!/P3DIM
M4=::M.H4>(^5/(KR&GK4L4*H8GBCA[/O?RW[2:?E!6W8RE\:.[<ABB,B""/G
M1+Z9<782&;87N"W$D**)#9[8,%4UL'74W&7V)M*'>?2$&1 0Y$8?.Y8Y"30]
M=?%1T%(ME$WZOAL^7KBR?(=8X]Z!3*8H<YS8MC/3(6K[P'3Z#]F^\TQ<FN^1
M@^%K'QZWJ+@6=Z?O>O%/6-<=IY>&1U;W!?M_NO_3&.9D+?^_^__N__'=[G?N
M\SQ;\5>&GWI@TI[?UHDXRA9S(QT2'9&-E1F>WK9+O\4^5,;EMXIEQMA]E=$G
M%5V]?W0>NN)M$EOMM?&F!=^CZ]P?.++#L=VF0P\B$*%%*3)-W&\ //@][GV_
MNS%E:AYBYOX7ZH"I6-H<^?!'O89L77_=XS:39T-?S,4]=IT6@W*%(1^F?O]*
MH_^3^Q@4QXD/,_KRHVI:I-MW.].Y@$',6)NV$\@+TR]YA ,%3%YX7\MZKF/O
M\>3MXT#5KFEA>2?G<__+O6BYQ_+*8<$*$^;X$@3'A%]P"XA7RIH9!1WDYTR1
MKJN*V57&#L]TP_UW7HYO,?RV<^ZR[*'=*>2Q5O/*??U&GY"C#.,G]G%A+>1)
M?=,A\Q;RL8\UNCJ=?K]L'B?,X'OUR"OVM8N>#.DI:9XXP);C]9?%2ZMP@MZ.
M$$*ON=;!)8'.]L7#/[/V'MN##O;18:ZRGD-9KA@[442XU#B4X,?<YZ/4L2&4
M1,-)1M36:0.))\7R(H?3?5)L3BBL]F-'<S%ZF%</6P'VM:)?^]K62GX,=!HM
MJ[[60FI!<):\CK#3VC#3/X]]E! ((8XL<]MKPQ>P T#M](OB;VG12.40*:-#
MBXZ$QA/E//(A'O%@PN;R9A.$ +':QF]1V"\%?TWJ[BP1&/VE1X%\Z8!\>3EL
M!+(U8=(:6Y[/T!<+L(^7U%#U\6^D4'3(<WXKCP=P&*(IFCR[[]Z"TH>V'YY\
MV+%',X? "B:"OK,_<I8/2_O+:E2OG[]W84RK\8I%Z8>>?6^"BMO*GAR]7M(G
ME+=89W'VQ>G[ ?VFY-_KXMK%58D.#GW-$O^TO&W*VU$2/M@G=S_ XEF.]8W8
MCF5R+.L]Z&%\#2/'RF>^_B=RYXL23$K<:SY,.>!*%D_'U\LZBGX(<\;_2.AP
MUGBPQCC].NWM@T\[_[Q9UQ29T2L'X6B.YN;7Z+PIWM9\52 MOTV9^?K57:UP
MV].*L;J(R;R1XOT;!@U#;4W@YKH7CWN/M\=^:P$SM;UIX]9RP&[[*%U@RE04
MR36Y(W9CX]"MXZ',P@RP:KSCK'2_'.#.<EYV7.'!I7FG;[:YT($= 8[Z5?$7
M6"\;B2MHJ!;N0Y0!*46*;4J<  8=TTQ#=.Z"=][PHTI,JY[+H<D7T2[?642[
MALE\=;="#10MJLT8,]PSE]OT0??.&SGW3(NVU[UI?-.4)Z<QT)?G/G=7PT]8
M5=U(/08_!+\-T?9EI: \R^<)L8R_/UF/=4(]_4,5AJ27S;UMM3@BE_X6<F+3
MS-7[WVQS-9QD8P[BIHOZO$[/5%"LY5@1:LPD[9Z7PY\6FN2 X/@O?Q;Z5?^:
MA'OCFGY4HVFXKN44/FR'L0 =E=)VL&Y4[]WJ*>GTW7X<0YN)H(%: 1]-+-(W
M.<$D\'2=MW]=<*7)SZ?EO^ITOG0Y97L:.F<1'(V'?1V#VC.TJ[)/_L]8?_HW
M:U'+K'SNJS91;"]"^AN8R6SN=@JN[[DV,=&3?G!=[,3 ??3V([F-.\P/S.M^
M/((_L,G& -(9K#ROG:?,ZSZ5B6+^+@E!V3 ZKU%/E>_V]CGT7;MFFPCE;M;!
MK?.H3A2.4J??-3 51;>>[T)FS>@7N8U&?):+(TM5>6A>2C%8Z5*93][5JZ61
M!YRC E+,%H<PWX-KC&G>"!_6<;-@X^F3>V.4_$A*^H.#RDB1)((W$ETKS?2*
MY8[BW<8*_DJPYB&%VK!?B@B=#6UBC.2O,Q(,C1<E*OL>7K7NY_@@AN:5#XK^
MD@W'/=[^+0*?IUU,+*NI*M'K/90IE5CZ7'@P>A4=PYF>Y#0_"MSQ-"X3\SC:
MW1E=N? MOS=.XZZ3M<*"VL7_/B^>$]"".?EFL@]A-$ \/;H-'ZT8;JRI-'3O
ML?&K$\E&B6*KA^:0,W8SQ:7<QSLSRZ6#3>1^Z*=@15&I%H+#"6I?[KQK2,66
MW#(<1ZXZY)6F3$4J7QKU.SU=G$&S?U'Q=0IM%?H>(9,0R6CNO HVT/BP].JZ
MUR>EFR-#]YEM^_D1$WU\]+;(.WPC'Q90!&I#@).G84),Q)JJ^DAX7U-O&)5?
MK&F)N&6@M;'MYN?V&S)W"7^XU@D]LE=SD)UK1R+/U8UWF)06#+Q:N1%3._+W
MZ8[9G;^2W^Z<\)AYA%U3>PL<Q/6'SORR8MW]SQ16X<_2)N\]D6#)R/-"IB*4
M(LI'./JY"H35@-_&A!\&,W:I&Q8KN.;W$U@^;-"D%=Y9:%U/I''/2I!U/KAY
M>34'"_8<D+G[L2-1YT]F.NAB1 L+K.FL)'&,4)(%/]CE#86UB J,5V9-FPZ)
M[6U4-\NTY#@!KY8T2U9BK5]I%[==_'OW?]:V</P_ +4<8#A3)'@=;:)(<<QA
MSY]$F>CFRU,6!3H1..2=.>SD59%CED)[K_I?!)(OC&]NM=[";3!794MQ)!O!
MVZ]$]1.L7RX3&/FIZJOQL0W+;T3V*I,D%PVZ1X6,7F.%.2Y@R>Q -FI[-"H#
M)9=@:_&Z.M3=,?(EREO-!R=P8N<!;0%7&P77$S"8,/8MK4$ J#+AP^H,!OFP
M*TF#P$#OP2*:#\K]=W4]!]<YL!TQ^A$^.2$&U/6'\&'S7U$H)J*F23]NK14-
MQ["[ ?F6@)><DV JW>$URG/T=^&LTPC:?UIC2.T;"W81=DA^\V2"A[P3:N3<
MG?VDD^*]07F3!S_P7!_/NT5$Q:+=9EXWC";+.YVW^_>0@3LT.6O1MP<2>4ID
MGVFKFE5O'2#J/DE&)C/:_&[')4-!DEJ\X%!;/.A(C6+*T;<]H@6;2<2541)^
MD$][/:/L$4H45! ZB-$]'XM_<_83[[=&-I!R^,N!EVNPJ["U:N]3>$VU*3ZL
M8/U'-&TVJ#%VF,.'X<\59^C(G?O7.,5QLQ!A2U&LF''W]J>ZA?$4$8KCHT>7
M\F\>[_V.22W?N'OS=\G3-BGKN,EJU]N?WQBU7Z;UB]U<6 M>"RTYKEMNVO,-
M _H=BII[C/W>5-94/@JO]51K+,44V!*8TJGKVFA=]$6/UP=??S5T4)6LW'(T
M\< H-AX@(8AA1]IDP43X'81,- I\L7Z$Z1=]C/GBJ\&O>T-:6M]W*>3\M@CC
MW4D4_6#"*>A*,,BBA0W27OT2J=(<@M"?2:W/<97 ]66QR+/2&2N$]!>E8_=P
M%_HX3Q?6UQTAO(<Z=//?]?5_9'=#=,+A&%M:X.UU=!KO^%CQ<%VX;+M#_VF6
MWTJ7['X(=C!OE>39P62MP]SG CE*9-9H./)"#3<S0: *7COQ@*"_TUPV4J-3
MI+XV+%J\],S[;[)?-JQ0]NV/CZ/25YLPRL%*59054@3WAKXIKI ^H][!J+=U
MA[MXZ.V!?W\T>2,::U^DB/U*(?!A67Q8.!(W5=Y5)--KTO:@.CS!H*1WG_O9
M-VX6GA<C6]O8;WXN1KX_9QZ3H<-&""=U!(!VE]XPY^[(VA],!U#'!^AA$68*
M#^CS&9T.A5'A]7\;N.'#%Z$0*9V#T-&M_VNOO+$U_27FD4\MX_<_&>-F&TYD
M<F7]%Y\)[=[C6Y%:A'U#[G[V#?[QE,54:LQ0@M'-6?:$QY51K\7Z4RGP'X/U
M/JE7W/\1^"G5N([W?=6DEEJ&\3M5RYC)>E?WIMYNM^:6 G&#UENS43MK_2H-
MCO\<C=NX%H&L^.%AK5U]VUK>9?M_G3@_I#ER2:PR=+J:'!^6O'_VIEU;\W-R
MH,.[A[Q0LN9[B7NCL]0;_TS%3743$96AM'%<BRVCN4<EL%-:;/K/T93[,;7D
MMS\F:+FIT0&:=K^5,_Y@#]*:=B+O#4CH[2/<:;8/7XE'Z,7:_:W>1@_AZ#VQ
M4M@5W*JEQHSGC/T:<'R$N/P2 BO2G5S!6?V.FUIT]Y1'7*7S!%GES(!G=Q-J
M3LW\I/WS=]9DR'U%^(;"F]$YFZIP[?K"^+*ZT&\#BX^/WSC\2N;U:>_!/$>3
M6D<?1"'DV1J3?]_=_S']L/Y4_.QX"O&*_JVGVN \O3@;3>,:?$^<+D)/59^5
M%158SW,[-1 ^N83Z[(Y+B*2CTY^:C?+V8H9=XON]O$>NM(U4%U75GI[[RI:\
M=WLB$O4"8%SEPY;V^0*BV(^>6Y^W"]+A,J7HK\LI0Z8]#4_GD%6!7\;GU@$G
MC%4'L^^:TH/SJ);JWRW/=ZEO-/?U>[WEO)Y5VMYG1!<N& ::.RH11SY^1EVK
M2R@RNPI%WGK)RG]74A;:Y!)4((A/[CZ4@ "/4_4<.CV[>O8'E'DI'6B$-3=,
M9V^U\?G@]-2NZN?HBY./*IQ/&WC63^?YD.-5G%^XM5J?_<>[=,U>IYZMT7"D
M4&>M@14.414,Q^.UE]<O/HQ@VU4W>/]](&/YSFA@XSD@^7?I5N-+/](/_#6Y
MF<SHXXGR87R8T!_0#[T]B:I7WWS]ED@KTX2S\5J_V6;Y&PZ4O$PT[6_QH)G7
M1SS9?[JN8$4_E@_;<L_^;V51V9S:=F9,@+!SE=])_3^45C[L5I=IJ^85K*@3
M:I!;L!C,WA-<7_:Q@^4&1DI:G_!'"EV =5 VO'DFF70*J%6^:#(;&M,PC@B0
MWK([<M6^#(R1V"_-V3;M5+M<^ ?$3/_3.(6Q?_&-3IDN_WY3DB/9/Z(OZ6/*
M&<ECKW-P\R&M]UB6#"L4)F6#KO!-Z^/P9=,QW6N"R -WOT6FD&4NVIZ[8H4J
M1Z@2J;> &C@NO*P)1.#!I/<%<\C<G>Z!3C4NO!%WD7[$G3Y?5?H J"7239R4
M>_\E6*_4EBZE\LE\_.GNP;U7W')S/.V+V<R+X8Z=X5.9JW(HU'U,:COGQ*B*
M0IR6?JW)1Z[<F%YKU2.L;?=WWDZFN[269ZO:C4CVN83>.$* 1OY&I,.GU0P(
MHKP#&?_]Z;)?1: FKL?#&*F$XHB,ZP.#)LFAT_+';O:5HF9L$)3LV)N7^;"0
MME_X[LT-+\T>#.G,M0%53 RUZ^8+E'5TR)_9&X<N2K\\3-I%VDOT;1&9W:5%
MAR?6X7<%.4?4CJZ!U4M_>EVCI>K86=2<3A4>FAFUY\+.F1W9FD%C;@7@[#AO
MQNU/V< "(++ZQV\E;H[@,V<Y@Z 6(-G1E&]#)B^+,SA9W#O_<;L\VRYPWQ"I
M546"0, 3='?1MA8M*DJ6X\ALZ*!(=N QXQT6DCG3+ATL%\,T-=[*SPO/&N*L
M(NRLS!>)AS.#I4[ 709]][ -L12B$#&8H@3.TF(>/@?QI#93,*1^8)8H#/)A
M)\*/LNU2:/ZA<5,G!L+-#76=#?N$AO9(/*8F)J#/0QQ@G??>C-B 2$)0G_)A
M8BU^%9CY'JS>& 14RIL92SG77VO\D;;X$S%WH'9+FCCW\>GRJWUZL)OEUG&H
MI=OLBQPM;@96SJP+G>'FR7NU89;I!P%O<=#*^I[S6#2;91M=^[8.][W0.??#
M_-U7N;7-!RK4Y_3!?1N<G?;LS;T[IX#@UPZL(\@[6 LP@*DRIOKP.A\FC=DX
MFZ)%9!\M>"HP]Z%?H3.R\L.@7>5*R?:>8)C@VM8,G0%B"'X*H"XO!K M,.6L
M0G"#[C_4HD?3,U@V4<V1S'NJ>'B/L^U#XQI#6Y7 [[%.W5$GU)+L/KU\,7T+
MYI^'V=*"8TEQJUN.L..P']I$N=4)ZC2))1%'9MLCS;FRW(JS><BPBDC=8S[W
MYK0,Y'HN'R!RY/7I@^ >MGR"/9@J-9X;)9VB5?OF'U-Q[^G+8XIJ=/M_> JC
MM]O/]\P&7ZK@N&HJXSV,"[Y?FWU[?86CX.V*3'D<H+4@3^;@.O3)J;,EV"$$
MH2"GS< ZYDKMJ,F"B_TU8*Y[IV7X&O=3$++19,[8"35]P5QOYS;9IRIY=9<4
M%'[<+Z "PGX&KF\GFAX45J\\?EQ4]81"AYAO==*#_Q90K>607=DM*'9$PLTW
MH.OS7KVGN1'$,*9-37KNI<M5@C)/)7/L3KF,/M*:<U,OV)7=/C=A3W\K.W='
M+KPM'? \B+?""][NNG+A(\;;..Z58VG>3\IZY:2>QR@T5.9$ZB.$/! QH$18
MN];W'*/J\$ZL&GQJ%]7X;M_4A)K&@T0Q'H3:IUU1K&'6-6Y!FRCOHX5 )HU"
M@@MY+;A=W-_2U,VN_ ,E5Z](@S\O(&*O=/A<"0S-T09=J?!$A+0Q/AF0-#^R
M]?[S'_7%,^T?!=I??JN5ZVLVT/U\S>-!GOV^)A6>[:S%T4_O:N7ICU)V(6)V
M\6&M!U<XBGV5P,1.N?=Q:%&:?*%+)V$9V;#A-X7(:K@I"_D%=%G^U^) HN"6
M*D/I<T'%MRP\N-4(ZI,V%3 Y.&J6<KLPO/X>77A:\W.NFCIA1-JE[N:$O\6$
MS?&K]B&@ENL0X;B$R[O!Z$=BKR.6]@55AU>K:S/MRB6KI'<G&F1P'^/S 6HQ
MO$:OH1,I-<!LIOV^*Y)F_"[VER)#ZVCVJQR48-7;VT5NYVPUS[LO6:B!R2AI
MWQU7 BU"K@W)H2^TY=[[I52#AF;--DH:F$W[#)=)?1I\OR._-/JQ[)!#57&3
M?<002.PBOC=VL@8LBSX_MY8_)_!?.NHY@N& 3"_O0@GBV^"^7PL:&=UEIPZ<
MM2,4&6KQ3LE)/X.(*,H.(.DGQ/%AHCU+BCRYIV%6].-JH=$G,4;6Z7>Y,:5)
M/&&4%-WB0JV%+#Y@V85@S8=%+/-A>:OP.%IUT$J;?L<TFX!VY,/(9.#;U_(?
M;LT5]9G%OJ$ZEXX/UA'R+H6&/2I]%)(_D=2\\Z*T"RH9_@;)D7_D ^66K@0/
MT"6<:<8:88XG8;5"B^JV$H.C&>/OL7M4S'U5&.T8,]_&FOS/)CBEB<;$/7I=
M T^M;F6EY>TE+HOMEBSD[(1D# (D!:Q,PD7F,HE('N")"> ':)NG<U03D":L
M6X5;*_8]*0^IP6W[B=V3Z5Q[L5(S^VMO^3\P^>S2)QYW;#]%<1X OO 0WB!<
MB$BMM3BV>6KY)U!CFV2!<-#OSG:GDX,*4=W-<066H8 XR: MU?7)VK=/LO9"
M8J&[DR6,[_U#$FK%1F''-T_HH$!]8#'T)4?GR^:I4^%&9D]:-#H3(5]'%,8
MIQC+G7H)7_^,>TTYE'QO>IDH.OAD8NWC6C_V'D"J1S#.#>  AE,1J.7'L>26
MB34S<8D)H;&TXPXHTV+%,3>)4(>TW_ZN J=($7?0=3!/O0GAM+)?*.;#(L;5
MZH?%TFMX<>P'A+@O[T>T'<>';CTI>^A'S$+N0_FGKJNWCGX1F>'!!V<9K"0_
M&HC__7NL^[-.=-/(0<^X[Z*W8WO5 TJCLFK5[#6>$L !2/,R;GE+*/L40++2
MXN992 *DX.N(26?]Y$+A[+:*;<_IE5P=GJR>EY-+M/Y#D]J>[3DS$Q=>_1FX
MNR$'VZJ*J/;=RRUN@V&LZ+\SV0@0/QM[IVY@%Y@S^+L%0>WCPV2\K%Z%G#NX
M-&09\EGSODWO$5?U#31WK*>#6._.4;6$P%4YMS$!/8O*\*S.IF=#6#*=$+>\
MSH<I@K$]2NY&9<_-EL7B0WNU;BM]%^D]?V)[LF-2!.RX'$]TD"V''2NJ<>]
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M<VU,Y^NU!9>E03.+[U, N+?GO1WUG6U0B_ZUF@.'-:59V8.DM<-5*/ P@B[
MF%^\^0Q4G)H-FU%G5FT)6MU86J(6NOVE6PF;\:3ZN+=0K*V;N[ PL=9,]&US
M*UK1+LS4=\<H^K94^GY$?/#+E-  5YS@1Q>A0T\:S?.B/NM\ *C?I.5:9C1
M)VKG@^2&MZ/X@"RU,EM"MOW?."2N O^.01%]^SCT3N:4'I3G!+)*B?*X.TPC
M14:"3%;>C+TMQ /_@0C*UH%/A=K%Q+?2L[O_S3KIC#2HH;^8'<K6P_;>\"U_
M'9RHKX"9T284;?_P*UW=UIOLI4:UE=MR?BW//I0YSY*#*-B2#-L7%*0I</%%
M?A5@RGZ3"Z>_'7\,^^JM/RM_%J'"RW1U/7_@)4P2)G*:H]7]>.7% 7G#PHBO
M/ YG*"9CK0D]ILU=)>U,>>*YOGHC@U/4G'HO9 5;'WS#/M-:WGVUEZO\;[9
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M+!#:>LU--J/J:\HQ]1><;7G*0+B<@&2/$_4%W*'%P='?QE;[ZM /EFN]X$A
M6?XU+5U7O4TS"\D_I"\P:H]*.R[!'X=(:*F.01JIN0=8#,_48DXGCXT?,#1D
M'DD6$J1TEQL?L\-<;9OV>+<[8FY4VV#=\S:U4Q?O&9[IT'CCY9RA]\P$0:D2
M9;U=Q]E+8D*Z:*%3G4!!BY3IM:_3Q1B,VE+LXQ'1\?-1^PY^E0L])CJ!>ZL*
MVO%0%4>Y3=%KF7/)=@]$)^01<N<Q:=<N=(")F0:.,1VZM<Z'(<UV;H,;P=UU
MU;,\G8+36V_Z%ZZ>?RB@3@*@I<T2_SQW83"($ A[(K-G23U7M$7$H,_T^JOG
MTO:.X*;QO7=[2X_^G/-F=>$6^:_TZTW [6IZ*Q,%@I:UIA!!Q4$W10_W?E'[
MWHGP/O+<;.H)+(X+HCFF ,<,OC+E$9W!B6 AO=$54QFX4RR5^K;.[\K7[Y4O
M5B]ZT0_'?MPZ^ =$6/>-QD<(>QST&MER?1]6H,+ K$)6M,LG_&N'M\I;@W;D
M'*A8PS=(%V@&M$9A6$M,W/*]!]1U@,BST+AHT^-_?B6"%6$J+D?2#1J=<XI>
M]3-<5,QM)&-#BG9(AQ>+(,6H.\-+VJP#5YJ6R%S0",%Z<%>DF]N0]@HV^?W%
MP$;66TFZ_!$GAKLQF;6:P.(QA2IL*'E&-+ E -UQ"-()8=Y=K^>%BFAP??1_
MD+('8?M-#R.<IF-CE6@]B1J[2@V[A3L>*==18BVI5K\?B)FU(N'T]*F"A :1
M)=+H=@O:KS0[943_U/.X.9@Y>UAN@'/HH,J?!P4XA*P-D/H!\D2_>'^X@#8*
M6B[YN]K'X?0U.7/A_4LPN^9QN[COGT.Z)G,W4X+U1SFBN/!5ED43<'L;JV="
M[/*/6,6$ R79V":"($H:J*:HI(1Q0;$Y@J4G8; ?TG?YO?:G$-13>R6\T@'A
MM-VHSRQ1P) ,?<@%B5!-#P.VAYL#LDI*,L]&?AT168/4[>__LL,*Y*3"5.=T
M- BQ,\.,>J@=/ 1Q'OA];.U*C5G]C9\.N]LM/'4M#:N50)).0_#?^'.4X V,
MQ)<1RR%YT4MO5CD^=9JY]6Z374NL,U/!&[<$Z,X5.<=RAW%*Z)>F*_<AYZOJ
M_DK;$;;>OT+0_2>!=[(M1XA6T +;NRB_FSX<NQSN ;Y6$1EH=:D^SOA*2_-N
M9_#<P.']C]4O)7R\%#:;+^U3:1>4>?*IFEF;[<)\_V@>G8\C>)<'M1_H*=3P
M(G>D(W!E]V0E;6B5,E-SI./N.R/YHS6**Y8V37:_:+@8(HP2P'D;;J=]<5AO
M+$G6M?\MOKPN^EUM16VT5X+?B-CWQ6\Q#GMW[7\L@G)!-UI"IF)??\"$1M&S
M&*J]Q,7N3>AGQ Z8[K<'Y<X9/*/70Y]?(O<*>2EP019W5!*NWKT3PW<:JVF7
M9S^?/V/:QV'T%.=P0=WC462[VTISK[R>SQ;@/VFZ(\F3D(F)L-JQ-:V$+/O^
M2A$%3I3ZM=+70XO$:PFSQ&F%- N%-[JZ;R2OF^V2-Y,404WR A%+\T/V7[G1
M\H]KN$PWIA3"'0%A7 3NYPK@JTPERK^F"C0ZY>@8\:W4FK]F.7TIK1U8>==_
M.U?7[JY:J^"^HA]G^=;TF</D":FQ9A2XE+;\7-XN^LVUWNMHP2/VVX*LYI9.
M5LUM$_D_T#\VZ.7V1=3!R[,MT_![]K#(8"XH4(L7C;;V,P7^QXW% ,"IL9:4
M^(?3DS\VK0^IKT$=@'SZ$Q6K+ZEV)9__=)V2QYEP=;MS@LLOPI;/,*_5IT#[
M W/\W]]6./*;1PXW<3 @BO:GIY%!@M>JZ[,2XY7E%,$3L,7(0406&=,H(D]<
M:6W0ZJO +@L!&D<'PK. XNC!\9\'9!$_GNV(")%4='!Y]7"'_K!3NT\FOM0I
M_X(U2IO#O]Y3T5F&(&M>*REG2;/ D!K5$M@%8((&<P,>A=*R+( Z<F2/I(NZ
M_EQ,8#C37U\ M.@YX?[][:TW'TMR\2<G!-7%>9KQ .<P4I7&1)1/8UI$Q)M=
M':P5HZ M,D4&]Q;G3EU1^O%Y;R/%Y#/GT;0(?^L#S>IX8^WBT477<*J"FQ%3
MZ,7K0Q03.;F]UZXL[I78$?)_\-:%:!8DD  HMU-)S(!FP[B-;GV\(45;/9"0
M6.%W]<)1/D&MF^2@JW=.-S\$.=FWHBQ1PR3:12Z(B&&<;J@9, Z<&AXRUI'%
M*K9N"P>:9%ZDS]VM':T5M@;U"'8/\9C9;9IYJ-"8>U.9E<++-,/+CB^>B9DM
MJJ_+2]'!IN1\&4UF@!#5ADJHTZ0L%"%3?@*XYHM/XL<+\ZEP0K5D'6<]S&&C
MS]-W=<T"-8,:@-$L8".;C)B<I9:< [T% 'I:Z+$S"7%37RK-&IUPP8 ]*M?S
MXJ;2J@VN!TL4YP@\8L)9!U]3+M,@L46<(WYT[[25YBL[PL2KF#;6Z1%,G?L$
M5_:: ET[.K0B=Y$IDT(=V$0M(+6[KK)2YJC,YGT:WW___A09 %^^@F\ 6!=Z
M+#&AE%IUJU9/,;KOH_"O^).48*'%,Z;Y07?O%BQ6.;CU[%_W^[T#0Y?,AD7^
M5S(_U_=O9/Z!*!5+OD?'+I^>$A79,KWICJC]]K.A5&E^%4U)&&1&P%*Q-%N2
M$"0>'8CF!=)-B_=$$NRBSHAKAPRV\;<YK"0<Z(F7W%H+N$K(D-ZJXH(ZP)4(
M7_-TU4)']J>QWVELM[];>D80Z_^ZG:<IW<@Y1M_!;]/[(5645:E>"5G)>V1_
MYGF!O'\%)O-.P9FTF<>!6X<J-;-?SN:%5&5(E=FIO]&X>_0F>H?G(UYH?73Q
M7L]TX!6Y[GK<QBTV/\5C*)[<+=[,Z]BGMV)^RL'4QSXCN% >2O'44C=MZNW#
MX+D@OK$FKX.??VY$#0)LTNP=E!B@HO<,,ZF%N;DA===0A3TK9_ID37(^PT#*
MU?NSBS_CD[#UB=*VFIWYN0TPZ>06BO*#E$L3^S><+^Z3W2WKX+JYV#.;Y\S&
M-\@&@&GVP0F$\EB6))/L6,0QQK,_(76.14_CP"/-H>_]Y$4KAJ^?7%"K=KF@
M:4)]B/WQ['Z$?9W>#Y*ZX3*,2N*A_4I?PQZ6"E!(BYP2;5^.. _ Z=HM4L3J
MAY1?X:-!7K0<C$EQ&<QE(>3[CZI26P?R%,)&+.J3QYY;[JQ2+FAW.#L'<H,$
M:$10"\@]X)%YF7#LLV6(GYPA^0DPV:9*<J918UORK/'5&+BH_HGN,V8&3K<[
M%**UY/%N')%N=G$P9"H;7:Z]+$H;8W#8N50J2HPE#PQ+/\;OI9A8VLQ]P5S1
M]6B-A'MUELSNO%%5(Y 7(!2O9&2N4V+^A48 U)Q8XE#&$7869*H$4C;7B .4
M@UNCM,G#+6S?5A^T3&LD7=Z%TBLCE.5;A<^(7(I7OO"UL<X^$%_9>-XQ)0R+
MYSQ3I\MR]D5Q08]O<CIAL@2?E-V<<5@I]E&%!/!I&@OV/^,3'4YC'Q6BT#]A
M5AF)2.7!G\OERITSS^!:L][$*^O\E':6)/0?9:2#EB"[T=ZX,:OIJK<$,>/[
M[YU=E&=R7FJ.6]Z=<>V(#%=+F6A5[K@N*XRX>15D!T**\-PI669N69D+XG^X
MA.8C^)U/L:<--Z?LA/G#]AEK%EDJ5U:FV<D09^%/HQO--3I,^C-U:MI+0Z[I
MMT%9LI7TO#9T>0]+*I3QM^Z&T[Q,?C-+JY=E-NT1W%B[_WF%S.$,U_%[G<^/
MW3U@$WSOW;>I2KPO*!T&_UO#'SV%A='L>BD'(5.%A I,*UH:*4='-VN>LN4!
M=H,<D&NB?;G>FA(6,YAAG>^6F>WQUL+QP/<R@7AO8MXL 3#@X^P=H^,:/0V!
M\K\%W=D%+.T2OQQ%8# B%/QX'2LQ;J/U^;5^Z\J8;UW=?4N&_XQ;8/0W'[?0
MH[N]S<^"O[SXOU!RXSJ""R)#FT43MF$,<*MHK*MT')5VMG)8[U70+]]?MD7\
M9)@!ZS+/DJKH1@A*&:J\C&F6Y8*$QKNRUQ PUPS)GH\),%WE;;4=,.=>SP^P
M'-_3O%F_U7()^\*K;ZMPE-6CKO.]S'T4744F7_EI;\?*<H(=0P8S==&-LJ:2
MJ$Z(U$J#*M(8J"LAY4_&:V5+QGSU%DX2NW_S><=LZ\QC='BU++\P?/(8(%)\
MG NR&@YT1E<](W3I+THX^6@GA(Y'!</CBWO4E>]E=/4J)NYMRMP',Q\A?URU
M7!XUK-NXO?J$IM*:N16N>2KEOA<7-'V\ER5 UX$T#!9)LX="N:"RA U7=='E
M\>9:9G(*5;BNG-EC4 7PW[D4;&R;8*)0I0*)O^%:!>9#:@:9PSPGQL%_5@0*
M5@^QX16Y7W*"7PU,YM=K$!0?W#=ULYNX0B@FS?[(UO[6(-;[94AF=\V-WM\>
M5(A4AV01B(_'9NY<RK<M60LDF$#/9:N%O7PG@4G[PJ,]N_]J"[#6WY/(QX;H
M1E/4:> #5,X3N:>?I5],0M1!Z:)Q^I ]Z1\,ZN["$=46P0XBI>-[/:S3+&%Z
ML3=+BB*<"A#I#%EV,MZ#>4:;FC0M.HII/,G239(PGPJGK>]?^%76L)%V*O5L
M\MG?A%<U42U5U#3X("^4[V>_YH*FL@A?VJE/[@=^0OU$ET-CC?7#;\VA?29:
M)3#BSGMCCDFMNALG!2F!D997(72?:LXI5"NV#+VL2>&"!)!7@2TF!+C5FJ-
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M>*T4CQ_V2)2-57KF&T)A/ 3N4\#$6#+IJ3&8Z3:RT!^0<W H&$L^Z?<KJ^?
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M:&Y3F=#^$U^5>-O2)M=[%Z2K6KM"S(X J*7P\)C'VVB73C?L1'62RL\3?!J
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MS8?:YI;6MO:.3YV?^_H'!H>&1T;'B*29[[-S\PN+/ZBK:^L;M$UP:_N773L
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M&RNTE,#WWZB(B[UH^OK)J.3=UV U;9)B%L5P*^F@&K5@-$M[]> +M8IUKR=
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M5=ZM6MY$^7NJP&RLYLZ[D8S-DH6=C5@V$.;-ZH91>MD Y=OT"&R=R@;V]KS
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MGD<:8CXBUC2@!1C&FK#^<C>%D>@'P8AIIJ+L ,6:\6( 05YA'C/J?6%N@!'
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MHC.\A]:AJL9R3^3Z_$[8=1;U+8TBX<_:UT\Q<QS<X+:+P;;R!^C;4%<#^FW
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M" V@F9XL@]C@>U8U5@D>N=C:MZ3SUZ P=2<">R,YX]'2%%0K(AI1Z;8\../
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M"W8\504108&WWJ-DOOI9=.%7_,VL:WZF3YS>]C.Y_4!+R,*)?SU6R.(\^_\
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M9:A>MIZX$QTI].F-G2/\2JE,7>WP5:YO?4!X6G)^YL8.3;"6L3^5-,7@^DF
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M18N4398BPCLA"?[(SI,@,-:.4Z$=)QFU0X\Z>[]=VID,WW_7/6>&N')P66!
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MWL^21ZMS6?LM'LHFK!Q6^MQ^J#V&B\W:[W_(OW?X_X- F!/_&U!+ P04
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MU7)']P88T/4QRVQ;S[  IDT)%!R"D(?1%2(,$1:P95'! J8OS^G9US&BDEC
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MPHYA_2]1^6#>>:\8D65!5$/%VZ^*B1;1+3J*A3^;G+AR6JX]AANF#)8<KSP
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MJ;1)]V#_.L/\0ER'TB^Q@):$0*8>QX;^/VXUO$*WY+" 6XAM"%.3!9 Z&EB
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MF?1X:8W-9S<3$SA$I4^$EK:'".R+C*ZW)Z%W@+=90'OP$8I:1$+>O%V2\^V
MTB)D*G7XGG*JOUOJ:6F]RURIK@"G*OX9\RN&; ,;T:(V4\(W6U9&$Z@59&B<
M[_?C>U,7S_7I?_Y1N_J<E&\6):1][=G.IW+G2,F?/_-6]5W%MHO$0_C0[BR
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MGX=]L ;E5IU;_GQ&4!T,7;A@8,XEW:?1;:X:?SHWM-/UI"3'_>C91E&Z*^A
MH9%F,12OR8*$"IPD\H;=8;3;XK8:H=<3J9Q.2LQ-O/]!(\G N<O,\#Z_(M[R
M)+?4I#V.;,L"0'7I3,I/YA<#%E#5T?(4A:R-I 8B'\$D3ZHY?1T+[H+[I:H3
M5_W5ZK\2]X]37.9*O3)T(QXZX<21R5<J!]:7C0F6F33:8GBT@H>UI5&2H6AA
M]*NDUA! ]1OW6ZVOC?S!(_!RWN5=[ZZ"@9/H=@9G:QJU-N"VR(WK_K1Y[:RJ
M_!]FG^1*TALOU\3JG4?NM+K%'(17%RQYTB2;WG33[(/[L\7(*HO<N _>O@P'
MY9KZRT?=X\72=TD^$PPGO XQ^_Q*Q"GW(S$<*F,L3?<E\V12G"9QK58R;<'R
MPWO6'C8$MFP_]WN4IL%O8W.ET^;,CM?NN\.$^93KDS:9 NR<R#4U$'P",AK!
M J@CH(](@LQ%9B]"N'/J*5>Q?QUBU/+7:BN-"5.M3J^;&<O6X"1Z_,_RR!]$
MZT<ON-]@&3L- ]4WZ1*"4W[+$'*S;V1;:I4TP3Z\U.5 \_#V]JR6[4>.#_DY
M#BYN7**.N_EV9VSW-%YCL\&NX):,.;JD/9._B:)%M2-[?Q$%D^T'KC60WZ4=
MXHI=L/,3^WY*XB!)VBZR<S_26O/N($ $5=!+O238*(;)/T;N:KD0,@XFMRM)
ME5'@K2)BWS^F;CKC?14>UM75?LQ:4UV9M;!VZ-PC)O,*^PQW!Z?@@FXZ!)V<
MQ(; 18-%IBW([LOWDD#X5&3XG?9N*TO',.2UJJ'ZLM62;X&+!_I#/R:J\:9?
MQ12@)V,QE?B(QD/,E@E!\ Q%& &>,]9"[26W8<*--4#>UITZOLY*-%BH3NR:
M4^.NZUG*#M//.16T7^RT> \QI-\#_47H4M5,P5 RO /#.V=U8W)NZ5E: #:*
M'N3:;&5H3;FZVJ;M:/)\\?G'))[*#TFW8C]T5)F-%"_OY*AF ;P748=!WQ)T
MDUX^F%F,E#&KH2@E4'A;Q#P#Z(0[5H%>$@L>)8H/I":>GDU(X>7UF<Y@[,?V
MZ(+'(UWZ]&"@ZJ_<C/82[]MXB!C]@,ZP?\K.<'V-U]=>9=][^L7GF^8)[N!8
M!Y?1A2.)M^6#QB\U&;F:N4><[%06>]9ERB7V63GD*)R@3D6 ")HU:&\!^E)B
MSELY-0]G[ZD:TL?L=&Y7_8 WJ?W\C?"]?=QRQ[CL_IWN^Y;O1#<]^X )8;/W
M(G@9I%G'D"F@21-'XJEGP>NY('2JENXAL8#/%NN?>N^%X;G21(V[]IU/ZDQK
MV8M7-BQ@;?L&[V8-U(=)@%=5+ZW1..@\@VSZDD"XU'%D^TCDM;-'GND5[O>U
M[.#M*J\R=1,__T-QQ^FW$7XWS_K!8QHY6$"3"WHR5=XTSA=&>#"%7<9,LHL6
MW9V2_U+^7"8)S1V3=<YYW^?N3)C0O.6,9DJVWR7MY?)E ]T&>F%>Q%%@;_*4
M4A'-$MW4ZTEV;Q.7J]>G&0;W'E[,5AJX:9B7T"J?W_;29F+9R#^BBWQ6Y#*?
M3]Q7&.RI(WZ)PIXJ_=MP3J-=A0K.G-3'C)<Z]6=*1Y4?RU*$,WW]O(6H/>',
M-@_7&T--5QE-=D:>Y(4YZCD6\#BV D[ M<M6D'67I<AV,*Y3I5??6P;"I*[T
M(AX(O?X 23V2W?.%[XRHVS.SXJ2:@Z@39%5HI3I=$3HM,O;@S*#.#.A+@Z*$
M(S\AII"SE]Q\I@QC,F.Z7ZAD&D*6AJOO:]/,5U^VQSU^!A@2QV*8_!_9:6$>
M]&8?/X)%DRM1&"XC[6V[&/**_5 E3'XAP*3.Z])"&:'[X-#K!JTY<[3:I[6=
MF3%F*^7<3M=_LN<T'?*AX^D&!E2-_(0.P57-1=["Z^OH-FU?'JXF+:/*<U9?
MC#LX3)P=M]#Y-J89<=+VQ(<(WKM:38VJZ"8WW&0R"ZA,:[<G5[?#QQY\RH W
MHR.9JO$>>H)CF[<H/96>&LC2-Y?/04;MRO?5FUVX.Q?GMOO43K3G]@";YI-M
M>T=,G1A92U"O.$MJ6+\>)$(>'P-I:52@X*-&Y@G!Y<AW/]N_SPFTZQY2>$'O
ML.4B=+4<#%GBH.3WU+']G684HB=)T,<$XA*6TD&BIDQ#'P?S4"20P]"=EI*'
MD.V!==>]W?-/4S2B*>^F#*H/>]_2P,H#/NK)VYGPEVS(@7X,YT![P\?@5 M*
MVE+).]#/!2R;Q,;)VT?1STPE\#F?>J"3$%HB[K 2M]'*%1[F>:,JC#L%YZ_:
M4Q:VLX:A\/_[U$ @6!G_<$40&4QK)=2'Z^@M'KM;^G)G2KS>_HY5'MP!]IT?
M0X@NPJOM$BEHIL B[>396DPK]"E<#&$$)17=[<TP.DC*//H*J5>G0UQ07E-/
M_L*?H-<:3\-HHV$;)2H7*#P)?J]N4YN]+!<]=7[EW&AI7[B<1N&*IE>R,S'W
M3W:F(5N*R*(NLC]!@P>WHST<&ZI;!7$2=#D*S_M%A.=TG,"LAO+>+KMF*Q_^
M4!</R731<;&*IR,APFE,83=R>P/9D'J)/$>74IB46@ #IWH_P>3F_8[;1RU+
MW*D.L)KI=QCW]#O:@?%431,M/[MU52LT5&5N$:%X&RH ]<:"ZK=1%RC8ECCU
M*]]0"'(.RMS]M5>JF','+V$]S^@FOV3(0KFH(G#NPL&,+5.FL,"P/FS,:[(G
MA3VMCQDI"&^4*<5PJB"ZXJ/1):_KN[-U><& GOG]<T.^1TX'=XNFRHI)42M:
M/[3+10Q0$=$H[DGL: =5=M!8VM,QR1$,_(03N-FOLQ^;;RM&<)A_P^5^(\38
MK!UF 6SU,H5*6,#S/71N%O!^?S$+*"C>ID$[)N0;* 6A^EA>ST;UAK[]OM[*
MLSU$AX$K@IF\J7M-:IYF<SV]<GPNMA ;#9T<93A9#D$GG^(X):P&K]5X.1O8
MA<U<?WXP^M0[HIL"Q#=D]^1:V FO9:(TLKIY8@>Y,6\:K0#&=YCV5<1H(O2=
M[2_5FNDL+4_;K%IJLW'1OC!+<0!(/@G)QI$=H:"Z*5UB\1..;(J(<I'J@]Z"
M\'DD(2\UQ[  @=7%L^1U\R*3TG252)A9@<G:3,;4@EDNJMQH(I!G_,I<-SNF
MWAXGMJ_L#/X,?V]/E["<-GVZ_VXE-A8CBA(AH>,,=.\[;S@YR2[Q%"%4'M.:
M=%H+EQZL;=U4DL4[>[$ [CQVK)P/'L3(Z[& 6,@NG#>.R].8#_0O;<"W(+@6
M[,6W"*E%PB"^U8#RM*<_!#=2DG PTN!0PK&<^&$HJ-53DAL\A"Y/^\U^N.\Q
MLBJ^PJ^2$SZQL?*V>URE]'';LG$7\!0B5>O[.5F^M9UN.J]JKA8BRLO-NNK,
M@%TB=$61Z47<Z%XVN+%AU 1#Q&Z4@!!JU("1_L/A3^H$U(EBQZNE>:X^(3<2
M=90Y8 )=[XY9P^'CS&9<N4Q4HR;8,6W:AGBBI$C!/:7?NE;=,&@$?S6VP#-@
M%?%]3XQ5M43>TY)3#FH>>(Z9FI0QM1IPD2EH3FJ080JH4PS8(T8:\R&C6UHQ
M!*+L^DJ4R_[Z/EWQ!1V#Y@"WBF;+49=#=D?G:-?B>5RY^DD77RKZP<D7$: 6
M?LF'C)NB$]_'%]$\0"]2>\.)9\E3ZK%N@R$UY+8G+Q6<K-YN#;G;G/57\+Z8
M&76HF<\=6,. >W!+9;HM#2K43K+NIQ7QV\%RX+$I2+SC1"(YS.K0?7M+CSV!
MEHL-1HVGH@W#WK?3PX9E.PGF>/;T]+'KX7'H),:%';]AAB@+<FD4[0!XYFQR
M<[8D'+1/<U2/S+6RT'G8J7@\P.2X+D8;+V-C(C&3/KLV<F2JPWB>QB:P32=Q
MD^E*!F3C/#*:J@:6D6A8#CJ$_%#&D5GR6J4I%WGKT]TK-H%U(3&SQUM\-(\]
M>*KF[V"IB<[P1D]6H,GF"83DZ7,8RN/IZN7JR3CU)HB(/KX6])[,LIB"&]H,
M[2'*@Q',@W*$BS(TJ;+9 [.SUG-Z!PDA03,T.?#,%*:%.,I)L@]I/+;03P3'
MSH(^.2/(1JH_'8^QC6B6_96% 4>^E%KZJ9]8["^.8F0%0^G'&47!0AX82+#8
MU8FK(+PUL=LX%!WD2OT:Y%%NY/-=%1$I=KY0+?:]W<'/3]XFAX[]Q\MR?U5X
MOZ#)EW1!5<Q2$#MT;4$[(UZ:"7A@;/$17T>+R_$^*>6A=7\^(U--&[4GR6NG
M=GN,E7*&^R+H$M,DD>4HFCQ=B;RRE$@9'F-7-3&C$R0MCW4,/\J<_+BCX+MY
M@>EJ&Z/HS;C4E?PX@,?)LW1G3??NH"\L &9]4A$?Q]Q)AX#I@<+Y%!42+*+^
ME(^W6/3$M-.WDE\3JCV/BBUB;=U?"A]V;)0FIX6CA').D=!<H#NL;[W;F7AK
MH*)8M3I,YXMS58>LP,=;MXXJIJH7E0AH<(JTLX"=C0ITJXJPEBG3EF61U@..
MGV]615[MOUYG]C)6VGK?>QM3.:G(U\POF/*[C]\Z>65 EK8F [7&M)YD]ZP.
M-#_RZ>8J;$HZZQLKY7:-[]HIKAU:-;DAA^J])A%<='/R5WP84QDTM,"O>\T(
M!KY>=$3YV>$%^'8;V12KQ(;X\R:>_]:HA.1L9@HDD*HCZH7RYB<4H_M*7+]I
M/_R<\\%,5K2/3^SL=3Y7@6E>]7@OUVA@$DIB0PDWS/81;"2;Y)T;80&4MR-X
M8WYVN8*V])&36S%\](.%2.N3@J28Y1T3SD; 6,?VX9R$B*W(;GQVY4#?2<7?
M>TA/B ),80_39B)?HQR;Z=9>?_;YX8K0SV]7/L%I$U<UBC$H^U/_H\<)?Q=[
M?IH9\PN. ^?5^\2Q^A.&<(84D39%%/0Z(+NBUV CU&3.Q>_J$QEQN<?N2E>M
MHM0UK[K<$./?Z_$1NND@TQ#=I%AO.H6)^+UE]+2"!42Q $ZCR^]V.>KN]"HW
MO3Z%%7).X6N>6+Q6-4ARN\QS+'LP1R$E:K\J[7&KBS 9W<J>N9;7=%,0?;W(
MX8M*MA6D55K4^?6AZ=V'=E'2KB:F:!]^*7ZLY*T&)X9LT(P(1PM^[0,]R0,M
MS%VT1[U5+."ZQS?'H+Q;RYGTU\XTOZK#+^\>7?"Z!"=30Z<:Y*=;LC6_+6WH
M&*]"]_]JN5AEGI,%K?TY62SBNF]&DN,3ND6=V0U=]X:+L.%#7-GO_QHPYIFQ
M/R'7@\I4ZJO(]+(R[A_U7K[C?>T**4+J8K&\<LC;T),<)S]Q2MV*!F8;%5$R
MH"'YD>'/8#&Z.AD?GFQ;0SOWIE'Q6\F2R7@]<]5:0/?%.";]@_^[92^J)^-E
MO7GQU47F'I!CDDW*.S.\NL>( @[=>JL'NPWKSCF\R#97WUMW6X,SM:^1ARY)
MG@TM1,):B+QTG>OYMQ=D+@_<J8=Z2S7\W,55]I8[6>[HN(AC)PN(@#%2T3\)
MC1 60%*XP0+:BW&Y(5KSQ\^EO/*T(TB'OW$:O3+J]%KZT:-G[WQ.B6O8QHF=
M%'@+<)P$.$+M-')#!/XE_U2@K-'_#U!+ P04    " #;@)Q6G>(;_\,W 0#:
MHPP %    &IN:BTR,#(S,#0P,E]L86(N>&ULW+WK<N0XEB;XOY\"6V,]$VDF
M1/ "DF!-=X\I%(I,K45(6DF9U=UI:S)<)5:ZG"HGI0SUTR_ BSO]1@?H),7>
ML>DLA402YWP@/QP<G,N__)\?3S/P*A99DL[_]2_N1^<O0,Q9RI/YP[_^Y=>[
MKQ#_Y?_\VS_]T[_\7Q#^^^>;;^!+REZ>Q#P'9PM!<L'!GTG^"/[&1?8'D(OT
M"?PM7?R1O!((_ZVXZ2Q]?ELD#X\Y\!S/W_SKXJ\!%BX.>00%\UV(7"HAC?T8
M!MCAKN/[04R#DX>_>@["DGD8.G%,(2(>@02I&[@7<R^4'@K<J'CH+)G_\5?]
M'THR 91R\ZSXY[_^Y3'/G__ZZ=.??_[Y\0==S#ZFBX=/GN/XG^JK_U)=_F/K
M^C_]XFHWCN-/Q5^7EV;)K@O58]U/__[]VRU[%$\$)O,L)W.F!\B2OV;%+[^E
MC.0%Y@?E GNOT/^"]650_PJZ'O3=CS\R_I=_^R< 2C@6Z4S<" GT__YZ<[%W
MR/B3ON+37#SHF;T6BR3EMSE9Y-\(%3,E??&T_.U9_.M?LN3I>2;JWSTNA-S]
MV-EBL?94+66LI71#+>7_V#?8IR/$[TG>?%O6'H0KU+WL2\8V3"][$_=.\8,8
M7N#&,$>+7+Y0YW,^UKN['.IHT8>7N*_7(LW);(378C5,0^29_L4W]5,UC'Y0
M"YD6XU34W1!5_,C%G(N2+=<>#1+^KW]1/]V_9/"!D.?[TU>2J'_/Q-=T<4MF
MXE:PET62)R+[(FC^G>35O_ZF%L1D?C47_R'(XBM)%K^1V8NXEPY&01A(Z#A8
M+734#R!Q:0A%P)U0((=&Q+W/EU_ O9C#7V]K80N)^A3G+Q:HY7N^_H7(TI<%
M6ZV;3[-=BZ%:!_7*B3_-R9/(GDEU@]))FQBEFO_VY444ED0R!^E<@#<EZ[]\
M6JD^^.S,)H;Y;&"XE;A@)?T)6&H&9;J 6K<3H 4'A>0GH-+M35TYFVG315E^
M9,[!K;(39V+Y9_!%_>4$:+6!4G_O%*9L3;7BB>EB$_F4]8S\BHHR!5H!NR09
M+7"K1E)SX'F?Q"S/ZM] _9N"CWH2YM/6VWRZJ/$@"W;@]:BN^,1295$^YW#M
M3=$6^!# Y>D0'T(Y^4JAOX!TP<5"[3]V@+/UJ7]^R9*YR+)3]H^7)$NT%7WZ
M(\GN.:;2BP(!J8?T'@'%$'N>A$1R%J$ A6&,;!AVSSA3H\Y:3-"0$_RN)?U_
M[2AT'ZYFW-@#6@.37A>@K(GJ  P],="^44:EE@.J;G+&H<N[D<&W-,O.TGFN
MUB$Q9V_7RII3/Y[-2/*47;X\4;&X#R(FF>]AR"D.(4+4@]@-,<24*4I@@21.
M:,,+AX><&D644H%4@N=26, *:>WXP0!J,ZKH%\"!64,+"QK2GH!*7E *? )*
MD?NC$'-X>F(3@P%')19S #8YQN+.;G1SO4A?$^TK58;/E_2%YO)E=LI8^C+/
MLWOI<4]9&@)ZL0B4 <(XI&IG!X7K.,HR0:[::-Z_B@5-3:FF;3B;;Z0YZ'"?
MRME"\"0',S4)(BNV!Z22%2P$$\FKMA@!41N(/[4[U))^6J$W(YZ^X!R8<FJ1
MP,T2M1-0@5O0T?D/Q>.9 !]NA';=D]E/_;&/"48]\4[K4*,RCHG2FUQC=(\=
MR_Q]_O?[JS]FY#%](J>YFJ>Y>/M9S,6"S'Z[_?A_IX_S3!E-<][XZ?KBNRB6
M7NY3SN*(0$$B#Z+(1Y#ZV(<!=P,9<BDYYB96SA$R3,WLJ=4 M1Z@4@2\9A]!
MI0#XG^3I^7\O_Z592RED1DW'S%<[8XTT"P,3V?X)4$HL(3_5D#=_OKX OY>Z
M&.Y@C_INJ@/-XC3NO>=C39C_EO-BO-[T@&BY#*D'Z:7%=Y!3+B_'/'F45:<'
MU>O%J(]'V:]1GPE]NT[_5!=7'Q&*D2NI3Y6IJW;7B <"QLSGT$?8)['$OB,#
MT\5G\^%36U6T?* 4T)R=MA [3/_'X#"T)VT%00>FWL+"G(*/P60D;K7"QHHM
M]RG?0H-;MXS&;_N$;1+7WFNZ[<V_""D6:I=T,6?ID[@C/T[5/C3/+D5^[\6>
M(Q5%P<#U8HA<YL,8AQC&D1,3S!V?26&W,]\_V/3VY;6L("<_U,9<+>=)(37X
M<)GF @3[=X^V.)MMP_O!;O CT@JT4DJ@Q 2EG"= 2=K?AOLP&CUMMUL&&G6S
M?5CAS:VVP1UVE,%%<G\^SY/\[91S]=9DUVF6D]E_)L]G*1?WF"*)A1=!+I1-
M@Z*80>SB"$8N"V)$6.2%OHDYTS[,U R;4E)0B7H"2F&!DA9H<<U(X@"R[031
M'UX#DT-7J(S)P0R)'<20"?;Q(7W]I!Y0<H+Z844%!QX["@V8J593@.'5]GN8
M933"=T&REX70IJ&.0/IUGM),+ JOZ\7\^27/;H36*)DEA>5XHT,=%LG\X3/)
MDNSL4;T6ZKKS+$^>=%3,*J1(,.Z&- PA8CH<(6 >)'& (*81<V,9HXAXIGNB
MH86=&A65DF;*3@&B%A9('8_TJL4%'T)#FV64F3Z\EYO2_ U,C6M18RMMRSR!
MIKZ@5!BL:WP"ECJ#0ND34*JM+@=+Q1NQ:1-Z#\SWL5-Z'T;:%T_FO;#:<X\U
M42U[^,%%&,TG,!:831_#:&/:6R!GZ3Q37U[M!9,<(3=4NPQE)!"(, DA]2B#
M/N<<,2YC[!D?X*T_>G*K^]7E[:_?SV_ +^>GW^Y^,6?P#<0.K[O=<1AXE:P%
MZ^ ^W0#!?-'I#L9(2T0MX,=^N'NWOBU,NW'#:+RX6] FB^VYPIYSOIS>_.?I
MM_-_KUX>/Y8D=#T& Y\QB&(1PIB&#I0,!XS34 0.-N6<]4=/C7-JZ<R_LPVH
M#I--=P"&=F56@G4@FPT0S,FF.Q@CD8TY*%:DLUOO%M+9N&$TTMDM:)-T]EQQ
M7-+&^8\D/TNS/'/OL2O\.!(8LLC5<=F,*O+Q?>CX@GJ!"!54LDN^QFJ(J9'0
M,@-!BP@*&;NE:#10-#MR.0Z;H8^3+6#IG)"QK7G/N1B- =XE#6-;P7T9&#NN
MM+<D3K_\=GIY=OZE6AEB+Z9"NJ(P'2"B/%:[EXA#'@GANQ$3CKFW<_W14_N(
M:^G,%]$-J Y;$MT!&/A+K07K8$EL@&!N270'8R1+PAP4*TMBM]XMEL3&#:-9
M$KL%;5H2>Z[H&N9!\XMYEB^*N2TR%(D;8R$='Q)*7(B8$^OJ, (RZDG/XZ'O
MR\C&DM@>8FHD5"1PKT3LE.^Y T@S8^(X>(;>[-@ATR%<8Y_RO85I; TP<GC&
M/@6WPS+V7MDYN^I9+/*W:S6C^>F<G__C)7G6S_YYD6;9/4(A]ZA'8!BYRL9@
M$L/8]3 ,*46"R0 +;)7@W3[<U#[Y6MH3\*SE+3(51"TQ(#E@RJ2S3JEJP]N,
M#?I#<6!F6 %XO01P*>P)*,3M-8_* );^,JG:!AL[E\I \1W95"9W=>.57\2,
MWZ5UD9)5L8JS&<FR1":"GU)%8X3E][[#>10$%%)=7@X1'$'JAARRR/&"0/"(
M!59."?.AI\8W6S5BM"HP3^%37>SE]UIT2\/#8CK,*&@8D,<P5';AVZBU\Y0N
M\N2_!"^<(B= [;#3A2A*\!09M$#]<RTQU&!&K(G,'MR>2,UBX%$)SAZ03;+K
M\(1NQ+<,F/V29&R6Z@/PY:<E&0\\'>0:A4$($8\#Q71> %T<$4:H)SBV*DC6
M,M;4J*T1TKT2MC.=M8%LQE\]03<P875&S9IR#/#HB6/:1AJ55 Q4WF01DUNZ
MT8:N6\M?9N)*GI'L4?^?-L=>R4S98YDRSFX?U;IT)Q9/%_-7D>7:3,ON="3-
MG?B1?U9J_7'OTD &$9&0",>'R%>[-AH@"9':J[$8>\QUB V['"_2U$CH.UG\
M(?(BXFVU M@Q3P_S9$90XZ(_,(]I\4^ _B]H:%%L!QOB@]\+!8#6 !0J]$AP
M_>'9$P_V(-"H=-D?@)NLVN.3>ZEH]H4\D0>1G?Y)U#-X&6CLR$!R(1B,@A!!
MY$0AC+D;0L>GL?3\@ AI%+9C/N34R+,2$9!2QJ,*F>U"V(P6^\5M8-K;+F16
M@U@)?-)7X+0]/,,4,MLUX'L6,FL!X$ AL[8[[8_NKX5ZI>:Y>F(=UWSU+!9$
M#U;:E'KT>Y<Y.*(DA$+J@D(HI!"[0D#/\RB.'2_PD3 ]T3<:<6H<LQ*Z3C5(
MYF I=YT7_*W-:]P1^G;V&030H7WO[X:E>:!![YB.%'_0P)8ML4V7V%:Y_KHJ
M7T^!U59 M00LF#UGM#@&*[6:X0UV-W:S"K^F"Y$\S,]_E%.LUP:]T:^B:=1>
M.^:!3V&(0[7'#ET!220)=&+I8RY=SR6177V+UO%L/H)Q2EPH<?7:J!WB6FP@
M*KD!JP2WW%FWPVUF'?8&X<#<7,D):D%!+6F/ 4U6F/1D#;:/-:HA:*3VI@UH
M=E-'#]_+\_,L$5E52?1>^I0)YC#H,!U:$5 ?4L<)(0T"#P=!'"#,K-QUZ\^?
MFFE7B/<&YB+_,UW\441.V+K>-@ T]*-UAV5@$J@EJVO+]NCKVJUS7XZKC:>/
MZX7:K=J62VG/9=T^7=/>&Z=2?4E?DU=Q][A(7QX>[\1<=^'(5OGJ#L9NR)75
M@+U09W]%/L2!RR%BOI D$E+M\89H2710LJG1A>Y.1+300"JIB^Y$&<A+X4$N
MYN5OAFE8='@:S:CG729G8-(:N(U1.>5%,Z, 5'  UQF_JY'QG(S<X.BP7)/L
M=60,9]>V1^8#=-P,UL]9G?Q>Y.+I]*DH/OXE?2+)_#Z*_-"/< #C(/:422=#
M&+,80<?'KN)VZC&[H'B30:=&W*MO?ZWFR.^EM)9Q'D:H&VX->\9RZ!UB1QCM
MMX<6N/2U2S09<MS-H@4(6WM&FWN[D<_=@LPSJ3Y>?1@J%J\)4XOGE?R:S,F<
M)62VR@C([M0(V>X_59]+Z$L>APS#0,0.1,(C,!:>"P-/AIZD8>S[1D5/AA!N
M<F162]I(;\DZ<EFODVC&>>\U-4-S8[=9L:;&(>#KB4)[%6U4JAT"U$U*'F2,
M#OG:_L<HT/6>,_XB/ =%E2_;"1ASW5! GTJU]?=#"6FDS$0/4Y>P2&+/+.&A
M98RI$:F6\I]!(2=0@@(MJ44B\QX@#Q_:]@#/P&2V"YDNN=Y[(+)(^CX>JI%.
M7[M!9I<)W@Y&6TKXGCO'RPUO%WTM2?S I1U32LE;P9]JQWZ]2)D0//NJ)+S*
M'\6BC.!3;'S*\N2UV+G?*[,3Q<*1, PYA0@S!JG+$10\\+E 7$8DOJ\:TYN9
MI)82&+WB<?F*-^48[@TO) 4?GA?)$UDDLS<P2YCV8Y<ALT_)3*F0SD5FV4;
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MX$^M$F!:)[4= (N55N!%JP7R2B^0:<7 4Z&9.4UWF\'#"^IP$S)61&P!?Z$
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M6T7;JP8Q+/"8'U-(0R0A0CZ!RBSV(7'B* P%CPB-.^3J[![-A@_&2;&IBT"
MA2AW9MEC\ES&*J=%MD:R:F] "DTZ)-OL@=Z,C'N"<V!ZK7M4;?2"Z/&@Q */
M/K-&]HPT?K)'N\H[<S0.W-*ACZC[,0R<HD_?%]VGSP_JLSU/;0J%2V"(8@P1
MP\HPQ,R'/N7,458C\B/?C$7:AID>?12"UAT@M>7WG;P!+;!%O\Q]F#HR=&/*
M(A@+K)C9YPI3Z7,8Q)*X'B=>A#SCYJP](#J&\;R&9]E1TP_ !_=C\!F<ORQ2
MX'YT8B<V=&"TPMO.OGV!-C#M;KU_!5X=FK;N_;#-N[;V@-9(1_@=4;/KVWH
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M,KG'CD*X2.[/Y[DBK%/.U0N4%6-<+:X7Z6NB%+EWJ(<CZFG2< A$GN0P9JZ
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M2F594AR&T.->',>^%P74LC76[H%L7KMQ<JBUG% 7)@-<GY=\T VH 3+LCG(
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M>0@*GQ#$',<3CO%)D=7(4R._BSE\+N4$BTJ/(@*?KS0YHG>SW:0<=JD.!O7
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MK-R?AT XPONY]]&C.3\/*=?T?1Z\MN/Y\PO-Q#]>%'><OZK_5*9HP$+B>Y)
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M+Z57IB"LY >U H4WNJ&"N3O:<CX.._>'0WE@6K4"N$.PH272YH< PR$^TH%
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M1,0AC5*;E4^B-!$)CGGFXU'2792Q^8_<VSZ -%*#U58)SS(6W<?%C;J&07L
M<PGL)+\"6ZV@7BRAU>L*;&0W?YT5A&5-T[D$I6;;/P.K6SW&*&#UBXNQ#E4'
MH[L@PU;$N!BPH]H8E[?8D6!KV>:_Z<.[@DF:D\P8;0H*0@V)LM0FA2<*DEA0
ME.L4$ZG]S+GV#L=GR=7EW6:(-+8(JWYOSWNGNXL\5JCA2:;M8^!(F,%P[9D4
M]P U0![=@@8D-B=,0I%7>V?#$I23XD<DY/96-Z+9751N[AUWQZT12YC /((1
MP99E$@5I$ML,\C%EC*:89YD?R[3T-CZ*\?/L<0'4C3("@=0S7]2]*;9>$7VX
M07C $H@RVGH:E"\<5#XD"Y=7.J:(8TL;TK;ZKI9%K5P;N2 F/(]SB16%6IJ=
M'))9#+FM,J%$QK6D<8P%]LH&=ZJ7L9U5%T*!=\]J69:Z]LWK=A+))&,HMR7-
M$A39 AU20HHD@QPGFG,6"_-[/[:]&,MA>+9$T_K8JTK@G]_-"J?\+< A\'4C
MWXLQZYEV-_+9Y$!EV?"K(G)-!,QZUP9!J 1W)_L8-I==FYI':>M:'PZ0H<X&
M+"Y>UK>*R>GL]:,R-/8TG=O5M(HO*[(#"(9U%&41))K88F!)"DF*$611BFFL
MJ;'12.>\=$XBC(V*CU-M@4H/L"P5 ;*F"?C1>D83:IS:N688]/LFHF;@*QU
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MQ.L(TJW;L;'+3FI0$WNO7NY%<6I.0^%&/>$![OU<,!"V':+5?* *%J[FU.G
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MF4H9QYI%O!JO3W/'X]@!1VLCTW!CI8P)._@HN2T-@^#>\_I1ZE#+( ;^*+4
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MII1&K_ 8Q9 HA<R?682D>T?@5C)STR+ISU'T%[#CM6GFFD2.LTU[0.TW=\)
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M;=?U(?SE51ZC/!FN0>CY[??H^OI,Q4EQ=$H/7DI>[_Q>=F ? O,(5.)?@1T
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MN]DM4XV\G=VM]-O];(M[^I'(79$OBRJ+^KCHUB[#_X-:B2)_+IT$B:0,(Y@
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M8"F(N(C2)"42$JLJ49;S3<U0O%F YTHRT^VVE+P\TY [V=V8K@MO.UKSB.+
M'/9Y'[4]68WG64OKCZ@L8?'$2EVSC4I!EJH?\XWM;?W(Y>-R\:C?TB_F7.<?
M*G]\6BMYJ6T4]K@M;F?ZI,Y@F"+"(V-<F4;>">> I)@#*5*897%&PL0J<=]Q
MWJF1S4;4@%6RZG>D+EE9F"[)RT6P6"Z J.J=EYU)W;C'=CGL.&@ D ?F(B,Q
M>- BF[.(]46PQ;L6>UOPLNQ*?1&P=7"WS"NN>LA;2H8Z$Y4C=IX(RW;648G+
M$8IC G.]O6>).)879:S"^RK><%=W#/%0Q2KD@":1IBY.$T!1FH&4*2AP@EF2
M6'6ZZYQI:F152G=.<;>3D-K1CQ>@!B8<!XS<R[)UZ>^K"-O)><8MN=:E[IL"
M:YTW]*."_WZ1N>D>]?E%7_18;VDJG$'&1 0R&&L6B$4">!(RD%+%(BA('-OM
MH;=-,C4"V,@85$*ZO?V-*-J]^.=B,_ [?P3+ %W=V@#P]-(W3C'J^]ZFY/&K
MWGIMWVV1YVU\\/W3LE@_U#;&+!1,LC 1(-&H 11Q[;6H% (2Q2B$BB">QFXQ
M_R?GLGJJ1XWXWXIJ#HE71E9@C*\>OLAI@&UW0,X!;:R]C^>]D/]2RIW[X7/7
MHP,*;_L=I^89>:>C0]VW>QQ=-_3,7S<9+^_92LG]G/D9CJ%0"E.0A1$!*,42
ML$P3A) *P5A(E"CE=F;4/-'TSH7*5-R &T$#L2>I8T9Z,ZQVM' ^5 -S0BD@
M*"4,ZA24X+(H3-B'^?EBFT]Y_<V([W'/H1T:7XGFS9.,FUG>JNB;5/+VJWL$
MVJQR=L=$GN7B,BMRP3;MGZ7 *8$9H%$6 :24_HE*!K*,9A1'+%0HM(ZS:9YC
M:BZ"$1/4<EX$E:0. 20G@&QG D_P#+XS\!:9/C$V)R!R"+$Y'ZJ1(FSZ0>86
M8=,.1EN S8D[QXNO:1?](+RFX])^UM#M^DD5>^G7YCM6MPM&@@@I(@DXIR%
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M0BXZ)2E+Z\/?(XN<!JN3.PFJ&JFBBVWMUKCKB\$[M=)+1B+>V\WP_%C ,>'
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M,>!D(6SH(J#:$O!):Z<=2T6TKO(:;8SEQ8G1=Z<<WAMJ."DF,><2$B]1@Z+
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M$/KH &;7 ?%/B^5R\<=T_G$UX4I&\@AKH0\W)"9+*\4%"[+61_(@I&C>3?(
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MY#Q8&52 G.KX""UK4V+.R=T))EEF56G>;6$_"L>"O38(Z9(=;*.L\8/Q7H>
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M&S-##S[J 7K;1B(/CH,1;(B_XE5>$N7+E5R?=)80+&N=@X6 T9!CS4(=ORE
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MV/Z/UO=56CG!9-0@':--%"E*\5'P^D [%\=\R*;U*=>2_H%+V%H :C82[8X
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M6-^*%YV"M]UJ('=]H1LB3BD-V4260R-"\T=<W.93G?<^A6  ?1"@#*]-2GR
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MY%\1!_46XOULFJ[G5?1WHYEE\B8P#=$P!4JH",%B("/E(TJG1>"MYZ@^3]'
M^?4A#[^&JAHM\"Z+5H[5 NJ2= 9%$2(X75_DZE!2#BZDYK-^ME,R[-G64M>=
M8+27X$< GX>WIF^GM#(NEI_(O5[YV/DCSE-5V&>D$SD(*8F?8#B=R)IS<-8S
MB,H%Y#%[][BK=^/Q4<]1-W#@/>1YUI,*1P?.WT+"FY3M)2I1LF,%4K0)E+%8
M>U9Y\"@P.9VS+[)7*-[1,NR0DA$![T#UC !FO\WF./D\?;TZP=./-W^F+V'Z
M&>L.NIB'Z>)JI4Y^65Q*!DT X@%K]^U,UD*1W7",#G;-,^VEUH%N-]*&G9 R
M;"C;@_(&+N,B'G"Q^% V]U6K?-B'[SB_38Y]*'7O70J>C91&0[T (/=%!(@E
M)TB,&8_(O>%=G@MT_=Y8:G)>,#/8FSJ:0:S=>.VW4_H1+\*?=9+XH:.RMRQR
M[-CKG]'5:(3U[6?N[MUN#R@6<W'<4700JRM?3&V/:2.@94(EAU8]?JEU],G_
M##G'VKO;I5_/IDL"=#TW;^Z&BHW:),T!O2;#762F+2(M(=A*KY(E\]TZ:MQ)
MS+"!8RLT/#97;60_H(%:S)>7[R;+R>>5*EZ'!:[JU%"YY S)A!6UZAP::YT:
M1=+<DJBR\B5U\HUH^7NHH5_=(6;[ET<"D^/4.6LFVU$AXX+^C74I&6/%"^;K
M:PI1YYYZBD&=5<"L=_6AIC*ITUW^7OBX^_XP*&FASYW0.%"X _NV%^$J;>8=
MDC<F$Y&IL38&NSE& PE$:^X23YSS+GU3[E8<BY(/U<SL:#$-K-Q/D\4WG.=P
MM>GIHF+"% )H"K(HYN(% F-T&F:9<M(Z<MVEQ>JC98<)0WI1\S$"&T'BY#;8
M>G6]H#!KL3C'SZOH?W7,2>T\EU)#5+69>,X!0JZ-_Z0J5M:19;%UOOA9@H8-
M7]MZ"NTU, 8XW="^WE.. F9KE %4GH)T;3*X$@UHV@S!T5_Y<2^$X^%SGX!A
M'<N&BGT,F8.E/+!UH8VSN/Z*\XU=S)DS:1,D5R1Y4>1 .4,'ID!F%2MD&&V7
MF0\/5QU8Z8>K9M9$3B,X!#9X/TO_N)XL)BO15\@;J:W,A3R@4 RHB+6^I*PF
M617AK)?N<;OVHX^#':0,>]78CQUI(?61@J?^.,>-IX9"L&)(*B'7'B#($8)(
M"()GETQ(02KW C!Z0-2PATX3U7> T^%Z&+K/PO5\LO@KAJOEE\V$]H2Y2,F
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M^@I,=-R5I)-7K9L?MZ1_V)3H26V47J$Q<JMRN^-%ME&D(*&80);2%%G'KWG
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MQ''(I?ZI-4\&4K\LZ@V"@^=O;HN;&M9<5%-L8\J+Q](70LHM)Q034AM/+8&
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M5#X"Y/QUE:9QZF=?5[/[ UI)"T<CYE=4\A+C!41_I*5W)4X+],F6TUXG#0Z
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M"(6HDHW,'[4U\N@=_?#QH<[?UM+H\%W]MK\H7X+OX+_^X_\!4$L! A0#%
M  @ VH"<5HG,H):G!P  ]"   !X              ( !     &$R,#(S,7%E
M>#,Q,6-E;V-E<G1I9FEC871I+FAT;5!+ 0(4 Q0    ( -J G%;.OG4KI@<
M *4D   >              "  >,'  !A,C R,S%Q97@S,3)C9F]C97)T:69I
M8V%T:2YH=&U02P$"% ,4    " #:@)Q6K6XG?! &   !*   '@
M    @ '%#P  83(P,C,Q<65X,S(Q8V5O8V5R=&EF:6-A=&DN:'1M4$L! A0#
M%     @ VH"<5A@/;CT"!@  ZB<  !X              ( !$18  &$R,#(S
M,7%E>#,R,F-F;V-E<G1I9FEC871I+FAT;5!+ 0(4 Q0    ( -J G%;A7<B:
MAS\  #NF 0 >              "  4\<  !E>&AI8FET,3 Q+3(P,C)L=&EP
M>&9O<FUP<RYH=&U02P$"% ,4    " #:@)Q6N[MDE0TY   H? $ '@
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M &IN:BTR,#(S,#0P,BYX<V102P$"% ,4    " #;@)Q6BZ^$>#,D  "J9@$
M%               @ '6&@0 :FYJ+3(P,C,P-# R7V-A;"YX;6Q02P$"% ,4
M    " #;@)Q6X-JA2 >$   ">04 %               @ $[/P0 :FYJ+3(P
M,C,P-# R7V1E9BYX;6Q02P$"% ,4    " #;@)Q63FB'A."+   >GP  $P
M            @ %TPP0 :FYJ+3(P,C,P-# R7V<Q+FIP9U!+ 0(4 Q0    (
M -N G%82)>4X)',  "N$   3              "  85/!0!J;FHM,C R,S T
M,#)?9S(N:G!G4$L! A0#%     @ VX"<5EDAY/)(/0  FU   !,
M     ( !VL(% &IN:BTR,#(S,#0P,E]G,RYJ<&=02P$"% ,4    " #;@)Q6
M+N_6F.8[  !S3   $P              @ %3  8 :FYJ+3(P,C,P-# R7V<T
M+FIP9U!+ 0(4 Q0    ( -N G%8UTEC+_3H  *Y,   3              "
M 6H\!@!J;FHM,C R,S T,#)?9S4N:G!G4$L! A0#%     @ VX"<5IWB&__#
M-P$ VJ,, !0              ( !F'<& &IN:BTR,#(S,#0P,E]L86(N>&UL
M4$L! A0#%     @ VX"<5N>Q\+=2M0  0/0' !0              ( !C:\'
K &IN:BTR,#(S,#0P,E]P<F4N>&UL4$L%!@     2 !( W00  !%E"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
